<SEC-DOCUMENT>0001485003-22-000121.txt : 20220825
<SEC-HEADER>0001485003-22-000121.hdr.sgml : 20220825
<ACCEPTANCE-DATETIME>20220825080046
ACCESSION NUMBER:		0001485003-22-000121
CONFORMED SUBMISSION TYPE:	10-Q/A
PUBLIC DOCUMENT COUNT:		95
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220825
DATE AS OF CHANGE:		20220825

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sesen Bio, Inc.
		CENTRAL INDEX KEY:			0001485003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				262025616
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36296
		FILM NUMBER:		221193030

	BUSINESS ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-444-8550

	MAIL ADDRESS:	
		STREET 1:		245 FIRST STREET
		STREET 2:		SUITE 1800
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Eleven Biotherapeutics, Inc.
		DATE OF NAME CHANGE:	20100223
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q/A
<SEQUENCE>1
<FILENAME>sesn-20220630.htm
<DESCRIPTION>10-Q/A
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4,d:4adf13376f39486da283bda7a521a795--><html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:sesn="http://www.sesenbio.com/20220630" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>sesn-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF81LTEtMS0xLTgxNzIz_6aad6bff-20a1-46ec-b06d-83f3626c0bca">0001485003</ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF82LTEtMS0xLTgxNzIz_143f0f15-e19f-4e61-8d86-956ce9345190">Dec 31</ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF83LTEtMS0xLTgxNzIz_ebf73534-f052-4156-ae74-9bc13dd330fe">2022</ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF84LTEtMS0xLTgxNzIz_811799cb-eae9-4387-bac9-2c418fd2c195">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF85LTEtMS0xLTgxNzIz_4d996a33-5ab5-480a-ad3f-19420be17771">false</ix:nonNumeric><ix:nonNumeric contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_4947fedc-4360-4141-b0e3-0237b2c47548">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_c6767d49-0588-49f3-8fff-685b494e5363">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_d6497809-9e60-4366-b51d-775001f6d3f2">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_dffcdb59-fa88-4ed6-aabc-b93cd31c5568">http://fasb.org/us-gaap/2022#LicenseMember</ix:nonNumeric><ix:nonNumeric contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_4843e629-dcdb-4616-b8a6-a27047f3d904">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i816282644abc45028662a05fb3344b4b_I20220630" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_97400fbf-3c91-4d39-b5d3-04d3e2f63a2e">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_8d631678-1039-4b69-9e83-f467e7b5b77b">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i816282644abc45028662a05fb3344b4b_I20220630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_bedfdad2-e676-46e0-be70-8fe59f2f9fc1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="sesn-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id869177d11624fb384af0cf8700149ba_I20220801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i816282644abc45028662a05fb3344b4b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i08198d39a53746e381e9ad22e2530e7c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0888396debb34c04a3b1ce7017d15b49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e2dde9a518a491ebd8912a185f23cd6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dfef576366a44c8899c23968e5a7571_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e31cbf599b140739ed935ff1dd609b8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9495f0a57df45ff8db57ca5375f6705_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fafc918b1a455ea5d13849a58f83dc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0975aa547f74b7a9de06d3efa3be13c_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibad650e0476f4f16801d09e1becece4e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib01a1af0204e41fd93a01011d3d198fa_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14a46440132b42f0b7fa05821b7ebc4f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de9e1ce23744a739794e84c9513c251_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2011e9ea8d46969474d1ff815da0fb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5212a49218248398de938ab0ff078dc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idad59db36cee439984f3d4ad8b4fb9b5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic947583800d54749af298a1e2b9bc920_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ee39dd3da244ec9bcff222871e71116_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i117a5180e4eb4c3391864589aa813213_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7012d9b8cefc416d86192851d3aa476f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i171789775ea34e329cab101dfc95862e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b5d4ce18c0f4291b85fddcf3869fa34_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idea9cc2fd581441895f394010022516a_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec33aebf75ea4629a482858c3bee531c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52eaa414326e448c937bf26df0576971_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib39f955c83294b19b2d55b161745582b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30af2746204648089c84cb29d5101717_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib30024337b1546b7bd2a070c42de470b_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dd0f583a45649359ab4f630a2d1d044_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eb92ef2739448ac91cb470697a88bf3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d04fd3863f8493db4c151a0f56ee9f6_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9147fb1c8cf34577b359bd45f28c4a7c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3b387a8bf0243d9b0d1e9d51425a534_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i732a7b94c2394e6caed25b643f1504ce_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae31b43c606e4c19b17a44b2508f083c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62880df550724456b3e687c3c6d85445_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73c2ea2a03e7419a8e4196a69096b610_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d7821756c804d898a7d8834c7925d7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7984a6629ab74eb390c3df7ff75f05d2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0cd0bb43b0ee429f964e6eb8b8925e53_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1dbbda2c1f497da6b3ad0608eb76ac_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07c0124fe234223a9d340e9c94f5559_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i407298c7856d4211867c26d5eaa28887_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief96b00f443a4686a885891ec4c615be_I20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i19de5e3ec9b24f1ea8494afb290825f1_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i826b000227f54693aaaf1920a6d1aa63_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f56438c3aeb45edb4022475af4e3db5_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a90ce4acc1b4bf68182efbf79fd5720_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00b74714225f4d449b61808db2c2c804_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4884e6cf1834287a8e4032056a092dd_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba330c2936d403bb2d4a10535dd51e4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iced2721a212d43848f8133e3f4186dda_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149ccd24ae824eb0955599b4c37f7358_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e27122d96e44ef1888f4f1425b3c91c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb703a0172774df7b5fad376a5cac8da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d011b45a374b0784b3c71627d06003_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie42072eca3cd43a19d6e850e7b53ebd2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc528568b4234010b987e7ed2c26110d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie23847c7ec884b868685a03832f736b6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icba9e1576f6248d4b9e8e786bce57457_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie44b4e5d665d480d86d36cea88a338ab_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00d97ca9441426bb9adfaa45c3d754c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:LitigationSettlementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c25a0b2ddf74ac2b722c896a5913d4c_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifedd00e94bff4f138a71518235d8f0c2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifefc2cc3cebe45d78a99c0e68849b7ca_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie19452cececa4a96a54f4c9ced19321f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5913171b77dd4a8db206d874b45307ba_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90478a97ea0d40c7a94bea0d8f484eac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4e724420d5a41518add1245efed2632_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="lawsuit"><xbrli:measure>sesn:lawsuit</xbrli:measure></xbrli:unit><xbrli:context id="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="i6f1af4670f5349589e2c8544533b3f92_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cad"><xbrli:measure>iso4217:CAD</xbrli:measure></xbrli:unit><xbrli:context id="i000d73058a0b4403961f473fd89fbb67_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ac9bf36e8db4b3398a967b1e06528c6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c8d5912a42e4ad2833bfc6f61c043f2_I20191129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-11-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78ad6147eb974d38affb24031a858c3d_D20210601-20210731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a0705a329ea41ed96157e39c6c49855_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7eda749d94fb48398a0924800d09ac3d_D20211129-20211129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-29</xbrli:startDate><xbrli:endDate>2021-11-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75b910d027ce46cda21c3171ea8cf644_I20210502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice21145cb84b458994eb2b4953cd1b79_I20210503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e03d5c4d214485ca8ef8d4f2b1c22b5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93e937a2ca743998879eaab73aba23e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78713773a6f644369d0e8eec39199597_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if34834f39ec94e458f57f689cde2c633_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81b6cc446ab44fa08e173a103f7b7289_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ba233a853c42b89272f4f6b9633315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90db0d74d54b4275b25f685df0f5b309_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6074b6e43f5c46f5a2bb46e072ef5f2d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4996e48caa5c4590b4980c71c163ae64_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b96cadcfc494bd094e17b7ef53a0601_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6b33ca5238c45cc9793e8772152abcb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>sesn:vote</xbrli:measure></xbrli:unit><xbrli:context id="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b97f878936d417582c679e49408c3cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id796b6b8583646e18ef4317244b84a3a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34c5a07fd1b449558c518b3bbcbe3efa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaca184cb85744059ede4889bd0bec15_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07151ff5feff4986a1a7cf1407f3f033_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89b961b26f78447680b3d6eea476fce2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d480b8de55f4a309d196db12c0a8524_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a77deceed914ab4aa6c3a9a9c4f3afa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife468ed832424422bc39059d7df8b085_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0adbc934f3b24c239d0f1300083008f6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a25de0176e248178dc11989f74804f0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47327dd48deb4402885aa3afa6af22a2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc6aa26487504d41b6a549bc657400e8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19b7d9796cd54f35ba0a1cef95f329d2_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c9a4489987e4bd2a05ab6cfd1a362f6_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a33702caa4644da8978da5e0013ddb8_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67fcaaf0286a4c1783c880c53e54d424_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e730560bfe346738f8e589866aba60d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ad0ec9b6a7b42cdbf789fb6d8f39ca9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i568a2b3022284d34a0aff47db073a523_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41e29d2263d34ad692781e2266eefd53_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec8d3d4dfe0d4122b647ec6d4619e69e_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia71281c8b42c4511ab6edd8ce3378ba3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc85ab1a955410a8b2ba5d9aef9c0d5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id53e901c0ef94dd18db696d73878aa08_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55970a0d5f344348a35d5e2c4bd4282e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84b0564ab20a40a485edffa15b757c33_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee95e6730e374d6e9aab606275edaf82_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342e97e8062b4c4cab492cc8c00c70d8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db64e1a961546e3bd8121ee3879f09d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieac62593b40f4880b423bfc9580273ab_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bc1a747a0f4fdd9e81b59820c9d0e3_D20190601-20190630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-06-01</xbrli:startDate><xbrli:endDate>2019-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacb6642dacce42dda98c5135fee1f003_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05439e7daefd4ac8b3d2d78445d47366_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08ec180c3533409b8010a63003f3a00d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib466f1439d304e268b42a9bfb03f0f4a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a67da80633540d9868f347e7148156e_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i177a51cfef854bb4a48b39dac3ead017_I20211001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b2d9dc879b4976951e57e3d6a98fe8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i570bf630b283493eb8aac676692c8fb5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cc8c46f0ceb44d5806951413bb59ee1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7729b36949f4e6f8b449bc2e11e0ac1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i044e86b9b1004169acd873b958541512_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66d0ce796f154e90aded5d0cbce94189_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ea04149ec74feea107a21a6ba9a68e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0710da839aa43a793cc2cb6c1c4a9b3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica4c1635be564e9db6a99db680002144_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8c92e1f22ad4644a192da4d2c4a4794_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f284269de6489baf1956eaba755358_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id083216cd3834a9a8398563d69c8b21d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i129a8282c6be44f2baa56e32efc338ec_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11cba79393924023a9e75dd2910cde3a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f9cc9d2301a4433a98cf0413fade87d_I20140228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2014-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic63732dc872f413f8025dd7bf4720b9f_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76c65c4ee1e64946ab281633bdefbe71_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5769fcff7b47898a71e23efd9d7b5a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id065aa16b3944940b083af3709622dd4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2092edc5bbb470eaa1bb592509fc775_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2acfaa03f15458fb09624b5d55af0b1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9efed9b3cf4e4e64b6b1d76a87c5d8a5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie802f22fd3164257a0a27630574179f1_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i854149fe8e0748178452739c0ae5c742_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifecdde588859469e8e663b340243baa1_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b29722132a2491b9d2cee4b49fb0c77_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d68c476afcf40a88a2b8fed6118ee9c_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2a1e9da126143cfb0de4e11868d0606_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7b4ebb5c66413dafd7bfce298dfeae_D20160801-20160831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-08-01</xbrli:startDate><xbrli:endDate>2016-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3267071fa5d04b21a986ab51df8e6d15_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ee271f6d7d2411fb58ddc98730fe4e1_D20160901-20160930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df0e9d706854cfeb872dc1154160218_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766fbeb7225c4f8d80f3cee6c943dbef_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02e5980cf4114748bd928cad4eae85c4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09f960acf0aa42bf81e936538879aed3_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia91fb5103aca4101b34beb81fb97be24_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679f24e2f48e415897b49d6af88b722c_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd9b09daca514c3cad0def62ecf0ce84_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-01</xbrli:startDate><xbrli:endDate>2016-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="period"><xbrli:measure>sesn:period</xbrli:measure></xbrli:unit><xbrli:context id="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id66556ce8bf24b0293558cdda62bbe4b_D20200730-20200730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-30</xbrli:startDate><xbrli:endDate>2020-07-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i954601fe3b9448cbaecd65eed3c97e5d_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1291fa4c92d24233b8c7dd158c7d657d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93a8a67c88394769861872b5ee4d03a3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia72f93a71c7a43cb954ae37e2265780b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i026b9908503a4d88b10ca249424b3644_D20201130-20201130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-30</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12906e74084048d2b9fe524e7469bfd5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e92c8a7aef406ca55775a1f5db7e70_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic828b0a647374e389c1cd7b05992e6a6_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4b92f7d8494337810a4188d290be4d_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b11a504e94346c7b3df6f09cff921f5_D20210805-20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-05</xbrli:startDate><xbrli:endDate>2021-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2b242b85564774a29503984368afdf_I20210805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5efc2997de54bc79f8412086513351d_D20210830-20210830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-30</xbrli:startDate><xbrli:endDate>2021-08-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>sesn:position</xbrli:measure></xbrli:unit><xbrli:context id="ic23bc63aeb3e40ed84c761fb713ce86a_D20220715-20220715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-15</xbrli:startDate><xbrli:endDate>2022-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic081fe4045014466be04516c1871acf9_I20220808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001485003</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-08</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4adf13376f39486da283bda7a521a795_1"></div><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV81NDk3NTU4MTU4ODM_911537a9-dd1e-4f88-9c04-b78a3721c533">10-Q/A</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Mark One)                                                                                                   </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amendment No.1</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6NDM2NDk3YjY4MzJhNDhhYWExY2NiMjYxZmY5ZTVkMGMvdGFibGVyYW5nZTo0MzY0OTdiNjgzMmE0OGFhYTFjY2IyNjFmZjllNWQwY18wLTAtMS0xLTgxNzIz_d142ce40-5479-46e9-9de5-0fc3dec1ac0f">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xMzY_2794d8f5-dfac-42c8-a5fc-13eecf4c60fa">June&#160;30, 2022</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.345%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MGYyNjdlYzFhY2MyNDViYmExNjlkNGI2NGVkODMyZmIvdGFibGVyYW5nZTowZjI2N2VjMWFjYzI0NWJiYTE2OWQ0YjY0ZWQ4MzJmYl8wLTAtMS0xLTgxNzIz_f18887f4-ab28-45c1-98cb-2ce4dc6b2a4d">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the transition period from _____ to _____</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Commission File Number:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;<ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg0_70744e98-7708-42b3-a6fa-f8d0a6f8ead7">001-36296</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg1_f378958b-9ce0-4ec4-ada3-21305b2d5210">Sesen Bio, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6YzNkNjE2NDQ4NmQ4NDgwYTljYTQzMzZjNzk0Njg0NmQvdGFibGVyYW5nZTpjM2Q2MTY0NDg2ZDg0ODBhOWNhNDMzNmM3OTQ2ODQ2ZF8wLTAtMS0xLTgxNzIz_3dfc2601-d90d-4138-80cb-f1fe19f21f91">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6YzNkNjE2NDQ4NmQ4NDgwYTljYTQzMzZjNzk0Njg0NmQvdGFibGVyYW5nZTpjM2Q2MTY0NDg2ZDg0ODBhOWNhNDMzNmM3OTQ2ODQ2ZF8wLTEtMS0xLTgxNzIz_84779fdd-2c6b-4f3e-9cbb-d9a63a3a6ec4">26-2025616</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-bottom:7pt;margin-top:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfNA_b4e3145f-e2b9-49d7-9161-fa3f63860c46">245 First Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfOA_7cc0cddb-3350-4d68-a7b5-fcff2fcea7a6">Suite 1800</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfMTE_8a45c5a5-19d7-4d5b-9b40-666abd9dfc93">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfMTU_197634ef-c03a-4ef2-8b23-6c624ea531f4">MA</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTEtMS0xLTgxNzIz_8f747c97-a03d-4680-9822-23be7f4bbeb2">02142</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8zNTY_e1613a07-b392-4978-ba54-4a24ba0853e3">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg5_667b21e5-4647-48ae-83ac-190d0be498f1">444-8550</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.472%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.472%"><tr><td style="width:1.0%"></td><td style="width:43.325%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.048%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.327%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTAtMS0xLTgxNzIz_848426a3-3a8b-4d88-a969-380ad7b02cb7">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTEtMS0xLTgxNzIz_b76384cf-116c-4aa6-8c19-fa460f06b01b">SESN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTItMS0xLTgxNzIz_9372ebba-3fa3-493a-9ac4-1e516228c66a">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg2_d07fc27e-14ec-4b87-8b39-91c57f8660af">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg3_eeded8d2-4ea0-4828-9636-6ddbc640bea4">Yes</ix:nonNumeric> &#9746; No &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer," &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:11pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:59.166%"><tr><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.343%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18wLTAtMS0xLTgxNzIz_84106c15-2c0c-4650-bc5b-9be139c4da8f">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18wLTMtMS0xLTgxNzIz_68ed8c3b-66b8-4f95-92d9-de337fb26b3b">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18xLTMtMS0xLTgxNzIz_d6d3012a-f4d6-4c41-8923-e53711ffa86c">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</span></div><div style="margin-top:4pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTgz_ccf7e112-72ec-4c3d-823b-9e781cd98563">&#9746;</ix:nonNumeric></span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were <ix:nonFraction unitRef="shares" contextRef="id869177d11624fb384af0cf8700149ba_I20220801" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTE4_37e12830-4fb7-43c9-9c30-ef88128a10e0">199,463,645</ix:nonFraction> shares of the registrant's common stock outstanding as of</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">August&#160;1, 2022</span><span style="color:#661de8;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXPLANATORY NOTE</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. (the &#8220;Company&#8221;) is filing this Amendment No. 1 on Form 10-Q/A (this &#8220;Amendment&#8221;) to amend its Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2022, filed with the Securities and Exchange Commission on August 8, 2022 (the &#8220;Original Form 10-Q&#8221;) solely to include Exhibits 10.1, 31.1, 31.2, 32.1 and 32.2, which were inadvertently omitted from the Original Form 10-Q.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The certification process had been completed and the certifications themselves had been executed prior to the filing of the Original Form 10-Q. Pursuant to Rule 12b-15 under the Securities Act of 1934, as amended, new certifications dated as of the date hereof by the Company&#8217;s principal executive officer and principal financial officer are being filed or furnished herewith, as applicable, as exhibits to this Amendment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except as expressly set forth above, no other changes, modifications or updates have been made to the Original Form 10-Q. This Amendment speaks as of the Original Filing Date and does not reflect events that have occurred subsequent to the Original Filing Date.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quarterly Report on Form 10-Q for the Quarterly Period Ended June&#160;30, 2022</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-bottom:6pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.749%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART I - FINANCIAL INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial Statements.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Balance Sheets as of June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_19">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Comprehensive Loss for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_22">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_25">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Condensed Consolidated Statements of Cash Flows for the Three and Six Months Ended </span></div><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;June&#160;30, 2022 and 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_31">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Notes to Condensed Consolidated Financial Statements</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_34">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_94">26</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quantitative and Qualitative Disclosures About Market Risk.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_115">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controls and Procedures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_118">41</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PART&#160;II - OTHER INFORMATION</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal Proceedings.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_124">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk Factors.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_127">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unregistered Sales of Equity Securities and Use of Proceeds.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_130">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defaults Upon Senior Securities.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_130">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mine Safety Disclosures.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_130">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Information.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_130">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibits.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_133">46</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4adf13376f39486da283bda7a521a795_136">SIGNATURES</a></span></div></td></tr></table></div><div style="margin-top:1pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i4adf13376f39486da283bda7a521a795_13"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements</span></div><div id="i4adf13376f39486da283bda7a521a795_16"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share and per share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:68.050%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.952%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMy0xLTEtMS04MTcyMw_6009ecce-dbfc-4731-9af2-fea3351f3ac6">72,090</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMy0zLTEtMS04MTcyMw_08334ad4-5fed-4ab1-92a2-100563ca7ff9">162,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNC0xLTEtMS04MTcyMw_8fdc0941-6a30-4ad8-9eae-f6c838bbd1b8">69,454</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNC0zLTEtMS04MTcyMw_383ec08c-8625-49b2-a9d8-9b6d63047832">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNS0xLTEtMS04MTcyMw_1c8b9d3c-ffbe-44b2-ad7e-30ecc2f3aeb1">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNS0zLTEtMS04MTcyMw_04e6933a-ccba-4123-a840-c6c1ccb0cb4b">21,011</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNi0xLTEtMS04MTcyMw_bcddac76-36f1-4331-b3a8-3a005444ad6d">14,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNi0zLTEtMS04MTcyMw_818c3578-2204-4b78-96b7-82a4b234515a">3,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNy0xLTEtMS04MTcyMw_aabbe5d6-7fea-4ab3-a257-57a1b216b537">757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNy0zLTEtMS04MTcyMw_e5dfaad6-61f7-48df-98af-28195f05ea36">18,476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfOS0xLTEtMS04MTcyMw_0e898afb-b059-4a84-b5f4-d6ea1c002c0e">156,420</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfOS0zLTEtMS04MTcyMw_fe749af5-c022-48b8-b526-9cd793e5b3f5">205,605</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTItMS0xLTEtODE3MjM_d5d7760d-c401-4e5b-b8d4-60df0882b778">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTItMy0xLTEtODE3MjM_289ea35c-65b0-41a3-912a-3755d01880cd">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTMtMS0xLTEtODE3MjM_86094727-330f-4865-95bc-ee2a0d670a18">19,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTMtMy0xLTEtODE3MjM_0b7e77eb-4129-4fd1-8daf-a33c82a879fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTQtMS0xLTEtODE3MjM_d562dc35-ae50-4cb7-bbf3-97685b846f9c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTQtMy0xLTEtODE3MjM_bbe6c306-503e-410b-8f32-02c0f57f3004">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTUtMS0xLTEtODE3MjM_6b1347ff-fa8b-439a-b25b-0205bd85488f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTUtMy0xLTEtODE3MjM_b78b0caa-2745-4af8-a2ec-a68a054efc4d">14,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTYtMS0xLTEtODE3MjM_9adeab32-5faf-4559-88cd-407a21e6be92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTYtMy0xLTEtODE3MjM_5723c927-3aaa-4141-a5b0-2dddc7f78e93">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTctMS0xLTEtODE3MjM_bebd0b51-952c-4244-92af-a52b1cea832a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTctMy0xLTEtODE3MjM_4d1393ef-7de1-4b36-ad8d-158aa2e7fce0">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTgtMS0xLTEtODE3MjM_1a665764-3af4-4aad-af21-bc6b43ef5f01">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTgtMy0xLTEtODE3MjM_72bb22b6-ce60-4710-b3a9-e08201f2b59d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTktMS0xLTEtODE3MjM_a784b7d6-a33e-46bf-b7c7-d608c8849569">19,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTktMy0xLTEtODE3MjM_389b0875-d1eb-4226-9873-d9d3f82cac92">35,142</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjAtMS0xLTEtODE3MjM_0372b835-16a9-48c2-b705-f797efafd7d4">176,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjAtMy0xLTEtODE3MjM_76709a15-dffa-419d-acd3-468cf35416e1">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjQtMS0xLTEtODE3MjM_542b950d-a2db-43d1-9151-f7b069c1d019">1,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjQtMy0xLTEtODE3MjM_eeaa9191-58a0-4282-9c43-e10a0abf18eb">2,853</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjUtMS0xLTEtODE3MjM_8c11befa-9d03-4d83-83ae-a760b523b596">29,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjUtMy0xLTEtODE3MjM_1814f821-312b-4650-9df8-317bfc7be04f">8,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjgtMS0xLTEtODE3MjM_1fd64ba5-e298-42ad-b6ac-bc82e413cf0e">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjgtMy0xLTEtODE3MjM_59dca2b4-5de6-4624-9de8-fcfe011e2801">460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjktMS0xLTEtODE3MjM_abda99a8-c8c5-4155-9e6c-103fb6ea568f">32,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjktMy0xLTEtODE3MjM_18adf6d7-4cc2-40be-b0f4-6c3c667fe2aa">11,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzItMS0xLTEtODE3MjM_4d389571-f847-4dee-abde-e21ac5de2ef9">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzItMy0xLTEtODE3MjM_a35fe3e7-fe92-41a3-a0d8-38aa99727a8f">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzMtMS0xLTEtODE3MjM_e06e8b04-531d-4f64-afc9-5a4c17e20aa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzMtMy0xLTEtODE3MjM_77826d26-d95e-40a6-a775-deeffb6299ca">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzQtMS0xLTEtODE3MjM_514696d9-7f9d-46a7-a6dd-e24575a5e1cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzQtMy0xLTEtODE3MjM_f75aef45-2ea2-4fe8-ac4e-73b4b7c7f688">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total non-current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzYtMS0xLTEtODE3MjM_6260bc46-7fdd-4c49-bdcc-1ef203b7dbb1">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzYtMy0xLTEtODE3MjM_f15e4ef4-3aec-4d5b-b42a-8fe717067e22">57,469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total Liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzctMS0xLTEtODE3MjM_29082eff-26b5-436c-90d9-dbe0ca6a149b">33,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzctMy0xLTEtODE3MjM_fa68336e-d905-4bfa-88a7-e013504f36a5">69,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; Equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF8yMQ_4059875c-e9ee-40ac-af05-3a92bac1ff02"><ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF8yMQ_e063d2cc-b846-4dd0-930e-b5194a2169e2">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF80NQ_6080b51e-ca1e-4ba4-9ede-4b40c95b23c2"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF80NQ_a347d7f2-c80d-4646-80ff-4b32359b6a78">5,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_2662d5c2-e437-4645-91a5-5f7a1918f7db"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_349e5195-bd0e-4c8d-9d3c-8a7eadc1f4cd"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_ba49e03a-cc6c-4709-99dc-a3f597bbae0b"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_c2bdefdc-8303-44e2-becd-0804d7e4e581">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMS0xLTEtODE3MjM_fa72f0b8-4ca7-412a-8e57-f33554cff25d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMy0xLTEtODE3MjM_14676be3-95c7-41fd-827e-c91195ee9a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:30pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV8xOA_3303f3af-21c9-4d1d-b7b9-3960be5f4d8d"><ix:nonFraction unitRef="usdPerShare" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV8xOA_cea24c3e-c310-4f34-b212-58639d5edcba">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV80Mg_6d3a05cc-ad1d-4715-ba55-852c2378b4b9"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV80Mg_9a5ac7ac-5e99-48ea-8a82-beeec1990818">400,000,000</ix:nonFraction></ix:nonFraction> shares authorized at June&#160;30, 2022 and December&#160;31, 2021; <ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_198d36f4-c41b-47e7-8f2d-ead81d882589"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_59ee66e1-578d-41a5-ac01-328c48f2bca6"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_ac13c67b-d492-4127-8da5-90dd401a8228"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_f214229a-3fab-4d62-be72-778a8cb946fd">199,463,645</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMS0xLTEtODE3MjM_5f59aa7f-d5d0-4fc5-9dc4-990be1b2cd9f">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMy0xLTEtODE3MjM_197e4f30-745b-47f0-b867-490e58e01225">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDItMS0xLTEtODE3MjM_58fe40ab-0e9e-4af0-a24f-a02d7842ca7b">491,464</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDItMy0xLTEtODE3MjM_e24d419e-e0cd-4f46-bfec-f79b5cb62044">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDMtMS0xLTEtODE3MjM_cf61a00c-5c10-4fc9-bd89-9692682beb42">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDMtMy0xLTEtODE3MjM_2645ce12-d778-46f2-b9f7-553bc2009f6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDQtMS0xLTEtODE3MjM_9bdab8f1-75db-4aea-b642-023c4386eff1">349,024</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDQtMy0xLTEtODE3MjM_67014757-7858-4650-8955-2309e8d22293">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stockholders&#8217; Equity </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDUtMS0xLTEtODE3MjM_41439625-f97b-441b-9d0d-fbb0bf627787">142,358</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDUtMy0xLTEtODE3MjM_bd08f432-efe5-4cd7-81fb-82b587bef1ad">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDYtMS0xLTEtODE3MjM_8aad2806-a9d4-44d4-9edb-32666ed9181a">176,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDYtMy0xLTEtODE3MjM_cf68f67a-e0c1-463d-8058-94ae12db1ae4">240,747</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_19"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:55.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_4947fedc-4360-4141-b0e3-0237b2c47548"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_c6767d49-0588-49f3-8fff-685b494e5363"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_d6497809-9e60-4366-b51d-775001f6d3f2"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_dffcdb59-fa88-4ed6-aabc-b93cd31c5568">License and related revenue</span></span></span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0xLTEtMS04MTcyMw_fc56402c-e593-4bd1-b595-a8bbdcc18381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0zLTEtMS04MTcyMw_d35e22d8-27f5-4c7e-b103-2f29f040183c">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC01LTEtMS04MTcyMw_699d96ab-6684-4426-8827-48393666f99d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC03LTEtMS04MTcyMw_8bc89500-3124-4619-b8fa-a7423b64d00b">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS0xLTEtMS04MTcyMw_6cccf768-6155-404b-b85c-db2581bb570c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS0zLTEtMS04MTcyMw_512e5dbf-d56e-4ed2-97f9-938ba26b70ea">2,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS01LTEtMS04MTcyMw_bde54e0d-299f-46fb-9689-5f4fd2bee12d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS03LTEtMS04MTcyMw_cdc1e193-f820-4285-9490-9a99b68df3d0">6,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC0xLTEtMS04MTcyMw_b4c2b69c-3347-4e0b-93a2-b4eb1e068f1d">29,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC0zLTEtMS04MTcyMw_2067611f-32c4-419b-863e-fd41b295fa4c">7,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC01LTEtMS04MTcyMw_1fb3eb2c-d373-492d-985e-8e957d75af48">34,705</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC03LTEtMS04MTcyMw_c0e63241-5b30-435a-a8be-59f0f59917e6">13,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS0xLTEtMS04MTcyMw_316e55e8-7e02-4cef-8c03-e8970d34e913">15,589</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS0zLTEtMS04MTcyMw_79006e83-5f80-4247-88ad-6738145509d2">6,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS01LTEtMS04MTcyMw_57d16276-f41a-4c99-a095-135926619700">24,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS03LTEtMS04MTcyMw_7825db19-393c-42fc-af8e-a465bbe8c81f">12,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtMS0xLTEtODE3MjM_a522af7b-e0f8-4fef-9e47-a5625b9a1970">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtMy0xLTEtODE3MjM_5d97468a-716c-475d-8f69-e6234d06ec2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtNS0xLTEtODE3MjM_79ba8ecc-859e-40ec-bbe4-46e9e4613be3">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtNy0xLTEtODE3MjM_94892cfd-3a93-4477-bd9f-ab008a7d9e2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItMS0xLTEtODE3MjM_d6e9fe3f-62ff-409d-900a-99c3550eb20a">37,300</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItMy0xLTEtODE3MjM_09997eb4-ef4b-4742-82e8-4d79bf577b09">13,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItNS0xLTEtODE3MjM_5b50f1d8-eb29-4e47-8274-d8e3894f1222">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItNy0xLTEtODE3MjM_3df30173-5e52-465e-8ec9-8ffe8207308b">61,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtMS0xLTEtODE3MjM_1f3e120e-1044-4b46-af8b-4179d302db38">35,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtMy0xLTEtODE3MjM_a779ccd7-2a7b-4a41-a3b1-fa39adf827f7">27,633</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtNS0xLTEtODE3MjM_a14a447b-c6c8-48ac-9f98-eb49aabc12c1">36,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtNy0xLTEtODE3MjM_715da502-a6bd-44b9-a402-6b6f97099aaf">87,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtMS0xLTEtODE3MjM_33f5e542-4691-4cb3-8cf9-0e661be77a8f">35,997</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtMy0xLTEtODE3MjM_6ab40c9f-9b8c-4d91-829e-e62006eff5b8">25,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtNS0xLTEtODE3MjM_777e2954-6103-4355-8f95-b75a7234a328">36,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtNy0xLTEtODE3MjM_f4b3c8c3-0dea-4f9a-9357-7a9497ef5237">80,620</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtMS0xLTEtODE3MjM_53959149-1852-40f8-b414-1fded076c749">162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtMy0xLTEtODE3MjM_09cfeb90-6c0d-4361-aa3c-0c288c01d5fd">43</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtNS0xLTEtODE3MjM_d2fdfdee-720e-4cbb-9ce4-6e85036911b7">191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtNy0xLTEtODE3MjM_b6f2d5ed-288a-4958-bc4c-e5bee97cd09d">46</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctMS0xLTEtODE3MjM_3e2bf00e-1581-47d0-aa9e-54661c72421b">35,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctMy0xLTEtODE3MjM_8afe3cbb-c2de-4fd3-9420-b7231e80c5e7">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctNS0xLTEtODE3MjM_4809017e-8d06-4ae5-9ab1-1a5091ed5260">36,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctNy0xLTEtODE3MjM_00e2190c-51f5-48a4-8f5d-002c94569754">80,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtMS0xLTEtODE3MjM_58f4ef59-13c4-4e21-b72f-c71e008858e8">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtMy0xLTEtODE3MjM_b2be0dfe-f187-409a-ac4f-02647d46f0e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtNS0xLTEtODE3MjM_c6978148-fd68-4edc-bab1-f8570589b22b">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtNy0xLTEtODE3MjM_7f3fd4d4-d45e-4ed6-915c-1ea0b20f3f99">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktMS0xLTEtODE3MjM_fe7f404a-1e3c-4e26-bb68-c3b2c0c9975f">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktMy0xLTEtODE3MjM_33ec3c13-ffd7-4c7a-aed2-b7b066e95e32">25,442</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktNS0xLTEtODE3MjM_1ac6e617-3b30-47b6-8cfb-bd764e6654e6">32,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktNy0xLTEtODE3MjM_90ef1be6-9521-4ce5-b9c4-b8dbd8d4a71b">80,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders - basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMS0xLTEtODE3MjM_a7ecb888-7f72-4599-b48c-4113f868e0e7"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMS0xLTEtODE3MjM_dd51984a-ee5d-4e18-a43e-7429232aa180">31,960</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMy0xLTEtODE3MjM_65cb7dec-92a5-4b30-9d42-fd488561bc93"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMy0xLTEtODE3MjM_69861aa4-3f17-4b98-b434-e57325879ccc">25,442</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNS0xLTEtODE3MjM_2ebbc695-fc52-4dd0-8dba-18301af192a9"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNS0xLTEtODE3MjM_f7d35c01-47a5-4b5f-bddc-edd9f6b77b56">32,767</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNy0xLTEtODE3MjM_226ba156-dedb-4cd3-88f9-695b5a923fc4"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNy0xLTEtODE3MjM_a2e30ad0-a34c-48d3-b4fe-3f4c584703d9">80,954</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share - basic and diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMS0xLTEtODE3MjM_37ff3b59-ceab-4dec-81f4-4561ca9494c4"><ix:nonFraction unitRef="usdPerShare" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMS0xLTEtODE3MjM_87becfb5-0922-4a44-9ee7-3817b8922042">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMy0xLTEtODE3MjM_8676b4de-5249-43b2-8f8a-932967756bb0"><ix:nonFraction unitRef="usdPerShare" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMy0xLTEtODE3MjM_cbc8451f-bb34-4866-b62f-a89624f83669">0.15</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNS0xLTEtODE3MjM_1f765df5-99cd-46b7-86e3-5b727ea68121"><ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNS0xLTEtODE3MjM_86863cab-94c6-4c37-a059-d505c1883b47">0.16</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNy0xLTEtODE3MjM_bf0fd9c1-f493-44f4-b4d1-e990ab6787c4"><ix:nonFraction unitRef="usdPerShare" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNy0xLTEtODE3MjM_e23df7ea-02ee-450f-ad10-f3204d68f173">0.49</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding - basic and diluted</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMS0xLTEtODE3MjM_10dede7e-ba33-434c-89cf-db1359ec4995"><ix:nonFraction unitRef="shares" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMS0xLTEtODE3MjM_80fd4f08-5fb7-4f8d-96c6-63de974315f0">199,464</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMy0xLTEtODE3MjM_1bf2c2bd-dd29-41d2-8100-ca2cd53fe288"><ix:nonFraction unitRef="shares" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMy0xLTEtODE3MjM_49bb69b7-38e7-4d26-8fe9-70a7c70bf56f">175,393</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNS0xLTEtODE3MjM_2bc5e500-ed1c-4091-bd87-6a1396d5362f"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNS0xLTEtODE3MjM_d8c8cdf7-3db1-45ae-8f36-5f4b58703860">199,464</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNy0xLTEtODE3MjM_aa77e433-5bed-4b3f-adb1-0990b90fcd81"><ix:nonFraction unitRef="shares" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNy0xLTEtODE3MjM_cea0d19e-c030-44c0-b6f3-6c2573f4e788">166,264</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except per share data)</span></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.391%"><tr><td style="width:1.0%"></td><td style="width:55.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.988%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.152%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.157%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy0xLTEtMS04MTcyMw_b85c5bd4-6fbc-4ed3-a88f-3b32264af7f0">31,960</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy0zLTEtMS04MTcyMw_a21285b3-b464-4790-bce4-ee8507960450">25,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy01LTEtMS04MTcyMw_fa45bf98-862b-47cf-a9b4-93c237c63a49">32,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy03LTEtMS04MTcyMw_83d3bfd3-eea8-424d-99be-7d8b8495d8ee">80,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC0xLTEtMS04MTcyMw_1302d74c-50b3-47b2-8dbe-a949f0c35a53">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC0zLTEtMS04MTcyMw_1ebd35fe-cf5f-4546-b001-52d412bc6c83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC01LTEtMS04MTcyMw_2fd4d84c-698c-44b4-8908-03089b6f55fe">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC03LTEtMS04MTcyMw_a46b3559-27d0-4ac8-a4ef-973c4bcbd0b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS0xLTEtMS04MTcyMw_111bf465-6537-432a-ad86-06a3e12e2397">32,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS0zLTEtMS04MTcyMw_469c39d8-c46c-41ad-88a3-cdb41f00b4a3">25,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS01LTEtMS04MTcyMw_e369e6f6-7196-4527-8cbb-defbee927301">33,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS03LTEtMS04MTcyMw_02eff8ad-b1b6-4d82-9cb2-60608727b74c">80,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands, except share data)</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.215%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.334%"></td><td style="width:0.1%"></td></tr><tr style="height:35pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Investments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders'<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0888396debb34c04a3b1ce7017d15b49_I20211231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0xLTEtMS04MTcyMw_5c1c56f3-3e61-4b81-a198-ae8618bb1cad">199,463,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0888396debb34c04a3b1ce7017d15b49_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0zLTEtMS04MTcyMw_f1c16c80-b20a-4543-b318-d38a706f63d5">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e2dde9a518a491ebd8912a185f23cd6_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi01LTEtMS04MTcyMw_c08b9f27-5b5b-46eb-ae3e-ab8cbb46bed0">487,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dfef576366a44c8899c23968e5a7571_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi03LTEtMS04MTcyMw_036a5bb5-67ed-47be-89d2-d934addfb213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e31cbf599b140739ed935ff1dd609b8_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi05LTEtMS04MTcyMw_ff2f580e-76f3-45f7-a680-3a292384cd84">316,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0xMS0xLTEtODE3MjM_b28cabd7-1c84-4e2a-aafa-ff8ae7565f79">171,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9495f0a57df45ff8db57ca5375f6705_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMy05LTEtMS04MTcyMw_c84e290c-76e5-42a5-9802-3963d747b8b1">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMy0xMS0xLTEtODE3MjM_72f93ea8-7a11-4796-bd71-686684259eff">807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64fafc918b1a455ea5d13849a58f83dc_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfNC01LTEtMS04MTcyMw_d466adbc-5545-49d7-8dd2-e539d329c6ed">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfNC0xMS0xLTEtODE3MjM_ed4d92bd-ea8d-4eed-88b0-e7cffb124412">1,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMS0xLTEtODE3MjM_1f36d076-b725-4b9e-a6a7-15d003a4fde0">199,463,645</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMy0xLTEtODE3MjM_bcb4eec0-5d2d-4669-b6e8-bf32a9448849">199</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0975aa547f74b7a9de06d3efa3be13c_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtNS0xLTEtODE3MjM_1f526ecc-a286-4630-be6b-f67badfe4e62">489,662</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibad650e0476f4f16801d09e1becece4e_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtNy0xLTEtODE3MjM_1a83ba40-5aeb-43bc-8df1-6970023c2094">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib01a1af0204e41fd93a01011d3d198fa_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtOS0xLTEtODE3MjM_59799335-43a1-45f5-aa93-07f3558ae6cc">317,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14a46440132b42f0b7fa05821b7ebc4f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMTEtMS0xLTgxNzIz_c3552eb7-ff71-4f27-a20f-05feec4182e9">172,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5de9e1ce23744a739794e84c9513c251_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTEtOS0xLTEtODE3MjM_ac33ea04-6029-47cd-b303-8cd63352e3f6">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTEtMTEtMS0xLTgxNzIz_52cae8d1-14b4-4a38-9e67-906e2adddbb1">31,960</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2011e9ea8d46969474d1ff815da0fb_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTItNS0xLTEtODE3MjM_486f22a4-a597-4a55-aa4c-34eb475cfd20">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTItMTEtMS0xLTgxNzIz_886660f2-4dc6-4241-985c-3fdb90a387e6">1,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if5212a49218248398de938ab0ff078dc_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTQtNy0xLTEtODE3MjM_6d05a181-b037-47a8-9b3f-702eec4dc305">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTQtMTEtMS0xLTgxNzIz_e51eda34-5c1f-481a-ba94-bdcb05e5b0c1">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idad59db36cee439984f3d4ad8b4fb9b5_I20220630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMS0xLTEtODE3MjM_3ceeda3a-0ad2-447c-b0f9-5b2bd05dc381">199,463,645</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idad59db36cee439984f3d4ad8b4fb9b5_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMy0xLTEtODE3MjM_5d1dad8b-061f-46e2-ba2c-8161b3eba43c">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic947583800d54749af298a1e2b9bc920_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtNS0xLTEtODE3MjM_b2c692db-4756-491d-81eb-242e3f081575">491,464</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2ee39dd3da244ec9bcff222871e71116_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtNy0xLTEtODE3MjM_7024a01f-19a0-44fe-8f53-3ca032b33f0f">281</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i117a5180e4eb4c3391864589aa813213_I20220630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtOS0xLTEtODE3MjM_c01b2ce0-6cae-4e0f-b601-afa01267a821">349,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMTEtMS0xLTgxNzIz_c051006f-8e64-4e08-934b-d1fe8e99ae24">142,358</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:38pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:35pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss Investments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7012d9b8cefc416d86192851d3aa476f_I20201231" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMS0xLTEtODE3MjM_3cb06925-fc91-4f12-af15-b094a805aa9e">140,449,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7012d9b8cefc416d86192851d3aa476f_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMy0xLTEtODE3MjM_9ab699f9-851b-4b2c-961e-d84ce179c03b">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i171789775ea34e329cab101dfc95862e_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktNS0xLTEtODE3MjM_81864bc5-f243-40c1-88bd-293158fcf64c">306,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b5d4ce18c0f4291b85fddcf3869fa34_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktNy0xLTEtODE3MjM_198a192c-5345-4c8e-841a-afd3a3fa58d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idea9cc2fd581441895f394010022516a_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktOS0xLTEtODE3MjM_00df8e85-1d26-4200-9a90-53cd111b350a">315,921</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMTEtMS0xLTgxNzIz_fff444a9-386a-4da6-9d97-129ab2bb1715">9,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52eaa414326e448c937bf26df0576971_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjAtOS0xLTEtODE3MjM_b721e70a-7961-4fcc-8124-90d4c161c2a9">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjAtMTEtMS0xLTgxNzIz_b468d738-b533-4069-bee3-c6d6ac8c44e3">55,512</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjEtNS0xLTEtODE3MjM_1d8ae17b-0f08-42c8-a92b-08313e70574c">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjEtMTEtMS0xLTgxNzIz_9f0b85ba-fe4a-41de-a9e7-cbe26f2f7492">958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItMS0xLTEtODE3MjM_43781a60-cca0-4578-a74c-e27b01f22eda">30,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItNS0xLTEtODE3MjM_8a4b1c4b-ab90-44ba-98a4-6b00fb368dd2">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItMTEtMS0xLTgxNzIz_002fde59-dfda-4016-8b2c-c1f81dbe5ca9">39</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercises of common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331" decimals="INF" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMS0xLTEtODE3MjM_b02ca74b-dee2-4ada-a721-1e8c51a3f56a">852,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMy0xLTEtODE3MjM_5356104b-6e0a-4809-87da-0762e7da7c79">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtNS0xLTEtODE3MjM_0b6d61f8-436a-4725-b47f-ef8ae1c9e9d9">468</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-3" name="sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMTEtMS0xLTgxNzIz_366e294b-1b7c-4295-bd25-ef1c8dfe4bd8">469</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjowZmQxMWY0Y2JlZTg0ZGI3ODI5ZTRmNTgzOTlmZTgxNV83NA_f39c04a2-6313-492f-aad1-c51af333f4e0">2.2</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i30af2746204648089c84cb29d5101717_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMS0xLTEtODE3MjM_f379640b-1efe-42c7-8e72-98cdfe760865">30,645,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30af2746204648089c84cb29d5101717_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMy0xLTEtODE3MjM_b46920e7-62de-4e68-8825-133390f6976e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib30024337b1546b7bd2a070c42de470b_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtNS0xLTEtODE3MjM_15f032c3-42a3-4931-ad29-b3a751d3047f">72,512</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMTEtMS0xLTgxNzIz_c32030b7-56d2-41b7-8e72-e8d20a75491d">72,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dd0f583a45649359ab4f630a2d1d044_I20210331" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMS0xLTEtODE3MjM_fd83e970-d6b2-4b8b-a3ff-2058e90a2cc7">171,978,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd0f583a45649359ab4f630a2d1d044_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMy0xLTEtODE3MjM_989424ec-67f5-4a51-8f43-2277e2a2ed7a">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb92ef2739448ac91cb470697a88bf3_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtNS0xLTEtODE3MjM_3980454b-7a31-44f2-99d6-ddc57b280ff0">380,531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d04fd3863f8493db4c151a0f56ee9f6_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtNy0xLTEtODE3MjM_16d0c79d-57df-4e71-a4cb-8f97a78996fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9147fb1c8cf34577b359bd45f28c4a7c_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtOS0xLTEtODE3MjM_3cb0c232-7ba1-4b2e-be58-f423a09d7ffc">371,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b387a8bf0243d9b0d1e9d51425a534_I20210331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMTEtMS0xLTgxNzIz_07eb9872-dc7e-4ba3-a80f-8d981e6fdcaf">9,270</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i732a7b94c2394e6caed25b643f1504ce_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjctOS0xLTEtODE3MjM_fa861e63-a954-451e-9fb9-631a48ad152b">25,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjctMTEtMS0xLTgxNzIz_636f346e-68c8-4181-a68c-66133d2dbabe">25,442</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae31b43c606e4c19b17a44b2508f083c_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjgtNS0xLTEtODE3MjM_bf9e283d-cde1-433b-b7a5-3ef28a9e2ea7">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjgtMTEtMS0xLTgxNzIz_2df8ce6d-236d-4771-a2f6-be4e71157bbd">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under ATM Offering, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjpiY2VhNGFiZDE4MjE0OTkyOGEyZjFhNTczYzFiOTY4OV83NA_09807cce-54e8-40d3-8245-c32b54770d1a">2.0</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i62880df550724456b3e687c3c6d85445_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMS0xLTEtODE3MjM_7db6c369-3e8a-4bca-a4ab-115485fe2a2f">16,482,152</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62880df550724456b3e687c3c6d85445_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMy0xLTEtODE3MjM_f74e4c10-c873-491a-8309-6aa1ff3ba744">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73c2ea2a03e7419a8e4196a69096b610_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktNS0xLTEtODE3MjM_31f0552f-b96a-41fb-8cc4-caf44ecfc43a">64,245</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d7821756c804d898a7d8834c7925d7c_D20210401-20210630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMTEtMS0xLTgxNzIz_23c292e7-62f9-46da-b74a-796e678b4eb8">64,261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7984a6629ab74eb390c3df7ff75f05d2_I20210630" decimals="INF" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMS0xLTEtODE3MjM_09fdf3ce-7cb0-47ad-87cf-50febb92c6bf">188,460,951</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7984a6629ab74eb390c3df7ff75f05d2_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMy0xLTEtODE3MjM_61cf431d-3067-4f9a-8ad3-8edba15da0ab">188</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0cd0bb43b0ee429f964e6eb8b8925e53_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtNS0xLTEtODE3MjM_99d5504c-4062-4ea5-81ac-c9329f7f9180">446,036</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad1dbbda2c1f497da6b3ad0608eb76ac_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtNy0xLTEtODE3MjM_d87e1f30-39f2-4128-92a1-56358a699fb8">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib07c0124fe234223a9d340e9c94f5559_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtOS0xLTEtODE3MjM_e2fa46b9-62fa-42f2-92c6-997aabb942fc">396,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407298c7856d4211867c26d5eaa28887_I20210630" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMTEtMS0xLTgxNzIz_4b075887-68d5-4a20-b348-23ff50e92229">49,349</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited; In thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:68.636%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Operating Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMy0xLTEtMS04MTcyMw_91482af7-407b-4b62-b042-f0b84303c905">32,767</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMy0zLTEtMS04MTcyMw_c99c693a-8a14-4ef6-b6dc-f9d8ac466d8a">80,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNS0xLTEtMS04MTcyMw_35bf9865-ad4e-4a73-a3c6-8708ef25520a">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:DepreciationAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNS0zLTEtMS04MTcyMw_9767d5f3-3144-47e4-82a7-9de428ecdf19">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNi0xLTEtMS04MTcyMw_2062b0d5-4b9f-4728-af55-ad5802bc819a">3,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNi0zLTEtMS04MTcyMw_c0b6d58e-03da-4fc5-a126-2aa71d9c7f57">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNy0xLTEtMS04MTcyMw_5b50f1d8-eb29-4e47-8274-d8e3894f1222">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNy0zLTEtMS04MTcyMw_3df30173-5e52-465e-8ec9-8ffe8207308b">61,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfOS0xLTEtMS04MTcyMw_a7112dc6-5ae6-4c5e-9ad9-abefcb1025c3">27,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfOS0zLTEtMS04MTcyMw_150e7df0-0745-4a07-b44c-ce68efe54f2b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable (net)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTEtMS0xLTEtODE3MjM_27e954b8-d557-476c-aadb-7042d1c8f693">20,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTEtMy0xLTEtODE3MjM_0e3b23b6-3151-4f01-989d-dc8136db8d06">2,303</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTItMS0xLTEtODE3MjM_42b1f87c-d071-42f3-863e-7bd0fe3cf5b2">10,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTItMy0xLTEtODE3MjM_b1f1e929-6601-4382-91ec-e7a885ae9470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTMtMS0xLTEtODE3MjM_eea1198a-6d7b-4207-9da9-565970849495">17,719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTMtMy0xLTEtODE3MjM_c8c5923f-5dd4-4cd2-adc3-573566e425b2">20,287</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long term prepaid expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTQtMS0xLTEtODE3MjM_18104084-24d2-45d7-8791-69e74f16bb14">7,192</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTQtMy0xLTEtODE3MjM_a2144cd7-3914-4ad5-8d46-9b05e6dfb3e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized loss on marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTUtMS0xLTEtODE3MjM_0ab71139-8ed9-4e6b-b003-20faf406c46d">281</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTUtMy0xLTEtODE3MjM_f6e40e52-7f16-45b5-9178-ced608f8697c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTYtMS0xLTEtODE3MjM_6f983dec-b906-4334-9896-7228ce87c5ff">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTYtMy0xLTEtODE3MjM_27ff555b-c9f5-4395-8957-037a1d4e8a4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTgtMS0xLTEtODE3MjM_b7c09cae-7e9c-44c4-8014-8ae9e7c1b407">1,186</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTgtMy0xLTEtODE3MjM_94d4c040-df65-4da9-922d-37758f331a8b">1,875</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTktMS0xLTEtODE3MjM_06b5e5f1-2960-4ffc-9270-f2b3a76f9963">17,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTktMy0xLTEtODE3MjM_0278beeb-fc7b-4040-a5fa-7b67dbb5f6ee">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjAtMS0xLTEtODE3MjM_4db5b460-f902-4027-870a-2b5a918b14d2">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredRevenue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjAtMy0xLTEtODE3MjM_25bf5958-5988-493a-850d-b1e8c57b0d6d">1,500</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjEtMS0xLTEtODE3MjM_571aecfc-a7fd-428d-b9af-09c7a84be936">1,441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjEtMy0xLTEtODE3MjM_199d137a-db86-42d7-9188-da48fd0774ca">41,616</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Investing Activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjMtMS0xLTEtODE3MjM_773eb765-a069-418b-9c28-1ac588ff0cd8">89,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjMtMy0xLTEtODE3MjM_43a8d699-4263-469c-b18a-9ee47e7e7660">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjQtMS0xLTEtODE3MjM_572da9c3-d4b1-41be-9ce5-4490dd74b4ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjQtMy0xLTEtODE3MjM_5f397494-b047-40ff-b0d2-19ed70ccd63a">49</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjUtMS0xLTEtODE3MjM_0438b914-745c-4e93-9d21-1ac62b3d5682">89,095</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjUtMy0xLTEtODE3MjM_19fcf548-6d28-46f9-b52f-b704eccd5dbb">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash Flows from Financing Activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under ATM Offering, net of<br/>issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjgtMS0xLTEtODE3MjM_2c44593e-cfb2-49a8-828c-48aa1d50aeb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjgtMy0xLTEtODE3MjM_1402dc93-f03a-4925-b667-5e3d4e036257">136,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjktMS0xLTEtODE3MjM_35b7c83e-afcb-4114-9543-801a74f1b7e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjktMy0xLTEtODE3MjM_61a53bb6-8893-4223-a0ae-20f3d158a3f2">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from exercises of common stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzAtMS0xLTEtODE3MjM_89a6f47b-297c-4631-b75e-0f86c21ab8e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzAtMy0xLTEtODE3MjM_18e401c0-be51-4327-a0e5-99996961a009">469</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 55pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzItMS0xLTEtODE3MjM_2e5c2623-2add-4533-a0f1-98a063716758">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzItMy0xLTEtODE3MjM_b37eae9b-addd-467a-906e-9cbb25722117">137,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzMtMS0xLTEtODE3MjM_a62c0763-e2d5-490c-a872-ec7f0051a1d1">90,536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzMtMy0xLTEtODE3MjM_f44595d5-9463-4fcc-a2b4-177407be17a1">95,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzQtMS0xLTEtODE3MjM_76f2f48f-546c-46bd-8708-5ee2e0b9b348">162,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzQtMy0xLTEtODE3MjM_3d55db99-1beb-4242-a3f2-f7e4a2b44ab1">55,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash - end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzUtMS0xLTEtODE3MjM_7b54b84f-d6c7-425f-8a54-018feedb12d4">72,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i407298c7856d4211867c26d5eaa28887_I20210630" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzUtMy0xLTEtODE3MjM_9e02a8c5-f1c9-493e-9669-4d44b79c4b85">151,056</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental cash flow disclosure:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzgtMS0xLTEtODE3MjM_8613229b-f40a-4d22-9e70-7db152dadfe8">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzgtMy0xLTEtODE3MjM_94b42cc8-2609-46dc-81de-228ac76b7c86">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchase of equipment included in accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNDMtMS0xLTEtODE3MjM_349de866-be4a-4dc5-be11-bb8ed194e3c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNDMtMy0xLTEtODE3MjM_19c1b197-a897-4fa9-a3d8-906c91c55d1e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SESEN BIO, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Unaudited)</span></div><div id="i4adf13376f39486da283bda7a521a795_37"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:NatureOfOperations" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNjE1OQ_3a4da1a7-cb35-4f09-929d-f55388a79bae" continuedAt="ib2bebbda73274f329ce4fa56e0b437e6" escape="true">DESCRIPTION OF BUSINESS</ix:nonNumeric></span></div><ix:continuation id="ib2bebbda73274f329ce4fa56e0b437e6" continuedAt="ie0710081dd66470cb8c1ffe511ef75a3"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued <ix:nonFraction unitRef="shares" contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930" decimals="-5" name="sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDA1OQ_34c58e8f-9dac-4c5b-91c8-47dbbd956bb1">4.0</ix:nonFraction> million shares of its common stock to the Selling Shareholders, which at that time represented approximately <ix:nonFraction unitRef="number" contextRef="ief96b00f443a4686a885891ec4c615be_I20160930" decimals="3" name="us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDE2Mw_6790b9cc-40e1-40fc-a174-281707775d00">19.9</ix:nonFraction>% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i19de5e3ec9b24f1ea8494afb290825f1_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDYyMg_453e191c-8409-435a-a1e2-73dcbf10851f">12.5</ix:nonFraction> million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i826b000227f54693aaaf1920a6d1aa63_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDc1MQ_8938e287-be9a-4fbc-8d67-0d6e43211b64">7.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i0f56438c3aeb45edb4022475af4e3db5_D20160901-20160930" decimals="-5" name="sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDg5Nw_cfcc1774-b265-4a98-8a24-a9b2a79d973a">3.0</ix:nonFraction> million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to <ix:nonFraction unitRef="number" contextRef="i4a90ce4acc1b4bf68182efbf79fd5720_D20160901-20160930" decimals="2" name="sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTAwOQ_407e3e56-b2cd-45e5-8538-7e15f6b077a8">2</ix:nonFraction>% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) <ix:nonNumeric contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTI3Ng_4740635d-a8fc-416f-8beb-982410f598b8">fifteen years</ix:nonNumeric> after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first <ix:nonNumeric contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930" name="sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTU5MQ_1350e039-e384-4f97-9cf5-93cd3528cc31">seven years</ix:nonNumeric> following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie0710081dd66470cb8c1ffe511ef75a3">became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.</ix:continuation> </span></div><div id="i4adf13376f39486da283bda7a521a795_40"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:BasisOfAccounting" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1OA_8939b86e-ff98-4372-9e54-609d031cae72" continuedAt="if1b920ece45f4eedbcb86a58ba83917d" escape="true">BASIS OF PRESENTATION</ix:nonNumeric></span></div><ix:continuation id="if1b920ece45f4eedbcb86a58ba83917d"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1NQ_243ab476-c381-4d36-bab5-cbc692c465e7" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1Ng_3226f22f-8142-48a6-8e5d-a627a0e47796" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1Nw_43a52c32-8f1c-429f-aaeb-e6064e25efd8" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div></ix:nonNumeric></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_43"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80My9mcmFnOmZmZmJiMjg1YTJiMzRlMzE5NmFhMGI5ZDNhMTRjNzVkL3RleHRyZWdpb246ZmZmYmIyODVhMmIzNGUzMTk2YWEwYjlkM2ExNGM3NWRfMzYw_eb5f5067-45e0-4b13-ae55-8180861b049b" continuedAt="ic3fb325431db4111b8489dfcdf8d29fe" escape="true">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic3fb325431db4111b8489dfcdf8d29fe">The Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</ix:continuation></span></div><div id="i4adf13376f39486da283bda7a521a795_46"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80Ni9mcmFnOjJjYjVlZjcxNWY2ODRlMmE4MjAxZjdmNjQzZWZjOGI4L3RleHRyZWdpb246MmNiNWVmNzE1ZjY4NGUyYTgyMDFmN2Y2NDNlZmM4YjhfMjQ3Nw_da8e4a19-ba63-4c14-82e7-71502695f21f" continuedAt="ie2ecb840d253461d9526e7aca58ac45c" escape="true">RECENT ACCOUNTING PRONOUNCEMENTS</ix:nonNumeric></span></div><ix:continuation id="ie2ecb840d253461d9526e7aca58ac45c" continuedAt="i5bcadb34714745a49ec4b9450ff88f8c"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80Ni9mcmFnOjJjYjVlZjcxNWY2ODRlMmE4MjAxZjdmNjQzZWZjOGI4L3RleHRyZWdpb246MmNiNWVmNzE1ZjY4NGUyYTgyMDFmN2Y2NDNlZmM4YjhfMjQ3Ng_258defce-7aa2-4262-bf57-2cecb8bf5687" continuedAt="i8cd5a7d3ce1142b2b79a5f67ee6c6559" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i5bcadb34714745a49ec4b9450ff88f8c"><ix:continuation id="i8cd5a7d3ce1142b2b79a5f67ee6c6559"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div></ix:continuation></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_49"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExNw_cccf1ea1-acff-4f5f-9b0e-8b5d723862ef" continuedAt="i8ab7ad892e49476cb9c7b737b5bd5935" escape="true">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ix:nonNumeric></span></div><ix:continuation id="i8ab7ad892e49476cb9c7b737b5bd5935" continuedAt="ie18d6670fdc44a2490c5c0ee5de3855f"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExOA_dca8b190-6623-490c-9b08-a8b44aa8e88a" continuedAt="i0dc1719edd134310b736a41f99852703" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div></ix:nonNumeric><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><ix:continuation id="i0dc1719edd134310b736a41f99852703" continuedAt="i6cccf8f5a7b5434ab945677c96bb19fd">Level 3</ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6cccf8f5a7b5434ab945677c96bb19fd">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.</ix:continuation> </span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExOQ_e0f8c4b4-d54a-4648-b18c-ee52a851e0c7" continuedAt="i932a5de3989e4856b6f6745ec3a56a45" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b74714225f4d449b61808db2c2c804_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS0xLTEtMS04MTcyMw_1e7e920c-5e79-4f0f-9770-62dad22e7998">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS0zLTEtMS04MTcyMw_18e24ef0-9d22-4996-aefa-6bf9887273c7">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS01LTEtMS04MTcyMw_2d3bcdcb-7c0a-4a3a-a57b-49516da3981c">40,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS03LTEtMS04MTcyMw_7e1a192f-645a-469e-8b7b-711d0fd8e891">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS05LTEtMS04MTcyMw_10c4bd09-1a60-42a1-90fa-055e101b90ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b74714225f4d449b61808db2c2c804_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi0xLTEtMS04MTcyMw_4755a319-9135-4527-a21a-686e4ad16a8e">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi0zLTEtMS04MTcyMw_36b5ab70-a8f0-4d7b-9562-1bd0aa905804">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi01LTEtMS04MTcyMw_d6d7d627-6caf-4298-aaeb-c2a31e21457f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi03LTEtMS04MTcyMw_bb56c8b8-6290-4cd8-9002-aa147c592d78">89,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi05LTEtMS04MTcyMw_23b72696-0a35-48c0-accc-76ff5b27897c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00b74714225f4d449b61808db2c2c804_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS0xLTEtMS04MTcyMw_43c03f0a-85b5-4f57-b031-a08368780fb3">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS0zLTEtMS04MTcyMw_7c30c5b1-6230-4932-8592-5e1c8f7cb8a4">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS01LTEtMS04MTcyMw_90c43df7-38b3-4ac8-93d3-2b5c983814f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS03LTEtMS04MTcyMw_722d86b4-1cd3-4140-9932-8952ac68e2dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS05LTEtMS04MTcyMw_966eae52-c0de-4d2c-9879-3a7787270ee4">1,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ie18d6670fdc44a2490c5c0ee5de3855f" continuedAt="icb5dd4c4e0ec44bd8dc1c01ccc5546d4"><div style="margin-bottom:6pt;text-align:center"><ix:continuation id="i932a5de3989e4856b6f6745ec3a56a45"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.473%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.627%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced2721a212d43848f8133e3f4186dda_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC0xLTEtMS04MTcyMw_47372c96-6467-49af-867e-e6eebcc9d03e">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC0zLTEtMS04MTcyMw_fc9e2df5-70f4-4a03-9b7c-14fff02a64a3">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149ccd24ae824eb0955599b4c37f7358_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC01LTEtMS04MTcyMw_bad5592e-314f-4fe9-a3a2-609adf0b5a86">16,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC03LTEtMS04MTcyMw_20330422-e377-4f28-ab27-e516048cb53e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e27122d96e44ef1888f4f1425b3c91c_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC05LTEtMS04MTcyMw_ae364cf4-c015-43c0-96b0-ddbeefca380a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iced2721a212d43848f8133e3f4186dda_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy0xLTEtMS04MTcyMw_888d20e8-db57-4b38-a19e-a08d6c8ae30a">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy0zLTEtMS04MTcyMw_1d36476b-6f88-432a-a2cb-ba8a33fb521d">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149ccd24ae824eb0955599b4c37f7358_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy01LTEtMS04MTcyMw_4ae0fa2c-7778-4b10-95f3-05094ff6d623">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy03LTEtMS04MTcyMw_d9eb5bc1-f626-47cc-acd1-9194131cf94b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e27122d96e44ef1888f4f1425b3c91c_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy05LTEtMS04MTcyMw_0e6e3e45-5bc2-4ad3-a869-99aa739d6bfe">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from <ix:nonFraction unitRef="number" contextRef="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU0Ng_f5aaaef4-10cc-425f-a001-f3fb3e96da4f">10.2</ix:nonFraction>% as of June&#160;30, 2022 to <ix:nonFraction unitRef="number" contextRef="idb703a0172774df7b5fad376a5cac8da_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU2MQ_c0f91ab8-cf48-40a5-8235-1c952444c4e1">8.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id8d011b45a374b0784b3c71627d06003_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU2OA_dd44d937-805c-4c2a-98dc-00fa27f3d18d">9.3</ix:nonFraction>% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential <ix:nonFraction unitRef="number" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNDU5OA_d9080129-974b-47b1-ab54-72da551e2126">2</ix:nonFraction>% earnout payment related to the Greater China region since those territory rights have already been out-licensed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjEyMA_a8190d7f-f82c-45eb-af3a-77bcc299f04e" continuedAt="i89dd6672294345bc9df31411cd0b5e5e" escape="true">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="icb5dd4c4e0ec44bd8dc1c01ccc5546d4"><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><ix:continuation id="i89dd6672294345bc9df31411cd0b5e5e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMC0xLTEtMS04MTcyMw_20bf8f5a-9a28-4933-ad30-cc6427e48058">52,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie42072eca3cd43a19d6e850e7b53ebd2_D20220101-20220630" decimals="-3" sign="-" name="sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMi0xLTEtMS04MTcyMw_73261a74-142f-4f58-8fda-77b225a7843b">50,200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc528568b4234010b987e7ed2c26110d_I20220630" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMy0xLTEtMS04MTcyMw_43325ea7-0264-445c-b5c1-39b8226b205a">1,800</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of <ix:nonFraction unitRef="number" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTQ2Mw_a84d3b3f-25ad-4bb3-9b09-e964d9d8d5dd">2</ix:nonFraction>% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the <ix:nonFraction unitRef="number" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTU2Mg_6671c16c-b622-4b15-9d8a-9298198f17fa">2</ix:nonFraction>% earnout was derived from the Company&#8217;s weighted-average cost of capital, which has fluctuated from <ix:nonFraction unitRef="number" contextRef="ie23847c7ec884b868685a03832f736b6_I20211231" decimals="3" name="sesn:WeightedAverageCostOfCapital" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTY2NA_7c8fbadf-81d3-4151-b741-cbb3050abf8d">9.3</ix:nonFraction>% as of December&#160;31, 2021 to <ix:nonFraction unitRef="number" contextRef="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTY3OQ_f5aaaef4-10cc-425f-a001-f3fb3e96da4f">10.2</ix:nonFraction>% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was <ix:nonFraction unitRef="number" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTkzOQ_f42385ae-b3cd-41ad-9799-5b8ceb2d5cf5">8.0</ix:nonFraction>% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjAxNA_5b50f1d8-eb29-4e47-8274-d8e3894f1222">50.2</ix:nonFraction>&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.</span></div></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_52"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNjk5_25a7aba0-8bf9-4bf9-bf3f-10bbd5303e00" continuedAt="i8c12f1cc60fa49be80fc255dfb86c0de" escape="true">RECEIVABLES </ix:nonNumeric></span></div><ix:continuation id="i8c12f1cc60fa49be80fc255dfb86c0de"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="icba9e1576f6248d4b9e8e786bce57457_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNjU_f04f06da-c180-4f4a-bdd7-26a3e1fd7e27">0.1</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfODA_c4037a19-f5b0-47f8-9e21-33d140f07698">21.0</ix:nonFraction>&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $<ix:nonFraction unitRef="usd" contextRef="ie44b4e5d665d480d86d36cea88a338ab_I20211231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMTM4_6f808512-d2b2-4b78-80e0-55b4bae60259">20.0</ix:nonFraction>&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMzUy_935a3bdb-d76d-4e2e-bdc6-b937c5b58680">14.0</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMzY3_98ae4fdd-e7dd-4d3f-a507-a7b356ee1c6d">3.5</ix:nonFraction>&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase is driven by expected insurance recovery of $<ix:nonFraction unitRef="usd" contextRef="ia00d97ca9441426bb9adfaa45c3d754c_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNDM3_a10ab14c-87bc-4a04-9fe9-be057e8a6d42">13.0</ix:nonFraction>&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $<ix:nonFraction unitRef="usd" contextRef="i0c25a0b2ddf74ac2b722c896a5913d4c_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNTY4_6ceb0ea1-9721-47b4-8b46-bdfc5aba22df">2.4</ix:nonFraction>&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.</span></div></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_55"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:OtherCurrentAssetsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNDc0_f19d1e29-490b-4020-83a4-cd73d8a7f095" continuedAt="ie871448c29ea42b282180f78bbb6b52a" escape="true">PREPAID EXPENSES </ix:nonNumeric></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie871448c29ea42b282180f78bbb6b52a">The prepaid expenses balance as of June&#160;30, 2022 is $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNjc_e904632d-9028-4466-9554-f23e7f940a38">0.8</ix:nonFraction>&#160;million compared to $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfODI_57fb7258-a817-4d25-8f9e-377e921424cd">25.7</ix:nonFraction>&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-5" name="sesn:ExpensesPreviouslyClassifiedAsPrepaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNDQ1_53e0ae8e-90b3-418e-841f-cd03c80c9fc1">25.2</ix:nonFraction>&#160;million of prepaids during the three months ended June 30, 2022.</ix:continuation> </span></div><div id="i4adf13376f39486da283bda7a521a795_58"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwOQ_1ae65a2d-6ffd-4294-93c3-497531ab6664" continuedAt="ic299c01e113747de99c6443cd3b58a4c" escape="true">INTANGIBLE ASSETS AND GOODWILL</ix:nonNumeric></span></div><ix:continuation id="ic299c01e113747de99c6443cd3b58a4c" continuedAt="i7db94c7827c74cdda1d94f1534919723"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwNw_88933c75-6a8a-4a31-8eba-6d195261b5c1" continuedAt="i26c0d78ddada4b6fa83989a553b201fb" escape="true">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><ix:continuation id="i26c0d78ddada4b6fa83989a553b201fb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedd00e94bff4f138a71518235d8f0c2_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfMy0xLTEtMS04MTcyMw_71b63e5a-2140-4b80-b284-61f87f6b4d47">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifefc2cc3cebe45d78a99c0e68849b7ca_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfMy0zLTEtMS04MTcyMw_96711c0a-dcf1-41cb-b971-994a6a0affde">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie19452cececa4a96a54f4c9ced19321f_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfNC0xLTEtMS04MTcyMw_ed1c49d0-856e-4f2b-93cf-6d6d7f2fc7a0">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5913171b77dd4a8db206d874b45307ba_I20211231" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfNC0zLTEtMS04MTcyMw_125ddebe-5c67-4a47-b72c-77ef1c74cb05">14,700</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum&#8482; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i7db94c7827c74cdda1d94f1534919723"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $<ix:nonFraction unitRef="usd" contextRef="i90478a97ea0d40c7a94bea0d8f484eac_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfMTk4Mg_95e5b9d9-ad7d-4fb3-8735-354eb0735b19">31.7</ix:nonFraction>&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights of $<ix:nonFraction unitRef="usd" contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNDE4Nw_05688097-655b-4987-8ba3-a06f0e94b956">14.7</ix:nonFraction>&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was <ix:nonFraction unitRef="number" contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630" decimals="3" name="sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNDMzMw_911d7f3c-06ac-44d6-b54a-396f7526532d">24.5</ix:nonFraction>%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#8217;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjEwNg_a5c521da-c994-4190-8656-577974656a5b">13.1</ix:nonFraction>&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was <ix:nonFraction unitRef="number" contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630" decimals="3" name="sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjIzNg_767cee26-7668-4619-a4eb-3534f810a1f4">24.5</ix:nonFraction>%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwOA_d3aed490-585c-457d-bb75-f2fd1c53959a" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"></td><td style="width:81.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMC0xLTEtMS04MTcyMw_8620a830-b6be-41a4-a406-ca28fcbbc803">13,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:GoodwillImpairmentLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMS0xLTEtMS04MTcyMw_7c1a4186-1a78-40a5-88cf-38764074a589">13,064</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:Goodwill" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMi0xLTEtMS04MTcyMw_5407922f-5016-468a-82a6-14bfdc23a7c9">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_61"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RleHRyZWdpb246ZGY1NDEwMWJhNWFjNGMxNDhmM2MwYmM2NWZkNGE5OWFfMTMz_2899a2a7-7ff7-41c1-8c54-ebd0b9ef2cad" continuedAt="i9636856b6d5543e6923417450e974851" escape="true">ACCRUED EXPENSES</ix:nonNumeric></span></div><ix:continuation id="i9636856b6d5543e6923417450e974851"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RleHRyZWdpb246ZGY1NDEwMWJhNWFjNGMxNDhmM2MwYmM2NWZkNGE5OWFfMTI4_be532793-95e7-434a-ad3e-b90836f8ef9d" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"></td><td style="width:65.015%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.428%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.626%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMS0xLTEtMS04MTcyMw_7e866451-22fe-407e-a14f-16ee7659e808">1,847</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="sesn:AccruedResearchAndDevelopmentExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMS0zLTEtMS04MTcyMw_fcb6f822-c200-4088-ab50-021b73304a91">1,841</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMi0xLTEtMS04MTcyMw_fdff577d-9d1d-4004-9df9-bf7c6b8dbf61">3,099</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMi0zLTEtMS04MTcyMw_28129dca-5edd-4512-8d5b-97275379907a">2,967</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMy0xLTEtMS04MTcyMw_0ae0b1dd-5f86-4249-9008-83c968d2f54a">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="sesn:AccruedRestructuringChargesRelatedCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMy0zLTEtMS04MTcyMw_6a387163-36db-43d1-8a88-928a34f9f832">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNC0xLTEtMS04MTcyMw_7a9c4536-41b1-4195-bac5-4041e7d83afc">507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNC0zLTEtMS04MTcyMw_76e9f29c-22f7-4183-98fe-45d22e90ae9a">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="sesn:AccruedLegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNS0xLTEtMS04MTcyMw_5869c4c3-6393-4cc8-bb2d-edf2d4c25555">22,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="sesn:AccruedLegalFees" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNS0zLTEtMS04MTcyMw_86039753-3523-4ab5-a1fe-227e22341434">1,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNi0xLTEtMS04MTcyMw_18df4c99-7861-4b08-866d-52e5e4c5f2e8">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNi0zLTEtMS04MTcyMw_d8ee6037-9d98-48bd-99c8-f9384c987262">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNy0xLTEtMS04MTcyMw_d5134933-6e5a-43e7-81b7-ca780434be72">29,851</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNy0zLTEtMS04MTcyMw_b5c0e6c5-356b-41b9-9c6e-bfc9e45da61d">8,255</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_64"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNjM3Mg_91e96aa0-26c1-4e40-b777-2467159bb82b" continuedAt="i2c314f40f9424ca18000ef740a361e13" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="i2c314f40f9424ca18000ef740a361e13" continuedAt="ib60f2c16f3b94708a273a79a25914ecf"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, <ix:nonFraction unitRef="lawsuit" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTIxNQ_875fa51e-69a0-4f90-9187-ef20a0dbcd2b">three</ix:nonFraction> substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The <ix:nonFraction unitRef="lawsuit" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTU5MQ_520261b9-1d7d-40ee-89ed-7edd7d6296c5">three</ix:nonFraction> complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The <ix:nonFraction unitRef="lawsuit" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTgzMQ_a1241674-6c14-4bf3-8965-4e0fdf0fa99e">three</ix:nonFraction> complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the <ix:nonFraction unitRef="lawsuit" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTk3Mg_206cdeaa-2f19-4944-a617-bbb7671d97cf">three</ix:nonFraction> cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The <ix:nonFraction unitRef="lawsuit" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="sesn:NumberOfLawsuits" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNDE4NA_52651805-ff33-460c-bf4c-648ac65918fc">three</ix:nonFraction> derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="ib60f2c16f3b94708a273a79a25914ecf"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-5" name="us-gaap:LitigationReserve" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNTc3NA_fc5c11eb-8581-4b1a-9861-ab12f9632ff1">21.6</ix:nonFraction>&#160;million to litigation related liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_67"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3Mw_fc4cc357-c1a0-421c-a5b7-0a53d5127125" continuedAt="i3f94bcc9f5cf40c599e4d3da5eff2061" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="i3f94bcc9f5cf40c599e4d3da5eff2061"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its <ix:nonFraction unitRef="sqft" contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630" decimals="-2" name="sesn:OperatingLeasesAreaOfOfficeSpace" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfODI_3c9a1b5d-dd64-41d0-a1a2-6848788a3477">31,100</ix:nonFraction> square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional <ix:nonNumeric contextRef="i6f1af4670f5349589e2c8544533b3f92_I20220630" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMjkw_a6c73a10-8117-4e4b-a660-c7feb91586bb">two years</ix:nonNumeric>, through September 2022. The minimum monthly rent under this lease is CAD $<ix:nonFraction unitRef="cad" contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMzY3_38c96517-3ec3-49fc-bdd4-36df83ea2e9d">18,100</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMzg1_bba43691-83f6-480b-84ba-cd612f0f0e43">14,000</ix:nonFraction> at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $<ix:nonFraction unitRef="cad" contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNDg2_de981cf0-4aa8-4f3b-9ab0-edf0a5dddf65">18,200</ix:nonFraction> per month related to operating expenses (approximately $<ix:nonFraction unitRef="usd" contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseOtherMonthlyOperatingExpenses" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNTQ0_fd5c2c33-be91-4122-a156-d43844e4d0ec">14,100</ix:nonFraction> at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $<ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNjY2_29b95280-5e70-41de-ab2e-7f72ada6c594">83,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNjcz_f28ffa81-5333-4d68-8ca0-2fea1974d00c">165,000</ix:nonFraction> for the three and six months ended June&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNzMz_544e0607-7d50-417b-a15c-ab33f76340d7">84,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNzQw_809ca5a0-75a9-43c6-b369-f68ac26dd9ee">166,000</ix:nonFraction> for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_4843e629-dcdb-4616-b8a6-a27047f3d904"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_97400fbf-3c91-4d39-b5d3-04d3e2f63a2e">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-2" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTAyMw_e6381c03-f929-4ee1-a916-88657a2e7e68">41,700</ix:nonFraction> as of June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-2" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTAzOQ_4d14af85-3976-464c-be5f-4390fe240d26">123,300</ix:nonFraction> as of December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_8d631678-1039-4b69-9e83-f467e7b5b77b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_bedfdad2-e676-46e0-be70-8fe59f2f9fc1">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-2" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTI4Mg_add54a51-7c08-4d46-87bf-d4cd3b8d2811">41,700</ix:nonFraction> as of June&#160;30, 2022 and $<ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-2" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTI5OA_7926b718-f9aa-4426-9361-4fb46ce782d7">123,300</ix:nonFraction> as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $<ix:nonFraction unitRef="usd" contextRef="i000d73058a0b4403961f473fd89fbb67_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTc1MA_bc7d5622-3205-4216-b4cf-a80a71782feb">2,200</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i5ac9bf36e8db4b3398a967b1e06528c6_D20220101-20220630" decimals="-2" name="sesn:OperatingLeaseMonthlyRent" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTc1Nw_004aaf50-b17a-494e-a1ae-953a1b55f58b">21,000</ix:nonFraction>, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_70"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczNA_15459bbc-b71c-4872-8762-0da41f4c9b5c" continuedAt="if60b34d7f03f4f929556f99874a90aad" escape="true">STOCKHOLDERS' EQUITY </ix:nonNumeric></span></div><ix:continuation id="if60b34d7f03f4f929556f99874a90aad" continuedAt="i4858679e1f0742ac923d0723522f981b"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="i8c8d5912a42e4ad2833bfc6f61c043f2_I20191129" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNDM0_02f23d1d-b19c-41d6-b43f-2d12d810fdc2">0.001</ix:nonFraction> per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i78ad6147eb974d38affb24031a858c3d_D20210601-20210731" decimals="-6" name="sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNjQ2_8accd469-b56b-4e19-a19c-a6efa313da9d">200</ix:nonFraction>&#160;million of common stock pursuant to the Sale Agreement of which $<ix:nonFraction unitRef="usd" contextRef="i5a0705a329ea41ed96157e39c6c49855_I20220630" decimals="-5" name="sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNzA1_64d0041c-b568-4f9b-9a3d-1f42ca746b76">97.8</ix:nonFraction>&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4858679e1f0742ac923d0723522f981b" continuedAt="i33e5e2c16ec041999934c8387971a285"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to <ix:nonFraction unitRef="number" contextRef="i7eda749d94fb48398a0924800d09ac3d_D20211129-20211129" decimals="INF" name="sesn:SaleOfStockCommissionFixedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMTc4Mg_dfc62715-9407-4ff3-be01-ec1201623598">3.0</ix:nonFraction>% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June&#160;30, 2022. The Company raised $<ix:nonFraction unitRef="usd" contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMTk5Ng_cd890d4b-9964-435b-b832-5afc57e02bff">136.8</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjAzMg_e2f9ea85-12f9-4866-9bdc-acd1df7b31f5">47.1</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjA4OQ_62adfb87-574f-48c0-b68d-fee4638e8e03">2.99</ix:nonFraction> per share during the six months ended June 30, 2021. The Company raised $<ix:nonFraction unitRef="usd" contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjEzNw_631386ba-5f9c-48c3-b57e-def155147e78">64.3</ix:nonFraction>&#160;million of net proceeds from the sale of <ix:nonFraction unitRef="shares" contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjE3Mw_a673e7d5-15b1-46b4-a2e4-d4fd760f9bf6">16.5</ix:nonFraction>&#160;million shares of common stock at a weighted-average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630" decimals="2" name="sesn:SaleOfStockWeightedAveragePricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjIzMA_bca58306-b70c-4c61-a174-6d029d319533">4.02</ix:nonFraction> per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjM1Mg_74e57a39-77cb-46af-a931-52ffcbfc6834">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630" decimals="-5" name="sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjM1OQ_0275853b-fe89-4431-885d-f9e07c757fe2">4.2</ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue <ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjU2Mg_f4ae62fb-a29e-4976-a3ba-03be01048390">5.0</ix:nonFraction> million shares of "blank check" preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjYwNg_693a429a-ded6-4786-b8df-92bacbf498ee">0.001</ix:nonFraction> par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had <ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_33fe28be-824d-4dcd-b34c-c035fa366bd9"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_5071d813-7fa9-43a8-a894-b2b0ed891079"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_b3a6a981-d08a-4efb-9ff4-1c5ace21f457"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_f6bfc898-35b3-46c3-b068-60c105a5b3e8">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from <ix:nonFraction unitRef="shares" contextRef="i75b910d027ce46cda21c3171ea8cf644_I20210502" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzMyMQ_397c577e-529f-4dfa-b48a-628becc7e045">200</ix:nonFraction>&#160;million to <ix:nonFraction unitRef="shares" contextRef="ice21145cb84b458994eb2b4953cd1b79_I20210503" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzMyNw_4a1a0e8b-7820-4471-820b-36e2f64f8e30">400</ix:nonFraction>&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately <ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_0624cacb-fe35-44f5-8a4b-e02f405bf12f"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_23e1e4dc-d6f6-45f6-8388-7b87db6667ae"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_e61e0c8d-6e0d-4768-979f-736058e7496e"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-6" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_f4c66783-2e6e-4c86-ad25-de1537c1585b">199</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczOA_98b4cbaf-f0d1-4589-8f1b-c88c8c961243" continuedAt="i07c7accc3cf64e23acf0b97f1de101dd" escape="true">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</ix:nonNumeric></span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><ix:continuation id="i07c7accc3cf64e23acf0b97f1de101dd"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"></td><td style="width:67.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.097%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.100%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMS0xLTEtMS04MTcyMw_9ba4cdff-db1f-4325-8316-444c92f2a623">199,464</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMS0zLTEtMS04MTcyMw_3982916e-c465-4955-852d-a07c131a4003">199,464</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e03d5c4d214485ca8ef8d4f2b1c22b5_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMy0xLTEtMS04MTcyMw_3143c7ff-57f9-420a-ad5d-c97aa01043fb">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie93e937a2ca743998879eaab73aba23e_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMy0zLTEtMS04MTcyMw_21a0e5bb-e535-4e3b-b22a-afe337216ccc">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i78713773a6f644369d0e8eec39199597_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNC0xLTEtMS04MTcyMw_dba21261-5b03-4099-bbf8-385540ea030c">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if34834f39ec94e458f57f689cde2c633_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNC0zLTEtMS04MTcyMw_e1b8f1eb-49b2-4702-850e-9f347d0458c8">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81b6cc446ab44fa08e173a103f7b7289_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNS0xLTEtMS04MTcyMw_388c0b57-026e-4172-8f8d-2fd7eb618207">8,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7ba233a853c42b89272f4f6b9633315_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNS0zLTEtMS04MTcyMw_b1038497-e591-4e23-a4d4-e5997891f419">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i90db0d74d54b4275b25f685df0f5b309_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNi0xLTEtMS04MTcyMw_a5249ca5-c6c6-42b1-9659-083ea8890551">3,076</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6074b6e43f5c46f5a2bb46e072ef5f2d_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNi0zLTEtMS04MTcyMw_1179b183-0c85-4c4a-87d8-17766a5ab1db">8,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4996e48caa5c4590b4980c71c163ae64_I20220630" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNy0xLTEtMS04MTcyMw_84b7affe-5ab6-4556-8fa2-d8b4d8bb950d">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b96cadcfc494bd094e17b7ef53a0601_I20211231" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNy0zLTEtMS04MTcyMw_40fc2b43-e0d7-4a8c-85af-4c40573492e5">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfOC0xLTEtMS04MTcyMw_1cdf400f-3efe-4848-857d-6553af57306e">230,263</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="sesn:CommonStockSharesIssuedAndReservedForFuture" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfOC0zLTEtMS04MTcyMw_21e83732-c6cd-481f-8bf8-66421a25ee67">229,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to <ix:nonFraction unitRef="vote" contextRef="ie6b33ca5238c45cc9793e8772152abcb_D20220101-20220630" decimals="INF" name="sesn:NumberofVotesEntitledForEachShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzgxOA_d8f8c77f-c478-4235-b767-e88c40ecb6b1">one</ix:nonFraction> vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div></ix:continuation><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i33e5e2c16ec041999934c8387971a285"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczOQ_203ebf01-fd76-4cdd-ba1d-9a2dcd14d5e5" continuedAt="i9f1feb20762a4603b2d083c00966072f" escape="true">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i9f1feb20762a4603b2d083c00966072f"><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.971%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0yLTEtMS04MTcyMw_8a70e5da-8202-4084-83dc-d529b95a362c">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b97f878936d417582c679e49408c3cf_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS02LTEtMS04MTcyMw_b8517259-bebe-4588-931e-65cf099c5a9d">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS04LTEtMS04MTcyMw_73bb14e2-a096-417f-b69d-b0af006259b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xMC0xLTEtODE3MjM_d7a896d2-801d-4f5e-8332-00ba7a60ba37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xMi0xLTEtODE3MjM_9d303348-75fe-4dc6-814e-81fbbe9e00af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xNC0xLTEtODE3MjM_30dc9ead-fe8b-457c-abe7-c7a592baac3b">132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id796b6b8583646e18ef4317244b84a3a_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0yLTEtMS04MTcyMw_1191f7cc-385e-4b0e-b70a-0751bdd7980a">0.55</ix:nonFraction>*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c5a07fd1b449558c518b3bbcbe3efa_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi02LTEtMS04MTcyMw_82a4bf62-240e-4cc8-bb2d-4350ece34e7a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi04LTEtMS04MTcyMw_8ab65b3c-5877-437a-b324-613a6699d599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xMC0xLTEtODE3MjM_b78b2bab-fdc8-4f88-9983-f50619e1fbbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xMi0xLTEtODE3MjM_79a2b8eb-ac20-47e9-92fd-b94db410e296">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id796b6b8583646e18ef4317244b84a3a_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xNC0xLTEtODE3MjM_1d4a914a-bb32-4b1e-ba4d-3ab76aa142b5">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ifaca184cb85744059ede4889bd0bec15_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0yLTEtMS04MTcyMw_63334804-00e7-41c9-9a2f-00cc3da1809c">11.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07151ff5feff4986a1a7cf1407f3f033_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy02LTEtMS04MTcyMw_455a09c8-f808-4c84-84e5-e6705805a5f3">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy04LTEtMS04MTcyMw_06a39415-5bb3-4f5a-aa12-d1c10a7056f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xMC0xLTEtODE3MjM_84455461-c477-4bc0-ac81-efaeb4fc4484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xMi0xLTEtODE3MjM_d317318a-9af5-4308-bfdc-295e861eb809">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifaca184cb85744059ede4889bd0bec15_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xNC0xLTEtODE3MjM_68dc0ff0-9570-4288-af99-28b8b51119e2">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i89b961b26f78447680b3d6eea476fce2_I20220630" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0yLTEtMS04MTcyMw_40779bc6-6c90-4759-afec-b8260b9ecf78">11.04</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7d480b8de55f4a309d196db12c0a8524_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC02LTEtMS04MTcyMw_a27ff05d-b702-4895-89e8-552652026dd8">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC04LTEtMS04MTcyMw_f4776b85-1d36-4ce4-8993-97b9db5e04a0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xMC0xLTEtODE3MjM_fbc6ea7f-fdc0-4ff8-9b15-d9cf7fe9a208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xMi0xLTEtODE3MjM_b26e3170-7e5a-4c3e-9ba3-360a2ee1cc10">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i89b961b26f78447680b3d6eea476fce2_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xNC0xLTEtODE3MjM_00d85465-44e1-4e84-8370-0e8e21de2c6e">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS02LTEtMS04MTcyMw_2de88ce8-848c-485c-a6df-3fb662c399e2">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightIssuedDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS04LTEtMS04MTcyMw_76f50bae-2deb-4e38-85e8-6dfb38a1bf1e">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xMC0xLTEtODE3MjM_598d2280-8cac-444c-8b05-49a56e9ad7bb">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xMi0xLTEtODE3MjM_095a4fe6-0c67-4f7c-9130-0bb06ab4bcc1">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xNC0xLTEtODE3MjM_770008bf-6f70-47bf-8887-81333eaf4725">199</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div></ix:continuation></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_73"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RleHRyZWdpb246MGE3NjAzYWE2OWIzNDQ2NzljZDUwOTViMzE0M2ZkNWZfMTM4OQ_2d170216-bb76-45f4-af83-7f956a9068a5" continuedAt="ibcb83b05eb604c4f80530c985d0c0cc7" escape="true">EARNINGS (LOSS) PER SHARE</ix:nonNumeric></span></div><ix:continuation id="ibcb83b05eb604c4f80530c985d0c0cc7"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RleHRyZWdpb246MGE3NjAzYWE2OWIzNDQ2NzljZDUwOTViMzE0M2ZkNWZfMTM5MA_22ab939d-8279-4a23-bc05-b8f635bd0a3d" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:45.958%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2a77deceed914ab4aa6c3a9a9c4f3afa_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi0xLTEtMS04MTcyMw_77c9eca1-7938-42ee-9b91-6e941e5189a1">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ife468ed832424422bc39059d7df8b085_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi0zLTEtMS04MTcyMw_01b950b3-f33e-472c-b4ea-ab86d66a91de">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0adbc934f3b24c239d0f1300083008f6_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi01LTEtMS04MTcyMw_c68c787f-f5e9-4e6f-be3b-cfdb71e0c0ff">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a25de0176e248178dc11989f74804f0_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi03LTEtMS04MTcyMw_fa22b399-95a7-43b8-a5bd-cd83e40235f8">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47327dd48deb4402885aa3afa6af22a2_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy0xLTEtMS04MTcyMw_7aab9f19-adf4-4bdd-be07-6f00c66b112f">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifc6aa26487504d41b6a549bc657400e8_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy0zLTEtMS04MTcyMw_5a6a8d6f-1d1c-49d5-960c-a8b02ddbdaa9">17,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19b7d9796cd54f35ba0a1cef95f329d2_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy01LTEtMS04MTcyMw_857b0233-bade-4f3c-be4e-301814843640">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2c9a4489987e4bd2a05ab6cfd1a362f6_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy03LTEtMS04MTcyMw_3021583c-c880-4628-ae9f-33ef3eabebe8">17,349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a33702caa4644da8978da5e0013ddb8_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0xLTEtMS04MTcyMw_849717ff-c13d-42f0-b28f-5d1eddcae47b"><ix:nonFraction unitRef="shares" contextRef="i67fcaaf0286a4c1783c880c53e54d424_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0xLTEtMS04MTcyMw_91a8a818-d76d-4463-90ba-608554620d28">8,063</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5e730560bfe346738f8e589866aba60d_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0zLTEtMS04MTcyMw_65114c19-a399-476c-ad9c-4810ff920759"><ix:nonFraction unitRef="shares" contextRef="i6ad0ec9b6a7b42cdbf789fb6d8f39ca9_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0zLTEtMS04MTcyMw_af2ab350-7802-4185-9eb3-b12fc788c84f">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i568a2b3022284d34a0aff47db073a523_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC01LTEtMS04MTcyMw_208be008-40b6-4e1a-b657-80cd151aa837"><ix:nonFraction unitRef="shares" contextRef="i41e29d2263d34ad692781e2266eefd53_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC01LTEtMS04MTcyMw_52f4d907-6812-407e-bfe8-2d2704b63d1b">8,063</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec8d3d4dfe0d4122b647ec6d4619e69e_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC03LTEtMS04MTcyMw_d4a856f9-7882-4b04-90e5-7b0b775c9e7c"><ix:nonFraction unitRef="shares" contextRef="ia71281c8b42c4511ab6edd8ce3378ba3_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC03LTEtMS04MTcyMw_d5d30a38-98af-47bd-ada0-3cc07d1b86e2">&#8212;</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS0xLTEtMS04MTcyMw_8ba4aa15-1fdf-4c11-934e-8a65f7bd6271">25,423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS0zLTEtMS04MTcyMw_60598642-7a02-42a6-b8f1-31af4532ebbb">18,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS01LTEtMS04MTcyMw_8329edd8-7592-4923-9cca-ac68b4135e1c">25,423</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS03LTEtMS04MTcyMw_f405d59b-9260-46aa-bcb2-4ac90c8b4cc8">18,743</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_76"></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyMQ_d0c2c42f-fc30-4276-b2bd-059ab34eeb23" continuedAt="i81d9e2f1c9094ba3a937d41ac42fde86" escape="true">SHARE-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i81d9e2f1c9094ba3a937d41ac42fde86" continuedAt="i4aca561db7244a3ca956abd0b31462db"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyMg_939b282a-90a5-4bea-8d88-cd8171ec8721" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"></td><td style="width:238.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.00pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:63.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc85ab1a955410a8b2ba5d9aef9c0d5_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi0xLTEtMS04MTcyMw_eeb9e1d1-8aaa-466c-bc62-8ff069f4bac4">473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53e901c0ef94dd18db696d73878aa08_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi0zLTEtMS04MTcyMw_bfd05e52-4d5e-4262-8f2d-745fe1e8e636">207</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55970a0d5f344348a35d5e2c4bd4282e_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi01LTEtMS04MTcyMw_f3ab2f41-6716-419c-9ce8-327306412b27">975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84b0564ab20a40a485edffa15b757c33_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi03LTEtMS04MTcyMw_d5b76350-152c-44f5-8ae1-3cf9b1b8368a">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee95e6730e374d6e9aab606275edaf82_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy0xLTEtMS04MTcyMw_02530c3c-cfec-4fa3-afb8-b0c0063a3ac8">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i342e97e8062b4c4cab492cc8c00c70d8_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy0zLTEtMS04MTcyMw_a8a3cbe8-9efe-4e25-9c30-6ace894fab0c">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6db64e1a961546e3bd8121ee3879f09d_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy01LTEtMS04MTcyMw_0fcbd128-5cdb-4409-9611-35838595c821">2,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieac62593b40f4880b423bfc9580273ab_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy03LTEtMS04MTcyMw_a59b3527-916f-44dc-b163-6f2d3fd362c9">1,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC0xLTEtMS04MTcyMw_07fa53e9-6f02-4ded-b76c-1f785b18ea28">1,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC0zLTEtMS04MTcyMw_3dfe9992-eafd-4437-96ba-b2c61d55a90a">1,259</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC01LTEtMS04MTcyMw_e9090a26-eaec-4dfc-ad0d-2b57bd096943">3,696</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC03LTEtMS04MTcyMw_98d7d499-e151-4b31-9902-63618181821f">2,217</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by <ix:nonFraction unitRef="shares" contextRef="i77bc1a747a0f4fdd9e81b59820c9d0e3_D20190601-20190630" decimals="-5" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTA5Mg_e724b5b9-a7b3-4859-9e24-5a819ec85af0">7.9</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by <ix:nonFraction unitRef="shares" contextRef="iacb6642dacce42dda98c5135fee1f003_D20210501-20210531" decimals="-6" name="sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTU2MQ_4d4a70c1-1bad-42c5-9e56-2597f4840efe">12</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately <ix:nonFraction unitRef="shares" contextRef="i05439e7daefd4ac8b3d2d78445d47366_I20220630" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTY2OQ_cfa0c016-caf5-4b08-bc15-386a6ac50474">3.1</ix:nonFraction>&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a <ix:nonNumeric contextRef="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNw_7e51667d-9087-4bcb-bb68-f6a4761fbb3f">four-year</ix:nonNumeric> period at the rate of <ix:nonFraction unitRef="number" contextRef="i08ec180c3533409b8010a63003f3a00d_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTg0Ng_800cbf6d-e732-49b8-a4fe-7de53a46d581">25</ix:nonFraction>% of the grant vesting on the first anniversary of the date of grant and <ix:nonFraction unitRef="number" contextRef="ib466f1439d304e268b42a9bfb03f0f4a_D20220101-20220630" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTkyMA_77178516-1f43-4fb6-91af-c4a58cedc2f1">6.25</ix:nonFraction>% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of <ix:nonNumeric contextRef="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjA3OQ_a3cd8fb9-b4d3-42c4-b131-6bc14e79775b">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="i05439e7daefd4ac8b3d2d78445d47366_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjEzMQ_d2c37fef-e671-43ca-8404-05b6abcaf5af">13.6</ix:nonFraction> million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i8a67da80633540d9868f347e7148156e_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjgzNg_3118cbec-1985-4aa5-af0a-d925e5ab4262">one</ix:nonFraction> share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately <ix:nonFraction unitRef="number" contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" format="ixt-sec:numwordsen" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzE0MQ_c60c6577-15a3-4d70-9c69-18d1b42cc504">fifty</ix:nonFraction> percent of then-current base salary. The fair value of PSUs at the grant date was $<ix:nonFraction unitRef="usd" contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzIyNg_407619b8-8da6-42db-8f7e-4ceb1357b225">0.4</ix:nonFraction>&#160;million. Each PSU represents a contingent right to receive <ix:nonFraction unitRef="shares" contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001" decimals="INF" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzI4MA_f8755f45-d41b-43fa-8ac2-79ffe20a320c">one</ix:nonFraction> share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $<ix:nonFraction unitRef="usd" contextRef="i75b2d9dc879b4976951e57e3d6a98fe8_I20211231" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc2MA_38d596d0-47e1-45cd-9e52-18fa4c6f44d3">87,000</ix:nonFraction>, <ix:nonFraction unitRef="number" contextRef="i570bf630b283493eb8aac676692c8fb5_I20220630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc2NA_1e06df41-8d73-4188-befb-674ff36a5f0e">20</ix:nonFraction>% of the PSU awards. Therefore, $<ix:nonFraction unitRef="usd" contextRef="i6cc8c46f0ceb44d5806951413bb59ee1_D20220401-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc5Nw_85232209-1cff-4cfe-a815-5139466435d4">11,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic7729b36949f4e6f8b449bc2e11e0ac1_D20220101-20220630" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzgwNA_556600d1-6152-414e-9dd9-54cd16af5ec7">33,000</ix:nonFraction> have been expensed during the three and six months ended June 30, 2022, respectively and $<ix:nonFraction unitRef="usd" contextRef="i570bf630b283493eb8aac676692c8fb5_I20220630" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzg5Ng_b4660de6-9c03-48e3-b4a9-a4e4b8bebece">54,000</ix:nonFraction> remains measured but unrecognized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4aca561db7244a3ca956abd0b31462db" continuedAt="iebe77d0938b1470ba2f3a982011e7393"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of <ix:nonNumeric contextRef="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNDg2Ng_ed2d9fc1-2aec-430b-aeee-f1fe6788230c">ten years</ix:nonNumeric> from the date of grant. There were approximately <ix:nonFraction unitRef="shares" contextRef="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNDkxOA_64c55c83-ab5f-4f48-b06f-547a2826c6a6">0.1</ix:nonFraction> million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately <ix:nonFraction unitRef="shares" contextRef="i044e86b9b1004169acd873b958541512_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTQyNg_f9c11519-71f3-4993-9b73-0f9eeba390f9">3.5</ix:nonFraction> million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNA_5c51f6b4-5191-493e-9ea4-c7186f2fcd59" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"></td><td style="width:41.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS0xLTEtMS04MTcyMw_75493444-e40f-4791-82dd-9239092e615d">15,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS0zLTEtMS04MTcyMw_4f87a760-28b9-4ce0-a81c-b9e155b088fb">1.93</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i66d0ce796f154e90aded5d0cbce94189_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS01LTEtMS04MTcyMw_d9764be5-98c6-4300-82a0-ba8692c5eb57">8.03</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS03LTEtMS04MTcyMw_268ea5d6-dbed-43bc-a7a7-64b0868bf80c">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMi0xLTEtMS04MTcyMw_bb3d01b2-0ddd-425a-86f7-7dd565ce0cd2">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMi0zLTEtMS04MTcyMw_12b86c2d-dcfa-424e-a8b9-ee51c467151e">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMy0xLTEtMS04MTcyMw_bfe7b78c-6d80-4ad3-b61d-10d15d173c12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMy0zLTEtMS04MTcyMw_ab2aa6f5-81ee-49d8-916a-b291884ae615">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNC0xLTEtMS04MTcyMw_9ee9d332-678a-41a3-985c-3a770e6c20b8">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNC0zLTEtMS04MTcyMw_458b1d50-7c20-426a-9bd3-796ab2777054">1.20</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS0xLTEtMS04MTcyMw_40bb1a11-dea5-4abf-8f5c-7363f7abaa64">17,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS0zLTEtMS04MTcyMw_70dc6896-7d50-44d0-b29a-3d50a939e498">1.83</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS01LTEtMS04MTcyMw_c24d6793-8bb3-4815-836f-ce92bce590bd">7.72</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS03LTEtMS04MTcyMw_12a7e154-997e-4bdb-8322-d4a7f84607c7">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi0xLTEtMS04MTcyMw_85b59f08-7d49-4b1c-a334-6df214fb526f">9,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi0zLTEtMS04MTcyMw_335e2079-4202-44fa-beec-cf1ef3ec9734">1.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi01LTEtMS04MTcyMw_6076eb26-17c5-44ed-9df2-67342cd957c3">7.11</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi03LTEtMS04MTcyMw_91955cae-317e-4b84-9308-571d65e187c6">64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense, related to stock options, of $<ix:nonFraction unitRef="usd" contextRef="i23ea04149ec74feea107a21a6ba9a68e_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTg3MQ_45b9c8ab-8977-422f-84ed-b3f6d3a128fa">1.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTg3OA_f9239527-6c3c-4bc1-9dca-06960bd15ca0">2.5</ix:nonFraction> million for the three and six months ended June&#160;30, 2022, respectively and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia0710da839aa43a793cc2cb6c1c4a9b3_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTkyNg_caa7463e-8fcb-429f-9a87-01511f32d4fa">1.3</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTkzMw_fdf8bb00-6b2b-44a0-a520-a3eb7f5f17da">2.2</ix:nonFraction> million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTk5OA_a0448256-9bce-4f07-bd01-372c6cd161c2">8.6</ix:nonFraction> million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjE0OQ_d14aa02d-4f73-490a-9bbc-c5e735bedc48">2.36</ix:nonNumeric> years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI1NA_34daa9ee-3d86-4c51-8679-520a970ae1c2">0.46</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI2MQ_523b55ec-29a8-4844-8672-5e2584fab98b">2.17</ix:nonFraction>, respectively. <ix:nonFraction unitRef="shares" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI3OQ_966fb8dd-adea-4721-a348-dc6bfa7adcbe">No</ix:nonFraction> stock options were exercised during the six months ended June 30, 2022. </span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNQ_eb073d00-49b9-4a08-8009-137bb341c9ab" escape="true"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"></td><td style="width:64.733%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMS0xLTEtMS04MTcyMw_0228ba3d-ebda-4db3-bcb2-2e8fa440e45b">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" decimals="2" name="sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMS0zLTEtMS04MTcyMw_908a4b4b-f30d-4da8-860e-1fa3663470aa">3.34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i78713773a6f644369d0e8eec39199597_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMi0xLTEtMS04MTcyMw_cdd98723-daac-4534-9b23-7559afe87e95">0.72</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ie8c92e1f22ad4644a192da4d2c4a4794_I20210630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMi0zLTEtMS04MTcyMw_2d6d2fde-5ff8-4c74-99ed-a6b023f4513b">3.34</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMy0xLTEtMS04MTcyMw_0d459035-8b66-4615-886a-49b0e59a4058">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMy0zLTEtMS04MTcyMw_2afc0359-fc3a-4bb2-a7fa-2c048930a0cd">6.04</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNC0xLTEtMS04MTcyMw_cd9d30ba-5dd2-40ab-8483-d9e9d7890b0e">2.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNC0zLTEtMS04MTcyMw_4c6203a2-d6a2-45d9-9251-987457fac289">0.9</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNS0xLTEtMS04MTcyMw_ba8c994a-6549-4280-b7ab-572d9c703eee">71.8</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNS0zLTEtMS04MTcyMw_dbcb2dce-f9fa-439d-858b-c15a2feef1c3">74.7</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNi0xLTEtMS04MTcyMw_a02e4027-53e0-4434-8ed4-14609cdc5410">&#8212;</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNi0zLTEtMS04MTcyMw_ab8e7e78-3376-45a9-b3ae-71d0bb725812">&#8212;</ix:nonFraction>%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iebe77d0938b1470ba2f3a982011e7393" continuedAt="i2fa076cf38c74fff9e48c7ea4361c871"><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAzMg_043cff08-f8e9-4f46-bd34-cb5c07aaa33b" escape="true"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"></td><td style="width:60.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.521%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.524%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMS0xLTEtMS04MTcyMw_67d92006-b22b-4489-9bf6-72ad99448c2b">3,041</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMS0zLTEtMS04MTcyMw_5d58e901-e871-4032-9271-91238cff9a71">0.80</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMi0xLTEtMS04MTcyMw_4f828429-76c0-48e7-8bb5-97504afa79ed">4,161</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMi0zLTEtMS04MTcyMw_758f18d5-da44-4258-8dc8-6db88147ef98">0.68</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMy0xLTEtMS04MTcyMw_6d506eb4-adb1-4692-92a3-c68fc5b09c6c">143</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMy0zLTEtMS04MTcyMw_7039e7b6-e85d-4c2c-b299-9fa5b5f25366">0.75</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNC0xLTEtMS04MTcyMw_bf917997-bba2-4bec-a07a-9a33ae0cb142">1,004</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNC0zLTEtMS04MTcyMw_17e17e1d-8569-4af9-8713-263e88ea8464">0.67</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNS0xLTEtMS04MTcyMw_49c55f7d-b245-4c15-8d80-42b212074e50">8,063</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNS0zLTEtMS04MTcyMw_76b5dfb6-c499-46fa-9975-17e300711974">0.72</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did <ix:nonFraction unitRef="shares" contextRef="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjY3NA_a5fc28c8-f739-4e67-96ca-01903d5706ec"><ix:nonFraction unitRef="shares" contextRef="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjY3NA_df07b31a-28c9-42a7-a68e-b9c630f00da9">no</ix:nonFraction></ix:nonFraction>t grant any RSUs or PSUs during the six months ended June 30, 2021. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2fa076cf38c74fff9e48c7ea4361c871">The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $<ix:nonFraction unitRef="usd" contextRef="id083216cd3834a9a8398563d69c8b21d_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgwNA_0d371e93-5a33-4674-8441-0727aca454f7"><ix:nonFraction unitRef="usd" contextRef="i129a8282c6be44f2baa56e32efc338ec_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgwNA_4d0e9a01-c016-4690-bc96-4271dc2f4dea">0.6</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgxMQ_0e3f59aa-f7bb-49a6-bdee-77a11fa6efe0"><ix:nonFraction unitRef="usd" contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgxMQ_6f8974aa-20b1-49f5-be66-958b7f5c0091">1.2</ix:nonFraction></ix:nonFraction> million, respectively. There was <ix:nonFraction unitRef="usd" contextRef="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgzOQ_720a6a5c-f58e-4ade-a569-a6b3d5f79bff"><ix:nonFraction unitRef="usd" contextRef="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630" decimals="INF" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgzOQ_890f4680-59ef-4a51-969a-20499eecb2ac">no</ix:nonFraction></ix:nonFraction> shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $<ix:nonFraction unitRef="usd" contextRef="i11cba79393924023a9e75dd2910cde3a_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjk0Mw_429b2787-bd90-464c-ba64-733abd291efb"><ix:nonFraction unitRef="usd" contextRef="i81b6cc446ab44fa08e173a103f7b7289_I20220630" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjk0Mw_563b662b-7b3a-4a82-9eab-e97b0a1e05ff">3.0</ix:nonFraction></ix:nonFraction>&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.</ix:continuation> </span></div><div id="i4adf13376f39486da283bda7a521a795_79"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjY0MQ_4afaa745-7e64-43e1-83c5-5e052ea54321" continuedAt="i07d16c8f9b214201808495f28baf6835" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="i07d16c8f9b214201808495f28baf6835" continuedAt="ie744bd4ef0234f11a8f1378b8a3ab890"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of <ix:nonFraction unitRef="shares" contextRef="i8f9cc9d2301a4433a98cf0413fade87d_I20140228" decimals="-5" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMzg2_6e707362-7455-4f59-9216-075357bc5cca">0.2</ix:nonFraction>&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by <ix:nonFraction unitRef="shares" contextRef="ic63732dc872f413f8025dd7bf4720b9f_D20210501-20210531" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfNjE2_4e48b947-c7c3-44b5-ac5f-88bda1153fd2">2.3</ix:nonFraction>&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a <ix:nonFraction unitRef="number" contextRef="i76c65c4ee1e64946ab281633bdefbe71_D20220101-20220630" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfOTYz_8b097815-238a-42a2-836b-0257da4da083">15</ix:nonFraction>% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were <ix:nonFraction unitRef="shares" contextRef="iac5769fcff7b47898a71e23efd9d7b5a_I20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMTM4Ng_87fa31f9-1c63-4308-9d4d-c14598177787">2.3</ix:nonFraction>&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to <ix:nonFraction unitRef="number" contextRef="id065aa16b3944940b083af3709622dd4_D20220101-20220630" decimals="INF" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMTg0Mw_e017b787-4228-4a52-94e7-dfa18c6f4ab9">100</ix:nonFraction>% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $<ix:nonFraction unitRef="usd" contextRef="id065aa16b3944940b083af3709622dd4_D20220101-20220630" decimals="INF" name="sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjA0Mg_8550787f-4e22-40c5-8d8c-5b3e746a5093">4,000</ix:nonFraction> per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie744bd4ef0234f11a8f1378b8a3ab890">The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first <ix:nonFraction unitRef="number" contextRef="ic2092edc5bbb470eaa1bb592509fc775_D20220101-20220630" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjQzOQ_67aeaa9e-a04c-4491-8427-37f015ed9739">4</ix:nonFraction>% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_82"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTEzOQ_758c0a8f-b78f-40e8-bc0a-7cfb171945c8" continuedAt="i5c0b76f3131f4db29de2f0e3e32f91c2" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="i5c0b76f3131f4db29de2f0e3e32f91c2"><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0MA_8f37f0a1-6158-49e7-9c9d-969986d9673a" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"></td><td style="width:63.870%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.817%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfMy0xLTEtMS04MTcyMw_0bfbb4f0-a9bf-4e56-9921-bc477b4ff8e7">55,939</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfMy0zLTEtMS04MTcyMw_92a5dcbf-9e6a-4523-a55d-7bcb62c01105">21,210</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNC0xLTEtMS04MTcyMw_3d826212-5d1f-4ac6-bfa8-5a8e62aeba04">19,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNC0zLTEtMS04MTcyMw_d5ae8eb7-3ab7-46b7-a66e-07ad6d60f700">59,456</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNS0xLTEtMS04MTcyMw_0ddab297-096b-45d2-a4e5-dcae92f682ab">36,642</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNS0zLTEtMS04MTcyMw_ad5378d5-747c-42e2-8f98-f702300262e1">80,666</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0MQ_1e13c53e-afc3-4d1d-bf51-10d1aa8d3f47" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:63.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNS0xLTEtMS04MTcyMw_f1b2e555-5d2f-47c7-9aaf-e998a760eff4">3,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CurrentForeignTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNS0zLTEtMS04MTcyMw_a8decd77-aea4-480c-aef3-54aae744dfe4">288</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNi0xLTEtMS04MTcyMw_89bce2d0-5a87-4b68-8573-4b0692687029">3,875</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNi0zLTEtMS04MTcyMw_75122650-bb73-4496-ad65-0b471558e29f">288</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0Mg_0fe1cf52-880d-42d8-af63-35541b7b3314" escape="true"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:63.632%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.161%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.163%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfMi0xLTEtMS04MTcyMw_ad1c0821-0e43-4db5-9d79-9e7a19d53888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfMi0zLTEtMS04MTcyMw_27407cb2-4576-43a3-bebf-910d9b1bc934">3,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfNC0xLTEtMS04MTcyMw_f7b14c34-15ed-4f4f-819f-a030a4f3b294">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfNC0zLTEtMS04MTcyMw_92b658c3-a9c7-4013-b438-e9463ad7e114">3,969</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMzcw_0bad64ba-e318-4a86-befe-34e386fb083a">3.9</ix:nonFraction> million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was <ix:nonFraction unitRef="usd" contextRef="ifedd00e94bff4f138a71518235d8f0c2_I20220630" decimals="-3" name="us-gaap:IntangibleAssetsCurrent" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNDc4_44b93f47-6c86-4c2d-b0b3-ffaf5552e92b">zero</ix:nonFraction>, which resulted in an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="if2acfaa03f15458fb09624b5d55af0b1_D20220401-20220630" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNTI0_0f04f25f-a7ff-4067-abf9-1cd44335d92e">14.7</ix:nonFraction>&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-5" sign="-" name="sesn:IncreaseDecreaseInDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNjMz_c24841ee-d0c4-439b-9e1c-c146ff6281e5">4.0</ix:nonFraction> million as an income tax benefit, partially offset by $<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNjgy_39029350-37a3-4bce-816f-9edb05d5b81f">0.1</ix:nonFraction> million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) (the &#8220;Qilu License Agreement&#8221;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $<ix:nonFraction unitRef="usd" contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTAyNg_679a3195-aed6-4373-b457-2eb43b1d0b7f">0.3</ix:nonFraction> million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div></ix:continuation><div id="i4adf13376f39486da283bda7a521a795_85"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="sesn:LicenseAgreementTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjE2OTQ_473c7e7d-5c2e-489d-a73d-c715cac7daf1" continuedAt="ibed2fc644e1d4fc5ad9d0837f91c72d2" escape="true">LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="ibed2fc644e1d4fc5ad9d0837f91c72d2" continuedAt="iab52b63f34904217b50327ad248dc607"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $<ix:nonFraction unitRef="usd" contextRef="i9efed9b3cf4e4e64b6b1d76a87c5d8a5_D20220101-20220630" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjUz_75e1d140-a312-4812-a2d6-b0883ae90a7f">0.5</ix:nonFraction>&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a <ix:nonFraction unitRef="number" contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzY2_8a03ccde-d6eb-4919-a043-fb785271b4c2">4</ix:nonFraction>% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is <ix:nonFraction unitRef="number" contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTA2Mg_6fa2f0c6-d252-4295-a8dc-e3146f3fd42f">10</ix:nonFraction>% or greater, provided that the royalty rate to Zurich may not be less than <ix:nonFraction unitRef="number" contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTEzOQ_be421c80-f473-4b07-abc8-3238f7a772c2">2</ix:nonFraction>% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $<ix:nonFraction unitRef="usd" contextRef="ie802f22fd3164257a0a27630574179f1_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzMQ_b4e6c2b7-3abe-4121-80b3-b91147922624">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i854149fe8e0748178452739c0ae5c742_D20210701-20210930" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzOA_369aa0c0-0fca-4104-917e-936fc3dd82be">0.5</ix:nonFraction>&#160;million </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="iab52b63f34904217b50327ad248dc607" continuedAt="i32d7c63bbb554780b2f8e4e3f04192ea"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#8364;<ix:nonFraction unitRef="eur" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjI5Mw_937ae177-4720-4dc2-a3af-2d2659de2eaa">2.4</ix:nonFraction>&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $<ix:nonFraction unitRef="usd" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjQ0MA_5a319b4b-e3f5-4c6b-8da2-20133cd11de9">2.5</ix:nonFraction>&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a <ix:nonFraction unitRef="number" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjUyMw_6d51955c-14bf-4dca-956e-55f21b91c404">3.5</ix:nonFraction>% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to <ix:nonFraction unitRef="number" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjY5Mg_30551dd6-0ed9-4b1a-a6cf-8e40bc471564">1.5</ix:nonFraction>% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;<ix:nonFraction unitRef="eur" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="-3" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzA4NQ_48cde6ac-ee1d-4090-8f87-3cbd8aa43c65">50,000</ix:nonFraction> (approximately $<ix:nonFraction unitRef="usd" contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630" decimals="0" name="sesn:LicenseMaintenanceFees" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzEwMw_fb64c5a5-80aa-4c4a-b5f2-e251717f0f49">52,148</ix:nonFraction> at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzI1OQ_79112045-aebc-4d0a-837a-cc61094adef8">0.7</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzI2Mw_678d85eb-f04f-48b0-9759-ec6e1d4bf712">0.9</ix:nonFraction>&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;<ix:nonFraction unitRef="eur" contextRef="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzQ4NA_d97d75d7-30dc-4fa1-ba2c-4b1c897f5a56">0.5</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331" decimals="-5" name="sesn:LicenseAgreementMilestoneAchievementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzQ4OA_048c4f36-2ec0-4dcb-87c8-faccb003b69c">0.6</ix:nonFraction>&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $<ix:nonFraction unitRef="usd" contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630" decimals="-4" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDA2OA_5428a9eb-29a2-465f-9e6b-280f6c9a4f23">0.25</ix:nonFraction>&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a <ix:nonFraction unitRef="number" contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDI1Nw_433513b4-37a7-42c3-b019-3944fbb8aa39">2.5</ix:nonFraction>% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than <ix:nonFraction unitRef="number" contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDU3NQ_180281d5-5113-4a12-9677-1b93dff773b4">1.75</ix:nonFraction>% of net sales. In addition, the foregoing royalty rates are reduced by <ix:nonFraction unitRef="number" contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630" decimals="INF" name="sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDY0OA_661d9885-ab0d-4d23-a96b-090345717008">50</ix:nonFraction>% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $<ix:nonFraction unitRef="usd" contextRef="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementUpfrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNTg1OA_f89d6e57-7873-44b6-bbdb-6fb2043fa5e0">7.5</ix:nonFraction>&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAdditionalUpFrontFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjAyNA_ee3bbf3f-069e-4e39-8593-5ca190fd1f7c">262.5</ix:nonFraction>&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $<ix:nonFraction unitRef="usd" contextRef="ifecdde588859469e8e663b340243baa1_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjIxMA_f57a476b-0dff-4839-9373-21d63f09c029">197.5</ix:nonFraction>&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $<ix:nonFraction unitRef="usd" contextRef="i4b29722132a2491b9d2cee4b49fb0c77_D20160801-20160831" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjMzOQ_a8d3ea21-8efd-4a3c-aede-640d81e4d0eb">72.5</ix:nonFraction>&#160;million in development milestones, the next of which is $<ix:nonFraction unitRef="usd" contextRef="i3d68c476afcf40a88a2b8fed6118ee9c_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjM5MA_56066336-17d8-41d0-b8a9-5d1a0278d490">30</ix:nonFraction>&#160;million for initiation of the first Phase III clinical trial, (ii) $<ix:nonFraction unitRef="usd" contextRef="ia2a1e9da126143cfb0de4e11868d0606_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjQ1Mg_01613410-ade8-45b0-a9a5-99f503ade19a">50</ix:nonFraction>&#160;million in regulatory milestones and (iii) $<ix:nonFraction unitRef="usd" contextRef="i8e7b4ebb5c66413dafd7bfce298dfeae_D20160801-20160831" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjQ5MA_7972f4e9-ad91-4f60-829b-cedef0a4898e">75</ix:nonFraction>&#160;million in commercialization milestones. Additional amounts of up to $<ix:nonFraction unitRef="usd" contextRef="i3267071fa5d04b21a986ab51df8e6d15_D20220101-20220630" decimals="-6" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjU1NA_4144fadd-8ad1-41e2-b3fc-1e76fa3f3bca">65</ix:nonFraction>&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $<ix:nonFraction unitRef="usd" contextRef="i1ee271f6d7d2411fb58ddc98730fe4e1_D20160901-20160930" decimals="-5" name="sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjc0Mw_ebb95cb1-a319-4bd0-8bc0-4bf8f9738383">22.5</ix:nonFraction>&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $<ix:nonFraction unitRef="usd" contextRef="i2df0e9d706854cfeb872dc1154160218_I20211231" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjg4Ng_a20cf78e-4212-4cd5-9e02-e42826bdb246">20</ix:nonFraction>&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i32d7c63bbb554780b2f8e4e3f04192ea" continuedAt="if4674f5c5cc2446c9bef27a87ff2c597"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $<ix:nonFraction unitRef="usd" contextRef="i766fbeb7225c4f8d80f3cee6c943dbef_I20220630" decimals="-6" name="sesn:LicenseAgreementMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzI5Ng_139b5105-5fa6-483d-9157-489db9c12a4d">20</ix:nonFraction>&#160;million with payment terms of <ix:nonNumeric contextRef="i02e5980cf4114748bd928cad4eae85c4_D20220101-20220630" name="sesn:AccountsReceivablePaymentTerms" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzMyMQ_b19f3048-e0dc-4e35-8352-9fc78fff7ffd">30</ix:nonNumeric> days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $<ix:nonFraction unitRef="usd" contextRef="i09f960acf0aa42bf81e936538879aed3_D20211001-20211231" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzQzNw_a8fe8e89-9afb-4e70-a0e2-18da67d1d559">20</ix:nonFraction>&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $<ix:nonFraction unitRef="usd" contextRef="ia91fb5103aca4101b34beb81fb97be24_D20220101-20220131" decimals="-6" name="sesn:LicenseAgreementProceedsFromMilestoneAchieved" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzU2MA_28b0456d-a829-405c-a3b2-1f1ff44185af">20</ix:nonFraction>&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from <ix:nonFraction unitRef="number" contextRef="i679f24e2f48e415897b49d6af88b722c_I20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzcxNQ_70837cd7-c80e-4fc3-b8cb-5503d8c175dc">7.5</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ifd9b09daca514c3cad0def62ecf0ce84_I20220630" decimals="INF" name="sesn:LicenseAgreementRoyaltyRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzcyMQ_27374077-a679-4259-9365-083759c3c520">15</ix:nonFraction>% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for <ix:nonFraction unitRef="period" contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" decimals="INF" name="sesn:LicenseAgreementOptionPeriods" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODA2MA_362c3205-44d8-4c4b-a75f-ee325980f532">two</ix:nonFraction> &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $<ix:nonFraction unitRef="usd" contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODU1OQ_30d4b1c8-409d-4abe-98a4-7faa5804cec8">135</ix:nonFraction>&#160;million within <ix:nonNumeric contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODU2OQ_ce9e1195-d782-4874-8adf-c9c851865f1b">30</ix:nonNumeric> days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within <ix:nonNumeric contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" name="sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTA3NQ_2899ffc0-18ba-46b9-885b-0c561c0faa46">30</ix:nonNumeric> days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $<ix:nonFraction unitRef="usd" contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTE3Mw_417f00ed-319b-4627-bb50-2444f3bb9cca">265</ix:nonFraction>&#160;million, which amount would be reduced to $<ix:nonFraction unitRef="usd" contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630" decimals="-6" name="sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTIxMA_ca0813b4-f531-4f3a-a630-1296b59504ce">220</ix:nonFraction>&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $<ix:nonFraction unitRef="usd" contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715" decimals="-6" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTA1MDA_7fdb9290-e6e2-4941-aeec-d5c126ac0da8">70</ix:nonFraction>&#160;million. See further discussion in Note 19. "Subsequent Events".</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTE3Nzk_a43653d3-ec11-41e6-91d3-866ca9e9c4c6">12</ix:nonFraction>&#160;million, and milestone payments totaling up to $<ix:nonFraction unitRef="usd" contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730" decimals="-6" name="sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTE4MjE_c0ac7e28-c0a6-4f8f-bf30-b28cb217f019">23</ix:nonFraction>&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a <ix:nonFraction unitRef="number" contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730" decimals="2" name="sesn:BusinessCombinationRoyaltyPaymentPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTIxMDM_6e5ca68e-8024-49c6-991a-79cd372e52f2">12</ix:nonFraction>% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) <ix:nonNumeric contextRef="id66556ce8bf24b0293558cdda62bbe4b_D20200730-20200730" name="sesn:CollaborativeArrangementRoyaltyPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjE2OTU_ef53f4e7-3f86-4f90-9913-b6c37290abf1">twelve years</ix:nonNumeric> after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="if4674f5c5cc2446c9bef27a87ff2c597" continuedAt="i87a44d9854094feea39f3f9dae67efd8"><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $<ix:nonFraction unitRef="usd" contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUwMjI_0c54161a-ec8d-4384-88c7-a61607951196">11.2</ix:nonFraction>&#160;million and was based on the up-front fixed consideration of $<ix:nonFraction unitRef="usd" contextRef="i954601fe3b9448cbaecd65eed3c97e5d_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUwNzg_b46c4ae1-dd45-4622-9629-e5af04805591">12</ix:nonFraction>&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $<ix:nonFraction unitRef="usd" contextRef="i1291fa4c92d24233b8c7dd158c7d657d_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUyOTI_66f5bb52-d546-4d13-9123-46fb956586ad">11.2</ix:nonFraction>&#160;million of the total $<ix:nonFraction unitRef="usd" contextRef="i1291fa4c92d24233b8c7dd158c7d657d_I20200930" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzMDg_7b7f72c7-9d58-4736-9480-f3ddae239166">11.2</ix:nonFraction>&#160;million transaction price was considered earned and the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i93a8a67c88394769861872b5ee4d03a3_D20200701-20200930" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzNzY_b5d15a83-b030-498d-a265-94756fe33cf9">11.2</ix:nonFraction>&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $<ix:nonFraction unitRef="usd" contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331" decimals="-6" name="sesn:BusinessCombinationMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU2NDg_ffa78f66-5540-42d9-8fde-317a6803dd0e">3</ix:nonFraction>&#160;million milestone payment from Qilu, the first milestone payment out of the $<ix:nonFraction unitRef="usd" contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331" decimals="-6" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU3MTk_abf31f1b-9f86-481a-8b5f-2838e5cef094">23</ix:nonFraction>&#160;million in potential milestone payments. The Company recorded $<ix:nonFraction unitRef="usd" contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU3NzY_3f4615a6-3410-4b9b-89c8-995568a43693">2.8</ix:nonFraction>&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="ia72f93a71c7a43cb954ae37e2265780b_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTYxODU_41219984-76fb-4c71-837c-c178c803857d">0.9</ix:nonFraction>&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i026b9908503a4d88b10ca249424b3644_D20201130-20201130" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTcwODg_c3c031c1-b877-49f4-aece-f1086de143ab">3</ix:nonFraction>&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $<ix:nonFraction unitRef="usd" contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc1MTk_9937cab8-587d-4879-be50-c4c66bf75cd6">1.5</ix:nonFraction>&#160;million as of December 31, 2020 and was based on <ix:nonFraction unitRef="number" contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc1NjM_ac3e60fe-7596-415a-b6c7-256a83b10ea9">50</ix:nonFraction>% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($<ix:nonFraction unitRef="usd" contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc3MTc_18b8009a-9ee9-4439-ac22-b22e60390449">1.5</ix:nonFraction>&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $<ix:nonFraction unitRef="usd" contextRef="ib2e92c8a7aef406ca55775a1f5db7e70_I20220630" decimals="-5" name="us-gaap:DeferredRevenue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTgxMDY_2841c319-b014-4300-a1fe-0c3181559db2">1.5</ix:nonFraction>&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $<ix:nonFraction unitRef="usd" contextRef="ic828b0a647374e389c1cd7b05992e6a6_D20210101-20210331" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTg3MTc_37c897d6-5336-4e68-a8e5-11b0f2185a6e">1.5</ix:nonFraction>&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i87a44d9854094feea39f3f9dae67efd8" continuedAt="i6e4dc6b858464933bdf47e9f8f25f1af"><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, the Company terminated the MENA License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ied4b92f7d8494337810a4188d290be4d_I20210805" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAwMDg_bb67d81f-3e94-44c4-8435-68afdf50f48c">1.5</ix:nonFraction>&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $<ix:nonFraction unitRef="usd" contextRef="i6b11a504e94346c7b3df6f09cff921f5_D20210805-20210805" decimals="-5" name="sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAyNjQ_d215bd97-2281-4e52-bd61-21948d9e691d">2.0</ix:nonFraction>&#160;million and is also entitled to receive a <ix:nonFraction unitRef="number" contextRef="i5f2b242b85564774a29503984368afdf_I20210805" decimals="2" name="sesn:RoyaltyRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAzMDE_1e42bbc6-b496-4784-af0c-61c043e1ed9d">30</ix:nonFraction>% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therefore, no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><ix:continuation id="i6e4dc6b858464933bdf47e9f8f25f1af" continuedAt="ibb16c685972946e4b923df42e0b7cc7e"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span></ix:continuation><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibb16c685972946e4b923df42e0b7cc7e">, 2022, the Company terminated the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</ix:continuation>"</span></div><div id="i4adf13376f39486da283bda7a521a795_88"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfMTIyMw_e5ef7ba1-65f5-4321-b184-6e9c09e4ee0b" continuedAt="ice7bb07c1b964434a47be324a4a95d00" escape="true">RESTRUCTURING AND RELATED ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="ice7bb07c1b964434a47be324a4a95d00" continuedAt="i6b0c2aa892c144a4924f571cd00a9b03"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by <ix:nonFraction unitRef="position" contextRef="if5efc2997de54bc79f8412086513351d_D20210830-20210830" decimals="INF" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfNDI5_f2127c09-8b0c-40bc-ad2e-80e810972094">18</ix:nonFraction> positions (or approximately <ix:nonFraction unitRef="number" contextRef="if5efc2997de54bc79f8412086513351d_D20210830-20210830" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfNDYw_37912e45-1e25-4851-ab55-e0c65e23f300">35</ix:nonFraction>% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfMTIyNA_56da16ff-f4a3-4259-8c9d-9255dbee3e6b" continuedAt="i2aba500b399e4dbfafa4cdeb12cdd326" escape="true">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):</ix:nonNumeric></span></div><div><ix:continuation id="i2aba500b399e4dbfafa4cdeb12cdd326"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:81.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.548%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231" decimals="-3" name="us-gaap:RestructuringReserve" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMC0xLTEtMS04MTcyMw_e2f1eb9a-30b3-4233-883f-db8525b4befe">1,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" decimals="-3" name="us-gaap:PaymentsForRestructuring" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMS0xLTEtMS04MTcyMw_6c9ea117-72b2-4e9f-96ee-6188643b8280">1,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816282644abc45028662a05fb3344b4b_I20220630" decimals="-3" name="us-gaap:RestructuringReserve" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMi0xLTEtMS04MTcyMw_c354c4b9-deff-4995-ba68-87cb2ae921d3">394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div></ix:continuation><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6b0c2aa892c144a4924f571cd00a9b03">Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</ix:continuation>"</span></div><div id="i4adf13376f39486da283bda7a521a795_91"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19. <ix:nonNumeric contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfODQ4NA_ee36ed15-2b52-4757-827c-7b60d47a7dcb" continuedAt="i7aba125d505140c588b1c0ca207f2b84" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><ix:continuation id="i7aba125d505140c588b1c0ca207f2b84" continuedAt="i4912b4cc804b4a2a874bcfac88f5032e"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i4912b4cc804b4a2a874bcfac88f5032e" continuedAt="i40c8148e7e944d57996b920919b7a88f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Development Partnerships</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715" decimals="-6" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfMzM4MA_bff56a23-0762-4696-a81b-02a3dff4af0f">8</ix:nonFraction>&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company executed an asset purchase agreement (the &#8220;Roche Asset Purchase Agreement&#8221;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $<ix:nonFraction unitRef="usd" contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715" decimals="-3" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfMzk2MQ_19e73d48-dee9-495e-8e60-263bc2250400">70</ix:nonFraction>&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $<ix:nonFraction unitRef="usd" contextRef="ic23bc63aeb3e40ed84c761fb713ce86a_D20220715-20220715" decimals="-6" name="sesn:ProceedsFromExecutionOfAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfNDIzMQ_37eeebba-ce75-419e-ade6-3364708724f7">40</ix:nonFraction>&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $<ix:nonFraction unitRef="usd" contextRef="ic081fe4045014466be04516c1871acf9_I20220808" decimals="-3" name="sesn:OtherReceivableAssetPurchaseAgreement" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfNDM5NQ_eaed9ee8-6702-4b44-9ec6-c019231acd21">30</ix:nonFraction>&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and Derivative Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><ix:continuation id="i40c8148e7e944d57996b920919b7a88f"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Market </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) to transfer the listing of the Company&#8217;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#8220;Approval&#8221;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#8220;SESN&#8221;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_94"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations, as well as other sections in this Quarterly Report on Form 10-Q, should be read in conjunction with our unaudited interim condensed consolidated financial statements and related notes thereto appearing elsewhere herein and our audited annual consolidated financial statements and related notes thereto and &#8220;Management's Discussion and Analysis of Financial Condition and Results of Operations&#8221; for the year ended December&#160;31, 2021, included in our Annual Report on Form 10-K filed with the United States Securities and Exchange Commission (&#8220;SEC&#8221;) on February 28, 2022. In addition to historical financial information, some of the information contained in the following discussion and analysis contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"). All statements other than statements of historical facts, including statements regarding our future results of operations and financial position, the impact of the COVID-19 pandemic, business strategy, current and prospective products, product approvals, research and development costs, current and prospective collaborations, timing and likelihood of success, plans and objectives of management for future operations and future results of current and anticipated products, are forward-looking statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to continue to assess potential strategic alternatives with the goal of maximizing shareholder value;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intentions to seek a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing of implementing and completing our restructuring plan following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;);</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the expected timing for incurring costs associated with the 2022 Restructuring Plan;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to preserve capital while we continue to assess potential strategic alternatives and seek a potential partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential impact of the COVID-19 pandemic on our ability to identify and assess potential strategic alternatives and seek a partner for the further development of Vicineum;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our projected financial position;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain intellectual property protection for our product candidates and our proprietary technology;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our beliefs regarding key advantages of our targeted fusion protein therapeutics (&#8220;TFPT&#8221;) platform; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our expectations regarding the amount of future milestone payments pursuant to our Asset Purchase Agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;), (the &#8220;Roche Asset Purchase Agreement&#8221;) and any future milestone or royalty payments pursuant our exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) for the development, manufacture and commercialization of Vicineum in China, Hong Kong, Macau and Taiwan ("Greater China") (the &#8220;Qilu License Agreement&#8221;).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and involve known and unknown risks, uncertainties, assumptions and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, among others, the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in identifying one or more strategic alternatives or ultimately pursuing a strategic alternative that delivers the anticipated benefits or enhances shareholder value;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be successful in identifying a partner for the further development of Vicineum;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our exploration and evaluation of strategic alternatives may cause our stock price to fluctuate significantly;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not be able to implement the 2022 Restructuring Plan as currently anticipated or within the timing currently anticipated;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the workforce reduction in connection with the 2022 Restructuring Plan may have a negative impact on our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our cost saving initiatives in connection with the 2022 Restructuring Plan may not be successful;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have unanticipated difficulties with preserving capital or unanticipated difficulties in terminating certain contracts and arrangements in connection with the 2022 Restructuring Plan; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may incur unanticipated charges as a result of the 2022 Restructuring Plan; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk that the respective courts may not approve any settlements agreed to by the parties to the ongoing securities litigation and the derivative litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to obtain, maintain, defend and enforce patent claims and other intellectual property rights; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to defend against pending or threatened litigation, which may be costly and time-consuming;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not meet the Nasdaq minimum bid price requirement during any compliance period or in the future; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">such other factors described throughout Part I, Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part II, Item 1A. Risk Factors in this Quarterly Report on Form 10-Q and throughout Part II, Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations and in Part I, Item 1A. Risk Factors of our Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for us to predict all risks and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless the context otherwise requires, all references in this Quarterly Report on Form 10-Q to the &#8220;Company,&#8221; &#8220;Sesen,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; include Sesen Bio, Inc. and its subsidiaries.</span></div><div id="i4adf13376f39486da283bda7a521a795_97"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our most advanced product candidate, Vicineum, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pseudomonas exotoxin A</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following our discussions with the United States Food and Drug Administration ("FDA"), which are further described below. We have turned our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, we intend to seek a partner for the further development of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Events</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Assessment of Potential Strategic Alternatives</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 3, 2022, we announced that we initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following the decision to pause further development of Vicineum in the US. Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in our workforce as well as additional cost-saving initiatives intended to preserve capital while we continue to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, we estimate that we will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8 million. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also expect to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and are in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">owned by us for up to $70 million. As a result of the Roche Asset Purchase Agreement, the exclusive license agreement between Roche and us was terminated resulting in no further diligence, milestone or royalty payment obligations under such license agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40 million payment to us upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30 million payable to us upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Update</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2020, we submitted our completed BLA for Vicineum for the treatment of BCG-unresponsive NMIBC to the FDA, which was accepted for filing by the FDA in February 2021. The FDA granted Priority Review for the BLA and set a target PDUFA date for a decision on the BLA of August 18, 2021. On August 13, 2021, we received a CRL from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality. On August 20, 2021, we withdrew our marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum for the treatment of BCG-unresponsive NMIBC in order to pause our plans to pursue regulatory approval of Vysyneum in the EU until there is more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox in the EU. In October 2021, the EMA issued its Withdrawal Assessment Report relating to our MAA for Vysyneum, as is consistent with the EMA&#8217;s standard practice when an MAA is withdrawn. The EMA Withdrawal Assessment Report reflects the initial assessment and corresponding questions from the EMA and identifies major objections in the areas of quality, good clinical practice, efficacy and safety. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, we participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, we participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, we participated in a Type B meeting with the FDA to discuss outstanding items related to our proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following our discussions with the FDA. As a result of this decision, we no longer plan to pursue regulatory approval of Vicineum for NMIBC in the EU. We have turned our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, we intend to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Prior Phase 3 Clinical Trial &#8211; VISTA Trial</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2015 in the United States and Canada, through our subsidiary Viventia, we commenced our single-arm, multi-center, open-label Phase 3 clinical trial (&#8220;VISTA Trial&#8221;) in patients with BCG-unresponsive NMIBC who have received adequate BCG and whose disease is now BCG-unresponsive, and for whom the then-current standard of care was a radical cystectomy. Based on safety and efficacy data observed with the longer 12-week induction in our Phase 2 clinical trial, the FDA agreed to our plan to employ more frequent dosing in the VISTA Trial, in which the primary endpoints were complete response (&#8220;CR&#8221;) and duration of response (&#8220;DoR&#8221;) in patients with CIS whose disease is BCG-unresponsive. In November 2016, the FDA issued draft guidance regarding appropriate clinical trial design for new drugs and biologics for BCG-unresponsive NMIBC, including the use of single-arm trials. The FDA finalized this guidance in February 2018 and retained many of the recommendations from the 2016 draft guidance regarding clinical trial design, including the use of single-arm trials. We believe that our VISTA Trial design was consistent with these aspects of the FDA&#8217;s guidance. In May 2022, we completed the follow-up phase of the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The VISTA Trial completed enrollment in April 2018 with a total of 133 patients across three cohorts based on histology and time to disease recurrence after adequate BCG treatment:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 1 (n=86): Patients with CIS with or without papillary disease that was</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> determined to be r</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">efractory or recurred within six months of their last course of adequate BCG;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 2 (n=7): Patients with CIS with or without papillary disease that recurred after six months, but less than 11 months, after their last course of adequate BCG; and </span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cohort 3 (n=40): Patients with high-risk (Ta or T1) papillary disease without CIS that recurred within six months of their last course of adequate BCG.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoints of the VISTA Trial were CRR at 3 months in patients with CIS (with or without papillary disease) whose disease is BCG-unresponsive and DoR for BCG-unresponsive CIS patients who experience a CR.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, preliminary primary and secondary endpoint data for each of the trial cohorts were as follows:</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 1 (n=86) Evaluable Population (n=82) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">39% (28%-50%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">26% (17%-36%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">20% (12%-30%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=82</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-27%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 2 (n=7) Evaluable Population (n=7) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">57% (18%-90%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">43% (10%-82%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=7</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">14% (0%-58%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pooled Cohorts 1 and 2 (n=93) Evaluable Population (n=89) Complete Response Rate, for CIS:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Complete Response Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=89</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td></tr></table></div><div style="margin-bottom:12pt;margin-top:3pt;text-align:justify;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 3 Pooled Complete Response Rate vs. Phase 2 Pooled Complete Response Rate:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:73.245%"><tr><td style="width:1.0%"></td><td style="width:16.265%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.217%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.218%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 3 Pooled CRR (95% Confidence Interval)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Phase 2 Pooled CRR (95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (30%-51%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">40% (26%-56%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">28% (19%-39%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">27% (15%-42%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">21% (13%-31%)</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">18% (8%-32%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">17% (10%-26%)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">16% (7%-30%)</span></div></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cohort 3 (n=40) Evaluable Population (n=38) Recurrence-Free Rate&#8224;:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.122%"><tr><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.059%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:64.582%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Time Point</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Evaluable Patients*</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Recurrence-Free Rate</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">(95% Confidence Interval)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">71% (54%-85%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">6-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">58% (41%-74%)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">9-months</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">45% (29%-62%)</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">12-months</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">n=38</span></div></td><td colspan="3" style="border-bottom:1pt solid #000000;border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">42% (26%-59%)</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8224;Recurrence-free rate is defined as the percentage of patients that are recurrence-free at the given assessment time point.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:center;text-indent:63pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Response-evaluable population includes any mITT patient who completed the induction phase.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Duration of Response:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median DoR for patients in Cohort 1 and Cohort 2 combined (n=93) is 287 days (95% CI, 154-NE), using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis of pooled data for all patients with CIS (Cohorts 1 and 2, n=93) shows that among patients who achieved a complete response at 3 months, 52% remained disease-free for a total of 12 months or longer after starting treatment, using the Kaplan-Meier method. DoR is defined as the time from first occurrence of complete response to documentation of treatment failure or death.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;We have conducted additional analyses for secondary endpoints. These additional data include the following:</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Cystectomy:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Across all 133 patients treated with Vicineum in the VISTA Trial, greater than 75% of all patients are estimated to remain cystectomy-free at 3 years, using the Kaplan-Meier method. Additional </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ad hoc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> analysis shows that approximately 88% of responders are estimated to remain cystectomy-free at 3 years. Time to cystectomy is defined as the time from the date of first dose of study treatment to surgical bladder removal. The first 2018 FDA guidance on treatment of BCG-unresponsive NMIBC patients states that the goal of therapy in such patients is to avoid cystectomy. Therefore, time to cystectomy was a key secondary endpoint in the VISTA Trial. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Time to Disease Recurrence:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> High-grade papillary (Ta or T1) NMIBC is associated with high rates of progression and recurrence. The median time to disease recurrence for patients in Cohort 3 (n=40) is 402 days (95% CI, 170-NE), using the Kaplan-Meier method. Time to disease recurrence is defined as the time from the date of the first dose of study treatment to the first occurrence of treatment failure or death on or prior to treatment discontinuation. </span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Progression-Free Survival ("PFS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain progression-free for 2 years or greater, using the Kaplan-Meier method. PFS is defined as the time from the date of first dose of study treatment to the first occurrence of disease progression (e.g., T2 or more advanced disease) or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:3pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Event-Free Survival:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 29% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to remain event-free at 12 months, using the Kaplan-Meier method. Event-free survival is defined as the time from the date of first dose of study treatment to the first occurrence of disease recurrence, progression or death on or prior to treatment discontinuation.</span></div><div style="margin-bottom:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Overall Survival ("OS"):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96% of all 133 patients treated with Vicineum in the VISTA Trial are estimated to have an overall survival of 2 years or greater, using the Kaplan-Meier method. OS is defined as the time from the date of first dose of study treatment to death from any cause.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data is as of the May 29, 2019 data cut from the Phase III VISTA Trial. The clinical data shown are based on the data submitted in the BLA on December 18, 2020. On August 13, 2021, the FDA issued a CRL for the BLA that included requests for additional clinical and statistical data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Safety Results</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the May 29, 2019 data cutoff date, in patients across all cohorts (n=133) of our Phase 3 VISTA Trial of Vicineum for the treatment of BCG-unresponsive NMIBC, 88% experienced at least one adverse event, with 95% of adverse events being Grade 1 or 2. The most commonly reported treatment-related adverse events were dysuria (14%), hematuria (13%) and urinary tract infection (12%) - all of which are consistent with the profile of bladder cancer patients and the use of catheterization for treatment delivery. These adverse events were determined by the clinical investigators to be manageable and reversible, and only four patients (3%) discontinued treatment due to an adverse event. Serious adverse events, regardless of treatment attribution, were reported in 14% of patients. There were four treatment-related serious adverse events reported in three patients including acute kidney injury (Grade 3), pyrexia (Grade 2), cholestatic hepatitis (Grade 4) and renal failure (Grade 5 or death). There were no age-related increases in adverse events observed in the VISTA Trial.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, we entered into a Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A., Inc. (&#8220;Fujifilm&#8221;) (the "Fujifilm MSA") for the manufacturing process and technology transfer of Vicineum drug substance production. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, we entered into a Commercial Manufacturing and Supply Agreement with Baxter (the &#8220;Baxter CMSA&#8221;) for the manufacturing process and technology transfer of Vicineum drug product production.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, we entered into a Global Supply Agreement with Qilu pursuant to which Qilu will be part of the manufacturing network for, if approved, global commercial supply of Vicineum drug substance and drug product. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Fujifilm MSA and Baxter CMSA on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. We are in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with the University of Zurich (&#8220;Zurich&#8221;) which grants us exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to our targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a License Agreement with Micromet AG (&#8220;Micromet&#8221;), now part of Amgen, Inc., which grants us nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a license agreement with XOMA Ireland Limited (&#8220;XOMA&#8221;) which grants us non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notwithstanding our decision to voluntarily pause further development of Vicineum, we have not taken steps to terminate the above mentioned in-license agreements because our outside the United States (&#8220;OUS&#8221;) business development partners have been granted sublicenses to the intellectual property licensed to us under these in-license agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">OUS Business Development Partnering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our OUS business development partnerships in the Middle East and North Africa region (&#8220;MENA&#8221;) and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022. In connection with the termination of our exclusive license agreement with our partner in MENA, we are required to refund the $3&#160;million upfront payment paid to us.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Greater China</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, we and our wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which we granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by us, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum for the treatment of BCG-unresponsive NMIBC and other types of cancer in China, Hong Kong, Macau and Taiwan ("Greater China"). We also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by us to develop, manufacture and commercialize Vicineum in Greater China. We retain (i) development and commercialization rights in the rest of the world excluding Greater China and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding Greater China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2020, we received a total of $10 million in net proceeds associated with the Qilu License Agreement. We are also entitled to receive up to an additional $23 million upon the achievement of certain technology transfer, development and regulatory milestones, as well as a 12%</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> royalty based upon annual net sales of Vicineum in Greater China. The royalties are payable upon the first commercial sale of Vicineum in a region and continuing until the latest of (i) twelve years after the first commercial sale of Vicineum in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of Vicineum in such region, and (iii) the expiration of regulatory or data exclusivity for Vicineum in such region. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers Vicineum in a particular region or no data or regulatory exclusivity of Vicineum in a particular region. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application ("IND") for Vicineum submitted by Qilu to the Center for Drug Evaluation of the China National Medical Products Administration was accepted for review in January 2021 and approved in March 2021, resulting in a $3 million milestone payment from Qilu, the first milestone payment out of the $23 million in potential milestone payments. We recorded $2.8 million (net of VAT) as license revenue during the three-month period ended March 31, 2021. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of value-added tax ("VAT") recovery. As such, we recorded $0.9 million of revenue during the three months ended June 30, 2021, for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. We will not be subject to VAT on future potential milestone payments to Qilu. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 20, 2021 we and Qilu announced the enrollment of the first patient in China in a Phase 3 clinical trial to assess the efficacy and safety of Vicineum in patients with BCG-unresponsive NMIBC. The open-label, single-arm, multi-center bridging trial will evaluate the efficacy and safety of Vicineum in approximately 53 patients with carcinoma in situ (CIS) with or without papillary disease, high-grade Ta papillary disease or T1 papillary disease of any grade. Patients will be required to have failed previous treatment with BCG for inclusion in the trial. The primary endpoints are the complete response rate (for CIS patients) and the recurrence-free rate (for papillary patients) at six months, with the complete response rate and the recurrence-free rate at three months, safety and tolerability as the secondary endpoints. Based on the Qilu License Agreement, the trial is being run at the sole cost of Qilu.</span></div><div id="i4adf13376f39486da283bda7a521a795_100"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License and Related Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenue consists of revenue recognized pursuant to our </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization partnership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> agreements, including the Qilu License Agreement, which is assessed under ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606"). In the future, we may generate revenue from a combination of milestone payments and royalties in connection with the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for the development of Vicineum for the treatment of NMIBC, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, benefits, travel and share-based compensation expense;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with contract resource organizations (&#8220;CROs&#8221;) and investigative sites that conduct our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with developing manufacturing capabilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with transferring manufacturing capabilities to contract manufacturing organizations ("CMOs") for commercial-scale production;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include direct and allocated expenses for rent and maintenance of facilities, insurance and other supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with regulatory activities; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses associated with license milestone fees.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. We recognize external development costs based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and our clinical sites.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocate direct research and development expenses, consisting principally of external costs, such as fees paid to investigators, consultants, central laboratories and CROs in connection with our clinical trials, costs related to manufacturing or purchasing clinical trial materials and technology transfer and license milestone fees, to specific product programs. We do not allocate employee and contractor-related costs, costs associated with our platform and facility expenses, including depreciation or other indirect costs, to specific product programs because these costs may be deployed across multiple product programs under research and development and, as such, are separately classified. The table below provides research and development expenses incurred for Vicineum for the treatment of NMIBC and other expenses by category. We expect to significantly reduce our research and development expenses as we turn our primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value and seek a partner for the further development of Vicineum.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not allocate research and development expenses to any other specific product program during the periods presented (in thousands):</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Programs:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum for the treatment of NMIBC</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,432&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,892&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total direct program expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,332&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,892&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel and other expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee and contractor-related expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,080&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,660&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Platform-related lab expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facility expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">268&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total personnel and other expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,512&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,896&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,813&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,408&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Research and Development</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,944</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,228</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">34,705</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,306</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and related costs for personnel, including share-based compensation and benefits, in executive, operational, finance, legal, business development and human resource functions. Other general and administrative expenses include facility-related costs, professional fees for legal, estimated payments to settle litigation, insurance, investment banking fees, patent, consulting and accounting services, and pre-commercial United States market research. Our general and administrative expenses may increase due to increases in professional and advisory fees as we assess potential strategic alternatives.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Viventia Acquisition in September 2016, we recorded contingent consideration pertaining to the amounts potentially payable to Viventia's shareholders pursuant to the terms of the Share Purchase Agreement among us, Viventia and the other signatories thereto and are based on regulatory approval in certain markets and future revenue levels. The fair value of contingent consideration is assessed at each balance sheet date and changes, if any, to the fair value are recognized in earnings (or loss) for the period.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income, Net</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income, net consists primarily of interest income earned on cash and cash equivalents and, to a lesser extent, any gains or losses on foreign exchange.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Benefit for income taxes is driven by the intangible impairment charge, changing the value of deferred tax liabilities. Provision for income taxes consists of income taxes incurred to non-US jurisdictions pursuant to our OUS business development partnership agreements, including the Qilu License Agreement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_103"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the three months ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,234&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,234)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,716&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,589&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,300)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,900)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(374)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,997&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,633&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35,997)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,598)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(43)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(477)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(35,835)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,442)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,393)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(31,960)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(25,442)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6,518)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any revenue for the three months ended June 30, 2022. Revenue for the three months ended June 30, 2021 was $2.2 million, which was due to clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS business development partner for Greater China and license revenue for additional purchase price due to the recovery of VAT by Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $29.9 million for the three months ended June 30, 2022, compared to $7.2 million for the three months ended June 30, 2021. The increase of $22.7 million was primarily due to the expense of prepaid balances related to consumables and manufacturing reservations as the balances were evaluated and deemed to have no future value ($25.2 million). This increase was partially offset by lower costs associated with manufacturing ($2.5 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $15.6 million for the three months ended June 30, 2022, compared to $6.8 million for the three months ended June 30, 2021. The increase of $8.8 million was primarily due to an increase in legal expense ($10.3 million). This increase was driven by the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.6 million), related legal fees ($0.9 million), legal fees related to the internal review ($0.3 million) and other legal expenses ($0.5 million). This increase was partially offset by a decrease in marketing and commercial expenses, which were incurred in the second quarter of 2021 in preparation for potential commercial launch but were discontinued as a result of the Complete Response Letter received in August 2021 ($1.5 million). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $37.3 million for the three months ended June 30, 2022, compared to a loss of $13.6 million for the three months ended June 30, 2021. The decrease in the fair value of contingent consideration of $37.3 million for the three months ended June 30, 2022 was driven by our strategic decision to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">voluntarily pause further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We intend to seek a partner for the further development of Vicineum. We expect that any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a loss of $13.6 million for the three months ended June 30, 2021. This was primarily attributable to changes in the competitive landscape, higher probability of regulatory success, expanded patient population, and to a lesser extent by refinement of timelines in certain markets outside the United States, which was prior to the receipt of a CRL from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Benefit (Provision) from Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, we recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, we determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7 million. In connection with this impairment charge, in the second quarter of 2022, we wrote-down the associated deferred tax liability by $4.0 million as a benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. No provision for income taxes was recorded for the three months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net l</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">oss</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended June 30, 2022, net loss was $32.0&#160;million, compared to net loss of $25.4&#160;million for the three months ended June 30, 2021. The change was primarily attributable to increases in R&amp;D and G&amp;A expense ($31.5 million), primarily driven by the reduction of prepaid balances related to consumables and manufacturing reservations and the preliminary settlements of the securities and derivative litigation. Additionally, license and related revenue recognized decreased ($2.2 million). This was partially offset by favorable changes in non-cash related expenses of $27.0 million (including tax benefit). </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_106"></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Results of Operations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the six months ended June 30, 2022 and 2021 </span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:45.889%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.650%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dollars</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Percentage</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and related revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,544)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,544&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,544)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,564&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,098&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,466&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangibles impairment charge</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,764&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(111,960)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87,164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,331)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(58)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from Operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36,833)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80,620)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(515)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Loss Before Taxes</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">44,024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(55)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefit (provision) from income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,163&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Loss After Taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(32,767)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,954)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,187</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(60)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Revenue</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any revenue for the six months ended June 30, 2022. Revenue for the six months ended June 30, 2021 was $6.5 million, which was due to achieving the IND milestone in China pursuant to the Qilu License Agreement, clinical supply revenue resulting from the delivery of drug product to Qilu, our OUS partner for Greater China, and license revenue for additional purchase price due to the recovery of VAT by Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses were $34.7 million for the six months ended June 30, 2022, compared to $13.3 million for the six months ended June 30, 2021. The increase of $21.4 million was primarily due to the expense of prepaid balances related to consumables and manufacturing reservations as the balances were deemed to have no future value ($25.2 million). This increase was partially offset by lower costs associated with manufacturing ($3.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses were $24.6 million for the six months ended June 30, 2022, compared to $12.1 million for the six months ended June 30, 2021. The increase of $12.5 million was primarily due to an increase in legal expense ($13.3 million) driven by the preliminary settlements of the securities and derivative litigation net of expected insurance recovery ($8.6 million), related legal fees ($1.2 million), legal fees related to the internal review ($3.2 million) and other legal expenses ($0.3 million). In addition, employee-related compensation, primarily driven by increased headcount and the retention program implemented in the fourth quarter of 2021 ($1.2 million) and increased insurance expense ($0.3 million). This was partially offset by decreases in marketing and commercial expenses ($1.7 million) and consultant fees ($0.9 million), which were incurred during the first half of 2021 in preparation for potential commercial launch but were discontinued as a result of the Complete Response Letter received in August 2021 and other general expenses ($0.1 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The non-cash change in fair value of contingent consideration was income of $50.2 million for the six months ended June 30, 2022, compared to a loss of $61.8 million for the six months ended June 30, 2021. The decrease in the fair value of contingent consideration of $50.2 million for the six months ended June 30, 2022 was driven by our strategic decision to voluntarily pause further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We intend to seek a partner for the further development of Vicineum. We expect that any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The change in fair value of contingent consideration was a loss of $61.8 million for the six months ended June 30, 2021. This was primarily attributable to changes in the competitive landscape, higher probability of regulatory success, expanded patient population, and to a lesser extent by refinement of timelines in certain markets outside the United States, which was prior to the receipt of a CRL from the FDA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provision for Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, we recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, we determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7 million. In connection with this impairment charge, in the second quarter of 2022, we wrote-down the associated deferred tax liability by $4.0 million as a benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the Qilu License Agreement. Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, we recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 net loss was $32.8&#160;million, compared to net loss of $81.0 million, for the six months ended June 30, 2021. The decrease of $48.2 million was primarily due to decreases in operating expense ($50.3&#160;million) and the tax provision ($4.2&#160;million) partially offset by a decrease in license and related revenue recognized ($6.5 million). The decrease in operating expense ($50.3&#160;million) was driven by non-cash adjustments ($84.2 million), partially offset by a $33.9 million increase in expense. This increase was primarily due to the reduction of our prepaid balances related to consumables and manufacturing reservations and the preliminary settlements of the securities and derivative litigation. </span></div><div id="i4adf13376f39486da283bda7a521a795_109"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, we had cash, cash equivalents and marketable securities of $161.2 million, </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">net working </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capital of $124.4 million an</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d an accu</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">mulated deficit of $349.0 million. We incurred negative cash flows from operating activities of $1.4 million</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> fo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r the six months ended June 30, 2022, compared to negative cash flows of $41.6 million for the six months ended June 30, 2021.We believe that, based on our current operating plans and financial forecasts, our cash, cash equivalents and marketable securities of $161.2 million as of June&#160;30, 2022, are sufficient to fund our current operating plan for at least twelve months from the date of this Form 10-Q filing, August 8, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have received no revenue from sales of our products, and we anticipate that operating losses will continue for the foreseeable future as we continue to assess any potential strategic alternatives that we may pursue. We have financed our operations to date primarily through private placements of our common stock, preferred stock, common stock warrants and convertible bridge notes, venture debt borrowings, our IPO, follow-on public offerings, sales effected in ATM offerings, our OUS business development partnerships and license agreements and, to a lesser extent, from a collaboration.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into an Open Market Sale Agreement with Jefferies LLC ("Jefferies") dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which we may issue and sell shares of our common stock, par value $0.001 per share from time to time through Jefferies (the "ATM Offering"). In June and July 2021, we filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of our common stock pursuant to the Sale Agreement of which $97.8 million of common shares remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for our common stock. We may sell shares of our common stock efficiently from time to time but have no obligation to sell any of our common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and conditions of the Sale Agreement, Jefferies will use its commercially </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable efforts to sell common stock from time to time, as the sales agent, based upon our instructions, which include a prohibition on sales below a minimum price set by us from time to time. We have provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. We did not sell any shares of common stock pursuant to the Sale Agreement during the six months ended June 30, 2022. We raised $136.8&#160;million of net proceeds from the sale of 47.1 million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021, including $64.3&#160;million of net proceeds from the sale of 16.5 million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issue costs, including sales agent commissions, related to the ATM Offering totaled $2.0 million and $4.2 million for the three and six months ended June 30, 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is dependent on our ability to identify and ultimately consummate a strategic transaction. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a number of risks similar to other clinical companies that have determined to focus primarily on pursuing a strategic transaction, including, but not limited to, those which are described under Part II Item 1A. Risk Factors of this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will incur substantial expenses if and as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">address our ongoing securities litigation and derivative litigation; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain, expand and protect our intellectual property portfolio;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduce our personnel and incur related severance and employee-related costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">wind down and dispose of the equipment and physical infrastructure that had been used to support our research and development activities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate contracts with our CMOs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">terminate our property leases in Winnipeg, Manitoba, Cambridge, Massachusetts and Philadelphia, Pennsylvania;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restore our Winnipeg manufacturing facility to the state in which it was originally leased; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">explore, evaluate and pursue any strategic alternatives in connection with the review process we have initiated.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of any pending or future litigation involving us or our business;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the outcome and timing of the process we have initiated to review strategic alternatives, which may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our obligation to make milestone, royalty and other payments to third-party licensors under our licensing agreements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenues, we expect to finance our cash needs through a combination of equity offerings, debt financings, or government or other third-party funding To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of existing stockholders. Debt financing, if available, may involve agreements that include liens or other restrictive covenants limiting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we are unable to raise additional funds when needed, we may be required to delay, limit, reduce or terminate our assessment of strategic alternatives. If we do not successfully consummate a strategic alternative, our board of directors may decide to pursue a dissolution and liquidation of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual and Other Obligations</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to our cash requirements from known contractual and other obligations, see the description of Contingent Consideration in Note 5 &#8220;Fair Value Measurement and Financial Instruments,&#8221; as well as the description of our leases in Note 11 &#8220;Leases&#8221;, and the description of our license agreement and collaborations in Note 17, &#8220;License Agreements&#8221; of Part I - Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements. </span></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of our cash flows for the six months ended June 30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:68.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.782%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Operating Activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,441)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,616)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Used in Investing Activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(89,095)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Cash Provided by Financing Activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(90,536)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">95,647</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Operating Activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $1.4 million for the six months ended June 30, 2022 and consisted primarily of a net loss of $32.8&#160;million, adjusted for non-cash items including, a decrease in the fair value of contingent consideration ($50.2&#160;million), intangible impairment charge ($27.8&#160;million), share-based compensation ($3.7&#160;million), and a net increase in operating assets and liabilities ($50.1&#160;million). </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used i</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n operating activities was $41.6 million for the six months ended June 30, 2021 and consisted primarily of a net loss of $81.0 million, which includes $6.5 million of revenue recognized pursuant to certain of our out-license agreements, adjusted for non-cash items, including share-based compensation ($2.2 million), an increase in the fair value of contingent consideration ($61.8 million) and a net decrease in operating assets and liabilities of ($24.7 million).</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Used in Investing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $89.1&#160;million for the six months ended June 30, 2022 and consisted of marketable security purchases. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities consisted of de minimis purchases and sales or property and equipment during the six months ended June 30, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Cash Provided by Financing activities</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was zero for the six months ended June 30, 2022.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $137.3 million for the six months ended June 30, 2021 and consisted primarily of $136.8 million net proceeds from the sale of common stock under the ATM Offering.</span></div><div id="i4adf13376f39486da283bda7a521a795_112"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements in accordance with GAAP and the rules and regulations of the SEC require the use of estimates and assumptions, based on complex judgments considered reasonable, and affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting period. Our critical accounting policies are those policies which involve a significant level of estimation uncertainty and have had or are reasonably likely to have a material impact on our financial condition or results of operations. Management has determined that our most critical accounting policies are those relating to the fair value of indefinite-lived intangible assets, goodwill; contingent consideration; revenue recognition; development and regulatory milestone payments and other costs; and research and development costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Indefinite-Lived Intangible Assets</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets consist of indefinite-lived, acquired IPR&amp;D worldwide product rights to Vicineum as a result of the acquisition of Viventia in 2016. IPR&amp;D assets acquired in a business combination are considered indefinite-lived until the completion or abandonment of the associated research and development efforts.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indefinite-lived intangible assets are quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of indefinite-lived intangible assets requires management to estimate the future discounted cash flows of an asset using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. We recognize an impairment loss when and to the extent that the estimated fair value of an intangible asset is less than its carrying value. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or changes in circumstances have occurred which could indicate that the carrying value of our intangible assets was not recoverable. If an impairment indicator is identified, an interim impairment assessment is performed</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. We have also experienced a sustained decline in share price and a resulting decrease in our market capitalization. On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of our lead asset, Vicineum, and intend to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. We updated the discounted cash flow model using the market participant approach and considered preliminary terms of potential partnering deal to conclude the fair value of EU asset. We concluded that the carrying value of our intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the difference between the purchase price and the fair value of the identifiable tangible and intangible net assets acquired under the acquisition method of accounting. Goodwill is not amortized; rather than recording periodic amortization, goodwill is quantitatively tested for impairment at least annually during the fourth quarter of the fiscal year, or more often if indicators of impairment are present. Impairment testing of goodwill requires management to estimate the future discounted cash flows of a reporting unit using assumptions believed to be reasonable, but which are unpredictable and inherently uncertain. Actual future cash flows may differ from the estimates used in impairment testing. If the fair value of the equity of a reporting unit exceeds the reporting unit&#8217;s carrying value, including goodwill, then goodwill is considered not to be impaired. We recognize a goodwill impairment when and to the extent that the fair value of the equity of a reporting unit is less than the reporting unit's carrying value, including goodwill. We have only one reporting unit. In addition, on a quarterly basis, we perform a qualitative review of our business operations to determine whether events or changes in circumstances have occurred which could have a material adverse effect on the estimated fair value of each reporting unit and thus indicate a potential impairment of the goodwill carrying value. If an impairment indicator is identified, an interim impairment assessment is performed. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, we observed continued trends in our market capitalization as compared to the carrying value of our single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis in advance of our typical annual assessment date of October 1. We reassessed the underlying assumptions used to develop our revenue projections, which were then used as significant inputs to determine the fair value of equity. We updated our revenue forecast models based on further expected launch delays in both US and OUS regions. We also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. We also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, we concluded that the carrying value of our goodwill of $13.1 million was fully impaired as of June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration on our condensed consolidated balance sheets is the result of our acquisition of Viventia in September 2016 and represents the discounted present value of future commercial launch milestones and net sales earnout payments due to the former shareholders of Viventia pursuant to the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value on a recurring basis at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant unobservable inputs (Level 3 within the fair value hierarchy), including internally developed financial forecasts, probabilities of success and timing of certain milestone events and achievements, which are unpredictable and inherently uncertain. Actual future cash flows may differ from the assumptions used to estimate the fair value of contingent consideration. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of our contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales were expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2033. The discount rate applied to the 2% earnout was derived from our estimated weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. Milestone payments constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, we intend to seek a partner for the further development of Vicineum. We expect any partner who acquires Vicineum from us will be obligated to make any payments to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June 30, 2022, we no longer expect to pay related milestone and earnout payments, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed. Therefore, the June 30, 2022 balance relates to contingent consideration related to projected net sales in the Greater China region as compared to the December 31, 2021 balance which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. A valuation allowance is recorded to the extent it is more likely than not that some portion or all of the deferred tax assets will not be realized. As of June&#160;30, 2022, we reduced our deferred tax liabilities by $4.0 million as a result of intangibles impairment charge, driven by the decision to pause the development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized income tax benefits represent income tax positions taken on income tax returns that have not been recognized in the financial statements. We recognize the benefit of an income tax position only if it is more likely than not (greater than 50%) that the tax position will be sustained upon tax examination, based solely on the technical merits of the tax position. Otherwise, no benefit is recognized. The tax benefits recognized are measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. We recognize accrued interest and penalties related to uncertain tax positions as income tax expense in our condensed consolidated statements of operations. As of June&#160;30, 2022 and December&#160;31, 2021, we did not have any uncertain tax positions. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are expensed in the period incurred. Research and development expenses consist of both internal and external costs associated with all basic research activities, clinical development activities and technical efforts required to develop a product candidate. Internal research and development consist primarily of personnel costs, including salaries, benefits and share-based compensation, facilities leases, research-related overhead, pre-approval regulatory and clinical trial costs, manufacturing and other contracted services, license fees and other external costs.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, we are required to make advance payments to vendors for goods or services that will be received in the future for use in research and development activities. In such circumstances, the advance payments are recorded as prepaid assets and expensed when the activity has been performed or when the goods have been received.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently issued accounting standards are discussed in &#8220;Item 1. Financial Statements - Notes to Condensed Consolidated Financial Statements - Note 4. Recent Accounting Pronouncements&#8221; of this Quarterly Report on Form 10-Q.</span></div><div id="i4adf13376f39486da283bda7a521a795_115"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information under this item is not required to be provided by smaller reporting companies.</span></div><div id="i4adf13376f39486da283bda7a521a795_118"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Controls and Procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in Exchange Act </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rules 13a-15(e) and 15d-15(e), that are designed to ensure information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and that such information is </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as the end of the period covered by this Quarterly Report on Form 10-Q. Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are achieved. Further, the design of a control system must be balanced against resource constraints, and therefore, the benefits of controls must be considered relative to their costs. Given the inherent limitations in all systems of controls, no evaluation of controls can provide absolute assurance all control issues and instances of fraud, if any, within a company have been detected. These inherent limitations include the realities that judgments in decision making can be faulty and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, controls may become inadequate because of changes in conditions or the degree of compliance with the policies and procedures may deteriorate. Accordingly, given the inherent limitations in a cost-effective system of controls, financial statement misstatements due to error or fraud may occur and may not be detected. Our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance of achieving their objectives. We conduct periodic evaluations of our system of controls to enhance, where necessary, our control policies and procedures.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, there were no changes in our internal control over financial reporting, as defined in Exchange Act Rules 13a-15(f) and 15d-15(f), which materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_121"></div><div style="margin-bottom:10pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II - OTHER INFORMATION</span></div><div id="i4adf13376f39486da283bda7a521a795_124"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1.&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309 and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against us and certain of our officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against our board of directors and certain of our officers in the US District Court for the District of Massachusetts, with us named as nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against our board of directors and certain of our officers (the &#8220;State Securities Litigation&#8221;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets and violations of federal securities laws, based on statements made by us concerning the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2002, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;1A.&#160;&#160;&#160;&#160;Risk Factors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, other than as set forth below, there were no material changes to the "Risk Factors" included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. You should carefully consider the information described therein and in this Quarterly Report on Form 10-Q, which could materially affect our financial condition, results of operations and cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our exploration of strategic alternatives may not result in entering into or completing a transaction, and the process of reviewing strategic alternatives or its conclusion could adversely affect our stock price.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have initiated a process to review strategic alternatives with the goal of maximizing shareholder value. Potential strategic alternatives to be explored and evaluated during the review process may include the sale of our company, a merger, acquisition or other business combination, a strategic partnership with one or more parties, or the licensing, sale or divestiture of some of our proprietary technologies. We are actively working with an investment bank in this assessment process, which we believe will be complete by the end of 2022. On July 15, 2022, we made the strategic decision to voluntarily pause further development in the US of Vicineum. This decision enables us to conserve cash while we continue to assess potential strategic alternatives. Additionally, we intend to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no assurance any transaction will result from the Company&#8217;s evaluation of strategic alternatives. Any potential transaction would be dependent on a number of factors that may be beyond our control, including, among other things, market conditions, industry trends, the interest of third parties in a potential transaction with us, obtaining stockholder approval and the availability of financing to us or third parties in a potential transaction with us on reasonable terms. The process of reviewing strategic alternatives may be time consuming and may involve the dedication of significant resources and may require us to incur significant costs and expenses. It could negatively impact our ability to attract, retain and motivate key employees, and expose us to potential litigation in connection with this process or any resulting transaction. If we are unable to effectively manage the process, our financial condition and results of operations could be adversely affected. In addition, speculation regarding any developments related to the review of strategic alternatives and perceived uncertainties related to the future of our company could cause our stock price to fluctuate significantly. Further, any strategic alternative that may be pursued and completed ultimately may not deliver the anticipated benefits or enhance shareholder value. There can be no guarantee that the process of evaluating strategic alternatives will result in our company entering into or completing a potential transaction within the anticipated timing or at all.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we do not successfully complete a strategic transaction, our board of directors may decide to pursue a dissolution and liquidation of our company. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments and contingent liabilities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There can be no guarantee that the process to identify a strategic transaction will result in a successfully completed transaction. If no transaction is completed, our board of directors may decide that it is in the best interest of our stockholders to dissolve our company and liquidate our assets. In that event, the amount of cash available for distribution to our stockholders will depend heavily on the timing of such decision and, ultimately, such liquidation, since the amount of cash available for distribution continues to decrease as we fund our operations and evaluate our strategic alternatives. In addition, if our board of directors were to approve and recommend, and our stockholders were to approve, a dissolution of our company, we would be required under Delaware corporate law to pay our outstanding obligations, as well as to make reasonable provision for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement, a portion of our assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject to litigation or other claims related to a dissolution and liquidation of our company. If a dissolution and liquidation were pursued, our board of directors, in consultation with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders of our common stock could lose all or a significant portion of their investment in the event of a dissolution, liquidation or winding up of our company.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">If we are unable to regain compliance with the listing requirements of the Nasdaq Capital Market, our common stock may be delisted from the Nasdaq Capital Market which could have a material adverse effect on our business and could make it more difficult for you to sell your shares.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the Nasdaq Capital Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of publicly-held shares, market value of listed shares, minimum bid price per share, and minimum stockholders' equity, among others, and requirements relating to board and committee independence. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 24, 2022, we received notice (the "Notice") from the Nasdaq Stock Market LLC ("Nasdaq") that we were not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A), we </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had 180 calendar days, or until July 25, 2022, to regain compliance with the minimum bid price requirement by having the closing bid price of our common stock meet or exceed $1.00 per share for at least ten consecutive business days. On July 26, 2022, we received approval from the Listing Qualifications Department of Nasdaq to transfer the listing of our common stock from the Nasdaq Global Market to the Nasdaq Capital Market. As a result, we were granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not regain compliance by January 23, 2023, we will receive notification from Nasdaq that our common stock is subject to delisting. At that time, we may then appeal the delisting determination to a Nasdaq hearings panel. Such notification will have no immediate effect on our listing on the Nasdaq Capital Market, nor will it have an immediate effect on the trading of our common stock pending such hearing. There can be no assurance, however, that we will be able to regain compliance with Nasdaq&#8217;s minimum bid price requirement. If we regain compliance with Nasdaq&#8217;s minimum bid price requirement, there can be no assurance that we will be able to maintain compliance with the continued listing requirements for the Nasdaq Capital Market or that our common stock will not be delisted from the Nasdaq Capital Market in the future. In addition, we may be unable to meet other applicable listing requirements of the Nasdaq Capital Market, including maintaining minimum levels of stockholders&#8217; equity or market values of our common stock in which case, our common stock could be delisted notwithstanding our ability to demonstrate compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delisting from the Nasdaq Capital Market may limit the range and attractiveness of strategic alternatives that we are able to consider, adversely affect our ability to raise additional financing through the public or private sale of equity securities, significantly affect the ability of investors to trade our securities, or negatively affect the value and liquidity of our common stock. Delisting also could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest in business development opportunities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are delisted from Nasdaq and we are not able to list our common stock on another exchange, our common stock could be quoted on the OTC Bulletin Board or in the &#8220;pink sheets.&#8221; As a result, we could face significant adverse consequences including, among others:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited availability of market quotations for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination that our common stock is a &#8220;penny stock&#8221; which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our securities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a limited amount of news and little or no analyst coverage for us;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we would no longer qualify for exemptions from state securities registration requirements, which may require us to comply with applicable state securities laws; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a decreased ability to issue additional securities (including pursuant to short-form Registration Statements on Form S-3) or obtain additional financing in the future.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our restructuring plans and the associated headcount reductions may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following receipt of the CRL from the FDA regarding our BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). On July 15, 2022, we approved a restructuring plan to reduce operating expenses and better align our workforce with the needs of our business following our decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2021 Restructuring Plan was substantially completed by the end of 2021. Execution of the 2022 Restructuring Plan is expected to be substantially completed by the end of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8 million.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our restructuring efforts due to unforeseen difficulties, delays or unexpected costs. For example, we may incur unanticipated charges not currently contemplated as a result of the restructuring plans. If we are unable to realize the expected operational cost savings from the restructuring, our operating results and financial condition would be adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_130"></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unregistered Sales of Equity Securities and Use of Proceeds.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any unregistered equity securities during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Defaults Upon Senior Securities.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Other Information.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:12pt;text-align:justify"><span><br/></span></div><div id="i4adf13376f39486da283bda7a521a795_133"></div><div style="-sec-extract:summary;margin-bottom:12pt;padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6.&#160;&#160;&#160;&#160;Exhibits.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit Index</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">No.</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Description</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000119312514056904/d679756dex31.htm">Restated Certificate of Incorporation of Eleven Biotherapeutics, Inc. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on February 18, 2014 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit31-ebioxcertificate.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500321000103/ex33-certificateofamendm.htm">Certificate of Amendment of Certificate of Incorporation. Incorporated by reference to Exhibit 3.3 to our Quarterly Report on Form 10-Q filed on May 10, 2021 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000071/exhibit32-elevenbiotherape.htm">Amended and Restated By-Laws. Incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed on May 17, 2018 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514018644/d613481dex41.htm">Specimen Stock Certificate evidencing the shares of common stock. Incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1/A filed on January 23, 2014 (File No. 333-193131).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000119312514448885/d704357dex1023.htm">Form of Warrant issued to Silicon Valley Bank and Life Science Loans, LLC dated November 25, 2014. Incorporated by reference to Exhibit 10.23 to our Registration Statement on Form S-1 filed on December 19, 2014 (File No. 333-201176).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500317000132/ex41ebiopre-fundedwarrant1.htm">Form of Common Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on November 3, 2017 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500318000027/exhibit41.htm">Form of Warrant. Incorporated by reference to Exhibit 4.1 to our Current Report on Form 8-K filed on March 23, 2018 (File. No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2017warrantamendmenta.htm">Form of 2017 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.2 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1485003/000148500319000082/sesn-2018warrantamendmenta.htm">Form of 2018 Warrant Amendment Agreement. Incorporated by reference to Exhibit 4.4 to our Current Report on Form 8-K filed on October 29, 2019 (File No. 001-36296).</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.091%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1*<br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesenbio_minorirosales-e.htm">Employment Agreement, dated January 5, 2022, by and between Sesen Bio, Inc. and Minori Rosales.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qa_ex311.htm">Certification of the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qa_ex312.htm">Certification of the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022x10qa_ex321.htm">Certification of the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="sesn-06302022xx10qa_ex322.htm">Certification of the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2022 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</span></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.947%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* </span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification is being furnished solely to accompany this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350 and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</span></div></td></tr></table></div><div style="margin-bottom:1pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><div id="i4adf13376f39486da283bda7a521a795_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="margin-top:6pt;text-align:justify"><span><br/></span></div></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:511.50pt"><tr><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:142.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:37.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:285.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SESEN BIO, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;&#160;&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer and Duly Authorized Officer)</span></td></tr></table></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><span><br/></span></div><div style="margin-bottom:1pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.199%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:55.059%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Monica Forbes&#160;&#160;&#160;&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:14pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>sesenbio_minorirosales-e.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>sesenbio_minorirosales-e</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- sesenbio_minorirosales-e001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">     January 5, 2022    Minori Koshiji Rosales, MD, PhD  c/o Sesen Bio, Inc.  245 First St., Suite 1800  Cambridge, Massachusetts 02142    Dear Minori:  It is my pleasure to offer you the position of Chief Development Officer at Sesen Bio (the  &#8220;Company&#8221; or &#8220;Sesen Bio&#8221;). Your start date as the Chief Development Officer will be January 24,  2022 (the &#8220;Commencement Date&#8221;). This letter summarizes important details about your  employment, should you accept this offer (&#8220;Letter Agreement&#8221;).  This Letter Agreement shall be  effective on January 24, 2022, which shall also be your start date (the &#8220;Effective Date&#8221;)   1. Title, Position and Duties: You will hold the position of Chief Development Officer with  the Company and you will report to the Chief Executive Officer (&#8220;CEO&#8221;).  You will have such  duties and responsibilities as are usually performed by the Chief Development Officer of a  Delaware corporation, including such duties as are reasonably and appropriately delegated to you  from time to time by the CEO or the Board of Directors (the &#8220;Board&#8221;), consistent with your position  as Chief Development Officer, and you will have the authority and resources consistent with such  position, subject to adjustments in resources consistent with normal operating decisions of the CEO    or the Board in the event of changes in strategy or programs or any other changes to resources that  are reasonable in light of the Company&#8217;s then current financial condition.    2. Full-Time and Best Efforts:  As the Company&#8217;s Chief Development Officer, which is a  full-time position, we expect that you will devote substantially all of your working time to the  performance of your Company duties in a satisfactory manner and to the best of your abilities at all  times.  You shall not engage in any other business or occupation during your employment here,  including, without limitation, any activity that conflicts with the interests of the Company, interferes  with the proper and efficient performance of your duties for the Company, or interferes with your  exercise of judgment in the Company&#8217;s best interests.  Approval of the CEO and/or Board will be  required for you to serve on other outside boards while you are employed by the Company,  including any outside for-profit boards, which approval shall not be unreasonably withheld, delayed  or conditioned. Notwithstanding the foregoing, you will be permitted to serve as an officer, director  or trustee of any charitable, educational or non-profit organization, without the Company&#8217;s prior  consent, provided that such services do not interfere with the performance of your duties to the  Company or represent an actual or apparent conflict of interest with your role at the Company.     3. Compensation: You shall receive an annualized salary of $395,000 (&#8220;Base Salary&#8221;), pro- rated for the calendar year 2022 based on your employment commencement date, and paid in  accordance with the Company's standard payroll practices, and subject to all applicable tax  reporting and withholding.  In January 2023, you will be considered for a merit review in  conjunction with your performance review (which generally is conducted annually) and consistent  with the Company&#8217;s compensation practices, as determined by the Board in its sole discretion.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        2  4. Annual Bonus:  You will be eligible for an annual target bonus of up to 40% of your Base  Salary, based upon achievement of both corporate and individual goals, as determined by the  Board or a designed committee of the Board (&#8220;Annual Bonus&#8221;), and shall be subject to all  applicable tax reporting and withholding. The determination of whether an Annual Bonus will be  granted, and the amount of any such bonus, will be solely determined by the Board or a designated  committee of the Board in its sole discretion based on factors upon which the Board alone may  choose to rely. All Annual Bonuses, if any, will be payable no later than March 15 of the year  following the year in which they were earned.  Your 2022 bonus will be prorated for the period  January __, 2022 to December 31, 2022.  Please note that you must be employed on the date  Annual Bonuses, if any, are paid, in order to be eligible for and to earn such a payment, as such  bonuses also serve as retention incentives. The fact that you may receive a bonus in one year does  not mean you will receive one in any other year.  5. Stock Option:  Subject to and upon approval by the Board or a designated committee of  the Board, you will be granted, on your Commencement Date, a nonstatutory stock option to  purchase 623,000 shares of Common Stock, $0.001 par value per share, of the Company (the  &#8220;Common Stock&#8221;), which option is granted pursuant to the inducement grant exception under  Nasdaq Rule 5635(c)(4) and not pursuant to the Company&#8217;s 2014 Stock Incentive Plan (the &#8220;Plan&#8221;)  or any other equity incentive plan of the Company, as an inducement that is material to your  employment with the Company (the &#8220;Inducement Grant&#8221;).  The Inducement Grant shall have an  exercise price equal to the closing price of the Common Stock on the Nasdaq Global Market on the  date of the Inducement Grant and shall vest as to 25% of the shares subject to the Inducement  Grant on the first anniversary of the date of the Inducement Grant and as to an additional 6.25% of  the shares underlying the Inducement Grant at the end of each successive three-month period  thereafter until the fourth anniversary of the date of the Inducement Grant.  The Inducement Grant  shall be subject to such other terms as are customary for the Company&#8217;s options under the Plan and  the previously approved form of stock option agreement under the Plan.  The Board or a  designated committee of the Board will consider annually whether to grant additional equity  awards to its employees and you will be eligible to be considered for such additional annual equity  grants.  6. Employee Benefits:  The Company offers a comprehensive benefit package that includes  group health, dental and vision plans as well as life and disability and time-off benefits. Your  eligibility to participate in these plans and receive benefits thereunder is subject to the plan  documents governing such benefits. Notwithstanding the foregoing, you understand and agree that  nothing contained herein will require the Company to establish or maintain any fringe benefits and  any such benefits may be modified, amended, terminated or cancelled at any time by the Company  in its sole and absolute discretion with or without prior notice.  7. Vacation Time:  As a full-time employee of the Company, you will be eligible for our  Unlimited Vacation Time off program.  8. Term of Employment; Restrictive Covenant Agreement:  It is important for you to  understand that you are an employee &#8220;at will&#8221;. This means that you have the right to terminate your  employment relationship with Sesen Bio at any time with or without notice, for any reason or no  reason.  Similarly, the Company has the right to terminate its employment relationship with you,  with or without notice, at any time for any or no reason.  As a condition of your employment with  the Company, you will be required to execute the enclosed Employee Non-Competition, Non- </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        3  Solicitation, Confidentiality, and Assignment Agreement. Your employment and this Letter  Agreement will be governed by the laws of the Commonwealth of Massachusetts.  9. Severance Benefits:  Notwithstanding the foregoing, in the event that Sesen Bio terminates  your employment without &#8220;Cause&#8221; or you resign with &#8220;Good Reason&#8221; (each term as defined below  and in either case a &#8220;Qualifying Termination&#8221;), you will be eligible for the benefits outlined in sub- paragraphs A or B below (the &#8220;Severance Benefits&#8221;), subject to the terms set forth in this Letter  Agreement:  A. If a Qualifying Termination occurs: (i) Sesen Bio will pay you severance in the form  of continuation of your Base Salary for a total of 12 months (&#8220;Severance Period&#8221;), such  amount to be paid in accordance with the Company&#8217;s then current payroll practices, except  as otherwise specified in this Letter Agreement, beginning on the Company&#8217;s first regular  payroll date that occurs after the Payment Date (as defined below), and (ii) subject to the  terms and conditions provided for in COBRA, and subject to your timely election of  COBRA and copayment of premium amounts at the active employee&#8217;s rate, the Company  shall pay its then current share of premium payments for group health and dental insurance  after the termination date through the earliest of (1) your Severance Period as outlined  above, (2) the date you become employed with benefits substantially comparable to the  benefits provided under the corresponding Company plan, and (3) the date you become  ineligible for COBRA benefits; provided, however, that such Company-paid premiums may  be recorded as additional income pursuant to Section 6041 of the Internal Revenue Code of  1986, as amended (the &#8220;Code&#8221;) and not entitled to any tax qualified treatment to the extent  necessary to comply with or avoid the discriminatory treatment prohibited by the Patient  Protection and Affordable Care Act of 2010 and the Health Care and Education  Reconciliation Act of 2010 or Section 105(h) of the Code. You shall be responsible for the  entire COBRA premium should you elect to maintain this coverage after the earliest of the  dates specified in Sections 9.A.(ii)(1)-(3) above.  B. If a Qualifying Termination occurs within twelve (12) months after a Change in Control  Transaction (as defined below), then: (i) you will be eligible for the same severance  payments and COBRA premium assistance as set forth in sections 9.A.i-A.ii above,  subject to the same terms, conditions, and limitations as described therein; and (ii) the  vesting of 100% of your then outstanding unvested equity grants shall be accelerated,  such that all unvested equity grants vest and become fully exercisable or non-forfeitable  as of the termination date for a period of 90 days following the termination date; after  such 90-day period, all unvested equity grants will no longer be exercisable.  For the sake of clarity, it shall not be a &#8220;Qualifying Termination&#8221; if you voluntarily resign without  Good Reason, your employment terminates For Cause or your employment terminates because of  your death or due to your suffering a Disability (as defined below).  C. The Severance Benefits will be subject to the following terms:  i. Solely for purposes of Section 409A of the Code, each salary continuation  payment is considered a separate payment.  ii. Any Severance Benefit under this Letter Agreement will begin only upon the  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        4  date of your &#8220;separation from service&#8221; (as defined under Section 409A(a)(2)(A)(i) of  the Code and Treas. Reg. &sect;1.409A-1(h)) which occurs on or after the date of  termination of the employment. To the extent that the termination of your  employment does not constitute a separation from service under Section  409A(a)(2)(A)(i) of the Code and Treas. Reg. &sect;1.409A-1(h) (as the result of further  services that are reasonably anticipated to be provided by you to the Company, or  any of its parents, subsidiaries or affiliates, at the time your employment terminates),  any severance benefits payable that constitute deferred compensation under Section  409A of the Code shall be delayed until after the date of a subsequent event  constituting a separation from service under Section 409A(a)(2)(A)(i) of the Code  and Treas. Reg. &sect;1.409A-1(h). For purposes of clarification, this section shall not  cause any forfeiture of benefits on your part, but shall only act as a delay until such  time as a &#8220;separation from service&#8221; occurs.  Further, if you are a &#8220;specified employee&#8221; (as that term is used in Section 409A of the Code and  regulations and other guidance issued thereunder) on the date your separation from service becomes  effective, any severance benefits payable hereunder that constitute non-qualified deferred  compensation under Section 409A of the Code shall be delayed until the earlier of (i) the business  day following the six-month anniversary of the date your separation from service becomes  effective, and (ii) the date of your death, but only to the extent necessary to avoid such penalties  under Section 409A of the Code. On the earlier of (A) the business day following the six-month  anniversary of the date your separation from service becomes effective, and (B) your death, the  Company shall pay you in a lump sum the aggregate value of the non-qualified deferred  compensation that the Company otherwise would have paid you prior to that date as described  above. Neither the Company nor you shall have the right to accelerate or defer the delivery of any  such payments or benefits except to the extent specifically permitted or required by Section 409A of  the Code. The Company makes no representation or warranty and shall have no liability to you or  any other person if any provision of this Letter Agreement is determined to constitute deferred  compensation subject to Section 409A of the Code, but do not satisfy an exemption from, or the  conditions of, Section 409A of the Code.  iii. Sesen Bio&#8217;s obligations to make the above Severance Benefits payments will be  contingent upon your execution of and compliance with a release of claims in a form  reasonably acceptable to the Company (the &#8220;Release&#8221;), which Release must be signed  and any applicable revocation period with respect thereto must have expired by the  sixtieth (60th) day following the date of termination (i.e., last employment day with the  Company).  The Severance Benefits payments shall be paid or commence on the first  payroll period following the date the waiver and release becomes effective (the  &#8220;Payment Date&#8221;).  Notwithstanding the foregoing, if the 60th day following the date of  termination occurs in the calendar year following the termination, then the Payment  Date shall be no earlier than January 1 of such subsequent calendar year.  In addition,  you must comply with all post-employment obligations, including those in the  Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment  Agreement that you shall sign as a condition of employment, in order to be entitled to  the Severance Benefits.  In the event that you are in breach of any post-employment  obligations, the Company shall cease providing the Severance Benefits.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        5  iv. The Company&#8217;s obligations to pay or provide the Severance Benefits will be  contingent upon your having tendered your resignation from any position on the  Board, if applicable (and any other boards on which you serve at the request of the  Company), effective as of the date of termination.  v. You agree to give prompt written notice of any reemployment during the  Severance Period or CIC Severance Period that results in eligibility for comparable  medical and dental benefits.  If the Company makes any overpayment of COBRA  Benefits, you agree to promptly return any such overpayment to the Company.  The  foregoing shall not create any obligation on your part to seek reemployment after the  date of termination of your employment.  10. Definitions:  For purposes of this Letter Agreement, &#8220;for Cause&#8221; shall mean the Company  has complied with the &#8220;Cause Process&#8221;, as defined below, following your committing one or more  of the following (each a &#8220;Cause Condition&#8221;): (i) an act of material dishonesty involving the  Company, embezzlement, or misappropriation of assets or property of the Company; (ii) gross  negligence or willful misconduct in connection with the performance of your duties, theft, fraud or  breach of fiduciary duty to the Company; (iii) your willful, sustained, or repeated failure to  substantially perform the duties or obligations of your position (other than due to illness or injury);  (iv) a violation of federal or state securities law; (v) the conviction of a felony or any crime  involving moral turpitude, including a plea of nolo contendere; (vi) a material breach of any of the  Company&#8217;s written policies related to conduct, ethics, equal employment or harassment; or (vii) a  material breach of your Non-Competition, Non-Solicitation, Confidentiality and Assignment  Agreement.   &#8220;Cause Process&#8221; shall mean that (i) the Company reasonably determines, in good faith, that one of  the Cause Conditions has occurred; (ii) the Company notifies you in writing of the first occurrence  of the Cause Condition within thirty (30) days of the Board becoming aware of such condition; (iii)  the Company cooperates in good faith with your efforts, for a period not less than thirty (30) days  following such notice (the &#8220;Cause Cure Period&#8221;), to remedy the Cause Condition; (iv)  notwithstanding such efforts, the Cause Condition continues to exist; and (v) the Company  terminates your employment within thirty (30) days after the end of the Cause Cure Period,  provided that the Company will not be required to provide a Cause Cure Period in the event that a  Cause Condition (x) is of the type described in clauses (iv), (v) or (vi) of the first sentence of this  Section 10; (y) is incapable of being cured; or (z) is required to be publicly disclosed under  applicable securities law or stock exchange rule.  If you cure to the Company&#8217;s satisfaction any Cause Condition during the applicable Cause Cure  Period, Cause shall be deemed not to have occurred.  If the Company is not required to provide a  Cause Cure Period, the Cause Process will be satisfied if the Company notifies you in writing of the  first occurrence of the Cause Condition within thirty (30) days of the Board becoming aware of such  condition and terminates your employment within thirty (30) days of such notice.  You are eligible for  no more than two &#8220;cure&#8221; opportunities during your employment.  &#8220;Change in Control Transaction&#8221; shall mean (i) a merger or consolidation of the Company with or  into another corporation under circumstances where the stockholders of the Company immediately  prior to such merger or consolidation do not own after such merger or consolidation shares  representing at least fifty percent (50%) of the voting power of the Company or the surviving,  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        6  resulting or parent corporation, as the case may be, (ii) a transfer of shares representing fifty percent  (50%) or more of the voting power of the Company to any person who was not, on the Effective  Date, a holder of stock of any class or preference or any stock option of the Company, (iii) a  liquidation of the Company, or (iv) a sale or other disposition of all or substantially all of the  Company&#8217;s assets.  &#8220;Good Reason&#8221; shall mean you have complied with the &#8220;Good Reason Process&#8221; as defined below,  following the occurrence of one or more of the following events: (i) any material diminution in your  duties, authority or responsibilities, (ii) any material diminution in your Base Salary; (iii) the  relocation of your primary place of work more than fifty (50) miles from Rockville, Maryland, or  (iv) the material breach by the Company of any provision of this Letter Agreement or any other  employment-related agreement between the Company and you (as defined below).  &#8220;Good Reason Process&#8221; shall mean that (i) you reasonably determine in good faith that one of the  foregoing &#8220;Good Reason&#8221; conditions has occurred; (ii) you notify the Company in writing of the  first occurrence of the Good Reason condition within thirty (30) days of the first occurrence of such  condition; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period not less than  thirty (30) days following such notice (the &#8220;Cure Period&#8221;) to remedy the condition; (iv)  notwithstanding such efforts, the Good Reason condition continues to exist; and (v) you terminate  your employment within thirty (30) days after the end of the Cure Period.  If the Company cures the  Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.  &#8220;Disability&#8221; shall mean your inability (as determined by the Company in good faith) to perform the  essential functions of your position due to physical or mental disability (after taking into account the  Company&#8217;s obligation to provide reasonable accommodations in accordance with the Americans  with Disabilities Act of 1990 or analogous state law), which continues for a period of 90 days  (whether or not consecutive) during any 12-month period. In connection with any determination  regarding your possible Disability, you shall have the right to provide to the Company, and the  Company shall consider in good faith, any physical or mental evaluation performed by a competent  physician of your selection.  11. Modified Section 280G Cutback: Notwithstanding any other provision of this Letter  Agreement, except as set forth in Section 11.B, in the event that the Company undergoes a &#8220;Change  in Ownership or Control&#8221; (as defined below), the following provisions shall apply:  A. The Company shall not be obligated to provide to you any portion of any  &#8220;Contingent Compensation Payments&#8221; (as defined below) that you would otherwise be  entitled to receive to the extent necessary to eliminate any &#8220;excess parachute payments&#8221; (as  defined in Section 280G(b)(1) of the Code) for you. For purposes of this Section 11, the  Contingent Compensation Payments so eliminated shall be referred to as the &#8220;Eliminated  Payments&#8221; and the aggregate amount (determined in accordance with Treasury Regulation  Section 1.280G-1, Q/A-30 or any successor provision) of the Contingent Compensation  Payments so eliminated shall be referred to as the &#8220;Eliminated Amount.&#8221;  B. Notwithstanding the provisions of Section 11.A, no such reduction in Contingent  Compensation Payments shall be made if (1) the Eliminated Amount (computed without  regard to this sentence) exceeds (2) 100% of the aggregate present value (determined in  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        7  accordance with Treasury Regulation Section 1.280G-1, Q/A-31 and Q/A-32 or any  successor provisions) of the amount of any additional taxes that would be incurred by you if  the Eliminated Payments (determined without regard to this sentence) were paid to you  (including, state and federal income taxes on the Eliminated Payments, the excise tax  imposed by Section 4999 of the Code payable with respect to all of the Contingent  Compensation Payments in excess of your &#8220;base amount&#8221; (as defined in Section 280G(b)(3)  of the Code), and any withholding taxes). The override of such reduction in Contingent  Compensation Payments pursuant to this Section 11.B shall be referred to as a &#8220;Section 11.B  Override.&#8221; For purpose of this paragraph, if any federal or state income taxes would be  attributable to the receipt of any Eliminated Payment, the amount of such taxes shall be  computed by multiplying the amount of the Eliminated Payment by the maximum combined  federal and state income tax rate provided by law.  C. For purposes of this Section 11 the following terms shall have the following  respective meanings:  i. &#8220;Change in Ownership or Control&#8221; shall mean a change in the ownership or  effective control of the Company or in the ownership of a substantial portion of the  assets of the Company determined in accordance with Section 280G(b)(2) of the  Code.  ii. &#8220;Contingent Compensation Payment&#8221; shall mean any payment (or benefit) in  the nature of compensation that is made or made available (under this Letter  Agreement or otherwise) to a &#8220;disqualified individual&#8221; (as defined in Section  280G(c) of the Code) and that is contingent (within the meaning of Section  280G(b)(2)(A)(i) of the Code) on a Change in Ownership or Control of the  Company.  D. Any payments or other benefits otherwise due to you following a Change in  Ownership or Control that could reasonably be characterized (as determined by the  Company) as Contingent Compensation Payments (the &#8220;Potential Payments&#8221;) shall not be  made until the dates provided for in this Section 11.D. Within 30 days after each date on  which you first become entitled to receive (whether or not then due) a Contingent  Compensation Payment relating to such Change in Ownership or Control, the Company  shall determine and notify you (with reasonable detail regarding the basis for its  determinations) (1) which Potential Payments constitute Contingent Compensation  Payments, (2) the Eliminated Amount and (3) whether the Section 11.B Override is  applicable. Within 30 days after delivery of such notice to you, you shall deliver a response  to the Company (the &#8220;Executive Response&#8221;) stating either (A) that you agree with the  Company&#8217;s determination pursuant to the preceding sentence or (B) that you disagrees with  such determination, in which case you shall set forth (x) which Potential Payments should be  characterized as Contingent Compensation Payments, (y) the Eliminated Amount, and (z)  whether the Section 11.B Override is applicable. In the event that you fail to deliver an  Executive Response on or before the required date, the Company&#8217;s initial determination  shall be final. If you state in the Executive Response that you agree with the Company&#8217;s  determination, the Company shall make the Potential Payments to you within three (3)  business days following delivery to the Company of the Executive Response (except for any  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        8  Potential Payments which are not due to be made until after such date, which Potential  Payments shall be made on the date on which they are due). If you state in the Executive  Response that you disagree with the Company&#8217;s determination, then, for a period of sixty  (60) days following delivery of the Executive Response, you and the Company shall use  good faith efforts to resolve such dispute. If such dispute is not resolved within such 60-day  period, such dispute shall be settled exclusively by arbitration in Pennsylvania, in  accordance with the rules of the American Arbitration Association then in effect. Judgment  may be entered on the arbitrator&#8217;s award in any court having jurisdiction. The Company  shall, within three (3) business days following delivery to the Company of the Executive  Response, make to you those Potential Payments as to which there is no dispute between the  Company and you regarding whether they should be made (except for any such Potential  Payments which are not due to be made until after such date, which Potential Payments shall  be made on the date on which they are due). The balance of the Potential Payments shall be  made within three (3) business days following the resolution of such dispute.  E. The Contingent Compensation Payments to be treated as Eliminated Payments shall  be determined by the Company by determining the &#8220;Contingent Compensation Payment  Ratio&#8221; (as defined below) for each Contingent Compensation Payment and then reducing the  Contingent Compensation Payments in order beginning with the Contingent Compensation  Payment with the highest Contingent Compensation Payment Ratio. For Contingent  Compensation Payments with the same Contingent Compensation Payment Ratio, such  Contingent Compensation Payment shall be reduced based on the time of payment of such  Contingent Compensation Payments with amounts having later payment dates being reduced  first. For Contingent Compensation Payments with the same Contingent Compensation  Payment Ratio and the same time of payment, such Contingent Compensation Payments  shall be reduced on a pro rata basis (but not below zero) prior to reducing Contingent  Compensation Payment with a lower Contingent Compensation Payment Ratio. The term  &#8220;Contingent Compensation Payment Ratio&#8221; shall mean a fraction the numerator of which is  the value of the applicable Contingent Compensation Payment that must be taken into  account by you for purposes of Section 4999(a) of the Code, and the denominator of which  is the actual amount to be received by you in respect of the applicable Contingent  Compensation Payment. For example, in the case of an equity grant that is treated as  contingent on the Change in Ownership or Control because the time at which the payment is  made or the payment vests is accelerated, the denominator shall be determined by reference  to the fair market value of the equity at the acceleration date, and not in accordance with the  methodology for determining the value of accelerated payments set forth in Treasury  Regulation Section 1.280G-1Q/A-24(b) or (c)).  F. The provisions of this Section 11 are intended to apply to any and all payments or  benefits available to you under this Letter Agreement or any other agreement or plan of the  Company under which you receive Contingent Compensation Payments.  12. General: The offer of employment in this Letter Agreement is subject to the completion of  references and your consent to, and results satisfactory to the Company of, a reference and  background check. By signing below, you represent that you are not bound by any employment  contract, restrictive covenant or other restriction preventing or limiting you from entering into  employment with or performing your duties or responsibilities for the Company, or which is in any  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- sesenbio_minorirosales-e009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="sesenbio_minorirosales-e009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        9  way inconsistent with the terms of this Letter Agreement. You also agree that you do not have in  your possession, and will not disclose to anyone at the Company, bring onto Company premises, or  use in the course of your employment at the Company at any time, any confidential information or  trade secrets belonging to any former employer or to any other entity.  You further agree that you  will not, as a Sesen Bio employee, engage in any conduct that would constitute a breach of any  obligation you may have to a former employer, including but not limited to any covenants not to  solicit or compete.  After the Effective Date, this Letter Agreement (and Employee Non-Competition, Non-Solicitation,  Confidentiality and Assignment Agreement, the plans, documents, and policies referenced herein)  shall constitute our entire agreement regarding the terms and conditions of your employment with  the Company and shall supersede any prior agreements or other promises or statements (whether  oral or written) regarding the terms of your employment.  The terms described herein cannot be  modified except in writing by you and the Company.  Failure of either party to this Letter  Agreement to insist upon strict compliance with any of the terms, covenants or conditions hereof  will not be deemed a waiver of such terms, covenants or conditions. In the event of any  inconsistency between this Letter Agreement and any other contract between the Company and you,  including the Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment  Agreement, the provisions of this Letter Agreement will prevail.  We are thrilled to have you join the leadership team at Sesen Bio.  Please contact me if you have  any questions or need more information.  Sincerely      /s/ Thomas R. Cannell, DVM    Thomas R. Cannell, DVM  President and Chief Executive Officer    I accept the above terms of employment as stated:  /s/ Minori Koshiji Rosales, MD, PhD  1/5/2022  Minori Koshiji Rosales, MD, PhD  Date  Enclosure: Employee Non-Competition, Non-Solicitation, Confidentiality and Assignment  Agreement  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>sesn-06302022x10qa_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i5a887d9c1c004138aeab60617afb6db1_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Thomas R. Cannell, D.V.M., certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q&#47;A for the fiscal quarter ended June 30, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:6pt;text-align:justify"><font><br></font></div><div style="padding-left:1.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.777%"><tr><td style="width:1.0%"></td><td style="width:5.498%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.246%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.065%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>sesn-06302022x10qa_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i2db9ab2ef1074b0fb25eb04f1ae52df5_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">I, Monica Forbes, certify that&#58;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q&#47;A for the fiscal quarter ended June 30, 2022 of Sesen Bio, Inc.&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:6pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:10.24pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:9.67pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="padding-left:0.75pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>sesn-06302022x10qa_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i8ba29d144a3a41e1b1db8137e269c819_1"></div><div style="min-height:42.48pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Quarterly Report on Form 10-Q&#47;A of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#47;s&#47; Thomas R. Cannell, D.V.M.&#160;&#160;&#160;&#160;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas R. Cannell, D.V.M.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:12pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>sesn-06302022xx10qa_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i830405b884f4407b9a96531f5af651e8_1"></div><div style="min-height:42.48pt;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div><div style="margin-bottom:6pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:139%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">In connection with the Quarterly Report on Form 10-Q&#47;A of Sesen Bio, Inc. (the &#8220;Company&#8221;) for the fiscal quarter ended June 30, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the Report fully complies with the requirements of section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:139%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="padding-left:0.37pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.923%"><tr><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.022%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.781%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 25, 2022</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name&#58;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Monica Forbes</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt 2px 1.02pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</font></td></tr></table></div><div style="margin-bottom:6pt;margin-top:5pt"><font><br></font></div><div style="height:42.48pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:6pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>sesn-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sesn="http://www.sesenbio.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sesenbio.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sesn-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sesenbio.com/role/Cover">
        <link:definition>0001001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS">
        <link:definition>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical">
        <link:definition>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS">
        <link:definition>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS">
        <link:definition>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
        <link:definition>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical">
        <link:definition>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS">
        <link:definition>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESS" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS">
        <link:definition>2101101 - Disclosure - DESCRIPTION OF BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DESCRIPTIONOFBUSINESSDetails" roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails">
        <link:definition>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATION" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION">
        <link:definition>2103102 - Disclosure - BASIS OF PRESENTATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BASISOFPRESENTATIONPolicies" roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies">
        <link:definition>2204201 - Disclosure - BASIS OF PRESENTATION (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES">
        <link:definition>2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECENTACCOUNTINGPRONOUNCEMENTS" roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS">
        <link:definition>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS">
        <link:definition>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables">
        <link:definition>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
        <link:definition>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
        <link:definition>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLES" roleURI="http://www.sesenbio.com/role/RECEIVABLES">
        <link:definition>2112106 - Disclosure - RECEIVABLES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RECEIVABLESDetails" roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails">
        <link:definition>2413405 - Disclosure - RECEIVABLES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSES" roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSES">
        <link:definition>2114107 - Disclosure - PREPAID EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PREPAIDEXPENSESDetails" roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails">
        <link:definition>2415406 - Disclosure - PREPAID EXPENSES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWIL" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL">
        <link:definition>2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILTables" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables">
        <link:definition>2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails">
        <link:definition>2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILNarrativeDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails">
        <link:definition>2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails">
        <link:definition>2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSES" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES">
        <link:definition>2121109 - Disclosure - ACCRUED EXPENSES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESTables" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables">
        <link:definition>2322303 - Disclosure - ACCRUED EXPENSES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails">
        <link:definition>2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIES" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES">
        <link:definition>2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="COMMITMENTSANDCONTINGENCIESDetails" roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails">
        <link:definition>2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASES" roleURI="http://www.sesenbio.com/role/LEASES">
        <link:definition>2126111 - Disclosure - LEASES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LEASESDetails" roleURI="http://www.sesenbio.com/role/LEASESDetails">
        <link:definition>2427412 - Disclosure - LEASES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITY" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY">
        <link:definition>2128112 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYTables" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables">
        <link:definition>2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYEquityFinancingDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails">
        <link:definition>2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYPreferredStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails">
        <link:definition>2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYCommonStockDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails">
        <link:definition>2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
        <link:definition>2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="STOCKHOLDERSEQUITYWarrantsDetails" roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails">
        <link:definition>2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARE" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE">
        <link:definition>2135113 - Disclosure - EARNINGS (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHARETables" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables">
        <link:definition>2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EARNINGSLOSSPERSHAREDetails" roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails">
        <link:definition>2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATION" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION">
        <link:definition>2138114 - Disclosure - SHARE-BASED COMPENSATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONTables" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables">
        <link:definition>2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
        <link:definition>2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONNarrativeDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails">
        <link:definition>2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONStockOptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails">
        <link:definition>2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
        <link:definition>2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
        <link:definition>2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANS" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS">
        <link:definition>2145115 - Disclosure - EMPLOYEE BENEFIT PLANS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EMPLOYEEBENEFITPLANSDetails" roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails">
        <link:definition>2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXES" roleURI="http://www.sesenbio.com/role/INCOMETAXES">
        <link:definition>2147116 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESTables" roleURI="http://www.sesenbio.com/role/INCOMETAXESTables">
        <link:definition>2348307 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofPretaxIncomeLossDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails">
        <link:definition>2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofIncomeTaxProvisionsDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails">
        <link:definition>2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails">
        <link:definition>2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="INCOMETAXESNarrativeDetails" roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails">
        <link:definition>2452428 - Disclosure - INCOME TAXES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTS" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS">
        <link:definition>2153117 - Disclosure - LICENSE AGREEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LICENSEAGREEMENTSDetails" roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails">
        <link:definition>2454429 - Disclosure - LICENSE AGREEMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIES" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES">
        <link:definition>2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESTables" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables">
        <link:definition>2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails">
        <link:definition>2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RESTRUCTURINGANDRELATEDACTIVITIESDetails" roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails">
        <link:definition>2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTS" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS">
        <link:definition>2159119 - Disclosure - SUBSEQUENT EVENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SUBSEQUENTEVENTSDetails" roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails">
        <link:definition>2460432 - Disclosure - SUBSEQUENT EVENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="sesn_MicrometAGMember" abstract="true" name="MicrometAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ViventiaBioInc.Member" abstract="true" name="ViventiaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" abstract="false" name="BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" abstract="false" name="BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" abstract="false" name="CommonStockAdditionalCapitalSharesReservedforFutureIssuance" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_AccountsReceivablePaymentTerms" abstract="false" name="AccountsReceivablePaymentTerms" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" abstract="false" name="ProceedsFromExecutionOfAssetPurchaseAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" abstract="false" name="RevenueRecognitionMilestoneMethodPotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" abstract="false" name="SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_WeightedAverageCostOfCapital" abstract="false" name="WeightedAverageCostOfCapital" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" abstract="true" name="CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockCommissionFixedRate" abstract="false" name="SaleOfStockCommissionFixedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightIssuedDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" abstract="false" name="SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" abstract="false" name="LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_RetentionProgramMember" abstract="true" name="RetentionProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseMaintenanceFees" abstract="false" name="LicenseMaintenanceFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantOrRightOutstandingRollForward" abstract="true" name="WarrantOrRightOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_OtherReceivableAssetPurchaseAgreement" abstract="false" name="OtherReceivableAssetPurchaseAgreement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_StockIncentivePlanTwoThousandFourteenMember" abstract="true" name="StockIncentivePlanTwoThousandFourteenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" abstract="false" name="ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_StockIncentivePlan2009Member" abstract="true" name="StockIncentivePlan2009Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeasesAreaOfOfficeSpace" abstract="false" name="OperatingLeasesAreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="sesn_BusinessCombinationMilestonePayments" abstract="false" name="BusinessCombinationMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" abstract="true" name="EczacibasiPharmaceuticalsMarketingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" abstract="false" name="StockIssuedDuringPeriodExerciseOfWarrantsValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OperatingLeaseMonthlyRent" abstract="false" name="OperatingLeaseMonthlyRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ExpensesPreviouslyClassifiedAsPrepaid" abstract="false" name="ExpensesPreviouslyClassifiedAsPrepaid" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_A2014EmployeeStockPurchasePlanMember" abstract="true" name="A2014EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_AccruedLegalFees" abstract="false" name="AccruedLegalFees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" abstract="false" name="SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_SaleOfStockWeightedAveragePricePerShare" abstract="false" name="SaleOfStockWeightedAveragePricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" abstract="false" name="StockIssuedDuringPeriodNewIssuesIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" abstract="false" name="SaleOfStockMaximumAggregateSalesPriceInTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ATMFacilityMember" abstract="true" name="ATMFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationTable" abstract="true" name="OrganizationAndBasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_AccruedRestructuringChargesRelatedCurrent" abstract="false" name="AccruedRestructuringChargesRelatedCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" abstract="false" name="ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_LicenseAgreementAdditionalUpFrontFee" abstract="false" name="LicenseAgreementAdditionalUpFrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" abstract="false" name="LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LitigationSettlementMember" abstract="true" name="LitigationSettlementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RoyaltyRevenuePercentage" abstract="false" name="RoyaltyRevenuePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyRate" abstract="false" name="LicenseAgreementRoyaltyRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRoyaltyPeriod" abstract="false" name="CollaborativeArrangementRoyaltyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_RocheMember" abstract="true" name="RocheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_MENALicenseAgreementMember" abstract="true" name="MENALicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_UniversityOfZurichMember" abstract="true" name="UniversityOfZurichMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementOptionPeriods" abstract="false" name="LicenseAgreementOptionPeriods" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_SharesOfCommonStockReservedForIssuanceAbstract" abstract="true" name="SharesOfCommonStockReservedForIssuanceAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_NumberofVotesEntitledForEachShare" abstract="false" name="NumberofVotesEntitledForEachShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" abstract="false" name="LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" abstract="false" name="SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationRoyaltyPaymentPercent" abstract="false" name="BusinessCombinationRoyaltyPaymentPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" abstract="false" name="DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OperatingLeaseOtherMonthlyOperatingExpenses" abstract="false" name="OperatingLeaseOtherMonthlyOperatingExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedMay2015Member" abstract="true" name="WarrantsExpiringNovember2024IssuedMay2015Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CommonStockSharesIssuedAndReservedForFuture" abstract="false" name="CommonStockSharesIssuedAndReservedForFuture" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" abstract="false" name="LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementUpfrontFee" abstract="false" name="LicenseAgreementUpfrontFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementTextBlock" abstract="false" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" abstract="false" name="LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" abstract="false" name="LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" abstract="true" name="CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" abstract="true" name="CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_ViciniumMember" abstract="true" name="ViciniumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_QiluPharmaceuticalCoLtdMember" abstract="true" name="QiluPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" abstract="false" name="RightOfUseAssetRelatedToAdoptionOfAccountingStandard" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" abstract="false" name="BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" abstract="false" name="SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="sesn_FirstIndicationMember" abstract="true" name="FirstIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_XOMAIrelandLimitedMember" abstract="true" name="XOMAIrelandLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_GermanVATRecoveryMember" abstract="true" name="GermanVATRecoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" abstract="false" name="IncreaseDecreaseOfPrepaidExpensesNoncurrent" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" abstract="true" name="WarrantsExpiringNovember2024IssuedNovember2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncreaseDecreaseInDeferredTaxLiability" abstract="false" name="IncreaseDecreaseInDeferredTaxLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchievementExpense" abstract="false" name="LicenseAgreementMilestoneAchievementExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_EBI031Member" abstract="true" name="EBI031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="sesn_WarrantsExpiringMarch2023Member" abstract="true" name="WarrantsExpiringMarch2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="sesn_LicenseAgreementProceedsFromMilestoneAchieved" abstract="false" name="LicenseAgreementProceedsFromMilestoneAchieved" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_WarrantsExpiringNovember2022Member" abstract="true" name="WarrantsExpiringNovember2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_NumberOfLawsuits" abstract="false" name="NumberOfLawsuits" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" abstract="false" name="LicenseAgreementPercentageOfRoyaltyOnNetProductSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="sesn_SecondIndicationMember" abstract="true" name="SecondIndicationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="sesn_LicenseAgreementMilestoneAchieved" abstract="false" name="LicenseAgreementMilestoneAchieved" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="sesn_OrganizationAndBasisOfPresentationLineItems" abstract="true" name="OrganizationAndBasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>sesn-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_0b8b810e-e957-4d8b-9372-9af13f6f4dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:to="loc_us-gaap_CommonStockValue_0b8b810e-e957-4d8b-9372-9af13f6f4dcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_19bb2fb3-4d6e-4a3c-916b-10acddbd555e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:to="loc_us-gaap_PreferredStockValue_19bb2fb3-4d6e-4a3c-916b-10acddbd555e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65e45971-565b-48bc-ad2d-0c8c1a4c0ec1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_65e45971-565b-48bc-ad2d-0c8c1a4c0ec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_df8a1487-c81b-4e7c-9078-7715b329c31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:to="loc_us-gaap_AdditionalPaidInCapital_df8a1487-c81b-4e7c-9078-7715b329c31f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8fd81e2-7fd9-4744-b4d4-c51121f88814" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_a1311f30-9c01-473c-ab59-32c6bb15ffb9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a8fd81e2-7fd9-4744-b4d4-c51121f88814" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2341f4ac-080c-40c5-9ab6-466d0bb7171e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2341f4ac-080c-40c5-9ab6-466d0bb7171e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_47707cca-073b-4290-b0e9-efd95e3c5274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_47707cca-073b-4290-b0e9-efd95e3c5274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_129c3f48-a4ec-41e6-ab24-cedcd3134047" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_129c3f48-a4ec-41e6-ab24-cedcd3134047" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59a3dac6-ebe5-43d9-9221-20889a051bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_59a3dac6-ebe5-43d9-9221-20889a051bc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_4ae6efd7-750a-49d4-841f-138a4db5d123" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_82200495-3519-43e2-a061-0fcbe7b4a4b6" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_4ae6efd7-750a-49d4-841f-138a4db5d123" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_17690a77-9957-41c2-a477-f723f5cf7182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64377ebb-efda-4466-835d-7af810e7fc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17690a77-9957-41c2-a477-f723f5cf7182" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_64377ebb-efda-4466-835d-7af810e7fc83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_07867dfd-ff41-4585-9718-87038f8cbee5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17690a77-9957-41c2-a477-f723f5cf7182" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_07867dfd-ff41-4585-9718-87038f8cbee5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_238f15c8-1220-4fd5-b652-24855d3c478b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_17690a77-9957-41c2-a477-f723f5cf7182" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_238f15c8-1220-4fd5-b652-24855d3c478b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b1a6dcc9-3605-4881-85bc-cf1c0579b63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_db078c38-6585-424f-8552-f3f845dcbc3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b1a6dcc9-3605-4881-85bc-cf1c0579b63e" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_db078c38-6585-424f-8552-f3f845dcbc3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1df86406-1853-4769-b153-cdb5ead815a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_b1a6dcc9-3605-4881-85bc-cf1c0579b63e" xlink:to="loc_us-gaap_LiabilitiesCurrent_1df86406-1853-4769-b153-cdb5ead815a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8915a812-f4d5-4344-bdcf-11b4c2ecc4bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_eaa0ec94-31ec-4a45-8b38-579d3b0b071d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8915a812-f4d5-4344-bdcf-11b4c2ecc4bc" xlink:to="loc_us-gaap_AccountsPayableCurrent_eaa0ec94-31ec-4a45-8b38-579d3b0b071d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_e03867a0-b6d1-4483-b3c7-d3fc37a44e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8915a812-f4d5-4344-bdcf-11b4c2ecc4bc" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_e03867a0-b6d1-4483-b3c7-d3fc37a44e69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_622cea37-320c-4662-a0b9-5414c6d6fd07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_8915a812-f4d5-4344-bdcf-11b4c2ecc4bc" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_622cea37-320c-4662-a0b9-5414c6d6fd07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bc2ffa50-9755-4abe-95b1-f1e60c9f615d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_5eb6136c-c3aa-4556-8ed3-c4119593a1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bc2ffa50-9755-4abe-95b1-f1e60c9f615d" xlink:to="loc_us-gaap_AssetsNoncurrent_5eb6136c-c3aa-4556-8ed3-c4119593a1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_d903bcac-bb75-44b4-9397-7fe337b5883b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bc2ffa50-9755-4abe-95b1-f1e60c9f615d" xlink:to="loc_us-gaap_AssetsCurrent_d903bcac-bb75-44b4-9397-7fe337b5883b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30953e9f-7163-4150-801f-3f23ebcd7f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_096b35ef-5a20-4ba3-86b7-a365bac0c67f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30953e9f-7163-4150-801f-3f23ebcd7f57" xlink:to="loc_us-gaap_StockholdersEquity_096b35ef-5a20-4ba3-86b7-a365bac0c67f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_f2dfcab6-d1b1-467d-9d47-649cd2a1fc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30953e9f-7163-4150-801f-3f23ebcd7f57" xlink:to="loc_us-gaap_Liabilities_f2dfcab6-d1b1-467d-9d47-649cd2a1fc27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bf36000a-dce4-4fc4-b2db-04e720722bec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_Goodwill_bf36000a-dce4-4fc4-b2db-04e720722bec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_8469fa5d-9a63-43a4-b62d-f9f501eea55c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_8469fa5d-9a63-43a4-b62d-f9f501eea55c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_52dad462-e9b8-4547-90de-97cbbe24c133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_52dad462-e9b8-4547-90de-97cbbe24c133" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_a0408e13-bc89-4397-86ed-f36ea60de520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_a0408e13-bc89-4397-86ed-f36ea60de520" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_780b54a7-612f-4e75-b054-0e826014707c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_780b54a7-612f-4e75-b054-0e826014707c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2d8db15-cc3a-48e3-822d-2e47b41835e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_a2d8db15-cc3a-48e3-822d-2e47b41835e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_deb34e8a-897d-4e18-9e06-6d5ee543810d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsNoncurrent_ae7fc484-5323-400d-ab82-5cea0fbe268b" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_deb34e8a-897d-4e18-9e06-6d5ee543810d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_07fe312f-d8f7-4a87-b526-cb4722dbc34d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4a91c112-88bf-4056-9203-9b5849f8ad69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_07fe312f-d8f7-4a87-b526-cb4722dbc34d" xlink:to="loc_us-gaap_NetIncomeLoss_4a91c112-88bf-4056-9203-9b5849f8ad69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_d4dbef4c-6941-441d-9054-cfe345463817" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44d4a9b0-fa35-4eb2-b761-dbdbd72529c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4dbef4c-6941-441d-9054-cfe345463817" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_44d4a9b0-fa35-4eb2-b761-dbdbd72529c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_8def4f8e-69dd-4bec-81ea-b82f3b3d80c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4dbef4c-6941-441d-9054-cfe345463817" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_8def4f8e-69dd-4bec-81ea-b82f3b3d80c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_bfc9ac2f-933c-4bed-b686-83d016996171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4dbef4c-6941-441d-9054-cfe345463817" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_bfc9ac2f-933c-4bed-b686-83d016996171" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e5cd77ac-c573-407c-886d-d0673fd6c53b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_d4dbef4c-6941-441d-9054-cfe345463817" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_e5cd77ac-c573-407c-886d-d0673fd6c53b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_cd73c6fc-5dcc-47e6-b761-52f4f93e2453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_60f4ac75-b497-430f-95a4-1191ad29a933" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cd73c6fc-5dcc-47e6-b761-52f4f93e2453" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_60f4ac75-b497-430f-95a4-1191ad29a933" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_a3a2b055-b1fe-40f4-91a4-fe4dc8d618c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_cd73c6fc-5dcc-47e6-b761-52f4f93e2453" xlink:to="loc_us-gaap_OperatingExpenses_a3a2b055-b1fe-40f4-91a4-fe4dc8d618c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d4b6e066-db91-43a9-a685-ff171a41b9aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_32c95b6e-324e-4b0f-82ca-c325a9fc5cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d4b6e066-db91-43a9-a685-ff171a41b9aa" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_32c95b6e-324e-4b0f-82ca-c325a9fc5cd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_baf2ee17-c0c3-4184-a862-227c1c1d726c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d4b6e066-db91-43a9-a685-ff171a41b9aa" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_baf2ee17-c0c3-4184-a862-227c1c1d726c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_6cc80a67-0f8c-4ce6-b6ea-cac9899cdd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_3bf852ba-eb5e-4009-b9d5-af0f05a454ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_6cc80a67-0f8c-4ce6-b6ea-cac9899cdd73" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_3bf852ba-eb5e-4009-b9d5-af0f05a454ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9d762fef-1a3d-4050-b074-f8334ee3cbf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_6cc80a67-0f8c-4ce6-b6ea-cac9899cdd73" xlink:to="loc_us-gaap_OperatingIncomeLoss_9d762fef-1a3d-4050-b074-f8334ee3cbf7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_347c78ce-2d04-4ee4-bf8e-86181a409247" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9cdfb16b-0127-433a-919a-2ab9ac130fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_347c78ce-2d04-4ee4-bf8e-86181a409247" xlink:to="loc_us-gaap_NetIncomeLoss_9cdfb16b-0127-433a-919a-2ab9ac130fcf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5812f308-bc74-4b30-b231-ff2759744fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d802767b-180a-4d9b-819f-07937df116a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5812f308-bc74-4b30-b231-ff2759744fbb" xlink:to="loc_us-gaap_NetIncomeLoss_d802767b-180a-4d9b-819f-07937df116a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5d5d2c6c-ac13-4187-85af-ff095ee8ebbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5812f308-bc74-4b30-b231-ff2759744fbb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5d5d2c6c-ac13-4187-85af-ff095ee8ebbf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_897d2b12-ed8d-4205-b309-11295b5edadb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_0029bd10-7d21-4e12-8410-2e09ffafdd74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_897d2b12-ed8d-4205-b309-11295b5edadb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_0029bd10-7d21-4e12-8410-2e09ffafdd74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_d70158c4-87ff-4716-bd6a-fb008625f97b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_897d2b12-ed8d-4205-b309-11295b5edadb" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_d70158c4-87ff-4716-bd6a-fb008625f97b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_997e9b60-6d6b-4179-840c-eb0efa4def85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_897d2b12-ed8d-4205-b309-11295b5edadb" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_997e9b60-6d6b-4179-840c-eb0efa4def85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be024cb2-bdc8-44ad-b2e3-400784dccc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cbdbab6a-964a-4394-9196-c3c4b48dabca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be024cb2-bdc8-44ad-b2e3-400784dccc20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_cbdbab6a-964a-4394-9196-c3c4b48dabca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d867d447-5eb7-42d9-878b-8898566eff99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be024cb2-bdc8-44ad-b2e3-400784dccc20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_d867d447-5eb7-42d9-878b-8898566eff99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304230a0-479f-4ba0-9a0f-b4848c5f2a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_be024cb2-bdc8-44ad-b2e3-400784dccc20" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_304230a0-479f-4ba0-9a0f-b4848c5f2a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd38ec62-05f6-48e5-bad0-c305fd050f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c91a8211-7599-491c-8ebb-3ac509f5f078" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd38ec62-05f6-48e5-bad0-c305fd050f1b" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c91a8211-7599-491c-8ebb-3ac509f5f078" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_51ad50d5-0519-496a-8645-34f21603b69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bd38ec62-05f6-48e5-bad0-c305fd050f1b" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_51ad50d5-0519-496a-8645-34f21603b69f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3f59d9af-83fe-4d51-8ec4-7defdadd8d08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3f59d9af-83fe-4d51-8ec4-7defdadd8d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_93234030-a47c-4b38-84f6-54128816d3d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_93234030-a47c-4b38-84f6-54128816d3d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c6ec917-a2df-4488-a36c-bc4060cc88ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c6ec917-a2df-4488-a36c-bc4060cc88ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4db85c7b-b8e4-44df-92fd-464c09bcafeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_4db85c7b-b8e4-44df-92fd-464c09bcafeb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c8a327a2-7bd2-46e6-935b-3a46c837db06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_NetIncomeLoss_c8a327a2-7bd2-46e6-935b-3a46c837db06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d9924a3-1085-465d-a873-9881aa39e1a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_2d9924a3-1085-465d-a873-9881aa39e1a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_565fcfd8-0d6f-4108-a8a7-e3a70369951f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_565fcfd8-0d6f-4108-a8a7-e3a70369951f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_094c2177-4d6c-48ee-a808-c8e7541f3cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_DepreciationAndAmortization_094c2177-4d6c-48ee-a808-c8e7541f3cd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_2977160e-9a33-4c33-8426-c0668c82f04a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_ShareBasedCompensation_2977160e-9a33-4c33-8426-c0668c82f04a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_87f5321f-5965-423d-9325-81b78a129ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_87f5321f-5965-423d-9325-81b78a129ba0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b67068-f0d2-45fa-b55d-ab08b863f24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_94b67068-f0d2-45fa-b55d-ab08b863f24a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2f41e8d4-f811-4ce4-b39d-40ef9b236116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_AssetImpairmentCharges_2f41e8d4-f811-4ce4-b39d-40ef9b236116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_45f36b2c-1c1f-41f8-a7c2-c914d4aed459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_45f36b2c-1c1f-41f8-a7c2-c914d4aed459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_03a02adf-c43f-407b-a9d3-f92d16a08c6a" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b36e444-f0ab-488f-8958-46ea0d212a07" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_03a02adf-c43f-407b-a9d3-f92d16a08c6a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_811570cc-a5e0-4675-91fa-b9672e1e7f26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_811570cc-a5e0-4675-91fa-b9672e1e7f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees_a4f6b62a-12b5-4486-a6a5-479fb84a703d" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_sesn_AccruedLegalFees_a4f6b62a-12b5-4486-a6a5-479fb84a703d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_072c2d3d-113c-4894-b402-d832566a263c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_072c2d3d-113c-4894-b402-d832566a263c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_627849ba-d5c4-4aab-93fd-f3055e12f739" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_627849ba-d5c4-4aab-93fd-f3055e12f739" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_3e605dc8-bb19-40d2-bdfe-56fc5e403a0b" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_3e605dc8-bb19-40d2-bdfe-56fc5e403a0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5003322-ff2a-4409-83e6-f054587db189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f913ea9d-9cdd-4ab3-84f8-3a85bfce8953" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_b5003322-ff2a-4409-83e6-f054587db189" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_fc4c74be-477e-4ed6-a7e9-3a904c85bced" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ae96b73-0320-477e-97be-dc2e794c2a26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_fc4c74be-477e-4ed6-a7e9-3a904c85bced" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_6ae96b73-0320-477e-97be-dc2e794c2a26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_cca30e6d-13ba-4b98-bcf1-f226cae2e19f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_fc4c74be-477e-4ed6-a7e9-3a904c85bced" xlink:to="loc_us-gaap_CommonStockSharesIssued_cca30e6d-13ba-4b98-bcf1-f226cae2e19f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304efa9f-373e-4edd-b126-840d4cbd3147" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b8970b54-a06f-45b4-85a3-6ca8d7079d12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304efa9f-373e-4edd-b126-840d4cbd3147" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_b8970b54-a06f-45b4-85a3-6ca8d7079d12" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8405086a-8972-450d-ab19-bc0e4f094f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_304efa9f-373e-4edd-b126-840d4cbd3147" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_8405086a-8972-450d-ab19-bc0e4f094f99" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_760150f9-f28e-466f-880d-d7afc35f6017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7a0cd8e-8fd8-403b-a671-3f379ec68c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_760150f9-f28e-466f-880d-d7afc35f6017" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a7a0cd8e-8fd8-403b-a671-3f379ec68c21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_488f4355-b1ae-453d-86af-6bde24a4d568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_81c78d8a-d5fb-48c9-ab7a-e84d6b37e2d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_488f4355-b1ae-453d-86af-6bde24a4d568" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_81c78d8a-d5fb-48c9-ab7a-e84d6b37e2d7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>sesn-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended" id="icefe9000e8fd4875944b736554aa2187_CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d91ebce0-e68f-4de1-9619-7a4eb33951b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_SharesOutstanding_d91ebce0-e68f-4de1-9619-7a4eb33951b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a4bae5-da18-4bd7-9b11-b45cc7446a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockholdersEquity_35a4bae5-da18-4bd7-9b11-b45cc7446a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3680e71c-00fd-441c-9e40-c80649ed752b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_NetIncomeLoss_3680e71c-00fd-441c-9e40-c80649ed752b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19a82174-c688-4d0c-ada5-2d2ba8d1e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19a82174-c688-4d0c-ada5-2d2ba8d1e84b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a8e831c-4d13-46d1-b01f-b3ee0fe9a749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a8e831c-4d13-46d1-b01f-b3ee0fe9a749" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_562947b5-c909-448e-a703-0511d09259d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_562947b5-c909-448e-a703-0511d09259d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_740318f2-5b1e-40db-9e29-2a80b51988d3" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_740318f2-5b1e-40db-9e29-2a80b51988d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_1b543e96-48c6-4cc7-951f-52f6172f2e69" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_1b543e96-48c6-4cc7-951f-52f6172f2e69" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9646b37c-0a16-4374-80f6-5bb3e2266ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9646b37c-0a16-4374-80f6-5bb3e2266ed8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07cf3857-81b7-4c65-ba80-1aa30ac4091e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07cf3857-81b7-4c65-ba80-1aa30ac4091e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a0741f5f-5d52-4170-847a-c064b6a2c14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a0741f5f-5d52-4170-847a-c064b6a2c14e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ea01bfa5-554d-45a4-a08a-1d064813977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7d7a0ef-fa60-4f85-91f5-6e78e25797c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:to="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2082e714-4e0a-40a5-b4ae-b4b0677f86a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:to="loc_us-gaap_EquityComponentDomain_2082e714-4e0a-40a5-b4ae-b4b0677f86a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:to="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a62009d-8635-47ae-893a-75b232b6a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_CommonStockMember_4a62009d-8635-47ae-893a-75b232b6a6c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e62033dc-efbc-48a9-af6d-92af5cd7c195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e62033dc-efbc-48a9-af6d-92af5cd7c195" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e0d0a41-1af1-4e52-8c97-31576ea7cd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e0d0a41-1af1-4e52-8c97-31576ea7cd73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_39d17b3e-bf35-4649-b2cf-08554aae40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_RetainedEarningsMember_39d17b3e-bf35-4649-b2cf-08554aae40e9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9b1fee1e-4525-4b61-80d7-5f93f424a918_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9b1fee1e-4525-4b61-80d7-5f93f424a918_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_00b21052-c818-4cae-8dbd-b804a713f0a1" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:to="loc_sesn_ATMFacilityMember_00b21052-c818-4cae-8dbd-b804a713f0a1" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended" id="i2617f87f4a8c460c8a30a152c424fe6d_DESCRIPTIONOFBUSINESSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_243742f0-6032-4379-a40c-3b157eda26ad" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_243742f0-6032-4379-a40c-3b157eda26ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3f01fff2-30b4-4646-9974-a74be9838943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3f01fff2-30b4-4646-9974-a74be9838943" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_6cc5b6c8-2c38-47ef-8b8d-44f6be914d12" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_6cc5b6c8-2c38-47ef-8b8d-44f6be914d12" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_5ad2894b-3a4d-4df3-8e71-9eee49b8910d" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_5ad2894b-3a4d-4df3-8e71-9eee49b8910d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_c5198dc8-3798-4420-8cf3-53ff3bffa32d" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_c5198dc8-3798-4420-8cf3-53ff3bffa32d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_faa13422-20d1-4821-8ebb-b1100ad730c7" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_faa13422-20d1-4821-8ebb-b1100ad730c7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d5f884e-7a19-42ef-a62c-325b7cf014e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4d5f884e-7a19-42ef-a62c-325b7cf014e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_5e57bc2d-6e6e-49ed-bfe9-16a0c5033d95" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:to="loc_sesn_ViventiaBioInc.Member_5e57bc2d-6e6e-49ed-bfe9-16a0c5033d95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9aa46017-bb1d-4073-8551-4992d3af7330_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:to="loc_srt_ProductsAndServicesDomain_9aa46017-bb1d-4073-8551-4992d3af7330_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:to="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_803f3361-2197-4d74-8932-2a524c2dc054" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:to="loc_sesn_ViciniumMember_803f3361-2197-4d74-8932-2a524c2dc054" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_fe5a4a2b-c11a-4864-9104-a2bd379a041d" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_fe5a4a2b-c11a-4864-9104-a2bd379a041d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_eda578d2-566c-48ca-b81e-214c26360341_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:to="loc_srt_SegmentGeographicalDomain_eda578d2-566c-48ca-b81e-214c26360341_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:to="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7e6cdab-e0ba-4402-98bf-19e8fb04213e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_country_US_a7e6cdab-e0ba-4402-98bf-19e8fb04213e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0b1b9872-1e85-4306-86f4-e61a07e02fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_srt_EuropeMember_0b1b9872-1e85-4306-86f4-e61a07e02fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_56cb2771-2776-4268-858f-354ca9cc15ab" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_country_JP_56cb2771-2776-4268-858f-354ca9cc15ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended" id="ic2b00837da604b64b6e140ed52320ff8_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_220c70c8-adad-4d3b-b5d1-e8544baf3eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_220c70c8-adad-4d3b-b5d1-e8544baf3eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01f0d85b-b730-41a2-9d86-a3e1f45c761f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01f0d85b-b730-41a2-9d86-a3e1f45c761f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aad01c0e-fb41-4221-a8c7-d73a64b8384d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aad01c0e-fb41-4221-a8c7-d73a64b8384d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b3f14b6-4048-49c0-9815-a2e868ed2f4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_8b3f14b6-4048-49c0-9815-a2e868ed2f4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dbdaa42d-44fb-49cc-97c3-85862059f663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dbdaa42d-44fb-49cc-97c3-85862059f663" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9afcec2e-e15c-468c-880c-25032e1886b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9afcec2e-e15c-468c-880c-25032e1886b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_9587cbbf-b7e8-43f0-9228-b9381bebb2ef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_9587cbbf-b7e8-43f0-9228-b9381bebb2ef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ada41fb4-8a51-4af0-b554-3f0665cf9709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ada41fb4-8a51-4af0-b554-3f0665cf9709" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0a631628-ca6e-4ade-842c-828bd90667f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0a631628-ca6e-4ade-842c-828bd90667f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1691992-dfb4-4dc8-bbbc-55071d3351e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1691992-dfb4-4dc8-bbbc-55071d3351e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2e86575-b185-4d34-84ee-b496c3456b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2e86575-b185-4d34-84ee-b496c3456b6b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended" id="i0f0c25afd50e46339e755f1bacdb7440_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_ba4a4d03-bf1f-4bfb-adaf-3ed618789719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_ba4a4d03-bf1f-4bfb-adaf-3ed618789719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_96d91a05-ce70-436b-8853-73c066e11ef1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_96d91a05-ce70-436b-8853-73c066e11ef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_5c105fe8-f4d4-4278-975b-10c1be1b1830" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_sesn_WeightedAverageCostOfCapital_5c105fe8-f4d4-4278-975b-10c1be1b1830" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64565849-6041-49dd-a742-203d33ba3999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64565849-6041-49dd-a742-203d33ba3999" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_efc3bfc7-87b3-40c0-81ff-654271d00fbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_efc3bfc7-87b3-40c0-81ff-654271d00fbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6a954ef5-fb1a-47e3-9d14-59193bbd8b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6a954ef5-fb1a-47e3-9d14-59193bbd8b6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:to="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7f8bc844-6c8f-4602-acac-0cc99a8f853e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:to="loc_srt_RangeMember_7f8bc844-6c8f-4602-acac-0cc99a8f853e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:to="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7cf47eb-cbc4-4550-aed4-526fd7511579" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:to="loc_srt_MinimumMember_f7cf47eb-cbc4-4550-aed4-526fd7511579" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1179fe3e-3588-4ffc-bc77-086ef2c99995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:to="loc_srt_MaximumMember_1179fe3e-3588-4ffc-bc77-086ef2c99995" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended" id="ice2906927a134589ac0e608c3e140c2b_FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_028b0c11-0854-4b8d-9c7d-0b9fc53ff132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_028b0c11-0854-4b8d-9c7d-0b9fc53ff132" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2c96392d-a19b-435d-811b-bcc62cd73ffb" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2c96392d-a19b-435d-811b-bcc62cd73ffb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f888b6bf-6f16-4803-888c-8d55b4c739d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc227e47-1370-4363-b6b1-3b0299bf6bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc227e47-1370-4363-b6b1-3b0299bf6bdd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended" id="id874e3679a7f46d289b1c97c9ad62491_RECEIVABLESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c91dc0f-1dc6-4715-a0fd-6941c892e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c91dc0f-1dc6-4715-a0fd-6941c892e21b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_d5719313-406c-474f-a7fd-6c88926b5d79" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_d5719313-406c-474f-a7fd-6c88926b5d79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_17b7533c-9260-4949-b87b-30e5d3e957fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_17b7533c-9260-4949-b87b-30e5d3e957fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_19516683-18b1-40b7-a4fe-b3c0f27792fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_19516683-18b1-40b7-a4fe-b3c0f27792fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:to="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b403dcc-a3aa-4491-a76a-55f213aca69f_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5b403dcc-a3aa-4491-a76a-55f213aca69f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_4e71bbbe-ad35-41f8-a5d3-bb9972b79370" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:to="loc_sesn_RocheMember_4e71bbbe-ad35-41f8-a5d3-bb9972b79370" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_bcb5dce6-c561-4222-bd6e-ecbc7dde2987_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:to="loc_us-gaap_ReceivableTypeDomain_bcb5dce6-c561-4222-bd6e-ecbc7dde2987_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:to="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember_28565a84-458c-451b-b58b-48fb287793fe" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:to="loc_sesn_LitigationSettlementMember_28565a84-458c-451b-b58b-48fb287793fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_12c6f350-f0e1-4d0e-bd16-5782f4fe3e82" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:to="loc_sesn_GermanVATRecoveryMember_12c6f350-f0e1-4d0e-bd16-5782f4fe3e82" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="extended" id="i0127c48199a54445b6790bc1c292eea4_INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_434b80d8-10ad-4fd3-ac70-94c61662be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_434b80d8-10ad-4fd3-ac70-94c61662be4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:to="loc_srt_SegmentGeographicalDomain_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:to="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_85793ac7-3216-45a0-86c0-8a36a2a2b0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:to="loc_srt_EuropeMember_85793ac7-3216-45a0-86c0-8a36a2a2b0b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_afecb3dc-600c-49be-8d03-ea13a9f5e96b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:to="loc_srt_ProductsAndServicesDomain_afecb3dc-600c-49be-8d03-ea13a9f5e96b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:to="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_d7d2f451-9138-4dae-9c89-82ff2703054c" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:to="loc_sesn_ViciniumMember_d7d2f451-9138-4dae-9c89-82ff2703054c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51187a0f-5976-4ab1-a203-6fbc96dbcb44_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_51187a0f-5976-4ab1-a203-6fbc96dbcb44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_16adc348-2212-4c90-887d-39d8d0a23482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_16adc348-2212-4c90-887d-39d8d0a23482" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="extended" id="i544faa16cfd94250bdbaf59c23fa68f0_INTANGIBLEASSETSANDGOODWILNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6f30a6a0-aba5-48a6-82a2-ba8344588b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6f30a6a0-aba5-48a6-82a2-ba8344588b01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_0bc07522-bc31-44ce-b4a6-032d82e53f26" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_0bc07522-bc31-44ce-b4a6-032d82e53f26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc1f17f5-5412-4f0f-945b-93303c922fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_us-gaap_Goodwill_dc1f17f5-5412-4f0f-945b-93303c922fb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7618b9a9-8189-4ae2-8430-dd84b5b25055_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:to="loc_srt_ProductsAndServicesDomain_7618b9a9-8189-4ae2-8430-dd84b5b25055_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:to="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_7f419179-556d-4cfc-9c49-0c7e297db1ce" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:to="loc_sesn_ViciniumMember_7f419179-556d-4cfc-9c49-0c7e297db1ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:to="loc_srt_SegmentGeographicalDomain_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:to="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_86b99c53-2063-43a6-b3f2-12b1ac33a798" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:to="loc_srt_EuropeMember_86b99c53-2063-43a6-b3f2-12b1ac33a798" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23c197b7-f91b-435a-a5f2-a84a0b3c7192_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_23c197b7-f91b-435a-a5f2-a84a0b3c7192_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c93f0729-07e0-4b2a-8486-973bf4978a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c93f0729-07e0-4b2a-8486-973bf4978a37" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASESDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LEASESDetails" xlink:type="extended" id="if51acc9b968444da93e30f86e3d061cd_LEASESDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_2032131b-7401-411b-8b9d-7b3bd4e4aee9" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_2032131b-7401-411b-8b9d-7b3bd4e4aee9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d273ff47-5da5-4e0e-9d56-d1b41308aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d273ff47-5da5-4e0e-9d56-d1b41308aa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_8f199b48-0649-4ccd-a3a0-c49005aac4f8" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_8f199b48-0649-4ccd-a3a0-c49005aac4f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_cb341580-4a7d-453d-af13-64d3b9d077f6" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_cb341580-4a7d-453d-af13-64d3b9d077f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9a2d523c-8510-4fde-ad6d-8840c8160be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseCost_9a2d523c-8510-4fde-ad6d-8840c8160be0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3b212a04-867c-41bf-82df-d5784d0fabd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3b212a04-867c-41bf-82df-d5784d0fabd9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcab4a74-5c27-4e8a-af7e-eed6c7239b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcab4a74-5c27-4e8a-af7e-eed6c7239b72" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d2947ccb-9bef-4748-aa26-0d4b4d80a221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d2947ccb-9bef-4748-aa26-0d4b4d80a221" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f9f03-73b3-4fd3-9676-945d820dbf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f9f03-73b3-4fd3-9676-945d820dbf15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:to="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:to="loc_srt_SegmentGeographicalDomain_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:to="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e1a954ed-6fd2-4081-b7ae-013dbf36e4ce" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_country_CA_e1a954ed-6fd2-4081-b7ae-013dbf36e4ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_cd10cabb-00d0-4ba7-b6f5-3031ef5fe0c3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_stpr_MA_cd10cabb-00d0-4ba7-b6f5-3031ef5fe0c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_eb555429-5e13-4e6e-99d8-ae3b00e79e6f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_stpr_PA_eb555429-5e13-4e6e-99d8-ae3b00e79e6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:to="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:to="loc_srt_RangeMember_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:to="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d2efd0e-60b8-4c19-b8c3-1b816bac2ee6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:to="loc_srt_MinimumMember_2d2efd0e-60b8-4c19-b8c3-1b816bac2ee6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c7391dd-dd97-4055-b88a-63debb0ac4c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:to="loc_srt_MaximumMember_1c7391dd-dd97-4055-b88a-63debb0ac4c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended" id="i29024c5aee27472f915c115f276260c8_STOCKHOLDERSEQUITYEquityFinancingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf8603e-270d-4799-9679-07cb2166f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf8603e-270d-4799-9679-07cb2166f6fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c0c22768-8980-4aa1-bbf5-189d6657c0f2" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c0c22768-8980-4aa1-bbf5-189d6657c0f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_dde3e024-d541-450c-8335-81b2a79b1fa9" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_dde3e024-d541-450c-8335-81b2a79b1fa9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_431f6926-09ec-4491-9b50-fe462f8f50db" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_431f6926-09ec-4491-9b50-fe462f8f50db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_93ab3fca-7b91-4fb4-98f0-b0b6964c24f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_93ab3fca-7b91-4fb4-98f0-b0b6964c24f7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_65636136-76af-4a4a-ac72-058b7518fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_65636136-76af-4a4a-ac72-058b7518fcdb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_4a72dca1-c6c1-446c-bb60-f98b7cc1f6c4" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_4a72dca1-c6c1-446c-bb60-f98b7cc1f6c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_eabf479a-f222-4e2e-8555-4780393c1aa0" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_eabf479a-f222-4e2e-8555-4780393c1aa0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:to="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c57deae-10c5-4677-806a-b38c68ae7854_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:to="loc_us-gaap_CreditFacilityDomain_5c57deae-10c5-4677-806a-b38c68ae7854_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:to="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_7d44ccdc-7a83-4cb1-9d87-dc35ebb5c7fe" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:to="loc_sesn_ATMFacilityMember_7d44ccdc-7a83-4cb1-9d87-dc35ebb5c7fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended" id="i044ff18f50254d05a1cd9c5ef7e3b8a8_STOCKHOLDERSEQUITYCommonStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7197f600-8b58-4937-b5ed-086817792108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7197f600-8b58-4937-b5ed-086817792108" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_04d0d805-cc59-468f-9a19-6ecbe69e965a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesIssued_04d0d805-cc59-468f-9a19-6ecbe69e965a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41b6bce2-c1be-4de3-af57-661316b15b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_41b6bce2-c1be-4de3-af57-661316b15b35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_09b67323-966e-4785-a3a1-89682fbe1076" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_09b67323-966e-4785-a3a1-89682fbe1076" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_cab5a501-a796-4ad8-8f6d-ba797e3a75c5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:to="loc_us-gaap_EquityComponentDomain_cab5a501-a796-4ad8-8f6d-ba797e3a75c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:to="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51155bbe-3f39-4415-94c9-cf6bbf5c0c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:to="loc_us-gaap_CommonStockMember_51155bbe-3f39-4415-94c9-cf6bbf5c0c46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended" id="if28300c418e644168ec640b4b8ff0967_STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_11003ed4-2836-407d-b432-5bf01bacef89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:to="loc_us-gaap_CommonStockSharesIssued_11003ed4-2836-407d-b432-5bf01bacef89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0a73fa4-4aab-4508-894c-606855e78061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0a73fa4-4aab-4508-894c-606855e78061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_5bc06bde-7764-4e84-ad59-ce260e23412c" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_5bc06bde-7764-4e84-ad59-ce260e23412c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:to="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f57799-07b4-42a3-a694-5afbcbb87430_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a1f57799-07b4-42a3-a694-5afbcbb87430_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_889c57c2-8138-42b4-b4b2-dfecbb62af8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_WarrantMember_889c57c2-8138-42b4-b4b2-dfecbb62af8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b147b536-e3e2-43b5-9ecf-502070fa8927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b147b536-e3e2-43b5-9ecf-502070fa8927" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3be2d85-0727-41d5-899c-92e93ad555fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3be2d85-0727-41d5-899c-92e93ad555fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_76ac6111-1150-40b7-af38-ab2602c655d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_76ac6111-1150-40b7-af38-ab2602c655d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_881e9ce4-6d3a-40ae-8271-cad16f012c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_EmployeeStockMember_881e9ce4-6d3a-40ae-8271-cad16f012c01" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended" id="i75a582ad3ded4659af05cddd32361c11_STOCKHOLDERSEQUITYWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c69955-89b7-4976-8aad-dc71baf8d451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c69955-89b7-4976-8aad-dc71baf8d451" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a2751f0-5ddd-4af3-9d4f-61a2fed340ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a2751f0-5ddd-4af3-9d4f-61a2fed340ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_190fadc3-364e-4ad0-922e-4958e1fde501" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_190fadc3-364e-4ad0-922e-4958e1fde501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2bcc1e1d-24d5-4f5a-8d80-9fdb645cf5a1" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2bcc1e1d-24d5-4f5a-8d80-9fdb645cf5a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_328904be-4e11-49e4-aa9b-de764aa30153" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_328904be-4e11-49e4-aa9b-de764aa30153" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dc0ce7f-86ab-4742-ab8a-813b7c1e71b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cee3ab70-47d8-495d-8859-e1275350199d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cee3ab70-47d8-495d-8859-e1275350199d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_1e7930cb-a610-4f9f-b550-4aad89594a0c" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_1e7930cb-a610-4f9f-b550-4aad89594a0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_95f745a1-0b1c-43f6-8fa9-9e8aaf6e5cb9" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_95f745a1-0b1c-43f6-8fa9-9e8aaf6e5cb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_0d7bd1aa-3163-42e3-84f5-6a06d69da35a" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_0d7bd1aa-3163-42e3-84f5-6a06d69da35a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_70735bbf-1177-4c1f-877c-b41233de0c95" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_70735bbf-1177-4c1f-877c-b41233de0c95" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended" id="iba6fcb792f3244888f342bdc3e12ab55_EARNINGSLOSSPERSHAREDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cc7b149-4d72-410b-a7ca-15dbbaaabcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cc7b149-4d72-410b-a7ca-15dbbaaabcde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3f18d7d5-8212-4de6-afe3-3c2c16bfc550_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3f18d7d5-8212-4de6-afe3-3c2c16bfc550_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b38f74ba-b311-4a22-a7ff-77c73fff0c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_WarrantMember_b38f74ba-b311-4a22-a7ff-77c73fff0c05" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d937bf88-3d6d-43fe-8988-626d427345e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d937bf88-3d6d-43fe-8988-626d427345e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13fb4b18-a387-4268-869a-86a8384ef5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13fb4b18-a387-4268-869a-86a8384ef5d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_74575bdd-beaa-4196-a327-f4b4a5f11751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_PerformanceSharesMember_74575bdd-beaa-4196-a327-f4b4a5f11751" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended" id="i1dec0197c64b41c3abe8bd373fdc10db_SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8ca85e4a-2025-402f-9ee0-262763258e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8ca85e4a-2025-402f-9ee0-262763258e80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_670eca1f-5e25-45f7-9745-f97f2f40fc53_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_670eca1f-5e25-45f7-9745-f97f2f40fc53_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d9c2add-f464-4d91-9f4b-090d9e47759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d9c2add-f464-4d91-9f4b-090d9e47759a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a4a0ff2b-58f4-4099-8b94-d1e6825818e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a4a0ff2b-58f4-4099-8b94-d1e6825818e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended" id="icc19f0767891471abcc03514419a4d30_SHAREBASEDCOMPENSATIONNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3f008c48-843f-4908-9bc7-9d45dcb2defa" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3f008c48-843f-4908-9bc7-9d45dcb2defa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57a35f5f-b087-45ab-9b39-7bfc8f55854b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57a35f5f-b087-45ab-9b39-7bfc8f55854b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc4a4e3b-d8dd-46b2-bcea-59ca3a4ad512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc4a4e3b-d8dd-46b2-bcea-59ca3a4ad512" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7c8b17d2-30ef-49ee-93af-3f11fb33bdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7c8b17d2-30ef-49ee-93af-3f11fb33bdd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8d356b2f-ffe3-415b-b0ff-d132669b6514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8d356b2f-ffe3-415b-b0ff-d132669b6514" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_970116a7-94af-4819-bd88-7bfa00d3c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_970116a7-94af-4819-bd88-7bfa00d3c46b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_0aff4c7b-4949-43a3-931e-a477e3419fe6" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_0aff4c7b-4949-43a3-931e-a477e3419fe6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_a6b367e5-5f3a-46f2-b6aa-f5d2d3161e99" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_a6b367e5-5f3a-46f2-b6aa-f5d2d3161e99" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85ba3ee5-ad89-45b7-807b-dbcdc691e438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85ba3ee5-ad89-45b7-807b-dbcdc691e438" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_5d0b6ee7-7d1e-4bf1-bbc1-7bd36b4aa624" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_5d0b6ee7-7d1e-4bf1-bbc1-7bd36b4aa624" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_85abeb9d-5901-40fd-a61b-73c66147669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_85abeb9d-5901-40fd-a61b-73c66147669d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b559af7-e2fc-411a-9d20-4c80b2699429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b559af7-e2fc-411a-9d20-4c80b2699429" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e8c27f80-2642-45c1-b605-9f2a89599064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e8c27f80-2642-45c1-b605-9f2a89599064" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e005e824-d362-44cc-a7e6-a9813b49e3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e005e824-d362-44cc-a7e6-a9813b49e3b0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4995ba87-07fd-4b7d-ae47-a218ffaaf8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4995ba87-07fd-4b7d-ae47-a218ffaaf8f4" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81ca27c8-f8ef-453d-ba2c-612decc153d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81ca27c8-f8ef-453d-ba2c-612decc153d2" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_489ae87f-b67a-4f80-b6e6-c01a14a6d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_489ae87f-b67a-4f80-b6e6-c01a14a6d598" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2094862a-c1aa-46c8-949d-4d7d04678068_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2094862a-c1aa-46c8-949d-4d7d04678068_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20576e00-0647-4fe1-a427-644414033941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20576e00-0647-4fe1-a427-644414033941" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bcc8f071-ab97-4bcb-b9dd-fcb70d52b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bcc8f071-ab97-4bcb-b9dd-fcb70d52b83c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7c85d164-163b-4748-ad5e-955771a97811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_PerformanceSharesMember_7c85d164-163b-4748-ad5e-955771a97811" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:to="loc_us-gaap_PlanNameDomain_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:to="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_3ce8e50b-31c3-4487-9e80-17a6f640c948" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_3ce8e50b-31c3-4487-9e80-17a6f640c948" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_8aa102f2-bf40-4a02-b89f-2a712715bd52" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_RetentionProgramMember_8aa102f2-bf40-4a02-b89f-2a712715bd52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_bef01072-7d4c-480f-b2fa-c9af344fc5ad" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_StockIncentivePlan2009Member_bef01072-7d4c-480f-b2fa-c9af344fc5ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:to="loc_us-gaap_VestingDomain_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:to="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f6386fa1-9537-4eb8-9cb6-ee0b51ff8aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f6386fa1-9537-4eb8-9cb6-ee0b51ff8aae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c661771f-270e-4e91-bba5-cb8ba094c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c661771f-270e-4e91-bba5-cb8ba094c21d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_44e3cbd5-05ce-43f4-ab84-4a203702fe04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:to="loc_us-gaap_GranteeStatusDomain_44e3cbd5-05ce-43f4-ab84-4a203702fe04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:to="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3dae9462-53d4-4ef0-b8ba-f499236e9802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3dae9462-53d4-4ef0-b8ba-f499236e9802" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended" id="i8e3ecc490e07458ca28227b28b6e642a_SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_ed96eb1a-2e3f-47da-8c00-643a8f772bc7" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_ed96eb1a-2e3f-47da-8c00-643a8f772bc7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0df5e004-e82a-4243-9eb3-910b6024b236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0df5e004-e82a-4243-9eb3-910b6024b236" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d66047-d004-4550-b503-f638b53b990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d66047-d004-4550-b503-f638b53b990d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d54b78c-131a-4ae7-9a48-f3b5ee977538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d54b78c-131a-4ae7-9a48-f3b5ee977538" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6df9619d-924f-4a46-8b00-abb8200c44c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6df9619d-924f-4a46-8b00-abb8200c44c2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c2b9ced-e463-43eb-bc36-16e748edd97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c2b9ced-e463-43eb-bc36-16e748edd97f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:to="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52711721-ffeb-4e26-8af9-ccf16a4ca9cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_52711721-ffeb-4e26-8af9-ccf16a4ca9cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8e4c1e96-707e-45a5-9e86-d40a9a5244ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8e4c1e96-707e-45a5-9e86-d40a9a5244ca" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended" id="i6d35639f4bdd410eb14333b680c068f2_SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef886896-9144-4a7c-bb6a-7878129971da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef886896-9144-4a7c-bb6a-7878129971da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b85f6c2b-160f-4184-acf2-3f5797b07ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b85f6c2b-160f-4184-acf2-3f5797b07ac1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8aaa354-a03b-4ad3-9f38-960a961f3e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8aaa354-a03b-4ad3-9f38-960a961f3e3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88082e1e-071d-4d27-9b95-e11fee1431f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06e618e2-cd99-4485-b290-9937c8f75c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06e618e2-cd99-4485-b290-9937c8f75c0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcf87c26-e34a-4bb9-818e-06ce36a3bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcf87c26-e34a-4bb9-818e-06ce36a3bae3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d53e75e0-6cf5-4bbf-a796-ccad1bd5108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d53e75e0-6cf5-4bbf-a796-ccad1bd5108f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_535da7d4-2791-4c37-9247-bbf1cc003a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:to="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29267168-e213-4fd0-aea0-830e0560b2ee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29267168-e213-4fd0-aea0-830e0560b2ee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea452706-db61-4aba-9252-e0e8ffd65985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea452706-db61-4aba-9252-e0e8ffd65985" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_33ad9921-7215-4cf1-a6b5-a18f286dc1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:to="loc_us-gaap_PerformanceSharesMember_33ad9921-7215-4cf1-a6b5-a18f286dc1d9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended" id="ide3723fb1a4144c6853586723da2ae12_EMPLOYEEBENEFITPLANSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b29cfc4b-f0d8-4182-a5c4-89dcb5034340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b29cfc4b-f0d8-4182-a5c4-89dcb5034340" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_53e4408c-c767-457b-a8f0-0315876c2ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_53e4408c-c767-457b-a8f0-0315876c2ce8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f69d46be-0c62-4896-95bd-6afe6d314526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f69d46be-0c62-4896-95bd-6afe6d314526" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c6ba13aa-81be-4721-92b4-0807486d966d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c6ba13aa-81be-4721-92b4-0807486d966d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4c338732-c862-4d13-a9a8-c2267dd68da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4c338732-c862-4d13-a9a8-c2267dd68da9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_3a8d18d2-0e72-4e22-937a-96b4cc6e90c0" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_3a8d18d2-0e72-4e22-937a-96b4cc6e90c0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_15fa0ef9-8240-4f99-9a42-5a06299da7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_15fa0ef9-8240-4f99-9a42-5a06299da7a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:to="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_02bd4824-776b-4eed-88e6-58604c13d9fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:to="loc_us-gaap_PlanNameDomain_02bd4824-776b-4eed-88e6-58604c13d9fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:to="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_3a2780c5-8ede-4153-bb2b-9de73d10caa6" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_3a2780c5-8ede-4153-bb2b-9de73d10caa6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_47561df0-6a24-409d-b5ea-d9df469d64a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_47561df0-6a24-409d-b5ea-d9df469d64a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:to="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_31b63e26-2e93-4763-b73d-327d09d777eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:to="loc_country_US_31b63e26-2e93-4763-b73d-327d09d777eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:to="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5f90a157-3335-4576-86ed-aaef99ad9f57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:to="loc_country_CA_5f90a157-3335-4576-86ed-aaef99ad9f57" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended" id="i5060c406df464c7fb82d1885edefb6cb_INCOMETAXESComponentsofPretaxIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fef6b490-4937-4605-a4bb-c65799e61b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fef6b490-4937-4605-a4bb-c65799e61b75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3f62956a-1f58-4231-8a66-7c5e953e12b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3f62956a-1f58-4231-8a66-7c5e953e12b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0efa284a-a4e5-4bff-8925-431feb94bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0efa284a-a4e5-4bff-8925-431feb94bbd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:to="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0dc196d8-dd58-40d1-934c-25bb4c516573_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:to="loc_srt_SegmentGeographicalDomain_0dc196d8-dd58-40d1-934c-25bb4c516573_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:to="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4c1f8c8c-85fd-4511-8b6a-3101f238df83" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:to="loc_country_US_4c1f8c8c-85fd-4511-8b6a-3101f238df83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_779a0740-53c0-49ab-9ff8-e8256cebde3e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:to="loc_country_CA_779a0740-53c0-49ab-9ff8-e8256cebde3e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended" id="iaed6a02935a24bd0a720b8d6f4e80ca5_INCOMETAXESNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_865c1068-9d1b-4d06-8ca7-0a22373aec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_865c1068-9d1b-4d06-8ca7-0a22373aec18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2a6bd6d8-a903-4634-b56b-dbe308258722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2a6bd6d8-a903-4634-b56b-dbe308258722" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d5b98473-6a86-45cc-8ad1-851c30952f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d5b98473-6a86-45cc-8ad1-851c30952f4b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_5a69906a-3a60-4143-9839-8d22dcc1e714" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_5a69906a-3a60-4143-9839-8d22dcc1e714" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_64d823f5-7a41-4a54-8ccb-d42683a63828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IncomeTaxesPaid_64d823f5-7a41-4a54-8ccb-d42683a63828" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:to="loc_srt_ProductsAndServicesDomain_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:to="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_c68af3e8-fc0a-4e7a-9338-8a8fdee964e8" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:to="loc_sesn_ViciniumMember_c68af3e8-fc0a-4e7a-9338-8a8fdee964e8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b821ce9c-946a-4780-86c4-0eb6d7b85003_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:to="loc_srt_SegmentGeographicalDomain_b821ce9c-946a-4780-86c4-0eb6d7b85003_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:to="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6c7d1f25-ffde-43f8-ade7-201d6af3ab68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:to="loc_srt_EuropeMember_6c7d1f25-ffde-43f8-ade7-201d6af3ab68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03c0f832-de5f-4620-aeb7-d7d8c8951a8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_03c0f832-de5f-4620-aeb7-d7d8c8951a8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_63ce9af7-c00a-4860-86a8-f708b07c264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_63ce9af7-c00a-4860-86a8-f708b07c264d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended" id="ib7ecde8c736f46199e5450f4deacb67c_LICENSEAGREEMENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_14e69c8c-3226-4af7-9e44-a87336f43582" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_14e69c8c-3226-4af7-9e44-a87336f43582" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_224f58ec-819b-4dc1-9979-1f57ce9692f0" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_224f58ec-819b-4dc1-9979-1f57ce9692f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_cd7d1f68-db11-4bb4-8cb6-f809cd7c8dcb" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_cd7d1f68-db11-4bb4-8cb6-f809cd7c8dcb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_7ed0c2fb-42eb-4970-8077-a79dc735953f" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_7ed0c2fb-42eb-4970-8077-a79dc735953f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_c89ab664-3ef2-4cc9-ba4d-740befa9d455" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_c89ab664-3ef2-4cc9-ba4d-740befa9d455" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_38b61400-d40a-4fc2-9580-0a92010532f5" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_38b61400-d40a-4fc2-9580-0a92010532f5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a6be1301-62f7-4a0f-a6c3-060b40b4885d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a6be1301-62f7-4a0f-a6c3-060b40b4885d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_980b06bd-cc78-42b9-8a54-601abb1f707f" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseMaintenanceFees_980b06bd-cc78-42b9-8a54-601abb1f707f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_8d79f36b-c35f-411b-a6c5-180d845bc0f1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_8d79f36b-c35f-411b-a6c5-180d845bc0f1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_9ea338b0-9e2b-4333-82fd-8dff7e0db1ec" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_9ea338b0-9e2b-4333-82fd-8dff7e0db1ec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_54db2e98-ea03-48fc-8e73-19b3b3bc0f65" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_54db2e98-ea03-48fc-8e73-19b3b3bc0f65" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_da54c8cd-a03b-48b3-9a16-621689b3896f" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_da54c8cd-a03b-48b3-9a16-621689b3896f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97ca15c2-5953-4a3c-9eca-ca0814ba11a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97ca15c2-5953-4a3c-9eca-ca0814ba11a8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_06be2752-88c1-409f-bf79-877955cb25d8" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_06be2752-88c1-409f-bf79-877955cb25d8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_e6b22608-b476-4607-8445-2d0527aa4cac" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_e6b22608-b476-4607-8445-2d0527aa4cac" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_a46eace7-91a2-4229-8957-cded6a299601" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_a46eace7-91a2-4229-8957-cded6a299601" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_027c4a10-c51d-4b18-865d-3a3785e86dbd" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_027c4a10-c51d-4b18-865d-3a3785e86dbd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_d1e5660f-a87b-4773-8053-44dd5ef7fb59" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_d1e5660f-a87b-4773-8053-44dd5ef7fb59" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_d51f2b72-fc86-4616-bb2a-eb713671497a" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_d51f2b72-fc86-4616-bb2a-eb713671497a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_0da90710-fc16-429e-b7ab-e51b3f28c794" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_0da90710-fc16-429e-b7ab-e51b3f28c794" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_89eb3482-b7e6-4875-b6cb-32dcc4277483" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_89eb3482-b7e6-4875-b6cb-32dcc4277483" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f1697a52-a3a6-43dc-baab-c8f46634305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_PaymentsForRestructuring_f1697a52-a3a6-43dc-baab-c8f46634305b" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9352bff0-7b66-41ad-9182-fbc65e236e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9352bff0-7b66-41ad-9182-fbc65e236e1f" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_cb7cc93d-9566-4a93-b9fd-e21567a10a20" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_cb7cc93d-9566-4a93-b9fd-e21567a10a20" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_6389cba4-83c1-4a9a-be5c-847410c39183" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_6389cba4-83c1-4a9a-be5c-847410c39183" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1d9d6dc7-1fd0-4830-b070-10b4aa2c2531" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1d9d6dc7-1fd0-4830-b070-10b4aa2c2531" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5cb9f132-e802-4bce-ac99-5d0b1112ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5cb9f132-e802-4bce-ac99-5d0b1112ee44" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_4b84ca25-d6e6-4b93-ac3f-551db57a1637" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_4b84ca25-d6e6-4b93-ac3f-551db57a1637" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_44fe1ee0-09bd-4f97-89d4-a3a85c092410" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_RoyaltyRevenuePercentage_44fe1ee0-09bd-4f97-89d4-a3a85c092410" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_05138008-3019-45d2-8fde-cb0e61d59d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_DeferredRevenue_05138008-3019-45d2-8fde-cb0e61d59d48" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b86b84d-a1f5-46c8-be37-324dd077146a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b86b84d-a1f5-46c8-be37-324dd077146a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_6864dd40-ca6c-44ea-b8e2-0b0223829d53" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_UniversityOfZurichMember_6864dd40-ca6c-44ea-b8e2-0b0223829d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_57be7119-d40b-4886-814b-080374e9dba5" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_MicrometAGMember_57be7119-d40b-4886-814b-080374e9dba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_d586a69e-c009-4236-8efa-965a72bda632" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_XOMAIrelandLimitedMember_d586a69e-c009-4236-8efa-965a72bda632" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e82c6a6d-031c-4e67-98ab-a0404709a3cb" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_RocheMember_e82c6a6d-031c-4e67-98ab-a0404709a3cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5313ec17-7238-4dd1-8c14-e7a46fdb6b6a" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5313ec17-7238-4dd1-8c14-e7a46fdb6b6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_5126f679-51bb-4f77-8730-dc0bb936fb46" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_MENALicenseAgreementMember_5126f679-51bb-4f77-8730-dc0bb936fb46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_20e81728-0176-447d-b159-df5a8f02c093" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_20e81728-0176-447d-b159-df5a8f02c093" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d85a841-3ec2-4668-8bb9-6de102d8ac24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2d85a841-3ec2-4668-8bb9-6de102d8ac24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_8ffc19ad-11fd-4d86-b4ff-3730d05bcc92" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_8ffc19ad-11fd-4d86-b4ff-3730d05bcc92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_a7589e63-e8d8-441f-9553-643aea372867" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_FirstIndicationMember_a7589e63-e8d8-441f-9553-643aea372867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_7b5a2149-bdb9-461c-b47a-2f468599f122" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_7b5a2149-bdb9-461c-b47a-2f468599f122" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_8cb6f348-6ee0-4bf2-9ea9-dff95f088b8e" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_8cb6f348-6ee0-4bf2-9ea9-dff95f088b8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_e4055132-7490-4aa0-a4cc-3bb3ee41c61d" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_e4055132-7490-4aa0-a4cc-3bb3ee41c61d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_1a1735b9-8cd6-4352-b2c8-1d3a177a082a" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_1a1735b9-8cd6-4352-b2c8-1d3a177a082a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_b70ffd26-bed8-410f-ae08-238d40266312" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_SecondIndicationMember_b70ffd26-bed8-410f-ae08-238d40266312" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fe0ca3de-aef6-4612-aaed-bb46c769c860_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:to="loc_srt_ProductsAndServicesDomain_fe0ca3de-aef6-4612-aaed-bb46c769c860_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:to="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_bb030fb3-1e3e-4045-bc11-b0b777935f4a" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:to="loc_sesn_EBI031Member_bb030fb3-1e3e-4045-bc11-b0b777935f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_24c53ea9-854e-42ef-80ab-385b207cd43c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:to="loc_srt_RangeMember_24c53ea9-854e-42ef-80ab-385b207cd43c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:to="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e91f2d0e-fc86-4dce-8472-1e256f0c4b7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:to="loc_srt_MinimumMember_e91f2d0e-fc86-4dce-8472-1e256f0c4b7c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_25a68084-258c-4246-b2d5-e4f8b28bd7d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:to="loc_srt_MaximumMember_25a68084-258c-4246-b2d5-e4f8b28bd7d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0cf60641-0f02-4dab-8ad5-a66381ac7549_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0cf60641-0f02-4dab-8ad5-a66381ac7549_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_d1297df4-f8e4-42ad-8bd4-0cf11457961e" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_d1297df4-f8e4-42ad-8bd4-0cf11457961e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9618bda0-a1f3-440d-9d9c-90b49fe8a53a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9618bda0-a1f3-440d-9d9c-90b49fe8a53a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_965bcc44-ba7e-4524-a600-0e8d7c4e2895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:to="loc_us-gaap_LicensingAgreementsMember_965bcc44-ba7e-4524-a600-0e8d7c4e2895" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:to="loc_srt_SegmentGeographicalDomain_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:to="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_01c79562-0136-4fa3-8b7b-c3e2232e6710" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:to="loc_country_TR_01c79562-0136-4fa3-8b7b-c3e2232e6710" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_03f4ec90-39d5-49cd-88c1-40fbf9aff182_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_03f4ec90-39d5-49cd-88c1-40fbf9aff182_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_64bb83a0-5d41-442b-b2b2-525455d97597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:to="loc_us-gaap_SubsequentEventMember_64bb83a0-5d41-442b-b2b2-525455d97597" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:definitionLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended" id="i7e86d46c31e24f5394ae9fcdc3b4ac70_SUBSEQUENTEVENTSDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_934dae32-8144-443b-aa04-af52623da2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_934dae32-8144-443b-aa04-af52623da2d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_2b29c992-c6c9-4bd2-ac50-07992c0a3e17" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_2b29c992-c6c9-4bd2-ac50-07992c0a3e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_122e8230-e359-49dc-8961-f6c40e6fc18d" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_122e8230-e359-49dc-8961-f6c40e6fc18d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_01f39612-85e8-4045-a877-90f1ffd5ba56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_01f39612-85e8-4045-a877-90f1ffd5ba56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2cc76e87-5790-4d9d-91c8-f1d632545594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:to="loc_us-gaap_SubsequentEventMember_2cc76e87-5790-4d9d-91c8-f1d632545594" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>sesn-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_52d12b58-4a62-4936-ae4e-61b24102f24b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_05e7a836-c412-4c07-b80a-b0242a57e393_terseLabel_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_label_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:label id="lab_sesn_XOMAIrelandLimitedMember_documentation_en-US" xlink:label="lab_sesn_XOMAIrelandLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XOMA Ireland Limited [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_XOMAIrelandLimitedMember" xlink:to="lab_sesn_XOMAIrelandLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9d95c8b8-ef35-4a0f-9f61-2adb9371bcb2_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_f1a059b3-0ee1-4518-89cd-aea02cf2b22e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_1d1f19a5-4c93-471d-b663-a7af005b0285_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a82ebbf0-0dcb-4121-8b60-f7e459aefee0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_fc2cc4fc-778f-4c3c-9a87-ecdcd0f667c1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_04fb8da1-561f-4c03-890f-62bd0e946d76_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_15a5ae38-0b40-4a97-8d42-19e9df941f13_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_e999dcc1-f3f5-433d-bfc3-3c81d6040cc7_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_a6d798f9-504c-4e7a-8197-858ea3c0d07c_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_28e706a9-a23e-45e3-925e-6aba7b08aa2c_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_34a9d5c0-3e9b-44e6-88f2-61d92e102d87_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares received per award (in shares)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ff008cbf-68a4-4ba4-917f-707c266f10a1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_5506eba8-2757-4ea6-976f-8eb9c99751cc_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Investing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LitigationSettlementMember_749f52fd-6b85-4b87-bacc-973dae9234b5_terseLabel_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement</link:label>
    <link:label id="lab_sesn_LitigationSettlementMember_label_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement [Member]</link:label>
    <link:label id="lab_sesn_LitigationSettlementMember_documentation_en-US" xlink:label="lab_sesn_LitigationSettlementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement Member</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LitigationSettlementMember" xlink:to="lab_sesn_LitigationSettlementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_99eefea0-78ea-4c0f-a72c-f8988d940164_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_aa6100a7-b30c-43c8-b64b-e283534b4ad8_terseLabel_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenue, percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_label_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:label id="lab_sesn_RoyaltyRevenuePercentage_documentation_en-US" xlink:label="lab_sesn_RoyaltyRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Revenue, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RoyaltyRevenuePercentage" xlink:to="lab_sesn_RoyaltyRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_74169976-3a9b-46b9-ae28-93fc0a8a6757_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9bdd99cd-7017-4e35-8dcf-7ee6ee6a8694_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_df020378-2346-46a3-ac5e-2db1e9b6940d_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4327846e-9a02-4f76-938a-20701545e6ea_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_c3e727c2-ac8b-46d7-a6b4-eec5f1e32a8f_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementUpfrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementUpfrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Up-front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementUpfrontFee" xlink:to="lab_sesn_LicenseAgreementUpfrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_c1f83cb9-32e2-40d6-a05a-0b1baba5df98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_83cc5157-7f74-4e4e-b9ac-3a45cfffd288_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party minimum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty on Net Product Sales, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_e97b108b-354e-41bf-bc84-6b842bd2ad91_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_858e9773-bcbf-4fb4-b5d6-06880f065097_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss After Taxes</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1a911807-7574-4e34-b45a-84014fa84d60_negatedLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_eea01bee-1500-45c5-aec4-a2f605d4331f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_2dc61d26-16a8-45a2-9a41-856ba097f3b0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_75175db2-59f9-4b26-92c5-256ec9f17c6a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_7db3b88a-6775-4438-a079-9e5364bb006e_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3c56971d-7bbf-4693-89fc-3d6cb5d5d97c_netLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_72ad5528-94c7-42c2-bf3e-1e7488ff3f98_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_c3b1e568-5679-4989-a86d-0c9f921eb5fb_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_dce06168-1c51-4f40-bff9-f6910d5d5188_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c118f2dd-c63e-4aaa-8463-88dbe35c40cf_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount Rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_e9873404-2068-47a6-9bd6-02aa789b6776_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space (in square feet)</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_label_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:label id="lab_sesn_OperatingLeasesAreaOfOfficeSpace_documentation_en-US" xlink:label="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases Area Of Office Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:to="lab_sesn_OperatingLeasesAreaOfOfficeSpace" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cd3cc86f-8de7-4d91-90e6-60094ec7b499_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original number of shares subject to the option vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_ec365fee-da9e-424a-b9f5-b8e7f4c61982_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_cfa00a90-97d0-49d5-ab3f-a691166d2463_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_e92d042b-6de7-4712-8636-c2113930f5d5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_ef8fea66-c777-449e-b794-691aaabc49df_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_8a394db4-4204-42a1-820c-d0776912def8_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on regulatory milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_57b82b67-f20f-4b5c-9083-e7c62b07aa6d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_328e6327-abd1-4aba-a4d8-abaf898980b8_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_f2016f51-956a-4bea-a9a4-21dd13db6957_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_26bab63f-a5e0-411e-bc44-7eec5ee7fc5c_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_148d8390-f98b-4366-a948-750a553595c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled or forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_312354b7-3cab-44d9-b004-de284c2e87cf_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_0e523cf8-d3f5-4dfb-a00d-e3923091dffa_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_912a190d-bf78-40a0-b06a-61fb2c52c10d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_GermanVATRecoveryMember_3b5d9e18-f884-46c2-ac12-b0b3b15d1841_terseLabel_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_label_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery [Member]</link:label>
    <link:label id="lab_sesn_GermanVATRecoveryMember_documentation_en-US" xlink:label="lab_sesn_GermanVATRecoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">German VAT recovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_GermanVATRecoveryMember" xlink:to="lab_sesn_GermanVATRecoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0f4ff178-e5f5-48b3-a370-d9699efdfd6e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_1f9cd6cb-9fd0-4d88-baa2-80038824b24f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_650d5f67-230b-48e5-95c2-9de5ac9b5294_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_b3864120-d255-4b5c-b202-3038e6a8f3c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for sale under 2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_4539d564-4a9c-43c6-80ce-be37684b964c_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_da9256e1-5390-4f3d-a50e-dd01140f2e6a_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_310c415f-1932-4d30-9b12-421820eb9b4c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_f7ce8bc5-d25f-4f93-9503-c0f66ef3eb6f_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Third party maximum ownership, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:to="lab_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_12479c56-ecb5-40ae-99f6-eb5f356b03b8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_eea8fb20-e6de-477b-8e71-db7b13a87189_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_7451a7f6-6089-4a01-a6e2-5c20069b859d_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D intangible assets:</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_41639d80-9155-4d49-93d0-e6b65d3466b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_b5a3802f-1bca-4353-967a-3a2c77db77ed_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined contribution retirement plan, maximum employee contribution deferred</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_7d17bf9d-7054-46d4-9c0c-fcc57000a53b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_8db40553-d4f5-4f87-b8e9-23e50ac52845_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled or forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesAbstract_label_en-US" xlink:label="lab_us-gaap_ReceivablesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesAbstract" xlink:to="lab_us-gaap_ReceivablesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_17990849-703f-4b66-ae74-532ee3a533b6_terseLabel_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECEIVABLES</link:label>
    <link:label id="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_9b013bd1-8f7c-44f8-9182-ff24261aa747_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4a2e11d7-db41-4970-a3b6-de981152f02d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_c16dd21f-b27d-4c5b-a258-10ca33af462a_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_125f3f70-3efa-41a4-ab70-d7cd31122458_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of voting interests acquired</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_8e16c602-1db3-47d2-96e6-15a30f403efb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_f27e35f3-1371-4c2b-987c-836274d81557_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment, percentage</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_label_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:label id="lab_sesn_BusinessCombinationRoyaltyPaymentPercent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Royalty Payment Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:to="lab_sesn_BusinessCombinationRoyaltyPaymentPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_d1237d92-7d64-4909-908a-a519a07c9cb9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be60a54b-4d31-4db7-b3f4-23c277a636f6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_188b462d-a02d-467a-8712-24bb9cb49974_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_3fefcef5-0aa6-424a-8a56-263295296270_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_37065484-e04b-4f36-9b84-c189b15d584d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements and Changes in Accounting Principles [Abstract]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_ed63aea4-29c5-4ad1-b178-977e90bb5934_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_975bc0c1-0c55-4624-bccc-35b25a205a7b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_da0d9183-3d62-4dd1-9fd8-575f24c46f34_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_5afdf636-bbb2-4cef-b6bf-5a6f73c06d77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_068075be-66e6-44ad-b7c7-b7be25b3933d_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aae65693-9bae-41f9-b203-8f582723defc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_f56459c3-2f4c-4fee-bd17-3dd410b3e760_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_bd04c315-6207-4135-b6f8-2d77fc4a26e4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_73f19c8b-c418-4a42-8f2d-65211962d605_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EMPLOYEE BENEFIT PLANS</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_0b839d0f-78ea-4a61-88f9-225b51b82d41_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7f82c01b-9d5c-4a14-839c-ded7134a9d11_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Operating Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_e1cb2a36-98ee-4964-a859-2622bf61cac2_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_7c4610e4-6338-473a-88f6-875e4e9e79cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_8df73a82-c736-4120-9afa-e84afa4ed70b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_FirstIndicationMember_c9bcc2d9-267a-43cd-b67c-9d36c4164d2a_terseLabel_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_label_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:label id="lab_sesn_FirstIndicationMember_documentation_en-US" xlink:label="lab_sesn_FirstIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">First Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_FirstIndicationMember" xlink:to="lab_sesn_FirstIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_f45a7377-6568-4f2e-8b2e-13a5077a9e7d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of common stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_df10fb07-0843-453b-8851-6fce990f879e_terseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_label_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009 [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlan2009Member_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlan2009Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan 2009</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlan2009Member" xlink:to="lab_sesn_StockIncentivePlan2009Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_f771cb03-c8e3-4a7e-916d-05357adc4676_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5cc6159e-1360-427b-a1db-d696ba48799a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberOfLawsuits_badf4522-7519-4e77-b885-98b71c697898_terseLabel_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_label_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:label id="lab_sesn_NumberOfLawsuits_documentation_en-US" xlink:label="lab_sesn_NumberOfLawsuits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Lawsuits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits" xlink:href="sesn-20220630.xsd#sesn_NumberOfLawsuits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberOfLawsuits" xlink:to="lab_sesn_NumberOfLawsuits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_17e0c489-eb50-4a3c-af1c-a2cf35f06517_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting on the First Anniversary of Date of Grant</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedLegalFees_212f966d-6ef2-42bb-b277-872277be7ee5_terseLabel_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal expenses, including preliminary litigation settlement</link:label>
    <link:label id="lab_sesn_AccruedLegalFees_label_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees</link:label>
    <link:label id="lab_sesn_AccruedLegalFees_documentation_en-US" xlink:label="lab_sesn_AccruedLegalFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Legal Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedLegalFees" xlink:to="lab_sesn_AccruedLegalFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4049a60d-0941-4834-92c0-5c77b9b44a31_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_012956ca-233b-47dc-b4b6-628c00ccc0c5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_eb349ae6-d8cc-4ffb-bdfb-6918a6369d19_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_0e6e83a0-afdb-478a-857d-b4770aa793d9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_a316699e-152b-4591-8a23-264478494acd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_2d65e849-b50e-446c-b270-6179691f015b_verboseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_6416363e-a085-4938-8b12-a2e319ce21bd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0315ddb6-a889-429e-831f-d465d2389410_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0b7c534a-8a25-4ce7-babb-aeb937b0f448_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_d990280c-5111-4c02-8d4d-79f47c310591_terseLabel_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match per participating employee, maximum</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_label_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:label id="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_documentation_en-US" xlink:label="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:to="lab_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_69aa8a70-6c64-453f-80b5-0d9655891f46_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_c39df82b-5b6a-4b0f-aa1a-dea851a96089_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_cdf4e460-d08e-4fae-95f2-575fc9937920_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_6443fb3c-d059-44c9-8293-2b2ca5426c76_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payroll-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e06d8679-fbea-4d83-b9c7-9cd4a32b93fb_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Loss before Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_90e26b39-8533-490e-919e-04cf284376db_terseLabel_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_sesn_A2014EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A2014 Employee Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_A2014EmployeeStockPurchasePlanMember" xlink:to="lab_sesn_A2014EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_8ac7bd76-3c7b-42d3-982e-8960f7b8a0ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0b971fff-99fb-49a2-b61d-53984685c33f_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_a98948b1-5ed0-4b9a-9ce6-54a6a1d0415c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EARNINGS (LOSS) PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_2e247c00-3a58-45d1-9e4c-b5f09f49efbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_bb006cde-fe3c-4ed7-9d2f-f3dc991beab6_terseLabel_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to company upon execution of the Roche Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From Execution Of Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:to="lab_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_7086d901-e478-46c2-aae1-7baf51622f9d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Benefit (Provision)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3231ba6a-3d5d-48a3-aab1-98c809877833_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_ba808bfa-1745-4bfb-ab33-177dd07a1d74_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_02a86d79-e31a-4ea7-8056-b744dc6461c0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period unvested stock to be recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_6cbcca3a-701d-4f85-86d2-7c8fd171ef3d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average Remaining Contractual Life (in years), Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_f4284531-c342-4f90-abb0-5c0d94dfff1d_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_9cdbf0b3-3983-4684-8174-b69474042a87_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate sales price</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_label_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:label id="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_documentation_en-US" xlink:label="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Sales Price In Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:to="lab_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccounting_872572a8-b7f8-4877-93b8-392bf52b13c5_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BASIS OF PRESENTATION</link:label>
    <link:label id="lab_us-gaap_BasisOfAccounting_label_en-US" xlink:label="lab_us-gaap_BasisOfAccounting" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccounting" xlink:to="lab_us-gaap_BasisOfAccounting" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_274d8d0d-e448-4779-a813-3f1c25adc7d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flows from Financing Activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_589eea6b-77ca-4b2a-a63e-1a93d8b2f58a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_1b3ef753-5e02-49d6-94f2-079c12bec359_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and related revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_8b604576-8099-4d42-ada6-51366143375c_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_b67362db-a46a-4849-9496-b9a98710c68f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock and common stock warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_305d2d4f-c2b6-4f20-81ed-62a217690d2e_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1e2e1065-e5b7-4acc-a394-6b08c975c745_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_1764f182-9223-43d1-8100-d95fec9e2b05_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_17512e45-632b-4ff7-9830-4921f0da48a7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Proceeds From Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementProceedsFromMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_dc28a831-b030-4610-b03d-9555d6483b5d_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, option periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_label_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:label id="lab_sesn_LicenseAgreementOptionPeriods_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementOptionPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Option Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementOptionPeriods" xlink:to="lab_sesn_LicenseAgreementOptionPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_af56305b-f562-44c5-bbb0-e458ab1f473a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9fe901ac-d5c1-4129-b1bd-e7aa0b4f56dd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_66fa9885-6bf2-4b38-b972-f7443cead403_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5d974e6d-f95a-4c32-a497-01530b440a46_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_23a0a077-1606-4e8d-876c-8698ef5256fb_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationTable_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_5118e950-3302-4e18-93c9-f4cd8c36508c_terseLabel_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_label_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:label id="lab_sesn_AccountsReceivablePaymentTerms_documentation_en-US" xlink:label="lab_sesn_AccountsReceivablePaymentTerms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccountsReceivablePaymentTerms" xlink:to="lab_sesn_AccountsReceivablePaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_fca9dba3-aed8-49fb-a4e2-f71525194fd6_terseLabel_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses previously classified as prepaid</link:label>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_label_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Previously Classified as Prepaid</link:label>
    <link:label id="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid_documentation_en-US" xlink:label="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses Previously Classified as Prepaid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:href="sesn-20220630.xsd#sesn_ExpensesPreviouslyClassifiedAsPrepaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:to="lab_sesn_ExpensesPreviouslyClassifiedAsPrepaid" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e3f23737-6b8f-4682-baf0-5905377e675e_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_0ec5ddec-654b-4b06-ae6a-36888915b423_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_b0140698-f6e3-497d-ba37-a0e9be39b043_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_76d57fdb-cc43-4992-87d2-2e0e3f734438_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b4a1c960-ee98-467c-b528-c0183dbb7f2c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_1f6de7a4-fe75-4b29-b8fc-fd8afbc285e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_61800bdf-4e2d-426f-a4a0-c8d58e4277fa_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:label id="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:to="lab_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_20d19260-024b-4d02-89b3-ebbe4cd46fdd_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_0a7f2500-f544-42be-b711-f0827b9b1157_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_28113651-bd43-49c4-9e5a-4f270ffe3cfe_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9bdab513-3c03-48d4-abf5-91600b9af5a6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CA_b19a5bf5-d34d-4016-9335-d059d15c71ea_terseLabel_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada</link:label>
    <link:label id="lab_country_CA_label_en-US" xlink:label="lab_country_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CANADA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CA" xlink:to="lab_country_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02d8a7a5-1a34-4e94-8775-9e40f930a0a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested grant restricted stock units (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_281c9e9b-ae44-498b-b1d0-083a4f346a31_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_59e7064f-a23b-49d7-b6cd-3fa098fbe51b_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2cd77adc-a3f4-4d45-a493-87df08c8cb2c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSU</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_daa8361c-fa9d-4ffc-b07f-e4647508ed8d_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commission fixed rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_label_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:label id="lab_sesn_SaleOfStockCommissionFixedRate_documentation_en-US" xlink:label="lab_sesn_SaleOfStockCommissionFixedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Commission Fixed Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockCommissionFixedRate" xlink:to="lab_sesn_SaleOfStockCommissionFixedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_2ac4414b-3d93-4f84-a6a3-4f2637e18164_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Intangibles</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_5eaf1d01-dc5e-4384-844b-9318291141e6_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsCurrent" xlink:to="lab_us-gaap_IntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_cedbe583-231a-456c-b7f6-42bb8a095ba5_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_273836b2-392d-4e6b-b43d-793830bcb777_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds (cash equivalents)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_cc6f2aef-1a89-4298-9e9f-9f0c57b940e5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_628b9fa8-5eb2-4897-b6ac-241085f62c1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_069e99a8-56ef-4340-8caa-938c199b7f7f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_dfe99026-2f39-4fdc-ba09-de7e3742dfdb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Option, Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_d41ac950-58ba-4cf7-9295-2c0df6aaeec9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of additional shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6a9ec046-0b82-4fb3-ab0d-8587307aaad0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_cf961d6e-ecf8-4c10-8429-96c50de4b9c7_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_82fc3605-7218-4d91-a6d9-2092f69aa6ed_terseLabel_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_label_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:label id="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_documentation_en-US" xlink:label="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Additional Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:to="lab_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a0e2d752-6617-4890-9afc-713a5b8fcb4c_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price per warrant (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_aad66545-74be-4703-a5ad-af81a2a258e6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_550024c5-f27e-4b0f-82be-4b6678fba048_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_1f55a28e-5b80-4d76-9ddf-8f11b4239568_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_601d3862-17bc-4e78-83e2-ac2e91212e1b_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_5c4d75a2-08c5-4e16-8a5a-11a1f0e9835e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_a4294fda-9e9a-4c90-933b-a5082a081aa1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0e781717-5f7f-4b03-998c-60cdabe13afc_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_cc0cbc72-988d-4d01-9303-d10a59674cef_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_6f4d17ab-9547-4690-97fd-775378b0261f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled RSU (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_8dcf25dc-ca7e-4cfc-a9de-17bd0b35b590_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_dedc91d0-7de3-4180-b9f8-07ca522d42b4_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, period to pay buyout option once exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_label_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:label id="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Period to Pay Buyout Option Once Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:to="lab_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_698c9e9f-e739-4e66-8b08-966c5a9d7127_totalLabel_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shares of common stock issued and reserved for issuance (in shares)</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_label_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:label id="lab_sesn_CommonStockSharesIssuedAndReservedForFuture_documentation_en-US" xlink:label="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Shares Issued And Reserved For Future</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:to="lab_sesn_CommonStockSharesIssuedAndReservedForFuture" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_91dc298d-5f06-4bf0-91ce-930bcc3a8f58_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_46f0dc7c-4d72-4004-8789-c6bc76293b30_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of units issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_142b0085-6c8a-484e-b066-91b552645285_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseNoncurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseNoncurrent" xlink:to="lab_us-gaap_PrepaidExpenseNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_28d536cc-edad-4d4e-916a-fdc2fd62d05e_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_027c6812-0da4-4f1d-96af-73df44554fd2_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_8ccb126b-a4d0-41a3-afde-ad904de3f0f6_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_aab2c48f-9f2c-4b8e-934c-efefa807ca41_verboseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_label_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:label id="lab_sesn_OperatingLeaseMonthlyRent_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseMonthlyRent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Monthly Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseMonthlyRent" xlink:to="lab_sesn_OperatingLeaseMonthlyRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_186c8a1e-57ae-4b7d-b589-70e2e75e8ba3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4354c15b-57b2-4e16-a8f5-9ad09e753c28_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_9d838ae5-946b-45ff-9efe-e499a987d0d7_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ba950a8b-d848-43c4-975e-731738f33385_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock available for sale (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a6bb379b-06a4-4d47-90e9-453d192b0ff5_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7dc0b62a-925c-4cad-909f-3190425ab7ec_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_b2bb9235-f5c4-4af3-a2ca-3dcd3089d9b0_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued to the selling shareholders (in shares)</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_label_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:label id="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:to="lab_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_078e6474-e7ab-4961-b002-3a72a1c5c677_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of the Status of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_42d4084e-190c-4c77-b595-d540595ed34c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_4b40cdae-a91d-4197-a9c6-4436dbd67670_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current tax benefit (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_462bd520-3118-476f-a8e6-518df5150c90_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_f7c573c3-8b3d-48ee-a8ab-18364ab62e6f_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e25e8c4a-5dd6-4797-a4f4-7a6df272bcb9_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_6649f44b-7a47-4aa6-8a2a-e07ee05d8a40_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_cb7cd499-01c2-49e7-9a96-c03011319c46_terseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Issued (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_8b43f678-940e-4989-9e56-d1cf3f95e4f0_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Clinical Development Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_d42895bf-1057-4faa-b7e9-7eaeea0b47e7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_c367282f-ff65-4f8c-977c-431088bf82e5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_e97c2279-57cf-4f59-b731-f5532fde0b48_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_196d75b8-422d-42eb-9e53-6b8790feb1ca_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_b35e850e-d72b-4b35-91a6-5826774f28ca_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyRate_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyRate" xlink:to="lab_sesn_LicenseAgreementRoyaltyRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_9a625065-0364-4995-a80f-b82c7adbb38d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivables</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_0d82fb2f-8365-49a8-8d45-74913f66e785_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_2058dc32-1d9e-426e-b901-f04ca0ce44f3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_d04f52f3-7f39-4e87-8c47-07e8ff8a0e2d_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_553e06ee-6723-4174-9825-c449764b3bb9_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance amount</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_label_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:label id="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_documentation_en-US" xlink:label="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Remaining Shares Amount Available For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:to="lab_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f3467020-9300-49fe-8ccd-d6e712e5961f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_d0409a9e-a1aa-4e4d-872f-a04e4f37d8db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_375aa272-7618-4043-ae52-7b3e807ed12d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_ab062827-9c3a-4d26-bd48-bddf3a2abf3c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_b26101d1-d040-4f8a-9949-86d57f7753e9_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">One-time milestone payment upon first sale of product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:to="lab_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_67e63e61-de49-4833-b8f9-6211c5993d5a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_2248e441-cc20-41cd-b65c-df0175524a38_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of base salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_b651a960-8104-4be8-8639-dc4988012f4e_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringMarch2023Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringMarch2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring March 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringMarch2023Member" xlink:to="lab_sesn_WarrantsExpiringMarch2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4afa93be-dda0-4a3d-84c1-66bc42a5ebde_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c81748e1-72a4-4b4d-99eb-eb227c72dc4e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d3dc2164-235b-48ad-9555-47239edd10bb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredRevenue_cd94d7e3-4e6e-4295-8ad0-c13017c28b71_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredRevenue_label_en-US" xlink:label="lab_us-gaap_DeferredRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredRevenue" xlink:to="lab_us-gaap_DeferredRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_6ec422e4-723c-4d64-be5a-bde0f62696f0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RECENT ACCOUNTING PRONOUNCEMENTS</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ATMFacilityMember_94081bf4-259e-4e57-aa7b-e75d48379e17_terseLabel_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_label_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:label id="lab_sesn_ATMFacilityMember_documentation_en-US" xlink:label="lab_sesn_ATMFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ATMFacilityMember" xlink:to="lab_sesn_ATMFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_68b94ee7-334b-403e-90c5-10820c0eb363_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9942c529-34e4-4cf6-b71f-eeb4eb6b9ea3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in the fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_52a1acd8-f74f-4c83-b584-3afa96e75527_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current benefit (provision)</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_94c0472c-5990-41ec-aa69-23cb98fa7fed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e4ddaa16-5aac-48ad-9545-723e50ae2e19_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss Investments</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RetentionProgramMember_a48c537b-4951-4e4d-8063-434ac9458d08_terseLabel_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_label_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:label id="lab_sesn_RetentionProgramMember_documentation_en-US" xlink:label="lab_sesn_RetentionProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retention Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RetentionProgramMember" xlink:to="lab_sesn_RetentionProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_12c8c38c-b135-4e5d-8652-b65a6d98a19a_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRoyaltyPeriod_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Royalty Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:to="lab_sesn_CollaborativeArrangementRoyaltyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_5abf6627-1eb5-44cc-852c-ae7ec81139eb_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7da8cc16-352c-4d6e-8244-5a350f752f2f_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_6a8c377e-cc6f-43ec-8486-6c524816f502_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_6994a74b-6b7a-441d-a3b5-ec26cc6b17a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d928daec-9a8b-411e-8691-13280f8c0a3c_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from Operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_450893de-a45a-4228-94b1-f42a25dc88a4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4a8289ca-4cb1-4744-be97-9f4fa8e8c69d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b0952b28-4454-4ed9-8dd9-b506838c2ade_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_eed68611-1299-403e-9de1-40ce5f9ee834_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_df663a39-b720-42a5-bfa9-85b53a8045bb_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Beginning Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_a6d6979e-3123-48b7-81c5-244123e95766_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Ending Balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_73937648-bd6d-4bf1-b463-035e6a03c33a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_180e7320-e0d1-402c-9e44-6b40bf4f558d_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INTANGIBLE ASSETS AND GOODWIL</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d55b4871-df2c-4468-b43a-733647d47e70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit (provision) from income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_7404a70b-515d-4a9e-8b4a-9081c42493c5_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_e6c6c1d6-44b3-4adc-81a3-7f4884b48746_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_11923a65-8b93-4a3b-812a-971cf94195e4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_4dc498e0-89cb-49f4-9ad2-7f5e0ee7751d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9757ee57-9c30-42a0-810c-412ac98fadca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_4deb7d9d-01e6-43ef-9c31-26ccdfe85229_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_74978a1e-02d2-43c9-a62c-686c60708877_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0abe60a1-d457-4a6a-8a2a-ce64ee3b2e16_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_97fe2fbd-31fa-4def-b5ee-dba582334800_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchieved_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achieved</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchieved" xlink:to="lab_sesn_LicenseAgreementMilestoneAchieved" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8af2153c-3b58-49e7-be5f-dfbf6c154bf3_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_ec00856c-80fe-4e43-a64d-b55dc37deecb_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, additional up-front fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_label_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:label id="lab_sesn_LicenseAgreementAdditionalUpFrontFee_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Additional Up-Front Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:to="lab_sesn_LicenseAgreementAdditionalUpFrontFee" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_0bc13e8f-c90e-424d-b06c-3109a533d899_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value (in dollars per share)</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_52de9f36-52fe-48d6-a3f0-1aa3fa854b2a_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_509aa3f5-4180-4dd0-8fd8-257504427dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_e61ee1e4-b1e3-48a0-94b7-12a0ac8aa076_terseLabel_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Achievement deemed probable, percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_label_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:label id="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_documentation_en-US" xlink:label="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:to="lab_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_0b5e27fd-6fda-4da9-8667-4d19350f0f8f_terseLabel_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_label_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:label id="lab_sesn_NumberofVotesEntitledForEachShare_documentation_en-US" xlink:label="lab_sesn_NumberofVotesEntitledForEachShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Votes Entitled For Each Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_NumberofVotesEntitledForEachShare" xlink:to="lab_sesn_NumberofVotesEntitledForEachShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_79e4e79d-3d49-4b5e-ad8c-29c4ea30a483_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 400,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_2153e53a-1a1d-4215-aca8-e798c5a8ec26_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_75761ad9-96d8-47d9-bd3a-d843dbaf7ae8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ae577c47-5ffd-402b-8cd6-00479ad42398_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_dd745cbc-e6f3-4357-ab1f-adb15760d4ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_85cfc6ec-cac4-45b2-8a8f-ea8069d7faf5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_a0d39a7b-e3ad-4015-98d6-550f0997d049_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_4720f6b2-bcdb-496b-a517-eb95909c33d8_terseLabel_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liability</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_label_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liability</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseInDeferredTaxLiability_documentation_en-US" xlink:label="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:to="lab_sesn_IncreaseDecreaseInDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_646bb8c6-764d-4627-85d1-9bbd178e5502_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_dd8caf61-5bf3-4350-a920-5aa99b402137_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_41b74c88-a1d6-478d-92ba-36d2e2a55a1d_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1e4996e7-00ee-47a2-b920-ff916be9b64c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash - end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_19491cfd-5a2b-43fd-aded-52e69b239a1b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) Canada</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_1e966fc1-4c20-4b97-b24e-32d1d90dcf97_terseLabel_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_label_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_sesn_OrganizationAndBasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:to="lab_sesn_OrganizationAndBasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_e86909fd-0a69-44e2-8f52-394bb7e03e0c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d9726d88-e9e4-4da7-8e85-722dc7495d98_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_2d3f205d-3ee6-46ed-a724-39fd8e85148e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_eb204239-3d67-47b2-958a-3535127db9f3_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - basic</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5a3cf7ea-50ef-42de-bedf-3ef1202da3fa_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_79eb0f48-0871-48e5-8998-0cceef91d923_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5c3d1dd6-c498-47ed-81b0-022d1f91cb63_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of equipment included in accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_a1dbad4c-df4b-4c21-9eed-169ae51a2d5f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employer matching contribution, percent of employees' eligible compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_4fd7de38-5a97-431a-8928-09ca43b02309_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_84c39527-aed6-4314-9765-d89d20747181_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_16d182eb-bdf1-4871-92ad-185fbd871662_negatedTerseLabel_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Cancelled (in shares)</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_label_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:label id="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_documentation_en-US" xlink:label="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right Number Of Expirations During The Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:to="lab_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8660d97a-5a73-49f5-8977-20e6732125bb_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_1ffd8ee4-1b68-4c00-aa14-ffc5b2ad8a60_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_e7d631aa-d0df-4e73-980c-6db4aa121c04_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost, including related operating cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_9d13ab5a-8fe4-4181-8dba-eeaa6cfc4da7_terseLabel_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charge related</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_label_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:label id="lab_sesn_AccruedRestructuringChargesRelatedCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Restructuring Charges Related, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:to="lab_sesn_AccruedRestructuringChargesRelatedCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_20cc3905-218c-45b1-a967-e1aa447f387e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contingent Consideration Liability</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_8fcf185c-0a22-4a1b-b03b-59dc1c2c5c83_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_5add3e7a-cb8d-45f7-a7d4-04e11376bd54_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_2d63d0b9-cffc-4a3e-97a5-a069a264ce45_terseLabel_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance for:</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_label_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:label id="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract_documentation_en-US" xlink:label="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Of Common Stock Reserved For Issuance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:to="lab_sesn_SharesOfCommonStockReservedForIssuanceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3309d31d-941d-45f9-aaf0-3dd2cab2fdca_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a3d7cf61-c282-4b32-8dea-f085f58572a6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_91951deb-8d8c-4281-80da-03595d7bdeb1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_9e8fb659-6513-4150-b591-05e96e4dc011_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for restructuring</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_0f7c98ac-1b35-410a-ae83-f698724fb9f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash payments</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0f0dd02b-7bf3-4e12-b2c1-bb47343d1922_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_e9b02ed8-6957-4f46-bb60-2a71010d8b43_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_8b765c4a-78cf-489c-bd9b-1e1912555580_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_f148c691-eadc-48fc-ab57-d4c5e83cbe45_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SecondIndicationMember_3ba73fe9-357d-4f19-9e6f-d17b0a59daad_terseLabel_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_label_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:label id="lab_sesn_SecondIndicationMember_documentation_en-US" xlink:label="lab_sesn_SecondIndicationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Second Indication [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SecondIndicationMember" xlink:to="lab_sesn_SecondIndicationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_9cad16ab-7563-4a3c-a650-95c766a8238e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_dd21623a-230d-41a0-996f-3135244ab337_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_label_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationMilestonePayments_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationMilestonePayments" xlink:to="lab_sesn_BusinessCombinationMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_ef8b4b17-8385-48aa-8330-c7fe8eb13b9f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_84739563-d379-4d45-b608-e42e50a7c264_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_da7b50f0-fccd-4144-8a90-a27445130501_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_ca436747-95db-40aa-9fe6-fd428891bd3e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EBI031Member_c83a708d-0cf7-4c9d-bc9e-d77612dabac8_terseLabel_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031</link:label>
    <link:label id="lab_sesn_EBI031Member_label_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:label id="lab_sesn_EBI031Member_documentation_en-US" xlink:label="lab_sesn_EBI031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EBI-031 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EBI031Member" xlink:to="lab_sesn_EBI031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_2450a5b4-fea1-4ab7-921c-863e2e3ccf99_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_cd1bd1ae-03ba-4862-b59d-3d386566502e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under second option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under Second Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_7a271e88-28b1-44b5-8123-715bf5680677_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_e2d0c5ac-9781-4552-b7e7-e323f0870ea4_negatedTerseLabel_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term prepaid expenses</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_label_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:label id="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_documentation_en-US" xlink:label="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) of Prepaid Expenses, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:to="lab_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_4ece1311-d1ec-4b48-b7e2-9ceff3ef86d7_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_82754548-f6ad-43f0-91e4-0f42cfe56161_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_c4c8b028-ff00-4ced-af23-314c4b4b2e10_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_b88292b2-2755-4621-9411-33972b26ab41_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_a7e88242-a5ac-47f6-aed7-875f51f5ed7a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_48ded939-5732-4688-9fbe-d03d2dd8d5f0_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on development milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_76e9e16b-2878-4d04-9c0f-ef16cb9c6046_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled RSU (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_62b0e07b-b952-45c6-ba6c-dfca974cdb97_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_097f2701-ed88-4b97-a14a-ddae3eaa79b2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RESTRUCTURING AND RELATED ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dc243d90-f976-4b13-8e29-be598d2d1d62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_abeb6dec-29a5-4f13-b5d3-3ea346722236_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_76cc08cc-2b7f-4329-976a-989c77d9dd94_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_908c3b80-9499-4638-8648-ceaa8025e811_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract" xlink:to="lab_us-gaap_AssetsNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_e5892865-47c8-4718-8e4c-7b8e6e4c11fc_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e76bfee1-ae69-4754-a329-97fa1d26b577_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8d9e55ae-b302-44ae-ac25-00871c6760cd_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_51e4771f-cf3a-4835-a51a-4ee4ca51960a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_a4790dc8-3616-491b-ae7e-bf59ff0905f6_terseLabel_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivable, asset purchase agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_label_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:label id="lab_sesn_OtherReceivableAssetPurchaseAgreement_documentation_en-US" xlink:label="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivable, Asset Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OtherReceivableAssetPurchaseAgreement" xlink:to="lab_sesn_OtherReceivableAssetPurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_0a1754fd-758c-42dc-ad3f-84a6ab0fbd32_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant under 2014 Stock Incentive Plan</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_f4b84909-2164-45c1-8fb7-16bf8c37bb24_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4fefce16-16de-4cd9-8a78-57795356b906_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_4c149f12-facb-4354-bea4-30f6e1c5c6cb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesLineItems_e8297f44-96f7-4f1f-9e0e-a740a5fd38a5_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_label_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_sesn_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesLineItems" xlink:to="lab_sesn_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e1b4b8a3-db53-44bf-885b-0b68539a6810_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_2af11395-1c8d-451d-a91c-76b1f7d0183d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c8c7b5cf-2448-4822-9872-c17f6be6154c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrants Outstanding and Warrant Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_46fe1b30-4dfc-4516-ad9d-f2a554fed48f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_a655e148-9caa-4395-bb2b-016e6cde0e50_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_f6278cf2-f54c-4bd8-aa1c-b7fb42e91ff3_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_6f44fb3a-6d02-4c59-969d-6622f0c97e40_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_a5a76ade-d697-4e23-9f33-5f14f7a277fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_07bcf6fd-a0f7-479d-91a8-252edcafbce8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_61c0410c-94d5-4160-9e44-9c869a2b8f81_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_291624f1-6fd7-4b39-93ea-83d980b912db_verboseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock warrants (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_6e622ba2-5a41-40bd-a391-0b2711644335_negatedTerseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants Exercised (in shares)</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_62739c24-5be9-410f-bd6a-c3743d3f71f5_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost, non-vested stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8d4c43f4-a282-4fd4-a0f5-6846539e458c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares under Option (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_89f86a68-5746-4f34-ba01-1f0a34fda0f9_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of net sales of quarterly earn-out payments during earn-out periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:to="lab_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_46df3fbe-1920-4019-aca0-7271f72a8505_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_0dc40c6e-8ed5-4f31-84ca-d3e220c50eed_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued November 2014 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_6e6ccfc5-fb42-4788-90ef-630e9b866085_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable (net)</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e1d539ec-87eb-40c3-96df-83b6142d6854_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c6ad2f40-a014-4cf5-acbc-a42c21a6c65b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_0dc794a1-0fb2-4f33-8b74-167520ff034c_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_23cc2adb-3457-4c87-b1aa-f4fa0f5deaa3_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock, issuance cost</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, New Issues, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:to="lab_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_6f7856c3-9bbc-4129-ab9a-fe0d5cb4eebc_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_3958b052-9469-42e6-a5de-5ca16835ac51_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_e30077a7-f97c-49dc-a6a4-bd3f06ecbd6c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_70d11e24-cfc0-498d-a9cd-00e5c80ee8dd_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:to="lab_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_3af475fb-bf50-4e01-ba46-b3b774e8f8cd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_bd483be4-c16a-48fa-841d-f870462845c8_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_5b8a3fcb-76c9-451c-84fd-6829bc286bca_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_91580a5c-8025-4497-b44a-9a164049fb8a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Composition of Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_1d07e6b6-6231-4812-8b3b-4c5c8f71d310_terseLabel_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_label_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement [Member]</link:label>
    <link:label id="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_documentation_en-US" xlink:label="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eczacibasi Pharmaceuticals Marketing Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:to="lab_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_509bd50e-b6f8-4971-a4f4-c0c876658b6d_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d795d1d9-dd9a-4cc5-83f1-e73a4030d625_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_72a92a77-495b-46e8-b02d-fbe786f95c78_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5b11bcdd-4b76-43de-8545-5766ac54de64_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_ecfccbc4-cbbb-4882-a90c-793d585846da_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_79c656b0-59d6-46c4-b1da-3e2f03784485_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_b4beb066-e1ff-45e2-b004-0378b73a90f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_85965051-7d60-4e96-8c3d-7e30ade1ab18_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NatureOfOperations_cb314ab7-409f-423f-9c61-a8bdf86dcda2_terseLabel_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DESCRIPTION OF BUSINESS</link:label>
    <link:label id="lab_us-gaap_NatureOfOperations_label_en-US" xlink:label="lab_us-gaap_NatureOfOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NatureOfOperations" xlink:to="lab_us-gaap_NatureOfOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_5a6a60c8-a7c2-45fa-852e-246c42a3c2b2_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_35a445a3-7714-4b63-a4c0-0576ffa3b157_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_4d752bc6-7939-4fb9-a943-9ca0ac6ee3e1_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_aceb0c4f-ca96-409c-abca-9df8cc225d5c_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e28090ac-24b1-492c-adeb-b6c54af2351b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_ff3ea67e-9427-4ff3-bec3-ea13c3db2c5a_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses related to achievement of development milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_label_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:label id="lab_sesn_LicenseAgreementMilestoneAchievementExpense_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Milestone Achievement Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:to="lab_sesn_LicenseAgreementMilestoneAchievementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_cef079fd-1d99-43be-8d79-4432e05ae0cd_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_UniversityOfZurichMember_e3483fa9-f8f3-4d84-bcb5-2f4d05fe16d9_terseLabel_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_label_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich [Member]</link:label>
    <link:label id="lab_sesn_UniversityOfZurichMember_documentation_en-US" xlink:label="lab_sesn_UniversityOfZurichMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">University of Zurich</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_UniversityOfZurichMember" xlink:to="lab_sesn_UniversityOfZurichMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_4ff056e6-c091-4ce5-9f52-c524a86896fd_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ab24d5c9-5ccc-4302-82e4-d7e287be691e_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Share Based Compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_cff8cf34-5597-4dc4-aa75-d24d94d4bfa3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_7b4bc187-d4fa-4f22-bff0-f6e190f2804e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_bc57389b-b798-4a0b-bf4e-40b7149fb927_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_fa9aaf8f-74d3-4f69-8a97-e9ca8cea6dc8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_68fc03b2-579d-48dc-8d57-4ac187138aa3_verboseLabel_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2014 Stock Incentive Plan</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_label_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:label id="lab_sesn_StockIncentivePlanTwoThousandFourteenMember_documentation_en-US" xlink:label="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Incentive Plan Two Thousand Fourteen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:to="lab_sesn_StockIncentivePlanTwoThousandFourteenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_de04519d-c01b-45e2-a645-919dc1742677_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue based on Specified Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_0cee89c8-ccf3-463d-aabf-a2a614f22938_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8618deb8-2ae8-46d9-9804-eca5829834d1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_03645ff2-20e0-43a7-9f49-cce6714198bc_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RocheMember_0152b2cc-4148-48a6-9496-16ea62fa0864_terseLabel_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche</link:label>
    <link:label id="lab_sesn_RocheMember_label_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:label id="lab_sesn_RocheMember_documentation_en-US" xlink:label="lab_sesn_RocheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RocheMember" xlink:to="lab_sesn_RocheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_78b22f63-9302-4f96-855e-67fcc57d562a_terseLabel_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercises of common stock warrants</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_label_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:label id="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_documentation_en-US" xlink:label="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Exercise Of Warrants, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:to="lab_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_85893eb6-ae9c-4c4e-9407-62dbf24dd9b5_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1d36af46-dbc9-4558-a8c9-4410ac82c224_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_631480b7-e242-44b1-9ffe-b728d30fd27c_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares of common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_56d72478-e75a-4019-b4d6-bd2e8465a9e1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_country_TR_42b29647-282c-4dbd-b1ed-9930eef5bddb_terseLabel_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:label id="lab_country_TR_label_en-US" xlink:label="lab_country_TR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TURKEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_TR" xlink:to="lab_country_TR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_52931568-cdd5-411c-b0c9-867f9a2f8ae4_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsNoncurrent_d81bd54e-ef61-4ba9-8ff1-9d9b59b577c2_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total non-current assets</link:label>
    <link:label id="lab_us-gaap_AssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_AssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsNoncurrent" xlink:to="lab_us-gaap_AssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_b3b6e1d6-8c67-494f-bf53-572360cb4af8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_e16a2efb-1153-4629-9fcb-d40a50087740_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_5f73d653-69dc-419a-81e7-cd70f21fcbc7_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_c7c6893e-8517-41e7-b7d6-1fa2683a69f4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SHARE-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_e916d527-0eef-432c-a872-4695f2a159b3_terseLabel_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_label_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd. [Member]</link:label>
    <link:label id="lab_sesn_QiluPharmaceuticalCoLtdMember_documentation_en-US" xlink:label="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qilu Pharmaceutical Co., Ltd.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_QiluPharmaceuticalCoLtdMember" xlink:to="lab_sesn_QiluPharmaceuticalCoLtdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_afe52111-7239-419b-a8dc-ff962462f602_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_68f106b8-d358-48d6-a4c6-5d7ff3fb1a33_terseLabel_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average cost of capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_label_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:label id="lab_sesn_WeightedAverageCostOfCapital_documentation_en-US" xlink:label="lab_sesn_WeightedAverageCostOfCapital" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Cost of Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WeightedAverageCostOfCapital" xlink:to="lab_sesn_WeightedAverageCostOfCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_48cdc375-0524-48c0-98be-435de9f81925_terseLabel_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_label_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:label id="lab_sesn_WarrantOrRightOutstandingRollForward_documentation_en-US" xlink:label="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant Or Right Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward" xlink:to="lab_sesn_WarrantOrRightOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_cd37a5c1-7d30-40aa-b8b6-2cbc972e2645_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_29966450-5395-44f7-a3db-e56c297e4182_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_f9e5f04d-962a-4100-ba32-fa259ccb2e9c_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViventiaBioInc.Member_14d552d7-5390-4d04-b4df-5df09dd7e9a7_terseLabel_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio Inc.</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_label_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc. [Member]</link:label>
    <link:label id="lab_sesn_ViventiaBioInc.Member_documentation_en-US" xlink:label="lab_sesn_ViventiaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Viventia Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViventiaBioInc.Member" xlink:to="lab_sesn_ViventiaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_6df81cf4-4b28-4d93-ad45-461df9acc076_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_bba01ae1-5972-4bde-87c6-0ddda7a72ec1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_47dca785-d5f3-46db-9506-407a0107c9c9_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment obligation, percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_label_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:label id="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Percentage of Royalty On Net Product Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:to="lab_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_45cb5cf4-dcce-4479-b181-e8c91bd95963_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Pre-tax Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_6775e5a8-90a7-4180-ab68-38bc4f374796_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_81195b56-e15b-49c9-a56b-cd2e643ccf00_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_981deaff-4a79-4930-b61c-9d1e53b2c748_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ACCRUED EXPENSES</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_763277bc-2f96-4845-a55f-fc000e63395e_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseMaintenanceFees_a4172695-ea90-4977-a59d-6b9691d8c549_terseLabel_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License maintenance fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_label_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:label id="lab_sesn_LicenseMaintenanceFees_documentation_en-US" xlink:label="lab_sesn_LicenseMaintenanceFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Maintenance Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseMaintenanceFees" xlink:to="lab_sesn_LicenseMaintenanceFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4d5fecad-1820-4f98-b975-e300fa583cc4_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_3434a92d-03ab-4eb2-88a9-4d54ae320bb8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d1b05005-df93-4871-aa4d-8e820bf3ba77_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_75f53bdd-d05c-4bf9-8ecb-ad7d389a4d8f_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to common stockholders - diluted</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_60f5a7a4-3c23-4ab7-95e8-4ae1eadefaf4_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_c00a9a09-3e3e-4efa-971b-c16833b48761_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_5725a28b-9ae2-45e0-b5cd-6eb8a6696b0c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting at End of Each Successive Three-Month Period Thereafter</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_2219eba5-0575-4830-b612-e95f0d800161_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_0426fb02-8f20-4e01-b289-7953db01d1b7_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2024, Issued May 2015 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:to="lab_sesn_WarrantsExpiringNovember2024IssuedMay2015Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_9085536a-9692-4406-b50c-ede78c8aeb5c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Common Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_b60a5e2d-254d-4416-b384-4c6ca65417a3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_89a2a99e-c092-42a8-86e0-4c7f4311629f_terseLabel_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Research And Development Expense, Current</link:label>
    <link:label id="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_sesn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_2021bd40-4305-4d9f-9025-d82ffaa9c89b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_0a5d0fc4-8f21-45d2-837a-210913624609_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_c5957085-999b-4604-93f4-56776aab3427_terseLabel_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_label_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:label id="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_documentation_en-US" xlink:label="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition, Milestone Method, Potential Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:to="lab_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_7589b27a-642a-4c3a-919d-0b9bed499245_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transaction price</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_8ec74ade-5744-434b-a848-128ab9036fb9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-tax income (loss) U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_45bea5d7-a5d6-4d2d-bf3f-cd91ed7de5b7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_7d9495d1-cd81-4fa3-a9bd-d4352f913862_terseLabel_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_label_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:label id="lab_sesn_WarrantsExpiringNovember2022Member_documentation_en-US" xlink:label="lab_sesn_WarrantsExpiringNovember2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Expiring November 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_WarrantsExpiringNovember2022Member" xlink:to="lab_sesn_WarrantsExpiringNovember2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_24ee3861-04d9-4037-a098-211bb5bdbcd7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_80570315-389d-4448-be09-1d663392e0f0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_db43ca1a-8135-4c67-9828-5afa816e6138_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, buyout amount under first option period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_label_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:label id="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Buyout Amount Under First Option Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:to="lab_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_281859e3-2324-44b0-9b2f-765d5c4836c5_terseLabel_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets risk adjusted</link:label>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_label_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Cost of Capital, Percentage</link:label>
    <link:label id="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_documentation_en-US" xlink:label="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Cost of Capital, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:to="lab_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_5cd79bdb-0e0d-4b88-ac6f-cc17611803a7_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LICENSE AGREEMENTS</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_label_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:label id="lab_sesn_LicenseAgreementTextBlock_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementTextBlock" xlink:to="lab_sesn_LicenseAgreementTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_3e416f9f-8752-49e5-964b-5499e4e6424c_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_b07bcf8b-777b-4965-ac37-8fdab3562762_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_45432beb-3829-4f12-8cde-9cf540e258f2_verboseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">European Union</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_c48f69ef-617d-48a5-9f9a-58bc99a7576d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_60d48ea8-1147-4401-b54f-4c51d9c9c0b9_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_9e42a0fe-0b0e-4e57-b7b5-a1c7fc6f74ae_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_b56c9fa3-4cb6-47d7-8f20-6945a38fc701_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss of investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_9b9db5f2-5fab-4fe0-a161-f69a99dd0b26_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fce3c4ae-eb00-4c7b-acd4-9665b461f2e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_24612d8a-bdb7-4728-ab02-2c2a8a2bddce_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d3c3ca32-ee39-4a09-8abf-38a5981b9cb9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_d43728d4-2319-42e8-87d2-db44ffd88d57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0e3fee43-fb92-41d6-a14e-e0829197e847_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_38173ffb-fa1c-43b3-99c4-e36be8b28c0a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Before Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_18f67e66-8299-4181-a06c-44bd7e5e88c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase price, discount rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_cb88e050-ab53-495b-bab3-1e722c20ce73_terseLabel_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average stock price per share (in dollars per share)</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_label_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:label id="lab_sesn_SaleOfStockWeightedAveragePricePerShare_documentation_en-US" xlink:label="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Weighted-Average Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:to="lab_sesn_SaleOfStockWeightedAveragePricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_3802ffe3-e2db-43fd-a801-15bb8a189806_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_IncomeTaxesTable_1335f863-babb-474b-8956-5aee7c1f8d87_terseLabel_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_label_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_sesn_IncomeTaxesTable_documentation_en-US" xlink:label="lab_sesn_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_IncomeTaxesTable" xlink:to="lab_sesn_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MicrometAGMember_c4f74730-8645-428b-bd25-20fa40810963_terseLabel_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG</link:label>
    <link:label id="lab_sesn_MicrometAGMember_label_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet AG [Member]</link:label>
    <link:label id="lab_sesn_MicrometAGMember_documentation_en-US" xlink:label="lab_sesn_MicrometAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Micromet [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MicrometAGMember" xlink:to="lab_sesn_MicrometAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0931cd85-ecf7-44a0-8ead-f094ced1056b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6883f5b8-19f4-4f3f-b492-2c93b7bd9dee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_a2c07e40-7990-4ca0-9164-89ae74195e9c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_16d5b774-069f-4f16-95ab-62954c0fc794_terseLabel_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which quarterly earn-outs are payable after date of net sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_label_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:label id="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_documentation_en-US" xlink:label="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:to="lab_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_0195bb39-9c3d-4ec9-9743-0feacafc9106_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1b6eda44-99ff-4808-bea6-bc0d0fc5e6e6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_82b1a7ae-1f45-4b7b-b49e-dc51a4f243a1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_404a84d2-ae3e-42a3-8e23-c369de00d317_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5126b3d7-5b63-4ad2-8689-6e9fed9db70c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ddceefe5-ff2a-44dc-8ee9-6fb1b719228e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_ffdb5360-ac9f-474e-a5a2-c1ddc48c667e_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, amount payable upon achievement of specified milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_label_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:label id="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Amount Payable Upon Achievement of Specified Milestone</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:to="lab_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_6ea858c7-bd91-4dc9-a290-94c0df86ba94_terseLabel_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_label_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:label id="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_documentation_en-US" xlink:label="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Related To Adoption of Accounting Standard</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:href="sesn-20220630.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:to="lab_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_ViciniumMember_7795751c-59cf-47eb-b0d0-1c414cbd521f_terseLabel_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium</link:label>
    <link:label id="lab_sesn_ViciniumMember_label_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:label id="lab_sesn_ViciniumMember_documentation_en-US" xlink:label="lab_sesn_ViciniumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vicinium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_ViciniumMember" xlink:to="lab_sesn_ViciniumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_f616fff9-6650-40ff-96f1-20632cb473f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_7ac590e7-71ea-4ed7-a438-ceef995f4539_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationReserve_ad3d0199-14b4-4863-8748-cfbef14cc107_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated litigation liability</link:label>
    <link:label id="lab_us-gaap_LitigationReserve_label_en-US" xlink:label="lab_us-gaap_LitigationReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Litigation Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationReserve" xlink:to="lab_us-gaap_LitigationReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_8db2f33f-52a1-474e-a72b-3c8e6e945431_terseLabel_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License agreement, royalty payment, reduction, conditions not met</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_label_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:label id="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_documentation_en-US" xlink:label="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:to="lab_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_fe93a87b-681f-4aeb-a6bb-fa076de926ec_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_3a6529be-c041-4747-a437-9d841368e3b2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_011d2607-b7d8-447e-97ac-66147113ef4d_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d783d140-d797-4235-b14f-576861bd1f29_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_960e7a94-4b44-4ef0-9daa-05b55fd934f9_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_ff8aca2a-6983-4c97-874b-bbac2212f4ae_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_074ea5a3-9a0b-4d38-acfd-8fea1dd1935b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_3a24bb56-5d76-4f8e-8b24-a17d5034d6c7_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_8bbcc870-4e79-4da5-8be4-47eba8b0a657_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_e73d5256-cee9-422d-a50e-3519cfc83d1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e457966-dd09-4e7b-b8ac-91be57780e68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant-date fair value of stock options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_7c41d312-b435-4683-aaf9-34eb43d98227_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_a5389240-3055-4ee5-9b07-7acefe6fdb31_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_MENALicenseAgreementMember_d7a59d79-fc24-43c2-88d2-47a49d01bcdc_terseLabel_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_label_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement [Member]</link:label>
    <link:label id="lab_sesn_MENALicenseAgreementMember_documentation_en-US" xlink:label="lab_sesn_MENALicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MENA License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_MENALicenseAgreementMember" xlink:to="lab_sesn_MENALicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_80664a8a-e1fd-4d76-8db8-ec1a2a7d79fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_82ef7a3d-9416-4d46-bfc0-7f42ac43fa2e_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangibles impairment charge</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_21738d88-651b-4a16-8e6d-b29d0cfe640f_terseLabel_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total milestone payments</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_label_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:label id="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_documentation_en-US" xlink:label="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Long-term Purchase Commitment, Milestone Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:to="lab_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_44701b15-6a49-411a-b386-19892c626404_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_2b9baf43-6579-4b56-880d-fc6eec6135fe_terseLabel_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue based on commercialization milestone</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_label_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:label id="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_documentation_en-US" xlink:label="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:to="lab_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2c8fe707-abde-4905-903a-41c78f492167_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potentially Dilutive Securities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_aee9b1a2-c8c2-4b12-8fd3-47acc476b47a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Option, Quantitative Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:to="lab_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_3d3bfbaa-0ab6-4115-b402-075531611e6f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of positions eliminated, period percent</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_c5d6b3c0-6be1-47b8-ae77-d4eb6eb44486_terseLabel_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related operating expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_label_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:label id="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_documentation_en-US" xlink:label="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Other Monthly Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:to="lab_sesn_OperatingLeaseOtherMonthlyOperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>sesn-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:bd7d11a3-10bc-42fd-8e59-e4fdb7cb7dd5,g:576be92b-fc15-4f28-a6f0-6569e48ccfd4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sesenbio.com/role/Cover" xlink:type="simple" xlink:href="sesn-20220630.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_d101e078-be76-45a9-ac91-7eb88be4a814" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentType_d101e078-be76-45a9-ac91-7eb88be4a814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_b00cf79a-bff6-46c0-a66c-7e75373a42da" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentQuarterlyReport_b00cf79a-bff6-46c0-a66c-7e75373a42da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_2fff10da-dbcf-41ae-84e5-3323c29f2b7e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentPeriodEndDate_2fff10da-dbcf-41ae-84e5-3323c29f2b7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_2ff07c06-b5bb-46a9-96ae-6e1a66ba5a0d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentTransitionReport_2ff07c06-b5bb-46a9-96ae-6e1a66ba5a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_45ba8851-f85d-4953-8e92-88d1ef04b320" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityFileNumber_45ba8851-f85d-4953-8e92-88d1ef04b320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_53261cf4-556e-4f84-935a-87e100f8132f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityRegistrantName_53261cf4-556e-4f84-935a-87e100f8132f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_31d9cca5-863e-4a93-acf1-1ffa8cd6fcce" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityIncorporationStateCountryCode_31d9cca5-863e-4a93-acf1-1ffa8cd6fcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d8928433-ba3d-4fe5-82be-c7dc0fc2e6cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityTaxIdentificationNumber_d8928433-ba3d-4fe5-82be-c7dc0fc2e6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_ef1df9a6-60da-4e4a-b272-e9e7e0f6a91d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityAddressAddressLine1_ef1df9a6-60da-4e4a-b272-e9e7e0f6a91d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_b65c456e-e153-441d-8a0d-fcecb5dd5852" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityAddressAddressLine2_b65c456e-e153-441d-8a0d-fcecb5dd5852" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0e492329-8b85-439c-b2ec-495a04708570" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityAddressCityOrTown_0e492329-8b85-439c-b2ec-495a04708570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_6a77cc60-1f7d-4f39-9b2c-f103a0334e0f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityAddressStateOrProvince_6a77cc60-1f7d-4f39-9b2c-f103a0334e0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bd19587a-12ad-41cd-8742-818918b7cf33" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityAddressPostalZipCode_bd19587a-12ad-41cd-8742-818918b7cf33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a3e2ba8b-2c2a-47de-bbe4-bea44716fb70" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_CityAreaCode_a3e2ba8b-2c2a-47de-bbe4-bea44716fb70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_68a0ad1e-d0c9-478d-afa5-fb03da1ad492" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_LocalPhoneNumber_68a0ad1e-d0c9-478d-afa5-fb03da1ad492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_e60668df-f124-4cdf-8fed-17ea1965edab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_Security12bTitle_e60668df-f124-4cdf-8fed-17ea1965edab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_16f9a214-3840-43f0-84a1-bbfbbf62ead5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_TradingSymbol_16f9a214-3840-43f0-84a1-bbfbbf62ead5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_cabd8c82-5f54-41e2-b31e-1d76cfb4096f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_SecurityExchangeName_cabd8c82-5f54-41e2-b31e-1d76cfb4096f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_b0b27198-3447-4234-a0e4-493a7db25e74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityCurrentReportingStatus_b0b27198-3447-4234-a0e4-493a7db25e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_1f00b485-6d56-484e-9db6-62f8439aa312" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityInteractiveDataCurrent_1f00b485-6d56-484e-9db6-62f8439aa312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_05d2dbf2-62e4-41a6-a727-f2ce6e893926" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityFilerCategory_05d2dbf2-62e4-41a6-a727-f2ce6e893926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_9ec6311f-f9bc-4253-9bd4-29fcdd87de74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntitySmallBusiness_9ec6311f-f9bc-4253-9bd4-29fcdd87de74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_5589a0b6-e71e-4e9e-86c1-64d588d41087" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityEmergingGrowthCompany_5589a0b6-e71e-4e9e-86c1-64d588d41087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_264918a3-172c-4ad5-85df-26ba6617db0b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityShellCompany_264918a3-172c-4ad5-85df-26ba6617db0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f80c1927-cede-46e3-be7f-309375ea2a16" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f80c1927-cede-46e3-be7f-309375ea2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_eec092df-8c00-4c79-a0a0-ceae428b767d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_EntityCentralIndexKey_eec092df-8c00-4c79-a0a0-ceae428b767d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_0738dbaa-06c1-44be-b338-743b732fbfc5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_CurrentFiscalYearEndDate_0738dbaa-06c1-44be-b338-743b732fbfc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_31c69e66-6ac0-4bad-80dc-a9c8eb9a4f97" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentFiscalYearFocus_31c69e66-6ac0-4bad-80dc-a9c8eb9a4f97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_f36ab581-c185-4c10-85fc-9901d9d42caa" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_DocumentFiscalPeriodFocus_f36ab581-c185-4c10-85fc-9901d9d42caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_31739b43-cd33-4ac8-a95f-e98b8d1dd99c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_5d0e6145-3374-4ec6-b2a2-370c60bfe796" xlink:to="loc_dei_AmendmentFlag_31739b43-cd33-4ac8-a95f-e98b8d1dd99c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_2682dd3a-a42a-41ee-9408-ca8061ee8c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_1844fe54-f348-4dfc-a15d-11b4e263355c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2682dd3a-a42a-41ee-9408-ca8061ee8c97" xlink:to="loc_us-gaap_AssetsAbstract_1844fe54-f348-4dfc-a15d-11b4e263355c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1844fe54-f348-4dfc-a15d-11b4e263355c" xlink:to="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f6dbb0d-2b6d-437f-a313-5e81ab9421d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8f6dbb0d-2b6d-437f-a313-5e81ab9421d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_a7f27a17-5695-43da-a6d9-315cc673bfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_a7f27a17-5695-43da-a6d9-315cc673bfd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_c61ae64e-a0c1-4302-8c91-1196bab4bd83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_c61ae64e-a0c1-4302-8c91-1196bab4bd83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_d63af483-4b03-4d79-86e2-786cd5efaed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_d63af483-4b03-4d79-86e2-786cd5efaed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6dd416a-e889-4ca3-8a04-b57c9c6f5adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b6dd416a-e889-4ca3-8a04-b57c9c6f5adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ac305104-ee24-46cc-81a0-417255632539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05be8187-ceec-4dfe-b77d-2e40717aa2c9" xlink:to="loc_us-gaap_AssetsCurrent_ac305104-ee24-46cc-81a0-417255632539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1844fe54-f348-4dfc-a15d-11b4e263355c" xlink:to="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e41d5cc2-c795-4e11-8f51-bbab9b317998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_e41d5cc2-c795-4e11-8f51-bbab9b317998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_61888dfa-54ff-496e-ba32-09b9ded406d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_61888dfa-54ff-496e-ba32-09b9ded406d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6d96e452-a75a-49f7-a22c-c3b7e353f591" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6d96e452-a75a-49f7-a22c-c3b7e353f591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd536219-f5f9-40e6-b06b-0e8b03389e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bd536219-f5f9-40e6-b06b-0e8b03389e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_73dd5f22-2b97-4c22-b46e-a7b4cc3e7d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_Goodwill_73dd5f22-2b97-4c22-b46e-a7b4cc3e7d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseNoncurrent_ebbfdcdd-c980-49f2-a4ea-5ecc8c025aef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_PrepaidExpenseNoncurrent_ebbfdcdd-c980-49f2-a4ea-5ecc8c025aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_186cb584-8f78-410b-87a1-5429e75f4698" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_186cb584-8f78-410b-87a1-5429e75f4698" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsNoncurrent_3d0f34d0-d98c-4fd3-95f2-c4353c71462d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsNoncurrentAbstract_e77b5710-fe62-4be1-9b09-5b154c9ed828" xlink:to="loc_us-gaap_AssetsNoncurrent_3d0f34d0-d98c-4fd3-95f2-c4353c71462d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d9fccdc1-4dd1-4363-b021-39c06c3e012b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1844fe54-f348-4dfc-a15d-11b4e263355c" xlink:to="loc_us-gaap_Assets_d9fccdc1-4dd1-4363-b021-39c06c3e012b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_2682dd3a-a42a-41ee-9408-ca8061ee8c97" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_554f2e5d-ca25-4768-9d4c-311e89a06a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:to="loc_us-gaap_AccountsPayableCurrent_554f2e5d-ca25-4768-9d4c-311e89a06a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d73c6118-53ff-47a4-a47c-7a94ca8d9a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d73c6118-53ff-47a4-a47c-7a94ca8d9a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_5ae9613c-8e46-4a27-959e-06d3270b73a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_5ae9613c-8e46-4a27-959e-06d3270b73a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6c8629c9-e552-4409-ad2f-deb59f0f74f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_3ff43607-60ce-4a08-a714-559fe4b538c4" xlink:to="loc_us-gaap_LiabilitiesCurrent_6c8629c9-e552-4409-ad2f-deb59f0f74f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_94bad982-bbfa-4e90-a3a2-268b39e99a89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_94bad982-bbfa-4e90-a3a2-268b39e99a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7935b2c3-efe7-4e88-a271-31969a9d4ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_7935b2c3-efe7-4e88-a271-31969a9d4ba7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9174990d-934a-4f9b-9bca-c6cf3325e44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_9174990d-934a-4f9b-9bca-c6cf3325e44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_773c287e-b2ca-4b90-976a-36e85d6e7021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_84f08ef4-d711-439e-be67-93f6ccafee20" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_773c287e-b2ca-4b90-976a-36e85d6e7021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_82940574-9e63-4ab0-8214-ca7fdcf7e7d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:to="loc_us-gaap_Liabilities_82940574-9e63-4ab0-8214-ca7fdcf7e7d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:to="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2e12d6e5-a2a6-43cf-ae81-c45d28fe8504" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_PreferredStockValue_2e12d6e5-a2a6-43cf-ae81-c45d28fe8504" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_b7fed7a5-e271-42c2-9c01-4f5d51bfbf40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_CommonStockValue_b7fed7a5-e271-42c2-9c01-4f5d51bfbf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_cf46a114-d79e-4e7c-8f38-226c4eec35a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_AdditionalPaidInCapital_cf46a114-d79e-4e7c-8f38-226c4eec35a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b4e0ef2-48e7-47f6-905d-6645901b743e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3b4e0ef2-48e7-47f6-905d-6645901b743e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b31b083d-7b3b-4000-9276-19955f1e7397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b31b083d-7b3b-4000-9276-19955f1e7397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e6bc0bb1-fac9-4d53-8c90-0ecb65dffaee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_8ae4e1ad-5c10-4cce-805d-2a0f4d49f3b7" xlink:to="loc_us-gaap_StockholdersEquity_e6bc0bb1-fac9-4d53-8c90-0ecb65dffaee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_692a239a-382f-4a9c-8d21-9d44e55ad1af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ea4dd042-625e-4206-a40c-adb094fcbb75" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_692a239a-382f-4a9c-8d21-9d44e55ad1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8be520c1-a83e-4568-9fc5-5d1d890a2acb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_8be520c1-a83e-4568-9fc5-5d1d890a2acb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_1d063b51-6a86-4887-ac50-e7e5d125e82c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_1d063b51-6a86-4887-ac50-e7e5d125e82c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_13e76a03-7559-43b8-a58c-e01ddb219c22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_13e76a03-7559-43b8-a58c-e01ddb219c22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_1b039577-df7f-4cf8-a5b3-003c6f5ad5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_1b039577-df7f-4cf8-a5b3-003c6f5ad5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_36a76d04-edd8-4f1d-a3f3-997b9b87d36e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_36a76d04-edd8-4f1d-a3f3-997b9b87d36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_99cc8719-8979-4c5b-8387-625b22f9c3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_99cc8719-8979-4c5b-8387-625b22f9c3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7ace5ef6-4c5c-4df8-97fb-49d60b651151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_CommonStockSharesIssued_7ace5ef6-4c5c-4df8-97fb-49d60b651151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_de17cecc-0e5d-44ad-b370-321dd1267d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ea0263-a009-4a60-a418-0142aae0992c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_de17cecc-0e5d-44ad-b370-321dd1267d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d835ed03-456c-488b-af05-efdea168463b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_d835ed03-456c-488b-af05-efdea168463b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_421c1253-ff6e-489d-8dbc-274c13391c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_421c1253-ff6e-489d-8dbc-274c13391c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7ac07488-3baf-4c33-9892-700399a76914" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7ac07488-3baf-4c33-9892-700399a76914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a03a9cd-a157-42f7-a414-4de02012a4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_3a03a9cd-a157-42f7-a414-4de02012a4ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_da694361-0126-4371-bb2f-df6d22613f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_da694361-0126-4371-bb2f-df6d22613f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0bf15bd8-16b1-4c4a-84bb-179d711787c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3e0b90d6-cfdb-4528-a651-f2a2bc0c2c03" xlink:to="loc_us-gaap_OperatingExpenses_0bf15bd8-16b1-4c4a-84bb-179d711787c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_95c471a2-0c82-442c-bd57-10d2a3963b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_OperatingIncomeLoss_95c471a2-0c82-442c-bd57-10d2a3963b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_98653d90-0a3f-421b-91ed-992ff5b7c30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_98653d90-0a3f-421b-91ed-992ff5b7c30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_6d15af63-26e3-4aef-8248-428cc6f86fdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_6d15af63-26e3-4aef-8248-428cc6f86fdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_82c72eb9-cbdc-4d45-9a62-f270c060c93b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_82c72eb9-cbdc-4d45-9a62-f270c060c93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_5d66e5f6-36c5-4822-8e42-801a350940dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_NetIncomeLoss_5d66e5f6-36c5-4822-8e42-801a350940dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3faba386-e0f9-4ffa-9a86-a565848953c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3faba386-e0f9-4ffa-9a86-a565848953c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0642f7f8-ba96-4fa1-8666-21ab5a09439d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_0642f7f8-ba96-4fa1-8666-21ab5a09439d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_cf42bffe-a7d9-48e9-9da2-b65e4c5ee888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_EarningsPerShareBasic_cf42bffe-a7d9-48e9-9da2-b65e4c5ee888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_cb1c4c77-80a8-47e0-af1c-f3f5a745a22e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_EarningsPerShareDiluted_cb1c4c77-80a8-47e0-af1c-f3f5a745a22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ab1259e-4c80-4242-8db1-2f37c8113e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3ab1259e-4c80-4242-8db1-2f37c8113e2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34c308e5-0620-49a5-88b6-7a49f0d723e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_34c308e5-0620-49a5-88b6-7a49f0d723e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_4fe658a0-2f10-431e-a598-e69f3ef5c491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_59c6f606-ea3a-4c0f-95ba-37682f9ffdd6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList_4fe658a0-2f10-431e-a598-e69f3ef5c491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_00972a07-fec3-44e1-a927-d5b896e8df3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8d94793f-041e-417c-a3ab-d7f6369886cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_00972a07-fec3-44e1-a927-d5b896e8df3c" xlink:to="loc_us-gaap_NetIncomeLoss_8d94793f-041e-417c-a3ab-d7f6369886cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac19d302-b0ed-48a9-a6a6-7d29d0ee32d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_00972a07-fec3-44e1-a927-d5b896e8df3c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac19d302-b0ed-48a9-a6a6-7d29d0ee32d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_34104271-8672-4400-89d5-c025657f6640" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_00972a07-fec3-44e1-a927-d5b896e8df3c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_34104271-8672-4400-89d5-c025657f6640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c9357db6-c4eb-46f8-b6bc-998c797c2cfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c9357db6-c4eb-46f8-b6bc-998c797c2cfb" xlink:to="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2082e714-4e0a-40a5-b4ae-b4b0677f86a1" xlink:to="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_4a62009d-8635-47ae-893a-75b232b6a6c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_CommonStockMember_4a62009d-8635-47ae-893a-75b232b6a6c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_e62033dc-efbc-48a9-af6d-92af5cd7c195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_e62033dc-efbc-48a9-af6d-92af5cd7c195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e0d0a41-1af1-4e52-8c97-31576ea7cd73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_2e0d0a41-1af1-4e52-8c97-31576ea7cd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_39d17b3e-bf35-4649-b2cf-08554aae40e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_6aaacf1d-4a76-499d-9da2-170bca08857a" xlink:to="loc_us-gaap_RetainedEarningsMember_39d17b3e-bf35-4649-b2cf-08554aae40e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b1fee1e-4525-4b61-80d7-5f93f424a918" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_00b21052-c818-4cae-8dbd-b804a713f0a1" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_b1f2f8f4-6242-4646-bfbe-7afc07af82e5" xlink:to="loc_sesn_ATMFacilityMember_00b21052-c818-4cae-8dbd-b804a713f0a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e03bd14b-37b0-41eb-a51d-d3fd2c062426" xlink:to="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1f919ec7-7f60-461c-9a4b-f9f94426b1d9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d91ebce0-e68f-4de1-9619-7a4eb33951b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_SharesOutstanding_d91ebce0-e68f-4de1-9619-7a4eb33951b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_35a4bae5-da18-4bd7-9b11-b45cc7446a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockholdersEquity_35a4bae5-da18-4bd7-9b11-b45cc7446a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3680e71c-00fd-441c-9e40-c80649ed752b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_NetIncomeLoss_3680e71c-00fd-441c-9e40-c80649ed752b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19a82174-c688-4d0c-ada5-2d2ba8d1e84b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_19a82174-c688-4d0c-ada5-2d2ba8d1e84b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a8e831c-4d13-46d1-b01f-b3ee0fe9a749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3a8e831c-4d13-46d1-b01f-b3ee0fe9a749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_562947b5-c909-448e-a703-0511d09259d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_562947b5-c909-448e-a703-0511d09259d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_740318f2-5b1e-40db-9e29-2a80b51988d3" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_740318f2-5b1e-40db-9e29-2a80b51988d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_1b543e96-48c6-4cc7-951f-52f6172f2e69" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue_1b543e96-48c6-4cc7-951f-52f6172f2e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9646b37c-0a16-4374-80f6-5bb3e2266ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_9646b37c-0a16-4374-80f6-5bb3e2266ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07cf3857-81b7-4c65-ba80-1aa30ac4091e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_07cf3857-81b7-4c65-ba80-1aa30ac4091e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a0741f5f-5d52-4170-847a-c064b6a2c14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a0741f5f-5d52-4170-847a-c064b6a2c14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_ea01bfa5-554d-45a4-a08a-1d064813977b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_SharesOutstanding_ea01bfa5-554d-45a4-a08a-1d064813977b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7d7a0ef-fa60-4f85-91f5-6e78e25797c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_ff2ad41f-46ec-4b8d-90fe-0566de70da5c" xlink:to="loc_us-gaap_StockholdersEquity_d7d7a0ef-fa60-4f85-91f5-6e78e25797c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8d30ea3-463a-4d31-bbe0-9a903597603d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0903e1cd-62a9-45aa-85cc-5559efdf3c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_d8d30ea3-463a-4d31-bbe0-9a903597603d" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_0903e1cd-62a9-45aa-85cc-5559efdf3c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="simple" xlink:href="sesn-20220630.xsd#CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_85a55d79-0a2c-4c42-b615-78a2c206a81a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_85a55d79-0a2c-4c42-b615-78a2c206a81a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_113c34d3-f898-46a7-9e89-fa0ac55e00c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_85a55d79-0a2c-4c42-b615-78a2c206a81a" xlink:to="loc_us-gaap_NetIncomeLoss_113c34d3-f898-46a7-9e89-fa0ac55e00c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_85a55d79-0a2c-4c42-b615-78a2c206a81a" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_4828bf0a-da38-41a1-ab25-74dd74538c74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:to="loc_us-gaap_DepreciationAndAmortization_4828bf0a-da38-41a1-ab25-74dd74538c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9b785e3c-a3b4-4130-9cad-0959161fb0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:to="loc_us-gaap_ShareBasedCompensation_9b785e3c-a3b4-4130-9cad-0959161fb0f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_175fdf80-1dd3-435f-9e5c-a94811a5c061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_175fdf80-1dd3-435f-9e5c-a94811a5c061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_74b11596-346b-4d91-b53d-6a181091138d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:to="loc_us-gaap_AssetImpairmentCharges_74b11596-346b-4d91-b53d-6a181091138d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_571bce7e-d86e-41d2-a10d-17f68e8abfb3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ac1377ea-d8ea-4fe3-b159-cce97319569c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_ac1377ea-d8ea-4fe3-b159-cce97319569c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6dc29b09-32f2-46c0-ab62-dbd5122bb5b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6dc29b09-32f2-46c0-ab62-dbd5122bb5b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_157a3bd2-63da-4a39-8936-913b19fd518f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_157a3bd2-63da-4a39-8936-913b19fd518f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_e269d243-6799-4a7c-80f4-9f5ce38990e1" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent_e269d243-6799-4a7c-80f4-9f5ce38990e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fa86f23c-a479-483a-ae1c-2e0ee103b908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_fa86f23c-a479-483a-ae1c-2e0ee103b908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_347ca954-06e6-4df9-820d-ea6c910d6a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_347ca954-06e6-4df9-820d-ea6c910d6a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12067215-6d59-4cfa-ae80-18b0fef69fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_12067215-6d59-4cfa-ae80-18b0fef69fb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0812dea5-5244-43f4-b363-c910629a78d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_0812dea5-5244-43f4-b363-c910629a78d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_48a4c9ff-aac4-4c7a-b69e-0cda47404454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_aaa10053-25df-4bd2-86b0-43e32647e063" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_48a4c9ff-aac4-4c7a-b69e-0cda47404454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5ecbc59-554a-4e8e-b108-6cac2307c6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_85a55d79-0a2c-4c42-b615-78a2c206a81a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c5ecbc59-554a-4e8e-b108-6cac2307c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0f0b26ad-334f-4825-93c4-54ae53fb85e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0f0b26ad-334f-4825-93c4-54ae53fb85e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_decd9e52-b319-40ed-80a0-b81d13780491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0f0b26ad-334f-4825-93c4-54ae53fb85e1" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_decd9e52-b319-40ed-80a0-b81d13780491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_740ffab8-baaf-4e08-8ccf-6a1fd7d882fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0f0b26ad-334f-4825-93c4-54ae53fb85e1" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_740ffab8-baaf-4e08-8ccf-6a1fd7d882fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5286499-e8d2-4d44-a9f8-8d86be424b9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_0f0b26ad-334f-4825-93c4-54ae53fb85e1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e5286499-e8d2-4d44-a9f8-8d86be424b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ca05385-b7d7-4dda-97c2-eb349e726184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_6ca05385-b7d7-4dda-97c2-eb349e726184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_11fd4aec-4ef0-4ba6-a28b-9d557bb182c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_11fd4aec-4ef0-4ba6-a28b-9d557bb182c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_365324e4-af1e-40b3-80be-4fc123ce047b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_365324e4-af1e-40b3-80be-4fc123ce047b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_154f6cf1-9ecb-4fa5-9324-0ff3579bc68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_da7d4bd4-afcc-46f5-9a59-3dcc283b88c1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_154f6cf1-9ecb-4fa5-9324-0ff3579bc68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_884b0eac-5f33-4433-8e51-8f1f7c019d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_884b0eac-5f33-4433-8e51-8f1f7c019d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04c02856-21cd-40a0-860b-6e5b8129767a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_04c02856-21cd-40a0-860b-6e5b8129767a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eab6daca-d8a2-471d-ba91-653cf4eb8bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_eab6daca-d8a2-471d-ba91-653cf4eb8bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_c06198f0-31e3-4833-86fa-728a7fa6073c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_c06198f0-31e3-4833-86fa-728a7fa6073c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_cccc4181-7e01-4d9f-8dcf-63d998c82748" xlink:href="sesn-20220630.xsd#sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_c06198f0-31e3-4833-86fa-728a7fa6073c" xlink:to="loc_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard_cccc4181-7e01-4d9f-8dcf-63d998c82748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5cc66bf8-7647-4bb6-ad07-42bf6e3ebece" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e7813b05-eb4e-444a-84d6-0450acca80e0" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5cc66bf8-7647-4bb6-ad07-42bf6e3ebece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3a2f151e-0147-4483-b199-c0b2d65cf960" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_5cc66bf8-7647-4bb6-ad07-42bf6e3ebece" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_3a2f151e-0147-4483-b199-c0b2d65cf960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c4e8c84-a513-4b9b-88b9-fc34559ceb67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NatureOfOperations_500718ab-2a68-4c85-ad1b-c586c41a04f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NatureOfOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0c4e8c84-a513-4b9b-88b9-fc34559ceb67" xlink:to="loc_us-gaap_NatureOfOperations_500718ab-2a68-4c85-ad1b-c586c41a04f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#DESCRIPTIONOFBUSINESSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96f6fc75-8cbb-4922-95d5-19e6799b6fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_96f6fc75-8cbb-4922-95d5-19e6799b6fc6" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4d5f884e-7a19-42ef-a62c-325b7cf014e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViventiaBioInc.Member_5e57bc2d-6e6e-49ed-bfe9-16a0c5033d95" xlink:href="sesn-20220630.xsd#sesn_ViventiaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f6a525f7-e7a6-40dd-b9e1-64aa3b85467a" xlink:to="loc_sesn_ViventiaBioInc.Member_5e57bc2d-6e6e-49ed-bfe9-16a0c5033d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9aa46017-bb1d-4073-8551-4992d3af7330" xlink:to="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_803f3361-2197-4d74-8932-2a524c2dc054" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a0c226cc-1427-4c05-a213-f89c94173d41" xlink:to="loc_sesn_ViciniumMember_803f3361-2197-4d74-8932-2a524c2dc054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3ba6b843-eaf8-4e9c-a5c2-6d1778293ee0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_fe5a4a2b-c11a-4864-9104-a2bd379a041d" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9f964ac9-7aaa-4541-b37f-9013c0aa6fdf" xlink:to="loc_sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember_fe5a4a2b-c11a-4864-9104-a2bd379a041d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_eda578d2-566c-48ca-b81e-214c26360341" xlink:to="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_a7e6cdab-e0ba-4402-98bf-19e8fb04213e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_country_US_a7e6cdab-e0ba-4402-98bf-19e8fb04213e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_0b1b9872-1e85-4306-86f4-e61a07e02fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_srt_EuropeMember_0b1b9872-1e85-4306-86f4-e61a07e02fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_56cb2771-2776-4268-858f-354ca9cc15ab" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3ae061f9-029c-4859-b504-7cfea7724c5d" xlink:to="loc_country_JP_56cb2771-2776-4268-858f-354ca9cc15ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_96f0593f-bc09-4064-9e9a-5ee366e7dc2c" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_243742f0-6032-4379-a40c-3b157eda26ad" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare_243742f0-6032-4379-a40c-3b157eda26ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3f01fff2-30b4-4646-9974-a74be9838943" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_3f01fff2-30b4-4646-9974-a74be9838943" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_6cc5b6c8-2c38-47ef-8b8d-44f6be914d12" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct_6cc5b6c8-2c38-47ef-8b8d-44f6be914d12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_5ad2894b-3a4d-4df3-8e71-9eee49b8910d" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods_5ad2894b-3a4d-4df3-8e71-9eee49b8910d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_c5198dc8-3798-4420-8cf3-53ff3bffa32d" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales_c5198dc8-3798-4420-8cf3-53ff3bffa32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_faa13422-20d1-4821-8ebb-b1100ad730c7" xlink:href="sesn-20220630.xsd#sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_11fca67b-6f99-47f6-b7e2-9a5cfc3b7a75" xlink:to="loc_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations_faa13422-20d1-4821-8ebb-b1100ad730c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="simple" xlink:href="sesn-20220630.xsd#BASISOFPRESENTATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ffa26cf5-f60d-4d4a-8b79-d414d6ee6c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccounting_427642d5-019d-4f33-8e56-c9d76fc36b98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccounting"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ffa26cf5-f60d-4d4a-8b79-d414d6ee6c6c" xlink:to="loc_us-gaap_BasisOfAccounting_427642d5-019d-4f33-8e56-c9d76fc36b98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies" xlink:type="simple" xlink:href="sesn-20220630.xsd#BASISOFPRESENTATIONPolicies"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e4da124f-c0dc-4a7e-97ca-106186c519ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:to="loc_us-gaap_UseOfEstimates_e4da124f-c0dc-4a7e-97ca-106186c519ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_bfe026a8-d7fe-4ecf-bfb6-a1e655435995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_bfe026a8-d7fe-4ecf-bfb6-a1e655435995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f01c18a8-0a7e-481e-b517-ec1effad2eab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_f01c18a8-0a7e-481e-b517-ec1effad2eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c3988e43-cc11-4e40-9f8b-d6ca56e9f8de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c3988e43-cc11-4e40-9f8b-d6ca56e9f8de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9c158aad-b29d-4633-bb52-0675e830e0ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a33cc457-e2a6-45cd-a86c-deba02cc508d" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_9c158aad-b29d-4633-bb52-0675e830e0ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_08c1f8bd-1c42-407e-b3bc-5c222d86df42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a86230a8-f29a-4778-8b7d-71a82ea19301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_08c1f8bd-1c42-407e-b3bc-5c222d86df42" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a86230a8-f29a-4778-8b7d-71a82ea19301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECENTACCOUNTINGPRONOUNCEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_e6529bd3-a9c1-4f67-af93-0db9228a0dcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9c95e722-2be2-4a45-b8b6-fa11cc7ace44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract_e6529bd3-a9c1-4f67-af93-0db9228a0dcb" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_9c95e722-2be2-4a45-b8b6-fa11cc7ace44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_cfe88d4b-eecc-4cb9-af39-f7efaaccc48b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_de02f89b-f659-46e8-8dee-ab40638c124e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_cfe88d4b-eecc-4cb9-af39-f7efaaccc48b" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_de02f89b-f659-46e8-8dee-ab40638c124e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_86f12778-1788-428a-bd9a-7e638cb90898" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1bc3eb82-e680-4c01-8c68-e91246b3e55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86f12778-1788-428a-bd9a-7e638cb90898" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1bc3eb82-e680-4c01-8c68-e91246b3e55d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_7c018cbd-6908-470e-824c-95a8b7208344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_86f12778-1788-428a-bd9a-7e638cb90898" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock_7c018cbd-6908-470e-824c-95a8b7208344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4c3b37b2-77ff-40ba-a5c6-60d74d418f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4c3b37b2-77ff-40ba-a5c6-60d74d418f6c" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_8b3f14b6-4048-49c0-9815-a2e868ed2f4d" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_c1be94ce-4060-454f-a84c-6c6b14d92ed8" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dbdaa42d-44fb-49cc-97c3-85862059f663" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_dbdaa42d-44fb-49cc-97c3-85862059f663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9afcec2e-e15c-468c-880c-25032e1886b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_f36f7cc3-1a9e-4604-bfa1-a1cd37030a17" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_9afcec2e-e15c-468c-880c-25032e1886b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_9587cbbf-b7e8-43f0-9228-b9381bebb2ef" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ada41fb4-8a51-4af0-b554-3f0665cf9709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_21468da5-5250-41d8-be74-a33858747224" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ada41fb4-8a51-4af0-b554-3f0665cf9709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a28c9ffd-1eae-43c2-bfef-20eb4c64a0c7" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0a631628-ca6e-4ade-842c-828bd90667f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0a631628-ca6e-4ade-842c-828bd90667f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a1691992-dfb4-4dc8-bbbc-55071d3351e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a1691992-dfb4-4dc8-bbbc-55071d3351e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_a2e86575-b185-4d34-84ee-b496c3456b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c516a7f0-1ec3-4bc4-bb84-32a7f9a2068c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_a2e86575-b185-4d34-84ee-b496c3456b6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_24f4434a-1ef4-4cb6-9a39-260951f7ff5d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_220c70c8-adad-4d3b-b5d1-e8544baf3eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_220c70c8-adad-4d3b-b5d1-e8544baf3eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01f0d85b-b730-41a2-9d86-a3e1f45c761f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_a38ded37-ab2e-42a4-8706-cd1740c76028" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_01f0d85b-b730-41a2-9d86-a3e1f45c761f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_a333da4e-1549-49b3-bde6-76392bd23c02" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aad01c0e-fb41-4221-a8c7-d73a64b8384d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_6f7dd11d-d85e-4304-aade-7ae97590e1e6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_aad01c0e-fb41-4221-a8c7-d73a64b8384d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4558025f-f764-4d3f-972a-e41bebeef42a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4558025f-f764-4d3f-972a-e41bebeef42a" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_efc3bfc7-87b3-40c0-81ff-654271d00fbb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_6a954ef5-fb1a-47e3-9d14-59193bbd8b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_a5860264-5c4a-4656-85fd-46dd9f66758a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_6a954ef5-fb1a-47e3-9d14-59193bbd8b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:to="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7f8bc844-6c8f-4602-acac-0cc99a8f853e" xlink:to="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_f7cf47eb-cbc4-4550-aed4-526fd7511579" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:to="loc_srt_MinimumMember_f7cf47eb-cbc4-4550-aed4-526fd7511579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1179fe3e-3588-4ffc-bc77-086ef2c99995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_131e0f4b-257d-4df6-9bbb-23322c691a0b" xlink:to="loc_srt_MaximumMember_1179fe3e-3588-4ffc-bc77-086ef2c99995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOptionQuantitativeDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresTable_f8d615eb-74dc-4a43-a6af-23bce23849bb" xlink:to="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_ba4a4d03-bf1f-4bfb-adaf-3ed618789719" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_ba4a4d03-bf1f-4bfb-adaf-3ed618789719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_96d91a05-ce70-436b-8853-73c066e11ef1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_96d91a05-ce70-436b-8853-73c066e11ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WeightedAverageCostOfCapital_5c105fe8-f4d4-4278-975b-10c1be1b1830" xlink:href="sesn-20220630.xsd#sesn_WeightedAverageCostOfCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_sesn_WeightedAverageCostOfCapital_5c105fe8-f4d4-4278-975b-10c1be1b1830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64565849-6041-49dd-a742-203d33ba3999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems_c1699999-71c4-4c06-bdf9-581c05e9f704" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_64565849-6041-49dd-a742-203d33ba3999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_aac93ac1-b094-4bf9-a912-6919e891c22d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_aac93ac1-b094-4bf9-a912-6919e891c22d" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_2ae8e1aa-53b1-44cc-99b8-daa55a3fa657" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_cc227e47-1370-4363-b6b1-3b0299bf6bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a21d3e0a-6983-4cb8-b1bb-611492d287dd" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_cc227e47-1370-4363-b6b1-3b0299bf6bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_40e26254-69de-4ecf-9d8a-36c99fb1fd3a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61fb748f-da30-47f7-973f-0eb029483548" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_028b0c11-0854-4b8d-9c7d-0b9fc53ff132" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_028b0c11-0854-4b8d-9c7d-0b9fc53ff132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2c96392d-a19b-435d-811b-bcc62cd73ffb" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:to="loc_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent_2c96392d-a19b-435d-811b-bcc62cd73ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f888b6bf-6f16-4803-888c-8d55b4c739d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_4945df75-d4d4-4495-98a3-3d6536213826" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f888b6bf-6f16-4803-888c-8d55b4c739d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_be8bce6b-ba2b-454c-b51a-c2afea4c427a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_3494283c-fc1e-45cd-b5cf-47d01b321615" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_be8bce6b-ba2b-454c-b51a-c2afea4c427a" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_3494283c-fc1e-45cd-b5cf-47d01b321615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RECEIVABLESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RECEIVABLESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesAbstract_2918896a-4a9a-4dd5-a38a-20dcfca28d46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_2918896a-4a9a-4dd5-a38a-20dcfca28d46" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:to="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5b403dcc-a3aa-4491-a76a-55f213aca69f" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_4e71bbbe-ad35-41f8-a5d3-bb9972b79370" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07da3e8b-1562-4a5c-8bf5-15172ae6d50c" xlink:to="loc_sesn_RocheMember_4e71bbbe-ad35-41f8-a5d3-bb9972b79370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_bcb5dce6-c561-4222-bd6e-ecbc7dde2987" xlink:to="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LitigationSettlementMember_28565a84-458c-451b-b58b-48fb287793fe" xlink:href="sesn-20220630.xsd#sesn_LitigationSettlementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:to="loc_sesn_LitigationSettlementMember_28565a84-458c-451b-b58b-48fb287793fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_GermanVATRecoveryMember_12c6f350-f0e1-4d0e-bd16-5782f4fe3e82" xlink:href="sesn-20220630.xsd#sesn_GermanVATRecoveryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_4e5c5aba-d6e2-4d8c-9644-c0516d85a3ca" xlink:to="loc_sesn_GermanVATRecoveryMember_12c6f350-f0e1-4d0e-bd16-5782f4fe3e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_a0f4b749-6be3-4b04-a8ea-9bcbfdba4463" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7c91dc0f-1dc6-4715-a0fd-6941c892e21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7c91dc0f-1dc6-4715-a0fd-6941c892e21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_d5719313-406c-474f-a7fd-6c88926b5d79" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_d5719313-406c-474f-a7fd-6c88926b5d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_17b7533c-9260-4949-b87b-30e5d3e957fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_17b7533c-9260-4949-b87b-30e5d3e957fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_19516683-18b1-40b7-a4fe-b3c0f27792fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_883a53c0-a8dd-4270-ba55-9d0ee3697d5e" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_19516683-18b1-40b7-a4fe-b3c0f27792fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSES" xlink:type="simple" xlink:href="sesn-20220630.xsd#PREPAIDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PREPAIDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2314d4be-12ce-4bdd-a394-0d6a4b651b10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_37baef67-0666-496b-aedb-6181c497c40b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_2314d4be-12ce-4bdd-a394-0d6a4b651b10" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_37baef67-0666-496b-aedb-6181c497c40b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#PREPAIDEXPENSESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/PREPAIDEXPENSESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_746462db-b2fd-45cb-aef0-3d8d3af0f7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_12f8c246-9d40-4921-b1e6-c4a0e64c4dc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_746462db-b2fd-45cb-aef0-3d8d3af0f7a9" xlink:to="loc_us-gaap_PrepaidExpenseCurrentAndNoncurrent_12f8c246-9d40-4921-b1e6-c4a0e64c4dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid_250002f4-55a6-40ce-a820-64858a2e5f49" xlink:href="sesn-20220630.xsd#sesn_ExpensesPreviouslyClassifiedAsPrepaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_746462db-b2fd-45cb-aef0-3d8d3af0f7a9" xlink:to="loc_sesn_ExpensesPreviouslyClassifiedAsPrepaid_250002f4-55a6-40ce-a820-64858a2e5f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWIL"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_854362a3-6396-4381-8ea5-5dca35190860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_70a637bb-e16c-4080-af37-4beb8b1b662f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_854362a3-6396-4381-8ea5-5dca35190860" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_70a637bb-e16c-4080-af37-4beb8b1b662f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_264a71f5-b668-4a48-a562-72b6bf52c7df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e5ffe5f0-70e0-4e98-9eeb-0bda94468a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_264a71f5-b668-4a48-a562-72b6bf52c7df" xlink:to="loc_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock_e5ffe5f0-70e0-4e98-9eeb-0bda94468a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_183739e6-51bd-4de2-87df-d5c8e9f5f668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_264a71f5-b668-4a48-a562-72b6bf52c7df" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_183739e6-51bd-4de2-87df-d5c8e9f5f668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e0c7bf-915b-4b3e-a251-175491e9f8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e0c7bf-915b-4b3e-a251-175491e9f8a6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5c8dcb8b-532f-4868-a9ca-28bcd2ae7995" xlink:to="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_85793ac7-3216-45a0-86c0-8a36a2a2b0b3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b520b020-b833-4daa-953a-e8e80a529ae5" xlink:to="loc_srt_EuropeMember_85793ac7-3216-45a0-86c0-8a36a2a2b0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_afecb3dc-600c-49be-8d03-ea13a9f5e96b" xlink:to="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_d7d2f451-9138-4dae-9c89-82ff2703054c" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_428f0609-2268-4824-8ae3-6078d05ffe7d" xlink:to="loc_sesn_ViciniumMember_d7d2f451-9138-4dae-9c89-82ff2703054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_51187a0f-5976-4ab1-a203-6fbc96dbcb44" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_16adc348-2212-4c90-887d-39d8d0a23482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_84312744-5a12-464f-9a89-397e8453af8a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_16adc348-2212-4c90-887d-39d8d0a23482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_1c6ade6c-4980-41da-8984-775264f43ff8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_434b80d8-10ad-4fd3-ac70-94c61662be4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_9d16df94-248f-442c-a6a9-5e5554946743" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_434b80d8-10ad-4fd3-ac70-94c61662be4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b9dd1fda-fe29-4e71-868b-7a334e3efa10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b9dd1fda-fe29-4e71-868b-7a334e3efa10" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7618b9a9-8189-4ae2-8430-dd84b5b25055" xlink:to="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_7f419179-556d-4cfc-9c49-0c7e297db1ce" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d0a74d04-7ee3-41af-bdeb-ffe26d4a3213" xlink:to="loc_sesn_ViciniumMember_7f419179-556d-4cfc-9c49-0c7e297db1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_06ff0968-c45c-4669-b5b2-dd40e7cd2f0c" xlink:to="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_86b99c53-2063-43a6-b3f2-12b1ac33a798" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e42dafaf-7b3c-47d1-a2fd-5bf42c5bd991" xlink:to="loc_srt_EuropeMember_86b99c53-2063-43a6-b3f2-12b1ac33a798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_23c197b7-f91b-435a-a5f2-a84a0b3c7192" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c93f0729-07e0-4b2a-8486-973bf4978a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_e1a4ba6e-c85f-440b-997d-f45321d36c8d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c93f0729-07e0-4b2a-8486-973bf4978a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_720e4243-96dc-40db-ac5a-b034327de9d9" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6f30a6a0-aba5-48a6-82a2-ba8344588b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_6f30a6a0-aba5-48a6-82a2-ba8344588b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_0bc07522-bc31-44ce-b4a6-032d82e53f26" xlink:href="sesn-20220630.xsd#sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage_0bc07522-bc31-44ce-b4a6-032d82e53f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_dc1f17f5-5412-4f0f-945b-93303c922fb9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_52345a40-9a24-4722-a00e-68606a23f440" xlink:to="loc_us-gaap_Goodwill_dc1f17f5-5412-4f0f-945b-93303c922fb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48098e11-4980-4841-81da-570982c699dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_970e98b9-bb97-4719-89bc-86c0f554e687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48098e11-4980-4841-81da-570982c699dd" xlink:to="loc_us-gaap_Goodwill_970e98b9-bb97-4719-89bc-86c0f554e687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_54289b44-e1f2-459e-8866-bd70d52f5045" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48098e11-4980-4841-81da-570982c699dd" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_54289b44-e1f2-459e-8866-bd70d52f5045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_19c3d4d1-7d5c-41b8-901b-bbdc2ec0ffb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_48098e11-4980-4841-81da-570982c699dd" xlink:to="loc_us-gaap_Goodwill_19c3d4d1-7d5c-41b8-901b-bbdc2ec0ffb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_d6297a2f-6a20-45be-a74c-66aadf9841c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_536a9976-f37b-4f01-ae13-73be4a893473" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_d6297a2f-6a20-45be-a74c-66aadf9841c9" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_536a9976-f37b-4f01-ae13-73be4a893473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_b5684f04-5446-407e-8321-ed71df63d3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cf2e8f47-a212-4aec-88f7-ae7ed33b7389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_b5684f04-5446-407e-8321-ed71df63d3a1" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_cf2e8f47-a212-4aec-88f7-ae7ed33b7389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_d48e0102-7afb-4629-8afe-a20b13936652" xlink:href="sesn-20220630.xsd#sesn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_sesn_AccruedResearchAndDevelopmentExpenseCurrent_d48e0102-7afb-4629-8afe-a20b13936652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de8a2c1f-2228-4972-be34-b7c835171e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_de8a2c1f-2228-4972-be34-b7c835171e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedRestructuringChargesRelatedCurrent_77f38d6a-9dba-40ad-aec5-9097e029721f" xlink:href="sesn-20220630.xsd#sesn_AccruedRestructuringChargesRelatedCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_sesn_AccruedRestructuringChargesRelatedCurrent_77f38d6a-9dba-40ad-aec5-9097e029721f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_93e416a6-2e68-4894-9500-737e7e3c1242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_93e416a6-2e68-4894-9500-737e7e3c1242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccruedLegalFees_4e8ed95a-acc7-4e71-8860-9ab1ce387cc8" xlink:href="sesn-20220630.xsd#sesn_AccruedLegalFees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_sesn_AccruedLegalFees_4e8ed95a-acc7-4e71-8860-9ab1ce387cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_727af1cf-34d2-459a-98d3-855b5c20d87a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_727af1cf-34d2-459a-98d3-855b5c20d87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7a65d02b-c477-4ff6-acda-b3d924130d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_f26fc4b5-b359-4f6f-ada9-29a5a55b39c2" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7a65d02b-c477-4ff6-acda-b3d924130d13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#COMMITMENTSANDCONTINGENCIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02ae3551-5eb3-4ecc-958b-56ab0f62e63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_848c6d94-2271-4699-a813-95b2eddbf5c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_02ae3551-5eb3-4ecc-958b-56ab0f62e63f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_848c6d94-2271-4699-a813-95b2eddbf5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#COMMITMENTSANDCONTINGENCIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70c46046-3a22-4234-be64-170f175da6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberOfLawsuits_22fc0ee6-102b-41f5-a62b-88e82c0802fc" xlink:href="sesn-20220630.xsd#sesn_NumberOfLawsuits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70c46046-3a22-4234-be64-170f175da6c5" xlink:to="loc_sesn_NumberOfLawsuits_22fc0ee6-102b-41f5-a62b-88e82c0802fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationReserve_701b6ef6-085e-4e19-97d5-999590a17cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationReserve"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_70c46046-3a22-4234-be64-170f175da6c5" xlink:to="loc_us-gaap_LitigationReserve_701b6ef6-085e-4e19-97d5-999590a17cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASES" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_68334cfb-5337-45ed-b02d-a43268db966c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0b41b1f2-7d1e-43af-8799-12b97d08b8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_68334cfb-5337-45ed-b02d-a43268db966c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0b41b1f2-7d1e-43af-8799-12b97d08b8d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LEASESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LEASESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LEASESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_dfd493f5-2ebf-470a-8183-0e48f624f7da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_dfd493f5-2ebf-470a-8183-0e48f624f7da" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:to="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6e5cea0b-e24e-4c5c-ba03-1ffc80a2a0f5" xlink:to="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_e1a954ed-6fd2-4081-b7ae-013dbf36e4ce" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_country_CA_e1a954ed-6fd2-4081-b7ae-013dbf36e4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_cd10cabb-00d0-4ba7-b6f5-3031ef5fe0c3" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_stpr_MA_cd10cabb-00d0-4ba7-b6f5-3031ef5fe0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_eb555429-5e13-4e6e-99d8-ae3b00e79e6f" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_PA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_1fe37ebe-cf75-4bb4-9e5b-196f7e9b0b60" xlink:to="loc_stpr_PA_eb555429-5e13-4e6e-99d8-ae3b00e79e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:to="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c7fa4449-eb8c-4eb8-89fd-982ebaadfad5" xlink:to="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_2d2efd0e-60b8-4c19-b8c3-1b816bac2ee6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:to="loc_srt_MinimumMember_2d2efd0e-60b8-4c19-b8c3-1b816bac2ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1c7391dd-dd97-4055-b88a-63debb0ac4c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_eb84b94a-9a28-4e42-be1e-980369d9ae57" xlink:to="loc_srt_MaximumMember_1c7391dd-dd97-4055-b88a-63debb0ac4c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_ade91353-19f8-49bd-be8f-ef2ca200187e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeasesAreaOfOfficeSpace_2032131b-7401-411b-8b9d-7b3bd4e4aee9" xlink:href="sesn-20220630.xsd#sesn_OperatingLeasesAreaOfOfficeSpace"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeasesAreaOfOfficeSpace_2032131b-7401-411b-8b9d-7b3bd4e4aee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d273ff47-5da5-4e0e-9d56-d1b41308aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d273ff47-5da5-4e0e-9d56-d1b41308aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseMonthlyRent_8f199b48-0649-4ccd-a3a0-c49005aac4f8" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseMonthlyRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeaseMonthlyRent_8f199b48-0649-4ccd-a3a0-c49005aac4f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_cb341580-4a7d-453d-af13-64d3b9d077f6" xlink:href="sesn-20220630.xsd#sesn_OperatingLeaseOtherMonthlyOperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_sesn_OperatingLeaseOtherMonthlyOperatingExpenses_cb341580-4a7d-453d-af13-64d3b9d077f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_9a2d523c-8510-4fde-ad6d-8840c8160be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseCost_9a2d523c-8510-4fde-ad6d-8840c8160be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3b212a04-867c-41bf-82df-d5784d0fabd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_3b212a04-867c-41bf-82df-d5784d0fabd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcab4a74-5c27-4e8a-af7e-eed6c7239b72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bcab4a74-5c27-4e8a-af7e-eed6c7239b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d2947ccb-9bef-4748-aa26-0d4b4d80a221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_d2947ccb-9bef-4748-aa26-0d4b4d80a221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f9f03-73b3-4fd3-9676-945d820dbf15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_c142c5fe-7628-4a48-a5af-af5682e3791b" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e69f9f03-73b3-4fd3-9676-945d820dbf15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITY"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITY" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_61fbf24e-d5cd-4eec-9fb2-17767ef31f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f608f13b-5058-4256-8925-4aea8a8996e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_61fbf24e-d5cd-4eec-9fb2-17767ef31f56" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f608f13b-5058-4256-8925-4aea8a8996e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_23f117a0-3723-4c1f-aec5-339f5a9b12a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_72db295c-033a-4651-87a6-230e83db54d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23f117a0-3723-4c1f-aec5-339f5a9b12a0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_72db295c-033a-4651-87a6-230e83db54d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bbc484ec-b1c2-4472-b248-adc1a1be3ad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_23f117a0-3723-4c1f-aec5-339f5a9b12a0" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_bbc484ec-b1c2-4472-b248-adc1a1be3ad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYEquityFinancingDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_21acdd33-529f-412d-892f-2fc4bd1f32cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_21acdd33-529f-412d-892f-2fc4bd1f32cc" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:to="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_5c57deae-10c5-4677-806a-b38c68ae7854" xlink:to="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ATMFacilityMember_7d44ccdc-7a83-4cb1-9d87-dc35ebb5c7fe" xlink:href="sesn-20220630.xsd#sesn_ATMFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_27a84a0d-6913-4eb5-acc2-e05f0626b883" xlink:to="loc_sesn_ATMFacilityMember_7d44ccdc-7a83-4cb1-9d87-dc35ebb5c7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_5ed0b4b7-e298-4c05-a025-a91b64bd586a" xlink:to="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf8603e-270d-4799-9679-07cb2166f6fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_2cf8603e-270d-4799-9679-07cb2166f6fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c0c22768-8980-4aa1-bbf5-189d6657c0f2" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction_c0c22768-8980-4aa1-bbf5-189d6657c0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_dde3e024-d541-450c-8335-81b2a79b1fa9" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance_dde3e024-d541-450c-8335-81b2a79b1fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockCommissionFixedRate_431f6926-09ec-4491-9b50-fe462f8f50db" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockCommissionFixedRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockCommissionFixedRate_431f6926-09ec-4491-9b50-fe462f8f50db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_93ab3fca-7b91-4fb4-98f0-b0b6964c24f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_93ab3fca-7b91-4fb4-98f0-b0b6964c24f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_65636136-76af-4a4a-ac72-058b7518fcdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_65636136-76af-4a4a-ac72-058b7518fcdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SaleOfStockWeightedAveragePricePerShare_4a72dca1-c6c1-446c-bb60-f98b7cc1f6c4" xlink:href="sesn-20220630.xsd#sesn_SaleOfStockWeightedAveragePricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_SaleOfStockWeightedAveragePricePerShare_4a72dca1-c6c1-446c-bb60-f98b7cc1f6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_eabf479a-f222-4e2e-8555-4780393c1aa0" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_644d765c-ca36-4949-bba8-c996219424bc" xlink:to="loc_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts_eabf479a-f222-4e2e-8555-4780393c1aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_65c435a1-3ff3-4340-9471-0cf726477081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_86205638-efb7-4050-9944-52a3e9f11e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65c435a1-3ff3-4340-9471-0cf726477081" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_86205638-efb7-4050-9944-52a3e9f11e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c4f55fe4-6a0f-4c8a-9c08-9b4bebf482dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65c435a1-3ff3-4340-9471-0cf726477081" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c4f55fe4-6a0f-4c8a-9c08-9b4bebf482dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_3b71cb53-7aad-4343-88b4-b1ac197f564f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65c435a1-3ff3-4340-9471-0cf726477081" xlink:to="loc_us-gaap_PreferredStockSharesIssued_3b71cb53-7aad-4343-88b4-b1ac197f564f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_932358c8-08ad-4acb-9c7f-ddc84ac69417" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_65c435a1-3ff3-4340-9471-0cf726477081" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_932358c8-08ad-4acb-9c7f-ddc84ac69417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYCommonStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f665179e-80fd-4145-a7f1-3add17474bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f665179e-80fd-4145-a7f1-3add17474bcf" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_cab5a501-a796-4ad8-8f6d-ba797e3a75c5" xlink:to="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_51155bbe-3f39-4415-94c9-cf6bbf5c0c46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_947c1fbb-014d-444e-8639-79c36f0680d3" xlink:to="loc_us-gaap_CommonStockMember_51155bbe-3f39-4415-94c9-cf6bbf5c0c46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_e4688717-b70d-4e62-9eb0-c372db1cd987" xlink:to="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_7197f600-8b58-4937-b5ed-086817792108" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_7197f600-8b58-4937-b5ed-086817792108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_04d0d805-cc59-468f-9a19-6ecbe69e965a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesIssued_04d0d805-cc59-468f-9a19-6ecbe69e965a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41b6bce2-c1be-4de3-af57-661316b15b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_41b6bce2-c1be-4de3-af57-661316b15b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_NumberofVotesEntitledForEachShare_09b67323-966e-4785-a3a1-89682fbe1076" xlink:href="sesn-20220630.xsd#sesn_NumberofVotesEntitledForEachShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_7d1ff8fe-a833-43f0-995f-a794cddecff9" xlink:to="loc_sesn_NumberofVotesEntitledForEachShare_09b67323-966e-4785-a3a1-89682fbe1076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1bde13b5-6329-4afa-bd52-3c1022289955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1bde13b5-6329-4afa-bd52-3c1022289955" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:to="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a1f57799-07b4-42a3-a694-5afbcbb87430" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_889c57c2-8138-42b4-b4b2-dfecbb62af8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_WarrantMember_889c57c2-8138-42b4-b4b2-dfecbb62af8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_b147b536-e3e2-43b5-9ecf-502070fa8927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_b147b536-e3e2-43b5-9ecf-502070fa8927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_f3be2d85-0727-41d5-899c-92e93ad555fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_f3be2d85-0727-41d5-899c-92e93ad555fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_76ac6111-1150-40b7-af38-ab2602c655d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_StockCompensationPlanMember_76ac6111-1150-40b7-af38-ab2602c655d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_881e9ce4-6d3a-40ae-8271-cad16f012c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9358ae55-54f1-4d4b-bdd9-4dcc16f955a0" xlink:to="loc_us-gaap_EmployeeStockMember_881e9ce4-6d3a-40ae-8271-cad16f012c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_93dba07b-700c-4c9b-badb-7cda992bd4f3" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_11003ed4-2836-407d-b432-5bf01bacef89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:to="loc_us-gaap_CommonStockSharesIssued_11003ed4-2836-407d-b432-5bf01bacef89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:href="sesn-20220630.xsd#sesn_SharesOfCommonStockReservedForIssuanceAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_b9e9eac1-a21a-4dca-b6d1-4218e9f739a1" xlink:to="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0a73fa4-4aab-4508-894c-606855e78061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a0a73fa4-4aab-4508-894c-606855e78061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_5bc06bde-7764-4e84-ad59-ce260e23412c" xlink:href="sesn-20220630.xsd#sesn_CommonStockSharesIssuedAndReservedForFuture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_SharesOfCommonStockReservedForIssuanceAbstract_f7cd9d9e-ed8c-4886-bd1a-d56970b1d94f" xlink:to="loc_sesn_CommonStockSharesIssuedAndReservedForFuture_5bc06bde-7764-4e84-ad59-ce260e23412c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#STOCKHOLDERSEQUITYWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_39ce8c9d-320f-45fd-af25-275bdfb17de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39ce8c9d-320f-45fd-af25-275bdfb17de2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cee3ab70-47d8-495d-8859-e1275350199d" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringMarch2023Member_1e7930cb-a610-4f9f-b550-4aad89594a0c" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringMarch2023Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringMarch2023Member_1e7930cb-a610-4f9f-b550-4aad89594a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2022Member_95f745a1-0b1c-43f6-8fa9-9e8aaf6e5cb9" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2022Member_95f745a1-0b1c-43f6-8fa9-9e8aaf6e5cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_0d7bd1aa-3163-42e3-84f5-6a06d69da35a" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedMay2015Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedMay2015Member_0d7bd1aa-3163-42e3-84f5-6a06d69da35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_70735bbf-1177-4c1f-877c-b41233de0c95" xlink:href="sesn-20220630.xsd#sesn_WarrantsExpiringNovember2024IssuedNovember2014Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7be2f598-b1f9-4422-bcab-ffbafc0a4ff1" xlink:to="loc_sesn_WarrantsExpiringNovember2024IssuedNovember2014Member_70735bbf-1177-4c1f-877c-b41233de0c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_b4de515c-60fc-4538-acfa-7de0ea0f0298" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c69955-89b7-4976-8aad-dc71baf8d451" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_81c69955-89b7-4976-8aad-dc71baf8d451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:href="sesn-20220630.xsd#sesn_WarrantOrRightOutstandingRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_c1b02b83-3c39-41c3-9b48-8ccbf62a4c0f" xlink:to="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a2751f0-5ddd-4af3-9d4f-61a2fed340ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_0a2751f0-5ddd-4af3-9d4f-61a2fed340ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_190fadc3-364e-4ad0-922e-4958e1fde501" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightIssuedDuringThePeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod_190fadc3-364e-4ad0-922e-4958e1fde501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2bcc1e1d-24d5-4f5a-8d80-9fdb645cf5a1" xlink:href="sesn-20220630.xsd#sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants_2bcc1e1d-24d5-4f5a-8d80-9fdb645cf5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_328904be-4e11-49e4-aa9b-de764aa30153" xlink:href="sesn-20220630.xsd#sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod_328904be-4e11-49e4-aa9b-de764aa30153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dc0ce7f-86ab-4742-ab8a-813b7c1e71b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_WarrantOrRightOutstandingRollForward_68ecc519-179a-4498-9ffa-30cca6262774" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_7dc0ce7f-86ab-4742-ab8a-813b7c1e71b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHARE"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_318d34f1-d71c-4884-800e-973dd51fc9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_5c6db88e-3761-4ecd-a791-bae35602b587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_318d34f1-d71c-4884-800e-973dd51fc9b9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_5c6db88e-3761-4ecd-a791-bae35602b587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHARETables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_92cd7bc6-1eae-4c87-9062-d5aef748fbba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bfc2b78a-394e-4270-81da-bbc3b336f42c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_92cd7bc6-1eae-4c87-9062-d5aef748fbba" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_bfc2b78a-394e-4270-81da-bbc3b336f42c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EARNINGSLOSSPERSHAREDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2262bada-bd61-4a92-9fa2-bdfdf85ee822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2262bada-bd61-4a92-9fa2-bdfdf85ee822" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_3f18d7d5-8212-4de6-afe3-3c2c16bfc550" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b38f74ba-b311-4a22-a7ff-77c73fff0c05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_WarrantMember_b38f74ba-b311-4a22-a7ff-77c73fff0c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d937bf88-3d6d-43fe-8988-626d427345e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d937bf88-3d6d-43fe-8988-626d427345e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_13fb4b18-a387-4268-869a-86a8384ef5d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_13fb4b18-a387-4268-869a-86a8384ef5d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_74575bdd-beaa-4196-a327-f4b4a5f11751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_bc6a60d2-22da-4bee-aae2-2d6bbea3c2a5" xlink:to="loc_us-gaap_PerformanceSharesMember_74575bdd-beaa-4196-a327-f4b4a5f11751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_64fb14a8-d9fd-4ae4-ae25-2030ad10be48" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cc7b149-4d72-410b-a7ca-15dbbaaabcde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_f61e80e2-e271-4952-9511-368385a1adab" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9cc7b149-4d72-410b-a7ca-15dbbaaabcde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATION"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5931049d-49ee-4f72-83fa-a37f6a067d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3e23d908-ecee-4be8-96e1-c23fd1b5155d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5931049d-49ee-4f72-83fa-a37f6a067d5e" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_3e23d908-ecee-4be8-96e1-c23fd1b5155d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24fbc185-f09c-4f04-8fea-3f8e5d2717fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b3a499a7-1c66-4b6b-aced-fe0377293991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24fbc185-f09c-4f04-8fea-3f8e5d2717fe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_b3a499a7-1c66-4b6b-aced-fe0377293991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f7c5b9e-25dd-41dd-9811-3a1c2fe4f950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24fbc185-f09c-4f04-8fea-3f8e5d2717fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_7f7c5b9e-25dd-41dd-9811-3a1c2fe4f950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b6c83570-9251-40bd-af98-e25fd9a812d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24fbc185-f09c-4f04-8fea-3f8e5d2717fe" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b6c83570-9251-40bd-af98-e25fd9a812d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5eccfcc3-27d7-4f74-91dd-a5dc0a8c8fa9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_24fbc185-f09c-4f04-8fea-3f8e5d2717fe" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_5eccfcc3-27d7-4f74-91dd-a5dc0a8c8fa9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80d08a48-e230-468f-8bbb-62116ee4b269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_80d08a48-e230-468f-8bbb-62116ee4b269" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_670eca1f-5e25-45f7-9745-f97f2f40fc53" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d9c2add-f464-4d91-9f4b-090d9e47759a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_6d9c2add-f464-4d91-9f4b-090d9e47759a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a4a0ff2b-58f4-4099-8b94-d1e6825818e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a8da4d5c-33d3-4aef-a110-1b48cb3db8bd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_a4a0ff2b-58f4-4099-8b94-d1e6825818e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4fe94ca0-8d02-4320-ab7f-8ff60af3e33f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8ca85e4a-2025-402f-9ee0-262763258e80" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9a0ce09e-f976-431b-b261-ca2830c4705c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8ca85e4a-2025-402f-9ee0-262763258e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7abdd63-6389-435c-bfad-2576a418da41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f7abdd63-6389-435c-bfad-2576a418da41" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2094862a-c1aa-46c8-949d-4d7d04678068" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_20576e00-0647-4fe1-a427-644414033941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_EmployeeStockOptionMember_20576e00-0647-4fe1-a427-644414033941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bcc8f071-ab97-4bcb-b9dd-fcb70d52b83c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bcc8f071-ab97-4bcb-b9dd-fcb70d52b83c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_7c85d164-163b-4748-ad5e-955771a97811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a0a4d32d-ec21-4fbc-bfb0-b505a0983c36" xlink:to="loc_us-gaap_PerformanceSharesMember_7c85d164-163b-4748-ad5e-955771a97811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c41cb34a-809f-41a7-b7ee-fd6d3ff4c298" xlink:to="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_3ce8e50b-31c3-4487-9e80-17a6f640c948" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlanTwoThousandFourteenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_StockIncentivePlanTwoThousandFourteenMember_3ce8e50b-31c3-4487-9e80-17a6f640c948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RetentionProgramMember_8aa102f2-bf40-4a02-b89f-2a712715bd52" xlink:href="sesn-20220630.xsd#sesn_RetentionProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_RetentionProgramMember_8aa102f2-bf40-4a02-b89f-2a712715bd52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_StockIncentivePlan2009Member_bef01072-7d4c-480f-b2fa-c9af344fc5ad" xlink:href="sesn-20220630.xsd#sesn_StockIncentivePlan2009Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_dd4c0a3e-2018-4377-a481-bcb5b0a234b5" xlink:to="loc_sesn_StockIncentivePlan2009Member_bef01072-7d4c-480f-b2fa-c9af344fc5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_1211ed3b-2dcd-4e56-9ba8-a79ad9951a91" xlink:to="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f6386fa1-9537-4eb8-9cb6-ee0b51ff8aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f6386fa1-9537-4eb8-9cb6-ee0b51ff8aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c661771f-270e-4e91-bba5-cb8ba094c21d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_281be5fc-d277-4cfe-afd7-80a797781acd" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_c661771f-270e-4e91-bba5-cb8ba094c21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_44e3cbd5-05ce-43f4-ab84-4a203702fe04" xlink:to="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3dae9462-53d4-4ef0-b8ba-f499236e9802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_5f199a7a-9353-41d2-8802-82d60d57fc55" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_3dae9462-53d4-4ef0-b8ba-f499236e9802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_243ceea7-02e2-44c7-b708-5f60abb211ed" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3f008c48-843f-4908-9bc7-9d45dcb2defa" xlink:href="sesn-20220630.xsd#sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance_3f008c48-843f-4908-9bc7-9d45dcb2defa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57a35f5f-b087-45ab-9b39-7bfc8f55854b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_57a35f5f-b087-45ab-9b39-7bfc8f55854b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc4a4e3b-d8dd-46b2-bcea-59ca3a4ad512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_bc4a4e3b-d8dd-46b2-bcea-59ca3a4ad512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7c8b17d2-30ef-49ee-93af-3f11fb33bdd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_7c8b17d2-30ef-49ee-93af-3f11fb33bdd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8d356b2f-ffe3-415b-b0ff-d132669b6514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8d356b2f-ffe3-415b-b0ff-d132669b6514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_970116a7-94af-4819-bd88-7bfa00d3c46b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_970116a7-94af-4819-bd88-7bfa00d3c46b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_0aff4c7b-4949-43a3-931e-a477e3419fe6" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward_0aff4c7b-4949-43a3-931e-a477e3419fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_a6b367e5-5f3a-46f2-b6aa-f5d2d3161e99" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary_a6b367e5-5f3a-46f2-b6aa-f5d2d3161e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85ba3ee5-ad89-45b7-807b-dbcdc691e438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_85ba3ee5-ad89-45b7-807b-dbcdc691e438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_5d0b6ee7-7d1e-4bf1-bbc1-7bd36b4aa624" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent_5d0b6ee7-7d1e-4bf1-bbc1-7bd36b4aa624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_85abeb9d-5901-40fd-a61b-73c66147669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_85abeb9d-5901-40fd-a61b-73c66147669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b559af7-e2fc-411a-9d20-4c80b2699429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_9b559af7-e2fc-411a-9d20-4c80b2699429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e8c27f80-2642-45c1-b605-9f2a89599064" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_e8c27f80-2642-45c1-b605-9f2a89599064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e005e824-d362-44cc-a7e6-a9813b49e3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e005e824-d362-44cc-a7e6-a9813b49e3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4995ba87-07fd-4b7d-ae47-a218ffaaf8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4995ba87-07fd-4b7d-ae47-a218ffaaf8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81ca27c8-f8ef-453d-ba2c-612decc153d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_81ca27c8-f8ef-453d-ba2c-612decc153d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_489ae87f-b67a-4f80-b6e6-c01a14a6d598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_37e0ca27-3487-46a6-8da5-5bbbf57fcf71" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_489ae87f-b67a-4f80-b6e6-c01a14a6d598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1246cd96-1fae-40bb-b8ce-2f177f7e315a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1246cd96-1fae-40bb-b8ce-2f177f7e315a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_db92e6cb-7df5-47dc-b414-1546efd22e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_db92e6cb-7df5-47dc-b414-1546efd22e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4e01d66-292d-41a0-93b7-468275a16b99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a4e01d66-292d-41a0-93b7-468275a16b99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31a6b201-5326-4e7c-8cd7-48f40c5ebdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_31a6b201-5326-4e7c-8cd7-48f40c5ebdf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d85f857-a6af-4294-95e5-7dde9f48663f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6a120859-01fc-4889-90e1-86dadf63c556" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4d85f857-a6af-4294-95e5-7dde9f48663f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f5520aa2-41dd-4a94-b1e9-d09e33e46a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_f5520aa2-41dd-4a94-b1e9-d09e33e46a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549a0506-ef46-4200-af97-bee5a3304e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_549a0506-ef46-4200-af97-bee5a3304e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc1ad890-e986-4929-a1d0-6cc513ec5715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_dc1ad890-e986-4929-a1d0-6cc513ec5715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b12aed60-448e-4bc7-98f2-9b03fac8a762" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_b12aed60-448e-4bc7-98f2-9b03fac8a762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_87026278-3b2a-4967-a255-c81b56da10c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_87026278-3b2a-4967-a255-c81b56da10c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7461adf9-7e18-40c5-8350-736838a11b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_47be69dc-5cbb-496d-a3bf-b1c22f6b85a5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7461adf9-7e18-40c5-8350-736838a11b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e33398ee-eb6b-4b8e-a0d0-a3faa46f9022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e33398ee-eb6b-4b8e-a0d0-a3faa46f9022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b048530d-e565-4d6b-95a6-fcb1b5bdc3a7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3177907a-d59d-4280-8b74-4c35f19fbf88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_3177907a-d59d-4280-8b74-4c35f19fbf88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_867880f6-9665-45cc-9544-417a8eff758f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_867880f6-9665-45cc-9544-417a8eff758f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b981f824-ebfb-4032-aafc-4fd359c50325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_b981f824-ebfb-4032-aafc-4fd359c50325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3ad5ce2-546d-4f8f-a13e-09f52078bec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_304614f7-4b3d-41e8-ab48-f6319e4e0e32" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_d3ad5ce2-546d-4f8f-a13e-09f52078bec6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef71fe2-dc91-4831-ac53-f1a1a1fbd3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0ef71fe2-dc91-4831-ac53-f1a1a1fbd3ae" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:to="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_52711721-ffeb-4e26-8af9-ccf16a4ca9cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8e4c1e96-707e-45a5-9e86-d40a9a5244ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f80d30f7-43f1-4813-9631-0c088ae71079" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8e4c1e96-707e-45a5-9e86-d40a9a5244ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_81ee6d61-bf3d-481d-85b6-1da7853ab68f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_ed96eb1a-2e3f-47da-8c00-643a8f772bc7" xlink:href="sesn-20220630.xsd#sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue_ed96eb1a-2e3f-47da-8c00-643a8f772bc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0df5e004-e82a-4243-9eb3-910b6024b236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_0df5e004-e82a-4243-9eb3-910b6024b236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d66047-d004-4550-b503-f638b53b990d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_a2d66047-d004-4550-b503-f638b53b990d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d54b78c-131a-4ae7-9a48-f3b5ee977538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_0d54b78c-131a-4ae7-9a48-f3b5ee977538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6df9619d-924f-4a46-8b00-abb8200c44c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_6df9619d-924f-4a46-8b00-abb8200c44c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c2b9ced-e463-43eb-bc36-16e748edd97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0e06d5f4-bd6b-4dd7-8869-bd1607ea99a2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_9c2b9ced-e463-43eb-bc36-16e748edd97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47d4d4dd-55f7-4c61-8df9-53cdfdf08134" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_47d4d4dd-55f7-4c61-8df9-53cdfdf08134" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:to="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_29267168-e213-4fd0-aea0-830e0560b2ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ea452706-db61-4aba-9252-e0e8ffd65985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ea452706-db61-4aba-9252-e0e8ffd65985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_33ad9921-7215-4cf1-a6b5-a18f286dc1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_bb7bb7ae-f472-4d61-8d92-c483d6e1b558" xlink:to="loc_us-gaap_PerformanceSharesMember_33ad9921-7215-4cf1-a6b5-a18f286dc1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6e86b7f6-2c9c-44e7-95a1-870a8588b150" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef886896-9144-4a7c-bb6a-7878129971da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ef886896-9144-4a7c-bb6a-7878129971da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b85f6c2b-160f-4184-acf2-3f5797b07ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_b85f6c2b-160f-4184-acf2-3f5797b07ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8aaa354-a03b-4ad3-9f38-960a961f3e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b8aaa354-a03b-4ad3-9f38-960a961f3e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88082e1e-071d-4d27-9b95-e11fee1431f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0b35cfac-777a-41d0-9774-08ff5d813e2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_88082e1e-071d-4d27-9b95-e11fee1431f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_234e5119-48c7-43b7-976e-5a45030d98fe" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06e618e2-cd99-4485-b290-9937c8f75c0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_06e618e2-cd99-4485-b290-9937c8f75c0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcf87c26-e34a-4bb9-818e-06ce36a3bae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_bcf87c26-e34a-4bb9-818e-06ce36a3bae3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d53e75e0-6cf5-4bbf-a796-ccad1bd5108f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_d53e75e0-6cf5-4bbf-a796-ccad1bd5108f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_535da7d4-2791-4c37-9247-bbf1cc003a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_66db5b66-4e3a-4611-9ac9-801417095b68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_535da7d4-2791-4c37-9247-bbf1cc003a7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b97b7f88-37d2-4654-90b2-5447baa78e21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_f2f8c73a-f534-46eb-b47a-3e0ade1c31a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_b97b7f88-37d2-4654-90b2-5447baa78e21" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_f2f8c73a-f534-46eb-b47a-3e0ade1c31a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#EMPLOYEEBENEFITPLANSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4dde2b18-b030-4b39-b72c-33249800139b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_4dde2b18-b030-4b39-b72c-33249800139b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:to="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_02bd4824-776b-4eed-88e6-58604c13d9fc" xlink:to="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_A2014EmployeeStockPurchasePlanMember_3a2780c5-8ede-4153-bb2b-9de73d10caa6" xlink:href="sesn-20220630.xsd#sesn_A2014EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_52cecea3-857e-40e8-9ce7-372785bf5668" xlink:to="loc_sesn_A2014EmployeeStockPurchasePlanMember_3a2780c5-8ede-4153-bb2b-9de73d10caa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_47561df0-6a24-409d-b5ea-d9df469d64a4" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:to="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_31b63e26-2e93-4763-b73d-327d09d777eb" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_4ef80f8c-06b0-4aca-8d6a-a72a16de984c" xlink:to="loc_country_US_31b63e26-2e93-4763-b73d-327d09d777eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_7f920f93-2cf4-4459-a761-6b89d592c8ce" xlink:to="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_5f90a157-3335-4576-86ed-aaef99ad9f57" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignPlanMember_ad6e6c85-da05-4569-ac45-da6e5b40752a" xlink:to="loc_country_CA_5f90a157-3335-4576-86ed-aaef99ad9f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_dce1cbc6-e829-4243-804c-50c7873605b2" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b29cfc4b-f0d8-4182-a5c4-89dcb5034340" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_b29cfc4b-f0d8-4182-a5c4-89dcb5034340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_53e4408c-c767-457b-a8f0-0315876c2ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_53e4408c-c767-457b-a8f0-0315876c2ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f69d46be-0c62-4896-95bd-6afe6d314526" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate_f69d46be-0c62-4896-95bd-6afe6d314526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c6ba13aa-81be-4721-92b4-0807486d966d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c6ba13aa-81be-4721-92b4-0807486d966d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4c338732-c862-4d13-a9a8-c2267dd68da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_4c338732-c862-4d13-a9a8-c2267dd68da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_3a8d18d2-0e72-4e22-937a-96b4cc6e90c0" xlink:href="sesn-20220630.xsd#sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee_3a8d18d2-0e72-4e22-937a-96b4cc6e90c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_15fa0ef9-8240-4f99-9a42-5a06299da7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_d8054709-3062-44c5-9724-8a1f0a851b87" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_15fa0ef9-8240-4f99-9a42-5a06299da7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ce2be692-4cf8-423d-b601-cd900253d2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bbf2ad2-d5e6-4fe2-bd15-081c947b7087" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ce2be692-4cf8-423d-b601-cd900253d2bb" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_3bbf2ad2-d5e6-4fe2-bd15-081c947b7087" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_8d0c0d71-d4c1-432f-8a5c-5cd679172f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1e1f0c64-77df-46a1-829f-efa26d24f212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d0c0d71-d4c1-432f-8a5c-5cd679172f62" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1e1f0c64-77df-46a1-829f-efa26d24f212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e8baa4f7-0e46-4a13-b902-2dcbdbe84227" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d0c0d71-d4c1-432f-8a5c-5cd679172f62" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_e8baa4f7-0e46-4a13-b902-2dcbdbe84227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_99470548-6dfb-490c-a2fa-0ef6046d246d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_8d0c0d71-d4c1-432f-8a5c-5cd679172f62" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_99470548-6dfb-490c-a2fa-0ef6046d246d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofPretaxIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_124ec28b-fc17-444b-8a44-a3b24bb9fd86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_124ec28b-fc17-444b-8a44-a3b24bb9fd86" xlink:to="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:to="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0dc196d8-dd58-40d1-934c-25bb4c516573" xlink:to="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_4c1f8c8c-85fd-4511-8b6a-3101f238df83" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:to="loc_country_US_4c1f8c8c-85fd-4511-8b6a-3101f238df83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CA_779a0740-53c0-49ab-9ff8-e8256cebde3e" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_645abda3-a6fa-4fcd-8e3a-6a08d8490424" xlink:to="loc_country_CA_779a0740-53c0-49ab-9ff8-e8256cebde3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_38f599a3-29c6-41a6-b01d-cb94d524c972" xlink:to="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fef6b490-4937-4605-a4bb-c65799e61b75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_fef6b490-4937-4605-a4bb-c65799e61b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3f62956a-1f58-4231-8a66-7c5e953e12b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3f62956a-1f58-4231-8a66-7c5e953e12b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0efa284a-a4e5-4bff-8925-431feb94bbd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_937c6870-2ba9-448c-a1ee-1998edef0cba" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0efa284a-a4e5-4bff-8925-431feb94bbd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofIncomeTaxProvisionsDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0f577105-5515-42e4-a527-eac5f1b6046f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c8cfd0a2-0fbe-4ac2-9366-63aa48eb6b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0f577105-5515-42e4-a527-eac5f1b6046f" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c8cfd0a2-0fbe-4ac2-9366-63aa48eb6b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_38ce22b3-159e-4240-9adc-2a7bd3e44c39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c8cfd0a2-0fbe-4ac2-9366-63aa48eb6b7c" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_38ce22b3-159e-4240-9adc-2a7bd3e44c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_66d305bd-aeec-4056-aff8-6c50bf24517b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_c8cfd0a2-0fbe-4ac2-9366-63aa48eb6b7c" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_66d305bd-aeec-4056-aff8-6c50bf24517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c738b27c-e12e-430f-b6a8-d46e9a7b0998" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b26b19c-f769-4383-8b21-caffc87db29c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c738b27c-e12e-430f-b6a8-d46e9a7b0998" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b26b19c-f769-4383-8b21-caffc87db29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_3e2dd21b-01a8-4b7d-a890-246c39d046b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b26b19c-f769-4383-8b21-caffc87db29c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts_3e2dd21b-01a8-4b7d-a890-246c39d046b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_4dd7c113-05ad-4a67-87da-1d815f14458a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_8b26b19c-f769-4383-8b21-caffc87db29c" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_4dd7c113-05ad-4a67-87da-1d815f14458a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#INCOMETAXESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_84624f71-2bd2-42c8-9f6c-5afd2e5eb2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_84624f71-2bd2-42c8-9f6c-5afd2e5eb2eb" xlink:to="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2cada7f3-939b-4d41-a4c2-85e2ea1bcea3" xlink:to="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ViciniumMember_c68af3e8-fc0a-4e7a-9338-8a8fdee964e8" xlink:href="sesn-20220630.xsd#sesn_ViciniumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8041001f-56fd-46bd-9e85-3b2f42968d62" xlink:to="loc_sesn_ViciniumMember_c68af3e8-fc0a-4e7a-9338-8a8fdee964e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b821ce9c-946a-4780-86c4-0eb6d7b85003" xlink:to="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_6c7d1f25-ffde-43f8-ade7-201d6af3ab68" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_adaa0faa-1a81-404b-a22f-e7758620e1eb" xlink:to="loc_srt_EuropeMember_6c7d1f25-ffde-43f8-ade7-201d6af3ab68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_03c0f832-de5f-4620-aeb7-d7d8c8951a8d" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_63ce9af7-c00a-4860-86a8-f708b07c264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9a7204ab-568a-4f5b-bee5-f9f79e8e0675" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_63ce9af7-c00a-4860-86a8-f708b07c264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:href="sesn-20220630.xsd#sesn_IncomeTaxesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesTable_492a1096-d760-4c3a-b7d9-4f01692615fd" xlink:to="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_865c1068-9d1b-4d06-8ca7-0a22373aec18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_865c1068-9d1b-4d06-8ca7-0a22373aec18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsCurrent_2a6bd6d8-a903-4634-b56b-dbe308258722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IntangibleAssetsCurrent_2a6bd6d8-a903-4634-b56b-dbe308258722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d5b98473-6a86-45cc-8ad1-851c30952f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_d5b98473-6a86-45cc-8ad1-851c30952f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_5a69906a-3a60-4143-9839-8d22dcc1e714" xlink:href="sesn-20220630.xsd#sesn_IncreaseDecreaseInDeferredTaxLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_sesn_IncreaseDecreaseInDeferredTaxLiability_5a69906a-3a60-4143-9839-8d22dcc1e714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_64d823f5-7a41-4a54-8ccb-d42683a63828" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_IncomeTaxesLineItems_ce53fdc7-7040-4b1e-a62b-65859737d95c" xlink:to="loc_us-gaap_IncomeTaxesPaid_64d823f5-7a41-4a54-8ccb-d42683a63828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_846606c5-b721-4cd4-bacd-26e9643590c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementTextBlock_534b00f7-8ddc-40a9-a51b-cd2d659b2464" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_846606c5-b721-4cd4-bacd-26e9643590c9" xlink:to="loc_sesn_LicenseAgreementTextBlock_534b00f7-8ddc-40a9-a51b-cd2d659b2464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#LICENSEAGREEMENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_644958a6-b0ac-46be-b17f-ed75d70a4f04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_644958a6-b0ac-46be-b17f-ed75d70a4f04" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4b86b84d-a1f5-46c8-be37-324dd077146a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_UniversityOfZurichMember_6864dd40-ca6c-44ea-b8e2-0b0223829d53" xlink:href="sesn-20220630.xsd#sesn_UniversityOfZurichMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_UniversityOfZurichMember_6864dd40-ca6c-44ea-b8e2-0b0223829d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MicrometAGMember_57be7119-d40b-4886-814b-080374e9dba5" xlink:href="sesn-20220630.xsd#sesn_MicrometAGMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_MicrometAGMember_57be7119-d40b-4886-814b-080374e9dba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_XOMAIrelandLimitedMember_d586a69e-c009-4236-8efa-965a72bda632" xlink:href="sesn-20220630.xsd#sesn_XOMAIrelandLimitedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_XOMAIrelandLimitedMember_d586a69e-c009-4236-8efa-965a72bda632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RocheMember_e82c6a6d-031c-4e67-98ab-a0404709a3cb" xlink:href="sesn-20220630.xsd#sesn_RocheMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_RocheMember_e82c6a6d-031c-4e67-98ab-a0404709a3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_5313ec17-7238-4dd1-8c14-e7a46fdb6b6a" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_5313ec17-7238-4dd1-8c14-e7a46fdb6b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_MENALicenseAgreementMember_5126f679-51bb-4f77-8730-dc0bb936fb46" xlink:href="sesn-20220630.xsd#sesn_MENALicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_MENALicenseAgreementMember_5126f679-51bb-4f77-8730-dc0bb936fb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_20e81728-0176-447d-b159-df5a8f02c093" xlink:href="sesn-20220630.xsd#sesn_EczacibasiPharmaceuticalsMarketingAgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_143efac4-10a1-4718-9d48-cb5487494465" xlink:to="loc_sesn_EczacibasiPharmaceuticalsMarketingAgreementMember_20e81728-0176-447d-b159-df5a8f02c093" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_2d85a841-3ec2-4668-8bb9-6de102d8ac24" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_8ffc19ad-11fd-4d86-b4ff-3730d05bcc92" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember_8ffc19ad-11fd-4d86-b4ff-3730d05bcc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_FirstIndicationMember_a7589e63-e8d8-441f-9553-643aea372867" xlink:href="sesn-20220630.xsd#sesn_FirstIndicationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_FirstIndicationMember_a7589e63-e8d8-441f-9553-643aea372867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_7b5a2149-bdb9-461c-b47a-2f468599f122" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember_7b5a2149-bdb9-461c-b47a-2f468599f122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_8cb6f348-6ee0-4bf2-9ea9-dff95f088b8e" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember_8cb6f348-6ee0-4bf2-9ea9-dff95f088b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_e4055132-7490-4aa0-a4cc-3bb3ee41c61d" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember_e4055132-7490-4aa0-a4cc-3bb3ee41c61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_1a1735b9-8cd6-4352-b2c8-1d3a177a082a" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember_1a1735b9-8cd6-4352-b2c8-1d3a177a082a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_SecondIndicationMember_b70ffd26-bed8-410f-ae08-238d40266312" xlink:href="sesn-20220630.xsd#sesn_SecondIndicationMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cb1e4df9-aead-44cb-b4be-7bf9bbd70282" xlink:to="loc_sesn_SecondIndicationMember_b70ffd26-bed8-410f-ae08-238d40266312" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fe0ca3de-aef6-4612-aaed-bb46c769c860" xlink:to="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_EBI031Member_bb030fb3-1e3e-4045-bc11-b0b777935f4a" xlink:href="sesn-20220630.xsd#sesn_EBI031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1bcf0f68-5688-47f8-8c6a-0699d5390e77" xlink:to="loc_sesn_EBI031Member_bb030fb3-1e3e-4045-bc11-b0b777935f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_24c53ea9-854e-42ef-80ab-385b207cd43c" xlink:to="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_e91f2d0e-fc86-4dce-8472-1e256f0c4b7c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:to="loc_srt_MinimumMember_e91f2d0e-fc86-4dce-8472-1e256f0c4b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_25a68084-258c-4246-b2d5-e4f8b28bd7d2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_811cb664-2e9d-4fb3-b488-2c7359dc2bac" xlink:to="loc_srt_MaximumMember_25a68084-258c-4246-b2d5-e4f8b28bd7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0cf60641-0f02-4dab-8ad5-a66381ac7549" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_QiluPharmaceuticalCoLtdMember_d1297df4-f8e4-42ad-8bd4-0cf11457961e" xlink:href="sesn-20220630.xsd#sesn_QiluPharmaceuticalCoLtdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6e4ae3e0-9f11-49f9-881c-990e1d9c06f8" xlink:to="loc_sesn_QiluPharmaceuticalCoLtdMember_d1297df4-f8e4-42ad-8bd4-0cf11457961e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9618bda0-a1f3-440d-9d9c-90b49fe8a53a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_965bcc44-ba7e-4524-a600-0e8d7c4e2895" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f0a552b0-2f6a-4aec-ad8c-c198d1dad0e1" xlink:to="loc_us-gaap_LicensingAgreementsMember_965bcc44-ba7e-4524-a600-0e8d7c4e2895" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_6d35e4eb-b99d-4f76-8aaf-115f51eb4e65" xlink:to="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_TR_01c79562-0136-4fa3-8b7b-c3e2232e6710" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_TR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_248b3d57-deec-4b96-ac6c-fcaf58215998" xlink:to="loc_country_TR_01c79562-0136-4fa3-8b7b-c3e2232e6710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_03f4ec90-39d5-49cd-88c1-40fbf9aff182" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_64bb83a0-5d41-442b-b2b2-525455d97597" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_e2d32afd-85a9-452f-93e6-5e26653a4219" xlink:to="loc_us-gaap_SubsequentEventMember_64bb83a0-5d41-442b-b2b2-525455d97597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:href="sesn-20220630.xsd#sesn_OrganizationAndBasisOfPresentationLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationTable_81cd522b-f200-49db-a8a0-128e712b9aa7" xlink:to="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_14e69c8c-3226-4af7-9e44-a87336f43582" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone_14e69c8c-3226-4af7-9e44-a87336f43582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_224f58ec-819b-4dc1-9979-1f57ce9692f0" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales_224f58ec-819b-4dc1-9979-1f57ce9692f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_cd7d1f68-db11-4bb4-8cb6-f809cd7c8dcb" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed_cd7d1f68-db11-4bb4-8cb6-f809cd7c8dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_7ed0c2fb-42eb-4970-8077-a79dc735953f" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum_7ed0c2fb-42eb-4970-8077-a79dc735953f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchievementExpense_c89ab664-3ef2-4cc9-ba4d-740befa9d455" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchievementExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchievementExpense_c89ab664-3ef2-4cc9-ba4d-740befa9d455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_38b61400-d40a-4fc2-9580-0a92010532f5" xlink:href="sesn-20220630.xsd#sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments_38b61400-d40a-4fc2-9580-0a92010532f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a6be1301-62f7-4a0f-a6c3-060b40b4885d" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent_a6be1301-62f7-4a0f-a6c3-060b40b4885d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseMaintenanceFees_980b06bd-cc78-42b9-8a54-601abb1f707f" xlink:href="sesn-20220630.xsd#sesn_LicenseMaintenanceFees"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseMaintenanceFees_980b06bd-cc78-42b9-8a54-601abb1f707f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementUpfrontFee_8d79f36b-c35f-411b-a6c5-180d845bc0f1" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementUpfrontFee"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementUpfrontFee_8d79f36b-c35f-411b-a6c5-180d845bc0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementAdditionalUpFrontFee_9ea338b0-9e2b-4333-82fd-8dff7e0db1ec" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementAdditionalUpFrontFee"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementAdditionalUpFrontFee_9ea338b0-9e2b-4333-82fd-8dff7e0db1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementMilestoneAchieved_54db2e98-ea03-48fc-8e73-19b3b3bc0f65" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementMilestoneAchieved"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementMilestoneAchieved_54db2e98-ea03-48fc-8e73-19b3b3bc0f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_AccountsReceivablePaymentTerms_da54c8cd-a03b-48b3-9a16-621689b3896f" xlink:href="sesn-20220630.xsd#sesn_AccountsReceivablePaymentTerms"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_AccountsReceivablePaymentTerms_da54c8cd-a03b-48b3-9a16-621689b3896f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97ca15c2-5953-4a3c-9eca-ca0814ba11a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax_97ca15c2-5953-4a3c-9eca-ca0814ba11a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_06be2752-88c1-409f-bf79-877955cb25d8" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementProceedsFromMilestoneAchieved"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementProceedsFromMilestoneAchieved_06be2752-88c1-409f-bf79-877955cb25d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementRoyaltyRate_e6b22608-b476-4607-8445-2d0527aa4cac" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementRoyaltyRate"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementRoyaltyRate_e6b22608-b476-4607-8445-2d0527aa4cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementOptionPeriods_a46eace7-91a2-4229-8957-cded6a299601" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementOptionPeriods"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementOptionPeriods_a46eace7-91a2-4229-8957-cded6a299601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_027c4a10-c51d-4b18-865d-3a3785e86dbd" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod_027c4a10-c51d-4b18-865d-3a3785e86dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_d1e5660f-a87b-4773-8053-44dd5ef7fb59" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised_d1e5660f-a87b-4773-8053-44dd5ef7fb59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_d51f2b72-fc86-4616-bb2a-eb713671497a" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod_d51f2b72-fc86-4616-bb2a-eb713671497a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_0da90710-fc16-429e-b7ab-e51b3f28c794" xlink:href="sesn-20220630.xsd#sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct_0da90710-fc16-429e-b7ab-e51b3f28c794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_89eb3482-b7e6-4875-b6cb-32dcc4277483" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_89eb3482-b7e6-4875-b6cb-32dcc4277483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_f1697a52-a3a6-43dc-baab-c8f46634305b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_PaymentsForRestructuring_f1697a52-a3a6-43dc-baab-c8f46634305b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_9352bff0-7b66-41ad-9182-fbc65e236e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_9352bff0-7b66-41ad-9182-fbc65e236e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_cb7cc93d-9566-4a93-b9fd-e21567a10a20" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount_cb7cc93d-9566-4a93-b9fd-e21567a10a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_6389cba4-83c1-4a9a-be5c-847410c39183" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationRoyaltyPaymentPercent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationRoyaltyPaymentPercent_6389cba4-83c1-4a9a-be5c-847410c39183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1d9d6dc7-1fd0-4830-b070-10b4aa2c2531" xlink:href="sesn-20220630.xsd#sesn_CollaborativeArrangementRoyaltyPeriod"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_CollaborativeArrangementRoyaltyPeriod_1d9d6dc7-1fd0-4830-b070-10b4aa2c2531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_5cb9f132-e802-4bce-ac99-5d0b1112ee44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_5cb9f132-e802-4bce-ac99-5d0b1112ee44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_BusinessCombinationMilestonePayments_4b84ca25-d6e6-4b93-ac3f-551db57a1637" xlink:href="sesn-20220630.xsd#sesn_BusinessCombinationMilestonePayments"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_BusinessCombinationMilestonePayments_4b84ca25-d6e6-4b93-ac3f-551db57a1637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_RoyaltyRevenuePercentage_44fe1ee0-09bd-4f97-89d4-a3a85c092410" xlink:href="sesn-20220630.xsd#sesn_RoyaltyRevenuePercentage"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_sesn_RoyaltyRevenuePercentage_44fe1ee0-09bd-4f97-89d4-a3a85c092410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredRevenue_05138008-3019-45d2-8fde-cb0e61d59d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredRevenue"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_sesn_OrganizationAndBasisOfPresentationLineItems_81e424e9-a40e-47b2-a8cd-5781999a97f0" xlink:to="loc_us-gaap_DeferredRevenue_05138008-3019-45d2-8fde-cb0e61d59d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIES"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e2a139a-9387-483d-b634-dff0616b8e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7de92627-e1d4-43ab-99f2-d1e33e9b61eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3e2a139a-9387-483d-b634-dff0616b8e2e" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_7de92627-e1d4-43ab-99f2-d1e33e9b61eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESTables"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ed0e9998-73ba-4c80-a76b-c505696ec6ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_14b457ef-8060-4de4-aaa0-3776bf12eadf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ed0e9998-73ba-4c80-a76b-c505696ec6ae" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_14b457ef-8060-4de4-aaa0-3776bf12eadf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c905d55-bd66-4f6b-b194-cd015bf60ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce76a2a2-f484-43c3-b74d-438e7b115c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c905d55-bd66-4f6b-b194-cd015bf60ab7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated_ce76a2a2-f484-43c3-b74d-438e7b115c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0ab0d67a-a56d-41cf-8f4c-d1344e96eea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3c905d55-bd66-4f6b-b194-cd015bf60ab7" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_0ab0d67a-a56d-41cf-8f4c-d1344e96eea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#RESTRUCTURINGANDRELATEDACTIVITIESDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b0f0689d-44d3-4f2c-ae1e-96419f7bc09b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_cfe0fcc4-aacf-497c-bfe8-565a96190949" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b0f0689d-44d3-4f2c-ae1e-96419f7bc09b" xlink:to="loc_us-gaap_RestructuringReserveRollForward_cfe0fcc4-aacf-497c-bfe8-565a96190949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_7514c1d8-3ab1-4307-b95b-c091259482a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cfe0fcc4-aacf-497c-bfe8-565a96190949" xlink:to="loc_us-gaap_RestructuringReserve_7514c1d8-3ab1-4307-b95b-c091259482a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_25090832-203d-4ede-a32a-f5bf5e0180c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cfe0fcc4-aacf-497c-bfe8-565a96190949" xlink:to="loc_us-gaap_PaymentsForRestructuring_25090832-203d-4ede-a32a-f5bf5e0180c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_4470db66-3270-4c13-9cdb-17e6fdbf8f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_cfe0fcc4-aacf-497c-bfe8-565a96190949" xlink:to="loc_us-gaap_RestructuringReserve_4470db66-3270-4c13-9cdb-17e6fdbf8f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTS"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTS" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_762d97e1-43ca-4b49-b02c-fe53fece1f86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_46056932-0deb-45ad-b418-5e351fb39318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_762d97e1-43ca-4b49-b02c-fe53fece1f86" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_46056932-0deb-45ad-b418-5e351fb39318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="simple" xlink:href="sesn-20220630.xsd#SUBSEQUENTEVENTSDetails"/>
  <link:presentationLink xlink:role="http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_ce5033b6-3a85-41a7-8f43-a42de8ac1447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_ce5033b6-3a85-41a7-8f43-a42de8ac1447" xlink:to="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_01f39612-85e8-4045-a877-90f1ffd5ba56" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2cc76e87-5790-4d9d-91c8-f1d632545594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_9cbc4f92-fd77-4a0a-9f9d-59be9af20b5e" xlink:to="loc_us-gaap_SubsequentEventMember_2cc76e87-5790-4d9d-91c8-f1d632545594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_716600e9-2436-46e0-9c2d-59df8bc3939a" xlink:to="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_934dae32-8144-443b-aa04-af52623da2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_934dae32-8144-443b-aa04-af52623da2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_2b29c992-c6c9-4bd2-ac50-07992c0a3e17" xlink:href="sesn-20220630.xsd#sesn_ProceedsFromExecutionOfAssetPurchaseAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement_2b29c992-c6c9-4bd2-ac50-07992c0a3e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_sesn_OtherReceivableAssetPurchaseAgreement_122e8230-e359-49dc-8961-f6c40e6fc18d" xlink:href="sesn-20220630.xsd#sesn_OtherReceivableAssetPurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_325f64a5-2c03-45fe-aab0-f589e085d805" xlink:to="loc_sesn_OtherReceivableAssetPurchaseAgreement_122e8230-e359-49dc-8961-f6c40e6fc18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>sesenbio_minorirosales-e001.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** /+-5@:VU6ZB88*R''TSD53KM
M_%FBO<H+^V7=(BXD4=67U^HKB*]JA452":/@L?AI8>O*+V>J]#E?%TQ\RV@!
M^4 N1^E<VK%6#*2"#D$5TWBZ YMIP..4/\Q_6N4G<QP.XZ@<5[N%LZ2L>C@O
MX,;&NOB0^5Y  :Y4<L>GU^M9\UW<3G=+*[>Q/'Y5@6S-]K0YY+<UL]:ZU3C'
M8^NPM24Z?O;H[:WD8PQR D,5!R#S7?>"?$=U/>_V9>2M,K*3$['+ CMGTQ7
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MH **** "BBB@ HHHH **** "BBB@ HHHH X7XG>/3X)T>(6B+)J5X2L <95
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MW:9NLL>8V/XJ17GWQAT3QQJ$YDLGDN]" !%K: AT(QRZCEN>01G'H*Y'P_\
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M0%/WL^XQ7TBH*H 6+$#!)[UCB.:+Y7.X(^-/%'_(TZO_ -?<O_H1KZX\-?\
M(KZ5_P!>D7_H(KY)\4*W_"4ZO\I_X^Y>W^T:^MO#7_(KZ5_UZ1?^@BNC&_!$
M2-2O'OV@O^1>T?\ Z^V_] ->PUX]^T%_R+VC_P#7VW_H!KFPO\:(V8'[/W_(
MPZO_ ->B_P#H8KZ KY__ &??^1AU?_KT7_T,5] 56,_C,$%%%%<HPHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *HWVBZ5J?_ !_Z;9W6/^>\"O\ S%7J
M*:;6P&+!X0\-6SAX= TQ''(9;1,C]*V$1(T"(JJHZ!1@"G44-M[@%%%%("C>
MZ-I>I?\ ']IMI=?]=H%?^8JG#X0\-6\GF0^']+1^H9;1,C]*VJ*I2:TN!4O+
MRQT?3Y+J[EBM;2$ N[?*JC./YD58AFCN(4FB</'(H96'0@]#7(?%>-YOAEK4
M<:,[F-,*HR3^\6N#\.:WJ2:OX:MM$UC5M1GE"IJEE=VY2*WC &2,J N.<8)S
M@5I"CSPYDQ7/;64,"& (/4&LBZ\*>';V0R7.A:;-(>2[VJ$G\<5L45DFUL,Y
M_3(?"EMK5QIFF6NF0ZE;*'FA@@5713T)P/>N@K@M$N;Y_C%XDMY WV-+2 QG
MRP 3@9^;'/?O7>U516:!!2$!@0P!![&FREUA<Q*&D"DJ#W/:O!V\3^)1:27#
MZUJJ^+Q=;$T46A\@KNQC[N,8S\VZJITG4V8FSV2Y\*^'KV0R7.AZ;,YZL]JA
M)_'%2V7A[1=-;=8Z38VS?WH;=%/Y@5>@:5K>)IE"2E 74'(#8Y%25'-+:XPH
MHHJ0(C;0$DF",D]R@J4    8 [444 %,DBCE $D:.!T#*#3Z* (XX(8B3'$B
M$]2J@5)110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3P .E '845ROPXO-0U#P%IESJ<LLT[J^V:48>6(.PC=O<H%/OG-=50 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M)K=Y(TR&6-6 S\C-CW&*GCOW\5^-]+UFVT[48=,T.UN)&EN;5X6FFE4+L16
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M0+;1CG<.#4,GCGQ#<VVOW6E:!9RVVAW=Q!.UQ=LAF$7)$8"'YMO)S@<@<\X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#S)?!]YK%E\0+&X@DMVO]0\^PF<;<NJ(4=3Z!U'/UK,DT#Q!JOP
MQ\5ZKJ>G3#Q%K:JOV0+\Z1QX1$ _!F_X%7L%,DFBB*"21$+MM0,P&YO0>IH
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MHJH29@$B!*^O(/Y5ZS10!P9\::U)IJ6FD>"M=;4/+"1M?1)! K8QN9BYX'7
M&36WX(\-OX5\*VNF3SB>[R\US,.CRNQ9B/;)P/85T-% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'!GQCXCOA?:GHNA6U[HUE=/;%/.;[5<[&VN\2A=N <X!.3M[5+K4\>H?$K1+
M:0[;71[&;59]PX#-^ZCR/4#S#^%96ES^)/"&GW_AVQ\.75[=F^FDT^[^7[*T
M<LA<-*VX%2NXY&,G''6M?0M&N[_4_&%_J<+V[ZC*+&'<I'[B./:'4'LS,Y%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO!O!/FEO,!5ATV_)^IKBKKQ%K5QX*\!7FA6^G:9#J&I0Q-;0[XT5MSD)A?\
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MH)/2H-$\/^(] L/#&HKHLL]WHB7-A=VBS1!IX7((EB.[;@$#@D'K0!-XQO\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@_W>2*ZO29;^?2K:75+:.VOF3,T,3[U1O0'O0!<HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M%BN,G;D$XSQS78V6HVOBSXH6&IZ-(;G3M,TZ:.>[12(VDD9=L8)') 4DXZ4
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M%+V=G"%60A1ERQ9@JA>A.>I&,U6\-1LOQ-\<N4(#?8,,1UQ"U><Z+9):>&_
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MF<3NH^7?M.?UK+T[7+/P[\.-6\(7ZRC7X_MEM%9"%F>Z,KN8V0 ?,K!QS]:
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MV\9<QP)O=_0*.Y)XK!L?&I-Y=V>MZ/=:/<6]DVH!99$E#P*<,04)Y!QE?<4
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MP#N4KG.!U)QS44'Q O;F\OM*A\)Z@VMV1#3V0GBVK&1E7\W=M.<X '.<^AH
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M"RFOI[A.MM;QJ3GV9V 0?\"/:NPT262?0=.FE<O)):Q,S,>22H))H O4444
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MV9TS"1)LRJ=7 .,D8ZXYP:2364\2_$GPG>Z;:7KZ?;17H>ZEM9(DWM&OR_.
M>,=>G. 20<8;:=>_\,YWEE]CN/M1DFQ!Y3;SF\)^[C/3GZ4 =M8>,KF;Q+9Z
M1J6@W.G#489)K&:29'\T( 6#*OW&P0<<UCGXIO\ V&VO#PW=G1K>=H;RZ\]
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MW?POUR"VADFF>) L<:EF;]XO0#DT .N?&(TZ[T;1]/T:XO+F_P!/^T6L:S
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M'FU3^SHHY+MA=+$PW@L%C4@[VP,]1Z9K FU?48?BO?'2])EO;FXT2V=8)I1
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M+ALHGXN5^4,[?OL;<DD8&W/&,YJQ\2]?UCP_H=G+I$"O)/?00O*90I3,B_*
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M=RI 7G*D8QUJ;2_%VH3:M86.M: VEC4HW>RD^U+-N*KN*. !L;;DXY'!YXH
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M!N*G+-AL# Z<FJ<OQ$1X/#SZ?I%Q=S:WYZ10>8$:*6(?,C9XX.X$YXVD\]*
M.VHKSS4O'>KKX<\5I_8JV6MZ+;B1XA=B1 CHS+*K[1NQM)VX'3%=/X0O]2U+
MPO87>JVRP7,D*,<2B3S 5!WD@#!.2<=J -RBN/C\9:E=:C<?8O#<UUI-M?&Q
MENX[E3*'5MC,(<9*ANIW9P"<5SFCZ[K&F:UXV&EZ$VJ>3JKS2E[H0*J^3'A5
M)!W-P>, =.>: /4Z*Y-O&%Y?:7HMWX?T*?47U2#[0OF2^3% @ )$DFU@&R<
M '.#Z5QGQ*\0?V_\)?MHMY+.XCU2.VN+=G#&*6.4JZ[AP1D=>XH ]?HKSC56
M;_AH#0%W':=&F.,\?>:K_P 6+C[)X+2X(<B+4;-R(QEB!,I( [F@#N**Y&R\
M87R>(K?2->T/^RFO(9)K.47:S+)Y8!=6P!M8*<]QUYJM8^/KFY.FWUQH,EMH
M6IW"P6E\;D,Y+G$;/%CY5<XP<GJ,@9H [>BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Q
M2T\.:/96UUH.L>']?OM4-[*B1P372V]S$\I99-RL(E4*PW9QR#QFNZ\.V5Q;
M_$?QC.]O*EO-'8"&5D(63;$X.TGKCC.*[&D) ZD#ZT >0C2=2_X9W@T[^S[K
M[<)(R;;R6\P?Z:&^[C/W>?IS6G;:_%H'Q2\9R7=I>RVTD5CF6UMGGV.(FPK*
M@)&<G!QCCDC(KTLD @$@$]*RK#08;#Q%K&L),[2ZF(!)&0-J>4I48^N: /)]
M3T#6&\ Z$[:7=BZNO%0U*2V6(L\$;O(PW@?=P",YZ9YKKOMC>#_'WB*]U"RO
MY;#6$MYK>XM+22X >-/+:-@@)4\ C/!R>:] HH \LC\*:A??"_69)H'LM5NM
M1GUNSBDX>WD\SS(P?0X !]-QI-$BN_$/P]\7^*I;207WB"TG^SP*"S"%(FCB
M0 =23N/'7=7<>(]!?Q+9K9#6+NRLVW)=1VFP&X0XRI8@E>_W<=36M:6L%C9P
M6EK$L5O!&L<4:]%4#  _ 4 >?ZGI]Z_AKX<Q)9W#26NH6+W"B(DPJL#ABPQ\
MH!(!STJ#Q;X>U#7/%7B>WMK>7%WX92""4J1&THED(3=TST_ UZ;10!YAX7L/
M#]WKNE/:>'_$"7ULK2S2W\MT([*385Q^];:[') VYXYJK'I>H#]GF_T[[!=?
M;FBN@MMY+>8<W#D87&>00:]9HH \\D>72OC#:7EQ97K6E[H<5E'/#;/(BS>>
M25<J#MX(.3@8KL-%UN+6XKN2*WN(/LMW):.LZA260X+#D_*>H]JTZ@M+*WL4
MD2VC""25YGY)W.QRQ)/N: /.?'":;)K-Y))I>O66N10 :?J6DQ2L;GY<A"8P
M5X;@J_;O@UI>'+75A\0)KS5+:19I- LTGE"8C,X9RZ@],@GH/45W=% 'CZZ3
MJEI;MK TV[E_LWQA=WLEND)\R2W<LID1>K<,",=1G%:\Z3^-?%LVHZ=9W<6G
MVFC7-HD]W;O!YT\V,*JN 2 %Y.,9->DT4 >,OJ%WJ/P_\+Z!;Z'J_P!NTZYT
M]+X264B+"(G16.XC#<C/RYXR3C%:LNA:AJ'Q+\=(+::.#4-$2V@N'C(C9S'M
MP&Q@XS7J-% 'C5_JM[J?P[T3P]!H.KC4K*6QCOD>RD581%(@+!L8;)4$;2>,
MDX KV-T62-HW4,C AE(R"#VIU5[^">ZL9H+:[DLYG7"7$:*S1GU 8$'\10!Y
M1X-TF\;QLOANZ1FTWP?+-+;N3D2&?F 'W1&?Z<5K:7JLO@BY\2Z?>Z5J=Q-<
MZE/?V#6MG),ERLN&"AE!"L&R#NQV-=AX<\.6WANSFBBGGNKFYF,]U=W# R3R
M'N<  <   < "MF@#R'3-+O? I\"W.I6=W+!::=<VMXUI TYMY)"K@,J G&05
MR >172^!S>7'BKQ?J-QIUW90WES;O;BYB*%T$(4'GZ<CJ,X.#7<T4 ><>*E6
M7QR\>N66LWNF&QC_ +.M[ 3>5)/O;>',9 #8V8+D*!FN>\/V]_H>G>$=4N-)
MU#;H<]_9:C!';2.\0E8E9$&,R(,+EESP?8U[110!YKX@O]5\4:3#J]GH5XMI
MH^LVU[;1R1LEQ>Q)_K"L3 $?>.T'DXI_B+4+[Q]X;UW2M(T>\6S%FKQW-W&]
MNTTZN&\I%< XPN"W&"<>]>CT4 >;>&++P[=>(K.YTW0=?2XM89)'N=1DNE2U
M<KM*8F;#,0Q'RY QG-<GI&JSZC\#;7PK:Z5J$FJWT!M[?;:N865I3^\,H&P*
M 3G)R".G>O=",@CUK*\,Z%#X9\.66C03/-%:(4620 ,W)/./K0!R=N)-$^+T
MIN+2]>VOM*M[:WN8K9Y(RZ.V0S*"%XYYQ5SXI6US/X3@EMK6>Y-KJ-K<R1P1
MEWV)("Q"CDX%=M1TH XC2VDU#XHR:Q%:W:6,^@1(DLUN\?S>>YVG<!AL8.#S
M@UQ'BO1M4G^&/C>UATV\DN+CQ')-#$D#%Y$\R,[E &2O!Y''%>V@@C(.0>XH
MW*6*Y&1VS0!YUXVCTB75\ZCI>NVNH16RBQU;2(Y6D<G.8\Q@X(/\+\<_6NO\
M/KJ4_A+3EUK*ZE)9H+K@ B0J-V<<9SZ=ZUZ0$'H0?I0!X]%<7UI\+)? 1T;4
MFU\02:>B+:/Y+AF($PFQLV;3G).>V*W+O1[RV^*_@YDMYY;6STN>"2Y6,E%;
M;@9;H"?>O1J* . TS3[L?&KQ%=R6LZ6DVEP1I<&,A&8$9 ;H2/2N3\/>'-&M
M-/T_P_J?A[7[G6H+A89HQ-=+:E5DR)]V[RMF &P.<\8KVH$,,@@CVI: .+\(
MV=S;^./&\\UM-%%<7=NT,CH560"$ E2>H!XXIGQ:ADD^'5]/$A<VDL%TR#NL
M<JLWY $_A7;%E! ) )Z9/6F31PW,4EO,J21NI62-N0RD8((]"* "":.YMXYX
M7#Q2J'1AT92,@US/Q*M;B]^'&O6UK!+//):E4BB0LS'(X ')K5\.Z(OAW2(]
M+ANII[:!F%N)N6BCS\L>>X7H"><8K4)"C)( ]30!P&B^/K2QT+3[2;0O$HE@
MMHXG T>8C<J@'^'VK&U?3=,MO&FL:IKFFZ]+;:I%;SV4FG_:1EEC"-$ZPD;7
M^4$;O4\\5ZSUHH \JO;5?#FL> -0AT/4+;3+."[2:WAC>Z>U:5%*JVW<QYR,
MU%<:==W>J?$7P\;.\CN=:7S+&8V[^3(/( YDQM'S#')KUJDR-VW(SUQ0!Y?X
M6L/#]UK6D&W\/>(%U"V!EGDOI;H164@0C_EJVUR22!MSP<]*W?A=9W-CX.:&
M[MIK>7[==-LE0HV#,Q!P>Q%=I10!P'Q&T^]\4W>C>$((KI-/O9C/J5W$AVQP
MQ\A-Q!7<S8P/8<8JEXL^&MY=^'II+3Q-K]W?V6+NQBN9XW3SH^5X" YZ@<]Z
M],HH \QM-8N[7Q;8>*[_ $75%M=5T2.WE2&RDDDMKA)&8HR ;@#N.#CG%<Y-
M#?ZQX,\:>7IMP+F7Q1%)]E1-\BKF \A<\A>3Z<UZGKGAN75;ZVU"RUJ_TJ]@
M1HA);%65T8@D,C@J>1P<9%3^'?#UMX;TZ2UMY9YY)IGN+BXN&#232M]YV( &
M> .!T H Y?XB:1%<ZQX>U:]M+^YTRS:>*[%@THEC$BKM<"(ARH* ''8]*Y_4
M/#5A?^%Y[[1M UE+>+5K>ZE2>:?[3?0QC:S(';S%(#MM'!.WZ5Z_10!Y1_9>
MC7>A^*KCP_H>M^:=$GMDN[UKDF9G5CY4<<Q+$Y5>0.IQ6IJFGWCZ+\.D2TG9
M[6_M&G41DF("!P2W'R@' YKT.B@#S#Q;X=U'7/$WBRWMK:7%WX<BA@E*D(\H
MDD;9NZ9Z?3-.\+V/AZ[\0:9+9>'_ ! E[;(TLLNH2W0CLGV;=O[UMKL=Q'RY
MXYKTVB@#R1=*U'_AG.ZT[[!=?;C#.!;>2WFDFX8CY<9Z<]*VI9)=+^,D5W<6
M5ZUK?:-%9Q3PVSR()1,258J#MX(.3@8KT&D)"C)( ]Z %KA=9_T[XR>&((>6
MTVPN[N?'\*R!8US]2#^5=U6/I'AZ#2M2U/4FFDN;_490\L\@ *HHPD:@=%4?
MS)- %C2=4_M:&XD^Q7=IY-Q);[;J/87V'&]?53U![UH444 <3XELKJ;XH^![
MJ*VFDM[<7_G2I&2D>Z$!=QZ#)X&>M6/%=I<W'BWP;-#;RR107\S2NB$B,&!P
M"Q'09('-=;D;MN1G&<49 (!(R>@H \_U6PO)/&?BN9+2=HIO#B0Q.(R5=\R_
M*I[MR.!SR*P]*LK*W^%OA2P\3>']3>%$<O/;PR^?8RACM)5!YBY!/(]!GK7K
MM% '*^ #J)\/S"^DOY(1=RBQDU%2+AK;C89,@'.=W49QBN8NM1D\._&35]4N
MM)U>XL[C3(88Y;.QDG4N#DC*C%>HT4 >=^)M1_X3SP7K&EZ9I6KQW*)'.L=Y
M9R6WF[)%?8K,!\QVXX]:;X7L/#MUXBAN=)T/7DFM[>0M=ZE)<JL#L IC"S-\
MS$$YV@@8Z]*]&I"0HR2 />@#P^VBOI/@;#HPTG4QJ.CW4+W5NUFX8@7)8[,C
M#X49^7.*V=9MM*NO%[>(M5T_79-)U*PB2"6TCNHWBEC=P4DCBPXW!@06&.#7
MJY(&,D#/2EH \M_L7R;CP"^FZ%?6-JFHW%Q-!,7E> .CG=(Q)*EB0>3P3CK7
MI\TJP022L&*HI8A5+$@#/ ')/M3Z* /*_"7@S4M<74/%>J:MKFBZEK%PTC6M
MLZQ&.%25B1PR$Y"_S%5F\)ZGH>I^)_#%J]_?:?XDTR:>&\N!N\N\VLK*[*H4
M;@0<G&< 5ZX&5LX(..#@TV:))X9(9 2CJ5;!(.",=1TH \?UO7Y]0\+^$]..
MC:E:SVVJ:<EX;NU:)(F5U7:K,,.2>FW/&2<<5U_A2RN8/'?CB>:VFCAN+FV,
M,CH560"$ E2>N#QQ3K/P L5SI_V[Q!JNHV.FRB:SL[DQ[4=?N%F"AGVYXR:[
M*@#Q/0O#6C66G6GAW5?#VOW>L17/D21I-=+;.@DR)]^[R@FW#8ZY&,9JU>:)
MI6F:SXCAUO1=?O;F\O9+JR%A)<B*Z20 [,QL$4AMP.['&#R*]BHH X72=*DL
M/B=&8;":"PA\-06T9(+(A69OW>_H2!COGO6/#IE^/A?X[M38W(N+B]U-H8O*
M;?*&8[2HQD@]L=:]2HH \BO=$L;#Q%'J'B#3]9DLKS2K5(I=/-SF*:,$-&ZP
MG.2"I!88X/3FM*QT?[-K?@%[#1+VPLXFOY989F:5K<R1DCS&)."Q.<$]3BO2
MZ0D*,D@#U- 'FFN:3J%WJGQ)6"RG?[9HT$5L1&<3.(I054]"<D# ]175^"-0
M34/"&F[;>[@>WMX[>1+JW>%@ZHH. P&1GN..M=#10!Y-K*Q?V_-<:%I>NZ5X
MJ-\JLD$4OV6\02 &20X\HH4R2>&!]Q71^&+.Z@N?&YEMIHQ<:G(\)>,CS%\B
M,97U&01D>E=M10!XOI]M-:Z/X/M/$5CK?]C)HY4VMG%/DW>Y<+*L?S?=SC=Q
MG-9NJZ3J+_"S5='AT348KN+Q!YXM1!)(1$\FY2K8.\ =2">G/6O>J* //]3L
M+Q_CGH=\EI.UG'I,L;W C)C5BS84MT!]JN_%"WO;GP@BZ?9RWERM_:R+#$N2
MVV92?H..2>!79T4 >;:A(WCCQIHHL;+4+>UTVWO#=3W=I) $>6+REC&\#<W)
M)QD<=:P_"^AZ-'!H>D7OAS7Y-;M98DN4>:Z%M"T9_P!=N+>44RH("]<@ 5[+
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 <+/X_O8X;K6(M$23PU:736TM[]JQ*0K[
M'E6/;@HK9_B!(!.*Y+Q3#J6N?&NRT^\T.RU"VM],>:VM)[YEC9?-(\X_(</V
MVX/0<TVT\*Z5817.BZIX/U?4M3-[*L<D3SK;7$3REE<R!O+0!6Y!YRO3FNLF
MTR]_X7E9:@EG/_9Z:"T!N A\L/YQ.W=TSCG% ')Z*NH:I\:/$-[K&B6,LFFB
MT.Z2^9AIZ;-VZ+Y/F)QN/W<'//-=C8^.]0G_ ++U&[T);;0=5G2"TNOM6Z8;
M^(FDCV@*K\=&.,C-4]'T2]E^(_Q!>>VGAM-1M[2*"X>,A)/W)5MIZ'!/.*P?
M"_AW28$T/3+OP9J[:U:21K=3223K;1-'_P M@Y;RV&5!"CUQ@4 =5<>.-6ED
MU&[TCPVVH:1IURUM/,EQB>5D.)#%%M.X*<]2,X.*@L?$7B&Z^*]]I8LX?[+A
MLH7VM<E2BLSD2[2GWSP"N1C'6J.E:EJ_@RTU?0X_#NI7]^VH3SZ<\,!-O.DK
M[E+RCA,;B&SC&*O0F]TSXO7-S=:;>O!J6FV\,=S;0-)"DBLVX,P'RCGJ>U &
M;H/C;3])\*7&JV'AY+/3QK[6=Z$N2?+W,JM<'*\\E<KQ]:['6_$PTG7M%TB*
MV$\^I/(7)DVB"&-=SR'@Y[ #C.>M<=X&\*7%[\/?$^AZO9S6OV_4;O8)XRIV
ML%VN >HR,@^U.\"Z7K6N7=]JWB2RN+.ZATV/1H!.A5FPN9I0#U#.1@]\4 :U
MEX\OYUTW4[C0U@\/ZG<);VUW]JS,-YVQN\>W"JQQT8D9&:Z;Q#K=KX;T"]UB
M\#&"UCWLJ#+,>@4>Y) _&O+O#'AO2K:'1M)O?!NKR:U:RQQW,SR3K:IY9_UX
M<MY;#Y0P4=SC KOOB#HMWX@\"ZIIU@H:[=4DA0G&]HW60+GWVX_&@"G;^+M9
MM-5TNU\1:##I\&JN8;::"\\XQR[2PCD&Q<$@'D$C(K.D^(>LRZ7J^JV'AF.:
MQT>XN(KMY+[8SB%B&,8V'/RC<<XZX&<4W4+ZZ\;ZOX:MK71=5LH[#4$U&]EO
MK5H5B\M& C!;[Y+-CY<C S3=/TK4(_AIXTLWLKA;FYGU1H(3&0\H<OL*CJ=V
M1C'6@#T"RNX[^QM[R'/E7$2RIGKM89'\ZXW7;);3XH>%KZ&>Z5[V2XCGC^T.
M8F"6[%?DSM'//2NBT.*ZM_!^FPK&$NX[")0DP(VN(P,,.HYZUQ]A?ZSXJ\4>
M&YKG0;[3;C2([B2_>Y@*0^<T7EA8F).\$DMD9X H TO^$SUBWO;.;4/#AM-'
MO+X6,4TEQ_I"LS%4=XBHPK$#^(D @U'+XUUNZOM=M=&\.173:/<&.9Y[WRED
M&Q6&SY#\QR>.@P.><5P2Z7.^DZ->2^&=<N/$-AJ5O=:O>3PRNQ"S OY621)G
MJ @P%';C/H7A:RNX;SQG+-:SQ+=ZBTL'F1E?,4P1C(SUY!'U% %C3?'$.JWO
MAJ&WLV$6N6,MXKM)S#L"':1CG[^,Y'2I)?%\RWGB:U@TB>ZFT7R!'% VY[EI
M4#  8^7!.">>,FN(TBUU+PY8_#W5+O2-1DAL;"XM;R*"V:26!G"%2T8&[&5(
MZ<47D/B"[7QOJ,&E:K:)?7.GND<:%+B6V4*LNS'\>P'@'(SCK0!V>G^*M3&J
M7FE:WI$-G?0V)OX?L]UYT<L8.T@DJI# X'0]:PH/B9JTWA+_ (2QO"X311'&
M[.;S,N"X61@FSE5R>3C.TG@5FZ5IT-KXTDO-(\,ZG9:7>Z-/:122V\FYY@RM
MEPV2@(& 6QD@^V>K\#:,S?"O2]&U:TDB+V)@N+>5"K -D$$'IP: -#7?$RZ5
M<:';6EN+VXU>[6")1)M CVEGES@Y"J,X[Y%7/$6GW^JZ'<6.FZBVG7$VU?M2
M+ED7(W;?1BN0#VSFO//AG9:C>Z[(VJ_.OA6%]%M9,Y$DF\[I!Z'RQ$OXFNY\
M9:KJ6C>%KN[T>PFOM1P$@BBB,A#,<;BHY(7)./:@#EK/2X/#GQ-TG3- NKUX
M9;.>75K>:[DG55 'E2'>3M8OD<8R,U2\9ZSJ&J>)=+_LZZE@TC2];L[6=HF*
M_:KAY5#)D=51>".[-C^&M'P?=6MJCZ9;:1XEAU*_W-<ZOJ&FLADEVGYW8\ #
MHJ]!P*QM9\!>(]+T+1=.T_Q%<7=O!JMLXC338RT1\W<9F(R6P26.>O>@#URL
M3Q-HEWK]G;64.I36-KYZO>>02LDT0!S&'!!7)QDCL,=Z?;ZL\/B"#P]<1SS7
M']G_ &HWI0+'*5<(PP.C9(; X 85D_$'5=7T[18(-&M+^6:\G$,MQ96QGDM8
MNKN%'\6.!GC)SVH Y7[9_P (;JWC!=!N+B;2=-T<3M%/.\Z07OS;45G)/*X)
M&?2G7NC/X/\ #VB^*8-1U"74UN+7^TI)KN21;M)65) 4)VC!?*X Q@5I:?;:
M=K'A#5/"&E:%K6EI/8S 7&I63Q"21AC<SG[SDD$]S@^E4;F[U7Q9HFB^%I-
MU2SNH[BV.J37-N4@B2%E9MDG1]Q0;=N>O.* -/Q-X5M#%KGB#Q)KEZ(XU+V1
M@NI+=+% O&U58!G+<Y.<D@8IUAH&L>*_#'A@Z_J%S!"EH)-1M(G:*2ZD*C;O
M=2" .25'4GVK)U759K_QO<OKOAWQ#<Z7I<P73K6VTYY(99!UG<]&.>%'0 9Z
MFKWC+Q!J6H66DVEGI'B&'3M0#OJ$MK8N;F*->!%@?<9SWZA>G6@"W\/=T6I>
M)K*SNKBZT&TO$BL))Y6EVML'G(KL22JMP.?6NVG:1+>1H8Q)*JDHA; 8XX&>
MU<GI7B*PT_PM>OI_AK6+&TTBWWI:S61@,B@$XC!^\>#GZ\]:ZJTN%N[*"Y52
MJS1K(%;J 1G!H X>^^):VOPZT_Q3!I37$]Z=BV(FP590YD&[;_"(W[<XJ_XB
M\4Q@V.EVEO\ :1JVGW-R90^/)A2+(;&#G)90.E<UHGAO4!\0KG2[O3YAH.GS
MWE[;3,A\J4W*H BGH=N^?\ZB\%:'K/E:Q)JUC<QRZ9I7]B6/F1D>>B%R77U#
M#R@".N* '^%?%^JZ+X&\*SW&A)_8;Q6MDUT;K$REL()/+VXV;O\ :SCG%;UK
MK6DP_$_Q% VEQV]U9Z='/<ZEYI)DCP#M*XP !WSVK*O-(U)_@SX;T];"Y-["
M=.\VW$1WILDC+97J, '/IBA_#NH:A\3O&>ZVFBL]1T1+2*Z:,B-G*A2 W0D4
M ;&E>,]:OWTN]F\,21Z+JCJMO<13^;-&K E'EC"X52,<ACMR,URWAWQ+K6A>
M'?$5[8Z#'>V%AJU_-=2R7?E,5$K,PC7:=V%Y))'H,UN^&?$6LP:9H'AU?#6H
MQW]LL5K?RW,)2WACC7:SK)]UR<#:!G.:@T_2M0C^&/C&S>QN%NKF?5#!"8SO
MD#E]A4=3NR,8ZYH ] M;R*\T^&]B)\F:)9E)'.TC(_2N6\.^+=8UTZ?>MX>6
M/1=1!,%U%=B22,8)4RIM 4'&."<$@&MW0(YK;PKID3PE9XK*)3$_RD,$'!].
M>*\]T:V4>*M*N/#V@:WH=U)<,VLVLL;I9"/8V[K\C-OV[2G7K0!2\)^+-7\.
M?#==0BT%;G2+"YN3=3M=;)"#<N6,:;2&"ANY&2".V:[S6=?UV"]>'1/#RWT,
M-L+B2XN+DP(^<XCC.QMS8&3T R/6N2AT;4Q\ M2TLZ?=#4'2\"VWE-YC;KB0
MKA>O(((]C2:MISW7BB^AUG0]4U17L[>/1XT63[,C;")-Y4A4._DEN<8QZ4 ,
M\6ZM!KVK_"_5K966&\OQ,BMU4,JG!]QTK0\/?\EX\8?]>-I_Z"M<_;:3JL^F
M?#"+^R-01]*O/+O1);.OD[0 6/'W?1NAKJM#TV^A^-'BK4);.=+*>SMDAN&C
M(20A5R%;H2* .FU_4]2T^.UBTG26U&[N9?+ :0QQ1  DO(^#M'&!QR2!7!>.
MM?FUSX0^+8[RR%E?Z?(MK<PK+YBA@\;!E; RI5@>0#6Y\0(9)=1T'[79ZE>:
M"))OM\%@DCLS[1Y6]8_F*9W>V<9KB+O1;]? GCW2+/PYJ%J]Y/%=65LL#/NB
M(B  89!<;3N4$D'- '<1>)-3MUTG0]$TF"^O!I,5Y+]HN_(41GY0%^5B6)!]
M ..>:LWGC"_,^DZ9INAL^M7]LUU):W<_DK:1K@,9& 8_>.T8'/M6'KUKITEK
MI%OKGAK6)'@T^+[+J6EQR-/#+C#1GR_F0C"D9RIR?2J^G1Z]H&J^'O$NMV.H
M7IDT9M.OC!"9IX6\P21LZ+DG(X8@'!ZT =GX9\22:W)J-E>V/V'5--F6*ZMQ
M+YB_,H9'5L#*L#D9 /6N8UF^U&T^,RII6GI>WDWA\*J2S>5&@%PQ+,V"0.@P
M 221]:U/!EK>7/B#Q+XDN;*XLH=4E@2V@N4V2^7#'MWLO5=Q)P#S@53UB>\T
M?XKKK+:3?W6F?V(+:6>UMVE*/YY8<#ENG(&2,@XQ0!-#\0I'T:5I-'9==CU(
M:5_9PG!5K@C<"),?<V_-NQT!XK8T#Q!>7VJ7VCZOI\=CJ=HD<Q6&?S8Y8GR%
M=&*J>JL"".,>]>=7GAJ^UFQO?$5WHM\]O-XA2_.G8:.Y>T6+R=P4$,'Y+;<@
MX'O78>"-.T>/4;^]TGPYJ&FQ>6D*W5^TJO/R25$<A+!5XY.,DG'2@#8F\2&U
M\<6WAVXM-B7EF]Q:W7F<2.A^>/;C@A2&SGI63J?Q"@TV[\0JU@\MKHRP1F6.
M3YI[F7&V%5Q[KDYXSTIOQ-@>WT"V\26X'VO0+E+Y.<%XP=LJ9_VD)_(5A'PM
MJEQ\)_.CM_-UVZO$UR:#.#)*95D,?/<( H]P* .EL_%6KV^OZ=I7B+18+ ZF
M'^R36UYYZ[T7<8WRBX;;D@C(.*9'X[W_  VNO%_]G8\A9V^R^=][RY&3[VWO
MMST[UGSW5QXR\7>&Y+32=3M+/2II+NZFO[5H,,8RBQJ&^\<L<XX '6N6E.K6
MWPJUGP9'X>U:75D-TH9;5O)=&F9PZR=&RK< 9)/&.] ':ZKXVU*'Q2GAW2-!
M6^OI-/2^5GNO*15+LK;CM. ,#IDDL..]=#XAUJ+P[X=O=7GB:5+6(R&-2 6/
M0#)Z<D<US=AIUXGQ:-^]I,MI_P (Y%!YYC(3S!,24STW8YQ73>('9- O2NE_
MVJ/*(:RR,S*>&49X)QGCOT[T <W?>)/%5KH>KRW/AVW@N;>Q:ZMY8K[S(6 ^
M\"VP$.H^8#!#8ZBH/#_B/Q/)X$T&X;1!?:G?1Q+&XNCY90Q!C-,^S]WGGY0#
MR0 >:Q-*TN20Z[9^&M/UNTT.?1IXOLFI))&BW3<((5E^8<%LX^7I56*2YNO"
MG@RUU#1?$ TG3XOLNJVB6DR2/*L*B,E5PSQ[MW(XSC- '3WGQ$ETSPCK6JZA
MI(BOM&NTM;NT2XW*2S1X=7V\C;(#]W/&/>LWQ1XK\8VUIH4L>B06!OM9A@2-
MK[+O&>51\(0N[#!L9VX[YXYF^T2_'@[QMI5EX:U"U^V7EI=V5LL#.&BW0\9&
M1O&TEER2.?2N\^)=O=O8^'[VULKF\33];MKN>.UB,D@B7=N(4<G&1TH ZTW9
MMM+^V7ZI 8X?-N%5MZQX7+ ' R!SS@9KRGQ=XGUG7? EK?7.@I::5J%Y9O:R
MK=>9*J^>C*9$V@*& XPQP2 >N:],U"$Z_P"%;N")9(#?V3HJSH4=-Z$#<IY!
M&>1VKR^^O-7U'X;Z1X:B\-:PFHV+V45YOM&$:+#(@+(W1\[0?ESQDG&* .U\
M0>*==TJ?4IK+PW]ITW3(A+<7$USY+2C;N;R5VD/M'4DCGBLN^\4:]-\2=#L=
M,M(9=+N=/>Z >Z*>:C&/YV&PX*\X7OD\BL+Q'I$^J:AXKM=0T'5-3U>X9DTF
M3;)]EB@,0"D-G8I#;B1U)QUS5NUEO+/Q)X+UF31M6:U&C/82A+)S)!+E!B1,
M94?*>3QWZ4 ;<_C^]CAN=8CT1'\-6UTUM+>_:L2D*_EO*L>W!0-G^+. 3BNU
MN+B.UM9;F5L11(9'/H ,FO&[/PKI5A#<:)JG@[5]2U,WLJI)&\ZVUQ$\I99#
M(&\M %;D'G(Z<UZYJUFU]H=]8Q\-/;20K[%E('\Z /+XK_5K+X4ZUXZAC1];
MU>-[AI7DVFUM^5B"<'.Q<$#C)8DFK&I:IK7_  DW@&[GTJ.75)+:]5+>.ZRK
MYCCPS2%1M&,D\''09-/L8[C7_P!G8V-C \MXNEM:&!1\_F1?(RX]<J>*NV;7
M6L>)? VH1:7J,$%I:WD5P;JU>(Q,8HP-P(X!((![X.* +T/C^6UL/$!UK2OL
MVHZ*\226]M/YJSF8#RMC$+]XG'(XK0TCQ)J;Z\FBZ]I,.GW5Q;M<VK077GI(
MJD!U)*KAEW+V((/6N0\2^&-2U>_\>B*PFD6?^S)K93E%N?)^9T5N.>,<'@D5
MJ>$=-T%_$:7>E>%=6LC!;MNO=1,\>QF('EJDC'<2,DD<# Y.: .C\02:Y%J6
MC-I5A]LLS<;;U1<B%HU.,2<_>5?F)7N<5QGCB]\1VW@+QL]_;26?E2*;&]AO
M,^=&91C:HYCVKM!]22:]2KC_ (I6-WJ7PTUNSL;:6YN98D$<,*%G8^8IX Y/
M H YB*S^%\KI&GBZ1I'( 4>()LDGM_K*H^/8=2U;XK>'M'N-%M+^Q2WGDM[2
M>^98[C"\N_R':1C@?-G'45TZ^+M+7!'@3Q&".XT,TFJ65[>?%[PIJL5C=?8H
M]/N!+*T1"Q,R\*YZ*?8T <I:0:EJ_P ;;O\ M/0+&<Z=:VQBBDOV*6:;@?,C
M^3YF[XP/K786WCZ^FBL]7ET18_#=[=+;0WGVK,P#OL25H]N C-C^(D @XJ+3
M=)O?^%P^)KR6TG2QN=-@BCN#&0CL ,@-T)%<OX;\,:59VNEZ)J'@W5[C6;>=
M(IYC).MKA'SYXDW>65P P4<YXQ0!V-[XUU=[O56T/P[_ &E8:1*8+J7[5LED
MD4!G6&/:=Q4$=2,G@547Q-XAN/BQ;Z7;V,?]F/I*77ERW!C8(\J@RLI3(=<%
M=GZCI5:RU'4_!5SXET\>']3U"XO-1FO].DM;<O#-YH!"NXX3:V0=V..1FK$S
M:CI_Q:TW5;W2KQX;S0DL7ELX6FCBN//W$,P'RJ ?O'M0!0T_QI8:+I7BG5;'
MPZD$%CX@:WU I<DF3+A7N/N]>0=OZUV6O>)?[(U+0M/M[47=UJUUY2*)-H2)
M5+22YP<A1CCOGK7*>"?#4]Q9>/=.U>RG@M]3UB[V>;&5\R)Q@.N>H]"*B^'F
MF:Y=ZXE_XBLI[>30]/72K4S(0)GW'S)ESU!58QGOS0!J)X_O6@363HB#PP]T
M+9;[[5^^P9/+$QBVX\O=_M9QSBNI\1.T?AG571BKK9S%64X(.P\BO)]#\*:3
MI]E;:!J7@[5[W5X;GR7E$DZVLD?F9$WF!O+ "X.WKD8Q7K/B"*2?PWJD,2-)
M)):2JB*,EB4(  ]: //_  9X&LM8\#:/J;ZKKMOJ%S:)*]S!JDP(<CJ 6*_A
MC%7_  YXJUJWT77K"^M9=9UG0[T6B^0H1KM6QY;MV7@Y8]@,\U2\)>++O0_!
M.DZ2_@_Q--?VMJD)0:>40N!C[[$ #WJK/X<U_3_"%_J%]#<MJ&L:O%>:M;::
MQ:2.UW &%"O+$*.=O)R: .AE\7ZY#;ZY97>C6L&M6%BM[%''>%X98F+#<'V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M52U:QFU+3I+6#4+FPD?&+BVV^8O/;<".>G2KM% &9H.A67AS2(M-L!)Y2%G:
M25MTDKL<L[MW8DY)K3HHH **** (?LEO]N^V^4OVGR_*\SOLSG'YU-110 44
M44 %%%% $-U:PWMI-:W,8D@F0QR(>C*1@@_A4JJ%4*H  & !VI:* "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G]?\ "D'B2[MS
MJ%_>G3XBK/IR.JP3LK;@9/EW,,XXSC@<5T%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#U/4_$UM\2O#UO-=00:
M/>SW,*VD2!FE5(&</(Y'!W 85>@').:[RO+/%WC;PU#\1/"OF:Q;+_9EW=K>
MY)_<$P,@#<?WN*[V+Q+I,][IMI#=B274K=KFTV*2LD:@$MG&!PPZT :U%%%
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M/!!'0FJEQX=\:65H;K2_&<UY<HN];74+.$Q3'^Z6159<^H--^,W_ "2;7?\
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MNM6UC3<2Q3Z2(VN#* %*NI964YY& ?3D&LFR^(>BWW@BZ\6(MTFGVP;S$DC
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M;6<TUC?6QFU,Z3,DJ+FUN<<+)ANAXP1GJ*VM0\0VVGZ_I6BM%-+=ZEYIC\L
MB-8URS/D\#D#ODF@#F?[ ^)&<_\ ";:=G_L$+_\ %4?V!\2?^AVT[_P4K_\
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M]R]K&"@5H9$5BRR G@C81QGGVYH R?[ ^)'_ $.VG?\ @H7_ .*H_L#XD_\
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M@9Z4A52I4J"IX(QQ7$^()_$FB>%/$]X^K,TEG";FPN5@C!*B/.UP5()W Y(
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M8$BG*$)-B9\LI/49)&?8U+\3+A]"71?%L432MI-RZ2JHSF*9"A_\>\NN]HH
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MD?AZ2)UL_#%Q>W499?E83D& ?@LDGY5F6$4G_" _%D;&RVJWY48Z\=J]OHH
M\9U6-SHGP> 1OEN+/=QT_=)UKT;QT"WP^\2  DG2[D #O^Z:N@HH \XU^-O^
M$5^'RA#\NJZ;D =!L-<?XMU%M7\/^*8K[5=7EUV*YG1-(MW9(H;='^5F0#!7
MRQNW,>2<#FO=Z,<YH \L\;ZPWAS6+'QMHZM=0:IITM@3"I8/+M,ELV.^6RN?
M0U6UGPNOAC0?! NKR]M+/3))%U"]LG(DBDFC.9"<'"F3()]&KURB@#BO <&C
M/=:QJ6D:AJNI"=XH9+Z^?>DVQ3CRVP,@;R">F>G2L[QM<>'[?Q&9KK6]1\-Z
MS':+Y%_#_J[I,L0A7!63:V<J0#\PQUKT;I1@'K0!Y/9^(7TSQ=X>\0>+/^)?
M]O\ #GD/+)&53[1YJN5/'RDKS@_2LK=->:7K.MQ6ER;>R\90ZE)$8F\QK=4C
MRVSK]TAL8R,>U>VXSUHH \X\2^,=.\3>$_%5GHJ27EK#HTSR7\:GRA(5($0R
M.6QSQTJ3Q(C?V+\/@J'Y=7L<@#H/*>O0P,=** "BBB@ HHHH **** "BBB@
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MA0._S<5Y39WFGMJ_@W58M0US43%= :E=7<DSQ02O ZA=A^526)'RCY> >HR
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M0^8S9*;HP=R!\<$YZC.,UB>$M4:R\9_$NZN#<3PV<\,@BC!=L"-R0B^IQT%
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M,'**V1SSC(S4D_CJ\DU?6-,TCPU=ZE<:5(%N"LZ1KM*!@06ZL<D!1_=YQD9
M.THKB+KXEV*6'AV[L=.N[T:ZLHM8H]JN)$7.QL\ [OE)S@8)Z4U]8M)/B#X<
MMM2TBYMM;N;"61,7>Z.  '<C!3M<^^* .YHKC9?'4]O>+)/X>O8=&:]%B-0D
M=5.\OY8;RC\VPMQN_'%5-+\7:Q/\1?$6EWFG&/2=.CA+2F:/$"E9&\P_Q-O
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M^(/A3Q#I.@:=<RVRV:21WDL;PB:8.&\E$=03PO)Z9(%>DT4 >:ZMK</CB_\
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MRPTS4H;BWU*WO;_[39R0I:K%\S*68 %B< ;2:?I^GWB>#_B1$UI.LMSJ&HM
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M(NI22LP5$7Q.S%B3P -_.?2KE]]N\9>/=3T%=3O-/T;1883<K92F*6YFE4L
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MINR2?*Y!QN /S=L>]9$.KZQ;?$W75LM%:\OIM-LG:V-TL<<./,W9D((SD@#
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M95F4$+@'/.!B@#G?!_C34/#_ ,-K.^?09[K2+265;N]^TJK*#.V62,@EPNX
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MA-*L($G*$)(R"0'!Z$],_6N;M;.Q@\+/;^)-"U*2S?7+Z47-O#+YMH?,8I(
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MLAL;@7(=\HF_$B;1L)7G@G'2@"^OA43>*DUW4=3NKYK;?]AMI%18K7<,$@*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M75FB^]M.3TSV]:TO!5E>R:MXC\0WMG-9#5[J,P6TXQ(L448C5F'\);!..HH
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M9Y(2(94>3*E'Z-P>E4OB=H^LS7EE?:#:2SW%Y:SZ1=&)<E(IL$.?0*5)S[T
M6M*^)BWW@/6?$ESIIM9=.!86C2Y,@:-7B.<<;PZ]N/>BTUKSOB1<62>'[6/7
MO^$?6Y-R]P1DEE_<$[>%#'[V">.E97B'PK?_ /"9V.E:?82OH.I"R-[*%RD8
MM"QVL>VY1&OX5KVVE7Z_'2]U5K28:>^AK MR4.PR>:IVY]<<XH XN77M=U?X
M0C4]8ACE7^UX7A>*8R2R8O3E-I4 !<!5Y.1Z5Z'I_B?64\66NAZ[I%M9_;[>
M2>TDMKHS?ZLKN1\JN& 8'(R*X73].U?_ (5HGAM]$U*._L-7CD<M;GRY$-YY
MFY&_B 7DD=*[S6K"[F^)/A6]BMY'M;>VOEFE5<K&66/:">V<''TH M^+_$TG
MA>QL+B*P:]>[OHK-8D?:V7SC&>,Y '..O6LZT\8ZA9Z[>:7XFTZUL3#ISZG'
M-:7)F0Q(V'!RJD,,@],&IO'5A=WZ>'1:6\DWD:[:3R[%SLC4G<Q] /6L[Q/X
M>O-;\:S1QQ.MK<^&[NR^TE3L221UP"?7&3CVH ;'X[UJ#3M/U[4] M[;0+^2
M)5D2[+7$"2D".21-@7!RN0&)&>]6T\8:M?>-]2\.Z;HL4J:9- +J[EN=JK%(
MBMD#;R_+8'3Y3DCBN<NVU?Q%X)TOP8?#^IVM^#:P7L\T&VWA2%D+NLF=KYV<
M 9/-=-X9TZ\M?B%XVO)[:6.VNY;,V\K+A90L&&VGO@\4 8\WQ'ULZ)J>N6WA
MV!]-TJZF@NS)>%9'$;[28UV8.!@G)'.0,XS6K;>,=57Q#HUKJ.C0VVG:UO%E
M,ER7E0JF\"5-H +*.@)P>,UA)HFJ#X2>+=/^P7'VRYNK]H8-AWR!Y"5('?(Z
M5MZUIM[-K'@22*UE=+.X9KAE4D1#[.RY;TY.* "_\8:[IL[7UWX?CAT%+Y;,
MRR7)%SAI!&)O+VXV%B.-V<<UFZ1_R<#XB_[ \'\UKD[[0;NZT&X$_A74[OQ1
M!?\ VB[OYHV8&-;@,/(8G#90 !5'3/X]GHNGWS?&76-9>QN8K"YTF!8II8RH
M+94E>?XAW% '1>*/$<F@Q6,%I9_;=2U&X%M:6YD\M2V"Q9FP<*H!)X-9*^--
M1L)M7T_6]+MX-3L=-?4X1;7!DAN8ER#ABH*D, "".^:E\;V-ZM_X>U^QLYKT
MZ1>-)/;0#,C121LC%!_$1D''>N=UA;O7[[Q#XC.FWMCIUKX;N;*'[;$8I)I'
MR[$(>0H"@9.,DT :,'C_ %A;+1M:O] AM]"U22&)95NRTT)EP$=DV@;"2.AS
M@@^U6=0\;:K&VL7VFZ)#=:-HTKQ7<SW12:0H 93$FT@[.>I&2"!7,QSZEXF\
M"^%?#,6AZC%,?L+W%T\.+=(8]CEQ)T)(487KS@XQ4=SX8T_3M5U^'4_!>HZS
M>WE_+=64UOO\F9)3N"NX;;'M8L#N'3GF@#JM2\;ZDWBI/#^@:/#?SS:='J$4
M\MR8HQ&S,I+?*>.%QCDEO8FK'B#Q-XATN74[BR\/13:9I<0EGFN+DQ/.-NYO
M) 4@[1W)&3Q4&G:/<6?Q6:ZCL7ATY/#T-K'( 3&K+,3L#=R!BN5\1:%/JE_X
MKM;_ ,-W^J:O=,ZZ5<NI-K# 8@%PQ.U2K;B1C)./6@#=N?$OB"Y^)^D66G0V
MSZ5<:8UVJR7+)YD;-'EV 0_,O("]#D\BH+/Q=9Z7;^/]2LM!AAFTBZ8SE)CF
M\< _,QQ\I_.J]DU_9>*O"6LR:'JS6IT0Z=*$M6+P2[U_UB]57Y3R>*SW\/:P
M=%^*<0TVZ\S4;EVLU\LYG&#RGK0!UT7C'68=:T:/4]$@MM,UF0Q6LJ71>:-M
MA=1*FT ;@#P"<53N/B!J_P#9VL:Y8Z!%<:#ILDT7FF[*S2F/(:14VD; P(^]
MG )QVJ_XETZ\N;KP6T%M+(+34DDG*KGRE$+@EO09('XUR,TNK>&_AYXH\,2:
M'?/+&M^T5[L'V9K>3>_F&3/!"L?EZY 'T /4](OCJFBV&H&,1FZMXYR@.=NY
M0V,]^M>7^+O%NL>(/AGK^IV^C0#P_/%+!#/]I)N&4,4$ICVXVEATW9 YYKT7
MPH/^*-T0'_H'P#_R&M>7/'KME\)+_P "Q^&]4FU2WBFMUF6#_1Y(]Y8.LG0D
MJ>%'.>U ';R>(]7:^&C^'M*MKV:RLH9[N2ZN3"B[P=D:X5LL0I/. ./6HV\>
M2ZC::&F@::MQJ6KQ23+#=3>4ELD?$AD8 GACMP!R:YW5O#EC:>*[K4M<\-:C
MJUK?6=MY#V,;NT,L:E6C948$9&T@GCKS5M=,N/#-_P"&=?L_#5S#90V,]I=Z
M;9DW$MKYKB0$#J_S [L=,]Z '>+_ !24^'UY=^)/"@DEM;Y+>6RFD/DRG<-L
ML<FWYEYR..H([5NZIXGUD>(+W2M!TBUO7T^WCGN1<79A9]^[:L8"MDX7J<#)
M KE_'P\0^,/AK?[- N87?4(C9VNPF=H58?.Z_P )SGCL,5?\<VUG>ZI,M[X6
MUB2]B@']FZMI(8R%B#\I9,;,-V;*\YH OW6LV;?$WPY9SZ&HO[O3I9DNY7Q+
M;#!)CVC@]P>:@D\>:U/INH:_IF@V]SX?L9)5:1[LI<3I$2))(TV%<##8!8$X
M[51ATC7V^)'@O4-1MI97MM%>*_N57*+.4.02.,DU4M&U?P_X&U/P4OA_4[J_
M_P!*M[*>&#=;RI,[E':3.U<;^0<'B@#I+KQK?7/B*WT;0-+AO7NM+CU*&XGN
M#%&J,Y7YL*3V7&,DENP!-5HOB#>S:/$!I,*:V^KOH[6\EUB!9E4L6\S;G;M&
M1\N22!2^'O#]YHWCFQ1XG>UM/"]O8FY"G8TB2G(!]<<X]ZRH].>VTWQ%#K7A
M6YU73;WQ'<2O&D9:18BB[)D3JPW#&5((R2,XH [S0K[5+RVG76-,6QNX)3&1
M%+YL4HP"'1L XYQ@@$$&LC4?$VK3^);K0O#NF6MW/8PQRWD]Y<M%'&7R40;5
M8EB 3V %0_#ZUN[6TU-#%J4&D&Z!TV#4RQGCCV+N!W$L%W[MH;G%5))+OPGX
M]UW4Y=)U&^T_68K=XY;"W,S1RQ(4*,HY&1@@].M '+?$KQ7J&N_""\NK2R6T
M7[0;/4XWN")+>5)E4HN%PX)SDY'!'!SBO2_"FF-I&A):'2;#2RK$_9K&4R1_
M7<54Y/?BO-?$'A?7)_@]KD8TR<ZGJVK-J/V&,;Y(E>92%..X5037L@Z"@#QJ
MXUOQ'J_@WXCKJT%J+:V:Z@!CNF<PNL2#RT4H,IU.[(.2>*ZG3O%FLV$OAV'4
M]%@@TK52EK;3)=%ID?RRR>8FT ;@IX#''>N?FL=4BTGXD:$=&U%KC49[J[M)
MD@+0S(\:A0KC@MD=*Z?Q'IM[<V_@D0VLLAM-4MY;@*I/E((7!9O0 D#\: (;
MGQYJ4<%[K4&C0R>&[&Y:WFN3<D3NJ/LDE2/;@JK9X+ D*378ZE?)IVDW>H.-
MT=M \Y /4*I;^E>1V_A/3=.-[I.H^"-0U74GOI3!<(SK;SPR2%E9Y VU,*V"
M",_+T.:]>N[&&\TR?3Y 1!-"T+ ?W2-I_0T >>^&?!5MXM\/6GB'Q3<WM[J6
MI1"Z79>2Q1VR/RB1JC   $=<\YJKXWT^\\._#5+/4]=N+R!=5@5;J1C'*EL9
M!\CN#EB!G+<?I5SP]KNL^#-%@\.ZSX:UB^EL%\BVO-,M_.BN8EX0YS\AQ@$-
MZ5%XIC\4:OX"2XU/2"UV=6@N8].LT\V6*W613M8@X9\ DXP.<4 0Z=:_"F?4
MK6*QUSS;MY5$,:ZS<,6?(VC!DYYQQ5Y+ _$#QCKL6J75T-#T>9;.&Q@G:)9I
M=H9WD*D$XR !G%7T\:0"12O@;Q,IR,-_9:C'O]ZJKKJ?@CQAK&H1:1>ZIH>L
M.EPWV!!)-;3A=K93(+*P .1TQ0!$;$^ /&FA6^F75TVAZS(]I+97$[2K!,%+
M(\98DC."",X_IZ-7 1)J7C7QAI&I3:1>:7HNC,\Z"_01S7,[+M&$R2JJ"3D]
M2>E=_0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &7HFA6V@PWD=K)*XN[R:\?S2#AY&W,!@#C/3^=:
ME<#)XS\0WMMJVK:+H]C/H^F32Q'S[EDGNO*_UAC 4J!D$#)YQVI;[Q[?W&K:
M+I_A[38+M]8TW[=;R7,IC6/E3\^ < *3TYS@=Z .]IDDT<6WS)$3>P1=S ;F
M/0#WJCJ$^HV^@37$$5JVHQP;]DCL(MX&2,@$XZXXKR(:MKUW\-O!6I:G''>W
M#:W9R6_ES,TL_+\.6 "DGC@D8H ]NHKBK7Q?J>G:[?:9XGLK*#R--?5(Y[&9
MI%,2-AU.Y0=PX/H:;IWB[7!<:+/K6DV=KINM.([9H;AGE@=D+HLH*@'< 1\O
M0\4 =O17%_%J1XOA;KSQNR.(5PRG!'SK7F^MS^ 8/#RGPGJ%S#XG?RULVM[N
MX4F4D<,7.S;USGB@#W:2U@FN(+B2)6E@W&)R.4R,''X<5-7)ZMXBU:UU/2_#
MVF6MK=:U<VK7,\EQ(4AAC3"LYV@DY8X %0V7B_5IK'7+5]$67Q#I$L<3V=M-
MF.;S "CJY (7!).1D;3UH [*BN+M?%FKVMUJ^G:U96 O[+3CJ,+V4S/%*GS
MJ=P!4AE_$&L^U^(.L?\ "%MXKO=%MX[*:"'[#;I.3--.[!<'(PJ%CP>3@9QV
MH ]!::-)$C>1%>3.Q2P!;')P.]<U:>$=-TCQ-<^*KW4[RYO7B,"RWTR[+>(M
MG8@"@ 9/?)_.N:O+G7G^)?@B#7K*RBDW7CQRV4S.C?N""IW $$<>H.?:N@^)
MFIV^C_#[5+^[TVWU*"+RMUI<?<DS*@&?H3G\* .L!! (.0>A%+7&7WBG58_$
M5AX>T;2[66:YTO[8DD\S)'#A@IW8!.,'C SDCH.:T?"'B&[UZVU&+4;2*VU#
M3;U[.X2%R\;,H5@RD@'!##KS0!T5,CFCF4M%(DB@E258$ CJ*X*]U;Q*/C+;
M:3:_8SIPTPW!BDGD7=&945G("D>8""%'3!ZC.*Y[P]K_ (AT3PEKFHZ=I5E/
MIVG:E?37!N+ADDE42LS>6 I' [L>3D8XY /8:*Y"Z\4ZKJ.JIIOAFRLYY%LH
M[ZXFOI61$63/EH H)+':Q] !WK9\-:XOB+0+;4U@:W>3<DL#-DQ2(Q1USWPR
MD9[T :U%<'?>-=:1-8U73])M)]"T>>2&Y:2=EN)O+_UK1J%VX7GJ>=IZ5L:+
MXH;4_%.K:+- D?V:*&ZM)58G[1!(/O8/3##!H L^*/#<?BG2SIT^HW]G;296
M86<BH9D(P48LIX^F*T=-T^VTG3+73K--EM:Q+#$N<X51@<]^E<5!\0+[48<:
M9ID$L][JLUAI?F2E4ECB!+SN0#A1M;@<G%+?^/M0T;0->FU+38/[5T62W$L-
MO*S131S.H5T) /0MP>ZT =]17%Q^)O$=KXFT_2M6TK3X5U:*=K(P7+N8Y(TW
M[)<J!R.ZYZ'K5;X9:MXAU>UU:?6#:O"NHW,<;),[NC+)@H 5 "#H.<^PH [V
MBN6UOQ%J:>)8/#F@V=K/J#6IO)Y;R5DBABW;1]T$LQ;.!QTKD_%GBC6=4^&_
MBF!;.UL]2TWS+74D^T,0$* AXB%R=P88#8[T >H07,%RK-!/'*%."8W#8/IQ
M4M<;\,M,DTWP78B33=+LA-;PR*;#),P,:_/)E1\Y[]?K4=YXK\07>HZNOAO1
M[.\M-'D\FX-Q<,DEQ*%#-'$%4C(! RW4F@#L_.C,QA\Q/-"[BFX;L=,X]*?7
MF,VH:Q-\5VDT?3H_MEUX<MW*:@[1+;CSI"0^T$[LD#:.^>>*VM.\7:UJGAJ:
M:UT2*36H-1?39X!.?(CD5L-(7QGRP,'IGG'O0!VE%<!<>/-2TS0?$\NHZ?9G
M4]"2.1EMIF:&9)!E2"0".C C':K<?BK7;7Q#H]MJVE6<&GZR[QVS0W#--"P0
MNHE!4+D@'[I.#W/< [2BO.;CQ_KIT/5_$MCHEI/H-DT\<>ZY87$OEDJ9-NW;
MLW#IG. 3['3?Q5K.I7EII^@6%C)=G3HK^[DO)F2*(29V1C:I)8X;GH .^: .
MSHK@QX\O]3AT.WTBPM(M3U,7&]-0N"L<#P,$D3*@EVW'C ' S76Z-=7]YID<
MNJ6 L;T%DEA602+D,1N5NZD#(R <'F@"VEQ#)-)"DT;2QXWH&!9<],CM4E>?
M6_B.WMO&7CU8-'M8[K2K2&>2Z4X>[_<EU#\=L8'M20>.=?6U\/ZQ>Z-90Z-J
M\UO;@+<,;B(S#Y7(V[=N>V<X([Y  /0J*R/%&N#PWX:OM7,/G?9D!$>[:&)(
M49/89(R>PS7-:MK?C&T\*Z[//I^F)-;Z>UU;WEK=.T) 4EEY4-O &1QM/'(H
M [RBO,[?QGXAT7PAX2>[T^VO[[5S%;Q>7<,2X:$,C.S*,,6^]U &3DUT-UJ7
MC%([&U@TK2_MKPO+=W,MPXM8B&PJ*0NYF(.>0 ,'K0!U=%>5:YXS\0:EI'A"
M^TB&VM&OM6%K<127#C]ZC2*8R57F,E#D]>!Q70W7B;Q'/J-_9Z+I6GW#Z3%&
M;XS7+J))F0.8H<*>@(^9L?>''6@#M**X=O'%YK%UHUEX7L;:>YU#3_[2D>^E
M9(X(<A0#M!)8L2..F#6>?B5J,%CJ-[>:+';PZ7JT-A?KYQ8Q1L%#2@XY 9AC
MID$'B@#TBBN?UCQ%+8^)="T2SMTGFU%Y'E9FP(8(URS\=R2H'N:?XK\1-X=T
MVWD@M?M=]>74=G:6Y?8'E<\;FP<* "2<=J -VBN1L/$NL6OB-="\0V5E%<W%
MJ]U:3V4K-')L(#H0P!##(/H147@/Q5K?C#3[?5[C2[2STF> ^6PF9I7E#8.%
MQ@)PPR3G(]#0!V=%<GXC\3ZGIOBC2M!TK3H+JXU&":1))Y2B1%"O+$ G;@GH
M,YP.^:R+OXAZCI7AWQ/+J6F6RZQX?:+S889F:&9)<;'5B 1D$\$=10!Z'17$
M77B[7;#3;62YT>T_M#5;Q;?2[1;AN%92VZ=MOR[0"2%SZ4^'QE?:3J.H:=XH
ML[6":UTY]3CGL9&>.6%#AQA@"&!QQWS0!VE%><R>.O$MCIVC:EJ.@V26>L75
MO# (;IF>W$K#'F@J!G:2<CN,'K6C;>+-<U/QMJ>@Z=I5H;?2[F%;JZGF9?W3
MHK?* #E^6P.GR\GF@#M:*X>[\6^(=.NH;S4-&M+?1IK];)5:X;[4JM)Y:RE<
M;=I.#C.<&FW/BWQ'=:WXBTS1-(L9#HS(7FNYV19 T0<*H53\W4=@,#UH [JB
MO.(?B'K,VD:-XC.BVL6@:A/#;L&N&-RAD;9OQMV[0W09R1@\9P-)O%7B"\UC
M5$T?2;&ZLM+NA:SPO=%+J0X4LR+MV@?-QN/.T]* .UHJGJVIV^BZ/>:G=$BW
MM(7FDV]=J@DX]^*XZ/QEXBL8=(U/6]'L8-(U2:*$""Y9Y[4R_P"K,@*A2,D
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M-A?RF:[TZ&Y"P3,?O9&TL V.0& -/?Q)K>JZ;HUUX=TNV9-0LQ>27%_,R10
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M"BSR$Q Q%E\M2N"6R"V<<],XH ] HHHH **** "BBB@ HHHH **** "BBB@
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MV*\UU]W\-]&O+BZ+7.IQV5Y,9[G3HKLK;3.3EBR]>2,D @&NN50BA5 "@8
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MBD4$QD,=^<9X&  >>F>R\.Z9>VOQ$\9W\]L\=K>&R^SRL.)-D)#8^AXKKZ*
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M+P,$8R1MG!0JQ!Y4@@XYKCYX/$UE_P )O=:1IUTMQ>7T$UL=BAI80J)(8]W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9U#M]U2>3]!0 ^BLL^(-.'B4>'_-/V_[)]L*XX$>_9U]<]J=X@UB+P_X?O\
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M%MX.GU*UM+G4'UFSM+B<0@>8AW%TYR0A.3MR:Y^'4HK>&.&&S^,*11J$1%B
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M8(N2%4* H&23P.2>:@T/P7I/A[7-4U>R$WVG46S()'!6,%F<J@Q\H+,21ZT
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ML9Q!=7,D$<;L2!DH_!(Y /0D>M=!X)CTVP\2SV)\,/X;U=K,,]M#(K6US&K
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MJT<?D*=BD#A<\X'%9^@0QZEX8^%NBWJ"32[MKB2XA?[DK1(S1JP[C/.#P<4
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MF\-PWL,TL(9B_G864DC._: -W7CK6!(L+6F@Z[I?ANWL[6YUZ"2'5I[L->W
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M#$'T:3<?^ U'XMCM=3\96.GQ^'8==U"WL7G\J^G$=K!&[A=Q!5LN2I XX -
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M,J*68A5 R23@ 5X]I6@Z3K?PFUS7]4LX)=8N/MUS+>R(#-#)&\@3:_5=H1<
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M7*"_^S^?@NNW&[:%ZYW'KC'2@!^@>'+#PU!>0Z>)0EW=R7DOF/N_>/C=CT'
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MXADGDA2:-I8L>8@8%DSTR.V: /+_ !'I\4/B#6R?#/B*1[L*R)ITS/9Z@VS
M,RC 0@\,#P0.<YKN/!ND3Z#X,T?2KHK]HM;2..7:<@/CD ]^<UK_ &JW\R6/
MSXM\*AI%WC* ]"1V'UJ*SU*PU%'>QO;:Z5#AF@E5PI]\'B@##'@?3%U+5[R.
MXOXUU9'6[MDN"(79EVE]N.&QWJ6U\&:39VFA6T0G\O1'+VF9,G)4K\W'/#&M
MK[;:_9!=?:8?LQP1-Y@V')P.>G6F3:E8VS,L][;1,K*K"255(+?=!R>I[>M
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M-9(VDCRC, =JL<*3@\&NL?PEK-[>:RKZ?I/ANUO]'>SD6RN]ZM)N'ENRA$P
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MI4#/'L9RNTGE0#SQW)/>M;0;:WU_Q];C68(KS[/X:M'@CN4#KF0GS' /&3@
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MH&CVC12V]VVJK?YN)U89EW#RP275FRI8\_2NQ^+G_)+-=YQ^Z3GT_>+5VQ\
M:'I^H07,(O#%;2F:VLI+IVMK>0Y^9(R< \G'IGC%;&MZ-9>(-'N-*U!&>TN
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MD[SL'<L=[=>3]*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5EGB0S-MB#.!YC8SA?4X!/%>-^-+>&PO/B'9Z?$D5I)H4%Q/%$N%6?<XS@<
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M/TJPU'XO>*);VUBN##8V2QB5 RKN$F3@\9^4#/U]:Y#18(I[;P;HURBMH_\
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M$B1BHR"""W)YQ4UEI>EW_P +/&.I:E!"U^]UJ,LURZCS(Y49@F&ZC&%P/\:
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MZ$;NV$L$1N(A)."T*%QF0  DJ.^ 1T]::;ZT5KA6NH ULH:<&09B!&06_NC
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MW5U#!:HH9IY9 J*#T)8\8YJ#5M8L=%T>XU2]N(XK6",N79P ?0 GN3@#U)%
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MY$FJWAU&:8[60I(=OS=5VJ%Q@\=J?9%&_:#N#&Q:,^&EVL3G(\Y<'/>NGO\
MP#X9U+59-1NM-WS2NLDR"9UBF9>C/&&V.>.X-::Z#IB>(GU];4#5'MOLK3[V
MYBW;MNW.WJ.N,T >3-+&G[+L6YU&8409/5OM(&/K77:%:VU_\3_&YOX(IY(T
MLX8Q,@;;"8B2!GL6W9^E:+?#3PD_V@/I9:*=F=H3<R^6K,<ED3=A"?50.I'>
MKNL>"]!UW45U"_LW:Z$?E-)%/)$9(\YV/L8;E]CF@#QJX6!?A%X<6V.;<>+,
M1$'.5\Z7'Z5Z/I6G6EW\7_%4]S;QS20V5DL9D4-M#"3=C/KM%;K^"/#CZ5;Z
M6=,46-O=_;8H5D<!)LEMPP<]6/'3GI6G!I-C;:K>:G#!MO+Q(TGEW$[U3.T8
MS@8W'H.] 'CN@PPR_P#"$Z;<(ATQ=?U,"%A\@9/-,0QTX.<"NMTFVL+3XWZV
MMDL<>[1H7N%3 "R&0]NQ*[3^.:O>)O"]M#X:BL=,\.Q:E;+??:I;0W+1R@LS
M,TD4A8;7W'(Y P2/:J/A'PO*NNZKJLVB-I-E/8I8P6D\XDFE&YG>25E9N26Q
M]XG ^E 'H*LKJ&1@RGD$'(->.3Q"/4-2^'Y&8[WQ'%.(^WV.1?M+@>V8G7\:
M]0\-Z1_8/AK3=)W*YM+=(BRYP2!SC/.,^M$GAS29?$D7B%[-3JL4'V=+C<V0
MG/&,X[GG&>: /,_#;/JNK^$_"\I+GPW+=R78/K QAMS^3AOPK#B1'^%?Q1W*
MK;=<NV7(S@Y3D5[18^'-)TW6K_6+2S6*_P!0V_:9@S'S-O3@G _ #/>H(?"&
M@P:;JFGQZ>OV3599)[V-I'82N_WCR<C.!TQCM0!R>K:;97'CWX?P2VL30):7
MLHC*#;N"0D$CH>>?J :YKQ8BV?\ PLJWMU$%J\^E^>L7R@(^T2GCU&<_C7J&
MG>$-$TI]/>UMI/,T]95M7EN))#&)  XRS'((5>O3'&*LMX>TEY]4FDLHY'U1
M$2]WDLLRJNU05)P."1P!0!R?BRSM-/\ %'@5]-MX8+H:@T""% N;<POO''\(
MPM8%M+'%\!/$YD=5PVI(<GHQFD 'U)(_.N^T?P3H&A7RWME:2?:(XS%$\]S)
M,84/54WL=@^F*K7'PZ\+75U>SS::6^VEVGB^T2B)W<89_+#;0QS]X#/?K0!S
MFGV\#_%O1"\,;'_A%M^2H/S"5,'Z^]:WQ=_Y)3K_ /UP7_T-:VK[PAHFHWNG
M7MQ:/]IT]0EM+'/)&RJ,':2K#<.!P<_K5_5])L==TJXTS4H//L[A0LL>XKN&
M0>JD$<@=Z /,=:_Y&KX1_P#7.7_T1'4FG:78W.F?%"XGM8I96O;N,LZ@D*(%
M( STY)->@S>&='N+K2;F6S#3:0"+%O,<>2"H4]_FX '.:DA\/Z7!!J<,5KMC
MU.1Y;P;V/FLZA6/7C( '&* /,I-/M+3P'\,[B"WC2X;4].=I0HWL9$)<D]3N
M).:DT]$D^(?Q55U5E-G;<,,C_CW->C/X;TF33],L&M ;73)(I;./S&_=-$,(
M<YR<#USGOFEM_#NE6NJZEJ<-FHO-35%O)"[,)0J[5!4G XXX H \XT@P#X?^
M -.MM(L[S4KP)+;?:G9(8WCB9FD?;RQ"YP,=3[5B:XDW_"(_%&&[6P,T4UL[
M+9*1"LAC0,5!Y!]??->EQ_#?PO#IJ:?%8SQV\<PGBVWDP:%\$?(V_*#!/ ('
M-6$\!^&HXKR)-,417ML+6YC$K[94'3<-V"W^W][WH Y'QM%'#XP^&J11I&@O
M9"%0 #[B5?\ !UE8:C>>.9=5@@FG?6)H)S.H)^SJB"-3G^';DC\:Z*#P3H%N
MNEA;.1SI4C2V;2W,KM$S8R<ECGH.#D"FZMX&\/:W?RWM[92>?,H2<PW,D(G4
M< 2!& <8XYSQQ0!YIX2MEU-_A<NHQ^>J6>H,BRC(*H5$9(/7"A2/H#VKM/"L
M<-G\1/'4<2I# 'LI"J@*H9H3N..@SCFNH_L+3!>:==K9HDVG1/#:%"56)& #
M*%!QC"@<CC'%4M6\+6%]8:^L-O&+O6;?R;AY'?:Y5"B9 /  /\.* -T$$9!R
M#SD5XE?3S7/AG2=7L]-TC3M)NM>@FM<N\EX[M<\N6/ 9OF)&3A>.U>SV5LME
M86]JK%E@B6,$]PH _I7.'X<>%62YC;3&,<Y+&,W,NV,E@Y,8W8C.X _)B@#)
M\-:587OCSQY-=6D,[M=00_O4#80VZ9 STSW]<#TKDM(#Z5\._ GC)"?^)2QM
M[P^MI*YC;/KM.TCTP:]>T_1=/TNXNY[. I+>,C3NTC.9"JA%)W$_P@"N6\2:
M1=6?A+_A#_#&@&2VN[=[8323#R+17)#,VYB[$;B0 #S0 O@A/[8U_P 0^+7^
M9+NX^PV+=1]G@)7*^S/O/X"E\122WGCJRL-,TO3[C5+?3WN#=ZB[^7#$[A=J
MHO5F*]>, =><5T^B:3;Z#H=CI-H,06D*PH<<G QD^YZGZU3UKPEHOB"[@NM1
MM7>>%#&LD4\D19"<E&V,-RDCH<B@#ROP_LNK7P797?V>33&\0:CN2,?N"Z^:
M8@H/\.XDJ#[5N?$S3_#]KX*\:'3T@74GAMY;R)&^X=P"-MZ*2-W(&3WKL7\"
M^&WL+NQ.FJ+6ZN/M3Q"5P%EZ[X\']V?]S%.MO!/AZUT:^TE-/#VE_P#\??FR
MO(\QQC+.Q+$CMSQVH Y#QO%'#XY^&R0QI&@O)\*@ 'W$]*IZEJ\O@*_\:Z9;
M@[[^-=2TE%ZF:<B%P/I*5./0UW<'@K0+<:5MLY';2I&DLVEN97:)FZG)8YZ#
M@Y [5:U/PSHVLZGIVHZA8I/=Z<YDM9"S#RVR#G .#RH/.>E 'FNN:%'X:U+X
M5:/'@_9;MT=A_$^U2S?BQ)_&M?0=&L-4\:_$>PN;:,PSO;PMA1D*]OAL>G6N
MWU'0=,U:^T^]OK;S;C3I#+:OO9?+8XR< @'H.N:HW7AS2[+6;GQ3;Z;/-J_E
M?,MO.RF?:I4 H6"%L< M^= 'G%A=7'B'2O#_ ,/[UM]W9:@\.JC^];VA#*3[
M/F$ ]^:])\;HDG@+Q"'56 TVX.",\B-B#63X0T&[_P"$CUOQ;JVGI87^J&.*
M*VWJ[Q0H !O9>"S$ G&<8 KL+BWAN[:6VN(UDAF0QR(PX92,$'\* /*&TZSN
MM*^$]M+;1-#)Y<DB;1AV%H6R1WY Z]:EUZXT[0O%OC2::Q$MD^@6[3VL3>5Y
M[%Y$ )'3((&>PKM=,\#^'](CLDL[.15L9FGMA)<RR>4Y38<;F/&WC'3VS5R\
M\-:/J%S?7%W9)-)?6HM+DLS8DB!)"XS@<L>1S[T <%9VM_9_$OPS:ZC:Z+:E
M]-NXQ;Z<&.(@(\*Y;&X CCCL:U?@_#$G@1'2-%=KRZ#,% ) G?&:V;3P'X=L
M9[2XALY?M-I+YL5P]U*T@.,8+ELLN.-I)7VJWHWA71_#]W>7.EVSV[W;EY5$
MSLFXG)*H257)/8"@#GK>""^^,6KIJ$,<S0:1;_9$E4,!&SOYA /JP )^E8ZV
M6@CQOX-TW3/*ET2%=0>WCWF2/[2I&X#.>5R^!VYQ7;Z[X2T7Q'-#-J-J[3PJ
M5CFAG>&0*>J[D()4^AXIMSX-T"ZT6TTA].1+.S(:V6%VC:%A_$KJ0P/)R<\Y
M.: /,?&\4=K<_$B"R18[9])M);A(QA1.689P.A*@?6NI\0:99:9XD\ "RM8H
M#'>R0AD0 [#;OD$]\XKHX?!7A^#1+W1UL-UG?'-UOF=I)SQRTA;>3P.]:5WI
M%C?W-C<7,'F2V$AEMFW,/+8J5SP>>"1SF@#@? =I;+\3?B!BWB'E7-IY>$'R
M?NVZ>E<!'_R:SJG_ %^_^W*5[S8Z%INFZGJ.HV=MY5WJ+(]U)O8^85!"\$X&
M 3TQ6</ OAL>%Y?#0TT?V/*_F/;>=)RVX/G=NW?> /6@#!M(8;WXM>5?Q1RB
M#P]$UHDJA@-TK"1@#WX4$^F*R->T_P /V][X-MM%2![)/$4D;*K;U1]LA=!G
M. &S\HX%=YK7A+1=?%L;^U<R6H*PS0S/%(@/! ="#@XZ9Q4-UX'\.W>A6FBO
MIRI86<@EMTBD>-HG&?F#J0V>3DYYSS0!R'B+3I=%F\2:LNG:5K_A^X<2ZC;L
M^RZMO+C56"MR"%50P4E2,\>M=SKNF0^)/"=_IW6.^M&C0MVW+\I_ X-9]S\/
M?#-W=>?-82,6""6,74HCFV !3(@;:YP!RP.<<YKIP,# Z4 >$7-]<^,-&M=4
MC#-=>&-#BO#ZK>+,"X^NVV<?\#K6U2:+Q!HWQ(\3Q'?;?V?_ &=9O_L1Q;WQ
M[%Y/_':]*TWPOHND#4A8V"0C4I6ENQN8B5FSGJ3@<G@8'-1VGA'0K'PQ)X<M
MK 1Z3*CH]N)'.X/G=\Q.[G)[T >=6MO!-+\'O-AC?=9NK;E!R!: @'\:WO#&
MDZ?>>,?'LMU9PSN]Y'"3(@;Y/(0D#/0'//K@>E='?^"M U+2M.TVYLF^S::%
M%GY<\D;P@+M&'5@W3CKS6A8:-8:9/>3VD'ER7KK)<-O9M[!0H/).. !Q0!SO
MPI=I/A;X>+L2?LN,GT#$#]*Y**W@32?BVR0QJRM<*I"@$#[,.!7J6DZ59:'I
M=OIFG0>19VZ[8H]Q;:,YZDDGKW-94_@CP_<:GJ&H263_ &C486AN]MQ(J3*R
M[#E P7.WC.,T <9J>F66G^%?AU):VL44JZKI_P"\50&.]3OR>IW9Y]:RH-(U
MS7-!\71+%X>2&XU2\6>\OII$FA97(1B0I V (5YZ8KU>XT'3+JTT^UFM=T.G
M2Q36J[V'EO&,(<@Y./?/O6=?^!/#FIZG)J%U8%YI65YD6>18IF7H9(PP5R,#
MJ#0!NVBRK90+.ZO,(U$CKT9L<D>V:\$T"WBN_@SHMM,NZ*;Q/%&Z^JF?!'Y5
M] U@VO@OP_9:3;Z7;Z>$LK>Z6\BB\USMF#;@V2V3SS@G'M0!@WEC:6WQ>T=(
M+:&))M&NHY%2, .JO'@$=P,UPNEP2GX,>#8K2"T8W6MI'.MSE8I0)YBBR$ D
MKO"#O7M,FDV,VL0:M)!F^MXGABEW'Y48@L,9P<E1V[5CVW@'PS:6%_81:;_H
M=^VZ:W:>1DSN+ HI;"<DGY<<_04 <5KVD:Q:Z?XSU'4CHEN;CP])')::=*Y9
MF4/LD964=BRY]L=J36M+2Q^'7@VVTRSL@;R^L!<BX!6.X)0L/.(!+ R;<YSR
M:[NT\$Z!9:?J%DEF\D6HQ^5=O-<2223)@C:79BV "< 'C-7[K0=,OM"&BW-H
MDNG"-8A"Q/"KC;@YSD8&#G/% 'G]YX5U._NO$ UB^T#2AJ.FQ6[I92L1Y@E/
MER2*X7(.2GOTJ/4))DLO$VFZ]H.FVNL?\(]<2QWFGL6AN(4!&-I *E692 <]
M>#7:6O@CP]:6%]9"P,T5^H6Z:YF>9Y0/N@N[%L#M@\=13],\&:%I*W0@M'D:
M[B\B9[FXDG9HN?DW.Q(7D\#B@#CK/0[B[\*>!;W1GTK^T[+34F2ROAA+E7AC
M5V^7D,/E^;!^]SUKJ? ]W;7>BW*P:2NE307LT5W:(X=$G#9<J1P0<@\ =>E1
M)\./#$6FP6,=G<)%;R&2!EO9A)"2 I"/OW*N !M!QQTK=TG1[#0]/2QTZW$%
MNI+;=Q8LQ.2S,22Q)ZDDF@#C?!]E9:AK/CF75+>&:Y;5GMY?/4,?LXB3RUY_
MAP37!3H)_A5\.9)T$C?\)!!"CNN281+,$&3VVA>*]<U?P/X?UN_DO;VSD^T2
MH(YF@N9(?/4=%D", X[<YJW?>&=&U&ST^SN;%#;:=-'/:1(S(L3QC"$!2.F>
MAX]J -)8(DA\E8D6+&-@4!<>F*\/2U@;X!7X$:J9-6V.R#!(^W =17NE<RG@
M#PU''?Q+I["&^E6:>'[3+L+APX(7=A?F /&.GI0!B>(+&WTWXB^#/[-M(;=_
ML]_$%B0*"JPJ54X[ ]!7*>&]%U[4_ ?AR9!X<MH5N8+Q+V2:07)F\W+9^3!=
MCN4C/.<5Z_<Z38WFIV.HSP;[NQ\S[-)N(V;QM;@'!R!WS63#X$\.0:NNIQZ>
M1.LQN$C\^0PI*>L@BW; W?('7F@"#XE65SJ'PWU^VM%9IFM&957JP7YB!]0#
M6IX>U6PU3PQ8:E931FSDME<,&&$ 7D'TQR#Z8K6KD+CX7^#[FZEG?2=@F??+
M#%<2QPR-ZF-6"G\J ,;5M5TWQ3XP\"302+=:/--?.A="(Y)HTPAPPYQ\Y!_*
MLGQ?%%:Z_P"/8;)%C@E\*^==+&,+YV9 I..^S]*](U+PUH^K:5#IEW8QFTMR
MK0)$3$82O"E"I!4CV(JO:>#=!LM*U#38K(M!J*E;QI9G>2<$;?FD9BQX) YX
M[4 <+K.A:6MG\-8A90A3>1*WR#+@P,S!CWW$ G/7O47B>"*UUCXD1V\:1))X
M;CD=47 9MLHR0.^*],FT'3;@::);;<-,=9+3YV'E,%*@]>>"1SFL?Q?X;BO=
M \27&GV9DU?4-+>TR'.9 %;8N"=HY8\\=: .2UG3].LO!_@"XTV"%+A=2T\6
M\L:@,^\?/SU.X%B?7J:Q_$\\UWX,US5[#3=)L=*DU0L)I7=[N:9+@(9 >BDL
MIP,G %>A:#X$T33SINH-8,M_;PJ51YW:.&0KARD98HI//(%23?#SPO<37LDV
MF;Q>%VEC:>3RPS_>94W;48_WE /O0!DZ-IUG>?%SQA/<VT<TD5K8HAD4-M#(
M^[&?7:/RKD+.U?3_ (::5XDLHR9O#6KW4P1!R;4W#I*@]MAS_P !KUO3M!T[
M2;J>ZLX&6XN(HHII'E>1G6(%4R6)Y )YZG/.:PM=LKC1/#<FB>&/#S7?VX3K
M\TRB&!I#EFD+MN()=CA0>A''% %3PJT7B'QMKWBL.LEI;JNE6$F>"B?/*P]B
MYQG_ &:[E65U#*P92,@@Y!K"\/>&+;P_X+M?#L:K+%#;&&3.5$C,#O)QR,DD
M_C5OPYI/]A>&]-TG>'-G;1PEES@E5 )&>V: /+A_R,OQE_[!T7_I-)5V_P!,
MLK'P1\.Y;:VBCE74],;S%4!B7 WDGJ=V3GUKO_\ A%=%%SK-Q]B'FZS&(K]O
M,?\ ?*%* =?E^4D?+BI9O#^EW%AI]E+:[K;3Y(I;5-[#RVB^X<YR<>^<]\T
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M382WVH745M:Q#+RRMM5>W7Z\4 0ZEHFFZO/937]JL\EC.+BV8DCRY!T88/\
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MSA/(-L3*Y1ANX!&1P>_%7]%\4:)XB,HTG4X+IH<&1$;#*#T)4\X/K0!K  #
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M!@\9%:?B;PU%HGA7QJT>IQE;FP^U#3[2%H(K=U4@.H#G&['(Z$C/:N[7PAH
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M.JAB@)R>0 >3ZUL7?@KPU?75[<W6CVTLU\NVX9@?WG&,XS@''\0Y]Z .8O\
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M4EQOC+F1F1PJN4+ %><9!'M761Z#IL.M2:PEN1J$J>6\_F-EE[*1G&!V'04
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M4Z_8QS),&AM;Q8XD E<< KP#C)Y[FO9R,C!KD!\+/ P;/_"-6).<\J3_ %H
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M]#NS[XJY\/I+27Q/XY>R*&$ZLO*="WE+O_\ 'MU0>-_^2K?#K_KK>_\ HI:
M.@N?&WA_1H+2'4]:B:XDMDF++$V64C_6,J@[%/7G J[>^*M"TZTM+J[U2VCM
MKM&DMY2V4D55WD@CC[HS7.>$7AB\9^.Q>,BW?VR)W,A /V?R5V'G^$?-^M<+
MH=M'<V7PXCDC#6;:S?26RL./*!D:/CTX!'MB@#V>TUFPOM&75[:X\RP:(RB4
M(PR@SDX(SV/:B+6=.FT0:S'>1-II@-Q]H!^7RP,EORJ\0""",@UXG*DUI#??
M"F-F4W.JH+8CJNG29F<C_=VNG_ A0!Z9?>-_#FFP6<UUJD:+>1">W54=W>,C
M(?:H+!?<C%7$\1Z/+::?=1ZA!);ZC*(;21#N65R"=H([_*WY&N8\/I#;?%CQ
M5#*J1R?8;'[$IXQ;JKAMO^R'Z_A7&63QK%I=Q&RC3F\>S&U<'Y/+*R ;>VTO
MNQ0!['_:=G_:QTKSU^W"#[3Y/.?+W;=WTSQ6%XM\<Z;X0N=+@O3E[ZY6(CYA
MY<>#F3@'., 8Z\UG07,,_P <KF.*17>'P^J2!3G:WGDX/O@@_B*;\1"%U?P0
M6( _MZ(9/_7-Z -S4_&OAS1V@2^U2.)YXA.B!&=O+/1RJ@E5]SBMBSO+;4+.
M*[LYXY[:90\<L;!E8'N"*XSPN\<?Q'\<"Y95NB]JZ%CR;?R1@C_9!W9]Z?\
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M_.?GQYWF9Z=MOXUA^!?%]QJ6B>(M1U^\AC@T[5KBW$K 1K'"@7&?S/-49/\
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M+\?9;-DYS9P,%9E]F/FL:Z;QI)9S#P(NF-$SMK-L]H(L9\@(V\KC^'9U[=*
M.QBUS3)K&]O8[M&MK%Y8[F0 XC:/[X/TQ5NUN8;VTANK>0203(LD;CHRD9!_
M(UY?I]W;VOPX^(?GS(FS4=41@QY#-G:/J<C'KFN[\(?\B3H/_8.M_P#T6M $
M4?C7PW-K?]CQZM U]YIA$>&VF0=4#XVEO;.:==>,O#UEJHTNXU2%+XW"6P@P
MQ;S' *C 'HPYZ#(R:\ON]0O;[PIX;U0W.E6&F7NMVTMKI5M:$.G^DY),F_[W
M4MA0,G'>NO\ "5O$?BMX^N2BF8/91AR.0I@!('U('Y#TH Z'_A,_#O\ ;?\
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M_L>+5H&OO,,(C ;!D'5 ^-I8>@.:9J/CKPSI,L\5[JT44D$ABE0*S,C !CD
M$X 9>>G/6O-+F_O;WPSX5U-KK2K#3+W7+66TTJUM"'0?:,DF3?\ >Y);"@9.
M.]=AX3MH6\1^/Y&B4O)J"QN2/O*($P#[?,?SH ZRWU_2KN_AL;>^BEN9[47D
M2*<^9"3@.IZ$9/:I5U6Q?6'TE;E3?I +AX0#E8R<!CVZUY%IR-I7PW\!^,8\
M[M'"QW9'>TE.R3/KM^5AZ8-=?X&DAN(]?\:WDL<46J7+-%-*P54M(<I&23P
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M/?GFI=7T33-?LOL6K6,%Y;;@XCF7< PZ$>AY/YTZUU>PO9;Z.VN!(]C+Y-R
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M(WB0 G<490V, \@5#:>/_#%]J5M86^JJ\]R=L!,3K'(V,[5<KM+?[.<YXZT
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M&FF:Z!$[FU0F3)R<\<Y/)]:GU/PWHFM7,-QJFD65Y-!_JY+B!79>^ 2.F>U
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MJ2#2S=2ZE<VRRRF,R;?+0D@!05W-U_AXK@;&ZLQX6\%37MQ');IXLG+2.H0
M^9.58K_#R0<=J]DU/P_H^M36\NIZ79WDEN<PM<0JY3Z9'L*P?$/@RWOM2T>:
MPTZQ2)-4^V:B/+5?/4Q.A+#'S$[AU]Z .:\7O'/XW\0-:LK^3X-N4N2AR 2Q
M* ^^ Q^E5]2N+"X^$G@JWT^2)KA[K34M40C<)59=_'J,/G\:[J\\)Z=:>%-:
MTO0-,LK&2^M)8PL,8C#.R%5W$#W_  I/#O@_2=*M=-NI=(L%UF"TBAENDA7?
MN5 K$-C/;&?2@##\#P+_ ,);X^FC51</J2IOQS@1 @?F37-6=SI\?[-MU:W#
MQBX6TGMY86(W_:B[#:1UW;R#Z]Z]=M[&TM)KB:VM889+E_,G>- ID;&,L1U.
M!U-4'\*^'Y-7&KOHNGMJ(;=]I-NOF;O[V<=??K0!P6LZ@W@#Q%I_B.^!$&HZ
M,UK>@GK=01^9&2?[S .@IME:7N@>&_"6E%;*/6M9O9+RXO[Z 2BWG9'E=E4D
M?O,'8.?6O2]0TO3]7MU@U*QM[R%7$BQW$0=0PZ$ ]^3S3=4T?3=;L_LFJ6-O
M>V^X.(YXPZAAT.#WH \@N9GDT#XJK+J4>HRB&,-<QQ"-7(@VG"@D<$;<_P"S
M7IW@?_D0/#G_ &"[;_T4M6?^$9T+]YC1K >9;BU?%NGS0CI&>.5X''2M&WMX
M;6VBM[>)(H(D"1QQJ%5% P  .@ H \Q$[^'5AN=,U+3M9\-76KA/L%Q$//MY
MI+CGRF_B*R,6PPR .O>I_#\$7_"-?$9O+7=)JNHASC[P$8P#^OYUVJ^%M 36
M3K":+8+J1;<;H6Z^9N]=V,Y]^M7(]-L88KF**S@2.Z=I)T6, 2LW#%AW)[D]
M: /,-"U"[EA\,Z=9WFG:5);^%[>ZFU*YMEEE:-L+Y:DL %!3<V<_PUS%_*)?
M@_X=(E\TCQ2<MMV9S<3'[O\ #G.<=LU[5=>%] ODLDNM%L)EL5"VJR6ZD0J,
M8"C' X''M3F\-:$XE#Z/8,);@74@-NIW3#I(>.6Y//7F@#BY/^3C(O\ L6S_
M .CS6C\3HHY](T.&5 \;Z]8JRL,@@R@$&NM.FV)U,:F;.#[>(O)%SY8\SR\Y
MV[NN,\XI]U96M\L:W=M%.L4BRQB5 VUU.589Z$'H: //_&,5Q)X_A2S!^UR>
M&]02+;U+93:/S-8VK75A<?L^:1;6$D37,L%C!:QH1O-R'CR .NX,&S]#7K+6
M5J]['>M;1-=1H8TF*#>JG!*@]0#@<>U9\/A7P_;:LVJP:)I\>H,2QN4MU#Y/
M4YQU/K0!S.@2QI\8?&,;R*KO:V!52<%L(^<>M)\3I;2&;P=+?%%MT\00,[/]
MU?DDP3[ X-==-H6DW.KPZM-IMI)J, VQ730J9$'/ ;&>Y_.I[W3K'45C6^LX
M+E8VWH)HPX5L$9&>^"1]": /+?'HDO?%VMII3>9<1^$+E)_*.3\S@HIQW(#$
M"KNE6$][>>#[FZ\7Z9/%$?.T^VMM/\MY%\EE90PD. %//'85WNDZ!H^@QRQZ
M3IEI8K*=T@MX53>>V<#FH]/\,Z%I-[+>Z=H]C:74N0\T$"HS9Y(R!0!SWQ1=
M8O#=A/(P6*'5[*21SP$43+DD]A4.HWMM<?&30((9DDDBTN[:0(V=NXQXS^1K
MM;RSMM0M);2\MXKBVE7;)%*@96'H0>#5+3O#>AZ1Y)T[2+*U,._RS# JE=V-
MV"!WVKGUP/2@#RB.&.+]EVWV(JYABDX'\7VE3GZYKK='AC;XV>)IR@,J:;:*
MK8Y .[(_\='Y5V']BZ7_ &2-)_LZT_LX  6GDKY0 .0-N,=>:FCL;2*^FO8[
M6%+N9526=4 =U7H">I R<4 >.V^GWMYX9\66=]XJTW3+%M3O([Z*XT_S)$+R
M'#;O,!)(*E>/3&<5K:O>WLLWBR&+4].TR'3;:*WNI&LEDN-08P!@6)8<'=M4
M8)R3]*[^Z\,Z%>ZK'JEUH]C-?QX*W,D"M(".AR1GCMZ4^?P]HUUJT>K7&E6<
MNHQ#"7+PJ9%';#8S0!YWHMM+/I7AN_T'Q#9V>NP^';5)K6]C\R*>#&03R"N&
M#?,I..XH\,:M!J'CWP_J=Q:P6$-YX>DCM(4P(A,L_P"\$?;E0"/:NYG\%>%[
MFT@M9O#VF/;P%FBC-JFU"3DX&.,GK5R_T#1]5L(["_TNSN;2+'EPRPJRI@8&
MT8XXXXH \A\3"&]MOB'+!METV;5M,B!7E'E5HA*![Y(!]Z[;Q0RV_P 2?!<H
M0G9#J/RJ.2!$AP/RKJ4T+28]+32TTRS73T(9;80J(P0=P.W&,Y /UYJS+96L
M]W;W<MM$]Q;[O)E9 6CW##;3U&0.<=: /&7U"ZN](\$7\VIZ9;VE[J]K/;Z1
M8VBHMNIDY^?=GC=@G &YL5TG@Z\TFVU'XA?;)8$9=5EDN=Y _<^6N,Y[??\
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M&-S82)+;0>&/L]S)&<KYY,C*"1W"?SK&\.QI)X8^$RNH8"[D;!'<12D'\P*
M/2])\8Z)K,=^UO<R1-8*&NH[J!X'A4@D,RN 0, G/M5.S^(WAB^EM8HKZ97N
MY4BM1+:2Q^>6.%*;E&Y?]H<#(SC(KBO'L,\VN>.([56,C>%XB0O4@229_P#'
M0:N>*M8T/4/^%?1Z?<6\\AU>UDA$+!C'%M(.<=!DJ,'N/:@#U.L]=;T]]>DT
M,3XU%+<7)A*,,Q%MNX'&#SQP>*GMM1L[RYNK:WN8Y9K1PDZ*V3&Q&0#Z<'-<
M;X_ T/4]"\9I\J:;<?9K\@=;68A6)]=K;6_.@#H[GQ5HEG=:E;W-^D3Z9"D]
MX65@L*-]W+8QDXX .?:J^C^,]$UR_P#L-K-<1W;1^:D-U:RP-)'_ 'DWJ-P^
ME>;7UI+-\-;GQ3>1-C5]9M]4O%(R5LQ,HC4^H$85OQ-=7XAO+74_B)X)CTZX
MAN)X9+FXD:%P^R PE221T#$J!ZF@#I!XLT4^%W\2"\/]DHK,T_E/P%8H?EQN
M^\".E:&H:C:Z7I=QJ5W(4M+>(S2N$+;4 R3@ D\>U>,2:K86W[.-]8RW40O!
M]HMS;[QY@D^T.=NWKP.?IS7M$MM%>Z8]K.NZ&>$QR+ZJPP1^1H S]1\5:)I5
MIIMU>WRQ0:E+'%:/L9O,9QE>@X&.YP!WINN:_IUC]ITZ746L[TZ?-=B1(3(8
M8D&&EQ@CY21P>O3!KR33+"Y\6Z:WAJ4LUSX8T>ZM"1_#=>88X3_WQ#D?[U:F
MGZB/%^A^-?%V,QG0AI\!_ND6YEF'_?<@'_ : -;Q'XIO['PQX)N](UN2[34=
M6M;>:\:W5#<Q/NW90K\N<#H :U8-=U-_C5=:"UT3IB:*+I8-B\2^:J[LXST)
MXSBN!O\ _DEWPK_[#%C_ .S5UMK_ ,G%WO\ V+B_^CEH V_'NOS^';;0KJ.\
M%K;RZO!#=NP!!@*N7!R#C[HY'/%:&C>,-%UVZN;6TN)4N;=!+)#=6\D#B,]'
M =02OO7/?%2:VMK+PQ/>E1;1^(;1Y6;[JJ Y)/L.I^E8_C5CK'C&YBT659[J
M/PM?K*8&#??P(E)'<MD@?C0!VFE>.- UK48[&RNY6EF#-;M);R1QW 7[QC=E
M"OCV)XYZ5IZQK.GZ#I[7^IW M[571&D*D@%F"KG ]2.>U>;:%:C48O!CW'C:
MTN(XWCGL;*"P17)2)@4RK$@!2P.1CUYK=^,#1+\.[EKA=T(NK4R+C.5\],C'
MTH V](\:Z%K>IG3K.YE%UY9EC2>VDA\V,<;D+J-X]Q3+7QUX>O-633H;R0R2
M2M!%,;>002R+G*)*5V,W!X![5SOBB[@U;Q[X.31[J&>Y2.]FWP2!MD30;0Q(
MZ L5Q]*YGPW8/>^"O#%K>^-+:W@2YMUBT\:>OG)<QR ^7D-NW;E()(Z9)H ]
M*_X3?0#K?]C1W<DFH"Y-LT,=O(Q1P 3N.W 7YE^;ISUX-4E^)GA-_L[KJ,A@
MGD$0N/LLHB1RVT*[[=J$D="1Q@]"#5#P#%&/%OCN8(/,;554MCD@1*0/U/YU
MQIAB_P"&8YQL7#RN6XZG[=C/Z"@#T_2O&NA:SJQTRSNI3=&,RQB6WDC69 <%
MHV90''/49]>E<[/XZM="\'>(-:75Y]<:TOIH(PUFT8AE &(3M4?*/[YXYZ]*
MM^(55/BEX'"J !#J"\#MY<?%>=VH)^#OQ+P,_P#$[N__ $*.@#OK[XHZ9::E
MH%LL%ZT>I"1I6-A<!HU5&^ZNS+'< , <#GH0:VM1\=>']*U*2QN[R19(2HN)
M$MY'BMRWW1)(%*IG(ZD5S.NZA9'QS\.+P7<'V4"]!F\P;,FW  W=*P4MYWMO
M'%K?>+[32+)M2NC=VTUDDCF*0#:X)8,0R%0,#M@4 >E:QXOT;0[^&QNYIWNY
M8_.$-M;23NL><;V"*<+GN:H> -<N/$&EZI=SW8NHTU:ZAMY%"@>2K_(!@<C'
M>L+PW+:Z%\1M:MM2OHU9M(L/LL]P1&98HU=789Z?-R15SX336]QX>U>:T %M
M)K=X\6!@;"^5_3% %^#QY9S?$&Y\+B&X!AA0B7[-+S*68$$[<!< $,3@D\&I
M1\1/#)OOLWVZ789_L_VK[-+]F\W.-GG;=F<\=<5A+*$^+WB2!9TBN9]%@6W#
M.%+-EP,9Z\D5SSW^F-^SDFFK)%]L-HMF+0$>;]JW@;=G7=OY_6@#V.>>*VMY
M)YY%CAB4N[L<!5 R23Z8K#T?QKH6NW9M;.YF$OE&=!<6TD'FQC&70NH#+R.1
MZU:U>.T'A*]BUJ1A9FR=+QU!)";"'(P">F>@KSJ[N-5M;.7P[%J]CXABO=%O
M/[.NHHU6ZM]L0VABI(96RHW  D@4 =SI7CG0-9U&.QLKN1I9@QMVDMY(X[@+
M][RW90KX]B>.>E5I?B1X7BN)X/M\KO;^=]H\NUE<0^5NWEL+P/D;'KCC-<CH
M5J-1MO!C7'C:UGBCDBFL;&&P17+)$<IE6) "[@21CUYK8^&EG;S:7XKCDB5E
MN-?ODE!'WQN P?PH ZZ]\0Z5I_AXZ_=7:II8B6;SPI(*-C:0 ,G.1QCO6=J?
MCOP_I%V;:[NIA(B+).4M976W5ONF5E4B//\ M8KS?2A-J,FC?#6X+2'2-4E>
M]+?QV<&'AR/[K^9&/^ U>$-TNK>.H+GQ9::/ ;UY+F"XLTE+P/"@5]S,"5V@
MK@#JI]: /74=9$5T8,K#(8'((KG+7QYX>O-633H;R0R23-!%,;>00RRKG*+*
M5V,W!X![5?T&W73/"FFVT4[WB6UE&B2E"K2A4 !VGH2!TKR.75IK[1?!VHW&
MN6,<-WK%K<)I%G;1I':KYO)+#YAM)P2<#<V.] 'ITOCKP_!K!TQ[N03+.+9I
M1;2&%9C@",R[=@;) QGKQUK=N[NWL+.:[NYDAMX$,DLCG 50,DFO,+Z^7P\U
M_JFAZW8ZCI4NJG[9HEW$/,6=Y@LGE-PP;=\P5@1W%=GX[U,Z/X(U6^%M;W)C
MB"^5<KNB.Y@N7'=1G)]A0 _1?&>BZ_=26UE-.)TB\\1W%K)"SQ9QO4.HW+GN
M/451B^)?A6=K0Q:A*T-TR)'<?991"';[JL^W:K'(X)!'?%<Q;SRQ?%+1X;SQ
M)%JTHTNZ&8X(XDC),9"C;U) S@DD#![UE^6D?[,5H$0*/*@?@=S=*2?SH ]G
M9@JEF(  R2>U<Q9_$+PU?WT%K!>RXN9?)M[A[65()W_NI*5",>#C!Y[9J_XN
M@N;KP9KEO9AC=2Z?.D07J7,;  >^:\]UO4=-U#X.^'K'2[B"2\N&T^&SAC8%
MUE5X]PP.05"MGTYH DU7QY=7?Q2_L2WU:_T[2[.V#R"WTEY9)YO,VE3NC8A,
M?Q 8]^:=X;\;WGB7XDZG;?VM?6VFVLR16EDFEL%F!0EC*[1[HSD9 )6M"S_Y
M.%U+_L7D_P#1RTG@'_DH'Q$_Z_H/_0&H U_#_BG2X/ J:W=^)&U.R5V4ZA+:
MF%I#OVA1&%!)SP !DUH:?XTT'4K.^N8[QH%T]=]VEU"\#PKC(9E< X(!P>]>
M/^$I%MOA5X'O;E@MA:^(_,N7;[L8+2JK,>P#%>?I78_$;4-'U30=?@TLPRZG
M;6]K+>7<,(DV6XG5MK,.N ';9GIF@#L-'\8Z+KDTT-G/.LT47GF*XMI(7:+L
MZAU!9?<4W0O&NA>);K[/I%V]RWD"<N()%0*<<%F &[Y@=O7!Z5S5I9M<>*[*
M\O/&=KJUY!I]P\-O;6:INA<*"S,C'C(3&>O;O5GX526NF?!_1[F9HX+>.VDF
MFD;@*-[%F)H [RN(\4?$+2;'2]>M[&^E74+*WF03K;.T,5P$)5#)M*;LXX)Z
M\=>*[.WGBNK:*X@D62&5 \;J<AE(R"/PKQ^RU+3;/X+^*K&_N(5OXY=1AN('
M8>8T[.^WCJ2<K@_X4 =C9:YYNI>#XKK7Y8;O4+ S&P%J&6];R@S,7V_)MZX!
M&>E:5OXXT"[UO^Q[:\DFOA<26[QI;R'RW3[VX[<*.P).#VS7 C_DH7PI_P"P
M3-_Z35J>#K5Y=*^(WV1/],FUN_C1AU)V+M'YL?SH ZC3_'7A[5-3CL+6\D:2
M9F2"5K>189V7.X1R%0KD8/0GI3+[Q_X;TW4Y+"YOG5X9%BGE6WD:&!SC"O*%
MV*>1U/'?%<%X<L_[0\/>"UNO&MKY$<]J]MI\=@@D$L0R8B0VX$ ,K$CUS6EX
M9UC0=(\'>(K;Q');EH-4N_MUK, [2EY25^0\MN!7'K0!T5MX]L[CX@77A@0W
M \F%")?LTO,I9L@G;@+@##$X.3@FIE^(GAEKX6POI=AG^SBZ^S2_9C+G&SSM
MNS.>.N*YZWE1?BGXF@AD2WN+C1+9;6-R$8M\X  ]B16%-?Z8_P"SE%IL<D1O
M&M$LUM 1YOVK>!MV]=V_G]: /1M2\;Z!I.J/IEU=R?;T,8-O';R.WSY*D;5.
M1A3D]N^,BNAKS[0(,?&/Q#), UQ'I-FA?OSNW?F5'Y5Z#0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M &;=>'M%O=034+O2+">]CQLN);9&D7'3#$9XJXUG:M>)>-;0FZ1#&LQ0;U4\
ME0W4#VKG+_XA:#IUY=02M>RQV3^7>7-O9R2P6S=P\B@@$9Y].]3ZQXWT+0[F
M&WNKB5Y[BW^T01V\+2F9-P4;-H.XDL.!VYZ"@#HJS[70='L;^6_M-*L;>\ES
MYEQ%;HLCYZY8#)IUWJL-GHKZI)%<M"D0E,<<+-)@C.-@&<^U<GH/Q+TZ]\'6
M.NZPDVGBXEC@9GMY%C\QR=NUB/F7CEAP* .HF\/:+<:FNIS:1827ZD%;I[9#
M*".GS8S5P6EL+PW@MXA=&,1&;8-Y0'(7=UQDDXK&T_QCI6I3Z=!%]JBEU'SO
MLR7%L\1<1 %CA@,## C/7-27?BS1K&35TN;HQG25B:[S&QV^8,H!@?,3TP,\
M\4 7WTG3I+6YM7L+5K>Z<O/$85*RL>K,,88G Y-,L=#TG2_+-AI=E:F-61#!
M J;5)!(&!P"0"?H*YK4?B/IMMX=U?4(+:_%WI\'F-9W-E+'(,AMC,I (0E3E
MN@YSBK-MX\TX^'=.U*Z@ODGO<)%:+92^=+)M#-Y<>-S*!SNZ8[T ;@T325TQ
M],73+(6#YW6H@41-DY.4QCKSTI8-%TJU>V>WTRSB>U0I;M' JF%3U"$#Y0<G
M@5G#QIH9\//K9NG6U27R&1H7$JS9V^5Y>-V_) VXS^%6-#\26&O_ &E+47$5
MQ:L%GMKJ!H98LC*Y5@#@CH>AH EN?#VBWFHIJ-UI%A/?)C;<R6R-(N.F&(SQ
M5S[);?;/MGV>+[5Y?E>=L&_9G.W=UQGG%9NN^)=.\/?9DO#/)<73%;>VMH6F
MFE(&3M103@#J>@K#UCX@6,?@G5M9TM;J2YM$EB,+6<GF6\X0L!*F,HHP,L<#
M'>@#JCIE@8;F$V-L8KIBUPAB7;,Q !+C'S$@ <^E,T_1],TFU:UT[3K2SMV)
M+16\*QJQ/7( P:Y/X7:G>ZOX:2^U#4=4O;J>..60WMIY$:,P)(A(10R^X)'
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MGO8?&T<FO1:4MJ7LX]-@MXC->DP*0SE@6;=NVC;C '7C->MQ0QP0I##&D<2
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MK3KNR2RN;"UFM$ "P20JT:XX&%(P,5(EE:1V7V)+6%;7:4\A8P$V^FWICVH
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M !/;^*M&\4:%X=$E^\6E3;KVV(:'S64@0AA]YR.>,XKM;[3K'4X1#?V5O=Q
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M743;'[*TV=NP2?[WRYQC/&:=/X\TN+Q#-H4-KJ-WJ$$R12QVUL7\L,JL'8]
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M?W$4D<T&EK%!F"2.,Y60(@= HW*=Q'6NC^%R*MEXF8* 6\1WQ8^OS 4 <YX
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M?P6C/;P./O!F')V]\ XK+U6_M-,^-^ES7US#;13Z')!$\SA%>0SJ0@)ZGVK
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MIF+#58K+4I$AM=0EMPL#R,/E3.[.2<C.,$C@D<T =6MI;)<M<K;Q+<.,-*$
M8CW/6GB&)4=!&@5R2X"C#$]<^N:KZIJ5KHVEW6I7TOE6MM&997QG"@>G<UCZ
M+XQM=7U)M/ET[4M,N_L_VF./4(5C\V($ LI#$<$C(.",CB@#HE544*JA548
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MQ!A&BH&)8[1C)/4_6N;O_'6E65Y8VD45Y?3ZA:&[LTLX@_GID<+DCG#;N<#
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M4'8_5<]C[T /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,X/M3F574JRAE(P01D&@#Q5KW3AXC\1K;:Y=:G#<>&)X[>[NYE?[0Z%V=8F
M 8*#DXSSN]*VM5 7X9_#\   7NCXQ]4KTX0Q@*!&@"C"@*.!Z"G;5P!M&!T&
M.E '/>.]4O=&\$ZGJ&GD+<Q(NV0IO\L%E#/M[[5);\*\Z\VQN?&]K!8>)KK5
MUO-'O;.&]NIT:)KAO+(CC95"[L8) SVKV<@$$$9!IBPQ(JJD2*J?= 4 +]*
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M0!YI=:E9>)OB$E[HMS%>6>FZ+<I=75NP>/=(5V1[AP3\I.*VOA2JI\+O#P4
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M;66.>&3P];M'+&P8,IE;H1VX%>@>5'YC2>6F]A@MM&2/3-*J(F-JJ,#' [4
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MOD*74'AB4.C=4;S(N#[C.*CU/_D"?%S_ 'F_])4KUK SG SZT;5Y^4<]>.M
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MCP]< ,M[*6524C/S+O&#O4X/!]:]9\F/S?-\M/,QC?M&<>F:##$91*8T,@&
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MV S[?9ZY?3-?TS0OA3J_A?4KA$UV 7MH;!O]=<22/(4*)U<,'7D9%>Q!0"2
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ':1W-\[+%)/' I52WSNP5?U(KS>Q\9'2+Z_%CK.IZYIZ:3<7C-J%JT;0SQ
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MUB>*6-$!S&$5@0<_7M6?X1\ 2^'/$M[J$UY'/9HDD.EVZJ1]FBDE:5P<]\D
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M 2S'Z8KKO%GAYO$>D1V\%R+6]MKB.[M)RNX1S1ME21W'4'V-;BJJ(J(H55&
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M*9%.Y6^5@0P);ZAJ<?"VH3W/AJZOM6%W<Z5<33SRM"%\XR(RX4#[H&[CKP*
M.3U'7=5\$OXSM(]4N]0CLM,AO;-[YQ(\4CET(W8&5R <'TI=?T&_TBZ\$R7&
MNW^HB76[?[0MXX<>;L<[DX&T?>&WIR/2NGU?P/'K>JZ]/=7(%MJVF1V&Q5^:
M,J7._/0\L./:L]O!WB?4KC07UK7+&1-&O(YT6VMF4SA006<EC\V#QC Y/7C
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MW30R1&&3>W+J1@Y([D5R^B^$K^R\1Z7K-]>VTLMIHQTQTAC90Y\P,'&2<<*
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MM*L]+M+0I!9N(V:69#(6?(.=HP-IX]JL_"A9E\*7BW+K).-5O!(ZC 9O-;)
M[<U:OO#.N6OBJ[UOP]J=E =0@BAO8KVW:0;H\A9%VLOS8.,'BKW@OPU+X4T.
M33I;PWC-=33^<5P2'<MS[\\T 844>H>,/%GB*%M;U'3K'298[2VBL)1&6<QA
MW=S@[N6  Z8'2L*U\0^(=:MO!]F=6DMKN?4+VPOKB%5'FB%7&X C 8A<CC ;
MG':NLN_#6NV'B'4M5\-ZC80KJ@0W4%] T@21%VB1"K#DKC(/'%1Z?X!&F?\
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M6:3S%7:#YDKOC'MNQ^%;M !1110 4444 %%%% !1110 4444 %%%% !1110
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MSUH ]'O-<M;+7=,T>593<ZBLS0E5!4"(*6W'/'WAC@UI5YG/HSZ'\5/"$?\
M:E]>6K6U^5%].9GC8(FX[SS@C;P>!@XZUD6VN2V^K:'?6.N>(=3DO-52VN+F
M:"2/3IXY&92(U;Y1CC!7^Z>30!['17EMM9:GXA'C2:?Q%JULFG:C<1V26ER8
M_+*QJW)'++R,*>!SQS2:7JFI^,[KPQI-SJEY9Q2Z NJ7DEC+Y,D\A94 W#E1
MG<Q QU% 'J=%>7^(KG5O#EOHGA^^UG5+J"]OIRUW8PL]X;9$W+'E 26R0"X
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M,>YXH ]4HHKA_&US =8TZRFUC68@T,DG]G:+%(;B8Y $C.G*HO(QP"3U.,4
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M8W%U]C7P]E=4%M,/]-N0S(H&TY\KY2Q]2<=J /3Z*** "BBB@ HHHH ****
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M9HUD #!6&1G!(S^-5#XEMSJFLZ;%:W4UUI5M'<2)&@)E#ABJISRWR$8..2*
M,[3O!%OI.L:%=65P5M=(TZ2Q2%ERTFXJ=Q;/7Y>>.]36/A5K-?$X-X'_ +;G
M>8?N\>3NB"8Z_-TSVK<TZ[:_T^"[:UN+4RH&,%PH62/V8 G!_&K- 'E,_A^_
MTSQCX,TG3M2CCO=-T.>-+B2#='*4,2D,FX':1GHV0<<\5L/\/KVYL-1N;K6(
MFU^\O[>_^U);8AC> CRD$9;)0 $=<\YKNS%&95E,:&105#E1D ]1FGT <))X
M(UF[U2[U*]UVWEN+_3)=.ND6T*QHC [/*&_*[6.3N+9R>G&-&\\'M=>&/#VC
M_;0ITF>SE,OEY\WR,<8SQNQ[X]ZZJLK3?$6FZMJ^J:7:2L]UI;HETI0@*6!*
MX)Z]#TH X#Q=9:9XT^(VAZ?IMVMQ+:[QK/V=@R+;HZN(I2.A,B ;>OWLUZ;?
M6[7=A<6R7$MN\L;(LT1P\9(P&7W'6GQ6\,)<Q11QF1MSE% W'U/J:DH Y+3O
M#6N2:]IVI^(-8M+PZ9'(EJ+:S,+.SJ%+R$NW.!T&!DY[5JZ]I^L79M9]%U5+
M*YMV8M'/"989U(QAU#*>.""#Q^-,TWQ5IFJ:]>:+!]I6]M%+2)-;O&"H;;N4
ML &&1U%;= ' W?P]O;O09(VU>$:S)J\>LFY6VQ")DV@*(]V=N% ^]DGFK'_"
M(Z\-6O;R/7;6)-5AA34]EF=^Y%V$PG?\F5X^;=CK7;44 <3X=\"W6C7>@2W&
MJ17"Z-:3V<82W*&2-RFTGYCR O/KGM3M4^'Z:JWB@R:@T9UJ6VFA=(_FMI(4
M4*W7YOF0'MQQ[UVE% '$P^$-<O/$^C:[KNN6US+I@F1(+6T,4;+)&4)Y<G<2
M02>G& !UK-'PZUL:#9:-_P )%;BTTF>.?30+(@EHY R^?\_S@#(PNWKD\BO2
M** .?T+PY)I&NZ]JDMVLS:M+%*46/:(RD80CJ<YQFN7N/AQK#>'M1\+VOB*&
M#P_<F5H8_L9,\0=BWE[]^"@8YZ9(XR*[37O$.G>&[)+K49659)!%%''&TDDK
MGHJ*H)8_2JVB^+](UR*]:&2:WEL<&[@O86@D@!&065P" 0"<].* -:S@-K8P
M6Y;<8HU3=C&<#&:\B\%>%-9\0?"K2]+.MPQ:%>*6N(3;$SA?-):-)-P 5B.Z
MDC)KO-)^(&A:SJ%O9V[7D;708VDMS:21170 R?+=@ W'-17_ (^\.:#=W%AM
MNF2QP+J2SLI)(;3//[QD7"^M $-UX,U%M8U=K#6(K72]8"?;(?LVZ9=L8C(B
M?< H90!RIQVKF_%MM'HOPVL/",VJ07?B2#[.ND1VJ;)F=' B<(6)  4[FZ<-
M7<ZOXQT?1XK)I)9KJ6_7?:064+3R3K@'<JH"<8(.>G-3:%K6C^)8#J6G8>2)
MVMY/-A*30L.J,& 93ST]Z ,6_P# :77PO7P;!=BWQ!%&;@IORZNKLQ&1G<P)
MZ]ZT_$_AQ]>@L9;6\^Q:EI]P+FTN#'O56 (*LN1E6!((R*WZ* .2L/">H2:G
MJ&L:YJ4%UJ=S9&PB^S6YBAMXB22 I9B26P22>P%8[_#"1_AMI'A+^UE#:?=+
M<&Y\CA\2,^-N[C[V.O:O1:* (+W_ (\+C_KDW\C7E'A#PEJ_B#X8Z#ID^M0#
MP_/%%-/ ;4FX90V\Q"3=C:6'7;D#CFO7B 1@C(-,CBCAC6.)%CC4855& !["
M@#$TWPXUAXQUO7C<AUU.*WC$.S'E^4K#.<\YW>@Q7+W/PYU:?0;SP^OB"&+2
M#.]S:HMH?-#M*9561M^&56.<  GCGM7HU9]WJ;VNK6-B-/O9UN]^;F*,&*#:
M,_O#G(ST& : .:N?">OPZK=ZGHNNVEE<ZG#$FH"2R,B&5%V^;$-X*G'8EAP,
MYI+OP1J$5]X=OM*UK%WI%O);/)J$37!N$<+N8G<#NR,]>_M6G:^--/N[WQ':
MI!<A]  -T65</E6;Y.>>%/7%7_#FNVWB;P_9ZS9QRQV]VA=%F #@9(YP2.WK
M0!S]O\/H#>^,7O;OS[;Q)L#1+'M:$*K+P<G)^;(.!TI^E^%M?6]L#K?B);RQ
MT^-HXH+>W,)N,KMW3G>0V!V  SS6[IVNVVIZMJVG0QRK-IDJ13,X&UBR!QMP
M>F".N*U* .,T;PIK^D?8--3Q%'_85A(&AB2UQ</&,[8GD+%2HX&0H) [4V]\
M(Z]J3?V??>(()]#^V+=;7M#]JPL@D6/S-^W ( SMS@8KM:* ,72#JIUW71>S
M/)8B>,60:(($7RU+ 'JPW'J>^1VJCK/AS59_$\6NZ+JEO9W#6?V*=;BV,P,>
M_>&7#+A@2>N0<^U=110!P6F_#RYT]M.B;5UFM=.U>34H=\!\Q@X?<CMNP3E\
M[L#ITK5U7P9#K&O:G?75P3;7^C_V6\"IAE&]F+AL_P"UTQVKJ** //O^$$\0
M7L>AP:MXDMY[?1;R"XMUALBC3>4>#(2YRVW(XP.23FNRUFRNM1TJ:VLK^2PN
MFVM%<QJ&*,"",J>H.,$=P32:7J;ZD;L-I][9_9[AH!]JC"^<!_&F"<H>QX^E
M1ZAKMMIVM:3I<L<K3ZH\J0L@&U3&A<[N<]!QC- '-R^![_6QJLWB/5+::YOM
M..FH;&V,211D[MV&9BS;L'J ,>]-C\&:_>7F@W.L^(+:?^QKA9(H[>S,8E4(
M5)?+GYSD<C '/!SQW5% 'GP\">(+.UUNSTSQ';PVFLW=Q<7 ELB[PB4G/E$.
M,';@<@C(R,5B7R:;!\7/A_H>D7$=P-&MKJ&:.-P[0*(=J[\="<=_ZUZY4*6U
MO#+)/'!&DK_?=4 9OJ>] '(KX1UVQGN[32/$,=EH]W=-=,GV7=<0%VW.L;[M
MH!.3RI(R:EU+PKK$7B"_U?PYK-O82:E%''>1W-J9EW(-JR)AEPP7C!R#@5N>
M'=<MO$N@6>LV<<L=O=IO190 P&2.<$CMZUG7'C2SB\7#PU;6&H7MZBH]P]O$
MICME<X!=BP]<\ \4 9EUX&U"&Z\.7NE:X1>:/!);O+J$37!N%D W,QW [LC/
M7O[5TGB/1D\0^&]1T=YC"MY;O#Y@&=F1C..^/2M.B@#ASX-UM[+1;EM:M%UW
M1]R6]RMF?)DA9 ICD3?DYV@Y!&#T%:OASPW=:;J6HZSJM]'>ZMJ'EK(\,/E1
M11H#M1%))QR223R371T4 <MK'AO59O%$>NZ+JMO9SO9_8KA;BU,PV!RX9,,N
M&!)ZY!STXK!N/AA=3^&$T$ZTIMH-7&HV\KVY,FW<SE'.[#'+'Y@!]*]'HH Y
MF7PHTGQ)A\6_; %CTPV'V;R^2=Y?=NS[XQBK'BK0+C7;2Q:RNX[6^L+Q+RWD
MEB\R,NH8;64$$@ACT(-;U% 'E7B_POJNF^'O%NN7>L0W;W^CF*\C%L4 =-VS
MROF.U0&Q@Y)QG/-;-AX2U?4/^$?.K:U!<Z3I;1W5M EJ4FDD5,1^:^X@[<]E
M&3UKJM<OQI^FF5M+N]25W6-K>UB$C$'N02!@=ZM?;;1+]-.$T8NC"9EA!^;R
MP0I;'ID@4 >6^'-$U_4[7Q=!I.MV]E:WNN7T,ZS6IE>/+8+1$,N"1Q@@CC/%
M=0W@&*/7_"-]:7?E6WAVWDMT@:/<TJM&$!W9&",9Z'-=?'%'#N\N-$W,6;:H
M&2>I/O3Z .+MOA]!]I\8&]N_/MO$A7=&D>UH0%9>#DY/.0<#I26?A#7IY;:+
M7?$OVJPM('ACAM(# T^Y-FZ8[R&(!.  !GFNUHH \[7P#X@;3=&M)O$=HW]A
M2POIX6Q(1A&-H,P\S+';Q\I4#)ZYXE'@?Q!8KKL6D^(K:"#6KR>XF6:R+M!Y
MG&8R''S8XYR. <#OU^DZF^J0SR/I][9&&=H0MW&$,@&/G7!.5.>#[5H4 <8_
MP_ACUCP==6=YY5MX;AEA6%H]S3!XPF=V1@\9/!SFD'A'7;*XO;71_$,=EI%Y
M=-=.GV7=<0%VW2+$^[: QR>5.,FNTHH :Z!XV0]&&#7G>G_#S6].\.Z;ID6N
MV;R:+=K<Z9*UD<8Q(&64;_FR).HQC%=M/J;P:U::<-/O9%N$9C=QQ@PQ;1T=
MLY!/;@UH4 <&/!7B**]UB^@\30I>:Q:QPW,WV,YB="P#1#?\H".0 <G(!R>:
MNQ^ [;3+S0KK0)Q82Z9']FERF\75N>61^1\V[Y@W8DG!S77T4 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% 'EGAW[=<7?B_Q!>ZMJ,T>B:M?+:68
MN6$6%7=AE_B&" !T&..M9GA_4]49O#>IVL?BZYU&\GA.I/=02FSDBE^^5!^1
M53<"I4#@>]>C:!X7CT6+7(I;@74>K:C/>NICVA!*%!3J<XQUXZ]*S]&\):UI
M+Z?9MXGDDT73V_<6R6P25T (2.27<=RJ,=%&<#- '+:=I-_XATSQ=?7/B'6(
MIK+5;Z+3Q!>NBP!#E<@'YAGC!R !@8YJ32=3OO'>J^']/OKZ[MK0^'X]3NEL
MYF@:XF=]G+(00HVL< CDBH_#?A_6=6M/%L.FZ^-/M;S7+Z*YC>T$S ;\%HVW
M#:Q''.1P",'KU5SX(>UGTJ\\.:B--O--LAIZM-!Y\<UN,$*ZY4Y!&001R3ZT
M </K^KZQHOA/QKI-MJMY)+HU_9"RNY9F,HCF:-MC/U8#+#).2#BKOC?PI'81
M^$X9-8UFYDN?$4"S2RWSY)=&R5 ("D%!C'W<G'6N@NOAS]M\+:MIESJ[2:CJ
MUW'=W=^8!\S(R$*L8;A0$"@9.,YYK8\8>&9?$UE8+:W_ -AN]/OH[ZWF,/FK
MO3( 9<C(PQ[T <]!=WEM\<H=&6^NWT^/PX'$$D[,I<2[=Y!/+8_B/-<E&FJ#
MX-CQE)X@U=M7M=TL!^V/Y859RNUDSA\@');)YQT %>CVWA":/QU!XJN=36:X
M325TZ2);?8';?N,@.XXR?X><>M5?^$!'_"L)/!G]I'#QNGVOR.FZ0OG9N]\=
M: *(MKCQ9\0/$%K<ZKJ5I::/%;1VT5E=-"/,D0R-(VW[Q&0 #D<'BKWPPNK^
M\\)2/J=Y)>7::A=1O,[$YVRL./0<<#L*Q?$5Q8:#XZN[A?%7_"/3WUG$;HW5
MHLD5R$RJM$Y( D4<8P>HX-:_PHLGLO <&Z.9(Y[FXGA$^=YB:5BA;/.2N#^-
M '.^-KU&O_$4]MJ?B2YO;"WS NF!X[;3W6/=B0A@KDGYFSG .,5<W7_B;QQI
M5E<:I?6UC<>&X[VXAM)VB\QS(!P5.5^]U&#@8SC-:U[X$O+FXUNWAUYK?1M9
MD::ZM5M@9=[($8++NX5MHR-N>H!&:MZ#X0N-*UBPU*ZU1+N:UT@:60EMY8<"
M0,'^\<'  ([]>.E '#_VGJMOHMSX=CU>^P_BU=&CO&F+7$=LRK(0)#SNQE0>
MO-;5OHHT3XP:-!#>WEQ:MI-RT:7<[3-&V^/=AV);!XX)X.<=:T[OX>K<V6JQ
MIJCPW5UK UBUN%A&;690@48)^<?*<],[JGTWP?J4?BVV\2:OKJWMY#:R6OE1
M6GDQ[&*D;1N)!!!R3G.1TQ0 >+[N[TKQ#X5U*.YF2R:_-C=PJY".)E*HS#H=
MKA<'_:KG-#\27D7CF_U6_OIFT34OML=I$SDQQ?9"@W*.@W 2MQUQ7=>*-!'B
M7P]<Z7]H-L\A1XK@)N,4B,'5@,C."H[US6K?#.+4? ND^&X=5DM9-/X^V+#N
M:3<CI+\N[C>';N<9[T <HFI:[!9_#BXN=2O1-K&J/<W*>>V&CD.Y(R,_="E1
MMZ5=T_1XH_&OQ)G^UW[&V@B**]V[*WF6S$AE)PP&?ES]WMBNTU[P;%K.H>&[
MF*Z^RQZ'<B=(A%N$@  "YR-O3KS5:7P9>#Q3K>J6NL+%9ZU L=W:/:[VW+$8
MU97W# Y!(P<X]^ #B+2PNM#^'G@[Q%;ZQJ1O"^GQM%]I;R&AD*)Y?E?=QM(Y
MQG(SFM?3O#HU_P 9^.5FU/4;6&.\A$:65RT!WFW3YR5P6QQ@'CKP:Z6X\%"?
MP5H_AS[>5&FFT/VCR<^9Y!4_=W<;MOJ<9[UHZ1X?&E:QKNH?:?-_M6=)MGE[
M?*VQJF,YY^[GMUH \[T75]4\66/@;2+S4[N&.]L9[J_FMY3%+<>40BKO7D9)
MRV.34VJ/<Z58_$+PR;VZN[&'0VO+4W4QEDB#QR*R;VR2,J",GBMZV^'DNG:)
MX?@T[6/)U70Q(L%ZUMN21),[T>/=R#Q_%D$9JQ'X&EFTSQ&-1U;[3JNO6QMI
MKM;?8D2;&1%2/<>!N)Y;)/>@#D])>XU+1OAOX;6]NK6RO-,>YNS:S-%)((HT
MVIO7D ELG'I3DMKC0M7^)B0ZA=2M;Z+"]O/+*6FC BF(^?J2#T)YQCGO732>
M IX=(\-1Z;K'V;5- B\F"[>VWI*A0*ZM'N'! '\7&*2U\ W*_P#"3S7NN-=7
M?B"R6UFE^S!!$0CIN50WW<.,+_L]23F@#F+*\U;5-&^&=O\ VS?PMJ4<PO)H
MYVWRJ("QR>YXX/4$Y'-)JVJ:CX+3QS9:=J-Y-%:V-K/9F\G:=K>25FC8AGR<
M9PV#GD5V&G>!1I\/A&/^T3)_PCRR*#Y./M&Z,Q_WOEQG/>HO$GA&SN!XHU._
MEN)K74=-2WDM[:',B"+>VY.?F;+9 QU'>@#&U71[WPMK?A".SU_5IK>[U)8;
MR.ZO'E\YO+<AN3P#@Y4?*?EXXKTVO%[6[_X2/Q/X-2#Q4OB&XM+G[0P@MA"M
MO"(VW-, 3\Y)0<D=\#DUZQIME>VD]^]WJ37B3W!E@0Q!/L\> /+!!^;D$Y/K
M0!H5Y1X7=XO&GQ6DC9D=3"RLIP01%)@@UZO7)Z;X*&GZQXKO_P"T#)_PD&SY
M/)QY&U&7KN^;[V>W2@#ATAU*Q^'WA?Q:VO:M-JKR6/F[[MS%)'(ZH4:/.T_*
MW)QDGG->R5R<_@D3>!=+\,_V@0+#[+_I'D_?\EE;[N[C.WU.,]ZVO$&C1^(-
M!O-*EFE@6X3 EB.&C8$%6'T(!H Y/6+E+/XC:M<R7RV*Q>%]QNF3>(<32?/M
M[XZX[UC>&KZ2R\:Z!;6<OB5K;4;:<7+ZR7V7#(BLLD:NQ*GKD  885OCX?W.
MH6>M?\)#KC:A?:G9+8BXBMA"L,2Y(VH"<G<Q8Y//3BGQ^#=;EUO1]:U#Q(EQ
M?::[*H6QV1-"R[77;OR';@[\D# ^7U .%2+5'^#TWB^3Q#JYU:T,LMLPO'$:
MJD[+M9,X?(!R6R><= !7?Z+?W5Q\2_$%M)<2M;1V%E)'"7)1&;S-Q Z G S]
M*1? 87X9S^#O[2.)4E7[7Y'3?(TGW-W;=CK4E_X2U,>)6UK1-<33Y;BUCM;I
M);03!PA)5U^8;6&XCG(]J .3M]5>Y\(F/4=:U5&F\074*Q60>2ZND61\0H0=
MR# !)'0+CC-9]WK>HVG@/Q];VMSK-JNFM"UD;Z5OM4 =48J7R6QG.,G.#75V
MWPYN-,T_3TTS7"E_I^H7%Y!<W%MYH(FW!D==PW<-]X$<C.*9=?#6[O++Q%:S
M>(6D&O0Q_:9)+0%EF3'SKAP NT8"=N.>.0"EKUEJ'A#1M,\4)K&J7;6UY'<:
MJDMRS1R0R ))MCZ +D%1CC%;<5[=:U\4FAMKN5=+T6Q!F2.0A)KB?E0P'#!8
MQD9Z%A6AXLU/0M&\+SV^OW*+:W%N]OY1^_/E<%47J6.>@K/^%WAVY\/>"+5-
M1W_VE=_Z1=&3[X) "J?=45!]0: .@UIM'LH$UK6!;I'INZ5+B8?ZG(VDK[D'
M'')SBO,?$T&H7OA#QIXQGMI;$:AI\=I:6SC$@ME8Y>0=F;>3CL,9KN?&7A6]
M\4?V7]DUA+ 6-Q]I*26@N$E<#"$J67[O)'7G'I2VOAS6;FTO['Q)K\.K6%Y;
MM T,=@MN5W<$[@S=LT 9GQ BBMM"\-FV4*;?6K 6X7M\X7 _X"2/I4GB:[M=
M/@N_#/AZPBEUS6A)(T*+A(_,&U[B8]E_5B,"BP\#ZF+S2O[:\1MJ>GZ2XEL[
M?[((F+J"J-*X8[RH/& .>34$/@CQ+8ZSJVHZ=XP@A;4KDSOYNDK*ZKT1-QDY
M55X'3OZT ;$.A'P[X?LCI.G0:CJVG6$=C \T@B:2,;<@O@[1QNQCJ*R?AR[R
M7GB634$:WUV2_$FH6FT!8,QJ(PA!.Y2HSNXSSP*NZAX3UB>[T_5K+Q$+?7+:
MV-K/<-9AH;I"=V&BW#;SR"&_.J<GA;5]%\,>([NSU>>[\3ZD!*;R.W5<NB@1
MHD>2 H QR3U)- ':W,(N;66 O(@D0H7C8JRY&,@CH?>O+(_%&K6WPQOM(DN9
M)/%%M>G0DE9SODE=ML<H/7_5G=G_ &2:]5W"*#=*X 1<NQX' Y->8:19:;XK
M^+UQXCTF8W&DV5O&99DYAGO0&12IZ,5C8@D="10!;L],GU_QAJFA7NKZH+#0
M+.T@C6"\DB>>61"S2R.I#,>!U..M95EKFK>5HEA-J5S*]CXNETJ2<R$/<PHD
MA428^]P5SGJ5SUKL]3\+:C_PD4VN:!K$>G7=U D%VD]KY\<H3.QL;E(8 D9S
M@CM5"7X=A?#EG96>K21:I:ZC_:@U"2$.9;DEBS.F0,'<1@'@8]* +2WEU_PM
M^2Q^T2_9!H*S>1O.S?\ :&&[;TSCC-)X@N[K2O'_ (9N1<S+IU\)]/GB+GR_
M,*^9$VWINRC#/7FI=&\)WMEXKE\1ZEK/VZ\FL19NBVWE(H#[AL&XX'L<G))S
MVJWXQ\,_\)7H!T]+UK&X2:.>"Z6/>8G1L@@9&>,CKWH X+P[XNOK"]UO6M2O
M)IM/U&PN=5L(IG)6)()738@[;D:)N/6F6=QKFF>(OA=87FJ7TDEY;W4M^LD[
M'S7,8<!QGG:6P,],<5TVO_#6UUK1- TJ.^:UATE5A8K%N\^#:JO&>1C=M7GG
MIT-:NL>$QJWC'P]X@^V>5_8_GX@\K=YOF)M^]D;<?0YH X?1?^1C^+O^Y'_Z
M(DKJ/A)_R2KP_P#]>Y_]#:IK+P.+/4?%UW_:!?\ X2(*"ODX^SX1DZ[OF^]G
MMTK4\)>'QX6\*Z?H@N?M/V2,IYVS9OY)SC)QU]: .)T[PY_PD'C_ ,<+/J>H
MVMO'<VX1+&Y: [S;I\[%>3C P#QUX-8=MXJU'5=*\+:;J<NLW"/'>&^;25?S
M[DP2^4F2F&"G.6(/)Q7<2^#=8M=?UO6-%\1I9S:L\9ECFLA,B!(P@(^<?,,$
MYZ<X(.,TB?#_ /LW2M#BT/5&M-0T=9%CNIH1*LPEYE$B9&0S?-P1@B@"7X?7
M6HRV6I6UY%JJVUO>%;&35(F2=X"JD!BW+;6+#)[ 50FM9O%_CW7]-NM3U*TL
MM'AMD@BL;IH-TDJ%S(Q7DD?* #QP>*ZO0M.OM-LI%U'5)-2NY96E>9DV*N<
M*B9.U0!TR>YSS61JOA34F\07&M>'];72[J\@2"[66T$Z2A,[' W+AP"1W!':
M@##GMM6O?$^A^#M3UR[DB@TR6]O+FT=K:2[(D$: LIR  <G!Y-8>NZGJVA:)
MXZT6TU6]?^RWL)K&YFG9YHEF=<H7SN(!4]3G#8KL'\"36L6C7&D:U-!JNF0O
M!]KNX_M N4<[G61<@GYAD8(Q4,_P\>]\/ZW:WNKF;5-9FAENK[[. H$3*418
M]W"@+CJ3R3F@"K-87/AGX@^&8[;5]3N4U4745ZEW<M(DC)%O5PIX0Y'\( P<
M5F^$9W@U[3K;7-3U^P\2L[_:8+YW>TO^&R(>?+ '!7;@@#&#7=:OX=&J^(-$
MU0W31?V6T[>6J9,GF1E/O9&W&<]#61:^#]8>]TP:QXD_M&PTN<7%O&;0),[A
M653+)N.[ 8] ,GK0!P]MXEUJ+P?XX>/4KDW7_"3/I]K-)(7-NCRHGR9Z !C@
M#H:V]0T!= ^(_@=;?4-0N;=Y+S='>W+3D.+=OF5F)(SDY XZ8 K4A^&ENN@>
M)=*GU*1UUK49-065(MC6SEE9<<G=M90<\9]JGM_!FL3^)-%US6_$:WMQI1E$
M<4-D(497C*$D;S\QR"3TXP .M '!:9K^JZAI5GXBM(?%MQKDUTLS*D$K6+PF
M7!B"_<VB/.&QG(SFNITFTO=<^)WBA;O6-22QTF[M9+>TAN61"YB5B&'=>/N]
M#N.<UJV'@S5M+:*PLO$CP:!%<^?':); 3*N_?Y7G;ON9_P!G..,UK:/X<&D^
M(]?U?[5YO]KR0R>5Y>WRO+CV8SD[L]>@H \KT_7]5U#2;?Q%:0^+;C79;H3!
M8X)6L6A\W!A"CY-HCS\V,[AG-=7IUE=^+=<\4W\VL:E:OIU^UA81V]RT<</E
MQJ2Y0':Y+-SN!&.*T[+P9JVF.EA8^)'M]!2Y-PEHEL!,JE]YB$V[[F2?X<X.
M,TL_@O48M:U2YTG7S86&KN)+RV^RB1P^T*S1/N&PL .H;!YH 3X3?\DL\/\
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MW,_VOPY)/.N\A9),Q?.1T)Y//N:9>:H\<WC^.[UF^LX4OK6"![?=)*F^*/\
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M/E<KYDC2?=SVW8Z]JV;+Q#8WVJ'3%$\5^L)G:">%D94! SDC!&3U!(Z^E:M
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MLLR3Q+RN4)&&!R0<]\<TP^ WMK+2FT[6[F'5M.:5EOYXQ,9O-.9 Z$@%2<$
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M_P#"MS]DU0'7+AKZ]O;?4$NWA4F*>(+AMN<%21]W@ '':N[HH XZT\%7T7B
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M+V^MXX9BT(C4%"<%0#P,$#'MG))J?Q'X9DUF\T_4K#47TW5=/+^1<B(2J4<
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M:>>,[LYYJ#1_"MSHOBC5=3M]6+6&I3&XEL6MQD2E0NX29SCCIBNFHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ H[444 >:7>O^(K6Q\7Z:=4=M;TV:.33F^SQGSXI0/*7;MY);<I
M/8@'@5O:%K<_B-=&N=/OY/L[Z<+JZW1H=SO\J*W P=RRYVX^Y[UI7/ABRNO%
M]EXC<N+JUMGMP@^Z^3E2?]W+X_W_ &I/#GABS\,6M]!8,<75U+<_,,B/><A
M/[H[#W/K0!YWKNL:SJOPBUVZN]3E6YMM6>T+P(B"2(7*Q;2,'C!]<GN2,@[N
MOVM[_P +*\)VT.HN+@V-\#=2Q(S@?N^0H 7/8<8]0>]__A7R2>#]6\/3ZG(T
M>H737?GI"%:*1I!)P,D$;@./2KS>%KJ7Q%I.LSZN9I]/AEBP]N )?,QO)P1C
M[HQCICG- $7@35=1U&TUBVU2Y%U<:9JLUB+CRU0RHH5E9E7@'#8X':LZYCO)
M/C7;1#5+M(!H<DRPJ$*+^_C#* 5/#8&3UXX(%;_ASPZ^@2ZLYO?M U&]>]<>
M5LV.P (')XPH]_>FW_AEKKQ99^(+?49K6>&V:TEC6-6$L1</C)^[R.H[>G6@
M#SJ*[UK2?#/CK6M*U-;7^S]>O)_)^SJXGP4RKEN@(X^7!]Z[&ZU_4-5U^?2-
M.%["+>PAN7DLQ 7WREMH_?'&T!.P))/48Y0^ G;P[X@T=M6S'K=U+<S2"WPT
M9DQN"_-TX&,YQSUIVI>!KFXU&PU;3-?GTO5[:V%I+<0P*Z7$0.0'C8D9!Z'/
M?Z8 -GPM+KDOAZV/B2WC@U5=RS")E*M@G#?*2!D8)&>N:Y+X:R/>>*/'E[=\
MWPUAK8[NJPQC$8^F,UW>F6/]G6*6YN);F3):2>;&^5SR6.  /H  !@#@5B7?
MA%D\13:_HFHMIM_<HJ7:F$2PW(7[I=,@[ATW!AQ0!>\17MKH6DWOB*6#S)=/
MLYF7'!*\,5_$HM<MJ>O:WH.@:%XDFU#[9!=2VZ7]H845%6; W1$#<"I88#%L
MC\ZZHZ']MM;F+6K@7WVF!K>1%C\J(1L,,%7)(SZDD^F*R;/P4\6G:;I5]JC7
MNEZ;*DMM"\(61O+_ -6LCYPP7CHJYVC.><@&,VH^)[_4/&EI%KJVHTAD:U>.
MT0GF'S-IW9XR>>Y[$=X8O$GB$:;X*\03:C&T.M7-M;7%@ENHC E0G<&Y;<",
M]<>U=+!X3G@O/$=TNI*7UP+Y@-OQ$0GEC;\W/R^O?GVJJW@60Z#X=TD:KB/0
M[B&XAD^S\R&($(&^;I@G.,9]J ,J.Y\8ZYK'BO3K#7[>R;3+A$M6%DC;BT0<
M(V[.%R>3R?3&,%VD>+-3\0Z!X9U)[M-/BOH)OM,=M&)+F69#M B0JWR9#,3C
MCCG'6OX:^T7_ (X\=1Z;K-O!YEU"#B(2L (%!=/F&"#D<[AD#CUW!X!AL;[1
MKG1-2GTW^S;1K$*L:R^9"Q#'[PX;<,[L'GM0!S:^,/$<_P /]#U2.[ACOI=9
M73[AGMU/FK]H,?(SA20.<>^,5NV-YKR>-M6\-7.M&</IB7UM<_9HU:W8NR%0
M ,,O /.3[]ZCC^'#0Z#!I$>N3M!!J8U&,R0*2K"0R!>",C<3D]^V*U+G2DTG
MQ)>>,K[40(8M.^SS1+;DA8D8R;A@DYR3V/'&.] &+HGB/5M3\-6]A->M'XE7
M4SI]V5C3Y&1BTC!=N-OE D''4@9KN#8Q-?QWDA9Y8HS''N/"9^\0/4X'/MQC
M)SROABSTO6/%>H^,].23[/=V\5O#*R,@F(Y>0*P!Z;$SC^ UV= 'GVB^*[F]
M\3Q:3J6I3Z=JR74OFZ9=0(L=Q -^PP/MRW\!SNSPW&*Z+Q?KLN@Z1#);A/M-
MW>064+2#*HTKA=S#N "3COBJO_"(2W+Z4NIZDMY#I=U]JMB;?;+N&=JL^XY4
M9[ $X&2><Z7B;P[9^*M!N-)O6D2.7#++$</$ZG*LI]010!CZI>ZWX3AUC6+R
M^34=&MM/,T<<JJMP+A<_+\B*NPC')Y!]JSM4US6_#VDZ!K\^H?;;>\GMXK^U
M,**BB; W1$ ,-K$<,6R/?FMJP\)W#6%S;>(M9GUSS[=K7]["D*K$WWAM3JQP
M,L3GCC'.8;/P9)'8Z9IFH:HU]INERI+;1/"%D8Q_ZL2/G#!>.BKD@9SW ,1M
M2\3WU[XUMHM=6U_L=T:V>.T0GF$2;3NSQD\]_0CO'%XD\0K8>"M?FU&-H-:N
M+>VN+!;=1&HEC)W!N7W CUQSTKHX/"4T%UXCN%U)2VN8\P&WXB(3RQM^;GY?
M7OS[56;P-(="\.:4-5 CT*XAGA?[/S(8@54-\W3!.<8S[4 945SXQUS5?%5A
M8:_!9OIERB6I%DC;\Q*X1MV<+DX)Y/TQ@LT/QUJ/BBST""""XAN;W3I+VZ:S
M$6\%)!%A/-.T MN/<]!WS3/#/VC4/&OCJ/3=9@@$MW$& B$K >2JET.X8(.1
MDAAD#CKG9U#X=VK6NC?V%J-QHU[H\9AM;J)1)F,XW+(K<."1GGOS0!CZCK/C
M;2?#]BU])#;7;:[#9++)%&[7-L[@*SA"51L$@@?ABM&WU7Q%8>+=<T-[Q=5D
M325U&R#PI%MD+.GE_+C*DJ.O(]:NZAX+GU'2K.UN-:FEN8;Z*_FNI(5+32QD
M%1M!"JO & .W7.29KOPE/=^(;_6#JABEN],.FE8X<>6N68.IW?>#,3_G- &3
MX5\4R:W+.L&KR-J%O9/]JTO4X%@E@N/EVL=J [/O GGJ*K:7XDU8>)O#-C+J
MC7T6JVMQ]JD$"B$31HK;H'"J67)(R=P(QSG-;=UX*75KE[K6+T7%P=.FTX2V
M\'D,8Y0 S,<G+<<= ,GCFJMGX"NH+KP]<S^([J:71%>*'%O&@>)D";2,=< 9
M//MB@#$\-3:M9^$O&NHQ:Q/+=6NH:AY;7,:.,Q=&.%!SA0,9VCL*U+/Q1?WX
M\&:2+DQ7FKZ:+V[NU1=P"Q*2$!&T%F;T( !XY&+\'@I[6S\0V<&KRBUUB2>7
MRGA4B!IOOD'@MWQG@9[TC^!U%AX>$&HM%J6@H(K2\$((:/8$*2)GY@R@9P1S
MR,4 8>I>*->TI/&6DF]22[TBP&HV5Z\"EGC*L=KJ,+N#+C('([59M=8\06?B
M'P?]LU1+JUUR&19K;[.B+$RP^8&5A\V<@@Y..> .E;%WX-%]I^NI/? W^M0B
MWN;I8<!(@I4*B9X #,>2>23Z $GA&:2Z\-W!U-=VA B,"WXERGEG=\W'R^G?
MGVH 3XCZOJ6@^![_ %32KB.&ZM_+(9XP^0SJIZ\#[WH:R[G4?$V@>.M'LK[5
M(;_3M;\Z)4%JL?V29$+C;@Y93C'S'/O4GQAEBC^%^KI)*L;2>4J9(!)\U#QZ
M^M;4.B/?:G8ZQ>ZC#>R6<3BR,4.R-6<8:0_,=S8&."!@GCF@#F?#%_XNU?1[
MG6)-=M/]$FOH!;2VJI',4++&SN.4 8 G&>!S4FD>)=13Q=I%A-J,M_9WVF2S
MRRO;JB>;'L):%@JED.X]<@C&#UK5L? R6_A'5O#ESJ$D]MJ+3LTB1B-XS*26
MQR01D\?KFH[3P1=1:OHNIW7B&YN+C3('M\?9XT66-MO& ./NC)Y)[8H @T:^
M\1^)= TGQ'INHP1"ZN!+)8S(ODBVW$%0P4OY@4 YW8SG@"H/#,-_)X_\:J=7
MN7\B:W2-941E :'<!@*#A2QP 1[Y.35K1_ $NB3O:6GB"\'AXS&9-),284D[
MBGF8W>7G^'C/0GDYU+;PQ)8^*=5UJTU.1!J0C:6U:)63S$38K9ZXQCC(Y'7M
M0!R^@^,M5O\ PCX4%S<I_:FN7DUN]UY:@1HC2DE5QC=M0*,YY.3G'.KJVIZ_
MX4TW5KF\NX=0@>XMX=+=E43*965&$H 1"%9LC&,C@D5"OPUA'@VPT#^U9TFT
MVY-U8ZA%&%EADW,V2,D,,L1CC(_.M"7P6-5\/7VF>(=5N-4FO45)+G8L)C"G
M*>6JC"X;YL\DGKQ@  JQ3^,K75KHQVUQ>:<UB[Q?;S;K(ETH.U1Y1Y1N!R,@
M]ZB\%^)QKVHB$ZO<FZ@M2+[2KZW2&>";*88 *"5^\.I'*U=T[PEJD-A<6^J^
M*;W4I#;O;VTK0I&8 R[=_P O+OC^(GU]34W_  C$S:I'K-]J"RZC:V4EK!<0
M6H1@'P2[#+;V&T8 P.3QSP =-7F_C/Q+K>B6GB&^M]33S=/,<EK:6T*RH(\*
M6^T$KE2Q+8 8' !&:Z[PI;ZI:^'X8=8O)+RZ5G GEC".Z;CL+*. =N..OKSF
ML#4?AR;^#Q%9KKMU#I^MR&>6W$*,4E(4$[CR5^4?+QTZT 1^*O%<^C:XMO?W
MMUH^F3VB&TU&.W62#[02V5F)5MHQLQTSEN?3LX[D0Z2EU<2K($@$DDD?(;"Y
M)&.HK#NO#-_<P7-L^M":VN[1;:>.YM%D!(# NN"H!(;N".!QZ[6GZ9;:;H]K
MI4*EK6V@6W17.2450HSZ\"@#RSQ7>ZGXB^#Q\0S:@\<5Y-;S?85C3RUB-P@1
M=V-VX?*2=V,YXQTZG4-9UC5=;UW2]'-Y"^F+'&CVRV[;I7CW@OYI^[@J,*!T
M;GIBF_PQF_X1FY\,P^([F/1&E62W@-NC20 2"39O/WER..,CCDC@Z.I>"+N3
MQ"=<T;Q'=Z5?3PI#>LL$<JW07A6*L,!P.,@?AUR 8=T?$%WXP\!KJUW/I][/
M;WC7-M;-&\:2I&HW+E6!R&/4G /&.<VKC7/$^N6NK77AU+E;BSOI;6VB"VYM
MY/*?:PE+MYGS$-]W;@$=>2=R_P#!RW-YH=W;:I<VUSI/FA9=JR-,)0!)NW#&
MXD9SC@YXJFW@2YM=>OK[1O$E]IEEJ,OG7ME%$CAY#]YD9@3&6[D<_I@ HWE]
MXKU'QS)H-KJT6E*^BI?#%JDQ@E,NTKR<-TZYQC/'0B);_P 47VJ>,K!-?2W_
M +(\EK>6*SC)RT/F8(;(QD\]3Z$=^EA\+FW\8KK\5X%5;!=/6U$/RB)6W#YM
MV=V3UZ8[=ZB@\*3V^H^(KU=24OK80.IM^(MJ>6-OS<_+Z]^?:@#F(?$OB+^R
M?!?B&748VBUBZMK6YL$MU$>)5/SAN6W C/7';'KLP:OK,OC/Q5I9O8O)L[*W
MFM/W _=%P^<\Y;[HZG\*<? DG_"/>']'75<1Z)<PW$,GV?YI#%G8&^;IR<XZ
M^U7D\+SQ>(M8UE-242:E;);M&;?*QA 0I'S<GYCG^E '':?XE\3_ /".>"_$
M%SJR3+JM[;VES:"U149921OW 9# X/&!VQW.M=ZUXCUQ==/A\74<^G7;VEJL
M:VYADDC"DB7S#OP22/EQ@8/)JTO@%X_#.@Z(NK8BT:[BNH93;_,YC.4#?-C'
M)SCKQTI\_@:[B\17>JZ+XDO-)CU!@]];10I(DK@8+IO!\MB.I&: "SUK5-<\
M2R:(96TN2PT^"XOO("._GR@_(I8,NU0IYQR2.>.8/A4LJ>&]22>02S+K-Z'D
M"[0S>:<G';)[5=NO!1C\0V^MZ)JDFF726JV<ZF(31SQ+]W<"0=P[-FKOA3PR
M?#%G>6_]HS7HN;N6Z)E15VL[%B!M'O\ X 4 <M+9ZI??%3Q'#I>JC3)#IMF3
M.+=9FZR8 #<8]>#^'6J?_"6>)F\$KK<MR(Y]%U-[/64MX483PQR;9)$W X(&
M#Z<-[5V5QX:N4\3W&O:;J8MI[JW2WN(YK<2H50DJ5PRE6&X]21[53N[GPYX(
MT6WT6],THU S*L9A>:2\D;YI,[5QN8MWP.<#@4 :5C?3ZEXDNFMKPMI=M!&I
M554K),XW\-C/"%#UYW^U8'CI+M_%7@V.#4KJVCEU!U9(@F,B%R&^93D]N<CG
MIGFMWP9H"^&?"6GZ6 1)%&#+N;<=YY(SW ^Z/8"E\1^&SKTVEW$5_)976FW7
MVB&5$5\Y4JP(;CD,: .1BM=3N/B+XTCT[538RK96)-P($D<L$DQPPVX]>/IB
MIM+\:ZEK&C^$HECE%]J]G)<W$EJL6\"+:#L$A"C+,#SG !X[CH+3PO<6>OZQ
MJT>IAI=3ABA99(,A!&"%.0PR?F.?4^E9!^&JIX<T2PM=:N+74=$+?8-1BB&]
M5;[RLI)# CJ.,X'OD V_"C^(O*OX?$$1Q'<'['.YC$DL)Z;UC)4,.G& >.*Y
MOQ6]TGQ>\'-9PPS3?9+W"32F-<;5S\P5C^E=EHNEW&FVS_;=1FU&]E(,MS*B
MINQT"JHPJCT'<D\DUEZOX4N=2\6:=K\6JBWFT^*2*"+[,'4AQAMV6YZ=L4 <
MM;W-R/C?;R^(X$L;N737@TN.U?S89U!+N6D(4[AS\NT#W];"^)M;U/X<W'CC
M3[X1^6)KJ+3VB0PM!$[#8QQOW%5)R&&">F*Z.W\((_BF'Q'JM_+?W]M$T5JI
M18XK<-]XJHYW$<9)/%4X? 0M=+O]"MM3>/0+V1V>S\G+QJYR\<<F?E0Y/!4D
M9.#0!2U;Q%J5S U[9ZB;."71UO;.VMHEEN#(P+%I0R$+&!M&<J"2>>F*LGB;
MQ#J$?@%[2^@M/[>A)N@+</AOLY?(R>QY ]ADD5MW/@</K=]?66K3V5MJ%FEG
M=6L42,"J JFQF!V8#$8 _*H+3P%-9Q>&4&MO)_8&?),ELO[P%/+P<$8&W\<\
MY- #=,OM8OO$5SX9EUMS+I-G%)>7T-O&DEQ+*6*X5@RJH5><#DD=,<L^%*RI
MX6O4GD$DJZM>!W"[0S>:V3CMS6EJ'A&63Q4OB+2=5?3KV2 6]TODB6.XC!RN
M5)&&'9L_A5GPIX:_X1>PN;7^T)KT3W4MSNE15VEV+$#:/4_X8H H-JNJCXHO
MH@NX_L#Z*UW''Y(RDOFJF2>IXSQD=:Y!/$_BM/A^GBJ768W>TU$PR6RVB!;B
M/[5Y)#'J.#QMQTYS7>R>')6\:?\ "2)?*L@L38K 8<KL+[\D[@<[A^7'O6,?
MAXS>")O"YU<_9Y;G[29OLXW@^=YV/O8^^/RX]Z .VD#F-@C!7(.UB,@'UQWK
MR'5=7UC6?@^E_=ZI*MW_ &L()7@1$$B"[\L*1@\8QTZXYSSGUT"7R,%T\W;C
M=L.W=ZXST]L_C7&K\/4_X0BX\,OJDA1[G[5%<K" T<GF^;TR01N[>E %?Q-X
MDN/#>KP6FIZG?6.ER6H$6KK;1R)]I+,"LWR$*,;,8"@Y;)].TTYY)-,M'EFC
MGD:%"TL9!5S@988['K6+=>'=1N?/5M966&YLQ;7$5S:+(K'+DNH#* 3OQCD8
M4=:U](TRWT71[+2[7?\ 9[2%((]YRQ50 ,GUXH XGPWXMN-1UV#3M2U*>PUB
M*24WND7<"(KQA6VF!MN6 .TYW$D YJ >)M<U'X<3^.;"^$9C$MU'I[1(86@C
M=@48XW[BJDY##GMBN@@\(2O/HKZIJ2WW]CN9+:3[/LE8["@WON.1@] !D@$Y
MQS6@\ K:Z3?:#;ZFZ>'[R1V:S\G+QJYR\:29X0DG@J2 3@]Z *37J:E\3O"=
M_&I6.YT2XF56Z@,8B ?SJO;:]XLU[1;'7]"M[B3SKC?]DD^S+;/;[R"-Q;S
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $  Z 4M%% !1110 44
M44 %%%% !1110 4444 ( !T I:** "BBB@ HHHH **** "BBB@ (!ZC-'2BB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>sesenbio_minorirosales-e002.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK\K9!$AP=OTSFN.\3ZT__"(_#VZT>^U**VO-8LTW3SGSI8F#?+*0?FSWY(-
M'K-%>?V=_>-\>M1L&NYS9KH2RK;F0^6'\U1N"],X[U;^)6JR:-I>B7B7$\,:
MZU:B;R"VYX]QW+@<L"!T[T =K17,:7XUM[W5YM+U#3+_ $B[2W-VBWP0"2$'
M!8,K,..,@\C-0Z7X]M-2O+"-]*U*SL]2)73[ZYC58KDX+ ##%EW*"5W 9 H
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M.XKF=*\>VVIZA86\FD:G96^I;OL%W<QH([C"EL !BRDJ"1N R!0!UM%<-/\
M$VS2VU"ZM]#UB[M-,GE@OIX8H]L!C8ACRXW<#=\N2 03BNUM[B*[MHKF!P\,
MJ"1&'\2D9!_*@"2BN03X@V;W\2'2M3339KS[#%J;1H('FW% ,;M^TL-H;;C-
M+>>/88=5U32['1-5U*\TQE%REK&F%5D#ALLP!R#@#J2#QQF@#KJ*Y&;XB:0E
MEH5U!;WUT-;C=K.."(%V90"4()&#SCT&#D@#-,7XB6,>D:Y>7VF:A97&B!&O
M+.54,H5QE2I#%6!&>_8T =C165J6OVNF7FD6TT<S/JD_D0E ,*VPOELGIA3T
MS6+/\0;.WOI%;2M3_LV*\%C+JGEIY"2E@F,;M^W<0N[;C- '7T5Y_!?WA^/E
MU8&[G-D- $HM_,/EA_. W;>F<<9K2^(?BF]\*:%!<V%E+<33744(=%4J@+J"
M""1RP) ]^N* .NHKE[[QDUI+:VL/A[5KK4)K<W4EG$L>^"/.W+DN%R3G !).
M*@O?B-HUGI.BZDL-[<0ZP62U6&(%]X4G85)SN)&W SS^= '7T5RESXX%N^GV
MBZ#JLVK7D+7']G1K'YL,:G!:0EPH&>!SS3+;XC:-=:/J>IK#>I'I]TMF\+PX
MEDG8+B-4SDMN8+@XY![<T ==17'R^.]FG:N9-#U*VU33[471L)A'ODC.0)%(
M<J5!!SSD8/&<9N^!=>O/$?A'3]1O[*:VN)8(V=I%4+,2@)= K'Y23QG!]J .
MCHKSB+Q3>:;\1/%UE'8:IJ[)]D>&UM2"(4\G+'YV"KDD<#DGMP:W&^(&DMX?
MTS5;2&\NWU.0PVEE#&//>09W*02 NW:=Q)P,=: .KHKDXO'MD+#6I;W3K^QN
M]'M_M-U93JGF&/:2&0JQ5@<$9!ZCG%,M?B#:7&H:9#)I.IVUEJCB.ROYHT$4
MSE2P& Q89 ."0,_3F@#KZ*Q++Q19WUCK-W'%.(])N9K:<,!EFB +%>>1SQG%
M9LGCRWD@TQM.T?4]1N+^Q74%M[=8P\4+8P7+.!G)Q@$Y(- '6T53TO48=7TN
MVU"W65(IT#JLR%'7U# ]"#Q7-WWQ!MK:?4?LNBZKJ%EIDC1WM[:QH8XF49<
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MP)X\\731,CZAICVL*,N"J16IW8^LCR?E5#4T?_A6?PK&ULC5K#(QTX:O<**
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M$>,[W"DJ,>YQ7C<&KZ?-?^#-5;Q#J>J2)>H^I37$A^SVLKPN I4 *C%B0!V
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M!(88(/RYR",5YWI]@EIH'@/5-4N]3T[34TN:TGNK)WC:"1F5DWE02%;:1Z9
MS6K=6.G-X;L[O1_[6N8;KQ/92/<:@6=[C:Z+YBYYV8 &2!]WTQ0!V=GXUGGU
M6XTJZ\.:C9ZB+1KRUMY9(2;E%(!"L'*JV2."1UZU%\-O$^I^*_"Z:AJ5A) S
M.Y2<F/9,/,<84*21M"A3N R>1FDU*-S\7="D",4&E78+8X!WQ\9K/^#E] ?
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MGC9HE1G/G/M((CP,ON5L'CUH ]<K!USQ'-I=_;Z?8:->:K>S1M-Y<!1%2-2
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MT9+QY^8J%R,D?PG' JYKUWI&H>,;'Q--K.J66A7FEFVBO[%Y(0)8Y6)1R!D
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M[L$*Q*,5!8!AR >_%=97DOAB/P]J6IZ!$FH^)K[4K8B9[2YFD:.QD2,@^:'
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MUF(+12  ]1P00P((Z@U2U?Q7-:Z[_8FD://JNHI +F=$F2)(8R2%W.W\1(.
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M"L(]QV@^:O..F: /1**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8XY%E;&WKN"?-MZ]NM=+#*WB7QMJ^NV%K=C3K?06T])9[9X3-,SER%5P&(
M'3J: .<T75-.L?@-X7N=9L9M1B>]"*BW#1,',TFUBP.2!Z=Z]$UCQ5>6VNMH
MNB:*^K7T, N+D?:5@2%&)"@LP.6.#@8Z#K7E\ND:F?@#X6LAIUW]KBU*-I(/
M(;S$'G2')7&0,$'\:[>ZOO\ A#_B)K.J:A:7LFG:O:6WE7%M:O.$EAWJ8V"
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M)9*09/-5)D,><X/S#J<#N<5TMAXV==0U2Q\0:4VD7%A9?V@W^D+.CV^2"P8
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MYEL5DC0L($?AY&(Z +D9]ZR[CX3I-X:;0?\ A*]=.G^2(4MW:$Q@#[H(\O.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQ[3O" \Y(S@XZ56;Q1KLOQ9@TBTLHIM)?2Q<@_:@NY&E4>?C;G(Y 3/.<YH
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MY'?U>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /'S>7WAWP!XI\,3:+J+W:?;VAG%NWV>2&0NXE,O
MW0 K'(SG(QC-:FA65T_BGP->+:S-:Q>&RCSB,E$8K'@%N@)YXK;U'X?IJ$U_
M&/$&KP:9J,ADN]/CD0HY/W@&92Z*W< XY/2NNAACMX(X(4"11J$11T4 8 H
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MF9F1_, V*/G^;<1C!J.72&TN_P!*TCQ!8:OJ-A::);V]E#8"4PO=+D2;C&0
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M 4444 %%%% !1110!PK^-M<N?MVHZ1X=6_T6RNFMG9+@_:9RC;7:*,*00#G
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M(7!8+$H4@G ZL0,G%2?#ZWO[;0KJ.[2_CM?MDAT^/4&)G2VPNT/DD_>WX!Y
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M$2X/W6=<)%CL!+O<#T%>O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR7CX#>^Y<'/?F@#J/M]F;9KG[7!]G4X:7S!M!SCD].M3@A@"""#R"*^>8?\
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M:<A3G!XR.M/T/Q9KFO\ B74K&UTNTCL-+U&2TN;F69MS* -NQ0.6ZYR0 ,4
M;?A[PQ9^'1=R13W5W>7D@DN;R[D#RRD#"@D # '    K:HHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** /,]*N/$?A#3[_P[8^'+J]NS?32:?=X7[*T<LA<-*^X%=NX
MY&,\<=:Z#0-.OK;Q_P"*[ZY@98+N.Q$,N,+(4C</CZ$BNDEU"R@NH[6:[MX[
MB7_5Q/( [_0$Y-6* /)=-\/ZWI&C>&=7&EW$]SH^IWTD]DF/->"=Y!N0$X)
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M9"%6X,,<9*@^^UASWKU*B@#@7?4/%_B_P]=#1-0TVPTAY;F>2_18R\C1E%1
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M#7_ GBC4[.PL/[ $%W:QAG?[3(BAHVE!^[C()V]< \UZ#X:_Y%;2/^O*'_T
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M]/D:[TW4K.:[BW+F)$#;B><<9'2@#TO7O^1=U/\ Z])?_0#7FOAWQ1XB\/\
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M3FLAJ-Q!+ C.K'8L07!*DC<, 'MG.">M-\;Z+J.I^*/!EU96K306.HM+<N"
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MES:7$5Q ^=DL+AU;!QP1P>11:"Y%G"+PQ-<[!YIA!"%L<[0<G&?6O'/"6O\
MBC0?A/9ZW;6FFR:-8"0RP2;_ +1-&)6WNK [5QDX!!R!G/.* /::*X34?%VK
M7FN7]AX?FT:&/3X8GD?4F;-Q)(N]43:PVC:5RQSRW3BNG\.:U%XC\.:?K$,9
MC2[A63RR<E#W7/?!R/PH U**\TNOB%JJ6E]K\']C_P!AV5T\1M7=OM<T2/L>
M13NVCD,0I4Y Z\UIS>(O$VI>+=<T+0H=*1=/BMY5N;Q9&!\Q"=I56&22.O&
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MZ)17D>O>+-?UCPSX4OM/DLK6:XUZ.QN0I=D:5)64;2",Q$H21U((&>M=%?\
MB?7GUNXT;3I]"@N=.M87O9KXN$EF=20D:A@57 SN).-PX- '=45D^&-<3Q)X
M:L-72+ROM,>YH\YV."0RY[X8$9K6H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#SJ.V\7:YJNAZ?K>E")-)U%KR?5%E3R[D*KK&(T!W G>,Y Q@USE[X1UN;P]
MJFF)X2BFUDWLEU)K$KPDW*^?YBB-B=P8J%7!P  >>U>RRRQP1F2:1(T'5G8
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MN+"&\@DO+8*9X%D!>(,,KN7J,CIFGW=[:V$2RW=Q%!&SK&K2N%!9CA5Y[D\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD@\_+\RXYQUJVUOXGU_QEX8U:[T'^S+/37N/.26ZCE?<\)4-\IQMS@#N<DD
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MS]D7^UEA13#YJXR)@Y^;.WISUI/BQ8WBW>B7NC3)%JUZ\FC[3UDBG0Y/_ "
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M<%O-#.'R9/,W@@CM@QFL+X@^']2UVY\+/IT E6PUJ"[N"75=D2YR>2,_0<T
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MCD*'3,@VTJ+O*-EVW*5#8;CE>G-9<?@+5;T?$2VNHTMX]<F1[&5G5@Q4$@L
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M!.3R1TH POAC<:_=W7B635+ZUG@CUBY@*QPNK"5=@RI+D"/ X7&?>O0Z\_\
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M1'U."X9IKF,L(3'M.[ (SP6X[G':L_4O%6J+KMSHD?B/0M+GTRUA-Q/?H/\
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M/,O)6& 7SPBAD!^O6@#T*BN T/Q9>KXFM]&N]<T;7?MMK+-%)IV$,,L>"8V
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ML,XW*S#V.*]8HH XJTTW7->\96&NZOIB:7;Z7;31V]N;E9I)99<!F)7@*%7
MYSS66?!VL'X'0^%_)C_M58HT,?F#;D3!S\W3H*])HH *\GT#P)KUA\/M!TBX
MMXEO+/7HKZ91*I B6;>2#W..U>E+K.G/K;Z,MW&=12#[0UOSN$><;OIDBKU
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M&"O(QWZUV]% &1X6TRZT;PKI>FWTXGNK6V2*60$D%@,'!/)':M>BB@ HHHH
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M[4:&-RWE_)DS!#\OT-:5MI>O:]XOTS6M;T^WTRWTF*806\=SY[RRRJ%+$A0
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M;FVDA23^X64@'\,YKSVW\/>*_LWA8#1=-LX]!GCW6\5T";G]VT;2!@N% SD
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#*G\-Z/<Z[#K<]A%+J4*[8IWR2@]@
M3@'GKC-:M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !65<^&]'O-<@UJYL(IM1MU"PS/D[,9P0,X!Y/.,UJT4
M%%%% !1110 4444 %94WAO1[C7HM;FL(I-2B7;'.^6*#V!. ?<#-:M% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_?S_  ]: +U%9NE^(-&UMYETK5;*^:$XD%M.LA3ZX-1Q^*= FU8Z5%K6GOJ
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MH'C&/Y4L;C['?GL;68A23[*^T_B:XW6$;4O 7BGQ9+GR=:U*! WII\4R1K]
M0&8^S4 >IZ1XL\/Z]<R6^E:Q97DT8W-'#*&;'KCN/<<5;76=,?3)M26^MS8P
M;_-N!(-B;"0V3VP0<_2N2\7100^+_ ALDC2Z%](B", '[/Y+;P,?P_=]NE<W
M;SQ0_ ;Q3YLBIB348SD]&:9P!]22/SH ])U#Q1H6E*6O]6L[8>0+C]Y*!F,D
M*&'J"2!6BUQ"MJ;EI%$ 3S#(3P%QG/TQ7FEK96U[\6_#_P!IA240^%A*@<9
M;S57./HQKN_$ME-J'A35["U'[^XL9H8@./F9"!^IH Y:P\3^,O$]J=5\.Z1I
M4.DN3]F.ISR+-<J#C> BD(#VS6_H_B=;KPY)JNM6CZ&UN[Q74=XVU8V4X)#G
M 93V8<&J7PXU:SU+X?:.UO(H-I:1VUQ&3@PR1J%96'8Y!Z]JP/%6NZ9XE/A>
M6UE\_25\2);7#LA$<CHK[<$\,N_'(R"10!VNE>)]#UNWGGTS5;2ZCMQF8Q2
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M7S"N?XMNW/M0!Z!+XAT:'15UF35+1=,8 K=&9?+;)P,-T//&*2#Q)HESH_\
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M B?PGNO-G3SLR!"W^UL_2K&M6]C#X(^'SZ<D0D74M.^RM&!D[A\_/NNXG]:
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M6B+;WTDLER@)Q(TGWR>>_M534?"&@:KIUE87FG1R6]BH2U 9D:%0 N%=2&'
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MDC179)&^;#$A3COD@]/0TFH^+_#VDZFFG7^KVMO=MM_=N_W=WW=QZ+GMG&:
M*\W@/PS<:5'IDFE1FSBN#<QQB1QY<AZE2#E?H"![4^[\$>&[[4H]0N=*BDNH
MT2/>78!U7[H=0</C_:!KH*KWU_::992WM]<Q6UK"NZ265@JJ/<F@#*NO!GAZ
M]T.VT:?3(VT^VD\V"(,R^6V2<JP.0?F/?O3-2\$^'=7,#7NFK(\$(@1UD=&\
ML=$+*067V.:?8>,_#FIVMW<6>KV\L=G'YMQR08TQG<5(SCWQ7(^ ?'ESXP\1
MZEYFL6"6T5S-%:Z;%;DR21+C;*9">^>F/RH [AO#VD-#IT/V"%8M-D$EFB#:
ML+ $ @#V)K!\=V&M>(K%O#-CIJ?8;]46ZU*69-L";LL%C^\SX QQC)'/%6/$
MWCW1_"NLZ7INH3QI)>L2[,V!#&%8ASP<@LNW'O[5G6_Q!L+#7?$5OKVIVUK;
M6EW'%9AAABAA1V/') +=>V10!VEI:PV-E!9VR".""-8HT'1548 _(5DZUX/T
M'Q#=)<ZGIZS3HGEB19'C8IG.TE2-R]>#D<U8OO$FBZ9I4.IW>I6\=E/M\F;?
MD2[AD;<?>R.>*LZ9JECK-A'?:;=175K)G;+$V0<<$>Q![4 9^H>#_#^J+IZW
M>F1,-.&+386C\D8 P-I'& ..G%0ZGX&\-:QJ+W]_I44MQ)M\UM[*)<=-Z@@/
MC_:!JIXB\3ZE!K]KX;\.V5O=:O-";F5[IRL%K"#M#OMY))X %-TW5O%UEKUK
MIWB#2[*XM;L-Y=_I0DV0LHSB57R5![-G&: -C6?#.C:_;06^IV$<T=N<PX)1
MHCC'RLI!7CT-,B\*:%!86%C#IL*6VGW N;:-<@1RC.'Z\GD\G.<U#=>-_#%C
MJITRYUNTBNU<1LC/PC'HK-T4^Q-6-5\4Z'H<SPZGJ=O;2K&LI1S\Q4D@$#J<
MD'IZ&@"R^C:>^M1ZP;5?[1CA, N 2&,9.=IQU&>>:35]$TW7K'['JEI'<P;@
MX5L@JPZ,I'*GW!S65+\0/"4,-I-)X@L1%=C="_F9!&2N3_=&01SCD'TJ[JOB
MG0]$E,6IZG;VT@B$VQV^8H6V@@=^01Q0!D:OX/L[/P)X@TKP]IR)<W]G,@&_
M+S2,A5=SN<GKC)/%2Z#X&T/3&L-1.E11ZG#"N6WLPC<J Y5<[5).<D#FM.+Q
M/H<V@MKL>JVITM02UUY@V+SC!]#GC'7-1V7BW0-1TN[U.TU2WDL[,$W,@)'E
M #/S \CCGI0 -X2T)M;N-9_L]!J%S&8YI5=AYBE=O*@X)QQG&:=_PBFA?\(Z
MOA\Z;"=*086V;)5?FW9!)R#DYSG-1VGC+PY?:P-)M=8M9;\YVPJ_+$#) /0D
M=P.16CINJ6.KV8N]/N8[BW+,F]#QN4X(^H(H H:9X3T/1[>[@L=/2-;Q=MPS
M.SO*,8PSL2Q&">,\9JP^@:5)I-II;V:&QM#$8(<G">7@ICG/&!^53Z;J=EK%
MA'?:=<I<VLA(26,Y5L$@X/U!%<XWB>6X\7ZC;1316^B:%!OU*X=<EY67<$![
M!5^9CUR0* .LDC2:)XI$5XW4JRL,@@]0:P+?P+X9M=%GT>+28O[/F<2/ SLP
MW#H5))*X[8QBN7F^)\&K>"1K.B2Q1W*7\$$T+G>8XWN/+!/ ^\H+#TS77Z3X
MN\/Z[?366EZM;75S$N]HXVYVYQN']X9[C(H ET7PUH_AY9AI=DL#3D&60NSO
M)CIN=B6..W/%:M8EOXO\/7>M-H]OJ]K)?AF3R5?DLOWE!Z$CN <BMN@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\NH;9$GO2IN7 YE*KM&?H.*K_P#"/:1_8\&D_8(?[/@*M%;X^5"K;EQ]",T
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MO+<G/ES(& /J/0^XJKH?A+0/#1D;1M*MK-Y!AY$7+L/0L<G'MF@#SW1/L0^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO7VJKX>EAA^*'C?[6Z)*8K)XS(0/W B.2,_PAMV?>N)\/R6J>&/!4\!5+/\
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M! _&I?.BW*OF)N894;ADCVH Q[3P?X<L5M5M=%L8?LDC2P%(0#&[ !F!ZY(
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MXH SG\,:%)H8T1M(LSI8Z6ODCRP<YSCUSSGK18^&-"TV/R[+2+.!# ;<A(0
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MF^7Q+J_AC6)O/N[0+=6EQL"F>U<D#(  W(P*D@#/!H ZNBBB@ HHHH ****
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MEM);K2;*9[/_ (]F>!3Y7^[QQ3#X7T!K(V3:)IS6ID\TPM;(5+]=Q!')]^M
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M1)N(DMT592>I8 8;/O0!R>I6"VWQ9T/^SH8Q#?:?=+JD2*-CQ)M\IF7H3N;
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M*TW19$9'4,K#!!&010!Y5X+T!/$6G>-+*XU*^ALIO$E['-!;,BB5<KD%BI8
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MV-Y6"AE1W\Q5)[Y()'XT 3>(?B3I6F>%;?6].+WR7-PD$86&0@'>JN' &48
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MWC;+:9K61897QG8LA7:6]L]1CKQ7(:G9!CXDO;GQ;#K&H1>&[F)H8+18PL3
MLK,R$C.5. >>34^KQI'X ^'BHH55U'2MH Z<"@#>T7Q[:ZUXLUG0D@N8_L3*
MD<IM91N.PL^XE<+@],XW=1FCPOXLTI]$T19/$$VJOJDLT5K>36IB,SH22I 4
M!2 "!G&<<9K.\,W,$?Q&\?VSS1K/)-:LD;, S#[/U ZFN.\+:9/??L[6%Y9+
MG4-*N)-2M/\ ?BF=B/Q7</QH ]BN]<T^RUBRTJ>?;>WJR/!&$)RJ#+$D#"@9
MZG&:S=,\=:!J^I16-I=2F2?=]FDDMI$BN=OWO+=E"OC!Z'WKC+&1_'$OB_Q3
M8!GC_LMM*TK'4DQ;Y"/?>RKG_9J#0+9-1T[P7]I\;6\T4<L$MG816*!]\<9S
M&2IW#"[E)(^M 'I^L:O8Z#I<VI:E-Y-I#M\R3:6QN8*.!SU(K+TSQQH.K:NF
MF6MS,+F5&D@\ZVDB6X5>K1LR@.!UX)XYZ5E?%_;_ ,*LUO<I9=L60.X\Y*I^
M(]0T_5O%7@./2;F">47CW"^0P;;;B%@Q..@.5'Z4 .\&>++B5?&EWKVHC['I
M6KW$,<DBA1#"G0<#G]2:Z+2/&.CZU)<16TES'/;Q"=X;JUD@<Q'HX5U!9>.H
MKS#1]3;2/#OQ'NDAMI6/B62(?:DWQ)OE1-[CN%W;OPK6MKAT^)SPW7B)=7E_
ML"Y3S1#'&JMYD;;!LZG'S8)) (]: .L@^)/A>YELA#>S-#>,B0W/V640EW^Z
MAD*[0QST)X[XKJW=8T9W8*JC)8G  KQZ:-(_V<]%"*%P+!N!W-S&2?U/YUZ-
MXTM[F[\#:];V:LUS+I\Z1JO5F*' 'N: *=C\0O#FH7MO;074X%U)Y5M<2VDL
M<%P_]U)&4*QX.,'GMFN0U'QQ>7_Q6&A6^J:CI^F6L"LRV^EM(\\WF;2&W1DK
M'C^(8'O2:]J>F:G\+O#%CI5S!)>7$^GI9PQ."Z.CH6X'(VA6SZ5IV/\ R<'J
MG_8 C_\ 1HH Z+QSXJ3P;X5NM7:!YI$^6) C,I<]-Q4?*/<X';J16%J7CJ.W
M\4>'IA<W,.D7EG=/) ]HXEED1D5 (ROF9R3@ <YSTJQ\8 3\*=>P/^6<9_\
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M5O93VWGN%W0K&RM@DXX?.<>M<=;(EQI6AW*J&L+OQ\]Q9\?*T)\W:1[9!(H
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M/QYJ;:/X(U2^6WM[ADC51'<INB^9@N7'=1NR?85Q]E<21_%;28;OQ+'J\O\
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MCG;NZ$\9(Z9KN[75[*]U2_TV"8M=V'EBY3:1LWKN7DC!R/2O']4UC1I/V?\
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MNL3?V#,GFB&.-5?S8SY8V<$X.<<D CUH ZWP+XOC\9^'8=1%O)!,1^\1HG5
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MMPY&0AD(VAO;MT/0UHZ1XSTG6-2N-/A6]M[N&'[1Y5W:20-)%G'F*& RN>*
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MRE\O .?NXQUYJU7&KXAUO4U\.WVE011VES*$OK6\MI8IV4[<O&#T506.3P>
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M]\U2\5Q--\!M;UR0$2ZWJ?V_GJ$:95C'TV*OYU[BFGV45FUG':6Z6K @PK&
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M"@G_ $6U.!_U[UZM#IMC;.KP65O$R%BI2)5(+?>(P.^!GUJ3[+;[IF\B+=.
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MKV$:7IZZ@=0%A:B](P;@0KYA'^]C-$VEZ?<7L=[/86LMU%_JYWA5G3Z,1D4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'+3^/]&@U&6V9+TV\-P+2:_6V8VT4Q(&QI.QR0">@)P36I!XBT^;6K_2&=H;
MRQB6:59EVAHFZ.IZ%>"">QZUY!9VEH?#&HZ%K?C:[L'^WSVUQI$<,#2,SSL5
M* H9&W!E8$9Z\=*W/B)I]SXPUP:1X?C$E_I%J[W]QYA02(Z\6A*]3)C)ST !
M[T =E_PG>CMH-KK$:7DL%Y,8;.*.W)ENFY_U:=2" 3DX&!FAO'FBQ^';S6I_
MM4$-C,L%W#-"4F@=F4 ,A_WU.>F#FN+US5;/6$\#ZYIVIR:%ID3SVLDZQQ_Z
M#*T858W#@JN"K)DCN/6LOQ5:Z>_PY\:WMKX@GUV6XGLHKFY>-%C+))& $,:A
M6^5@"1GI0!Z/_P )YI(T9]5>#4([<W MK97M'$EX[#*^2O5PW8^Q]*J7OC+2
M=2\+:Y*UQJFE/I\8^V+Y/E7=L",JP4Y'(Z'D=:@\>R1Z9K/A#5[HB/2['466
MYD/"1;XF1';T4,0,]LUF>-O$6C:[X(\:)I(6X:ULE2>^A56BD)Y"+(#\Q4=1
MVR* .C;Q=I^EZ7H\:+JFJ3WEFL\*06YEGDB"KF1P, ?>7/3D\5+-XYT>/2M.
MOH!=79U$LMK;6UNS3R%<[QLX(VX.[.,5R##2O[(\(R/XE?P[K4>B1FVO&V"*
M6(HFZ-A)\K\A3MR".M9;:I?ZMJ'A/7-2UP:+'-;7MF-2MXXQ$[K*NT_O0542
M(FX>N.#0!ZKHFN67B#3S>61D"K(T4L<T922*13AD=3R&%9FI^.-,TS69]'^S
MZA=ZE#$DQMK.V,KLC9^88[#')..H]:K> ;:Q2TU6[L-:N-8%U?,\UW+&J*\B
MJJ$IL4*RX4#(X)!K'BUG2](^,VO'4KN"T$NF6HCFN'")D%R5W'C)ZX[[3Z4
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M?CW0[ZQMKVWDF:WN=3_LN%_+^_-S@_[IP>:YG1KW3/"/Q#UJ#6-0CM8KC2[
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M=[<6C1P7#G[H5C_>QQD#/:I;KQ[I%IJ4UH\5^T,$XMI[Y+5FMH920-K2=N6
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MT9[:%P<,&<>AZD @5S'Q"\67R^,?#V@6,NM6ME<F5[F;3K?=)< 1JRB%B#N
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MWD=CA551RS$] *XKP9YOA+Q1?^&M;D6>_P!2D:]M=59=K7XQ\R-Z.G91QMZ
M=[WQ*(MH/#FIS9^PZ?K<%Q=MCB./#KO/L&9: -?2O&6GZI>7%DUM?V-]!!]H
M-K?6YBD:+.-Z]F&>.#P:S;?XG:!<QV-Q'%J/V"\=(TOS:,+=9'X",_8Y.#U
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M)96ZQL_F%%B4 M_>QCK[UAVWCC3Y;75)+FRU&PGTRV-W/:7<(24PX)WJ Q#
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M2!,OYAVQ@9;^]TZ^]<W=_$'2K.^N(FM=0>SM;@6USJ,<&;:"3(!5FSG@D D
M@'J:DU7QWIVDZA=VK6.IW,=CM-[<VMMOBMLJ&^<YSPI#':#@&@#IO*C,HEV+
MY@&T/CG'IGTJ*.RM(;F2XBM84GD^_*L8#-]3U-.EN88+1[J615@CC,C2'H%
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MZ())L;.UQ@D%201P>".<5A_%+7]3\.^';"ZTJZ^SS2ZG! [;%;*-G(PP([4
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M%1%"J/H!4E% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGPQ:UCD66ZT;7_MNH62<RI"MT2Q*=<8.?P/I7N],6&)'=TC17?[S!0"WU]:
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MQ;6]8N;CP;XSTF+Q"GB/2[?3$EBU !"T;LQ!B9T^5S@!L]>>:[#Q8 NL> @
M !J8  [?Z/)7;1V\$47E1PQI&?X%4 ?E3RJD@E0<<C(Z4 >#^(-<&K>%+VZU
M#Q'=MJJZC^^T6$HL5I%%<CF1 NX *H.YCR2*[OPO)!<_%GQC<PNDL;VFGM'*
MA#!E:-SD$=0>#7=?9X=TC>3'ND&'.T98>_K3EC1#E45> .!CITH \/AM=+BT
MG6]#U[Q=JME.VH7,,NCV_DEYQ+*2AC0QEW#A@<@GOTQ6SXGO]-T'4M9O]&\4
M2Z3K]LB>=IUT%>/4F6-=A6,\L6&$W(>HZ<5ZJT$+3+,T2&51A7*C<![&AX(9
M)4E>*-I$^Z[*"5^A[4 4[F9)?#LTU_:2,C6A:XMD4LQ!3+(!W/48KSOPSJD-
MMKNEZ-X<\4'7=&O+:7=9S%9)=/54RA+C# 9PFU^1FO5*CC@AA9VBBC1G.6*J
M 6/OZT >%R>(M+/P&LM"6[1]6B\B&>S4YE@*7"[BZ]5 QU/&2!WKKK'Q!I&@
M_%?QD=6O(+)9HK'RY[A@B$K$V5W'C/(('4\^E>BBV@#NXAC#2??.T9;Z^M+)
M;PS*RRPQN&P2&4'..E '@VIQN?AUX>O"C)#?>,A=VZLN#Y3R2E#CMD<_C71Z
MD;72_B#XGDU;Q=>^'DNA;W-OY;1*ES&L01L>8C;F5E(VCGD<<UU'B[PCJ?BO
M5=)CDU"UM]%L+N*],2P,9Y)$SQNW;0I!],UUTD$,Q4RQ))L.5W*#@^HH \KT
M[^R_!OB3PM?3W,\&@RZ')9V]UJ "&.0R+*!(< (2N0,XZ8I?&7B/3=8\-Z5K
M-I$\.F6OBBU,EVZ!8Y41L-,".J9XW'TKU26*.:,QRQK(AZJPR#^%#0QM%Y31
MH8\8V%1C'IB@!EK=V]]:175I/'/;RJ'CEC8,KJ>A!'45X=IMU!+\)8+:*19K
MK1-;%YJ-FGS2QPK=LS%DZXQS^!]*]V5510JJ%4#  & *:D,2.[I&BL_+,% +
M?7UH \^OM8TWQ3\1/"7]@WL&H+8?:;JZFMG#K#&T6Q0Q' +,1QUXJS\7SL^'
M=S*0=D5U:R.0,[5$R9)KMXH(8 1#%'&&.2$4#)]>*>RJZ%'4,I&"",@B@#@[
M>^L]5^+^GWMC<PW5M)X>F,<T3!E;%R@."/Q%<CK%O))%XGN5GGMX++Q;;W-S
M/;J"\,0CC#2 $$?+N#=#TKVA(HXPH2-%"C VJ!@>E."*-V% W=>.M '!>$(=
M&NO%UU?V/BF_\074%B('F=HG@1'?<%#QHH+Y7.,G -4_C9_R*6E_]AFV_P#9
MJ]'BAB@39#$D:9SM10!^E*R*XPZAAG.",T <8X!^-T)(&1X=?!_[>%KB-2/V
M==:U)U8VFG>.(+N[*C.R)4C#,0.P+ _A7M>U=V[:-V,9QSBDV)AAM7#?>&.O
MUH \W;7M+U[XP:$VDW4-Y%%IEVK7$#!XRQ*':&'!(&"1VW"N.D\0Z9'\ (]
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M"Y'K7H>K>.;#0[ZQTK[%J5[>W5I]HMH;>,.\H! V\L/FP=QSQ@$YKS?40?\
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ME6&=MI8 ?-N&0#C(&:KW7Q)LHO[4-MHNL7J:5/)#?/;PH5AV=6R7&1C)P,G
MR0.,T_$ZXM/A\ , :O:].W[B2H/#RX\,?$/CKJVH_C^[6@#6U;7](E\0>#F^
MUZINU/S)+$6DFV"4;%;]\I(R,$8X.#FMG0O$MCKVGW=Y"LMNMG<2VUPEP K1
M/&<,#@D>_7H:\OP?MWP6XZ6C_P#I/%4WC/[;H?B;6M!TY64>,XX5MF ^6.;<
M(IS_ -^R&)H [.+XAV-WI>EW=AI>IW<^J+)):V<<:"5HT.#(V6"JO3!)YR*?
M=?$71;/P_::S/'>)!/>_8'B,0\V";Y@5=<\8*G.,]L9S7,^)]+L=!\8:)+<Z
MO?:'HR:0VGPWEK(J*CHZLJ.S*0 R].F2M9NH6FF+X=\/7&EW.HWMM>^,;:=K
MC4 -TS9*EUPHRAV@@XYH [F3QR$CLXU\.ZT^H7:22KIXBC$R1(P!=\N%499<
M<YYZ5)/XXLTT[3+FUT[4KNYU(NMO8QPA9@4SYFX,0%VD8.3],UF>.I- CU?3
MWU/6+W0-02&0VFJPN(T(R-T3$Y5LX4[6';@USG_"5:A=VGAM?$.O3Z3IMU'=
MM)J4""W-XT<@6'D@^7O3+X&,]J .QF^(FCVWAH:Y<Q7D,"W@L9X9(P);>7=M
M(<9QQU.">.F:EL/&]M=ZKIVG76DZIIL^HB4VOVV)4W^6 2.&)!(.0".QKRMY
MK>3P?JECYEP\R^+;>8QWA)G,4C1F-W!Y^8 GGW]*]+^).GSS>&5U>Q3=J.B3
MIJ-N!U;R_OI]"FX8[\4 ;8\0VC>*SX=2.9[M+07DCJH\N-"VT G.=Q.<#'05
M%X@\36V@/9V[6UU>WU\[):V=H@:27:,L>2  !U)(QFL3X=J=5BU7Q=(C*^N7
M6^ .,,MK'\D0([9 +?\  JA\67,6A_$'PYK^HMY6E+;7-G+<L/DMY'V,I8]@
MVTC- %FZ\=B7P]K<]II>I1ZKIB%9[&2-/-@+(61S\VTIQG()X!K,^#]S>7_A
ME=0OWUR:ZN8TDDN-1N!)#*<M_J1N.T#H>!VJK!<1:YJOCO7].;S=*?24M(KE
M0=EQ(D<A8J>X7<!GI6_\*N/A=X>_Z]1_,T 1MXSOA\4&\-+I%X]HMDLID5$^
M\TFWS,[_ /5@<=,YSQ7/^%_B$=*\)/<ZE9:SJ$-M>7*W>H(@D2W'GN%#%F#$
M!2OW0<#'TK1NM1M-*^.J&_G6W6^T..WMFDX$LOV@_(I[GD<5C6BX_9]\0<<D
M:C_Z/DH [K5_&$&G:BNGVFFZAJUWY N9(K!$;RHB2 S%F4<X. ,DX/%:VDZK
M::WI-MJ=C(9+:Y0/&Q&#CT([$'@CU%>67:6>E^,+FZUKQ)J.@VM]IEF]M/;2
MK'',8U970ED;+#(('7YCUKT#P39V5CX0L(M.-\;1P\T9OP!,0[LY+  8R6)'
M'0B@#*UGQY;HNM6MGIVJ7$.GH\5UJ-O&IAMY-F2"=P8[<@DJ#BJV@>+WL/!7
MA6.6TU'6-5O]/2416^'D8*B[W=G8 #+#DG))K"T_Q!IWAW3O&NA:G(4U:74;
MV:WM"A,ETDPS&4&/FSG'MCG%5-.UA;;1?!FG:IKMSHFC/H*3B:W81M<3C:/+
MWX)X4YVCDYH Z7Q%\1VMO#&EZKH^G7DQO=02T=7B4- PE"R1NI88<X91U&><
MXK8O?&R6MQ%:0Z'J]Y?FV6ZGM+>.,R6T9) \S+A=Q(.%!).#7ES7<$/P\;S7
MG4Z=XM2XO%N<F:",SE@\O?)!!SWK=U"[TE/'6IZK>^*[_2--U2SMI[&[LYE2
M*Y"!E9=S(V6!P0!SAJ /4=*U2TUK2K;4K&3S+6YC$D;8P<'U'8CH17/:AX]M
MK2^O[>TT?5=3CTT[;VXLXD:.%L;BOS,"S $$A0<5>\%65E8>$-/AT_[=]D96
MEC^W "8AW+_, !CECVZ8KC]$\2:5X+D\5Z=KUPMM>-JMS>PPR [KN*7#(8_[
MY/W<#."* *_Q+\7W4UAX9AT,ZH+'5[VW+7NGLJ--$^?W4;%@RR'@\@#WZBO0
MM+=K3PU#(MKJ3-% 6%O=.)+EL9.UB6(+'IRWIS7DUYIEWI'@KX56-[&T=S%K
M5J9(V'*;BS;3Z$ X_"O;J /'[SQ[J>M?"G4-8D@O=-DAOX@MTI$:F/[8%VJ5
M8MD(-K9 SSUKN=-\:V]]K\.D7&E:GITUS$\UH]Y$JK<*N-VW#$@@$'# '%>7
M6NH6DGP6O=&\Y?[1LM53[3:G[\6Z_!&X>XKO_%L33?$7P;&IVL\6HJ&]"85H
M MVOQ"T^[N[8+I^HIIMW<?9;;5'B46\TF2 !\VX D8#%0":Z>]=HK&XD0X98
MF8'T(%>+>&K31)M$T/0=3\1Z^=5AGAAET2.1#Y,L;@Y*>7D1@J&W9Z=Z]GU#
M_D&W7_7%_P"1H \^\&>.VMOA'I'B3Q+<3W,D\[02S)&"V3.R*2!C@ #..>.A
MKI=*\9P:CKW]CW.E:EIEV\!N8!>QJHFC! )4JQP1D9!P>:\O\/KGX >%5(S_
M ,3B'(/_ %^M7<^)X7N/B9X?AC.UY-+U!%;T)$8% &+XU^(@OO 6IW6DVFL6
MMNY6.TU95"1R,)0#M*MO4'! ) !Z=Z]#M-=M;SQ!J6BQI*+G3XX9)68#81*&
M*[3G/\)SP*\9U'Q+I@^ P\-[C_;5M#%;7%AL/F0-'*NYG&/E'&<G@D@=37:'
M7=-\,?%3Q"^M72V::A8V;6K2 XFV>8K!<=6RPX'/- &XWCW2AH*ZJL%Y)YEZ
M]A!:I&#-/,KLNU1G'\).21P.<4V#Q_I9T_5;B_MKW3I]+"&ZM+F,>:-_^KVA
M20VX\#!Z\5YWI$YL] \->(KJ&6.PL/$-\UZ&0DVZR-*@=P.@5B,^F:W_ !?K
MMKXQ\+ZK_8:74]IIMS:3R7]HN1,%D#R"(X.YD4;NA&<=: .JL?&EO<RWEO>:
M7J.FW=M:F\^SW:(&EA'5D*L0<' ()!!(K*7XJ:3]ET^_ETS5X=*O]JPW[VZF
M,R%<A,!BV<@KP""1P3UK%LT\/ZC=:C>Z9XEUC7KFUT>X'G32))!$K@90LJ+A
MSM!V_P"R:AN%'_"J?AT-O'V_2LC'N* .VTGQI:ZCJMWIEWI]_I5W;6XNS'?H
MB[X,XW@JS# (YSTJ#2_'MEJ=[8Q-IFIVEKJ)(L+VYB58KD@%@!ABRY4$C<!D
M"L+Q/93ZC\1M1LK;_7W/A"YAC[?,TN!^IK'\,)X?U)O#%F_B77[W4K>2*4Z4
MSH19RQ(<^:OE@HJD%>3SD8SF@#JKCXFV$4&HW%OHVL7=MID\L%]-!"A6 QL0
MQ.7&1@;L#) P2!FF:AX[N8O'6C:18Z7=W5A>6CW!EB1#YH.S8ZDL,*N3NSSR
M, UDZ2N/AM\0..M[J_X_>JE;ZC::-XI^'U[J,ZVUK)X>,"S2<*9"L9"Y]: /
M0_%OB!/"WA34=:DC\W[+%N2/.-[DA5'XL0*YVW\*>+KRP2]OO&]]:ZM(F_R;
M:"+[-"QYV;"I+ =,DY-:_P 0-"N/$O@75=*LR/M4L0>$$XRZ,'4?B5 _&N7U
M#QWX0\0Z'#;Z[JU_HE_"P>>RB>:WN4E (*84;F')QC.>* .CN?$\_A/PII]]
MXN6,7;S1VT[6(WQAV) ?G! P,G&<=LT2^-UAT^RF?0=8%[?3/%;:>T*+.X4;
MBQ!;:JXYY(KSVXM[Y?ASI7]H+?E)O%,+VPU%F:;[.9OW>[<21\O8UV/CO5S9
M:[HEE>ZU/HNC7*3O<7D+!&>10NR/>0=N<L?4XQ0!??XA:1!X<;6KF"\@BBO1
M8W$$D0\VWE+!2& .,#(/!/!XS3K+QQ%=:I+IDVB:O9WHM7N[>&XB0&Z1>"$P
MY&[D?*V#SS7F4-Q;MX;U>R$UR\P\6VDX2\),[0NT.R1P>?F )Y%>AZR/^+M^
M%C_TX7W_ +2H D^'GBV\\7:++=WFG7%N5GE"2NJB-U$CA57#$DJ  V0.>F:O
MZWXLCTC4TTVWTG4M4O3!]I>*RC4^7%G&XEF4<D$ #).#7.?!_4;1O"LFCB=?
M[1LKNY^TVQX>+=.Y&1[U'XFUE!XXN=-U?7M0TJRBLHI+&WL6V27LC,X?!"EF
M884!1ZYH W;GX@Z/!8Z)=QQWES'K0;[&L$6YF8+G802"&)^7Z]<#FGV'CK3K
MF#6'O[6\TJ;1XQ+>07J*&6,J65AM9@P(!Z'J,5Y[X1FCE3X:0!LSVEYJ,%Q&
MQRT4HBD)5O1L$'\15OQII]UJ>K?$.TLXVDG?1+,HB#);:TC$ =R0#Q0!I:SX
MTN-2O_",<.GZQI N]7A9?M(""Y@*/D'8QXR4)5L'IQQQZ!K&JVNAZ1=:G>LP
MM[9"[[%W,?8#N2< ?6O-M>\7Z+XFU#P.FCSK<E=8@EE,:G%O^[<!'_NL<GCK
M\IKL?'^IWVD>#+Z]T^5H9D,:M.J;S#&TBJ\@7OM4L?PH ;IWC:UNKF[MM0T[
M4-(N+:T-ZT=\B@M #@N"C,.#U'49%.T3QE%K-];VS:/JM@+J$SVLMW"H2=!@
M\%6.TX(.&P<5P%E?Z+#X_P#.74]2UW3;C0KJW6:XE\X74@>-GAAX 8[ >!QD
MX['&EX0U6UM_$^F:7X9\27.L:+/!(9[.X_>MIZJH*?/@,HSA-C9_2@#H_'_B
MR\\*V>F/96$]S)>7\-N6C56"J77*\L/F89"]L]2*L7WC2.TN[6P@T;5+S5)[
M873V,"1^9;QDXS(6<*#G(P&.2*R?BQ(MMH.C7DI*VUIKEG//)C(CC#\L?:J<
M/B#2=$^(NHZSJ%_#%I6M:=;/8W[G$+F,N&0-TS\P;'>@#M?#^OV?B33/MMD)
M4"R-#+#.FR2&13AD=>Q%9FM^-8-'U&XLHM)U/47M(5N+MK.)2MNASC.YADD*
M3A<G JA\-U>>V\0:L(W2TU36)KJTWJ5+Q;44/@\@,5)'MBL#Q+JQNO$_B'2]
M1UO4K.2"*--*TRQ?RVO-\>2W )?+DKUPH'/K0!UNH>.],LIM*AAM[V^EU:V:
MYLDM(PQF4;3CDC!PP/.  #DC%7?#GB:W\1I>*EI=65W93>1<VMVH62-L!A]T
MD$$'((->>^#[FWO-6^'+02+)Y.@7$+[>=DBK"K*?0@@BNI\*C_BX7CK_ *^+
M/_TG6@#5USQ3'H]_;Z=!IE_J=_-$TPM[)%)2-2 68NR@#) '.2:JS^/=*3P]
MIVKV\%Y='4I?(M+.&(>?)+DADVD@ J5;))P,=:Q/%VLI#XVCTW5M>O-&TH:>
M)X/LC;'NYS(590VTDD +A%Y.ZN.T._@TO3O!^IWKR1VVC:QJ-OJ7G?,]J\QE
M"&7'3J,GIS[T =CIOBPS_$36);TWVGV5CH<<MQ:79P('$CEFPI*GY-OS*3D8
M^E5-=\<3:F/"_P!FL-9TJ.]UJT,4LZB-;J$MR/D8X!!!VMC(['!K'URYC\7^
M(O&7]A[KE9?#"Q021J<7!$CD[#_$,Y7([@U8UGQ=HWB"P\#6NESBXGCUFP>>
M-%/^BX^7#_W6R< 'D\^E '3IXBL;+Q3XP^S+K5[?:=#!)<6AD5H0"F5\A2PV
M\<MG'?K6)+XU34OA);ZYXBBUNP#&'?-IS+"\K,1AHR'^YG@YP?:DTF-Y?BG\
M3D12SO9VJJ .23;]*Y/6M4LM0_9NL;:UN$EGLC:PW,:_>B??]UAV/% 'K^L^
M+8=*U:+2;;3K[5-2>'[0UM9*A,<6<;F9V50"<@<Y.*J2?$318O#T.M2)>+ U
MZ+"6(P_O;>;."KKGJ#UQGMC-9-QJ=EX4^*>J7VN7"6=EJFGVXMKJ;Y8]T1</
M'NZ!OF#8[URY1KG2O[6$3K9ZIXXMKFUWH5\R+>B!\'G#%2?IB@#T72?&=OJ.
MMRZ1=:9J.EWBVYND2^1%$L0."RE68<$C(.",U7TOQ_9:G?V,)TO4[6UU%F6Q
MO;F)5BN" 6P,,67(!(W 9 K-\1S7%M\3;*XM(O-N8M O7BCQG>X:,J/Q-<7'
MK5A<R>#=5F\2ZAJ<ZW\,VIO-(/LUF[1.-I4*!&VYL =< T =GX&U"]N_'_CV
MVN;N>:"VN[=8(Y)"RQ HV0H/ !QVJ[XYUR>RN](T>WU2/25OVEENM0<J/L]O
M$H+;2WRAF+*H)Z9-97P_'_%R/B+_ -?EM_Z ]6/'L%G9>+?"GB/580^E6+W$
M-S(R;U@:11Y;L/0,N,]B0: -CP6\TEK>.GB:'Q!IIE'V2Y#(TJ<?,DC( I(/
M(XS@\]JF\1:?K^JWUC::;J3:9IN'>]N8-IN&(QL1-P(4'DDXSP*YCPWJFF#Q
M3XP\3Z<=OAQ+6$RW$49\N::-7:1T 'S87 )'4^M2^./'UK8V^CV-IJL>F_VS
M%YYU&5#_ */;X!W*N.7;("@].2>E &7>^(]=TCPIXYM1J\EY+HLT4-GJ3HGF
M$R!"4; VED+8)QWKH_#*0RZP6M_B%-KAMPWFV0EMG'3&6$:AA@^_6LZVU3P3
M_P (!J-IHUO_ &_IED$>]MHE,DDFY\F1]V-[94L?]WZ"J$M_X<\0>-?"9\&+
M;2W%G,\EU/90[%AM?+8%)" ,9)4!3W]* +?AO7=8EN?"NI76IS7$?B$W'GVC
MJ@C@VHTB>7A01M";3DG.<]:V="\40ZKK]Q<S:O;065P?L^E63RHKW*J2'G"G
MYF#,"%QQA<]ZQM9\*6"Z[::%I$EVL]TLLD@,Y:/3K1V_?&)?X6D/R+Z9;& *
MQO$,%E82^+-&6**+5;J>P&C0A<.\:I$J>5WPCJ^<=.2: /7KJZ@LK2:[N9%B
M@@1I))&Z*H&23] *Y2R^(=G=3Z>;C2-6L;'4I%BLKZZA18IF;E!PQ9=W;<!F
MM'QOIUSJW@;7+"S4M<SV4J1*.K-M.%_'I^-<+JWB+3/%?AKPWH.C3";57O+-
MI;5%/F6BQ,K2-(/X-NTCG\,T 12Z[JFL_&673YK?Q)#86,$31VEI,D2AC(,R
MR@/\T9_$X[5Z]7G6DC_B_GB _P#4'@_]"%>BT %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 C*KKM90
MP/8C-*  , 8%>42>-=9UOPMX_6;3;RQ6PCNHX)]\:^04A7]V2KEM^26R,CWK
M>T7QT F@VM[I&I06NHI'!:ZE-L\N:79D<;MX#8."0,T =S2!54 !0 .@ KD+
M[X@VUG<WKKI.H3Z583_9[W4XPGE0N" WREM[!2?F(!QSZ5U5S=0V=E-=SN%@
MAC:5WZX4#)/Y4 34A )!(!(Z>U<OI'C!]7FABET'5-/BO+=I[.XN%0I*H /.
MQB4."" V*Y'P7\0)-/\  &A7.HZ9JMQ8[4@N-78JR+(S[<G<V]@"0"V,9XYH
M ]7I%55&%4 =>!7+ZWXT.DW]W;6^A:EJ*6$*SWLUL$"PH02,;V!=L G"YJ/5
MOB!8:==:7:VUC>ZC/JMJ;FR2U129A\N!R1CAMV3P #0!UM%<I?>-GMKHVEKH
M&I7]U!;)<WT5OY>;57&0K%F 9^#\JYZ47'CFWD^P+HNF7NLRWMH+Y$M2B;("
M0 S%V49).-O7(- '5!0"2 !GK[TM4]*U&+5M+M[^&*:))T#".="CIZA@>A!X
MK-M/%5G>:5K6H)!.(](N+BWF5@,NT/WBO/0]LXH W=JABVT;CP3CFEKD)?B!
M:"72;>UTO4+N[U73Q?VL$2IEE.WY6)8!2 V22<<'G. 2+XA:</#FI:M>6=Y:
M2Z;<?9;FR=5:83';M1=I(;=N7!!QS0!U]%><R^([_4/B5X3L[G3M0TES%>/+
M;3R*5E7RUVG*,5;!!X/(/;D9U;;XA6MQ<6\O]E7Z:/=7/V2WU5@GDR2%MHXW
M;PI88#$8)QZT =@54L&*@D="1TH*@D$@9'0^E<HOCJ&X\57/AZRTC4+JZM+B
M.&ZDC51'"C*I$C$MT^;IU.UN.*Y+PMXN;0K3QSJFJO>7=I:>)9H#A]_D1EPH
M(#'A!D<#IZ4 >L$!@00"#U!HP!C@<5D:YXCM=#.F))%+<2ZE=I:6\<."2S G
M<<D?* "2:YG3?%6CZ;%XUU**/59!I5VYO$GE#@L <B$%L*OMQ0!WU%<C:^/(
MI]7TVUGT;4;2TU1BMC?3!/+F8*6 VABRY )&X#-0W?Q&M;9]4GCT?4[G2],D
M>&ZU&)4,:R+]X %MQ /!8# /MS0!VE%4M-U)-4T2SU2"*01W5LEQ'&V-V&4,
M ><9Y]:\MO?&NM:YX \<2S6%Y8&RDN(H+D/&OE;"H\O*,6WC))(X]": /7F4
M,I5@"#V(I:X_3O'"R:EI5A=Z/J-I!J2E;*]G";)V5-W0,67(!(W $TDOQ"M8
MKB64:5?MHT-U]CEU8!/)63=L/&[>4#?*6 QF@#L&57&&4,/0C-!4-C< <'/(
MI:\P\$^-+FV^'FO>(-<GN+U;#4;A>,%_+4J HS@<9H ]/Q7/^*M$U7Q!:#3K
M/5TT^PG5H[TK!OFD0XRJ-N 3(R"<'K5.T\<QSZY8:?<Z-J-E!J6_[!>3A-DY
M5=W0,63*C(# $^U8OB?QY]H\->)O[.TO4VLK6"YM3JL101I.$(^4;MY ; W@
M8!]AF@#O[.T@T^Q@L[6,1V]O&L42#HJJ, ?D*F(# @@$'J#7+^&O$,4S:1H4
MBSO>MHD%^TS$%64X0@G.=V>:67QUID&FZO>R0W(73=0.G&)4#//-\FU8P#SD
MN ,X[]* .G "@   #H!2UREIX[M0^H0ZUI]YHMS8VAO9(KK8VZ#D%U9&8'!&
M".N2*DTCQD-1U2VL+W1=0TJ2]B::R-WLQ.JX)'RL=K $':V#B@#IBH)!(!(Z
M>U+7GZ_%>P;1X-;.BZHNB-*(I[]ECV0,7V<KNW, <9*@@9QR>*V-,\:+>^(8
M='O-&U#39;J![BSDN@F)T7&[A6)5@"#M;!QUQ0!T[*K##*#SGD4M<=;_ !"M
M;BXMY?[*OTT>ZN?LEOJK!/)DD+;1QNWA2PP&(P3BFW7Q!5;K5K;3] U349=)
MF,=WY C4(H4-N!9ANR"<*.?E/ XR =EM4L&P-PZ''-!4-C(!P<C(Z5Y]K/Q"
MNTU/PC_8FEW5[8ZRK3YC\H-*HB9O+7>PVL#M8YP,# )/%=[<7$=K:2W,V5CB
MC,C^P R: )"H(((!!Z^]!16 !4$#H".E><>']-UWQSI$7B+4O$NJ:7'>YEL[
M'3'2)88L_)N)4EV(P3VYK=M;O6/"7A75;SQ+>)JD>GB2:&X@0+-+ HR Z\+O
MZC@X/% '5TA56()4$CH2.E<E!X]BGT6?5QHFJ"T+1)9?NU+7K2'"^6N[@9QR
MV!@YZ4Z'QS"NG:Y-J&E7MA=Z-;_:;FSE*,YC*LRLC*Q5@=K#KU'- '645QUK
M\0(9[[2TFT74K;3]5<166H3!!'*Y4LHVABR@@'!(Y^E0^$_%^J:[XKU_3[K2
M+F"UL[A8HY&,6(<1J2KX8DEB21@$8/44 =L% )( !/7WI:QM?\0?V*;2&'3K
MO4;V\D*06UL%!.T;F+,Q"J .Y/>N4\2_$6YMO UQJVE:9=I>PWJV-Q%,(\VL
MH=0P<;L'(88*Y^\#P* /0]J[MVT;L8SCFEJK974UUIR7,UC/:S,I)MI2A=3Z
M$J2N?H>]>3ZCXVUK6_A]XWEEL+RP-E/-%!<AXU\K8R#RB48MO&221Q[F@#V*
MBN1L/'"3:QIVG76C:C9Q:D&%C>3A-DY5=QX#%DR 2-P!/M3)?B%:Q7$LHTJ_
M?1H+K['+JRA/)23=L/&[>4#?*6 QG- '8!5#%@!D]3CK055B"0"1R,CI4=Q<
M16EK+<W$@CAA0R2.W15 R2?PKF-*\=1:C?6$-QHVHZ?;ZF"=/NKD)LN,+NQA
M6)0E02 P&0* .LZTBJ%4*H  Z 5PLWQ.MQ8WNH6V@:M<V&GS2PWUQ&(PL'EL
M58X+@OP-WR@X!&?2M74_&45KJ=IIFF:9=ZO>W-M]L\JU**$@S@.S.R@9/ '?
M% '2JJJ,*H Z\"EKB/AMJDFKQ^)KEWN"G]N3K''<9W1*$C^3!^[@YX]<UIZO
MXM^P:T-&T[2;S5M2$(N)8K9D40QDX!9G8 $D' ZG% '24@50Q8* 3U..M>8>
M//'L\WPKU#5M M[^"8L;::7Y(Y+"19%1ED!;(;D@;<]0>.M=7X%MWMO#42R6
MFJ6[LVXC4KH7$KDJN6#!VPI],COP* .EI"H.,@''(S7(7_Q MK*YOF32=0N-
M+TZ;R+[4H@GE0.,;OE+!F"Y&X@''/I5K6O&#:9?R6=EHFHZJ\%N+FY>UV!8H
MSG'+L-S':3M7)H Z:FE%+!BH+#H<<BN9O?&]G'::0^F6=UJESJ\7GV=M;!59
MHPH8NQ<@*!N Y/4XKFO$_C2.]T70]1MUO[-[;Q'!:WUH01,K*&+1$*2&SQ@
MD'(H ]-I"H888 CKR*YS1?%O]IZ[/HE[I%[I>H1VXNDBN3&PEA+;=P*,PX.
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MC$)JT); ^Z/(DZUS,&M6^@^!_%OAF\@N#K EU#R[;R&/GI*699 <8V8;))/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD^,I;W5+*RU'0KW2CJ$;2V+SNC"8*-Q4A22C[3G:>P/I6,/BK$=$37O^$?U
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MX..H:;?3VEU'<P1AXFZJ\BJP(.0>#Z55N=4U7P_\3=#T"+4Y]1L-6MYFEAN
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MGV H [*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M3*Y(PN<@8;&<^E>NT4 <7X<\5:=XB&G;='N(]0LXS]I-U9M']@.S#@.R@9)
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MINL6MN8[BUM7G$<L093&P0$C(8$'&.M %RW^($%Q8:5.-.ECGN]7_LBXMY)
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MRQ'H.]<9\+Y;[Q'+>^+]5A,=U+#%IL*MSA81^]8>S2E_^^16I\0S.(='$@U
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M&$:,[ =K97C. 0:R?^$7U9/A4;S[')'KEOJ+Z[;6N,NC^:9!'@=24)&/4XH
MZ_5?'%II.O7^GS6[M;Z=IIU"\N5;B,9(6,+CEFP2.13=+\6ZA+J]EI^MZ"VE
M'48GDLW^U+-N*C<R. !L?;SCD<'GBN6@\-ZEXC^'_B_4);26#5O$3R2Q6\ZE
M)$BC^6"-@>APO_C]3>'=.\.ZCKEBUCH7B&.[ABD>6?4);H)9.4*%<2MM=CN(
M^7/K0!F^-_&E_KOPOUJ_M]"ECT.X1H[>_%R#(P#A0YBQE5)& <D\@XQS7K,\
MD\5A));0">=8R8XB^P.V.!NYQD]Z\5N[O4(O@M<^"UT+59-=M8#;21)92&/:
MLF?,63&U@5'&"22>G>O;T_U:_04 >*_#[47M[KQ5XNUW3"3:7]V)M0:]+M J
M@'R%CQ@@9P",=17<6WC?4HKG2FUKPX^FV.JRK!;7 NUE99'!*+*@4;2V,<$X
M/!KE-%\,:IJ7PV\>Z1]EF@NKW5[R2V69#'YH^0J1GLQ7&>E:>IZI+XU'AO2[
M+2M3@N;?4;>\OS<V<D*6JQ?,REF #,3@#:3GK0!MZ=XUO=7\3WVCV&@221:=
M>FVO+MKE56-< JX!&6)Y^4=,=>16.OQ4N3X;B\2MX9F70UE\JZN?M2[X_P!Y
MY99$VY=0<>G.?3-:O@:SN;76_&4EQ;2PK/K#21-(A42+Y:#<I/4=>17)_P!D
MZC_PSJVG?V?=?;O,8_9O);S/^/W=]W&>G/TYH [.P\7W[^*+31M6T%]-_M""
M2:RE-RLI?9@LKJ!\C ,#C)'O6MXE\00>&M&:_FADN':1(8+>+&^:5V"H@SQR
M3^6:QM?M+F7XE^#[F.WE>""*^$LJH2L>Z- NX]!G!QGK3OB'I]Y=Z)87EC;2
M74VEZG;:@;:(9>5(V^95'<X)('M0 6WB[5$U=-'U;P^MCJ%U;2SV"I>K+'<,
M@!:,OM&UN1V(QWKC/A>E]JOC'Q'K&HZ3YEU'JUS;F]>^+&U"@ 0JF,,!G&[C
MZ<5T*WA\7_$#P_?Z?9WT>GZ/%<R3W%U:R0!I)$"+&H< DCDG P,#FG?#"QN[
M*3QA]KM9[?SO$5U+%YL93S$.W#+GJ#ZCB@#=\0>(KK3-2L-*TS2QJ.HWJ2RI
M&]P($6./;N)8@\Y=0  >_2N8\1^,O$D,OA9;+0I+66^OS%<6]Q.J,S*'!BSM
M(VG 8..H ]:U/'B:/-+81ZYI.HRVRAWAU+3TE:2TEXX_=#>NX=^GR\UR=T=9
MAT7PAJNI6^JW<&GZW*YDDMV>Z%J0ZQ/*BC=NQC/&>F>30!V5WXNU.36KK2-$
MT :A=6,4;WQDO%A2)W&Y8U8J=S8YZ =.>:B_X6%!<Z#I5YIVG3W.HZG.]M!I
M[.(W65-WF!V.0H7:<GGMQS6;9ZH/"OB_Q!>7]AJ3V.L^1>6<UO92S$L(@C1,
M%4E&R!@-CK6)8Z/JV@VGAKQ/=Z9=-Y&IWUW>6<,9DF@BN@P!VCDE?E) Y&3Z
M4 6_'VOWNI_#7Q!;W^E3Z7?V5Q:+(GF>9&X:>,JT<@ ##&<\ CH:[9?$ZW7B
MLZ%IUHUW]F7=?W0?;':DCY4Z'<Y_NC&!R:XOQQJ6H^,?AWXABL=%OX[436B6
M4C0NLUSB:,NPB*[E5>Q/7!/&*T_#VF7G@+Q,=%BCN[WP_JKF>"Z*F62VN<#>
MLK ?=?&0Q[\>] '4>)O$,/AK21>2027,LDR6]M;18#33.<*@)X&3W] :S=-\
M5WS>((]$UW11IEY<0/<6K1W0GCF"8WKNVJ0PR#C'3O47Q#L+RYTK2[ZRM9;N
M32=5M]0>WA&7EC0D,%'=L,2![5G+=-XN^(&B:E86=['IVCVURTMQ=6KP!Y)5
M5!&H< D@ DG&.E %>V^*5Y/X:MO%#>%YH] 8J+BZ-VI>(%MI98]N64'@G(/!
MXQS5VW\2Z_-\6+O15L$;3(;*-_\ CY7@,[?OONY)(P-N>V:X72-4FU/X&67A
M2UTK4'U6^MQ;P!;5S"R-)_K#*!L"@9SDY!'2NSB\S1?C [W%I>M;7VDP6MO<
M16SR1F19&R&900O!SSB@"+PWXNT+2_!OB#6;729K.WM=5FA>W28S/<3DHN5W
M="Q91CH*V['Q;J*:]8:3K^@_V7)J*N;22.[6X1F0;F1L*-K8Y[@X/->?Z1X=
MUB3X<>(8X]-N1>P>)7U"&VDC*-.B21M\N>N0#CU(KJKB_/C/QCX:?3;#4([3
M2YI;N[GN[22W",8RBQC>!N8EN<9  H 8?B;?OH%QKT'A>632K.62.[E-XJLH
M1RK&-2OS@  G[O<<X->A1RI+"DJ'*.H93Z@UY?;:9?K\"M<L38W(O)!?[+<Q
M-YC;II"N%QDY!!'KFO0[=;B/P]$L"XNEM0$5QC#[. ?QH YRV\;ZB;[3CJ/A
MJXT_3-2N?LMM<33CS0YW;/,AV@H&VGN<<9IESX]NA<:Q-8^'YKS2=(E>&[O%
MN%5MZ#+[(R,L%SR<CO@&N!A@1K+PSJ1TGQ#<:O8W]O/K=U=17+F-LD.%0\-\
MQR-@("CWYZ"VOKOPUIWB_1)M'U&:[N;R[NK.2.V9H)8YAN#-+C:NW)W9(Z<9
M/% &Q/\ $B06_AG['H4MW=^(+-[BVMTN NUE56VEB,8PQ);C 4\'I5RX\7:N
M;U]/TWPW]MOK2UBGU"+[:L:V[."1$K;3YC\'L!C'/-<KX9L[F6\^%EU';3/;
MP:-.)950E(RT,>W<>@SSC/6I=>TC3;#QYK=_KUAK<UMJ,<$MG-IC7)!=$V-$
MPA(PWRJ1NXY/- '32>.1>6VC#0--;4KS5;=KJ*"280K%$N S2-@XPS!< ')J
MO<_$6.TT"#4)=(N/M7]J+I5S9+("\,Q." >C]B.F0PZ5S.H^&M.TZZ\-ZA=Z
M)J]MHBZ;);26]I/.\UE(SB5=YB;>P.7!Z@''M4UQH\'_  CVBR:+H6IVD,OB
MBUNI$NC++*Z*P4S.')9 0H^]C  SUH W5\<ZV-=E\/R^$V763 +JWB6^5HGA
MR5+/)M^3! &,')(^M2P?$(3>'%O?[(F&JMJ+:4--$JDFZ4D%?,Z;0 6+8Z#I
M4IM+G_A<BWGV>7[+_P (^8O/V'9O^T [=W3..<5Q-UX=NIM,OKJZTW4)+>T\
M87-Y-# )(YI+9@4,D>W#-C<#\O4 T =E+X[FL-*UZ35-&-KJ6C6ZW4EHMR)%
MFB8':R2;1QE6!RO!%+!XXOAJVD17_A^2ST[5W\NSNVN59]VPNH>,#Y-P!QR?
M?%<M>:3I=WX.\7S^'=$UD/+IWV>.YO&N'>ZZG9''*2^%)ZX&23BNE\365U,W
M@?RK::3[/JD+S;(R?+40R EO09(&3ZT 1^ _$GB#7-9\11:GIZ16UKJ#P(PN
M%;R"J1_N@ HW#DMNSWQ71:AKZV'B?1M%-N7;4UN&$N_ C\I5;ICG.ZN:\#2R
M:=XJ\6Z5=V=Y%-<ZM+>PR-;OY3Q,J $28VYXZ9S4WC2233/&'A37I+2ZGT^S
M-U%<O;0-,T7F1J%8JH)QE<9 H M:MXZCTL^*@=/:3_A'X()FQ+CS_,4M@<?+
MC'O3(/&U\-;TJVU#P_)9V&KLR65T;E68ML+J)(P/DR <<GWQ7&ZK#J6LV7Q,
MO(M(U"-+^RM!9I+;LLDP5''"XSGOCJ 1D \5U_BBSN9]0\$-#;32+!J:O,40
MD1KY#C+8Z#) R: ,KQ%XTOM3\,^*'L-!DET:VANK-[\7*ARZH59UBQRBMU.[
M. 2 :NZ7XFO;71O#VC:/I/\ :FHG1H+J97N1 D4>T*"6(.68@@#'8]*YN&[O
M-$\$>)?"#Z-J<VJL]\MKY5H[1SQREV602 ;< -R"<Y&,9XIDFAVEC?Z+J/B"
MPUAK";0+6VWV)N T$\8)*2+"0W(;C(Z@]* .KO?B3!:Z'HVHQ:3<SRZE>-8&
MT#@213KN!0]B=Z;>H'.>E=7I=S?W6E13ZAIZV5ZP)>U$XE"')P-X !R,'IWK
MSB?152S\$-I>A:A96_\ ;QNY8+@O++&I$G[R0DDKG@G)X)P>:]4H \<N?$OB
M#7? 7Q"&IV*PPVLEW!'(MPK&%D5!Y0 49 R3O[YKJM-\97]O=:#::CH$EIIV
MJ;8+2\-RK.7\LLH>/&4W!3CD^^*Y1X[N/PQ\2M ;3=0^WW5[>WMN!:2%)HG"
M!2K@8)/H#FNL\2V5U-_P@WE6TTGV?5(7FV1D^6HAD!+>@R0,GUH +KX@3P"]
MU&+0I)?#UC<M;7&HBY4,"K;'=8L?,BMD$Y!X.!78W;$6,[*V"(F((/M7CD'A
M[1[&*_T36= \07VIO?3"**VFNEM[J*24LK[E81* K?-G'(.:]BN(@NFRQ1J<
M"$JH')Z8% 'DFF:*P^$T'BI_%6OVVI+IQN_.?4Y&C\P*2 48E2"0!COFKDU]
M=7_Q2^&]W=*8I[G2IYIHQP [0Y(Q[$U<\ _#?PV/"&AWFI>'(?[3%NCR_:8V
MW"3_ &E;C/X5:\06%Y+\:/!]Y%:3O:06MVLLZQDI&2A #-T&?>@"]?\ C?4=
M.N)KFX\-7$>AP7BVDE]+.$DY<)Y@A*Y,>XCG/(Y I]UXRU)_$FK:%H_AYK^[
MTT1.[O=K#&5D3</F*G![ 8.<$DBO.=8LI]1T#4A=Z3KM]XIBOFEN&99_)AA2
M?<OEC_5LIC "JH).<]LUZ'X6CFD\>>+=0-O<1VMXE@\$DL+1^8!"<XW <C."
M.H/!H W/"^OP^*/#EGK$,+P+<!MT4ART;*Q5E/KAE-:]<#X&NKCP]X&T>WN]
M+U!IKG4I[<I' =T(>>4B20'&U,8Y]QZUWU &'KOA>WU^>*6;4=6M3$I4+8WT
MD"MSU(4\FN$^&?ATZUH$&L7VO>();F*]F4*=4EV,(Y2%!7.", 9]:]7KB/A3
M9W5AX)$%Y;36\OVVY;RYD*-@RL0<'L10!SF@>)]6T6P\67%EH$FI6MEK=_-=
M3-=+%M4/DA 02Y"C..!R "3TZ^[\9337&GVGA_2CJ=W>62ZAMDN! D4#8"EF
M(;DG@ #L>F*Q=)T^\C\#^.H'M)UFN+_5&AC,9#2!L[2HQR#VQUK ?0K:RN_#
MVI>(+#6#82>';6S9[$W >WGCYVR+"0V"'QR."IZ4 >G^'=<B\0Z.E_'#);OO
M>&:WDQNAE1BKH<>A!Y[UYQJ]SIEQ\5M<L_$'BJ\TFRAM+9K:--6:T0L0=V!N
M /:N[\%6-G9>'4-CI=WID4\LD_V>\D9YLLQ^9]Q)!8 '!.1GUKC+RXM]'^+&
MOWNJZ#J-[:7-G;)!+!IKW*[E!W<A2!U% %WP'J$J^(-?CL]:N]6\+6T4;07M
MW-YVR7!,B)*?OJ!@GKCC\;*_$:[&EP>()_#DL/AJ:156^-TIE6-FVK*T..%)
M(_B)P<XK*T[2YO$'C+4K[2-%N]#T:XTB2SG:YMOLWVJ=C\K"+J=H)^8C/:J%
MS<WNJ?"VV\!+H^I1Z\8(=/E1[1Q#$$90TIEQL*;5R""<Y% ';:]XKU;2[N^6
MP\,SWMGI\(FN;EYQ &&"Q$0*GS" .>0,\=:KZKX_:VU'2+#2M'EU.XU>R-W:
M 3"($?*<,2,*-I)S[8P2:Y?Q%9OJ&M^);+5-.UF_OY%$>BQ1&9;41F$#=N4A
M!A]Q8MSP ,]*L^&H+JX\3>![K[!>1PVWA^2VG::V>/RI5V*5;<!@Y4X]>HR*
M .DF\7ZI)K<ND:7X>^VW5G;Q3:AF\6-8&D&1&I*G>V 3V'3GFJWPHN/M?@IK
MC#@2:A=L!(,, 9W.".QJHM^_A+XB>)+B^T[49K;6$MIK26TM'G#/''Y;1G:#
MM;@$9P.>M:'PNM[VV\'%-0LY;2Z:^NG>&12"NZ9C^(YX/0T 3WWBW47UZ^TC
M0-"_M273T0WDDEVMNB,XW*BDJ=S8Y[ 9'-4;KXF6T>B:%J5II5S=-J]P]HEM
MN"R1S*&&P]L[UVYR ,YZ57M[\^#/&/B5]1L-0EM-4FBN[.>TM))P[",(T9V
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M@Z+'J,ME D]Y)-=^0L>_.Q%^5LL0I/.![UDI\3S+X=LM7BT.=S=ZPVE1VOG
M29^<*QR, DJ!MZ#/7B@#T&BN3TKQ9J3^(+S1-;T9+.\BLOM\/V2X^T+-%NVD
M#Y5.X' QCG-06'B_6CJFF6VL>'5T^/5E?[&?M>^175"^R5=@V$J#T)P1B@#L
MZ*\R\,^.=8BTGQ5JWB"R3['IVH7$2>3<^8X=61%@5=@R,GAL\D]!70V'BO48
M=7CT[Q)I$.F/<6TEU;R0W?GHRQXWHQVKAE# \9!&>>* .L) &2<"BO'O&7BK
M5]?^&TM_)H"VVCW\UL;6<76^4+]H0JTD>T!0P'&&."1ZYKUJ\NX;"QN+RY?9
M!;QM+(W]U5&2?R% $]96OZ3=:SI_V2VU>[TP,W[V6U5-[I@@J"P.WKU'(Q6!
MI/C'6[Z;2[FZ\+R0:1JI M[B*X\Z6(,I9&FC"_(K#N"=N1FJLOQ U233K[7M
M/\.I=>'K*217N#>;)I4C)$DD<>T@J,-U8$X[4 =EI.E6>B:3:Z981"*UMHQ'
M&G7 'J>Y/4GUJY7'7WC:Z?Q%;:+H>DIJ$UWIBZC#/)<^5&$+E?F^4D#&.1DD
MD#'>LA?B3K4V@:AJL'A52FCR2Q:HDE\%V/&3O$7R'?A<-D[1S@9H [+Q-H,/
MB?P[>:-/,\,5TJJTB %EPP;C/TK6KCK_ ,:W0U^PT?1](%]/?Z;]O@DDN/*1
M1N P_P IP,'.1GG QSD92?$77+C1]4O;?PJC/HLDL>II)?!0K1Y+"([#O.WY
MN0O4#F@#K_#VA0^';&:SAG>4374USE\ YD<N1QV&:UZX/4]?TFZ\:>!6;2!<
MSZG#/-97CRE6M5\H,?E PVX$#KQ67I?BWQ=+/XUF?2[21-.F81HU^0(2L2?*
MO[OY@1E\\<\8[T >H45YSX>\9:VG@CPZ]WIJ7FLZJJ1V:_:_^/@>7O::1MGR
M  $D -V]:T_^$\>STK5WU72S!JNF2Q0O903"03M+@0^6Y R&)QR!C!STH [.
MBN9T;Q'J4VO'1-=TJ+3[U[8W5N8+GSXY4#!6&2JD,I9<C'?.:G\3^)'T(6%M
M:61OM3U&?R+2V\P1AB 69F;!PJ@$DX/TH WZ,\XKC[3Q7K,E[J&BW.AV\6O6
MUNEU# +TF"YB9MI82;,K@@@@KZ>M<G\"K2:7PZ-:N-+M_/O/-,FJFY+SW#>:
M<JR%> ,==QZ=.: /7* 0>AK@M:\0>(K?XIZ3H]C9026+V<LK*UWL\T90%R-A
MP4YP.^3R*PM!U_6M'M_&5QIFA1W]M9ZY?3W,DMWY.0""5C&UMS #/.!R.O8
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M[\Y)H@2I!8HI5@<#H>M '8T5Y[;_ !%U233-&UNX\.+!H>I200F8WFZ:)I2
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M;=9X-YVA@R[ESUQU%><^&_'&M67A;Q#KFOV\,]O;:A/% D%PSR-+YH185!4
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M;K6-;>+=0T_4+FQ\46%K9R1V$FH12V<[2QO%'CS%.Y5(9<K[$&I?B'H<^O\
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M$WE9#2*-NW:"#P3D@'Z5)=^.M9>]\/:=I6E6L][K.E_;4,TS)'"^%)W$ G:
M3T&20!WH [^BN.UG7/%ED9FL](TWR;*U6:>6ZN&1;B3:2T<. >F.K8ZCBH+G
MQO?W-]X>M-$TV&=];TYKV)KF4HL. A^<@'C#'H,DX'?( .XHKRKQ-XS\1_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 9FNZ%:^(;&*TNWF2..XBN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#C]3\>BSOK^*QT
M+4M4M=,.V_NK79MA; 8JH9@78 @D*.*ZR">.YMXIXB3'*@=201D$9'!KR/PY
M8^(I/#?B/4;+Q$^G36FJ7\B6Z6\;I)(LC,?.+ DYZ<$8 !YKTSPUJK:[X7TO
M5GC$3WEK'.R#HI902![<T :E%%% !1110 5!>W2V-A<7;J62")I6"]2%!/'Y
M5/6=X@_Y%O5/^O27_P! - '*:=\1-0U;3H+^Q\$:W-:W"!XI%> !E/?F2NNT
MB_GU+3H[FZTZXTZ5B0;>X*EUP<<[21SUZUYQX M?'3^ =$;3]4T*.S-JOE)/
M92LZKV#$2 $_A5OXA6E]<:5X,M-4N8S=2^(+:.>6S#1 @K(#MR25XXZYH ](
M#H0Q#*0O!.>E*&5E#*00>A!KRF3P=H<'Q=AT>WL4@TJYT9KFYL8R5AGD24*I
M=>C8W9Y[@5S^M6\>F?#WXFZ39CRK&SU&+[-"#\L08Q,0OH,]J /=@REBH8;A
MU&>17-Z7XL.I>.=>\-_8O+&E1P/]H\W/F^8H;&W'&,^IKCO&'AO3/"MGX?UW
M1XO*U:/5+:.2[5B9+M9&PXD.?GW9SS5.:_N-+\??%:_M"1<VVDP2Q$=F6WR#
M^!YH ]@#J6*A@6'49Y%.KR#5/#NE^&_ 6A>)-*A$>M1364K7JL?-NC*Z"0.W
M5PP=N#5Y=87X>:QXRL91_HKP'6].0]&9_DDC'_;7;@?[5 'J#,JJ69@ .I)I
M<C&<\>M>*_V%=:==>%_#5WHC:Z$TV?4KRS:=(UENGD0,[[R ^W>0![@]J+VT
MUS3]%TW0;O0IUT^]UY_(TK[;&2]J(C(("^[:%WAN">@Q0![2K!E#*00>A!KF
MO$WC >'=5TK3(M)O-2O-3$IABM2@/[L MG<P'0Y_"LSP-I6IZ5K6KYT Z)HU
MPD4EO9_:8Y%28;A(5"$A01LX]16=X^CU&7XF>!4TFYM[>]*W_ERW$1D0?NES
ME003QGO0!O:9XZBNM>MM$U/1=3T>_NT=[5;Q$*3[1E@K(Q&0.<&NK+*&"EAN
M/09Y->7:C%K6B^.?#.K>++JUU.![DZ?8FRC, MIYE(WLAW%\A<9W#'7%8']F
MZMXDM->U"V\*S7FM/J-RMGK'VZ)'MFBD*QJH9@RJNT COSZT >X%@H)8@ =2
M>U (8 @@@]"*\PCT.U\0?%S58M;MEGB32+222T<YB:3+<L.C8YQG(YSZ5SLC
M3:3H'B;0-,CF:Q/BB&RCM8IMA$,NPM$C$_(&Y7K@;C0![BKJR[E8$>H-<1X<
M\<:MXKT>]U;2_#:&R4.+$RWZJ]RRMMP5V_(.O.3TK,\/^%IF\07EO<>#H](\
M-WECLN;)KB*6*2=74HP1&.#MW9..<"N(\-Z/IT'[.6KZM%9PIJ$UM<127"K\
M[J)N 3Z<#\J /:[KQ!;Z9%I"ZJ/LUWJ4J6Z0(?,VRLI8KD=0,$;OIZUK%E!
M+ $],GK7B7B/1-,OQ\*GN[&&9KE;>WF+KGS(Q$I"GVR2?QK9\5^&8-.U>ZO=
M0\+OK'A\644%N]G(/.TM(U(/EQDCCHV5.1B@#U6BL2PTK2+ZXTOQ%!YEQ<)8
MB*VNGD;+0N V2.A)X.2,UMT <IXC\8WGAZ2\<^%M4N[&TB,TEY \7E[0NYCA
MG#<<]NU5],\=WNIV0OAX3U2WLGM6NH[J>2(1E0A=?NL6&[@=.]:GCK_DGWB3
M_L%W7_HIJS]'_P"2/6'_ & 8_P#T0* -SP_K"Z[X>TS5#&(&OK6.Y\G?N*;E
M!QG SC/7%:190P4L 3T!/6O%%\/:;I?PT\&^(;:#;K(FTU_MNX^85=D4H3_<
MVMMV],"GW>GWOB;4_%LQ\*S:K>I?RV=GJ O8HFLO+1?+$89@5()WDCKN[T >
MTUQMQX]:?4KNR\/^']1UO[%(8KF>W:..%''5 SL-S#N!71Z5]O.@6/\ :"A=
M2^RQ_:!D$"7:-W(X/S9Z5R?P>:+_ (5GIJ+Q/&\R70/WA-YK;MWO_3% '0>&
MO%%EXGM9Y+:.XM[BUE,-U:72;)8']&'\B.#6TKJ^=K!L'!P<XKA/B+J5O_PC
M]Q86%Y'%<7&H6EG?M;N!+$DKJ#NQR"4XR>QJI>:'IGA#Q_X2_P"$?LX[!-0>
MXM;N& ;5G18BZEAW*E<YZ\T >C%U#!2P!/09ZT!E+%0P)'4 ]*\".@6"_ VY
M\1",_P!L6US+):WFX^9;[;P@!#_".IQZL:[6;0-.\,_$WPB=*@^SO?0WL5XX
M8EKD+&K@R$_>;=SD\T >D%E# %@">@SUH9U7&Y@,G R>IKPW3/"VE7/P6U/7
MIH]VK6RWMQ;7>\^9;-%+(45#GY1E<X'4L:V=32S\4WQ>;PY-KU_#I-O]J^T7
M*0V]D9$+_N\\^8<Y) X 7D4 >M9Q2*RLH96!!Z$'K7C>GVR^)IOAC'JSR7$<
M^D71N%9C^_ 2+ASW&0"?7'/4T^;PLLS>/] T2/[,-/FL]0TR&/[L-QY7F?(.
MVXKC\: /8J*\R35XOB'K_@Z. ?Z';VPUR\0=%D'R1(?<2;SC_8K9^)DTO]@:
M=8)+)%#J6JVMC<O&Q5A"[_,,CID#'XT =DKJX)5@P!P<'-<EH7C2Y\0>(=6M
M+71PFE:9=26<]_)= ,94'(6+;R,]]W>L6^\/:1X=^(/ANQTFPAM;+6;>\M-0
MM(AB.>-(@REEZ$@\9ZX:L+X=^#?#=^OC07>C6<PM]<NK>'?'G9$NTJ@]A0!W
M7@CQA>>,[%M471A9Z3(7%K.]T'DEVL5.4"C;T/<]*ZM65URK CU!KY]\-6%O
M9?!#1+NPTX-?ZQJ"6-X\+B*6XB-TX,>\D8W!0N?0UU4>C:CID7B6:#PO_8&B
MSZ#.LENMU%(C7"@[6"H3@E2P)QS@4 >L;ER1N&0,D9H5@RAE((/<&O)M*\$+
M<_"C3+C2[9+C4[VVLKB\6>9D^VQ+M8P,_P#"NWY1VP!GO72> 3I,-SJUG8Z-
M=Z%>1M$]UI<Q'EQD@A9(MI*D-@@D=2O0=P#M6=4&68*.F2<4M>>>+;73];\8
MK8GP]-XAN[6Q#26\UPD=K;*['#_-_P M&VD<=AVK5^&%Q-=?#C1Y)Y&=PDD>
M6?<=JR,JC/?  &?:@#K2RJP4L 3T!/6AG5!EV"CU)Q7F&E>&M*\:S^+;_74+
MWD6JSV5O<[R'LXX@H0QG^ C.[/<GG-3VNC6'BCXAZQ9:ZHU6UTBPLX[1+K#H
MWF*S/*5^Z6.T#=B@#TFF^8FTMO7:.ISP*\/FA,^CV&A-//\ 8K'QU_9]N1(=
MRP;'.P-UXW,N<Y'X5O0>#-!7XK7NC)I\:Z.^CQ7DFGC(@>;S70.4Z$A?U.>M
M 'JF00"#P:165@2K X.#@UX9]D6;PCH>CF:6.T@\;/8Q;9"&2$-, @;J."0/
M3-='=:18^%_'TMCHELEG9:AH%R]S;0\1EXR-LFWUPQ&: /4-R[MN1NQG&>U0
M7=TMM87-TH$GDQL^T-U*C.,UXO8Z7%HWP-M]:L8I6UC4;:VM9KI92LAB>9$V
M!B<* N%'3'6MS3]#U'3-5N+BQ\)'P_I3Z7<0WD:W<4B2N #&VU&/S#YP6ZD-
M0!W_ (<UI=?\.Z9JIB$#7MLEQY._<4W#.,X&<>N*U"RJ0"P!/0$]:\03P]IN
MF_"GPKXCMX,:TDNGR+>ECYF&D12F?[FUMNWIBK-[I]YXFUGQ;(_A675[J.]>
MSL[X7L41L@D:[/+#,"IR=Y(ZYH ]F+!02Q  Y)-&Y=N[(VXSG/%>60Z(==^(
MVG6OB>W$\J>%H'O+9V#1O.)B#N X8 EL#D9P>PJC8Z!=WWAG6-)TNT2]LM)\
M4RD:5+.8TGME4'R0QX #/N /'R\T >IZO=7]KI,MQI-@FH78V^7;M.(0^2 ?
MG((&!D].U74)**6&UL#(SG!KQ#Q@^E)\&?%EKIFG7FDRPW5O]ITRYP!;.9(C
M\@!(V,/F&#@Y/2NOEQX<^)6D:D6"66O:?]CN&)PHGB7?&Q/J4W+^% 'H5(K*
MZAE8,#W!S7A]PUW?^'#KPM9;D^+?$,4;6ZRB)I;) XBBW$C:&$?/(R&]Z[3P
M7I&I:7XFU!X_#9T'1;BU0_91<Q2)]H5B"RJA.W*D9XYVB@#HKWQ!]C\6Z7H7
MV8,+ZWGG,^_'E^7LXQCG.[U&,5M*P90RD$'H0:\\\8Z5::U\4/"=E?KYEJUI
M>M)"20LH'ED*WJ,X..^*Y76A)X<D\9^'M$CDCTY[G3!';02^6(OM#;950DX3
M> !V W4 >VJRN,JP(Z9!HWKNV[ANQG&><5Y1;Z)J.F7&K7%IX4_X1_1Y=%N(
MKF%;N)TDE S&X5&/S8W@G'.:SCX?T[2_A]X)\0VT.W63<::S7I8^:RN45D)[
MIM.W;TP!0![064,%+ $] 3UKEO%7C"?0M9T;1=/TK^T=3U5I?)C:X$"*L:[F
M+,0>QZ8[5Y_=:=?^)K_Q9/\ \(K-JE^NH36EEJ0O8HFL_+ $8C#,"N#\Y(Z[
MN]2^(/#EE?\ Q/\  (UO2[9[W4;2X.J*RAA+*ENOWL<':1Q]* /4K.\U6759
MH+O2X[>R6%'2Y6Z#EY"!N39@$ <\]\5+H^KV>O:5#J5A(9+6;=L8C&<,5/'U
M!KSC3]/L[GXR>+M.FMXWLFT:WB,##Y2N%&,>E:?P7TRRL_AII=W;6L<5Q=QE
MKB15P92'< GUP* /0695!+, !U)-!( ))  YS7FP\/:9XA^+GB2+5K=+NWBL
M+-A;2\QLQ\P;BO0D#(![;C6#8-:2>'5\-75I>ZLEOXCN[33M/28*L\4.6"RL
M_6- >F>H7K0![.&#*&4@@]"*IZIJ"Z=HU]J"J)OLL$DVP-C<54G&>W2O''N+
MO3= \5:/!;'1[9]9LK;[+!<;Q:1SB/S C#@!LG@=-QKL]4\&Z'X=TS6KS1U_
ML\R:/<1264+ 1380D.5/)8=-P]>: .K\/ZK_ &YX<TW5C#Y'VVVCN/*W;MF]
M0V,X&<9ZXK1+J&"E@&/09Y->*^!+G_A*9_#FC>(()K.PL-+M[C3;&9<)J+JN
MUIF.>0I&53T(8U'XU2TNK'Q7KFFZ#<75Q9W##^W+F[1&MIHMHVP+][8I&,<9
M)/6@#VXL%QD@9.!D]:4D $D\"O-X='L/%_Q*\0)KMLMY%IEI9QVD,A.V/S59
MW=1V8D ;NHQ7'67V@Z#IFB);S:Q;77B:_6X@-PJ&\$8=@KNQ () 8@]=M 'O
M"L&4,I!!Z$51N-8L[76++2I9"+N]21X4 SE8\;B3V^\*Y;P'I>IZ5JFLK)H1
MT71Y_*DM+/[1'*L<F&$FT(2%!PAQQSFLSQ+H&DW_ ,:/#K7>GP3&:QN))"ZY
MW,FS83[CM0!U_A[Q$NN'50T M_L&I2V S)N\S9M^;H,9STYZ=:VV=47<S!1Z
MDXKQ^Q\*Z/K6D_$"]U*T6YGBU6_$#2$GR"$!W)_=;/4CDX'I4RM:^(K'PG;W
MFBW'B/4QH45U):S3HELBN%'FONZR$J0.O\7UH ]-U/6+/2/L?VR0I]KN4M80
M!G=(^<#]#5ZO!GTVTU;P?X$&I6<<S)XE:PVRMYA6 2S#RMW\2@*H_P" BO=;
M>"*UMHK>"-8X8D"1HHP%4#  _"@"GHMUJ5YIB3:MIR:?=EB&MTN!,%&>#N &
M<CGI5]65L[6!P<'!Z&OG_P -PFZ^"7A6#S9(_-\1PQEXV*LH,[#(/8\]:Z^^
ML+/P7X\E?P_:1V:R^';N>2&(8222)E*,1W;DC/7F@#U$,I8J&&X=1GD5S?AG
MQ9_PD6K^(; V?V?^R+S[+O\ -W>;U^;&!MZ=.:YWPEX,T63P]X8\0B62WUAX
MX+R;4$EQ+=/(@9TD9L[E8L1CV&,5QUQ_R+OQB_Z_FH ]XK/UO5%T?0]1U'8)
M6L[66Y\K=M+[%+8SSC.,9Q7+>+6']N> QGDZG_[0DKD(=!TW6_ACXI\3ZA$&
MUJ4ZA+]L)/F1>6758P>R;5 V]""10!ZWI>H+J.BV.HLHA%U;QS;"V=N]0<9X
MSUJXS*JEF( '<FO&%CFUC6=*L+CPT?$%G9>'+-XK1[B...-Y P:3#D!CA H/
M;!]:NOX8\0OX=T+^U/#_ /:MOIDUTLFCW%XC.\+-^X;=DH[1J"N">_K0!ZW1
M7-^!9=+D\,HFD1WD%M%-+&;6\SYEJX<[HB.<!3P!D\8KI* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .0U3X>V&I7M]+'JFJV-OJ)W7]G:3A(KDXP205)!8  [2,UM+H-M%J
M&G74$US!'I]NUO%:128A*D #<N.2 HQSQ6B9X5E\II4$FW=L+#./7'I0T\*+
MN>5%7;NR6 &/7Z4 245%)=6\*HTL\2*_W2S@!OIZU(74%06 += 3UH 6BFF1
M%+ NH*C)R>@]::L\+S&%98S*!DH&&0/7% $E9'BB^AT_P[>2W%G?W<+IY3Q6
M$/FS$/\ +E5]LYJ/Q?KS>&/">HZTEN+AK.+S!$S;0W(&,X..M:T=Q#*YC65#
M*H!9 P)7/J* /#;*>RTVRALK)OBQ!;0J$CB2T4*H]!\E:AU_3)K/3;>]T?XB
M7S:=J":A#-<Z=ND+J" K' RO)X !]Z]?\^'S_(\U/.QN\O<-V/7%#W$,4B1R
M31H[\(K, 6^@[T >8OXTTI_%47B(^%?&OVR.S:R"?V4=FPN')QUSD>OX5S/B
MS5[2^\+>*;72O#'B\7NN2QS2?:M,81JRE.A'(&%]^:]1U3Q6^G>/=!\-"T5T
MU2*>1IR^#'Y:EL8QSG'K3=3\;65MX>\1:E8 74NBF1)8F;:'=45B >>/F SZ
MYH \]BU32?[0T^>[T?XB7MKITHFL[&XT[=#"X&%/ #-M[;F.*T+?Q+H=OXBU
MK6CX3\:RS:Q%'#=12Z23'M1=H '7D=<DUZE:7L5U%&1)'YS1K(T0<$KD ]/Q
MJS0!XC97^CVLMBDNC_$6[T[3Y5EL]/N-.W0PLOW.@#,%[!F.*/%OB2U\4^)/
M#=T_@_Q3]ETRX>:X<Z6^]@-I6,+G!!=5)R?X?>O:I9X8%#32I&I. 78 $^G-
M8_A_Q VMSZY&\"PC3-1>R#!\[PJ(VX\<??Z>U '!Z]XNT[79K.Z'A[QW87]F
M6\B[M-+PZA@ RD-E2IP.".PJF^MZ))H"Z9)X=\?O*MU]M6_;3V-PMQG_ %@;
MH#VQC&.,5[!'<0RP^='-&\7]]6!'YT+<0M,85FC,H&2@8;@/7% 'ENA>,K+1
M'NIWT+Q[J%Y=%3-<WFF%F(4850%PJ@9/ '>JOB7Q#I?B74=-U"30_B#87>G"
M4036.F[&'F !L[@>PQ^)KT[3=>T_5;W4+2TFWRV$P@FZ8W;5;CU&& ^N:O17
M$,Y8131R%#AMC [3Z&@#QJQU31[?5K74[_1OB/K%Q:,7MO[1LFD2%CQN55VC
M=[D&DO-4TBZO;R2/1OB):V5]-Y]WI]OIY6&9^-Q/&Y=V/F"L,UZ'X(\5OXNT
M[4;J2T6V-IJ$UD%5]VX)M^;H,9STKHYKB&W ,TT<88X!=@,GTYH \QM_&>E6
MWB:[UY/"OC7[7=6\=LZ'2CL"H21@=<\^M9\FM>'YK;6X)?"GCATUBY%U,?[,
M(:*0!=K1D8*D%01UY%>P,Z(0&91D$C)]*2*:*>,20R)(AZ,C C\Q0!Y1HGBV
MSTB]FOI]'^(.IWDL8A\Z]TS.R,'.U53:HYY)QD^M4;34_#]EX#F\'Q^&?'9T
MZ975I&TO][AVW'!QCJ?2O2=7\3)I^IZ':6Z17*ZE>M:NZR?ZK$;/GC.3\N,>
M];K.JD!F W' R>IH \;U?6-%U?2-&L3X=\>VKZ,8VL[JWTS$J%%"C.<@Y &>
M*BN]7LKEY'2S^)<!N85BO?*TX?Z5M7;N;*G:Q'!*;:]J9U3&Y@N3@9.,GTK.
MTF\U"YBNWU.UM[4Q7#I%Y,_F!HAC#,<#:3SD=J .#T[Q9IPUS2FM?#_C>UBM
MH%L8;8V#+:A20 SC/50!\V>!7IU4;^\G72)[K2TM[N=4)B1Y@B.?0OSBI8+A
MAIT-Q>^5;R&)6E D!1&(&0&[C/>@!NJZ=#K&CWNF7#.L%Y ]O(8R P5U*G&<
M\X-0VVBVUKX;BT)'E-K%:"S5F(W[ FS.<8SCVJ\LT31"59$,9&0X88/XTB3P
MR2O$DJ-(GWD# E?J.U &'-X/TZ;POIOA]I;D6FGFW,3!EWGR2I7<<8_A&>!^
M%5=3\"6FH:A>W,.JZII\>H8^W6UG,J1W! VY.5)4E0 2I&0*ZEF5!EF &<9)
MID<\,K.L<J.R'#A6!*GT/I0 L4200I%&NV-%"J/0#@5R=[\/K.35;K4=+U?5
M]%FO&WW2:=.JQS/W<JRL WN,58\$^+'\6Z;J-W+:K:_8]0FL\"3<&"8^;.!C
M.>E=''<031&6*:-XQG+JP(_.@#G8? 6@P^&;S0C#-+;WK>9<SRREIYI<@^8S
M]=P(!![8I=*\&PV&L0ZK>ZKJ6K7EO&T5L]](A$"MC=M"JHW$  L<DUT(N(6F
M\D31F7&[8&&['KCTH\^$3"'S4\TC.S<-V/7% '.'P)I9\$3>$_.N_P"SY6=F
M?>OF_-*93@[<?>/ITK3O=!M;_7=)U>5YA<:9YWDJI 5O,4*VX8R>!Q@BM2HX
M;B&X#&&6.0*<$HP.#Z<4 >6^#OA^NJ>"(8-2OM8L[>XN;A[S35<)'/B=\;@R
M[E!4+D*0"/KFNOO? ]E>:S/J"7U_:QW<<<5Y:6\BK#<J@PH8;21P=IVD9'%=
M''/#*SK'*CLAPP5@2I]_2GEU#A"PW$9 SR: .8T?P)IVC3:1)%>7TW]D)/%:
M+,Z$+'+MRIPH) VC'?KG-3W-OIWA:[UGQ(ZWTTFH&'SXH(3,<HNQ=B(N>G7.
M?PK?#J690P++U /(IKW$$<32R31K&IP69@ #]: .)^&?AIM&L=4U6>Q>QN-8
MO'N5M7^];P[B8XSZ$;F)'8MBNIUW1++Q%I$VF7ZN8)<'=&VUT8$%64]B" 0:
MR?'7BQO!_AQ-6BM4N]UQ%"$,FT8<XSG!HNO%;VWQ&L/"HM%9+JQ>[-QOY4JQ
M&W;CVZYH DTGP?#IVKKJUYJFHZK?QQ&""6^=#Y*$C(4(J@$X&3C)QUJQH7A:
MQ\/C5OLDEP_]J7LM[/YK [9).H7 &!QQG/UK:)"@DD #DDTR&>*XC\R&5)$Z
M;D8$?F* .;LO 6CV/@>/PDK74EA&2T<CR 3(WF&0,&4##!CD'';O3K3P9!%#
MJ(O=6U/49[^U-F\]U*NZ.(@C:@50HZDYP237113PS@F&5) #@E&!P?3BN<\5
M^*W\-ZCX>M4M%G&K:@EDS%]OEAOXAQS]* +$WA*RE\+6&@I<WD,5@D2VUS%(
M%FC:, *V<8)P.>,')XJ30?#46B7%W=O?WFH7UWL$UU>,I<JF=J@*JJ -S< =
M2:L17FH?VY=V\]M;1Z;'$K17 N,NS'J&3'R@>N:P?"'C.\\6ZC?M#IMO!I-M
M<2VR3M=;II'0CGRPN IS_>H NZKX.MM3UMM434M1L99H%M[I+24(MS&I) ;*
MD@C<PRI!P>M7?#?AVU\+Z8VFV,\[V@F>2&*4J1 &.=BX ^4$G&<GGK6G%/#.
M"894D"G!*,#@^G%.DD2)&>1U1%&2S' % ')ZK\/K#4KZ_GCU/5+&#4L?;[6T
MF5(KGC:2P*D@D#!*D9%6-0\$V=Q>P7NFWU]HUU#;+:>98,@WPK]U&5U8''8X
MR/6NC6:)HA*LB&-NCAA@_C2)/#+(\<<J.Z'#JK E?J.U '.Q^!-(ATS2K&-K
ME4T[4%U)9#(&>:<;LM(Q!W9+$GIVZ5I+H5JOBB3Q 'E^UR6:V17(V;%<N#C&
M<Y8]_P *K>+/$B>&_#6IZI$L5S/8P^:;<R;2>0.>I'7TK;C;?&KXQN - 'F_
MBWP;!;Z?HFG6:7LT-SXH6]N&4DO%Y@E+,&4#: 2,'MQS72:=X*MK.^O;^[U+
M4-2OKJV-I]HNW0M%#UV(%50.>2<<D5/XL\3)X<\/W6HPI%=36\D*-!YF"/,E
M1.<9Q][/X5=2ZU%O$,MH]I;C35MPZ7 GS(9,CY3'C@8SSF@"I#X1TN+P8GA6
M199]-2W%O^\;YRHZ'( ^8'!!'<57T[P;%:33SWFL:KJ<TELUHCWDRGRHVZA0
MJ@9.!EB">!70I/#)(Z1RHSIPRJP)7Z^E"W$+S-"LT;2H,L@8%A]10!A2^#=.
ME\)6/AMI;G[%9>1Y;AU\P^4RLN3C'51GC\JK:IX%M=1U&\NX-5U33EOP!?06
M<RJEQ@;<G*DJ=N 2I!(%6O#_ (F36#J@G2*U-EJDVGIF3_6[,?-SCDYZ5>O;
MK48=6TZ"UM+>6SF+_:I9)]CQ8 V[5Q\^3G/3% $4'ARQMO$":S"95G2P73UC
MW H(E?<.V<Y[YZ5FR^!+!HKKR+[4+6XGU)]36Y@E420S,NP[?EQM*\88'J:;
MI'BVXU?Q)XJT>.QC5]$,2Q.9?]<71FYX^7E<=^M7/^$D73M(TRXUY(K2[OKA
M+40P2B51([$+AN,C')/:@#.NOASIFH>&]4T>_O\ 4;EM4DCEN[V21//<H5*@
M';M &P# 7IFM+Q+X3T_Q5H*:1?27$44;I)'-;N%D1EX!!((Z$CIT)K<21) 2
MCJP'7:<TH=6)"L"5X(!Z4 8M]X6TV_\ #<&A,LL-K;+$+9X7VR0-'C8R-V88
M'-&A^&TT:YN;N74K_4KVX54>XO9%)"+G:JJJJJC))X')/-:\EQ#%(D<DT:.Y
MPBLP!;Z#O2O-%$&,DB(%&XEF P/7Z4 8.O>$+/7]5L-4DO+VUO;".1+::UD"
MF,OMRW(.3A<8/&"<@U7M_ 6E)I&JV-Y/>7\FJN)+R[N9!YSLN-A!4 +MP-N!
MQBNF66-XA*LBM&1D.#D8]<UAS^)%3Q=I>BPQQS0WUK/<?:%DSM\LH, #KG=Z
M]J (++P9#;F\>]UC5-2GN;5K/S;N528HFZA0JA<GC)().!4\WA#3Y_#>EZ$T
MMR+736MVA8,N\F$@IN.,'.T9P!^%7M9URQT&W@FOI"BSW$=M&!R2[L%'X9//
MH*1[S4/[>@MXK6V?37@+O<_:/W@?)P F.1C'.: ,;4O =IJ%_>W$.JZI80Z@
M0;ZUM)E2.X( 7)RI*DJ "5(R!5^\\*Z?>>(M%UIVG2XT=)4MHT8;")$V'<""
M3@=,$5KFY@5D4SQAG)" N,L1V'K2K/"\KQ+*C2)]Y P)7ZCM0!D6WA:QM?%N
MH>)$DG-Y?0);RHS#RPJXQ@8SGCUJ+PIX3M_"%C)8V6H7UQ99S#!<NK+;C))5
M,*#@ENY/05N>?#Y_D>:GG8W>7N&['KBI* /.V\-W.I_%#Q%=I>:EIC"RM$AO
M+7"[Q^\WK\ZLK=%[9''2M8_#W38M)TVSL;W4+*XT^9YX;Z*13.7DSYA<LI#;
MLG.1Z=*ZIKB!)EA>:-97^ZA8!C]!7+>,/&4OAW4-'TNPL8KW4=5F>.)9KCR8
MXPH!+,V">X[4 ,C^'&C+%JL,L]]/;ZK&BW<4TP;?(N")LXW"3(!R#CVJ2T\
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MU358--U&1Y;C3H9U$)D?[S#Y=PYYQG&>HQQ78QRQRAC'(K[6*MM.<$=OK3Z
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M)=V]TENNT3(L6]2V.I# <GGFM7XG:;+JW@\6<5I+=>9?6N^*-"Q*"9-QP.<
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MIN$%W92B.1%;&Y>005.!P0>@H \G\8Z;J>D_"2>TU&R%E$-=C>RM1.)A# S
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M2)N&UAD@@@CJ"* /)-0CEA\#^.--^R1:7'#K%EY=I:S>8EL7:W+;&P,<\X
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M($?RX X Y!.!C- ',Z#X3T+7K?QY<ZK9PW4PUF]B224;C;@ '*9^Z<G.1@G
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MO*E[=3XQA6&4C7T55( 'UKE=)\/Z3XA^'&O^(-6M(9M8GDOIGO)%S+;M&[A
MC=4"A%P!BO4])TR#1='L]+M2YM[2%((]YRVU1@9/KQ7.7GPZTJ\GO<7NJ6]E
M?RF:[T^WN=EO.Q^\2,9&[OM(S0!@>#[VXU'QUHU[=L6N;CP;;RRL>K,9<D_B
M37-ZZIF\&^,%CE*,?&*J)$/*G=",CW%>GZMX,L-4O[._AN[_ $R[M(#;)+I\
MHB)A)!\L@@@KD9''%5D^'>AQZ)<Z2GVI;6YOEOW_ 'V6\U=A^\0202@)SDG)
MYYH W-'T/3/#]C]BTJSCM;?=O*(/O-@ L3U).!R:T*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNCIN4#<<<-R<BM&/5]2N4\/SV\-B(+^(270FG*N@**P$8Q\W).<X[5Y#8_\
M)!_'G_85N?\ T..N@UG_ )&+X0_[DG_HB.@#T.S\5:/>ZGJ5A'>1K+I[HDS.
MZA264,-ISSC(!]^*UY98X(C+-(D<:]6=@ /Q->5:)X0T;6M;^(NG/I]I'YMP
ML$<JP*&A#P@Y4XX^;YN.]5[?4[CQGHWA3PG>9-XEVPUM"<X2S(#!O]]_+_.@
M#U35-3M='TNYU&\D"6]O$TKG(Z 9P,]3Q3++6;"_T>'58[B-;22-9-[N $!
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M<KL8\J 1NP.Y/K6A P\2SZ<3X;M-;U2'0;5KV75+GRX(!*I;"KL<[VPQ) '
M'- 'H>K>)-,T2[TZVO9PLM_-Y,0W#CY6;<V2,+\I&?4BKTM]:02Q1374$<DW
M^J1Y "_^Z#U_"O%+"QL]5T?X5OJ%I;79DFE@<S1K)OC5'VH21RHP, U>ETN^
MU_5O&2#PKIVJ'[6UE'=7-X(GM8TB38L:E&V@;M^01DGVH ]EK)TG4+R:WNY=
M5^P0^7=-'$;:?>I3C;N) PY)Y'TJ;08KZ'P]IL6IL'OTM8UN65MP:0* QSWR
M<UXA:IYGPC\;H&9"WB@C<IP1^_@Y!]: />(;VTN)Y88+J&66(XD1) S)]0.E
M4O$'B"P\-:6VH:C(5A#H@5<;F+,%& 2,\L,^V:X^^T32] ^)O@S^R+"WLO/B
MO89O(C"&5%B5@'(^]@C.3S4GQBM+:Y\$(\]O#*T=];!&D0,5W2J&QGID<'U%
M &ZWBJ)/&?\ 8[-;K9?V7]O-V90 #YOEXSTQ[UO)<P26PN8YXW@*[A*K@KCU
MSTQ7GMSX=TBZ^,-K8S:=;-8VWA\O%:>4OD@_:"!\F,'&3@8Z\]:Y2YBDM=)O
M]$L+**:Q?QM]F^P-+Y43Q>6)/*S@A4+@<8QSCO0![9;W=M=P>?;7$4T//[R-
MPR\=>126UY:WJ%[6YAG0'!:)PP!].*\Q/A#7+U?$=NFEZ;X=M-2L(XQ;P70D
MB:=7.&8*J[0ZG8<#D#O6;K5VNC>'_$\">&4\.:^=*7/V&5?L\\'F!#(A0 !E
MWGDKN (H ]@M[VTNS(+:ZAF,9VN(Y VT^AQTJ1Y8XMOF.J;F"KN.,D] />O.
M="\/:K9^+M&O+?PMIF@V=O!+!<FTO1(;B,K\@90B[B'"G)R>35SXK6\5WI&@
M6T[%89M>LXY"&VG:6(//;@T =M;7MK>;_LMS#/L.U_*D#;3Z''2N;\!>+W\6
M^#(=?O(8;/>\BNH?Y5"L1G)^E9#:58>'_BYH<>C6<%E'?:;<I=PVT8C1EC*%
M&*CC.21FN+\$R6C_  9\/V%QIC:I->:LZ6]EYWEQRNKN_P"\)!&P!22,'.!Q
M0![='?6DUK]JBNH'M_\ GJL@*?GTI8[VTENGM8[J%[B,9>)9 74>XZBO$]4C
MFM- ^)]E+I]CIH2TM)39V,N^&-V5LD?*N"0JD\5U.KZ#IF@^(_ ESIMG#;W+
MWS0RSH@$DRM Y;S&ZN21G)SS0!Z&M[:/=M:+=0M<J,M") 7 ]QUJ9F"J68@*
M!DD]!7E%AI,7AC5].CUWP];3H^J%K3Q%92#S6EE=M@F'#\[MIY93P*['Q]/9
M1^$YK>]M)KQ+R:&UCM89?+,\CR*%0MV4GK[9H WX+^SNH&GM[N":%,[I(Y R
MKCKDBA;^R>Y%LMW T[+O$0D!8KUSC.<5Y+]GN-/U_P 56LFCZ;HXE\+/*]II
MTV^-B&=5=OD0!L$CIT'6B;0=,TSP+X!U2ULX8]2:^TQWO @\Y_,VAPS]2""1
M@G&,#M0!ZO=ZC:VA,3W$"W)1GCA:0!GP.PZGI5'PGK4GB+PIIFL2PK#)>0+*
MT:G(4GL#7#Z+HVEZ]'X[U'5[6">\75;FW6XE4&2".)%\O8W5,#Y@1CGFNE^&
M'_),?#O_ %Y)0!TIOK02K$;J 2.YC5/,&2PY*@>H]*$O;26Z>UCNH7N(QEXE
MD!=1[CJ*\P\)Z39F^\>:ZUI'/J5GK%V+1Y$#&$B-6RF>A)/)'7 K,\,:%K-W
MHOA*_L?#6G6LT<MO>2:N-0#3W"OS-O&P$EU9LJ6../2@#V*2^M(;F.VENH$N
M)/N1-( S?0=31/>VEJ\:7%U#"\IVQK)(%+GT&>M>:>'_  ]H7B?1O$^H>(88
M3=OJUVDU[(0LMJL3X0+(>4"*H(JC+8W>O>+?%:?\(U8>((D\BTBGO+Y4:&(P
M*PV91L;BQ;<",D^U 'IM_=ZA#K&FP6R61M)B_P!I::8K*, ;?+7'S<]?2M"*
M:*>,20R)(AZ,C @_B*\BO;;4;/QA\)K75G62_ABNHYG5]X9A$HSGOG'6GR:O
M+X$L_&V@P B=95N]'0=6^U':%4>BRYH ]4DU&QAMA<RWEND!.WS6E4+GTSG%
M6%974,K!E(R"#D$5X\V@7&D^*-$\-V^@V6N0:9H D6WO+@11B9Y2)90"C!F)
M [<;O>NY\ Z9J.C^'I;+4+>*V"W<S6UO%/YRP0LVY8PV!G:21TZ 4 2V'BJ*
M;7_$%A>M;VD.F3PPQRR2A?,WQ!^<\9YQ6_-<P6T!GGGCBA R9)'"J/Q/%><Z
M+X>T;6_B5XZ?5+&WOFCEM8TCN$#K&&MUR0#T)P!GK\M<CHLE_?6?@O3%TR#6
MK6 :DT-K>7'EQR^5,(XV)*L&V(3@8[Y[4 >Z"YMVACE$\1BD(".'&&STP>^:
M;;WMI=M(MM=0S-$=L@CD#%#Z''2O'M7T+4;+PRUEJ%C#IMG=^)K-[:TM+KS!
M;J[('56 7;\VY@ !C=6QK=A:>%_'L4N@6-O8N_AZ]9DMH@BNT90ID 8)![T
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M%M;*O$,,81!GD\#CDDFO%A;6^C?#_P")-]IEI;VEW'K-S9I/!$J/% SQ HI
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MM;>YTZ]D"RKE=V^,L"N6R00<9VCFHH+?0=5\9?#R>QTU!82Z;=A(;E [J$5
MJL6R25.0.3CM7;7/@+1ITLQ"]_9/:VB62R65[)"SP(,*CE3\P'OSR:=?>!-"
MO8-)B6*XM/[)4I9O9W+PO&I #+N4Y(( SGK^)H \T\7$7?A?Q/K6F:#IL%FF
MH,6U.[N6-V\\<JIOC&P[0&7"C<..PSBNNLM'T_5/B]XFDO[2&Z\FQL@B3('4
M%A)DX/&<#&?0GU-:US\./#MW)?&>&ZD@O&DDDM3=2>0LC@[I%CSA7.3SVSQB
MM?3/#UAI-]/>V_GO=3P102RS3-(SK&"%R2>OS')[T >2:-;PW$'@[1+F-7TD
M>(=14P.,I^Z,IB4@\$9[5T7]GV&G?%3Q%'80Q0J_AM9)(XE"JKF1QT' R #^
M.>]=5<>!M"N-&_LMH)DA%VU[&\<[+)%.S%BZ.#E3EC^=.TWP3HVE7=Q>0)<R
M7=S;&VN+B>X>625,YRS,22>V?0 =!0!Y3H5G#J'PI^&=I<IO@EUS;(AZ.N;C
M*GU!'!'<&MWQ3"F@>*O%!T6".S+>$))RML@0&19' ? [@=Z[NS\%Z)8Z5I&F
MP6\BVND7'VFT4RL2DGS<DYY^^W!]:M7FA6<VHW.K"U2:_DL6LMLKD1O'DML8
M<C!)Y..E 'FWB#0-"TWPOX!N+&UM[><:IIR)+$H5IE8AF#$?>R0&Y[C-=]X\
M@BG^'_B%9HDD4:=.X#J" PC8@\]P0"*\[LO"TU]<Z#96WA;6--EL;Z&XN);^
M\,UM:QQMO,=N2[9#,% P!QUKU^[M8+ZSGL[F,26\\;12H>C*PP1^1H \F;1M
M.N--^%=F]G"+>XVRSQJ@596^R9)8#[V<#.>HX-0>+HQH6I>/H]'B2S670[61
MT@41KDR.C-QT.S/->A:9X&T?2H]-2$WLHTV9I;3[1=/)Y1*>7M&3PH7@+T%:
M$OAW3)]2OK^:V$LU]:K9W <DJ\0W?*5Z?Q'\Z .,T?P]J]MXMT*]70]"T>TM
M898)?L-X7>XB*?*N/+7=APAR3Z^M3?&JUMYOA7K$TL$3RPK&8G9 60F5 =I[
M9'I6_HW@K2-#OH[RW-[/-#&8;<W=W).+>,XRL88G:. /7 Q6CKNAV/B31;G2
M-2C:2SN HD17*DX8,.1SU H X2ZTK3I/&W@O2I;&V73397%XML(E$<MP$C 8
MKC#,%)(S6'XIMX=-?XEZ?I\20V+:1;W$D,2A429@X) ' +* 3ZXKT_5_#&F:
MW:6D%TDR-9L&M9X)FBEA.,95U((XX/K5:'P1HD.B:CI1BGEBU+/VV::=WFG.
M,9:0G/3@>E '$^(M&ATWPOX0L=+TNRE%_J%O]K28^6MXXB=P)G"DMEQGD')X
M[UG^*--UO2/#?C"^FL]-TFVOK2UCDMM.N3)AO-V/(1L7;NC8@\<[:]4U+P_I
MNK:,NE7D+/:H$\O:Y5XRF-K*P.0PP.0:R9?"%EIOA_68K.R?5KN^@*S#4;MW
M>ZPI"HTC9(') QP,_C0!SOB;0M%TCQIX#;3;2WLY#>O$$@0()(UA;!('7;G@
MGIN/K5#1-'TK5_A?XDU/5K2WFU"XEU"2ZN)4!DC='<+ACRNT*N!VIVB^&Y+W
MQ-X>FMO#^LZ?#ICM-<W&KW)E*XC9$AA)=B5RQ/&!@#OBNOOOA[H%_>74\JWB
M17DGFW=I#>21V]P_=GC!P2<#/KWS0!PMI<W-YX\^$]S>,S7,NCS/*S=68VV2
M3[FI+#0-*O/!'Q"O+NQ@N+DW^J;994#,@4L5"D_=P<GCN<UZ5<>&M+NM>TS6
M9("+S34>.U*L55%==I&T<'BB#PWIEOI>I:='$XMM2DGEN5WDEFESOP>V<]NE
M ' >'+:WUWQKHZZQ#'>+!X2M9H([A0Z[Y&Q(X!XR<*,UJ_"ZUM;*7Q?:V1'V
M:'7I8XU!R$ CC&T>PZ#Z4GBG0K>TNM%\KP]JEW9V5J;9+O2+QH[J$# $9 92
MR$#KDX(]^:FC>!KFZ\!>(--FL5TTZQ?&X@M7DYMHQY83<5SE@(]Q&3DG!/6@
M#T>YMXKRUFMKA!)#,C1R(>C*1@C\J\:2XNI/"(^&3RO_ &BNJC26?/SFQ'[W
MS?IY(VU[/-)Y,$DHC>0HI;8@RS8'0>]<-X<T:?5O'M_XTO\ 2)--S:I96<%Q
MCSF4'+RN 2%)X4#.<"@"#0=)T[4OB)XO34+&VN/L*6=I:Q3QAUAMS#NPH/0%
MBV?I7+Z Q23PC;(Q-G:>)M0MK0DY'DJLH4 ^@Y ^E>EZQX.TO6=1_M!WO;2]
M,7DR3V-V\#2QYR%?:1N'UYI+OP3H5WH%GHJVKVUI8NLMH;:5HY('&<,K@YW<
MG)[Y.: ,NQ=6^,^L!6!*Z+;!@.Q\V0_R(H\2<?%#P/\ [NH?^BEK9T?PEI.A
MZA+J%HD[7DT*PS3SSO*\H#%@6+$DG)Z^F!T J37_  SIWB-+;[;]HCFM)/-M
M[BVG:&6)B,':RG(R.#0!YGXO=6E^*X5@2NG6(..QV.?ZUMZSHNFZ+K7@&;3[
M.&WG^WF%ID0!Y%:!]VYNK9(R2>]=%'X \/Q6.J6@MYFCU6)(KQGN'9Y@N[!+
M$YW?,<GJ:UKW1+'4)M.EN(V9].F\^V(<C:^TKD^O!/6@#RJTTK3-1^#7BG5M
M0MH'U*5]1GFN70>8LJNX0!NHQM4 >^.]/LH=1U#Q/810Z+IFJK;>&K+RH=1G
M,:QJ^[>RC8X))4 GC@ =Z[>[^''AV]N;Z26.[$-\[27-HEW(MO)(PP9#&#MW
M=\^H!ZU:O_!6DW\=C@WEK-8P"VAN+.Z>&418 V%E.6' Z]Z /.;WP[/#:> ]
M#UE;=XO[9N%\F"8RQB AV$6X@9 7Y",=!BND\0>&);37SJ.D^']'UFR2P6TE
MTF39$\"AW;=%D%1NW'(.,[1S73Q^$-$AAT>*&T,<>D2&6T59&^5R""3S\Q.X
MDYSDG-,UGP=IFM:A]OEEO[6Z:(0RR65Y) 9HP20K[2-P&3[\T <):0:#JOCK
MP)<V.GQ_8)M'G:)+A-[A4"! Q;))7IDDXK*\3D77AC7-<TS0=-M[+^U-XU*Y
MN6:\DF2=4+QC8=HW+@+N''8=*]-O? VAWJZ2%BN+1M)0QV;V=P\+1H0 4RIR
M00!G/]356X^&_ARZ:]$\-T]O=O)(UJ;N3R8Y'^\Z)G"L<GD=,G&* ,K3=&T[
M5/BUXNDO[.&Z\FVL5C2= ZKN1\G!XS\H&?3/K7(Z!!#=P> ]&NXUDTO^U]3S
M!(,H3$93$I!Z@'.![5ZYIGA^QTJ^N;VW\YKFZBABFEFE:1G$2E4))/7!.3WK
M/G\"Z%/HD>E&":."&Z:[ADBG9)89F8L71P<@Y8_G0!@Z'86.G?&?7(K"&.%&
MTBW>2.(!55S(V< <#(P?J<]ZN^,3%>>)=#TV#1;;5-4"3W,(O9S';P( JL[@
M*VXY8 ?*<9)XK7T;PAI.@ZC+J-FEPU[/"(9KB>X>5Y0&+ L6)R>>OH .@%2:
MYX6T_7[BUN;E[N"YM=PBGM+EX) K8W+N4@X.!Q[4 >2_9OM'A$Z;<QV\40\<
MQV[0V;DQ1 R+N6,X! RS=AUKH?$MK!X>\;RS:):PV4K>%[YMMM&(PS1E2G [
M@]*ZR#P!X?MB5@MIHX?M<-Z(%G?RUFBQM8+G / SZX&:UY]$L+G6H=6EB+7<
M-N]LI+';Y;D%@5Z'[HH \HUC0M%M?A!X4O+>UMX[GS=.=9T0!Y'=D+Y;J<Y)
M(/<#TKT_Q7?6>F^$M6O-025[2*TD,J1,5=EVD$*1T)SC/:L6/X8>&HXTA,=[
M);12++;VTE[*T5LP8-^[0G"\C\B1T)KJ=0L+75=.N+"]B$UK<QM%+&?XE(P1
M0!Y;8V=[I'COPDK:'I&D>99W<<<%C.9)718E(64[%!P0O.3SFL.[T?2)OV<)
M-8F@A_M&6%KE[W:!*\[2D-E^ISDJ1Z<5Z=:_#_1+6YLKL/J$MY9RB2&ZFO9'
ME  (\O<3]S!(V]#D^M>?:QX3GU&QU+1+;PAJ=I?7=RX1_MIDTV$,_P TZ O@
M,5R<;,@G Q0!O?V-I^L?&J==2M(;N&'08)$AG0.F_P QP&*G@D D#TR:PQI&
MK^(8O&@30]&NFGU.Z@_M"\O#'-;^7A8R/W;;0BA6'S"O5H="L8->DUI(V^W2
M6JVC/O.#&K%@,=.I/-9>I^ M#U74+B[G6[3[65-W!!=R1PW6!@>8BD!N ![]
MZ .)2SUO4?'&L17&B:/K=Q;:=96[_;[DHJ!HRS[!Y;9#/NR>/NBN\\$:??:5
MX,TRPU&6*6YMXS&6AE,B[ QV ,0,X7:.G:C6/!VE:S>1W<AO+2Y2'[.9;&Z>
MW9XLYV-L(RN>W;M6OI]A:Z5I]O86,"P6MN@CBC7HJB@#Q^+3K&W\)?%:6&SM
MXY([J\B1TB4%4\E3M! X&>W2M?5-$TW1[3X>W5A9PP77]J6T;7"(!(X>%]^Y
MNK;CR<]:ZR;P'HDU[JUR5NU&K1LEY ETZQ2%EVEM@.-V!UK3N] T^]ATR*>)
MF339X[BV <C:Z*54GUX)ZT >1>)R+KPQKFN:9H.FVUE_:F\:E<W+->23)<*A
M>,;#M&Y<!=PX[#I76Z;IUB?C?K<AL[<R)IEO*K&)<JY=\L#CJ?7K6M<?#?PY
M=&]6>&Z>WNW>1K4W<GDQR/\ >=$SA6.3R.F3C%7/^$-TO^W+/65DOEO[:!+<
MRK=R SHIR!+S^\YYYZ]Z .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:V%KJ'Q"\'I=P),D7A^214<97<#$ 2#P<9S]<'M0!Z#;:MIU[IYU"UO[6>R
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MH2.H!P:9!J%E=1SR6]Y;RI [1S-'*K"-E^\K$'@CN#TKAO%]_'X1\=6/B63
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MI(9K<ZU>KL3F,JK3[5&>J8 &#VXH ]=@\2:'<V,E]!K.GRVD3!))TND*(Q.
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M@#M+G5=.L]/&H7-_:PV1 87$DRK&0>AW$XYI;75=.OO^/2_M;C]V)?W4RO\
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M1Q-C&Y8RVT-_M8SGGK3M1\#>'-6U-]0O=-$D\A4S 3.J3%?N^8@8*^,?Q T
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MJQ-EJ$ GMRZ2%"Q7YE8,IR"#P0#1+I-C/JUMJLD :]MHWBAEW'Y5?&X8SCG
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M)FBG,HPAC-VHPY'.SH#[$UNZWIGB*T?6]7N9-#MKE/#MW"+?37?S9  "C[6
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MKPF)2,$!D(." ,C//>FQ^!_#<+.8M,2-7FAN"B2.J"2+'EL%!P",#H.<#.:
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ME_\ $+1_#Z^'[75=3LY9]2B5Y+E) D83RV/G '/R,RX'UZ\5:^)7_)-/$?\
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M[.?>O-+X6P^"]H+/;]E_X2=O)V]-GG/MQ^&* /;=4\6>']$O8K+4]9LK2YE
M*133!3@G )]![FG:SXHT+P]Y/]KZK:61F_U8FD +>X'I[UR/B&SOK#5/$6LZ
M0VDZM9S0(NKZ7=MM=1''T5QD#*$':PQSGO2>$9K/4?B#KMPT*JDFDZ>UC'*H
MRMJR,6 'IN.#[XH [&\\2:)I\,$UWJMG#%<1--"[S +(B@$LI[@ CIZBJ]YX
MR\-Z?:V=S>:W900WJ"2W:24#S$/\0]N1STK@[JR\.W?C#X;V^CQQ3:*G]HM
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M)*ZHBC+,QP /<TV"XANH5FMYHYHFZ/&P93^(H DHHHH **** "BBB@ HHHH
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M<&,9))^\<<C-[PW/XI\-Z!8>$K;P[-)?6DWD#4)=ILS;^9GS,A@V=A^[C.:
M-G7=>\5V=SJ4UAI6FQZ?8)N5K^X99+S"[F\L*"%'8%NIKF_%_BS7KQO MWH+
M06]GK%S!*JR3.CNQ4GRY-HQY>&&<9R1TJ"Z\.7%UJWB:#4_"#:OJU]=2'3]2
MNDCDMH;=E C^9CE-G.5 R3^D-SI.NKX1^']PN@7[S^'[N(7MHH3S2J*%+(-V
M&&1QS0!U4FL&/XHZ)I-]I.GMJ,VE/,]]&"7B()W(A(SL)!Z^M5&\<^(KG0KW
MQ3IVDV$OAZU:5E22=Q<SPQL0\BX&T?=8@'L*=)I^I:C\7-!\0+IEU!8+I$D<
MK3!0T3EF(1@">>1TS63;6OB#1O -]X#A\/7MQ=LEQ:6M\A3[,T4K-B1G+94A
M7.5QG(]Z .AO/&>IW/BVVT+0;"UN?M>DIJ45S<R,B(K.5RV 21C& .<GL.:O
M^$O$FH:O>ZUI.KVEO;ZGI,Z1S&V<M%(KIO1EW#(X[&LS1_#MYI7Q'LYA"[Z?
M:^&(M/%S_"TB2_=^NT9JYX;TN]L_'WC2^N+9X[6]EM#;2GI(%AVMCZ'B@"]K
M?@?PYXBOA>ZKIPN+@((P_G2+\H)(&%8#N:\\^$O@?P[K/@>QU74-/,]]]HF_
M?-/(#\LK!> V. !7LE<3\)](O]#^']I8ZG:O;7233LT3XR 9&(_0B@"G9>)H
MH-?^(36^CV<-QH\,<SSH,/=GRG8>8?;;@?6JL_Q!\26>@Z-XDN-"LFTC46@C
M^SQ3L;D&0?*PR-N">@SG!&3UPR#P[JZZW\4)FL91'JEJB63<?OR('4A?Q('X
MU/JN@ZI/\+_"FFQV4C7MI+IQGA&,QB/;OS],&@#5LO$VNVGC&UT+Q#8Z=$E_
M;2W%M-93.^PQXW(^X#/!SD8^E4;7QWJ\EI8Z_/IUBGAR^N4@C(F;[3&COLCE
M88VX)*DJ.0&')K0UW2+R]^)'AN]2W=[&"TO8IYAT0NJ!0?K@UQ_ASPA::9'I
MNCW7P]2XU6UG6.;5'5%MVC5O]<'R26*X.W&<\''6@#U&VFU1]:OHKFTACTU%
MC-K.LF7D)'SAE[8.,>M:%9]MJ%W/K=]92:;+#;6ZQM%>,P*3EAE@HZC;T-:%
M '"?$:YEU%](\'6<C+<:W<#[0R'!CM(_FE.>V<!1ZY-'PWN9=/75O!][(SW.
MAW)6%G.6DM9/FB;/? )'M@50M?!DWBOQEK?B#Q#'J%FD;BRTR.&Z>!_(3EGR
MA!P['.#2S^#9_"?C71=>\/1W]Y%.S6.J)-=/.WDMRCY<DX5ADXH T_#OBGQ#
MK[VVHPZ9I\FBW%P\)6&Y)N;8 L \@("]5Y4'(R.M=+KEY?V&D33Z98?;KT;5
MB@W[ 26 RQ[*,Y/L*\]BTRZO/%>F7UEX2O=$UM+T/J=Y$ZK:S0C.\9#8EW<8
MRN<G)QBNH^(5A>ZAX:CAM;6>\A6\@DO+2!L/<6X<&1!R,Y';(SC% #O#OB'4
M[GQ!>Z%K4-@+R"WCNHYK"1FC>-F9<$,,A@5_'-<I\;AJ4NC:/:Q1V;Z?<:I;
MQR+*[!G<EL*P QLXY[^U7/"FE2:?\0);^T\)MHVD7NG"")8X8TVNCLQ:95/R
MLV>.O &<=!H?$_1]0UG2=%BTZU>X>#6;:>14Q\L:[MS'V&10!:T'4KFQ\21>
M$YM-TVS6+2_MQ&GY$2LT[)M4$#C STZDUQOQ+UZ77?A/XR66!(O[/U9;%=I)
MWJDL1#'W^:NGUH:CHOQ)AU^+1[[4K&?2?L+?8E5GCD64N"0S#Y2#U]JY'6?#
M/B/4/A=XSLWTB1=2U'6S=PVJ,&)0O"W!S@X"D9]C0!LZY_R6GP!_UY7?_HHU
MZ1=FY%G,;,1&YV'RA,2$+8XW$<XSZ5PVKZ)J4_Q4\&ZG%:2-965K<I<3#&V-
MFC(4'ZFM[3_ _AO2M:;6++3$AU!F=C,)'));.[@G'.3VH \ZLO$^JCX$WNO^
M(;'3]7MRY:.&X=Y#+FZ*D2!A@!3C;C/"CI78WWBC5H_$>F^']'TVS>6[TLWB
MR3R,L<.&4?-@$E<' QSDCH.:XAM#U^;X$ZGX/_L&_35+1PJ[@NRXS=>9F,AN
M<+R<@5W-MI-^GQ'TK4&MG%I%H#VSR\864RQG;]< _E0!CQ^.?%MUHNLW<&BZ
M6LN@RS1:AYEP^V9HQN(AP,_=P<MW('K6Q/XOU'4[O3;'PY:V9N+K3DU.62_D
M98XHGX1<*,EB<^P"FJ6GZ)J47AOX@6[V<BS:A?7LEHAQF57A55(^I!%84_A%
M+:?0-2UKPI+K5L-!M[">WBC626UGC&<[21D'<P)!X*B@#T3POKI\0Z*+N6W%
MM=1S26US 'W".6-BK 'N,C(/H17/:CXPUPSZU<Z-IUA/INBR-%<?:)V2:X=%
M#R"( 8& <9/4UN^$+%+#P]$B:'#HOF.\GV*)@VP$\;B.-Q !(&<'C-<#?>%;
M73]=UXWO@1M?GO[MKNPND1"AW@9CE9F!0*X/.#P: .DN?&6J7WB6UT;P]8VD
MPN](CU.*YNY&5$5G*_,%!)XVX [GKQ60OC_Q5/X:U/68=#TU%T26:'44EN7S
M*\1._P G"] N#ENY(QQD[>GZ+=6?Q*AO$L!!IT7AV.S4QG,:.LQ/EKT/"X[=
M*RH- U5?A[XZL#92"ZO[S4I+6+C,JR9V$?6@#1O?%^L7/BJVT+0=/M)6NM*3
M4EN+N1E2)2Y4[@H)/\. .YZX%<?\1/$5SKWP;\2PZA:QVNI:;?16EU'$Y9"P
MEC(9"0#M(8$9YK2CN[[0_B5I[#2[J\$7A6"*Y@M@IE3]\>0I(W8(P0#GG/:L
M[Q#X7U_6/AOXNG729TU'6]3CN8+$E?-2)6C"[L' ;"$D9XH [C4?$6K-X@M_
M#GA^ULY+Q+);RYGO7811(3M50%&2Q(/I@"LO_A8E[;6L,M_IL,+6NL#2M6"R
MEE@W ;)D.!E#N7J,\U/?0:CX=\<GQ!%I5WJ-A>Z;':3I9A7EAEC8E3M)&5(8
MCCH14.F>$KC6_#GBS^V[8V4GB*X>5+=R&:W0(JQ%L$C<-H; )QQ0!M:UXK.E
M^*;'2(X4>,VD]_?RL3FW@C'# =RS<?@:RM.\9ZV6T6_U33;&#2-:E2*W$,[-
M/;F0$Q>8"-IW8 ..A(ZUD?#W3K[Q7X8UC6]891>:M:#3(Y =P$,49C+@_P"U
M(9&_*H_"GANSM+C1;23X=K;ZI9LGVS4I5184*#_6QN"2[,P! P.ISC% &M/X
M\U9;*Z\0Q:?8MX:M;IH'+3-]I>-)/+>91C;@$$[3R0.HKMM3U&#2=)N]2N21
M;VL#SR$<G:JDG'X"O)[+P=9Z89M)N_AZNJZ@;V0PZBZH()87D+!Y),Y4JIP5
MVD_*,9S7I_B+2?[;\+ZGI".(S>6DENK'HI92 ?PS0!R:>,_$=E8Z7KFL:5I\
M.BZA+"A2&=VN+592 C/D;6Y*Y QC/>N:^Q:OJGQZO!>6&BW;VNGQO&MR7=8H
MO-!#)E3B7GZ<GFM2ZCU[Q+X:T?PI/X=OK*:*6V&H7<VSR$2%E9C&P8ERQ08
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MJ&A^$=7TBY\ K<6^][*6_GOWC(*PM,C,!GORVWCTH O67BGQE?ZEJ^A0:3I
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M>?OD-U]0*UIO$OC*T\46_A^XL-&>XU&V>>TFB>3R[?81O$N>7P",%<9..G4
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M+$89'U:\9HR<E"96)&>^.E5;<?\ ")?%Z:#[NF>*8C+'_=2\B'S#VW*<^YH
MG/PGT<==;\2#_N*R4?\ "I](_P"@UXD_\&LE0^*!_P )7\2-%\,+\UAI8&K:
MB.Q8<0QG\<DCN*EUGQ?XBT2YEOKRTTJ#2H[U+?[(\Q-Y)$T@03+@[?XMVW&<
M=2#0 O\ PJ?2/^@UXD_\&LE'_"I](_Z#7B3_ ,&LE6;[Q%XCU#7M6T_PS:::
MT>D!%G>^9\SRLN_RTV_=P",L<\GI4M_K?B>6#3GL=/T_3!-:^=<S:O+\L4G
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M>#UKKJ\]LO$GC:_UC5_#\5GHBZGIGER27;&7[.Z2+N10F=VXX;)S@8[T6WQ
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)N_B!<(-4N]/\
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M1PRM#(#M7HN0 <#TJ+1;>+5M.^%NB7\:S:9/93W$MO(,I-)'&NP,.A W$X-
M'L*7-O)"LR3QM$W"N'!4_0T]W2-=SLJKZL<"O*-0\*6EWXG\6>$M+ACM+*]T
MB"]2&$;(X+L.P1E X7.U2<8SBG0:RWQ";P7IDJG<F=2U>,C&UK<^6$8>C39X
M]%H ]1DO+6$ RW,* MLRS@?-Z?7VI6N8%N%MVFC$S#*QEQN(]0.M>2Z+X9T?
M6;+XAW.IV$-W*FK7R1&9 WDX13E,_=8D\D<\#TK+NM%L+?X+:%XC6W1M<5[*
M<:BPS/N,J+C?UP%. ,XP!0![=+<00,BRS1QM(<('8 L?0>M.:6-#AW53@M@G
M' ZFO)+^QNO$'C+Q<DWA.VUT1/%9Q27%XD1M4\E6'EAE)4DN6W#'/TI7T6XO
M_&/@33/$R"XGCT>X6\B9]Z3,FSA^S D D="10!ZLMY:O;FX2YA: =9%<%1^/
M2J&@>(]-\2:)#JVGRG[+*&8>9A6 #%<D9XZ&N M]$TNT\;>-M%@T^U32IM*M
M[EK(1+Y/F#?\P3& > >!U&:L?"3P]H]U\)+(2Z;;9U*WEBO71 CSIYCKAF&"
M>..O% 'IBLKJ&5@RD9!!R#7&W_C?4(_%5_H.D^&+G5)K&.*2:2.ZBB $@R/O
MD>AKJM/L+72M.M["RB$-K;QB**,$G:H& ,GFO-$_X2+_ (7'XK_X1_\ LO=]
MDL_._M#S,8V'&W9^.<T =1I7C5KGQ!#H6LZ)>Z-J-Q&TMLL[I)'.%Y8*Z$C(
M')'I73FX@%P+<S1^<1N$>X;L>N.M>:^&1JGB7XBS7/BB>U@U/PWOCMM/M(V"
M%9E \_<Q)8,O &!CO@]>9TS2M<U_PR^IV7A6UDUJ>^DNH]<>^19ED6<X&"NX
M* NS;G&!0![BUQ DR0O-&LK\JA8!F^@K,_X2;3/^$G/A[SQ]O%K]J(R-H7?L
MQG/WL]J\^\2Z-%I&KZUJ^O\ AQ-5TJYG2Y_M>VD'VO3E54&,'#!5*[LH>A.1
M2VNA:-<_M :AYFEV4J?V.EXNZ!2/.,P_>]/O_P"UUH ]1DN[:)7:2XB18_OE
MG "_7TJG'>:@_B![8V]K_9HMQ(DZSYE,F1QLQ]W'?->7>&_#>F>(?BWX]75K
M9+NVMY[=DMI>8R[(PWE>A( (&>FXU>9S8?'#6GM8P&M_"V8D X^5UP,?@* /
M4!<P-<-;K-&9E&3&'&X#UQUK-L/$NF:EKNI:/;3AKK3_ "O.Y&TF12P"G/)P
M.?2N*\(>$_#UUX-\-:]<E+?56,-Z^IHZI/-,_+*\A&6#%BI4_2JO@/0-'C^*
MGCEDTJR5K&XM3:D0*#!NC;=LX^7/?'6@#T+1KZ^N;1FU6&TMIS,R1I!<>:&4
M=#G Y]NU:3.B%0S*I8X&3C)KP?P_I\]Q\(-1U.R7=?Z+KLVIVWN8F!8?BFX8
MKK+[4AXJ\9Q:E8'S;+P_H[:A%QD-<W$9,8([XC&?^!4 >DK<0/.\"S1M,@RT
M88%E'N.U%U=065I-=7,JQ6\*&221S@*H&23^%>-^&-#U>YTOPIJ6G^%;6VNE
MEM[NXUD7Z&:YC?F8N-NYMRLQVDG''I7:_%J*YF^%GB!+4,9!;ACMZ[ ZE_\
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MFF?#SPCJ%E;0P7LEWIQDN(QA[HNZ,PD/5\GYN<XQQ0![(]Q#'OWS1KL&YMS
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MV4E])-_PA'Q#2SEN?M<NFI;$6KR[MVXIG/+#<1G!/:O:O/A\_P CS4\[;O\
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M([0/H\VF33)=+#,+JYV*@_B&1GY^F%-:5Q>VEH\:7-U#"TIVQB20*7/H,]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYO&2XBG2X8*<>6=NW:% W=/KBNLTC1M/U7XJ>-'U*R@NC'!8HJS('5=T3;L
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M\2 /(SLH;YARVX,V?6@#U<D $DX ZDU0MM<TF]BGEM=4LIX[<9F>*X1A$/\
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M*E0 >@)+'CK5SX4N[> K>/>SP07-S#;LQSF)9G"<^@ P/84 =K1110 4444
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MM<N(6:_TY9%MI Y 4.NULCH>/6LV;P%H4UYJUPT=THU:-DO(4NI%BDW *6V
MX#8'7K6U)JVG0Q0RRZA:I'.I>%VF4"10NXE3GD!><CMS2:?K&F:M;-<Z=J-I
M>0(2&EMYED52.Q(.!0!#=Z#I]]'IL<\3,NFSI<6V'(VNBE5)]>">M6K^PM-4
ML)[&^MTN+6="DL3C(8&H-.UW2-7:5=,U2RO6A_U@MKA9"GUVDXJ,>)M!:YMK
M9=;TXSW(!@C%TA:4'H5&><^U &-9_#G0+.[MIV_M"Z6U<26T%Y?RS10L.A5&
M8C([9SBK&J^!-#UC4)[RY2[1KI56[CM[N2*.Z"C $BJ0&XXY[<5O6]Y:W;3+
M;7,,S0.8Y1&X8QN.JMCH?8T6]Y:W;3+;7,,S0.8Y1&X8QN.JMCH?8T 86J>!
MM%U6[-RXO+5WB6"865W);K-&O"JZH0& !(^G%/U'P5HVH_9&"7-E):0?9H9;
M"Y>W<0_\\R4(RO X/2J=KXUM8M>\0V>M7NGV%KI]U%!;R32B(R;XE<Y+'!.2
M>F.*Z"\U?3-.L5OKW4+2VM&QMGFF5$;/(PQ.#F@"G;^%=&M'T=K>T\K^R!(M
MFJN<)O7:V>?F)'<YYYZU:M]'LK76;W5HHR+R]2..=]Q(98\[>.@^\:<VL:6F
MEC5&U&T73R-PNC.HB(Z9WYQ^M2V.H6>IVJW5A=P75N_W98) ZGZ$<4 97B+P
MAI/BB:RFU)+CSK(N;>2WN'A9-X ;E"#R !573/A_X>TK4XM2CMKBXO8<^3->
M74MP8L]=N]B ?<<U.?&>BKXO/AHWL OA )>9D W%MHCQG._OMZXJAX4\<V6K
M:%I\^KZAIMGJ5Y),J6WG!"X69XUVJS9.=H_'- &S;>&M*M-9U35HK?-WJBHE
MV78LL@1=JC:>!Q^=9FG_  ^T#3KVVN(H[N1+-_,M+:>[DD@MF]8XV8J",G'I
MVQ6UJ.MZ3H[1+J>IV=D9CB,7,ZQ[S[;B,U>!# $$$'D$4 5-5TNSUK2[G3=0
MA$UI<(4D0DC(^HY!]ZQ;3P)HMG?6=^IOI+^T<LEW->R/*P( *,Q/S)@#Y3Q[
M<G.N-<TDW:6@U2R-S)*\*0B==[2*,LH&<[AW'452T/5IIM&N+W5=1T:012N&
MGL)2840?WF8\,.] "Z!X4TSPR]U_98N8XKARY@>X=XHR22=B$X7))Z5'J7@W
M1]5U@ZG<I<"=T6.=(KEXX[A%)*K*BD!P,G@^N#Q5^SUW2-1$1L=5LKKS=WE^
M3<(^_;C=C!YQD9],BL#P?XYL=;\/://JFH:;:ZMJ$6\6:S!&8[B!M1F+'./>
M@"_IO@O1=)FT^6TAF!T]IFM \[N(A* '4 G[O P.@_&I+RVM= FU37[73+R]
MO;P0K/%:X=Y-F57"LP P&.:C3QGHLGBZ7PV+V#[;'"LAS,F"Q9AY8&<EQMR1
MZ$5+XG\4Z;X3TQ;W49D4/*D4<>]59RS*I(R1D#=D^@!H R/A_P"&IM&M]5U2
M^LX[/4M:O7O)K=&#>2I)V1DC@D9)..[&NEU?2;+7=)N=+U&'SK2Y39*F2,CZ
MCD'/-17/B+1+*PAOKK6+"&SG_P!5/)<HJ2?[K$X/X5=MKF"\MX[BUGCG@D&Y
M)8G#*P]01P: ,*+P3HZ/H\DGVNXETAWDM);BZ>1U+XSDD_,.!@'I5V#PYIEO
M;:M;QPL(]6EDFNQO)WLZA6(]. .E5/\ A,]%'B\^&C>P"^$ EYF0#<6VB/&<
M[^,[>N,5HQZ[I$VJ/I<>J63Z@F=UJLZF48ZY7.: *TGAC2I=,TG3V@8VVDR0
MRVB^8<HT0PA)SS@>O6J.I^ ]"U;4)[RXCNE-UM^UPPW4D<5UM&!YB*0&X&.>
MHZUKOKFDQ72VLFJ62W#3>0L1G4.9, [,9SNP1QUY%1'Q+H(GMX#K6G>=<DB!
M/M2;I2"5PHSSR"..XQ0!IJJHH55"JHP !@ 5D:9X7TG1]9U/5K*V\N\U)E:Y
M<N2&(ST!X'))..M6;76])OKZ:QM-3L[B[@_UL$4ZL\?.#N4'(YJCI.L2&VU*
MXU;4M%:&WO'A22SF^6),@*DI8\29."/<4 &C>#]$T#1;O2=.M3#9W;.TR>8Q
M+%E"GDG(X 'M5>;P)H,WABR\/>1,EC8R++:F.=UDA=22&5P<@C<>?>M:TUS2
M;^^FL;/5+*XNX,^;!#.KNF#@Y4'(YI$U[1Y-5;2TU6Q;45SFU6X0RC'7Y,YH
M CTWP_8:5>SWMLLQN9X(8)999FD9UB!"9+$Y/S')ZGO4NDZ/9:'9O:V$9CA>
M:2<@L6^=V+,>?<FL[3?&>BZKXDU#0K:]@:[LB@($R'S25)8( <G;CYO2M&SU
MS2-0O9K*RU2RN;J#_6PPSJ[IVY4'(H S-7\$Z/K.HR7\IO+:YFC$5P]G=R0?
M:$'19-A&[&2.><59_P"$6T<?V.([,1+HY+621L56/*[>G?@]ZG\07=S8Z%=7
M-G<Z?;7$:@I+J+E;=?F ^<@@@?UQ69=^-M(TO5])TC4+^S6\OHF<NLZB-,*#
MDY.0&)^7UH Z6L?3_#&DZ9K^HZW:6VR_U';]HDWDAL>@Z#WQUJP==T@:K_99
MU6R&HG_ET^T)YO3/W,YZ>U7V944LQ"J!DDG  H Q=%\):-X>L;ZSTVU,,-[*
MTLXWEBS,,'!)X&!P!TJJW@+0&\)VWAH6TJ:=:R"6 ).XDB<,7#*^<@Y)[]ZU
MM/UW2-629].U2RO$A.)6MYUD"?[V#Q4<?B/0YKR&SBUG3WNIT#Q0K<H7D4C(
M*C.2,<\4 ,T[P[I^EW[7T G>Z>VCM7FFF:1G1"2N2Q.3\QYZFJTO@S0IM)N=
M,DM&-M<7;7K?O6#K.S;BZL#E3GI@\5?L==TC4VG6PU2RNC;_ .N$%PK^7_O8
M/'0]:CC\2:%->0V<6M:<]U.H>&%;I"\BD9!49R01Z4 5](\):5HTEU-&MQ<W
M-V@CGN+V=YY)$'1"SD_+R>!Q69;?#3PW:K @BO)8K65);6*:]ED2V*L&'EJ6
MPHR!]1QTIUKXIO)_BG?^%VA@%E;Z:EVL@!\PN6 P3G&.?2MM?$.B-JATM=8L
M#J .#:BY3S<^FW.<T 5E\*:8GBE_$<0N8K^556;R[AUCFVJ54N@.UB >,CBK
ME_H]EJ=W87-U&7EL)O/MR&(VOM*YXZ\,>M6+>\M;MIEMKF&8P2&*41N&\MQU
M5L=#[&H&UO25=E;4[(,DC1,#<)E75=S*>>H')'8<T 1OH6G2:Q<:I);A[FXM
M!9R[B2K1 D[2O3JQK)TWP!H.EWMK<PI>2BS)-G!<7DDL5L<8S&C,0O' ].U:
M(\5^'3IYU :]IALE?RS<?:X_+#_W=V<9]JMSZMIUMIHU&>_M8K$J&%R\RB,@
M]#N)Q@T 9A\&Z1_;U[K"+<QW%]'LNDCN76*7Y-F60':3MXSCWZTS_A!]!_X1
M>V\.BU<:?:MYEN!,PDA<,6#*X.X,"3SGO6K'K&F36$=_%J-H]G(P5+A9E,;$
MG  ;."2>/K45MXBT2\>Z2VUBPF:T4M<".Y1C"!U+8/R@>IH S[7P/H-MI-_I
MSVTEU%J)!O)+J=Y99R/NEG8[N,#&#QVI^E^#]+TAKJ6+[7<W-S#Y#SWMU)-)
MY?.$#,257GM3O#/BW2?%EM/-IMS$YAFDC:,2*S@*Y4.0"<*VW(SU%7[[6M*T
MPN+_ %*SM2D?FN)YU0JF=NXY/3/&?7B@"OX7T=M \+Z;I+LK/:P+&Q0DKD=<
M$\D9]:73O#NF:5>:I=6L!$NIR^==;F+!VQCH> ,=A4EUK^C6-S;VUWJUC;SW
M !ACEN$5I >FT$Y/X5AZOXIO-/\ B/X=\.10P-::G#<232,#YBF-21M.<=N<
M@T 267P]\/V%Y;3Q17;16DGFVMI+=R/;V[_WDC)V@C)QQQVQ6S9:)8Z?JFI:
ME;1,MUJ+(]RQ<D,47:N!T''I0VO:.NJC2FU6Q&HGI:&X3S3W^YG/2L^V\9Z+
M=>++KPY'>P&]MXT8CSD^=R6S&HSDLNW)';(H LZ[X;T_Q"ML;PW$<UJYD@N+
M6=H98R1@X92#@C@BLT?#SPXL5W$EK,L-WY)GC%S)M=HF5E<C/+Y49;J>^<FK
MV@:I/<Z-->:I?Z/-Y<KAI].E)@5!_>9CPP[U<TW7-(UE9&TO5+*]6+B0VTZR
M;?KM)Q0 V^TFSN=2L=6FA>2[TY9?LY5B,;U 88S@Y '6N3T/2+C7/B%/XRU#
M1I=,2"S%E917.WSI.26E<*2%X.T#.<$^U=2OB;07NK>U76].:XN0&@B%TA:4
M'H5&><^U276NZ18WT5C=ZK96]W-CRX);A$=\],*3DT +K6C67B#1[G2M1C,E
MG<J%D16*D@$'J.1R!3-8T'3]=TY;&_B9HD=9(V21D>)U^ZZLI!5AZBL9?&4%
MKXKU[3M6NK&QL-/CM3%/-((RS2JY()8X/W>,8[U?UK5IHM/T^ZTK4=&CCN+F
M-?.OICY<L; Y$94\N>-O;K0!63P)H0T>]TV2*XG6^=9+BXGN7>>1UP4;S"=P
M*X&,'BHT^'OAY9EFDANIYC%)#-+/=R.URD@ 9923\XP!@'I@8QBMB]U_1M,\
MW[?JUC:^45$@GN$386!*@Y/&0"1ZX-789XKF!)X)4EBD4,DB,&5@>A!'44 8
M6D>"](T>\^UQ&\N9EB,$37MW)<>5&<91 Y(4' S]*K67P\\/V-Y;SQ17316L
MOG6MI+=R/;V[_P!Y(R=H(R<<<=L5T"ZE8/9RWB7MLUK#N\V82J43;][<V<#&
M#G/2AM2L$LXKQ[VV6UEV^7.95"/N^[ALX.<C'K0!%9:/9:??:A>6T96?4)%E
MN&+$[F50H(';@#I1HVCV6@:1;:7IT9CM+==L:,Q8@9)ZGD\FL9_%(TFQU_4=
M9U'1WM-/E<1)9S?O%4 D1R;CCS3C&!WJI+X\MI=2\+FRN+)]-U5;AKF9I ?(
M\N'S,;@VU2#P<Y_"@"YJ?@'0M5O[F[F6\B-YC[9%;7DD,5U@8_>(K -QQ[UI
MMX>TPZGINH+;!)]-A>"UV$JL:, "-HXZ*/I5C3M6T[6+<W&F7]K>PAMIDMI5
MD4'TR">:E%Y:M>M9+<PFZ1!(T <;PI. Q7KC/>@"66-9HGB<95U*D>QK&?PG
MI#^&(/#K6[_V9 (Q''YC9'EL&7YLYZJ*TS?V:W4EL;N 7$<?FO$9!O1/[Q'4
M#WZ56TW7]&UB22/3-6L;UXOOK;7"2%?J%)Q0!G:OX*TC6=1>_E-Y;74L8BGD
MLKN2 SH.BOL(W#D]>:V=/T^TTK3X+"Q@2"U@0)%$@X4"D&IZ>=/;4!?6QLDW
M%KCS5\L8.#ELXX((/TJR"&4,I!!&01WH 6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R
MKPEIT"0?$+6(;:.35(=9OTMYF0,\>U RA3VY8].M4O#F@:W=:!X+N8K;PU9V
MUO+;7,=W'=2?:)59?WBG,>"[J6R-W7Z5ZGIFC6&C_;?L,'E?;;I[NX^<MOE?
M&YN3QG X'%95CX#\/:=J<5];6<BO#(TL$+7$C0P.V<M'$6V*>3T'&>* /-/$
M<DEWX0U36M.TC2K+3)=7$B7,TKO>2S+<JAD7C"Y93@9X7-=!XFTR73+WQ)K+
M:5I?B'0[H"348&D"75L(XE#!6Y! 50P7*D$\>M=+-\.?#%P]X9K"1X[MG=X3
M<R>6CO\ >=$W;48^J@&ENOAYX<O)S+/;W3>8J).@O9@ER% 4&5=V)#@ $MDG
MOF@#%\,0V.L_$/Q=<W<$=RR164=L)T#%+=H=V!GH&8L3ZD5R&G6=O>V7A?3I
M8Q+ID7BN]AMD;E6@42E5]USD8Z8XKU/5_!FBZU>)>7,,\5TL7DF:TN9+=GC_
M +C&-AN7V-6$\+Z-%!I4$5BD46E/YEDD;%1$VTKG@\\,>N>N>M '.:;;6]A\
M9-5CM88X(I=$MY9%C4*K,)9%#$#OCBNY!# %2"#T(K.ET'3I]3N=1DMR;JYM
M/L<K[V^:').W&<#ECSUYJQIFFVNCZ9;:=8Q>5:VT8BB3<6VJ. ,GD_C0!7\0
M2:5'X?OO[<>--+>(QW)DSMV-\ISCGO7!ZO9:]\.=$;6-+\2S:EHUGLW:;J2+
M(QC+!<1S##9 / .1TKTFZM8+VUEM;J%)K>9"DD<BY5U/!!'I7+VGPU\+V=S!
M*EG<2);N'@@GO)I88F'0K&S%>.W'% '/0<_'G7S_ -2\G_H:URXT33O^%">'
M9A:QBXDNK1VG Q)EIPI.[K]TX]A@=J]B7P[I:^(+C7!;'^T;BV%K++YC?-&"
M#C;G Z=<9J'_ (1/11X>M=!^R'^S;5HVAA\U_E*-N7YLY.",\F@#G);&TTWX
MQ:,MC;0VRR:-<(ZPH$#*LD>T$#TKS2/_ )-DU_\ ["#?^E$=>]2Z18S:U;ZN
M\.;ZWA>".3<?E1B"PQG!Y4=JRAX$\.#PO<>&Q8'^R;B3S98/.?YFW!L[L[AR
M >M '/WQ?4/%-G9Z9HVFW6HVNCQO-=ZG*_EQ12,0$5 #EB4))XX&,]JXRPM8
M-5\*?#>UNECFMGUJY1D7F-D#S849ZI@ 8].*]7U3P7H>KWD%U=VTOFPPBWS%
M<21B2('/EN%8;USV;/>FVW@G0+26W>"S=?LUX][ GGR%(I6!#%5W8 .3\HXY
MZ4 <GXHMX+3XP?#R"VACAA1;X+'&H55_==@*S+[4I_!+^+_#-ID3Z@RW6B(.
MI:Y;RV5?39(<X]#7IMYH&F:AK>G:Q<VY>^TX2"UEWL-F\8;@'!R/4&N6.D7G
MBKXA:=K.H:+)I]AH2RBW:Y9#)<S/@9 4G"*!D9.<D<4 =3H&DVWA[0-.T:W(
MV6L"Q+V+D#EOJ3DGZURWQEBCD^%6LLZ*Q00LI(SM/FH,CTX)_.NCU#0EOO$^
MC:N=@.G+. 23N/F*%P!TQQDGKP,=35S5M)L==TJYTS4H!/9W";)8R2,CKU'(
MY .: .*U/2=/G^+7AVWDLX#!!I5U+'#L&P-YD?.WIW)^O-<CK<#V\GBC3+""
MV6TF\3Z>CV\I*0,'2,D/M!PK,%S@=Z]6TWPII.E7%G<6\4[3VD+P0RS7,DK!
M'8,P)9CGD#KTQ@4Z?PKHMS'JT<]BLJ:LRO>*[,1(RJ%4]?E("C&,<C/6@#GO
M#VBZU:^.I]3U"'0K*.73A#):Z;.[-(RR I(RLB] 77/N!47C66/3_B%X&U2[
M(2QCFNK9I6X5)98@(\GMG:PKI-$\+:5X?FGGLHYWN9U5)+BYN))Y"HZ+N<DA
M1GH.*O:II5AK>G2Z?J=I%=6DPP\4@R#_ ('W[4 ,UC6M/T&Q^VZG<K! 9%C!
M(+%F8X  &23D] *X_P ,6-GJ?C7QO+J=M#<72W<5N%G0/MM_)4J #T4Y8^]:
MNF?#KPSI6H07T-E--/;G-N;JZEG$'^X'8A3[]:M:QX*T36[]KZZAN([EXQ%+
M):W4L!F0=%?8PW#ZT >6Z%:PZC:?#RTN4$]BFK:@D ?Y@T2"38.>H^4#Z"NL
MT'0=*D^*_C$/I]LR);V>V-H@44NC;R%Z9.Q<GVKL5\-:0C:28[)(QI.[[$L9
M*K%E2AX!P>">N:GM](L;35KW5(8=MY?+&MQ)N)WB,$+QG QN/2@#QC0K6TO=
M"^%UM?*LEM_:%ZFR3D':9=BG/49"C'X5M^(I=,T#QEXK/V#S--F\.Q/>6ENW
ME":5I6C4$KC:2IQGTK:UOP-:-J'A#3;+36;1;*YNGG42-^Z#QN0VXG<#O;((
M.0<8QBMZU\#Z!:Z?J-E]DDN(]2&V\>ZG>:28 8 +L2W Z<\=J .0T^VO]/\
MB=H$-Y9:/8NVE72"'3&8GRP8]H<D#(!'''K7.1:380?LVQ7T=K$+S;'.+C8/
M,#BX !W=>!@#VXKT^T\!Z!9W-I=1P7+7=K(7CN9+R5Y3D ;68MEEP!\IX]NM
M6O\ A$M%_P"$6'AK[&?[)"A1!YK] VX?-G=UYZT <CK.I0_#_P ?ZAJL_P N
MF:UISSL.@^U6ZYP/0M'^9%=#\/M&GT;P?:B]'_$QO6:^O6(Y,TIW-GZ9"_\
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MN8[F[AG2=(O(,MM=20,\778Q1AN7V-;%G9VVGV4-G:0I#;0((XHT& J@8 %
M' ?#C2K&36O&.IRVL4EXOB*YBCE= 6C4!3A2>G+'..M<+H*K-\,]/M)P#977
MC%(;M6^ZT1D!(;V)"U[CIFC6&CF]-C!Y1O;I[NX^<MOE;&YN3QT' XKG=6\(
M6.G>"+_2-%T&"^AFE\]K">X91*Q8%BKDY5N,CD $#I0!EWUAIUE\:]!-G#%#
M/)I=T9HXE"C *A6('?[PS_LCTKD(=)L+?]FR&^CM(1>;8[@7&P>8)!< !MW7
M@<?3BNJ\+^&Y7\:6VKQZ#>Z18V5I+%NU&Y$UQ<RR%1R=[G:JIQD]^!UKK_\
MA$M$_P"$57PS]C/]D*H00>:_0-N'S9W=>>M '-:;:6Q^-VN.;>$NNEVTBML&
M0Q=\M]?>G_%R&*7PE:F2)'*ZG: %E!P#*H/YUT=UX5TF\\1P:_)#*NI0H(Q+
M%.\8=0<@.JD!@">A!JSK>AZ?XBTF73-4@\ZUE(+*&*D$$$$$$$$$#I0!R5O9
M6EQ\8KV"[MH62ST:'[#"R#:BM(_F,J] <@ D?2I?AVB6][XNL[50NGV^M2+
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M_$$]H'U2SC:*"?>PVJ<@C&<'[S=1WHMO#6DV?B.\U^"T":G>1K'//O8[E
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MN>O(H VZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;5_"=W,_AJTM;-6%N+)Y!)/"T)!10PPPQAO^ YKT>.6.4$QNK@$J2IS@CJ*
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MGU</&7+O=S3+=!3(&SA6+*3CG"YKL-!L+2Y^+'C6XGMXY9$BL8T+J#M5HFW
M9]<#/T% '80ZQIEQ-;0PZA:R2741FMT29298QU91GYA[BI6O[-+^.P>ZA6\D
M0R) 7&]E'!8+U('K7C5A;OIWPOT#Q1:(3+X<U*YD*J.3:FXD25![;,'_ (#7
M:>$-GB#QCX@\5AA);!ETO3W'(,4?,C ]PTA//^S0!UNI:KI^C69N]3O;>SMP
M<&6>0(N?3)[^U0P>(=&NM)?5H-5LI-.CR7NEG4QICKELX'XUS'B!([CXL>%(
M;Q5:V6TO);=7&5,XV<X[D*21Z<UR7B]$@N/B?#:*JVQTJUDG5!A1.0_./4J
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M;6JZ]IK7%T 8(UND)D!Z;>><]O6MJO#X]/M(/V9XKB.WC6<K'/YNT;_,^T*
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M/4]-FTZ]@6>TFC,<D3]&7TK&M/ GARQFM)H-/83VLADBF:YE:0$@ @N6)88
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M2MKN.$XE,3@[._([5S6L?$/39)-*B\/:M87DLVKVUI<(CAR(G8AB.?;[PR*
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M_ESJK9,;8!P?0X(-<SK'Q)\-Z1<:,CZC;/%J;$K,)@%CBVM^\)[C<NWZGVH
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M(?%?A^XUIM&AUBS?45)4VZR@MN'5?<CN.HK6DD2&)Y)'5(T!9F8X"@=23Z4
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M$/.82+'L(Z$(">XQ2VNF-INM>"K.]O;"[LFUO4)<6?\ Q[Q3%'*1@$G!5RX
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MC#%B21@G@\<FH]&\'>'_  _=M=:7ID5O.R>7OW,Q5,YVKN)VCV&!0!B?%/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>sesenbio_minorirosales-e003.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME9'51N!/!!Z5!/\ $FQBCN;Y-(U6?1+:9H9M5BC0PJ5;:S ;M[(#D%@I'!H
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M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!YAKNM>
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M"6=1 OSJ,88#!/X4S3]0TD>/O"=Y:>(-2U>V83P27UW,7A$\D8V1KP%5C@Y
MZ<"O8L#.<<T@  P  * /#$O[8_!GQEHGFXU.UN+IYK8@AT!GX)'H<UT%M=P^
M'-?\(Z]JK^1I<WAQ; W+@[(9?W;C>?X=P! )]*]4P,YQUH(!&",B@#Q+Q$XU
MG1?B!K]FK2:7?3:;!:R["!/Y4B!W7/5<M@'H<&NY\3J3\1_ I .!+>Y/I_HY
MKM** ,_2=:LM;BNI+)V9;:YDM9=R%<2(<,.>H]ZXO5[S_A"?B1<>(+^*7^PM
M7LXH)[N.,N+::(G;O !(4JW7UKNK'3X-/6<0[B9YWGD9CDEF.3^ X ]@*M4
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MPG@,S@[0YABPI/8FO5=/UFSU.\U"TMF<RV$PAG#(0 Q4-P3UX(Z5H$ ]110
MCHLB,CJ&5A@J1D$>E>;?!G3;6PT;7S!;+$QUJXBR!SY:8"+] "<?4UZ510!Y
MU'K%AX0^)'B>?7KE;*VU6.UGL[B4$)((XRCH&Z;@>=O7#5S$>_3-)T;Q+?0R
MVVFS>++C42TD9!AMY1(J.XZJ#P?^!"O:R >H!^M*0",'I0!Y/=:M:Z[XR\37
MNGLTUG_PBK1QSA2$EP\F2A/49.,^H-=G\/$V?#GPXNW;_P 2Z#(QWV"NEZ#
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M+'N WMGKV [UQ/\ :\1^$'_"#BWG_P"$F^S?V=_9WD-OW[MN_.,;,?-NSC%
M'?:AXV^S^(+W0M/T2^U+4;6&.<I T:JR/GG<S #& ,=3D8!YQEK\5;.31H=<
MBT/5&T;<L=U>,$46SE@I!4MN;:2 2H(]SS4WANUDM?B=XB5PQ5=-L(Q(1PQ
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MBBB@ HHHH **** "BBB@ H/(HHH X>3P'J5Y'%I^I>*KJ^T2.X6?[+-;J9I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#M@R/@G:/4X!/X53L-<M=1UG5=+A647&F/$DY90%)D0.NTYYX//2@#3HHHH
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MP/'-)"R X;> 6*MN&3U&*JVG@"\TK1-"CTS5XH]5T=I_*N9;8M%*DS%G1T#
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M3NSNSP0.U>CZAX8U"3QY:>)M.U*& BT%C=036YD\R(2;_E(8;6ZC)R/:H(O
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MI/S;$D\L=S;?PIUEINHWOB/3/"&IZSJ9M].T5+R[>&\=);JX>0J=T@.XJ,'
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M4@LU25H])T-'$DZC'S%T(*HI.>HR6'I7/V.NZH^@:'&;W44\KQ>-/S<R$3O
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M%:SIUYJGP-O?%5UK.HR:E?6_VB=&N6-N4:0?NQ$3M4 8P0,Y'7M7NB_='TH
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MEG))#9XP*T]6OO[7N=*34[CQ']M;2HIYM(T9)(GMY7ZR2NK#!R"H5NFTG!H
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MNHA)OP!N^0DYY&:BMOAQ8QZ/XETRZO)9X-=OY+YF50C0,Q##:<G)4@$'VZ4
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M.AZY:6/BJ?6[FXAFO+B0.;2:%V'F(%WE0@5OE(4$;17>?%;_ ))=X@_Z]O\
MV84:7X*U#2GM+.#Q-=+H=G-YL%BD*K(%!)$;3 Y:,$],<C@G%;7BC0D\3>&;
M_17G-NMW'Y9E5=Q7D'IQZ4 <7J.F2^$M7\)ZG:ZGJ$UQ?ZA'8Z@L]T\D=P)$
M8[MA.U=I7(V@ =*YBWU75-3TA_$-EI_BJX\0O=O+!+#O-GY:S$"$)OVE-@P?
MESG)S7H5OX*NVU?3+C4]?EO['26,EE:M;JA#[2JM(X/SE03C@<\TV'P3?V<S
MVUAXEN;31'NC=&QBA42*2^]D6;.50MGC&<$C- &3;:-_PD_CWQC::EJ.I?8;
M62U$%M!>20JC- I+?*0?H.F220:YJT\0W^I^'?!6GZB=9OX+F&[DO!IS-Y]S
MY,GEH&96#;><MSR0*]5TS0$TWQ!K>K+<-(VJO"[1E<"/RXPG!SSG&:P;?X?-
M8:)HMMIVL26VHZ0\S6]Z8 X996)='C)P5.1W!RH- '$^(+2ZNOA7XKCOK?6H
M+.PE\S2_[0ED24Q,JY1_F_>*K;@-Q/&/2K7B"!O#O@OP*-,O+^'[9K-@9RUY
M*Y8-&<K\S'"' ^4<>U=O>>#KC4_!VJ:'J6N7-W<:D29;MXP!'G& D><*H"CC
M/4DYYHUSP1%K6C^'M/:^>(:-=V]TKB,'S3$I4 C/&<^] '-6>B1R?&7Q+-;S
M72W46GP30%KJ38)'W_>7=@KGHI! ["F^"6AM-=TZTU*;Q#IWB(PN+N#4)GE@
MU%POS-&Q)0X/S#;@@<8Q747G@^>7QA/KUGK,MHEW:K:WENL0)D5<X*/D%#\W
M49J/3_"&I)JFFW6L>(Y=4ATLLUI&UJL;;BA3=(X)+D*Q[#DYH C^(%W=;=!T
MBUNIK1=6U-+:XG@?9((@K.P5ARI.T#(]ZQ+Z%_"/BJ32]-O+W^S]0T6ZF\B:
MZDF\F:(##HSDLN0V",]A79^)O#L7B/3X8#<R6ES;7"75K=1 %H94Z-@\$<D$
M'J":S].\'S#5KC5=>U4ZK>RVALD*VX@CBA8Y8*H)Y)QDD]J .:O=1O5^#GA6
M[6\N!<RMIGF3"5M[[GCW9;.3G)SZU)X8T6U7XQ>,[@279>V%I)&#=R%<R1N6
MW+NPPY. 00O;%64^&EZVCV.CW?BB>?3M.FAELX1:(A41N"H=@?GP 5'0<YP2
M!6Y%X5N+7QS>>(K/5FBAOXXDO+)K<,)3&I5"'SE>OH: /'K.]N]/_9?EN;*Z
MFMIUO"%EAD*,,W !P1S7HNJ64NM_%6/2;B_OH]-_L%9Y;>WN7B$K>>5&2I!'
M7G!!. .G%)_PJN#_ (5@_@G^UI/*:;S?M7DC/^LWXVY_#K75+X?1?&/_  D/
MVAM_]G"P\G;QCS-^[.?PQ0!YA+J^H:;X=N]$2ZU6XMQXK;2U:"1I+H6H3S3&
MCDYSP5SG.#3[W6=6\-Z#XJFTFRUVQTP6$3VAU7<S6]PTGEML9F8XPRM@G@@U
MVLO@&&2SU.-=1FBN;K5O[7M[E(QNMIL*!@'(8?*0<]0Q%2GP=<:EI.KV7B+6
MY]3_ +2A$!V1"".%1G!2,$@-DY+$G.!V% '+Z[X7@\/:[X(-K?7\JOJRK.MU
M=/-YLGE/^\^<G:?O9VX!STX%=5\2;F>T^'&O7%M-)#/':,R21L593QR".15"
M/P)J=Q?Z+>:QXHFOWTBX$MNHM%B5AM*G?@G+'(^;M@\<FNB\3:(OB3PUJ&C/
M.8%O(C$90NXKGOCO0!P)6\UC4OA[82ZG?16UYHLLEX(;AD:?$<)Y8'.<GKUP
M3SS6YX'233O$WBW04N;F:PL+BW:U6XF:5HQ+"'90S$G&>F36G:^$8[74/#EV
M+QF.B6#V2KY>/-#*B[CSQ]SISUJYIF@)IOB+7-7%PTC:JT#-&5P(_+CV<'/.
M>M ')>.8I8_$D=UJUOKL_AX605)-(FD4VL^]BTDBQL&(V[<'D#!XYJ;1+]YO
MB#H\,&L3ZC8OX9,JS,_$[><@$A7IN([XSR:WM8T+6;K4S>Z1XDET[S(A%+!)
M;BXC."2&16(V-\Q!/(.!D<5EGX?/8-HTV@:U)IUUIMFUD99;=9Q/$Q#'<I(P
M=PSD>O2@#C?$T]Y>:#XOA^V2[X_%%K%;L[;A",P8V@\  G..E=*^GGPC\0_#
M<&GWVH2VVKI<PWD5U=R3AV2/S%D&\G#9!!Q@8/2II/AC#/H6JZ7-K-U)_:6H
MQZA-<% )-Z["P&" ,E,Y&,9X'%:=AX2O1XDM=:UK7'U.6QBDBLH_LRPB+?@,
M[8)W,0 ,\#KQ0!:T/Q9#KM\]K'I&MV;+&9/,O]/D@0X(& S#!//3V-=!110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !17C^E^&K?7M"\8:A?WEZ]U:ZKJ"V4BW4B?9-C$J5 (&<\
MY/; Z"I/MUOXJL_#?]HV.L:Y?OHL=S+I]G*L,2%\#SW8N@W$JP R>_'>@#UR
MBO$A/J&L>$?A];S7]Y#)<:K-:32"8^:8E,J;2P/+;5QN]>:Z/7])T2WU73?#
ML&F:SJR6EF\J:5:7)6.-6?B:21Y%);(8*"Q[\4 >E45XSI=S=^(-(\"Z!J-S
M=_9+R[OUNU,Y$DJ6Q<1QNZG)Z+G!YVU9N[)M#U[QQ86EY<FSA\,F6VB>=G^S
MY$O"DDGJ"1SQD#H!0!Z[17E-GIFG:7\+;+4KV^U=K[6K:R2>6UF9Y[AFVE88
MP3A<@E<C'&<GO6>LDVEIXVTZUTW4-&M/^$=:[CL[FZ$I23$J^8A5WVY '&>J
MYH ]FK(T/7H]<FU:..!HCIU\]DQ9L[RJJVX>@^;]*\XNM(3P_P"&O"7B>UN[
MQM8DN;%;J=[EV^TI+M5T*D[=OS< #C IVG>%['7/^$]N;][EC#JUS]G6.X>,
M0N(D.\!2,MTY.?N^YR >N45X^R7^K:!X5UG6=,U/7=);1T%Q%8SL)8[@[3YQ
M0,IDRO'!)')QS7H_A2:SN/"VG2:??W%_:&("*XN3F5P"1\W .1C!SSQSS0 S
MQ5XKT[PAI2ZAJ*SNCRK#'%;IOD=CDX R.P)_"M+3=0MM6TRUU&S??;742RQ-
MZJPR*\NUGQ-I][\6Q]NAO;C3/#T#1H+:RDN%>[D W9V*1\J''/?-7OA+K$$;
MZQX507"0Z?.T^GK<PO$YM)&) VN ?E;(S[B@#TVBN*\?2375_P"&=!$\T%IJ
ME^4NVAD*,\:1LYCW#D!B #CG%8MU:)X6\6ZCHVE/-%IM[X>N+HVQF=UBFC;:
M'7<25R&P<=P* /3ZYOQ%XSL_#FIV&G2:?J5]=WR2/#%8P"1B$QNR-P]:R/A9
MHL,'A'2];FFN+G4[ZQB$T\T[M\@ VJ%)VC QR!D\D]:S_&_]J_\ "U?"']C?
M8_MOV6]V?;-WEXVKG.WGI0!TFC^.M-U765T>6SU+3-1DC,L5OJ-J86E4=2AY
M!Q]:T/%&O1^&/#=[K,L#3QVJAC&C8+98+U_&N&N3K5C\1O#FI>,DL7C9I++3
M'TQF"13RKSYBN-QW*N 0<#N.];?Q;S_PJS7L'!\I.?\ MHM ':T5YKJ>BP^$
M/$OA._TVXNS<7]_]BOS)<O)]K5XV.YPQ(R&7(QC&?2N5TR;5=7T2#Q#8Z!XA
MG\237?VA-16=!;LHEYBVF7_5[ 5QMZ\T >J6?BJ&\\<:EX86U=9;&VCN&G+#
M:X?' 'XUT%>327TFE_%KQYJ$(#2VN@).@(ZLJ!A_*JM_I,>A?##3O&MK=WC>
M($CM+V:[:Z=C<&1TWHRD[2I#D 8["@#V.BO)-0OKO2[3QIX8CN91=W>IPI8,
M7.Y4O<#"GL%(E^F*2WNKJ\TOPWX/-S,;J'79;6Z?>=SV]JQDY/7YE,/_ 'U0
M!ZT[I%&TDC!44%F9C@ #N:Y[2_&-CJ&C1ZO,CVEA<W:VUE)+DFYW/L1@H&0&
M;IGMR<"L_P"+%W-9?"_79(&*N\*P[AV$CJA_1C6+\3= TX:+X/M#"WE0:Q9V
M:*LC(!$QP1\I'91SU';% ';6^O1W'BR]T$0,)+6UBN3*3PP<L ,>VW]:UZ\Q
M7POIVI_%+4]-N1.=.MM&M%%LL[J'PT@7<P.YL#/4]3D\@5SR:C>)H.F>'BNI
MW]D?$-[9O#;3?Z1-;P;V6+>S+QP,_,#M7'M0![?5<WL(O_L0):<1^:X X1"2
M 6/;)! ]<'T-<=X"@O[34M9M_P"R-3TW13Y,EE!J$BNT;D,)57#OA>%.,]2:
MZ&Y\,Z;=^);?7Y%F%]# ;<;96".AW<,O1L;VQGU^E $>I>*]-TO18-4D%Q+%
M<R+%:QP1%Y+EF^Z$7OD D=..:K:3XTM=2UA=)N=,U32K^2-I88M0A5/.5<;M
MC*S D9&1G-9EY\/;6UT"RT[0=1FL+JQOOMUC+<,9PLFT@H0QY3:2,#IU^L4'
MB7Q!I.MV>G>+-)T]IKE)OL.H:>Y*,Z(79"KC<A*KUR0<8H [VBO$/#YU6]TW
M0]=L=!\0R:[/<0W-UJ3SIY%Q$[#S%*^:?W>PG:-@QM'2M^U\02>![;QQI]U(
M\C::YO\ 3Q(Q8O'./D09Z@2Y7\: /4**\7-A<V%_H/AC5M.UC6X;;1_MUU;V
M<P!DN9)2&:0M(FX+@@#/&>E&J1ZX/"OAS3KMM3TTOXJ2UMFGF!N!:.LFT,RL
M<D X!R?NB@#VBBO-O$&CZ'8WFD^'+?3]9U-(8)ITTFTN2%(9QF:61Y%/!)"@
ML>2>*Y^.>_O_  =X7LI+N^M2/%+V))GS,D*F=?++@G)"C;D$] 0>* /::*\H
MU#'@3Q/XBCT,S16R^&)-1%N\SRJ+A'90XW$]NOKBMSPWX*M[6VT/7+34;Y-0
M\E)KV5[AY1?!TRP<,V.IR"!QB@#NZKW]Y%IVG7-],&,5M$\SA1D[5!)Q[X%>
M)Z+-JNJZ)I_B&QT#Q#+XBGN4NFU'ST^SR(9?FCV^;_J_+RH&WL*]=\5?\B?K
M?_7A/_Z+:@#FXOBGI\FG)J1\/>)4TYHQ+]K.GYC$>,[R58_+CG.*[.QOK;4[
M"WOK.99K:XC$D4B]&4C(->5>'K7X@7OPMTVUTU_#PM)M-2./?YHF\LICJ<J'
MQWQC-5#J]G>^&? VD:7IVK7&CS"X2YL+>15GD-NH78S;E!&\EC@C..G:@#VB
MBO%]476+#P3K]O%::KH^GC4;%M,%Y*K2PAY8Q(JD.WRAAD G^+%;UYIMOX.^
M(.AMI+702_L[[[9'+<R2B=HD1U9MQ/S9)Y]Z /2JY:;QD6\;-X8T_2+F]FMT
MCDO+A9$2.W1R,'YCEC@YP*\Z\/?VI>:=H.N6.A>(7UR>XAN+O4I)T\BXB=AY
MBE?-/R;"=HV#&T=*T?#OAC21\;_$J"WEVV<-I<0?Z1)\LA 8D_-\PSV.1[4
M>AQZ^UMH^HZGKEC)I-O9229,KB3?$H&)!LSP>>.O%;*L'4,IR",BO )4_M+X
M*^.Y+R269[77;AH2TK?+@Q@#KR,,>#QS78^(O#J:=-I1.B:GJOAJ"T=6M+&Z
MD,L,[,&\TKO#2<9 Y..<"@#N+SQ+IUAXBL-#N#,MW?*S0'RF,9QDX+] >#Q[
M?2L7_A8VE/I\6IQ0W)TX7WV&\GEC,;6CG&UG1AG82R\]MP]\:'AF'3=0T#1K
MRTOKK4;:",FVFNFRY/*Y?@$L 67GD<]^:/$FBVDO@W7[1UW"[MIGF=SDL^S
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MRS1R(H<A6P,@<J.#W%:OQGM(;GX6:N\JL6MPDL9#D8;>%YP>>&/!XH [T$,
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M@EU'4KB=##=0R#]Z2OFGY<-N4;1C:.E 'M%%>9^ ]&BU3Q)XEU>_GN9Y-/\
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MUN]N--L8X+JWTZ1$"I*$&W<X&YE4G@'T&<XKI-.\-0:=%KD:7$CC5KJ2YD+
M?(715('M\M;E% ''Q>"+K3['3(-&\27VGO96:V3,(TE29%Z$HP(#<GYAZXYK
M>T/1H- T.WTNTDD:.%6_>2G+.S$LS'IR6)/XUH2.L4;2.P5%!9B>P%5M,U*U
MUC2[74K*0R6MU&LL3E2NY2,@X/(H SO"GABW\*:3)9PSRW,LUQ)<W%S,!OFD
M<Y+''X#\*2]\,07?B[3?$D=Q)!=V<,ENZH!MGB;G:WL#R,=ZW:* ,;Q'X=@\
M1V<$;W$UK<VLZW-K=08WPRKG!&001@D$'@@UGV7@S9<:C?:IJUQJ6IWMH;(W
M,D:1B*$Y.U$48')R<YR0*ZFB@#.T#2(] \/V&D0RO+'9P+"KN!E@HQDXK(\2
M^#I->UK3=7M=9NM+O=/CECBD@C1\B3 ;(<$=!7444 <A9^!2=9L]5UO7M1UJ
MXL6+VL=P(XXHG(QOV(H!;T)Z5L^)] @\4>'+S1;F5XH;I0K/&!N # \9^E:U
M% ')VG@ITUNPO]0UR\U&'3-WV"VF1%$1*[=S,H!D8+P"?KUYJ.#P+):7'D6O
MB'4;?1?M7VK^S8@B@,7WE1(!O"%N=H/<C-=A10!SL/A"SC\7ZKX@>9Y7U*U2
MUEMW V!5 'UYQ63!\.0D%GIESK]_=:!92I+!ILB1X^0Y1'D W,BG& ?09SBN
MXHH YG4_!5EJGC33/$LL\RS6*;?(7&R4C?L+=\KYC$?6BR\%65EXYO?%*3S-
M/=1E/LYQY<;$(&=?<B-<UTU% &/XKT)?$WA34]&9@ANX&1&/17ZJ?P8 US<%
MDWQ \$V5M?3W&F:QIMS&TS*H+P7<)ZX;AE/4=B"*[RB@#"TOPW]@UV?6)[^6
M[O)[.&UE9T50WEECNPH !.X\=*SF\ VHTV2W@U"Y@NAJDNJV]V@7?!,Y)( (
MP5PQ!!Z@UUU% &/H6BW.E?:IKW5[O4[NZ<-)+-A%4 8"I&ORJ/IR3U-;%%%
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MFBCC$>\ ,S% "[8&,GWXYKJ** ,;7M$N=5>TN+'5[K3+RU+%)80KJP88*NC
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MP/D9PH*C'8;:V:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:C:SL!LGB8@<=\C(R/0U8T_Q%;ZEXBU;1[>&4MI@B$TYQL+NNX(.Y(&,^F:
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M+Y%D=V&!CP$4AC@ #. 37J_CC0I?$_@C5=(MV"SW,'[DDX&]2&4'VRHKH:*
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M4/48XX(.16#;?VAI>@>%[/79M:T_0));QI!$THG1-V;:*5H\NORD\ ]@#TH
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M[X(/X4 =!IGB*+5?$&L:7;V\FW2VCCEN"1L>1UW%5]U&,_6O/?B5>ZK>>/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJJT8)<,Q4!2 #UQTJS%XNT>74+6R\Z:.2\1GM&EMW1+@*,G8Q&&XYQW'(R*
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M_P#@(QR<1ZWKMW>P^$?&4&DZ@;;3YY/[1L?(;SH!)$4+;" 6V$GD#D&O3:*
M/./%$LOB+PK<ZIH&C7#K#>6MX5,#6\U^(G#, " _"@8)Y)!QT&2"ZT/6]/U3
M5-+T>_CGCTN>*6\OXI4>,%2?*!D^]SDG;D#'7FO1^M4]5LY-1TF[LHYEA:XB
M:+S&3?M##!.,CL?6@#RZ"*+Q-\+_  9HU@CO?(UC*W[L@VRQ@%Y&)' V@X/\
M6X8SFNF\.-)9_$CQ?!/:W2F\FMIX)/(;RV00*I._&W[PQC.<UTGAW27T'P]8
M:2UP+A;.%($D$>PLJ@ 9&3S@5IT %%%% !1110 4444 %%%% !1110 4444
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MHHIX&4S1#@LHZDC^Z<-[5Q.L:?%XK\(ZU-X9\.SV=Y)!'MFO+<P2W#)(LGE
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M;=6K!5L7$]SLF1F=D +!0H."V"<'MC(!Z'H^N6NMI<O:QW2"WF,+?:+=XB2
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M ;X^(6BM!>LL6I-/8OMN;06,AGB&-VYDQD+CG)X_&M8>(M.DT^QO;:5KE+]
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M+K--4T?6!+I[M!<1QV3%@3(YW '&Y0,$L,CD=^*])W"6#<AR'7*GUR* /,O
M7C_3;3P9X=M]8N[UKBZ7RFOIH9&A,K.V%:8C;N/UX[XKMM5\4:?I NFF6YE2
MS027;6\)D%NI&<MCVYP,D#G&*\YL]-NM4^#-IX*^P7<>L-LMY4FMG1;?$VXR
M%R-N HR""<G &:O2F/0?%^OVFN^'=1U*RU6=;FSNK6V:X5P8U1HG"]"-G&>,
M>@H [R3Q'IP:QCMY&O)KZ$W%M%;@,9(@ 2_) "_,.21U '-8.J^,/#6K>"]3
MO9+S4XM-C'E7$]O;3Q21MG!"MMZ@C!QP.AQFL76Y(_#GB7PY?6VF7=E+%IDT
M+Q6=BUW%'%N0B(I&000W.X''&.<\4;U=/N?A#XDTW0QJ%]J$[O+<0M82QS--
M,^[(B*Y"G!QU&%ZDYH [V]\6Z1I6I6VE3O=->30&:&-+:21I%7'W2!\QY' R
M?7%5V\?Z!'X;DUZ2:YCLXIS;3!K9]\,H8*4=<?*<D#G Y'-95RTDOQ*\,W:6
M=\;:/3+B.2;[)*$1G\O:&.W /RG@URFI6U[+X#\;VL>EZFUQ=^(3<6\0L9MT
ML9EA.]1MY&$8Y]J /2[#Q;I>H:S-I,7VI+N.#[0JS6SQB:+."\>1\PS@<>O%
M9%CXK\.:-X9U+65O=1ET^._E6:2XCED9)2V&4 C*J&. #@"HKQI)/BSI%ZEI
M>FU729XFG%I)L5F=&52VW .%/%<C>6E]+\*/&-FFEZD;JZUF>6"#[#+OD1YU
M965=N2-H)S0!Z58>+-+U#7'T>(W*7?DF>/SK=XUFC! +1LP 8 D<CUR,BH+K
MQQHEI!]JEDN#8_:3:"[BMVDC:8';L&T%C\P*Y QGC.:RM0:2?XI^'+N*TO6M
MDL+F.2;[)($1G*%0S;< G:>M<7:W6F1Z-)H&HIK-MHL.JR7*Q_V1-(0BSEPO
MGIE2I89R%R <9XS0![3%*LT"3+N".H8;T*$ C/(."#['D5A#QGH^;1VDF2SO
M)O(MKUHB()9"< !O<@X)P#V)J_J47]M>&[N&RN%'VVT=8)U/ WH0K#\P:\VF
MM+S7?A%:>#6TZ[MM;C6VLI$>!PL)BD3,N_&W;M0L"#SG YXH [6[\=Z-:7VI
M66+Z:[TY4:XA@LI'<!@2"!CE<#.[IR.>:V]-U&UU;3;;4;&436MS&LL4@&-R
MD9'7I7&::9+?X@^-+F6SOA;S6MHL4IM)"LI1'#!3MPQ!8=*T/AC#/:_#C1;6
MZMKBVN((/+DBGB:-U8$]0P!H KKXJ.N7?BC2%M;ZU73T\I)E5HVW>67+;A]W
MJN._YXJGX%\9V*^%_"UC?S7CW=];)&MU+"[123;<E#*1@OP>_4$=:9:&XT_Q
M3X[BGT^_*WOES6\L=J[QR*+<*<,!@G<,;1S[8R1CI;WB> ?AU;'3=1^T6.I6
MCW47V*7="J*P8L-O &1S0!W^J^+=+T=;F6Y^T-;VC!;N>&%G2W)P?G(]B"<9
MP",XK6DNX([%KTRJ;=8S*9%.04QG(_"O,(/*T?7=>T?Q!X7U'4EO[Z6ZLI[>
MU::*XCE.?+8]%*G(.[ QUP.OI"6$<FA+ITL"01-;"!H83\J*5VE5]AT% ')>
M"Y+KQOHH\2ZK=7D<5Y(YL[*VN7@2"%6*KGRR"['!)))ZC %;=L'\,1:K=:MJ
MLT^G>:CV[W!WO$I55\L8&6.X<=2=PZFN:\"WDW@O1$\*Z_:W<<E@[I;7D5K)
M+#=1%BRD,@.&YP5.#QWJWXZ@U36O#MM?:;83O_9VI6U^ML5*RW4<398;#R.N
M0#R=O3I0!T-MXFL)]2ETV1;BVODA^T"WGA(>2/IN3&=W/&!DCN*RA\2O#AL(
M=0$MW]ADG,#71M)!'"V_9^\8CY,MZ\\C.,U4NXQXB\=^&]:L8KE;328+J2XE
MDMWC)\Q JQ@, 2W4D <;?4BN2DM+YO@9J.FC2]2^W/?NR6WV&7S"#>>8"%VY
MQMYS0!Z19^+]*O-7ETM!=QW*0&X02VLB">,'!:/(^< D=/7C-97_  M+PM]G
MMKK[1="SGE,)NS9R"&)PQ7$CE<(21T/.,$X!J/4#)-\5O#]W':7C6R:?<QO/
M]EDV(SE"H9MN 3M/6N0T8C6/@K>^'K:UGGO[N>Z@AC\AMI9KER'W8VA5ZDYX
MVXZ\4 >DZGXNTO2I[V*7SYFL(%N+TP1%Q;QMG#-^"L<#)P,XQ3;WQEHMA>:?
M:RSS-+J$336HBMY'$JA=WRD#YC@C@9/(XKB=>74&?Q+H4NG:DP72$AL'LK9@
MM\WDL"TDJCDJQP$+ 8SPQ(J6Q^TR:S\-93INHQI9Z?/%<L]G(!"S01H QQ\N
M64CG'3TQ0!U!\?Z&OAZ[UN0W:6EE.;>[5K5_,MW&,ATQD=1S[BMB;6;:"73H
MG2;?J#;80L9/.W<=V.@P"<GTKD_"E@M]?^-[2_L;E;34-08@7%N\:S1-$B$J
M6 R,@CBD^'UCJB-+%J["4:'OTJSFSDS(&!,A]RHB7V*-ZT ;&FV=SH>I^(=3
MU#5;R32I")T6]E#+;[=YD*8^['@J #S\I_'2L=<M[Z]6T%O=0RO#]H3SHBH>
M/(&0>G<<=1W I^O>6?#VI":S>]B^RR[[5 2TZ[3E !SD]/QKC?!UG?Z5XD%C
M87U_?^&C9,Z#48666RDW*%B#L 2",_*>5VC/;(!J?$?7KG0?"S26@G6>>:*
M2Q(3Y:M*BMR.C;6./?I5*WMM$T_QGI;?VCX@ANM0:1[33IY)O(#+&PD)##'(
MYP3UP0.:F^**33>$D@MK2ZNIFO;9Q';6[RG:DR,Q(4'& #3?$IDG\?>";J&T
MO)+>"2Z::5+60K$'A*KN.WY<GCF@#0B\?:'/J36$)O9)TNQ9RXLY<12$9&\E
M?E7GJ< X.. 35RU\46-XUOY,5VT=U$TUM*("4G11G*D>HQ@'!/8&L'P8)8];
M\9M+97<:SZB9X3/;/&LR>4BY4LH!Y4BLGPI97>EZ_I":#)J7]@W*2/=Z5J,#
M_P#$L.PE?+=P"OS';MYR"2,CD '5^#/%)\5Z5)>FSGML3S(JR1D#:LC*.>A;
M"\@=#3M7\;:-HNJ2:;=&[:]2V-UY,-I(Y:,$ E<#YNO;. #G&*R_AFMQ9Z!<
M:5=V5W;W%K>W1<S0,B$-,[*58\.""#E<C]*+@2CXS6ES]DNS;#19+<W MG,0
MD,R,%+XV@X![T /O/&]_)=7XT+0&U*UTZ-'O)9+CR&RR"39&A4EG"D$@[>3C
MK3KGQQ+=7VFV/AO2QJEQ>V U$F6Y%ND5NQ 4EMK?,3P!CL:Y35-$TS3?%7B*
M36]"UN_^WS+=6,FG&X*2YC53$?*8*K!E/+8X(YXK1AMW\'>+[#44T'4!I,^A
MQ6(BLXGNFM)4<L$;;DD8;&[ID4 7K;XE>?I]Q<OHTL#P:U%H[PR3#<KN4#,<
M CY2Q&!G..O-=)=:^+;Q?IV@?9BQO+6:X\[?C9Y948VXYSNZY[5Y7''J6HZ#
MXGOX],N&N+7Q;#?2642[Y?+3R6*@#JX7J!W!KJ[>^N-?^)^C:I;:5J,.F0Z=
M<Q?:;FU>(%RT9QA@"!QP3C/.,XH Q_AAJ=SI7PYU*YM=.N-2N3K,\<5M#U9F
M=0,MSM49R6/0 UU$?C:\MK3Q"NK:,MKJ.C67VXP177FQSQ%7(*OM!'*,#E>/
M>N$T33=:T[X:O!/8ZM!"WB)I+^*WBD2=K,M\Q4##D$[<[><9J8:;Y,_C!-*\
M/:I:V6J>'7CL=]O*S3.JR@AMV2C$L,*V"1CCG% 'HOA/Q#J'B6S_ +0GT8V%
MA-%'+:2/<!WF# DDJ -HZ8SU!S@5T59'A2&6V\':'!-$\4L>GP(\;J596$:@
M@@]"#VK7H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***S]>U,Z+X>U+
M5!$)C96LMP(RVW?L4MC/.,XH T**X*#QYJR)HNI:CH$5MHFKRQ0Q3+=[YHFE
M'R,Z;0 I..AR,C/I5C7/&&N:.=0U!O#J_P!A:?,(YIY;DI/(OR[I(X]I!4;N
M[#.#0!VM%<_I?B4WOBS6/#]S:BWGL4BF@<2;A<0N/O@8&,,"I'/-<Y=_$V6W
MTW^T8-%-Q;2ZY_9%KLG^:XP&'F+\N.74J!G\10!Z'2,P52S$ #J2:XZY\5:[
M;R:7I']B6C>(K]996M_MA\BWA0XWO($R<Y48"]2?2L7Q/XDGUCX?>-M,U&Q6
MRU73+4K<11R^;&RNFY'1L D$ ]0",4 >E>8@V_.OS_=YZ_2G5XSJ/^H^#7U@
M_P#1,=>JZ]K-OX>T&^U>[#&"SA:5E7JV!P![DX'XT :!95QN8#)P,GJ:6O*_
M$&JZ_>ZAX)&M:+!8K/K<$\3071FV?NY/DDRJX;YATR#@],<[^K>,=;TF2[OY
MO#RIH-I=+;RSRW)6=U+!3*D>W!3+<?-D@9H [6BN M]?\0O\6M2TQX+4:5;6
M,3L#=$;$+.?- V<N>A7(  ZFI;/QWJ4T>FZM<Z)%#X>U*X2WMKD7),Z[VVQR
M/'MP%8XZ,2-PS0!W5(64,%+ $]!GK7-^/]3U'1_ NKW^EI&;F&V=@[R%/+&T
M_..#EAU XSZBN+OM3UPZS\.[RXTV*?4Y([L1PQW)*R;H$P[N5&WJ6;@XP<9H
M [MO#CMXU3Q)]MPZ69LA;^5\OEEPY.<YW9'7ICM6]7':?XQU-T\0VFH:&?[7
MT9(W-K8S&9;D2*2FPE0><$'(XI;+Q-X@_M:71M2T6R@U.2Q:]LQ%>L\4@5@I
M1VV J067D CGVH ["BN(^%>M:UK_ (*M=0UA(CYQ=H9UF+O*/,?.Y=HVXP ,
M$Y'I5W4_$VJ/XEFT#P]IEM>75K EQ=S7=R88H@Y.Q/E5B6.">F * .JHKAU^
M(9ET"">'2G.M3:BVE#36F "7*YW R8^X "V['3''-22^-=0T?2]6F\0Z$]M<
MV C\K[+(9(;PR':BQN57YMQ ((XSF@#M**XY/%/B"P^VKKGAQ(#%82WL,UI<
M--"=@R8G;8-C^G4'G'2I[KQBUMX5T#6OL(8ZM+9QF+S<>5Y^WG..=N[T&?:@
M#JJ*XR#QCJNH>--1\/Z=HD<D>FW,*7=W)<[56)U5L@;>6Y;"_P"SR1D4N@^+
MM:UQ[._CT&+^P[V5XXYXKO?-$ 6 >2/:  2O(#$C- '945G:YJ%UIFDRW-EI
MTNH70*K%;1G!=F8#D\[5&<D]@#7/VWB;7Y)]5TBXT>QBURTMX[J%$O6,$T3L
MRYW^7E2"K<;>>/6@#L ZEBH8%AU&>12U\Y>';K6M"^"UYXFT_3+&.ZN0XEUC
M[6WVI]TY4DJ4Z@X ^;WZ\5Z_=>)=>2[L=&MM'LI-=GMWNIXVO6%O;Q*VT$R>
M7N8L2  %]?2@#KJ*X*_^)#V7A_3K\:+))>SZM_9$]B)ANBG&_(5L8;)08/&0
MP/%=?I$VI3Z7'+JMI!:7QW;X89O,1>3CYL#/&.U %UF"J68@ =232]:\7NM=
M\1ZSX'^(RZM;VRVUM)=0*R71<PNJ1CRU4H,IU.[(.3TKK;#Q;K%E=^'[?4]#
MBMM,U4K;VLZW6Z9'\LLOF)M &X*> QQWH [NBN$N/'NH1V]WK46BQ2>&K2Z:
MWENS=$3L%?8\JQ[<%%;/5@2 376:VY7P_J+HQ#"UE(8'D?(>: +]%>*+H^C:
M?\)K;Q+%K=_9ZXFEI=).-4E)>X\L,%\MG*G<W&W'>N^N==\4[;2'3?#L5Q,+
M&.YNI;JX,$>\CF),*V7X/7 ''K0!UM%<=IGCV+4M4\/0_8C%9:[8-<6L[2<B
M9,%HBN,<*<YSSCI5?Q#\07T:X\1K;Z8+F#0K2&6>4S;=TLC<1@;3T3YL_08H
M [@C((/?TKE-,\'7NDPI8VOBG5!I<>1';-'"SJO]T2E-V/?K[UG7/C?7[+6M
M/L+GPS%G5T<Z:$O<MN4!B)ODPGRG<2N[&"!FI(?'\]II_B'^V]+6#4=$>)'@
MM9_-2<S >5L8@?>) Y'% ':V]O%:6T5M @2&) B(.BJ!@#\JDKD+7Q5JUKJ,
MFG:_I%O:73V4E[:FVNC*DHCQOC)*J0PW+V((/M63;_$36'T;1_$-QX=AAT._
MD@B=_MF9XS(0N_9LP4#''7)'.!G% 'HM%<#H6N^([SXI^(M,GMK;^S;-+=<"
MZ8F)661E=5V?,S_+N&1C'5J7XM%SX<TN%9IHEGUBUAD,4C1L49B",J0>10!W
MM%>?ZSX!72-*N=1\+ZMJNGZE;1M-$'OI9X92HSLD21F!!QCVZU<L?%^LZUX=
MT"]T71([FYU.V,TSSS&*WMBH&X%@K$DL2 ,=B: .THKR[Q)XXURX\+:5>:78
MQVMU)K2:=>QO=$&.5)@IC#!3N1MI!;C /0YKH;CQ/K\NI2:7I6AV=S?V5M'/
MJ DO2D<;N"5BC;82S$ G)"@#&>M '4WEG#?6[6]P"T+_ 'T!P'']T^H/<=^A
MXJ8LJX!8#/ !/6L[0-9@\0Z#9ZM;(Z17,8?8_P!Y#T*GW!!'X5RVA-_PDGQ"
MUS6+C+VNAR?V;81]0DFT-/)C^\<A0?0>] '=T5Q5MXPUN._TMM8\/)8:=JMR
M;6W8W):XB<JS)YL>T ;@IZ$X[T_3O%VM:I>?:+/08IM%%\]DTR7>;A-KF-I&
MBVX"@C.-V<<XH T-3\,7%SKC:QINN7NFW<D*P3*B1RQR(I8K\KJ<$%FY!'6M
M+3M/73MS37<MW=S8$EQ/M#OC.  H  &3@ =R>I)J'Q-KT'ACPY>ZQ<1O*EL@
M(B3K(Q(55'U8@?C7#:IJ&NW'CGP/#KFDV]E(UY/+&UK<F9,?9WRC95<,,CID
M'G!XH ]/I&=4QN8+DX&3BN$_X3[4/LQUP:-%_P (P+K[-]K^U?O]OF>7YWE[
M<;-W^UG'.*Y35K;4];^._P!EOM$TZ^CL]+\VVM[B\;RTC\_ F'[L_O,'[N,?
M[7% 'LJNK$A6!*G! /2G5YI9>+K'2K;Q_J=EH,4,VDW;&?;.?],<9^8G'RG\
MZUX?&.KQ:UH\6IZ'%:Z;K+F.UF6ZWRQML+J)4V@#< >A.* .RDC$L3QMD*ZE
M3M.#SZ$=*Y;3/!][I=M%I\7BG4VTJ%!'';-'#O5!P$\T)NQCC/!]ZSI/'VH+
M;S:XFC1-X8ANC;/=FZQ.5$GEM,(]N-@;/\6<#.*NS^*]7N?$6IZ?H>BP7MOI
M.Q;R6:Z\IG=EW;(AM(+!2/O$#)QQUH ZNWCABMXXK=46&-0B*G0 < "GAE8D
M*P.#@X/2N*^$;B3X8:.X! ;SR,]?]=)6#H>J:_::_P"-H]#T6"_,6K--*UQ=
M&$-^ZC 1,*V6.T]< <>M 'JE-=UC&78*/4G%<7%X\FUJVT5?#>G1W5[JEHUX
M4NIS%';1*0K;V"L2=YV@ =B:Y3XE:Z=?^%_G2VIM+NVUF*UNK<OO\N5'P0&X
MW @@@XZ$4 >PT5RNJ>)M3;Q++H'A[3+:\N[:W6XNYKNY,,40<D(ORJQ+'!/3
M %4=.^(9O;S1[>;2S;-=WMQIMX&FW?9;J)=P3@8<-@X/':@#N*3<N_9N&[&<
M9YQ7*:5XU74_'>J>'!9^7%:*?*N_,R)V01^8H7'&TRJ.I[URVN:_)?\ A6U^
M(UG:?9I=*O75-K[C=6/F^6X;@<'[X'."H(H ]5HI$97174Y5AD$=Q69KVHWV
MFZ>LFFZ8^HW<LJ0QPA]BJ6/WW;!VH!R3@T :E%<+/X\OM-T3Q)-JFDPQZGH2
M1RR007)>*9)!E65RH(Z,""O:IX?&&KPZ]I%MJFAQ6NGZPS):3)=;Y8V"%P)4
MV@ D ]"<&@#L)2PB<JZHV#AF&0/<C(_G6-X3\/#PQHBZ8EXUU"LDDJ.R!6^=
MRYS@X/+'%<5XE\7:MK7@GQ3=66BPOH*6]W9BY-T1.^U61I5CVXV!L]6!P"?:
MN]\,_P#(J:/_ ->,/_H H TRZJP4L 3T!/6F^=%L#^8FPG ;<,&N!\*NNO7W
MB/Q?>()E66:PL(V/"6T7#8]"[ D_05@'Q'H?_"FM U3_ (16W_L^>_6.+3?M
M!V0MYL@WAL9)R"<8[T >FZWI\^L:>UK9ZM<Z;,)%;S[7:7&#G:=P(P:L:;I\
M.EZ?%9P%V1,DO(VYG8DLS,>[$DDGU-<AKY_X1GX@Z'K-O\EMK<O]F7Z#H\FT
MF"3']X$,N?0^U=+XDUN/PYX=O=7DA:9;9-PC#!=Q)  R>@R1SVH U:*XVY\5
MZ_H^BZQ?:SH$$9L;(W<+VMX9(9L9RA8H"K#CL00:T=5\3-IL7AYQ:"3^U[R*
MU(\S'E;T9]W3G&W&..M '0*RMG:P.#@X/0TA=595+ ,W0$\FO)_#NN:_IJ>,
M9-(T.&^M[37;V:X>:Z\HOR"4C 5LL ,\X'(ZULW_ (GTC4?%'@"X724NGU:.
M>:SNY)"KV@\M6.% P20<'GC% 'H-%<+>^.]1ACU+5;71(I_#VF7#P7-R;DK.
M^P[9'CCVD%5.>K G:<5;U#Q7JL^NW>E>&M(M]1>PACENY;B[\E09 62-,*V6
M*C.3@#(]: .OHKS34?%OB6Y\7>$(M.TL6\&H6]Q,]I>SM"[,J#<L@V';LSD=
M=WM73^/=3U'1_ VKW^EI&;F&VD8,\A3RQM/SC@Y(Z@<9]10!TE8.N>&FU>^M
MM0M=7O\ 2[ZW1HQ+:LI#HQ!*LCJRGD9!QD5@V_B[6[;1O#UD^EV]SK^K1Y@C
M^UGR_+1%9I9'V9'4<!3R< UL^'?$EUJ6J:CHVK6$=EJM@(W=89O-BEC<':Z,
M0IQD$$$<8H N^'O#UKX;TY[2VDGG>:9[BXN+AMTDTK?>=B !G@= .@K5#*V=
MK X.#@]#7!>+-=\1V/Q#\,Z9I=M;26UTERY22Z:,3%$&0V$. N01UR?3%8^B
MZOKNG7_C=M&T:"]2WUB:>9[BZ,((\J/Y$PK9;Y3UP!D=<\ 'JU%<8?&USJD6
MBQ>'=-BNK[5+'^T-MU.8H[>'Y1EV"L22S;0 .Q/:MKPUKIU_3))Y;4VEW;W$
MEK=6Y??Y4J'! ;N.A!]"* -FBBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ K \<_\ )/\ Q'_V#+G_ -%M6_5/5M-BUC1K[3)W=(;R!X':,@,%=2I(
MSWYH \R-QJ'B?PSX3\/1:)J,,T4UE-=W,D!%ND405BRR=&W8& .>><8K(\1Z
M!=ZKIOBBVN?#.IZAXDDN9WM[R5&,"6X;,?E,3M^X H11G<>>YKVBPLTT_3K:
MRB9FCMXDB4MU(4 #/OQ5B@#R[XB7%]I\>A^,=$MY4U"2-M,-O,ICD<3J?+#*
M><K*%./<U;USPK-IGASP+I&FVTMPFF:U9O.T:$X50^^1O0;CDGWKI[CPG;7O
MB:'6[V]O;HVS>9:V4DB_9X'V[=ZJ "6Z\L3@DXQ6_0!Q/B.*[T?QWI?BB.PN
M[ZR%C+8726D1EDBW,KJX0<L,J0<=*YW4=*U76]&^(&M)I5Y"=6M(K:QM)8BL
M\BQ(PW%.HW,QP#S@5ZQ10!Y1?Z'JKP_"D)I]RQT\P_;,1G_1\1(#O_N\@CGT
MKM/'VBW/B'P'K.E68#7,]N1$I.-S A@,^Y&/QKHZ* /,=5U75/%5]X1\CPYJ
M]M'9ZK#<7SW5J8Q$0CC S]Y1DY8<#CGFN:UO0KO4=%UN&X\,:I?>*!>2S&]E
MC8Q"%9=R>2Q.#F,!0BC.3R*]SIC2QK(L;2*)'!*J3RV.N!0!YWBY_P"%F7EU
M)I6I_8-;TB""*X6U8B%LMD2_\\R W>L/PQX:TRTBT?2+WP1J4NLVLL<=S<NT
MJVJ[#_KQ)NV,. P4#.3C KV.B@#G_'-A<ZIX$UVQLXC+<SV4J11KU=BIP![F
MN6T\7FJZSX O%TG4K:*PBNH;K[5;-&8F^SJH)ST!.0#WQ7I-% 'E_B/3-=_M
M3QW<:;:WH-S;:>L+P J\R*6\Y8V[ML)''.2*CT#3K>Q^(FFZGI/A;4-/TF>Q
MFM#-+;N',I:-MTBMEE7 (#-C)S[$^J5"UW;)')(]Q"L<;;78N %;T)['F@#B
M?A(+NQ\$VVA:AIE]97FF[XY3<0%$D+2.08VZ.,8Y'J*)Y+KPI\0=8U:72]0O
M=.UBVM]LMC;F=HI80R[65>0"&!!Z5WG6HXYX97=(Y4=HSAU5@2I]#Z4 >3Q:
M!K=G8VOBAM*N&N1XBFU:734 ,ZV\J&/ &<%PNUMN?4=:U/$,VN^-?#VJ"PT.
MYMH+.2VN+%;U##-=R1R!W78WW5P, G&2:](HH XF36]5\6PW^FV6@7UE92:=
M,DL^I0F!O.9=J(BG[W4DMTZ<URSW&K:IX0\):)%X;U>*XTR\T\7SSVQ1$$3*
MK%3_ !CC.1P "21QGU^B@#C?"VGWEKXY\:W4]K+'!=7-LUO(ZD+*%A )4]\'
MBN;L[1I/%6FW>B^&M9T+5GO0VK(%9;)XN?,);_5N3QM*C)/->K44 <G\0X;Z
M?PY$EI#>3VXO8#?0V6?.DMMW[Q5V\GC&0.2,US?A;3DL/'=Y<Z?X:O=,TJ_T
MM8K=G@89='8L9 <E"<C ;D@#Z5ZA10!XS9>&]:/[-$FB'3+E=4".WV1HRLAQ
M<E\;3SG:,@=ZTM?LK/6?$>G>*-2\-ZS=:7-I[6;P+;RK<6TBR%E9HE(;:P+#
M//;UKU)W2*-I)&5$499F. !ZFB.1)8UDC=71AE64Y!'L: /+KO06;1/"ATGP
MU=:;$/%$-[+:LS22)& Z^;)G.W("DC/&0*]3IBRQM(\:R*9$P64'E<],CM3Z
M /'Y[+5(M"^)&@G1M2:YO[JZO+25+9FBF1U0*%<<%N.G6NK\2:=>7+>"?(M9
MI/LNJ0R3[4)\I1#("6]!D@?C7922QPIOED5$R!N8X'/ I] 'B]IX4TS3TNM&
MU+P5J>J:D;V413(TJVT\+REE=I VQ,*V"",Y7H<UZSJ\+2:!?P0H69K61$11
MDD[2 !5M;B%YFA6:-I5&60,"P'N*DH X7P1X#T"R\,Z%=77ANQBU:.SA:626
MU7S5EV#).1D-G\<UF^(M/-UXXU :QH&H:S;R6T*Z0D:LULC?-YF\@A4.[:2S
M=AQZ5Z94<L\, 4S2I&&8*I=@,D] ,]Z /)3IEY;?!73;B2TFL]7\+NMVJW"&
M/+0DEP">JLA8 C@\5+<Z'J-[\$]<N!9RS:QK^[4)((U+/F1U*(!U^6,*,>QK
MN_$/A2V\320)?WU\+!"#+812!8;C!R/,XW$>P(%;H      Z 4 <CK]A=S^/
M?!5U#;2O;VKWAGE525BW0%5W'MD\"N9\1>%M3UB^\?K%82R"Y;39K4-E%N?)
M 9T5O7C;[$BO5:* /,]%TG1IKNZFT?P=JEB\=A,/M=_YL;!V&/*1')W$C.2.
M!@=<TV[T;4F^"N@::MA<&^A_L_S+<1G>FR6,MD=1@ D_2O3J* .#TT7>E_%S
MQ \^F7S6VKPVGV>[B@+0CRT8,'<<*<GO3_BG:7EUX>TU[*QN;U[;5K:X>*VC
M+OL1B6( KN:* //M9\4ZYK^EW&D^'_"NLV]Y=QF'[7J< MX;=6&"Y))+$ \
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M&8HX)WDE0!CUYQ0!DQV>K:M\>+XW^EZ->/9V<+1K<3.ZP1>8"'CS'_K.^,
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M$L.JY& 1]#S^%:-% '$^$]1U;0=#M-!US1KYKNPB6VCN;2+SH;E%&$8,/NG
M&0V.:7Q?X=U3Q#8:7JEK%%%J^DWRWMK;._#J.L3MR 6 ZC@' R1\U=E--';P
MO--(D<4:EG=V 55')))Z"EBECFB26)UDC=0R.IR&!Z$'N* .4UW4M1UKP[=:
M7I6DWT6H7L+6Y-W%Y<=MO&TNS]&P">$+9./K7/:]X:N-'L_ VEZ387=]!HE]
M%-/)%&/N*I!;D@$DDG KTZJYOK1;Y;$W4 O&3S%MS(/,*9QN"]<9[T <'XCT
MG4?%7C#PQ=V&E7%@FEW?VBXU&XVQL8QUA4 EFW=#D8'XTC:$VK_$GQ =3TFX
M?1=1TR*S$KQ_([*23[CKP<#D?2N]M;ZTO?.^R74$_DR&*7RI VQQU5L="/0U
M8H XGPM<:[X>M+G0M9L;V^CT_P"6QU")0_VJ''R*W.1(!\IS@''7O3]*\+VN
MJ>'I9M:@U%+O40\M_;_:YHQN<<IL5@I"KA!QR%'6NSHH XKX9#5['PPFBZS9
M74,NG.T-O-,H G@!_=G@G! P,'TIVNG6)/&<-M+I=W>Z$]E^[%LZJAN-YSYV
M6!V[<8!R.3P3C'9U'//#:V\D]Q+'##&I9Y)&"JH'4DG@"@#R32M(UN#P=X#L
M)]$O8Y]*U59KI=JMLC42 OP3Q\XXZGGCUT=:\-ZGKNL>/+:&VF@CU73K>"TN
M)%VI))&'W#/4#+ 9/OUKTJ&>*Y@CG@E26&10Z21L&5E/(((ZBI* /,+ZXUW6
M[?P?N\+ZG#=:;J<,EZC",*NV-U8JQ;#+DY!Z?CQ75^/=$O?$/@K4-.TYE6]8
M)+!O. SQNKA3]2N/QKI*BFNK>WDACFGBC>9MD2NX!D;&<*#U. 3@>E '*6VH
M:QXPT:[TZZT*\T036DD%S+=E?OLA7$05B6 )SN..@'.>.>DT?5];^%UKX'O-
M,N+;4(Q;VDTY7]RL43J?-5^C95. /FR>0.M>HT4 >>Z5J(L/BIXUW6EW.K06
M!!MXC)\PC?"D#IG/!/'!R16?8:-X@\-Z9X>L&T^[GL)[BZN-3@T^11)&\C%H
MDW;A\@R0Q! )'7'![FP\-P:=XBU+6H[N[>XU$1K.DA39B,$)@!01@$]^<\YK
M9H X'P5H$W]A^)M%UC1Y+2TO-2NW5&*[7AE/ 7!/0=\#MCVF^'EEJ-MI,]UK
M$PN9K7=IUM+&"QDMX'90^.NYCG/KM6NDUW0XM?M(K:6^U"S$4RRA[&Y:%V(!
M&TL.JG/3Z5>M+6"QLX;2VC$<$*!(T'15 P!0!Y1_8NL?\*3&A_V1>?VG]M\S
M[/L&=OVSSLYSC[GOUXKI=4L+K4/B18W26ETMB='GM)+GRR!&\C*0.>>@/TKN
M** /,/!]KJ5A9V/AW4?!$8O[';"=5,41MGC0X$H;.XMM'W<9SU(YQ+'I^H_V
M?\18SIEV'U1Y39#R_P#7!H!&,>GS#OCCFO2J* /-H=/U:TO_  !?KI%W,MAI
MLMG=1KM#0R-'&HW;B/ERC<C-='\0-!N_$W@C4=+L'5;QPDD.XX#.CJX4_7;C
M\:Z:B@#AK^VO/&%_X8D;3;NP_LV\%_=FX3;Y;*C 1J?X\LW5<C Z]!4WAN"[
MA^('BV[GL;F&UOWM3;3/'A9/+BVM].?7&:[)W6-&=V"JHR6)P /6F03PW5O'
M/;RQS0R*&22-@RL#T((X(H XGXFRM!!X6E6)Y2GB*T;RX\;FX?@9[T7FFW&I
M^+KSQ''9W*6UOHTEA"KQ%9+B1VW'"'D*, 9(&2Q[#-=#KWARW\0M8&XNKJ'[
M#=)>0B H/WJ9VD[E.<9/'2M@#  R3[F@#S0>'-8O?@MIFE0V7EZQIZ6\@M+H
M +))"ZML/8AL?3GGO6KH]S)?VUQ<IX*ET5H[9UD,L$8EDD(P$CV')7U8X[<=
M<=O10!Y0FD:M'\-_!6FG2KPWNG:C9RW4(CYC2)\N<]#QTQU_.NDCANE^*]UJ
MIL;K[ VBI;+/Y1P9%E9RN.O1AVZ\5V=5;[4K#3(A+?WMM:1L=H>XE6,$^F2:
M /+;;0=:B^$VDVITFZ.H:9JR7LMG@>8Z+<M(=O."=K9Z^U;UH=3F^)5SKDFA
M7\.GRZ(D"NX3<'$KM@J&SD@]!G'&<9X[U65U#*P92,@@Y!%+0!Y)!HNKQ?";
MPOI#:3>?VA97]O)/ $Y18YM['.<'CT//YUU*6UVWQ<&IBRN18'1!:_:#'A?-
M\[?M]?N]\8[5V5% '*^,9=8CN=&%C:7=SIC7+#45L6"S[=AV;3D$+N^\00<#
MKR:X>YT'6AX(\=Z1#X>NHI=0U!IK.-=A#JPCP 0W;:<GI[DU[%10!Q.J07=U
MX_\ ".H16%V;2T@NEN)3$0(C(B!0>_53TZ5S=_X8UK5;'Q<MI93174FLPZG8
M+.-BW(C"?+GMDJ>N.U>I0WUI<7,]M!=02SVY FB20,T1/3<!R,^]6* .*NK2
MX\5>)_#.HBPN[*#2FEN9S=1^6P=DVB-?[W)))'RX7KS7(7^DZ^OP]\2^%X?#
M]]+=OJ,DT4PV"*6-[@2*5.<DX[8XP<XKV2B@#BHXKT_%8ZO)IMW%9'0Q;&1D
M! E\XOL^4G)V]QD9XS7,1Z'K2_#^"$:1=F[L_$0U%K;: [P_:3)E<G!.T],U
MZY10!YOXKTB36KR?4(=-U?2]>@ME.G7]ER9"02(9=I*X#==WRX/#=:[NV_M%
M=#A^T>4VIBV7S,<(9MO/X;OTJ[10!Y%#9^(;R;PCJ5[X>U.34[*^9M1EF>/J
M8W7]V-V%C!(Z #IU.:ZOPI::CIGBGQ1#<Z=.L%YJ'VR&[ROE,AC1<#G.[*GC
M'X^O944 <?XQL[\^(O"FJV>GSWL6GWDIGCM]N\!X60'#$#&2,\U4T^WOH/&?
MC.^FTZZ6WO;:U6W<1Y$K1QNK ?BP'.,UW=% 'CMIH6M:3X?\&:D_AU]2;2K2
M6RU#3'13*%<J=\8;AB"@Z=0?KCTCPWF2TEN1HBZ/%*P,=LT:+*0!]Z0(2 3V
M&3@#GK@;5% 'G/BBWU[4M4\2:=/I%Y>64VG[-*,+JL&\QL',N6&6WD8R#P.
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5IH\*1W6L7MU<3PZS<&(JT).Z-$8G>&V@(%P .N:Z6+2-6O/BUI7B-],FM[
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M_)@=21DXXH [:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M50M_L@DD#\:\>@A\*:5!J&F?$+07AU*XN9C)K5Q9F5)P[DHR3@$IA2HQQC%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU>KX,LO$46ILD\$DGD;K>4($9'\SG8=H;*YZGBO2:K7VH6>F6C75]<Q6\"D
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M#U. 3^% ' :9I&JQ^.-(UJ#PG#I6FK:S6;V\3PK)%N*,)'"G!7Y< *21C/?
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MW?S@;%6%D./7DCI0!DP>(?&NL6OB.]TZ72K>+1K^ZMXHIK9W:Z$1R 2'&SC
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M6(CXPN&^8_,=W2HO[(\8:GHWA72KG0X;)-%OK*6XE-XDGGK"0"4 Z# +<\]
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MVC=2W+11^8N"'F+K\V<#@UOZSHE]>>*?"-]#&IM]-DG:Y8N 5#0E%P._)[4
M<M;^*_&U]X/O_%$#Z5'!ITEP3:-;N3=1Q.VX[]_R':N ,'D$]\#8USQ+JCBS
MNK'6=#T33;BR2YBFU,AFN)&Y$87>NU0,9;GKQTKE/#B^*+[X;ZCHFF:3#<0Z
MC<7L$5ZUTJ+;J\SJ^]3\Q(^8C;G.1TQ6\/"^K:/XCF:ST6UU2";3[6RM;RYE
M0"R\I2IRK<E3D-A>IX]Z &3^/-=O[3P2VCV]FEQXABF\Q9PS+$ZQ@[A@@[0=
MQQW QQUK2US4_$6F-9VT_B#P_I:+:[I+Z^4 7,^<%%C,B[5Q@DY/7VK)\/\
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M?PKB-&\9W;:IJVF+XATS7Q#I3W\5W9QJOE.IVF-@K,".5([]: /2:0D*"2<
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MV(G7&X'C/&1TH Q7TG6M4\(>);6?2=.TV?4+26WL[6W8%ES$5'F2  $ECV'
M[FL?7O!.LZA\(-%\-P)"=1M!:B53( H\O&[![UZ/:W,-[:0W=M()()XUDC<=
M&5AD'\C4>HZA::3I\]_?3"&UMT+RR,"0JCOQ0!RNIZ1K=O\ $ZS\1:?90W=G
M+IO]G3[IQ&T'[[?YF"#N&.P_2L[^PO$.K^(-&N=3T+3+.\TZZ$T^LVTX+7"*
MK HJ;=P#9&0QP!GK79Q:]IDTVFQ1W:,^IPM/9C!_>Q@*Q8<<<,IY]:LW]];:
M987%]>RB&UMXS)+(02%4#)/% ''?%E97\$;8'5)FU"S$;L,A6\],$CZT^'3?
M$.N^--(U76--MM.M-&CF,:QW7G&XED79D?*,*%SUYYZ5T<MOI7BG1K:215O+
M"?RKJ$Y90V"'1NQZX-:= '!Z%X)NA\)[CPIJC)#<7"7*%D.\)YDCLI]\9!Q4
M$FD>*_$46B:3K.G6=E::==0W-W=QW?F_:C#RH1-H*AF )W=!ZUU>M^*M#\./
M FKZE#:R7&?*1LEGQUPH!./>M@'(S0!YQXQ\#:GK7BI9K!HETG58X(-95GVL
M4AE#J0.Y*Y3Z5J^*_#6H:MXQ\'ZE9I']ETJXFDN=S[2%95 P._0UV5% 'G2:
M)XJT=_$>DZ78V=Q8ZO=374%])<[#;&8?.&CQEL')&#SGDBJ]GX/UC1;3PU?1
M:59:I=66E#3;VQFE5<@$,KHY!&0P(YZAJ[?4?%'A_1[E;;4M;TZSG/(BN+E$
M;'K@G-:<4T4\*312))$XW*Z,"K#U!]* ."U'P]XAN--T;58;#2XM9TS4&NUL
M(&V1-$P9#&7Q@OM(^; &1TJUHFE>(;CXAS>)=7L[>SMY-+%G';QS^:T9$N[#
M' !)Y/' X%;L/B[PW<7XL(=?TN2[+;1 EVA<GTQGK[5=U'5]-T>%)M3U"TLH
MG;:KW,RQJQZX!8C)H Y_QCI.JW.H:!K.CVT5W<Z3=/(UK)+Y7FH\91L,00",
M@\U@77A;Q+JS^,;R\MK6"76=(2UM8$GWB-P)!M9L#/W@2<8YQSC)[G3_ !#H
MNKRF+3=8T^]D49*6URDA ^BDTR^\3^']+NFM=0UW3+2X4 F*XNXXW /3@D&@
M#&UOP]?WVG^$88%C+Z7J-M<W.7QA$C=6QZG+"L+_ (1_Q9IFF^(?#FFV%G-8
MZE/<S6VH/=;?(6;)96CQDL"3@@X.1G%>@6&J:?JL!GTZ^MKR$'!DMYED4'TR
MI-+?:GI^F+$U_?6UHLKB.,W$RQAV/11D\GVH X"'PIJ^C'0-1@TBRU:>WT6'
M2[VSEF5"K1X*NC,"#@EP>G!%7;_PWK>I6GA:2:UTZ"XLM86^NH;3Y8XX@'
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MPKT&B@#@-=\$7VN:IXL)>**#5+"UBM9&.<2Q,S#</3=M_6M+0(=<DU:*6_\
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MMHL>9- \:Y.!DJ0* /-;'QGXDOO!'@F]MY[8:CK-\UM.\D(V!<2_-M&.FT'
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MK((1E V,D)D+G&>,X'2@"?4+K6-8U_X:W-I<PP:A?:5<R2W+1;ECW10L[!.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MJ"^O;?3;"XOKN3R[:VB:65\$[449)P.3P*GK \<_\D_\1_\ 8,N?_1;4 ;5M
M<Q7EK#=0/OAF19(VP1E2,@\^QJ6O*[:]\3>&_#WA76KC6$GL;E[2VN--^S(J
M112@*I5P-Y9<KG)P>>!TJAJWQ&G637=0A\66=E-IMU+%:Z*\*,+E8C@[V(W[
MG(;&TC''6@#V.BJT-TMUIL=W%D++")4SU (R*\MT7Q9XGA^%\OCK5M5AG#69
M2"Q-NB()#((UE=QSUS\HP,'UYH ])UG0-)\0VR6^K:?!>1HV]!*N2C>H/4'Z
M5-I>DZ?HEBEEIEG#:6R$D1PH%&3U/N?>O.='\=K9^((+1_%D'B2VN+.>:4QP
M)&]O)$N_C8!E&4-P<D$#FM/P\WC74]/T;Q'_ &Q;S0WYCGN-+>W1(HK=^?D<
M#>74$'DX)]* ._HKS:#4?%7B/2]:\0:;KHL(+2XN([&Q%I'(DJPDC,K,-V6*
MG[I&/>H&\5>(?$FM^&K/1K]-,@UC13>S.8%E,# J25##D]5YXYSCB@#U"J>E
M:K9:UIZ7^G3^?;.SJK[2N2K%6X(!X((KC;:Y\2:]XHUBQLM?^PVVBB&W!%I&
M_P!KG:,.S29'"\@84COS7'Z#XJET7P%X5TZ358-%;4KJ_:XOG17\E8YG)5 P
M(W%F4 D' SQ0![=5.?5;*VU6STR:<+>7BR/!'M)WA,%CG&!C<.OK7F4?Q!U!
M]!U&RT_5K;4[]=4MM.LM4$2A76?&'9!A2R_.., E1Q5Z2RU?3_BOX4AU+5FU
M.,VEZT4\D"1R [4W*0@"D?=(XSR>M 'I=%<]XRO[G3]#6:WUBRTA3.BS7MU@
M^7&>OEJ00SG@ 'CK7%6WC75CX?\ %*V&J_VN^ER6Q@U'[& XBEQO8QJ &,8#
MG@<XH ]6HKD_!5_/J"7,R>*;7Q#IQ"&*=8T2:)^=RN$ &,;2,@'KFH?&NJSV
M%[8Q'Q3:Z!9R(Y9Q&LMS,XQA41E(V 9).,]!0!V54UU6R;67T@3@WZ6XN6BV
MGB,L5#9QCJ",9S7G-IXRUO6] \,V-G?Q0ZEJU]<6LFHI "/*@+[I%1N S!5X
M(P,GBJ]QJ&I>%/''B74-1NQJ4MAX:66"9HQ&TH$KE0X7 SNR,@#C'% 'IVHZ
MK9:2MLU[.(A<W"6L/RD[I7.%7@<9]3Q4=KK>GWNKWVE6\Y>]L0AN(_+8;-XR
MO)&#D>A->9Z_:>)(K'P;=ZMK8U!;K6[!YH3;)&('+;AY94 E1R,-DG@Y'-:9
MU_6]0\4_$'1TU(V\&F6MN]DR0H6B+1;VZCG)'?.,\4 =QJNNZ;HE@E]J%R([
M9Y%C6149P6;H/E!_.M&O%8=8USPG\#M U"SU9GEGDM4CWV\>(8FX*#CGZGFN
MTO;[6]?\;ZAH6EZLVDVFEVT,D\T4$<LDLLNXJHW@@*%7TSDT =M17E<OC'Q*
M=$M;6*YMAJ\'B<:)<7!A'ES+@D.4[9!0D CH<$9K:T^_U_2?&]UH-]K":I%+
MI+7]O+<PI#Y4BR;"I,8'R'(.<$C% '=5G:7KVF:U+?1Z?<B9["X:UN0$9?+E
M7JO(&?J,BO/= \7WG_"5Z'8/XMM==.I&6.[@@MU6*W=8V<&)U4%ERI7YB<@Y
MJW\*?^0IX[_[&*X_G0!W%WK>GV.JV&F7,Y2\O]_V:/RV._8,MR!@8'J16A7%
M>)O$&I:=\2/!VD6LX2QU(W7VJ/8IW[(P5Y(R,'TK%74?%VL6/BR^MO$"V,>C
MW]W%:QI:1N91&-P5RP^[C XYZDD\4 >GT5YW#XBUOQ5>Z#IFG7XTE[K1(]7O
M+F.!97^?:JQH'! &2Q)(/ %/O]4\662Z'X<GO;5-8U.]FA&I1Q!O]&B4N9/+
M/RB0C QR : /0:*\XNM=U[P[>^(=%N]4_M"6'0I=5L+V2!$D0KN4JP4!6PVT
MC@>^:H3ZOXTL].\)ZO\ VY!*VNS06LEF]H@BA,T999 1AB5QDC.">F!0!ZM5
M73]-L]*MVM[&W6")I'E*KT+,2S'\22:X"3Q-K/A+5/$MGJNI'6(K'1UU2VDD
M@2)P<NIC.P $$J.<9%4_#_C>7_A(=#M7\7VFN_VH6BNK6*!$^RR;"ZF,J 2N
M5VG<2>0<T >JT5R?Q"UG5-$\/VUSH\D:7DFH6T"^8H96#R!2I]CGJ.?2L];_
M ,0>'/&>FZ5J6M?VK::O;7#1L]M'$T$T2A^-@Y4@G@Y/'6@#O**\V?Q9K(^"
M%IXD%TO]JR1V[--Y2X):94;Y<8Z$CI5DW_B75_B5K.AV>L+8Z;81VEQN%LDC
MG<#F,9'1NI)R1MXQF@#T"BO--$\0ZOJGB62"7Q/;6NH0W\D<OA^ZMDC'V<.0
M"C8WNQ0!PP)&3T K3TOQ%J=SX6\8WLMP&N--OM0AM6\M1L2+.P8Q@X]^O>@#
MN**\VOO$5^^B>&KB\\6VFAQWFFI/-(L*27-Q,54_+&RE0@R22!UP.*JP>,?$
M.J>'O!\ME>VZ7>IZA/97$Y@!1U3S5\P*>A^0/C(YXZ4 >ITBLKH'1@RD9!!R
M"*\RO;WQ'9R^+/#USK\ER\&D+J%K?&VB22,$N&0A0%(.SKC(S70?#&VNK?X=
MZ(;F^>Z$EE#)$&C5/)0QKA!M'('J>: .M#J7*!@6 !(SR :6O+-,DU#3_B?X
MZU&XUB:2UTZVMYI+?R(QYL?E2NJ9QD;,G!')[YHFUOQ9IG@>T\=7>MI-$ZPW
M5QI0M8Q$L$C+\J/C?N"L#DD\CI0!ZG6"GC;PM)J@TQ/$&FM>E_+$(N5W%NFW
MKU]NM:NHVSWNEW=K%*89)X7C60=4+*0#^&<UY7%>6.B>$;;PMXY\'W%II\$:
M02:A:QB6U8K@"4NGSQDD9R1G)ZT >NT5YCXA\9J/%=[I"^+[?P];6%M"T;M$
MDS74DBELDN#\@7;TP3NZTNF^+]9\9#P[IVFWR:7<7FGRWU]=Q0K(0(Y!%MC#
MY #/DY(/ H ],9U09=@HR!DG')Z50DUO3XM=AT5YR-0FA,Z1>6W* D$[L;>H
M/&<UYKXXMO%4>@Z);ZGK*"4>(;>!)[>%/](C,@,4KJ1A74@_*/E-;[ZYK%E\
M5=&\-RZAY]E)H[3SEH44RRJQ&_@<=.@XH [NBO+(M:\6:GX'O/'5IK:011K-
M=6^E&UC:)H(F;Y7<C>694)R".3TK0&M:]XD\8C3=+U7^S=.ET6WU#S%MTDE1
MG9AA=P(Y&,DYQMX'.0 >AUF:QXAT;P_'')J^IVEBLIQ'Y\H3<>^,]:R? >KZ
MCJNC7L>JSI<7FGZC<6#W"QA/.\ML!RHX!((X%<N]YJ5S\5/$YL=!BU>YL;>U
MMXC<W AC@B9"[ $JV6=FZ8Z+R1W /1)]8TRVTK^U)]0M8]/V!_M32J(RIZ'=
MG'--TG6]+UZT-UI.H6U[ &VEX) X!]#CH:\SM;C2=;O? 6F6>F_8M-%[?23Z
M;(=PAN($;Y#V.'8D=NG K<FN;/P[\6+^X9H[6RG\/F\O"!A2T4P4.??:Y'X4
M =K+J-E!J$%A+=P)>7"LT,#. \@7J0O4@47.IV%G=6UK<WEO#<73%8(I) K2
MD=0H/)_"O,+*TN[GXD>%?$FIH\5[JOVQHX'ZVULL(\J/'9L,6;_:8^E:GC#1
M+&T\;>%M62(M?7>LHLDSL6(18) $7/W5XS@=R30!Z+117F<.I^*]?T#5_%.G
M:XME!;RW'V'3Q:1O'*D+,O[QB-^6*G[I&,T =MKOB71_#5O#-J]ZELLS^7$"
MK.TC>BJH)/X"M&VN(KNUAN8&+13(LB$J5)4C(X/(X]:\;\3RW_B/Q5\-]6M]
M6EM%U-7FMXQ!&_V1C"C,1D?-G/\ %G&.*]1UF*^B\)7:0ZC)'>Q6A/VP1KN+
M*N2VW&T9P>W&>* +5[K%AI_V+[3<JGVVX6VMR 6$DC D+P#V4\GCBKU>'6MK
MJD7PW^'9BU$33SZM:FU\Z%0ML#%* /EP7 Z\G)Z9KJIO$6M>$=;UNRU75#K%
MO;:&VK0/) D3JRN5,?R  @\<XR* /1ZAN[NWL+26[NYXX+>)2\DLC!511U))
MZ"O+M \<S?V[H,,GBZTULZHYAN[.*!$^RN4+*T94 E05VG<3U!KK?B5_R33Q
M'_UX2_RH VQ:Z;JTNG:LJQ7+0J9;.X5L@"1<%E(X(*FKY.!DUYA%JNL6'@[X
M;V6CW,5N^HPP6\K21AP%^RYS@]QC(&1G&.E-U.]\1V?_  EWAZY\02730:,-
M1MKTVT22(/G#QD* I!V=<9&: /4%974,K!E(R"#D$4M>0VNOWGACX>^#;*;Q
M$EK_ &M%$1?W$"8LH%@5BBC&&.<*"P/WN<TES\0=0A\&^+WT[78=4N-'^SR6
MNII"@\Q)6 *LH&W<"'&0!P1Q0!Z9;>'='M-:N-8@TZ!-2N!B6YVY=AZ9/0<#
MI6G7G6MWGB[0[+1!_;4,U_JVL10,&M4$5O&\;DH .6"D Y)!..HS5K3M0U_2
MO&6HZ!>ZQ'JB'2?[1MI[J%(/*<.4*L8P!LS@YQD4 =BVFV;:JFIM;J;U(3 L
MW<1D@E?ID _A4&DZ]IFN&]&G7(G-E<O:W&$9=DJ_>7D#./4<5Y]X=\77A\6Z
M)IS>+;?7AJ*S)=10VRI';R)&7!B=5&Y<J5Y)[&K7PD_UWC;_ +&6[_I0!VFK
M>)=#T*2./5M7LK%Y06C6YG6,L!U(R>:-*\2:'KCNFDZQ8WSH,NMO<+(5'J0#
M7#>,]0LM,^*V@7%_9SW<']F7*^7!:M<-DNF#L4$_C5>WNK#Q;\0]$N?#6D3V
M9T>20ZE=RVOV8JC1D+"5.&8DD'!' YH ]5JK/IMG<W]I?36ZO=6>_P"SRGK'
MO&&Q]0*\BOOB7,L.IZS'XKM();2[D2#03"A\Z&-]I#,1O#L 6&#@9'%=MHGB
M*[7Q?XATC5KE6@BBCU&PD9 O^BN,,#@<A6!&3SS0!V-%>0_\)[JK:)H]QJ&M
M1:1'X@O;F>&[EA0FTLX_N(H(P7;*\MGAJ63Q_J@\*ZW_ &9K%OJEUINH6D5O
MJ B55N(IG08< 8!&74D = 1B@#UVBN&@N_$&A^/=(TO4=;_M2TU:WN&V-:I%
MY$D05OD*C)4AL88D\=:S/^$NUK_A1!\3_:E_M;R=_G>4N,^=L^[C'3VH ],H
MKS#Q%XT;_A+M6TK_ (2^V\.IIL<2Q*\*2&YE=-Y+;P<( 5&%P3D\UVOA'6V\
M2>$M+UB2-8Y;J!7D5>@?HV/;(.* )-8\3Z%X?*#5]6L[)I.46>8*S#U ZD5<
MT[4[#5[-;O3KR"[MFX$L$@=2?3(KAOAS86NKMKGB6_@CN-2N]3N(?,E4,T,4
M;;$C7/0 #\<\U>UZWTWX>Z'XC\4:39B.XFB1FMU.(6ESL5M@X!)89(ZT =K4
M-Y=P6%E/>7+^7;V\;2RO@G:JC).!ST%<+<W7B;PG?^'Y]4U[^U;;4KV.PNH'
MM8XQ$\@.UHR@!P&&,-G(-8][>^)/$O@OQ3KT6L+#8HM[!;Z;]F0H\,89"6?&
M_><,1@X!QP10!ZE:7<%_907EL_F6\\:RQ/@C<K#(.#ST-35Y#_PE_P!D@\.Z
M$_B:'P];Q:#;74ERT22/,[+M5%#@@ !23QGD#BNY\!^(9?$OA>.]GEBFGCFE
MMY)H1A)BCE0ZCL& #?C0!TM<YXS7PLNCQW'BU;9K"&92GVA2P,AR  HY8]>,
M&L2WN?$GBW5M?;3->_LBSTR\:PMXTM8Y?-E15+M(7!.W+8 7' KBO%^I:EXM
M\)^ M;>^-HUUK5M ]M'"C)'<*\BF4$@D\J<*21B@#VC3+VTU'3+>ZL#FTD7]
MU^[,? X^Z0".GI5NJVGP7%M8Q0W=XUY.@P]PT:H7.>NU0 /PJS0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !67XETZ;6/"VK:9;,BSWEG-!&9"0H9D*C) /&3
MZ5J44 >=+X6\4W]EX?T+5#I@TO2YK>:6[AE=I;D0@;$\LJ N2!D[CTR,=*MQ
MZ'XLT6XU.QT+^RFL+Z\DNXKNY=O,M#(=T@\L*1)R25^8=>:ZVTUC3KZ_N[&T
MO8)[JS*BYBC<,T1;. V.AX/Y50U/QGX;T;4DT[4=:LK:\;'[J24 KGIN_NY]
M\4 ;+*6A9,Y)7&:XC3/ MTGPBB\'WUS$EVL!3SX<LBR"0NC#(!(!V]A74ZOK
M^DZ!:I<ZKJ$%I%(VU#(W+GT4=2?I3]-UK3-8T[^T-.OK>YM.<S1N"JD=0?0C
MN#0!B:?;>*=1F>'Q!#I5MIYMGAEBLY&E:X=L#=EE78H&>.3SR>*RM%T+QKIM
MII6@F\TZ'2M.D0&_B=C/<0)]V/RRNU21@$[C[5TFC^+_  ]K]W+:Z3K%I>3Q
M#<T<4F3C.,CU'N.*VJ //?\ A&O%>D6>L:)HG]ER:;J,\TL%U<3.DEF)<EUV
M!2'P22OS#WJ]IO@J72?%&@7=K+$VG:7H[:<=Q(D9LKAL8QCY3GGO7:44 <3+
MH?B;1_%>L:AH"Z;/::QY3R"\E=&MI4386 53O! !QD<]Q69I7@77="\/^'6M
M9K*YUC1I[HE9798KF*=V+*6"Y5L;#G!&1CD5Z310!P^K>'?$GB'PU*+Z?3K;
M5XKZ*^L(HMS0P&(@JC/@,V<-DX&-W XI+;0_%&I>-]'\0ZPNFVT%C!/";2VF
M>0@N%^;<5&<D=., #DYX[FB@#F/&&BZCJ4FC7VEI:SW.EWOVD6UTY2.4%&0_
M, <,-V0<'I6-:Z!XUL]8UO58;G21=:G';R@%G*1O$2/)QMR49#C?P0>=O/'H
M%% '(^&]"U.'Q-J/B#4[/3]/ENK>.W^RV,AD#E69C([%5RWS8''0=:36=&UZ
M/QK%X@T6+3K@OI_V%TO)6C\G$A<.NU3N!S@KQG YKKZHW.KV5GJMAID\I6[O
MQ(;=-I._RP"W.,# (ZT >?6W@;Q+IUC826\^GSZEH^JW%Y:222,JW<4Q;S%D
M 7]VWS]MPXJV_@K7-=U?7;[7I;&"/5='_L]8;5VD-N=S$<E1NZ[L\<G&,#)]
M$IDLJ00O-(<(BEF..@')H \YF\->-=7M_#MIJ9TB"'1K^VN9'@GD=KH1'!."
M@V<9..<D]0!6G8>#KZ#QEXRU6>:W%IKD$$4 1B739$48L, =3Q@FNKTS4K76
M-+MM2L9#):W,8EB<J5W*>AP>14=QK-C;:Q::3),3?72-)'"B%CL7JS8&%7G&
M3C)X'- 'G%SX#\4:C\,K#PM<C2HKC3[B Q2I<.RRQQDY)^3(/3CG\*Z;4-%U
MW3?%]UX@\/Q6-T+^VC@N[6[F:'YHR=DBN%;LQ!!'XUT&HZYIVE6*WMU<JMNT
MZ6X= 7'F,^P#Y<_Q''M6A0!Y[#X#U--.TTRW5K)J!\1+K>H,I98\\@I'P2<#
M:!G&<=JT/$7A"\UOQ%>WD=Q%#;7.@3Z6&R=ZR2."&QC&T#WS794R66.&)I97
M6.- 69V. H]2: //8O#OB^:Y\,74\.CVXT*0(+2&X<K*AB:-GW;/E(!!5,>N
M3TK7\$^%[[PY>^)9KR2!UU/59;V#RF)*HW0-D#!^F?K75>?"94B\U/,=2ZIN
M&64=P/3D?G6%JOCOPKHE\;+4M=LK>Z'WHFDRR?[V/N_C0!2\0^%[[5?'WA37
M8)(%M=)-S]H5V(=O,0*NT 8/(YR12Z7X8OK+1O%5G+) 9-6OKNX@*L<*LJ@+
MNXX/'.,_C73VMW;WUK'=6D\4]O*NZ.6)PRL/4$<&IJ //;?PEK^A#P]J6D?8
M+G4;#1X]*O;:>5DCF10I#(X4D$,#U7D'M4USX7\3W-KI>K3:A9S^(M/OI;N.
M-LK;B.12C6X8#=@*>&()SVKKM6U>RT.P-[J$IBMQ(D>X*6^9V"J, 9Y)%7J
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M'('/K_.L_4M%\0:9XJO-=\-II]R-1@CBO+6]E:+#QY"2*RJW9L$8[#FNQHH
M\\C\!:I8:)IES9WEK)XDLM0FU)Y) RP3/-N\V/C)52&P#C/RCBK=KX.N=>U#
M4]2\906;M>VL=E'8VLKE(H5?S#E\*2Q?!X Z#K7;LRHC.[!549))P *%9717
M1@RL,A@<@B@#S^[^%6C_ /"3Z)?65J4L[0S-=(][.78E1Y>W+'HPYY'XT[Q5
MH_C;5]=TZXL;?01::9>_:K<S74JO)\C+AP(R!]X]#VKOZ* *VG-?-I\)U*.W
MCO2O[U;=RT8/^R2 2/J*X,>&/%>E:5JOAS1SI;:5?2SM!>3S.LMHDQ)=?+"D
M.06;:=P[9KT6B@#AK[P/<#5O S:?+"+'PZ'27S6(=U,:HNT $$_+SDBNROK;
M[9I]S:[MOG1-'NQG&01G]:GHH \VTKP=XD7P]X6TK4%TV/\ L'4H9A)#.[>=
M"B2*3@H,-\PXZ=>16UK7@Z76_%-]=SRQKI]YH,FEL 3YBNTF[<!C& /?KVK<
MF\0:;!XCM] DG(U*X@:XBBV,0R D$[L8'0\9HL=?T[4%U!H)F"Z?,\-RTL;1
MA&7[W+ 9 ]1Q0!BZ#;>,HI["UU0:3%96<>R::W=I)+PA=JG:5 C_ +QY/(P.
M*T_%^D7&O^#]6TFT:-;B[MGAC:4D*"1QD@$X_"J%O\1/#5WI-QJEO=7,ME Z
M(TRV4V&+$@;?D^89!Y&<=ZZF@#BH_".H)I_@6 RVV_0?+^U'<V&VVYC.SCGY
MCWQQ4VI^$[S4?$NN7PFA2VU#0QIJ<DNK[I"6(QC&''>NOJC;ZO976K7NEPRE
MKRR6-ITVD;1("5YQ@YVGI0!Q%GX6\41>'?#N^/2TUCPZRQVRB=VAN8?*\I@Q
MV H2.1@'! _"UK_A[Q1XI\#:YIE^^F6]Y?%!:V\3LT<"JRD[I-H+$X)^[QQ7
M<-+&DB1M(JN^=BDX+8Y.!WI] '.^)M!NM9F\//;/"HT[5([R;S&(RBHZD+@'
M)RPZXK,\1^#KW7-?U2[CN88;>\\/R:6K9.]9&<MN(QC;@^N?:NUHH \]B\/^
M+I]2\,ZA<P:/;KHKF/['!.Y62-HC&\F[9P0,;4QCKEO34\"^%[[PU)XB:]D@
M<:EJ\]]#Y+$XC?& V0,-QVS]:ZOS8_.\GS%\W;NV9YQTSCTI] '-WF@7=Q\0
MM+U]'A%I:V,UO(I8[RSLI! QC'![U'=^';V#QW:>(M)D@1)XOLVJP2,5\Y!S
M&ZX!^=3D<]0<9%=110!PEIH7BS0_M6DZ.=*_LR:\DN(;R=V,MLDCEW3RMN'(
M);!W#J,T?$'P7J?B2:SN=$NX+2Z\F:QNWE)&^UE W 8!RP(R!P.3S7=TQY8X
MV17D56D.U 3@L<9P/7@$_A0!R^N>&KI#H-[X>2U%SHFZ.&VN6*QRPL@1DW $
MJ<!2#@\BJ>KZ!XF\1>%[BUU&33H;R6^MYXH(68QP11R(Q4OMR[':QS@#)QTK
MMB0H))  Y)-)'(DL:R1NKHX#*RG((/0@T 8&JZ%=7WC7P[K,3Q"VTV.Z2968
M[R950+M&,'[ISDBN(F\#>,'\ 7/@F)](2Q0L(+TS2>9*GF^8JLFS"GL3D].!
MSFO6*8\L<;(KR*I=MJ!CC<<9P/4X!_*@#D+W1_$6E>)=3U3P_#IMU%JJ1&:*
M]F>(PS(NP.-JMN4J%R.#QUKJ=/BNH=.MHKZ=)[M8U$TJ)L5WQR0O89[5%::O
M97VHZA86\I>YT]T2Y3:1L+J&7DC!X(/%7J .$_X1[Q-X9UO4KKPL=.N]-U*<
MW4UA?2/$89F^\T;J#PW4@CZ4LO@W6O$&AZ[#XFU9#<ZK"L45O:%C;684Y4J&
MP6;=@ECC.,<5W5% '"G0_%/B#4-$7Q$FF6]GI-RMX[6D[R/=S(I"'!10BY))
M&2>@K/?PCXLL]&UWPSIKZ7_9.H27#P7<LKB6%)LEHR@4@G+$!L\ YP>E>E4V
M21(8VDE=4C0%F9C@*!U)- '"0^&=?T*XTK4=(CT^[N8](ATV]MKB9HD8Q\K(
MCA3T)88(Y!%==HT6I0Z5"NKS037YRTK6Z%8P220JYYP!@9/)QFKX((!!R#10
M!P_]B>*/#^K:T_AV/3+FSU:X-V/MD[QM:SLH5SA5;>IV@XR#VJE??#J[7PGX
M0T33[J%SHVJP7UQ+.2OF!2[2%0 >2SD@'\Z]%ID4L<T8DBD61&Z,AR#^- #Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *9-&)H9(F+ .I4E3@C(['L:?4
M5S]H^R3?91$;G8WE>;G9OQQNQSC.,XH X3P;I5CHOQ'\56&G6R6]K%9V 5$^
MDN23U))Y)/)K%M-2T?1G\:Z)X@@=M3U'4+B6* P,[WL$BCR@A ^; ^7'\)!Z
M5L:5H?CRS\7WVMSGPV5U 6\5RD<D^42+<,IE?O$,>O'2K^L:9XXGN-2L[#4]
M+;3;[(CGN483V2LH#*JJ-KXY*DD')YS0!Q&B:C=K;_#O58;5]7U-=*FA_L]&
M D$?RCSPS?*N-H4EB,[N#5?5KV0>$O'5Y+!+97E_JEK#=Z6G^LMXV,:')X!:
M1=QR"0<]3S7=S^#;_1K_ $;4?"SVAET[3O[,>VOF94FARK [U!*L&7/0YS4
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MWF:4M*95208PHW8!8$D@8Q0!H33>(-<^(&O:';:]-IVGV=K;2HT$,;2*[A^
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M(*'(. 0>V#[UFR^&O&.LW?AV76;K2(X]'O8[AUM6D8W&U2I<[E&T\\+TY//
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MH5$9! /4E2<=Z[?Q)I+:[X8U324E$3WMK) LA&0I92 3^=<?!X:\7V[>']1
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MF$5XS+'(K(5(RH)!Y]* .<T[2M7U/Q_XVALM=GTR..:T)E@AC>21_LRXSO!
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MYR<\_2LC4_'%Q,^O:C#XDOK74;"[FAL-+ALF>WE6)MNV0B,[BY!YW#;D=,4
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MFF[0TUQ(2,*SJ<(-I/3)SS6'=^*/$=MH4^GIJ8;5+#Q+!I@O'B7]_"Y4J74
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M]1^)T6EV5RR:;IEB;B^" $2RRG$2$]1A59N/:L?XJ6D]Q/X1\K4KRT677;>
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M[=JZ?08M5@T>"'639F\C&UC9[O+(' ^]SFM*B@ HHHH **** "BBB@ HHHH
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M><DFL_0?#/C#2_$M]JESJVC2Q:E/'+>1QVDBG"($ 0E^.!WSS0!1\)6L%_\
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M:Z1FU>[N[A'"G$8F& #ZXH XV\\8OJEYH=IJ6JZIIMM+H<&HSMI-M(\DLTO
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MFDECO_!/A'PEX7NKN\MVO)YWO9-*B>65$&Z4QQ;06'+JNX#@ F@#UZBO(?\
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M: "\\*/=?$33O%(NU5+.R>U-OLR6+$G=NSQUZ8K$7X;3)I?B6V75$$^JZO\
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M5B6Y*DC=WJYXS\(ZSXBTAM$TS5;+3]'>W2)X9+0R."K9&UMXP,!1C'8UVE%
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M&3;7;P%HY P*NC)NSM8''!R,"B;P+?ZI:>(+C6-4MY=6U:Q^P))!;E(;:+G
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MV.-K*0P!(]"*ZNB@#@=2^&QOOAQJ'AA=4S>:A<_:[J_DA_UDQE61FV \ [<
M9X&*[Q%VHJ^@Q3JSY-4,>NPZ7_9]\PEA,OVM8@8$P<;6;/#<=,4 <?<^ =3D
M'BRR@U:U73-?,DI1[9C+#*ZA<[@P!7CIC-;^K>&GU-?#H%TL?]D7D=TV4SYH
M6-DP.>/O9[]*Z&H#>VRWZ6)G07;Q&98<_,4! +8],D#\: .1A\):_ITEQ8:3
MK\%IHMQ=M=;?LI:Y@WOO>.-]VW:6+8)4D;CUKLW19$9'4,K#!4C((]*=6?!J
MAFUNZTW^S[Z,01J_VN2(""7/9&SR1WXH Y&R\&^)_#D3Z=X9\1VL6D%F,$%_
M9F9[0$Y*HP8;AD\!NE6)/AZ%\.V]I!JTYU>WOQJ:ZE.N\O<]V9,@;2"5V@CB
MNVI&8*I9B H&23VH X^V\'WNHZK=:GXHOK:[GFL7T^."SA:***)_OGYF8EFX
MY[ 5DO\ #_Q%=Z)INB7WB.U?3]+F@DM3'9E995B8;1*2Y!PHQP!S@GI@];=^
M*--M8]&E5VN(=7N$M[66##*2R,X8G(^7"GD9[5KS2>5#))L=]BEMJ#+-CL!Z
MT <A=>%M>M=2U23P]K=K8VFJR>=<)/:F5X)=H5GB(8#)"@X8$ C/M6^MEJ4>
MKVLJZH6TZ*U,4ML\2EY9<C$A?J. >!QS4VDZ@=5TN"]-E=V1E!/V>\CV2I@D
M?,N3CIGKT(J[0 5SEIX8>V^(&H>)C=*R7=E':B#9RI4YW;L\_3%='10!SOB;
MPY<ZM=Z9JFF7L=GJVF2.UO)+%YD;JZ[71U!!P0!R#D8K+'@.?4K7Q!)KVHQS
MZCK5J+1I+:$I';1*#M5%+$GEBQ)/)]*[:B@#A(_!WB&]O- N-:UVTE_L:Y66
M..VM&C$JA&4ER7/SG(Z8 YX.>.JURRO[_33%IFHFPO%=9(YO+WJ2ISM9<C*G
MH>1UK1HH \_U#P%JFO:?KC:OJEG_ &EJEO!;![2V9(HHXI"XX+$L22>2?2ND
MUCP^VJ>(- U,7 C72II96C*Y,F^(I@'/&,YK<HH \V_X5WKO_"/6^A#7[5;+
M39TN-.VVAW,R2AU$YW_, ,C"XR<'MBM_3/"4]EXZU?Q+->QR'4;6& PI$5V,
MB@$YR>#CI7544 <SX"\*OX,\)6^B27:W30O(_FJFP'<Q;ID^M4[SPKK</B_4
MO$>BZM:0S7D$,!MKJV:2/"9Y)5@<Y(QCW!!SQV5<_P")?%]CX8FT^VGM[R[O
M-0D:.UM;.(/)(5 +'D@8 ([T 8D'P_N;#2=/>QU91KUG>37YO9H,QSRS9\U6
M0$?*P..#D8%=+H5CJ]I%<2ZUJ<=[=3R;PL$7EPPJ  %0$D]LDDG)-6[34K:[
ME,"MLNDACFEMGQYD2OG;N Z'Y6'X&K= & _AUW\?1>)?M*A$TQK'R-G))D#[
MMV?;&,5G7GA?7K;5M4N?#NLVME;ZJPDN4N+4RM#*%"&2(A@,D!>&!&1GVKL*
M@N[VVL8TDNITA1Y$B4N<;G8A54>Y) H YS4=%\3B8_V3K]L;>:V2":/4;4S;
M6 (,B;6498'D$$9'X5R</A^^TCXCZ9IF@ZA'%/IWA=(D>[B,D<RB<J0ZJ01G
M@Y!X([CBO0XM=M9O$MSH2I*+JWMH[IV(&PJ[,H .<YRI[5H>3%Y_G^4GG;=G
MF;1NVYSC/7&>U '#K\.Y9M!NX[K5<ZY<ZDNJ_;XH<+%<+C9M0G[@ VX)Y!-7
MK#PQJUSXACUSQ%J-I<W-M;26]I#9V[111;\;W.YF)8@ =@!76T4 <4W@.1OA
M;;^#O[03S(DB3[5Y1P=DJR?=SWVXZT_7O#/B/5AJFG1:[:#1M3!66.YM#)-;
MHRA66)@P7!Y(W X)[UV5% '*VG@XV?Q"?Q,EV#"=*73EMBGS##AMV[/MC&*Y
MVU^&VNV_@^#P@_B&V?0V_P"/D_9&%P5+[V1&WX"D]R"1D]:['Q-XHL?"MI9W
M-]'/(EW>1V<8A4$AWS@G)''!JW_:A_M_^RO[/OL?9_/^V>4/L_WL;-^?O]\8
MZ4 8Q\'Y^(O_  DYN4\C^RO[.^R>7_M[MV[/3'&,55T;PKXAT<6.EQ>((1H5
MC*&B1+4BY>,$E87<L5VC@$A02!VKLZ* *NI6AO\ 2[NS#[#<0O$&(SMW*1G]
M:Y*'X?M'\/\ 2/#PU+9?:3)'<6M\L60LR,2K%">1@D$9Z&NPAO;:XN;BVAG1
MY[8JLT:G)C+#< ?3((-3T <C8^%]5N=>_MOQ#J-I<7<-J]K:0V=NT<4(?&]S
MN9B6. .H  K3\'Z WA?PGIVB/<"X:TCV&4+M#<DYQDXZUL32QP0R32L%CC4L
MS'L ,DU@^%?%UKXOMI+NPL-1ALQ_JKFZA").,D$I\Q)P1W H K^*?#.HZKK>
MAZUI%_;6M]I1F"BY@,L;K*H5L@,IR,<<U9TCPV^F/XA9KI9/[6O'N1A,>7NC
M5,=>?NY_&MG[;;?;Q8^>GVLQ>=Y.?FV9QNQZ9XJGH&NVOB/2$U*S25(7DDC
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M?(!R6R><=!7H^BZ%XAM+ZVDU7Q*+VUM(C'%##:^29B1@-,=S;B!V  SS5,>
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M8!-AC$B*I7.3GIUXZ]* //[#5Y+;5_#M[8ZMXDU!K[4EM[F]NXY([&ZC</\
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M92"K D$'U'>NMT6PNM.TQ+>^U&74+K<SRW$BA=S,2<!1]U1G '8"@#S;QMJ
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MC[GW<\XKG]$U;5;W3M(U^TM/%<^N7%S%/<2E)#92PN_SQA=VP($)VD+G*@T
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M7=K?6RAY;2]MVAE53T;:W4'U&:I^*] U:^U+2M;T"YM(M4TWS52*\5C#-'(
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M<JG/8[3@_@<'\* -BLGQ!X@M?#UG#-/'+/-<3I;VUM  9)I&/"J"0/4DD@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&<'&:[NB@#E[?PG=6?C;4M>M=6V6NIK']KLFMPVYHXRBE9,Y7L<8.<5F:?\
M#2'3_ FG>'4U647.FW7VRTOTB :.7>S ["2"/F((SR#7=T4 <E9^#KM]1N]4
MUK6?[0U&:R:QA>.V$,<$;<MM3<<L3C))[8XITW@E)O VE^&?M[!;#[-BX\KE
M_)96^[GC.WUXS75T4 <;K'@S5-6-_9/XFF&B7\A>>SDMA)(JG&Y$E+?*IQP-
MIQGBNLNK=;JSFMB\D:RQM&7B<HZ@C&58<@^AJ:B@#C+#P3J7V[39-=\23:M:
MZ6_F6<#6RQGS "JO*P),C*"<'CGFK.O^$]0U[3-<T]_$$T5MJC1JBB '[-&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=QZ*>P8]AUK8EE2&)Y97"1HI9F)X ')->+>)KZ]O? >L:G;C1]-T>?52$MQ
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M8 R <]J /5]*U?3];L5O=,O(;NV8E1)$V0".H/H?8UB^*=>O+._TG0M(\O\
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MRBM_+233'^(.V!,91H\'< .FW=O]NM 'J5IXW\,W]I>W5KK=I+#9*&N65_\
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MPL\#(P8>&K$D'(#*2/R)Q70SZ)IES;6=M+8PF"RE2:VC5=JQ.GW"H'3%7Z*
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M:]Y']IZ;%.UNI6)\E713U 92#CVSBIE\/:0EE8V2:? EM82K-:Q(NU8G7.&
M'?D_G6+=ZU-!J/BI(==@GEL+$31Z>+;#VC>7N#,^?G#'G&.*B\,?$#1=2T_1
M;2\U>W.LWEK"TD8! :9HPS*#C;NR?NYS[4 =0=-LVU4:F;=#>B VXF[^66#%
M?ID UDV7@CPUIJA+/2((4%REV%7.%E3.U@,\8W'@<<UEZ/XCU&[^*GB309Y4
M.GV-K;RP($ *LZ@MD]3UK7TSQEX=UG43I^GZK!<70#%47(#A?O%"1A\=]I-
M&A/I&GW-^;Z>TBDN3;M:EW&<Q,060CH02!5#1O!WA[P_=-=:7I<-M.R;/,!+
M%5SG:N2=H]A@5#XW\40^$?"M[JCLGVA8V%LD@)627:2JG';CVK#\'>-('\'?
MVWX@\2VEQN$9D(MO(6W=U!\H=2YR>W7% '5ZUX>TGQ#!%#JME'<I$_F1[B04
M;&,@@@CBJZ>$/#\:7:1Z3;QI>6ZVUPB#:LD2C:%(''  'TI=/\6:%JEA>7MG
MJ44D%DI:Y)#*T( )RRD!AP">G.*?I/BC1->N9K;2]1BNI8(TDD$>2%5QE><8
MZ=NH[T +?>&=%U+1(=&O-/AFTZ ((H&SA-@PN#U&!QG-5;_P1X:U2*TCO-(@
ME6TA$$))8%8QT0D')7V.1534/'^DZ;XWM?#$\@$\T)=Y#N^1R4")@+SN#$YS
MQCWK*T/XD:9!;WJ^(]7MX+A-3N8(P4(VQ)*40MM&%'&,MC.#0!V/]BZ:+RQN
MA90K-8QM%:LJX\E& !50. , #\*NNBR(R.H9&!#*PR"/0UDZSXIT3P^(#JFH
M10&<$Q+@NS@=2 H)P/7I6E:7=O?VD5W:31SV\R!XY8VW*ZGH0: ,&#X?^%+:
M PPZ);*GFI*/O95ESMP<Y &3@#CD^M=)6%+XS\.0:V-'DU:!;_S!%Y9S@2'H
MA;&T,?3.:2_\:^'-+U7^S+W5H(;S*JR-DA"WW0S 87/&,D4 5'^&W@R34#?-
MX=L3.7WD;/D+>I3[OZ5O2Z9937]K?26R-=6BND$G>-7P& ^N!^59^J^+M!T2
MXDM]1U**">-%=HB&+;6S@@ $G[K=/0U4?XA^$HTM';7;79=@-$X)*X)(&X@8
M7D$?-CH?2@#2NO#>C7RZB+K3X91J007@<9\[8,+GZ=L54M_!/ANU\@P:1 C0
M"0(PSNQ(,/DYRV0 .<]!4VM>*]"\.RQ1:KJ,5O)*I=4(9FVCJQ"@D+[GBM6"
M>&ZMX[BWE26&50\<B-E64C(((ZB@"D^@Z7)I5MI;V49L;7RS##SM3RR"F/I@
M?E7%^(] U.;Q->7\7@W2-5E=$^Q7_GB%HF"X'GJV=^UN00.@'0UU \9^'&UO
M^QAJT'V_S?)\KG'F?W-V-N[_ &<YHNO&?AVRUD:3<:M!'?;UC,9SA6;[JLV-
MJD]@2#0!2TWP+I:>"](\/ZO;Q7PL(4 <Y!$@'+*1@KR3^%;VF:58:+81V.FV
ML5K:QYVQQC R>2?<D]S19:K8ZC<7EO:7*2S6<ODW"#(,;XS@Y]JHS^+M MK2
M\NIM3A6"SN3:3-S\LP_Y9@8RS<]!F@"Y_8VG?VW_ &U]DC_M+R/LWVCG=Y>=
MVWZ9YJ'_ (1S1_[ .A?8(O[+*E3;<[<%MW\^:AC\6Z#+H4FM)J<)TZ)Q')-R
M-C[@NUAC(.2.".XJ'_A./#/]G7.H?VO;FTMKC[+)*,D>;_<7CYC_ +N: .@Z
M5S>K> ?"NNWYOM2T.UGNF^_+@J7_ -[:1N_'-6X/%F@W.B/K,6I0MI\<@BDF
MY&QRP7:P(R#EAP1W%,TSQCX>UG5'TW3]5@GNT4OY:Y&Y0<$J2,,/=2: +KZ'
MI4FBG1FTZV.F%/+^R^4!'M]-O3KS]:JZ/X4T+0//.F:=% TZA97R6=U'0%F)
M./;.*A'C;PT=;_L8:Q;_ &_S?)\O)QYG]S=C;N_V<YIU]XS\.Z9JPTN\U:"&
M\RH9&SA"WW0S 84GMDB@"T?#VD-H4>B&QB.FQA EMSM 5@R_D0#^%,N?#.C7
M>NP:W/I\3:G H6.YY# #. <'!ZGK6M10!2T[2;#2=+CTRQM8X;*,,JP*,J 2
M21SZDG\ZS=+\$^&]%U 7VG:1;P7*@A' )\L'J$!.$S_LXK?HH HV6C:=IU]>
MWMI:1PW-\ZO<R+G,K $ G\S5ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** ."\,_\E@\=?\ 7'3_ /T4U-2WBE^/<TTD:L\/AU#&2,[2
M9V!(]\9'XFNUATVRM]0NK^&VB2[N@@GF5<-(%&%R>^ :!IUF-3;4Q;1B^:$0
M&?;\YC!R%SZ9.: /(_%U]>W_ (1\<W=O/I6F:9%<SVDL'V0R3W<J *69]X"L
M2!CY3@ &NGT>..;XNW%RRAY5\.VH5SR0&D?.#[X%=++X0\.SZI/J<NBV4E[<
M(4EF:($N"NTY^J\$]<<5:T_0M*TJ17L+""W=85MPT:X(C4DA?H"2?QH \RT;
M35OH+R.TU:'3-5MO%FH2Z;YL8='8;@R%,C(*LW0Y'459DUZ]G,>DS:1HD7B
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ML=/MH[:UB!$<42X5<G)P/J369J7@SPWJ\LLNH:+9W$LK^8\CQ_,S;0N2>O0
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MFD &2FX9(ZYX)K5T[Q'I?AGX.3:MH\<POY7:-XKAS).^HN=K"0GEFW<]L@4
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M,>]=!INI6>L:=!J&GW"7%I.N^*5.C"N0T6&+_A<?BF;RU\P:?9#=CG!WY_\
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M 6,@=\LN1UQ7!VG@7QN?AU-X7FM?#K1WBM+//+<S><9G;?O;"8W!L?\ ?(H
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M73_#.K:9J<(TN^U-(KBX(!4P^7(6!R,K@H,]",8K=T7Q;H?B&2YBTV]\R6V
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M"SE,\I7[V(MN_C'7&.GJ*T-$U[3?$-FUUIEQYL:2&*161D>-QU5E8 J?8B@
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M2 .?8>E6CHVF'2ETLZ?:G3T"A;7RE\L '(PN,<$ U0U7QAH>C7BV=W=M]J>
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M0YC=02, D<8.* -F_L+/5+*2SO[6&ZM9,;X9D#HV#D9!X/(!J=55%"J J@8
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M4&/E(' QTH \Z\21:9-\0_$$.L3-!ILOA9%N94!RBF=QNX!Z?2M#0-5O]/\
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M7UO?W,(633+OQS;&$CE)<%%=AV(+ \]\&O8=3T72]:A2'5--M+V)#N5+F%9
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M_P (OB*HU$WTAU=)//=55I4)M]LFU0!M;&00,$5U.N?\E,^%W_7O=?\ HA:
M.L^(^IWFC> -6U#3[AK>ZA1#'*H!*Y=0>O'0FI=-\<Z)JFKPZ9#)=)/<*SVK
MSVLD4=TJC+&)V #@#GCMR.*SOBY_R2O7L@D>4G [_O%K.\1:IINM:_X$@T>Z
M@N)AJ'VD+"X)C@6%]^0/NCD#GOQ0!T(\>:"=6^P":X_X^/LGVK[-)]F\_./+
M\W&W=GCKUXZUOW=U!8V<UW=2K%;P(TDLC' 50,DG\*\3T2Q^T>!+?2-5\;BR
M47GV:;3!9Q-,EP+C(48^<DOAL^ASTKU/QOJDFC>"=7U&*WBN'@MV(CF7<ASQ
MEAW49R1Z"@!NB>--(UZ^^Q6OVR&X:'SXDN[22#SHL@;TW@;AR.GK4$/Q!\/7
M&IQV23W&V6<VT5V;606TDV<>6LN-I;((Z\FN*,\A^(6@6Y\5IK$[6%XB2)'#
M'%"[HFU5,8ZG&=I)( 'KS?\ !WB+PW:?#CP[INH>1/=H\5F=/*+),MR'P<QG
MD$,-V>W6@#IM2^('A_2M1GL[F:Y(MF5+JXBM9)(+9CC DD4%5/(ZGC/.*GUC
MQKHVB7AM;AKJ>5(A/,+2UDG$$1SAW* [5X/7TKD/#VO:'H&B^+K7Q%-;K+#J
MUY)<VDVTO.DC;DPA^^&4@#UZ540S6WC?Q0?^$GC\.0RQ6MQ'#<6L)WP" +QO
MZ!2K*0.A^M &[XK\1W</B[P'%I=__P 2_59Y?.\O!6>/8I7G'3G/'K6SJ'CS
M0=,U*:RN)K@_9W6.YN([:1X+=FQ@22 ;5/(ZGC/.*\^OK*VT[5/A':V5W)=V
MB23>3/)&8V="B%25/(X(XJ-8,6'C*PU7QFFDVS:G>"ZLGM(G=HY3E67/SMN1
MEQCZ#I0!Z/K'CG0]#U-M-NI;A[X1I(MO!;O*[JQ8 J%!S]UB?3%1ZAX^T'3-
M2FLKB6Z(MY%BN;F.UD>"W=L8620#:IY'?C/.*PM&M$M_C+.A8RO!X;MXUE=<
M,1YI!/MG KE/&.L7&H^%O&3R:[%8K'=7-HFCVUO%OGV<;Y"07)8#<2,849SQ
M0!W[^.XD^(W_  BWV*[*BU60S+:2']XS[1R!CR\?Q],\9XJW!X\T&XU5+".:
MXQ).;6.Z-M(+>28$@QK+C:6R".O)&!7-07]H/C(K_;8$%WX9B2V=I !*QG;
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M4[6ZN&C;3+=+B[?82L:N?E&1U8]E')J+3_&VDWHO1.EYITEG;F[FBU"W:%Q
M,_O #U7@].G>@#;DL;2:R^Q2VL#VN OD-&"F!T&WIQ@5. %    '  KE;;X@
M:7<K-BRU:*5+<W444UBZ/<1 @%HP1\V-PXZ\]*H^'/B-;:AX(M]?U6UN;620
MK&(TMGQ/(Q(581R9,^WO0!<@\/:OJ/C&#7-?EL?(TU94TVUM-S8+\&21F ^;
M:,8' R>:Z2]T^RU*W-O?VEO=0$Y,<\8=<^N",5CVOC71[C3-2OIWGL5TP9O8
M;R%HI8!C()4\D$=,9SVKF[SQP=2\4>$[2Q74K 75VYE@N[9H3/#Y+D$9^\,@
M=.1QG&10!WL=C:0V7V*.U@2TVE/(6,!-IZC;TQ[5%::-I=@(Q9Z;9VPB+-&(
M8%386&"1@<9'6C5M6LM#TN?4=0F\JVA +M@D\G   Y))(  ZDUFZ9XPTS4OM
MJR+=:?-91">>'4(# ZQ'/[S!ZKP>1TQS0!M6]M!:1>5;01PQY+;(T"C).2<#
MU-,O;"SU*W^SW]I!=0Y#>7/&'7(Z'!&*Y:#XEZ'.UAN@U.!-0GCALI)[-HTN
M"Y #(3P1R#ZX.<5NV?B"POH=4E@=RNF3R6]SE,8=%#-CUX(H O0VEM;.[P6\
M43.%#F- I8*,+G'7 X'I44FE:=+8&PDL+5[,];=H5,?7/W<8Z\US%]XDTR]O
M?"%U'JVH6R:JS/:0PH ET"JG$N1D  CTZU2M_B= -9\20WFF:A'8Z1M/FK9O
MD+LW.7[#U'3(YH [5-,L([2.TCL;9;:(AHX5B4(A!R"%Q@$'FIFMX'N$N&AC
M::,%4D*@LH/4 ]1G K,U3Q+IFD>'O[=N9F:Q*QLC1*6+[R FT#KG<*T+N\M[
M"PFO;N40V\$9EE=^B*!DD_04 230Q7,+PSQ)+$XVNCJ&5AZ$'K4%AIEAI<)A
MT^QMK2(G<4MXEC4GUP *YNT^(^AW4]A"T6HVTFH2K%9BYLWC\\-G#H3U7ID]
MLCCD59M_'6D7FNR:-:I>SW<-T]K/Y5LS+ R@'<[=%4YP">I!]* -6+0='@>5
MX=)L8WE</(R6Z NP.03@<D'G-3/IEA+?I?R6-L][&NU+AHE,BCT#8R!R?SK
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MBN_^QVO[G_1H?W'^J^0?N_\ =]/PJ"^LLB6\LK6R.J",K!-<)T/8%@-VWZ4
M>3^'8;K4-<TCP#>!WC\+WLMU<.X_UL,>#:>W/F X_P"F==U\3;6XO/AIK\%J
MC/*;1F"J,D@$$@?@#5CPMX=NM*GU+5-6NH;K6=3D5[B2%"L:(HVI&@/.U1GD
M\DDUNWL,UQ8W$-O<M:SR1LL<ZJ&,;$<, >#@\X- 'F?B7Q+H6N7_ (#CTF[M
M[M_[7@ES P;R4\MQM;'W2?0X/RGTK1\"M]GNO']U%#YDRZW.0HZOMC0A?S)_
M.IK'PAKUSJ6DOKESI M-,G^U!=.MVC>ZG"E5>3/"XW$X&<FNYCABA+F*)$,C
M;G*J!N/J?4T >'G6X[RT\%:E>>*UNY9=2MKFXL84ACMK%2#G=M7<FTML^9N>
M?3CK/#:+_8/Q$.T9;5[_ "?7]TE=X-*TY8YHQ86H29M\JB%<2-URPQR?K4ZV
M\*+(JQ1JLA+. H 8GJ3ZT >/Z=>VNFWWPFN[ZYBMK8:-.AFG<(@)@BP"QXJW
M/JUMH-]->^&O$D<T<^K>7<^'+M%+F9Y@LGE#B1#DEP.1WZ5ZA-IUE<01P36=
MO+#%@QQO$K*F.F 1Q1_9UC]M^V_8[?[7C'G^4N_'^]C- %?7M(@U_0+_ $FX
M_P!5>0/"3C[N1P?J#@_A7F?@N]NO&/B/0HK]6W>%;)UO0W>^+-",^I"QL_\
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MZMOLUQ;0S0<#RI$#+QTX/% 'E=WJ=IJNL_$NXL9DGMQH$:+-&<HY$<^2IZ$
MY&1W!K%O_P#DF'PJ_P"PQ8_^S5[<EE:1HR):PJK((RHC !0=%^G)XH-E:F**
M(VT)CA(:-?+&$(Z$#M0!YKXZU"?P+XK;Q'9Q.Z:U8/8LB+G-X@)MR?J"5_"N
MW\):$OAKPIIVD [GMX1YK_WY#\SM^+$FL[4/#NJZ[XHL[C5;FS&B:;<"ZM;6
M!&\R64#"M*3Q\I)( [XS75T >,.L5I<^-;/5O&DFBQ/J$\LMCY$#&>&5!M9=
MZEVW+\N%[KBK_C+3)-:M]"\(>'9G_MJQL_._M&0F-K6#RO+PY&"&EX&WZG'
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MBGB;[T<J!E/U!IJV5JMI]D6VA%MC'DB,;,>FWI0 W3D6+3+2-%"HL**H'0
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M+\70H)/]JWAP/:O;(-/LK:XEN(+2"*:7_621QA6?ZD#)IZ6MO&)0D$2B4EI
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M_3/"NK7_ (JFN[PZK:W-]9(8DMM/7S,'>H7*;20N6;)Y/K@ [_0OB!_:6O\
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MD;<#/;UK,TS3YM#U#P[_ &QXBNO#B2^&X($N,Q(ID1V9HF:52 0'4XXZ'TH
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M+=6Y#;L$$Y'*G!P>0<5OWGQ"TBRU"X@>VU%[6UN!:W.H1V^;:"4D#:SYSP6
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M&E:7>6-I';WU_/J%I]KLTLHA(9UR.%Y'.#N], G- '2I9VL<8C2VA5 V\*J
M#=ZX]?>E^RV^^1_(BWR##ML&6'OZURUGK%A<?$AK+SM8CU$Z0MRUI+(!:I&7
M'.S/$H)P3Z9YJ$?$S2C&+W^SM4&BF;R1JY@7[-G=MW9W;MF[C=MQ0!V#P0R0
MF%XD:(C&QE!7'IB@6\*P"!88Q"!@1A1MQ]*Y[4O&=M8:Y+I%OIFIZE<V\2S7
M7V&%7%NK9V[LL,D@$A5R<=JI_#'4IM7\%1WL]U+=&2[NMLLKEB4$[A>3S@#
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MT[U'..,\4 =PL:(2515+=2!C--GMX+F/R[B&.5,YVR*&&?H:XO4?&UW8^/\
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MMO\ :?M'D1>?C'F[!NQZ9ZUS>J^/]%TCP[I6N7'VAK/4S&(/+0%@'0ON89X
M4$GKBKFL^(K&RU%=&E%T;B>RGNB]N!^ZBC RQ)(P23@=>?2@#<(#*58 @C!!
M[T@C18_+"*$QC:!QCZ5Y#XD\0-_PJ;PWJ6@ZIK"PW&IPHMQ=SG[3(A=PPD93
MSR.F>@%=#<:C?+\>;331>3BQ;03,;82'RR_FL-VWIG'&: .[@MX+:/R[>&.)
M,YVQJ%&?H*3[-!Y/D^3'Y7]S:,?E6;XC\26'A?3XK[4?-\B2XCM\Q)N*ES@$
MC/3UQD^QJCI/C.UU+6Y-(N--U+3+L6YNHUOXE02Q @%E(8]"1D'!&>E '0S6
M\%S%Y<\,<L?7:ZAA^1IVQ/+\O:NS&-N.,>F*XV+XE:7(L-V=-U6/1YIA#'JS
MP*+9B6V@_>W!2> Q4"NNNF*V<[*2"(V(([<4 .,$1A\HQ(8O[A48_*E>*.3;
MO16VG*[AG!]17FGP]\7_ &#X/:/K&N75Y?7,\TD"<F:>XD,SJB+DY8X''/0>
MU=18>-;2ZN+VTN].U#3;ZTM3=M:WD:AY(1U="K%6&>.O!H Z0(BNSA5#-C<0
M.3]:QO$&E:E>V4"Z+?P64T,OF&.: 203KSE'7@X.<Y!!R*Q;;XF:7=+IERNF
M:M'INHO'%#J$D"B$2/T5CNR.?ESC;GOWJY?>.["RUB\T]+#4KM; *;ZZMH \
M5KN&[YCD$X')"@X% #_#7AR^T_5=1UK5[RWN-2ODBBVVL1CA@BCSM1022>6)
M))KHIH(;A-D\22IG.UU##/XURZ_$#39]$TG4;.SU"[DU;>;.RAC4S.$^\Q!8
M* .Y+=QZT3_$31;7P^NL7,=Y#"+U;">*2("6VF)P1(N> ."2">"",T =4L:(
M6*HJENN!C-,>VMY(/(>"-H?^>;("OY=*IZ+JK:SIXO#IU]898J(;V,1R8'1L
M G /YUP6C>.9=,N_%D=S9:SJPL]8G+&V02"U@"I@?,PXX8A5R>"<4 >FHBQH
M$10JJ,!0, "F/;PR2I*\4;2)]QF4$K]#VKGKSQMI\,.FMI]M>:M-J4'VFV@L
M4#.8@ 2[;BH4?,!R1R<5J:'K5IX@TM+^S\Q49FC>.5-DD3J2K(Z]F!!!H N"
MV@6X:X6",3,,-($&XCT)ZT]8T0L515+'+$#&3[US&K^.K+2M0O+5--U.^6P1
M7OI[.$.EJ"-WS98$G;\Q"@D"KR>*=.?7K/2?WH>^M?M5G<$#R;A1@D(V<E@"
M#C XYH V/)B\KRO*3R_[FT8]>E*41G5RJEESM)'(^E<R/'ND-I%YJB1W;VD%
MW]CA=(@QO)=VW;" <O\ -QG@<'L":(O'-B=/UBXO+#4+&XTFW^TW-G<1J)?*
MP2&7#%6!VL.&ZC!Q0!TGV>'8R>5'M<[F&T8)]33BB,RL54LOW21R/I7)V_Q#
MTN;1KO6'LM2AT^'RA!-+;X^V,Y("P@$ESG [#D8)'-">,[+4;35[.[L]6TF[
MM;%[J2"=%CG,."/,C*L0<$8Z\'&: .H^R6P\W%O%^].9/D'S_7UI3;0&83&&
M,RA=H?:-P'IGTKCM+\8:=9>$]!DL8=:U5]1C8VD+[9+J55Y9G8L%XR,DGN*O
M2>.K!-)M+R.PU*6YN[A[6+3U@ N/-3.]2I( VA22<XQWH Z588EB\I8T$>"-
M@48_*FPVT%O%Y4,,<<?]Q$ 'Y"O/?%WC-+KP%<:G927NF36>IV]O=QR_NYH"
M)H]ZMM)R"K=B00:Z'2_&MKJ&N1Z1<:9J>FW,\336OVZ$(+A%QNVX8\@$$J<'
M':@#HS%&45#&FQ<87' QTI]>7^ ?%;67A'Q#JFMWEW="#79[>$,S2R-DHJ1(
M"<G). .G-=GH?BB#6;RYL)+"^T[4+=%E>UO457,;9"NI5F!7((X/!'- &NEG
M;19\NWA3<V\[4 RWK]?>E^S6_FR2^1'YDB[7?8,L/0GN*EHH B-K;EHF,$1,
M7^K.P?)]/2@6T"W!N!#&)F&#($&XCTSUJ6B@"C;Z5;VVKWNIJ7-Q>)%')N(P
M%CW;0./5V/.>M6IK>&X4+/#'*H.X!U# 'UYJ2B@"-H(6+EHHR7 #DJ/F Z9]
M:)((9HO*EBC>/CY&4$?E4E% $,EK;RF,R01.8CF,L@.SZ>E2>6AD$FQ=X& V
M.<>F:=10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5SGCC^R/^$9D&N?:4L#-%NN+<D-;-O!67<.5"M@[NU='00",'D4 >*:SJ5[
MJ/@GQ;IUKK+^)-+L8[2>#4 BEP1,&DC+( )"JH&R!D;N:Z"_\2Z3XB^)/@DZ
M/>)>PQ/>&2>'E%+6YPN>F[ )QU'?&17I*(D:A4554= HP*$C2-0J(J@=@,4
M>5>#O%NF>&/!5GX;OT>?7[2Y:S?2D7,TKF8D, >"I!#[NF.];_A$#_A(O'AQ
MR=27G_MWCKMMB>9YFQ=^,;L<XIV* ..^%7_)+O#_ /UZ_P#LQKC?$5QX7M+[
MQ+!'JVLV%]-*_G:"C!5U&9E&UD4 L5D) )5AGOBO8\8Z4TQH7#E%+CHQ'(H
M\ITN"/X=ZWX<N=<E%M92>'TTV6Y;_5Q7*/YFUFZ '<V">NVM'P_9W'BG4/%>
MNZ9J5UIUIJ5U;QV=Y#&NZ2."/:64.""K,6 ..U>C.BNI5U#*>H(R#2@ # &
M* /,_$MK/X7OO"&JZQJUSJ%E8ZE+]JO+E%!B$L3(A;8  H;OCO6;?^*!<^-_
M$NM>&]MV]KX7_P!'F1=R2NLK'<O]\ G''=2*]=90RE6 (/!![T*JJ %4  8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'*7OQ+\'Z??W%C=:U''<V\ABE3R9#M8=1D+BMS1]:T[7]/6_TNY%Q:LQ42!6
M7D=>" :\V\*^*6T35O%]L/#^N:CN\07+^;86HE0?*@VDEASQG'N*VM9\0ZAK
M=]X9T>Q&HZ'_ &O+<-</-$L=S'%"N2J@[@I8D<^E '?45YAJ&J:OX:F\6Z'_
M &O=7BP>'Y-5L+FX*F:!@'4J6 &[YE!&172^!+74FT*VU?5=8NKZYU*UAF:)
M]HB@RN0$ &>C#)).2,\4 =*;B 7*VQFC%PR&18BPW%00"P'7 ) S[BJFCZS9
MZ[9R75DSM$D\D#%UVG>C%6_4&N%N]-FG^/4!&K:A$@T7[2(XW0+Q.BF/E3\C
M;02.N>XKG].L]7A^'GB+7;/Q!>V4FG7FH3VMO;[!$VR5V/F J2^2".H &..N
M0#VJBO*=6\7+J/B);&_UO5-'M(--M[@#2[9Y'EFE!;+,L;X50!@'&23UQ7:>
M!M6O=:\(65YJ(?[7\\<CM$8C)L=E#[2 1N #8QWH Z*BO+H-6NV\83VNJ>)]
M0TC5_P"TF6TLKB$"RN;8/\JH=N&9D[[MP8].,52\8^))],GUS4;;Q3J4NH:?
M,#!965F[V<*KMS',P0KN/S9)88R.F* /3(]<LI?$<VA*S_;H;9;IUV_+L9BH
MY]<@UI5Y!XG\86OA#XIZG?2J)+F?1;>&UA9MJO(TK8W-T51U+'H*T_$.HZIX
M:TC1-/U3Q!=?:]6O'-]?VL!D:&,(79($56(&0J@X) ))]@#TRBN&\ ZU+?:C
MK.G+?:AJ&GVIADM+N_MWBE(<-NC)9%W;2N<XZ-[4[5YM0UWX@CPW!JEWIMA:
M:<+V=[,JLLTCN55=Q!PH"D\=<T ==J.H6NDZ=<:A?3"&UMHS)+(<G:H&2>.M
M4O#WB&T\2Z?]NLH;R.W)&QKFW:'S 0"&7<.5(/45Y=XGFU*]^'_C?1]0U>\F
MET&;:DZ[%:YA=%9%E^7!QN.2,9P*]#\":>^G^#],WZA>7GG6L,@^TLI\L&-?
ME7:HPH]\GWH Z2LFX\1Z?;>)[/P](T@U"[@:>)0F5*+G.3VZ5R,$>N>,;_Q'
M=6?B&\TO^S;Y["P@@">5OC527E!4EP6;IV JK?BX'QR\)B\,9NO[&F\XQ9V%
M\-NVYYQG.* /3J*\@OO$T]EJ<5_;>*-2U"[_ +7CMY8(;-_[.$+3!#&'V;=R
MJ1\V_.X5MV)UK7?B?XEL6UV[M=+TB>SECMX-H,A:%6*$D'Y,AL@==W48H [*
MSURUO&U'Y+BW2PD:.:2YB,2';R65FX*\?>Z5H(Z2QK)&RNC ,K*<@@]"#7C.
MH:IJFL^$?BA%=:I=!-.O)X[<(5&(@I_=]/NGH>_O6Y:SZCX3N?!D\FJWEWH^
MHQK8W*W+*WE2R(&A(PHP,@K]".M 'IE%<CH6I7VL^/-?E6Y<:/IJQV$40QMD
MN,;Y7]<KE5_.NNH SK+6K:]FU",1W$ L)#'+)<1&-#CDLK'AEXZCBKT4L<\*
M30R+)%(H9'0Y# \@@CJ*\BGU35-9T'XIV]SJETL>G2S+;>65!1%C8[.GW3C!
M[X[BN]\!6367@C2%:\N;KS+2&4-<,I* QK\BX ^4=LY/O0!T=9^FZU9ZK<ZA
M;VK.9-/N/LT^Y<8?:&X]1AA7GW]K79\8W-KJGB?4-&U3^TBMA:3PC[%<VVX;
M54[<,S+GG>&#'VJ/2]'U#5-9\=/;Z[?:;'#J;-$+,JI:7R4.7)!RHP/E&.^>
MV #U6LGQ'XCT_P *Z2=3U-I%MA(L>8TW'<QP.*X,^))=6\)^$KK4_$5WIS7U
MH99X=,MV>ZNI  ,J$1BJ@Y)P.X&17.>+M8NM8^"=RUW<37$EKK7V59YXO+ED
M1)L*77 PV,9&!R* /7[CQ'I]KXGL_#TC2#4+N%IXE"94JN<Y/;I6M7F^M?\
M)?O#/_8*N/\ V:MOXD:EJ&D^#9;O2KCR+P75LB.1D?-,BD'V()!H ZVBO/V?
M4_"OCO2+:;7;_4K/4[6[>XCN]A"/"JN&C"J-N<D8Z5AB[\1R_#=_'X\0WBZA
MY1OUL1L^R"(-GRMFW)^08W9SGF@#U?[1!]J^S>=']HV>9Y6X;]N<;L=<9XS5
M35M:L]%2T>\9P+JZCM(MJYS)(<+GT&>]<!IEK)?_ !IN;Q=5U%8SH]O=+%O3
M:5:1CY1^7[G?'7)/-:GQ46X?1M#2TD6.Y;7;,12,NX*Q<X)'?!YQ0!W=%>;7
MNH:EX%\4)#-K%]JUA>:7=W7EWK*SQS0*')4JHPK XQ6/H/BNY-YX=NXM>UC4
MKW4)XX]2LYK"1+9%D'+1DQ@*$8KSN.1F@#V&BL3Q=>/8^%KZX358M*954?;9
M4WB++ $A>[$$@#GDC@URW@O6I'\97FCP:GJ^H:>=/2[1]6MVBE23S"K;2R(6
M4C!Z8!!Q0!Z!+<0PO&DDBJ\K;8U)Y8]< ?3FFK=6["8K,A$)(E;/"$#)!/;
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M$' ..>_ ]\X5KXAUZ]TC2O#_ /:TR7MQKUUIDNI*J^<8("[$CC <A0,X]^M
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M>"[L2$%LJ31LP"*!D%<#G))_2G#Q%JYU[XHP?;Y?*TJRCDL5X_<,8'8E>/4
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M(Y601EU="%&WE2".F#7,+=^)+CX8WWBYO$]^E[827#V\,801,D<S#$BE<N2
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MJ@$2)=R"--W^Z 6_&JWBKQ)K2:7\0-5L-0EAMM+\BRLMF,+*-IF;IURX7\*
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M]4\1O>&&)86#21021E9BPZJOEG.?88K=\8^"?^$@\(66@:=-%:1VDT#Q[U)
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M7RY%D??T;&5]P.I ]"#S7VOQ$?A5<^+)O$VHG4=+E=(%1PL4B13;/WJ8^<L
M<D^WOGT^R\//:>,]3UXW(=+RU@MQ%MY4QECDGOG=^E8A\ RGX:ZAX3_M!/,N
MGF<7'E'"[YC)]W/;..M %2:'4_$'Q*U?2CK>H66EP:?;3^59R^6_F,7'#8)
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MH/'<;63,Q_=J<<)[5Z_7-2^%7D^(]OXJ%THCATPV/V?9R27+;LYZ<XQBNEH
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MZ; T4<4[)Y+%02R8/RD^HKF?#R7OASX1^&_%5CJ&HM':3I/?VK7#-&]L79)
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MS@>GS+G\:[J@ J&>UM[DQF>WBE,;;D,B!MI]1GH:FHH **** "BBB@ HHHH
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M-M"^8P&"V!TR><5,      .@%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MGZU>M?'(TOQ/XKM=0_M&^6UNX_)@M+5IC!%Y*%F.T?*N2>O7G'0U/\-?^/\
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M0]3221M/O@%V*VW#HV\;""#]TX)QQT-<;<>()KN#PY?ZM=V<L.G>*&M9-3@
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MNR#@5Y=8F\\7>'-3OV5A?>&]&@M8\]?MD,GFR8]\PQ#\:TKBX37OAY\0O%J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?0&"[MXKB$G)CE0.I_ U#<Z3IUY'%'=:?:SI#_JEEA5@G^Z"./PJY10 @ 4
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M!P6!&&';![5H44 </I7A/69/$&F:CK3:/;PZ6)6M[;2H619)9%V-(^[I\N<
M>O6NUEBCGB>*6-9(W!5D<9##T([T^B@"D^CZ9)8I8OIUFUHARL!@4QJ?4+C
MZU.;2V9(4-O$4A(:)2@PA' *^F/:IJ* (S!$TRS-$AE0%5<J-P!Z@&D6W@3S
M=L,8\TYDPH^<XQSZ\5+10!3N-)TV[@B@N=/M)H8O]7')"K*GT!&!4[6MNS1,
MT$1:'_5$H,IQCY?3CTJ6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHK/UG6K#0-/-]J4S16X=4++&SG).!PH)H T****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI5G:R%2\,"1L5Z$A0#C\J .,NKKQ'K'Q#U?0;+6VT[3K6RMYQ)%;QO(KL7&
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M  [T ><ZAXA\/1?"W0K/3$":[I4MFQMUA*RVDR2(LK2<?+D[AD_>+#KFNO\
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M0E2^TXR<[3C('X4 =K1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO$+^-/B#I]E*;DZ;8PR:;:E!A96AW8'&3ENQ- 'I-%<#X#U3^TKYC!XON-5
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MD7R!M) XW;<9P ,YX'2K'C34A;ZU:6L_BJXTBV:W:06^G6_G74K[L!B-CXC
M]AD]Z .XHKF_ .LW6O\ @G3=2O7$ES('220)LWE)&3=M[$[<X]ZY0:W?R^,K
MNSO?%,^D:FFH;++3;FW06MS;!AMVL5R[,N>0^0QQCB@#T^BO'-7\;SS7GB*Y
MC\3W5A>Z9=2V^GZ;%9F2&;RN#YI\LD[V!'##:,5N)?ZYXG\;OIUOK%UI6F/H
MUM?,MNB>:KN6^4%U.,]^/X1C&30!Z/17E\'B/4SX4O[74_$D=C/INMMIDVI&
M$&:>)<,/+0*1YK!@.%/0G%47\7ZE!X.\;BQUF\NSI*1265]=VWE3@.H)#*R+
MG!!P2O(- 'KU-DD2*-I)'5$0%F9C@*!U)-<%>MJVD^$1?:EXO^RS7\T+33O"
MI^SJW+16ZA3ECT&0QX)KE=1UF[U3P5X\TZ'7M1NK73K6.6"ZN+<0SNDD;[HG
M#1KE<J>0H.#UH ]H5E=%=&#*PR"#D$4M>3WNM2Z':>&-!N?$U_:6UU9-=W%\
ML"O/M 0)$FV,A1ECR5)PO7FNI^'VNSZSIVH13W<E\+*\:""]DA,37$6U65F&
M!\PW%3@#.W- '7T5Y_,VNZ[\1==T6'7KK3],M+6VE'V5(_,#N'X#,IP#@D\9
MX&".<YT'B;4I_"'E:IXD33KBRUF;3+N_CA!FN5C)QY2!6&]AMZ*<8)Q0!ZC1
M7D2^)]=;PKXBN-*U6[OCX?OXIXY;FV$4MU:[%>2*12B] 7^; )P*ZG4O$%SJ
MOB?PMINAW92WNXSJEW*B@DVJJ-J\@X#LP''/!H [2BO%SK/BL?#&?QF?$=Q]
MIL;B3RK411^3-&MP4(D^7))&1D$8 '?)KJ/.USP]X[T"VO-=N-0M]8AN?M,,
ML:*D4D<8<&+:H('48)/'4DT >@45XI8?$"XN+.PU]?$=W/?W%VAET469\A;=
MY-NQ6\O.Y5.[=NY(-='!_P )%XBU7Q;"GB2ZT^WTR],=H+:./=GRD;#EE.4!
M/08)W')Z8 /17FBC>-))41Y3MC5F +G!.!ZG )_"GUXO-<ZGXKU#X8ZA+K%Y
M9SZA#.9/LRQ@)(L#$R*&4\MD@YR,= #S7LX& !G/O0 M%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9XT/2AK+:P-.
MM?[39=AN_*'F;<8QNZ].*T** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^4X*G'0<U!J/ACQ FHZ+KFG:C9W.LV5H]G=M>QF..Z1L$GY!\A#+D  UVM%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YOQSJ5OI7AI[JZU
MBYTF(31K]JMHA(X)/"X(/!Z=*Z2O-_CG_P DUE_Z_+?_ -#% '27NI6\7C_3
M-.;6+F*XFM9)$TY8@8I@,Y=FQP1Z9[5TE>;:U_R7[PQ_V"KC_P!FKOK'4[+4
M_M/V*X2;[+.UM-M_@E7&Y3[C(H MT444 %%%% !63XFUV#PSX:U#6;G!2UA+
MA<_?;HJ_BQ _&M:O,O'YU#Q3XOTCPCH[6NZSQJU\;I6:+"MB)'"D$Y.3C([&
M@#2\ ^)-=N[^_P!"\5^2NL00PWD?EQ[ \,BC(QZH^5)]:UM1\=:-INHW>G-]
MMN;ZTVF:VM+229U5E#;L*#\N",GISCK7$>*8_%?AW7-(\<:S-H\EOIT@M;S^
MSH)48VTK $MO9LA3@@#')KI?"XC?XF>.)DVMN^P8<<Y'D$CGTH V;'QCH>HW
M&E0VMV9#JL#SV;>6P654^\,D<,.X/-76URQ'B%="\QCJ#6QN_+"$A8MVW)/0
M<\5Y/8V4R_!O2-?LHRU[H%_<7\:KU:-;B42I]"A;\A78^ "NMWVN>,>3'JEQ
MY%D6&/\ 18<HI&>FYM[?E0!;\7ZUJ5KJ^A:'IEW;V$VK22@WL\?F"(1J&VJI
M(!=L@#)['@U8T:/Q/INJ7$&MW]MJ.E^1YL=^(E@DC<'E&4'!&.=PQTYJOXSN
M_"TLMCH?BNUC-I?;VAN+G"PI(N/E\S(*.03CIG!YKB)K<6M[K?ASPCK5SJNG
MW&@7;R6S77VE;2;&V((_)4MEAMSVS0!WVF>/-#U:]CM;9KL&='>UDEM)(X[L
M*,MY3, 'XYX[<UH:?XDTK4_#8\06USNTWRGE,K*5VJF=V0>1C:?RKSS08K;4
MU\'^?XY6\\MXY[/3XK.(,&2)@58H-R@*64YP.QYQ69JRSZ??:U\-K<LG]MZG
M%-:%>J6D^7N,>RF.0?\  J /1)_'VB16UC-&+ZY:]M_M<4-M9R2RB#_GHRJ,
MJON>O:I;[QUX=T^QTV]FO\VVI([VDD<;/YFU=Q  &<XX ZD\=:Y"]MYM-^)>
MI11>)(_#T,FEVOV4R01.LD<9D5E!DX&TD' _O9JC!I]C;W_PTAM+YM2LVO[V
M>*XDA\O?N5WR%QP QX[="* .YN_'FD6D5H7AU*2>Y@-RMK#8RR31Q X+N@&4
M&>.:FN_&_A^SM-,NI+TO!JB,]FT43.9L '  &=QR %QDGCK7/:]K,Q\;ZA9-
MK\'A^WL=/AF,X@B>>ZWL^0ID!^5=N, 9RU<OX0:*=?A:A(=HI=25U;&Y'"/P
MP[$<<4 >EZ7XRT;5;749UEFM?[-YO8KV%H)(!MW LK $ @$@U'HWCC1=<OUL
MK<W<$\D1F@6[M)(!<1CJ\9<#<.1TKS[QM;3W-]\28[:-G?\ LS3I&1!RRJSL
M_P#XZ#77ZKXA\/Z[%#I^DRV]_JMWI]R]C);A9#;@Q8W%AS'G(7W/% &AIWCS
M0M4U*&SMY;D"Y9DM;B2UD2"Y9<Y$<A&UCP>AYQQFIO&VJW6A^"=8U2R95NK6
MV:2(LNX!AZCO7G?AR"WU'1/!L-UXW#B*:V>WTN.SB\Q)HER8SM&\!=K*2?QZ
MUV_Q._Y)EXB_Z\GH Y[4;WQSHG@YO%#>)=,O(X;5;M[.?3?*#J0"5#K)G/.!
MQR<5UMUXOL-/TG2[N\BN1<ZE&KP64$#33L2H9@$49^4'D]!7FEQI/PRC\&17
M;ZW;QW\-HDR%-7:9UF" C$3.P)W?P[:LBZUR\U?P;JFKZP-!O+O198FN9+>,
M@S;T8J0_RHS* W;[I% 'H$GCGP_%HEMK$MZ8[*XN/LH9XF5DEYRCJ1E2-ISD
M4_1_&.DZU?7-C%]KMKJWB$[PWUJ]NQB)QY@#@97/>O/+JRLTT[29;?6O[:6[
M\9V\LUQY C0R@;6"@?*1E1R.,YK5\9VUQ=^.M0MK-6-S-X/O8X@O4L9%  _$
MT =1IGCS0]6OHK6V>[!N%9K666TDCCN@HRWE,P ? YX[<UQOAOQC?^)?B;JD
M$E[K-MI]G-'':V4>FE8R"A+&=F3<G(R,E?:F:!%;:G%X.\_QRMWY;Q3V>GQ6
M<0=62(Y1B@W* NY23@>O-:O@'_DH_P 1/^ORV_\ 1;4 5_\ A8-MHGP[M=7M
M+Z_U\SW8@CN9[1@3F4*P8(HQ@$[?4@#FO1;&\2_LH;N..:-)5W!)XFC<?56
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M%XFM+>ZAP^I:-J$8,=RZQ+C:#AP63: 5R": /4 0P!!!!Y!%<C\,_$.H>*/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
-110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>sesenbio_minorirosales-e004.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'@[WP)LE\^7CCIG/:DT+Q9H5AHGB;5?M.JFUL-4FBN/MLGFMYH*C9" 3\A)
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBCR H<@'(&!R!7HVF>'3I'B34]0L[D+8ZEB:>S*?=N!P9%;/&X 9&.2,YK=
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MY+$(WF*#.[[R,?=VMG=T_&NZT53_ ,+6OVV\?V#: ''_ $TDKNL#.<#/K2T
M>)!CI\,>M7"/]@T[QK>2W;!2?*C;<GF$#L"1S[U>U6\A\9^-]:CT)C<1S^$;
MFUAN5!"2R&4<*QZ@;@,CC)/H:]?H  & ,"@#R+PPOA[5+SPY;CQ!XAO]2MV2
M<Z?)(&6RDC0@^:NP; .4Z\Y&,UT?PM39I.O?+M+:_>D\=?GKN< $D 9/6EH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *X[XB>)]2\,:582Z98R7$ES?0P%U
M*84%URN&(Y8;E!Z#J2*[&N%^*^Z/PO8W11VAM-5M+B=D4MLC60;F('.!0!0E
M\1ZE;?$V5(])U&YN)]"@D72TE3]VWFR;F9BWEC P"<G/ &:VXOB!8R^'$U-;
M"]^U/>G3ET[:OGFZ!(,?7;Q@G.<8&:IZ1<PZE\5[K4;0F2TGT" Q3;" W[^3
MU%<9=:;*UG=ZA.;^"SLO&5Y-<RV9998H74IYJE1G +#..Q- 'J.@>(QK,][9
M7%A<:=J-D4\^UG*L0K@E65E)#*<'D'J"*Q_%NIZK=^)=*\):+>&PFO(I+J\O
M50,\,"$#" \;F8XR>E1^!H-$FU74]2TB\UG4<QQ6[W]_*TD<H&Y@L9;!.W)S
MQCYOK47B];K0/&>D>,(K.>[L8K:2PU!;="\D43,'60*.2 PYQVH M0^%O$&B
M:I8W.D^)K[4+4RA;ZUUB42!HCU:-@N58=AT/M4E]X[,5YJ4>FZ!J.J6VEN8[
MZYMC&%C<#<RJ&8%V /( J&+XB6FM:C96/A6VFU6269?M4QBDBAM8OXF9V4?-
MZ+W-8NC^(;+P4?%&EZRLT=[)JES>6D0@=S>1RX9/+(!#'/RD=B.: .EO/'5H
M%TA-'L;C5[K5H#<VT-N53$( )=V<@*.0.>_%<]H/C".VU#QQJ^H)?)!;W=M&
MEG(-TJ2&)$\I5SC)?C@X.<YQS6+X?@D^'^H>$KWQ"LEO:MH+V$LQ1F6WG,HE
M"O@'&02/J*JWL,^OP^,]1M;6_2!-8T^]58HVCFD@C5,O&,9SM!<=^G>@#T[1
M/%#:EJLVE7^DW6E:BD(N5@N'1Q)$3MW*R,1P< CJ,CUJQK^O-HHM(K?3;K4;
MV\D,<%O;[1G"EB69B%4 #J37+>#HO#U[XI>^TG4]=U::WLS&;R\F>2&,.P)C
M!< [_E!P!QCFI_'VHFTUC0K>^U*]TW0I_/-U<V;,C-(H7RT+J-R@Y<\8SC%
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MV(G=&>!&1X\J#\W(('?-.N==:V\4^'O&>KZ?=:=IEUIUQ9R>:A<VK&17C:0
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MMP#)-(V<*,D < DDG  K-L_&4US<7NG3>'[ZWUJU@6Y73WDB+3Q%MNY'W["
M>#DC%4_'JO9:GX8U]HI9;+2[]FN_+0N8XY(V3S"!R0I(SCUJMI%[!XG^*/\
M;>E%YM+LM):T:[V,J22O*K;%) W8"Y)'3(H QO@S=:AJ]K<ZUJ4.JS7-R\P:
M^N+T/ <2#$:1;SM(QUVCH0#BO6*\\^"L4D/PX@26-XV^U7!VLN#_ *PUZ'0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%<;\1O$FK>&]*L)=)LVFDN;Z&!I Z#:#(ORX;NXW+GMUX
MXH [*BN3N_%]]'>IIUCX<NKW4TM5NKRV2XC46RL2%4N3AF.UL >F<U6OOB18
MP6GA^>ST^[O3KBRBVBC 5Q(B_<8$\'=\I.<#!/2@#M:*XV?QQ>Q:O!HB>&[J
M769=/6^-JMQ'MC!=E(:0G:,%>O.<C%9__"T7DT.XU>#PQJ,EK8.\>IDR1J;5
MT;#J 3^\(')QQ@CG.0 #T*BN,O\ 5]);XD>'+8V]S)>W=G-+:W"3LL2IM).Y
M,X8D="1Q56;XDR_8M4O[/PU?7=EI-Q/#?3K-&@C\IB&*ACE^!NP.@(YS0!WM
M%<SJ/BNY2:SAT30[K5Y+FU%YN2188UB/3YWX+'/"CGUQ7.ZW\0=1DC\)77A_
M3)IK;5[G#J[QHS85]T!#'Y6!&=W3Y<9YH ](HKC+'5M,;XGZA:-:7,&IQZ4D
M\\SW!,0CW+\H3.T$'^(#M5=?B3_H$6M2>'[V/PW+*(UU-I$X4MM$ABSN"$XY
MZX.<4 =W17(WGC2Y'B'4]#TK0+K4K[3UB>0),D2;77<#N8\'L!R3SV%;/AK7
MK?Q/X?M-7M8Y(H[@-F.489&5BK*?<,"* -6BN1O?&MS_ &GJ-IHOAZ[U:/3&
M"7DT4T<85]NXH@8Y=@",@8ZXKCOB3XJNM8T#PLVBV]X^DZQ?VP::"Y6%IPQ;
M-N>0RDX&3T!'6@#U^BLC28Y-/\,1)!I<T$L,+%+&2Y$K@C)">86()/J3WKRZ
M[\8:SK7PEN]5U*UFM@FI1&.Y21/G07@!0*G/RJ O(^;WH ]HHKE=/\8SR^(X
M-'U70KK2GO(9)[.2:6-Q*J8W!@I.Q@&!P<_6JMG\0!=2V5T^BW<.AW]P+:TU
M-I$(=V)5"8\[E5B, GU&<9H [2BJ&M:O:Z#HUUJMZ6%O;)O8(,LW8 #N22 /
M<UBZ?XON)-1.GZOH=SI5U):O=6RR3)()D3&X94\.-RY4^M '4T5YXGQ53^R-
M.UR7P[J$>AWK)%]MWHQ21N /+!W$;OESCKTSQG8T[QG-/KL^CZGH=SIEVMFU
M] ))HY!-$IVGE"0K D<<T =75>^M?MUA<6GGS0>=&T?FP/LD3(QN4]B.HKAK
M;XH>?HUEKTGAV^AT"X9$DOVEC_=,S!<E,[B@8X+?D",9BLKJ1?CYJ\4D[BW3
M0D?8SG8I\Q<G'3\: -:R\&ZDVJZ9=Z]XDDU6+2V+VD/V58?WA4J'D8$[V )]
M.3FNPKA%^)/^@1ZV^@7L?AN24(NIM(G"EM@D,6=P0GOUQSBN@T7Q'#J^K:SI
MAMWM[O2KA8I$<@[T9=R2#V89_*@"QK'A[1_$$<<>KZ9:WJQ$F/SXPQ0GK@]1
M^%6=.TVQTBR2STZT@M+9/NQ0H$4>O KC_P#A9EL\%G/#I-W/%?ZC/86?ELI,
MYC!PXS@!68$#)XZG I8/'^HW-]?:1%X3O6URSVO+9_:8M@B895_-SMYZ8ZY^
MAP =S17'Q_$"VO/#^CZAIVG75U>:N[QVM@"J/N3/F;F)PH7:<GZ>M,N/B';6
M.@7VHW^FW-M<Z?=Q6EY9EE9XVD*[6!7(92'# CK0!V=%<C;>,[QM;&DWWAR[
ML;JXM9;FP62>)OM.S&4)4X1N1P>.>M0?#?Q-K'B?1[B[U2P:%1<S"*8R1D,!
M*P"!5Y&P #)Z]>: .UHIDT?G021;W3>I7>APRY'4'L:\H\2>'KW2?%'A;3K?
MQ=XG,&J7,L4Y?426"K'N&T[>.?K0!ZU17(W%S#X!TF.-KK6-;NKZ[6&TAN;@
M2RR2,.%#' 50%))/ YJWHGBF34-:N-$U/2IM+U2* 7*PO*LJRQ$[=RNO!P>"
M#C&10!T=9GB'0K3Q)H=SI5YN$4RC$B'#1N#E74]B" 1]*YSQYXGUG0-1\/6V
ME:>]P+Z_6*1A)&OF#:Q,0W="< [N@QUK)L=?U:U^('BZ&ST6[U*Y*V4AMEN$
M1(!Y'(+L=N23P!UP3VH ]#T^&ZM].MX;VZ6ZN8XPLDZQ^6)&'\6W)QGZUG^)
M]"?Q)I!TLWK6MI,ZB[")EIH@<M&&R-N[H3SQD=ZR$\?VUYH6C7VF:=<WEYK!
M=;6QW*C@IGS-[$X4+@@GZ8ZUK^'O$"Z[#=+):2V5[93FWNK25@S1/@,,$<,I
M5@01US0!#K7A>+6FTJVEG$6DV,JS/8I'Q.R?ZM2<\(IYVXYP/2M^N:U?Q5<6
MFLR:3I.B7&K7<$"W%R(I4C6%&)"C+'ECM.%]JC3QU82#0+@03#3M:_=PW;8
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MYX('7'?% &W17DUWXFU::#X>ZI?Z?=+<S3MF"*1&:[+6IVL I"J&9NAQMZG
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M2JY2/&3VS6#X U^W\/>"]3M;VUOS>:7=7$EQ;1VKE]K3-MVY #9!!X->GT4
M(K;T5@" 1GFN'\:6\TOCGP+)'#(Z17LYD95)" Q'DGM7<T4 <5X]BFMM0\-:
M^MO-/:Z5?L]TD,9=DB>-D,FT<D*2"<<XJOI-TGB?XG#7=.CG;2K'2FM3=20M
M&LLKR!MJ[@"0 O)]37>T4 <%\2W-I/X4U.2*9K2RUF.6Y>*)I/+38XW$*"<9
M([58\*;IO'OC&]6.06]R+!X9'C90Z^1VR!Z\CM7:T4 >&V6D-!X=\'ZEJ@U6
MUT^TFU*&[ELFEBE@\V8E'/E_-L.S![?,*]$\!VNE+#J5]I4>K&.YG -UJ<DC
MO=;% #KYAW;>=HR!]WTKKJ* /*_$%E8:;\0=6OM=N]<LK/4+:W>UGTV:X1'>
M,,K1MY7\7W2,^IQ4FH6"7O@W1O!.CZ9?6RZH#-,U\I=[&#S/,>1V)/[PL?E!
M.03VQ7J%% 'DS6]_;?"WQ-X*DL'-_I5G)' T,)"WD)!9)%QU<\A@,G=]:@U"
M73M3E\+:_+/K$.CPV,EA<W%EY\$EO+B-ANV /L)4J3@C.*]@HH \CGTVR?1-
M*NM&M-8:*X\564SS:@TDDDZHRKYWSDL$P ,MCIZ8KJ=0MYG^+6F3+$YB&BW*
M&3:=H8R1X&>F:[.B@#@/@]>1GP!8Z2Z3Q7^FJT5U#- \9C8NY RP / [9]Z;
M/=)I7QN,UY'.D.H:/%;6TJP.Z/*)F)7*@@'!!YP*]!HH \DALKH?L[:E:_9I
MOM#1WF(?+.\YN'(XZ]*EUB7[1XGU"PUE];8"TMUT>RL9)XH[ABAWDM'@9W\$
MN< >U>K44 >)Z;>II=K\,-3O(+N.TTN&[M+U_LLA,$IA"A64+GD@CI7J/C""
M6]\#Z];VT;2S3:=<)&BC)9C&P  ]2:VZ* /*-+O(]7B^&CV<=PXL9#;W6^W=
M/*=;,@@[@.Y STSWIWC'0[_6=?\ &5M9V\KR3Z#;"' ($CI*[; ?4XQ^->JT
M4 >:>&(O#NH^)]-N+!O$][=VL<DI?4+BX:.S8KM*N)3C<0Q&%STSTYK2^*J2
M?\(O97*0RRQVFJVEQ-Y2%RL:R LV!R<5W-% 'D>J?V3_ ,)I?:WJ5]KUKI>K
M6=O)976GO<PJ[(&5HW6, [N5(##N<59ATJ*UUSX;"PTW4+:SCDOYFCO,O+%Y
MD1;]X<G!)8GDYY]:]3HH XV."7_A=$]QY3^3_P (^B"3:=N[[0QQGIG':N<@
ML[D?"[X@0_9IA+-?:H8TV'<X)."!WSVKU6B@#RUK2Y_X6CX!F^SS>5%H\JR/
ML.U#Y9X)[&IM,M+A?AGXXA-O*)9;K5BB%#N?<7Q@=\]J],HH \B:<)>:38Z_
M)KD6GKH5I]AM=/,\?VBXP1(K&+!WC" !B ,Y]ZRK&5M,\*^!Y[RUNXET;6YX
M]07R)':W),N,X!+#YE^89ZU[E10!Y=%8S:I\7_$,D4<J6U[X<6**=HV5<L5Q
MU'7GIUK*N-1;4/A+!X%CL+Q?$AMXM.>S:U<",JRJ9"^-NS"[MV<=*]FHH XW
MPU;2P?$;QD[QR"-TL DC*0'Q$P.#WQ2_"^"6W\"V\<\3Q2"ZNR5=2IP;B0C@
M^U=C10!YOI>M6_@?6O%-IK,-XIO-1?4+)XK6247*R(HV*5!&X%2,''4=JYV_
MT'4].^&W@"RN+.47<?B&WN9XE4L80\DLF&QTP' /I7M5% !7CCZ3=+X^D\!"
M%CHT^HKX@+?PBW&2T6/3SPO'H:]@E5WB=8WV.5(5\9VGL<=ZP?#WA=M'OKW5
M+_49=3U:\"I+=2QJ@6-<[41%X51DGW)R: .>&I0>#OB'XDN]82XBLM7CMIK6
MYCMWE0M'&8VC.P'#< @=P:YM+2\TO2-'\1WUC=0VS^*9]4FB\EFDMX)0ZJSH
M 2.JDCJ-U>S44 >4W=ZVO>*O$^H65I=FRD\+-!;S20.@G(>0_*& /4XZ<XST
M(-=MX$B>#X?^'8I(VCD33H R,,%3Y8R"/6N@HH **** "BBB@ HHHH ****
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M],L-1C:SU*+4+YKFSDA6V6-6^1F< %BQ PN>_:@#I-%\8VFJ>%;S6[B!K+[
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M7EL,!MQX'3!ZXKC/#EM>>&].\"Z]>V%Y]DMM.GL;U4MW>2V+L&5F0 MC*D'
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MN.,\MC\* .AT[Q;>G7H=&US1&TN[NH'GM"MRL\<P3&]=P PP!!QC&.]8EO\
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M-AHUNUQ"L@E!PTA&QN-P((QP.>#73:7XKU*36;+3=<T+^RWU")Y+-ENA-N*
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M8G^SXK<ZKJ"=IE5]L49_V=_)'?:*GUWQEJNCR:E<Q^&)IM'TS'VF[DG\IW7
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBEEDM[BVG2XM;F'&^&13PPSP>,@@\$$T >:>)-/FU2]\66>HZ1K&H:Q,SII
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M]:JW7AZ"^\2V>M74TDIL8V6UMSCRXW;AI/4MC@9Z#/K6Q0!Y#=W%_K?PVL/
MJ:)JD.LF.VLKCS+1UA@6)DW2^;C85PA(P23D5T/V"\_X7S_:'V2?[%_PCWD_
M:?+/E^9Y^=N[&-V.<=:[VB@#D_B987>J?#?7+.Q@DN+F2W^2*,99L,#@#N<
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ML+,QW$Y)) P-HYY%9.MZU=R_#31-%ET/4K6ZLI[""]:YMFCCC,<B+\CGA]S
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M>YTY;R:T%PGEO-!C>%/W@I/0D9&>V:FT^PM=+T^WL+*%8;6WC$<4:]%4# %
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M^S!H MQNFGG+A @7: %+$J"?3.,&NYN8 NE300IP("B(.?X< 5YS!X6U*^^
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFGW)DC)SC80P!S@Y!&01Z4SQ-XBO-,U#2]'TFTAN=5U-I/*%Q(4BBCC +NY
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M,2#"5W1R\] RY_(U@V7C_5M6T_1$L-)MQJ>MF:>VCN)66.&UC/$DA )RP*X
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME\1Y;I+'R-/70K>UC*',:NLCG8#WP".W2N5U/P[K0\):YY>F7$LR^*VU*.!
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MU:74K:24*+>Z3STD5 ^>K $8(X[FO7I)$AB>65U2-%+,[' 4#J2>PIL$\-U
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MPV1P2,8..#VTK/PQ9ZO::Q:Z=X&B\.I<Z9+:B[GCCCE,L@QM"H6^0=221GC
MJG>+XHUKPYX<T8^%[RUFTV]LGOIII(_+98G4$Q88EAQNS@8 [F@#T7Q#K5OX
M<\/7^L7*LT-G"TI1>K8Z*/J<#\:P]-UGQ9;WUJ=?TJP73[F%Y&FL7<FS*KNV
MR[NN1D97N.E:/C30I/$O@S5='A=4FNH"L3-TWCE<^V0*R;/5?$OB":WTVY\.
MS:7:&WD34Y[MD.6*8"P;'.[YCG<1C ]: ,L^._$B>&4\8R:7IX\/,1(;<2/]
MK6W+;1)G[F<'=M].]:5QXF\17WBW5]!T*STTFQ@@G6ZO'?81(I.TA>221QT
M .<\5SCV'B6?X=I\/VT"Y2\$:V+ZEOC^R"$,!YH.[<3L'W=N<UUF@Z/=V/Q
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M@X9A@GJO6L(^![_^R=+U?5= 34IAJMY?WVD91V$=QGA=QVLR80XSSSS5V_\
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MW/NY;YB  ,5UVEVFJZ?XY\6++H]VUIK(BFM[Q"AC7;!M*O\ -D'<,# /Y<T
M4?#WC9E^&GAZ[TO1+"WOM7NVL[.P@_=6\;>9)EC@9"@*6..23[UL1>*M:TW5
MKW1]>MK W:Z;)J%I/9EQ%*$X9&5N0P)!ZG(/:N7T'PGK^E_#7P@_]FNVK:%?
MR74M@74/)&SR!E4YV[MK@C)[5M36.K>*/$5UK<FCW>GVMKH\]G:PW9033S2X
M).U6("@*!R>2: (X/'/B4:-H/B*\TS38]'U*2VBDB61S<)YI"B0'[N-QR%ZX
M(YST[3Q+JDFA^%]5U6&-9)+*TEN%1^C%5) ..W%<=>>']5D^%7AG2DLW-]:-
MIQGAR,IY;(7SSCC!_*NN\4Z;-K/A+6-,MRHGN[*:"/<<#<R$#/XF@#.U3Q1<
M6&F^&;I+>)FU>]MK:4$G""5&8D>XQWK%;Q=XJOQXBDTC3M+$.B7DT#/=.^9P
MBAMJA>C8/)/'(XZU0E7Q%KEIX/LSX9O;)=)U&UEO9+EX\?(I4F/:Q+*,DDG'
M; /.-S0=&U"UTSQI%/;,CW^IW<UL"1^\1XD"D<]R#UH B/C74]9FT"R\.VEH
M+S4]-&J3/?,Q2WA^4 87!9BS8[=*Y_1_$E[HM[XTO;FQB.JS:M:V<5L)?W;S
MM$B*=Q&0G\6<9Q[U-I6DZWX5G\*ZR=%N[X1: NE7UK;%#- P*NK %@&&00<'
MBJESX3UW6[7Q+=W^AIYTVKVNHV]A-(A6XCC108B<D9*Y4]MW?'- '2_\)?K&
MFG6;+5X--DO[32I-3MI+)W\J54R&5@W((;;WY#=JT_!FLZ[X@TR+5M2L[*TL
M;NWCEM8XG9I>1DE\\ '@@#G!YKF[;0H+C2?$7]C^!$T/SM*FMH9)(XH[B>1U
M.4"H2 O"\DC)KL_"5I/I_@S0K*ZC,5Q;Z?;Q2QGJKK&H(_ @T <;X^2RB\7:
M?>>*-/NK[PLEDRXCB>6*"YWYWRHO)&S@$@XYJ72=1\+^%O"VM^(?"]]]NTIB
MC1Z?#+^[AF.$"J#RF]F7(/3J!6]K6K>(=&UQ9H-&EU;1)( "MEM^T0R@G)(9
M@&4C'3IBN.OO"&J>*H/%>H+HJZ2-2MK9+>QN&3=<20R>9OE"DJN[A.I..M '
M26?BO5=-UB.P\3IIBI<6DMU#/I[NRIY0!D1@W?:<@CK@\5%H_B7Q;J$>E:M)
MHMDVBZFZ[(H)'-S;1.,I+)GY2,8) Z9[U0T?P[I^HW%Q#:^ (_#\;V,L,MY-
M'$DBR.NW;&$)W+@MECCM4_AR^\6V.FZ%X;_X1UX)K'R[>]OYV5K8P1C:6C*O
MN9V & 1P3STH S/#NM>(I;#Q[=:R-/O+2QN+M&@)D8;XX4_=J&X\H@'(ZY)]
M:OZ;XPN3X3\(V^BZ380ZEK<;?9[;F.VMD1=SMA>< 8P!U)JO9Z9K-I%\0-&?
M1KIO[4EO+NSNU*&&021!53.[(;(]/QJ#3O#VMZ-X?\":HNERW%YH<,L-Y8(R
MB4QRKM8KD@%E*J<9YH UKCQMJ^D6_B.SU>SLO[6TK3O[1@:W9O)N8L,.A^92
M&7!&3UIR>+?$=K>^'[G4].T^/2=:G2WC2*1S<0.Z%D+Y^4YV\@=/4UE:KHNM
M>)AXLULZ1<6;7.AG2]/M)V3SI?ON68!B%RS  $_E6YKVC:A=Z=X+C@MF=['4
M[6:Y (_=HL3AB>>Q(Z4 =K1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445E>(M;B\/:+-?O&TT@Q'! GWIY6.$C7W+$#]>U
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M"S2(3]=[(/I7L#,%4LQP ,DT +52_P!5T[2HEEU&_M;.-CM5[B98P3Z L17
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M@N[RUT^UDNKVYAMK>,9>69PB*/<G@4 87@^Q^R6=U*/#5GH"S39CMH%02-&
M,-+L^7=G=P"<#%95Y;ZSX>\?ZCK-AHL^K66K6D,<@MY8T>&:+<!D.P&TANH/
M&.E=A8:C9:K9I>:?=P7=K)G9-!('1L'!P1QU!%6: /(HO!6MR: +G5-$MKV]
MM_$-QJ4FG.Z.ES#*"&"EOES\V1NQ]WM6L^@3WW@[Q5!IO@RTT-[VR>WM($6%
M)YR4;_6;#M49( &[U)Q7H]% 'EC>&]3M++P4]_X<;6K?3=*^RW&GAXF\FY*Q
M@.0[!&QM9<Y.,Y%7- \)W<WACQ9X>US3(K""_N9;B*2%D,"K(BD!,'(,;+W
M' (]O1ZRM>\/V7B2Q6RU![K[/NR\<%P\0D&,%6VD;E.>AH X/X=:5>^)O!VK
M:OK+C[9KEM]A61>0((XS$&'^\V]_?(J3POX?DLY]'LYOAYIMK=V6T7>K-' 4
M8HO$D)7YRS, >0,<YKTBVMH+.UBM;:)(H(4$<<:#"JH&  /3%2T >4#2_%6E
M^#M>\&6>@27'GF[6SU 7$:PM#,6;YLMN#_.1C&,XY YKT;0+::S\.:7:W";)
MX;2*.1,@[6" $9''45HU5O=3L=-\C[=>06WVB40P^;(%\R0]%7/4GTH \HFT
M;Q9%\-]5\$6_AV22?-P(KXW$0AEC:5I!M^;=N(.,$ #J3VKM=+T>_M_B%?ZG
M+;E;.72K:W23<IS(C.67&<\ CGI7644 >47_ (5U]/#%UY.FM-=0^+'U:.V6
M5 TT F+ J<X!(.<$@ULMI&L:A\5]$\2/IDMM8II#PS>;)&6BD9F(0@,<G!'(
MR/>N^HH XCX?Z#J>BZEXNEU"U,*7^M375L=ZMYD3'AN"<?0X-5_$VD7C^.XM
M4E\,CQ!9-IXMK>-FBV6T_F$LS"0\!@5^8 GY<8KOZ* /';SPAXCF^%'_  C:
MZ3_I]KJQD'ER1K'-&9VDWI\W"X;H<'CI75^++'5HO''AK7]/TJ74K>SCN89X
MX)$5U\Q5"M\Y (X.>:[":]M;>YM[::XBCGN6*P1NX#2$#)"CO@ GBIZ /*%\
M)R:7=:G8GP#I^LSW-]+/::E.D!B$<C[L2EOG!3)& #D 8KJ=,T2]M/B9JNJ&
MU$>G2Z;;V\,BLN"R,V5"@Y& 1VQ7744 8WB[3;C6/!VM:;: &YNK*:&(,< L
MR$ 9[<UR>F:=KE]>^!+FYT2>Q&CB>&[6:6,E1]F"*XVL<@MP._'(%=Y;ZA97
M<KQ6UY;S2)]Y8Y58K]0#Q5F@#S?Q)X,U/7=4\8A((Q#J%C9+:/*P*22PNSE6
M'4#.T'([U?\ "^FH-<CN(OA_8^'TAA;S+EHX!*93@;8_*)^7&[+'&>..M=S1
M0!R/C;3-2EO= US2;,WUQI%VTCVJNJ-+$Z%'VEB!N&00"1FN;O\ 1O%?B#6_
M$.IKIDFEB]\/M8V0DG0R+)O8X?:QVDY/0D $<YR!Z1#J=C<7]S80WD$EY:A3
M/ D@+Q;AE=PZC(Y&:M4 >5Z?HE_#XB\+ZG8>"%TFRT]G@N8T: 3MYD13S#M;
M!13ZDL<DXXYKQ>$]<N/"^N>'I]$!DBU9]3M)9Y(VM[P>>)!&1DD;ER#D8&>:
M]<HH XOPIIT::S)=0>!;/P] D&P3-'"L\DA(RH\HD;,#J3R<<5/XOTO4FUC0
M/$.EVAO9])EE$EHKJC2Q2IM;:6(&X8! )&>>:ZJ26.%"\LBH@ZLQP*;<7-O:
M0F:YGBAB'!>1PH'XF@#C=(T[5=5\6ZEXGO\ 39--1M.73K.UFD1I67<79WVD
MJN20 ,GI4_PMT74/#WPYTK2]5MS;WL'F^9$75MN978<J2.A'>NN61'B$J.K1
MD;@P.01ZYJ.VO+:\0O:W,,Z*=I:)PP!].* ."UK1;X^.[Z_E\,1Z[%=6D,-A
M-.8C%9LI;>'#G(!)#94$G&*VOAWI]_I'@FQTK4K-[:YLM\!W,K"0!B0Z[2?E
M.>^#P>*Z66>*!0TTJ1ACM!=@,GTYJ2@#S'6]'U36=9A8>$1::Y!?(\6O6TT:
MQB!9 =S$-O8F,%2A4\GTJ5++Q)I$WBS2+309+M-8O)KJTOQ/&L*"6-5(<%MP
M*E>@!S[=:]!BOK2>\GLXKF*2YMPIFB5P6CW#*[AVR.F:6\O;73K22[O;B*WM
MHAEY96"JH]23TH \TL=$\2Z+<>"KZ+1GNAI6B-:WT"3QAPQ$8VIEL%LKGKC
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MV4/O20.^ Q!+ Y(X(H XO6572=.\3>'$+P^'K/7K$W"(2!#9SA'E08^ZF[/
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M* "BBB@ HHHH ***P_%5[J-AI"RZ=<6%H[3(DMW?L!%;QG[SX)&XC@ 9')H
MW**\M?X@ZE;>$_%EQ%J&F:M=:(83!?6B?NIUDP<%0Q 8?,#@^E;(U?Q/I/BS
M0K;5[BPGL]::6,P06[(UHZQEP Y8[QP020/7 Z4 =G=W=O86<UW=S)#;PH9)
M)'.%10,DD^E.6>)[<7 D7R2F\29XVXSG/IBO)=<UGQ-XD^&GB+Q!%/8KH\T%
MU%#8&W/F&!2T9D,N[AN"V-N,#'?(],TB*.?PU812HLD;V<:NCC(8% "".XH
M/^$AT3_H,:?_ .!*?XU;M;VUOHS):7,-Q&#M+0R!P#Z9'UKS#Q;X2\-VWC_P
M/;0>'M*B@N;BZ$\264:K*!#D!@!AL'D9K<\67;^!=/T>W\*:5IML^I:M':M
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M-1V^4(F5C-LW\9WXSWQ[5=\ >(K+3/AUK-Z\KG2M'O;N.V+YW&W4[HU&>>C
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MU_T:11(%1NFXMO!W#@9QSC)]0JK%J5G-J5QIT=PC7ENB22Q#JBMG:3]<'\J
M..\5>%]4U7X-GPW:1(VI?8K:'89 %W(8RWS=/X32Z_X8U._U?P-<6\2-'I$Y
M>[)<#:-BCCUY':NZJMJ&H6FE6$]]?3K!:P+ODE;HH]30!R+^%KZ?XM7>N2Q+
M_94^A_82X<;BYD!(QUZ9YJGH-CXWT?3-+\,165I%;6,JQOK!G5Q);*V<+%C<
M'*X7G@=<UV$OB+2(?[,\R^B7^U"!99S^_P @$;?P(K3H \CU#P;XEF\/>(-!
MM]&L?.N[N>Z&K23J6N%:3S$3;C<&Z)D\ #C-='%I^OV_Q(CU]=(1[/4--AM;
MD?:D#6CJY8Y'\8P?X:[FB@#RK3?A_K2>"-:T^3R(-2?7GU6P+/N0[61DW$=,
M[2/;-;L=AX@\1^+-%U+5])CTFSTCS91&;I9GGF=-@QMX"J"3D\DXXKJKK6=.
ML=3LM.N;N..\OM_V:%LYEVC+8^@J]0!YRGA#6%^"EWX9,,?]J2QW"K'Y@VY>
M=W7YNG0BNIAU.]C\6PZ*UO%]C_LS[3YP;+B02!-I'I@Y![X/I6[2;%WE]HW$
M8+8YQ0!R?Q T;4]7TO2Y-)MTN;K3M5M[\6[R"/S5C))4,> >>].T72]3'C?4
M==O;1;:*\TZUB$?FJY212Y9<CKC<.>]=710!Y/K'@37KSP1<Z9#;Q&ZD\1R:
M@JF50/),K,#GUP1Q6YXSTS6=9^WZ;)X6T[6+*:/%C=/.L;6K%<$ONR<AOF!3
MMQBN\HH S[2UO;/P[!9K<I+?PVBQ">8$J\H3&YAU()&3WKAX/#>JZUXFL=0U
M#PW9Z+)%#/'J%W;7",;T21E-H"C)7<0V7Y&T5Z110!YSX;T'6]+32=(F\+Z,
MJ6!2.;5V*-YT2#"LB !Q(<+RW .3S2P:;XQ\-IJ^D:%IUK/!>WLMS9ZC)<JJ
MVHE.Y@\9&6VDG&,YXS7HM% '$1Z3KNF_$V35H[)+ZPOK""UGN!,L;0NC'+%#
MU!SG K TOX?ZW%X$U'3Y!!!JJ:XVJV.^3<C%75D#$=,X(]LUZ98ZE9ZDL[6=
MPDRP3/;RE?X9$.&4^X-.OKZVTRPGOKV98;:!#)+(W15'4F@#D(;#7_$7B_1M
M5U?28])M-'69TB-TLSSS2)L_AX"J,]>22.*SAX/U@?!"?POY,?\ :CQ2J(_,
M&W+3,X^;IT(KT*TNX+^R@O+659;>>-98I%Z,K#((^H-34 5[E;H:=*MFT2W?
ME$0F8$H'Q\NX#DC.,XKS^V\/ZQJ7B>VU:?PU9Z)/#;3QW<\%RC&^9TVA<*.5
M#?-E^>!7I%% 'GD_A+5W^#VF>'%AC_M*W6T$B>8-H\N5&;YNG135;4/"^O/>
M^*[.WTBRG_MMV:+5YYES#&T2IY93&[*X.W''S9KTRB@#S:U\,:[/XI\!:K<V
M*6\>D6,]O>KYZL48Q%%QC[P/!XZ9K6\'>'=1T;Q5XOO[R-%M]3O4FMBK@EE
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MII\/DP3ZHESDRV\3 @+%MR'(4 Y.!S0!U6A:U>:AXM\4:=.4-OITUNEN%7!
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M=J7"A597 !(!PX! .,BJ][J>O:SXXO="T;4(-.M],M8IKB:2V$[2R2EMJ8)
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M10 4444 %%%% !1110 5E:5X;T?1+FZN=.L(H+B[;=/*,EW/7DDDX]NE:M%
M!1110 4444 %%%% !1110 4444 %%%% !69K7A[2?$4$4&KV27<,3^8L<A.W
M/N >?H>*TZ* &HB1QK'&JJB@!548  ["G444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %<MX^T'4/$'A^&'2_(-Y:WL%Y&D[%4D,;YVD@'&?I74T4 <0WAS6;_XBZ%X
MHNHK2WCM=.D@N84G+E9&)P%.T;AR.>/I5=?!FJ#X<^(]!+V_VS4;B\DA.\[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH X"S\2>--<U+6H]%T_0?LFG:A+8[KRXF1V* '.%0CHPKJ--U"\@AM+;Q
M%)IMOJET[K##:3,RR;1N^7> 20H)/%>?>%=*\27VK>+Y='\2QZ9;CQ!<JT+:
M<LY9MJ9;<6&."!CVK5U:WO['Q;X CU745O[E;R\#W(@$(;-N^T;02!Z=>: .
MVFUC3;>2[CFOH(WLX1/<JS@&*/GYV]!\IY]C7.Z]\2O#.B:3>7BZG:7<MKY8
M-O%.-S,_*C/J0"?H#7+>(YHY==^)BQNK&/PRB. ?NGRYC@_@1^=1^*+"UL?V
M=8!;P1Q[K.P=V"@%F,D1+$]R22<^] '3W'CVQA\4V*C4[#_A'Y]+FNVNRXVE
MUE2,8?.,?,1CUKH[3Q#HU_H[ZO:ZI:2Z<@)>Y64;$QUR>V/>N7U&TMY_C1HI
MEA1_(T:XDCR/NMYJ#(]\,?SKB]<CF1_$]M:+;I _BRQ\U)P?(PR1G]X!_"7V
MYH ]8T_Q/H6K6%S?6&K6EQ:VP)GDCE!$0 R2WH, GFI-.\0:1J]S+;:=J5M=
M30QI)(D,@8JKC*DX]1S7 ZGI>LQ7'B74M7O=$$[^&[B%[73]ZNX&2DC*Q.0/
MG7/OBND^']O8Z5\-]!F58;='TZ"661L+EF0,2Q^I/6@#K*XBY\:1Z'X0UK6-
M0UG2K^2VN)XK46YV*9%3<D#<G,G!SCUZ5VX((R#D&O$O#@!^$'Q)R <:AJ9_
M\A+0!WGPY\27?B?01J%[JNEWD\BQNT%A&5^REESY;Y9LM^70UU%GJ-EJ!N!9
MW44YMYF@F$; ^7(.JMZ$9'%8W@%0/AWX;P ,Z7;9_P"_2UR/B#5U^'?C36-1
M*_Z%K>GM<1)V-]",;0/]M2OU(H [J?Q/H5M8W%[/JUG':VTYMYI6F 5)1U0G
M^][=:+7Q/H5[I$VK6VK6<MA!GSKA91MCQUW'M^->>6&@?V!KWPZTO4,.1'>W
M$Q?D/>LBN2?4C<^/I5/QPBKJWQ#2S4>2WA^![L(./.W/M)]]GZ4 >N3ZC9VS
M6JSW,49NG$< 9@/-8@G"^IP"?PJ2YN8+.VDN;F:.&")2\DDC!511U))Z"N$\
M5W$+:C\/8Q(I>34DD0 _>40/DCV^8?G6UX^NX;7PI*DUA#?FZG@MH[>=BL;2
M/(JJ7(YV@X)^E &AI?BC0M;MKBXTS5K2ZBMAF9HI ?+&,Y;T& >?:DM?%.@W
MTLT=KK%E,T-N+F79,"$B(R')Z 8(/T-<!G4D^(&M0ZI<:;)=?\(Q(76PA:-5
M'F?*&W,Q)Y..G!Z5FFQCM/V=M+-G#!'YZVC7+R+\K*TZ;MY')7L?]GB@#U31
M_$FB^(!*=(U2UO?)($@@D#%<],CT/K4^J:OIVB61O-4O8+.V!"^9,X49/0#/
M4^U<GIFE:VOCVSU'5KS08YDT^6#[-8!UDFB+(02&)RJL!SVW>]6O&%S*==\.
M:=8V-E/J<\TTUM/?;C%;^7'\S;5(+-A\ 9[D]J .CTS5;#6;%+W3+R&[M7R%
MEA<,N1U''?VK.N/%>G6WB"YTB6>))[:T^ULA?]XZ\D[%[@!22?<>^.?^&[SG
M4?%Z7$UK+*NK_O&M$*1;_)C#;5))'(YYZ@UVS65H]XMXUM"UTJ&-9S&"X4\E
M0W7'M0!A6_CGP^?#UKK-YJ^GV]M<DJC?: R[AU4'N1WP*OR^)=#@M+:[EU>R
M2VN4:2"9IU"2*HRQ4YP0!UKG]>T!XM9TJX\+S:1::G8PS^7IUS'B*6*0IO8!
M.5.X+\P!Z\]:Y/[5INJ^(/ 0GTN#3EBU348IK12&C6Y0'.T]"#(,CW- 'IVE
M^(M&UJQEO=-U.UNK:$D2RQR@B/ R=WIQSS3='\3:'X@:9=(U6TO6A_UBP2AB
MH/0X]/?I7E/C]6AUSQNNG[$CDTFP-[CA=QN""7Q_TRSGVS6_>Z7XC35X=2N+
MS0(+NWTJ\BMH--#I+.A0;0 QY57"'CIGWH [.V\6>'KW6'TBVUFQFU!"0;=)
ME+Y'48[D=QVK/3Q-#IW_  D%WJFNZ7+:6,P54B.QK;.<)*23\Q. .E8_AB#P
MQ_PKGP7+?K %46K6C@D'[85[%>2Q;=D=#SFLSP8 ?$/Q/! (^V]_]QZ &^%_
M'^I^(O!^H:S/XD\.V%R%#K T38L1YNT&4E\G<.G Y(KO]0\1Z1H5A;7&L:K9
MVRS* CR.%$AQDE1U([^U>/,H'[)>0!DQ#)_[?*Z4IK<OQ%M!I1TOS4\.0&+^
MT5=AM,C!]FTCG[F?;% 'H-YX@T>PTA-6NM3M8M/< I<M*-CYZ;3WS[5BZ)XL
M77/&E[86-U:W6E1Z?#<PRPG=EV=U;Y@?]D<=CFN+L-,;3=?\#V-[=V%W:?VG
MJ<JBS)-O'+M+)&,]"K&0 =B*Z+1$M$^-/B86H0.=-M3.$_YZ9;K[[=M '7ZM
MK6F:%:"[U6_@LX"P0/,X4%O0>I]A3%\0:.VG6VH+JEH;.Z<1P3B4;)&.<*#T
MSP>/:N/\6+JTGQ.\.KIIT\2K873V_P#:"N8_,W1AMNT@[]OZ;JYO5]$EM]*M
M;;4KG3+M;SQE;/-!89,418 /&0>02<D@_P![WH ]%C\=^%)K*YO(_$.G-;VS
M!9I!.N%)Z?G@X]<5>3Q'HLFFVVI)JMH;*Y<1PW'FC8[G.%!]>#Q[5RC6-JWQ
MV24V\>]/#N]3M'#>>5S]=I(SZ&N(NX;/_A'9;:Z5%L%^(#1NC<((_,.1[#DT
M >P:/XFT/Q TRZ1JMI>M#CS%@E#%<]"1Z>_2N=^'WC*;7?  \0:_/:VVV659
M9?\ 5QJJM@$Y/%,U&..+XS: ;5%69]*NA=;!@F(,FS/MNSBO./"P5_A9X0BN
M #8R>*56Z#?=*[WVAO\ 9W[>OM0![-8^,/#FI65U>6>M64UO:+ON'24?NE]6
M]![UHS:E8V^F'4IKN%+$1B4W#. FPC(;/3&*XO7K2VN?BSH=LD2-]ITF\BOT
M ^_ =@4-[;B0/QKDK5Y[_2]/^%UR[/<6NJFWNR>KZ?#B96/H&4QH* /4;_Q=
MX=TNXMX+[6K&VEN5#Q)+,%+*>C>P/J:GUCQ'HWA^.*35]3M;)921'YT@7?CK
M@=\5YS%9:W?:YX\AMSH*P270ANO[220N(/(39RI ";22,]]U1Z79^(8/&=I:
M6%YHUY<VWANTCCN+P2.DL>YP[QE3SDA<GO\ +0!WFK>(;NSN-$ETW3X]1TR_
MG6*:[BN5'E!RH1E7^,'<2<= I-2:%K.HZCJ6KV>HZ4+)K*<+"ZSB59HVSM;C
M[K8 )4\@,/6J?@/2/[,\-0P37-A>-%<7#0R6?S1Q!I&)1">0%)*X]L5TT<4<
M081HJ!F+':,9)ZGZT <YXGU^[L]2TG0M($1U74Y20\J[D@@3F20C(SQ@ <9)
M]JNWWBSP_I>IQZ9?ZS96][)C;#+,%;GID=L]L]:YY?F^.\GF=5\.#R0?>X.X
MC_QVN7\6W5U?>&O'EW8VVC66F1R36MT]S&\EQ=3(BKN!#!4YVA>O3.* /2]6
M\4Z#H5S%;ZKK%E932C*)/,%)&<9P>@SWZ5I37,%O:R74LJ);QH9'D8_*J@9)
M)],<UYW>V.I17-YK6BR:3JGG:;!'JNF7S8?:J$C:XSM+*QX88/6NW\/W=KJ'
MAK2[NR@,%I/:120PD?<0H"J_@,"@#B[OXH6FH>#[[5=!GMFN[6]C@,3.)"(V
MN!$'(&,!ER1]:Z_3/%.@ZS?36.FZO9W=U""9(H90S  X)XZC/<5Y(L,<WP$N
MXG4%7UG8P'<&_7BNU\2K;:;\1O!LT4*Q)':Z@K")0/W:Q(0O'8=A0!TMMXL\
M/WNL/I%MK-E+J"$@VZ3 OD=1CN1W':L_0O'FA^(/$.I:-97D#SV;A4VR@F<;
M0S,H]%)VGW%>?F:^?3/ EWY&C:?I=UK%M-8V5LCM.BON/,A;!X;YOEZGK76^
M!E4>,O'> ,C4X_\ T2M &KXG\<Z-X4O],L]1NH8Y+V;8=\H3RH]K'S&S_#E0
MOU-7=0\6^'M*N+>WO]:L;:6X4/$DLP4LIZ-[ ^IXKG?'84^+O N0/^0HXY_Z
MY-6%'9ZY?Z_X\B@;01#)<B*Z_M))"X@\A-G*D )@L1GONH ]$U/Q'HNC,RZE
MJEI:,L/GD32A3Y>X+NQZ;B!]35>^\9>&]-1VO=;L8-A0,'F (WKN7CKRO/TK
M@]+TB/\ X6/X2M;Z:#46L_#!*SK\Z2LKJH<9ZY!R#^-;7AZQM9_BIXZDE@C=
MA'8Q#<H.$:$[E^AP,_04 =&?&'AM=0M; ZY8?:KI5:"(3J3(&&5QSW[>O:MB
M5BL+L&52%)W-T'N:\0MK.W@_9NTZ:.%%E%S!-Y@'S;_MBKNSZ[>/IQ7M=]_Q
MX7/_ %R;^1H P=*\2VEKX/MM7UOQ!I4\;,RM?V[>7!(=[ !<D\\8QGJ#6UIN
MJ6&L6*7NFWD-W:OG;+"X93CJ,CO7D/@'3)M1^%/@R33]1LK76+2ZNKBRBO%W
M1SG?,KJ5!!X5B<CD5Z#X*OS=Q:M#<:7;:=J5M?M'?):OOBEE*(WF*<#JI7J,
MC'- '00WUI<7ES9PW$;W-MM\^)6!:/<,KN';('%4+GQ5H%GI2:G<ZO9Q6+R&
M))VE&UG!(*@]R"#P/0U@>'75/B?XYWL%^2P;DXX\IN?I7)^$K"?4_"/AF_T7
M4M/CU>UN=1FM;>]!:.YC:=P_ .X8ROS#.,^] 'ITGB31(M$76GU:S73&^[=>
M</+;G& >YSQCK3[;Q!H]WH[:O;ZG:2:<@+/<B4>6H'7)[8]Z\LGO;[4M9\,Q
M6&F:7IM[!JM_'<P3EI+4WBQ@[P5P22&<CN#GN*9XBTR]LK'4Y-6O-*DAOM>T
MTZA;6&X1PKN4.9%8\;@(R<]>M ':#QS::EXN\/6&AZA9WMA?+=_:6B.YE:-$
M91UX^\>HYK9\5W\VF^'KBZ@U2PTR1"@%U?KF%,L!R,CKT'/4US6NQV:?&;P@
M8EC%V;.]$FT#.P*NS/MG?C\:A^.?_))M5_ZZ0?\ HU* .PU'Q)HNC;EU/5;2
MU=(EE82RA3L)VAL>A((%6M-U2QUBQCOM-NX;NUDSLEA<,IQP>17&K:P3_&RW
MEEB5WA\.*T989VDSD9'O@D9]S4_PZ18I?%T4:A8U\17.U0, 92,G'XDT 6M7
M\0:W+XH;P]X=M+!KB"U6ZN;B_D<1HK,5555!EB=I.> *N:'K.IO::A_PDEA#
MILU@^'N$D)MIH]N[S$9@..H(/3%9FMZ)H?B?Q/)';ZM>Z;XDT^W0-/8RF*40
MN25!R-LB9SQS@^F:XKQ%J6NG1-?\.:CJ-MJ8TW4-.#7\L7EJ\4L@)295X^4@
M9QU!H ]5T?Q%HWB%)7TC4[6]$1 D\F0,5STR.V:@M/%_AR_U&;3[36[":[A#
M%XDG4L OWOKCOCI7$:QIOB.&[U?5;N]T2/4$\/7<,=MIP=99!@%'PQ.0K# /
M;=CO6SHMOX77PCX+DN5MUVK;_P!FLI*L9S'T&WJ3\V0>#WH DT_X@Z3XCTS7
M3I6JV-O<Z>9@LL\@= B 8G(&/W>3^G6MI-?L--\,V6IZQK%@(I(HRUXK!(IF
M(SE,GH>H'/%><V04?"WXEX R-1U45)X?5)-2^%J78!MQH<CVX;H9Q%'^H7./
MQH ]'M_$^AW>CR:M;ZM9R:?$<27"R@HAXX8]CR.#ZTVR\4Z#J.K2Z59:O9SW
M\6=]O'*"PQUX[X[^E>5^.E5+GXEI: " Z99-<!.@G+'!^NW'Z5UWB2RMK'Q7
M\/TM8$A6&[FACV+C:GV=_E^G H [VN-T#QR=?\;:GH\%JJZ=:V_FP7A;F<B0
MQN1VVAE8 ]]IJWX]N-7A\,O#HUI=W%Q=2K;R-:!3+!$V=\B@D L "!R.6!KB
MM&O@/B+_ &;9>&M6TZ'_ (1Z.RBCGCC'DJ)'P[8<_+VSR<]N] &J?'NOMHK^
M+8])L6\+I(3M\Y_M;0!]IF QM]6V]<=ZU;_Q+KE_XDNM&\+6FG2M8P1S75S?
MRNJ9D!*(H0$DD#.>@KF+>^MX_P!FV17(#II<EDR=Q/S'LQZ[NU:EMH^K:7XB
M>;P_JNDB_FTZU35+*_W$H8U*I*NPYZ9&#@''6@#J_"OB >)-"COFMS:W"R/!
M<VY;<89D8JZY[\C@^A%<QX>^)$FM>,3ILMC'#I-XUQ'I5Z&)-RT! ?CI@\D?
M2N4L=5O=%^%>I_8;AKO5/$&MW-OILH 4SM+)L\T#L/E9AV'%.US2/%MAX'TJ
MWL_"=K:OX<,=W;W,>IB1\QC+_($&[>-V1GDF@#VJL2_\8^&]+U(:=?:Y86]X
M<9ADG4,N>F?3/O5S1=6MM>T2RU6T;-O=PK*GJ,CH?<=#]*\^\,Q6,OPX\7OJ
M21&5[S4?[1,@&=P9L;OHNW'IQB@"[\0?B$/#FIZ5HVG:CI=O>7DV+F>\.Y;2
M+&0[*&'7/&3CBNPBU6VM?#D&J7^HVKVXMDEEO4^2%P0/G7DX4YR.3UZFO*I?
M/<?!UKL$SL!O+CD_N4QGWQBO7M0 _LNZ&!CR7X_ T <*?B9;:GH&@:KI,ULH
MO-5M[2]BD<.;='W9#$8VG"YYKK]'\3:'X@:9=(U6TO6@QY@@E#%<]"?;WKRF
MUMH+OX2_#BWGC62&76+19$(R'&Z3(/J.U;?C)9;?QQJLE@NRZ;P=>;#&,$LL
M@V].XSQ0!W.G^*M U;49=/T_6+*ZNXLEX8I@S#'!^N.^*D\0:Y9^&M!O-8OR
MPM[5-S!1EF.<!1[DD ?6O/M%TC6+BT\$SS7OANUL;1XI+,VPD2:5#$0T:EC@
MEE)) ZXSVK=^+$$LG@*XN(HFF6SN8+N6-1DM''(K-^0R?PH B.M_$1=/.K'P
MYI'V8)YITT7<GVO9UQNV[-^.U=%+XITFST*TU;5+D:7!<HK*E]^ZD#$9VE3S
MN'H*M?V[I?\ 8?\ ;7V^#^S/*\[[3O&S9C.<UQ<.H6NN?%;0-0(<V<V@2W&G
MB>,J?,:5-Q /1MF/PH [.UU[2+W2&U:VU*TET]%+-<K*#&H'7+=!COFN</CJ
MSU+Q9X=L="U"SO;*^:Z6Z:)MS*8X@Z]^.?4<BN#\4"-+_P ;PQA5T=M8TG[4
M%XCRVWSL]N?DW?K77>)X[6/XM>"S;I&+XV]\/E R4$7R9]L[L?C0!U<7BK0)
MM:;1HM8LGU)25-LLP+Y'48]1Z=:U9)$AB>65U2-%+,[' 4#J2>PKQ;PYI6O:
MG\._#^^]\.VEFMU#<)<2"1;@7 FR06)QYC-N4^N2*]*\=7]MIO@G5;F[LEO8
M/*\MK9F*K+O8( 2.@RPS[9H M:1XIT'7WF32=6M+QH!F1890Q4>N/3WZ5 GC
M;PO)>VMFFOZ>UQ=!3!&)U)?=]W'U[>M<?;KJEM\4M'@U672?/&C70$6G0O'L
MCW1X#%F.X9!QP.AXK 2RMK?]F>SDBA19,6\^\#YO,^TI\V?7''TXH ]7U/Q1
MH.BWL-GJ>KV=I<S#,<4TH5B,XSST&>YJEX&UN[\1>%(-2O?+\]Y[B,^6N%PD
MSHO'T45C>&H[>;Q_X]-\D;2B2VC82@$"W\@$#G^$G=GM3O@[Y7_"L=-\@YA\
MZZ\L_P"S]HDQ^E '=4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 4[#2[+3&NVLK=83=SM
M<S[2?GD8 %CGN<#\JAUO0-+\1V:6FK6:W,*2"1 6*E''1E92"#R>0:KIXN\/
MR:K'I::K;-?23R6ZP*V6,B??7';%)9>+_#VHZLVE6>KVLUZI8>4C\L5^\%/1
MB.X&<4 );>#O#]G;7=O;Z9%'%=VWV6X +?O8_FR&.<G.]N>O/6KESH6F7FA'
M1+FSCETTPK#]G;.W8N,#UXP.>O%4KKQIX:LM4DTRYUJTBO(AF2)GY7C.">@.
M.<=:O6VM:;=W-O;V]Y%)-<VPNX44\O"2!O'MR/SH KZ;X8T;29+:2RLA'):P
MO!"YD9BL;-N9<L3G+#/-22>'=(FBU**6PADCU-MUXCC<)C@*"0?8#IZ5A>./
M%ATGP1K^I:+=0O?Z85C<%=PCD+)D,/\ =;]:OR^+=*TC1-,O-<U&"UDO($=0
MW5VV@MA1DX&?PH ET[P=H&E6E[;6>G(D=['Y5R7D=VD3!&TLQ+8P3QGC-+K'
MANUU#P;<^&[=(X+5[3[+$I!98E PO?)VX&.>U9OB'XB:%X?M-(NGNX)X=3G1
M(G23Y?+)^:7(!R%]*MP:PMUXO@@M]<M'M9M-%S'IXB_>N"W$P?/W<<8Q0!T$
M:".-47HH %95OX8T6UTN_P!-AL(TL]0>22ZB!.)6D&')YSR!VJN_C?PQ'J_]
ME/K=H+P2>28R_ D_N%NF[VSFI=4\7:!HLLT6HZK;V\L(0O&Y.X;\E>!R<A6Z
M>AH T[*SM].L;>RM(A%;6\:Q11CHJ*, ?@!7'ZYHVI^+?%.F6]]I,=MH>DW@
MO?M$DR.]W(H(1549*KDY.[KC%;T_BS0+;1(-9EU:U73K@@0W ?*R'GA<<D\'
M@<\'TJ[I>JV&M6"7VFW<5U:OD+)$V1D<$>Q'I0!'K&AZ9K]F+35+1+F%7$BA
MB048=&5A@J?<$5!IWA?1-*TVYT^STZ)+6ZW?:$;+F;(P=Y8DMQQR346J^,?#
MNAWR66IZO:VMRP#>7(W*@G +?W0?4XJ;4_$^B:-(8]1U.WMG$0FVNW)0MM!
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MK'I<>JVS7TDTENL"MES)']]<=L5;U?6]-T&R^V:K>Q6D!8('D/WF/0 =2>O
MH JZ)X4T3PZ\TFEV"PR3*%>1G:1BHZ+N8DA1Z=*KZ=X&\,Z3JHU*QTB"&Z4L
M48%BL9;[VQ2=J9_V0*LCQ5H+:$=<&K6O]F X-SO^4'.-OKNSQCK20>+-!N=&
MEUB'5+=["%]DLV[B-L@88=0<D<'U% $(\%>'1=:G<C3(Q+JB/'>X=PLP?&[*
MYP"<#) !J>[\*Z'?Z-:Z1<Z=&]C:!1;QY8&':,*58'<"!QD'--T[Q?X>U?5)
M--T_5[6XO(P28D?D@'!([,![9IJ>,O#DFN'1DUBU;4-YB\D/_&.J9Z;O;.:
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M7(S\N,EN/2KVGZC9ZM817VGW,5S:S#,<L3;E;MU^O% %JBBB@ HHHH ****
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MR8?"6AW%W?;X[;6!,(_)1UV[I(R"6D4$_,O7CI772>"=#O=%TK3=4L8KX:;
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M?\(<GV7?_P ]-Z;]OOLQ^%>GP:386T5Y%#:QHE[(\MRH'^M=@ Q/N0!5&_\
M!_A[4].L]/O-)MY;6R 6V0@CR0!C"D<@8 []J /)-3V-)XK_ +,>U2U_X2NQ
M\YIE+0#[FXR $97S,9Y%=1JFF:LEWXAU#6-6T:2\/ARXA:TL(7B=DY*R,&=B
M0#N /^U7<0>%]"M;*[LH-)M$M;M56>$1C9(%4* 1TX  _"H]-\(Z!I%I=VMA
MI<$,-VFRX !)E7!&TD\D8)XSWH I?#JU@M?ASX>6&)4#Z?#(V!U9D#,3]236
M9\(/^2=6@7_4"YNA#_N>>^*V]>LM0MO"ATKPS;1Q3-&MI Q8*EK&1MW\\G:O
M0#))Q5[0=&MO#V@V.D68/D6D*Q*3U;'4GW)R3]: .6\(>5_PFGCO[7L^U_;(
MMV_&?L_DKY?7^'[WZUQ7A>WBN5^'*21A[0:GJ;VJL,CRU$C1D>PP"/H*]4UC
MPAX?\07*7.JZ5;W,ZKL$C ABO7:2,9'L>*O'1].\VPD%E"K:>"+3:N!""NTA
M0.!\O% '+Z*H3XN^*=H WV%BS8[G]Z,G\*B\6$#XH?#\DX_>7_\ Z(KL(].L
MX=1GU".W1;N=%CEF ^9U7.T'Z9/YU5UOPYH_B."*'6-/AO$A??&)!RC>H(YH
M Y3PI:6[Z]\097A1GEU#RG8C.Y! GRGV^8_G7&^%!K$DG@+^SKC3XI?[ G%N
MVH0O*F\2)O"!64[]F._3->RVNEV-BUTUM;1Q-=/YDY4?ZQMH7)_  ?A5&Y\(
MZ!>:/;:3<:5;O8VN#!%@CRO]TCD?@: ,[P+ITVG6NK^?J.GWLL^IRS2"P0K'
M!(0H=,%F(.X$D9ZM6?X<,/\ PLKQW]K*>:/L>/,Q_J/)]_X=V[/O78:;IECH
M]A'8Z=:Q6MK'G9%$N ,\G\2>]4-6\(^']=O8KW5-)MKJYB78LDB\[<YVG^\,
M]CD4 >7^#[L_\(MX3TW1K;3VN;K4=0DLKJ]C9X[9(WD)954@EBK8'([U1UV2
M9OA_\3%N+NVNI5U.W\R6VB,<;/\ N Q"EFQR,'DY(->N77@[P[>:;'IT^DV[
M6D4S3QQ@$;)&)+,".022<X]:7_A#_#H2ZC&CV@CNH%MIT6/"O&H 52.G&!CO
MP* .5UM=:D^+T']DW&F0R_V'^Y.H0/*I_?'S-FUUPV/+SUXK=\!Z<^FZ'=1/
MJ-C>[[^XES8J5AB9G):-02<8;=QFK$O@?PS/I-KI<FCV[6=JS- G.8RQRVUL
MY&>_/-:]A86FEV,-E86T5M:PKMCBB7:JCV% 'FGB35F^'GB[6[R-3]GUZP,]
MJ@'!OX\(% _V@R'WQ1::"GAKQ+\.M*NB&CAMKPEVY#WC(K,WU.7Q6_JFBZKX
MH\7::=2TZ"UT31KHW<3F8227<H!$9  ^11G)!Y) KIM6T73=>LOL>J645W!N
M#A)%SM8="#U!]Q0!Y1XY4-J?Q&^Q@&(:%;?:MG3SMSD9]]GZ5TWBN[MWUOX?
M1),C/+J E0 YW(('^8>WS#\ZZS3O#>C:5IDVG6.FV\-G/N\Z()D2[A@[\_>R
M..<U3T[P/X9TEXGL=&MH7BE$L;@$LK $ @DYX#-QTY- '/\ PRM8%O/&EV(U
M\]_$EW&TF.=J[2!GTRS'\36QXOTY]0N]&>PU6VL=:M9WFL5N4WI,?+*NI7()
M^5CR.16[8Z99:;]I^Q6R0?:9VN9M@^_*V-S'W.!46L:%I?B"T6UU6RBNH5<.
MHD'*L.X(Y!]Q0!Y7J%_J5_?Z-"++2-.U*U\1R0WC[&EM)KK[-NCD."K$D, ,
MG(8#/2H_&FFWMKX4\>7FJ:II=Q=7$%D+FVTZ)H_**R#:S*SL<LI'U"BO3U\)
MZ NA-H@TFU_LUCN:WV?*6SG<>^[/.>M87BCP5 /AYJFA^&=-@AFNBCA%8+YC
M"122S,>3A>Y[4 5O%2V8\1_#X::(MXOF^S^5C_CV\AM^,?PXV_I7(WM_>WOA
M+0-45M(T[2+S7+>6TT^"W8S FYR6,A?&[[Q;"]R*]3T[PCX?TC4Y-1T_2;:W
MO'!4RHO(!.2%[*#Z#%5_^$"\*_Z9_P 2*S_TS_7_ "?>^8-Q_=^8 \8Y H P
M?"EK _Q9\>W31JTR-9(KD9*J8 2!Z9P,_05R6IW][>^#=-U1&TC3M(N];ADM
M;"&W8SEOM0RQD+X#\,QPOJ*]@L](L-/NKFYM+6.&>Z""=U',FQ=JY^@XK*/@
M/PJ6O6.AV9-[GS\I][+!CC^[E@#QCD T 8GADC_A9_Q"&>?] X_[=S7GWA3;
M_P *J\!?:,?8?^$C'VC=]W&^7;N]M^WK[5[,/"FA+K4.L+ID U&&,1)< '<%
M"[0/?Y3CGM3H?#&B0:"VAQZ7;#2VSFT*90Y.3P??GZT <EXFVGXH:?\ 9L>>
M-"O?MFWKY65\O=[;\X_&N?EMH+?]GSP\8HE0J]A,"!R':=,M]>3^=>EZ3X5T
M+0H[A--TR"W%P-LS $M(.F"QR2/;-3MH.E/H\.D-8PG3X=GEV^/E7805Q]"
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MI-C"98S<I?69E)MS;J%;<)% 3&X=.H--TS3(+;QWX!M6NDU!+30IO)N@N!(
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MQ6K3*[Q!\_.%V[L8')^9>.IR,5%I_BW0=4TJZU.TU.%K.T)%Q(^4\G R=X8
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M:'['YD]Y*L0&6?>,$Y 7Y20 #6IH\MH?B_8&9D-P_A.#R"QY/[UBV/?'Z9H
MN^//'!M/A?=>)O"^H0RD/&L4X0,!F158%6'!Y(P1D5TNK^*]%\/K;C5K]8)9
MT+(@1G8@=6VJ"0!Z]*\;\7%'^&GQ$DMR#9OXB!B*_=+;H0Y'_ L_CFNSFAUI
M_BIJ(T[4M/LIFTBU,7VVU:8O$&DW;,.N &Z]>HH ]%M+NWOK2&[M)DGMYD#Q
MRQME74]"#7#V/Q#L-/U+Q%#XAU..%+34W@ME$18K$(XSDA 3C+'YC^=;/@&P
MCTWPA;6\.I6^HP^;,Z7%LFR,AI6;:HR< $D=>U8?A6WA:\^(4AB4O)J<D;L1
MRRB!, ^WS'\S0!U.I>*=$TFPM;V\U")8+O!MF0&0S C.4502PQSD"D?Q9H*:
M39ZJVJ6XL+R0103Y^5G.>,]C\K9SC&#FO*?"\>K2W?@?[!?V=G(_AMUMWO;<
MS*S"1-ZH ZX;;M/7H#4VLZ1'%HVDP7&IV>JK>>-H9)S;0^7$C-D21[2S?Q!B
M>?XC0!Z.WCOPTND6VJG5$-I=.T<#")RTK+][:@7<<8Z@5=B\3:--9:?>1:A"
M]OJ,P@M9%R1+(<_*/0_*W7&,&N0\21:J_P 5])&G7UE92/I$RV[WEL9E9A*A
M=4 =<-MVGKT!K#N+(:7!H<LNL6>H"7QF)II;6+RHH9&C=63!9L?.">O5J /4
M9]:TZVOY;&:Z1+F*U-X\9!R(0<%^G3-95OX^\+76H6MC!K$+SW>T085MKEAD
M*&QMW$$?+G/M7+ZY<PS_ !,UR**17>#PE*D@4YVL92<'WP0?Q%4;N"*#X+>"
MO*C5-L^E2# QAF="3]26/YT =UJGC30-+U"33+G5(H[]4!,>UB(RWW=[ ;4S
MVW$5E^'O&UM'\/\ 0]:\1WZ1W-]".5C):5^<A40$G@=A67X:GL8+?XB#5'C#
M+JMRUR)2,^08EV9S_"5R!^-<MX6CU1V\ "POK.SD?09UMY+RW,R&3S$+JH#+
MAMN.<] : /6/^$KT'^R;75?[3@^P74RP0SY.UI&) 4^AR".<8QS5G1M;T[Q!
MIXO]*N1<VI8H) K*"1UZ@?G7DVOZ0L7AI(;G5++51>^,+=[C[+#Y<<;L562/
M:6;N"3SU8U[2  , 8 H \]F^)EE?VGBVWTN39>:3;3/:R%&/FE(=Y;!7 PW&
M#UQ6KH'CW0]133-/EU6%M6N8$+)L8*\NP%E#8VE@<_*#D=*Y)&7^SOBZFX;L
MS';GG'V6KFL016_@KX<I%&J*FJ:9M"C&,KS^>3^= '7W?C;PW8:Q_95SJL,=
MX'6-D*L51F^ZK.!M4G(X)'6J3>/M+7QZ?"K-B80*_F;6_P!:7P(\;?3G=G%>
M?^+]0O;[P-XMOHKK2],TS[?-;_8H[/=-<RHX4N[[QAR5W<*<  ^]=?:NH^.5
MWEAEO#L)&3U_?M0!V>HZC9Z3837^H7,=M:PKNDED;"J/\\50TCQ9H6N074VG
MZE%(EJ,W&\&,Q#&<L' (& 3DC'%8/Q+98[/PY-.0+&/7K1KIF^ZJ9;!;_9WE
M.M9GQ/FTJ?0/$T%B%?7UTE&N&B0EA:^:"0S#CIO.#SC)Z4 =5I7CCPWK=^EC
MI^J1RW$BEHD*.GF@=2A8 /C_ &<U#>_$'PII\CI=:S"C1RM%( CMY;*VT[L
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MKLQ # V><V/TQ7>4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[BSCA>[N;J&T@-P2(D>1PH9R.=HSDT :G]D:=B]!L;<K?'-T#&")SC;\X[\
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MNG*JV;^4,PA3E0I[8/(JO:>./#M[JZZ9;ZB'N'D:*,^4XCD=<[E20KL9A@\
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MU_Q&-(OKZ\C=BMFLJH),E;8#'I@%CDY!YK1FUF^T?X@6VF7TWG:9K,3&Q8H
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MF55EF5 '<+G:&;J0,G&>F: /$M(EL[;0?AR]Z42V37KT9?A5/F3;?IAL5?\
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ML0QAL@J6CP.ZD_C56YUJXU2[UZ6TN[#0+6TL+8S!K)9+BY\R'>JDDCY5W;%
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M4Y!*K&K8/U!'X5[#JNB:7KENMOJNG6M]"K;E2XB#A3ZC/0TT>']%%M-;#2+
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MX<$4OQ4\93IM<FVT\*XY^4I(>#Z' H UY/'/AR+2=.U1M27[%J)9;:41N=[
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M222  .237&Z'$A^-'BN4J#(MA9JK=P"&)'Z#\JW?&L.EW/A>>#5[Y["UDDB
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MF:"WNWMG6WGD&<HDI&UCP<>N.,UTU %=[&TDO8KV2U@>ZB4K'.T8+H#U ;J
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MQQCG% %^PT'1]+N)+C3]*L;2:7_626]ND;-]2!S5A;"S2WF@2T@6&<LTT8C
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M*:5J4UL+62ZM8Y6A48"$J#@>WI[5;O=*T[4FC:^L+6Z:(YC,\*N4^F1Q5L#
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M[I5(RI.<#^]FNP\(W>B:%X9T*PAU.>>/4'E-E)<PE'G+,TAX"@ <DC@#&,4
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M[>#Q#922RN<+&@8Y8GL/>GZ)/;WGQ9URZMI8IXI-(LVCEC8,K*6D.01U!XH
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M>*/'3A1N.K@$]R!$N/YG\ZE^)9^SV7A_4I0?L6G:W;7-VV,B.(;EWGV4LIH
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MG'I%M;M- =Z22J6=L$<':I&<=* /6K_6[/3KS3;6X+B749C#;[5R"P4OSZ<
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MZAI=J9))M/VBXD"?NU=AD)N[MCD@=.]>;2RQ7GP>\*>'((1/K&JVENEBN2#
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MELY^\0N<8SWJ2_\ '=C9ZQ?Z1!IVJ:AJ%D$:6"RMPYVLH8-DL!CD#D@D] :
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ML>X94D D$$=""1P:AUWQ7::'?6FG_9+Z_O[M6>.UL8@[[%QN<Y( 49 R3]*
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M%4:^N+>VWQVFY0W[PY!R%()V@X% '5O%'*%$B*X5@PW#.".A^M!BC,HE**9
M-H?'('IFN+OO',UM\0[#P]!IEW<6DUHTS310AMV60*ZG=]P MN..N*?HGB/1
MK=O%EX^J:D\&FWCB\-^X9(",Y6$#G9Z#K0!U\\$-S"T,\22Q-]Y)%#*?J#21
M6T$!!BACCPH3Y% ^4=!]!7-Z;XZL;_4K.QGTW5=-DO@39O?VXC2XP-Q"D,<'
M'.&P:I3_ !/TB*WNKJ/3M7N+6RFDAO+B"U#);%&*L7.[IQGC)P02!F@#L3;6
MYA>$P1F*3)="@VMGKD=\T6]O!:PK#;PQPQ+T2-0JC\!2&Y0V1NX@TT?E^8@B
M&2XQD;?4GM7DGA/Q9?:GXP\1ZKJA\1"UTZXF6*V556V@B2-B5E7/^LX]^<<T
M >MW-I;7L0BNK>*>,'.V5 PSZX-)/9VMU (+BVAEB!!$<B!E&.G!KF+'XBZ+
M?:1=:QY-_;Z5;VZSF]GM]L4F['R(<DLP)VD => 35C2_&MGJ&K0:9<:;JFEW
M5U&TEJNH6XC$X49;:0QY Y(.#CM0!OM9VKLS/;0LS@!B8P=P'0'Z5)+#%.H$
ML22!2& =0<'U^M<4_P 4]$6S-\++56T^*<P7-XML#%;,'V?.=WK@\9X(SC-:
M.G^.=.U#7;;2OL>HVSWD;R64]S;[(KI5&28SG/0YY XH Z3R8O/\_P I/-V[
M?,VC=CTSZ5&ME:)=M=K:PBY88:81@.1Z%NM4]<URU\/Z>MW=)/+OE6&*&WCW
MR2R,<*JCN3_2LM/'6EC2;Z_N[>_LGLI$BFM+BWQ/O?&Q54$ABV1C!- '2)%'
M&SLD:J7.6*C&X^I]:<RJZE6 92,$$9!%<U:^-[":UU22YLM0L+C3+8W<]I=P
MA)3%@D.H#$,#M(X/48.*I6_Q,T>XBM;D6.JI875Q#;PWLEL%A9Y<XPV[H"-I
M., ^M '66UG:V49CM+:&!"<E8D"@GUP*DBABA#"*-(PS%B$4#)/?ZUFZIX@L
M])U/2M.F65[K4YFBMTB4'[J[F8\\*!U/O7.^'O%6B6?A;6-7.IZK<6=IJ$L4
MKZ@?,D$F5'EQA>JY("CKDT ;/BSPZ?$6EQ);SBVU&TG2ZL;DC(BF3ID=U(R"
M/0UKVL)CB#R0PQW,@!F,0X+8YYP"1]:Y_3_'6F7<UY!>VU_I$]I;&\DBU*$1
ML8!UD&"00.AYR/2G:/XVL=8U""R-AJ5C)=1--:->V_EK<H,$E#D\@$'!P<'.
M* .BEACGC,<T:21GJKJ"#^!K TCP[-;^)M3\0:E-'->W*BVMECSMM[93D(,]
M23\S'UQCI6?\2-7ET31=+O8[N6VC&KVBSO&2"8C)\X..2",Y'>KVD^-+'4]7
MDTN:QU'3+P0&X2/4(!%YL0."RD$],C(."/2@#HI(TFC:.1%=&&&5AD$>A%1P
MVEM;A!!;PQ!%*KL0+M!.2!CH,US>F^/]+U.^M(4M-1@MKYREE?7%OL@N6 )P
MC9SR 2-P&<<5%??$;2+"[ND>UU*6RLYOL]WJ,-MNMK>3(!#-G/!(R0"!WH Z
MP0Q#S,1(/,Y?Y1\W;GUIEM:6UE$8K6WB@C)SMB0*,^N!6!JGC6ST_59=,MM/
MU/5;N")9;A-.@$GD*W*[B6 R0"0!DD=JCG^(.A0Z=H]^CW%Q!JS,EKY,)9F=
M03L*]0V05QCKQ0!TLD$,Q!EBCDP"HW*#P>H_&DM[6WM8!!;P10Q#I'&@5?R%
M<A%\2;":2ZM8]%UQM4M6_?::+0&=4(!#XW;=IR,'=SZ5=/CO2&T#3-7M4N[Q
M=3;99VMO%NGE89W+M) &W:V22 ,=: -Z#3[*V4+;V=O$ V\".)5PW3/ Z^]*
MMC:)=M=I:P+<L,-,(P'(]VZUSX\=Z4=&EU!H+Y98KH63V#0?Z2)SC$>S.,D$
M$'.,<YK1T+Q#;Z\MRJ6MY9W-JX2>VO(O+D0D9!X)!!'0@F@#1^RV^V5?L\6)
M3F0;!\_U]:>T4;E"T:,4.4R,[3ZCTK"UKQ=:Z/J*Z<EAJ.I7IA^T/!80"1HH
M\X#-D@#)! &<G!P*XOXD^.9SX:T-_#TFI)!J]W IOK2, ^4Q;,:D\K+E>F.Q
MH ]--E:-=B[:UA-RHP)C&-X'INZTDEC:2W274EK ]PGW)6C!=?H>HKQ[Q+XC
MU*+5O"?AVV7Q=:VDS3M<L0HO;D*H90KYYQDYZ<8KNKGQUIVD;K4V6LW8L8(W
MOIX[?S/L@*AOWQR#NV_,0H)'6@#IY+&TENDN9+6![B/[DK1@NOT/458KG-5\
M9V&FW%K:V]K?:K=W,'VF.#3HA*WD]/,.2 %).!SSVK UCXFQ1'PW+H]A>7MO
MJER4D*6^6 4.&C + B4,HR#V!H [E-.L8G=X[.W1I&#N5B4%F'()XY/O3C96
MIN6N3;0^>Z[&E\L;BOH3UQ[5R3>(M.M/&6L;KC6Y+JTTI;N:P)4P+&,'*)_S
MT['GUK7N?%NE6O@W_A*I)7.F&V6Y!5<L5;&!C/WLD#'K0!GZWX7U#7M1M+*>
M>R@\,VTL<YM(8CYL[)@A&.=H3< < <X%=;7*:AX^T_3[B:'^SM5N3:PI->M;
M6P<6:LNX"3GKMY(7<0*Z>WN(KJVBN()%DAE0/&ZG(92,@C\* %,,1F$QC0RJ
M-H<J-P'IFHIK&TN)XYY[6"6:/[DCQAF7Z$]*JZYK=GX?TQK^]\UD#K&D<*;Y
M)78A515[DD@5D1>/--;3-8N[FSU"RETB(37=I<PA9E0@E6 #$$'!Q@]C0!TS
MPQ22)(\2,\9RC,H)7Z'M0L,22O*D2+))C>X4 MCID]ZY>T\?Z9=ZK86?V+4X
M(=0)6RO9[?;!<-MW85LYY )&0 >V:S_$7C^S33?$$%E;:HPL8IH)-2@@_<03
MA#\N_.[()&2!@=R* .SBL;2"XDN(;6".:3[\B1@,WU(Y-2F&(S"8Q)YH7:'V
MC=CTSZ5E>$KB:[\&:'<W$KRSRZ? \DCG+.QC4DD]R36'HFI7GB+Q=K=^MS+'
MI.CR-IUM C$+-. #+(X_BP2%4'CJ>M '8I#$DCR)$BR28WL% +8Z9/>F?9+8
M1O']GBV2-N==@PQ]2.YXKRSP@WB[Q#X$L_$=QX_DLY)HY)&62PMC$FUV7D[0
M<?+ZBM&'6O$&O_":P\5P,UKK-HC7AAC)6*Z6-F#*R]U=!D>A((H ]&:*-W1V
M16=,[6(R5SUQZ5P.J^#?$NKQ7VE76KZ:^EWTA$UW]D*WI@+;O*RI"'CY=V.G
M:NSTC4X-:T:RU2V)\B[@2=,]0& .#[\U5T/Q'8Z_87-W;>9$MK<26UPDZA6B
MDC.&##)QZ_0T :R*J(J*,*HP!Z"H!I]DKR.MI 'E8-(PC&7(Y!/')KF5^(ND
MS:7IEY:6>I74NJ>8;.S@@!FD1#AGP6 5?<D=14H\?Z/_ &#>:K)%>0BQN$MK
MJUEAVSPR.RJH9<XQ\ZG()&.E '3F*-I%D9%+J"%8CD9ZX-1)96B73W26L*W#
MC#3",!V'N>M5+W6[2QUO3-)F$GVG4O-\@JN5'EJ&;<<\<'BLG0O'>G>(]0^R
M:;9:E(JM(DMP;?$,+H2"KOGACC( SP1G&: .G95=&1U#*PP01D$5!#86=M;M
M;P6D$4+9W1QQA5.>N0.*SO$'B6S\.I:+/#=75U>2^5;6EI'OEE8#)P"0, #)
M)( KE=&\8QS>,?%-U>W%W::;I^GVTDEM>*5-LW[POE.>2 IXSGC&>* .^2V@
MC9&2&-61=BD( 57T'H/:G>3%YWG>6GF[=N_:-V/3/I7/Z/XSLM6U!;&2PU+3
M;B2$W$"ZA (_/C&,LI!/3(R#@C/2JVF?$'2]4O[.".SU*&WOW9+*^GM]D%RP
M!.$;.>0I(R!G'% '4R11RKMD177(.&&1D=#08HS*)2BF0# ?'('IFO,9?'^H
M:QH7CJ./3[^Q;38+@6MQY6PQ%(0<.P8XDW$D8[8K:T+Q]92QZ'9W5IJB?;XX
MX8-1G@Q!<2[,X#YR2<'!(P>Q- ':+#$F_;&@\PY?"CYCZGUJ.ULK2R5EM+6&
M!6.6$484$^IQ4]<7XC\;7.B>-M$T2'2KRYBO$F>5H80Q8*HQY?S#H3EL]!B@
M#K_LT'V?[/Y$?D]/+V#;^72DDM+::>.>6WB>6+_5R,@+)]#VKSG2?'3:7=^+
M$O;;6-4%GJ\Q(M8O-%K;A$QDD@!<AR ,G@\5U%[XUTVVATUK2"]U.;4H/M-M
M;V,0>1H< ^8=Q 5?F'4CDXH W_LT'D>1Y,?DG_EGL&WUZ=*EK/T76;/7]+CU
M"R9_*<LI21"CQNI*LC*>C @@BM"@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \'\0ZX
M-6\*:A<ZAXCNVU5=0(DT2 HL=K%%<CF1 N[ 50VYCR2*] \)RPW/Q'\:W,$B
M2Q2II[)(A#!U,!(((ZCFNT^SP[Y&\F/=(,.=HRP]_6G*B)]U57H.!CITH \8
M\,*#9?#@$ C^U]3_ )W%;^L?\CKXV_[%F/\ ]K5Z0(T&W"*-IR..E!1222HR
M1@G'44 >.65G,?@/X;UNT0M>Z%LU&(#JRH[>8OT*%OR%2/8W'BWP/XZ\36D;
MRRZR&BL% ^9K6#Y5"CU8ASCOD5Z^$4)L"@+C& .*555%"J  .@ H \R\/G0=
M7\4:)<6_C/5-<N[>.2YA@8PLD *;&\W9&"APV,$CD5'X(731\%;S^U;>273W
MDO?M20J6<IYS@D <Y Y]L5Z='!#$SM'$B,YRQ50"Q]3ZT]55%VJH ] * /(5
M\4W^CPZM;^'O$@\4V4&CS7<3R!)I+.12H17D3A\@L<-\WR4RRU'3?^$_\(7$
M?BRYUI&$\<MU-)'Y$<TD7R1KM4!78@_)DD<#N,^O16\, 80Q1QACDA% R?PI
M$MH(T5$AC5%;<%"  'U^M '"?"NU@N? %S!-$KQ3WUZLJD<.#*P(/X<5S?A:
MWO+_ ,1Z7X)O5D>#PC=2W,TCCB51@6?_ (ZY./\ 8KUN\CNA83+IIMX[HJ?*
M,R$QAO\ :"D$CZ&L?POX<FT3[?>ZA>+?:OJ4PEN[E8]B\#:B(N3A5' R2>2>
M] %/XG:?=:G\-];M;*)I9S"'$:#)<*ZL0!W)"D8K!\0>(M(\87W@^R\/WL-[
M<C5H+^1(&#-;PQJQ<R ?<ZA<'')Q7I=1QP0Q.[QQ1HSG+%5 +'W]: //O!O_
M "6#XB?6P_\ 1+58^+$J6V@:/=S,$M[;7+.6:0](T#\L?05W@10Q8* S=2!R
M:1XTE0I(BNC<%6&0: .&TJZM;_XO7MY:313P2Z!;M'-&P964S2<@CJ*XF>!A
M;37\E]<6%E9^-;TW-W;A=UNKAD$AW @ ,P!)'&ZO;UCC3&Q%7 VC QQZ4>6F
MUEV+M;.X8X.?6@#B?!,&DS:[J^HZ=XBO]=F\N&WGNIC&T1QN951HT4,1N.>N
M,BJ^LZC9^'OB]::GJ]S%9V%WHCVD-S.P2,2K,'*ECP"5(//7%=[%%'#&(XHU
MC0=%08 _"B6&*=-DT22+G.UU!&?QH \8A\2/#!XNU+3+K[%:WGB&UB>_:,'R
M('2,&<!AC!'()&/F!J2WN;*3Q7XBAL];NM66Z\./%:W-U*KFY=3(66(JH#@9
M[9YW>E>QM%&RLK1H5?A@5X;ZT+#$FS;&@V#"84?*/0>E 'B4%[8WOA7X=WT6
MO/96>FQ?9+Z]M'0M9RO %4/N#!1D%22.-WO7>>!+?2FO=;U#3==OM::>2**>
M\N-AC=HU./+9%4-@-@D9Z"NO%M L;QK#&$?.Y0HPV?4=Z?'&D48CC141> JC
M 'X4 <!\0Y_^$7U71_'*1LT5B6L]05!R]O+]TG_=D"G_ (%6%=Z/<Z)X \-Z
MMJ$;&:/78=;UA@I)7S"Q=B/]C>GX+7:^(O#>H^)=0@M;N_MX_#L<D<TUI'"?
M-N60[@CN6P$W ' &3C%=21D8/2@#S>^U"R\6?$;1GT"ZAOXM.T^\:ZGMG#QK
MYJJL:%AQN)!..O%<C+XDTJ3X&Z7HD5W')JD36D4]HIS) 4N$W&1>JC(QDXY(
M]:]RA@AMTV0Q)&N<X10!G\*06T =V$,8:3ER%&6^OK0!Q/AY5/QA\9M@;A:V
M !]BC_X"MGQN-(;PQ,NN/<16#2Q!KBW)#6[;QLEW#[NUL'/;O70A5#%@H#'J
M<<F@@,I5@"#P0>] 'BNL7VH:GX>UW3+;Q _B#3--:RO%U*V1&E0";,D9904D
M950/G'U!K5BCT34+O4+RS\7ZCX@O+71KG#,T3PQ1R 9#-&BX8E00I.>#Q7J<
M4,4$?EPQI&@_A10!^0JI?:;'<:1>V-ND<!N89(\JN "RD9./K0!Y!+KNEZO\
M&_#WANPN8FUJX%A;QV2G]\C*\;,Y7J%VJ6W=,$'/-2>+M8;4['QG;7WB&\M[
MZW>>UL]#M"BF6(1 AV7:7=6!+$YP *]3\.Z*NB:!I=A)Y4MQ96<5LTZI@MM4
M#COCBM/R8O.,WE)YI&TOM&<>F?2@#S30;BUO_BMH]U;2QSQ'PB"DB,&'^O4'
M!_,5C^+-8;4H/&=I?>(;RVO;<S6MCHEIL5IX_)!#LI4NZMDDG(  ->QI%''C
M9&JX&!@8P/2CR8O.\[RT\W&W?M&['IGTH \ILM:TRW\?>$-0FO[=+.Y\.-;P
MSM( CR[T^0-TW<8QZ\5@FQN=0\.?%:"TA>:4:UYOE(,EU2178 =\JIXKW(VT
M!5%,,9$9R@VCY3[>E/5%4DJH!8Y.!UH \XU[Q!I/C#6?!]IX?OH;Z>/5(]0E
M^SMN,$"1ON\S'W,E@,'!SQ5/3E ^#WCG ',NKD^_,E>HQP0PL[111HSG+%5
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MK_:I^RQ-G+_,"H.0%R1@;LUYKJ-Y8 ^/8H-:N=22X\/J;:YNY58W(0RAS&5
M#*I.,@=<U[K)&DJ,DB*Z,,%6&0:;Y$.%'E)A5VCY1P/3Z4 <#XG 6S^'H
MU>U  [?N)*YVSU_2]$\!>,/#^HW$::RMQJ""R;_6S^:6*,J]64A@<C@#DU[&
M44XRH.TY''2F&"%I?-,49DQMWE1G'IGTH QO!7_(A^'O^P9;?^BEKG_AE^[T
M'7[1_P#CXMM:O4F!Z[B^X'\017> !0   !P *P+;P[+I_C*ZUFQG1+748E%]
M:L#\TJ#"2H>QQ\I'? /44 >.> T^%#> -._X2-M*&J;'^T>8["7.]L?=.<XQ
MTKT+P3?WB_#?5+O56N380O=-8R7@(E:R4$QE\\],\GMBN\%M I!$$8([A!6-
MXKT*X\2Z6FDK="WL9Y5^W$ [Y(1R8U/;<0 3Z9]: *'PP@EMOAEX>CF!#_8U
M?!]&^8?H17&>,A?>'_%&K:/IJN$\:0QQV[*/EBN=RQS-[?NFWD^JUZ]'&D,2
M11(J1HH5548  Z 5S%MX;U&Z\7)KNN7]O<"R62/3;6VA*)"'X+L226<KA>P'
M/'- &#>+I_@SXBZ'<W<D=GHO]AOIEO/*=L<4BR*P5F/"Y4<$]<5S'B"0:MI7
MQ"\0:>#/I4USIOE3Q@E9A;NAE=?51TR./E->URQ1S1F.6-9$/56&0?PI51%0
M(JJ$ P% X H \YOO$6E:_P#%#P9_9%[#?10K>F2:W;?&I:$87<.-V 21U'&>
MHJ[\)%5?!]P0 "VIWA/N?-8?TKMX[>&%56*&-%7) 50 ,]:>JJ@PJA1UP!B@
M#@_&EW!H_CSP=K.H2K!ID)N[>6XD.$ADDC786/;.UADUQVNSQ^*;[XB2:(6N
M8VTVQ:.2 9\\1NS,4_O?=91U!([U[9)%'-&8Y45T;JK#(/X4+&B?<15P .!C
M@=J /+M.FT>]URTU'3?%VI^)-2L;*XNK:W)B>-,Q[=LGEQJ5)R %)!R.G%<^
M-<M+M?!FJ77BRXU&X.H07&H1EXUM;$LCC#!5'ED,=H#'/#5[?'!#"6,42(7.
M6VJ!N/J:06T"JRB",*[;F 088^I]Z /'SJ%G!I?Q7TJ:YBCU"22[G2V9L.T9
MMQ\P'4CWK>\0@+X;^'@   U?3P .W[MJ]#,$)D,AB0N1M+%1DCTSZ4XHI !4
M$+R..E %.QUFPU&]O[.UG\R>PD$5RNQAL8J& R1@\$=,UQ7C/4+/2/B;X+O]
M1N8K6S6*^C:>9MJ*Q1, D\#-=O::;!9WM]=QES+>R+)(6(XVH% 'M@9^I-69
M(8I@!+&C@'(#*#@^M 'G_A@#^S_B$<#)UB[R?^V,=<?I,<=HWA"^O_$-UH%E
M<>&8K>*]B:-$,J-N,;-(K 95@1TSMKW((HSA0-QR>.M,D@AEB\J2*-X_[C*"
M/RH YKP#;:=#H$]QIE_>W]O>7DUP;J\50TK$X9EPJC:2N0<<YS74T@
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M^&  Z:C8?A_H[U1T+Q;HGA^#QU;ZI<);S-K5[)$C@YN<A1M3^\V1C Y&1ZT
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MMY4G(Q]*M>/+B/2/$_@_7[TE-,LKJ>.YFP2L1EA*HS>@SQGMFN1UV=/&6O\
MC-="W7*S>&XXX)(U.+DK(Y.P_P 0)RN?44 =_IWCF"_NHK:71M6LI;F![BR%
MS$B_:U49(3#'#8(.UMIQ7$>#?$MWJ/C#Q)K&M'7XK73[N=%5YE6TLXD0DK+&
MK\OCT#<XYK0\.-X<UCQ)HDMIXHU[6+VV5[A()I$=+4^65;S0$!0_,5P3G-9.
MF:==:KX:^+%C9HSW,VJ78C1>KG&=H^N,?C0!W^C^-K;5=1M;*;2M3TYKV-I;
M)[V)56Y51D[=K$@XYPP!Q573/B/I^KQW,]GI>JO:6L<[7%R85$<;1;LH3NY8
MA<@#LRYQFN>\-GPYK'B#0GMO$^O:M?6X:X2VED1TM#Y95O. C!0_,5P3G-2>
M"E"_!S6L#!9M2)]_GDH WK+XCZ7>Z+/K7V#4X=+C@CE2YE@ 6=G( CC )+/N
M(7TSW[U=T[QG:74UY;ZA8WND7-I;?;)(K]5!,'.9 49@0,8/.1Z5Q=W8RW'P
M(\-/#]H5+2.PNYC:C]ZL:,C.RC!Y RW0]*@FT[2/$-IKYT'Q#K'B#45T.X@2
M661)(5$@&(]RHOSDJ.* +WB#QW+J=GX>>SL-9TN&^UBR\BYF41I=1&09'RL2
M R\[6 R/6O4:\;U?Q;HVM^&_!5AITPGNHM5TTW$*J<VNUU4A^/E.[Y<'KVXK
MV2@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** $95==K*&'H
M1FEKB[[XC6MG->S)I&HW&D6$YM[S4XE0Q1." V%+;V"DX) ..>M7-0\9^3K%
MQI>DZ-?:S<VL:2W7V5HU6$.,J"7898CD 9XH Z<*JDD* 3U('6EKD)OB+I":
M7HM_!;WMS'J\KPV\<48\P2J#E&4D8;<I7TSU..:KP_$.2XN[S3(_"^K-K5IA
MI=/S%D1D9#^9OV8/3 .<]NM ';UA>'/#QT,ZMYDZS_;]3FOU^3'E[\?+[D8Z
MUDO\2=*&BZ'J<5G?S)K,CPV\,<8,@E4-\C#/7<I7KC/?'-6+'QW9N=5BU>QN
MM'NM+MQ=7$-UL;,)SAU*$AAP1QWXH ZHJ"02 <<C(Z4N*YC2/&0U'5+:PO=%
MU#2I+V)IK)KO9B=5 )'RL=K $':V#BL=/BI:2:/'K::%JIT8/Y=Q?%8PL!W[
M.5W;F .,E00/J"* .WOTO)+&9+":&&[*_NI)HRZ*?=002/Q%9'A?PVV@Q7D]
MW>F_U34)O/O+LQA-[8PJJN3M50  ,FJFJ^-AI^IWMI:Z'J6I)IZHU]-:B,B'
M<NX !F#.=N#A0>"*75_&?]GWDEO8Z'J6J>1;+=7+VRHJQ1MG'WV7<V%)VCF@
M#J:155!A5"CT Q7 :OX^O(_$GA6WT?2[J^T_5X)+D-'Y0,Z>7N 7>PVE<ACG
M'' SR*O:7K>CQ^-?%T?F7\<^GQ027KW$VZW5?++ QKD[>!SP,F@#LJ3:N2=H
MR>IQUKC+3XAQ3-I\]UH6IV6EZE*D5GJ$XCV.S_<W*&+(&[$CN.E+<_$%5N=6
MM]/T#5-0DTF9H[SR1&H10H;<"S#=D$X4<_*>!QD [.BJ>DZG;:UI%IJ=FQ:V
MNX5FC+#!VL,C([&O,;GQKK6M>%_'RRZ;>V*V"7$<$X>-?LY2)?D)5RV_)+9&
M1SUH [U/#Y7QO<^(&G5HYM.CLO(*<@K(S[L_\"QC':MPJI7:5!7I@CBN)T?Q
MT-^AVEYI&I6]MJ*I#::C-L\N>39NZ;BZ[@"06 S4]YX_ALKRX+Z-J1TJVNQ9
MW&IX011R%@OW2V\J&(!8#'UH Z/58=0FTZ1-*N;>UO3@1RSPF5%Y&<J",\9[
MU1\+^'4\-Z6]N;E[N[N)GN;N[D4*T\SGYFP.@Z #L *P[;Q?JD_Q0O?#W]D7
M/V&"UC;S 8OE)9OWI.[.P@   $\'(%3_ !$\4:AX7T:TGTZQEN);B\A@WKLP
M@,BY4AB.6&5'H>N* .@UF#5;G3FBT>^M[*[)&)IX#,%7OA=PY].<>U0>&O#\
M'AK1(M.AE>=PS2SW$GWYY7.YW;W)/\A7&S^)=0M?B<432M3N)I] AD32DD3*
M/Y\FYF)?RUP  6SZ 9K<B^(&GR^'!J@LKT7!O#IXT[8OGFZ!P8NNW/&<YQCF
M@#K-J[MVT;L8SCF@JK$$@'!R,CI6)H/B1=:N+RRGL+G3M1LBGGVEP5)"N"59
M64E64X/(/4$5D>+M5U6X\0Z3X4T.[%C<WT<ES=7H0.T$"8!V \;F)P">E '9
MT5Q<7ACQ'HFIV-SI7B:]U*V,P6^M=7D5PT9ZM&RH"K#L.A]JFOO'8AOM1@T[
M0M2U6'3&VWUQ:^6%B8#<54,P+L >0HXH ZZBN3O/'^G0OHJ65K=ZB^M6[W%B
MMLJYD"A3@[B-IPV>>!@YJA'\2O/M[X6_AG5Y;W379=0M%\H-; #.2Q?:V1D@
M*23@_B =T%51@* ,YP!2UR-Y\0M.@&A"TLKZ^DURW>>QCMT7<^T*=IW, IPV
M<G@;3DTZU\>V<FF:Q<7FGW]E=Z05%W8NBO*"PRFW:2&#9X.: .K95888 CKR
M*6N7L/&8GN+ZTU'1[[3+VULS??9YS&QEA&1N5D8C((P02,9%9]M\2[:XATJ^
M.B:I%I&I210Q:A((PBR2< %=VX#/R[L8STR.: .XK#\7: _B;P[+I:7"V[/+
M#)YC+N V2J^,9'7;C\:DT/Q':Z[-JD$44T$^FW;6L\4P .0 0PP3\K Y!I?#
M7B&W\4:.-4LX9H[5Y9(XFE 'F*K%=XP3\I(.* -8*H)( !/4@=:" 001D'L:
MY&^\>K#=ZBFGZ%J>IVNEN8[ZZMO+"1L!EE4,P+LH/( XK.U;Q]=IXG\+VVCZ
M;<W^G:K!+<!XC&#.H0$!=[#;MR"V<>@SR* ._"@+M  7IC%"J% "@ #H!7F.
MD>+[W2[_ ,8*-*U35Q::O+))Y#+MMX1&F -[#/1B%7/?ID9Z>Y\;VIM]*.DV
M%WJMUJEO]KM[:WV*PAP"7<NP"CY@.3U.* .HHKC[OXCZ39>'K/6)K:]$=Q?_
M -GO;^6/-@F&[*LN>H*$<9SD8SFK>B^+QJFM?V1=Z1?:9?FT^V+%=;.8_,*?
MPL><@''N* .D(!!!&0>QI<8&!7+:-X]TG6M/UN^A2>*#2'D$QE &]%!/F+@\
MJ0IQG'2LZR\2:7JOC?06\G58+Z_T@W<,;R@0K$23\Z!L;_?!^M '==:15"J%
M4  = *Y32?'*:M=VGEZ'J<>FWSM'::BRH8I2 3DA6+(#M."P&>.F:B3XA6KW
M"2_V5?C1I+K[&FK$)Y)DW[!QNW["WR[\8S0!V!4,1D X.1D=*RO$&F:AJ5G$
M-+U5]-NX9EE601^8DF,@I(F1N4Y]0>!1XDU^W\,:%/J]W#-+;P%/,$0!959@
MN[DC@9R?:JFL>,=/T;Q)H^B3QS/<:F2$DC *1<@*7.>-Q.!C/- %?2/"M[!?
M:IJNKZM]IU6_MUMO.M8?(6WB7=@1@ECG+%LDGG%4H/!VN75YI7]O^(H]0LM*
MG6YACCL_*DFE4$(TK[SG&<\ 9/)J]J?CO2M)O-8M[F.Y(TJ*!YGC0-O>8D1Q
M(,Y+GCCIR.:73/&!NM;@TC5-%OM(O+J)IK5;DQLLZKC< R,V& ()4]J .GI-
MJ[MVT;L8SCFN7'CO3S\/SXQ^S77V$(7\G"^9@/L]<=?>L:XO;H?'ZTLQ<S"T
M;P^93!YAV%O.8;MO3..] &GJ_AKQ)>7.HQV'BA;?3]0&'BGL_.DMP5VMY3[A
M@'T(.#71:7I=MI&D66F6RG[/9PI#%NY.%& 3[\5YMXU^(#ZA\/\ 6[O3=-U2
M#3RC0VVKHRJC.'VY #;PI((#8QGTKTV1B--9LG=Y).?PH L%0000"#U]Z"BL
M "H('(R.E>5^#/'[V'@3P_/J.F:K/8LD=O/J[E602LVW)!;>0&(!;&,^M=5K
M?C<:1?7T,.AZE?PZ=&LM]<6X0)"I&[C<P+D+R0H.* .KHK"L/%=CJ'B.318D
ME$OV&._AE8#9/"YQN7G/!P#D#K5&Z\?:;:SZS%]FNY?[+GAM28D#?:+B4#;%
M&,\L,@'. ,T =45!() )'(R.E+BL'0O$PU:^NM-N]-NM,U*V1)7MKDHQ:-LA
M75D8AAD$'G@BH_$7B^W\/:GINFM8WEY>:D)?LT5LJDNR!25Y(Q][.3P "210
M!T)5202 2.A(Z4I (((R#VKD[3Q[9R:?K,U]I]]8W>C[3=V,B*\OS#*%-I(8
M-T!!ZU9T7Q6=3U672;[2+W2K];?[4D5R4;S(L[=P*,1D' (/(R* .B "@
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MEF,4<@+$ =< Y_"NTHH \MO]9LO%WQ&\/'1I'GM5L+^(WBQL(][HGR@D#)&
M3_O"L3PQ9:'+IV@:'J&J>)9=8MYH8YM'69BEO+$P.]E*X$0*[LYZ8QFO;:*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$BA"*&.3@# S[T <58>/(O%/A74=2&A:A%HBZ;/-)=&54+LJ_-$F#NSC/S=
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M]S82RQF*9=K!9#'R P)Z\96@#J[SXD:?9:!9:K+87N9]0_LV6U"@RP3C=E2
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M$YBLY81G>P;"",,O&#R", T :/AV_*Z[\4FOI+B:TMI ?+64@J@B<L$.?E)
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M!8LWNP  'Y5G7OCY[3^PH?\ A']0:_UCSUBLWVI)')%C*MGC').[.-HSSD4
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MY@?1[FWM9H7D7<SRE%/3C"E^N3D#(ZT =W161J.O1Z?XBT71V@9WU3S]D@;
MC\I-QR.^>E<=I?C#2-&\,^,-;LM*N4CTW5IDNHGN2YFE#*&=2V=H.1\HX&*
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M$@'&<9] :SO$%E>^(/"GQ&UNPL;MK?4WM%LT:!EDF2#8&<(1G!^;'':O4YM
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MRVDD2QLT# )\P'/!SV''/-:WQ3BNIO!JBSM);N=;^T=88ER6Q,IQ^G6NUHH
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M>]>@44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!X[=>)?$.M^#_B)'J5@L-O:?:84=;E6\AEC3]T
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MZ!XIUC1]:AL&LIK.\@MUN(YK.;<K L(L.R$JPR 1]TU/_9_AR+PIF?PCK/\
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M/@_87FG^$KZ*]M)[:1M4N'"31E"5)&#@]CZT 0W^I:C9?&"^CTS3&U&YDT2
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M+0'RBOSG(S\IW?,=ISF@#TC3?%M^_B6#0];T(Z7/=P//9NMTLZRA,;U. -K
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M\;F7<I!(!_&MOPJL^K>-M=\3"TN;;3Y[>WL[0W,+1/,$W,S[& 8#+ #(YYH
MVF\2+#XVC\-SVIC,]F;JVN=^5E*MATQCAAD'KT-9>H_$&UTZZ\0*]E++;Z/Y
M$1EC8$SW$N-L2+CJ,KDYXS4'Q,B>QTFQ\56R;KKP_=+=8!P7@;Y)DS[J<_\
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MF9B$CVXY) )ZC@4 ;M%<[XC\2W&E:CIVD:9IZW^JZAO:*)YO*CCC0 L[M@D
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MPXM)K>\\]=ZKN,;_ "+@XS@C(.* .NHKS@_$K5I/#EQXB@\,*VE64LB7;-?
M2820JS1KL^8  'DCG([9KT2*19HDE0Y1U#*?4&@!P(/0@TN<UXY)KYD^#WB6
M\\,Z'%IJ)<W4,X6];*8'S3*=O+'(^7CZUUGPLTS^S?!=F?[&M=.^T00REX+@
MRFYS&#YCY4;6/IS]: .A7085\72>(?.?SGL5LC%@;0JR,^[USEL5K5QNO^+M
M:TB34[J'PT9M(TL!KBYEN?*>5=H9VA0J0P4'J2,D$"GZAXQOQXH'A_1M&2^N
M7T^._CFEN?*C",[*=WRDC[HQC).[H,$T =?17!VWQ'<VFG3WNCFW$FKOH]__
M *1N%I.#A2#M^=2<#/&,]ZW[WQ&;?QEIGAV"T\^6ZMY;JXE\S;]GB7 5L8.[
M<QV]10!'H_A1=.UNYUJ]U*ZU/4I8_(2:X"*(8LYV(J@  G!)ZG KH:YOQ;XJ
MD\,G24ATU[^74;P6D<:2A"'*L5Z@C&0 >F <]JSHO&]_:W&L6&M:+'::C8:<
MVIQ1PW?FQW$*Y!P^T%2& !R.^: .UHK@K7XAW;>%'\2WN@-;Z?+%";&-;D/-
M<RR$*$VX&T;B ">HYP.E7(O%NMVNL6VE:UH-O:W5_#*]@;>^\U))(UW&)R4&
MTX[X(ZT =C29&<9&?2N1A\?6DGPT?QE);&-([=G>U+\K*I*>5NQUWC;G'?I5
M*'6;6?XG:3;7N@)!K,^A_:6N_M!9H%+',.W: V#GYN/I0!WE("#T(.*X_P /
M^+]7UQK"]'AX+HFH,P@NHKL221@ [6ECVC:#MQPQP2 :R-$\7Z+I.C^,M6BT
M4V2:?J\T,Z0RF1KR?<%##(&TLQ QT% 'I%%<A:>+-7MM<TW3O$6APZ>NJ;EM
M9K>\\\+(J[O+D^1<' .",@D5D-\2-7DT"]UZU\,*^F:?--'=L]]M<B-RK&-=
MGS84 G)'.0,XS0!Z-1445Q%-:I<JW[IT$@8\?*1G/Y5P1^(NI?V(?$X\.K_P
MC&__ (^?M?\ I'E;MOG>5LQM[XW9QS0!Z$3CK17C'C9-1U[XMZ-IESH=GJ5B
MEE--;6DU^5BG'_/1L(=I'I@].M>B>.=3U#1? VK:AID*-<P6KL"TFSRP%/SC
M@Y*]0.,XZB@"YJ.A0ZAX@T;5GG=)=,,QCC &'\Q-AS]!S6OT&37DM[JVM/J?
MPYO[K3%EU)UNA'!%<[O.W6PP[.5&WJ6/!P >M= WBR:[T?Q=8:_H<4=UI%DT
MMQ:QW1DBN87B=@ ^T$9"LIXXH [H$$9'(HKS_2_%CQ^'?"MGX=T& 3ZI9M/;
MVDMX8XK>*,+D;]I+'YU  'J>,5V.C7UUJ.F1W%]ITFGW6YDEMI&#;2K$9##[
MRG&0>X(H OT5P/AV[N9/C'XSMGN)6@BM[(QQ,Y*H3'S@=!FNI\1:Y%X=T.?4
MI87G,95(X8\;I9'8*B#/JQ H U:*XU/%FMP7%WINHZ#;6^JBR:]M(TOB\,Z*
M0'4OL!5EW+D;3G-<4OC/QD/AAX?U$VL#3WMY;Q?:_MOSRAI!P5\O"[L%3R<#
MGF@#V>BN0N?%.N-J7]E:9H-O=:E;VJ7-^CWVR* OG;&K["68[6/0# YZU2O/
MB3MM?#<NFZ-+>2Z[YR10M,(VBEC'*-P1][()[ $\]* .\HJMI\EW-I\$E_;I
M;W;(#+#')O5&[@-@9^N*\[\<KJ?C#Q3_ ,(KHM_<6?\ 9MB]]<S02%#Y[*5@
MC)'OEB.XH ]-HKD="\;6UW\-U\47P9#;6SM>Q@?,DL>0ZX]=PX'N*H?\)[K5
MF^A_VMX86UCUJ[BM[=X[WS/+#\_O!L&& YP,@\\C'(!WM%<9I_C74=6\3ZCI
M5GH2_9M,O3;WEY)=!55-H(91MY8_-\O8#KR*AL_'M].FGZI/H8A\/:C<K;VU
MY]JS,-[;8Y'CVX56./XB1D9H [FBN'O_ !UJ$!U6_LM"%UH>D3-#>71NMDI*
M?ZTQQ[2&"<YRPS@XJ>\\9:C)XFN-!T/1HKZXCLXKQ)Y;ORHBCEAR=I(/ QC.
M<GIB@#L:*\U'Q/U-_##>)(_#!&F6CF/4/,O )(V5]K^6H4APOJ2N>F.*W]2\
M4:F=;N-+\/:-%J4MG D]T\UWY"KOR4C7Y6RY )YP!QSS0!U=%</+\0VN&\.Q
MZ1H[WLNNVTTL*R3"+RFCV[E<X. -S9/^SP#D5EZ]X[UQ/!OBL+I<5EK>C@1S
MA+O>D:21[DFC;9\QY!VD#ZT >F4@()(!&1UK,\/7.H7FA6D^J6T=O=/&"R1S
M^:",<'=M7D]<8XKC;3Q7I.DZKX_O8]$\B;2FA:ZFCFW->L5;;D$83'3OUS0!
MTWB7PO\ \)/Y5M=:I=PZ9Q]IL8-JK<@'.&;&X#L0",BM]$6-%1%"JHP !@ 5
M@Z)JVN75]):ZSH26(\H313V]UY\3<X*$[5(8<'H01WXJ+Q'XEN],U73=&TK3
MDO\ 5+\2.B2S^5'%&@&YW;:QZD  #F@#I,C.,\BBO*]'\3/I/B'X@:SJ>GR0
MW$!L(VLXW#EI3&454;C(8E<' X/('2NDA\5ZY%>RZ9J6@VUOJ;V;W=DD=]OB
MG"$!T+[ 59=R]B#GB@#L**\R\*>.-;_X5[I.H:CIZWFHZC,MO8!;KFZ=BY)?
MY?W84*?[W K8F\=7>G:5X@;5='CAU31;9;IK:*ZWQSQ,#M9'*@CE6!RO!% '
M:T5P=Q\0-2LO#\6N7GAQDL[JZMH;.-;H-++'*<;RNWY3T(4GG/)%+_PFOB&/
MQ"WAZ?PO"NJS6_VJU":ANA,>XAC(^S*D''0-DD?6@#NB0!DG ]Z6O,O$'C.T
MU#X6Z[J&N>'4G.G7GV*]TQKD[&D65!Q(%Y'S*PX]JW;_ ,6WMKX@M/#VDZ(M
MW=7&G"\C9[GRXXP&VD.=I( XY&220,=P =A17#P?$&1M N;BXT=DUB#4_P"R
M?[/2<,)+DXV[9,#Y2&W9(X /'%3?\)S+I<.LIXDTU+&[TRS%Z4MY_.2>$D@%
M&*J<[EVD$#DCUH [(D#J:*\K\0:QKE_J'@E=8T./3UGUN&>%HKKSL#RY/D?Y
M5VM\PZ9!P>>.>K^(NKZEH?@/5M0TM%-S% W[QI-AB!!&]>#D@XP./K0!U-%<
M2?%VL6]GH>G_ -C0SZ_J4;.D O?W21( 3*\FS(ZC@*>3BM3PWXDGU>]U+2]1
ML!8:KIK()X4F\V-D<91T? R#@]0""* .BHKFM=\2WMIKEMH6BZ9'J&J36[73
MK-<>3'#"&"[F;:Q)+'  '8U0E\=7::9IZCP_<)KM]=R6<6FS2; '3)=_,QS&
M ,[@#G(XH [2BN*_X3F\L8M>MM8T>.VU32=.;45AANO,BN80&Y5RH(^92IRO
M'O44'CO5!/H=S?>'EMM'UF:."WG^U[I4>12R%X]HP&Q_>R.^#Q0!W5%<=:>+
M]7U"_EDLO#PGT>*_:PDN$NP9PROL:3RMOW0W^UG'.*R_#WB/7]1\1>,+?4]/
M@.G64FS8+S=Y6(0=BC8-P;J3D8)Q@T >B @C(.12UXZ/%EY;_#7P?>>%-%@T
MZTO]32#[-]L/[O\ ?M^[W%#D.5;+?PYZ&O0M*\13WWB2\T2ZL$M[BTL[>YE9
M)_,7=)NR@^4< KU[^@H Z"BO+O$GCS6I]"L[K1]/CA+>(1IDA:ZP6V3!0/N'
MB3!!/\(_O5T5SXIUQ]2;2]*T"WN]0M;6.XOU>^\N.%GSMB1]AWL=I.2%&,9Z
MT =?574K>XN]/F@M;Z2QG<86YC16:/GJ P(/IR*@T#6;?Q#H5GJULKI%<Q[M
MC_>0]&4^X((_"N'U[QAJ>J^'O%$FGZ&DVB6D=S9R79NL2NRH5=TCVX**<_Q
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MD+,&V,L"@X(ZC(R#W&.!0!W]%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2 1A<@YK.N?#%AIVK:_%J7@F^UJ\O+^6ZLIX WDS+*=P1W#8CVL6!W#IR,T
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MJB[G=V )  QT&3FLH>*=>E76M&ETRR@\06-NEQ&%NF,$T+9&]7V;@1AA@KU
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M+II;PJ\JQ/@F,!"/NX)R1UP,XK/\*:#ID5UHEL_@*]@U6T*&[O+@LD$#HO\
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MS4V@ LHZ G![UBQZ'J@^%?C+3S83_;+J[U!X(=AW2!W)4@=\]JU]8TR^FO\
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MUMP)8=.>:]9LK=+2PMK:*%88X8EC6)6R$   4'N!TH GHHHH **** "BBB@
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MDMO9B2*+*[(8BP!(4=%!ZX%>;>-O$OB^R^'^N/+8PZ=?V4L4;W<$S^7+'(5
M>!L [@6 (/3GGM6GJ^KS6GB_P39:QH^F3ZE>O= 7$3,WV4JH.8RP!^8$9Z4
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MNTT#7M2N-:O="UNVM8=1MX8[E'M)&:*:)RRY&X @AE((/M0!TE%%% !1110
M4444 %%%% !1110!#<6L%VJ+<1+(L<BRJ&&0&4Y4_4'!J:BB@ HHHH ****
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M#X3UC4O#VI7.J: 995\4MJITQF4F>W:-5*J<X+ ,>^"4KI_#-I9Z:-7U/1O
MTFEK%;8A$@6*>\8 L4V#.T9"@$GDGIQ7>44 5[&>6ZT^VN)[=K::6)7>!SDQ
M,0"5)]0>/PJQ110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?E'SCH<8R.N<TZ^\0ZIX0U3Q="VH7&IPV>DQZA;B\VDI*Q=2,J!\N0#CMVH
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MT,3?Z=';K<LO& I8J!GURIXH TJ*S-'O;^YM))-5MK:TE$[(BPW'FJR?PDG
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M&"$;YU8A@">0>_(K=CN()49XYHW120S*P(!'7-*MQ"TQB6:,R@;B@89QZXH
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M(TC+$\89CD[5D95'X  5N:5X?M-'OM0O())Y)[\Q-.\SALF.,(#T[@#/O3]
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MN$#I\P<%MIXR,8SVW'UKC+$7;W&CZ!:Z9#JNFVNNZJEO8W-QY<4BPD>6"2K
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M%=+%J=A/';O%?6TB7)(@9)5(EQUV\_-^%2RW,$,D4<LT<;RG;&KN 7/H!W-
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MQ4M_X%T34=8GU*5;N.2Z"B[BANI(XKK:,#S44@/QQSU'7- %/X4_\DN\/?\
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M!ZQJ6/RK]/0>E4+[P-8V&A:Q+9'4+Z_?3+BUMOM=W)<&-60_)&&)QDA??@4
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M.-A(\LK#)>5W;H2 "QS]*=\/?"H\'^#[33'6,73%I[GR_N^:QR0/8#"CV44
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M  *58E<$<8Q5ZVT";7/$OC/P_J<6F6\EYI-MO33]WEI)NDV.00#N'RGIT H
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M9C.4!<.MPP4ANHP%&* /;9[B&UMY+BXFCAAC4L\DC!54#J23P!7#R?$BTO\
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MYCP.I[5J6VB:?:ZS>:O% ?M]XJ)-,SLQ*K]U0"<*.^!C)Y-<G<>)/'6E6?\
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MUAM'CUBQ;4E)!M5N%,@(ZC;G.?:@!FD^%]&T,ZB=.LQ =1F::ZP['>S9SU/
MY/ P.:AM/!F@V.DZ9I=O9%+/3+G[5:1^<Y\N7+'=DG)Y=N#D<U-?>*_#VEEA
M?:YIUL5E,+"6Y12' !*G)X(# X]QZU9U#6]*TJP6_P!0U*TM;1\;)IIE5&SR
M,$GG(]* (;_0[2>]N-42TBFU)K%[)?.9O+>,G=L8=,%L9.,XKS33O"-Q=WV@
MV\'A&\T=K"]BNKNYNK[SX8EC^;RK?,C':S8Z!1@#/:O3VU[1TT<:NVJ68TTC
M(NS.OE$9Q][..O%3:=J=AJ]FMYIMY!=VS$A98) ZDCJ,CO0!+>6D%_93V=U$
M);>XC:*6-NC*PP1^1K$TOP3H>CMI[6L%P6TYI&M3-=22>5O0(P&YCQM  '0=
MJJ>,?$^I:%?:)8:58VUU=:K</ @N9FC1=J[LD@$_I51/%^OZ5K^EZ;XFT2TM
MXM3E,%O=6-V9563&0K*RJ1G'44 =#-X:TBYN-4GGLEE?5(4@O [$K*B A1C.
M!C<>F*@T3PAH^@73W=G%</<O&(?.N;F2=UC!R$4NQVKGL*LW?B30[#4XM-O-
M7L;>^FQY=O+.JNV>F 3GGMZTNH^(]$TCS?[1U:RM3"%,@FG52H;.W()[[3CU
MP?2@ UWP_IOB.P6SU. RQI(LL;([(\;CHRLI!4CU!K,M_ 'ANW6['V!I6O+8
MVMT\\\DCS1DY^9F8DG)^]U&  < 5K/KND1Z.-7?4[-=-*[A=F9?*(SC[V<=>
M*R-?\<Z-I/@VZ\0VVHV-U$L;_9L7"[9Y0I(C!SR>.@YZT +:> M LKFSNHX;
MIKNTD\R*YDO)7EZ8VEBV2F.-A^7VY-)!\/O#=O97]DEE(;2^?S);=KF0HK;M
MV8QN_=G<<Y7!K!T'QAJNK>&].U&7Q%X32>ZNH%D12P$:NN3!_K#^^]/H>*Z&
MV\<Z'=>+[KPVE];?;+=%/,Z_/(2VZ-1G)90N2.V: +FA^&=,\/M<264<S3W.
MWSKBYG>:63;]T%W).!DX'3FGZYX=TSQ#% FH0N7MW\R":&5HI8FQC*NI##CW
MYI=-\2:'K-S+;:9J]C>3P\R1V]PKLHZ9(!Z9J[=WEK80^=>7,5O%N5-\KA5W
M,< 9/<D@#ZT 9=CX3T;3]'O=+@M6^SWP<7;22N\D^Y=K%I"2Q..,YX[5H:9I
MMIHVEVVFV,7E6EM&(XDW%MJCH,GD_C5?3?$>B:Q=36VFZM97D\'^MC@G5V3G
M'(!]:;:^)M"O=4ETRUUBPGOHL[[>.X5G7'7@'/'?TH BNO"NDW?B.#7Y(95U
M*%!&)8IW0.H.0'52 P!/<&JECX#\/:=J45];6DH:&1I8(6N9&@@=LY9(BVQ3
MR>@XSQBMVSO[/4;-+RRNX+FU?)6:&0.C8.#AAQU!'X5GR>+/#D5J+I]=TT0&
M+SA)]J3:4W;=P.>1N!7/KQ0!-8:#INF0W\-I;F-+^XDNKD;V.^23[YY/&<=!
MQ4!\*Z,="L=%^R'[!8O$]O%YK?(T9W(<YR<$=S39?&/AF&&TFEU_3$BO/^/=
MVND EYQ\ISSSQ]:M:KX@T?0DB;5M4L[%93B,W$RIO/MD\T /?1[&36XM8:$F
M_BMVMDEWGB-F#$8SCJ!SC-9MEX)\/Z?I.GZ9;6)2ST^[%Y;1^<YV3 DALDY/
M+'@\5HW6MZ591Q276IV<$<L;2QM+.JAT4 E@2>0 1D^XK)U+QYX>L/"MWXAB
MU2TN[. ,%,,ZGS) ,B,'/WCZ4 :-[X=TK4;^6]O+033RV3V$A9CAH&.60C..
M2.O6LNU^'OAVS>UECM[II[2598)Y+V9I$V@@*&+9V8)&S[IR>*M_\)IX:32K
M74I]=TV&UN>(I'NDVLPZ@'/)'?TK:AFBN(4FAD26*10R.C JP/0@CJ* .:_X
M5[X;^SZK;?8YOLVJ,6NK?[5*(R2P8E5W84D@'C'Y5;U/PAHVJV]C%/!-&]@N
MRUGM[AXI8EP 0'4AL$ 9&>:LW'B70[/58]*N=8L8=0DP$MI+A5D)/0;2<\]O
M6L&U\=65KK?B"UU[4-/L+>QO([>U:601F0&)7.=QY.6[=J -2+P9H,&D1:7'
M8XM8[I;S!E<LTRL&#LV=S'('4G.*T)M(LKC6+75I(2U[:QO%#)N(VJ^-PQG!
MSM'6F:AK^CZ581W]_JEG;6DN/+GEF54?(R-I)YR.>*YOQYXTET'P7!KNA2V=
MXLUS%&DA/F1LC-@D%2,_G0!L>,/#P\4>%[S2UE\F=P)+>;_GG*A#(W_?0&?;
M-06FEQ>);/1-3\0Z4]OJVG/YBQF0@13=&(VG#*<9&<\8JK<>)[Z+XL6OA=8X
M/L$NE->,Y4^9O$A7 .<8P/2KOCG7+KPWX+U/6+)(GN;6,,BRJ2I)8#D @]_6
M@"V?#.CM)J[O9+(=7"B^#L668*NP<$X'R\<8JMHW@W1=#N9+FTBN'G>+R!+<
MW4D[)%UV*78[5]AZ"K=EXDT34=1ETZSU>QN+V'/F6\4ZLZXZY .>._I0OB30
MWUDZ.NKV)U(=;03KYF>N-N<YQVH S)_!EA'8^'M/T^%8+31[U;F)6D=B@4/P
M,DY)+8Y/0GVKH[B".ZMI;>9=T4J%'&<9!&#3G=8T9W8*BC+,3@ >M9,7BSP[
M/?P6,.NZ;)=7"AX84ND+2 C(( /.1R/6@"D_@+P\VCZ=I<=K/!;Z:S-:-!=2
M1R0[L[L2!MV#DY&:C?X=>&&695L)(A*8V/E7,J;7C&U9%PWROCC<.3SDG)K4
MOO$VA:9J,6GWVL6-M>2XV037"J[9Z<$YY[>M1W%_<IXMM+!=1TM+>2V:1K.0
MG[4[ GYD&<;!WX]: *G_  @GAXZ%>Z1+:23VU\ZR7+S7$DDLKKC:QD+;LC Q
MSQBMK3M/ATO3X;*W:9HH@0IFE:5SDYY9B2>O<US/B[QWINC:+K/]G:IILVM6
M-N\JV;S!FW+U!0$'CN*ZRWD,MM%(V-SH&./<4 <]'X"\/1ZL-06TE#K/]J6#
M[3)Y"S9SY@BW; V><XZ\]:TH/#^F6\6J1Q6Y5=4D>6['F,?,9E"D]>. !QBH
M[OQ5X?L-373;O6]/@OF( MY+E%?)Z#!/?M4VHZ_H^D,ZZCJEG:,D7G,L\ZH0
MF[;NP3TW$#/KQ0!"_AG27TS2].:U)M=+DAEM$\QOW;1?<.<Y./?.>]<CI7@"
MUU*_\3S:W:747VO5I7C:&ZDA^T6YCC #;&&Y<AN#[^M>AHZR(KHP9& *D="*
MS(O$NA3ZNVD1:Q8/J*DAK5;A3(".HVYSD>E #)O"VC3W>CW+62B31@PL-C,J
MP@J%("@X(PH'.>E4=2\ ^'M5O[B[N;6<-=$&ZBANI8HK@C@>8BL%;\1SWJ_>
M^*O#^G:DNG7NMZ?;WK8Q!+<HK\].">,]JFU#7]'TDN-1U2SM&2,2LL\ZH0A.
MT-@GIGC/KQ0!RWCO3+[Q'8)X.L=%=;&Y,/GZ@Q18;>)6!(09W%_E  QCGK73
MWF@:9?Z?9V%Q;!K6SDBE@C5BH1HR"G0]L#CI5>7QCX9AAM)I=?TQ(KS_ (]W
M:Z0"7G'RG///'UJUJ'B#1])+C4=5LK1HXQ*RSSJA"$[0V">A/&?6@![:18MK
MD>M&$_;X[=K59=YXC+!B,9QU YQFJ,WA#0I[#4+*6QW0:A=&\N!YC9,QV_.I
MSE3\JXVXQBEE\8>&H8K2677],2.\&;=FND E&<97GGGCZU9U7Q!HVA+$VK:I
M9V(E.(_M$RIO^F3S0!FQ>!/#\>DZAISVTT\6HA1=R3W,DDLP7[H,A;=@=@#_
M #K6O-'L;^\L+NYA+SV$AEMFWD;&*E2< \\$CFDNM;TJQCCDN]3LX$DC::-I
M9U4.BXRPR>0,CGW%)I^NZ3JNGO?Z?J5I<V:9WSQ3*R)@9.2#Q@<\T 5=*\*Z
M3HNK7VI:?#-#->NTDZ"=S&78@LPC)V@D@<@4:[X5TGQ%+:S7\4PN+4MY%Q;S
MO#*@;[P#(0<'TJQI7B+1==$ITG5;*^\DXD^SSJ^SZX/%)IOB/1-9N9K;3-7L
M;R>'_61V\ZNR]LD ],T 9@^'WAE=-N;"/3VB@N)H[AS'/(KB5  KJV[*L,#D
M'GDG.33?^$:TGPRQUK3=+OKF_@A\HK!<,\MR"V3OWN Y!8G+'([=JZ=W6-&=
MV"JHR6)P /6LK3/$^@ZU<R6VEZS87L\8R\=O<*[ >N >GO0!A^!?#MQI]QK6
MOZE91V6I:W=>>]LC!O(C PBDC@MR6)'&6KL)(TEB>.10R."K*>A!ZBL>7Q?X
M:@F@AEU_3$DN&*Q*;I,N0Q4@<_W@1]016T2 "2< =Z .?M?!/A^S\*R^&H+#
M;I,V[?!YKDG)R3N)W9SCOQBI+OP?H5]X>M-!N++=IMH8S#")'7;L^[R#D_B>
M>]<QJ7Q2TZ;PQXEO=!N[*>^TDL(HVE603*NS]Z%4Y*9?&?4=:ZZR\2Z+J&H/
MIMKJUC/J$0S);1SJSKCKE0<\=_2@"*^\*Z3J'B"UUV:&5=1MD$:313O'N0-N
M"L%(#+GG!R*!X3T4>&)/#@M#_94@=7@\U^0S%V^;.[J2>M3#Q)H;:R='&KV)
MU(?\N@G7S,]<;<YSCG%:%Q<0VEM+<W,T<,$2%Y))&"JB@9))/  '>@!ZJ$14
M4851@5S-E\/O#>GQB*VM)EA6[CO(X3=2F.*5&+*44MA1EB<#@]\X%<OX=^(M
MYXFO]?:#5_#=G:6;7,=I#,Y:5UC7*W#'>!Y7<D#H#SQFNUL]>LX-&T^XU;6-
M*\ZXA,@FAF"PS;5W.T>X\J!SU.!0!;ET:PGUB/5I8 ]Y';O;*Y8X\MB"R[<X
M.2!VK*TKP+X?T;4(KVSM9A)!N%LDMS))';[OO>6C,53/3@=.*LS>,/#5M':2
M3Z]IL27:A[<R7*+YJ],KD\C/>JTOCG0X?&2>&7OK9;QX!)EIT'SEE58L9SO(
M;('7'UH Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "N#^*+BTL_#FJS _8=-URVN+ML9$<?S+O/L"PKO*BN+>&[MI+>YA2:"52DD
M<BAE93U!!ZB@"KJ>M:=I&C3:O>W<<=C%'YC39R"O;&.I/8#KFN0T$VVI_%;Q
M)=7""1ET^R^P^<F&6!U=GP&&1ENOZUHVGPR\'V-Y%<PZ,I:%]\4<DTDD4;>J
MQLQ4?E6EK7A+1?$%S%<ZA:,US$AC2>&>2&38>2I9&!*^QXH \GBM+>XBT^P,
M2OI:>/9H[:+'[OR@CG:!TV[MPQTZUV5EI=@?C;JLAM(=PT:!@-@QN,CJ6QZX
M &?3BNJ3POHD5GIMI%I\4=OIDPGM(T)412 $;N#R?F;KG.<U:32;&/6)=62
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MJ]0 5P7PD_Y%?4?^PQ>?^C#7>U1TK1M/T2VDMM.MQ!#),\[J&+9=CECR3U-
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MG^Z78X/TH \_BTO7-:L?',*IX>6UN-4NXKFYU!Y%FB5<!&) ( 5-C+Z=:W]
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M\DDC!511U))Z"L_PS;26?A;2;66[CO'ALXHS<Q'*S80#>#W!ZY]ZYWXL$?\
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MD%%W,01MPV!_=!H ])HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MFXLSNR\9).  >!GUKJ8]*L8=5GU2.W5;V>-8I9@3EE7.T>G&36==^,O#EAK
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MJW5E^\H/0D=P#D5AW/BGQ/!I6O3#0K(W6FW("*;S]W)#][.['#A<';_M#Z4
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M,N@'74U6V.EC@W._"@YQCUSGC'6I]'UW2]?M6N=*O8KJ)'V.4SE&]&!Y!^M
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M?G+&),$#A@3@=J .OT7P;X>\/3RSZ7I<4$LB>6S[F<[/[H+$X7V&!5>'X?\
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MH,]<UU6M>#O#OB*ZCN=8TBUO9XT\M'E7)"Y)Q^9-3Z-X:T3P\CKH^E6EEO\
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M1A01[5;BT;3H+BTGBLXDELX#;V[@<QQG'RCV^4?E0!Y!XB$<>L>)DE"KI_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIJNGP7]A<)<6LZ[XY8SD,*X_PS"O_"TO&DSHIG$6GIOQS@Q,2![9 _(5)\*
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MZFL&]^(%K%XAT"9=02/0[RSNI9F>(@LZ-&J@9&[.6(P!SGO5GXM_\DK\0?\
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MQ:&ZT^Y2X@$CQ^8F<;E)5A^!!KC- N+6V^)7C<W\L4;F&RD0S,!F 0D$C/\
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M^@^(+I[73=066X1/,,3QO$Y3IN"N 2ON.*ICXB^$FEMD&M0G[00L;;'V9)P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MF2>VG021RH<JRGH16*WCGPZFL_V4VH$7/GBV)\B3RA-_SS\S;LW9XQG.>.M
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MKZ/X;T7P\LJZ1I=K9>:09#!&%+8Z9/?%8L/CZPF\?7/A<)*'AA0B7R).92S
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M3!J.G7(FM-SJ7*E-I4D,"& (P0>HI^D:O8Z[I<&IZ;,9[.<$Q2;&3< 2,X8
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MK.)E 7.W:#D_,N!U.>,TFG>,=!U33+W4+>_"V]@2+LSQM"T&!GYE< CCVYH
MGT?PQH?A]I6TC2;2R:7AVAB"EAZ$]<>U3?V%I7]C'1_[/MO[-(*FU\L>7@G=
MC;TZ\UR%SX_MM3\2>&+30[Z017EVZW,4UJT32Q>2[*0)%!VY4?,OYUN?\)UX
M<_MK^RO[0/VGS_LV[R)/*\[_ )Y^;MV;NV,YSQUH T%T6$>)VUS*^<;,6@4)
M@[=Y8DMW[8';GUJ[=6MO?6DMK=P1SV\RE)(I%#*ZGJ"#UK%O/&WAZQUEM(GO
MS_:"S1PFW2&1F#. 5Z+TP1D]!GDBM'5-9T_14M7U"X\A;JX2VB8HQ!D?[H)
M.,XZG ]Z (M/\-Z)I/V;[!I=K;?9@ZPF., QAR"P'IG S]*L'2=/+WKFRMRU
M\ +HF,'SP%V@/_>^7CGM3=1UFPTJ:RAO;CRY+Z<6]L@1F,DA!.. << \G@=S
M69!XX\.W&L#2XM0W7#3&!6\EQ$\HZHLNW86X/ .: +6F^%= T>WN;?3M(L[6
M*Z7;.L40'F#&,-ZC!/'O5I](TZ2QMK)[*!K6U,;00E!MC*8V%1VQ@8]*R;_Q
MUX<TS57TZ[U I/&ZI*P@D:.%FQM#R!2J$Y'4CK3]9\;>'O#]XUGJ5^8KI8TD
M\E89'9E8D# 53G[K<#I@D\4 =!6*/"'AT37DPT2Q$EZP>Y;R1^](8,"WK\P!
M^O-;5% %>:QM+B\MKN:WC>YMMWD2LH+1[AAMI[9'!K/B\*>'X=:;68M&L4U)
MF+&Y6%0^X]6SZGUZUCZ1XGO[[XG>(O#LRPBQTZW@EA*J=Y+J"<G//7TJ2/XE
M>$IFM?+U4M'<LJQS"WE\L,WW59]NU"?1B#R* .LJO8V-KIMG'9V-O';VT0(2
M*)=JKSG@#W-3LRHI9B%4#)). !7/Z3XX\/:YJ*6-A?-)/(K/#O@DC695^\8V
M90' _P!DGUH NZIX;T36[FWN-4TJTO)K<_NGGB#%>_?M[5CZ_I&H6VGW5EX3
MTC389=5,GVRZE?RUB9@ 9"@4^8Q!/IR.<YJCXL^(FDV.BZ_#IVI%=4LK>94E
M%N[1)<*A(3S"ICW9Q\I/7C':M-_&>E:3I^DKJUW(;Z\M4F$4-N\SL-HW.5C4
MD+D]< 4 :.D>';#2?"UMX>2)9;&*V^S,DB@B52,-N'^UDD_4U:?2M/EBLXGL
MX&CLG5[92@Q"RC"E?0@$BN @\827O@[Q-JMQXG&G6UMK+P6NI1VBSB.',>P!
M IW9W8R03\V>U;>I>/\ 3]+\::?X<E$KM<0-)+,+>1MK?)L VJ00=QR>BXYQ
M0!TXT^S%^]^+:+[7)$(7FVC<R DA2?3)/'O5'2_"N@:)>2W>EZ/96=Q*,/)#
M"%8C.<<=!GL*HZ+K%O)JGB,2>(A>1V,P\V&2W$*V P25+X&\8&<DG&*=I7CO
MPYK-_#96=\YFN 6M_-MY8EG &28V=0'XYX)H U!HFEC2'TD:?;?V<X8-:^6/
M+(8EC\O3DDFH[SP[HU_J-IJ%WIEK->6>/L\[Q@O%@Y&#['D5DWOQ&\+6#SK/
MJ39MY7AN/+MI7$+*VUM^U3M&01D\'!QG%=-%+'/$DL3J\;J&5E.0P/((- #Z
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X#XOLJ>#
M;9F8*HU2T)). !Y@KOZJW^FV.JVIM=1L[>[MR0QBN(Q(I(Z'!XH Y_Q-XXT#
M1M#N9SJ5K<W#1LEO:P2K))/(1A555))R<5QVB6FIZ%8^#_"WGV.EW\6ESW<M
M_=6ZRR1?.I:&/) !^?YO9:]%L/"WA_2[@7&GZ%IMI..DL%HB,/Q S4^J:'I.
MMK$NJZ;:7RPMNC%S"LFP^HR.* /%I+I)/AW?S->K<JOC!9&N=H0.IF0[\#A0
M<[OQKJ[D:C)\5-8>Q\0V>E^=IML\+SVJSB:)6D#;277 5NO7[PKNY?#NBS)>
M)+I%BZWNW[4&MU(GV_=W\?-CMGI45SX4\/7EC;65SH>G36MK_J(9+9"D7^Z,
M<?A0!1\!6-OIW@VR@M-334K?=+)'=1Q>4KAI&;"KDX )('/05R-S='PZ+C4-
M(U;3]5T&XU?%QI-U$/.BG><!_*;J6$AW!67MP>AKU"**."%(H8UCC10J(@P%
M Z  =!6<?#6A'5_[7.C6']I9W?:OLZ^9GUW8SGWH Y#PO#&8?B(Y1=[ZM<HQ
MQU401X!_,_G6'X:U"[DT[PCI=I>V&E/'X=6Z?4KBW6639E5\M"Q  XW-UZ"O
M5XK"S@%P(;6",7+F2<)&!YK$ %F]20 ,GTJE<^&=!O8+2"ZT73YH;/BVCDMD
M981Z*".!P.!Z4 >):Q.L_P %9F%P+@_\)*Y,FS86S<,<[?X<YSCWKNM3_P"3
MA-$_[ <O_H;5VLGAW1)A<"71[!Q<RB:<-;H?,D'1FXY(]35IM.LGU%-0>S@:
M]C0QI<&,&14/50W4#VH XSXNM;IX*C:Z -LNHVAE!&04\U<_IFJGBZ5=2\?^
M&(](FCFNTL=1D8PN"5C:$*A)'8N5Q]*] NK.UOHUCN[>*>-7615E0, RG(.#
MW!Y!JIIOA_1M&FFFTS2K*REG_P!:]O L9?ZD"@#RSPYI\U_X1\')=>,;&*UC
MGM6M[)-. E$\9!,6X29W9#*3CU)KLOBP,_"W7Q_T[C_T-:Z"#PYHEMJSZK!I
M%C%J#Y+726ZB0D]3NQGGO5V[L[:_M9+6\MXKBWD&'BE0.K#W!X- '&>*HHX?
M%7@%8T5%2^E10HQM7[._ ]N*YS1+W3[+X(Z_:ZE-"EW"-0AO8Y&&\SL\F 1U
M+'*X^HKU6:SM;B:"::VBDDMV+PNZ F-B,$J3T."1Q5&X\,Z#=ZHNJ7&C:?+?
MJ01<O;(T@(Z'<1G(H @\/07L7@32[>7<M\FF1(V[J)!$ <^^:\Q\-Z=<7W@7
MPS!>>,;&VM4N;<168TX><ES'(#Y>[S,[MP()QW)->U5F1^'-$AU=M6CTBQ34
M6)+72VZB0D]3NQG/O0!Y'XQU.ZO_  3XONEU*PTVT%[<6HTV"T4RW#HP4N[9
MSO.W<2!PHSVKK]/2&;XXZA<@*[+H$&QQSP96S@_@*ZQ_#6A27]Q?/HU@UW<H
M8YYFMT+R*1@ACC)!'!]:GL](TW3Y%DL]/M;=UA6!6BA52(QR$R!]T>G2@#SS
M1/\ DK_Q%_Z\[3_T37(^&$NO^%;?#>6&_BL(TU.Y4W4T(ECCD8SB,LI(')R
M<C!(KW1--L(KRYO([*W2YN@%GF6(!Y0!@!CC)P..:B&AZ2-(.DC3+,::01]D
M$"^5@G)^3&.O/3K0!Y3XLT]K?PEX_NY_$=MJU]+:6T5TEO:>2L14G;G#,"Q#
M?D!7K>F0QV^E6<,*!(XX$5% X "@ 57@\.Z+:Z4^E0:38QZ?)]^U6W41O]5Q
M@]!U]*T54*H50  , #M0!P6GS11?&O7DDD1'DTFUV*S %OF?IZUR2Q1Q_LO?
M(BKF$.<#^+[3G/UKURYT32KS4K?4KK3;2:^MQB&XDA5I(_\ =8C(ZFG?V/IG
M]E_V7_9]I_9^,?9?)7RL9SC;C'7F@#SSQ#J=U=:EXQ2'4K#1[>PAC@F LUDN
M+XM#N&XD]/FV* "2<_2J_A,17'B7P!(=LAC\*L5;KM;$*G\<$BO1YM!T>YU6
M/59]+LY=0B&U+IX%,BCV;&:6RT+2--:)K'2[.V:)62,PP*A16.6 P. 3R?6@
M#FO!H"^,?'(' _M&$X]S;IFE\8^*=)30_%>D3W(@N[73'8K,0OF"2-@NSGYN
M>.._%=;#9VUO-/-!;Q12W#!YG1 &D8# +$=3@ <U5OM!T?5+NWN[_2[.ZN;<
MYAEF@5VCYSP2..>: . M[Z]34H=/34+#03I>@VDES>3VJR3RA@WR L1A%*G/
M7EJQ?"8CN(?A6K@2;)]1R&7&&5)",CL00..U>M7N@Z1J5[;WE]I=G<W5MS#-
M- KO'SG@D9'/-%OH6D6DZSV^EV4,RRO.LD<"JPD<8=P0/O$<$]Q0!Y?XSC9K
M_P")JQJ23H=JQ '7 EY_(5L>)-5L+O4_A[#;7<4TDFH),HC<-\GD.,\>Y'ZU
MZ!]@L_M$]Q]D@\ZX01S2>6-TBC.%8]P,G@^IJA8^%O#^FX-CHFG6Q643 Q6R
M+AP" PP.H!(S[F@#R7Q%JMSJ'@:]U%]4T^PM+C52D>D6UH@<E+H99WSG?\A=
MC@5V>A11/\9_%=QM4R+862J_HK!B<?7:/RKJ#X7T!KF[N6T33S/>*5N9#;(6
MF!ZACCG/?-6[32]/L)#)9V-M;NT:1%HHE4E$&$7('0#@#M0!Y-XBGNO#&L>)
M/"ECE6\4M'-I>!PDLS"*XY[8'S^U>M:9I]OI.EVFG6J[;>UA6&,?[*C _E7,
MVV@ZOJOC2WU[7XK*"'3(Y8].MK>0RG=)@-*[%1@[0 %'3)YKL* //O$>KZ:/
MBCX/8ZC:!88M064^<N(R4C #<\'(/7TKNIF:>PD:U=2SQ$Q.IR"2."#63-X*
M\*W$TDTWAO2))9&+N[V499F)R23CDUM0PQ6\$<$,:1Q1J$1$&%50,  #H!0!
MXXEYIJ_LVO9,\?V@6C6IMR1YGVKS"-NWKNW\XZ]ZV;A94^-OA9)SF9="E$A]
M6R<_K7<?\(SH)U?^UO[&T_\ M'=N^U?9D\S/KNQG/O5Q]/LI-0COWM(&O(T,
M:7!C!D53U4-U ]J ,GQI;Z;>>%KJVU6^:PM97B470_Y92>8IC;IC[X7KQZUY
MYXJO]5/AOQ=H>JS:?J=U#HRW$>I6</ENT6\C9*N3@\%A@XQGBO7;FV@O+:2W
MN88YH)%*O'(H96'H0>"*I:=X?T;1[6:VTW2K*T@F_P!;'! J+)V^8 <\>M '
M&>)=5L+OQ!\/X;:[BF=[[SE$;AOD\AQGCUSQ^/I5/PMJF@Z=\/M9@\2O;MY&
MI7:ZC;S*':1VG8KE.K$@KCCFN[L?"WA_3-IL=$TZV*R^<IBMD4A\$!A@=<$C
M/H33Y_#>AW.JIJL^CV,NH(05NGMU,@(Z'=C/':@#FO"L<7_"S/'$JQA6/V!0
M2,$+Y&<4_P"$X ^&^G < 2W( ]!]HDKKXK.V@N9[F*WBCGN-OG2J@#2;1A=Q
MZG X&:2TL[6PMEMK.WBMX%)*QQ($4$DDX XY))_&@#S/4[H^'1JNK:/JVGZG
MH[ZD3?Z->1#S%G,@5Q&W7=NY"L"/2KV@:E9:9JGQ!%[<Q0M'J'G,KL =A@3:
M<=\XX]:["3PUH4VKKJTFC6#ZBI!%TUNAD!'0[L9S[TZY\.Z+>:I'J=SI-C-?
MQ8V7,D"M(N.F&(SQVH \E\.3V=M+\(Y+UT1/L-XJ/(< .40#D],YP/<BM/48
MM*U3Q?XU%QJ7V*Q9=,A:]CP1'=JQ:,YY&0=@.>.<'%>D2>'M%FM8;:32+![>
M&-HHHFMT*HC8W*HQ@ X&0/2EMO#^C6>ER:7;:591:?)G?;) HC?/7*XP?QH
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M-YI-E<7L./*N)8%9TQR,,1G@T >->&DOFT[X<R6VIPZ9NM=0CBN+BW$JB4R
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MZ /3=-\<:'J6K0:5#/.+F=6:W:6VDCCN=HRQC=E"O@<\'ITKI*X;Q6B1^)O
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M\MU'+=*7M3<V<L*W( R3&SJ W'/':O++BWN+K0?B]';(SR?V@&*KU**VY_\
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M<,N=PCD*[7(P>A[<5Q4%S?6*V6@:?KUGX@L-0T^YCTZ01J+JT"P$H2RG#*0
MN2 <D56\.6R:AH/@R.Z\;0M%'-;/;:='8H)!+$N3$2IW# #*21ZYZT >Q5SG
MBG4H-/NM"2;6YM--SJ,<*)% )!=,3_JF.#M!_O<8]:Z.O-OBM_R%? ?_ &,=
MM_.@#I-2\>:#IE]=V$LMU->69 G@MK269T!4/N(53\N&'/3G'6MO3=2L]8TV
MWU&PG6>TN$$D4B]&!^O(^E<GX51/^%D>/)-HWF:R4MCG MQQ^II?A+Q\,M(
MZ S@?]_Y* .LU&_ATS3Y[VX$IAA7>XBC:1L>RJ"3^%>:R?$J34O"/AS7(WDT
MX3:M;Q7^^%EC\IMY8*SKAAA1DK^=>EWX)TZZ &287P!]#7C>ESVEY\+OAS D
ML,QCUJS65%8,5.Z3AAVZ=Z /3M'\8Z-K=Y<V=O+<0W-M&)I(;NVDMV\LG <!
MP,K[U%I/CG0M:U"*RLYY_,G5FMGEMI(X[D+]XQ.R@/CKP>G/2N3\;6]Q=>-M
M3@LU8W,O@Z]2,+U9C(N /Q-5]#MXM2'@YY_&\%TL;QSV-C#91J^5B8%"5.5
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M.8(^?G?:#M'!]^*J7GB#3+GQ'X5,&NW*+J2326MO;H&AO%" Y<D9&T'(Y'-
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M(2 3'(&X(Z_-QQ0!G7?@?Q%JB3:;?KX?%I<W"O>:I;P&.[N8ED#A"@4*&.T
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MHTV73;.2P7@6KP*8A_P#&/TKE/$/C".]^'7B+4]&FN;6]L(75TFA,4UO* "
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M*IR./+P3E^F>,\4 =C1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1KBWD#SN$#HL"YP3UQGD=MP]:]!^Q6GV9+?[+#Y$9!2+RQM4CD8'08KG=/\
M",2:]XAO=4M[*\M]1NHKB".2,2&/9$J'(88!R#TH \K2)XO!WPP+HT:2^)EF
MB1AC$;SNR?FI!_&NZ\/ZKIV@>,?&L.LWMO93RW<=XCW,@3S(#$H4J3U *L..
MAKO9;2VG\KS;>*3R6#Q;T!V,.A7T/TJ*\TO3]1:-KVPM;EHSE#/"KE?ID<4
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MUW%OI6G6EU)=6UA:PW$O^LECA57?ZD#)J9+:",2A(8U$K%I J ;R1@D^IXH
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M: ."U6_L];^)V@G2;J&[%AIU[)>26[AU1)%18P2.,E@2![9KGI$5/V:-."J
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M'%2M;0.8B\,;&$YC)4'8<8R/3CB@#C(N/C#K'OH$&?\ O[+7 :;_ ,FGS_\
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M2SV=O+);G,+O$K&,_P"R2..@Z4 6:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *0D*I9B  ,DGM2UQ'Q/U6YM_#D6B::V-5UV8:?;8
M_A#?ZQ_H%SSVR* ,'0O'FMW7BNRU&]E3_A%-;O)['35\I08V3 C<MC)\PK(
M#7=Z_P")['P\UI%<1W5Q=WCE+:UM(3++*5&6(4=@.23TK@M9^'OBV?P2FA0Z
MYI306$:/9I%IS1R"2+E,/YAPQ(QG!ZFH[3Q?9:AXA\%>*]2FBM+.YT^ZM)99
MCLC@NLIN5B>%SM8#/7% '81?$30I;#6;Q3=JFCQH]ZCP%7CW9^7:>=PVG(IR
M>/M(?3+C4?(U!;5)4A@=K1A]L=SA1 .LF2.HX[].:\XU?4+35+3XMWMB0]M+
M:6>R51\LN(V&X>H..#W'/>NF\:V[1>&O!UTM[)IUG97EN9KJ)5/V93"R*Y#
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M1TI@^(.C'4Q:B&_^SF[^Q#4/LQ^RF?=MV;_][Y<XQGO5/Q:H7Q3X#"@ #4)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<MY*PVL1+7$A<HGEIW+@ CZYZ5='CW34TC5K^[M-0LY-)19+NSN(@)D5N58
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M'S'?RH]\@P[;1EAZ'UK*U_Q+9^'EM5GBN;FZO)#%;6EK'OEF8#)P,@8 Y))
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MJ^UEW ':W4>QKE;SX@Z597MS$UIJ,EE:3BWNM1C@!MH),@%6;.>"0"0"!W-
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M2NT;3VQQ2-%&Y0O&C%#E21G:?:@!]%%% !1110 4444 %%%% !1110 4444
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M7VFE/M$=I$A 5D#ALLP&,-C'4D' .,T^3Q[I1T/2=3LX;R^;5N+*TMXP9I2
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M]O$K0VS8!(.6#-M!!;:#BI=1\<6EEK<FBVNG:AJ.H+;)=+%9HC!XV+#<&9@
M!MY)Q]X8SFO.YH=)TZZ\5:;X@\2:WI\]QJ-Q*FFVCJ/MD,W*^6I0ERP.TX/!
M'.*Z_0+1++XHWMM&)/+@\/V<2&7E\!Y!R?7@9H TX_'^E2^&X=8CM[YFGN39
M1V(B'V@W )!BVYP&&TD\XP,YJIJ/CICX7URXM-*U*'5=.C82V<D<?F0$QEDD
M/S[2G&<@GH>*X*6U(M3J4]W>65A9>,=0-U=6A >W1]Z"3)! 4,0"<=&KH;2#
M1IM \::CI.LZIK#OIC6\M[=.KQ/MCD(6-E5=V-QSUZB@##T;6HK7X4OK/B"Z
M\9)YYMWENTO1ND9F./(^?Y4YPP^7(QUKN+SQG?6_Q/M_#4>D7LMJUD9GDC1#
MDET42 EQ^[7+!N,YZ UP'B53_P ,RZ,,'.RUXQ_MBNPU?4;31_C=IMQJ$ZV\
M-UH;VL#R<"28W"D(#ZXH V=/\>6FHWUM''I6J)8W4S06VHO"OD2N,],,6 .T
MX)4 UU=>1:3JVGZ?KVEP^$M;O"MW?^5>>&[I=YM48L9&"D;HMIR>NT_C7IVE
MZS9:P;T64C/]BNGLY]R%<2IC<!GJ.1R.* +]%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<"@*H)(4 GJ0.M+10!A^*= ;Q%I]K:I<" P7T%V6*[LB-PVWKWQC-;855S@
M9.3@=:6B@ I J@DA0">I ZTM% !1110 FU2P8J-PXSBEP/2BB@ K#U_2M8O9
MK.YT76183VY;=%-!YT$ZL!PZ@J<C&00?6MRB@# \,>')="&H7-Y??;M2U&X^
MT75P(O+4D*%557)PJJ !R36\0#C(!QR,TM% !BD9588901Z$4M% !2,BOC<H
M;'(R,TM% !C(Q2*H4 *  .@%+10 4FU=V[:-V,9QS2T4 %)M4$G:,GKQUI:*
M "D(!&" 0>U+10 @  P  /2A551A0 !V I:*  @'J*,8Z444 (54L&*@D=#C
MI2T44 &!C&*0*%4*H  [ 4M% !@8QBD(!QD XZ4M% "!5#%@HW'J<<TM%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5@>)]1N88+?2=,?;JNI,8H'QGR$'^LF/L@/'JQ4=ZWZ
MR-7\+Z)KT\4^J:=%<RQ*41WSE5)R1P: ,KX:1^1X#LH0[N(IKF,-(VYB!<2
M9/?@5UE8'A#PK:>$=&-A;;&9II)9)%4KNW.Q7@D]%(7\*WZ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>sesenbio_minorirosales-e005.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***Y3XBZEI^D^$WNM3EU.*V$\2EM,E\N;);CG(X]>: .KHK(L
MO$5K>^)-3T(1317FGI%(WF !94D!(9"#R 00<XYHT;Q%:ZY>ZK;VD4VW3;HV
MDDS@!'D !8+@Y.W(!R!S0!KT444 %%%% !117+^)(=;@M-8U.WUR:T@MK1I+
M:WAAA8%E0L68NC'D\8&.GO0!U%%<1X47Q#K'A[0-9F\17#B\MEENX6MX !OC
M."A$8((<J><\57\ ^-K2X\*Z-'KNM1/K%[+,@\TA6D;SI%48 P"0  .,XXH
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M<R[,9:,_+C\?>K/ACQ!J,_C+7_#5]-'?)IJQ2QWJ1A&PXSY<@'R[A[8R.PH
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M4Y)P"QSQC&:RM)O[";PS\*TDGB/DW8$@DXVE8G'?T8@9]>.M>W8&<XYHZ=*
M//\ 0/L&H?$?Q_8R-#-%<I9H\6X$2#R65Q[^AJ+P3:ZD-1'A_4DD:W\+2/'!
M</TN Z_N&^JQ,P(]2OI7;ZQ!J-SI,\.DWL=E?,!Y4\D/FJAR"<KD9R,C\:9H
MNF/IEFZW%R;J\GD,US<; GF2$ 9"CH  J@<X"CD]: +5\T:V%RTREHA$Q=1U
M(P<BO-O"%Q=:;K^BZ78ZM!K^@3VTAM)6 ^U:<BJ,*Y7JIX7D YP.U>H4@502
M0H!/4@=: .)^([7%J/#FI['?3;#5HI[\*"=D>& D('\*D@G\^U5;F--8^)0U
M71YDN+6'0Y8+N>W8.CLS9CCR."WWFQV&/45Z#2*JH,* !Z 4 >+6\-GK7P8T
M#P_IYA?75DMQ%!'CS;:9909'8=4VKNR3CK[BNNL+VU7XS:Z&N8@1I-N#EP,%
M7D+#\ 03Z9KNPJABP4 GJ<=:6@#Q2SELY/@@93>K";35VG5PI=%<7A9/, Y"
M'()/8<C/ .]IVNZ'J_B+6?$$.IZ?J%Y_8YMUTFRG+M,B;I&/S*I8DG:,+P/K
MQV?B31[[6+6U_L_4A8W-K<K<(7A\V.0J#A77()'.>",$ ]JBL-&U*6]MKW7+
MG3YIK5F>!;*T,05BI4L2SL3\K,,# YYSQ@ \WTS6K"ZU_P"'%[#>HUNJ7$7V
M:VA(ALV:WPL(."Q8' ()).,X&:U]#U"TM=,^(EA<S+%<C4KZ=HWXQ&\:[6/8
M!NWKVKT_ '84M 'CVD7GV"V^&.KW$B_V-!I[6MQ-GY+:=XE52Y_AZ%<GID],
MU-K\<<DWQ'UBUFC_ ++N=$%OYJL/+GN1$X^4]&(!5>.YQU%>M$ @@@$'L:
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ME/M?E,J.Y:,E02!G Q[<^QKI/'FA2^(/"%[:VI*W\(%S9..JSQG<F/J1C\:
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M);V2>8M $\O<#&N?EP.O S7":?JEKIUO\+-4NVEBLK"VNK2[E,+GR93 JA6
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M"TBS,'W1!]H,@ "G/.,XJ6ZG32-'^%.J7RR165G$JW$OELPB+6H4;@!D<\4
M==8:QI7_  L77+8B^BO;:QBFN7FGS;JA /RKG ([G%0P?$>*2&TU&?0M2MM"
MO)5B@U.7R]AWG",R!MZHQQAB.XZ9KG3I\^K_ !.\=0VRL!?:!'##*5(4L\8
MY/UJI?:S;Z]\+].\%V<-P/$+QVEG+9- X:V:-TWN^1@* A.<^E ':W?CEUUG
M5=(TS0-1U.]TQD^T+"8T4*R!P=S,.3G '4D&M[0-;M/$>A6>L6._[-=1[T#C
M#+V((]001^%<]X5B=/'OCAV1@KW-KM8CAL6Z]/6CX4QO%\--'21&1P)<JPP1
M^]>@!U[X\,5WJ2:;H&HZI::6YCO;JW,86-P,LJAF!<J#R *?>>/K&.YTFWT^
MRN]2EU:T:ZLEM@H\P#;P2Q 7ALDG &#WP*YO2/$%EX+B\3Z3K"SQWTFI75W:
M1"!W-XDIW)Y> 0Q).TCL1S47A'1KW1=?\#65["ZS6^@W*R@C_5L7C.TGU&<?
MA0!W/AKQ,GB*.]C>QN+"]L)_L]U:W!4M&V P(*D@@@@@BL75O%NKV?Q+T[0+
M;2+B>SEM9)9&1XAYGS( XW,"%3+ CJ<\ U+X3C=/'/CAF1E5[RV*DC ;_1TZ
M5G^([Z#1_B[H%_?EXK2739[5)O+9E,I=2%X!P30!F:#XUN]'T_Q).^D:IJMM
M8ZQ>M=7$;IMMXA(>!O8%L*,[5Z#%==J'C)(KFSM-(TRZUB[NK47HBMV1 D!X
M#LSD 9/ '4X/I7-:3!*OPY\>H8G#O>ZL57:<MG=C'K6$+.UTW4M&U#6]3U?2
M;"Z\.V<,=U92O$OFQ@[HW*@\X8$9]Z /6-#UFU\0:/!J=F)%BER"DJ[7C925
M96'8A@0?I6C7.>![2QM/#$3:?'J*6]Q+)<#^T3^^8LY)=L\_-]X9YP>:Z.@
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MA:7-Y Z$K)\N[;%G>P7<,D#UP#BNEU"_MM+TVYU"\D$=M;1--*_]U5&2?R%
M%FBN+M/'L[3:7)J?AV]T[3M5E2&SNY98WR[C,8D13E-W;KSP<4R?X@W#2:RN
MF^&[V_&CW$D5VZS1QJ H!RNX_,2,_*/3W&0#MZ*I:9J<.KZ+:ZI9!GANH%GB
M#<$AER ?0\US%Q\1K*#X?0>*Q87#K,XB2R!'F>9O*%?3(VL?PH Z76=.?5M(
MN+&.^N;&25<)<VK[9(R#D$'\.1W&16)I?A2_3Q!;ZUKNNG5;JTA>&T5+5;=(
MM^-[8!.6( &<@8[5-J7BNVB;1+:WB>=];CD>!D( 2-8MY<^V"/Q(KB_!OCJZ
MTKX?>'[F\T6^ETK9%;SZHTR?*[/LW;"=Q4,0"WY9[@'K%%<=!J>E#XK7]C]G
MN$U&+2EFDN6G/D^5O'&S. <\YQ4=C\06O)+&Z/A^_BT._G%O:ZD60AR20K-&
M#N5&(X8^HSC- ':T5Y3H7BW4='@\6RPZ)>ZK;V6MWLES,LR((8PV=J[CEB "
M=HZ#'K7IEI?QZAI4&H68,D5Q L\(/&X,NY?IU% %JBN:TWQI8:AX(F\4-');
MV]O%*\\$A&^)HR0R'WROZBJ7_"=7%P^GVFF^'[J\U2ZLEOY;7SDC%M$WW=[M
MQN)_A'/!H [*BN0A^(%G-IMC=?8;F.:?5ETB>VD*A[:<D@AL$@@<'CJ"*V'U
MZ)/%T/AXPN9I;%[T2Y&T*KJFW'K\V: ->BL/Q#XA?1I;"TM=.EU#4+^1DM[:
M.18\A5W,S,QP !^/(JA-XU>'2[6230K]-6NKIK.'3'VJ[R*"6(?.TQA06W@X
MQ[\4 =717&7/Q!BL/#FM:C?Z5<6UYHS(MW8M(K,-^W:RN.&4ALY]B*=!XZD_
MM#2HK[0KNQM-5N6M[.YFD0[ODW(64'*[^0 >>.: .QHKGM4\76>E>(DTB:-S
MML)=0NIP?EMX4XW,.IR<C\*IZ5XVEO=0TZ"_T*[TV#5%8Z?/-(C"4A=^UE4Y
M1BH) /H>] '6US4GA:XOO%<&L:KJK7=M9.TEA8K (TA=AC>QR2[ $@$XQGI6
MGKNK?V)I;WBV=Q>R;TCBM[=<O([,%4<\ 9/)/ %<U<^.+^/1_$ ?09[76=*M
M1<M://&X:-@V)%<'! VMD=?EQWH [>L70M _L2\UJX^T^=_:=\;S;Y>WR\HJ
M[>IS]W.>.O2J_@;5M2UOP?IM_JMHT%S+;Q,79T/G@QJ?, 3A0Q)^7@CTKG+?
MQ7KNH>+?%VCS:7(EA86Z*L@FC_<9BD8.<'<V_"X SM[XYH ]%HKRWPEXYN=-
M\%>&9+W1+YM+ECM[1]4:5/\ 6MA=Q0G<5W<;OQY&,]'JGCE[.[U(66A7FH6.
MDG&H7<,B*(CM#L$5CERJD$@?3K0!U]%16UQ%=VL5S X>&9!)&XZ,I&0?RKC-
M$^(\>LV-QJG]CW5MH]I',UU?2R)MC:,G*A<[FR #D#'('6@#N**Y32?&4]YJ
M=C9ZEH5WI8U*-I+&2:5'$NU=Q5@IRC;?FP?0\Y%9%W\43;Z#=^(D\.7LN@Q,
MRPWPE0><0VT'9G<J%A@-],@"@#T*BL:P\0Q7_B/4=&6!TEL8()FD)&&$H; '
MTVUD#Q]!+I$5U;:;<7%Y<ZA+I]K9(RAI9(V8,=QX5<(6)/04 =A17'_\)['#
MIM\UYI-U!JMG<PVCZ=O1F>28@1;7SM*MGJ<8P?2LWQ/XWUS3O!>N7B>'KO3]
M3LHQS(\;QHK@[95?[K[2.5ZC(R,4 >A45G:'>7E_H]O<W]D]G<.N6A:17/UR
MO'/6N<N_'TRR:G-IGAV]U'3=*E>*[NXI8T^9!F01HQR^WOTY! S0!VE%>0?$
M?7KW5[[PA::=:7D^C:G<+,#;7@@^W*4#"/(8,O7O@<^HKTJ)YM,\+1/;Z9+Y
MMO:KML6N S@A1\AD8D$CIDDYQUH U:*\8?Q?K&J?#WPKK6J6MQ&YUNT8RPLI
M-VN]\A43IT"X.,UWFG>-'DUJZTK6M(GT>XALS?H99DE5X%.&.4)P0<9% '5T
M5Q^F>.GO;O3?MFA7EAI^K-MT^\FD0B4[2RAE!RA902,UV% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P/Q@A:;P3&!;R3
MHNH6SR(D9D)0."WR@$D8KOJ* /'/%%WX6UG0YK/PEX<N6U]ROV*:TTB2U>"3
M(PYE*+M [\UN_:V\(>/KO4M>\[[+J>F6T?VV*!Y$6>+<&0[02N=VX<8->C44
M >-EM0M]*N=6G_M/3=&UKQ(]Q<O;HZ7"6GE[48A1O0,R+DC!P1ZU0N88ET[X
MA6UA9ZJ(=0TN"6P-V)I)+A$#JS R98?,1A2<X(.*]SHH \]\703V_AGPEJ:6
MTTL.D7UK=74<499UB$91F"CD[=P./8U'I^K1^(/B[9:A86]RVFQZ--$MW);O
M&DC^;&2!N / QSW.<=#7HU% &;H.M6WB'1X=3M(YHX92ZA)TVN"KE"".W*FN
M.TVVN%^/6M7+02BW;1HE64H=I.]> >F:[JQL;?3;-+6U0I"I8@%BQ)8EB23R
M222?QJS0!Y]\);:>VTKQ$MQ!)$7U^[=1(A7<IVX(SU'O2^-KM8_%>F6^KW6J
MVV@/:2MG3S,IFN0RA4=HOF^[D@<9->@44 >#"=M,T'3H7T^^2>T\:K<&TF5W
MF\MQ(Z?,V?,;;Z$DD>]=)J]]%XI\37VJ:8D[Z?IOA^\BEN9('C5I9,8C&X D
M@*2?2N]U_0$UYM)9KAH?[.U".^&%SO*!AMZ\9W=?:KVI68U'2[NQ+E!<PO"7
M SMW*1G'XT >0_VO'X@^%WAKPG9VMW_:TZ6"-$;9PL<:-&YF+XV[-JYR#_%Z
MYKHM$M;A/C5XQN&@E6"2QM@DA0A6(09 /0UV^B:8NBZ#IVE+*95LK:.W$A&"
MX10N<=LXJ_0!X9X6T^_L?A-X/U%["Z;^R-9:[NK=8F,@A+R*S!,9.-X./3-=
M;X@\9WNL^'-:?PU:7ZVMM'#_ ,3-(G1VW2 2B)&4$E8\G=Z]N*]&HH \<L_[
M.A\;1W>EKK,^G76C75K'>WK7$HFGRC%5\S)48'7 !.0.E5/[1.J?!S2O!<5C
M?1Z]=0VUN+9[60;%$BL92V-H7:,YSP>#R#7MU% 'E=SH]YJ/Q4\:01PR(E[X
M?%M%,RD(790,;NG>JGA:ST*ZE\.V4J^*;C5[5XGGL[BXN##92Q+RS!SLVAA@
M8SG(P*]?HH XOXLVLMY\+M=CA4LZ0K,0.ZI(KM^BFJ_C75?.M/#EQ]LOK;P]
M>3;[ZYL"X?88BT0+1_,JLV 2/;GFNZDC2:)XI$5XW4JRL,@@]0:R?#6@_P#"
M-Z5_9D5V]Q9Q2,;59%^:&(G(CW9^8+R ?3 [4 >07L _L'QU96=CJBK=R6%S
M9I=K-)+-"'B4ON?+=03@G('88X]%\46TTWC_ ,%.D<AC26]\QU4D)FW(&3VY
MKLJ* /#)M4:S^"=[X,;3[Y]?M8)+:2U6TD( $A/F;\;2I7D'/)( KV69KF/0
M9&M$#72VQ,*GN^WY1^>*O44 >&0W%K+'X3U0OX@O;^UOX)M9N+LW+1VSE65E
M\L_*#O; V+P!UYYZ_0[6=/"7CY&@D5Y=3U)HU*$%P5X(]<UZ)10!Y/JL4VA_
M#OP3XM2"3[3X?M;8W$6,.UN\2QRI@]^0>>FVNP^'^E3Z;X3@FO5QJ.HR/J%Y
MZ^;*=Q'X JO_  &I/$'A63Q)?6Z7NJRC1HV2273$B4+.ZMN&]^I7.,KTXKI*
M . O;V+PG\2]0U;5$G33-4T^&..Z2!Y%CEB9LQMM!()# C/!YKE-5LKV7P/K
MNN&PNT@O?$<6HQ0F%O-%LCQKYA3&X9"EL8SC%>U44 <+IMPFJ?%8:K:+*]C-
MX>01S-$R G[0W'S $'V-<C?:/<RV.JWDL&HK;6?C.6[G-F72;R#$$,B%?F.-
MV?E[ U[110!Y'<V.CWGA7QC>:&NNWTATE[87M_+-*)N&;RX_,.X[3Z#&6^M>
MD^'$:+POI,;*49;*%2I&""$'&*TZ* /.9M7A\/?%?6K[48+F/3Y=-MH_M:6[
MR(KAG.T[03R,\].!ZBN>M+*^MK6R\7OI]W]C_P"$GN=2>#R6,J6LJ&,2&/&[
MC ;&,X.:]GHH \LU+4+WQ!XDU'Q#X7AN)(]-T"X@M[AK=D$UR[!E1 P!; 7/
M3&2!67ITFG+XJ\':K9/KU[#%+)%?WU\US(JS20.JKM?@'<3DJ !P,\U[/10!
MYGX7T>[O/AGXJTQ87BN;RZU*.(.NTDN6"GGL<CFL;4?$,>L>"/#.CV>GW[:A
M:7>GK?0M9R+]E\MT#;B5 ZC P3QD] :]EHH \D\2W-I:ZUJ-SH']MZ7XL^T@
M+9112-!J)! #LN#&59?XL@C'/(KO/&^E7.N>!]:TRT&;FXM'6)<XW-C('XD8
M_&M^B@#RS4]:B\8Z9X<T/3;2]&H)?6L][%):R1_8DB(9R[,  <C &><\5K>&
MK:>/3_'H>&13+J]VT8*D;P88P"/45WM% '-_#Z*2#X=^'HI8VCD33X0R.,%3
MM'!%<5IND71^)4GAR:SE.D6=_<ZTLC(?*82Q*JH#TR'EE./:O6:* /)? 6GZ
MA-K-S'?VTZ)X:TZ32+9I4($K&5_G3/4>7'$,^]-ELKK_ (9TTZU%M-]H$5IF
M'RSO&+A">.O3FO7** /,I=,N;SXU:\HBD2&Y\-^0LY0[-Q<#&>F:?X1\7-IW
MA_0/#*Z1?2:[;B*QNK5H7C6!4^5IFD*[2N!N&#SD 5Z510!YUHEK<)X0\?(T
M$JO+J>IM&I0@N"."/7/:NI\%QO%X%\/QR(R2)IMNK*PP5(C7((K<HH \<US2
MKJ/QS=^"H8F.D^)+R+59&'W8XTR;E?JS)'_WW71W=Y%X2^)6HZIJD<Z:9JEA
M D5U' \B1R1%@8VV@E20P(['FMW0O"LFFZQ<ZUJ>J2ZKJL\0@6>2)8EBA!SL
M1%X&3R3WP*Z.@#QFXM+U=$E\326%VEI+XNAU;RO);S5M%PGF%,;AG&[&,XKH
M]-U1->^+=MJ-C;W3::NB31)=20/&DC^=&2%W '@=^_..E>AT4 <?X]_L1H-/
M37;:_6W\UFCU*RWAK*0+P=T?S+NR1G!''/:N&G@OK[3]&U;5+K7+C1M.U6YB
M2^C$D-X;1X@J3-L ? ?()P"5YQ7M-% 'C.O:=IMS\-?&5UH,&MW37*P1?:K]
MY96NMC@CRQ)\Y"[F&< >F<5W?CW1I]7\#W"62D:A9!+VR('(FB(=0/<X*_C7
M5T4 >5:9I=]XR\-^-->>UEM[S7+=[.QAG4JR0QQE5'/3<Y8G\*3PO;^'[_5=
M#CC_ .$INM1ML32PWEQ<-%82*A!WB0[<Y)48SU]*]6HH Y'XB75Y:Z!:M!/>
M6]H]_"FH3V8;S8K8D[V4J"PYV@D<@$UQ%I! =7\5P:7:ZJUOJ?A\I827AGE:
MZ91*&PTF6'+# .,]0.>?9:* .4^'&I6]_P" ]'B@\T265G#:SI+"\921(U##
MY@,X]1D5SL5RNG_$CQQ:7,5PDNJVMNUD1 [+,$MW#88# P>.2*]-HH \JN[.
MY/P+\.VPMIC.G]G;H@AW+B6,G(ZC%4+RPTS2=;\36^NR^)4FN[V2YL[?3I[A
M8[V.15^51'\I;.5.<=L\5[)10!3TFTBL-&L;."*2&&WMXXHXI&W,BJH !.3D
M@#'6O-?#^A7VH_ C4M)C@>.]N!>B.-U*EF,SE1SZ\?G7JU% 'EGAVV\/:MK.
MEBU;Q3=7\"/*XOKBX:.P?RRI#B4XW'<5 7)_#FN:O]<33O@7>>$[BSNUUNRM
MVM[B VSA459,F0N1MVE>0<\D@"O>*R/%&A+XF\,W^BO.;=;R+RS*J[BO(.<=
M^E '(#5H/"_Q)U6YU2*Z2WU/3K3[))#;22B1X]X9!L!^;YAQ7*6^EW#>'M%U
M74K;5;.UM-<U!KU;-I$GMTE9P'S'\VT' )7/!/45[>B[(U7.=H IU 'ED%KX
M6;0M;O?[,\0ZGIES-;P7-W=/-*\BH21+'N/F;8RQR0/IG!K+OEOM1\#>--/T
MF[U76-&6SB:REO8W,OF9)DC1F4,Z@!3SG&<<U[/10!E>'-5M-9T*UN[)I&A*
M!,R1-&<@ $88 UY_IFM1^$-%\0^']1M+UM2-Y=R6<4=K))]M64EHRC*"#G=@
M\\8YKU6B@#R&[T&_TM/A382P2/-8SA;DHI81GRQG)'0 \9]J]:N%+VTJ*,LR
M$ ?A4E% 'B6A3&Z^'?@O2X[>Z%]I>NV:WD+VSJ83YKGG(P1CG(SCO75>*])N
MM6\=2VL$;@7/A>]M5EP=H=W0 $] :]#HH \A\+6F@W=QX>LW7Q3<:M:M')/:
M7-Q<&&QEC7EG#G8%!&!C.=W KUZBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y/Q_K6H:5I%E::1(L6I:M?1:?;S,NX0
ME\DR8[X53^.*ZRN2^(.C:AJ>CV5YI$2S:EI-]%J$$!;;YVS(9,]LJQ_'% %"
MX^'M[;6?VC1O%FNIK,8W)/>7K30RL.TD9^7:?8<5IZEXJOK;68M"TS2!JFK+
M:BYN@MP((85)VC+,"<D@X&,X&:S)_B0]W8FWT3P]K,VN2#:EG=6,D20N>\KG
M"A1WP>:ADNIO"GQ O-7UBWG:SU73K=&N;.VDF2*>(L&0A 6 (;()% %N7XDV
MT'AZ+4WTNZ$XU1=*NK(,#)!,3@@8X;L1CKD=*:OCO5QKDF@S>$YDUAH!<VT"
MWJ-')#D@LTF,)@C&,'DC%<LVE:E<:;'JC:==1#4O&5O?QP/$1)';AE4.Z]5R
M%R<] 179-:W'_"Y8[OR)/LP\/M'YVP[-_P!H!V[NF<<XH J/\2X8?#,>K3Z1
M<I.NJ_V5<V2.'>*;=M.".'[8Z9S6AIOB^[D\0'1=;T.72[J2V:ZMBLZW"S(I
M 894<.,CY>?K7GVJ1W>G:-=3/8SM(?'RSPPE-K3+YBE=N<9!Q@'I6_J-]=^*
M?&-OJ7AZTO -'TJ\VSW-H\(:YE50D8$@!)!7)XQ0!N:=XVOI]2TR'4_#ESIE
MIJK,EE/+.K.6"EPLD>,QDJI.,GT.*HR_$>^:QU:_L?"]Q=66D7,\%[*;I(\"
M)B&* C+G:-V.!R!DG..0LTM!=>$=5@L?$-Q<VMW&VKWEXETYCD:)U*['X/SG
MDHN%XYYKI=,L;M/ASXY@:TG6:>[U5HHS&0T@8OM*CJ<]L=: .FTWQ=;ZCXF;
M1A;O'YFGQ:C:3LW%Q$W!X[%3CCGK6/K5T_C*U\16.F12V]WH,RFRU!7^]=JF
M\J!Z#(5@<YW&L;Q*EQX=\%^$?&$5NYNM!@A2YA(VL\$D:QR(0>X8J<'I@UU'
MA2R_X1+P L^IL!<B*34-0D;@F5\R29^F<?A0!J>%-<7Q+X4TS654(;N!9'4=
M%?HP_!@15K6-5M="T:\U2]9EMK6)I9-HR2!V [D]!]:XCX?WP\+_  Q\(6]]
M;7+OJ$BPIY2 B,S,\BL^2,+@@9]2.*Z'Q_I%SKO@35].LT+W,L&8T!P792&"
M@]B=N/QH JV?B_4VOXK#4O#<EA=W=M)/8(;M'$[( 3&Q _=O@@]QUYXKS_P1
M=:W=:QXJ\0/X>DO]2@U*X@2:34PHM@,#R0IX(4$\XYKI?"UKX<O/$VGW.FZ9
MXB>ZM8I)'GU&6Z\NT<KL*$3'#,0Q'RYZ9J7X<V5W:VGC47%K-"9M>O)(A)&5
M\Q"%PRYZ@^HH Y?X8ZN^C>!%\27VDW-S>W[F&.[^V^9+?S-.42,(QPF#QGT!
M->@6WC7[.VIP^(=-;2;G3[3[<Z"83I)!R"RL ,D$$$8')'7-<!I'AZ^E^!'A
MN*?3[_S=.OQ=W%I$'CN#$+B3=L PP;:VX8P3CBM"3PYI'B+1O$<?AJQUE[F3
M2VMHK[49;C;(Q;=Y2B<YZHN3C SUH ZFP\9ZM<7%K'>>%+JT2_A>2Q?[0L@=
M@NX)+@?NBPZ9R,\5R]GXOO-5^%NOZKXHT=[BPBEF^6.["&51.0(P4 *[.!N[
MXKJ-$\:R:M=Z7IMGHFH"4Q_\3%KJWD@6RVKTRRX=BW "GISFN"5+EO@SXI\-
M_P!GWXU6WFG9H#:2?,&N-RE&QAL@YX)H ]%TCQ1;G6=+T 6+VT=SI*7MI(TN
MX,HP#'SSN4$'.>14-_X_MK'4-;MA833KI9MX=T3#,]S-]R%!Z\C)SQFLGQ#8
MW=EX5\)>(;6SGEOM"-N\D$49:5X'01S(%ZYP0<?[-9,OA74)?A;#>75G<RZG
M<ZI'KE_;0%DF;=(&9$QA@RQX  P<KQS0!W6B>);J^UB;1M6TEM,U%(!=1QBX
M69)8BVTD, .0< @CN.N:LZ_K-[I9LX--T>?4[NZ=E1%?RXXPHR6>0@A1V'&2
M>E<UX-L_#\OB.:_T:QUMC%:^4;_49;C;\S F)5G.2?E!) P/6G>/)-NNZ)'J
M9U0>'F2?[2-/$Q+S?+Y:OY/S[<;\8X)ZT 61X^+:*DZZ/-_:K:D=*_L\S*,7
M !8CS.FW:-V['X5NZ%JM[J<-PNHZ1/IEU;R>6\;N)$<8!#(XX8<_@00:\PTB
M'3K30]=TO7/#.K'3Y-;^U;/*F>6UA>)3%,&&68@K@[264DYXKL?A\]VT>JHM
MSJ=UHR3J--GU-&69EV#>/G 8J&X!89Z^E %W5?%=W#X@?0]$T9M4OH8%N+G=
M<K!'"K$A06(.6.#@8Z=ZXOXA^-;[4?A)J-]I-G<6D@E-I?L9PDEE(LJ*R<?>
MSDC(/0YK<FO!X0^(NMZEJ5O>'3M8MK8Q7-O;23JDD093&P0$@D,".,&N4U_1
MM5G^#7BZ?^S;M;G6=6-_!9^43,L;31!=R#D':FXCMF@#TCP5IW]F>'([?^R#
MI?S%O(-U]H+<#Y]WOZ5PEQXH\0ZSX<^(L-_I_D6UG%<Q1NMPA^SE8%_=@  M
MDDMN]\5ZS;@BVB!&"$''X5Y'-Y]O9_$[19+&^^VWS7-S:A;61DFC:  %7 VD
MY&,9S0!T6C^-+VUB\.6]_H$]OINI"*UM;]KA2S2&/*[H^JAMIQSGU JQ>?$"
M6V:_O8="GGT'3KAK>[U$3J"I4[9&6/&653P3D=#@'%5_$-G=2Z-X#2.VF=H-
M5LGE54),:B)P2WH!ZFN230](L!JVC:UI?B.[U&6_G,%M:372P7D,LA96!5A$
MHPV&R1C!S0![-/<PVUI+=32!8(HS([]@H&2?RKRCQ9XOU+6O!UC=OH%Q8Z=?
MWUFUG=&X5V93,C N@Y0,H)')]#U%>D:UIC7OA74-*MOE:>RDMH\GH60J.?QK
MRW4-9GU/X<Z'X?M]&U7^T[*6QCOHGLI%%N(I$!.XC:V2!C:3P2> #0!V^N^,
M=1TBXU%[?PS=7>G:8@DN[LS+%\NW<WE*P_>;5Z\CG(K/NO%NMO\ $W3=)T_3
MQ/I4^G&ZSYZ+YB,T8\WD9&S+#;WSFN;\36TFJ7/BZRU*RUN]UIVDCTFWA,ZV
MRP&(;7!0B,\[BV[))&,'I5VQOA9^,_"6KS6>H"QFT V D%E*2D_F)\KJ%RO0
M\D8[].: -]_B#(H?41H<S>'([O[*VI^>N<A_+,@BZF,/QG.>^*Z_4+ZWTS3K
MF_NW\NVMHFFE?T51DG\A7C.F^'M%M-//AW6=)\1W>K"[>$VT$]TMO/&TI*R@
MAA$$VD$Y(Y!XS7JGC#2IM<\&ZQI=L1]HNK.2*+)P"Q4X!/UQ0!A6WCV]']EW
M>J>&Y[#2=4ECAMKMKE'96D_U?F1@?(&X[G&>:Y'S-4USXX746HZ)+<1Z?;P-
M#;_VCM2V&\'S@!@,3UV_A6AJ&J/XM\/Z#X;L],U&+4ENK1KY)[.2-;-8F#.2
M[ *?NX&"<YK6TFSND^-WB&\>VF6UDTR!$F*$(S C(#=": +OQ-\0:KX;\(27
MNDP[IS-%&9MZCR@TBC."#G.=OMG/:IKKQ9JD=W:Z7:>'6N=9>V-U<6OVQ$2W
MCW%1F3!!+$'  ['IBJWQ7M+F[^'E\EI;2W$J2V\ICA0LY59D9L =< $_A7.:
MVFDWOB^/Q)J,6N#1=0TY(8;BS2ZA:.6.1\K(D>' 8-D;AC@^M '07GQ)MK;1
M]&OH=*NIY-3NGLQ:A@)8IUW QGMG>NW.0.<]*DG\;:G;ZI8:._AF4ZQ>6;W2
MVRW:%8RK[=K28P!CYMWX8)-<\^CQQIX&?3-&U&TMCK4EU+%=%Y)8PRO\\A))
M7=P>3QGGFNDN;6X/QAT^Z$$IMUT2:,S;#L#&9"%STS@'B@#.3XDZC/I>HW=M
MX2N9)-(>1-4C:[11 4R2$;'[P[1NX XQZU8U77M%NO%O@61]/FN)]3CGFL+D
M3L@@4Q*QW(#AL@@<]*IZ98W:>'?B.C6LZO<:A>M IC(,H," %?4$\#%9/]FW
M_P#;OPB?[%<[;2QE6Y;RFQ"?L\8P_'RG((YH Z*;X@7\AUHZ7X9GO4T:YEAN
MG-TL8P@!RF1\S8R=O;CGFM"?Q==W-MI4N@:#<:F=1M!>*SRB"**,A<!G((WG
M<,*/0]JS/#MG=1:/X\62VF1I]6O7B#(09%,2 %?4$CJ*Y>S1H+7PM9>(K?7/
M[)3P_ (;6R2X7?>9PR/Y6#N"[<!B!R: -K7_ !_JLFB^&-0T/37 U'54M)XY
M)45E=796@.01R48;ATQ[UJPZI82?%:VLKC29(=:?0Q.]Q]J+)&GF8,6P?*2&
MS\V*X6*&ZL/ ^@)-I=_$^B^*_M%["())&BB\V5MP."9!AU^9<YS73I!-J/QO
MM]4BMKH:?/X:VK.\#H 6E)"G(&&P<[3S[4 6V^)$_P#9DNOP^';B7PS%(RMJ
M N%\QD5MK2K#C)0$'OG SBK]YXTNCXCO-#T?0WU*[@MX;D/]I6*)HWW<EB#C
MH,#G.>P!KBX+RZLOA5/X#;2M0?Q"()=.2%;20QN&8@2B7&S9M.[)/K75^&-,
MN-.\?ZRLD4AA32["!)RA"R%!(#@]^WYT ;_A;Q#'XGT*/4DMI+5R[Q36\A!:
M*1&*LI(X/(ZULUP'@Z\E\/\ AV7[7IM^[76OW,*I% 2RB2=MLC XPF.2WI7?
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9&OZ#%K\>G)+.\
M7V*_@OEV@'<T3;@I]C6O110 4444 <[K7A7^W]6M9K_4[E],MW28:8J(L4DJ
MG*L[8W,,X.W.,@5:\1Z GB735TVXN9(K)Y5:YCC',Z Y\LGLI.,XY(X[UL44
M 5I]/M+D6PEA!6UD$L*@D!6 (!P.#@$\'CH>PJS110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQAY)"!D]2  ,COWK;MIC<6L,S0R0F1 YBE #)D9VM@D9'0\T 2T444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7&?$*\O-$@T?Q%;W,\=MIU\GV^)'(22WD^1RR]&*DJ1
MGIS79U2U?3(-:T:]TRZ&8+N%X7]@PQGZT <PE[=ZS\5WMK>ZF33-#L0;B..0
MA);B;[H8#A@J#(ST)KM*YGP=X2;PGHMQ:/J+WU[<RM-->O%L9VVA5^7)X"J!
MU_G6QH]I>6&D6UK?Z@VH74:8DNFC$9E.>NT<"@"]1110 4444 %<WXT\+_\
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MS,GGR JQSRN !@\8 KLM/UN7PWXM\6Z?J]Y-+9QP#6K1II"Q6 @B5%ST"NO
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M:G-<R_:/)_U?FN6QMW<XSCJ,^U8+:5J3?%>\72=52SNK;0K6/?+;^;'(OF2
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M50/Y4J'@E3]X8)!'O0!PUWI3:!\2#';7][+"/#=W)"+FX:62)@Z9P[$MC@$
MG@YQ5B\U74%^#7AJ_6^N1>3'3?-G$K;WW21ALMG)R"<^N:W++P3>MXF_M[6M
M;%_<M826#Q16ODQB-F4_*-Q(Q@YSG.[M@"LQ/AMJLFA6.AW7BCS=-TZ:&2T1
M;$*^(W#*)&W_ #84%1@#L><8H 9IMG>Z[\4_%$5UK.I1Z?I4]E+!:07+(A=H
M@Q##^[\I^7H=QS7-W&O:NGA;XHSKJ=YYMCJC):OY[9@4./E0Y^4>PKU#2?#@
MTOQ/K^L_:O,.KM QB\O'E>5'LZY^;/7H,5STOPT671_%VG_VL1_PD5V;DO\
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MQOCA1&QZ@ 5PUC\-[NT\/#0'UY9--@OX[RT7['AX@LQE*LV_YLDXS@8]#TH
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MTG;M<;T)4'GG/2N(TG5-5U+1[#Q%9Z?XJG\03W2W#3C>;-XC+\T03?M\L1Y
M^7.1G- 'N5%>;V/B*3P?/XWLM3N)9TT[.J61FD+%X)1Q&"><+("H^HKGU.HV
MK^'?#^NKK^I*VF2:G?1:?(_FRSR2 !78,K!$R1@'&<4 >T45XQJ-UX@'A31[
M)I]8TUF\5Q6=K-=DK<&U<-MWG)W8W$<YSL&:Z#Q!INE:9-I&@>?XBOXU2:?^
MS;&>1II\D?O)9=ZD*I)P"P!+>U 'H]%>,0W^JW_AOPW9#4=3M6_X2B73S))-
M_I @43 ([ G+!0!G)Y /.*OZG=3^ ]=\2P:3<W;VJ>'#J,4-U</.([@2,FX%
MR3@\$C/.* /6**X;2?"DFD0Z=KEKK>I/<);F74$N+AYTOLIG[K-A"&Y!4<=,
M5Q>A7^JW=AHFNVEAXIGURYN(9[NX?>;2:%V'F(%WE0@0G:0H(VB@#U[6M7M-
M!T:ZU6^+BUM8S)(47<<>PK M?B-HTUY;6US:ZOIQNI!%#+?Z?+!&[GHN\C&3
MVS2?%+_DE_B'_KT;^8K%UA_$?C31[?01X5N=,MYIH'GOKNYA(B1'5R55&)+'
M;@=.M 'I-(0&!# $'@@UX[J=[<ZWK'B>1[7Q1->6=T]IIDFELX@M2B+@D!P&
M8L26W \$"KCP:EXH^(&DZ;JMYJ%C%-X8CN[ZTMYVA)E\W!4[3\OS'G'/RXZ4
M >C6]_*VLW&FC2[F&W@B5TNR%$,A/\*X.<CZ5HUY5-K=]I'Q'\</'<32P:;H
M"W,%N\C,@=4!SMSC)QR:KW^GS^'OA]IGC.#5=2EUI?LES=22WDCI<B5T#QF,
MG8%PYQ@#&!0!ZXS;5+'L,UF>'-<@\2^'K+6;:*2*&[C\Q$DQN49(YQQVKB=-
MTY_%NK>+-3N]1OX9[#4)+"P$%T\:6PCC4[M@(5B6;)W @].E;/PI_P"26^'O
M^O7_ -F- '8T5Y5IVER>+?#VO>)+S5-2BU$7-VMBT%Y)$EHL3,J (I"G[N3D
M'.:IVUS?^-/$7A*&[U&]MK;4/#IN+V.UF:+S6#+G&T_+EL<CG&1WH ]AKB[G
MXD:$;B9;6QU758;5RLMW8Z>\\,3#K\X&#CVS6KXL\ZP\ :U]A:3SH-,F$+;B
M6!6,X.>I/%-\"06EMX!T".R"BW^P0LNWN2@)/U)))]S0 V]\<Z!9>#_^$J^U
MF?2?EQ+ A8\L%QMZ@Y."#R*NZYXDTOP[IBZAJ=SY4+LJ1*%+/*YZ*JCEB?05
MPOQCLK"Q^$&M1Z?;V\$;W,<DBP* #(9UW$X[YZU?U)4G^+?A**[P88M,N9K5
M6Z&?Y 2/<)0!K:=\0=)O=4M]-N;75-+NKHXMEU.R> 3GT5CP3[=:Z2\O+?3[
M*>\NYEAMH(S)+(YX50,DG\*CO[*PO4A&H6]O,D4R2Q"=00L@/RD9_BR>*K^(
M=&B\0^'=0T>>1HH[R!HC(O)3(X/O@T 85K\1-%EN[;S;'5;*&]=8K>]N[!XH
M9F/W!O/3/;.*["O.+O6O$WA>QB3QCH^FZKHD3QI+J-FW,8W +))"X['!.T\=
M16%J=]<ZWJWB>5K7Q1->V=V]IIDNEEQ!:F-%P2 X#,6)+;@>"!0![)17G6C:
MGJ6F^.K(ZQ)-#%XAT>.<P3,=MO=PJ#*B@\+\K9..ZUS+ZSJ=YH]MJ<LNK26_
MB?7'*PV3MYRV,:/LCC&1M+;,D@@D$T >UTC(KC#J&&<X(S7C.IW>J:=X.\:)
M96VOZ=I<=G%-8MJ+N)89=Q$BHY8MMX4]>,FN@U/3;71O"MHMYK&MRW6JW4+7
M"VLKR3WC[2S11\CRU/.=I "KB@#T>BO$;W5+ZQ\(^/+.R.KZ?%8FSDLXKZ<M
M/;^81N ;>QVDKD#=W-=3=:8WACQ]X5:TU'49CJ;W,-^+BZ>1;C;"7#;6.U2&
M7C: !G'2@#T6BO,/">AW?BOPU8^*SKFHVNN7<[7(E$[O#'&)2/)\G<$*;1CU
MSSFL6^O[[6KGQ+>1VGBF;5K6^GMM+FT\M]FM_*^5!M#A6RPRVY3D&@#VAF"(
M6/0#)KAX/BOH$UG'?-9ZW#I[C=]MDTR7R O]XN 1CWKK+6:>XT2&>YB,-Q);
M*\L9&"C%<D?@>*\I\):KXBO/A/8:+IWA&YG\^P:WCO)KF%("&!&\C=NP,],9
M.* /88I8YHDEB=7C=0RLIR&!Z$&G5Y#>H;77K'PK?V^O:CI^CZ+;*(](9TWS
M'<OF.5=3P(QM&<<FH;B7Q#>6G@G3;Z\U73YI]2NK6621S'/+;A6VE\'[Y3'/
M.&YZT >J7.HSP:S96":;=30W"N7NTV^5!M&0'YSST& :T*\SU%)-$^*W@31K
M*[O!8?9KP/$]P[^9B-B"^3\Q!Z$U1L-.E\3^"M8\77.J:E%JQ>[ELWAO)(TM
M%B=U1!&"%(^3G(.<F@#UJLK1->@UUM3$$4D?]GWTEC)OQ\S(%)(QV^85P&C7
M$OQ \162:K<W<=I!H-I>FWM;F2 /<39)<E""< 8 S@9K8^%T#VMKXHMY+A[A
MHO$-TGFR'+/A8P"Q[GU]Z .S&H6AU-M-$ZF\6$3F'N(R2H;Z9!'X53\-Z]!X
MF\/VNL6T4D4-R&*I)C<-K%><?2N)LM%M7^.NJS-)=[HM-@N% NY NXNP((W8
M*_[)X'I7(V6EOI_P-B\4P:EJ$>J60::U,=TZ1Q*+@C9Y8.T@C.<@DY],"@#W
MFJTVH6EO?VUC+.JW5T':&,]7"8+$?3(_.O-?&DMK=ZSK>R3Q)?W=E:KY:Z9(
MT4.G/L+!F;>H9CD,<[L# Q5(64?B#QQX!O[^:[,]]HC7,QBNI(QO$<9R K#:
M"3R!P>^: /8**X_XIW5Q9?#+7+BUGE@GCA4I+$Y5E.]>A'(KG/$EO+X?LM$T
MY;G6[QM;O?,U)[69GGF"1,[)'R-BD@9"D84&@#U.BO(DB\1/I>N6.D:=XBAT
MI9;2>""[E9+DQ;C]HBBD9B>54$?-_$0.M17^HV5OX)U@Z%J.MVTD5]8B33]0
M>19[(M.@(!<EMKCW(X..] 'L5<SHOCC2]7T;5]5<26=GI=W+:W#SXZQ@$L,9
MX^;ZU6\075Q%\2/!MO'/*D,R7WFQJY"OMC0C<.AQVS7E!M8[CX+>/9':4-!X
MAN)$V2,@)W1+\P!^888\'(Z'L* /H153)=54%\$L!R:=7E_B/2?[(O-/6ZMO
M$5YX8BLF4?V?>3/+!<%RQDDP_F.NTC!R0N#Q7=^&IH)_#6G2VVI2:G T"[+R
M3[\P[,WOZ]\]: )=-U&>_EO4FTVZLQ;3M$C3[<3J/XTP3\I]\&M"O$)-8U-?
M!7Q2G&H7?FVFKRI;OYS9A4.N IS\H]A74WFEOX9\;>%)K;4M0FEU*>:WO_/N
MGD2X_<LP;83M4AER-H '2@#T:JNIWR:7I5YJ$JL\=K \[*O4A5+$#WXKEOB5
MJESI^@V$%L;P?VAJ,-I*;'_7^6=S,(^1AB$QGWKFH#=V]CXKM;73==M-"DT.
M65$U8LQCG"L&",S,<,I!QGJ#0!VMEXL_M+PYI&M6&D7US%J3HOEQ[=T"MGYW
MYQM&.<9ZUT6Q0Y?:-Q&"V.<5X?)>W=E\)?AJ;2ZFMS+JMI%(8I"F]#ORIQU!
M]*ZVTTZ3Q=XR\42WFI:C NF3QVE@EK=/$L!\I7:3:I 9BS?Q C QB@#M-4U&
M?3S9B'3;J]^T7"PN;?;^Y4]9&R1\H[XYJ+3=>@U/6=8TR**1)=+DCCE9L8<N
M@<;?P/>O(5U?5?\ A7WP\GDU*Z:YN/$BQ7$JS,#*OGR@J3GE>!P>, 5T>G^&
MH/$7Q#\<+>W=ZEO'/:A(K6Z>#YS;K\Y*$$D8& >!SQ0!W^J7TEG/8+'I=Q>^
M?<")GA"D6X/_ "T;)'RCVYJE:^*;6Z\:7WAA8)A=6=LER\IQL96(P!SG/->7
MG7]7N/#OP\:;4;EISXB^Q7$JR%3<(DK(-^/O9"C.>IKIM'_Y. \1?]@B#^:T
M =?:>(8SH2ZKJMI/I"&01M%>8WJ2X1<[21R2,?6MFOGJW$NM_ C1;O4;R]N+
M@:PD9D:ZDRP:X Y.><#IGIVQ7HUMO\(?$B#3VN[E]'UFQQ +FX>7RKB 9(W.
M3C<ASUY(H [^N9U[QI!HVOV>A0:9?:EJ=U$TZP6@3Y(P<%F+LH'.?RJG\/);
MO5;#4O$=U/,Z:O>/+:12.2L5LIV1@*>!D L<=<URFK^&["[^/EI!))?!+C1Y
M+ERE],A#^:1A2&!5?]D8'M0!Z[17ENFZ4_C#2/$.OWNIZE%?)>745BT%Y)$M
MFD1*IA%(4G*Y.0<YK.L[O4/&NO>$(;S4KVWM]0\/M/?1VLS1><P=<XV_=RV.
M1SC([T >QT5A>)KZ3PWX'U2]L\F6PL)&A+G=\RH=I.>O(&:Q-"\)26$6D:W;
MZYJ377DB74!<7#SI>ADR1M9L(0QR"HXZ8H [BBO&X+.ZO_A3/X\?5M13Q";>
M74(YDO)!''M8D1"+.S9M&W!'.36K8VS^,/'>K0ZA>W\>GG2[&X^R074D2B1U
M<YRI!XYXZ$XSG H ]/IOEH9!)L7>!@-CG'UKPWR;\?!Z7Q9-K>J2ZQITK+:S
M&[<*J17'EA60':^0#DL"3GKQ76G2F\1_$_Q'87VH7XTVWL[-Q:07<D2EV#_-
ME"#Q@\9P203G H ]'HKQ^TU,S^&X]%U74]9NVM-=NM/C@L2QNM0CASA6<,I
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5B^)?#J>(K*",7D]E=VLZW-K=P8W12 $
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MJY5KZS2%2SD($.V0G*AE4 C!/7!%54^']] OAR6V\1-%?:' ]HDYLU82P,
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M#=++Y0S,8]WRD9XSN]ZQ?$-UI>A>-=7=_$E]H'VZ&*2ZC-HKI>87;NMWY*N
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MDBGA.'BD1@RNON"*Q[/P1./$=CKNK:]<:G>VD4L #P)'&4< 8VKP.Y)YSGT
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M2^([QM7U-8D?48HTB:)(R2JHJ\#[S9]=QH ZVO/_ (V?\DCUO_MA_P"CXZ]
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MZ4Q\JP\[^T&D'_+([=NP'WSGVI^B-=V7B[Q3;^(TB'B+4--%RKVC9MFMHP4
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M,\$Z0EG%Y:S6D,SC<6R[1KD\D_ETKSJUM;;P[<_$[6M.@*7VG$_99-[-Y9:
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MYU2%3$'9P%(^9BWWNO Q0!Z/17B=C+=ZU%X)TV]O[J1$U;4+&282L'GAC60
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M_M7%MY'V#49K#E]WF>7CYN@QG/3GZUM4 %%%% !1110 4444 %%%% !1110
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MB>""UN(FYRDDBOO/U-:WCQ?[1UKPKX?N&?\ L[4KV7[6BL5\U8XF=8R1_"6
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M1-BA%1<\@<YXSW%9/PO\,'0=&OKV:S>RN-5NWN1:R'YK:$L?*B/I@$G'8L:
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M[.#C:..-NW&.,5%-X"MKW0=6TS4M7U.]DU546YNI70.%7[H10H10.>B\Y.:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 5D>(O#MGXFTY+2[>>)HIEN(+BW?9+#*OW
M74\X/)[=ZUZ* .1@^'>E+>7EY>W>HZC<WMA)I]S+=S!C)$Y!(X4;<;>,8 R>
M,G-,@^'=E%<:==2ZSK-Q>:=(&M;F:=2\:!2IC V8VL#AN-QP.>!78T4 <E#\
M/-)BCUFW:YOY;#5G>66R>8>5'([!B\>!N5MP!')Q5[1?"L6D:@]_-JFIZG=F
M'R$EOI@WEQYR54*JCD@9)!)QUK?HH Q_$'ANT\0QVIFFN;6ZM)?-M;NU?9+"
MV,'!((P0<$$$&JVE^#['38-3#7-Y>7>IKLN[RZD#2NH4J , *  3@ 8YKH:*
M ,SP]H5KX:T&TT:Q:5K:U0I&96!8C)/) 'KZ52N_"5K<^+(/$<=]?6M['"L$
MB6\BB.>-6W!7!4Y&2>A%=!10!R5I\/\ 3K*\@:+4-4_L^VN/M,&F&<?9HI,E
MA@;=V 3D*6(![5L:1H%IHMUJEQ:M,SZE=&[F\Q@0'( ^7 &!@#UK5HH YG_A
M!=*_X0C_ (1+S;K^SMV[?O7S/];YO7;C[WMTK3O-"M+[7M,UF5I1<Z<LRPA6
M 4B4 -N&.?NC'(K3HH Y*W^'FC6NB7&DI+>&WGU(:FY,B[O-#JV =OW<H..O
MO6OJ/ARPU76++4KKS&EM(9X$C##8R2A0X88R>%&.16M10!Q,?PRTY;:SA?6-
M:D.GNC6#O<*3:!>BI\F,8P#N!.!C-7D\"V$6HZU<Q7^HQPZPL@NK195\DNZ[
M6< KD-CWQ[5U%% '+'P#I0\.Z5H\,][!_91W65Y%*%GA;D$AL8.02"",$=J1
M/ .F'2]8M+J[O[R?5XQ%>7L\JF9D P%!"A5 R< +WKJJ* ,F_P##MGJ/]D><
M\P_LJX2Y@V,!EE1D&[CD88],5/K.CV6OZ1<:7J,1DM;A<. <$8.001T((!!]
M15^B@#F]*\&6VGZO%JEUJ>IZK>6\;16TE_*K^0K8W;0JJ,D  L<D^M6]"\,V
M/AZXU6>S>=GU.\>]G\U@0';J%P!@?G6S10!QOQ%N7N?#MUX>MM(O-1O=4@,,
M C@8Q1L3@/))]U IPW)SQ6E8>$=.M_ \/A:YB%Q9"U$$P.1YA/+-Z@ELMGUK
MH** .7TSP1:V&J6NHW6J:IJDUDC)9B_F5UM]PP2H51EB.-S9.*HW/PQTFYAU
M&S;4M673+]Y)9-/2X40K(_)91MSU^8 DC/.*[:B@#&MO#-C:^(DUR-YS=+IZ
MZ< S#9Y2ON!QC.[/?/X5?U'3[75M-N=/OHA-:W,;12QG^)2,&K5% '-Z3X-@
MTR^6[FU;5=2EBA:WM_MTX<0HV,[0%&2<#YCD\=:0>!]+'@^S\,>9=?8+1HWC
M;>OF$HX<9.,=1Z=*Z6B@#'U#0;6ZUF'6V,WVRUM)K>-5(VE7P3D8R3\HQS7"
M^"?A[#=^!=!CU2ZU>*W5$GGTB23;"TJMN^9"NX#(#%<@9YQ7J5% &)%X7L(O
M%]SXF#3&]N+06;HS Q[ 0>!C.>/6L>+X:Z5%Y5L;_5'TB&83Q:2\X-LK!MP&
M-NXJ&Y"EB/:NSHH \Y\6Z<GCGQ9HVDKI5X+;2KPW-[?3P-'$4 _U2$X\S>=N
M<< "NSO]"M-1UG2M4F:47&F/*\ 1@%)D38VX8YX/M6G10!F66A6EAKNJ:Q$T
MIN=2$(G#,"H\I2J[1CC@G/)K&7X?:7#H6EZ9:7=_:OI;N]G>PRJ)XRY)89V[
M2#G!!&.!7644 <RG@;31IT%I+=7T[QZC'J3W$TP:6:="""QQC' & !P.,5IS
M:%:3^([;7':7[5;VTELBAAL*.5)R,9S\H[UIT4 <AIWP]L=+T*;1;;5]86P:
M5)(H_M*@V^UR^U"%R%)/.<Y%=?110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW//)"_Q$#)QWQBL-?%=V-3TJ+^QM;>UN]/-PK"T7=Y@5B4FY C; 7 &,L^.
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MO?1JK/$Q(#J59@1D8Z]:S_&_C"[\,WVA6UKIMU=?;[U8I#%&K93#$HN6'SG
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M&QC_ (3JQQZ?V,G_ ,57+^'?$>/@7<ZMXBU;6RB7C*]U97!^U >< H5F/3D
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MN,]Z .I"@= !2)&D>=B*NXY.!C)JIJ^JV>AZ1=:IJ$OE6EK&9)&QG@>@[D]
M*X2_\87.H^*_"%JEEK&D?:;R1GANU$8N(O)<_P +$'!VY4\@D<4 >C>6@W81
M?F^]QU^M(88VC$;1H4'12HQ^5<JWQ"TQ;UE^PZB=.6Z^QMJHA7[*)=VS&[=N
MQN^7=MVY[UQ^N^(-3U/XP1:*8O$D&G6EB91;:>ZQ-,XFV^:Q#C=%C'4Y]NM
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M8NL?G3KG*MS\T6<@^I'2@#NQ%&)#($4.>"P')_&E9$9E9E4LOW21T^E<Q?\
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M_#)L_!GA7PSHE_*T=Y=*(5&PG?<,#(^2.G.XY-=;@8Q@8JK>:=!?36<LQ?\
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MLY'UFU\^2+ %TAWDA%1B2IP!M(&3VKUB_1I-.ND0%F:)P .Y(->,Z+J%I?\
MPZ\!V-O)YESI^N64=W%M(:%MTG# CCI0!Z/IGC6"[U6[TS4=,OM'NK>U-[MO
M=F'@!P7!1F'!ZCMFHM*\=V^I7MA%+I&I6-KJ>?[/N[E$$=SA2P& Q925!(#
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ML$4D<,KV1C,B%"ZB)@'P>0#C(SVQ5C7/]&^,7A6XE_U5S8W=M&3T$@VOCZD
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MJ$*0T3^8>"".O%=_<ZG9^$OBAJNH:W,+6PU2PMQ;7<@/EAXBX:,MV;#!L=Z
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M<KAM^-W ?&,UZ-8#_B6VHZ?N4_D*\4_MVSTWX)ZGX0G$A\06L-S;RV(B8O\
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M7VE6RWDEF7C=I(&)&]&5BIQ@Y&>U;&M>+++1_#]KJZ))>1WDD,5I%#C=.TI
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MX^#_ (XB\B3S)+S4BJ;#ELR'&!WK;UN&5M2^'96)R([KY\*?E'V9ASZ5W]%
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M1C:#\P(Z>]<EI4<]SX/\&N;5D<>,FDDB W>5^\GSG'H>,UZ=K'A_6;K5FO\
M2/$UQIOF0B*6"2 7$7!.&16(V-SR1P>,BK_AS0K;PUH5MI5J\DB0[BTLIR\C
MLQ9F/N6)- '+^(+E/#GQ,T_Q%J"R+I4VE2:>]RL;.L$GFK(N_ . P!&?45@Y
MTW4Y?%_B'5-.OIO#VI7-G##+%$ZR!85P;D 8<*&(PP&>,XQFO6J* /([2^LK
MC2=;L]0N=7\0^$HWMO)OI(V,T#EF+D. KNL9$;;@"1GOS70_#^^FGU'5K6TU
M:^U?084A-I>7RG>)#N\R,.5!D  0Y[;L9KNZ* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH X.;XCW!MM7N[#PS>7EKH]S/!?3">- OE$[B@/+G W8'0$<YK3O?
M&3&YL;30]*FU:[NK-;_8LJPK' W"LS-W8\ >QZ8K TFTN4\!^/(FMY5DFO\
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MBHPD0L) S] J[&R>>W'-<]XV\2W5[X'U)=0TFYTR^T_4+(31!O-5U,R,&C<
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MX_,@<J63<1G!! ..V0.._2K%>=:!XVU9M8\73:W9+;Z5I4I+.)U;[.$B4E0
M 7W<MGU.*OVWCN_232I]7\-RZ=IFJS)#;7)NED97<9C$L8 V;O8G!.#0!VU%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% 'DFFZU-H.A^+M.O-&U4W5
MYJE^]@L5C(ZW6]B%PP4@<_WL<8(S5WP]H%_I'C'P?!<6TI6R\.-;SRA"427*
M97=TSUQ]*].HH \CU72=+TSQ=XBEUVPU^87\J7-@^FO=;9\QJK1D0G:'#*?O
M8X(YQ4M_9VUAJVE:=J>F:Y%H$>D1BQT^R:>0"YW'='(T1Y8+M +';UYKU?(S
MC/-% 'BNA6U]HNF^&-1FTF_ \/ZEJ$-_;)!([QI.S[73C,BC*Y*YX-;WBC5K
M[Q;X4OS9Z+>I91:C9"TEDA=9+D"9&D?RBH957U/7D\8KTRB@#D->M;B7XE^#
M[F."5X(8;\2RJA*QEDCV[CT&<'&>N*3X@V=W):Z)JEI:S7?]DZK%>300KND>
M(!E;:O=@&SCV-=A10!P-I<GQ9\1],U>PM;Q-,TJRG5[FYMG@$LLI4!%#@$X"
MDDXQ1\)+*[L/#>IQWEK-;N^KW+JLT90E21@@'L?6N]) ZD"EH X'XB65W=Z_
MX(DMK6:9(-:229HXRPC7'WF(Z#W-1WNGW<GQXLKP6L_V,: \37 C/EAS*QV[
MNF<<XKT$D @$CFC()(R,B@#Q":[O;3X,WG@D:+JDFNVT$EL\264AC*"0GS!)
MC:05Z8.2>,5U7V\^&/B)>WM_8Z@]KJ.EVJ6\MM:23@R1EP8SL!PWS \X%>C4
M4 >-:=8:M9:/I6O3Z1>A]-\1WES=6:Q%I5AE+J751]_;N!XSD9(K?\2ZW>>+
M? WBR'3]&O19+9;+6:6%TDNI"#N"1,H; X&>Y)]*]&HH \EFC>"T\'6NO6^L
MC1$T-%:"Q2?)O L8"2B+YON[L X&<UEP:=>CPS#IJZ/?P36_C"&Y:W>&1_+@
M>7<IWG(<!>K G&.>M>W49% '&_$NRE/AE=;M!_IVA3KJ4/.-RI_K%SZ%-W'T
MI_PZM)?^$?EUN[C*7NN7#ZC*K=41_P#5)^$87]:O^)?"Y\3^5;76JW<.E\?:
M;&$(JW.#G#/C<!V(!&16^JJB*B*%51@ #  H X/7IV\._$VS\0W5K=RZ9<:4
MU@\UM;O,89!*)%W*@)P02,XZBN4O+/5M4\/^.+U-&OHWFU:TO8+=X2LDL4?E
M-E5[G:I..H/'6O:** /.GU5O$GQ(\*W^GZ?J TZUBO%DNI[22%=[QK\N' /&
M.N,$G )P:J^"=.BU/P=KO@[5+.[MYS<7:R^=;.J;9)&*LCD;6Z@C![9KT^L[
M6K&[U+3S:V6JSZ9*S#,\"(S[>X&X$#Z]10!Y_P##!=2US5)]9UF,B?1K9=#B
M).=TD9S-)]20@S[&MSXK6MS=^ KD6EM-<R17%O,T<*%W*K*I; ')P 372:%H
MEGX=T:WTNP5Q!"#\SMN=V)RS,>[$DDGWK1H \Y?5H]-\=+XKDM-0;1=4TM;8
M3I8RL\,L<C$!XPN]0P;@XZBM3P';74EWXBUVXM9[2/5K_P VVAG0I)Y2(J*S
M*>5+8)P><8KLJ,C.,\T <!?ROI?QIM;ZXM+QK.\T5;&*>&W>1!-]HW;6*@[>
M#G)P*RK;3;]?@1K=B;*Y%W(+_9 8F\QMTTA7"XR<@@CUS7JE% 'D6H:/I^G^
M*KF^\06FMFTOK"U-O-IS7.!+&A5HG6$YW'Y2-PQUYZUZ'X1L;?3O"UA;VNG7
M&G0[#(+2XD+R1%V+$,22<Y8GKQG%;0((R#D44 >;6%]<?#S7]<M=1TV_GT74
MKU]0M+ZSMVG$;R8WQR*H)7!'!QSFI=4N-<\?^&_$EE:Z3+8Z7-8F*Q:]0Q3W
M,_)SM)^6/@#D9YS7HE% 'E^I:I)XRL?#NB66EZE#>17UK<7XN+.2)+1(CN?+
ML I)(P-I.<U;TJPO$T/XC(]I.KW.H7C0*8R#*# @!7^\"<@8KT6B@#S.\T^]
M;P)\-X%L[@S6U[I;3QB)MT06/#%ACY0.^>E5=!\41>']0\;I<6%_-OUF9K<V
MMH\PFD\M!Y>4!VG[OWL [NO!KU:LC1-"AT.?59(YWD.I7SWKA@!L9E52H]OE
M_6@#R^RTJXT.Q\+Z3XF@UAM*BTEC]GT\3$&\:3=LD\GG(4X&3MSFC1K"]CT_
M0M/.DWUO-9>+GGFA>)V$43"5E;>00RX(&[)]SS7L^<#)I-PXY'/2@#D&LYW^
M,#7+6TAM#X?\DRE#Y9;[1G;GIG'./2N/\*:3=GQRGA2>-CI7A.YFO8&)R'$P
M!MU/N@>7\A7K-[#-<64T-M=-:S.A"3HBL8SZ@,"#^-9GAOPW!X=M[G;<SWEY
M>3&>[O+@@R3/C'.      !P!0!-;:[;W7B*_T18+E+BRBBF>1T C=9,XV'//
M*D'CJ*YGXB_Z+J/@_5'_ ./>UUJ-)F[()%9 Q]@2/SKLH[&VAO[B^2("YN$1
M)),DEE3.T>P&YNGJ:@UG2;+7M(NM*U",26UU&4=<X/L1Z$'!![$4 <;XOL;N
MX^*W@*ZAM9Y+>W-YYTJ1DI'F, ;B.!GMFL[2--OH_$?Q2D>RN52[2/[.QB8"
M;]S(/D./FY(''K7H^F6LUCIEM:W%V]Y+#&$:XD4!I,=SCOZU;H \LTQWT+]G
M&0:C#);RII4\1BF0HP=RZJ"#SR6'YUWGA6RETWPAHMC.")K:P@AD![,L:@_J
M*;KGAZ'7[G3C>3N;.SG%PUJ -L\B_<WGN%/..A.,]*V: /'_ !)I%VGCZX\)
MVT9.E>*IX;^X*G B$1S<#_@>V/G_ &JZ/4)CX5^)%QK5Y:W;Z3J&FQVXGMK9
MYO)EC=CM94!(!#<'&,BMO1/"HTS6+G6;[4[K5-4GC$ N+A4411 YV(J  #/)
M]2*Z*@#QR[TW4Y-%O_$QTN]"2^)[;55M/)/G_98BB[O+ZAB 6V]<5OVNH2:_
M\4=/U.ST^_73(](N(5NKBU>$/(9(R0 X!''0D#/..E>B @]** .-^%%I<6'P
MPT.VN[>6WGCC??%*A1E/F,>0>16=\4(M3L#IGB'1;*XN[ZV6XLS';QEF*S1$
M*Q [+(J&O0Z* /'/$GA6_P!,GTGP_IMG/)9:QIMKI5Y-"A*Q>1*I9W(Z9C>0
M9/6NAO=/NA\=M(NX[.;[%'HCQ&98SY:MO;"[L8!QVKT*B@#QFRTG4E\"?%&!
MM/NQ-=:G>O;QF%MTRD#!08^8'L15S7],U"7P'\-(([&Y>:UU#3&N(UB8M"%C
MPQ<8^4#OGI7K5% ' :G??\(Y\4Y=4O;.^>PO=(CMXIK6TDG'FI*Y*$("02&!
M&>*XK7M,U>]^$7BJ/^Q[U+RZ\0R7"6ODLTFUI4;( SD8[C(X->Z44 9;ZU##
MXAM=$:WN/.N+5[E)@@\K"%05)SG=\PXQ69XY739-'@BUG2+K4-.><>:]JCM)
M:D E90$^?@\97D9]*WS9VSZ@E\8PUU%$T*/D_*K%2PQTY*K^0J<D#J0* /')
MXM5?PVUU FLZCH^F:_9WEF;R%S=O;IM,F%8!V4,3C(S@'TK:.I3:W\1(=7L=
M&O[C3HM#NHD:>V:$7$F]#Y8#@8ST!8#//85Z510!Y;X56WA\5Z?'X5AURTTQ
MXI3JFGWL,R6]J=N4">8,!]^!A"1C/85AZ+<WMK\+]$T6:UUJT&G:@(M;6"VF
M218&>4_(RC++G9N*$D ^]>W44 >-VEFD$WCF+3M'U2WM-4T('3_/BF=I]B3*
MV2^2K$L,*Q!((..:O:!IE_%:_"L26-RAM$G^T!HF'DYMG W\?+SQSWKU8$$9
M!R** /*_%OA[4=:UGQM!:VDS&XTFS\@X*K,\<CN45NF> .O&13M'TGP[K&I*
MNE:5X@6Z2SG#76I2W02T=TV;,3-AF(8_=SC&<UZED9QGFB@#Q*_U*\N?@_;^
M$X]#U4ZS:);6]U#]BDVQB*5,N'QM8':,;23SGH":]:CUN&3Q)/H?V>X6>&V6
MY\UD B968KA3G)((YXK3JNME;I?R7PC_ -)DC6)I,D_(I) QT'+'IU_ 4 <G
MXUAN+/Q#X8\2):W%U:Z7/.ETEO&9)$CFCV^8%')"D#.,G!K U%+CQ1J?BK7[
M&QO!8+X:ETVV::V>-[J5M[G8C ,0.!TY)XKU.@$'H<T 8G@V&2V\#Z!!-&\4
ML>FVZ/&ZE65A&H((/0BL8V=S_P +M%[]GE^R_P#".F+S]AV;_M.=N[IG'.*[
M2B@#QV^T;2M+UWQ)%KFF>(+JXO;Q[JQ73Y+H17:2*OR?NCL5@P8'=CC':KXO
MK7PI\4+9&L+N/3X?#$$!6&-[AK8"9]H8+N8CC!(SSC/K7J=9*Z#$OB^3Q#YS
M^<]BMD8L#:%5R^[/7.6Q0!Y7<Z#=ZIIEUXCN-,U(64WB3^T#:Q"2*Y-H(O)\
MP*I#AN=V!S@5?FM+9/#OB+4O!^G:_'<""& 7\[W!FFC\S,BPK,=^54M@X')X
MKUO(/>B@#RC08=/M?B/I>H:1IFL)I4]A/:"\NTN7,DQ:-N1)ED7 /S' )SZ5
MAZ9ITUW\+M#TNYTO5OM'AW4Q-J-M'#+%*8R\P)B88+D!]WR'.![U[G10!X_?
M>&],U[PMXH7PQI6L&>2Q2**[U"2?_22K^88T68[N"HYP!EL>M:.KZ^_BO5O!
MQT_2-46.VU6.:\>>RDB%NWEN-IW 9ZG)&0,#GD5Z?10!B>,H9;CP/K\,$;RR
MR:=<(D:*69F,;   =37!O%>6?P]\"VU_%JD&E*D::LEFDHF51"=BL(_G"[\!
ML5ZL2 0"1S1D9(R,B@#Q1K!TT3XAV5CHNJ6T=_91SV$4T,SO*@CV'YFR=Q;G
M83N /3@XT=2TO4'LOA.%L;EC:26YN0(6/DXB0'?Q\O(/6O6@01D'(I: /-K/
M4I?#GB?Q=8W&F:C-<ZE=+<V'DVKO'<!H57&\#:N&7DL0!65X=TK4(A\*/-L+
MI/LD5X+G="P\DF$@;^/ER>!FO7J* /+O$VDZ=9^/[_4]=MM9?3[^S@$$^FM<
MX66,N&C<0'.2&4@D8Z\]:[7P?8VVG^%K.&TTVYTV%@THM;J0O*A=BQW$DG))
MS@GC.*W** /(Y].NKVY^(WAHVEW'>ZL[3V4C0/Y,H\E<?O,;1R,<FK>HZI+X
MQTWP]H5GI>I0WL5[:SWXN+.2)+1(B&?+L I.1@;2<YKU&B@ HI"0.I S2T %
M%(2!U(%+0 4444 %%&0._6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#CM,\8:MJMU%<VWA
MTR:)+>/:+=1W0:9=KE#(T6WA-RG^+('.*M6?B_[7X<\0:M]BV_V1/=P^5YN?
M-\C/.<<;L>AQ[UQS0AO$]K<Z'H.N:-K[ZDG]H1I'(+*:'?\ O'=O]4P*9((^
M;)'>FB?4=*T+QIX;_L+59]0OKN^EM&BM6:&2.8$JWF8V\9Y&<Y& ">* +$^O
M7UQ\1]#U'3-+%S=ZCX9\Q+=Y]B1[I4<EWP> .,A222..:V$^(<W]EW"S:-Y>
MN0:DFF-8&Y&PRN 4;S<?<*\YVYXQBL2R.H:#XF\,ZE/HVI2V<'A=+6Z>&U=V
M@?<AP5 R2"O*CD#G& :(;;[7;>)M;U?PM?7FE:SJ,(^QM"PN$@CC""?R_OYW
M#.!A@.: +?C3Q;XITWP#JUW_ &*-.U"UECB:9;K?&$<J!)&VP;CD[2"!C.>:
MZ*[UWQ+&MC;6WAB.74)XWEG#7A6V@"M@#S?+^9FR"%VCOZ5Y_J>E:K??#GQ=
M8Z5:ZU<:66MGTNWU!'-P=KJTH0/\Y3@;0??%;&NWD6M^(["]U/1O$%SH,NGL
M+:TCM9D/VH2D-YJ+@@E0NTO\N,GWH UY?B*1HFAWT.C32W&IWKV!M!, T4R[
MP1G&"-R8SQP<^U(_C36HQKNGW6A06^LZ?8B^AC2]WQ31$D%M^P$%=IXQSBN6
MT#2M2@LO"]A)HU[;2Z;XDN)+A/(<QQQL)BK*^,,F&4;NE=/JNEWUUX_UN6*T
MF:&?PS]FCEV$(TIDD^3=TSR#CWH YZ?Q++)\)] U/Q7H<>H^?<VJQ?Z8092R
MY$S84;3G/R\_6NVUWQ!KME?SV^D>'#?0VMN)YKB>Y\A&SGY(SM;>V%YZ 9'K
M7G&I6^HZM\'/#FEV^BZL+[3KRSBN()+*16&P$,P!'*C^\.*W?$5BU]XQUJ#5
MM'U74_-AA314C$OV5<IA]S*0B'?DDMSC&/2@"+Q3JD.M^+/A;JEKN$%Y-+.@
M;J T:'!]^:BL=3N-&^)'Q/U*VLS>RVEM9S"W\S9O"PY(!P><9[<U3L]-U.X7
MX5 :3J*'2VDAO?,M77R"J(N6R.%)!P>A[5T_AC3+V'XM>.;RXLITL[I+,0S2
M1$1S;8L-M)&&P>#B@#8U?QK;V/@^QUZQMS>MJ+01V5L)-AF>4@*N<'& 23QV
M-:7B76CX=\,:CK)M_/-G TQA#[=^.V<''Y5YMX3T>[_X3P^&)DSI'A2XFN[9
MLY#>> 8%/NBM+^E=I\3/^29^(O\ KQD_E0!4A\<:C'?Z.VI^'_L>E:Q*L-I=
M"Z#R*[*6021[1MW =B<=ZCN?']Y%%=ZM%H8D\-V=RUM-??:@)2%?8\BQ;>45
MLC[P) )Q67=WEYXJ/A'28='U*WFLKZWO;Z6>V9(85B4G"R'Y7W' &TGCTK$M
M?#&DV$5YHNK>$]:U+4VO91&89+A;:YBDE+*Y=6\M %;Y@<'(Z<T =O<^--1?
MQG>^&M+T'[9/:+!*\[W0C01."68Y4\C@ <YR>F*XG2EU'5_C7K=UJ^AVLSZ:
MMH5\S4"5L$*[M\?R88G&['&#WKM-"T^YM_BCXHNGM9H[26TLDAF9"$<JKY"L
M>#CC-4-'T:]D^)_CR6>UN(;.^M;6*&Y:,A)/W6UMK=#@]<4 ._X6-J T4>)F
M\.X\,%Q_I7VL?:!$6V^=Y.W&WOC=G'-7KWQKJ'_"8W/AO2="%]<00PW!F:Z$
M:")\[B25/(X  SG/;!KD6DU67X7+X!_L+4QKGD+IY8VK?9@H8#SO.QLV;1GK
MG/&*ZO0],NK3XHZY<-;3BT;3+2&*X:,A'*[L@-T)'&10!6N?B#JQC\03:;X:
M6Y@T*YEBNI)+T1[T10Q*#8<MC)QQCCDYXFA\?WKW.AW4V@F'0]:G2WM+MKD&
M7<ZED+1;>%;''S$XZXZ54TS3+^/PY\18GLKA9+O4+Y[9#$P,RM @4H,?,"00
M,=:COM+U!_!GPZMUL;EIK2_TY[F,1-NA58B&+C'R@'@YZ4 =/XZU34-%\$ZO
MJ.F1(]S!;2.I:39Y8"GYQP<D=<=_45PU[K&M/??#J_N],$NHO]H\N"*Y#>=N
MMAAV8J N<Y/!P >M=YXVLKC4? NO65I$TMS/83)%&O5V*' 'N:Y#3FNM5U#X
M>7,6EZE#'IXGANOM-H\7E,+4+DY' +< ]">E &M#X_DL[?Q NOZ5]BO=%CBE
M>&WG\]9UESY>QMJ\EAMP1UQ5_2O$VIOKL&D:]HT>FW%W \]HT-WYZN$(WHQV
MKAQN![@\\\5R?BSPUJ6M:MXVCM[&9Q<6&GM;D@HL[12,[(K],\ <'C(K0\)Z
M?X?E\2076E^%]:M9+>!V:\U)KA!"[87RU65CN)!.2.!@<\T =+XH\22:!'80
M6EC]NU+4;@6UK;>;Y8)P69F;!PJ@$G@UQ::]?6?Q$U[4M2TL6]UIWAGS7MTG
MWI+LD=P4?:.#TR5!!!XXYWO'4%W;:KX9\0V]E<WL.E7DAN8;:,R2".2-D+A1
MRVTD<#FL&>'4_%/BKQ)=6^D7UM:7GAE[*TENX&B\URS]0WW3ENAP<#.,&@#K
M;WQ=]CT+P]J?V+?_ &Q<VEOY?FX\KS\<YQ\V,].,^U86@>(_$&H>,/%MEJ&G
MPG3;)D3:+O/DCR=P &P;M_4G(QG'.*Q9;[4-9\/^"M+MO#^L1S:;J.GM?M/9
MO&L(C(5L$CYAGG(X &21Q6QI8NM/\?>-+2?3;_;JGE36EPELS0N%M\$%P, Y
M&,'O0 SPOXNLK;X;:!<Z%X?$,FI7$EM8:6MSE0_F2%BTA&0H",Q.#CI6E)X]
MGL-/U5=3T@0ZOI\MO$;2.Y#1S>>P6)ED*C"DY!)'&T]:X;1_"UXGPK\%OJFC
M:C(-+O9WO;"-9([@12-*NX*I#Y&Y6P.2*Z*RL-#BT76KJQ\#ZI/83F&"9+LR
MF:[B!RS)%*2WR;L@<$G..E '9Z%J>L7D]U;:SHHT^:$(R217'GPS*V?NMM4[
MACD$=QZU4UWQ-=V6N6F@Z/IJ:AJD\#7+++/Y,4,*D+O9MK'EC@  ]ZQ_ ,$E
MOJ^IIIL>L1>&Q#%]FBU59%9)LMO$0D^?9MV=>,YQ4FN?:- ^(UOXE>QO+O3;
MC2SI\S6<#3/ ZR^8K%%!;:02,@'! H 9=_$G^SO"^L:E?:2T-_H]U%;7MEY^
MX#>R .KA?F4J^X< \8KJ-!OM4U"R>?5=*&FR&0^5#YXE8QX!!;  5N2"O.,=
M:\NU[1]6UGPOXSUB/2;U'UB_L3:V;0-YYBA>-=Y0<C.&.#R .:]EH X^Z\6Z
MO<ZSJ5AX=T&/44TMECNIIKSR TA7=Y<8VMN(!&2<#)Q7-:OXI&KZ_P##W7=(
ML9;I[M+X0VK.(SO\M596;D *0V3S]TX!K1L;Z?P3K_B6&\TC5+N'4;TZA9S6
M-H\XE+HH:,E0=K K_%@8.:P;#1]:\,#P!<7&D7=RUF=0GOX[6(RF#SOFQQU(
MW=!R=IQF@#=UCQ-=:KX0\;Z1JNFKI^JZ?I<KO''/YT<D;Q.5=&P#V(((XK)M
M=1TZP\!_#)=0TE=0>YN;.&W9IBGV>4CB3@?-CT-3W=M?>(O^$\URWTR_BM[G
M1#I]C'/;M'+<LJ2%B(R-W5@!QS5&]T357\'_  M@73+PS6.HV3W48@;= JCY
MBXQ\H'<GI0!V=UXPU*37M2L-&T$ZA;Z5L%[.;H1L79=VR)=IWL%(ZE1DXJ+3
M_&^HZWX7T?5-&\/O<W&J/(%C><K% J,PW22;3C.T8&WDG':J%C=7_A3Q5XF@
M?1-2O5U.Z6\L9K6 O'(3&JE'?I'AEZM@8YKD= BE?P3X)&I6FI7>@A+W[7#I
MR2ONF\T^5O6/YBOW\=LXS0!T7BGQWK0\ WU]8:>MGJ5IJ*Z?>*;D'R'WIRAV
M_.&#@9P,!L]JT[_5H5\?>#K75] B76+J*Z,4Z79<6FU"6 ^4!]PXY Q7%SZ/
MJ,?@#Q=IEMX>U"WE_M>'4+>U$+.6@)A("MR'<!&W*"2"*Z;5%NM<^)W@36[3
M3=06QCBO?.DFM7C\G*%5W@CY,D<9ZT :,_CK59EU6^T?PZM]I&ERR0S3O>".
M24Q_ZSRDVD,!SU(SCBI;CQY+/JNF:?H>D_V@^IZ9_:%M(\_E(%W ?/\ *=HP
M>HR<X&.<U@V%Y?>%-!UWPW+H>JW5Z]S=-8/;6C217*3,60F0#:N"V&W$8Q5S
MPOX=O]#\7>'H)H)&BL_"YM)KA4)C$WFQDKNZ9X) ]!0!<B^(5P='N'FT;R]9
MAU1=)-E]J'EF9L%3YNW[A4YSMSVQ71Z%J6J7RW,6KZ0=.N8'"_)-YL4JD9#(
M^!GT((&#7#M8^0OB\:OX:N]3TV\UM6>)(6+>5Y*#SHU R^& 'R\]2.E;'P^B
MN89-72$:LN@B2+^SEU4.)5^4^8%\SY]F=N-WO0!?U?Q1?Q>(AH&A:5'J%^EN
M+JX:>Y\B*%"2%!8*Q+$@\8Z#-<=XZ\8ZEJGPGUNXL;!K.YMI7L=25KK#VCJZ
M A2!^\#!ASQPWX5NWLL_A;XBW^LW&GWUUIFJ6,,?G6=L\YAEB+?*RH"P!#<'
M&,US6L:'J][\*_&MR-+NUO-;OS=V]CY1:81[XE7<@R0Q"%B.U '<?#[3/[*\
M*0P?V-;:7N(D\J"X,PDRB_O&8J,,<<CVZU+H'B^'5=&U2]O;?[!+I5Q/!>PF
M3?Y9CY+9P,@K@YQWK9TM&CTFR1U*NL"!E(P0=HXKRWQQI5[%XX.D:>"+3QG%
M'#=E3S$8&!E?'O"2OUH Z*U\?:CJ=KHL.GZ KZOJEJU\+6:[V1V]N&PKN^PG
MYLK@!>_M3I/B&]MHNHSWFD&'4]-OH+.ZLOM 8 RL@5U?;RI#Y' /!'%-UB*3
MPUX_L?$"Z==7&E/I1TV064#3-;E9 Z$HH+;2,C@'&!7-ZKH^KZSHOC#Q!!I-
MXC:A>V,UK921E9Y(K8IEMAY!;#$*>>!QS0!Z+J.O_8/%.B:+]FW_ -J)<-YV
M_'E^4JGICG.[U&,5C^$/&>H^+I//BT'[-IJ/+#-=/= D2HQ "KM!88 )/&"<
M<X-9K:A<^(_B-X6U&TT?5(=-M(KQ9+BZM'AP[HO!##('RXR>"3@9P:T?A?8W
M>G>"UM[VUFMIOMETQCFC*-@S,0<'L00: +OBCQ7/X?U31M.MM+:_N-5>6.)5
MF$>UD7<,Y!X]3V )P>E4(?'YL8M>3Q'IO]G7>CP+=21PS^>DT39VE&PO)8;<
M$#G%5/'EY)I_CGP/=QVLUUY4UX6B@7<Y7R,,5'<@$G Y.,#FL+6M$U'QY+XN
MU&QL+NVAFTR"RL1>0M US)'(9B0KX(&<+DXZT =5;^,=7M=0TJ/Q!X>33K75
M91!;S17GG-'*5+*DJ[%P2 >A(SQ3M,\8:MJMU'<6WATR:))>/:+=1W0:9=KE
M#(T6WA-RG^+('.*R=2U&Z\;WWAJSM=%U6T-GJ4.H7TEY:/"D B!.P,P =BQ
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MJ]H\<BV1CPWF$D_NV.<;2G)ZXH Z?0_&&K:W)9WD?ATC1+V5HX;N.Z#RH 6
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M*G.5R.#0!UU%<1IWC35I)='NM4T2&TTG6I%CM)4NB\T;.I:/S4V@#<!V)P2
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MC[D4&)RK )AE/+=C^%;^G:)<67Q,TJ>'3&M=.M_#?V4!"7CA?S5(B#]R /Q
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MK+[)/;OIUP(&:4#$F5#!E]L$5K5!!9V]K)/)!"J/<2>;,P'+M@+D_@H'T H
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M[2M%$<)$S$K<RG!=",<!<K^-7)?%FH077AW1]'TBU>74],-S$))2D5OM"<'
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M!!('*AMV3Z+P*O2^(?$T^I?V-ING:7)J5G:1W&HR37#K COG;''A2Q)VDY(
M Q67%X?NXM=^'\UKH"Z;:V7VU[FV@<.EJ9(N 6]2Q[=\_6H/$WAFQC\<WVKZ
MMX4N-?LK^UA6)K:(2/!+'N!4KN& P*G/3(H ZG3O$6H:YHNBZGI6F(T=W-LO
M8YI@K6JJ2LF/[Q5E(]ZV]3OH]+TJ\U"89BM8'F<#T52Q_E7-V5\/"V@^'K1?
M#OV%;VZ6W:TMY0RVC2$MDGOSUQW)^M;?B.PDU7PQJVG1?ZRZLYH$^K(0/YT
M<#H^JW7A3P#9>+KVW2YN=:O(;K5IV8@Q0S'"E?9%9 %Z=:[#6?$<MAXFT'0[
M2W2>?4GD>4LQ A@C7+/QW)( ]S63X7@M?%_P>L-.F&$GTP6,P(YCD1?+;CL0
MRY_"J'PZTG79=3N-;\36;V][;64&E6RR$$LB#=))]'?!_"@!GAR#3_'7@SQ)
M81:5;:7MU6XA1K;@B=-I6?/9]V#^%=+X"UV?Q)X(TS4[H8NWC,=Q_P!=$8HQ
M_$J3^-8/PXLKKPOX<\2SZU ]G'_:]W>9EXS#M4[_ *<'\JO?"FTGM?ASIKW"
M&.6Z,MV4/82R,Z_^.D4 /\1^(O$NERZE<V.C6;:9IL(FDDN[AD>Z 7<PB 4@
M8'&6ZFNJL;N._L+:\ASY5Q$LJ9ZX8 C^=>4Z_P"';G4M5\56][X5FU;5+UF&
MEW\RJUM;P&)0H#,?D96WG &22/K7HOA-ICX2TE;BUGM9H[6.*2&==KJRJ%.1
M]1Q[8H X<_$G7_\ A$W\5_V'9#2+6=HKI3<MYSJ)3&6C&W&!QU/)!] 3O6GB
MC78/%FEZ5K6E6=O;ZO%,]HT$[/)$T:ABDH*@9VG^'C([]:YI_#FL'X"ZAHHT
M^;^TI))REMCYR#=,X_-3FNJ\0Z;?77CSPA>V\#O;VGVWSY0/EBWPA5S]3Q0!
M4D\6^(;&^LKC4]&M+72;R_6Q2,W#&ZCWN421EQMP3C@'(##K6;I/B;7K;QCX
MUFU8VG]D:0L;RJD[LT2"$N/+4K@ENK9(YZ9KEHO#MZNCZ5*?!EY)K^G:C!=Z
MIJ,T:M+<;)@7\ERV9,]>,  8ZX%='/HVHW?B7QUI<FF7J0>)+6,6E\$!AC(M
MBA$ASE3NXQ@T ;FG>*M=2^T?^W=*L[6RUHE+5K>X9Y()"AD5)05 )*J>5Z$8
M]ZC\,>+=;\3W=U(NDVD&E6=S<6MQ,\S&1W0D+L7&,?=R2>Y Z5C>$]!TV/5-
M)6/X>2:??VR[KR^G 1(75<9B8$^82W3&.#D^E;_P_P!+OM,\/:I!>VTD$LNI
MW<J*XY9&<E3]"* ,SP;XBN;SX8:;J'AWPU:PS7-PT,=E$^R"#]XP,C'&0HP2
M<#.34>N>(+[4_ _CG2M5MK6+4--L'WM:2EXI$DB9E9=P!!X8$'TKGM%\-ZQ8
M?"CPQI^IZ-?3V]MJ4DFJ:;"/WLD):0KE<C<NXH2O<58CT"^BM/'=M8>%9M-M
MM8TI3I\$,2 95)$*/M.%D8L&QZ'KD4 =_P##_P#Y)SX:_P"P9;_^BUKBO#^I
M^)+2?QHVA:797,5MKEU-*UU.R&4[4_=QA5/S8'4X'S#WQW?@JSN-/\#:#9W<
M30W,%A!'+&W5&" $'\:X[3;O7/#+>+8G\-:E=_;]5N+BP>V16#EE4#?DC:N0
M#NZ8SZ4 7KKXB7EU+X:AT'2XKJ77[.2X@$\Q01,H4D.0#P 6SC^[@=:NS^(_
M$MSJ5QI>D:9ILUYIUM#)J#3W#I&9G7=Y46%)/ SN;'4<5BZ%X2U/1=;\ Q26
M[/'IFF7,5W,G*1R.%.,_7('TJ+Q!X8L(/&^KZGJWA"XU^WU&.%[:2VC$C12(
MFQHV!8;0<*0W3K0!T0\4ZQK6E:1>>&]+MV2_MS<2SZA*4BM\8'EG:"2^21Z?
M*:JKX^N;CP]IDEKID3:WJ%[)IZ6CS_NDEC+"1BX&2@"$\#)R!6)?Z#Y&I:(-
M2\&S7>CQZ64BTJSVSQ6MVS[FW!BJG@XW'@8/UJEI6@ZWI&G:7=+H$PN- UJZ
MF>SMPH66WGW@F#D!MH88''3% %_QWJNM3?#KQ%:Z[I2VUQ9RVC)/:,SP7*M/
M&?D+ '(Q@@^WK716WB;7K7Q9IFDZYI=C!!JR3-:M:W#2/$T:ABDF5 )V]UXR
M*Q_$\WB+Q=X.UV*/0;BUMC+:"QAG7;<S;9D:1F7<0J@#COP36]X@TZ\NO'G@
M^]@MW>VM'NS<2 <1[H=JY^IXH O>*_$)\-Z5%/%:_:[RZN8[.TM]^P232'"@
MMV'4D^@K*@\2>(;774T'5[#3$O[RTEGTZ:WG<P2/'C=&^5W+C<#D \5/X]TJ
M^U#2]-N]-MS<W6E:E!J"VP8*9E0D,@)XSM8XSW%4+<7_ (I\>Z1K!TB^T[3M
M'M[@!KZ,1O-+*%7:JY)P%4G/J: .9^$-C?7&L>(M7O-/TIYO[8NHIKW>S7*.
M-OR(2O\ J^?4'VKT37[_ %VWGM+70].MIWFWM+=7DI2&!5Q@':"26)X ]#6%
M\,M(U#2+'Q$FH6LENUQKMU<1!Q]^-MNUA['!J'QKIS7/BW3+C4M!O-<T1+25
M%M+=!(J7)9<.Z$@$;<@$\#VH )OB'>1>'-/OETA)=0FU@Z//:I-\HE!=24?'
M()48)'0^U2'Q9XEL]1U32+[2=/DU.'2VU.S%I.[1S*K;3&=R@ALD8.,'-<UI
MGA[6(-.T_3CH,EHUGXM2^:.)1Y*6[%VRA'55! / QQ7:OIUX?BS!J8MW^Q+H
M<EN9L?*)#.C!?K@$_A0!#J'CN.+X?V/B33[9;F?4?(CM+4OC?-(P79GV.[/^
MZ:Z'5]5AT+0;S5;[_56D#32A.^T9P/KT%>9^'-#N5^)=QX>(5M#\/74FJ6X!
MR%>X4&.,CML+3$?45Z#XOT63Q%X/U;2(7"37=L\<;-T#X^7/MG% '/Q^+_$5
M@='O=>TBPM],U6>.W7[-<L\UJ\G^K\P%0",X!P>">]<KIMEJVJ?'75Y=0TW1
M;J:RAM2#-([BVCR&#0Y3_6=^V#WK:O9-9\76F@:+)X>U#3Y+6\M[C49[E56%
M%A.XB-@QWEF  QV.3BM+1=(U"W^+WB;5);61+&YL[9(9R/E=E4;@/I0 [XIZ
MKK.D>%$GT=XHG>[@BDE:5D=0TJ@!< ]>A]B>M9-W<^((_BM:+;V5A)JTOAXK
M(#.XMXO](R6+;=Q'  &,DGL.:W?B=IM]J?@N6/3K62[N(;FWG\B+&]U2568+
MGJ< \5'I\5[J'Q)@UXZ;>6ME)H)@_P!)0*R2?:,[& )P<#/TH K0>/K]M#F$
MVEP_V]'JYT9;9)SY+SX#;]Y&0FPENF>,5M:!KNI7&LWNAZY:6T&I6T,=RCVD
MC/%-$Y8!AN ((92"#[5PVI^#[Z]M=9FN=&>]BB\4G4A9M@&[M_)6-MF2 3RQ
M&2,E<5U'@G2]-MK^^NM,\'OH5N42-)KA?+FG.26'EY.%'RX)/)SQQ0!VE%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=GS?*<D</M//.* .CHKB?#?C6^U/P;=Z[=:'?2/%+/L@M0DC2!960(@#9)
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MI-I=U/!I9NH[G3"WELK!U*L&9B&!7UY![5SUAX-U^V\!:E8W&E-*S^(S?R6
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M"6+XA:C<Z-96Z6UC;^()]2FTR83NWV:%X03))G()7:!@9!RP&:R_%7B[7I/
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MLH92&(.#D8S6,_A/7KK3I=0GL1'?ZAXDM=2EM1*I-O;QLH 9LX+!5R<9Z\4
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MX., =:OK#K7A/Q3KUU9Z%<ZO8ZN\=S$;66-6BF"!&5P[+P=H.X9Q0!R_C+Q
M?$_A3P1J3V_V:<^)[>*>#=N\N5&D1@#W&1Q[&NM3Q!''\7-0TJ2PL42#11=M
M?"+]^1YB@H6_N=\>HKF[_P "ZZGA#PK9I;)<7\/B%-4U 12*%B#.[O@DC(7<
M!QUK>/AG4+CXO:GJLULPTFZT'[$+@.O,AD4E<9STSSC% "Z/XD\8:K;:;KL>
MEZ?)HM_*NVUC+"ZA@8X65F)V' PQ4#H>#6<WB.^FN?B/#IECIEG=Z2D;)<K"
M0\X\MF)D(.68 $*>Q-6/#K>,M(TG2/"Z:$J/8ND$VJ22HUNULA^\BAM^\J
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M$,O)27<P*[6SR <B@!X\>:IK%UX;AT"SM/\ B=Z?+=;[LL1;LA3.=I&X#+#
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MNBAI A! 3KM&0V2.U6)O%VM:IXGM](\/06 AN='AU-+J\5R(P[L,%5(W9 7
MX[G/&#C7?A=],UG70W@2S\0/J%VUW97LJ0%4+@;DE+G<H5@3P#D'UKI=/T.\
MM/B+_: LXH=.708;)#"0(UD65B45>H 4C'&,4 <?XD\6>)-0\!RNC65G?VFN
M+IEZT/F;799DP8SG(4Y&0<G!(KH[C6KNV^)7AK1K^PTN:[NK&>26]CA.^,J#
MQ&2254XY!K$U3PGKTGA+Q'%!IYDNI/$IU*W@\U 9H1)&V0<X!(4\'!XK5GTO
M6-5^)_A?Q&=)FM;."QN([D321EH68,%4A6.2>.F>M !J?C#Q#HU^+G4(M&AT
M\WZ6WV#S2UYY3R"-9<ABO.0VW;T[YJ#2/^3@?$/_ &!X/_0EKGI/">M_\(V]
M@GA".36+>_%W<ZI(\)>]"W D_=/NW;F7'WMH !'>NOTC1=47XN:MX@GL7@T^
MZTN&*-W="?,!4E2 2<C!YZ<=: .+N/%&K:A\&DU/2;;3-(+ZFL$L=I$T8 \]
M0"NT\$G[WJ":]!T_Q#JUOXU3PYKL=EFYL/M5K/:JZK(ZMB1/F)Y *L/:N(L?
M!7B*W^"DNC-II_M6/41=+:F5,NJSJ^ V=N2 >];OQ%N;Q/"6F>+H;)['6-*N
MTE@M;AE+L)&\IHCM)!W!@< GH* .D\-^(+K7M8U]1#"NF6%V+.VE4'?+(JCS
M2><8#' P.QJMXFU;Q'9Z@8],_L:SLXX/,^TZI(<3R9/[M%5@5P ,L<_>&!Q6
MAX/T,^'/"FGZ8[;IXX]UP_7?,QW2-^+$URVL:'?-XYU2[E\,1:RE[;01:?=3
MF)HK+:&#APYRHR=WR@D]* )&\=ZMJ/\ PB":-86GF>(;.:<_:6;;;LBH<DCJ
M!N;C&3@=.M,D\?:KHVE^*$UFTLY]4T62!(_L>Y(K@S@>5PQ)7DX/)JIX5\.Z
MY:W/@87FER6ZZ+:WMK=,TD9&6$81AAB2&P<=^.<4[Q#X.UG5KGQRUM JM?'3
MYM/=W7;*\ #%>N1R,<XZT -U)_$:^/O \.OKILA:YN726P5T53]G?*,'))ZC
M# \\\#OZ;)(D,3RR.$C12S,QP !U)KSZ8>)/$?C'PKJ,OAR?3;'39IFN?M$\
M3/N>%E! 5C\H/&>IW= !6Q\0[+6M5\+/H^B0EIM1E2VGF#JHMX&/[QSDC/RY
M&!D\T >;,]ZZ'XO@2_+J7RP\_P#(+'[D_+Z_Q_K7I/BKQ/<Z<^BVVES:=&^J
MR,L=Y?D^0BA-P^Z1EFX &150?"7P:++[)_9UQY6S9C[?/C&,=-^/TQ6-I>G^
M(=,\'6N@ZWX637;"RGEM70O$TDT"_P"HE168+TRI!(88!]: -74_%'B+3+;2
M;*\BT>RU._NY8/M<\C&TVHI96 !#9?@!2P.<]:I^,/$.K:/X-L[G6]&TFYO#
MJL5ML=?-@=23ME0$Y4XZ G(YJOIVCZII7A<V5UX2_M'1I[Z:0:1+-'+-9P$+
MY87>VPX8.2-W&X8/!K+U+P7KUQ\/X].L]+EB']O)>6NGR7"LUI:C^$L6QUW-
M@$XW8H [&]U_Q!?^+K_1/#L.FJFF0127<M\'.]Y 2L:;2,?*,ECGKTK$A^(N
MMW'AW3+Z+2K47M]KLFE_9G9@$ \P#+9Z@J,G!&,X'2M"2/6- ^(.M7VG:0=6
MM]7@MV98;F.-[>6-60;PY!V$8.X9Z'BN9\+Z3JFI^'=#E2))Y+7Q;/=73QL
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M444 %%%% !3%AB2625(T623&]PH!;'3)[XI]% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@I()&, BB/2X_#.IP-K6@6=_I\NK^=;:]:2@7$<LLQ*><.&(W,$)!(Q@$=J
M.FG\<W,&G:Q<'PSJ9GTRX$;V^4W21'/[U3G&, G'T^M=;!,MQ;Q3H&"R(' 8
M8(!&>143:=:/#-$UNC1SOYDJD9\QN/O>O0#![ #I46M6OV[0M0L_M/V7S[:2
M+S\X\K<I&[\,YH 8^LV4EG>RV5W;7,EK&S.D4H;:0"<-@\=*H>&/%%KK>AZ1
M<W-Q:0:A?VJ7'V191N^9<\*3DBN)TRUCT*ZBTS5_#%GIVIC2[B&SU'39/W-V
MJH"X90 0< , X/?!K)_L/3+'X+^&=5M[*%-26;3YQ=[!YNYI4!^?KC!QC/0
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M)^[R2V1CGZ57T.:37K+PM;C0;36-8AT%)I)=4N"L$43MM!V['W.VSKCH.O-
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M'G&Y9T)._J26)'7VKI-(T33=7^*'C.74[&"[,:62HEQ&'5-T/S8!XR< 9]J
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MU?P^=7GCDTU(V:.YCO<1F!U.&#$\8![U>M-9TO4+.2\LM2L[FUCSOFAG5T7
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M][;P^<WEPR,&#;5Z!?F8XZ9-7+VQL]-U&[\2K9W5S??9%MFCMQO=XU8L JY
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MVI7]K91,=H>YF6-2?3+$4 8VK>!])U;49[]I;^TGN4$=T;*[> 7*@8 D"GG
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M"4VEU#<"&1H9#%(&V.O53CH1W'6O-=8U9/ASXPUZY*@6.LV#7ULF.#>1 *R
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M%VQ&Q57!D?DX(:1@.O.W%;/AN:YL_%ZZ;KFAZ=:ZL=/8V]_IK'RIX4= RE"
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M)<ZG?31110H2OFN$#M@D*">Y(Q7'^ O'IUKPY<ZYKVN:&D:HDDD%OF,V0)8
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M@'6NAH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ%XFT?7M,L?$UEI1M=3E-O!<Z=+(?+EVE@KJXZ$*<$>E;?\ PEWAX:Y_8O\
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MU./85H:9JMAK5BE]IMW#=VSY"RQ,&&1U'L?:N3DVGXWP_:<8&@'['NZ;_/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;;Q65P&$T07(EW##;R>6R..:K6W@KPY9VEG:P:3 D-G<B[MTRQ\N88PXR>O
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M_LRR_M?^UOLR?;_(^S>?_%Y6[=M^F>:SM4\&^'=:U!;_ %+2+:YN0 I=P?G
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MM=.LXK.RMXK>VB7;'%$H55'H *I?\(YHPUXZX--MAJA78;H(/,(QCD_3CZ4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\SID94$J2"1727^C6\^I:O-XH\86=R&T5K:X2UL_(,4+R K(Q#OT(.,CN>U
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M9QV:M-=R*H7>[[L[FXP0.% /:NCT:[@A^*5PTT\:";P[:NC.X <"1\D'OC-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF9Y)(_X6D;<-NX<X4="*W=+\275OI5F?%5HNF:C<7OV!$BS)'/*<[63&2%8
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MY98>F: .LTGPOH.@RO+I.C6-E(XPSP0*C$>F0,X]J6X\,:#=ZL-5N=&L)M0
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MC,VZ4I&%\PXQEL=3@ <^E 'B/AF.^"> Y(=9BTE9="GA@N)H%E4R"1"R ,0
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MPC;MZ[M_/ZUT_AJ!X_BGK/V@ W,>C6*.QY.?GW<_4#\JZX^'M%.J_P!J'2+
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MK/J6C:?>3)PLEQ;)(P_$@T <9K7C:'6=*L9-(2**"XUI+"#4[Z!7A4A68S1
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M'-XJ\._$'Q79[I5N;9]/TXKSNMH0=Y7U#OO_ "KUQ+.VCLQ9I;PK:A/+$*H
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M@AFEC*,Z8RI*GD<$<5R'@36].\*_VIX4UR\@T^]L[Z>:$W4@C6X@D<NLB,V
M>I! Z8H Z+1=1U[3+?5%\7&T%M8 21ZK%B..>/!)+)DE&7'/8YXI^E>.M&U;
M4+>QC%];S72E[0WEG) MRH&28RP ;CG'7'-<KXV\1P>+_ 7BJVT2":[M+%82
MUY$ 8I]LBO*D9_BVJIR1QS5KQ3J^FZ_JO@FWT6]M[NX.K1WBBW<,4MTC?>QQ
MT&"!S]* -:Z^)?ARU6X<R7LL5K*\-W+!92R);%6*DR,%PHR#]1STK1U;QAI.
MD7%I;.;J[N;N,S106-L]PYC'5\(#A>1S^5<3I4:#X5^/B%'SW>KEN.I^<?R
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M+:*1HKBXBLI7CMF5RA\Q@N%Y'?M@]"*Q]8_Y. \.?]@B?^;5F6$:#X&>+2%
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MM_I+6[(K9_C*X!_.O(IM5TN7]GN+1HIH3J;6L=@M@&'G?:@X4KLZ[MPST]Z
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M!U]: -&*TMK>:::&WBCEF(,KH@#2$="Q'7\:@M='TRQN9+FSTZSMYY?]9+#
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MP=I!D] >">GO74W+E;.9T/(C)!'TH @L]'TS3II)K'3K2UEE_P!8\$"H7^I
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MLT+O$3C>H/49X]J\^\.^*99_@6NM>(=>U.W?[0RR7UKAIQ^]VJ!D$8Z#ITH
M];-I;-=K=M;Q&Y5=BS%!O"^@;KCVJ1T61&1U#(PPRL,@CT-8>M^++#0KJWLG
MAO;V^GC,J6MC;M-+Y8X+D#HN3C)ZGI7)^+O&#74/@F_T#494M-1UR&WFV@J7
M3)#1N#R.001[4 =]:Z1IMD(A::=:0"(L8Q%"J["W#$8'&<<^M3K;0+-+,L$8
MEE $CA!N<#H">^,FJ.DZ]8ZU-J$-JSB73[EK6XCD7:5< '/N"#D'O1HFNV7B
M&TFNM/:1X(KB2WWLN [(<,5]5SD9]J +%CI6G:9YGV"PM;3S#E_L\*Q[CZG
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ME;<"2#P?E-=RMM C2LL,:M+_ *PA0"_U]:9:V-G8(R6=K!;JQRPAC" GU.*
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M!7N9H-69TM1#"69G4'*%>N[(VX]:B?QC;ZOH?B&&VAO].U33[.21[>[B\J5
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M8MX!.9Q#&)B,&0*-Q'IGK3E14W;5"[CDX&,GUIU% #4C2-=J(JJ.RC IOV>
MW G\F/S@,>9M&['IGK4E% #51$SL55W')P,9/K36MX6B:)H8S&_WD*C!^HJ2
MB@!@AB6-(UB0(F-JA1A<=,#M3MB[P^T;@,;L<XI:* (5M+9$*+;Q*A;>5"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2:ZN9%B@A1I))&Z*H&23] *2TNX+^R@O+659;>>-98I%Z,K#((^H- $U%%%
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MOBSK=YX?^&VK7M@[1W)5(4D7@IO<*6!['!.#ZXJ#PYX8\6^'HTT)-6T^3P[
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M/&A7AB6Z6*5S/$)#M$@_AVY(XY/3IGC4TDRK\4_&36Z(TWV&Q*J[%5)VR]2
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M&:&%5)'FNN<X)&,9&"PYK3G\57-E86QF-I=37][]FL9K-'DBEC\O>9=JEF.
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M*>"P7<0.Y KS;6[^UOOAKXN.G^*;S5K9+-1)::BF+FUEW<DY52%(QP1U!P:
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M<ZS ^O65\;ZWF%OB",D%3#M!W&/:Q&2=W.?:K^M^./#_ (?OEL;Z]8WK+O\
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MA9"\;9 8#G!]JZ.B@#BY/#GB6UUIM>TR]TI=1O;6.#48)H9/(D9,[)$(;<"
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MT>HW%_/;RWVI79NYQ;1E(D.U4 4$D]$!)/))-/TC09=-\3>(=5>='35)('1
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M,1@\52O/AC?77@RYT,ZM')/-K)U(W,D9^8%MQ! [GVXKTE$6-%1%"HH 55&
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M5L4)^U+%)YD8_/(.>U:&N>%9M6\;^&M?2YCCBTC[1OB926D\Q HP>V,5U-%
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M "BBB@ HHHH **** "BBB@#@OAC''<#Q-JLP#:C<ZW<QSR'[RK&VU(\^BKC
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M9/,CV<'/&.M:6H6,&IZ;=:?<J6M[J%X90#U5@0?T- 'EGA[6[V/5O#TMM?\
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MG@\]:[SP3J.H:KX.TV[U6*6.^9"LPEB,3,58KN*D C=C=CWK+?PIK6FWXO\
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MPV@7T-V\GE'$PC).T#/&<]>:Z[Q!IC:WX<U/2EE$37MK+;B0C(3>I7..^,T
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M.IQWH ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZBAPSIA ^,$CDJ0>3WKRZQU37H;[X9M=ZG>^9K$UW=7<9G;:ZN%>-",_=56
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MZO:R2- CA,.\^W.6+Y/S\$>E>CZOJ3Z5X3OM51TN7M+&2X# ?+(50MGCL<4
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MAU;4KNRU#39II8KZY:;;+&Z8==WW<AB"!Q[4 =]1110 4444 %%%% !1110
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M;A;=+7_2$4OO,2R[L!"2?X<X.,UU]S;0WEI-:W,:RP3(T<B-T92,$'\#4M%
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M\8]<4 ;5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKI&3L*Y(VL 2.X]JJV?PXBL].T>S35)733=8;5%=X\M)DN=A.?\ ;^]WQTH
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M+X) ZG'J*\E#-(8XM21HM8G\96;ZK:E0(X\IF)5P3N0A4.X\DYR!7>7.E?\
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ME:U$&H-- (XV 8["GS?NP"V,?-GUR:R_AGHENVL^(/%-NDRV%_</'IBR@KB
ML7=E!Z*\A) ] * *6E.UEXHMXO$-[K^FZ[)J+A+B25WL;Y"[;(D&3& 4P "
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MDX+#>"!@=.*U6\!W&IV^I_\ "1:[/J%S?6Z6Z/#"+=+=5;>K(@+?-OPVXD]
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M2Y))Y/)Z#CI7,:Y?:B;?Q2EOJ-S!(OBBSAAD60YB5A#D =,<GCH: /8@H&<
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MG=K1(2R[(F4-M3/W2&7!R3FNM^)6IW>D?#_5+JPF:"Z(CA25>#'YDBQE@>Q
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M<-/$PVO\Y)R0<&@#U6BO(/#GV^'4/#EYIVD^*1=32(-6NK]RT%S&Z'<Y!D8
MAMI7 &!D5332GOOAEX@\0W.IZFVI6$]])8RK>R(+?RY7( 4-@\@\D'C Z 4
M>P-J%G_:BZ6TRF\: W A(.3&&"EO3&2!5NO*K'2[74OC19WMQ]H,TGAR&_.V
MYD4>;YP'0-C;@#Y/NGKC->JT %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4F!NW8&?6EHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH YRT\(PVF@Z[I0NW9-7GNIWD*#,9GSD
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M#))[8KIJ* "LCQ)X?@\2Z3]BFFEMY(Y4N+>XAQO@E0Y5USQP?T)K7HH XP^
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M'N*PM- _X0GXH<==1U//O^Y6@#IK?X@Z7<ZII]JMGJ*6FHN8K+47@"V\[X)
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MK!I=W,(;?5)K<+;R,QPISNW!2> 2H'-5;_Q=H_C"SN=$\/2?VC=WFF7)\^
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M1=QVX8LN5Y&X#(IECX]M]0N8/*T;5OL%U(T5K?F)/*F=<\##;E!VG!8 'VH
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MU%<GX/\ B"+7P;X=?4K#5YK>:.&VEU>10T7G,=OS$MO(W<%L8SW- 'IP4+G
M R<G%&T8(P.>OO7*ZMX[M=,OKZ"+2M2OX=- .H7-K&ACMLKNP<L"Q"D,0H.
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M8N5"K\P')ZG%<[XS\7C4_A9XENM.-]INHV&V&>*0^5/;R;T/52>"#D$'!!H
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M;T0RP"XB6413 !T##.& ) ///- %FBBB@ HHHH **** "BBB@ HHHH ****
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M6Z-@+DXZ9%7)=1N]'^"OAF6UN)+&-[?3XKN[C0%K:!@@DD (." >N.,YKTL
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M&*2)0BCZ232<?[->P44 >.>"8KG4-2N8+M'(\*:5-I2EQUE,CKN7U_=11_\
M?52W*$?L\Z&H4YVZ?QC_ *;QUZ]10!XS>1Z7I&N^*[77_$6M:7)<WKW,%I:2
M!5O8I(U \M2AWMD%" >PK=T>PAT_XL:1:01SK!;>$EBB^T#]XH$R@!L<;L=:
M]((!()'3I2T >,WD>EZ1KOBNUU_Q%K6ER7-Z]S!:6D@5;V*2-0/+4H=[9!0@
M'L*]7T2SAT[0=.LK=9UAM[:.*-9\>8%50 &Q_%@<U>(!() XZ4M 'A%A?VLG
MPC_L42@ZC8ZW']JM2#OBW7V1D>XKN/&MI+>^//#=M#P\VGZG$K=@6CC KO\
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M4C9K=@$RP'S<'([<9ZB@#7F^)$*6]SJ<.AZE<:!:RM%-JD?E[!M;:SJA;>R
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ML6)'RCCH>HR 3:#K6LZI\1?$FH7FBZ]<MITL:P6<6H1I':#RVRK)YH1BV/\
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MSL(]@ED:-F#$DD*JC8223P"*P/%GC/[7X=AF\B_TN\T_7+.*^M7_ -8@+AL
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MA Q(VPX93UVG\J /1J*XVY\=7+:KJ^FZ3X<O-2N=*D"W&R9(UVE X(+'DG)
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MAN@Q1'.2 &*_TS7.R_$.XDEUA=-\,WU^NCW,D%XZ2QH $YRNXY<D9.T>WJ*
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M*<D\LV[D<XS77:=XVF%_H]E?:%>6=IJ8\NRO99$(E<)N 9 =R;@"1GGU YP
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;7*:GOA9!$Q0)@L1@EG^88)R!FO5:BN4FDM94MY1#,R$)(R;PC8X.,C./3-
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M!0%7)PH55 R2>*VZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>sesenbio_minorirosales-e006.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\5\\$:;80@!+Y+C<,9X'/!R!QF:#XAV%QJ&FQC3=133M3E$%EJ3QJ()I""0
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M9UBF #JK#(R 2 <>]<A;_%;3;C2[;65T?5TT69E2347B010L6V_,-^[ /!8
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MHRBW$#8>,GHRGU% 'G.K^*=*\2^-_ [:1(;J%+V9GN!&P5"8'PF2!\W!)';
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ME<=>G%:VDZ=;Z=\1_"=K:Q7*6T'AR58EN@/-0;TP'QP& .#7II .,@''2EH
M\V@\0:=X*\:^+/[?F-JM_)#>6<C(2+A1$$*)@<L&7&WKR*R=1GM_^$PBUS7=
M1U;PO9ZGI$!A:.41;71G+12':0&PZL!QU/>O7B <9 .*" 1@@'ZT >4Z?96-
MMK?P_?3?[0>TGO-1N%?4!B5B\3DL1@8#'YAQT(I_B."6?6OB3'%$[O)X>A5%
M49+'9-P/4UZI10!SG@35K#5_!FERV%RDZ0VT4$A7^"18UW*?<9KHZ  .@HH
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M!9F9V3*$'E2H*^H]0* (T\87EYX%T2!]0CMM5U&%C<W[%4%M;QMMEN#G@$@
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M.[A9K2[TZSA?(X92LH8 _C0!T.N^);70X-.=HY+E]1NX[2VC@()=GYSR?N@
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MG8PGVF$ ^J^;+^5<]=ZB-0T"RO\ 4+_6[O7;?4X)]5MB\H@L42X&[,0 0 #
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M[=I!=)#)YA2(M@MM!;MC)P,T =E_PGEQ']JM[OPUJ-GJ,=HUY;VTKQ'[1&I
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M$6.%" 0_)R<Y/RC)^4^U;6O:PVBZ>L\5A<W\\LJ00V]N!EW8X&2>%7N6/ H
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M"WB#7]/G^:X:*V,31LUV[3NB1(BD8*X5<G&<9H Z_P 2Z!_PD5E:6_VG[/\
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M@\BM6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3=*I*@CYR V["YX%>X44 >6:RO\ PL/Q&6T-9FL[71;VV:\DA>)&FG4(J#<
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MQ!Y[&LG3=9M_ _B#Q3;:S%=H+[4#J%G+%:R2BX5XU!12H/S KC!QU':O1Z*
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MFJO5Q^[PP/WQN&[^&LA=9U>W^)^IK:Z+)=W\VCVCM:?:E2.$[I-VZ0C'4@<
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MBM.RL]3;XX6M_>6DB@^&5CFF5#Y0F\W+*&Z9Z\9Z5RSI=/\ !GQ3X;&GW_\
M:L%S,[0?9)/F5KD,I1L8;(YX)XYH ]$N/%9LQHVE:+I$E_J%Y9"YCMC<"-8(
M %&YY&![D <$DU5G^)$-GH5_>WNE7$%[IU[%9WECO#LAD*A65A]]2&!' STK
M-)E\->*="\0WUI=MITN@)ITTD-N\IMI58.-ZJ"P!R1G'4<UBZG87^KVOB+7X
M=.O$@U36=-^RQ20,LCQ0,BF4H1D \GD#@9H [G3O%U]+XG@T35]!DTR6[@>>
MSD-RDPD"$;E8+]U@&!QDCWK0\3>(X_#EE;N+66\N[RX6UM+6(@-+*V2!D\*
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MYKN9[*Z/Q^MKT6TQM!X?,9G\L^6'\XG;NZ9QVH UT\=Z>_PY/C+RG%LML93
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MIX<O?$>FS6&E^(VO+5'EDDU":Z\NR<KM*D3':S'<1\N?6O3* "BBB@ HHHH
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M).!U)S70444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MK8:#I\6OVUW=75SJ$EI%<V]F5\Q-S;)Y4X\L,!D_4'O79T44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@Q P!^->77U]=:EX5^%%U>3/-<-K5NKR2'+-M8J"3W. ,FNIT?\ Y. \1?\
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MYLDN.$'-06%KK%UI7C#0M)L;ZR6VN;22'3)[T>8L;!6EB64.VT.JG'S<;NU
M'L%%>-WFJV>D>$?$$?A_^V=$OV:U@ET^^9LVGFR^69HR2?O GE6QE0>#6[J.
MBVG@GQ-X5GT1KF%;Z]-C>1/</(MPK1L0S!B?F4KG(]30!Z/17B4>B17WPO\
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M:U6DNYOC3X0EOXO*O'\/NT\?]V0YW#CT.: /5**\<L=)CUWX7ZCXUN[N\7Q
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M-K'DB>*3!1?+0J-O&>0><YK%C^&UJD$6F/K.I2>'X9A-'I#F/RAAMP0OMWE
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M\3:OKEO).\^IGYXY""D7)9M@Q_$QR<YYH Y1M3'BSQ)<ZI;NWV+3?#?FJ W
MGNE+_F(U'YUSNCQR:A\-_AI;R7-P@N-4:.5XY"KLA$^X;AR,CC/4=J](\-^!
M--\,:)J.EV<]S)'?LQ>25@752@15&!T51Q3-/\ Z?IVC>'M,CNKIHM#N3<P,
MQ7=(Q#\-QT_>'ICH* .,U=%\#:WXM@\/*UI;_P#"-?;EA1R52<.Z"0 DX.,?
ME1K'A;3_  _IG@J\TV6>&XGUC3TNW\]F^V;F#%G!/+9&<^A(Z5WVJ>&;*ZU/
M4=8FBFNI+C2FTZ2S# ++'EFP,]&.XC.<5YG:V*:Q<^%=/L;CQ)>3Z?J%O.]O
MJEL8TTV&+YF#-L4,W 4$ECZ8R<@'HGQ)M(+SX;^(5N(PXCL)I4&2,.J$J>/0
MBN';P[IY_P"%9:=#&]O;W2S2SB*1E+DV@+#.<@-C!QV)KU;5=-@UC2+S3+K=
M]GNX'@DVG!VLI!P?7!KG]+\#I8-H3W.L7U\^BO(;5IA&/D:+RMAVJ,@#D'KD
M\F@#@]89_!A\>V'A_P VUMDLK*6"&*0_N9)7:-V3)^4D8/U K;\,Z1?:9XPT
MZ72_"FHZ+IKP2Q:B;B[BD24X!C<A9&)<,"-V,_-75WG@[3=0U#6KF[,LJZO:
M1VEQ"2 H1-V"N!D'YNN>PINC>%I]-U&.]O?$&IZH\$)@MTN2BK&IQDD(J[VX
M'S-DT 9GQ!9[NZ\-:&TLD=EJFI".[\MRADC6-G\O(Y 8@ XKGM8"^ /$FHQ>
M'4-O:S>';J]-HK%HTGA(VR!3G&0<''7%>@>(O#UKXCL(K>XEF@E@F6XMKFW8
M+)!*O1E)!'<C!!!!-4=,\'0VU[>:AJNH7.L7]W;?9))KI44+!G)C5$55 )Y/
MK0!C^&/!&FV]EX?URTNKF#4S%'-=7(F9S?;TRRR;B002<CTQQ61X1\+VGBSP
MK:^*;NZN8/$%U<R7/]HI,V^';,P$:@G;LVKMVXQUKHM-^'L%C=Z<9]:U*^L-
M+?S-/L;AD,<# $*<A0S[02%W$XJ.7X;6<CRVHU;44T.:Y^U2Z0I3R6?=O(SM
MWA"W)4'% !X2D9O$/CD,Y(34E R>@\A*X'3K5M8T;X4V$]Q.L-VEVEQLD93(
MGE$LI(.<$ CUYKTB[\#)/KE_J%MK.HV4&I;/M]G 4V3E5V]2I9,J,$J03ZBE
ML/ >GZ<OAE8KJY8>'Q*+?<5_>>8I4[^.P/;% '*W_A73+[XK67AUXY%T6#P[
MN-FDSJL@6X(56(.2 3GKV%9=Y:7/B#5/%#GPUJFI75K>/9:=>6UW'&MB(XUV
M; TBD-N.\G'.1UKU(^'K8^,!XD\V7[4+ V'E\;-GF;\],YS[UEZEX(%WJ-]<
MV.N:EI<6I8^WV]H8]LQ"[=P+*2C%0 2I&<#O0!R\6DR^(?B'86?B1)&/_"+P
M2WEGYF$>?S6!W;3A@"6XZ9QZ"LF%Y8-$?PS%<3QZ;+XR;2L+*P9+7;YAB#9R
M 2-O7H37J,'ARTMO$BZW')-YRZ>NGB,ME?+5RX.3R6R>N:S9O 6F7&FZG9O<
M70-]J1U19T<+);S_ "X:,XXQM&,YZF@#GO%6AQ>!?"7B"_\ #=Q<VB7%O%$+
M**3*QNT@0RIN/RMM?'89 -)X9TB^TSQAI\NE^%-1T73'@EBU W%W%(DIP#&Y
M"R,2^X$;L9^:M^W\ V<D>IMK5_=ZQ=:C;"TFN+G8A6$$D(@0 +R=V>N>:MZ-
MX6GTW44O;WQ!J>JR0PF"W6Y**L:'&20BKO;@?,V30!E>/R][J7A?07EDCL=3
MOV6[\MRAD1(V?RR1SAB!GZ5FP:#INE_$:3PS:6Y71-3T=KB>P$C>6LB2J X&
M?ER&P<8S@5V7B+P[;>([*&&::>WGMIUN+:YMV D@E7.&&01T)!!!!!JMH?A9
M=+U2XU>]U*ZU359XE@-U<A%V1 Y"(J*%49Y/')H XOX%Z-I\'@U=4CM@M[)/
M/"TNXY*"3@8SCL*U=8L;?Q/\4QHFK*T^EV6D+=I:,Y"22O*5WL ?FP%P,],F
MNC\)^&+7PAH2Z39S330K*\H>8C=EFR>@'K4>N>%EU75+;5K/4KK2]5MXF@6Z
MM@C;XF.2CJZE6&1D<<&@#S+5A/8Z/XC\/6EW<1VFG^(+!+)Q(6:!)3&Q12<\
M*2< ^M;]]IMGX*\?Z=)H<+P+>:7?/<Q>:[B=H@C(S;B<MDGGKS70K\/].&AO
MISW=Y+)-?QZA<W<C*99YE=6RW& /E P , <5KWN@6U]XBT[699)/.L(IH4C&
M-CB4*&W<9_A% 'E/AJQU:>T\-:UI_AG55U66:"XOM7DO(BMU#)@R[AYF2I5B
M5&W(P.!7?_$S4;O2_A]J=Q8SM!<-Y4*S(<&,22*A8'L0&/-)IO@1=,N+2./7
M=4?2;*7SK732Z".,\X!8*'91GA2Q'3K70ZQI-GKND76EZA%YEK=1F.1<X.#W
M![$=0?:@#@M6\/Z=X)U[PI=Z!$]J]WJ2V%THE9OM,;QN27!/S$%0<]:9\.-"
MM+W5==UR\,L]Y9Z]?0V9>5ML";B#M7.,G<<DCICTKH]/\%&#5;*_U37=1U=M
M/#"R2Z$86$D;2QV*-[XXW-GJ:T_#_AZV\.Q7\=M++(+V^FOG\S'RO(<D# '
M[4 <W\2H6NI_"5J)YH4GUR..1H7*,4,4FX9'(R.,CD5BV7@W1O\ A9>KZ#Y$
MG]B'3H+PZ=YS^29B[IO(SZ#ITR<]0,=_K.@6^MW&E33RRHVFWBWD03&&8*RX
M.1T^8]*6+0;>'Q3<Z^)93<7%I':M&<; J,S CC.?F/>@#RG2Y)[W0/#'A>>Y
MN/[.N-=O+28^:P9X(3(R1%LYP< =>@Q6S>6-OX7\6ZKH^CJUOIM[X<N+I[1'
M)2.5&VAU!/RY#8..N!72M\/]..AC34N[R.2._?4;>[1E$L$S,6RO&"/F(P0<
M@\U+8^"XH9-1N]0U2\U+4K^U-G)=SA%,<//R(J*%49.>G)H \\@T\:/\'M,U
M:T^US:OK$5E:7%RDY$K1.Z+Y:%B%7Y?E!XZY)[UTWA#3+[3/&!:Q\,7VAZ)-
M9,MQ#/<QR(TX92CJ%D8@E2X)[\5TO_"'Z<W@F'PK*\\EE#;I DNX+*-F"K@@
M<," 0<=13M%\.3Z9?R7]]KFH:K=-$($:YV(D:9SPB*H))QECD\4 8GC=/[5\
M6>$_#MR\G]F7\ES-=1(Y7SO*C!5&(Y*Y;)'?%9*Z'I]CXRUWPI# 3H5SHT>H
M?8S(VR*9967Y>?ESM!('I7:^(?#<'B".T<W-Q9WME+YUI>6Q'F0O@@_>!!!!
MP01@U!HWA.+3)M0O+G4+K4=2U!%CGO+@(&V*"%554!549)P!R3S0!ROP.TBP
MMOAQIFIPVX6\NDE6:7<<N!,X'&<=A1?:%IEW\>[66>U5W.BF[R6;_6I,BJW7
ML !Z5V7A7PY;>$O#5GH=G-+-!:APCS8W'<Y8YP .K&JVJ^$UU'Q/8^(+?4[N
MQO;6$V[^0$*S0E@Q1@RGN.HYH \R@\,Z=>?#7Q7K=PLKZA:76I36<PF93;-'
M([+LP<#YADGJ<^@%7;J:;Q+XG:'4_#U]K]O:Z39O'!!<1QI')*K,\A#.N6.
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M8(;B."93-83J&,KHF0&+$CYE.?E]*6#3-&\4?$;2HI)9-0TD^%HIHTN')^T
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M9HVF3=$&[@9(^E=#K.FQW/CNXT9/"7]M:7I>FP+;6*W$<44!D9]S[7898[0
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M 1&68!23VZXS7<?#[3]4TNPU*UOM,DTVS^V-)I]K)<)*88F524!4D!0^[ [
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M62PV[ _*UQ. [,/I'M'_  *NKT31+#P[I,6F:9$T5I$6*(SLY&YBQY8D]2:
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MYM73?)#@?*X92I^Z#T'-=09H@RJ94#,2H&X9)'44+-$\K1+(AD3[R!AD?44
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MC%3@,P/4>E=#X:\36GB>QGG@@N+:>VF:WN;6Y3;)#(N,JP!(Z$$$'!H SG\
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M(8>8X 8#CIP.*R=.\ :;IMY:21WVIR6EE(9;33Y;G=;V[<X*KC)QDX!) [4
M>=MJ%UI9^,5Y9.T=S')%L=>J91AN'H0"3^%;NN^&]'\)V?A'4=!LX;6^75+2
MV-Q"N)+F.4[75V'+[@<\YZ5V=GX.TFTN]>GV23#72#>Q3,"C#:5P!@8!#&J6
MG> -.L+RQGEU#5+Z+3SNLK:\N0\5N<8!4  D@' +$XH YC0O#.B^+M.\2:IK
MT8^WMJMU%]N+!9K-(GVH(W/W-H4'^>:K^*;6PUB_\1O;^'EUR6RLD@N-1O[M
M$2V(B+CR?E)W88,2,<GK76ZC\.M)U*]O93>:G;VU_()+VQMKG9!<MP"67&>0
M!G:1GO4MUX!TJZU.ZNC/?16]X$%W80S;+>?:H5=R@9^Z " 0" ,@T <+%IEA
MK?BSX;76IV5O=SWFAO+</-&&,KK#&5+9ZD$DCTS4/V^ZTS6_C'>V3,ES#!;M
M&Z]4/DO\P^G7\*[EOAUIWV718H]3U:&;1E>.TN8[A1*(V !C)VX*X  XS@=:
MTK/PCI5GJNNZ@$DE?7 BWD<K!D8*I4 #' (8YZT <+K7AS2/#'ACPOK&BVD-
MOJ<5]9*+J)<2W(D8+(KMU?<&).<TNE^%]'UV;Q_/JEC%>,FISQQ"9=PA_<H2
MR9^ZQR,D<_*/2NJL/A[IMC<V+OJ&J7EMISB2RL[NYWPV[ 84J, DJ#@;B<5K
MV/AZRT\:L(3*?[4N'N+C<P.&90IV\<#"CUH H?#VXENOAWX>FGD:25K"+<['
M)/R@<UQ&D>'M)\2>!_$>NZS:0SZM/<7K&[E&9;8QLRQA&ZH%"J0!BO3M%TFV
MT+1;/2K0R&WM(EBC,ARVT=,FN?OOAWI=Y<7Q2_U2UL]0D,M[86USL@G8_>)&
M,C=WVD9H \ZO].L=>UCX57VJZ?;7%UJMNYOGEB!-SM@0C?G[WJ,^M>NZSX?L
MM7\+7>@-$D5I-;&W147 C&,+@?[. 1]*AOO"FF7VJ:'?LLD3Z*7^R1Q$*@#*
M%((QT  QTK5O;M;&RFNGCFE6)"Y2",R.V.RJ.2?84 >2IJ=QXQ\,^&/"%YG[
M=+>M;ZRA.2([,@R;O]\B/_OJM;P_X=T?Q?J/C"\\06,%]<+JLUA&TZAC;P1J
MH01Y^YU+9&.3FKO@C0FE\5>(/&,^F3:>VINL=K;W"[9%C50&=E_A+LH..ORB
MM74O ECJ&HWEY!J.J:<;\ 7L5C<"-+C VY8$'!QQE<&@#AO!=]<ZCJ'PWN;R
M5I9CINHQF1SDN$9%4D]\JHJ'QD0UI\6\$'$=A_Z*6O0]1\#Z5>VNDPVLMWIC
MZ0I2RFL)0CQ(5"LN2""" ,Y!Z56_X5SHITS6K!I;YTUE8Q>2//ND<I_%N(ZG
MJ?TP* -7PUH&GZ%IBK8VZI+<*LES-U>>3'+N>Y))KC;/P[I.O_%?QB-6M(;V
M.&&RV03KN0%HVRVT\;L# /49/K7I,:"*)(USM50HS[5YY'X5FU3XC^*[Q[G5
M=,W1V:07EF_E^8OEMO4%E*L 0O;(/I0!Q?V47_AWPMHTTLK6<'BR>PC;>=S6
MZF5=N[KC;E?I73>*M-LM(^(GPTL-.MH[:TBGO1'#$N%7**3@?4DUU\7@;1H-
M/T2RA6=(='N?M5OB3):3YLER1\V2S$].35O5?#-AK&NZ/J]RTPN=)>1[<(P"
MDN #N&.> /2@#S:'PUI.L:?\2KO4;..YFAU"[$!E&[R"($;<G]UB<9(Y^4>E
M-.C6-CX<^'6OPP@:S=:C8?:+\\S3":,[U9^I!SC!Z  "O2K?POI]M:ZW;QM-
MLUF:2:YRPR&D0(VWC@8 ]:9+X2TZ72-$TQFG\C1I8)K8AQN+0C";CCD8Z]*
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M"CUH Z?P3H)\->#].TR0[KE(_,N7/):9SN<Y[_,36#\/R)M1\<7TK 7#:[-
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G_\
MA(I+KQJV@6$"2I:0";4;AF.(2_\ JXU'=FP3ST ]ZM:+J%Y<V6_5A80W#3,D
M:VMQYBL!TY./F]17-_#?]]=>,KN3FX?Q%<Q,3UV1A%0?@/YUY_X=TZ>Z^#%[
MJ-DN=0T;6IM3MO=HF!8?BNX8H ]TN9?+B*I)$DS@K$)3@,^.!ZG\*R/"OB+_
M (2+3)9)K?[+J%I.UK>VN[=Y4R]0#W4C!![@US-K>0^-?B5IUY;MYFF:)IRW
M:GL;BY7*9^D8S[%JL^'_ -Q\7O&$,7^JFM;*>0#H)-K+^9 'Y4 =)JOB/3=&
MO].LKR<)-?RF*(9'&%9BS9/"_*1GU(JEIWBJ*YUK7[*\:WM8=,N8H(YGE \S
M?$K\YXSSBN=\?:5IU_X^\#B\L+6X\ZYN(I/.A5]Z"%F"G(Y /./6HM#\,Z-K
M7COQPVJ:=;WBI<P11I/&'6,&W3)4'@$\<CG@4 >BS7,%M 9YYHXH1R9'<*H_
M$T^.1)8UDC=71AE64Y!'J#7A6A27^IZ5\/[)M)@UJ&/3;J=;2[N!'&[I(L:L
M<JP8HIX&.^>U>D^ M*U+2+35(+VP@T^VDO6FM+."X$JP(RKN0$  #?N(&!C=
M0!T\][:6RNUQ=0Q", N9) NW/3.>F:1K^S22&-KN!7G&8E,@!D_W1W_"N!31
M--UGXQ:\-3LX;R*+3+4K#.@>/<3(-VT\9 R >V3ZUQ0T#3(_@3JVI_9(VU"U
MGF^S73C=+ (K@JBHYY4 #H#CD^M 'NEQ>VMH4%S<PPF0X022!=Q]!GK5#4O$
MFF:3JVG:9=SA+B_9Q$"0 NU2Q+9/ XP/>N&\1P6NM>(M:6#PS9ZM<6EA'%>7
M6IW0CBMPR,X6(;'(;#;B1CMS6)9V%EK&H?"674[*VO)+G3KA9VN(5D,H2W4J
M&R/FP22,]"2: /8Y+RUBN([>2YA2>3[D;. S?0=31/>VML&,]S#$$ +>9(%V
M@G )S[UXVVE:GXD'C!D\+V-_=2ZG<V\6J3WPCFM?+^6+8"A*A %88(SGWK7B
MT&#7/BX(?$-M#>-#X=MY)8) 'B:;S&!8CH<9;'US0!Z#:7>H2Z[J%M/%9K90
MK&;=XYMTK$CYMZ8^7GIZU<AO;6YEDB@N899(CB1$D#%#[@=*\MM+VVT[XF_$
MZ]O&E6V@T^VDE,)PX409.T^OI[U!H]D^E^,O!!B\-6&APW"7$2F"Z$D\\?V<
MMB;"*"<A3G+<T =QX-\53>)YM?26U2#^R]4FL$*,3YBIT8^A-6+CQ(+7QNFA
M3)%';'2WOVN7?;M*RJF.>,?-G-<O\)O^/KQQ_P!C+=?S%2:UI.GZQ\:=,@U*
M"*XA30Y9!#*H9'83* "IX;&2<'N >U '?+=VS6ZW"W$1@;&V0.-ISP,'I3?M
MUIY,LWVJ#RH6*ROY@PA'4,>Q^M>(>)K:/3_#7Q"T?3Q]GT^VU:P>V2+A86D,
M+.$'0 -S@<"NF\6Z);:3JGA/0M&\/V=U8S7%Q<2V#RB&.YECB&UI&*MN(!+<
M@Y*C/2@#TV.X@EMQ<1S1O"1N$BL"I'KGI3;:[MKR+S;6XBGCSC?$X89],BO*
MY=/GTC1-<MM7\/QP:?JVH6J6.C6-Z"K3-@,A;: B,55B,8P6K,U";4?#USXU
M%KI=CHLW_".QS_9M,FWHK;Y%$G")M<+Z#L#F@#V:&]M;B62*"YAEDB.)$20,
M4/N!TK#\)>*X?$/AW3M0NFM[6ZO/,VV_FC)VR,G /)^[5'2O"'A;2I- O[*.
M"PNX8O+A>!EC:[W)RK]Y/[WKD9KS:/0-+C_9ZGUH64)U5 \\=ZR RQLMP0NU
M^J@ =!QR?4T >Z7<QMK.>< ,8XV< ]\#-8_A?Q)#KV@:5>S/;P7E];+<?91*
M"PR,\ \D5IZD<Z/=GUMW_P#037BIT+2K#X :?K]I:PC6;>.VNHKX*/.$OFJ
M-_7&/EQTP* /<HY8Y@QBD1PK%258'!'4?6B.6.7=Y<B/M8JVULX(Z@^]>:7.
MK1_#SQ=XG,PVZ?J5DVL6JG@&Y0!98Q[L2C?C74^ M#ET#P=8VMUDWTP-S>,>
MK3R'>^?H3C\* %N?&6G"/Q#%9R)-=Z- 9)$+#:[>49  0<GC@^E7M#URWU?2
MM-G>6".[N[.*Y:V60%EWH&Z=<<]:\VL](TV#4/BG/%I]I'+!&RQ2)"H:,-:D
ML%..,DDG'6F3:!I>E^!_ .J6=E#'J1OM,9[P(/.?S-H<,_4@@XP>,8'84 >M
MR7EK%<1V\ES"D\GW(V<!F^@ZFIZ\5;2M3\2#Q@R>%[&_NY=3N;>+5)[X1S6O
ME_+%L!0E0@"L,,,Y]Z];BCOF\/I'.P&H&U"N5/'F[.<'_>H YC_A.]1U2ZNE
M\+^&)]8L[65H9+QKN.WC=U^\(]V2^.F>!FMKPSXGMO$EC<3+;SV5S:3&"[M;
MD /!(!D@]B,$$$<$5B_".6W?X8Z/%!A7MT>&=.A24.=X8=CGG\:J?$35+/4M
M(@TFVO$>*36[/3]46)\%$=@61B.F1@'ZD4 =U;7MI>JS6EU#.JG#&*0-@^AQ
M31J%D98HA>6YDE&8T\U<N/89YKAK_2]/\/?%#PE_8ME;V(OXKR"ZCM8Q&LL:
M1AU+ <':V.?>N#CT#34_9^MM92V1=66XCDCOP/W\9^UA!M?JH"\ #COUH ]X
MAO+:XEEBAN89)(CB1$<$H?<#I3!J%D98HA>6YDE&8T\U<N/89YKA)M%TSP_\
M5O"R:18P62W-C>13B! OFJ@C*[L?>.3G)YKC-.\.Z,?V>Y]:-M"=4CAFN([[
M:/.BDCE;8%?JH&T# ..OK0![A<7MK:-&MS<PPM(<()) I8^@SUITMS!!GS9H
MX\*7.]@,*.I^E>5ZVD&OWVM2)X8L]3NK;388[Z[U.Z$:6Y,1DVPKL8@@/N)&
M.<>E0:590>(-9^'BZJ@NT?PX\LJ3?,LK 0XW@\-S@\]P#0!ZS'>VDL4<L=U"
M\<K;8W60$.?0'N:DDECBV^9(B;V"KN8#)/0#WKR";PR+J#Q_I.C0K;2:=J%O
MJ&FQ0KA8KA84D^0#@;B"/QK7L=5A^(7B_P -7$ !L-,L!JLZ]0+F4%(T/NN)
M#0!Z4S!5+,0 !DD]J@@U"RN87F@N[>6*/[[QR!E7ZD'BN0^)N9M*T33I&(L]
M1UJUM;P XWPL22I/H2H'XU1U'1=+TCXG>';73=.M+>VU6RO;>_MHH56*:)%0
MKO0#!Y)&2.AQ0!?\*^-KSQ7K^IQ6]I81:38W4MH)&NB;B5TQ\RH%QM.?6NQN
M+JWLX3-<SQ01 X+RN%'YFO,O@]I&F1+XFNX].M$N8-?NX(IEA4/'&-N$5L9"
M^PXK9\8K;:CXITC34T&+6]1BMYKE(+R<1VT4>50NX*MN;) 'RG'/2@#M?M$.
MR-_.CV2$!&W##9Z8]:BCU&QFBDECO+=XXCB1UE4A#Z$YXKQ6.V%WX0TC3+B-
M(;=/&S6WV>WE+)%'ODS&C8!V\D X''I73W'A?2/^%EW>AVMC;V=AJ?AJ1;B&
MVC$:,1,JAMHXW ,<&@#TEY8XXC+)(J1@9+,< #ZTK2(L1E9U$8&XL3P!ZYKQ
MR&_N?$GA30/ EXQ.H?VBUAJHS_RPM"&<Y_VE\KGONKT/QX OPZ\2*  !I5R
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MM4^"&I^(;^U@?6IX+N^DOV4>>DZ.Y7#_ 'EVE5  /;WH ]AFO+6V#F>YAB"
M,YD<+M!X!.>@J2.6.:-9(G5XV&593D$>H->6Z1IUMXD^(L$^MVD5VQ\,6<[P
MSH'0RL[Y8J>"1EL9Z9-;OPQB2UTK7;&%=EK9Z[>P6\0Z1QA\A1Z 9- '87-[
M:62JUU=0P!CA3+(%R?09K \<^,(?!GAB;5?)6ZFRJ0V_FA/,+,!G/H,YZ5AZ
M;I6G^(OB7XO.M65O?&Q6UMK6*ZC$BQ1-%O;:#P-S$Y/M7GWB*SMI?@W>+)!%
M,-,UZ2RL)Y$#NEN+C 56/.,<?0#TH ]QT.ZOKO2DGU-;%+DD[A93F6(#M\Q
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M>YX%=)#J=A<2F*&^MI)!&)2B2J2$/1L ]/?I26NIV.H02RV%[;72QY#&"57
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MA-$\.ZO!KWAN\@T'1-(M;-'CDDL[TN]Q"T9&TCRUW?-M;))Y&>]<S%H6F?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5DRP& O8YXQ7K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% 'BWAZ#4KSXQ>*M1UC3=%FET
M[[(TTLDSO]C3RR<P9CY.!DYV\^M=)_PG^NQ:!#XLN-$M$\-2,K8%RQNT@9@H
ME*[=O<':#G!ZT_1_#U])X]^(4EU;2PV6JQ6L5O.1\L@$+*Q7UP36+-!KU_\
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M[4CA0X,LC,%10>V6(Y[5KUS'C_1[W6_"4\&FHLE]!-#=01LVT2-'(K[<GID
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M@AT. =IST(!!!K#O/$FMWOB34-&\-Z?8S'3$C-W<7T[1KO<;EC0*I).W!)/
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MYP"TI+$87CC-9?B[6_&4%MX746]EI]W<:TEK,HN'*2D;BN"O/E,%R0?FZ#%
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M/JC-7%:QX0\167@GPZNDVK3:N;6XL[\*P!7[6I:1R<\[9,&O7\@DC(R.HI:
M///$7AB[7Q5\/AIEF\FGZ.\J3.N,1)Y:*N?^^>U5)--UBVUCQ_8_V->2QZU
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M($E@&*@ $Y[5VWC?0IO$W@K5-(MV5+BXA_=%S@;U(90?;*@5T%)D;L9&>N*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKBY@MYX/L]U+:2)-MR'C;:WW21C/O7)KH>H^%O%/AVZM-.NM4LK70SI#M;E
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M//.<?B<"GZ=JVEW?CEEDT>ZLM9_L>.>2>YVC$!?A.&/(;=G@=*J/IVJK\0]
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M2^R6,IAO-5NH=-AE7JAE;:2/?;NJEXEO(?"5UX)T;3]-L7M9K]+-//BW- H
M&Y#D8;WYH [VH#?6BWZV)N81=M&95@+C>4!P6"]<9XS7-Z!XJFN)_$UKK0@@
MGT2Y;>8@0IMBF^.0Y)Y*YS]*Y/6]3U34_AAI_CRXMXK;5=.F&H6J1 C_ $=G
MVF-B2<[XCD]NGI0!ZO13(I5FA25#E'4,I]C3Z "BBB@ HHHH **** "BBB@
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M;*6\O;B.WMH5W22R-A5'J30!Q/COPUJVM?"!]!T^U$NI&"V00^8J\HZ%OF)
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M:YG:XGD=R[R2-U9F/)[#V  H POB-H^HZSX9B32K875W;7MO=+!Y@0R"-P2
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MJYR..W6L+4O!.J7L7B"4Z?;W#G7XM4M+:X=#'=QI&BLC=0N1O'S#KCM7I]%
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M+6'(B1G+[ 3G:"23@=AV'% '!^/?"&MZIKPFT.,?9M8M%TW5G\Q4,40E5O,
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M"322RR[0S'9D!0JX'.<FHO#?A74[/X-GPQ=I'#J+V-S;D;PRJTADV\CM\PH
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M,5NZ\"\+^6RD>@(8X]!2KJ7B[5_%7B+0]/U.RLTTI+8K<R6GF-(\D(8KMW
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MW8MV,DXZD@#/6JFM>.-<L/A=K^H3?8YM5TC5#I[2F#]U-MD0;]A/!*MTSUH
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M1\V?DP-O8Y(/2JNC>/;PWV@S7?B30M176)EAFTVS*>;9,ZDI@AR6 ("MD=Z
M/3;FZM[*W>XNIXH($QNDE<*J\XY)X'-5K/6M*U&4Q6.IV5U(!DI!.KD#UP#7
M+_%PHOPQU8RX\L-;EL],>?'FN6U6\\&ZSJ6A0^";>R?6X]3@E$NG6OEF*$-^
M],C!0-FW(()YSTH ]?HKRC5?B'>++KM_;>(M"LTTFXEABTBY*>=>"+[Y+%PR
MEB&"@#L.N:U+KQ%XCUKQN-#T&[M+.TETF'41=3V_FM&&9@0%R,D_+UX !]J
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MB00E-D1?')VJ<MC&3Z<UIVVF^)=4\=Z1X@U/3K:PM+6TN(#;K<B9U9]A#%@
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MC6.\M&+;EVNZ["V.G(Y%=99:9KVL^.++7=9TZ#3;;3+66&WA2Y$[2R2E=SY
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MES=6<D"2L<?,RD G';UKC[?1?$TFK^%]0_L'3]/MM'=H7LH;I2S*\1C:0,%
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MWARH"_>QUK8ETCQ!X>\4:MJ>@6-EJ%IJRQ-)!/=&!H)8TV;@=K!E*@9'7(H
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M+-,N[Z&[O],TY=0L;W[.J%T;<I#H/ER&7MU!JX^J^*-(UCPU=:CJ=O<V>LW
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M;:$2LT430QR85S@$CE<D8SSC%=II5Q/=Z/97-U&([B:WCDE0 @*Y4$CGT.:
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M-U;F4N8FW+\TC,,' [$4 <];VFN7WQ2\90:1JD>F((K%I;@VZS.6\IMJ@,<
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MJNG#R_L31EO,;Y?WGF9X^]C&.U %^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH JZCIECJ]A)8ZC:0W5K*,/%,@93Z<&JNB^'-&\.Q2QZ1IT%FLI#2&->7(Z
M9/4X]ZU** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **Y'_A86C?V,VI?;+-8?MOV
M/+W  B;G_6G'R'"DX^@ZFJNH>*?$<_C:Z\/>'[#2IA;V<=TTU[<2)N#DC VJ
MWI0!W%%<=IOC#4(/$-MH'B?2$TV\O%8V=Q;S^=;W)49902 58#G!'/Y5IZ;J
MKMJFNK=ZOI<MM9,I$<)VO:+@D^<2<=LCIP#0!O45E:5XET/7(YY-+U:SO$@_
MUIAF5M@]3Z#@\^U)I/B?0M>FFATG5[*]EA&9$@F5RHZ9X[>_2@#6HKA_!_Q#
MTS5M!T@ZQJVFV^LWRD_9A*$).]E4!2<C.!CUK>-_/_PF8T_^T].^S_8O-^P<
M_:MV_'F=?N=NG7O0!M45Y[X=\8ZIK7A+Q)J%S=Z;83Z?J<]I#<7"$0QHFS!?
MYN?O'N.U:E_X_P!&T._T33=3U*R^T:A#YDDZS!(XP$W!^3]UB,+0!UU%5K'4
M+/4X#/8W4-S$KM&7B<, RG!''<'M6')XJDDUW28-.LXK_2+YY(7U&"Z4^5,H
M8[=G5A\AR1TH Z6BL/PQK6H:S;7O]J:3_9MW:736[1"=9E8;58,&''1AD=B#
M4UYXIT#3]5CTN\UFQ@OY,;;>2=5<YZ<$]^WK0!K45QH\<VFG^*?$=CKFH65C
M8V#6J6SRML9S)$78$D\\CL.!707?B'1K#28]5NM4M(=/D ,=R\RA'STVG/.?
M:@#2HKCO&7C)=-^&^H>)O#UU:7GDJAAD!\R-LR*IS@^Y[]:@U3Q;J5GXI\$:
M;$L'D:VDS719"6!6-6&TYXY)]: .XHJ"]O;73K.2[O;B*WMHAF265@JJ/<GI
M68GC#PW)=7=LNNZ<9K-6>X3[0N8E'WB>>,=_2@#:HK-TWQ!H^L6$E_IVIVMU
M:1$B2:*4%4P,G<>W'/--TCQ'HNO^=_9&JVE\82!(()0Y7/3..WO0!J45D:?X
MJT#5M1ET_3]9L;J\BR7AAG5F&.O /..]0W7C3PQ8RI'=:_IT+O(T:J]PH.Y6
MVL.O&""#[T ;M%,EFCAA>:5U2)%+LY/  &2:ABU&RGTT:C%=PO8F/S1<*X,>
MS&=V[IC'>@"S16+?>+O#NFVEK=7NMV,$%VN^W=YU E7^\OJ/?I5T:QII@LYQ
M?VQAO7"6L@E!69B"0$/\1P#T]* +M%59=3L8;J2UENX4N(X#<O$S@,L0.-Y'
M]W((S5>P\0Z/JMTUKI^IVMU.L2S,D,H<A& *L<=B"#^(H TJ*Q=2OY[?Q+H]
MG'J>G00W'F^9:3@^?<;5R/*Y[=3P>*;>^,O#6FOLO=>TZ!O-:';)<*"'7AE/
M/&,C/I0!N45F:MXBT;0K>*?5=4M+.*8XB::4+O\ ]WU_"L?Q#XL73;CPW-:W
M5FVFZE=,DURS IY0B=]RMG ^Z.>F* .KHK'L_$FDZUIEY<Z+J]C<"!&W2K('
M2)L$@O@\#C/T%<IXB\9:IHO@C0M4MKS3-0N;S4(;:6YMT)@D1BP)3YO8#J><
MT >AT5A7.JO;>+/LTNK:9%9)8-<26;\7 PQS+G./+ &.G4=:H:!\1O#>OI(8
MM3LXG%XUI'&]PNZ4[BJ,!_MXR!WH ZRBJUWJ%G8&W%W=0P&XE$$(D<+YDAZ*
MN>I.#Q5?7M9M?#VA7NKWI(M[2(R,!U;T4>Y. /<T :-%<Y8Z^^E^%K;5/%]Y
M8Z=-/\[(6V)%NY6/)/S,!P?4@\5H'Q%HHT4:R=5L_P"S",_:_.7R^N/O9QG/
M&/7B@#3HJEI>KZ=K=F+S2[ZWO+<DKYD$@<9'4<=#[5!JWB31-!DACU;5K.R>
M;_5K/,$+>_/;WH U**Y/PYXM2[T;6-3UBZM+:ULM4N;59BP1!'&^U"23U/'U
MJQJ7CKP_8^$[KQ%%J5K=6<*L%,4RGS) "1&#_>/I0!TE%8,?C+P\WA^#6Y=7
MLHK&7"B5IUV[\<IGNPYX]JO#7M(;3[:_&IVAL[IUC@G$R[)&8X"J<X))XQ0!
MH45BIXO\.26J72ZYIYMW\S9+]H4*WEXWX.>=N1GZU"WCGPJNFIJ+>(=-%I)(
M8EE-PN"XZKUZ@$'\10!T%%8.L:LT<FBO9:OI=O!>7*+_ *2=WVI&_AA((!8]
MCS4NH^+?#VD-(NHZU8VS12"-UEG4%6(#8(ZYP0?H10!LT5G7NOZ1INEIJ=YJ
M=I!8R!3'</* CY&1M/?(Z8I5U[2&T8ZPNIVATP+O-WYR^5C./O9QUX^M &A1
M7'VGC2WU;QKIVG:1>V=YIEQ8SSR2PMO(D1T &0>.&Z$>E6_%WB&;P_-H)C>!
M(+W4TMKEYNB1&.1B0<C'W!R?>@#I:*Q+7QAX;O;"ZO[;7+"6TM,?:)EG4K%G
M@;CG@'UK2O-1LM.L'OKV[AM[1 &:>5PJ $@ Y/')(_.@"S16?K6M66@Z+<ZK
M?SI%;01ERSL%!/8#/<G 'N:Y)OB+:WB>%;VPNK,6&I3.E\SR!OLVVW,I4L"
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MY:XZY;.!CWH TJ*S](UW2M>MFN-)U&VO8D;:S02!MI]#CI6A0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% %!]$TF2WN+=]+LFAN)/-GC-NI65_[S#&">!R>:Y#3 !\<== X']C6_\
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MVD<R.S21L<D,222<]SS[UJ:?I]KI6GV]A8PB&UMT$<48)(51T'/- ' >,/\
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MQUTXPK&MRVAS&;:,$CS4"D_^/?E2_$^*TGD\'Q7P1K9_$-N'5_NM\DF ?8G
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M.CK9J-/N?,\Z'<V'\PDOSG/))_.M&&&.W@CAB7;'&H1%] !@"@#Q#4[;2?\
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MF"/<-5L/L'EX^YWQCMLSGVJ/P[9V[Z3\1Y6A1GFU2]CD8C)91$N ?;YC^9H
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M+;Z3JUK=S1+N9(GR=N<;AZC/<<5PNK:Y>Z NK6_BS2-*U&Z3199(;NS!3[1
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M:W4'Q"!*;I2T('VJ7;Y@!&5W[,\T >MV'BK0=4TVZU"RU2VFM;12UQ(K?ZH
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MT31+*"\U+5+:WMY\>2[/GS>,_+C[W'/%$GB71(M#76WU6T73& *W7FC8W.,
M]SGC'7-<1H#:.WQ*TC^RMIT@>'&_LK.['^O^?9OYSMV^^/:HM0&@?\)AX232
MQ%_90UN]^TA=WE_;O*.WKQG=G&.,]* .YL?%>@ZGIMUJ-GJMM-:6BEKF17_U
M( R2P/(X!/-7)M6L((+2:6[B2*\D2*W8MQ*[C*@>I(KS+QHH/BSQ@+4 @^#9
MOM83O)N?R]W^UMW8]JN>(+J ^'/AO&)4+S:II[1@'EE$9R1[<C\Q0!UM_P".
M/#&ENR7VMV<#I*T+*S\JZXW CMC<.>G-4];^(>@Z%KVE:7=7D ^WHTAF\T!8
MD"Y5CQR&/ K#\-6=N]I\1Y7A1GEU6ZBD8C.Y!"A"GV^9OSK'T)B=1^#Y8Y/]
MEW8Y_P"O>.@#TSQ%KUGX9T&[U:^D58;>,L 3C>V.%'N3P/K7*2?$:TN+CPK>
M6M]:1Z7J!N/M[NP(A*0>9MW<8(.,UN?$#_DG7B3_ +!EQ_Z+:N2F@AN]0^%"
M3(LB")W 89&5M RG\" ?PH [K2O$VB:Y93WFFZG;7%O;DB9U? BP,_-GIQSS
M2:-XIT+Q#)+'I&J6UY)$ 76)^0#T..X]^E>8>.EDCU'XB"VVIYFG::TW!P5\
MQ@Y;'4;,Y]JZFQTO66\;:)?ZKJGA]6@M9TAM]/B>.2>%@N0-SG*J0AXZ9]Z
M.]HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!UBUN[FQU&.6.S3?<95E:-<$[BK '& <''.* ':KX5T+6[*VL]0TRWF@M?\
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M-09PK \$?,?SJEHOA'0/#UQ)/I6F0VTTB[&=<E@N<[023A<]A@5M44 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!YO\)_^):_BC0+P[-3M]8FN)$;[TD<@4I(/4''7Z5N_$/5[K3?
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MUH P_#TW]M1^%[?5$-YK7]@&>6._(-O'"S*OG,I&6D. .HXW9(R,XUE%'?\
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M/T:SMKV7.Z:.( \]<>F>^,4 4O'TUA'X;6'4&N#'<W=O!'% X0S2&0;8V)!
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M2],MK6VE),D:)P^1CYL]>..: ,.WTGP[]MTW6=#E2&ZELI(;1;5@$N$*[@7
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&(523T SP,TM%
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MES+X6U>.S#&Z:RF6';UWE#MQ^.*Y3P[J7A<^!/!4=T;>4NMK'91A=[+<A,9
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M58 J1@@]Q7AVNV+P_#&ZTS2/%D-[H<\AM=.LDML73R-)A8"Y;.%;K\H.!V%
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MZ5IZW\]^ME;B\N(Q%-/Y8WR(.BL>I'M7!>#_ (F::_A;2FU_4Y&U"9C'-/\
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MZ9XJT>TM[&WATBYU&*RDN)FW23EXV<^6H^ZJ[<$GDGH,#)U?$<WB22\L-/\
M#Z00)/O:YU&XC\Q;=5 P FX;F8GZ#!H V-0TZRU:RDL]0M(;JUD^_%,@=3^!
MJG:^&M#LM)ETJVTBRBT^;/FVRPJ$DSUW#'/XUD^$-:U6\U+7-$UIK:>]TB:-
M/M5M&8TF21-ZDJ2=K#N,^E;6L:[IGA^VAN=5NEMH99E@21P2-[9P"0.!P>3Q
M0!3;P7X8>WL[=M TYH;,DVZ&W4B+)R<<=SS]:FG\+:!<VUW;SZ-8R0WDOGW"
M- N)9/[[<<M[]:RX_B1X8D\]1>7 GA*@VS64RS/NR04C*;F! )R >G-7H_&7
MA^7PT?$(U%!I@)4RLK A@=NW:1NW9XVXS0 ^]\(^'-1BM(KW0]/N([-!';K)
M;J1$@Z*O'"^W2MA$6-%1%"HHPJJ, #T%8>E>,=%UA[F*VN)DGM8O.F@N;:2&
M58_[^QU!*^XS5.#XC^%KFXLHH=1=EO61()_LTHB9W&50R%=H8Y^Z3D=#S0!M
M#0M)"7R#3;39?DF[7R5Q<$]2_'S?C5>T\*>'K%;1;71;"$6DC2V^R!08G8 %
M@<<$X'/L/2L.'X@6EWXNUGP[%'.DME"/+E^S2X:7$A8$E=J@!1@DX;/&:H^$
M/B3I=SX=T)-8U)WU*\BC22?[,XB,S#A#(J^6&.1QD4 =O:Z786-S=7-I96\$
M]VX>XDCC"M*P[L1U/)Z^M4+K37T;PY<VOA73K*WN6!\B)5$42R-_&P [=>G.
M,5J7EW!864]Y<OL@MXVED?!.U5&2<#D\"N=M/B%X8OK^TM(-09FO"$MY6MY%
MBE<C.Q9"NTM[9SGCKQ0 VW\#6<'@&/PJ9=\6U3-/(@8R/O#N^#_$6R0>W'I7
M55SNI>.?#VDZG)87EZR2Q%1.ZP2/' 6^Z)) I5,Y'WB*76O&_A_P_>FRU&]9
M+L1+*((X))'96) VA5.?NMP.@!/2@#6M=+L+*ZNKJULK>"XNV#7$L<85I2.A
M8CJ>3U]:B@T+2+73)M-M],M(K&?=YMLD*B-]WWLJ!@Y[UF:=JD,WC76K$:\]
MP]M#"[::UML6U!4'=YF/FW=<9.*CL_B%X9OK^"T@OW/VB7R8)VMI%@FD_NI*
M5V,>.,'GM0!NRZ=93I;)-:0R+:NLEN&0$1.HPK+Z$ D BDM],L+2ZNKJWLX(
MKB[(-Q*D8#3$# +'OC)ZUDZEXVT'2]5DTRYO'%U$JM/Y=O)(EN&^Z9'52J ]
M?F(XYZ5%\/-5O=;\ Z1J6HS^?=W$1:23:%W'<1T  Z"@#0TSPOH.C7DMWIFC
M6-G<2C#RP0*C$=<9 Z>U3_V)I7]D'2?[.M?[.(V_9?*7RL9SC;TZ\U+J=P]I
MI5Y<Q8\R&!Y%R.,A217)^%/'4-S\.M'\1>)+F"U>^<Q,ZH1'O,C*H[X&%ZGB
M@#MJR+3PMH%CJTFJVFC6,%_)DM<1P*KDGJ<@=^_K4.C>,-%U[4)K"QN)?M<4
M8E,,]M)"S1DX#J'4;ESW%7=9UO3M L#>ZG<""#<$4[2S.QZ*JJ"6)] ,T 5[
MOPGX>O\ 5%U.[T2PGOE((N)+=6?(Z$DCDCM6C]BM?M_V_P"S1?;/*\GS]@W^
M7G.W/7&><5D67C+0+_2KW4H[\16]C_Q]_:(VA>#C/SHX##/;CGM2:/XTT/7+
M\6-G<3+=-'YL<5S:RP-(G]Y-ZC</I0!H2Z'I4UK>6LNG6KV]ZYDNHVB4K,QQ
MEF'<\#D^@J.U\.:+9&Q:VTJSB:P#K:%(5!@#YW;#CY<Y.<=<UBO\3/":)')_
M:3F%W\MIUM93'$VXKB1]N$.1_$1V/0@U>U3QGH6CW\EA=W4AO8T20VT-O)+(
MRMNP555.?NMG'3'.* -6/3+&&"Y@CLX$BNG>2X18P!*S_>+#N3WSUJG?^%]!
MU2RM;._T>QN+:T 6WBD@4K$  ,*,<#  P/2JX\9Z ?#D>OKJ"MITK>7&ZQL6
M=\[=@3&XMD$;<9J2Q\6:)J&E7>I1WHCM[(D77VB-H6@(&2'5P&7CGD<T 6X]
M$TJ*UN+6/3;1+>Y $\2PJ$D&T+\PQ@_* /H!4.G^&="TFRN+*PTBRM[:X&)X
MHX%"RC&,,,<C![UFVGQ!\.7L5T\-U<;K:'[0\3V<R2-%G&]$*AG7/=0:Y]?B
M!:Z[\.%UQM7F\//OC$UPMB\PC+-@*H9<.#TR,@4 =GH_AO1/#XE_LC2K2Q\W
M'F&WB"%L=,D5:O=-L=26%;ZT@N5@E6>(3(&V2+T89Z$9/-9^M>*](T"XAMKV
M:5KJ=2\=O;6\D\K*.K;4!('N>*C/C3PZNB6VLMJD0T^YF$$<Y5@!(<_*PQE2
M,'.[&,<T 7-7\/Z/K\4<6KZ9:WR1G*">(/M/?&>E/_L32OL%O8?V;:?8[=U>
M& 0KLC93E2JXP"#S5'1?%^BZ_?3V-C<2_:X4$K0SV\D+E"<!P'497/<5?FUB
MPM]9MM(EGVWUU&\L,91OG5,;L'&.,CC.: +U8[^%/#\E_=7SZ+8-=W2-'/,U
MNI:16&&#''.1P?6I;'Q#I6I:QJ.DV=VLM]IQ47405AY>X9')&#T[$X[UA3^*
MM,U'5/#LEAXD>W@O+B>*.W6S++?-'A67<RY0*0>1C/O0!TAL(;?2&L+*&.&%
M(3%%$@VJHQ@ #L*YGPAX$TS2=$T634M'T]M;LK9(WNA$K,&48R&QSCL:SY/B
M1#J \76-@L\-SI=M(UK,UK(-S+"7);<NU<-P >N,\BKWASX@Z/>V>B6=W?NV
MI7EO$IE:W=8I9R@+()-NPMG/ /7CKQ0!O:IX8T'6KJ*ZU31[&\N(1A))X%=@
M,YQDCIGM5TZ?9F_COC:PF[CC,23[!O5"<E0>H&0.*?=W=O86<UW=S)#;P(9)
M9'. B@9)-8^B^,M$U^YDMK&XF\^.+S_+GMI(6:/.-ZAU&Y<]Q0!J+IEBFIOJ
M:V< OWB\EKD1CS"F<[2W7&1TJBGA/P]'K!U=-$L%U$MO^TBW7?N_O9QU]^M9
M<7Q+\*3M:>5J3M%=,B1S_9I?*#-]U6?;M5CD<$@^M;NG:UI^JW-];V<_F36$
M_D7*%&4QOC..0,C!X(X/K0!#J7AG0M9O(;S4M(LKNY@XCEG@5V49SC)'3/:K
MUG96NGVXM[.WBMX0S,(XD"KEB23@>I)/XU7TO6;#61=G3Y_.6TN7M9F", )4
M^\H) SC/49%9FI>-]!TS5)M,N+QQ=0J&F,=O(Z6X8?*9'52J9Z_,1QS0!;U3
MPMH&N74=SJFC6-Y/&,+)/ KL!Z9(Y'M5R[TK3[Z*WBN[*WGCMI%EA22,,(W7
M[K*#T([$5R'ACQM##\/-!U7Q#>/+?7\9"B* O+.X)SMCC7)P!S@8%2^(/B3I
M.E>&+;6;)GO$N;E+>-1#)P?,57#@+E&4$_*0"2,"@#M:R(O"V@0:RVL0Z-8)
MJ+$L;I8%$F3U.<=3Z]:J7WCC0=/BM'GGN2UU$9HX8[.9Y?+'!=HPNY5'JP%/
MOO&OAW3K*PO+G4XUMM01I+6559UE"KO., \X[=2>!SQ0!<U?PYHNOB(:OI5G
M?>4<QFXA#E?7&:T(H8[>%(88TCBC4*B(H"J!T  Z"N<E\?\ AV!8!)=3B:XM
MQ<PP"TE,KH6*\(%R3D'C&< GIS59_B=X22RBO/[2=[=QEW2UE;R1N*_O<+^[
MY!'S8Z4 ;5_X9T+5-1AU"_TBRN;R''ESRP*SK@Y')'8]/2F77A3P_?:?!876
MBV$MG;L7A@>!2D9)R2HQQDDY]:J:AJL$?C/0K,:^T!NXIGCTY;<.MX I.[S,
M?+MZ]1FJ]W\2/"UDTXEU"4_9Y7AN&CM97$#*Q5MY52%&01D\''&: +6J:=<Z
M5%-=>%=#TQM4NML4LDK>0H55(5F*J2P7@;>..]2>$/#<7A;PS;Z5O6:4;I+B
M4+@2RN2SMCTR< >@%&K^+]%T1K9+NYD>2YC,L4=K \[M&,9?$8)"\CD\5D>(
M/B/I.CPZ#/;L]Y!JTZ*DL4,C@1$$EAM4Y8$ ;.O)XX- &[IGA70-%O)+O3-&
ML;.XE!#RP0*C$=<9 X'M6O7-6FKP7/CI[*/7969M-6X&DM:;0BEAB7S"N<\X
MVD]^E,7XA^&&OQ:C4'PT_P!G%S]GD^SF7.-@FV[,YXZT =117/:GXWT'2;ZY
ML+FZE:]MPADMX+:260!AD$!5.1@<D<#C.,BM72M5L=;TNWU+3;A;BSN%W1RK
MD C..AY!R",&@"Y1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110!Y_\ #^VBNHO'%C=+N,OB
M"\693U*.JX_ J:XG3;"X\6Z=_P (Q*6:Y\,Z1=VI(_ANO,,4)_[XAS_P*O48
MM N]-\=7&LZ>T1L-3A5=0@=B&65!A)4XP<CY6''0'FMRWT^RM+BXN+:SMX9[
ME@T\D<2JTI'0L0,L>3UH \<.HCQ?X8\;^+2,QC04T^ ^A\GS9A_WW(!_P&NG
M\11)#I'P[2- BIJUDJ@#&!Y+C KN(M'TNWT^6PATVSCLI=WF6Z0*(WW?>RH&
M#GOZU+)8V<RVZRVL#K;N)( T8(B8# *^A ) (H \:M;">Z\)>(;#4O&%IIEH
M=2NXKVVDL%DE5WF)!W;PQ+ J5P.XQTKK-+ECM?C1JT,]PGFOHUJJER%,A#L#
M@=ZZ^?P_HUSJB:I/I-C+J$>-ET]NAD7'3#$9XJ2YT;2[S4(-0N=.M)KVW_U-
MQ)"K21]_E8C(_"@#R-8HT_9>FVHHS"[G ZM]I//UK7,>H)\0?%X3Q+9Z.KK;
M3%;JT27S8!"%W LR_*&#@^_UKT?^R=-_LPZ;_9]I]@(Q]E\E?*QG.-F,=>>G
M6HM2T#1]9>)]3TJRO7A_U;7-NLA3Z9!Q0!YKIFF6EGXN^&EK#=_VA;P:;>-;
MW+1%-Z[%VL%/3@\5Z9KD5Q/X?U**TS]I>UE6+'7>4('ZXJ=K&T>Y@N6M8&N(
M%*PRF,%HP>H4]0#@9QZ58H \;U*^TZZ_9YTZPLIHFO9;:TM8+=&'F&Z#H"H7
MKN# D_0UTWAB%#\7?'4S*#*L6GH&QR 8B2/QP/RKJX_#FAPZJVJ1:/8)J#$D
MW2VR"4D]3NQG-7(K.UANI[J*VACN+C;YTJQ@/)M&%W'J<#@9Z4 <A\6D63X;
MZA&ZAD::U# ]P;B.D\4*1\2? XCPK8OU4XZ?N!_]:NQNK2VOK=K>[MXKB%B"
M8Y4#J2"".#QP0#^%$EI;37,%S+;Q//!N\F5D!:/<,-M/49'!QUH \?LK[3H/
MV=+RPN98EO([6XM);9F'F?:B[#:5Z[BY!_6MS2G-E\7[.&_E2.Y/A2",^8P!
M>03X(&>IS7;OX<T.351JKZ/8-J .1=&V0RY]=V,Y]ZEN]&TO4+RVO+S3K2XN
M;8[H)IH5=XCG.5)&1SSQ0!RWQ-80Z5H=W,<6-KKEG->,?NK$'(RWL&*FLWXB
MWVDZKH'B2RTH17.N1Z/ODFMT#E;?>"4+CUPQV]^M>BS017,#P3Q)+%(I5XW4
M,K ]00>HJKIFBZ5HL+PZ7IMI91.=SI;0K&&/J0!S0!PWBW4--U2U\$0Z1<03
M2RZQ:3VJ0L"1"@)=L#HH3(/UJ+0(H_\ A$_B,VQ<R:KJ>\X^]\F.:[FP\.:)
MI5W)=Z?H]A:7,F=\L%LB,V>N2!FK<>GV445Q%':6Z1W+,\Z+& )6;[Q88^8G
MN3UH \OTF G2_#U]HWB6UTS7H?#MHLUO>Q!X;BWVDKG)!&&W_,IR,\CI52PO
M[_6?%>AZG:ZA:>'?MOA[$(:U66)F68F18\LH'!1O<8KT^]\,Z#J,%M#>Z+I]
MS%:J%@26V1EB4= H(X' X'I4M_HFDZK9QVFH:99W=M'C9#/ KJF.!@$8'% '
MEL-O:Z1J/A._DUN'4M+?7KZ2:\6'R85GDC95 &2,>8'P0<9/%:/Q"U/0KSP[
MXA;3A"]W:7.GG4;J*,8($R%07'WMJYX_AS[UZ))I6G2Z9_9LEA:O8;0GV5H5
M,6T=!MQC%,MM$TJRTU]-M=,LX;%P0]M' JQMGKE0,'- ''ZUJ=E>_%GP9!:W
M,4[Q07SOY3A@H:-=N2/7:?RKCHYX6^ GBNW$J&:.YO-\88;E_?\ <=1UKUZQ
M\.Z)I?E?8-(L+7R69HS#;HA0L,,1@<$@ 'UI/^$;T/S+R3^QM/WWO%TWV9,S
M\Y^?CYN>>: .!U+;HFE^ O%^0D5E#!9WS] +:>-5W-[*^T_C6)=6MS=_#B]\
M52R?9Y-9UNWU":62/?Y-HLRK%N7^)54*V/0U['-I]E<6!L)[.WELB@3[.\2M
M'M'0;2,8&!Q[4\6MN+06@@B%L(_+$(0; F,;=O3&.,4 <7H=A(WCQ+V\\6VN
MJW\6FO']GM[-8L0NZD,S*Q'WEX!]31X$^;Q;XZDB_P"/<ZJBKCIO$2[_ -<5
MT2:-:Z#I=X/#6D:=;74BEDC2,0QN_;>5'2H_"7AX>&=!2R>;[1=R2/<7EQC'
MG3N<NWY\#V H Y^6Y@LOC8[WTT<*SZ J6SRL%!*SL74$]^5./2N&EN[.7P_X
MFU"V=/L*>-()FF7[FS?#E\^A/.?>O9M3T32M:CCCU73;2^2-MR+<PK(%/J-P
M.*<-'TP6MQ:C3K06]S_KXA NR7@#YAC!X '/8"@#CK_4;.\^,?AV&VN(YGAT
MZ[,GEL&"[C'CD=^.GT]:R_ $4<7P%G9$"F2WOW<@?>.^49/X #\*]!L= T;2
M_*^P:38VOD[O+,-NB%-V-V,#C.!GUP/2K$&G6-K8_8;>SMXK/#+]GCB58\-D
ML-H&.<G/KF@#Q[PY&DOA/X3JZA@+YVP1W$<I!_,"KOCV&>77_&L=JK&5O"L9
M(7JP$LF?_'0:]1CTG388K6*+3[1([0EK9%A4"$X(R@Q\IP3T]31=6"2?:9[9
M((-0E@,*W9A5F4<[<_WE!.=N<4 ><>*=6T2_A^'D=A<6\TAU>SD@6)@Q2(*0
M<XZ#)48]?I77>/M2.D^"=0NQ;6MP1Y<82[3?"-\BIN<=U7=N/TKG-/\ !6M3
MW^DKJ&G>'M-M;"[2]GETM2)+V9%8(2NQ0HRQ)Y/H*]#N+>"[MY+>YACF@D4J
M\<BAE8'J"#P10!Y;'--'\3!!>^(8M6G&@72EXX$B5"7C.P;2<G'."20"/6JD
MT21?LZZ&$0+C[ XP/XC<1DGZY)_.O3H/#6A6T5M'!HVGQI;,S0*EL@$1888K
MQP3WQUJR=+T]M/33S86ILDV[+8PKY:[3E<+C P0"/3% 'F_C#4Y? 'B^_P!7
MMHV:+Q!IYCC11G-_$,1?]]*P'OMKN?"6A+X:\*:=I .Y[>$"5_[\A^9V_%B3
M65J.@:QXA\5V$VJK8Q:'I5S]JMHHG9Y;B8 A&?*@(%R3@$Y-=?0!Y_\ $+5=
M.35?"<3ZA:K)!KT+S(9E!C7RI.6&>!R.OK6AXL\9QZ;#866DW=B^HZJ6%M//
M,OD0HOWY7.<$#L.YX]:V;OPIX<O[J2ZO- TJXN)#EY9K.-W8^Y(R:)O"OAVY
M@@AGT#2Y8K=2L*/9QLL8)R0H(X&>>* ,;1M+BM/#EW:>&->M+C5Y91/=:C-M
MN#)*Q&YG56&,@$ 9   ]*Q/%]GJT>C^'(-?O;6_G?Q-98>"W,2;,_=*ECGG/
M/O7>:;HFDZ-YO]EZ796/FX\S[+;I%OQG&=H&<9/YFK-Q9VUX(A<V\,XBD66/
MS4#;'7HPST(['K0!QIBC;XZ+(44NOALX;'(_TFN)REO!]JN"%T^U^(,SW+-P
MD:Y8*S=@ Y7GW%>T?9+;[;]M^SP_:_+\KS]@W[,YV[NN,\XZ9J+^R]/^S7%M
M]AMO(N79YXO)7;*S?>+#&&)[D]: .$\03PWWQ,LOL$J2O:Z'>&\:)@=J/M\L
M,1ZL"0/QK%GBCB_9\\/!$"X.GN,#^(SQDGZY)_.O4-.T+2-(MY(--TNRLX9?
M]8EO J!_J .:E.EZ>UA'8&PM39Q[=EN85\M=IRN%Q@8(!'IB@#A+">&+XH^.
MXI)4226QL_+1F +XB?.!WK"EB2/]G'1@B!<"R?@?Q&YC)/UR37JD^B:5=:E'
MJ-QIEG+?1+L2YD@5I%7G@,1D#D_F:D.E:<=/33S86ILDV[;8PKY:[3E<+C P
M0"/3% %'Q=_R)>N_]@ZX_P#1;5YO?WNG7?P>\(66GS0M>23Z=%;Q(PWK,KIO
MXZ@C#YKU'7K*74O#NIV$!437-I+"A8X&YD(&?;)K-\.^$M-TFPTN:;2[#^V+
M:SB@ENT@7S"RQA3A\9/3\J /.X[6Y>U\<6M]XML])LVU*[^V6\]BLC^5(!M;
M)<$Y0J!@=L"M[2+)+?XR0QN_VB2V\*0QK,RX+?OB"V.Q./UKMKOP_HU_J$5_
M>:38W%Y%CRYY;=&=,=,,1D8JV+.U%\;X6T(NS'Y1G\L>84SG;NZXSSCI0!Y-
M-#<W/Q$^*,%F&-U)HL21!>I<P8&/?-2:WJ&G7WP4T"RTR>%[R?\ L^&RBC8%
MQ,LD>X =00%;/IS7JD>GV4-]->Q6D"7<X"RSK&!)(!P S8R<=LU4M_#FAVFI
MOJ=OH]A#?N26N8[9%D)/7Y@,\T <7X;U'3M,U+Q_%J]Q#%,NIO-*DS %H&A3
M9P>HP"!5KX7:A9V?PS\+07-Q'#+=1M' CM@R,&8X'J< UUEUH&CWVH0ZA=Z5
M97%[#CRKB6!6D3'(PQ&1BI8](TV*.UCCTZT1+1BULJPJ!"3G)08^4\GIZT ,
MUW_D7]2_Z]9?_0#7CNCQI-\$_ 44BAD?7+564C((-T^17M[HDL;1R*KHP*LK
M#((/4$5431],BLX+./3K1+6W<20PK H2)P<AE7& 0><CO0!R]^ /C+HQ'4Z-
M= GU'F1TSQU*EIXG\%WMXZIIT.HR+*[G")(T+K&2>WS9Y]Z[)K2V:\2[:WB-
MRB&-)B@WJIP2H;J <#CVI+NSM=0M9+6]MH;FWD&'BF0.K#W!X- 'FOQ!U#1+
M_2=7.GI%-+97FGR:Q/#&"'A$H(5G'WMHR2.PK4\1W=KJ/Q!\$1Z=<17%Q'-<
M7#M"X;9 82"21T!)4#U-=A8Z/IFF6)L;'3[6UM&SN@AA5$.>N5 P<U'IGA_1
MM%:1M+TFQL6E_P!8;:W6,M]< 9H \LMXHU_9OU@A%!=;UFXZD7#C/Z#\JZ?0
MD5OBQJ4K*#(NA68#'J 7?/\ (?E79#2M.&G-IPL+46+[@UMY*^6VXY.5QCDD
MD^YJ2.RM8KIKJ.VA2X9!&TJQ@.4'12>N!DX'O0!XHB7*BPEAOX]/@B\8Z@IN
M981)'"["01DJ2!U) .1@L*M^)].>/0_%=]+XBBUJ</I_]I1V]H(ECCCE#'.&
M()V$Y] .:]:?2-,DLY[-].M&M;AV>:$PKLD9CDLRXP23R2:6QTC3=+LC96&G
MVMK:G.88(51#GKD 8YH P[[6/#M]JL-M ]M>:J]A/+;RPJ)#'#@9.X?=#$KC
MUQ7E.LW$,W[,6EI%-&[1FW#JK E3YIX/I7MVF:#I&BF4Z7I=E8F4YD-M L>_
MZX S4*>%_#\=O/;IH6FK!<.))HA:)MD8="PQ@D>IH YJTGAL?C)K/V^5(GN=
M*MS9M*P 9%9_,"D_[1!(_&N+98KVVDN(@LFFW?CZ%X".4E7*JS+V*E@W/?FO
M8-4T32M;B2+5=-M+Z-#E%N85D"GU&0<5+_9FG_9K>V^PVWD6SJ\$7E+MB9?N
ME1C"D=B.E '*7( ^-6G$=3H,X)]?W\=)\0V32W\/^)V.Q-)U%!<2?W;>8>5(
M?_'E/X5V!M+9KQ;PV\1NE0QK,4&\(3DJ&ZXR <>U%W:6U_:R6MY;Q7%O(,/%
M,@=&'N#P: /$3J,_A/1]/\8LK+<^(+*_,GO-*3/;#\@5'UK4U71E\/>(/A+I
M( W6K3QN1W?RTW'\6R?QKU6XTK3KJV@MKBPM9H+=E:&*2%66,J,*5!& 0.F.
ME/GT^RNKFWN;BT@FGMB6@EDC#-$3U*DC*YQVH \O2>%+CXLV[2HLS(S+&6 8
MC[)U J?58DB^'?P[6- JKJ.D8 '3[O\ B:] FT#1[C4'OYM*L9;R2,Q/.]NC
M.R$8*EB,D$<8].*L/IUC);V]N]G;M#;LC01M$I6)D^Z5&, CMCI0!B^/-3_L
MCP1JE[]EM[K9&J^5=+NB.Y@N7'=1NR?85R%K-/%\5=*@O?$4.JS#2KH9B@2)
M(R3$=HVDY)QG!)(&#WKTZ>"&Z@D@N(DEAD4J\<BAE8'J"#U%9]OX:T*TCMX[
M?1M/B2VD,L"I;(!$YZLO'!/J* /*Q$D?[,-F$0+^ZMWX'\1NE)/US6QXRU1O
MA_XQG\111EK;6M/>W=%&0;V)28<_[RDK^%>B?V3IO]FC3?[/M?L"@ 6ODKY0
M .1\F,<'GIUKG-7T#5_$?B:P&I+8Q:!IMT+R)(W9YKF51\FX%0$522< G.!0
M!H^#-"/AOPCIVF2'=<1Q[[A^I>9CN<Y[_,37*^&]1T[3+OX@1:O/#%,NJ2S2
MI*P#- T2;.#U! (%>D5G76@:/?:C#J-WI5E/>PX\NXEMU:1,=,,1D8H \:\,
M1WPMOA\]OJ\.E"32+J*&XGMQ,OF^8A* %@ Q4=<_PD5>\06D%CX)U"Z&O0ZK
MYWB6VFN9XH!#''('C5P.2/X020<9S7J\^@Z/=:6FF3Z58R:>GW+5[=3$OT7&
M!U-/.BZ6=)_LHZ;:'3MNW[)Y*^5C.<;,8Z\T >?W9OI/BGJLEGXDM-+$^F6S
MP236R3K-&K2!PI+ #:QR<?WA67#IEG;7GPUMH-035;0ZC>SQW(A\M6)#N-JY
M. &Z?08KTVX\,:!=V-O97.B:=-:6W^H@DM49(O\ =!&!^%7#IUBS6K-9VY:T
M_P"/8F)<P\8^3CY>...U '(-&C?'-'9063PV=I(Z?Z37/64,:_#GXGE8U!;4
M-5+<=<)Q7J?V.V^V_;?L\/VOR_*\_8-^S.=N[KC/..F:C&FV"V]S;K96P@NF
M=KB,1+MF+?>+C&&)[YZT >6$Y^)'PM)Z_P!DS_\ I/5S1XHQ\//B*0BYDU'5
MR_'WOO#G\!7HW]EZ?]HM;C[!:^?:(4MY/)7="I&"$.,J,<8%.33K&.WN+=+.
MW6&X9VGC$2A92_WBPQ@D]\]: /,=.U2Y>32+*'5;#1%M/#5I<S7\UNDDTJL"
M-H+G 1=N3UY-8FFW,2^#/AS++.H6/Q'*)'DPFT^9/]X?PGVKV"X\/:+=O:/<
M:18S-9@"V,ENC>2!T"9'R@8'3TI)O#FAW%M/;3:-I\D%Q-Y\T36R%9)/[[#'
M+>YYH \_D$EQ\==7%HX,LGA;]RRGJ3(-I!_*LN:^TU_V<8M/BDB-VUI':+:@
MCS#=>8!MV]=V_GU[UZY!I6G6UTMU!86L5PL(MUECA57$0Z("!G:,#CIQ5=?#
MFAKJIU5='L!J).3="V3S<^N[&<^] ',>&(<?%#Q>\H#3K::<A?OS&^?U _*I
M?A6 /!(4< 7]X /0?:)*Z^.TMHKJ:ZCMXDN)PHEE5 'D"YV[CU.,G&>F:+6T
MMK*'R;2WBMXMQ;9$@1<DY)P.Y))- $U%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.6WC
MG0[W6VT>UFGFO$N)+>54MW*Q,G7>V,*,@@$\''%-T_QYH.IZE#96TUQ_I#LE
MM<26TB07#+G<(Y"-K'@]#SCC-<SX.M9)](^(JVJXNY]<OXT8=2VQ=OZG]:QO
M#=O#J&A>#8;OQNC)'-;/;Z8EE'YBS1#)C.WYAC:RDG\>M '=WGQ"\.V-]>6T
MUS<;;)C'<W*6LC0128SL:0+M#=.,]3CKQ4U[XWT:RMM/ES=W+ZA +FW@M+62
M:5HL [RB@D#YAUQUK@++5]*T_P"&'C'2]2N(1J*W.HQ2VK,/-DD=F*$+U.05
MP?;/:K%AJ\P'A_3AK=KH$%OX9M;I[UX8FEF##!16D! 5=H)XSDB@#N+KQSX=
ML]&T_5YM0 L+]BMO,(V(8A68@C&0<*W![C'6HI_'FC06>GS,FH-+J&\V]HEE
M(UPRH<,QC W #U([UYEI;0W7A?P#$[^<\?BF;S%D4!PWFSL-R_PGH<8%=O?W
M=MIGQIMKC49XK>"YT%H;:69@JF19]SJ">,[2I_"@"C;>+Q?Z/XUOY]>N+33K
M.\1+>[B@W/;(8XR0$*YSN)!!&1D^E=/<>,=&TB+3[>[O+B>YNK07%N$MW>2Y
M4;1D*HY8[@=H'J>@->7:M=VM]X$^*EU9,KV\FH*4=?NOQ%EAZ@G)![YS76:<
MBMX]\&%E!*^')"I/8_NA_(F@#I[;QQH%SH%[K1NW@M+%S'=BXA:.2%QCY60C
M=GD8&.<BFZ=XZT34]3M=,C>Z@O[D,T=M=6DD,A55W;B& ^4C.#T.".HKSCQ'
MB.X\97$@_P!$MO$6FSW0 R!$%B+$CTZ$UTFJZMI6J?%_P<-/N8+J2*"],DL#
MAU :,;5+#C/!./?WH [;4]<L-(N=/@O96B:_G%M;G82K2$$A21P"<'&>M%[K
M=AI^JZ=IEQ*1=Z@7%M&J%MVQ=S$XZ #N:S/'FA2^(/!][:VI*W\0%S9..JSQ
MG<F/J1C\:X[P]>3?$*ZUCQ3;QL@@TD:;8J1C;</'YDQ&>X9D3/\ LF@#JH?B
M+X<GNXXDGN?L\L_V>*^-I(+623.-HEV[3SQG./>MVSUBROM2U#3[>4M<Z>R)
M<*5(VEU#+ST/![5Y-?ZIIEW^S]8Z1:3PMJ4MM;645FK#S?M0= 5V]0P8$_AF
MNET75]/T7X@>.?[3OH+4EK.8><X4N@MP"R@]>01QWH W)?B!X;@TFPU26^9;
M._:1;=S"_P YCW;AC&0?E./7MUK;TS4(M5TV"^@CFCBF&Y5GB,;CG'*GD=*\
M8T%$G\._"L21\?VK<MM<<@@RD?B"!7N5 ''-\3_"XB$XN;IK42&.6Y6SE,,#
M;BN)'VX0Y'?L0>A%:FL^+M*T2\ALIOM5S>S1F9+:RMGN)/+!QO*H#A<\9->8
MZ3K.C0? OQ#9RW-NMT?M\30,P#O(\CB/"]3G*@?3VK=\*S)H'CN^AUV>.VN+
MC1-/^SO<.%#"-66503W#$$C\: .M?QOH(T*VU>.ZDGMKJ7R8$@@=Y9).<H(P
M-VX;3D8XQ3/^$ZT+^QQJ0FN2IN?L@MQ:R?://QGR_*QNW8YQCISTK@-*BTV_
MM+V];6VT=KKQ/=W.B:@J@HQ\O:Q^8;"K8DX)&>U75U&'6[3[-K&OVMCJNGZP
M8K#7+&,"&>809RP;*9V.RE2<$C - '0Z]XOTFZ\%7>J1:W>:1#!<+!-.MH?/
M@DW#Y&C=<@G(ZCH<U#JGC Z)\2GL+N:YELGT:.:&TMK=II))C-("5506/RKS
MV %</X[UB\U/X4>)K:^FLKR:PU*W@.H62;8[K_5MG&3AANVD D BNOGO["P^
M.2M?310-+X<CCBDE8*,_:')7)[D#./\ 9- $?CWQOO\ A/?^(?#&H/%-'-'$
M)/+VO$WFJKHRN.#R1@BNJU;Q;INAO;6UU]JGO)HO.%O:6SSR!!P7*H#A<]S7
MC_BQTNOAA\0K^U8/8W.OJT#J<K)AH59E/<%@>?:NMU!+R#XG7C#Q+'H7VC2;
M9H))8(Y%F5&?>H,G *D@D#^]F@#TC3M1M-6TZ"_L)UGM;A \4B]&!_STK@X;
M_P 7:_XU\3:=INOVFG6FE2PQQI)IPG+[XPQR=ZXYS^==!X"M+2S\(VR6.I-J
M5K)+-,ER8?*#[Y&8X7L,DXQQCIQ7,>&]:TK2?B3X]&I:G961DN;0H+F=8]P$
M/.-Q&: -C1_$FM6/BN/POXHBM&N+J%IK"_LPRQW 3[Z,C$E7 YX)&*?HWBG2
MK72-;U&XUZYO[>UU*2W=I;<AH9,J! BJN7P2 , DYK'74;?QM\5-%N]%<7.F
M>'HKAKB^CYB>65 @C1NC$ ;CCBN=\*Q:5/X5\61:MJ$FG1'Q;*8;R/@P3AHS
M&V<$ ;@.6XH ])M_'&A3:9J%_+//:1Z<%-W'=V\D,L0;[N48;CN[8!ST%5)?
M&=EJ>A:[_9S7=KJ-E8R3^3=VKP2J-C%'"N!D9'7VKD;[Q5JEC9:SIMU?Z1JL
MD$MC&NLBW7RXUFE*YF0$KN3&X8..0>*JSW('B[Q##-XB_MB3_A%[B,3M'$B[
M@Q8QKY8 8@$$]2-U '5^&/B)I5WI6@6]]<W1O+R"&(W;VKK!+<E!N02[=A;=
MD8!Z\=>*U;#4X)O&VNV$>LW$\]M#"SZ>\($=ME00ROCYMW4\G%<!>:GIE_\
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MU)X%5O\ A.M*AT.PU"Z6\CDO3L@M19R^?*X&6"1[=Q ZYQC'>H/BB"WPP\1
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MU!H_B#2X;GQ5<RZW>30Z;<G[4+M0$M, DK'@9*\>YH Z-M+T]]/&GM86ILE
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M)8;-W2V9&VDNP& ,@^^.<5;M/'FBWFM6VF1_;%-X6%I=26S+;W)49(CD(PW
M)ST/8F@"*W\'PR^*?$6H:M:V%[9:DUJT$,T8D*&*,H2P9< Y/&,_A6_=Z3IM
M_:1VMYI]I<6T9!2&:%71<<# (P,5AS^/M$M]3DM'^V&*&X%K-?+;.;:*8D#8
MTF, Y(![ G!(J74_&NEZ7J\FF-%?7-Q#&LMS]DM7F6V1NAD*CC(!..3@9Q0!
MKMI&F/*\K:=:-(X0,QA4EMGW<G';''I4EQ;H["X2"![N)&$#R+]TD=-V,@'
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MV9_*7,@]&..1]: //M.DCF_:%OY8G5XW\.(RNIR&!E3!![BG_!7_ )%75_\
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M%5_"=LK %3JED"#W'G+1J"J?C1HK%02-&N2#Z?O(_P#$UVDL,4Z!9HTD4$,
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M7)(!%>H"WA%O]G$,?D;=GE[1MV],8Z8]JABTRP@2%(;*VC2 EHE2)0(R>I7
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M:WA=8U:&-EC(:,%00A'0CT(K%\::%/XE\':EHUK+'%/=1A$>7.T'<#S@$]J
M.3U_6-+U_5? MGHMU!/<KJ271BA8%H84B??O Y7J!@XYXKE=$LX)O!=OH>L>
M.)[1EO/LLVD);0-*LXGR !L,ARV'SZ'.<5[7!I]G;7$ES#:6\=Q*,22I& S_
M %(&31_9]D;[[:;.W^UXQY_E+YF/3=C- '&>$T7_ (6I\0)-HW[[!=W?'V>L
M70+>>\\2_%>VM<_:)C''%@_Q&!P/U->I)!%'+)*D2+))C>X4 MC@9/>B.WAB
MDDDCAC224@R,J@%R.F3WH \=U+6=+U/X&:;H-A=0MK$\%I8Q6*L/.6X1T# I
MU&TJQ)([5U7AE%/Q>\=R%1O6'3E![@&)\_R'Y5V2:;8QWK7J65LMVW#3K$H<
M_5L9J98(DEDE2)%DDQO<* 6QTR>^* /*;5%'PP^)9"C+:AJQ/N>:T=754M/A
MD%  6^@  [#[,]>B"UMQ%)$((O+E),B;!AR>I([YI6MX&$0:&,^4<QY4?(<8
MX].* /$;.TMV\+:IHFM>-Y]/']H7%O<Z4EM"\C,\[%2@V&1MVY6!&>O'2NKT
M36--\.>.O&L6MW\%I++);W,3W#A#-#Y(7*Y^]@J1@=Z[Y]/LI+U;U[.W:Z08
M6<Q*7 ]FQFEGT^RNIXI[BTMYI83F.22,,R'V)'% ''?" @_#'3"L9C!ENL(1
M@K_I$G&*S?#FOZ-HWC3QVNIWUM9N;V.7=.X3>@A7(7/WL=P.FX>M>D10Q01^
M7#&D: D[44 9)R>![U7N-*TZ[!%S86LV7\P^9"K9;INY'7WH \AL;"YTKX3>
M%/%"0NESH=P]Z4Q\QLY96\Q?^_;*W_ :[7X=PF^M=4\53*1+KMVT\6X8(MD^
M2$?]\C=_P*KWB[1M;U^T_LBQO+2STNZC,5]*59I]A^\L8^Z,KQD],UT%K:PV
M5G#:6T8C@@C6.-!T55& /R% '"^*-9>/QNNF3^(8_#UG%I@NC=!(O-N"9"I1
M6D5@ H4' &26%3_"6>.7P)'$)F>:&\NUF63 D1C<2'#J,;6P0<8'6NRN+&TN
MY(I+FU@F>%MT321ABA]03T/TI\5O! TC0PQQM*V^0HH!=O4XZF@#SG1]>TCP
MOJWCBW\0W<%M*VH->A)V ,]N\2!=@/W_ +K+@9YXHTO5-.TSXD2WM\$TJSU/
M0[9M/%V%A"*C,6BZX5AN4E<UZ#<:?97DL4MS9V\\D1S&\L2L4/L2.*6[L;/4
M(A%>VL%S&#D)-&' /K@T >,3[+W3KO480'TZ_P#'%L]LV/EF4,B,Z^JEE//?
M%=Q*BGXX6K%02/#LN#Z?Z0E=D;6W:*.(P1&.,@HA084CI@=L4[R8O/$_EIYP
M79YFT;MN<XSZ4 >(:I+#;^'-=FG4M!'X\#R*%SE0\9/'?O71>)[NV\4>.-(@
M\/WD%Y-;Z3J#326T@<()8U2,%AP,MT'M77>*/#;ZU964%EY$#0ZI;WTI88#B
M-PS=!RQ [UM6MA9V1D-I:06YE.Z0Q1A-Y]3@<T >1>&H[+4=)\'VUWXXGE>*
M:V:'2$MH-\4T(R8V"IO4+M923VZGFJUTZ7'A3XG:5#.G]H_VS-=?9E8&5H5,
M+,P0\D;5;MBO98]/LH;N2[BL[=+F3AYEB4.WU;&33EL;1;QKQ;6 73KM:81C
M>1Z%NN* //=*6PU+Q5I5TWCJ77;JWMIY[>"."':L;J%8N8E&WJN Q&2*P2BK
M^S%9!5 'DVYX]3=(<UZ]:Z=96)D-I9V]N93F0Q1*F\^IP.:?]DMOLHMOL\7V
M<8 BV#9P<].G6@#A+&]M;/XVZY#<W,,,MUIMH($D<*92&?(4'J?I7H-02V-I
M-<Q7,MK!)<1?ZN5XP63Z'J*GH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#B[CXFZ-"+YH[+5KF+3Y
MY(;V:WM"Z6Q1B&+G/3@GC)QR0*IZGXN^P_$6P$4MY>:?=Z&T]O:6:&0SR&5=
MK*O3.S)R< "N?T3Q/H6D>&O'=IJ%Y;V]R=5U%E@E8*]P&)4; ?OY(V\9Y%7/
M!EC/8>,?"]K>(5N8/!ZJZL.4;S8\CZCI0!U-O\0M%N+.UN62\@$^H_V8Z3P[
M6M[@]$D&?E[<\CD5JZKXBL-'U'3;"Z9_M&H-((0BY "+N=F/90.IK@[?0!XF
MTWXC:4IVS2ZNS6[YQLF6*)D;/;Y@*3P7J+>-=3O/%>I6LAAT[35TT0>623,5
MWW.%ZYSM0>N* .LT?QUINLW]K;16FI6ZWJ,]E<75J8XKH ;LH?\ =^89 R*H
M>'?%.BVGA75=7;5M3N;*UOI8Y9=0PTBOE1Y:!1RN2 HZY-8/A;5K?3M=T+2_
M#GB@:UHUZKK_ &=,4DGT^-8RRG>/F500J;7]0.M<OHB.OPSOKT(\EOI_B\7E
MTJ*6/DI*A<X'4 <_A0!ZG:>,M/U5=0LI;?5-+O(+1KEH;N#RIC#R/,3D@X/'
ML<9%4](\7:38>!M'U".YU;5([US#:"9!+=W+[FX(&!D!6YX  IUWXLT'7?[4
MLM)DCU"6+2I9I+VVVR11*00(RX/#'KM]CFN&\,ZO-8?#7P%9-JRZ-8WKW"W.
MI$(#%M+LJ!G!52QR,D=N* /1/^$^T9/#M[K5PMW;0V-PMM=PSQ;)8'9E4!ES
MT^=3D$C!I^F>-M/U+7(M)-GJ5G/<1-+:M>6IB2Y1<9*$\\ @X(!QVKRB^NK2
M;PUX[MX]1FOC)J6G2QR7;+YL\6^W428  *'& 0,$8KT?Q+_R4WP-_P!O_P#Z
M)% '2:WK=CX>TN34=0D9($*J BEG=F.%55')8DX K*L?&]E>7-S9OINJVFH0
MVQNELKFVVRSQC@F, D,<X&,YR:S_ (F PZ;H>I.K&STW6K:[NR!G9$"P+D#L
MI8'\*J2ZG8^)/BKX>ET2\@OHM,L[J2\GMI!(B"0(J*6'&203CKQF@#*^&FOZ
MEXE\1ZQ?ZC/KIV7]Q!#"R!;.&-=NU&':09_E7H1U^R7Q./#S^:E\UK]K3<OR
M.@;:<'N0>H]*X[X/_P#(,\4?]C'>?^R5=^(T3:;'I'BZ!3YNAW0>?:,EK63Y
M)ACO@$-_P&@#8O?&>C:?>ZM;74SQC2;=+B\E*92,/]U<CDL<< "HM+\;6.I:
MK!ILUAJ>FW5S&TELFH6WE>>JC+;#D\@<D'!QVK@+S3;J[^%6I>)9+>22YU74
M8M8GA"Y;[*LJ%$QW"Q*&_.M_6-:TSQ3XT\'0Z#?V]^]M<R7L\EK()!#"(F7Y
MR/N[BP&#S0!TJ>,=*?PC<>)AY_\ 9]N)2_R?/^[<HV!GU4U6U;Q]I6D:G'IC
M6VHW=_+:I=16UG;&5Y$8D< 'J-I)[ #K7FSZ_IEE\$==T&:\B&L1O?0O8!AY
MP)F=L[.NT*=Q/3 -==IBJ?C1"Q +#PI%@^G[^@#N-3U.TTC2KC4[Z0Q6MO&9
M)&P20![#DGVK'L/&VFW;7:7=M?Z4]K;&[D34;<Q$PCJXY(('?N/2K7BT:8WA
M34EUE)6TUH2+CR@2RJ2/F&.>.N>V,UYEJ=WJ&I:-XB\-:5XC7Q19-HSW,<Z;
M'F@974")G3ARZ[B,C=\M 'H>C>-=/UG4(;(6>HV4MS$9K4WML8A<H,9*'/.
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M;3OB#K5DRSZ5=76EV\,Z\I.T4B"0J>C %@,C@XKNO$W_ "4SP+_O7_\ Z(%
M':T51TO5[#68)IM/G\Z.&=[>0[67;(APPY Z'OTJ]0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDA1C)]:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM6C5#1+6&ST*PM[>-8XH[>-551C VBK] !1110 4444 %%%% !1110 4444
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MAU&SD+P2#J59<$=1@@'K0!?K!L_!7AK3]5&IVFBV<-X&++(L?W&/4J.BD^H
MKD[OXHVVI>&?%LVC2>5?:4DIMF:-B'5%3]X0R@#YF(VGGC-=-I/C?0-2OK?2
MH]4CDU*1,B/8P$C*,L%8C:Q'.0"<8- %VX\+:%=ZU_;$^F6[ZCY9B^T%?F*E
M2I!]?E)'TJ=]#TM]+M],:RA-C;^7Y,!'RIL(*8^A Q]*H/XU\.)K?]CMJD0O
M?-$&W:VP2GHA?&T-_LYS[5KWU[!INGW-]=/LM[:)II7_ +JJ"2?R% &9JG@_
MP[K6H)?:EH]K<W2@#S)$R6 Y ;^\!Z'-:']F67]J+J?V:/[<L'V<3X^81[MV
MWZ9YKBM.U3X@>(]-CUK3H]#TZSN%\VTL[V.6262,\J9'5@%)&#@ XS6Y:>+$
MMO"T6K^)K<Z)*',,L$QW?O 2,)CEPV,C R10!?\ %%C/J?A+6=/M5#7%U8SP
MQ*3@%VC90,GIR167X=\$:+I<6FWTFCVL>KP6T:R3!<E9-@#$=LGG+#DU=LO&
M.@:CIU]?VVHHUO8*7N]R.CPJ 3ED8!AP">G.*JI\0O";WAM1K4 D\MI 7#*C
M!1EL.1M) Z@'(Q0!N6NFV5C<74]K;1Q2W<GFSNHYD;&,GWP!67)X*\,RZQ_:
MSZ)9M?&3S3*8^K_WR.A;WQFDL?&OAW4;'4+VUU)6@TY=]WNC=&A7!.2K -C
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M"JIJUQ)>K/R3;-&NS(ZE2G ]>U=U=:1IU[IR:=<V-O+9)M"P/&"B[<;<#MC
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MWT:QBU%R6-RD*A\GJ<]B>Y[T7?A/P_?ZNFJW>BV,]^A!6XD@4OD=#GN1V]*
M.8T&2$?&#Q $.Q6TJR,:M\IV_-V//I7GNAE4^'=G+/@6$7C5'O"WW1%O'+?[
M.XK7M]SX?T>\U>WU:YTVUEU&V&(;EXP9$'/0_B?SIT&@Z3;:=/I\.FVJ65PS
M--;B(;)"WWBR]#F@#D?$KQS?%+PPMJRM/%87SW6PY(A**$W>Q?I[YKEC!%#^
MS1IWEQJORVLG _B-TA)^O)KU+2/#.AZ"LRZ3I5I9^=Q(88@I<>A/4CVJ8Z)I
M9TA-).GVW]G(%"VOECRP%(8?+TX(!_"@"\S!5+,0% R23P!7":+?6A^+/B9A
M=0%7L;%5/F#YC^]X'K7<3PQ7,$D$\:R12*4=&&0RD8((],5@0_#_ ,(6T\<\
M/AK2XY8V#HZVR@JP.00<=: ,?QU>6J^(?!JFYA#1ZSEP7&5_<R=?2NR.HV*S
MVT!O+<3708V\9E7=,%&6V#.6P#SCI61>^!O"NHWDMY>^'M-N+F5MTDLMNK,Q
M]22*T(-"TJU-B8-.MHS8*Z6FR,#R PPP3TSWQ0!Y9X3T'3]5U/QE+>:_J>GL
M/$-VGE6FI-;J1\OS%0>3SU]O:MKX=:A::5<>*=(BOK>;0-'FC>'4W**&+H6E
M$D@PK%2.6///-=1<^ _"5[=RW5UX<TR:XF<R2226REG8G))..235NZ\/6#^&
MKO0[.UM;.UG@>$1QP+Y:;@1G8, ]<X[T :D<B31)+$ZO&X#*RG(8'H0>XKP0
MJ&^&WQ14]#XAE!_[^QU[O:6R65E!:Q9\N&-8USUP!@?RJE_PCNC?9+RU_LNT
M^SWLIFNHO*&V:0D$LP[G(!S[4 <WXGBCA\>^ 5B145+B[10HQM7[,W ]N!^5
M1_& A?AO>,3@"YM22>P\^.NSGL;2YNK:YGMXI)[5F:"1E!:,L-I*GMD$BB^L
M+34[*6ROK:*YM9AMDBE4,K#W!H X^6.&?XW64I5',?A^5HVZ[3YZC(_ D?C7
M$:HEP+K5/LUQ!:HGCB)WFGCWQ1DP#:SKD9&\IW'.*]=T_P /Z1I+0MI^FVUL
MT$)@B,484I&6W%1[%N<>M/?1-+DM[V"33[9X;YR]U&T0*S-@#+#N< =?04 <
MUX<TR\@\;ZE>ZCX@L+Z_-C##-;6EJ8=B[V*._P [<\N![5G>((=6?XN60T[4
MK.PDDT5U@>[MC,KD39D5 '7#8V$\G@5VFCZ#I.@6[V^D:=;643MN=8(PNX^I
M]:-7T'2=?MDM]7TZVO8D;<BSQAMI]1Z4 >8ZAH[Z5X*?Q#::G;ZK=Z/K<FJF
M2SA\M I;;<1*-S8&"Y//:H=6$OB;1/B%XKM"9(C:-I>GLO.;>(9F9?4,Q;_O
MFO6X=,L+;3!IL%G!'8B,Q"W2,"/8>J[>F#DT6&FV.EV$=A86D-M:1@A((D"H
MH)). /4D_G0!PFGZ;>W'B+PM>7WBG2)T@262QMK2Q,331-%M(!\QOE *GIV%
M<PD$4?[+TNR-5W1-(2!U;[3U^O _*O5=*\*Z!H=W+=:7H]E9SRC#R00JI(SG
M&1T&>PJ?^P]*_L8Z/_9UM_9I&W[+Y8\O&=V-O3KS0!R>G.J_&W6E9@&;1[;
M)Z_O&I?BJP30M&=B JZY9$D] /,KJ;OP_H]]JMMJEUIMK-?VN/(N7C!>/!R,
M'V)/YU/J6F6.L6,ECJ5I#=VLF-\4R!E.#D<'WH Y*UBBD^-M_/M5G308 C]<
M S29Q^0KE=,O)H9)=+LH;%;J\\87ZV]S>P^8EJ45F+*N1\^,@<CJ:]3L=$TO
M3'1['3[>W=(%MU:*,*1&I)"?0$DX]Z@N_"^A7]E-9W6DV<UM-.;F2-X@0TIZ
MO_O'UZT >1:O)+)X=^*BSZC#J$RK;![B&$1*Q" '"@GIC:3GJIKVG37232[1
MD964PI@J<C[HJFGA?08RY31K%?,MOL;A8% :#_GF1CE?:K.EZ1I^B6*V6EV<
M-I:J2PBA7:H)ZG% 'DSNO_"O_BM'N&_^U;X[<\XV)S72>)8(K;_A7B0QK&L>
MJ0QH%&-J_9Y.![<"NJE\)^'Y[Z[O9=&LGNKR,Q7,IA&Z5#C(;US@?E5^?3K*
MY-J9[6*3[*XDM]R@^4P! *^AP2/QH \:TK2M5U'X=7%I>>*-*TZS-_+'<)-8
M%IHKC[22,OY@^<MM(XZ$5ZEXRTVXUCP3K>G6HW7%Q92QQ*/XF*G _$\5))X4
M\/RZTNLR:-8MJ2D,+DPKOW#HV?4>O6MB@#D_!GBK1]0\%6%U]NMX/LULD5U'
M+($-NZ* RN#]W!!Z]JY[4_$%CX@\2>!-9C65-&.H7<22W";%DE\IEB<9[$AM
MI/-=??\ @GPOJ>H&_OO#^G7%V3EI9+=26/JW'/XUI7NDZ=J6G'3[VQM[BS("
MF"2,,F!TXZ<=J /,?&C)+XJ\9-:D,D7@Z6.[*=!*6<H&_P!K;N_"K.L6=M_8
MOPPA\A/+34+3:NW@8MV/\P#^%=Y9>&M#TW2Y]-L]*M(+*X!$T"1 +*",'=_>
MR..:M2:782I9I)9PLMDRO; H,0L!M!7T(!(H \Q\8 +XA^(&!C=X44MCN?WP
MJ76I+&;P+\/H].:(NVHZ=]D6,C(V@;_R7=GT[UVGBKP^FJ^']=2RMH/[4O\
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MUGM5TFR6WG\OS8EA4*_EXV9&,?+M&/3 H YKQ3'L^(G@80*JN/MZ)@8P/L_
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M'ELPW 9(P>/3-7ZJVU[8W-U=6]M<P27%NP6XCC<%HR1D!@.0<>M6J "BBB@
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M?V;/8VTMAL$?V9XE,84=!MQC P,>F*MT4 9EMX=T2ST\6%MI%C%9B02B!+=
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M^F3WJ'2?$&CZ]&\FD:I:7RIP_P!GF5]OU /% &E1110 4444 %%%% !1110
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M<)QD8/% '>44B[MHW8W8YQTS2T %%%% !4%S96EZ%%U:PSA>5$L8;'TS4]%
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M/M)!0%<$CL:AU/P3XIU.T\5Q7#Z:TFNQ6TBLLSA8)(V4>7C9RNT?>X)(Z#/
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MU';9)?VMV85B<H7*,KA<*<$#! '6LBV\+^*%T;PS<F#38M:\.?N(8A<.T5U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKN[N(-;N+<H;6-R,21J]P%502P3<=OW>.E 'L%[>VFG6DEW?74-K;1@%YIY
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M_#FIW/C%];L;V&U_XDTMA$Y7>\<S2*ZOM(P5&/6NIIDTT5O$TLTB1QK]YW8
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M&1E7() ."!UJUK7A_P 4^)_!NO:;J=QID%S?HL=K!"S-%  026D*AF)_W<#
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MJA[YRQKN** .'\%>";OPSK6JWM[<V\T# P:<L9.8+;S9)=K9 YS(.F?NBF^
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MHW$X.>F,#&>37:44 >8Z?\-M6LO ITL7MFNJVVL?VK9RC<T0<.&57X!P1D'
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&HV4$IA?:(H@5!&T 9W$$;B3R?2@#I+G2M.O;NWN[NPM9[FV),$TL*L\1/\
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MR)%!8\CTQ4.D^*O[,UZ)+/6=:UNQDLKB6[_M"SDB\F6--ZLC-&H 8!AMY[4
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MKRV2.*-0JJ!;)@ #I4&L:38Z;\4O"$UI;)%+=S:A-<2 ?-(YA')/4^@'8=*
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M1(A0CJN 0>N.M4&^'U[I^CZ%_9&I0MJ^E7<MX9[N(^7<O*&$NX*<KG><8SC
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M9+X#NS;ZG)!J$45_)KG]LV,IC++&VQ5V.,C((# X/\7M7<NZQHSNP55&22<
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M_=@A'7:RD,%.,'@X%64\+7/]N>'=2N-4:ZETJUG@E>6,![AI @W<<+]WI[T
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M<7+KM,TKL69L#IR>!Z 5D7?AC7[75-4F\.ZS:65KJSB6X2XM3*\$NT(TD1#
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ML2Z-NSG_ &.GO61?> KN634KNTU*&.\EUF+5K4RPED1D0)L< @D$ \C'4>E
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MTNGQS1+;6ELT<>UU R"S$[LCGM@  =R =I1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5!>WD&GV%Q>W+[+>WB:65@"<*H))P.O J>L7QA_R)&O\
M_8.N/_1;4 9%O\4/"EP\ -Y<P)<%5BFN;&:*)BW3YV0*,^YKL:\C;4=5\3_#
M&T\,6'A/51+=Z=!;"\NUC2W0;%!EW;R2!C(XR>*N^*Y8QJ]W9C6O$<]Q9V,8
MCM=&CD46KX)$DSJ<,6X(5N@'0YS0!Z?17F6EZ_JD.I>"-;OKR5[#7].2SN8R
MQ\M+LH'1PO0%_F7BLSQ'K>LW'A[QQXCLM2NH+>WN8+#3525E5?+E199  ?XF
M+#/H"* /8**\QU31]2TWQWH&EP>)M9-OK,-R+\R7)8DQ!7!B[1$DD?+C /&.
MM9EWKFJ>&M-\7Z1;ZEJ%P+74[.UM+B5C<7$*7"H6"DY+$9;:.3DB@#V&J\5C
M9P7#W$5K!'/)]^5(P&;ZGJ:\QT_4;ZSO=3@T[_A*3I;Z1/*TNL0S@P7" ;2D
MD@R-P+< ]5&*K*FJZ?X-\(^*F\0:K/J-S-8+<1R7+&"2*4JI0Q],X;[W4GG-
M 'K$=Y;37<]I'/&]Q;A3+&&RR!L[<CMG!_*EO+N#3[*>\NI!%;V\;2RR'HJJ
M,D_D*\MTK2+Q?'_Q$FTR_OFU&VBA-HDMTQC:62W<J'!X8*Q^4'A:O^![FVFU
M5;0ZUKT.I_8V^VZ5K6]V=N/WL>_C .?N9!!' H ZJ'QOX;G&CF+5H6&L%A8'
M#?OBIP1TX.>,''/'6M^LB/PY8QVUG;88PVLYN0I"_/*7+[CQQ\YW8&!G';BJ
MWC6[2T\+73OJTNE!V2,7,$1EE^9P-D:CDNWW01G&<]J .@HKR"'6+RQ3QA8V
M5QX@BMHO#[WUO_:[/Y\,P$BED9CN"G"GKP0<8JU)#J>CV7@O7_[>U2XO=1O;
M.WO(I;@M!(DRG<!'T&.,'KQDDGF@#U"ZN$M+2:YD!*0QM(P7K@#)Q5;1M5@U
MS1;+5;59%M[R%9XQ( &"L,C(!///K7G4-K?^*-/\7:U+K6HV\UK=W=I900W!
M6"..$;0&C^Z^X@YSZ\8KK?AX,_#?PX/^H;!_Z * +^J>)-.TO1M4U-Y3/#I@
M;[4D&&=&"ABN,CG# X)[UH6:P+9Q&VA6*%EWJBJ% SST'UKQ&#25M? GQ/N/
MMVH3-%>WMJ$GN6=6 6,AV!ZOVW=<5U,UG?\ AO5?!U]'K>I7,FHW2VE[#-<%
MH'#0LWRQ]$P5&,?CF@#TRBO$#XDU34-.O-?LV\63:T+R5K2WMK69['RTE*B+
M"C8P*J<MUW'KQ7LFH7"P:3=7+7*VBQP.YGD7(API.XCN!UQ[4 6Z*\D\.ZI+
M:^+_  S%9ZAXENX-369+J?54D6"YQ"TBR1*_W.5X"XX-4W.M:C\*-3\<1^(M
M4@U2>*XG2-+@B"*(.RB-8^@(4<,/FW<YH ]GHKSBW2\\6>,9M.GU?4K2RTO2
M[60)97+0M+-,&)=F'+8"C@\5S<VK^(XO!=P/[<N6U*/Q?]A%T6/*"0+MP.-G
M^STH ]KHKRWQ$SZ%JVC>&6U+Q-=6,D,][=2VK23W<Q!157<@W*F6).,#H*HK
MK&NSZ99:!]IUJSBO=?%G#?7D3PW36?E^80&8 [L@INZX% 'L%%>;VZWWA[XD
MRZ8VOWCZ2N@37<?VZ8R^0XE0%F).6 &2"3GDC.*R-#U.2#Q+X96SU/Q->1:F
MTL-W<ZBDD=O=#R6<21*_W/F4$!<<'O0!ZQ;7MM>&<6T\<I@E,,NQL[' !*GT
M."/SJ>O#]*DN/"_@_P <ZM8W^HO=QZ[/I\7F3-,!NFBC$FP_>D ;KU.,5TWA
M:\NK?QC:VM@OBJ?2[FUD%TVM038CE7:4=7D'&X;P5''3B@#T2"UM[8R&"WBB
M,C;W,:!=[>IQU-35RGCNZBAT^Q@EU:_L1<72J8=-B9[F[ 4DQ1E?F7U+#L,<
M9K@;S7]5M/ OC."RO=6A;3;ZS%E)J+,+J)9&A)5B3N(R6QDY*M0![317F.I:
M/J.G>/="TF#Q+K+6NLV]S]N\RZ+,3$$8&/M$26P=N,#ICK6=<:UJ_A_2O%NC
MVFJ74TEMJMK96-U=R&:2!;@1Y^9N3MW-C- 'K]%>?3VESX.\7>&X[75]4O+/
M5)I+2ZAO[II\L(RZR+N^Z<KSCC!Z5F0ZSJ9^ 6I:H=0N3J"1W96Y\T^8NV=P
MN&Z\  #Z4 >J5!=WEM80B:[GCAC+K&&=L LS!5'U)('XUP#V]]KWQ%NM*FUG
M4;;34T:VN&AM;AHF:0NXSN'(]\8)P.<#!Y+6%N]2\%6EM>ZKJ$SZ=XL_LQ)O
MM#!Y8Q. K.1]Y@ ,,>10![G65!K]I=>([K1+=)I9[2)9+F55'EPEONHQSG<1
MS@ \=<5>L[86=G#;++-*(D"B2:0N[8[LQY)]Z\L\.ZQ<:3\$=9\70D?VE?/=
MWS.1G$AD9%/T 5>/:@#T?6-<M=$;3A=)*WV^]CLHO+ .)'!()R1Q\I]?I6G7
MD^O>'9]&;P3,VM:E>F76[47*WERTJO(5<[UW?<_B&%P,'IQ67=>(-2U*+6]6
MM9/%;:Q!>SIIT5E:S/9!8G*K&P4;'W;3N)R03VQ0![+]LMC?FQ\^/[4(A,8=
MWS;,XW8],@BIZ\LM+,2?&74-0EN=2C,6BPWGD?:7 !+L3&5_N#^[TSFL;1O$
M&JW5CH^NV[>++G5[JYBENHC:3FQ>!W =%&-@54.0PYRN<\T >V45YQX9MM0U
MSQQXDFO-;U(6>E:KBUM(K@JA)120X_B3IA>G+>M<KYFMCX1OXQ_X2/53JEI<
M.;=3<MY6Q;DIM=.CY&>3GL.@H ]QK/TK5#JBW1-A?6?V>X:#%W%Y?F[<?.G)
MRASP:XW[+>^&_B+X;MDUK4KV+5H;I;R.[G+H7C17#HO1.2>%P,5RL?B'6S\-
M_'=XNJW7VRT\0O!:RM*Q,2":$! <Y"X)&!V)H ]LHKSR:UO/#'C_ ,-1QZUJ
MEY%JJW4=['=W!D1F2+S%9%Z(<CHN!@XKD]*\1ZK?:9I_B&V/BRYUJXNDFD@6
MUG:Q>!I,-&HQL"B,G##G(SF@#VV1Q%$\C9PH+''M5#0=9MO$.A6>KV:RK;W<
M8DC64 , ?4 D?K7#65K?^*[SQ7J<FM:E:OI]_-8V,%O<%(8Q$B_,T?1]S$YW
M9X]*W/A=_P DP\._]>:_UH WK'5#?7]_:_8+ZW^QNJ>=<1;8Y\@\QG/S 8YZ
M5H5Y"=<U;;\6O^)E=_\ $O3-G^];_1_W3GY.?EY /'I5Z>#4M#E\&ZS_ &[J
M=S=:G?06U[%-<%H)%EC8G;'T7! QCGU)/- 'J%%8GBZ[6R\*:C.VJG2@(\?;
M1%YK19('RKW8YP/<BN TSQ#/H6MZNEJWB![&+0)]1$.N;RYEB8<H7^8 AN1P
M,B@#UJBN"\->'=7>QT'7U\3:C+>7"1W&H17,ID@F1TRR)'P(R"1M(Z8YS6?H
M&G:QXPT1O$\/B/4;+4I[R5K6(2DVL,4<S((VA& P*H<D\Y/6@#TVBO/;2TNO
M&GB;Q(;O6-4L[73+I;&TAL+IH K"-6:1MOWB2W&<@ =*YN/7-?UZP\#6K:Q<
MVUS=7M[8WMQ;ML,RQAU+8Z;L+D''#<T >S5F:/KEKK;:BMJDJFPO7LI?, &7
M0*25P3D?,/3Z5QG]G3ZEXY/AEM:UB/3-(TR.7,=ZZ33RR.PW22#YF "]/6L3
M1Y&TWPOXGM[S7KRU=O%4D#7-M"7N;KB/]W&%Y$C@=0..3B@#V&BO'/[;O[/0
M/'UI:76N0PV.GQ7-F=3=Q<P,ZR!L,QW8R@(R>.:V+FVU'0-4\'ZF-<U.YGU.
M\2UOH9[@M!('B=LK'T3!7C'XYH ]+HKS/1-.U?QEI5UXCA\1ZC8ZB]],ME&D
MI^S0QQRE%1H1P^0IR3R<UFZOK-SJOB'Q&DMSXICDT^46NGKHUO,T,;B-6+OL
M!#DLWW6S\N/6@#UZBL?1IKW6/!]E+J"365_=62^>NTQO%(R?-@=5(.?I7F5U
MKGB#5?A]H>C66HW,'B(R745S/'(?,S:(^[<>IW.(@?7=0![(QVJ3@G S@=36
M58^(+:YT2+5+R"YTJ.1Q'Y6HH(I%8OL4$9.-QQCUR*Y2W\07/B7Q9H36-U+%
M91:(VIW*1N0LC3 +&K =<8<X/<5P22WOB#X*^$[[4=4U"6Z?68XGE^TMN<&Y
M(!8YY*A1M/;M0![6NN6K>)Y/#X27[7'9K>EL#9L9V0#.<YRI[5IUYC<: UY\
M63IHU348;:+PY"))(KEEGEQ/( &E^][G&"<#G&<[WPZNKR72]7LKR\GO/[-U
M>YLH9[AMTC1H05W-W/S8S0!+K'Q&\.Z#=W-MJ,M[$UL?WKBPG:->,_?"%2.?
M6K&A^.-%\0WHM-/:]:1D,@,MC-$I4?[3*!W]:J?%'_DF'B+_ *\V_I5NYFEM
M_AM--#(T<L>D,Z.AP580Y!![&@#HZ*\?6ZU;1_A?INNRZWJ]SJ>MI96[N',O
MD+(5!,4>#^\V9YY)8YJ_H^JW%AJ>J16UUXBM=$.E23M>Z]:S,+2X0@!@T@!8
M%6)VYZIQC- 'J-%>3>'=2N+7Q=H=M87OB.XAU&VN!/)K2R"*=U0.LD8?E><\
M# P14W@R[==<T^VU?6M>L_$95_MEAJ19H+P[3N\G/R  X8%#G P1UH ]3HKR
MA=:U0_L\7&K?VC=?VB(9B+KS3Y@(N&4?-UZ<5>OK?4=>^*MSHS:WJ5GID>D0
M73QV=P8V:3S& P>P/?')V@=* /2:*\[T_P 2S>%KCQEI^LW4MQ_98;4[-YW+
M-);2 E4!/)VN"GXBND\$VNI6G@_3AK%U-<ZE+'Y]P\SEBKN=VWGH%SMQ[4 4
MKKXD>'+74+NQ:6^DGM)3#,(-/GE5''4;E0BMC0?$FD^)K22YTF\6X2)_+E4J
MR/&WHRL 5/U%>>>&]?U/1]:\:+9>&;_58?[;FD>6VEB4*=B?+AF!)P,\#O4%
MIJ^H0>%O%_Q)MXH;9M6MX18VZ.)3'Y8,8=\#!?<WW>VW!H ]?HKRG1]4N]*\
M061L1XMNK*2VG_M$ZS;3B,,D9=)%9QA"2I7 P/F''%96H)KD?P@'C*/Q-JHU
M:[CBN)U^TD0[))%&Q$Z)@,,%<'@CH: /:ZQ?$WBBQ\*6-K=W\<[QW-U':((5
M!(=\X)R1QQ69H5]=3?$?Q;9RW,KVUO%8F&)G)6,LCEMH[9P,_2O-_$-]=:A\
M*]$N+RXEN)O^$I*>9*Y9MJSS #)[  #\* /=:@EO;:"ZM[66>-)[C=Y,;-AI
M-HRV!WP.:\Z\9W4<NNZE$NL>(Y+BUM%,5IHL<BI9N0Q#S,IPQ;@@-T Z'.:R
M'AE\2>*OAM?WFH7\<^H:5-/-]GN6C <0QL2H'W<ECG'48% 'J=GJAN]5O['[
M!?0?9-G^D31;8I]PS^[;/S8Z'I@UH5Y.?%6J:7XA^*5Q]JFGCTJVMY+."5RT
M<3&)CPO0 M@G'6I[^TU'PGHV@^(4U_5;N[DN[6._CN;II(9TF(5P(S\J8+97
M:!C'>@#U&BO+K73]0\13>-'N?$&KP1V&HS1V26MVT7E$1(V21U'(PIX'/'-=
MGX(U*YUCP/HFHWC[[FXLXWE?&-S;1D_CUH WJ*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *I:SI_\ :VAZAIOF^5]KMI(/,V[MN]2N<=\9J[39)$AB>65U
M2-%+,S' 4#J2: *FCV']E:)8:=YGF_9+:.#S-N-VU0N<=LXKG+WP?J,NOZM=
M66M+:Z?K C%]#]FW2_(GE_NY-P"[E '*G'44D?Q-T!S%*T>IQ:?,X2/4I;"5
M+5B3@'S",8)[GBNQH \H\56L&@_#6U\'3ZI%>Z_&(5TB.VCV3LZ./*<)N;&-
MIRW P#737'@1)_AC'X/CNQ 1%$KW&S?EU=9';&1G<P/?O77&&(S"8QH90-H?
M:,@>F:BO+^UT^*.6[G2%))4A0L?O.[!57ZDD"@#,U+P^=0\5Z'K?VGRQI:7"
M^3LSYGFJJ]<\8V^ASGM63>^ H[^7Q*\NH.AUB:WN(FCCPUK)"JA&!)^;YE![
M>E=#)J4B:[%IHTZ\:.2$RF]51Y*$$C83G.[OTK0H Y>VT#7[B*_&MZ_%<_:+
M-[2**VM/)B3<.9&4LQ9_Q  SZU'<^##<>#-$\/\ V\*=,:T;S_*SYGD%3]W/
M&[;ZG&>]=910!QTO@W45\5ZUJECKGV6UUF%$N8E@_?1ND91'CDW?+C(/(/2I
MM-\-:RVO66JZ_K-M?/I\4D=JMM9^1DN &=R7;)PO08%7]?\ %^B>&9+6'4[P
M1SW4BI#"BEW;)"YP.BY(&3Q6Y0 5A^*M D\0:7##;W8M+NVNHKNVF:/S%62-
MMPW+D9!Y'4=:JZSX[T?1=2ET]X[^[N;>,2W*6-H\_P!G0\@R%1A<CGUQS4]Y
MXST2TTFPU%;B2ZBU' LH[6)I9+@D9PJ 9X'7.,=\4 8-QX"U:^O=1O;SQ!%)
M<:GI<NG78%F0BJP;88AORH4MD@D[N>1GC7O_  F;[1_#MA]M"?V/=VMR7\K/
MF^2,8QGY<^O./>K&F^,-'U*RU"Y\V6T_LX9O8KR)H9+<;=V75N0".0>AJOHW
MCO1];U&&QA2^MIKB,RVOVRT>%;E!R6C+#YN.?7'- &7/X%U6.?6K73-?2TT?
M6)I)[F!K3?+&\@Q)Y<FX !O<'';UKI_#FD'0/#6FZ09_/-E;)!YNW;OV@#.,
MG'3UK-UCQUH^CZF=+VWM]J*J'DM=/M7N)(U/0L%&%_$U;\/>*M)\3I<?V=-)
MYULP2XMIXFBFA)Z!D8 CZ]* .;F^'M^\'BK3XM;B33->>:?RFM-TD,T@4$[M
MXROR],#Z^N_JWAHZH_A]OM?E_P!D7:7/^KSYNV-DV]?E^]G//2MYF5$+NP55
M&22< "L70?%FC>)KB_BTB[^T_875)752$)8$C:3]X<'D<4 8T7@_6K"6>RTO
MQ&+/1)[MKHPK:YGBW/O>..3=@*6)ZJ2,FNEUO2HM<T*_TF=V2*\MW@9UZJ&4
MC(^F:OUE:_XDTKPS9)=:I<^4LCB.)%4O)*YZ*BJ"6/TH YJ/P7K\E_H>HWWB
M.WEN]'DQ L=B4B:(QF-]R[\EV!'S9P,<#DUY_KCV=KX/U[PS8>*<VXGFAMM"
M:TV7OFLY*Q [LM'O.[(7D<9Q7J.F>/\ 1=1U2'3)8]0TZ]GSY$.I6;VYFQ_<
M+#!/MG-:.JZM8Z5JFDPRVK2WNHW!MH#&BEEPC.S$G'R@*<X]1Q0!Q&M&V\.^
M+;.=?$T&@7UQI4<-PU]:B2WG6,D JY90)%R>,G@CCUJ^$?";:_X*(2]FCMV\
M2/JMM<3Q[GN(DDRK$<8WXSGWSBNW\6^*M \+VMM)KS@1W$A6)?),AR!DM@#@
M =3VS70HRLBLA!4C((Z$4 <_XA\/7>HZCI^K:3?QV.J6(D1'EA\V.6-\;D=0
M5.,JI!!X(KG/%>E/I_A.VN]=\13_ &^VU..\CU-+3=%:R$[0#'GB$ D'+=\Y
MKM]6U:QT+2Y]2U*X6"T@7=)(P)QS@  <DDD  =2:R-&\::3KNHG2Q#?6EXT1
ME2WU"T>!I8^A90P^8<T <+I-@GBWQ[JQ?7(]9@E\/26%W?6482")I9!MCCP6
M&0H9C\Q.3^ Z%/!&OR2Z'<WGB2WDN=%E7[*$L2L;1["C[U\S)=E(YR ,<#DU
M>3X@>&K6]-G$+F.U2X^S->I9N+19LXV&4#;G/&>F>]=?0!PD?P]N/+\2:?-J
MZMI&LW,MZL2V^V:WN'96#"3=@A2N0-OX^NUHVD^(8-1^UZWK\=ZD<)BC@MK7
MR$8D@F1\LV6XP,8 R>.:Z&B@#GO$OA^\U:[TK4=,OXK/4=,E=XFG@,L;JZ%&
M5E#*>AZ@]JYVZ^&U]>6FO6TWB 2#6C;S3R/:?,LT3H<KAP A";0O;CDXY]#H
MH Q-0\/F_P#%FBZY]IV#3([B/R=F?,\T*,YSQC;Z'.>U9-]X @U$>)UN+YPN
MM30SQM&F&MGB10I!S\QW(#V]*[&B@#D;+PMJ]QK^GZMXCUFWOFTU7^R0VMIY
M"[W7:9'R[9;;D # &:QKCX;:M+X>U+PS%XDCAT*Y>62&,669H][E]A??@J&.
M>@)Z9%>CT4 8-CX<-GXLN-<^U!_.L(;+R?+QCRV8[LY[[NF.W6L*]^'<MQX?
MO["'5A%<S:V^LP3FWRL3F3>$*[OF Z9R/IVKNZ* *]BEW'8PI?3QSW07][+%
M'Y:LWJ%).!^)KS[PQI%O_8_B+X;ZGNC6)IFML<&2TF8LKKZE69@?0@5Z333'
M&9!(44R*,!L<@?6@#@QX%UZ]DT,ZQXFBN8]&NXKB!(K'R_-V#&9#O.6(XR,
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M!DTGQUJGB,7QDBO YAM#%@0/)L,K!L\[C&#T%==2,RHI9B H&23V% '(>#?
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M-V;=^!C.,G'YUJT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@8WA2058]R#S5K0?"4VGZU+KFKZQ<:MJ[P?9EF:-88XHMP8JD:\#) )))/%
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M7, @A>RA^S);X.=ZKN;+YQDD]!C&*K+X,U6\NI;S6/$LD]XMG):6LUE;"U,
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M^6RBR1;EH^FTS9].-VW-7[WP2(KG3+WPY?+I%WIUJ;*,F#SHY+?@['4L"<$
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MT-+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_BI,^8?+'[C*LO'//WJU-2\,1:C:Z# URZ#2+N&Z0A0?,,:,H!],[JWJ* .
MN_AI)=Z9?Z.WB&Z31KB:2XAM$@0&*1W+\OU=0Y+!>.V2<5IKX.ND\51Z\NM-
MYDUI':ZA";5"ET$SR.?DSD\#-=910!Q^D^"K[2I;*U3Q->MHMA)OMK%8U1@!
MG:CRCYG09^[@9P <U7N?A[.[ZO:V?B&YM-'U:62:ZL4@1COD'S[9#RJMW'UP
M1FNXHH H:)IBZ+H.GZ4DIE6SMH[<2$8+!%"YQVZ5SL'@F_-U8QW_ (EN[[2[
M"Y6ZM[6:%?,WJ24WS?><*3Z G R378T4 <S;^#8;?PGK&@"\<QZF]TS2[!F/
MSRQ.!WQNJHW@>X@OTN=,U^XL5DLH;*\5($8S)$"%96/^K;#,,C/7UKL:* .#
M3X9Q)I.AZ:=6E-MHNJ#4+0>2,A Q81$YYY)^;K6W;>%(K?QY>>*A=.TMU9K:
M&#8-JA2#NS^%=#10!S_BOPLGBJWTZ)[Z>S:QO4O8Y80"V]58+C/ P6ST/3I5
M*S\$M)J5_J'B#5'U>YNK(Z>,P+"D=NQRRA5)Y8]3GM76T4 <KHOA34],NK'[
M5XHO;VPL%*6UKY2Q9&W:/-9>9,#ID#G!.36AXJ\.Q^*=";2Y;AK=6FBE\Q5W
M'Y'#XQ[[<5M44 8?B+PZVM/8W=K?R:?J5A(TEM=)&)-NY=KJRGAE(ZCCH.:I
M3>$)[[PIJVCZEKEU>7&J!A+=.@ CR  (XP<*H Z=SDD\UU-% ',7G@[SM(T.
MWL]2EL]0T5%6TO5C5CQ'Y;!D/!5AU'TYXJM?^!Y]6\*W^D:IKUU=W%]<1SR7
M3( $V,C!8XP<*OR#CU)))KL** ,77_#L>O76C3O<-"=,OEO5"KGS"JL-I]!\
MU5]<\-7&H:M;:QI>JOIFIPPM;M*(5F26(D-M9#CH1D$$8Y]:Z*B@#D;WP1)=
MZ1IL0UV]&KZ?<M=P:G*!(_F-G<"AXV$,1M&  !4NA^$)=+\2W6OWFL3:A?75
MJMO,7B5%^5B05 ^Z,8&/;.<FNIHH YWQ5X7?Q$=,GMM2?3[[3;G[1;SK$LHS
MM*D%3P00:IW/@[4(]5NM2T?Q%+IUS?1QK??Z*DJS.B[1(H/W&QQW'3CBNNHH
M S/#^AVGAO0[72;+>8+=2-\ARSL269F/<DDD_6N8OOAR]]!K.G'7[J/1M4FE
MN)+)(4#++)R3YG4KN^;;QZ$D9![JB@#C;CP=KDL<D4/C"ZCCN8%ANT:U1PV%
MVEHP3^Z)'4#(SSC-=3I]C!IFFVNGVP(@M84AC!.2%4!1^@JS10!P5G\-GM-"
M.AG79I=,COH[RUB-NH:';-YI4L#ELGC)Z5TFH>'8=0\2Z;K,DQS8P3P>3M!6
M02A0<GVV_K6S10!Q^D^"[[2I;*U3Q->MHMA)OMK%8U1@!G:CRCET&>F!G !S
M78444 !&017G^C> /$6@:3;Z7IGCNY@L[<%8H_[,MVV@DGJP)/)/>O0** .0
MU+P5<ZU8Z'%JNNRW5SI6I)?_ &G[,B&8H20A5< #!QD>E78O"447CF]\4"[<
MRW5B+(P;!M4 @[L^O%=%10!R \!0#P#8^%/M\GE6CQ.+CRQN;RY1)TSWQBM>
MZT".Y\6:?KYN&62SMI;<1!>&$A4YS[;?UK8HH X:R^&UM9>%FT(:C*R-JBZC
MYIC .X2*^W&>GRXS[UNZMX9M]7U[3]3GF<"TMKBW,('$BS!0>>V-OZUN44 <
M OPXO38:9:R^*;F0:/)$^F$VJ!80G W@?ZP[?ER<=^.35[_A D;5-?=]3D?2
M=<#&[T\PK]\H$++)U'3.,=:[&B@#F='\,ZK97L$VI^)KO4H+:)HH+<PK"I!
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M** "BBB@ HHHH **** "BBB@ JGJ]Q)::+?7,) EAMY)$)&<$*2*N5G>(/\
MD6]4_P"O27_T T >?Z//XXU'P+;>)_\ A,+-&DL_M1MY]+01C )VEPP(''6N
MW\(ZU-XB\(Z7K%Q;BWFN[=97C&< GTSV/4>QKR/PMI?PLG^'^F/K>HV$=Z;5
M6N%.J.LBO_US#]?;;^%=YX#\1RQ^ ])NO$5P\;W5T;2SDGC*O.K.1#D <%E
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MSMZ9K&K:)HFI7'C1K6&/3W^74(>$N8L##; 25;)QM[GIFN;^'GB/2O"_A_\
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MTU#PSITUE=0W,8MXT+PR!P&"#(..A]J ->BBB@ HHHH **** "BBB@ HHHH
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M!):X"^2T8*8'0;>F*YY?'VC2Z#:ZK E[-]JN&M8K2.W)N#,N=T>SL1M8G/
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MN(M61VLC;PES*5 .T*.=QR!C'7KB@#;?3-/DGEG>QMFFF79)(85+.OH3C)'
MX-3O!#(8R\2,8SNCW*#L/3(]#61X?\4V7B*2]@@@N[6[LG5;BUO(?+ECW#*D
MCG@C.#GM6+XLN]<E\9:!HFD:RVEQWEO=2S2+;1S$F/R]HPXX^\: .K73+!+Y
MKY+*V6[88:<1*)#]6QFE.G6+74ER;.W-Q(FQY3$N]E]"<9(]JX_3-9U;0?%=
MWH?B+5X=0M5TQM32^-NL#Q(CA75U7@CD$$8Z&M#3/'NFZG<+ MEJEO)-;O<V
MHN;4Q_:XU ),63R<$'!P>10!O1:5IT$444-A:QQPOOB5(5 1O50!P?<5)]CM
M?LOV7[-#]G QY.P;.N>G3K69;>*M)NO"/_"3QSG^R_L[7)<KA@JYW#'J,$8]
M:S)/B'I2SQVL5GJ=Q>RV<5ZEI!:EY6BDS@X!XQCG.,9 ZD"@#I+C3[*[FBFN
M;.WFEA.8WEB5F0^Q(X_"E:PLVB6)K2 QJ_F*AC& V<[@/7D\^]<A_P +4\/'
M3H]2CBU*6PR%N+I+-C':,6V[93_"0>H&<9'J,ZVL^,+#1[\6(M;^_NA#]HDB
ML+<S&*+) =O0'!P.IP>* -Y88DF>98D65P [A0"P'3)[XK%\0Z1?W>E)!H<U
ME:R),)7@N;8/!<+SN1QC(!)SD<Y%5[WQWH=G%I,@DGN5U:)Y;(6T)D:8*%.
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MTER.V03QDXYQ0!V"0Q1/(\<2(TAW.RJ 6/3)]::UM UPMPT,9G0%5D*C<H]
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5D>*=*DUSPGJ^E1,%EN[26&,GH&92!GVSBM>B@
M#S[PQ\1_#MMX7M;?6]1@TK4]/@6"\LKMO+E21% .%/+ XR,9ZU0UK7CJ$W@W
MQ9?6,^GZ1;ZG,KFYXVQO&R13./X 3@\],CFO2);"SN)TGFM())D^[(\8++]"
M>E3.B2QM'(BNC##*PR"/>@#RO6[VUUWQ=X@U#2;B*[LK+PK<6UQ<P,'C\UV+
M*FX<$@*3[9I;]$_X0#X7KM&!J.E'&/\ ID:]/AM+:W@\B"WBBAY_=H@5>>O
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M$0PD\N,,@ )7YB.2!UKU7RT\WS=B^9C;NQSCTSZ5'%:6T$TDT-O%'+(<NZ(
M7^I'6@#BOC)Y9^%VJ"4@1^9;;LG''VB/-8MO#\'+6YBN(=2TM98G#HW]J2'#
M Y!P7KU*6*.:,QRQK(AZJXR#^%5_[+T__GQMO^_*_P"% ' 0LK_M%2LI!4^&
M@01W'GBN*L5#?!7Q0K $'Q)@@]_](AKWP0Q"7S1$@DV[=^T9QZ9]*:+6W$;1
MB"(1LVXKL&"?7'K0!QNNJ#\7/")(!(L[\@^G$?\ C7&^)_\ D7/BS_U]0_\
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M3:&H_P"%N^+&P-WV&Q&?PD_P%=D+:W5MRP1!MQ?(09W'J?K[T\1HLC2!%#L
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MXR:Q<:=-'/ NC01^?$=R2$2ODJPX8#.,CN".U3?$F[7PY<Z#XO*EDTR>2&X
M[Q31E>?^!K'7<Q6T$&WR88X]J[!L4#"^G':G2Q1S1F.6-9$/57&0?PH \,U2
MWO?".@Z7'&&-]XDT1M/DP.?MDDH<$^_^D3?E71ZG80Z5\8/AYI]N,0VNGW4,
M8_V5A('\J]0>&*0H7C1BAW+N4':?4>E#0Q-*LK1H9$R%<J,C/H: /%)[^T3P
M3\4],>YA6_\ [3OIQ;%P)#&1'A]O7;[]*['Q4H6[\ !0 !JL8 '8>1)7;-96
MC2R2M;0F21=KN8QEAZ$]Q4K11N4+(IV'*Y'W3[>E 'DFCZ]I.@?#?Q#H>K7<
M$.K6\M]%):2,!+.TCN4*IU8,'7!%2:%/#X3\7>'5\074-A_Q2,5KYMU((U\U
M) 63<>,@'I7J3V=K+<I<R6T+SI]R5HP67Z'J*6XM+:[55N;>*8*=RB1 V#ZC
M- 'A^I7D5[\-/'5_%N^SMXH68,5(_=[K8AL>A'/T->W65]::E:1W=C=0W5M)
MG9-"X=&P<'!'!Y!%2&WA9)$,,923.]2HPV?7UI8H8K>)8H8TCC7A410 /H!0
M ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAI.OZ9X;/C?2=6G2+4IM4N;F"U?_ %ETDJ+Y?EK_ !Y^[QTQ0!UWP\N[F_\
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M7<^D7#BXM@&2'*X5&;LSG@+UX.: -O2O'&GZS?6MF;#5+);^-GLI[N'RTNE
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M31M/K<31V$FEHH,\<JG#,RGHHP6+=,4 =)>?$'2[*]N8VL]1DLK2<6]UJ4<
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MM;FSO)3B)S&K*R[NF[!5@.X-<Y DEK;6?CB6&5-.;Q//?L3&=R6<L9A64KU
MX5OH<T ;U]KVM>"+S5K"\U.35XAHL^I6,UU&BR+)%PT;;  RG<ISC(Y%:.DZ
MM?:+KLEEK6M/>VC:,-3DN+A(T\EE;$F-BK\A!! .2,'FJD5QIOCGXBK-8O'J
M&C6&DS6US/&=T4DD[*/+#=#\BDG'3(J!/"ME=>+/[$M[B\O+2SBA.IS7<WF'
MRU):"T4X'RD_.W<@+DG=0!TGA/6I=4%Q-J%]"EU=MY]OIA=!+:V^!LW*/FW,
M/F.>A;':M?6]:LO#^D3ZGJ,ACMH0,[5+,Q)P%4#J22 ![UY?IQM3?Z38Q^5_
MPDT7BFYFNT&/.$):8L[=]AB* 'H<J*ZSXG0RGPU9WJ1/+#IVIVM[<HBEB88Y
M 7X'7 Y_"@"Y8^-[:[OS87&DZMI]\UN]Q;V]Y JM<JOWA'AB"PR/E)!YKCO
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M &O/'<6T-C_RUF>29]A1>K#YAR.,@^E 'INK>/-.TK76T5;'4K[41"DRP64
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMC<H.#D9'2@* 20 ">I]:6B@! H484 #T%+110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7!^/IWN-=\.Z&U
MC/J%M>?:)Y;.%P@G,2KM5V) " N6.3SM'!Z5WE87B#0[G4KG3]1TV[CM-3T]
MW:&2:(R1NKKM='4$'!X.0005% %7P-+8_P!C7-I96]W9_9+N2&:RNI YMGX8
MHI!(V88%<$\-^%=/6+X;T.71;>\>[NUN[^_NFNKJ9(_+0N0J@*N3A0JJ!DD\
M9[UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
; 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>sesenbio_minorirosales-e007.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHJ"]O(-/L
M+B]N6*P6\;2R,!G"J,G@=>!0!/17+Z-XUBU75+>PN=(U+3);R!KBS-XB 7"+
MC.-K'# ,#M.#@U4C^)&GR312_P!FZD-'FN?LL>KF-?L[2;M@_BW;2W&[;C-
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M-[9/"A1SC- &]17E%QXXBT;X;:_K7A^+5[N2WU&6W+ZA(LODRY4%N6_U0)
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M\BW-G<A/4?K0!Z-17!:'JNI:)XVU/PYJNM'5+&WTU=16[GC1)+<;RI1R@ /
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M(43;O)VG[V<\9H ]5HKE-6T3Q!K6NSEM>N-)T>&%/LZZ>R"660Y+-(64X X
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MROJ=F^E2(@ZW&"ULV/\ >RN?2O3ZYB\\+WFK>*+74=4U1)M-L)?M%GI\=OL
MEQ@/(^X[RN21@#K0!H>%M#C\-^%].T>,AOLL(1V'\;]7;\6)/XUPMIX4TGQ'
M\4_&SZK;SR>3]A$1CN98>L'/W&&>@ZUZC10!Y'HNAKI.F>-/ L=LHU6>TFFL
M[PCY[Z"16";F/5D8[#_^NF^&%\/:I=^&[8>(/$-_J5NZ3'3I) 5LI(T(/FKL
M&P#E.O.1C->O4F "2 ,GK0!X@-=L])^#6M^$[I9#KMK%>PRV?E-NP9'?S>F-
MFUMV[IQZXK>@UBP\-^/=.OM8N%L[.[\,V\$,\@.QY$D+%,_WL,#BMO5/!>NZ
MI%?Z9)XK<Z'?2,TL,EJ'N$C8Y:))=V O4#*D@&NTCACAACBC0".,!47T X%
M'@OB*5KSX->.)U@EC\_Q&\BI(A5PIEB(R.H..U=CX@U=%\8OIVL:WJ6EV,>G
MPR6%O8,8WO96+!P&4%F884!0>^:],I, D''(Z4 >%66H6UAX-\ 75W(88M*U
MN2&_9\G[,_[SASV/S#\ZZ&*/^U/C1KWV5\I=^&%6*4=#N9<']<UZJ0",$44
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MEMP JN2.&8G&WKP<UY-?ZA:W?[,W]FP2[[VP:&.Z@VD/"QG. P['@U]"@ =
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M=;58[*5;2]5;)(2MK(<,?D/S;6(('K7<1^';S^WAJH\3ZJ]L9#(+',?D8/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.LDRH6$(,J89L D#( S_ +0KD_$:MK7A/X@Z[:02O8:G?:>EH3&P,RQ-"C.
M1DJ3GGVH ]#E\="WTN&[N-"U**XO+H6VGV3!/.N\KN#@;L(N,D[B,8YJ&;XA
MQV5EJ[:CHE_::AI5NMU-8LT;L\!./,1E8JRC!SSQBF>.=VG>(/"GB*6*1]/T
MRZF6[:-"YB66(H)"!SM!QD]LU3TU[3QC\1;[5;-&N-$CT7^S9)VC94G=Y-S*
MN0-P"CDCNU '3:YXJLM%T.UU39)=I>2PPVL4&-TS2D!0N2!T.?H*P[;Q-HFG
M>)O&L[C4$DTJ*":^:24O$5\LLOE)GY3@<\#)KEO!UGJ&H>)=(\.:A%*;;P=Y
MY>5U(6=]Q2V(^D>6JU81Q1>//BC+?Z9<7UD\%H)+>*/<TZ>20P49&3CT.?QH
M [&Q\3SWYN;74O#^IZ6WV1KF,S%&$D8X(#(Q"N,CY3@UD:!XQT?3_AQH^IV5
MOJ<\-[,UO96DTGFW,TID<;=S-CJK'). !63X=O8AJEUIWAW6]1U?03IDSS)>
M!G^QR#:(T61E#<@M\AR1MK"\-6]QIWPR^'VLS6T[6VE:A-)>(L;,T<;O,GF%
M0,D*6!.!T.: /1[3QLK3ZC9ZGI-YINHV5FU\;65D?S81G+(R,0>1@],$BJ-M
M\2(KA-)O'T+4H=(U22*"#4)/+VB23[H*;MP7/&[&,].,&L34+V'Q7XHU'5]'
M\R?3;'P]=6SW0C8))-(01&I(&[ 7)QTR*=J,$O\ PJ+P1&(GWI+I&Y0IR,&/
M.10!TDOCC;J-S';Z%J5UIUI=?8[B_A"%4DR <)NWLJE@"0/7KBJ]G=7'A_XE
M2Z+)/))INM0/>V8D<MY,Z$"6-<_PD$-CH#G%<QK^H6.GZY?W/AR\U;3?$YO0
M&T@QLT.H-N"[S'@KAEYWJ1@<GFNB\1?Z5\7?!D$7,EG;WUU-C^&-HUC4GZL?
MTH Z?Q!KUGX;T>74KT2-&A5$CB7=)*[$*J*.Y)(%8]GXSFDU+^R]0\/W^GZC
M+;27%G!+)$PN@@Y575BH?D<$CKG-0_$FUN9=!T^^M[>6X&EZI:W\T,2[G>*-
M\M@#J0#G'M68VJV?C'XB^&KG0W>ZM-)CNIKNY$;*B&2,(B9(&6)R<=@* ,?X
M;WVIZ[XSU_4M3L]79X=3GMT=[Y?L]FBCB(Q!\%AGJ%(S@YZFNF\9>+-6T+Q+
MX=T[3M*GNX[Z9_,\MX@90L;DQKO88(.ULG P, ]JI?"R*2*?QIYD;IO\273+
MN&,CY>1[4_XAW46E^)_!>K7>]+"UO9A/,$9A'NA(7. >IH IV'B?4;'QCXR@
MMM(U+5Y(KF"3R(9$"V\?D(3R[ 9)SA5R3@UT#>/+.?2=&N]*L;O4;G6$:2TM
M(]J/M49<N6(50N0"<]2 ,U7\' MXQ\:SA6$<MY;,C%2-P^SIR,UYUH^GI:>'
M? VJ:K=:GIVFI8W5K/=63O&T#M*&3>5!(5MI'IG% 'L?A_7H?$%C+,EO-:SV
M\S6]S;3@;X95QE3@D'@@@@X((JAK?BR;2]1EL;'0=0U22W@%Q<M;E%6)"3CE
MV&YCM)VCFJ_@*VTM-/O[W2GU6:&[NRS7.I,6:X*JJ^8I/)7  !(&=OIBN<\1
MWPG\9ZOIVK:AK,*I;PC2+#3Y9(1=EE.\[D^\=_R\G"@9/K0!T=YX_L(3H2V=
ME>7[ZY;O/8I J@OM"MM.X@+P^<G@8.:HQ?$B2XBOX[?POJLNHZ:Y&H68:(&W
M4#(;>6VON&<!<DX/MGF?![>???#0(DF;33KVWG#(1Y4BI&"IR.#FNET")U\4
M?$)C&P#SP[21][_1EZ>M &C<>.[+^S]%FTVRNM1NM:C\VRM(=JN4"AF9RQ"J
M%R 23U]:@?XAV=MH>LWU[IMY:W>C-&MY8/L,B[R-A4@E64YR#GL:XKPV_P#P
MCEMX#U_4HY8]-71Y;&>;RV(MG9E92X R =I&?SI/$$%QXGTSX@:YI5M/-8W-
MK:06C")E-SY)WR,@(R0,X!QS@XH ]3U+7H-,UG1],EBD>75)9(HF7&$*1ESN
M_ =JY>3XGQ?V;=ZG;^'M4N-.L)I(KZY3RP(=CE20"P+\#=\HX!'?(%"^\2Z?
MXG\=^"9M',US:PW-PTUQY+*D;-;OA"2!\W7([<9ZBJUC!*/@KXMC,3B1FU3"
M[3DY>3'% &W=>,M4'Q+L=#L]*GN-.FL#<F1'B&\,Z 2C<P(5<L".I)X!XKI]
M?UVS\-Z--J=]YABC*J$B7<\CL0JHH[DD@5P"7L.B_$;PM=ZAYD-O<>'19Q2&
M-BIF,B$)P.#CUKH?B3:7,_ARTN[:WDN3INI6U])!$NYWCCD!8 =SC)Q[4 36
M?C.9]372]1\/W^G:A/;R3V<,LD3BZ"#+(K*Q <9'!Q]:XWX=WVIZ[X[U_4=3
MLM89K?4IK>-GOE^SV2JI B:(289N<9"L,X.>IK9DU:S\9?$'PQ/H3O=6NE"Y
MN+NY$3*D>^/8B98#YB3G'4 4OPPBDBU+QP9(W0/XBN67<,;AQR/:@#J=?U]]
M&>SM[;3+O4KV\9EAM[?:O"C+,SL0J@#U/)/%9,OQ$TZW\.IJ]S97L6W4!IUQ
M;%0TL$V[:00"0P'!^7.01BJ7CO4?LOB#1;74M3O],T*:*=II[)G1I)ALV1LZ
M#<H(+D 8R17%68']C3V"PWRS)XRM;GRKS>TWD.T91W+<G(!SDY&#F@#T*/QW
M(M[>6-]X=U&RO8;%[^""1HG-S$AP0I5B _(^4GO5VY\::9;>!%\78DDL6MTG
M1$ WL6P F,XW;B%^M4-2C<_%W0I C%!I5V"V. =\?&:XS3]+N1XTB^'S0M_9
M.G:DVMJW\/V;[T47N!,Q_P"^: /77NUATYKVX1XE2'S9$(W,@ R1QU(]JYS2
M/&QU'5+&RO-#U#3!J432V$MR8R)PH#$$*Q*-M.<-VSZ5J^*+G4+/PKJUSI2%
M]0BM)7MU"[B7"DC [G/;O7ENGWFF'Q=X-U*TU36M2@666*\O;V65XDFD@940
M*PVJQ;.0HXX!ZT :WC#Q[)?^!?$%SIVE:DFFK%+;PZO&Z!#(IVY #;PNX8#8
MZ^E=)-XO>TO+/1K#2+W5[\64=U<+ \:B&,\ LSL 6)!P.O%><G68--^"FH^#
M9H+EO$%I!/;268MW+8\QF\S.,;=IW9SST'.*Z:TU:T\(^/;^[UII+>TU73+,
MVL_E.ZEX@RM'\H/S?,#B@#*B\1V/_"N?$&JZPVK2V3>(IQ&MO,T4Z*91L7)(
M*@9Y7\*ZR\\6ZO#\5+?PY#I%Q-8FP,[LKQ#=F1%\WE@=JY92/O$] 1@UYOKJ
M7-W\'/$<GV*XAEG\32S"!XR'4-,#@CVS7>:M?0:/\:]-O+\O%;7>B/9PR^6S
M*TQG5@F0#@XH L:+XIT&PB\8ZB6OXH=,OY%O6N93("X_YY#)PI/ 7CK5^P\;
M/+JMA8ZKH.H:0=1W?8I;EHV61@-VQMC$HV.<'T/>O.H]'U#4?#GQ/M[6UEDN
M&UTW$46TYF$<JR$+ZY"D"NHU77K'QQKOA6TT)I;AK345U"[?R746T:(XVN2!
MAB6 QUH NS?$V,6-_J%KX>U2ZL--GEAOKA#&!#Y;$,0"P+\#=QT!&:U]4\6O
M;75M:Z3HM]K$TUL+P_9RB(D1. 2SD D]E'-<GIT$H^$7C:,Q.'>75]J[3ELF
M3&!WS5234%34=/T_7-1UBRLDT6T;3[73GEC-W,01(-T?)880!<CKGWH M>-O
M$8U6P\ :II5S<0VU_KUJ& 8HS*20R. ?4$$<CBO1-9OY=+T:[OH;1[N2",R"
M"-E4MCKRQ Z<]>U>)A9)/!7PZM1#-]HL?$\<5U$RL6A<2N2&_ @Y]Z]MU>)Y
MM%OXHU+2/;R*JCJ25.!0!QOAWQUJ,W@/2M5U'1;ZXU"\,<,$</E?Z6[*3O&&
MPB<');&,5I+XY4:'JU]-HM_'=Z1($OK ;&EC! ;>I#;67:=W!Z UP.E^(HA\
M/_!]A_:=[I^G0.+76;BW1XY;=EC8HA;;E0S@ D?F,U=\.^(+'PS?^,+D1:G<
M+-]GFL(;OS))[U2@C4@OEB&?@9Z C@8H [\^+M/FUG2M,L%>^EU& W:O 04B
M@QQ(Y)X!)P.Y-9D/Q"MYIX9_[(OET2XNOLD.K$IY3R%M@.W=O"%N Q&,XKFO
M!>CWG@'7$LM5AB,?B&,,MQ AVVEP-Q^S9YQ'AOD]P?6L3P]IFBIHVF^&]7U#
MQ-)K$5PEO-I$4\GEJR29$FTC;Y0P'W9QCWXH ]%D\<?\3&XC@T+4KG3K:[^Q
M3ZA"$*I+D*?DW;RJD@$@>OI6MXHU6XT3PQJ6IVMJ]U-:P/*(T*@\#);YB!@=
M3WP.,GBO.M;O[&PUV]N/#=YJVG>)6O@LFC-&S0WS;PI<I@KAEYWJ1QR>:]$\
M602W/@W7(((VDEET^=$11DLQC8 #WS0!Y]<^+=4GTGP#JU_9WT,T]VOF11,A
M:]W6Q(951L89CP&QCN!776'CB*635[?5-*O=,O-+MQ=2V\NR4O$0<,A0D-]T
MC'K7&Z5J%MJVE?#(6;/*;&X2WN1Y;#RI%M&# Y'8]^E7/%D^JZ?XO\47^D1R
MF\C\-P^2Z1[B#YTF2!W(&3CVH Z73O&LUW>BRN_#NHV%W/:/=V,4SQ$W2IC*
M@AB%?YEX;&,]:@^'/BG5/%6BSW>HZ=+ !<3"*9FCVNHE<! %).5  )(&>V:Y
M/3+G2E^(7AF]T[4M8U&Q:*YMVO[Z666-IW5-J+N&%/!S@ <@=L#=^$=] OAR
MXT5RZ:C8WER;B!XV4H&F<KU&#D'M0!U%KXEM+C6M:TMXY()=)2*25Y,;71U+
M!E]A@@^XK(L?B/I=]X#O/%@MKJ*UM-P>"0 2YX*C&<?,&4CG^(5S?Q.AOK#7
MHI].BD=_$&GMHCF-2=CM(NQSCIA7EY]JJZSI$D'CN+PC;6TG]EZM<V-^Y"GR
MUCMT82*3T!/DP_G0!V5SXWE_M&XL-+\/:CJ<]G&CWHA>-! 77<$R[#<^.<+5
MBS\;Z9J,OAT6:S21ZZLS0/@#R_*7<P<9X/4<9Y%<YIVN6/@GQ1XJ@UYY;9;Z
M]%]9R^2["X1HU4JI4'+*5(V]>17/Z;#-X5LO 6L:U!-9VD5UJ$ER6C)^R_:
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M7V!5>+.8Q\V22!G(X&1DUFMKUEXD^)_A6ZTGS;BR@MKU6NA$RQEV5/E!(&2
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M]/662P&@/$ERT;*DK?:$)VY R!D<^N?2F?&*&2;1?#PBC=RNOVK$*I.!\_-
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M4M3'&)'C(&>.F1DCFH+*&U/B774TJWU9[34O#[P64]Z9Y3<R*7+;6ER5'S
M'&>HZ\^QT4 >)1&UU'PEX%O9&U:*TT2,V>IM9K/!-;,T(7=\H#%0R@$KGAJM
MZAI5E/X8U#6/#UIKEZ+?4K*YDFO7EE>]C@8,3&)#O(4,PZ#.WC->Q44 >:RZ
M[!XF^)OA&ZTJWNY;"VBO1)=O;21IO:,?+\P'(QSVY ZUJ_$^P.I^&;.T,$DT
M<FJV8D2/.=GFKN.1R.,\]J[6B@#G='\">&M"U!;_ $_3 EVJE4FEFDF9 >NT
MNQVY]J\IUIWU+P[J#7PU^\\30WYDN;8-<"WM84N 00@Q&R^6!C@DDY[$CWBB
M@#RGX@W-[HFKV7B708WE;7K,Z00H*GSG&ZWDP><@[AST%:>H: NB:A\.M,LX
M7>WT^Y>-G5"0,6[@LWID\_4UOR>%9+WQ5!K.IZK+=P6;M)8V/E*D<#D8WDCE
MV S@GIDUTE '&Z+!*GQ4\5SM$ZQ/9V(20J0K$"3(![XXKS^QTAH?"_@_4M27
M5;6PL[K4HKN2R:6.: 2S.4<[/FVY4 X[,*]RHH \?U'3M/G\'ZC=Z';:U.MS
MJUB&N=0>21[D1RQ_.N_Y]H!(R0/N^E=?KT$S_$_PA,D3M%';WX=PI*KE8\9/
M;.*[&B@#QOP[=:3%\/[O0=?TO4)S:ZE*;R.*VE#VRM.S),& !('!RA)&<XQF
MNL^'US<2W.L0P:AJ.I:%$T/V"[U!&$A8AO,0,P#.JX3!([D9.*[BB@#A9_\
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M;N^T*<9Z9QVK$L+2X7P3\2HS;RAYK_4VB4H<R Q  J.^>V*]-HH \E2RNO\
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MC=)Q9+'L,H &]0SJ.0,XKTW^P$_X3,^(_M#;_P"S_L/D;>,>9OW9S^&,5L4
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M9ED5TW!02%(&,XZBMVQ\*R1^)WU[5-5EU&ZC1XK)&B6..UC8Y8*!U8X +'G
MKI* /&-9M;W6-+\9^)K.PNVL[J]TZ2UC,+++-%;,F^14(S@_-CCD+70/K<'B
M7XE^%+S2X+J6PMX+U7NWMWC3>R)\HW 'C'TYQUSCT>B@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H+V[BL+"XO)SB&WB:5SZ*H)/Z"IZ
MRO$UE+J/A36+& $S7-C-"@'=F0@?J: . MY88_A1JWB_Q':27TNKQ"\N+=9F
MCQ 6'E1(PY50I!XZDFN@E\8C33X>TK3=%GNIM3T_S[2%9P-@14^5F;H K9+'
M^[T)(%<_?.^M_LWQK80R3RMI,,(BB0LQ=-J, !SP5/Y5I6%E=+XM\$2M:S".
M#0IHY7,9Q&Q6'"L>QX/!]#0!?A^(4,6BZU=ZMIDUC>Z1.L%Q9)()F=W"^6$8
M8#;MPQTJ2'Q+J5TU[I>L>'Y]*N'L9+B!UG6>-U P074#:XR./R-<GK^B:I>7
MWCF>TL9Y9(M1TV]@C"$?:1#'&65"?O'@CCN,5U<'BT^(Y;JTTS2;XV2V,CSW
M=S!)!LEQA8E5U!=NN<<#'?- '-_#7Q%_9/PQ\%QS1/</J=Y)9AR_*$O,VXYZ
M_<QCWKM+[Q9:Z=XAO-+NHF2*TTHZI+<[N @=E(QZ_*37F>B65_I7PJ\!WESI
MU[C2M6-Q>0K;L98HB\REMF-Q WJ>G0UIZG%=>,O$WB&33[&\CM;OPL]G:3W$
M#PB:3S&/ 8 @9;'.#P3TP: #Q)XIU35]+\,SW.@7&FV=]K-C):S?:5D+*9 0
M)%&"A*\XY'!!(/7H+36]+M_'OC!8-+E74+"SAFN;@W#%;A?+W*H0\)@<9 YK
MFM1UR77O#WA+3+/1]4%W9ZEI[:@LMC(BVOENH;+,H!Y],\ DXJ[#I]Z/B/\
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MNKJ**>XBN1&PRW^KQU^;UJWHM_)KGQ;EU:WL+V/3/[#\B&YN+9XA*PG#' 8
MCKQD G!/3FG_ !?L[J^\(6L5I;37$@U*V<I$A<A0W)P.U $MEK%SH$%AX<TC
MPJW]HF&2Y>P.H I;Q;R S3-G)9N@QZ],5/+\08WTC3)K'2Y[C5-1NI+.+3FD
M6-DECW>:';D +M.3SV]:QO&.EV4'C^/6-:CU;^RKC35MA<:<]P#%,DC-AQ"=
MV&#\9&,@U2>Q@T(^$_$MCHFJV^F6M[>/=PS"2>Y19T*"9E)9^2H)'4;NF: +
M=CXE:U^(/B34M:M)=/73]#A>X@,@D VO(V4(X;((QT.>.U='I7BZ]N-7LM/U
MC09=*;48WDLG:X67?M&YD< #8^TYQR.#SQ7$ZO9WWC35_&#V&GWD4%YH,45E
M)<0-#]H99';@, 1D\8.#C!Z$5J^&+7P[?>(],FL=+\1M>6R/+))J$UUY=DY3
M:5/G':S'<1\N?6@#4\/?$&Y\0Z?-JD/AR[73((IFEG657<RQD_NXXP-SD@#D
M8&3CM5W2/%U_<ZU::9K&@2Z5)?0//9L;E9=X3;N5@ -C ,#CD=>>*YCPW!KF
MF_ BYCT^VN8-81+MHH_+(E!,SG*J>=VTY'X53TN/3(?'?AG4M(L=<>PVSVT]
M_?+<R%YI$&T$29*\@Y8 +D]>#@ V/@Y(\FC>(R[LQ'B"Z W'.!A.*U=6U#2X
M?BEX>L9].DDU*>UG:WNQ<,JQ*%.X%!PV?4]*SOA'975CH_B!+NVFMVDUZZD0
M2QE"RD)AAGJ#ZT:]974GQM\)W<=M,UM%972R3+&2B$JV 6Z#- #I?B1>MIVJ
M:E9>%[BYL=*N)X;V;[4B;1$Q#% 1E_E&XC@<XR3G&KJ'C*7[?9Z=H.DOJU[<
M68OBAG6!(H"<*S,P/)/  '8]*Y_3K"\3X7^-;=K2<3S7&JF*(QG=(&+[=HZG
M/&,=:AT^:3PAK^G:OJ5G>G3KW0+6U:6&U>8P3Q9.QU0%AD-P<=0: -^3Q]G3
M=+-MHMY)J^I3201:;*PB9'CSYA9SP%7&=PSG(P.::?'S6NGZ^=3T>2SU/1;8
M74MGYZNLL9!*LD@'(.TCIP:R-0U#4I]6\+>,[W0[RVLK9[N">W6-I9H890!'
M*T:C<,[ 2 "0&K-UR&Z\3+XUU^QL;P63Z$-.M/,MWC>Z<%W9E1@&P"P XY[4
M =!+\1;RVN=,^T>%[Q+75@5TZ5;A&>:3;N563CRPP[D\=\<XN6?CU8X]?77M
M,?2[C1(4N)XUF$X>)P2I1@!DG:1C'7%4]:L[F2Z^'Q2VF86]VIFVH3Y8^SL,
MMZ<\<UD>*/#^HZUK7CNVM;:4M=:1:+;L0565T9VV!NF> /;- '5:5XLOI]8M
M--UG09=*DOXGELV-PLHDV %D; &QP#G'(X//%5?B1XAUCP]I&GR:1;"22YOX
M('D\Q5V@R+\N&!^^,KGMUK)\+VOAR]\2Z?<:=IGB-[NUCDE>;49KKR[-RNTH
M1,<,Q#$?+GIFM/XIPSR>&+.>"VGN%M-4M;F58(R[B-) 6(4<G'M0!=O_ !-K
ML$T-K9>$Y[JZ%J+FY!NECBBR2/+60@AWX/ QVYYIJ^.[1K?P]?\ V25=*UH!
M%NV8#[/*P^1)%[9.5SG&17,:K>V^L>*KF35+;7KFPFLX6T6UMDN88YG.[S-^
MS;M;.W_68PO-4--BOM7^&VA>!8M/NHKFX4V^HS3VKJMG%&^78%A@N> F,\G/
M:@#M6\>VBVNO:A]DF;2])D$ ND(/VJ;(!2->^&(7.<$FD@\:SVMS<6_B+19-
M)E2RDOXMMPLZRQ1X\P @##KD?+[]:Y&XT?5/^%>:OX(;3YY+G1WAEM)(4,:W
MUNLJR JPP/-P"I .=V#WJ]HUMX>GU*:]T?1/$&HRVEC,Q;49;@)N8 & +.<%
MF'7 (&!DT =/H/B;5-5NK9+[PW<6%M=P&>VN5G6=".#MDVCY&(((Z@\\U;\2
M^(U\/06BQVDE[?7TXMK2TC8*9'().6/"J "2>U<7X1^S0>++&'PJ-<ATAH)3
MJ-A?13+!:-@; GFCY7W9&%)&,^E;GCF"XMM6\,^(8K6>ZM])O)#=1V\9D=8I
M(V0N%'+;202!SB@"2+QQ-"VKVFKZ,]AJ>G6#:B+<7"RI/" >4< =Q@Y QD=:
MJV_Q"NI/[%O+GP[/;:/J\L4%O>-<*6#R#Y,QXR%)Z'/H<#-8VIF7Q5K/B#7-
M.L[S^SH/#5Q8122VSQ-<S.2V$5@&( 4#..IJYJUC=OX"\"P):SM+!?:4TL8C
M):,+MW%AV [YZ4 =7XQU2]T3P?JNI:?;B:YMK:2107"[<*26YZXZX[XQ7 77
MB#6)O^%=:G?:;,U[+))MABF5C=%K7Y7.,*H+-D@_=&37H'C&UGOO!.O6EM$T
ML\VGSQQQJ,EF,;  >Y-<-I4[:J_PVDMK2]"Z>9+>[\ZUDC\IUM-ISN XR<9Z
M$]#0!T5MX^6"/75U_2Y-+N=&A2XFB699Q)&X.THP R25(Q@<XJSI7BN^GUFU
MTS6M"DTF:]A>:S)N%F$FS!9&P!M< @XY'7GBN4\7>']1UK6_&L%K:RL;C1[0
M0'!59721W**W3/ 'XBK?A:T\.7GB:PN=-TWQ$]S:Q22//J,MULM'9=I0B8X9
MB&(^7/3- &A\5;N:T\-6!CU&XT])=5M89KBWN#"RQ,V'^<$8&*IZ?I?A5M1M
MA:_$/5+J?S5,<'_"2&3S&SPNW=\V?3O5OXK0--X:TYA9S7<46K6LLT4,)E)C
M5\M\H!R,56M?$W@R*[B>W\*WT,P<;)%\/R*5.>#G9Q]: (M"E<_'#QFC,QC6
MQM2%SP/D%1>'/&VD:1\,M'U;3-$N8;"[O_LD=F+@S2(S2,"0S9+<CI[XJSHM
ME=Q_&?QA=O:S+;36-LL<S1D(Y"#(#="1[5R?AK2=2B^$G@NUET^[2XA\1P2R
MQ-"P9$%PQ+,,9 QSDT =NOCO5QKDF@S>$YDUAH!<VT"WJ-')#D@LTF,)@C&,
M'DC%9?B7QGI>I?"_4M3UK0KAX[2]^QWFG"Z*,DR2!2!(F,@$@Y'6MUK6X_X7
M+'=^1+]F'A]H_.V'9O\ M"G;NZ9QSBO/O%6DZE-\+_'%O%I]V\\_B666*)86
M+2)YD9W*,9(X/(H ]'U;Q?<V7B@>'=.T674+]K%;U,3K&@4NR'<Q'R@8'/))
M8#'>H;/QQ+>^')[Z'0;Q]2@OSITNG1L&*3A@#F0<! ""7/&*([6X'QADNC!)
M]G_X1](_.V'9O^T,=N>F<<XKC[B+4;*PUCS8]3M]-G\7RO?O:)()3:&,?,NP
M;MA8*"5YQF@#HM3\<ZK%X9\3,-%-IK>CV_FR0&Y61%1T9EE5\88#:?EP#\N*
MEL?&6JQ^'=!6XT5[C7-4C'D6RW* 2JL:L\S/C"+STP3D@8KD(=/!'CRTTO2-
M4A@U71%.FBY29VN-B3*W,F2I+,,*Q!((..:ENH[35M-\&:Q<VNL_V;IML]A?
M_9XKB":!S''AL( [(&3:2N1SWQ0!V$GQ!BMM"N[JZTN>/5;:]33VTP2*SO</
MMV*K]"K!@0WIGCC%94>JZE>_%G0+?4]+?3;B/3KMC$)Q-&ZDQX(8 9(P000"
M/QK)O=(M1X>CUS0-%U@Q6>O6M_*+II9+B\BB&TR*DA+X 8X!P2%SCI6Q#JA\
M1?%/0]0L;"^_LR#3[J/[7/:R0JTA*$KAP#Q@<D8)SC.#0!I?$AKAK+0+6WOK
MRS6\UNWMI9+.=H9#&P?(W*<^GY5GRV=SX0\:^'+6QU[5KZ'5)98;BRU"[-Q\
MBQEA(I;E=I SV.:O?$K21K5EX>LI+22ZMVURV^T(BL<1X<,21R!SUK8T7P7X
M<\.W3W6DZ3!;W+KL,O+/M] S$D#Z4 91\<7L-[;R7?ANZMM'N+X6,=[+,%DW
ME]BL82,A"W .<X(.*UM \31:U+K%O+;FTN=*NVMIXW<'@ %9 >/E8'(KR.6-
M[K0]/O+RPU^\\26>I07.KR2K<E+=4G!;8GW&&,;0@/RY/:M_X@PZAIWB-)]$
M5O\ BKK0:3+@;?+ER-LI!YXB:0>VV@#<A^)ANK?0Y+70;F9];>Y6RC$R@L(L
M88Y&%##)]@,\]*6W\?ZO=RZE86_A&=]7TMA]LM3>H(T0J&0K)CYBP)P,=CG'
M&7ZCH_V#QMX!M[&UD^PZ?#>0[E0E8E\A57<>@SCOUJ?P_:W$7CWQS/)!*D4[
MV?E2,A"R8MP#M/?!XXH </'J7NEZ%/HNF2W][K,+306K2K$(T4#>SN<@ $@<
M Y)XJ*X^(L-IH2W]SI5REU'J::9=62N&>*5B/ND<.,%2,8SD=*X/3=!^R>'_
M  3J.MV>K1V$%A<6EW]C\^.6V=G#(S+%A]IVD'C'(S6S/I-HV@:;<:)I&K0Q
M3>)[.9VO3+)+,B.H\XAR65<#^+' S0!U-KXQU1]9N-&OO#;VFH_8FO+.+[8C
MK<*K!2I8#"-DCU'O6%X4^(&LS^!=.U+4=):ZO=0NOLUCMN$47+L\AP> (PJI
MC)SG%;M_:W#_ !9TFY6"0VZZ1<HTH0[%8R1X!/0$X/'M7%>&9M.3X66&@>(=
M U2<6%RT=\JVDRO:,9)6252HRV..4)(W<T >GZ%JM[J<-P-1TB?3+JWE\MXW
M<2(XP"&1P,,.?P((-:%W)-#9S26T'VB=$+1P[PF]L<+N/ SZUY_X=UZ3P_H&
MN:C.VMZCH%K<1#3Y+N)C<LC!0_\ K-K%%8\%NP/7%>C4 >)R>+-:UGX9Z9K&
MK6DB@:Y;O'-%(K-.HNF!0(H&-H4+S]ZO0-/\8W1\0MH^N:*^DR/:/>02&Y29
M7C0@.&VCY6&0<<CWKSW1TN6^&^C:"=/OUU+3->@:ZB>TD 53=LVX,1AAMY)!
M..]=EXJTJYU3QYIT444@BET:_MVG"'8C/L R>@[_ )4 6-.\>3W<NEW%UH,]
MGH^K2B*QO7G5F8L"8]\8Y0.!QR>HSC-=#X@UNW\.Z)<:G<I)(D6T+%$,O([,
M%5%]RQ _&O,?"VE:&P\/Z=<Z/XDDUNT>+[3#-/=""UDB&?-)9O**;E&T+G((
MP*[3XD:3<:QX,GBM8)KB6">"Y\B!BLDBQR*S*I!!#;0<8YSC% #['Q7J4M]<
M:7?^'VLM5%HUW:V_VM9$N5! *AP/E8$J""/X@<D57C^(=I=Z9H\MA92W&I:G
M<&W73RVR2%T_UWF''RB/N<>GK61X>_X1F#5I]8TS3O$4PL+)V:\O&NGVDD9A
M1)3EG.W/RC' YYK+TO3=9T#7HOB!=Z<S'693'J%A#!NDLH7VB)P ,EAM7S/7
M/3B@#K-2\;WD6H:G#H_AVXU6VTHA;Z>.X2,J^T,4C4\R,%()'')Q4$VM:/=?
M$CP['_9L[WUYILEQ;7;2NGE1D$E6BZ$GW&16;9ZS)X&U3Q3:7FEZC<RWVH/J
M&G&VM9)5NO,11Y8900K!EP=V.#FENK?4[KXQ>$]2N-.EA TB7[1L!>.&0@DH
M7QC.3CMF@#:TGQG?:M<6T\/ANY.BW4[00WZ3*[<%EWO$!E4)4\Y..,XJN?B#
M)@ZB-#F/AP7?V4ZGYZYSO\OS/*Z^7OXSG/?%<Y:-;Q^)M/D\-66NZ5JDVH#^
MU-+>*7[((B3YKMN'ECCE60\DCCFLO2?#VBVFG)X<UC2O$=UJZ730M;0SW2V\
ML9E)68,&$03:0QY'(/&: /6_$-_=:5X>O[^SMA<W%O"TBQ%PF<=3D^@R??&*
MY/P[XNU^7P%HM_=:%<7^IWHBCB$<JA9LIN,TC 8B7@\$=<#O77Z[!)=>'M2M
MX4+RRVLJ(H[L4( KRFSU)I?!7@ZQNH];MM)LP+;65@MKB*176'Y%.P!RA;J5
MXZ T =J/'%R-"U>\ET&<7^CS".^L$G5V5-JOO1@,.-C!L<'@U=A\86E_K^G:
M7I,7V\7-K]LFN(WPEO"?N,W')8\!>O!-<1X?U)_"\GBU[+P_JOF74L$NF6<T
M4SM.&C5%+.V<?,,D,<J,^F*N^"M!O_AYKB:;<Q?:[/6U$TEW;P<6]VH^:,[1
MQ$1]S/ (([T >G4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MUS4M8^(WAZ]M+N6+04U&6PACC<A;QUAD,DAQ]Y0RA5Z\JQ[T >I45YM#I?\
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M3*G;CU&><#'>F0_$+.B7<UQI$L6LVU^NFG3%F5B]PV-@63 &T@[MQ' !XXH
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M$D3;E4C+ A3C'7%=M;3R:U\1M$UFWL;^.Q.DW,9>XM7BV-YL>%8,!@G!(SU
MR*[NB@#D?"EG<V_BWQE-/;S117%]"T+NA59%$" E2>HR".*BELKH_&BVOA:S
M&T70'B-QY9\L/YZG;NZ9QSCK79T4 >1:EHFF:9XF\1MK>AZ[?/?7/VJP?3FN
M=DX:-08SY3!58,IY;'!'.*NZ]IVAVRV%G>>'==T^6TL(TT^^T@332Q\',&^/
M/*D#&_(.<UZA10!Y'8ZMJ>C^/-"N]>M+J>\/A8+?FWA,LD3&8$L40$GD ':#
M@G/055OM O==L=6\12Z3J!M9M?M[Y;$*\5S+:Q1^4S*H(8,0S,!P3CWKU Z#
M"?%H\0^=)YXL38^5QMVF0/N]<Y&*UJ /))_"^E^(/#WB6'PUH>J6\\M@((;S
M49)U\]MV_P I4F.0,JOS8 R?K76:/XQN]:U+3[*U\/ZE IC9M1EO;=X%M2%X
M52PQ(Q;CCC'-=?10!P/PH>:S\,OH5Y8WMK>V-Q.9?/MG1&#S.RE'(PW!'0T:
MF\VF?&6QU*:QO9;*ZT;[ D]O;/*JS&<-ARH.T8YR>*[QW2-"[LJJ.I8X IU
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M:V>.6Z?+NQ6,C=C) &1SVK>\1V%Y-IO@5(K2>1K;5K22<)&28E$,@+-_= )
M)/K7=T4 >7Z>+JSO_B#I,VFZ@)[^6>ZM9%M7:*5#  ,.!MSD8QG.:I^'](U*
M'PK\,X9=.NTEM+UFN4:!@81Y<HRXQ\HY'7U%>N4UY(XRH=U4L<*"<9/H* /-
M?%_A[4=;\3^)H+6VEVW7AA;>"4J1&\HED8)NZ9Z<>]4->\0SZQ;>"K?^QM2L
MS#K=E]J:]MFA$<@R-B[OOGJ<KD8'7D5ZM<V\=W:36TP)BF1HW"L5.",'!'(^
MM<K8> DMKW3IK[7M5U.WTQM]C;7;1[(F *AF*J"[ $X+'B@#AW\/Z5IUUKMA
MK'AO7=1O[F_GEM5M)+D07<4K;E!9&$:8W$-NQTSS7::%ILUE\2-;D6TEBLO[
M,LH89"K;#L\P%0QZD#&:[.B@#QFZTW4K3PE:7+Z7?/\ 8O&;7\L4=NS2>0)G
M.]4QEA@@\=J]@L[E+VSANHTE1)D#JLL91P",\J>0?8U-10 4444 %%%-9T3&
M]U7<=HR<9/I0 ZBFHZ2+N1E9?53D4*Z,S*KJ64X8 ]/K0 ZBFNZ1@%W503@9
M.,GTIU !135=&9E5U++]X \CZTZ@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MLSQ'JW]@^&M3U;8'-G:R3A#_ !%5) _$UIU0UO2XM;T*_P!*F8K'>6[P,P'*
MAE(S^&: .(T/X>66MZ#:ZKXDN]0OM9O85N)+D7LL?D,XW!8U5@JA<X'';\*T
MIM1U3P7H.EZ3-<-X@UF\NC:V32GRBZ\L#*W/W4'+ 9/IWK.T3Q3KGAS1;?1-
M:\)ZU=:C91BW2?3X!-!<JHPKA\C;D 9W8Q^E)J=KXHD@\->)M2TY9[_3;Z6:
M?3['YGCMY49-HYQ(Z C.,9YQ[@&E'XRU&QN-7TW6],MX-3L=-?4H?LUP9(;F
M)<@X)4%2& !!'?-9C?$77(+'0]6G\-1_V9K+1P6RQ7>;CS9$)3*E0H5B, YX
M!!..E17EKJ/BC6M<UV'2KZUM(O#\^G6T=W"8Y;B5R6)"'D 84<XR3Q4U[H^H
MOX,^'MLME.9[&^TY[J,(<PJD9#EAV /6@#0A\9ZK:7VMZ=K>DVL%]8:8=3A%
MK<F2.:+YA@DJ""&7'3_Z].#X@:RNGZ-KE_H$%OH.I/#%YBW9:>$RX"NR;0-A
M)'0YP0?:F>*K"['BSQ#J/V>3[$?",L GV_)Y@DD;;GUP0<5B13ZEXE^'WA?P
MQ%H>HQS.MBT]T\.+=((]C^8).A)"C"]<G% '4:AXUU:-]8O-+T6"[T?19&BN
MY7NBDTC( TGE)M(.T'N1D@@5+=>,M2NO$K:'H&EV]W(VGQ7\=S<7!BB".6'S
M84GLN .N3TQ7(W7AC3].U?7XM3\%ZAK5Y>7TMU936^_R9EEP0CN&VQ[6+ EA
MTYYKKM(TB>Q^(]U.EDT&GKHEK;1,,E R._R!CUP"* *L/Q!O+K1K+R=)A36K
MG4Y=*:VFN=L,<T88N3(%)(PO  R20*U6UWQ''HI9_#6=7^UBU6%+C,!!P?.\
MS;D1@=?ESD8QWKE8=-:VT/6+;7/"EUJFG7?B*\FDCCC+2QQLQ,<R(/F8$\94
M@@'/-9[:9JHT2&.73]>G\+KK._\ L^7>]W]D\G #+G>8Q-SM)SC&: -O7?&6
MOQ>$/%<?V"UM-;T>(>:T5RS1B.2,LLL;; 2PY^4@<CK4>HZY+#9>!F\0Z'9W
M=[>ZA#'#(MRS^0Q Q,"5&6[X_6L2/P_>?8/'EAIOABYTZ#5M-CDT^'RL!MBN
MI5CG"R$D';G.#[&KVKP:EK]I\/9[;1=3A_L_58/M27%L4:)450SD=E]_:@#I
M[GQ3KE]K>IV'AO1[2[CTIECN9KN[,(DE*AO+C 1N0",DX&350_$:2[M?#,FD
MZ0US+KHG1(99O+,,D0^8,<'@$-D^B\ ]*AM+F]\%^(?$B3:)JE_:ZE=_;[2:
MPM_.#,R*K1MC[A!7@GC!ZUG^'_"VKZ3=> 5NK1_,MGU&>],?S) TRLP4D<=6
MV^Y% '6>&?$=_J>JZOHVKV$%IJ.F&)G^S3&6*5) 2K*2H/\ "0016%XWLK'5
M/B!X8T_5)I4L9+6]=U2Z> ,R^5MR58'N>]:^C6%W#\2?%%[+;R):W%M9+#*5
M^5RHDW 'OC(S]:J>*?#<.O\ C[PVU_I27VF06MX)O.B#QHY\O9G/&3@X^E &
M;HDD'A[QWJ6F:#=7>HZ3'I!O)K07+7)BN ^%5&8D@NN[Y<]@:U;+Q5XA75;*
MPUC0K2TEU.WEEL1%=LY61%#&*7*#:<'J,C@U<UG0%TKP1K-GX1L+>PO9;:3R
M5M(UB+2;3@@C'S>AKB-*TJWM?%_A?5=(\(:G8V<#26]Y<7%NPG:22/:"P)+%
M5/5SQEJ .NMO'UO+\-I_%TUL86MX9/.M"_*3(2OE9QU+8'3N*K_\)CX@N=<&
MA66@6W]IC38;Z0W%V4BA+DAD8A"200 ,#G)Z8KFKW1+D_%&7PK$H.B:A=1>(
M;A0?N[,AT(]'E6,_G78V5A=I\5M5U!K>06<FE6\23%?E9Q(Y*@^H!'YT 8 ^
M)>MR>%I?$D?AJ%;"P=HM022\Q+N5]K^4 N& ZY)&>1CC-=!J'B;5I];GTKPW
MI=K?26EO'<74EU<F%1OR4C7"MEB%)R< <>M<O_86J_\ "FO$NF_V?<?;KBXO
M6BM]AWN&F8J0.^1S3-8\-V-IXMO-2UOPSJ.KVM_9V_D/8QN[0RQJ4:-E5@1D
M;2">.O- &[)\0IKD>&ETC2#<S:[#.T<<TWE^0\6W<KG!X!+9(_N\ YK.UKQM
MKZ^$_%\!T^UM-;T6(>:T5TS1B.2,LLL;;,EA_=('(ZU8LM#GMO$'@62UT-]-
MM+6VOC/;HYE6U:15(5G]2<_CFJNNZ!JE[/\ $M8+*5O[0L+9+0[<"=EA<$*>
MYS@?4T :%MXI\1B#1-*33-.EUF]LVNB9KYA%Y2;!G=Y>XNQ?H!QSS77Z/>75
M_I4%Q?6#V%TP(EMG</L8$CAAU!QD'T(KS^]GLM9T#1H=<\$ZU/:Q6^Q9DMG%
MS;3J%! 1<.JGLX."5Y'>NL\#0ZG!X2M(]6-S]H#2;!=MNF$6]O+$A[OLVYH
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MS#YLNT,8XP$;D C); R:X;XBZ_=^+?#/@^XL;*!M(U35+97BGN&1GEW.I@D
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M&W$I#*2 <$$=1D'([9H Z70/"MIH%Q=W@NKR_O[O:)KR]D#R,J_=48  49/
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MSTC.V4R8YR&^51QN-1WWC;64BU?6+#2;2;0=(GDAN&>=A<3"(XE>-0NW"G.
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MY0<?K5;3M!TW2] CT2VME^P)$8C$_P V]3G=NSU)R2?7)K15510J@*H&  .
M* /#KGPU?3:#*C^#KJY\2V]^+J\U29$8RHMP'_<.3EB4P HP  1UQGT3PO97
MD?C#Q9J$]I-!;WTEI);F5<%@(%#?B#P?>NNHH \@T;1=;\.Z5X*U=]'N[A],
M^W07MG H,RI,Y*NJDC."!D=<&NF\)1:K<^//$FM7VE7%A:7MO:+:K/C>0GF
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MFDBF+?.F2-V#M8#C(KVBB@#DO ^FV-FNH7&G^%3H%O-(BQB0!99U4?>=!G:
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M$$4\FGQ!GCN(MP_U9.0K!LY&<'@^M8Z>&M:DL;2_FT^2.YOO%T6JRVV0S6T
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M*;2X(8YLC#.KN2/7@$4 <P/B%XID\'W'B9-'TV.UTV1HKZ"29S)*R/MD,1'
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M.>XU73YHBBM$/LSLA4"3+^_\.>E3:-K.M6_@QO\ BE+];_3[>**.TGEC0W)
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M&EWFE>+==F;PV-(T_4H;>:V2%8PD6P,I1PAXD.0V ".3SQSW] 'EVN6'BA?
M4$&M67VKR=3C;48]*D=I+RS'WV['<S<E1_",<=*L^#X? 5YXBAOO"%XMA=V\
M3I=:=$&A,RD?\M(G /RGG<!U[UUOB6YUZRMK:ZT*SBOC%.#=6C,%>6+!!\MB
M0 P.#SUQBN7>'4/%WC#0M1_X1F[TB'3)))9[R^\M99 T;)Y2!&8D$MDDX'%
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M1O%5]I#:-:1:<;)(994>:X)<-N<(2 !C@$YH [VBBB@ HHHH **** "BBB@
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M^&[/Q?J%GI2Z%<-%)):1B3[3#!(P"OO)VL0&4D;1]: /2**X?_A)?$FH>/\
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MRS.$5><<D\#FIJ\7\7:_XFU_X2W^MSVNFQZ-?*ABMXP_VB*,RJ$=F)VL3@9
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M/# C)Y'7F@#IZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUC3ETTZ;IDUW*UM/&YEN46>1I"'# )@$@#!Y7)ZXKO\ 1_$\VK>+[K3D2/[
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MS8^?9F128]S;SOYPK?*N">*U]?\ #-WK/C*.<IC3I-$NK"68,,JTK+@;<Y/
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M:E=3QN74XB=5"OP>""N>>F* -2^U^\'C[3/#U@D+1&UDO-0=U):.,';&%P<
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M_/S-@GF@#U:BN'_M?Q/I'BW0K75[BPGL]9:6,P06[(UHZQEP Y8[QP020/7
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M* "BBB@ JGJD-W/IL\=A=K:7)7Y)VB\P+SS\N1GC(Z]ZN4UP61@.I&* /#/
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MT:Y^14V[AN! (+8'/7BJ$_@[Q(VE^+]#2SLWM=3U)]4MKEKG D)DC?R'3;D
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MC;Z5=22W.]\':RJ!@=^AH RTU3Q=K=YXHCT_5+.PATB\>*!FM!*TV(U8(V2
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M%YAPI*2*^">V=N/QH S/$.H:SH\>G6U[XNTC2XC'(T^HW,**\TFX;42)FP
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M=;=[9/<*-H(]31'XEUS5[?P;I>G75O97NK:8-0O+LVXD$2"-"0B$@99GQST
MJ>'P;J,7PHU31&,3ZWJ<-Q+<ON^5[B4DGGT&0,^@J%?#&OZ-!X/U/3;6VO+_
M $C3!I]Y://Y8D4H@)1\$95DSR.0: ,./7]2\*:K\0]1OWM)]0@_LZ&.8@QQ
M2,ZE$=AGY1\P+#/8X-:FG^/3IVJSVMUXETOQ';_V;/>B6P"*T+P@,R,$9AM9
M22">?E/6FOX(\0:POB^?4_L5M=:NUG/9JCF1(G@Y5&. 2,A03CG)P*VK72]9
MUJ.^M-5T/2]'L9[&2V802":61W&TL& 4*H&>#DG/;% '(>(Y?%-[X$T?5]4U
M"TGM]1O+&9[2.V\O[*'E1DVODEL< Y'?.>.?1?''_(@>(_\ L%W/_HIJXFX\
M/>-M1\*:3X<N+#3X8]+FM2]VMWN^U)"ZXVKM&W@;CD]1C'/'H'B:PGU7PIK&
MG6P4W%W8S01;C@;F0J,GL,F@#@+'5?%'AWPYX6UB[OK272[HVEK-IZVVTP1R
M *K"3.6897/&#DXQ6_HGBZ>"W\4P^('C%UH$\CR,B[=]L5WQ/CU*Y'U%97_"
M/>*]3TOP]X<U*SLHK#39K:6YOX[G<9UAP518]N0Q(&3G'!Q5/Q_H9U3XAZ-8
M64ZK_;-N8-6A'4VL,BR!SCIGYDR>N[% '<>#;O5=0\):=?:UL%_=1>>Z(FT(
M&.57'J%(S[YKA_!T]U;>(?B?/9+ UU'>AHA</LCW!&QN/9?6O5  H    X %
M>8R^ =9FM/B!"&MT.N7"2V>9#AE7DJ^!P#T/L: &:?XOU>;5IM'LO$^DZ]=7
M.F7$\,EI"H%M<1[=JG:Q#(V[OS\M+K?Q%U-/!WAK5-)2)[F\MVO[Y63<%@A0
M&< =CN( -:=OI7B6?Q=H>MS:/86-I:136C6,5R&:)'V?O-P4 \KC:.@ YYX@
M\,^ ;RPUW7!J7DMI#036FFQHV2L,\KRR CMR5'X4 ;R:]=7OQ"CTBS>,Z=!I
MGVRY<+DL\C[8U![<*S?E73UP7@+PQKWAS1=4GU,VTVMSI'%#AR4:.&$1Q!C[
MD,3_ +U=IIS7KZ9:MJ,<4=\8E-PD))19,?,%)[9SB@"S1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %33-,LM'L$LM/
M@6"V1F98U)(!9BS=?4DG\:MT44 %%%% !1110 4444 %%%% !65IOAO1](O[
MN_L+"*&[O&+3S\EWR<XR22!GG XK5HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M T32K'47U&UF@OITA@:.X3#@N%9P<X*IG+'M5A=8>Y\2V,-IJVCR:=<V9G6
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M9ZT 6**I2ZSI<#7BRZC:1FR56N@TRCR PRI?GY<CD9HTO6-,UNU-UI=_;7L
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M/I]CK6GW-XF<P0W*,_'7@'/%61K.F-I;:H-1M#IZ@EKH3+Y0P<'+9QP01]:
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MH!M-7M3IX\G5Y#+?+YK_ +YSU/7C\,4 <SX@TVSTS7?A_P#8K:* QWS0JR*
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M[P2O'7D*Q_ UY3XLO+R[\"^)]2LX-'T_2'U&12KH[W,\R3!#)NW *Q9<@8.
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA<DD]?<FKE% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M HHHH **** "BBH+N]M;")9;RXB@C9UC5I7"@LQPHY[DG H GHHJK8:G8ZK
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M3Q#HM_?ZEX3FMH0Z:??B:Y.\#8GE.N>3SR1TJ_XN\.Q^*O#%[I#S&!IE#13
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MNI+2:>RODLWN+,YAGVS1$.O)P"&'&3SFKNG>$=<TG2_"+W?A^/5O[-CO(Y[
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M;P<%R22 IPV%],<U!%I>M^(/%+:[J.E'3(;339K2TMI)TDDDDD(+.2A*JN%
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MU8Z0D>PB)IC,%4XSG'ED-UH ]%HKA8?&E[J-GX)^PI"+K7'WW2NI(CCCC+3
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M&;:2)0VW)8[U()&< Y[#I6IXRU^ZT'2[3^SX8I=1U"]BL;039\M9)"?F;'.
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M4D,"""1P:S=0\'Z_J^A^)KZ>TBAU76KRSD2S68,(88'3 9^A; 8G''I7J%%
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M-/E:-TDN@1?0LTA.WC$9!*'#9SSTK=\#Z#=:.VKW,^GV^E17]RLT6FVT@=(
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MX94O<29P6MS&-OK\QH JS>,]9\,1>++;69[;49M(M[>XM;A8O($GG$JJN,D
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MXEIKNU/L(T=K,G=\WF&8/T],#K0 OC#4+[3[.U:UU33=)@DFVW-_?E<0KM)
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MN-4:^V#SA."TBL'ZC& !@]!74?V?XC\2>)]#OM6TFWTFTTB22<A;L3O/(R%
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M<8XY +_BB_2.Y\%>-+-3&UQ<P6DP_OVURO1O7:VUA[YJWIG_ !//B[K=S/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHA'(]ZUM&US3/$.GK?Z5=QW5L6*[TR,,.H(/(/L1F@#0HHHH **** "BBB@
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MW;Z=H4,GGN[A3YK-&#A!R #@$^O2NFLO"+VGA_Q'IAO%8ZQ<WDXD\O'E>?G
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MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JO>7MKI\
MGNYTAB+I&&<X&YF"J/J20/QJQ7G?Q>LEN]$T9C<747_$WM8B(9VC!#R#D@'D
MC (/8]* .Q37;63Q/-H 27[5%:)>,Y V;&=E !SG.5/:M.O,9/#PO?BO-IIU
M/48K6'P_ ':*Z=9IL32 ;I<[L=2<')..<9!QV\0ZG:>'H]$DO]6G4>);G3&N
M;;=+>-;1!GV@CYBYP!N'(&: /9J*X3P)=7HUG5K%8->&CK'%-:/K$4HD1SN$
MB!Y/F8<*1DG&32>(X[W4OB7I.CIJE[:6$^F7$MQ':S&,R;73&"/NG)^\.<9&
M>: .\I"0 23@#J:\K@OIM+TCQAH]SXCU"WMK#488+6\;=<W0258V\I#]YF))
M53R1NSVJ"QFEEN_$VAQ3>([?3SHRWD::G/(+B.0,X)1RQ8(VT9&>H- 'JME>
MVVHV4-Y9S)/;3('CE0Y5E/0BIZ\>\.K/H_@WX<&TU"_"ZA?P>>CW+LI4P2'8
M 3PF0#MZ<5T6OZC?0^.=:MHKR=((_"KW"1K(0JR^;(-X'9L <]>* ._HKQV*
MYU72?A5I^OOK6KW6JZS'9VS.)&E\E9&49BC_ .>FW//)+'-;O@^ZNH?%[6=G
M!XF.C363/(VM13?NKA67&UY.?F5FR,]5H ]%I&944LQ 4#))["N,\9W%W=^)
M/#/AN"]N+*WU.2XENIK60QRLD*!MBL.5R6&2.<"LE;.:T\3:YX0;5=4ETV72
M4U&!WO',T#"1D9%ESNVG:#@GU'>@#I_"OC*S\7Q27.G6&HI8C/E7EQ"$BGPQ
M4[/F)/(/4"NCKS3X'Z9';_#?2]0%S>.]PDH,4EPS1)B9Q\B$X7ISCK5^]AG\
M5_$'4]'GU+4+/3]*LX'6.QN6@:264N=S,N"0 H '3- '>4V2-)HVCE171AAE
M89!'N*\ZO+?67UOPUX-OM>NY(VM[BZO+RV8P37*(0(T+*<C[PW$$9QVS6-K^
MH:GX<TWQWHEMJM_)%96$%[8SRW#//!O)#+YA.XC*Y&3D9- 'KD$$-M$(H(HX
MHQT2-0H'X"I*\LU32M2T_P 4>%8(/$FKAM;\Z+4"UR65@L7F$QJ>(CP0"H&
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M$DZK=7".\41ZNJ8W$?3</SJS0!@>"O#7_"'^$;#0?M?VO[(''G>7Y>[<[/\
M=R<?>QU[54UCPMJ,OB$Z[H&L1Z;?2VPM;E9K7SXY44DJ<;E(9<GG/0XKJJ*
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M7#D#YAM.1UY_Q9;^"_(\&:UX>^W[O[3:[;S_ "<>7YY8_=W<[=WJ,X[5U=%
M'%CP5J5GJ0N=)UX6:3V,%E>@V@=W$0(5XSN^1L,1R&'?FJ*_#>^MM"T:QLM>
MCCN-%OGN;"9[/<!&V[]VZ[_F/S'Y@1].]=W-=PV\L,4C_O)VVQH 23CJ>.P[
MGI2P7<-TTJPOO\IS&[ '&X=0#T..AQT/'6@!DMM)/ICVLLH,DD)C>0)@$D8)
MQG\<9KD=)\$:IX>\):-I&D>(O)N=,:7][):[H;A79F*O'O[9&"&XQ[UT5]KU
MO8>(-)T>2*5IM3$QB=<;5\I0QW<YYSQBI=)U*;4X;AYM-NK$Q3M"JW( ,@&,
M.N"?E.>/I0!4\,Z#+H=O>M=7@O+Z_NFN[F98O*4N55<*N3@!44=2>]&F^'O[
M.\4Z[K7VKS/[5%N/)\O'E>4A7KGG.<]!CWK;HH XH?#_ !\,XO!W]I_ZME;[
M7Y'7$_F_<W?AU]_:EO?!%]/J6LBVUS[-I.M,'O+9;8&7=Y8C8))N^4,%&?E)
MZX(ZUVE% '!P> ]7T_\ L:\T_P 001:KI]A_9LDSV.Z*XMP04!3?D,N <AN3
MG@9Q2V_PW,6E:K;RZW-+>WNHIJ<5[Y(#07"A<-MS@C<IXXX./>M[7?%-IH.K
M:)IUQ!-))J]P;>%H\81@ <MD].>U7;;4II]9O+!M-NX8K=4*7;@>5-N&2$YS
MD=#D"@"GH>EZU:W=Q=ZUK:W\DB+''#!;^1#$ 2<A2S$L<\DGMBHO$?AN;5K[
M3=4TZ_%AJNG,_D3/#YJ,CC#HZ9&0<#H0015'2?'T6O1:E<:5H>JW-I9"14N
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M>BZEC099[<@K*%'J%.?^ U+J&A76KZY9>*_#>N06LLMC]F9I+;[1%- 6WJ0
MRX())SGO77UD6.M6MQXAU'088'CET^&&5VP A$F[ 7'IM.: .;M_ART&ER6;
MZS),\FNIK3SR0#<S*4)0@-CDJ>1C&>G%;NH>&8]1\46FL33CRH+*>S>V*9\P
M2E<G=GC&WICO6]7)Z;X[AUF[U6+2]&U.ZM]-:6)[I401RS1C)C3+;B3T'&*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q?%WB&'PMX5U#69L'[-$3&A_CD/"+^+$"MJN?\
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ME65E/WE8'!&1VYJC9^"F)UBYUG5'U#4=5M?L4MPD(A6*'# )&F3CEB3DG)H
MX--%1/"WPSMK:\O(3>7,4LDOVAW=-UH=PC+$[!@$ +@+G(%7-6OKKP'J/BZV
MTJ[O)+:+0X[^WCNKAY_)F+O'N4N2<< D9[5T^F>!+NTL_#UO?:[]L&AW DMB
M+01YC$1C5#ACT!SN_2M'4?!MIJNMZG?WDS/#J&EC39;<+C"[F;<&]?F].,4
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M@LMJ99?WC0C^ G<Q^I]A7H]8_B?P_!XGT&?2YII("[+)%/']Z*1&#*P^A H
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MDG'7J#R.11JFH7O@B7QM9:5>7CP0:=;7-HMQ.\[6\LK-&2I<D^C8)ZBNRL/
MT=A;^$XA?N__  CP?:3%CS]T9CYY^7[V>]3:CX*L]5U36[J\G=X=6L([*2%5
MP4"%B&#>N6].,4 <?I-U=Z-KUK-I>F^*EL3:7']HG6/,:-W6/>D@+,=K%E*G
M& =W2L36=&EN/@HOB:XU74)M3O4M[FZ:2Z=HI1),AV>63L4+D8P 1M^M>F:3
MX<UB"\276?$LVIP10M#';K;B!&#8!:7!/F-@>P&3QS7/3?"^]G\.'PV_BF?^
MQ(F#6MO]D7>@#[E5WSEU'88';TQ0!Z'.2+>0@X(4_P J\1T+4M8O_A'X+?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGGC).23DFIM3NKC7=9\422:;XGNKVTNWM--GTR0K#:%$7!P)%RQ8[FR#P0*
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MR2ED9E+DD=CUZBM/6?#J^%=:\&KINI:B(KC54BNXYKR207#>6Y#G<3@\'(&
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M,-U#)CS<KYI^7#94;01M'2N]L?!#1^(K77M4UN[U._@@DMR98XTC:-\<;%
MQ@GU.>>@PW2_ \NESV<*>(M2?2+&3S+73OD4)UVJT@&]T&>%)],YQ0!4O/\
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M+;G&QHV?<3ZY[51T;P?=:7=V37'B34KZSL%*6EK($15&W:-[* 9"%X&[Z]:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS=795&7R 8BBH^0-K,QQM//!H V[7X@6MS?6B-I&I0:=>W)M+7494012RY(
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M/&=O!/9VVF:=>ZO=75J+Q8;0(-L!Z.Q=E ST SDX-<SH\;#P%\0AL(+:EJY
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M',\4921"=IRP."!Z,: .YNOB%I4,6B/;6U[?'6HI)+)+:,%F*!<H02,'YN_
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MA5PH/S$^W?% 'H-<3JO@S7-334=./BR4:+J$C&6"2U#SI&WWHDE+<*>0,J2
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65XFTC
M^W_"^J:2'"->6LD*L>BLRD _GBM6B@#SK0OB1I.D:%::9XF^TZ7K-G"L$UK)
M;2,9&4;=T952'#8R,'O64_AW4M<\(>--=GLYK.^U>5+RQMY5Q+&MLH,.X?PL
MVSIVS7K5% 'C*7,USX<E^(S6LPE&NQWBQA#YGV1 +8J!U^Z7:K-GIEQ:Z#\/
MYKF)OME[KG]HW7R\AYHY7.?3&X#\*]=HH \M\:Z3=ZQXQ\16=G&S37'A'RXL
M#[S^>Y"Y]3T_&F^&1X<U;7=$^SZMXDU&_MLSF"YE9H[%Q&5/FA@-I^8J!U)/
MIS7JE% 'FO@=(8/A=J_V[3I[N W5\9K2*/+S(9&R "1DD5DV-]"/[1TWPUKF
MH:SH3Z/=-/#=AG^PN% C59&4-SEAL))&VO8** /+M1AD_P"%2^!T$;;EFTC<
MH7D8,><U7\J1?B5\2I"C!&T>(*Q'!_<=C7K-5=2M/[0TN[LM_E_:(7BWXSMW
M*1G'?K0!XZVMV>N_"7P[X2LA*=;N8["(6OE,&14:-S*>,;-J[MW3FO2?'NEW
M6M> M;TZR4O<SVCB)!U=AR%_'&/QK2T#2_[$\.Z9I/G>=]BM8K;S=NW?L4+G
M&3C..F:T: /+-6\0V'C*S\,Z/HWFR:@NHVEQ=0>2RM9)$=SF3(PI&-H'<GBM
MKP%$R>(O&[,A7?K!()&,CRTKN:* .0^(VDW^I>'K:ZTJ#[1?Z5?P:E#;YP9C
M&>4'N5)JC+\5]#FL"NEPWUYK3+MBTH6DBS>9_=?*X4 ]3G&,]:[VB@#SF?4O
M^$:^(@UOQ$@LK74M&BA,XS)%#<(Y9HBX'&0V03C.#7.W4,U_8:AK<=O,MGJ?
MBNQEM0\94R1(T:>9M(R Q!//:O:** .,U5'/Q;\..%8H--O 6QP/FBKS>WNH
M9_@8-" <ZEI^I1K=VIC8-'NO2PSD>E>]T4 </XX8Z9XH\)^([A)#INGS7,5W
M(B%O)$T6U7('.T$8)[9K'DNH_$OB?Q)K^E[YM+@\.M8+<A"$GE+/(0F1\P48
M&1W->H44 <9\)D>/X6Z DBLK"!LJPP1\[5@I?06'Q&\?6-TS17&IVEL]DA1O
MWX2V<.5.,<$5ZC10!Y1>PR?\*-\+QB)MZG3,KMY&)(\\5F^*KQ]4C\8V.H:A
MK+:PC30Z?I%I))'&T'E@K(548=3EBQ8GICT!]IHH \HM=:L+7XA>%M4FF*6-
MYX>^R03^6Q5YO-3Y.G!X[UT_Q*M;F?PO#=6T$EP=/O[:^DAB7<SQQR!F '<X
MR<>U=A10!Y[K/B.W\>:'KNA>&XY;Q9-+E)O I2-92,+#\P&6//T[UD:GK]EX
ML\->'_#NE"9M6-U9FYMC"ZM9+$RM(TF1\NW:1[YXS7K-% 'EEEKMIX>U'QOI
M%\)AJ5Y?R7-G;+"S-<I)"@79@8/(()Z#OBL18)O[.^#H\I_W<B[_ )3\OR+U
M]*]NHH \LTS7;3PO=>,=%U))AJ5WJ=Q>65NL+,;M)479L(&#R-I],<XKI_AD
MC1_#3P\CJ586: @C!%=910!YWX-L);JP^(%JJF.2ZUR]1&88^]&@!^F37-^%
M[;0KFV\-Z3=ZGXEGUBUD@\W2C*Q2TEAP=SJ0 L8*\'/0C&:]HHH \'\27[:K
MX=UP7^HZU<>((KR3S-+B>18+:".;(9D4!2GEJ"&.<DBMOQ1J^BQZAJ.K:)J^
MJ:3XB:))+>&*-GBU;]V#$1'@JX((3(P1@YZ5Z[10!YK8:W;^$?&WB*X\2L;!
M-6CM;JWF9&9'*Q!'C# 'YE8=.I!K&TJPNXQX4O)[6:$7_B>[OTAD0AHXY$E*
M;AVXP?QKV.B@#S'Q5<:II_C7Q-?Z3$[7L7A>,P%4W?.)I.@[D#G%9>G7FE#Q
M[X4OK#5]7U2T(GMY;^]FDDB\^2,;$4,,*QP<@  <"O8J* /"].\06<?P1E\,
M-#.-;NX[BWMK+R6WSF25]K)Q@CYN3VP:Z6&RFM/CIHT;JS"'PN(FD ."PE8=
M:]/I&#%&"G:Q'!QG!H \;O\ 2[F/QG=?#Y(6.DZOJ$>L[@/E6V&6GC]LRH@
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MEI&H:QJC+!';O?WLIDB<99MD;$ DJ>3V&ZNZHH **** "BBB@ HHHH ****
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M!+-$?M/E@$H<,=C8(X/YU!\.?$^K^)],O+G4]/>%%NYUBF+QD%1(P$>%.<J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[%R$?<H!D\N,CY]@/.2,D$#.*L7OC"[EU[^R?#VD+JLD=JEW<2O="!(T?.P
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M=G'.*W=2\<7MO/JTNG: ]_I>CN4OKH7(C;<JAG$:$'?M!&<E>>!6-?:;?O\
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MUFTNYTMXS(XC1CN(4<G&>U.T037GQ*U/5EM+J.RN=(M1%)/ T>3OD)7Y@,,
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M=J[,R+OV2*%^0E?0MZ5S6F>*]3U/P5XQO/$FCI<:=:37B&-;S!*H<&#Y5!
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MG!],TZF12":%)55E#J& =2I&?4'D'VI] !1110 4444 %%%% !1110 4444
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M:_8^!_$7B/5M-@N(K*]F$:K>'/\ K@GE?ZOA5!X;G..@KHKGQIJEEID%Q<Z
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M8Z'/H\-Q</*(+F1FE<<*)&#$E20H^4GBMZRLK?3K"WL;2(16UO&L448Z*JC
M'Y"IZ . @TR^7X[7FIFSG%@V@B%;DQGRS)YJG;NZ9QSBL4Z)JG_#.O\ 9/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<6EFD,I'RNR^9N /MD?G0!GVWC^[U#0-*>STJ,ZYJ-W+9+9RSXCBDB+>8S.
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M<W+3R*.(PT#*"?3)(% &2_CS7)]&O?$VGZ':3^';1Y?F>Z9;F>*-BKRHNW:
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M@%V?#ZR:?I=LS87S$0/,?9F)5<^@Q5O7/B3'I?AOP]J]O9"Y7556>1/,QY,
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M[0H+?0WOUL@SW#?:@&D\M92FW;M+$'&[.#FJ5Q9W6A?$G0[^'1+M]-_L7^S
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M+2F-U7>8Y 5'S;03D9&5(K&\6>%M1U_Q+XDB@@98KSPXEM!.PPC3"61@N?\
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MY,61D>8?E3/MN(JCIGA"6T\$VFBQ:C<6<\F)=0NX2/.G=N93O/(+$XW=0.E
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M!))PN ,=3D\8-*+X@:E<Z/8(EC8P:S<ZI-I<@N)V%M%+$&+'<!D@A?E'4DT
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MN+VYAMH00#)-($4$].3Q4] 'GD]AJ6J?%?PUX@32[N"PCTV9)C.JJT+MNPK
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M):.(7BO-0U2"X>!B"T440\R0G''R\#TR: .J\37%]9^&-2N=-:%;N&W>2,S
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M7VX^7'7OBM>$>)/"-[XBM--\/S:FNIWLE]87,<L8B2211N6;<P*A6&<C.0:
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MT-5NH)B-DTYE$C1L>F"HV>GX4 :MGXKU>TU.YTO61I4UP=/EOK6;3V;RV\O
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M$)+/Q!%>H8-=MI8UB\A9 =SL&#MF,$%"IY]J /4**** "BBB@ HHHH ****
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M23R!%+'H,D]3Z5QLGB;Q'JWB^^T/04TR*WALK>[2[NXW? D#?*55ADG QTP
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M%EX-4\)V5S:6<&G:WHZS0&!"OEW*HKM&.<!-AX&,\=30!W-%>?ZM\0+NQO\
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M*P+[+A#G)4D$QL-W!(ZG->H1R)+&LD;JZ,,JRG((]0:R%\+:4/$AU]XI9M1
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MBBN4(^[(@&#@\@C!SWJCXBT36[+Q9;^+/#<,%W<?9OL=[I\TOE?:(@VY2C]
MX)/7@BI;";QEK6NVEQ>V*:!I5KN:6W^T)<37;$$!25!54&<]<D@?@ 8B^*O%
MFH^&;_QAIK:8NDVQFD@T^6!VDN((F8,QE##:QVL0 I'3K5R7Q3KNM>*[;2-
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MLRM(JX4@C:<D<\\9'?-9NI1^(E^)FB00W5@^J/HURLMV;=A#&OG(=PBWY)P
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MLO+N(+;ZE=QR6Y#@[U$04\#IR.]<WH'A?4]%@LM"_P"$/TB=;6<*=:F\IE>
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MKB5I)./X<?*O-+X,\):]8>&]>_MJ./\ M:[MDL80L@8&&&#RXSG/!9BQ/UH
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MI Y"CLOH*L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+A 58'^''([TFA^,;B'P5X>O-8^RB^U2*/R"]UL60F/>SNQ4;!@'@;NP&<T
M=S5 Z-8'6UUD0;;\0FW,JN1NCSG:P!PV#R,@XYQ7(3?$V.#1?$-V=+$USH90
MS1VUTKQ2(XRKI+@9'7(QD'M5G4/'&IZ5%!/>^%[B.WN;ZWM+=Q=QDN)2!N*]
M5(Z;3^8H [6HKBY@M(3-<S1PQ @%Y&"J"3@<GU) KE$\8:JVOWF@GPX1J<=N
MMW;K]M4QR0EBNYWV_(01C #=?3FJ&I>-;+4/ATNN7OA[[5 ;I;>YL9G1EBE6
M81\DCY@'P00/RH [^BN6O_%EY!XN?PY9Z))<W/V#[;'(UPL:,-X3!X) SGGD
M]..XCT_QM)J7ARQU&WT>X:\N;XV#VH;*P2JS*Q=P#A!M)W8[CCF@#K:I7VKZ
M?IDUI#>W<4$EY*(;=7.#(YZ*/>N!\5^*+S6/A_XQBM3'87VDB2WN=C>>DB&/
M/R-\I!(;J1D$=#3;W6]9\/V'@.UFN+.]?4K^&"61K7;MC91@*-QPP_O?I0!Z
M;17#_P!I^)?$FOZW;:'J%GIMEI,JVP::U,[7$VP,V?F&U1N XR>IK+@\=:]K
M47A&/38K.UN]8-Y#=^:A=(9(.&91D$@$,0,\Y SWH ],HKDO">K:Q)X@U_0-
M9N8+R;3#;R1W<,/E>8DJL0"N2 05(X-0^(]9UY/&VE>'M&EM8$OK.::2>>$R
M>3L9?F"@C=UQC(Y(/;! .SHKS&\\:^(-'TCQ)9WDEI/JNBWEE&MTD)1)H;AT
M )3)PV"PX.,XKJ]8UN[L?&GAG2H?+^S:B+KS]RY;]W&&7![<F@#HZ*\QT3Q5
MXNU'PYJWB1S9O;:<+R..RCMR7NGC+;6W9^4#"C !)P?45=TKQ!K<FA:AJ\>O
MZ-K=DFG2W"R6L/EM;SJNY4*AFRO7K@C'O0!Z#17$WWBK4;?P3X6U9/)^U:G/
MI\=QE/EQ,5WX&>.IQ67XR\7:OX?N=4NSK^@V260#VNDSE6GO4"@L2=X*DG(4
M!3T% 'I5%<-=ZWXAU/QO)H.CW5I96ITJ&^-S-;^:\99W7 7< 2<+U.!@]<BN
M3\1Z[XAU?P-&LM];07=IXB73+IXK<[9V2==C@;OE&0"5YS[4 >RU1U72++6[
M(6FH0^; )4E"[BOS(P93D$'@@4^*&^721#)>1/?^45^TB#";\<-LW=,\XS^-
M>3>%?$&O:+\/9=1:[M[Z\U#5GL[*&2 H%N)+AE+NP8DKDEL #&,9[T >R45Q
M5MJGB#0O%^DZ-K=_:ZG;:O',(9XK7R'AEC7>5(W$%2N<=\BJOQ<?44\+6OV"
M]2V1]0MHY08MY;,JE><C !&2._3B@#MAJ%H=3.FBX3[:(1.8,_-Y9.W=CTR"
M*LUYC<6WB!OBPEI::C:)?'P[']HOWM<J +A^5BW=2<=6P!GK2'Q]JMIX:EAO
MKG3H=6377T4WTR[+==HW&9E+<?)_#GKB@#T^BN+\'^*)=1UW4=#N-8T[6&MH
M8[F&^L H5T<LI5U5F 92O8\AAQ3O$NLZ]'XTT?P_HTMK"M_:SRRSSQ&3R=A7
MY@H(SP2,9ZD'M@@'57]E!J5A/97(<P3H8Y DC(2IX(W*01^!IUG:6^GV<-G:
M0I#;P((XXT& J@8 %>::GXV\0:%X<\8P7<MI<:OH!MWBNDA*)/',05)3)P1\
MP.#CI5_6/$6OZ!IMBFIZII5M?:Q>!(99HMD.GQ;"[;B6'F, , DKDD4 >A45
MY@OQ%NK'2]>@%]INMWU@ULMG=6A"Q7!N&V('"L0"K YP>1CI6U)J'BGPM#?W
MVNSV>JZ7!82W33V\/V=XI4&?+V[CN5AG!Z@CF@#M:@O;VVTZRFO;R9(+:!"\
MDKG 51U)KSK1/&]Z-8T..^\1:%JB:NWE2VEAM$EE(4+K@AV++\I4D@<D?2LC
M7M7\3>)/A7KOB-;JR72KJ&=8M.^SG>( Q0/YN[[_ !NQC&..,\ 'JG]M:;_:
M=OIOVV+[;<0^?#!GYGC_ +P'I5^N!B\07<'Q&\.Z D=N;2XT8W#N8\R!AD !
MNPXZ5C_\)3XSN?!6I>*8;S388M,FN/\ 16M2WVI(I&!RVX;/E&  #R,YYP #
ML(_A]X7BU-;]-+ E6;[0L?G2>2LN<[Q%NV!L\YVUTU<--KNNZ_XJ?2=!N[33
MX+2PAN[B:XMS.SO+DI&!N7 PI)/6K_@/7M3\0:9J<NKQ0Q75KJ<]H8X<[5"$
M#&3UYSS0!U5%>>ZIXDUN?QCJ>CZ?K&DZ=<60B-I8WT)+:AN0,2'W#"Y)7Y02
M"#FH]:\8WK^)=3TRV\1:'H7]F1Q974"K&ZF=-^WEUP@!49 SDGTH ]&HKS>+
MQIK?B"[\+0:,;2T76M-EN9I)HS+]G="@)4 C=@E@!D=0>V#C>*]<\12^ /&V
MF7>H6YO-'E2*2ZBM]GVF"5%(&W=\C?/U&>G3O0![#17G&I>)-3TN\TKP[<^)
M=)L+F2S:\N-3NX%1=FX*D:1M)@L><DGHI..:KCQ_K-UH6DMI[Z;<ZA+KQT>>
M9,M;RX1R)5P<@$;&QD]Q0!Z+J.G6>KZ=<:??P)/:7"%)8WZ,#_+Z]JEMH$M;
M:*WC+F.) B[W+M@# RQR2?<\UP@\4:QX9UK6K#Q!=V^I0V>CG5HIH+?R&PK,
MK1E=S#J!@^]6]%G\;%]*U*_FT^\L+] ]U:PP>4UDK+N4JY8^8 < @C/<4 =K
M5#3M&L-*EO);.#9+>3&>XD9R[2.>,DDDX & .@'3%>9VWQ+NI+2T\0-K^AM:
M7%VD;:(I7[1' \FP-NW[C( 0Q&W&,]*]$\4ZZGAGPMJ6M/'YHLX&D$><;VZ*
M,]LDB@#7HK@)=6\6>')]"N]<OK"]M=3NXK.XMX;4Q&U>4':4;<=P#<'(I_AS
M6O$WB'Q1K,7VFSM]*TG5)+9AY!:2X0*,)G.%QG);G.1TQ0!WE9B>(]%DL8[X
M:K9BTD=DCF>951V4X(4G@X(/2L#XG7US;>#_ +%9RM%<ZK=PZ:DB]4\UPK$?
M\!W5SOQ(M--TF;P)9_V6UUIUM?&,645OYQ=!$0%"?Q4 >DV>J:?J)86-_:W1
M7[WD3*^/K@UDZ1I/AMO$&HZOIZI-JJR-!<RM,\CPMU* ,3L!R#A0 :\[G;1+
MGQ_X6?2?#T_AB6*Z9I+NZL/L2W*E2/(7 P[,>QZ=NM=7JO\ Q(_BWH=W!\L6
MO6\UG=J.C/$OF1.?]K&Y<^E '=56DU"TBU""PDN$6[G1I(H2?F=5QN(^F1^=
M<?\ %^2]A^&.KS65TMN50"7,>XO&Q"E0<C:?F'//3&.:R-6@U]/'GA&VCU"T
MEU-]/O5>]:V*QHI,9W"+=R0,#&[KS[4 >H45P-AXA\2)9>*=-GGTVXU;1IHT
MBO)5\B%TD17#R#)QM!).#S@#WJA8^+-3NY];T>U\3Z3JLT.F?;H-2LX%(B8,
M0T;(KD$]"#D=>] 'IC*KHR.H96&"",@BN;TWP!X9TG4(;ZSTS9- 2T :>1TA
M)ZE$9BJ?@!5#X4QWZ_#O1Y+V]2Y62V1H0L.PQIC[K'<=Q]^/I5G1?$=T?%'B
M/1-8:%&L"MU:R*NT/:.."?4J0030!U=%>96/C/Q'J]AH4-M]EMKWQ%<W,UK+
M+"6%K91\@E<C<Y&W'('S5)J/BW7_  ];^*--OY[2[U#3=,&I65VD'EB5"64A
MTW$9#+V/(/:@#TFBN5USQ!>Z>OA0P>5_Q--0BM[C<N?D:)V./0Y45;\:Z_-X
M9\)WFIVT*372;(H(W^ZTCN$7/ME@3["@#6N-0M+6[M;6>X2.>[9D@C8\R%5+
M$#Z $U'8:OI^J27<=C=Q3O:3&"X5#GRY!U4^]>>ZC;^(+3X@^!HM:U"UU!'N
M+EEFAMO(*/\ 9WRI&X@CG@\'@YID'CG58M%\<7JPV@DTK6&M(7$!VI'YBJ9)
M IRVT$L?I0!ZE17%Z?J?B'^P=4NX-7T/7(U@$EC>QD0IOYW+* S *O!R"#U'
M'6LO1O',MOK=]8W?B#2O$%M#I<NHFXT]50PM&0&C(5V&"&!!Z\&@#TBBO*[K
MQ-XVT_P?IOB::XTV6+4Y+;-JML5-HDSKM(?<=_RG!R!RP/;!V$UKQ-JWQ%UO
M0K"YL[73]+:UE>62 R.RNFXQCD#+?-\W; X.: .\HKR2X^)=TMI=>($U_0TM
M+>[:-=$<K]HE@2386W;]PD(!8#;C&.N:O:SXYO7U?7$L?$6A:7'I#>5%:WVT
MR7L@0.V<NI5>0H(!Y!/M0!Z;17FD_C;4-8U.Q@T_6--T)+K2X+^U%_#YGVMY
M-V8PQ90 N #C)^:N]!U*30\L((=4:VY"DO&DVWMG&5#?I0!>I'=8T9W("J,D
MGL*\NU+XAZR?AUH6J:7# ^LWJR-/$Z':!!&[3X&>.8\#_>%=%=^*+FY\4Z;8
M:68FLY-)EU.Y9UR2APL(![98D^X% '2Z9JECK.GQ7^FW4=U:2YV31G*M@D''
MX@BG+J%H^I2:<MPAO(XEF>$'YE1B0&^A(/Y5XU=Z]KOB+X5^$-42\M;*6\UB
M**9(K7Y2WVDA"!N& "F2/XL]170&V\02?%2]M++4K6&[_L.V^TW[VN\9$DGW
M(MW!)]6. #UH ].HKFO ^MW^MZ+<_P!J>2;ZQOI[&:2%2J2-$Y7< 2<9&.*Z
M6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "J>K:9;:UH]YIEVI-O=PM#(!UPP
MQQ[U<HH XOPPGB7PSI-OH5]I+:E%9((;:_M)XU$D0X3>CLI4@8!QNZ4OB70-
M9U"70];MO(DU32;PW M0^U'B==CQJY'WMO1CQG/0'CLZ* .,GT2^U'Q#?>))
M;"2"4:2VG6MH\B&1BS%F9B&*@9V@?,>Y]!6/_P (UKJ^"/!FE#32;K1[ZUGN
M@)H\;(2=VT[N2<\=/?%>EU4CU.SFU.?38YU:\@C266(9RJMG:?QP?RH X_4=
M,U)?%^O:R]DR6$VA_9%D,B$[U+L25!SCYL?45D:%I5_XI^%OA;1I+%K>T\NT
MFGNFD0JT495P$ .[<VU1R !D\G SZ7>V<-_936EP',,RE'".R$@]1E2"/P-0
MZ3I-GH>F0:=I\;QVD"[8HVE9]JCH 6).* /-_$GA7Q3K&G>*[*33K6[N+R??
MI]]+= ;( R%854CY2-IST!)))-=)%I^L'XD1Z]/INVU_L;[&WESHQ$OF^9QD
M@D8XSQSVQS73:;J=GJ]@E]I\ZSVTA8+(N<$JQ4]?0@C\*MT <7X4\-SQ>$=5
MT77K(1Q7EU=.R^8K!HYG9NH)P0#^=2?#C3;NS\,17.H7?VRYN JQSXQNMXQL
MA_-1O^KFMK7?#.C^)8[:/6+);I+:7S8E9V4!L8YP1D8/0Y%:JJJ($10JJ,
M8 % &=K\=S+HL\=I90WTCE%:VG("2QEQO4YXY3=U[USW@WPO)X>U?5)+."?3
M]$N$C,&FS3"3RILMO90&8*I!7@'J#T&*[.B@#B]<TC6;+Q]9>*M(M$U"-K$Z
M=>6AF6-PF_>KH6X)!Z@D<?IA-X.\2WFG>(6$5K8W\NM)J^G,T_F*70)A7 '0
M[2,^_2O0KS6M.T_4;'3[JZ2*[ORRVT1!S*5 +8^@(J_0!RUB_B?7=-O(=9TN
MVT@/:R0B);H3F21AC?D#Y5'/').>V.>:C\->++?PIX6FM+2TBUKPYB-+62XW
M)=1^7Y;C<!A21@CKCO7IU% '">(K/Q1XH\!:Q9W&E0VEY>PB&WLENED\OG)=
MY, <^@SC ]3BSXMTO5=8T70H[33V,]MJ-K=SQM*@V+$P9AG."3VQ^.*Z-M:T
MY-<316ND&I/!]I6WP=QCR1N],9!%7Z .173M37XFS:Z=/D^P-I"V8;S(]QD$
MADZ;NF#C/K[<US,GA3Q _P ,KW01IO\ ITVJ&Z4&>/;L-R)N3GK@8QZUZI10
M!R/]G:F?B:NO?V?)]@_L?[&3YD>\2&42=-W3'&?7VYKG+;P[XJL_#L-K'8!U
M&MS7EW9?:D3[5;2.S!=P.."5RIP#C'(KU!F"*68X4#)-4M(UC3]>TR+4=+N4
MN;.7(25 0&P2#U]P10!Y_P#\(=KMQI_CJP-C96D6LQAK,QSY4-Y*H$P%& "O
M)X]@:DU#P[XCUVV\$R7&F0V<VCZC%+=1_:ED_=H%&X$#G.#Q7I5% '"C3_$G
MAGQ!KEQHVE0:I9:M,MT@:[$+6\VP*V[(.Y3M!R.1R,56T7P/J.C7?@PM)%.-
M,^W27\JM@&2<9^4'DC<2/H*]#JHVIV::K'I;3J+V2%ITAYR8P0"WIU('XT 8
MVD:->6?COQ)JTRJ+2_ALT@(;))C60-D=OO"N?\42:E#\5] FTNVCNIH],NF:
MWDD\OS4WQ@@-@@'D'GCC'&<UW.IZG9:-ILVH:C<+;VD !DE8'"C..WN1426.
MG7U_::XD2R7*VY2"<,?]6^&(QTYP#R* . O?!FOZYHGBR]N8;:SU?6)K62WM
M#-O6)+8J45G QEBISC@9%::V'B?6_&OAW6]1TJWTZTTY;E7@%T)GS)'C<2 !
MC(  '/4FNQO-3L[":TANIUBDNY?)@4Y_>/@G _ $_A5N@#C/"FA:YH'@B]L8
MQ:QZJUS=36_FDO'EY&9-VWG!R,^E9<'A;4]8UVZU"XT&S\/";3+BSN#!<+*U
MV\NT!F" #"X)R>3FO1Z* /+/["\97_AWPWHESI-G:1Z-=V3RSB\$GVE(6491
M<#:,#=SSD 8YR%U'PCXCEM?%ND6VF6#?VS//.FK2S#=L=?EB*8W9&-H.< '/
M;!]2HH XW0-&U:/Q?_;5_:);1OHL%FT8F#E94D<D<=1@CFL+4?!>NOX6U>"W
M@@DO'\2-JUO$TP42Q^:K ;OX20#UKT^B@"O837-Q8PRWEJ+2X9<R0"02;#Z;
MAP:\QLO!?B1?"EQH3VEM#<:=JG]I:;>&X#)<.)C(JLH&5&"1GWKU:B@#B;?3
MM>\0>,-(UC6-,BTJUTB.8Q0BZ$[S2R+L)RHP%"Y]R3TJY\0M#U#7O"WV?2XX
MY;R&Z@N8XI'V"3RW#%=W;(%=510!R6FZ9JT_CP>(;ZR2TBDT9;5XA.)"DHF9
ML9'4;2.:P9_!&JM9ZC.MO:S7<?B635[6WF<;+B(H$*,<':2I;J."!7I=5+'4
M[/4C<_8YUF^RSM;3;<_)(N-RGW&10!C^&8-2^T7=S?:'IVCPL$2""W*O*<9W
M,[J N#Q@#T.3S7/^*Y-2A^*GAN;2[>*YGCT^[9K>23R_-7=&" V" >01GCC'
M&<UZ'6)K4N@Z3?66N:L\<%PA-G;SN6ZR$'8 ..=HZCM0!P^K>#?$.O>&_&ES
M/:06^JZ]]G2"S$X811PX"[GZ;C\Q...E=3XQT"[U./2+ZQMK:[N]+N?.%K<D
M!)T9&1TR00#AL@D8R*VVUK3DUU-$:Z0:D\'VE;?!W&/)7=Z8R"*OT >?WWAG
M6/$7AC5()-+TS1+EY89M/BBP[*\3!P9748(+#& . 3UJS+9>*O%D%]8:S9V^
MC:7/I\ML\*3K</-*XP'! &U5YP.ISS7;T4 <-X=T_7HKO3;>]\-:-8Q6B;;F
M^1UD:X(7 ,0 !3)P26Z#CWKGY?"_C&V\ :CX&L].LWMMLT=MJ378 >)G+A3'
MC(?G;UP.N3CGUFL?4?%6A:3JEMIE]J<$-]<D>5;DY=LG .!T!/&30!SI\+ZF
M?B7H.N>7']BLM(:TF;>-PD.> .XYZU%;^$]5C^%.M>'VCC_M"[^V^4OF#:?-
MD=DR>W#"N_HH \[2RU?0/&9N-)@L-0GO-*MXKNQDO1#+"T6567&#F,Y(X'45
M8^%*S_V+K;W,J32R:[>,TL8PDAW %E]L@XK?\1>&O#VLJ+S6K*.0VD;$3AV1
MT3JPW(0<>W2KNA1:7%H5DNB1PQZ8T*O;"%=J[&&00/?.?QH Y#QGI.O:ZFHZ
M5)X;TO4[:=2+"^DG$;69*@98$%LJV6!3J,#BHIO#>L:)KE]>6FB6/B!-0@@W
M/<RK&\,\<8C+'<#E6"J>.<@\5Z)5.VU2RO+Z[LK:X66XLRJW"+D^66&0">F<
M<XZT <W#X?U-?%OAW4IH[,1V6FSP77V8;(Q*YC/R*>=N5:LG7?!6K:I9_$"&
M(0J=:,#619^&V1("#Z<J17H<LBPPO*^=B*6; ).![#DU#I^H6FJV$-]87"7%
MK.N^.6,Y#"@#A+K2->GU+3/$<OAJSN+I+-K"[TR:Z1B%W!DD1RNW.=V0>S59
MN/#VM7]IX;DFL-.M)[36A?7%O:'"11!9% S_ !N R@D 9[#BN[HH XK7?"-S
MKGBW4IY=J:=>^'GTPR@Y99&D)SM]@<TW1$\;DZ1I=]965C9V*A+R\2X$WVQ5
M3:%1-N4W'!).",<5UG]IV?\ :QTKSU^W"#[28><^7NV[O3&>*9J^L:?H.F2Z
MCJEREM9Q8#RN"0N2 .GN10!PN@^&]<T.WLM!C\.Z/+;VL^T:O,RMNMP^?]7C
M=YFWY>N,\YKL/%>A+XF\*ZEHK2>4;N!HUD(R%;JI/L"!6NK!U#*<@C(-5;G4
M[.TO;.RN)UCN+UF6WC.<R%5W,!] ,T <5-IOBKQ-/H5GK6EVNGVVFWD5Y=7*
M78E^TO$#M$:@9 +8)W8P*V/!^AWNC7GB62\1%74-7ENX-K9S&RH 3Z'*GBNH
MJCJ.M:5I'E_VGJ=G9>;GR_M,ZQ[\8SC<1G&1^= ',_%&UGD\()J-M&TLND7L
M&I>6HY98G!;_ ,=+'\*A\8V.IZ[+X5USPY;0:BEE<_;-C7 B$B-'@$,0>N?2
MNOL=2T[5[=I+"]M;V'.UF@E61?H2"12:7I5EHM@ECIT'D6J$E(@Q(3)R0,DX
M&3T' [4 </K&E^+O&IL+#4])L-&TZ"\BNIY5O?M$K[#D*@" *2>Y-6M:_P")
MQ\6O#EE!\RZ-!/?79'1#(OEQJ?<_,<>@KNJI6.D6.FW%Y<6EN$FO9?.N)"Q9
MI&Q@9)). !@#H.PH R/'VAW7B7P+JVD6)075S$!%O. 2&#8SVSC%9]MINMZC
MXL\/:Y?Z;'8BTL[J"XA%RLI1G*;<$ 9SM)]J[2B@#S77O!FL7UUXJN(;>"=+
MV_L+N"VDE 6Z2!4WQO\ W<[2.?:IX-"\17?BN35+G2K.RL[W29=.,$4ZLUKS
MN5FP '+'(PO08KM-/UK3M5N+VWL;I)I;&7R;E5!_=OZ'-7Z .4^'MEK&D^$K
M/2-9T^.UEL(U@1X[@2B8#^+@?+]#7-?%32[BZUK0!I5RL.I:KYND3*/O/:2#
M=(WT3;G_ (%7H.D:UIVO6/VW2[I+FVWLGF("!N!P1S6--'X+\/\ B2?4KN[T
MRSUFX3+R75X!)L/]T.WR@X[  XH K^(?#M[!>>'=5\/VT,LVA[X5LI)/+$L#
MH$*AL$!AM4C/'%95SX1UKQ/_ ,)-J.J0P:==ZEI?]F65L)O-\I!N;=(P&,EV
MZ#. .]=_:WEM?6R7%G<0W$#_ '987#JWT(XJ:@#SA]+\7:W-X5^W:1:V$.D7
ML4MP!=B5I=L;*77 X ST/)W=L<]-XXT&X\2^$;S3;.1([PF.6W:3[HDC=74'
MV)7'XUT-% 'G[V'BS7O%WAG5M1TFVTVTTN69IHA=B9W+PLNX8 & < #KR<XQ
M3- \.^)?#Z>+KFUM[)[G4-9>]MHIY/EFA+#*DC[C%<@$@X/45Z'10!Y1>>"-
M8U6T\07%MH=EHOVZ"V0:8EPK)=/%-YC-(4&U=R_)WZG-7I?#VNZEX@CU"]TB
MST[3+C2[G3)K>*X4M;(^T^:2  V<$;1T !SR<>DT'WH \4UF3Q ?AOH>F7$>
MFFRM[NQMXKVUO!,+\+*BIY:@<<#<23_#TYX]#T30[VQ\>^*M7G1!::DMF+=@
MV2?+C96R.W)%2V?@+POI^IIJ-KH\$=S&YDC(+%(V/5E0G:I]P!71T >;:?X;
MUS1%DT6T\.Z/=V_VQY(-5N64[(7D+D/'C<S@,5&#@\<BI[OP_K&DZYK4NF>'
MM,U>#5)A<PS74JH;64HJ,'!4EDRH8;>>2/>O0JJ:;J=GK&GQ7^GSK/:RYV2+
MG#8)4]?<$4 <CX@T_7+BW_LV;POH^NZ<]JB(N]8!!-@ASA\_*>""O(QCGK72
M^&M-N-'\,:7IMW<?:+FUM8X9)<D[F50">><5J44 >>>'_!-_8^.M4N;Y(7T1
M?M+:>@;)!N61I05[8*D?0T> O!VKZ'::N=7,;W+01Z?9E7W?Z-$I"$GMDL<C
MVKT&218HVD<[40%F/H!532=6L-=TR'4M,N5N;.;/ERH#AL$@]?<$4 >:6G@;
MQ!9?"30-'6W@DU?2M12]:W,X"R!9V?:'Z D,*ZS2-+U1O'-UK][:):Q7.E06
MYB$PD*2*[LRY'7 8<UT/]IV?]K?V5YZ_;O(^T^3SGR]VW=Z8SQ1<ZG9V=Y9V
M=Q.L=Q>LR6Z'.9"JEB!] ": ,;P;HUYHMOK*7BJINM8NKN+:V<QR/E2?0X[5
MTE%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9/B?4;S2?"^IZAI]O\ :+NV
MMGDBBP3N8#C@<GUP*UJIZJNH/I5RNE201W^P^0TZDQ[NP;'.#T]LT <):>(=
M6'A?6]8M/%.EZ]:P:7+<1RQ0+'+!<*I95* D;2 >&P1COFM35?$>HVGA[PC>
M1.@FU.^LH+DE 04E7+X':LS_ (1'5==U/5+Z^TG3]"-WI$^G.+6?SFN'EQB1
MR%487!QG)^8U#_8'C'5+#PO87UCIUG#HE]:32O'=F0W(BX+*-HVC&3@Y))'3
M'(!;34O%WB.?7+[0=1L[6#3+R2SMK*:V#B[>+&XO(2"H+9 QTQFJ:P:[?_%/
M68M/O(M*E?2K-[B8Q"=D.9/D4$@'DGYC_=Z<Y%S^QO%^@7&N67AZ#3YK75;N
M2\@O9[@HUE)(!OS'M.\ Y(P?K6SI&@ZA9>-=2U:ZF2>&XT^UMQ+P'>2/?N8J
M!@9W \4 .\":U?ZWX>>34VB>^M;N>SFDB7:LC1R%=P';( XK,&H^(_$'BS7+
M72-3M]/LM'>.!4DM1+]IF9 [;R2"JC('R\]36MX,T2[T+3M0@O/+WSZG=72;
M&R-DDA9<^^#62=)\3:%XJUN[T2SL;RSUEHYMUQ<F(VLRH$8D!3O4X!P,'M[T
M <=X<\52Z/X \)Z:-4L]%DU*:^>:^N]K+ D<SDA0Q +%F4#/OQ3/%7B>_P!;
M^&GB2WBUVTO&TR\@A>]M(U*7D,C)MZ$A6!8@X_NX[UO:7X&US1/#WAF6.*RO
MM4T9[M9;>63:EQ%.Y)PV#M880C(QU%:.O>'/$/B7X?:QI]Q;Z;9:A=RI);6T
M+$I&J.C!7DP-S':>0 !D4 5==\37NEZY9^&[SQ=I^ERQV1N[G4[F"-3,6D*H
MB(S;1@*23ST'3-49?'^N7GA[P_)I<]A+?W>LOI,TR+N@E*AP)5YSM.%?@],B
MMJZTSQ&=;M?$\>AZ?->2V1L[S3)+SA LA:-TE*8)^8Y&!U[XI]_X;UW4X?"T
MMTNGI=6&JB]NTMLK&D>' 5<CYB RC/&<$T 07=[XLM?%&C>&(]:MY9KFPGFN
M;]K)005D7#+&#C.#MQG'.3G&*S+75O&]]IGB15UNSAF\/3S1"X%DK&]*IO 9
M2<(,$#Y?7VYZ^[T.[F^(FFZXGE_8[?3Y[9\M\V]W0C ],*:I:?X:U"VM?&<<
MGE;M7NII;;#_ ,+0J@W<<<@T 94_C34I]7^'/DB&.#Q! \UW'L#$?ND<!2>1
MRQJ--5\7ZS'XJGLM7M;&'1K^XAMP;19&FV(K!6)/"\@9')R?3EZ>"-76\^'$
MI^S[?#ULT5[^\_B,*)\G'/*GTK:T;PY?6.G^+()O*WZIJ%S<V^ULC9)&BKN]
M#E30!DWWBN^N_#WAW4W\0:7X<M=0LEN)YYPKR-*54B.-'.-O+$GD]*YK6M=U
MCQ-X0\(7T>JP122>(H[*62" -',Z3,$F&3T^0-MZ'=[5O:=X6\1Z!<>'[RTL
M-/U">UT./3)4FN3&+>12"9%.TY!Z' !X%59/!?B>+PS;V8CLKF]TWQ"-6A8S
ME%NU\QW(/RGRS\_OTH VO[?U2T^*UAX;N+F*:T.A?:II/)"L\HD*EO8'&<5C
MIXC\77G@B?QW;ZA:QVB+)=1:0UJ"K6Z,>&ESNWE03D<9[5MIX<U:[^)]AXHN
MH+>&V71/L<\*S;RDQD+%0<#<N#UX^E8Z^%O%EKX.G\"VT%@VFN'MX]6:Y.Y+
M9V)(,6WEPI*_>QTH T#K7B#7_&-SI.D:C#86']F6UZMPUL)9%,A;Y0"0.<#D
MYQMZ<Y&SX%UJ_P!:T"9M4:)[ZSO9[*:6)-JRF)RNX+VR,<4W2/#<^F>-;[44
M"#3WTVVLX1NRV8R^<CZ,*RK2#6?!F@W3)':23WOB)G"NQ(,-Q< #&,?/ALXZ
M#F@#N;AS';2NO54)'Y5Y3I7CGQ'>?#'PMJ\+VK:IJ>K+92%H@(RK22*.!T^Z
MN<<\&O5IT,EO*B]60@?E7FFA> M9T[P%X2T:?[-]KTK6$O;C;)E?+$DC':<<
MG##B@#;T?4->T_Q\_AW5]3BU."?33?0S+;"%HV60(R8!((^8')YJ]K>LWVE>
M,_#MKO3^R]2,]M*"HRLP3?&<^X5ABGR:)=M\2+?7AY?V*/29+0_-\WF-*KCC
MTPIIOCC1+[6] C&DF)=5L[J&\LS*<)YB.#@GT*EA^- &'X=\;WEYXJUR/47B
M71UCFGT]U3!\NWD,4Q)_BYP:YS2;OQ+K_BOPS>FZ@M-1U#0KB9YC &$$+3HR
M;4R 6V[!SZD\XQ6GKGP[U>7P7X=TS2IX$O[2"2TO9'<@-%/'B<@XY.[!%=4/
M#L\'CS3=4MUC33K329+$+N^8,70J /3"F@#E+[Q?X@TOP+XR:YNK>YU30;H0
M177V<*LJMY; LG3.'(XXK6GUS6]8U71M!TJ^AT^>;25U.\O&MQ*0I*JJHI.!
MEBQ)/853USP1J^H:#XZLX/L_FZW=1RVFZ3 VJL8.[CC[AJ]<^']<TK5-&UW1
M[>UO;NVTL:9>6<T_E"1 58,C[2 0P/4<@T 8WB;_ (2;'A&'4#9?VNFO-%#<
MJI\N5/*D"RE >#@Y*9ZCJ,UT/A_4=;M/&VH>&]8U&/4E6QCOH+E;<0LH9V1D
M(4X/*Y!JN_A_Q-J3^'[S5[BUDN;75WOIHHSA+>$QNJQ(=H+D;AR>N3[5KQZ)
M=K\2)]>/E_8GTF.S'S?-Y@E9SQZ8(YH K^*=7U-=<T;P[HUQ%:76I>=+)=R1
M>;Y,40!.U20"Q+*!G@<U6N;KQ9I7AR_74=2TF&:&Y1(M7N,1Q_9V(W2-'G&]
M<D!<@$X_&UXJT75)M9T;Q#HL<$]]IAEC>UGD,:SQ2* P#X.U@54CC'6L?5-#
M\7:SI\%]J$=A-=6^K17T&D>:/*6%%*^69=OS,2V_)! (&* ,ZS\>:BNE>*TL
MM5M/$$FE6\,]M?00  B3<&#HAP=FTMQU%6QXMU#2/">L:^OB+2_$=A!;JUO-
M&@B:.=FVA'"DC9\RGG##D>]3P:1XUA\0:MK,,.EQ7&HV<"QQM,S);-$[$1'Y
M06#*QRXQ@D\$ 9IW'@;4O$<VMW5WIMAH+7NGBV6*VF\[S9ED$BS2$*HX*@#J
M<$^U $_AWQA*?%NGZ/)XJTOQ"FH02L6LU16MI4 ;'RDY0C=C/.5ZUN>,M<O_
M  Y<:)J,;I_9+7JVVHJR E4D^5),]@K8SZYI="3Q)+JD<FIZ/I.FVL,+*_V>
M7SGGE.,,IVKL4#/!R3FM#Q;86&J>$=6LM3E2&SEM7$DK](QC(?\  @'\* ,+
M7?%MW8>++NWM]ITS1M(EU'4@%!+L0?*C!_A.%9JRI=<\6Z+X=TOQ9J6IVMQ:
M7,EN;O3DM BP13,JC8^=Q9=Z]<@\T_X?^'[G6/AU?7.NNQO_ !+"3<28^81&
M/RH__'!N_P"!4C>'?%FKZ#I?A75;73X=/M)(/M6H17)=KF.%@5"Q[1M9BJY)
M.!SUH Z#0-<OM0O/%<5PZ%=-OV@M\*!A!$C<^O+&K/@?5KO7?!&CZI?,K75U
M;K)*57:"3[=JPAHWBC2M>\0QZ7:V,UCK4PG2[EN"C6K&-4;,>T[_ +N0 1[D
M=M[P3I%UH'@O2=)O=GVFUMUCD\MLKD>AH Y?1O$>MZQXCGB37]-@NK?4)(9M
M N( D@MU<KO5\[F8H X(&TYQQ65I"^)%MO'%YH^JV]A%9ZS>3*CVHF,[A58A
MB3\JX ''/)]*VM6T'Q+KU]:6VH:5I.;2_CN(M<CFQ*L22APJQ[<ABHVGYL<D
MUIZ1X;O[+1_%EK+Y7F:I?W=Q;[6R-DB +NXX.10!F:CXJOKG0_#VI/XBTOPW
M::A8K<RS3A9)&E95(CC1SC:,DD\GITZUROB[7Y_$OPK\.:C<O#).=?BA>6 8
M20QR2)O4=@P4'\:Z/3_"_B/0;O0;VSL-/OY[?0H=+E6>Y,8MI$.3(IVG<IS@
M@8/RBL^[\ ^)+GP;;Z$_V1YK37OMZW'FX$\1D=RVW'RM\^-O/UH T;K_ ).,
ML?\ L7#_ .CVK?\ 'FN7>@Z+:SVUS'9I->1P7%])#YJVD; YD*].H5>>!NYJ
M"?PU?R?%VV\3+Y7]GQZ.;)OG^?S/,9NF.F".:V?$']M+:0R:+!:7,B2YGM;I
MM@GB((*A\':<D'D$<8H X_4O%>IZ%X5BGF\0:/>"_P!0CM++6  (DC92S/(H
M.W*A7Q@X/RYQR*RKSQ9>WVA^+=(M?%%CJCVNDM?0:E:1(24PP>)U4[0W P1V
M;..*O)X$U62SO-0BL=-TZ].J0:E::6DFZW4QIL968* "X+9(7 XZ\UN'2M?U
MS0M?M+^PTW2EOK)[6U@A?S65F1@7=PH&"2O '&* +O@""\@\"Z.+R]%TSV<+
MQD0B/RT,:X3@G./7O7#:9I^LGX\:U_Q/$#QV$,DCFS4[X2X/E=>./XNOM7?^
M#(-6L_"]E8ZS906MS9Q);*(;CS1(J(J[\[1C)!XYQZUGV/AN^M_BEJWB*3RO
ML%WI\5M'AOGW*03D8Z4 <ZGB+Q=J'@NZ\=6FHVL5G&LMS!I+6@*O;QL1AI,[
MMY52<CCIQ5N[\0^(M<\;P:)H.H0:?9W.BPZE]HEMA,T6Z1API(R3\HY.!R:K
MIX7\667A"Z\#V=O8-IDHE@BU5[DAH[:1B2&BVY+A6(&#CI70:?X6N-.^(*ZK
M%L_LR+0HM-CRWS[TE+<C'3;CF@#DK*'6&\7_ !&-QK E@M[>-9(OLRCS%:V<
MH <_+MS^--T;4?$_A_P-X/U=M2MFTZ46-H^FBV'$,FU WF9W;^0WISCMSOOX
M=UZV\7>*YH+6UFTW7[= )S<;'@=(#& 4VG=EL<Y&!Z]*DN_">I3?#KP[H2>3
M]LT][ S9?Y?W+(7P<<_=.* .JU[4O['\.ZGJ>T,;.UEG"GOL4MC]*X[P]INL
MZ=\*+*XT26-]<N(EU.8SJ&^URR?O'1CV)!V@]L"NQU[3?[8\/:EIFX+]LM98
M-Q[;U*Y_6N-T"\UK6?A18V.BM';:Q"BZ9=/,V#9O'^[D;'=@!D#W!H M>'/%
MUYXTUV*;2%:VT.SA_P!.::+YY+E@#Y STV=6([D#WIOA#_B4>//%GAV/BR#P
MZE;1]H_.!\P#T&]<@>YJ31?!DW@_Q#;/X>"_V-<P"+4+>60[A*@PDZ^K'HW3
M/!ZU'X0_XF_CSQ9XBCYLB\.FVLG:3R0?,(]1O; /L: -2]UF^L/B)I>ERNG]
MF:E93>4NT;A<1D,>?0H3Q[5S?ASX@7MQ%XCO=6,0M(+5]3TT*NTM:AY4 )[G
M]VI_X&*W/B%X>U37=&M9-">*/5[*X\ZW>5MHPR,CC/\ NN3^ K!\2?#J]O++
MP[I^DR0QVUO:+IFHEV(+VN^)FV\<G]V?^^C0!FZ7_P )/JGCG2V:_@M-4N?"
MT4UW=&W#^7NG9MJID#=D@<\8!ZFIM7\;>(--^%_B6^DGMI=6T75#IXN?( 68
M"2/YRG(!*R=/:NU70[I?B.VN@1BQ_LA;( -\WF"8OT],&N2U_P !:SJ7@?QA
MI$'V;[5JVLF]MMTF%\O=$?F..#\C<?2@#;U#5=;U?Q5'X>T;4(M-$&GI>W5V
MUN)F+.Q5$520 /E8D\]@*PM=/B:36_ L5Y]BAUL7=Y%YZ*6B*^2P\T+GKM^;
M;GKQ6]J6C:[I?BF+Q%H=I:W[2V"V-W9S7'DD[6+)(K[2.,D$$=,5'%X>\1W6
MJ^%=2U>ZMKBYL+FZGN_+^58UDC94C3@;@N0,GD]: +'A?4]93Q5K?AW6+Z/4
M#9Q07$%TL A8K)NRK*.."O!'K6/\0KW1M/\ '?@ZXU[R?L BOPWG0^:N2L6/
MEP>_M72V&B7=MX_UG6I/+^R7=G;0Q8;YMR%]V1Z?,*75M%N[WQOX<U>+R_LN
MGQ7:SY;#9D5 N!W^Z<T <39:MHUMXLU;Q3X:LMFB6.ARF]DAMS!%<3*P=% (
M&Y@H;Y@.,@5>EUOQ;HF@Z5XIU/5+6YM+J6W^V:>EH$6".9@!L?.XE2R]<YYZ
M5WFLZ9%K6AW^ES,5BO+>2!F'4!E*Y'YUPK>'O%FL:+I7AC5K33X-/LY8#=7\
M5T7:ZCA(*A8]HVEBJY)/'/6@"AIU]JFC>./B'JUWJ@N+72HH9I;<6ZJ9E%NS
MHH;/R[<X[YZU)H?CNY_M?05N?%6CZO\ VM)Y-Q86BH'LW9"RE2K$LH(V'=Z@
M^U:<WA35I?%OBR.2WMY-$\2V\<4ER)]LEL5@,?\ J]OS9..XQ^E7/#UEXI@G
MTVSO]*T>VMK)-EQ>12>8]UA=JE%VCR\G#$DGTH YO_A(O&=UX*U;Q/%JMG F
MES76RV-F'%RD4C9WMD%>!M&WTSGGBRSZMJ7QFTN6#51!;R:']K6$VRMMC:6/
M?'G/5B =W4=,5IVWA'4XOACKGA]O(^W7IO?*P_R?O7<IDXXX89HD\/Z[I_C+
M0M:L;6UNXHM)&F7<;W'E&/YU8NORG=T/'% $&B>*=;U ^.U22Q$VE7KPV37&
M(HD !P9&'8=2?:D\)>+9[OQC_8A\36'B&"6Q>Y\^UB6,P2(ZJ5^4D%2'R._%
M4G^'^LR:7XYM\VN_6-26\M%9R5=%</L?CC=C!Z]:U[32_$\WC72]?N].L+6U
MCM);)[**ZWF!&*,)-VT!B2N-H P .3S0!1^!W_).A_U_7'_H=5-;U3PSIGQ<
MU!O$HM3$^D6PA^T6QF&?,DS@!3BNC^&?AJ_\)^$1IFI>5]H^TRR_NGW#:S9'
M.*O6NBW</Q"U'6V\O['<:=!;)AOFWH[L<CTPPH XW0)I+6W\9:QX82UTW1[B
M6 V$E\AM[8,%VS3!2!A>1CH"5IUAXLUF_DU[2-&\26.NW<&FB]LKV&W0;9 Q
M!B95)4YP,'MNKKO'&B7FN^'T@L4AFG@NX+H6\[;8[@1N&,;'!P"!Z'G%9NE:
M7XE/CR/Q!J%G90VUQ8&S>WAN"S6H5]Z\[0'+$G.,8R.N.0"OJ/C:YO\ P3X?
MO=":--3UZ>"W@W+O$+$YE)'<(%<&JDFK^+=5N_%R6&K6UC#HMPP@)M%E:;$2
MOL;)  Z\\D[NV.:?@G0MWQ(UR2&=9M%T2YF&GA1\L<]P%:90>GR8*^V\UT^F
M>'+^T?QB9/*QJ]RTMMANQA5/FXXY!H YV+Q1XJ&E>%O$]Q>V@LM7N[:WFTQ+
M;A$F.T.)"=Q;H<=.<=LFMK/Q"N1>:_<6WBC1]..D3R06^E7(0O>&(?-N)8,-
MS95=OIWK<D\(:HW@/PEHP\C[5I5U8RW'S_+MA(+[3CGIQ36T+Q'HU_K,.C:9
MI5[;ZG=O=PW=W+M-H\@&\.FT[P&!88(ZXH :=?U[Q!XOCTO1K^'3["?18-2$
M[VXED0N[#"@D DC;R>!@\<\<QXDUC7]8\""*YU**.ZLO$:Z9<RQVXQ<%)TV2
M8S\N" 2!P:]"M-"O(/B!/K3F$VCZ3#9C;P?,61V/R]AAAWKF=1\#ZW+X7UFV
MMQ;->R^(FU:VC>0A9$\Q6"EL?*2 : 'ZMKNMVOB4Z#+XJL-*GALXI+::[LU"
MZC*Q;=R6PH!"C:O/.:]!C>Z73DDGBC:[$(:2.%B5+XY"D\XST)KC-<MO%>KV
MDUK=^&M%O[2\@ 6">[_X\Y,$'),9\P=""H!'(]ZZC1]-N-+\,6.F&Z$MS:V<
M<'VAAG<ZH%W$=^1F@#CO _B'6?$$]I=OXCTR\\Q&.HZ3Y'DS6+8^ZO)8[6PI
MW#GD@URN@:AXGT'X06_B.SU*UCLK!I&&GM;!O/C^T,&W29RI.3C Z >M=?;:
M%XAU3Q1HNHZOI&E6-QICL\^HVL^^2\!C9-@78"JDL&(8G&,"HAX+U8?!:;PI
M^X_M)XI$'[SY,M,7'./0^E %ZXU+7?$'C'5-&T?4XM*M=)AA,TQMEFDEEE4L
M  QP%"@9[Y-9EEXVUBXAT*"?R$O?[?ET?43&GR2>6KG<H/W<X4_G6I<:3K^A
M>+=1UK1+&UU*#58(5N;>:Y\AHY8E*JX;:P*E2 1UXK*?P/KEEH.G75NUI=:[
M;ZV^LW,1D,<4KR;@\:L02,!@ 2.U &YJ&LWA\;ZEH99?L*Z!]K"[>?,,CH3G
MTP!Q7"^"-9U&Q^$W@K2M(EB@O]7NYK=;B2/>(4$DKNX7H3A> >.:Z^QT+Q#=
M^+]0U[5(+.V6ZT?[%%;PSF0Q,'9@"VT;NI.0.^.<9.+I?@37]'\!^%88!:2:
MYH%W)<>2TI$<R.TFY-^."5<<XZB@"[HT.J6WQFF@U6\CO9$\/CR[E(A$70W'
M\2@X!!R..,8XJ;X@B^;Q9X)737BCNVO;A4DE7<J9@8%MN1G ).,C)%6]%T?Q
M#-\09O$VL6]I:PRZ6+..VAG,K1$2[N6VC)/)R!QP.>M3^,-$UG4M9\.:EHWV
M8R:7<2SR+<.5#@QE=N0#C.<9[9S@XQ0!A7GC'6?!T_B*QUFZAU22RTU-1LKC
MR1 7#.8]CA3C ?'([$T_P]XRF/BS3-)E\5Z5X@74HI=PLU16M947?QM8Y0@,
M.><@<TZZ\&:OXKF\0W^N1V^FSWVGII]G!%-Y_DJK&3>[8 .7P< =!6YH4?B6
M74X&U32-(TZV@B82M;R^<]Q(< %/E78O4\Y/./>@#JJ*** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHK)\3ZR/#OA?4]8,?F&SMWE5"<;F X'XG% &M5/2]5LM:T
MZ+4-.G$]K*6"2!2,[6*G@@'J"*YK1;3QG!=Z9>7VLV^HVEU&3?6[6Z0_9R5R
MIB*\L >"&SD<UP.AW?B;0_@_%XCL=8CAMK!I733_ +,C+.@N&#;W/S G+8VX
MP,?6@#V^BO/?&6OWEAJDJ#QA8:)$MH);6V6%9YIY.<F16!VIP -O7GGBJ=UX
MK\1ZQ/X&M])NH;!_$&GS3W+F$2")ECC?<H/7&6 &<9(SG% 'IU%>=>)]6U+2
M+J&SN?'-CIABL5,?^CI)/=S#(9Y$*D(G P%]3R,4VV\5:UXI3POIVG7::7<Z
MEIAU*]N4A60HJ[5VQJV1RS=3G % 'HS,JC+, ,XR32UY+XXM_%4>@:-;:GJ\
M8D'B&W@2X@@3_2(S(ICD=2,*RD'Y1P:LZWXNFM?$MSH-UXUM=$_LVUAW7$UO
M$7O)W4L2588" ;<A<'+=: /4:SY=;TZ'7(-%DN-NH3Q&:.'8WS(.ISC';UKS
MG_A-?$.O0^!DTB[MK2;74O([J01"1%:( %U!]"'(&><C.:V6UO6M/^)^@>&9
MM1^U6LNE/-<NT"*TTJDC?P/EZ=!Q0!WM%>;:G-XLM?&6EZ)I_BIKN>X?[3=1
M-I\*K;VBGEF8#.2?E7U.?2LS7/B#,-2\0/%XNL-)DTJ9X+33)HD8W;1J"QD)
M^8!FRHVD8QGF@#URJ>GZK9:J+HV4XE^RW#VLV%(V2I]Y>1SC/4<5Q-OK^L^,
M/$45GH^J'2+*'2K>_F=($EDD><$JGS@@*%'..3FI_A;]I_L_Q&+TQFZ'B"[$
MIC&%+97) /09H [NBO//&NOWNF:K<H/&%AHR16HDM+185FFG?G)E# E4R !M
MZ\\U2O\ QG?78\.27&NQ^&K+4]*2[^V&V61)+AL9BW/E5 !SS@G/6@#U"LO5
M_$FB:!L_M?5K.Q,G*+<3*A;Z G)J?1VO'T>T;4)K:>[,0,LMKGRI#_>7/8]:
MXCX=Z?::S+KOB74+>*YU*ZU.> 23*&,,,;;$C7/0 #MUSS0!W6GZE8ZM:+=Z
M=>07=LWW98) ZG\15JN*URVTWX>:)XC\4:5:".>:)7:V4[86E!VJVP< DL,D
M=:J7-WXG\*7V@7&JZXNJ6VI7L=A=0&U2(0O(#M:-E . PQALY!H ] I"RA@I
M8!CT&>M>7#5?&&J:-XKU2WUZ.R31K^]BMHELXW\Y822 Y(X& %XYZDD]*AGG
MU;7?B'X+O8M6>T6\TB2[6)($81;EC+J,CG=QR>1CB@#TBQUO3M2U"_L;2X\R
MYL'5+E-C#RV8$@9(P>AZ9K0KS$>,-;+?$T?:E_XD46ZP_=+^[/E.W/'S<J.N
M:F.J^*=+?PKJU]K$=S;ZQ=P6MQIXM45(O-0L"KCYB5(YR<'T'2@#TBBO-!K/
MBO5[#Q'XAT[58;>VTVXN8+33C:JRS+#D%F<_,&8@XQP.,@U0E\?7$\?AVROO
M%%MH+7&B0ZC=7KQ1L\TC\!%5AM X9CQZ 8H ]:HKRF#QQKFK:5X<73;^S:ZN
MM7GTRXNEB#13*BOB55]P%? (YXZ5:O+[Q'9S^*O#USKS7+P:0NHVM]]EC22,
M$N&0A1M.=G!QD9H ]+5E=0RD%2,@@\&J.JZWI>AVPN-5U&ULH6.%>XE"!CZ#
M/4US_P ,+>ZM_AWHAN;YKH26<+Q!HU3R4,:X08ZX]3S69H5C;>(/B;XIU+4X
M4N7TMX;*QCF4,($,8=F4'@%B>O7M0!V>E:WI6NV[7&DZC:WL2G#-;RAPI]#C
MH?K5^N<NM"T70M1O/%D-J;>YALI!.+<[$F1?FRRC@L,<&N/FUSQ;IO@BU\=7
M6L1RPNL-U/I(M4$2P2,ORJ_W]P5@<DGD=* /4Z*\_:\\3Z[XT\3Z/I^N+IMG
MIJVS0R+:I*^Z2+=M^88VY!)SST (K!A\4^+I/ .E^-YM5@1#-#'-IL=JNR5#
M*(F8N?F#$Y;C ' QWH ]>K,UCP]I'B!($U>PAO$@??&DHRH/N.A^AKDS=^)]
M=\=>)-&L=;73+'3EMFCD2UCEDW21YV_,,8R"3G)Z 8K#?XC7S:)H=IJ&KVFC
MWMS=W=K?:DT:E4^S':2BM\NYR4ZY R>* /6E4*H50  , #M2UY&WQ U/_A%]
M7_LS5[35;O3M3M+>&_2-0ES%,R<, ,!N64D =,BM_P"W^)= \9V.FWNJKK$.
MIV5S+'$;9(3%-$%.%*\[3NQALGWH [VBO.O NO:IKES:SOXJL[Z1HB=2TB6V
M6"6S?'1 !NPK?*=V01SG-9UIXRU"V\0Z1%-XMT_59[V_^R7>FV<*F& ,&P8Y
M0 Q*D*#N)SD\"@#U&6XB@AEED<!(5+2'KM &>@]J@TK5;+6],@U+3I_/M)P3
M')M*[@"0>" >H->;^$QK%KK/CZ^DUJ2<VMRZE&MXP)'6!=CD@<8  P..*72?
M&6OZOX+\&Q17<4>M>()I4DO&A4B*./>SLJ<*6VJ ,\4 >IT5YS=:[K_AV_U[
M1KS5!J$D>A3:K8WCVZ1NC)E2C*HVM@[2#@=P<U776/%=A8>$]?O-9BGAU:ZM
M+>XTX6J*B+.,!E<?-N&03S@G/ '% 'I-S=065K+=74T<%O$I>261@JHHZDD]
M!658^+_#6IW:6MAX@TNYN'^[%#=HS-] #DU2^(W_ "3;Q)_V#IO_ $ UP.MZ
MGX=\2^$+31_#FGR7&OO]G^S21:;)&;>164F0R% %  .3GF@#V6BO-?&_B2_T
MC4M1*^,-/TPVUL);+3TA6:2=@I)\[(RH)X&TCCG-:.F^*=1;QAH\-ZZC3-?T
MI;FS3:!Y5PJAI$SU(*MGGTH [FBO*]6\9>(O[.U[6--N(A:1:S;Z;IT;Q*5<
M*ZI,Q;&2&8D ]L<5=FF\86GC>W\.'Q)'/%J%D]S]J:QC5[4HP!$:C@@[@!NS
MCKSCD ]'HKRF7QSJ^D>&]3MM1U2V^W6VO#2$U2:%51(V4/YKH,#*KNXX&0*9
M'X]N8K+Q1:6/B6VUQ[+1WU&TOXXHPT;KD,CJHVG!VD<="<YH ]9I RDD!@2O
M! /2O.6U3Q3I5QX5U2^UB.YMM9NHK6XT\6J*D/FQLRE''S$J5YR<'T'2L;19
MO$6EM\0]4MM1DU"ZL[IU6W-LG[UUB3:_RC/RJ/NCKB@#V"J=MI=E9WUW>VUN
ML5Q>%6N'7(\PJ, D=,XXSUKF?!.IW.J2S3Q>+;3Q#IQB!)$*13P2YZ%4 PI&
M>&&01WKLJ ,_4-2TZWN;73+N?;/J&Z.&%=V^3 RQ&WD #JW ''-3Z?I]II5A
M#8V%NEO:P+LCBC& HKB?#R2ZYX\\8ZIYNR:S*:38R%0WD )O<@'@Y=@?P%5H
M?'6HI\*KS4;@*?$EI*^F21!1S>[_ "UPO3DLK8Z8- '=V^KV-UJ=WIL-P#>V
M@5IH2I5E##*D9'(/J,CM5TD 9)P!7GGB6.ZT/7O VM33B6_>Z31[Z55"B=9D
M/4#L'7<!VS6]\0?M(^'VOR6EVUM+'8S2;U0,2%0DKSTR!C/49XH V+G5K&TO
M;&SGN L]^S+;)@GS"JEC@@8'R@GFKM>._9-7CM_AC%#J:RWDN\PSRP*! C6?
M0*N-VT9(SU.,UJ77BW6O"0\76VIWZ:JVF6<%U9SRPK$<RED"N$P" P!R,'&:
M /3JJ:EJNGZ/:?:M3O;>SM]P7S;B0(N3T&3Q7GWAOQF6\7Z9I \7V?B./489
M?,$,4<;6TJ+OXV=4(##!R1@<U=^+CK%X:TJ1K=[A5UJS8PHH9I '^Z >"3TQ
M0!OP^.O"5Q-'##XFTB261@B(EY&2S$X  SR:O0:]IESK5[H\5T&O[)%DN(=C
M9C5AE3G&#D>AKF=.UFPN=1MX!\/]8M"\@ N)M.A5(^?O$AR0!Z@5F:"Q7XX>
M-V'46-H1_P!^Q0!WFC:UI_B#3(M2TNX^T6DI8))L9<X)!X8 ]0:OUY#I?CCQ
M->_"SPUK"W4+:MJ&L)9R.\*A&5I73! ' P!R,&M=9?&$?CF3PJ?$JRQ3Z>-0
M%\UE&)8 )"A1% VG)*G+ X /UH [C6=:T_P_IKZCJEQ]GM$*JTFQFP2<#A03
MU-7P<C(KR+5_&_B/3/A;K=]]MC?5])U=].^UB!0)5655W%,;02K=JZ35+_Q#
M?_$0^'M-U1-/L_[(2\>86Z22*_FLOR[AC)XZY  /&3D '<TA( ))P!U)KSBT
M\2:X_@_51>:YIUG=Z9K$FG3ZK=(J Q*RGS GW3(0P 7IFL:Y\2:AJ_@[QU86
M_B,:@FFV2S1:@ELB/(CQONC8  ?P$;@ >: /8 0P!!!!Y!%+7D\WB*[\.>'O
M".D77B>&Q&HVQGDU*>",&"%(TQ&BD;2Q+ 9(/ -$/Q!U&XT*XL-/U:TO]1;6
M8-*M=52)2C), PE*#Y2RC>"!QE?PH ],EU6RAU:WTN2<+>W,;RQ1;3\RIC<<
MXQQN'YU<KS:.TU:Q^+N@P:EJ?]I)_9EVT5P\*Q2<M'N5@F%(& 00!U]LUW&O
MZS;>'M OM7NS^YM(6E89QN('"CW)P!]: )8=7TVYU*?38+^VEOK<!IK9)5,D
M8.,%ESD=1^=27UE;:E8S65Y$);>92DB$D;@>W%>'6;V_A6R\.^.9M1M9-4N+
MMY-<2.92QANB.H!S^[(3CUS7HOBK5=:3Q?X:T;1[Z*UBU..Z,TK1+)M$:HP9
M0>_) [<Y.<8H ZC2]*L-$T^.PTRTBM;6/.V*)< 9ZGW/O5RO,=/N/&>HWOB3
M1?\ A)DB?1)%\N^%E&9+C?&'574C: O<@9.>V.7V7B[7/$UIX1L+&ZCT^\U:
MQ>]O;M85D,:IA2$5LC+,>^<#UH ]+HKRO6?%OB'P]I'C#3Y]02YU#2(+>YL[
M\P(K/'*V,.@&W(((R!SGI77>(M8O=/\ %'A6QMI0MOJ%U-'<*5!W*L+,!D].
M0.E '34A90P4L-Q&0,\FO*/[:\8WO@_7O$<6O16W]DW%YY-N+.-Q<)"[<2$C
M(X&T;<=,DG/$SMJFJ_%[0KF+5I+:&;0S=K"($8(A>/?'DC^(@'=U':@#U*BB
MN(\9ZO<V&K6T#>+;+0+-H"R_NEFN)I<_W&! C [CDDXXH [>BO+[?QAXAUK3
MO WV&ZM[>XUHW,5U)Y(9?W:-EU!_W2P&>N >*6[\7:YX4A\8VVH7RZM+I-K;
MW-G/) L3$S;E"N$P" P'3'% 'H=]JMEILMG%=SB)[R<6]N"I.^0@G;P..%/7
MTJY7EFNV'B&PUOP2-7UH:FDFKHSEK9(C%+Y4G"[,94@MUR>!SS77_$#6)M \
M ZUJ=LQ6XAMF$3#JKMA5/X%@: -?3]7L=6-S]AN!.+:9H)653M$@ZJ"1@X[X
MS@\4:IJUCHMD;W49Q!;!U1I64E5+' +$#@9(Y/ K"MO#UQH_@C3=,TO6!HXL
MH5::Y\A)0P"DN3OX&6)8FLWP.=6\4>']5F\07G]H:1J#-#8B6V2%Y+?!4NP4
M#A\Y /0 'O0!W@((R.117&?"Z]N+GP1#:W<AEN--N)M/>1NK")RJG_OG;79T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZJ&^(A\VU_XJ*/99_.WRGRW7Y^..6'3-;&K^&;Z^TKPI:Q/ )-*O[6YN"S$
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MC*MUQP1TKTJB@#@9?"VNZY<ZYJ^K)96M[=Z/)I5E:03-(D2ODEG<J,DMCH.
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M'C"O'D)(K*K9X;!7 Z#FM.*W\10QZ-&U[9W!C)_M25XRAE&TX\L#@?-CKVH
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M40 J92, #&.IKI-+T/55\92^(=1-FAGTN*T>*W=FVR+(['!*C*X8<]?:L)_
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MG0NL:%MJJ%#+EF.>XP%[YKB_"FNS:#I/B.6ZBC>_N?%<]HBQ*S(97"<@#+$
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M\(^%M&66Q,NB7EO<O(9'VRB$\ #;P3G\/>O0** /.M";5A\0O'8TZ.R<M-:
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M0H$51[ <"IJ .(D\'WVI:OHNHZDFGI?:9<^:=1MF;SYXP& C8;1P<C)W'H<
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M^?$/BNQU5+U8;3;&FHVI3/VI(I!)&,]OFR#[4 <K+K&HV,N@^'_$6MZU _\
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MH.[G[U7-3O=5\*:GKNC1ZQ?7EM)X=N-1M9;MP\UO-'E3A\ D'(/.<$5U.O\
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MF(+LAW;#ZA@"N/>N?O?$TWBB;P9:Z+=2VXU0C4;MX7PR6T:@LA(Z;G94_ T
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M_ &G^'QJN+[3KS[=:7R0\)*'+#*$\C#$$9Y!KK= UVV\1:8;^TCE2(32P8E
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M!YO<66F>+_C#97FD7:W5C80)/JCP,&A>:-F^SJ6'!<%F;'HHKU)UWQLFYEW
MC<IP1]*YVP\16;Z%HVHZ9HU\]KJSH52VMUS 'YWR@' 4=R,UTE '&6WA77[B
M_P!)_MS7;6]LM)G^T0&.T*3S.$9%,CER. QSM R:(_ LB?#*[\(_;U+SK.OV
MGRN%\R5I/NY[;L=>U=G10!QDWA#58M<OKG3M8AMK/5(88KU6MBTH\M-F8FW
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M1P0^5# H&-J DGGJ23^5:]% '"^,0=#\7^'O%K#%C!YFGZ@__/.*7&QSZ*'
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MC;<-I*\<@CC(Q0!-I.IWWCS5]$L;V_O+6T'A^'4KE+*=H&GGD;;RRX.T;2<
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M5EQ'G[H" 8S79:;%>P:?#'J-U'=7:@^9-%%Y2L<]ER<<8'6@#QGPS;#P]/\
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MHHH **** "BBB@ HHHH *:\:2H4D174]0PR*=10 @ 4    = *6BB@ HHHH
M**** "BBB@!K1HSJ[(I9?NL1R/I3J** "BBB@ HHHH **** "BBB@ HHHH *
M.M%% #418T"(H51P HP!3J** "FO&D@ D16 .0&&<'UIU% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-5$3.Q57)R<#&
M3ZTZB@ HHHH **** "BBB@!JQHK,RHH9OO$#D_6G444 %%%% !3=B>9YFU=^
M-N['./3-.HH **** "BBB@ HHHH **** &I&D8(1%4$Y.T8R?6G444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8'BO2] N
M]+DU'Q!:K-;Z=#)-N9F&Q<9;&",_=%;]9'B?16\1:!/I8N! )WC+N4W959%9
MEQD=0I'XT 9W@'0O[#\,('A\B>]D:\E@#$B$OC$8S_=4*ON03WKJ*** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>sesenbio_minorirosales-e008.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2[N=1,Z)M14VCRB%8DR9)Z#'. :WM&\7)J>J#3+O2=1TJ\D@-Q!'>J@\Z,$
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M75OM%Q8PRWMZP=)O+F0CRV"C<!O()Z<>U=KXF4GXD^!2 <![[)]/W%=H  ,
M8%% 'C>@ZCX?7PAXBT/7OM!:'69Y+J*!6$MLIG!2?CD*IVMN&<8[UU'@+5)K
MK5]4L+779M?T6WBB>WOYU!9)&+;HC( !)@!3GJ-V#7>8'IUI  !@  >U 'F/
MQ2GNO#^IV6O6$3M->V-SHQ*#/SR+O@/X.K?G6+XAT5M'UJU\%VD;&S\0VUA
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M.FX 9'X5YC:Z_8Z%X)\6^&+YG&M^??K'9^6Q>X64LR.HQRI#9)[ '->R  #
MXI,#.<#/K0!Y'I>J6?AO7/!NJ:O,+2PG\)I:)<2 A/-!B?:3V. >M9=RKZMI
M?B'5(A?06EOXK@O9'A0K,MN(XP95!!/ 8/TR .E>X$ ]0#2T <!X,BT&\\47
M6HZ5KFKZW-#9B![NYE$D"JS[MBL%&6!7..P/O3?B)>6^E>)O!6J7TGDV%M?S
M":=@=L>Z$A<GMDUZ   ,  #VI2 >HS0!YGHWB/2?"'B#Q5%KEV+07UZ-1LY9
M%.+F%XT "<?,05(P.:WOAE876G> -.BO('MYI&FG\EQAHUDE=U!'8X8<5UI
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MSG81GI5CQ?X?LO#?AW09-*L773M)UJ"_NTC#2/Y?S!Y#U9B"P8GDX'M7HM%
M'GB:I9>+OB=H5YH4ZWEGI-G=-=740)C#2A%2/=T+?*3CM7#:3-;W7PH\/V@N
M[J&?P_JXFU5;4$3VD9DG7?C!Z;@W0\ U[V  ,  #VI< =J /&]2@T.\\,>,=
M0TC6=7UJ9-&:V>\N9!)"0=S!$8*,L#R<9QN]ZZ7Q0A^S?#\*OW=8MN@Z#R)*
M[X  8  'M2T >2Z;J%K;?\+-T::41ZC+<7=U';L"&>(P+AQZBJ&DZH^G^ O
M-I>:M<:/H]S!-]LO(3L8,HS''OP=FXECZG;BO:<#.<<TA (P1F@#P/4IX/\
MA7/Q'LHY;QY6NX;F(7I9IY(6$ 20[N2#@XSSVKV[0^/#^F_]>L7_ * *OT4
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MMF1 L!QAV9R ,DX ZG!]*X?2O$]AH.@^,[#4(KB*[N-6U%K2+R';[7N8A0A
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M+*D;NL%W;32;%+%4692QP.>!3-.O+?5OBS%J=DQFLYO#F(YMA ;_ $D^H]J
M+T'Q L9/#LNIO87L=U%>_P!G-IVU3,;K( C&#M.<@YSC'-:.A>)/[7O+O3KO
M3KG3-2M%1Y;6X9&RCYVNK(2&!*D>Q&*\RU'39IK/6KMQ?16UEXS:ZN)+/<LJ
M0^2J&1,#/R[P>.P-=?X(@T*XUZ_U'2+[6M39+=+=K^^E:2)@6+>6A;!)4\G
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MF.=R@EO7BM'P9#H%WXFN-0TC4=<U66&S\AKV]F>2$*SAC&I< [LH"<# SZT
M=%XB\3)H4]A9PV-QJ&I:@[);6D!52P49=BS$!5 QDGU%<;8>-&L?$'CO6+^U
MOXH=-M;)I+"1@7B;$FX+R5YX.0<$8K3\8W,>A^._#/B&^#KI<45U:SSA"RP,
MX4H6P#@':1FN3U-IO$P^)\^FVEP\5UIUG]E)A93<!%DRR@C)S@X]>/44 >I:
MGX@M]+O-'MI897;5+C[/$5QA#L9\M[84]*Q)?B%;Q3S3C2+Y]$@NOLDNK IY
M2R;MA.W=O*!OE+ 8SFL#4/$UAXFU_P $'2//N(H+_?<2^2ZK"Q@<!&) ^;KQ
MVQSU&>=L=+T:WTN?PUKNH>)CJ?VR6!M)M9I DZO,2KHN-NPJP8DG'7- '?/=
M7'AWXF6UDT\DFF>(8I'CC=RP@NH@"VW/173G'JOO7:UPGC ?:/'_ (%L8N9D
MNKBY;U6-(B"3]2P%=7INL6VJS7\5NLP:QN#;2^8A4%P ?E]1R.: .2\=:OJ&
MG>,_ ]I9W<L,%[?21W,:' E4!< _F:YOQ/J6K:K\8+719=,UI]/M]/:=+.SO
MT@\\^:5$Y(D7*X &TD-QTK:^(<,LGCSX?.D;LJ:A*6*J2%&U>OI4D\4G_#0=
MK-Y;^5_PC97?CC/GMQGUH ZKQ-XBM_"VDC4[R"62U$\<4SQX_=*[!=[9/W02
M,_6EUOQ%;Z)=:3:O#+<7&IW8MH8XL9'!9G.3]U0,FK6LZ5;ZYHE[I5T,P7<+
M0O[!AC(]QU_"O-OAT=1\0:_%<ZQ$PD\+6C:2"W(>Z+$22 _]<TC_ .^S0!T%
MQ\1XHX;S4(-"U*ZT*RE:*XU.+R]@VG#LJ%M[(ISE@.QZXK?M?$=I>>))-%A5
MVD2QCOA,,;&1V91COGY<_C7F=CK-OH7PNU'P5=PW!\0QQW=E%9+ [-<-(S['
M3 P5(<'/UK1L[F#P/XVL?[=D>"!_#=K9QW C9T>:)VW("H/S8(..] '?:%KT
M&O+J#0121_8;Z:Q?S,?,\9P2,=C63JGC5K'5+ZTM-!U+4HM-"&^GM?+Q#N4.
M %9@SG:02%!ZU2^&+RRZ=K\\MO-;F?7;N41S+M90S C(]>:PO&=YI-EK>JW=
MCJ&KZ)XHCC7R4AC9X]3(0>7^[PRR#/R=B,<\"@#<A\8:M/\ %"308](N&TY+
M&.7?NB&-SD><<MNVXXV_>R#Q5FU\?)/?68ET/4;;3+ZZ-I:ZA+L"229(&4W;
MU#%2 2.>.F:PDU.33?BT)]3B-O=:CH$$4"[&*/<>8Q,88 @8)[GI7)G4H;O3
M?#FJ7>I:W>ZK;:I:W.LK,TH@L<288&/ 1<$@  9P": .ZT3QS?W'B3Q3%JFF
M3VNE:4P)G=XB+=5BW-NVL68MR1@' X.*U=(\:_VAJ5E:7NB7^F+J*-)82W)C
M(G"C<00K$HVWYL-V!]*X>[C-YJGQ+\.IO34]519;&(QL//46X^ZV,=1CK5WP
MPGAW5-=T3[/J7B;4+^VS.T%U-(T=BX0J?-#@!3\Q4 9)SZ<T =9\1=0T_2O
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MG)IL4TD=['$)C!<020N8\XWJ'4;ESQD=*CA\5Z-/J%K8I=L)KL,;5GA=([C
MR?+<J%?CG@G(YZ4 ;5%9^M:YI_A[3VO]4G:"U5@K2B)W"DG SM!QSQD^HIG_
M  D.FC7(]%,T@U"2'STA,$@S'_>SMQC)QUX/'6@#3HKE]>U[19]*/GZS>Z=&
MM\EOYUNCQN95<?NQE3D$_*<<<D9I\GBV ^-F\,+!=K(+/SVG%LY +.%7!VD8
M^]EC\N<#/6@#I:*\W\'^-;+3M)NHM?U>>2;^U[FV6:9'D"*)2B!V4;4!Z#.!
MZ5Z+-*L$$DSARJ*6(1"[$#T4 DGV% #Z*\NU_P :3:[\+)]?TN>^TV5+I "(
MVCS&;KRP-Q&#E>NT\$X-=SIOBC1]6U2?3+.[+W<$8E:-HG3=&3C>A8 .N>-R
MY% &Q16*/%FBF_MK,W;*]TYCMY&A=8IG'\*2$;&/!X!Y[4GB_P 1P^$O"FH:
MY.GF+:QY6/.-[DA57/NQ% &W17-:5H^J7.E07>JZU>KJDT8D?[.RI% Q&=B)
M@@@=,ON)Q5BQOIM%T>TAU^\\_4)))(PT<19[@AF(*H@)^Z < <#KTH W:*PS
MXOT%='N]5>_5+2S<QW)>-U>%AU5D(W ^Q%0CQUX<-[':'4=DLL1FB+PR*LJ@
M G8Q7:Y&1\JDGMB@#HJ*Y^/QOX=DTB]U0ZAY=K8R&.Y,T,D;Q-C.&1E##@^E
M%CXW\.:CK2:/:ZDKWTB%XXS&ZB0#KL8@*Q'< G&#Z&@#H**P_P#A+]#^UQV_
MVPYENC9I+Y+^4TX_Y9B3&W=D$8SU!'6H;OQSX=L;F_MIK\FXL IN8HH))&0,
M"0<*I)&%))&<=\9% '145BOXMT-&TL?;2W]J@&Q9(799LC/!"D9QS@XJU-J%
MO/>7.D17$L5\MOYI*0L?+5LA6!(VDY!P/]D\<4 :%%<WH,MWH/A>'_A(=0FN
MIA,R1S2Q?OI%9R(P53.7(QP.?7H:U].U6TU1;@VK2$V\ODRK)"\;(^U6P0P!
MZ,I_&@!-7MM0N].DATS4$L+IB-MP]N)@H[_*2 ?SJMX:\/V_AK1UL899)Y&D
M>:XN)?OSRN<L[>Y/Z "IM1UFRL)5M9IIOM,L;.L=O"TT@4<%]JJ2 "1R1C/%
M<K\/?$ E\$OJ.I:C-= ZA<11S2Y=Y!YK*B@ 9)QC  _"@#NZ*Y;4O'ND6/A_
M5]3A-Q</I8Q<6HMY%E1B,J&5E!53_>(QCG-:,'B*S;2[2[F\]'N%&R$6LOF.
MV,G;'MW$#UQCWH V**YYO''AQ-*CU-]31+5[C[+N9'#++G!1E(W*02,@@8J*
M/X@>%Y7C1=44-+.]L@>&129$&YAROIWZ'M0!TU%<R/B!X:-M<SB^ES:N4GA^
MR3>=&0,DF+9O"XYW8Q[TNK:SHUU!H$YUV>UBO+R%[-K1B!=D_=C; /R-GD''
M3J,4 =+17/7GCCP[8W5]:S7Y-Q8!3<11022.@;)!PJDD84DD9QWQ5M_$ND+9
MZ?=)=B6/41FS$*-(TXV[OE502<#D\<=Z (;'PX(/%%_X@N[K[5=SQK;VX\O:
MMM .=B\G)+<EN_' Q6Y7)ZWX^TS3O"K:Y9^;>1M.+9 D#_)*7V$2#&4P3R#@
M]AR15JXU/3+CQ-H<1U6^MKR1)F@L-CQK<C;\QD5ES\H&1G'7OF@#HJ*Q;[Q7
MHVFM.+JZ94MW$=Q,L+O% QQ@.ZJ57J,Y(QD9QFB^\6Z'INH)875^JW<D)G2)
M$9RZ#'*[0<GD8 Y/84 7-7MM0N].>'2]033[IB-MPUN)@H[_ "D@'\ZK>&O#
M]OX:T=;""62=VD::>XE^_/*YRSM[D_IBI]&UO3_$&GB^TRX\ZW+M&249&5E.
M"K*P!4@]B*NRR+#"\K!BJ*6(1"QP/0#DGV% #Z*\M\1>-9M=^%&H:[I4U_IL
MT,X",L;1DI]I\L?,1@DJ.0IX)P:[K3_%.C:IJTVEV=V7O(H_.,;1.FZ/.-Z%
M@ ZYXRI(H V**Q3XLT5;ZVM&NV5KJ4PP2M"XBED&?D60C83P> ><'%4[GX@^
M%[5;MI-2)%G+Y5QY=O(_E' )+;5.%&1\W3WH Z:BF12I-$DL3J\;J&5E.0P/
M0BJ'B#5AH>@WNHF-Y#;PO(JI&SY(4D9"@D#CD]!0!I45P7AJ]1]*TCQ1>ZYJ
M:&>SC2[M9TD\JXGD52#&C#KDD#RQ@UTT'BC1YTOF%V8VL &NHYHGCDB!&02C
M -@CH<8/:@#7HK"T;QCH/B"[6UTN^^T2M;"Z4")U!C) SD@#J1QU'I5K4?$&
MG:7<BVN99#<&%I_)AA>9Q&IP7*H"0,G&3WH TZ*KV%_:ZI807UC.D]K.@DBE
M3HRGH:Y^^^(GA73C="XU50;63RIPD,CF,X!YVJ>!D9/09'- '445G2Z[IL5I
M;7*W'G1W2[[<6Z-,TJXSE50$D8(YQW%9[>./#::9;:B^J1K;7%Q]EC9D8$2Y
MV[&4C*D'KN QWH Z&BN1F\4>'M9GTAH-=N[=CJ)BBBA1X_M$J@@Q2!ESMYSS
M@<=:V-1\2Z5I<DZ7,\F;9!)<>3!)*(%/(+E%.T8YYQQSTH UJ*S[C7--MK2U
MNFNE>*[(%MY(,IF)&1L"@EN 3QV&>E<OX)U>;4_%GC",WUW<VMO<VZP)<J4,
M68LLNT@;?FSV[4 =Q15*_P!6L]->&.XD;S9R1%#%&TDCX&3A5!) [G&!D5F7
M?BW3QX6O];L)&NDM4E!1(7+)*@)*.@&Y"".=P&.] '045QG@N.?5;+2?$!U;
M5#)-8)]MMIU<0S2NBMO17&% )."GRD8K=N_$FEV4\L4TTN89$BE:.WD=(W;&
MU695(!.Y>"?XAZB@#6HKGX]0TT^,+Y$U:\EO(+)3-IRAFBC7<?W@4+RYSC@D
M\=*?9^,="U"TM[FTO'FBN+DVD12VE):4 DKC;D8 .2>.#Z4 ;M%<Q%XTM)/%
MFJ:(;:\ T^".1Y19RMN9MY.,*>,*,'N2<9Q5ZV\5Z-=^'CK]O=M)I8S^_6"3
MG!P<+MR>>.!0!LT4B,'17&0&&1N!!_$'D4M !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !4<\\5M \TTBQQH,LS' %244 >$^%/#,S?#C0]>TBS7_ (27
M1)IYGM)8]K7"&5R8V4C.XI@JW8]*ZGQ1KT>IVGAGQ1:VVH3:997#MJ%M )([
MBW62(IN*J0WRDG..H)ZBO3:* /-+B'PGJ^A:I?V]IJ<=E?RVJS:HIG69I%?Y
M)%\S+8C.T[L8Z^AK"\0SZN?AOXUL]1OHM7M;:* 6FK)$%:X4L"48CABG R/[
MWKFO:*PO&'AZ3Q5X8O-%2\6T6Z 5Y3#YA !!X&X<\4 <[J\5OXD\7>$9M'97
M;37FGN)XUXMXS%M"-Z,S%1M//!XXKG; .OP<U'P9?V\A\0Q1SV@M&4EYY&=B
MDB?WE)8-OZ#!)/%>NP+*D"+,Z/(!AF1-H)]@2<?F:DH \ZTV/^S_ (J6<=U,
M':V\,);27#?=,JR@D;CQG W8ZXYK"TBVT^[\%V]K?7=YIDRZ]=26M]!E&M'+
M2LCMD8",I(YX.ZO8J* /'KVY\0'0;#5=3@DU.#1]<8SW.FHT3WMMY1C^T*J$
M'(WD?*<';Z<UVGA*30-1O[S6-#L[HB>-$FO[GS@TQ'11YO)VCOTY &><=;10
M!PWBF4V7Q(\)7\L,[6RPWL)>*%I,.RQ[5.T'!.#CZ5BQRQ&'XHY_Y>-_DY4_
MO1]F"?+_ 'OFXXSS7J=% 'E>EZLL$_A.RN()K6-O#\:_;[>T9YY)!M#6P8*2
MF-NXCKG'(QSC:89(/A=X,:2UNT&E^((WO UN^8E$LN21C) W+R,]:]MHH 9#
M*)X$E57574, ZE6 /J#R#[&O.])TB]L/&=WX66+.@)<+K<+YX0,Q_<8[8F&\
M>RFO0;R*:>RGAM[@VTTD;+'.JAC&Q& P!X.#S@UFZ!HMQI,$CW^I2:GJ,^T3
MWDD:QE@HPJA5X51DG'JQ/>@#E]%O!X<\;>*X=<8PQZA/'>6=S(IV3Q^6%,:G
MNR[0-O7G@5S5MIEUX7\+^![K4H)H;6SUB6>9?+9C:Q2B78& !( W+GT)Q7LM
M% '!>$;M;KXC^,IU@NDAN5LFADDMW17"PD'DCCJ.#@\]*3Q/=R:%\2M#UR_C
ME.BFQFLVG1"ZVTS,K!FQG 8*%S7?44 >2I=QSV7Q2:.*X"72,8&:W=1+FU"@
M+D<DGH.IS5FXMK2\T/PDR:S<:%JUOI0^S:@H'E*0L8>&56^4Y('RG!RI]*]1
MHH \LMM?U!G\*G7=._LZ:X@N?,O[6R9WW[P D8VDQ^:H#GC)X P:QK;RHOA:
MXN$O[:XTWQ#Y\;/:R/Y<GVHE2XQEUP><9/([U[96+XBT*?6DLI+35)M/N[*?
MSX9$C61"VTKAT/###'N"/6@#D=!U[P]J?BG5M8_MB)M1N+!8%M?)EB"11Y).
M9%4NQ+=AP,#WK,T^ROKK]GNRM=-MI9+ZUCBD>T7*2,8YA(Z8X(8@'W.1ZUZ%
MI^D7ZW$-SK&J+?SP$F$1VP@C0D$%L98EL$CKC!/%;- 'F<3Z'XRL[R;P]9:D
MVK_V=<6XNKXSJ;1G0@1[I#@L6(X7(&"<],P^%+[0M<CT6QN-(U4Z_IK1F2UN
MS<;+.1!AI-S'8!P< <G(&/3U*B@"AKFDP:]H5]I-R/W-W T+''3(QD>X//X5
MY9M\3G1]#\7364[ZKH<ZZ<]H#S<QY,,S_5GVD9Z"//>O8J* /._'MD=.^'EG
M8DF:X%]:R2%%),C^>KRO@>^YC]:LS7*6?QC2[E27[-=Z$D,,R1,R,XG9B-P&
M!A2"2>W-=W10!XG=_O/@SXMMXT<W$VK7#QQ!#O<-<!E(7&3E1D'T'M7M,4J3
M1++$X>-QE6!X(I]% 'B!E(^ [Z,]O<K?VUXL<L#6[@AOMN\@9'S?+\QQG ZU
MUNKG[9\4K<6DP!F\/7$"3K]U9'=2@W#C. 2!7H5% 'DGA*YT74-,T70-3T;5
M6\0:6\*M97!N#'#)%A?.#$^6% !(^N .179?$7PU-XM\":GH]JP%U*BO#N.
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ML3!HW4,K#N#R#45[:)?6KVTKNL4@VR!#@LIZKGJ ?;!]ZG5510JJ%51@ #
MH \1ED(^!.I:*]O<C4(+QTD@:W<'<;S?@<?-\OS<9P.M=?J[K=?%+2S:3 "3
M1;F%9UY57=D* D< G!('M7H%% 'D/A.?1KS2-(\-ZOH^JOX@TQHHVLIVN#$C
MQ\"<-GRPN!NS^ !R,V8Y(CIWQ1'>Y>;R1M.9@;8(-O\ >^;(XSS7JM% ''>'
M?$VG6&D>$]&N6F6\O=/B6/\ <L5#)& 59L85L@C![UK^+Y%C\&ZUN/+6,R*!
MR68H0 !W)/:M&>RBN;J">4LWD-OC3/RA\$;O<X)'ISZU9H \IF-Q%X5^'6KQ
M1RS66D& :C#&A9X<P>6791S\A)R,9&<UI7:1ZCXZO_$5E*K:9!H#VDMRG*32
MLY95!Z,0!SC."P%>B44 <G\,L+\-]"BVE)(K58Y$*[61QU!!Z&J&O:DL7C]+
M">VGM8Y=-_=WEM:EYKIMYS ) IVJ/O$#!YSD8Y[NB@#B_A.Y_P"%::- \4T4
MD$1BD66)D(8,<]0,_4<5DZ+J>E6/B[X@1:BR#S+J+,;+DSK]G4%%'\9_V1D\
M].:]*KGM!\.7.CZYK>HRW\5P-5F69HUMS'Y950@ .\Y& .W6@#S73K&[\#6G
MA&Y\0V^H'34TR6TN7M'EW6<CRB5=_EG=C&%/7E?85I>(8M(7PS83Z3IT\%I=
M>(K:\8RK(7N '4R3,K_,!QU/7&>XKUFB@#AO'LT9U3P:RMN5-9CF=E&0L?EN
M-Y(Z+EASTYJKX?O$\.>(?%UAK^Z/[;?M?6LLB$K<PNBJ$3^\R[=NT<\\"O0Z
M* /%]$LM1\$#P+>:Y#<#3K>TNK>=@A?[$\S[TW@9(^7"9[8-=7X+NX[KQ]XT
MFBCG$-Q-:O%*]NZ(X$"@D$@#K^8YZ5WM% '"ZS)+HOQ5T[6[T,-'GTJ2P\_!
M*6\WF"3+G^$, !D\9%9@M&BM?B/K*[DT[5(]MFNTCSF6W*,ZCON<X!'WMN1V
MKTVB@#G_  -(K^!-!0'YXM/@CD4\%'6-05([$'M7%>(?/T_6]5U3PU?R+J)N
MHTO-!NDWQ:@<(NZ,'D';C++D?+SC!KU6B@#A(KF&'XQZG<2MLA70XD,A!V[E
ME=F7/0D*0<=:Q+:5?#WC"V\5K:_\2;Q#*Z- B,7M'(&)RO;?L&_@;?ESR#GU
M:B@#A=-G%I\7-=$L4VW4+&S-LZQ,R2!/,W'<!@8R.I[U2L-(O;#QO>>&(XLZ
M!-<+K:-GB/YCNA]LS!' Z8W"O0KF.2:UFBAF,$KHRI*%#%&(X;!X..N#67X?
MT2YTJ*274=4EU34I@JS7<D2Q95<[5"+P ,L?JQ- &S1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5!>W<5A87%Y.<0V\32N?15!)_05/65XFLI=1\
M*:Q8P F:YL9H4 [LR$#]30!YY#JFH:7\,;OQ?+.L>N^()(FCFD.4MDE<)$HS
MP%1&W>YSFM'PG/H<?B#.D>,=3O3':N]W9Z@\LGVD<8FC,F,8.<E,@@CI55[%
M_%?P&T==/@%U/;VMK(MO_P ]'@*[X_J=C+]:LRWT?C;QMX<FTW3M0BM],6XD
MO9[JT>#RQ)$4$(W@;F).2!D#&: ,B.#5KOX<3?$ :YJ::UY+ZE'"+EOLRQ*2
MPA\K[I78,'C.><UT%W?'1O&?A_7+8LNG>)0MI=PD_*)BF^&0#^\0"I]1CTKG
M8[V_M/AM-\/O[*U!_$'DOID8%J_D/&Q*B;S<; FPYZYSQBM_QI:JEQX!T"W.
MZ9-7@F4=_*MXV+G\L?G0!V>MZO:Z!HE[JUZ6%M:1-*^T9) '0>YZ#ZUYYKOB
M#5]0U7P6FI:%-I7GZQ%+$1<K*&3RI,J^ -K?,IQR.O/%=7\1=(NM=^'VM:=8
MH9+J6WS$@ZN5(;:/<[<?C7+:OXA/BO5?!W]G:5J82VU6.:\>:RDB%NWEN-A+
M 9ZG)&0,#GD4 ;NH>.+W3KBXN)O#=TNB6UV+66_DF","6";UB(RT>YA\V>1R
M!6OH_B1-5UW6M'DMFMKO2Y45E9]WFQNNY)!QT//';%>2Z[;2ZGH&L+>6&O7W
MBF.]DDD4BX\B"!)LJ4'$;+Y8&  22<^XZ+XAW-[I&H:9XJT"*1YM7M&T<J5*
M,7E&ZW<J0""K9SD9&<4 ;</Q$DU!(5TK1)+N>[O;FWLE:Y6-)XX,!YMQ'"Y.
M ,$FNHT34KC5-.$]WIMQIUPKM');S\E64XR&'#*>H8<$5QNN:+X?T+PWH&B:
MIIM_+86<96/4K%)#):RJH^;]U\XWY8Y'&1SVK:\ 2:C)X=D^WRWLT2W4JV4U
M^A6>2V!^1I 0#GKR0"1@T <'J$FJ:Y\<&L[[1)+JWL;%9(+7^T=B1CS@!<<8
M!)'\)Y_*NJG^(=U]COM7LO#EQ=^'[&21);Y;E%=UC.)'CB(^900><C.#4=I9
MW2_'C4+TVTPM6T)(Q.4.PMYH.W=TSCM6!97T_A_X=:EX)FTO49=;5;NTM8X[
M.1DN1*[E)!(!L"X<9)(Q@T :>J7BW7QM\'2V\Q>VGTNXD4J3M<%20<?2JGA#
M7;?0;KXDZKJ,LAM;/5Y'('S''.%4>I. /K3X]"OM-^)?@.$P2R0Z?HKVTUPB
M$QJRQE>6Z#)%9"^&]6U+1?B=:064PN+G5OM%JLB%1.$</A2>N=N,].: .YM_
M&>I0ZCI]KK?AN33%U,F.SE-VLH,NTL(Y  -C$ XZ\U#<_$BW@^'EOXJ339I'
MGD\E;$2 /Y@<JRYQVVL>G:L_4M6'CC6/#%KI=CJ*"RU%-0OI+FSDA6V$:-\A
M+@ L6;&%ST/:J&F:)>CXERZ'-8S'1;.^N=8CF:,^2YFB55C!Z9#R3'% ':S^
M*[==0\.6EM UP=<5Y(F#8$<2QARY]>JC\:Y+P]XUT;1_A]'J^G:+<P63ZI]D
M-L+AIGW-(%+@MDGUV_A4?PWTO4O^$BE_M.UN(H_#UD=(M'F0@39F<^8A/4>6
MD0S6!X>TG4HOA9IMM)I]VDZ^)XI6B:%@P03J2Q&,XQSGI0!Z+I_C&Z;Q"='U
MS1'TF1[1[R"0W*3*\:$!@=H^5AD''(]ZQYOBA<6^@)X@E\,72Z/<NJ6=Q]H3
M=)N<*K.F,H",D'GL.,BK7BC2[G4?'^EI%%)Y4FCW\#3!#L1G\L#)Z#O^5<3K
M6M3#X-6GAV72-1@O[$6=M>B>U=(X1'+&NX2$;6W$#&TD_-GH* /:;V\@T^QN
M+VY?9!;Q-+(W]U5&2?R%>6>)_%>J:QH6@W,^@7&G65]JUB]I<&Y5RRF56 D4
M<IN7GN.Q(.*]$\4Z=-J_A+6=-M\>?=V4T,>3CYF0@?J:\TU'6YM:\)>%](M-
M'U07UG?6'V])+&1%MO+=0V6*X;D?PYXR3C% '7ZEXYN;6YU1[#0)[_3=(;9?
MW:3JA5@H9Q&AY<JI!/(]!FL;4;Q;KXX^%);>8M;3Z1-(N"=K AB#CZ5C7>D:
M5I>K^)+?7-/\17%U>7TMS91:?+="*\CD .P>6=@8'<IW8XQVK9FTB:T^+OA$
MVUA<1V%IHTD&[!=8L A49^1G&!UYH 2S\9:5H=KXNU2ST2=$L-:,.HM]J9RY
M+;6F .< 9SM&!77Z_P")8]%GT>WCMS=W&JWBVT,:.!A2"S2$\_*H&37'^"M!
M>]D^(EAJ=I-%:ZCJUPJF2,KYD; C<N>HYX(JO\/K+6=4\06D^O6<\)\,V!TV
M%ID*B:<N5>5">H\M$&?]J@#>'Q!D(_M$:'-_PCGVO[+_ &GYZYSO\OS/*Z^7
MOXSG/?%3/XVO)O&&H>'-,T"6]GL)(1<3&Y6.-(Y$#;R2.HSPHR3@],5P6C^'
MM%M--A\.:OI7B.ZUA+HP/;13W2V\J>:2LP8,(@FW#'D<@C&:[GPQ:7$/Q*\<
MW$MO*D,[V/E2,A"R8A(.T]#@]<4 7])\:V>H^#+KQ'/ ]HMF)Q=V[L"\+Q$A
MD)]>/U%:VAZC)J^A6.I36K6CW4*S>0S;B@89 )P.<$5Y=XCTB[3Q[<>$K:,G
M2O%4\-_.5.!$L7-R/^![8_\ OJO7GC#0M$/E4KM&.U '"O\ $B?^S)M?A\.W
M$OAJ*1E;4!<*)&16VM*L.,E 0>^<#.*YGQY<ZCK7Q-\/Z2^D27VF-!--#:IJ
M'E)>?+G>2,8V]@?ZT07ES9?"J?P&VE:@_B$02Z<D"VDACD#,0)1+C9LVG=DG
ML:V[O2;NU^*O@G;!-+;V>ESP2W"QDHI"8&6Z#..] '4^*]2O="\$ZEJ-A:B2
MXM+-Y%C,@'EA5)+9/7:!G'?%<'=^(-8F@^'>IW^G3->2SMB&*96-T6M3M?C"
MKN9LD'[O6O0?&%K/?>"=>M+:-I;B?3KB.*-1DLS1L ![DFN%TN=M6B^&[VUG
M>@:=(UO=^=:R1^4ZVA!SN XR<;NA/&: .BM_'PMUUQ/$&ER:7<Z1;I=2Q+,L
MXEB;.THP R25(P0.2*M:5XKOI]9MM+UK0I-)FO87FLR;A9A)LP61L ;7 8''
M(Z\\5R?C+P_J.M:]XO@M+65S/HEJ(3@JLKI,[[ W3)P!U[BK?A:U\.7GB:QN
M=,TWQ$]S:Q22//J,MT$M&9=I0B8X9B&(^7/3- &A\5;N6T\-Z>8]1N-/CEU6
MUAGN+>X,++$S8?YP1@8JGI^E^%6U&V%K\0]4NI_-4QP?\)(9/,;/"[=WS9].
M]6_BM"TWAS36^QS7<4.KVLL\4,!E)C5\M\H!R,56M?$O@R.[A>W\*WT,P<;)
M%\/R(5.>#G9Q]: -F;QU8Z?=:[;:Q"UA)I,8N!N;=]I@/"R)TSEOEV]FP.]1
MR^,+];;2((?#\KZUJ<+W"Z>URJ>1$N,M(Y'R_>48P>3CM7,^*M#U7QSX@GU"
MPMEMT\.'_B7_ &F# O[D,KL#N'^J&T*#T+'.>*9KIM=:U;0/%6J6&M6^F2V$
MMK<I;">.:SFWJPWB+#E20RYP1G:?2@#IF\?PKH(NSIEQ_:AO_P"S!I@==_VK
M^YO^[MQ\V[IMY]JAN_']SI6CZS=:QX>N+.\TN..9H!.)(YD=MH*2@8.#G(QD
M5SDNDP6FCZ5X@T31-76UL]<^VW$-R9);F>+88C,%<E^FTA3S@9Q5_P 5ZM>^
M-_!7B:ST?1[QK..U0V]Q-$\3W4@;<R)&RAB %'/<G % '9:QX@72=7T;3OLS
M3/JDLD2,'VA"D;/SZYVX_&N)T;Q9JNK>&_&T_B'2"^G6,E[&RI=*"%C0 VX*
M@'IN^?WJ6\UP>*/&?@VYTS3M1-G:W4S7,\]G)$L3- X"_,!GODCC.!GFLRR,
MT/AGXE:!)97JZA/<:G=PI]EDVRQR( A5\;23G@ Y]J .F\.>++%(_">E6^F2
M6EEJ^G&6R9IS)L**"8B3R3M.<D\XJWJOCRSTG6-6LY;662#2K%+NZGC.<.[8
MCA"]V;J.>]<Q+H]^OP=\,7UO:3_VMH4=M>QP>61(VP 21XZ\H6&/7%0MX;U+
M6_AEXCU![.<:MKEW_:'V9LI+Y4<BF*+L0=D?'NU '9:3XIO;C6XM)UK1'TJZ
MN8&N+7_25F655(#J2 ,.-RG'(P>M9OQ/FN$TO0H+>_N[%;O7+6VFEM)VA?RW
M+!AN4@C_ .M5+PI:>'+OQ/;76E:?X@DFM8)&:ZU*6Y"6[-A3'B8\L1G.T$#;
MUZ5=^)^EG5].\/VALVNX&UZT-Q&(RX\K+!BP'\.#R3Q0!A>,+(^#-%&L:-XM
MUJ;4HYXE@LKS4FN4NRSA3'L;.<@GD<C%==JOBJ^AUJ?2M%T*35;FT@2>[Q<K
M"L0?.U02#N<A2<<#&.>:YO7_  =IO@_6M)\6>'M @*6DGDWUK;6P=FA<@>:B
M@$[T.#QR02.E5==TW3+'QYJ^HZ[#KGV/4H+>2SGTQ[D*SHA1HV$)^]PI&X=S
MS0!TI\=M?KI:>'M(DU.XO[-KWRY)UMQ%$&"G<3GYMQQ@>AYIM[X\GM9]"M(_
M#U\^H:Q%,T5I(PB>-XMNY7)X Y)W>@R,Y KG[^P\-V6CZ':ZCH6NZ3#';-+9
MWMJ9I)[21VW-$S1[F#'.?FR.W45GIJNIZ?KG@"_UR"^GF2VU(3$P%K@0[D".
MT:C.[9L+ #/)XH Z^+XAP6^F:[-K>FS:=>Z)L^TVBR"8N)!^Z,;# ;<>!TYZ
MU/9>,-036M/T[7O#\FE'4MPM)1=+.K.J[BCX VMC..H..M<3JVEZAXNC\9:Y
MI=C<F&7["+%)HFB:[^SOYCX5@#@YP,CDBMZ^U1?&WB7PQ%I5GJ"PZ=>&^O9K
MFSD@$&V-E$9+@98EL8&>A- #W^)EXVC7NLVOA>XGTW3YI8KR;[4BE!&Y5BBD
M9?  8]!SC)(-:M_XRO!J<UGH6A2ZM]FMHKJX9;E8=JR!B@0,,NQ"DXX'3FN;
ML]/O5^"_B>T-G<"YE.I>7"8CO?=))MPN,G.1CUJ'7DTE5M3?66OZ9K4&FPK9
M:EID4Q:<[/\ 5GRP02&X*N._H: .LO?%]X;^+3]%T&?4+W[(EY<133+;?9T?
M.U6W _.<-\OL<D5LZ#K5OXAT2UU2U61(IU)V2##(P)5E;W# @_2O+YM.^S:]
M'JOC.#6$;4=)M-\VF-< )<QJPDC<0'J=P(R,=<5V>A7NG^&M"T&RAT?4K*+4
M[ADB@F)D>%WW29E9F)&>3W.3B@#5\5>(/^$7\/3ZPUF]U#;%3,D;894+ ,PX
MYQG./0&H]>\3PZ.FD"& WDVJW<=M;QQN!D,"2^>?E51DUKWUG!J-A<65T@>W
MN(FBD0_Q*PP1^1KRSX=6>HW_ (D2VU56:/P=#)ID$C=)968@./I"L8_X%0!T
M5Q\0+PQ:EJ&F^')[[1=-EDCN+Q;E$9O+_P!88XR/G"X/.1G!Q6S9>*[74?$E
MOI-K&7CN-*75(KD-PR,^T#'ZYKAK#4I?"_@_6?"=SIFI2ZL);M+)(;.21+M9
M69D<2 %0/GYR1C!J2RAD\">)?#TVJV]V]HGAJ/3&GM;:2<+<(X8J0@)&1G!Q
MVH [S0=?379=71+=H?[-U![%B6SO*JC;AZ??Z>U4M<\1ZK8:C)9Z5X;N-3\F
M 3SS&801@$G"HS [W^4G Z<9/-9WPX6[*>)[F[L;BR-UKLT\<5PA5C&T<6T_
MI^8([5C^(E%UXVU2UUJVUJZC-O"NBVMHTZ02,5.\LT1"AMV,ES@+B@#;N?B#
M$?\ A'5TS2[B_DUZUDN+1%=4(*A#M8G@<.<G/&T]>!38_B'';:1KUSK.ES6-
M[HCHEQ:)*LV\R &+8PP#NR!T&*YCP=;71N_AV&LKN,Z?I]];77FV[IY4@6(8
M.1WP<'H>U'BC1-4OKOX@O:6,\K^;IES @0_Z0(55G5/[QPI&!WXH OW^LZM>
M>/\ P3;ZKHLFE2M<7,BJ+E9DD7[.V02H&&!QD$=^"><;OQ.U_5/#7@:]U+28
MLW"E$,VY1Y(9@N[!!W<D#'OGM6)>:X/%'CSP;<Z9IVHFRM)[AKBXGLY(5C9H
M& 7Y@/?)Z9P,\UL?%>RNM0^&>LV]G;R7$Y6)Q%$I9F"RHQP!UX!- &-J.LZO
M#\1]#E.BRMJ$^D7*C3TN5*AO.3EI/N@;1G..^.36Q!\04&AZE=7VDSV^I6%Z
MM@^G)(LC23OM\M4;@$-O'/&.?2J]K=#6OB5HVL6=O=_86T:Y3S9K9XMK>='P
M0P!!X.,]0,CBN;US0+Z^D\63?8;V6*#7[.]\N ,DD\*1H'\HC!+ %L;3G(XY
MH [[1/$MU?:Q/H^K:2VF:E' MRD8G69)8B=NY6 '(;@@CN.N:H>.M4U)+G0_
M#NCW1L[W6KEXS=A06AAC7?(RYXW8P!]:I^#+/P_+XAN+_1K'6V\JU\DW^HRW
M&T[F!,:K.<Y&T$D#'O5KQYINI?:=#\2:1:->W>B7+R/:(?GF@D39($]6Q@@>
MU $,W@/4--\F[\/>)]76_BD5G74KU[B"X7(W!U/0D9P5Q@U>U#Q;??V_>:/H
M.A-JMQ81H]X[72P)&7&50$@[F(YQP!D<U0G^(,^J)%9^&-$U*XU25U5A?64D
M$-L,_,TK,!T&>%))-5H-07P9XV\2RZK:WQM-5>&ZM+BVM))U=EC"-&=@.U@5
MX!Z@T 7)/B1:G2=#OK33+JX;5KE[1;8$+)%,H;*,#Q]Y=N<@#KTIEOX[UBYU
M*^T5/"4IURS"R/;_ &Y/),3#(?S<=2>-N,_D:YS2M#U2V3P=/=6$\4L^O7>H
M30E"3;)*LA4/C[O!7KW.*ZW2;6X3XJ^)+EX)5@DL+-4E*$*Q!DR >A(R* *G
M_"RX9-&\/W]MI%U/)K,TELELKJ'CF3<"ISQC<N,\ #FKVG^-9GN=6L=6T2YL
M=2TZU%Y]EAD%R;B$YP8RH&XY4C&.N*\\LVN=$TWP)+<6%T9(M:U!W@$1\S83
M,2P7J?E.X <GMFM;5[K5=<U?Q+XE\-6U\BVVA+86LS6SQ232F4R.8U<!B57@
M<=>E '8:1XMO[K6[;2]9T&32IKVW>XM";E9A($V[E; &U@&4XY'7FL.+XI7$
MOAR#Q*/#-P-"+!;BZ-T@:/+["53&74'@GCOV&:R=*CTR#Q]X<U'2+#6VT\QS
MVTU]>K<R%YG5=H(DR5'!RV N3UXX;_9E_P#\,VM8?8;G[;]G(^S^4WF9^T9^
M[C/3F@#T+2O$B:EXBUG1)+9K>ZTQHS\SY$T;KE77CIP01V(I?#7B)/$L%_<P
M6S16MO>2VL,K/GSPAP7'' SD#Z5QOQ,>_P##>JZ=XIT>%I+NXADT>2->KM*"
M8#_P&0?K7<>&M$B\.>&M.T>$@K:0+&6_OMU9OQ8D_C0!BW'C.^_M*_33O#=S
M?Z?I]R+:ZN89E\P/A2VR+&YPH<=QGG&:PK/6=6LOB'XV@TK1I=5F$MHY0W*P
MI&OV=>-S9^8G. !V.2.,TO%C6R:QJ5SH]GKNE^+Q*%MOLD4K0:AC&QGP#$4Q
MP2Q!&#GI74^&+:YB\>>-)YH)$CFFM#&Y0A7Q;@':3UP>* '1>-I=2\/:-J6B
M:'=7\VJ;MD!81K#MSO\ ,DP0N""!ZGI7+_$/Q&^N?!CQ'/\ 9I;"]L[A+2Y@
M,@8Q2+-'D!AU!# @^AK*TN*XL?"W@^TUN'6+?1,7OVR.SCG5S-YI,2R"(;PI
M!8CL3C-4M2T^Z_X5;X\TBVT;4H+B34H[JWM9(I)':%V@VG<<[FPIR,D@@YH
MZC6Y9!\4_AL@=@KVMWN&>#^X'6NX\4Z^GA?PW=ZQ);M<+;[,Q*VTMN=5Z_\
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M7@!OKQC->VT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3<!0!$S!W:0CA0%ST)Y Q6)XS\17E[X3SJ.CW.GWNGZU9+- I\U9!YBL#$^
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MUFQDA<Y.,#FM+P+%Y'B.\BT5=:C\-"T7$6II*JQ7&_[L7FC=MVYSVSBO0J*
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M-$TTD?V&_BODV8^9H\X4Y['- '&S^?XS\;1WEC87UO96&E74!GO+5[??--M
M0!P"<!22<8KGWO+^]^&N@^'(- U@:AI\]BEZLEE(JQ"*5 2&(P^< _+GC).
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MD+B::-9%+R-&1E%!S@GL,\5Z510!R.K6=S)\4?#=VEO,UM%8WBR3*A*(6\O
M+= 3@X^E-^(.F7-W8Z1J5I9O>R:/J<-\UM&,O+&N0P0=V ;<!WVUV%% 'EU]
M93?$+Q%?7-E87ME8#0KC3C<WMLT!EEE(VJ%8 E5P23C&345S?:CXJ\,Z1X0;
M0]4MK\2VR:F\]LR0P)"RL["0_*VXH-N"<YKU:B@#GCX.L#X@_MK[7JGVCS?-
M\O[?)Y.?3R\[<>V*\]2XU#1_AQK_ (+_ +#U6?556]B@,5H[1312,["02 ;>
MC],Y)&,9KV.B@#R6XMF_M33[?Q!I6MWEDNBVJ:?:VB3",W&")!)L("O]SER
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M01)M(.T'N1D@@5-<^+]0O]=CTKPQI]K>E;*.^GGN[EH8U23/EJ-JL2S $],
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M1.7C+ICE20#@A@>:P/[6\2O\99-*C-F=-CTQ)C$T\@_=F4@OC;CS.",=,=Z
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M'&<C%:/BC3KC4M7N)+/PGJ%GXG2Y5;/6+-@L+QAAAY9 PR-O!1@3V&:]4HH
MP_&6B2>(_!NK:1"ZK-=6S)&6Z;^JY]L@5R5[)K/C"+P_I,GA[4-/>TO;>[U&
M>Z55B00_,5C8,=Y9@ ".W)Q7I/2B@#AM#TC4+;XN>*]4FM9$L;JVM4@G(^60
MJ@# ?2K'Q-TV^U/P:Z:=:27=Q#=6]QY$6-[JDBLP7/4X!XKL:* .+TZ*]O\
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M!7(^5LY!K-3PQKMMHUOK_P#9SMJ2^(Y-;DTU74R"%P4,8.=I<)@]>N17J]%
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M0U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#=]8V,UZ-/U5)YXH"N_R]CJ2-Q ."P[T 8D-^^E?%+Q'-;Z7?7DTFF6DOV6
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M#L6K:RZ2:E?HA=TY!C1=J8]B 9/K(:ZR@ HHHH **** "BBB@ HHHH ****
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M/<I"?-B<L<QJQ)(3/;UK.'COQ?+X,N/%D5EI"V-E)*)K=Q)YDZ1RE69"&PG
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ME!).&4C'/6L>V\:^(;^'1K%5T;3]5O-/_M*ZDO-_DPQLV(T5=P)<]^>-I^E
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MS)&R$G[C,O.>F1S71-X@NIOB"GAZTBA:UM[$W5],P)9&9ML:+@X!.&)R#P*
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MKEEJFE>.K?Q1I^F2ZG;R:>;"ZMH'194Q)O1U#D!N201D=0:YS5_">OZQX/\
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MT-<[9^!]5M?#'AJ;5= @U:YTJZO3=Z:QC;S8YY&.]-QVDC", 2."1P:]?HH
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M<#((ZGZU5OO"S6&OG4[OP=#XC@O-/MX63; \EM/$I7'[P@;6!&2#U7I7I]%
M&7X<M'L?#]G!)IUGIT@3<]I9 "*)B22%P .IY/<YKB].;Q/X:\1^)GA\(W6H
MVVH:A]IAGBO($!78J]&8'M7I%% ''W.M^+;[0;P67A:;3]39DAMC<W4+HN[(
M:4[6/"=<<D\8'6L[0O!]]X-U=+#3A-?Z#J<)&H-)*-\-R%P9_F/(D'! S@@'
MI7H-06M[:WR2/:7$4ZQR-$YC<,%=3AE..A!X(H \P\-^%9-*CTS1Y_A_IDMW
M9RJDVLRQP&)XE/$JD?O#(0!P1P>IK0@B\4^%)M?T_2=!.HC4;Z:]L+P3QK%$
MTN"PE!8, K9/ .1QQ7HU% ' O!XAT'QQ=:JFBR:O'J6GV\,CVDD<8CGC+9R'
M880[LYYQ[U@OX5\2P^!;1'TT3ZE9^)?[4>VBF3][&)F;Y"3CD'(!P?QXKURB
M@#@?[(U>^^+6D>)7TR6WL%T5H)O,DC+12EV.P@,<G!'(R/>LZZ\%ZO)\0&MD
MMA_PBMSJ,>M32>8O$Z(08RN<D,X1SQBO3Z* /.-=\-BV\9ZEJ\_@V#Q+;:E#
M#L^2!GMY8U*X/FD81AM.1T(/%=KH%H]CH-E;R6%G82+&"]K9C$43'DA< <9)
MK2HH ***@M+VUOXWDM+B*=$D:-FB<, ZG#*<=P>"* )Z*** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *RO$__(IZS_UXS_\ HMJU:S]=MI;WP]J5I NZ:>UE
MCC7(&69" ,GW- 'CGAV\^$7_  A&EQ:K!I$FH&QB6X5;4F=I=@W %5R6SZ'K
M70:-KNM^'? /A;3+F2&VU?49)(XYM68XMH%+N&D&02P38H7(Y(STKH;?P>VH
M_"O3O#6I#[/>16$,>]&!:WG11M92.ZL.QYK,U+1=?UG1?#>J:MH=K>ZOI,KB
M[TZ1XV2Z1D*,R$Y4'[K@''0B@"&7XA:A9Z1K$,MQI-S?Z?=6L']H0Y^R>5.0
M%F<!B5"_-N&[J.O-6M7\4>)?#W@C5=9G;2=2:W:W-G=6BL([A7D5&!3><$9X
M(;!R/0U9M+76;;1K^XL?!FD632SHHTP>6LD]N!AP[+\F_D[0<@#@]:XKQ+H-
MYIW@CQ;>PZ,N@65Z]@+?3_-1PLJW"[I=J$JN<J, \[>: .V37?$VC>*='LM?
M.F366L&2-/LD;HUK*J%PI+,=X(!&<#GL*RAXP\5W?A2Y\:V2:7_8T7F31:?)
M$_G2VZ,06,N["L0I(&TCI6C)9>(/$OBS0I]3T4:;9:0\EQ+(URDHN)2A11&%
M.=HW$Y8 ^U8T6A^+-/\  USX#MM&26)UEM(-6-T@B%O(Q^9DSOW!6(P >1UH
M V9?$NOZQXMDT;06L(+8Z9!?I=W4+2% Y88VAADG"XY&,'KQ6=_PG^KGP_9"
MX?3+#47U>;2;J^G5C:PM%O\ GQN!^;:  6')ZUO:+X<NM*\<7-VL?_$M&CVM
ME#*6&6:-GR,9ST(K)L](U[2-)U.)_#]KJUM>:W>7$]C+)'NDMY&)1EW'9G."
M5;MZ&@"SJ7BC7=&T:R@O7T@:I?WWV6UO=Q%J8MA<S,I;(P 1MW<G'.#5_P )
M>)+K4M4U31K^[T^]N;%8I4N[#B.:.3=C*[FVL"I!&3VKDH_ NHKI*7<6@VRI
M;:P;ZVT">9)$6!HO+>/<<H&))<#.T&NCL'OM&T37=8C\):;I!A@+VUJAC224
M(I8^:Z?*!GH,G'.: .VKRN7QKXPD\+ZQXCMTTE+32+N>)[>2)R]RD<A!(8-A
M/E]CD@]!7IEA</=Z=:W,D?EO-$DC)_=) )%< OA361\+_$VBFU'V^^N+U[>/
MS5^822%DYS@9![F@"Y#XC\26?B3P_'JBZ<=.UTR*D$,;B6U81F107+$/P,'@
M<]*J:KXQUW1M2$]]=Z%';'4$MO[)#[KOR7D"++N#XW<AMNWIWK7U?0]0NM7\
M&3PPAH],G9[H[U&P&!D'?GYB!Q7%/X0\1#PN^DQ>&+4ZA;WPO)M2>>+??[;C
MS!L.=P9ACE\ 8QWX -"/Q';>&_B)X]GDC>XNYY-.AL[.+_67,I@.$7^IZ <U
ML:GXEU_3$T32;R[T:SUK45EFGN95;[/:QIC( +@NV64#Y@#R:S+CX<MXA\5>
M*M5U*T-E/>)9OI5ZLBM+;2I$-Q&T\$.J@^H'!Q4M]HWB#4ET#6]8\-VFHZCI
MRS6M[8-)$RW"/MQ-$6^4'* [6P?F(H Z3P;XBGUV#4;>\DM);W3KHV\LUF<P
MS JKJZ\G&0W(R<$&L!KCQ"_QO>TCO[1;&/24F\IH7/[HS88??QYF1][&,8&*
MZ;PI:3VUA/)<:%8:*TLQ:.UM N1&  #(4^4OUZ< 8%9%]INL6GQ6@URUTLWN
MG7.F+I\TB3HAMV$Q<L58@L,'MDT 90\7^*[SPK=>-+%-+&C0^;-%I\D3F::W
MC8@L9=V%8A20-I'2N\>ZFOM!-YI1C\^>V\VU,P)7<RY3< 1QR,\UYW%H?BS3
MO ]UX$M=&2:)UFM8-6-T@B%O(S?,Z9W[@K$8 /(ZUZ5I]FFG:;:V,9)CMH4A
M4GJ0H '\J .*/Q F?X5)XDBMHSJTBK;+:$''VPOY>S&<XWY.,YQWJ8:SXIUC
M7[_1])GTNU.DPPK>7-Q;O*)KATW[44.NU0,9))/-<_::#)+\8[O2XI$?1+2=
M=?EB'/EW;H453Z$D-(!6_)::[X:\8:WJ>FZ*VKV6L"&79#<1Q/!,B;"#O(!5
M@ <C)'/% $&F^/;_ %#_ (1E'M;>&XO=1N-/U"/EA&\*OG8<]"5!YSP?QK?M
MM=NIOB!?Z"R1?9;?3X;I& .\N[NI!.<8PH[5QZ^$-?TC1]!U&&TBO]6M-6GU
M*]M(IE0-YX<,J,V!E0PZXS@UN>']/UV7Q]J6OZIIRV5M=:?#!#%YRR,A5W)5
MMIZ\YXXY R<&@"C\0+C7D\6^$+;2KZUMXKB[?"S0NV9%B?E]KC<N#]WCGG/:
MJ6FKXEE\>>-H=$FTZW=9[5I9[N%Y [?9TPJJK# ZY))QQ@'MN^.=,U:XU3PU
MJ^DZ?_:#:7>/++;+,D;,C1E<@N0.,^M6O#6E:A9^*/%&HWEMY,.HS6\D'[Q6
M)"P*K9P>,,"* ,.T\>:MKNC^%8M+M[2#5M<CEDD>=6>*V6'B1MH(+9. HSWY
M-%YXWUK0+;Q'9:K%97.I:7;PW,%Q"CQQ312-LWNF6*[""6P>0.,50T?PGXAT
M#1O"&HPZ<MQJ.CK=0W5@)T5I(IF)RKD[=PPIP3SDC-:MMIWB:74]<\4G2;:&
M_N+>"TL],N9U;="C%G#LI*AFW-CD@<9H >_BG6=#\-:IK6I7&D:O90P+):76
MGDQK)(S;1&P+-QDK\P/0GBG:)XJU)?$]EH^JZEHNHC4())(I-,RI@D0 LC N
MV5()(;C[IXK!D\"WNM1>(/LN@0^&[>^LHXULWEC9)[E)!(LC+&2JCY0OJ03Q
M72>&[&Z.LQ3R>!],T&*&%O,G'DM*\IP,1F/HF-V2V"<CCK0!4^*_]G_V9X=_
MM;R/[/\ [=MOM'VC'E[-LF=V>,8K&M!X3/Q#\.GP']B\X&;^TCIF/*^S>6<>
M9M^7._;COFNQ\9Z+=ZT- 6V@69+76(+JX#, !$H<,>>O4<=:Z*&V@MU*PPQQ
M*>H10N?RH \Y'B[Q7>^%KSQG8+I8T>#S98K"6)S--;QL0S&4-A6(5B!M(Z4D
M>IZYJ7Q@L#97]HNF3:&MZD4D#DF!Y4W#AP/,..&Q@ XP>M0Q:)XLTSP3>>!;
M314FBD6:UM]5-TBQ+!*S?,Z9W[E5R, ')'6M-M U;0_'^C:AIVFMJ&FQZ,FD
M2.LZ1M#MD#;R&(R,#H,F@#,C^(^H-91^(C>Z)_9$EV(O[-!/VL0&3RQ+NWXW
M?Q;=O3OFM8:YXNUGQ!XCTS1VTJUCTF=$CFN87D,NZ)7"8##').6]",#J:R=$
M\*7VBP6^A?\ "$Z1=^1<D#6;@0LC6^_=N*_ZPR!3MQC&0#G%=9X<TB]T_P 2
M>*KRYB"07]Y%+;MN!WJ(44G /'(/6@#A[_Q+XA\2-\/-0TZYL[(:G([M%)$[
MJ)EC<-NPXW)@G"]<\Y-=-I^OW4GQ0U[1OL%DYL].BF66./9-,Y ^5G)^[GIZ
M5SUKX5\2:1X8\!R1:3]KO="FD:ZLTN(U;#JRY#$[3C([UHS^%->NO&GBW4XX
MA:1:IHBVMK.95)6;8!@X.1@]\=N* )=*\7ZU%XFT?3M7O]"N6U0R1R6=@V9;
M&18RX#'>V\?*5)P.>E1?"_\ Y&/Q_P#]AV3^M4;+P_KD5SX4NK;P=;Z=%H\P
M6XA2>'S9MT31M(&!QM4G/)W-GIQST/@3P_J6B:UXNN+^ 11:CJKW-L0ZMOC.
M<'@\?0T 9'CS_A'?^%B^&_\ A)_L']G?8;O_ (_MOE[]T6/O<9ZU%X7?3(?&
M^M3>!8(9]'32@9HK5MMM)>AR453]T,4X)' R,UU&JZ%<7_Q!T74VM8Y;"ULK
MF*5G*G:[F/;\IY/W3SBKOBK2+C4O!FK:5I12WN;BUDBAV_(-Q!XXZ9Z9]Z .
M7TOQ9KA\0V6CWNIZ!>W&HVTS(E@"393HH8*_SMO7J,_*>*GM_'\W_"K;OQ'=
M6\::M9B2VFM5!VB[5O+"8SG!8J<9S@UG66BZR/$?AG4[;P?;Z59:>9+>:VBF
MA\W$D>TR$J<%%P.,ECDG%5;C09)_C*^DP2(VCR/#K]Y"/X)T#1J#V^9MCX[[
M: -E==\87GB=_#EN=*M[F'2[>[GNI('=4D8L'4*'&02!CG@ ]>*Q_P#A.?&,
MG@BY\4^1I$46ER/%=6IC=C=&.3:[(VX;!Z AN0:["ST>^B^)>J:P\0%C/IL$
M$<F\<NKN2,9ST(KG/^$2UG_A4FOZ#]E7^T;N:[>&+S5PP>8LOS9P,@]S0!?U
MCQ;J$_B2XTG2=2T;35L[:*>6;5 6\UY,E8U4.N  ,EN?O#BJ:>/-9U<>$H]'
MMK%)M<AN_.,^YT@DAVAB"I&Y0=_'?Y>1R:=J?ANZL/$]SJP\*6OB*"_M((VC
MD:$26\T0*_\ +3C8P(R0<Y7I5V'P]J8\0>#;UM.L;6/3[>\%Y'982*%Y53 5
M>IY!Y ]^] '/^(O$?B<>$O&^EW-S8KJ&CQ)NN[>%T$L$T9/RKORCCGG)'M6C
M)XA\0Z>OA_19=5T6TNKVT>?[?=0.(GV[ L2J9!ER&R26[<"G:YX1U?4I/B"(
M84 UBSMH[)FD7$C)&P8'GY>2!SCK4MP=>O-#L+;5/ D.H67D>5/8R7$#RQR*
M  X+-L*D9Z'<,9H [+1Y-1ETJ!]6A@AO\$3+;L6CR"0"I/.",'!Z9Q7#^*/&
M.N^'9[^_GN]"M[.SF41Z9*^ZZNH<J#(&#_*3DD+M/3FND\#Z3>:'X2M+"^41
MRQM(RPB7S/(1I&9(]W\6U2%S[5P&J>#M?NM$\2Z/#X<M)+V]N[BY36)IHR9D
M9]Z(/XPV,)SA1USV(!TNI>)=?N/%VJ:/H]UHUO-IZ1-%9WRMYM]N3<2C!AM7
M^'(#<@YKL[C[9)ITGV4Q07C1_(9E+HCX[@$9 /H17G_BNPUKQ':W-I>^![>[
M>:$&PNQ<Q+)9.R#(D8MN!5\G,>01CBO0;"&:WTVU@N)O.GCA1))?[[  %OQ/
M- 'E'A#Q3K^F_"O2K^:2TO[W5;Q;33DD5UVRR32 F5MQW 8)X X&/>NNL=:U
M[2O%]CH/B"6PNTU*WEEM+JT@:$J\>"Z,I9LC#9!SVZ5RND>$_$T7P_TW1I-*
M2#4O#NH1WMH[W*&*^*RNQ4%22F5;'S <D>^.EM++6_$/C;3-<U/2&TFTTFWF
M6&*6>.22:64*K'Y"0%"KW.23TH T]?UV[T;Q'X<MPD)TW4KB2UG=E.])-A:+
M:<XY*L#D>E9>B^-;O4/B!JNCSPP1Z7$)4LIP"'D>#RQ,&.<'!DXP!]TUI^.=
M'N]8\,NFFQB34K6>&\LU+!<RQN& R>!D C\:XS5/!?B2+P#H@TN"-_$<+7#7
M0,JJ ;I)!-\Q."59U/7^"@"FNNZ[XC\0^"=6MH;..ZO1JGV3S$;RXX,H%=QG
M+':,X!&21TK=E\5:S:Z%XVL]7BTZ[O\ 0;<2+(D+"&X1XBZAHRQ/8@C-:A\+
MW%EXF\&M90@Z=H]E<6TK[@-N8XU3C.3G:>E9VL>%M7NY/B&8;8,-9LH(K']X
MH\QEA92.OR\D=<4 /@\4ZM>Z5X0TW1XM/MM2UC3EO)9)(F,%K$L:$[8P03DN
M !GBLSQ?=^)/[$T9=6L+8ZE;>)K1+=X7VPW8R2CXR63)."#G&"1FK</AW7M$
ML_!FJV>G"\OM)TP:??6 G1&961,E&)VDJR>O(/6K&H:;XK\06FF7&H6,,#P^
M(+:\2S252UO:QGDN^<,W4X&>H S0!?TC6?$%MXW/AW79-/N5GL&OH)[.%XMF
MUPC(P9FS]X$'-4/B?<:U;R^%TTJ\M[=+C6H(6$D;,2YW%<X893Y3E>IXY%;4
M^D7K_$VRUE8@;"+29K9Y-PXD:5& QG/13STJK\0=)U34K/1+G2;,7L^F:O!?
M/;^:L9D1 P(4L0,_-WH P+5/$;_$WQ);Z9<:?%=&PL#<W<\+/&&"R<+&&!^8
MD]6X [U+%\0M2NO#^BQDZ;9:SJ%W<6DL]P3]FA\@L)) "P)SA<+D<MUXK>T#
M3-23QKKFM7ED;6"_L[)8U,JN5=%?>IVD]"P&>A[5RL?@C5+?2],NY]&MM1N-
M/U6^G?3IGC(G@G=N5+97</D8 XZ$<4 6+[XB:EIOA+Q+<%]-OM2T2:W43VH)
M@N(Y67#!=Q(;!8$;CRM:&I>)/$FCVVG6FH3Z-;ZIJ]TP@D<,(+.%4W-O)8;V
M'08*@EATJAKGAK5M:^'FO65GX7T_2+J\EA^S6=N8ED9$D1B964[,\.0 >![U
MO>-] GU.XT;5+;3+?57TR=VDL)]@$\<B%6P7^7<#M89P..M $O@_Q'<ZO=:M
MIE]<6-U=Z;)&#=6/^JGCD7*L!EMIX8$9/(JKKFNRV?Q1\*Z,MG9R17T-RSSR
M19FCV(2 C9X![\<UH^$[2>".\GF\.6&A)+(!#;VZIYA0#K*4^4G). ,X%9NN
M^']2O?BIX4UNW@#:?I\-TMS+O4%"\9"\$Y.2>PH K>'_ !/XAU[4FN+:?1GM
M8[Z2VN=+PRW5M&KE-[,6^]P&V[0"#P:W/'6O77ACP;J&L6<<<MQ;",JD@)5L
MR*IZ$=B>]<M>Z)K>LZ_IT]QX5M;+5+2_CEDUVWG15>!'R0 #YC;D^7:PP,GF
MNE^(.D7NO>!M2TS3HA+=S"/RT+!<XD5CR2!T!H SX];\3Z9XOT73]:.F2VFL
M^<J):QNKVKHF\ L6(<8!&<+SV%98\7>*[[PO>^,M/72QH]N9I8;"6)S-/!$Q
M#,9 V%8A6(&TCI72>(-(O;_QAX4O[>(/;:?/</<ON V!X61>"<GD@<5R<6B^
M*]+\%7O@:ST5)X9!/;6VJFZ18E@E9CN=2=^Y0Y& #G'6@#T>VU&WNM)AU-"1
M;2P+< GKL*[OY5Y#XLUGQ1KWPCOM>N%TY=*OU1DLTB<30Q&5=C&3<0QZ9&T<
M'@\8KUNTTN*UT&#2 Q:&*U6V![E0NW^5>67F@^-9?ADW@B/0HS);(L(O_M<?
MESQI(&78N=P8@ '=@#GGH* .I?Q%-'\6[G1186KQ1:$;P3+%_I#,) -F[/W?
M;'6F^#/$7B#Q$MCJ3W6B7>G7<9:X@M RS6#%<JK$L=YS\I&%.>>E*WA[6%^+
M]SXAA@C%DVA&SBF=P1Y_FA@"H.[&!U_6J.GZ)JM]XQTG5Y?"D&AWEJSMJ-]#
M<1E;P&-EV*J'+ L5;+@$;?6@#/M/&_C.?P#'XU>'2!8P@O-9"*3S)HU<J[*^
M["'@X&#TSGG%=GHWB*?5/&&MZ65B^QV5O:30.JD.WFJY.XYQ_",<"O-O#4'B
M;6?@W:^&[/1U>&_C>)=2-P@CBB:5MQ="=VX?,  "#P<]178'3M=\-^-;^^TO
M1#JECJ-E;0JRW21&!X0RC?N.2I#9R 3[4 <YKOB7Q'K/A_PY>6US96C3>)Q8
ML!"Y!*3L(R<.,K\GS#OG@BM_4/%6M-KEYH]GJN@6,^EV\)N9;Y2!=3NF[:B^
M8"B8QR2Q^8>E8Y\(>);;P+H\/V&.YU33?$7]J26\<R+YT8FD;Y6)P,A@<$_K
M5^\T*_A\1W^M2>";761J\$$A@FD@,EG.B;"C%^"I 7E2>0>#0!VGAC7$\2>&
M=/UA(_*^U0AVCSG8W1AGO@@C->;>'KOQ7:Z+XJOM%.F):V&L:A+Y5U$[O=$2
M%F *L @QP.#DYZ"O4-%MI;/1;.">VM+:9(AYD-FFV%'/+!!Z9S7GMI8>,=&T
M7Q)I4'A];HZI?WDMI.MW&JPK*QP9 3G&#N^7)YP0* +T_CNZU>[TZUT>^TK2
MUGTR+4IKC4OG \S[D2J&7)X;)SP,<5AZOXGU_P 00>#;C3[JQM))M7>VG0(\
MB&XB\Q2<AANB.,@=>1SQ6@_@F;P_?:;<1^';;Q);QZ1!ITT+^4'CDBSB1?-P
M-K;B",YX'6K&LZ#KG]D>%KVST"Q6\TW4OM=QIEA(D2!"'&%9L*6 *Y/&3G%
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MZK="$HL4DA?]Z#^\++N(P <X'(JSJ/ANZTSQ-K-W!X.L?$$&IF.:!Y#"IMI
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M<11DDG ]3C&3W.: -2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJD[%D<#@9[ G\JX/0/%^HGQ9IFDWVO:'JYU&&5I8M. #64J*&VDAVW*1N&2
M<B@#T6BO)QXO\9S> [CQ@D^EQP6,DNZS-LQ-RD<K*3OW?(<#  !Z9SS@=;IG
MB.\D\>7^@WPC$$MG%?Z:ZK@M&?ED5N>2&QT[&@#JZ*YGP9KM[XDM]2U*81#3
MS?2PZ=L7!>&,[=Y.>=S!OP%8EUXEUZ\\6:KIFFZGH]I/I\J)!I=[&?,O5**Q
M</N& =Q VJ<;>: .ST?2++0=)@TS3HC%:0 B-"Q;&22>3SU)J]7.:+KEW?\
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M$>CVFI:WH-[)J5PUO<:98D&6Q;8S*=P<E@"NTD@<GBE^'/\ R/GQ#_["4?\
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M,:XT=M)L[<SK*V&+,SN5X')  &>!72>('T&UGTJ^UN2.*2&["6,CLPQ.ZLH
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ML[EPBS12* P#$$!@54C(QUH 9X&\3/KJZK9S:A9:E+IMPL0OK+'EW$;(&5L
MD!ADJ0#C*U6U+4_$5]\0+GPYI=];6-JFFQ79N7M_-=&,CJ0JD@'.!UZ8/'/&
M[X;AU-+6XEU2QL+"267=%;6GS>7'@ !WP S9R>  ,XJM!HMW'\1KW7&"?8YM
M,AM5.[YMZR.QX],,* .5A\;:\WA^"QW6CZ_+KLFB"Y,1$0V$EIMF?[H^[GK[
M5H?VEXDTSQ%)X<OM6M[E[S3Y+JQU 681HI(R R,@;### @\=ZIMX(UF.QN+F
MV^S?VE;>)9M8LT>0A)HV)&QF ^4E6/8X.*U;#1]:UGQ:/$&MV<&G1VUC):6M
MK'<>>Q:0@O(S  #A0 !GO0!6^#RWY^'.F7%Y?"Y2:,O$GD[3$-S9!;)W9/.>
M*FDU/Q%KOC+6=-T?4;73K31EA1C+:^<;F:1-^#\PVJ!@<<\GFK'PXTO6M \*
MP:'K%E!"; >7#/#<>8+@%F.[&!MZCKG\*K2Z7XDT+QEK.I:+I]GJ%IK*PLPG
MNO)-M-&FS)^4[E(P>.>* .;\#ZYJ&G^'_"5JBQQC4M9OHKI"-V &F? /^\.M
M=%K_ (TNM U_Q"DB))9:;HB7T<>,%I2[K@MZ':HK'L_!7B/2?"_AXQ):WFK:
M/JL]X\+2^6MQ'(TF<-@[6PX//3FK5QX.USQ)J?B&YUF.VLHM6TA+**.&7S3;
MLK,1N.!NY(;(QUQVR0!N@^,[D>)M'T^Y\4Z+K@U19%DBL-@:SE5"XQM8ED.&
M7)YSCGG%6_B^;]?!L9LKT6R->VR2@Q;B^94V\Y&,$ ^_2K^@6_B-M2M/[1T+
M1]/@MXV%Q/#()7N),8!C 5=B]2<Y/.,=ZG^(.A7_ (A\)RV>F")KQ)X;B-)6
MVJYCD5BN>V0#0!GW&H>([SQ/'X6L=6MX);2P6[OM1-F&:1F<JB)&6PO"DDY/
M:M+P;KE_J::KI^K&%]1TF]:UEEA38LR[0R/MR=I(;D9ZBLR;3_$MKXDB\56>
MD6TMQ=V(M+[36O0I0JY9'23;AN"01@>U:G@[0[[2H]4O]5,(U'5;QKN:.%BR
M0C:%2,,0-V%49.!R30!S<T&M7?Q>URWTB_AT_=IEJTMT\'G,N&DPJJ2!SD\G
MTZ<Y%9OB'J,>B6]C>WVFZ?JW]L3Z5<ZC. MO&(06:4*Q R5V@ G&6_"MN\TO
MQ)IOC_4O$.F6-K?6ES906WV9[GR79E+'<"00,9Q@]=W7C!RH? VL6^E6NJ-%
M8W.NIJ\^K3V;O^Y<3*4>(,1U"[<,1C*_C0!M>"/%#ZQJ&KZ5+J]CK!T\Q/'?
MV6T++'(#PP4D!E*L#@],<4FO:MKS>/;'P[I-U;VL-UITMQ)/+#YC1%74;E&1
MD\XP>.<\XP=;PW%JH^UW&IZ9I^FK(ZB"VM2'=5 Y,C@ ,2>@ X'<U!<:)>2?
M$BRUU0GV*'3);5CN^;>TB,./3"F@#D+?6_&][HGB.1=6L(9O#L\\)F%EN^W-
M&N_YANQ&-I4<9Y/MSJ:GXGO[C2=!U#_A(-)\.65_8)=23W6UY&E95(C1&(&T
M!B2>3TZ5<L/#.HV^D>-;:01>9K%Y<S6N'X*R0JB[O3D&LJR\,^(M#O\ 1;RU
MTRPU&6'0;?2W$]SL%K+'RS@[3N4YYQS\HH 9:^-]9US0O"MMI\]I!JFM7%Q#
M)>+'YD:);E]\B*3R6VC )Q\U4)-7U'PKXS\6:EJTD-]/8:#"\4J1^4)QYC[=
MRY.T[CM.#VSQG%3V7@[Q/I-CHUQ#!:76HZ%J-W)&IGV+>P7!8L>G[MOF& <C
MBK4W@W7?$>I>)+K6DM;*/5])2T@CBE\TV[*S$!C@;N2&)'KCMD@"Z!XSN/\
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M_P O[ED+X/?[IQ6;?^$_$CP^+-(M++3_ "M;FFF7599OG5'0 1%-N<C&T'.
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M+J%L=@&SRV*RC/?JK<],URNE>/\ 6X_A_P"(M0U;R_[6M(HKBT58P!MN8U,
M([D.Q4^N* /2H-4LKG4[S3H9P]W9K&UQ$ <H'!*<].=IZ>E1ZMK>G:%!!/J=
MTMO'/.MO&Q4G=(V=J\ ]<&O.]*L?$=W\0?$EM;ZS'8W*V.G&\NUMDE9Y!&XP
MJGY0"=Q/'8 5%>^/-?A^'>@ZH)H5U&;6UTZZD6(;9%621&(!Z9V ^U 'K-4Y
M-4LHM6ATMYP+V>)IHXL'+(I 8YZ<$C\ZY.ZOO$'B'Q;K&DZ-J\>DV^CQPJ\G
MV59FGFD7?@[NBA=O3DY/-8U^GB.\\?>%XY);73]7DT>Y6ZFC7S4BP\>XH#P2
M<#&>F[OCD ]1I,@$#(R>@KD_!>J:K<7NOZ/J]VE[<:5>+$ETL0B,J/&KKN4<
M C)'%8FLV^JS_&W28X-8:"$:9+,D?V=&VKOC#IS_ 'MH.>H[4 =YI^J66JQS
M26,XF2"=[>0@$;9$.&7GT-7*\<TD^);;PQXOU;2M8AL8=/U349TMS:K+]H*.
MS,'9ON@XVC;@]3DYP-35?'K76J6%B?$EEX:A?2H;^6>9$=I))<[8U#\;0 23
MUY'2@#T^BO,=,\>:G<1^%M4GN+>33+R\FTJ_:%!L,X8K%*AZA6*^N/F%=+9:
MS?ZG\1=2TZWD4:1I5I&LXV E[F0[@-WHJ8R!W84 =317)^-M4N=-^P!?$=AH
M-G(S^?=3A7F8@#:D:,-IZG)[8'K7)R^/=<;P):7]C=6MW?+KZZ9]H$06.[3S
M"H;;_#N&W..G.* /6**\UU[Q!J?AV[TG0-3\7VEI/=)-=7.K36L<>U%*A8XT
M)*Y)8\G/"FMWP#XE?Q%IM^LM];W\EA>/:_;;8 )<)M5E? X!PV"!QD&@#K:I
MZ;JEEJ]LUS83B:%97B+ $8=&*L.?0@BN4EO]?U_QOK&E:5JR:7::-' '/V59
MC<2RJ7^;=T4+C@8)SUKF/!^M:GINA>'(5:.)M0\1WD%X@7<"-TS$ GD?,HYH
M ]>IKL$1G.<*,G )/Y#K7#^(?&-WH'B?6T;;)8V'AX:BD.T M-YCK][K@[5%
M9'A_QQ-_PD>B6<OB[3==&J;H[BVMHT4VDFPN"A4Y*94K\V3R#F@#T;3-3LM9
MT^*_T^X2XM902DB=#@X(P>00000>15NN%\-_\2?XF^)M#BXM+J&'5H8QT1W)
M27'^\R@_G7=4 84WC7PK;SR03^)M'BFC8H\;WT096!P006X(-(?&OAC[%=7D
M>OZ=/!:J'G:WN%F\M20H)"$G&2!7*?%W2=-B\%27$>GVB3M?6VZ185#',RYR
M<9YJW\4--L+#X8:\]E86T#M%&"88E0M^]3@D"@#OJ*X0WWB70_&/A^VU/5H;
MVTUAIHI;9;58Q;.L9D'EL/F8<$?-GUKE(_BA*UG'X@_X2K32'NPI\/B--XMS
M+L^]G?YFWY_3MB@#UZ_OK;3-/N+^\E$5K;QM++(02%4#)/'/2I89H[B".:)M
MT<BAT;U!&0:YWXA_\DX\2?\ 8-G_ /0#7+PZCXG\.6'A74[W58;BPOY[:SGT
M\6JJ+=95PC+)]XE3C.>#SP* /3:S_P"W--_M_P#L+[4O]I_9_M7V?:<^5NV[
MLXQUXZUYUXI\::CH%_J%R_BO2Q-:W2B+0X8UD,D.Y1\[_>60@DX' XZU<_YN
M-_[EK_VO0!Z317E4'C34;3Q#I45QXKTO4;B\U$6=UI-G&K);JY8 I*/F)4A<
M[NN3P*N1ZCXNUMO%;V>N0Z?#I%]-#;8M$D:7:BL%?=T49ZCD[CSQ0!Z317G-
MMXIUOQ2WAO3=,NXM+N;_ $C^U;VY6 2E%RJA(U;CEF/)SP*;KGB77O#FFZ;I
MNM:KIUC>7M_) -79 $%LBE_,*'Y1(>%V\C)S0!Z117%>!/%+:W?:SIC:Q;:R
M-/:)XM0MU5?-CD!X8+\NY2K#C&1CBGZQJ6LZGXW3PSI&H+ID<%@+VZNQ LLA
MW.42-0WRCH220>U '675U;V-I-=W4R0V\*%Y))&PJ*!DDGTJEH?B'2O$EF]W
MI%VMU;H^PNJ,HS@'N!GJ.:\N\6ZEK>I_#KQCIE_J,8N]$E,-Q+%;J!>0LJLA
M(_@.&YV^E>@^!K2]M/".G+>ZA]LWVT31?N%C\I/+7"?+UQZF@#>GN(+2WFGF
M=4BA0R2-_=4#))Q["FV5Y;ZC8V][:2"6VN(UEBD (#*PR#S[&O*K.WU5O%/Q
M*>?6&EA@@57B-N@\P&V8H,]5VY[=>]&DWWB;0/!7@W5VU6%[";[#:/IHM5VB
M&0*@82?>WX(/IGC'J >N45Y)K7Q!N!?^()8/%FF:6^DSO!:Z7/&C-=F, L7)
M.X;FRHVXQCO7J&EWZ:KI%EJ,:E8[J!)U4]@RAA_.@#.C\:>%99Q!'XET=I2V
MT(M]$6)],;NM;E>&>&-<\$CX9II>H6"WVJ-'<1FWCTUY))',C[0'"8SR,'/'
MX5U&EW'B9?\ A&O!<5^-.OH=%6\U"[:)9I% (C6-0WRYSG).>E 'I1(4$D@
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M[3[3;:\=1<F0[?*,LC\''WL../UKT&\UNPT_5+#3;F9DNK\N+9!&S!]@!;)
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MP_:PZ5-#JMQ=,MT]RRFT29FSE-AW_*<C!&"2.<9.G_PB^K>&=3AO/#UG9:C
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MV2[8<1J WE_+STXSBKKZ'XFT/7M8O/#BZ7<VNK2+.T=[,\1MYPH4L-JMO4@
MXX.: ,OPQXTU?4]6\,OJ#QK;:I:W=K-"B *MY;N<N#UPRJW&<<5'X;\>Z@[>
M(K[5YD>P6SDU33%"!<6R22IM) Y/R(>?[XJSJ'P\U"/X>:9HVCW\ UG3[C[5
M'=SY1&E<OYI.T$@$2/CCTIGB/X;76HZ9X<T_3+FW@@LK9=/OC(6!EM28RX7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>J^*]6\3WZZ[?V0TR^>PL;:!P(08T4EI%(^?<S<Y[=,5J?"C_DEOA[_KU_\
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M=<BNDU/PIKWB#PKK6FZQK5LUSJ*HL:V]N5@ME4@_*"2S$XY)/I@"NS50JA5
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M:WG,9WE6.">RGG<HZG&>E:J>$-;L9KJSTGQ$EGHUS=-=-$+7=<0EVWND<F[
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MSSMSZC/M7,ZU9VWA76/#CIXE@T?48M*_LXW5]:[K6YBCVG:3O4(X/S ;NY%
M&O\ #Z?4VO/%%GJ6I37[66J&"&24Y(C$2%>!P#SDXQR2:S+W21<_'NV8W^H(
M/[%-R$CN6505G1=F/[AP"5Z$\U9^%<)-OXCOTN9+NVO=6>2&\D&/M("(K2+V
MVE@V,<<<5L:KX8O[CQM8>)=,U*&VDAM397$,UN9!)"7#G:0PVMD=>: /.[#3
M+U/AIX@UZWUW4[2XL+J_GM(K6<QQ+LE=OG4</D@YW9XP![ZNJ>(I-8\3/9WU
MQXBAM+;3K:54T**4EII@S%G:,$X   4\'GK750>"FA\":OX:^W@G4#=D7'E?
M<\YF;[N><;O49QVIL_A+5;._AU'0-7M[2Z:RBLKI;FU,L<PCSL< .I##<W<@
M@^U %_P-?:EJ'@^QGU>.X2^&^.0W$)B=PKLJN5(!!90&_&J,O@"&33=4LDUS
M6(TO;L7<+)<?-9OO+_NCC@%B2>O]:Z/2K.?3]+M[6YO9;Z>-,27,H :1NI.!
MP/IV%7* //M#MTE^,6N&[=IIM-TNT@LWF.6V.&,C?4L!DUV=WIFGSZA:ZI<6
ML;WEDK^1,1\T8888#ZBL3Q%X1GU+6;;7M&U1M*UJWB,'G>4)8YXB<^7(A(R,
M\@YR/RJ/3/"FJ2:];ZWXEUM=1N;166TM[>W\B"$L,,V,DLQ'&2>,]* .-@_M
MC4?AC<^/?^$@U.+5_)EU"*%+@BVC1&8B+RONE=JX)(SDYS6K U]XL\=7-K)J
M^HV6F-HUI=FWL[AHF\QR_1ARHQUQC.%],&R?A[JB:-/X9M]?BB\,3.W[C[)F
MY2)FW-"LF_&WDC)7(!Q71V/AM;#Q9>:U'.HBGLH+-+<)CRQ&6(.<\_>QC':@
M#RK5A>:IX,TJ"^U74)9+#Q9_9@F$Y5Y8Q/A6<CJX &&ZCK77S7=]I_QDT#1(
M]1O'L/[&D9XI9BWF.K, [Y^\W'4U8O/AW--X=N;"#55CNFUMM8MYV@W*CF3>
M$9=W('3.15]/"-Y+XVTKQ/>ZE#)<6>GM:2Q16Y19&8DEAECM'/3GZT <*D>L
MW?PRU?Q/)XEU=+_3Y;Q[017)6-5BF?"NO1\X(^;/& ,8KHHVO?&/C:ZLIM5U
M"PLM.TVUF$5A.83)-,&8LQ') "@ 'BM:'P0T7P_U+PO]O!-[]I_TCRON><[-
M]W/.-V.O..U8.MBU\-^,;:2'Q3;:'>3Z7'#.U_:[K>X2,D!E8NH$BY/&3P1Q
MZ@&$GB36H-#_ +.O]4U.>:X\375E/=64;/<>1$I8K$J@E<[1]T?*"<5)J&NZ
MMI_A#QBMC-X@CLK:V@GL+O4XI8YHW+8D0.X#,.%(Y.-Q%7_!OA>75_!KW5G?
MS6]PFNW&I:9?3Q;S(N2H=UXRKKNSTZY%=)J/A#6=>\+:UIFL:_'+<ZFJ(K0V
MQ2"V52#A$+$DGN2WIZ4 9UY9:AX=\9>&"-=U2Z_M66:VOHI[@M$Q\EG#(G2/
M#+QMQQ47PHTL6TOB>X^W7\S)KEY;;)[AG4A67#D'J_'+=:Z[6= .K:UH6H"Y
M$0TJX><ILSYFZ-DQG/'WL]ZH^&?#%_X=UG69%U*&?2]0NY;Y;<VY$L<LA!/S
M[L%1@\;>_6@#+UF-+WXS^'K:\ :WM=-N+JV1NAGWJN<=R%Y'I78:AI.GZH;4
MW]K'.;6=;B N.8Y%Z,/>LKQ5X47Q%]ANK:^ET[5M/D,EG?1*&,9(PRLIX92.
MH]JS8_".NZIJ-E/XH\0QWMK93+/%9V=K]G225?NM(=Q+8/.W@9H RM.LK_QI
M+XCU&;7M5L6M=1GL;"*SN3%'"(L*&91PY+9)W9XXK,T_6]7\77/@19-4N[)-
M3TVZ>_\ LC^696C*#(Q]TD@\CD!CC'6NGG\'ZU:7FK#P_KT%C8ZM,T]Q%-9F
M5X96 #O$P< %L9PP.#S5JR\$6^F:IX<N+*X*6VB64MHD+)EI=X7YBV>#\N3Q
MSGM0!R.G:3J=^?%VF3>)];%OHL[+8NEXRR@M$)/WC_>< D  GUSGC!;ZEK/B
M2?X?0/K%Y:)J>E3RW[6TFQI2JQG(QT))ZCD G&*[>P\,&RN_$D_VL/\ VS+Y
M@'EX\G]T(\=?FZ9[5Q-WX<O=)\3> -&L-36.\T_3;M([EH-R.5$0.Y-W*D$\
M;LCKGB@"OJ>O:MX3C\6:'!J=_=+;RV(L;F8FXN(5N6VN 3RY&"5!R<D=:M:=
MJ=[9ZAJ$&FOXHDTR32;B1Y=8AF!@N$ *LDD@!&X%N <948Q6\GP_EO=/UUM8
MU03:MJ\D,C75M#Y:VYAP80BDGA2,\GG-:%MH/B&X2^&MZ_#<">S>UBAM;4Q1
M+N',C LQ9OQ  SZT <0HU>P\%^$O%;^(=5GU"XFL%GC>X)@DCE*J5,?3.&^]
MU)R<U:O+R:V\77::]KFN:-=OJ _LV?YCI\D.5V1D#Y"2,@[L')ZUU-QX+:?P
M5HOA[[>%.FM:,9_*_P!9Y!4_=SQG;ZG&>]5]7\(Z[JXO--G\0Q/H5Y/YLD4M
MH6N$3<&,22;\!<C )4D#Z4 <MXUU5H)_$=]9Z[XBGOM/7= FG0R+9V3(@;9+
MCY').2Q.<!L8&*N?V?\ VC\;K"Y>^OX_,\/B]\N*Y95#":,;,?W#C)7H3S6I
M?> -2NXM>TR+74@T76)I;B2);7,ZR2+RHDW8V;@#C;DCC/>K"^#]9B\0:-KD
M.M6BWEI8#3[L-9DI/%O#Y4;\HW'7)_I0!R*>+=:T_1/B1>)>RRSV6K_9;+SF
M+K 'D$8V@\ #=G'3BM_4+*\\%:QX:N+?7-5OHK^_73[R&^N6F63>C$.H/W"&
M7/RX&#BKEO\ #BW^P^+;*]O6F@\0W;7/[N/8T!)RN#DY(.#GCITJ>V\)ZU>:
MMI=UXCURWOX=*<RVT5O:&'S)=I422$NV2 3@# R: .02#5M3\%>*]=E\2:O%
M<Z9=:@UBL%TR(@A9F4,/XQQC!X P !SGU+1;N2_T'3KR;'FW%M'*^.F64$_S
MK"M?!K6_A'7M"^W!CJLEXXF\K'E>?N[9YV[O49QVKH-*LO[-TBRL#)YAMH(X
M=^,;MJ@9QVZ4 >7^"?$]W9>"VTZU\)ZSJ<GVF\5)(XXQ;R%IY#@NSC YP3CL
M:F;3CX>\/>%?#FHZSJRSP6CF73]$20SSL,?-YB<K&A)'8'(],5W?A30#X9T"
M/3#<BX*332^8$VY\R5I,8R>F['X52UOPYJ=SXDM]=T75+>RNEM&LIA<6QF5H
MRP<%0&7# CW!S0!PT'B'6+3PGIGB.2_OWMM%UJ:SODN"0\MH9#'NE7NZ94\]
MP:WM;U/4-0\6ZRMC?3PV&@Z-(\HAD*B2ZE0E,XZ[47</0L*;-IND^!_".N:?
MXCUJ*?3-1>>2))4"W$AD!+J.?WC$G(P!C^4_@+PI=V7PS>QU&1UU3587DNI)
M!EE9TVJ"/54"C'J#0!R\D>NVWA+P5KT7B?5?[3U6>SM9S)-OA\N=,9\H_+N'
M!W'DD$G.:TK[4+[P/XB\06]OJ=_?VL?AQ]4CCU"X,Y2='*\$\A3QD=*Z:7P6
MTOAGPOH_V\ Z'<6<QE\K_7>0,8QGY=WU./>K&I>$(=5\37>IW4^ZVNM'?2I;
M8)R59RQ;=GT.,8H XOP[J5_!K?A][2;Q9>M=MY>J_P!I6DXMR&C)\Q-R[8\.
M!@+@8-4436;KX8:KXHD\2ZNE_82W;V@CN2L:K',^%=>DF<$?-GC '2N\T3P_
MXCL;FQCU#Q(ESI]@A2**&T\IY_EVJ9F+'.!V4#)P344/@AHOA[J/A;^T 6O/
MM/\ I/E?<\UV;[N><;L=><4 <]'8?VC\;;&Z>^OXR^@)>^7'<LJ!A,HV8_N'
M&2O0FO4:Y"X\(WZ>*]*UW3=4AA>VL%TZYBFMC()8@X8E<,-K9'7FNOH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQU<7L\LMC>SSV=I$[DQQQPIY>] >!EPQR.X% 'HM<O+XOL(O&C^'K32[Z[U
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MZ7H][J<\1ECLH)+@JH&XA%+$#/?B@#@?"7@Z_?P#X4G@N7TC6=.CE>%I8?,
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M3&X88KSCZ5K4 >5>)++3_"_PRD\&76H_;]0E0II%O#%MG9M^8L $YVMC+<#
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M\'M6/8^$;]+_ ,/7VIZREW<:,D\8,=IY0E61%09&XX(VYSSG/:NLHH Y._\
M MMJ=WXEEN;R39K<5LFV-=K6[0@[75L\G<0>G;O5O1=&URUU'[9K/B(Z@$A,
M,4$-L+>/D@EW 9MS\ =@,G YKH:* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3TQ[]:\K0P:S;^&-%L/$.HZK/::C:M%IL]F(9+&*-@6:X(')505!)QSP#UH
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M!QT=3W4\$<50N?A]/J<%_-JVO2W.JW"P+#>1VR1+;B&0R)MCR0?G))R>>G%
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ML#!MX*LX?=GUXQB@#RWPYHMS'\)/#5U86^J7EK-*)M5M+.\D6:6("0 1Y88
M8J2JD9Q7H?@.?39M&N!I=]J$]O'<LOV?4-_G6;8&86W_ #<=1DG[W7%9VE>
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M+Y@#.(T9CU(7<2,\<5D:KHZ^"-2\+WNF7^HO)=ZG%I]\MS>23+=+(K9=E9B
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M44 %%%% !5;4;Z+3-,N[^<,8;6%YI-HR=J@DX]\"K-8OC#_D2-?_ .P=<?\
MHMJ ,*+XGZ5Y$%W=Z1KMAI\VPK?75@5@4-C:6<$X!R.>G-=OUKRB(^*_$WPX
MLO#L'AA;2VO-/AMSJ-Q?1,BQ%%!<1KEB2.@XY/-2>*K;3[S6M0M$L]?UBYT^
MQCC"VEP(8=/;:6#[C(F9",-_%P!]* /4Z*\KTS5+ZRN_ ?B:[N99+?6M/BTV
M_P!S';YS('BDQTW%@RD^]9?B.[O=1\)^.?%,-W/'')=0V.G%7("QPS(K.O\
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M,PFN4=0ML !@L"<G/3CTKR_P_P")+C2M9U7Q)?7,KZ=K5G>7UM'(Y*J+60A
MH[;HF!XZXJ"&+4=*U/X46MS=W#7%T;J>[#2-\[NBN0W/."V!Z8H ].U'Q-86
M.GZ[<QN;B718&ENH4!!!$?F!<D8R5Q^=:&GW:ZAIMK>JA1;B%)0IZ@, <?K7
MCL>AV%M;?%BYBCE$MO#<1Q%IY& 5K7)R"V#SW.2.U:$FBQ>'[#P)K5G<WG]I
M75]9VUU,]RY$T<L9W(4)VA1Q@ <8% 'JMY=P6%E/>74@CM[>-I97/1549)_
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M:-&!SD@[@&^[BI8='TK4/C+I-R)I[U'\/)>)<FX<&9UE0)(=I Y !(P%/<4
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M'+&W1E/^>M<:OP[U$6/]D'QKK)T3;Y?V39%YOE_W/.V[MN./IQ7>44 <M?\
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M2$5.?8\GDYQT QMZK))XA\:ZC;ZCX=U+7;:RLK4016MPD20O(I=I"&D7YCP
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M-X92K;CSTX/2EB^'6E"PURTNKJ]NUUEHY+F260>8)$ PZD 8.X!NF >@ XH
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M[CAN;K4;2SOWMW EB25U!+$<@E. 3V- '=@@]"#]*,@$#(R>E><W6AZ;X/\
M'_A,>'[5;&/47N+6[@A)"S(L1=68=V4K][KR:X@Z%9K\#[CQ* _]M6MS)):W
MF\[[?;=E0$YX'4X[DF@#WW()(!&1UHR 0,C)Z5YQ-H.G^&/B?X3_ +*B:!]0
MAO8KU]Y+7.R-65I"3\S;N<^]<IIOA?3+GX,:CX@E#MJUJMY<6MYYC![9HI9"
MJH<_*,KG Z[C0![D2!U(&:6O&I&N?%?B>^.I>%9_$$=OI]FL4:W4<2VS2Q>8
M[ .R_,2<;AR-E3QZ/?W^L^ -)\4)-YXL;]+N%I@QE5#'L#LIPV0$)YYZ'J:
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ME$<Q38QV JR^G-;6J^%M&\-^// PT>U6S1[N=9(8V.V3$#8<@]6'(SU.>>U
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M(.S*.S,6SNZ\"@#T>D!!&001[5XCI\<FL1^#-*O;FXF@@UK4;+S#(=\L$:2
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MH$L;%@)$)4X8!AP?0T <OJ7@2WOK^^GM]8U33X-1(:^M;255CG. I/*EE)
M)4C(%:L'AZSMO$;ZW&\PN&LDL?++ H(T8L".,YRQ[UIM+&CJC2*KO]U2<$_2
ME>6.-69W50HR2QQ@4 <K>?#_ $N\T/4]+:YO$2_U%M2,R.H>*8L&RAVXP"HX
M(-='I]K)96$-M+=SW<D:X:>?;O<^IV@#\A5?6-<L=#TT7][+B R1QJ4Y+,[A
M%QZ\L/PK0!!&000>XH Y"[^'UL=5NM0TC6=6T26\?S+J.PE41ROW<HRL Q]1
MBK,/@'0HO#-YH31SRPWK^;<W$LI:>67((D+]=P(!'88Z53F\>3W6HW=IX<\.
M7VMI92&&XN8I8X85D'5%9R-[#OBM?PSXHL_$UK<-##<6MU:2^3=V=TFV6!^N
M"/0CD$<&@"MI?@Z.RUB'5K_5]1U>\MHFBM7O63$"MC=M"*HW$  L<G%1GP'I
MA\#3>$OM%W]@E9V:3<OFC=*93@[<?>..G2NFCFBF!,4B/M.#M8'!H,T0=5,B
M!GSM&X9;Z4 9U]H-KJ&O:3K$LDRW&F>=Y*J1M;S5"MNXR>!Q@BO._!O@'^U?
M \-OJ&HZO:6MS<3M>::K*B38G?&=R[U! 7(4@$?7->JK+&[LBR*SI]Y0<D?6
M@S1!E4R(&?[HW#+?2@#G=5\'17VI_P!HV&JZAI%T\"VTSV#(!-&N=H(96 (R
M<,,$9J>W\):?:WVB7<4ER&T>WEM[=6DW!ED"ABY(R3\HYR.IK;>6.+;YDBIN
M.!N.,GTIQ95^\P'&>30!S=[X)T^]NM8NC=7L-QJ<EO*TL,H5H'A&$:,XX/'.
M<@U4D^'MG=V=^NI:MJ5]>WBQ*;Z5T66$1/OC\L*H5<-STY/6NN22.2,21NK(
M>C*<C\Z(Y$E3?&ZNOJIR* .7LO T%KKD&M2ZOJ=UJ*PO!/+,\9^TQ-CY& 0!
M5! ("[><YSDUG?\ "K--?P=/X6FU?59=+>1'A1I(]UN%8L%0[.A)YSGH.E=N
MD\,B%TE1D7@L&! K#_X2.75/"L6M>&K6/4&FP8HIYA &7=@DL0<="?>@!-:\
M)Q:IJT6KVNI7NEZG'";<W-F4S)%G.QE=64@')'&1FH(O >E0Z596"RW9%MJ*
M:HT[2!I;BX5MVZ0D<Y/7 'MBNEDECA3?+(J+ZL<"G;EP#D8/3GK0!F2Z%;2^
M)[?7VDF%U!:O:J@(V%'96)(QG.5'>EUC0K;6I=,DN))4.G7JWL7ED#<ZJR@-
MD'C#GICMS6@DL<N[RY%?:<-M.<'T-8GBKQ*?#-M8.FG3ZA/?7BV<,$#JK%V5
MF'+$#^ ]Z -QT61&1P&5A@@]Q7#K\,+(6%M9MKFL-#8R))IH,L?^A%&#+L^3
M#$8QE]W&0.IK0TSQF]QKEOH^KZ%?Z/>72.UK]H:-TGVC+*&1B-P'.#VKIQ+&
M93$)$,@&2@89 ^E 'G.JZ?!XW^(NBM%87@M-!>1[N\N(&B29PR[(EW ;_G0.
M2!C XZUVMWH-K>>(].UN2287-A%-%$BD;&$FW=N&,Y^48P16F&##*D$>HI/,
M0#.]<<GKZ4 9-IX;L[*ZUNXCEG+ZQ())PQ&%(C"?+QQP.^>:RSX!LHM,T>VL
M-1U"QN=(A,%K>PLGF^60 RN"I5@< XQU QBNG-Q (EE,T?EL<*VX8/T-/DD2
M)"\CJB#JS' % '.+X)L/[/TZUDO+Z9K+45U+SY90TDTPSRYQC!W= !T&,5H2
M>'[27Q,->=Y3<BQ:Q\O(\LQLX<G&,YR/7IVK4W+@'(P>G/6F+/$ZLRRHRJ<,
M0P(!]Z ,3PGX5B\(Z<VG6NI7UU9J?W$5TR,(%R3M4A0<<]\]!5/5? T6IW=\
MZZWJUI9ZC_Q^V4$J>5-\H4_>4LN5 !VD9K:T?7+#7=&@U:RES:3*75G^7C)&
M3Z=*T%974,K!E/((.0: ,G3O#MEI>M:AJEL91)>Q00O&2-B+$&"[1C(X8YR3
MVK&/P]L8K.RBL=3U&SN;*ZGN8+N)D,BF8DR*0RE2ISW'85UX8'."#C@^U&]=
MN[<-OKGB@#C'^&FEO8:U8G4-3^S:RB"[4RHQ:1<9E!*D[VVC/;KQ6C=^"].O
M+KPY<23W0?0/^/4*RX?Y57Y_EYX4=,5>AU&]2^U3^T+2"VT^U"M!<BX#M*N"
M6++CY,?4YK,N/&EN;;PS=V,!GMM=N4A1G;8T:M&SAB,'GY<8]Z -?7M&M_$.
MA7ND73RI;W<1BD:(@, ?3((S^%8EIX#M;?4]/N9]5U*\MM-.ZPLKB1#%;MMV
M@\*&8@$@;B<5U,<L<JEHY%< X)4YYI7D2)"\CJB#JS' % ')OX M#>3&+5M4
M@TV>Y^US:9%*JPO(6W'G;O"EN2H8 G-=/>VJ7UC<6DI81SQ-$Q7J PP<>_-2
MAU*A@P*GH<\&FB>$AR)4(CX<AA\OU]* ,5?".F'P9%X6E\Z73X[=(%9GQ)A<
M;6W ## @$$#J*ATWPA%:S7,VHZKJ.L23VQM#]N==JPGJH5%49/&6()..M=$C
MK(@=&#*1D,#D&DCFBF4M%(C@'!*L#@T <3'\,+'[/8VEQKFLW5GIT\4UC;RS
M)MMS&P*@83+<#;\V< D#'6KUYX%MKG6[[48=5U.TBU';]NL[>11%<;5V\Y4L
MN5X.TC-=5O7;NW#;ZYXILDT42EI)$15ZEF  H Y0_#W3H]&T:QL[^_M+C1U9
M;*^A=?.0-]X'*[6!XR".PI5^'VF+HKV)N[]KM[P7YU(RC[3]H' D!QMX'RXQ
MC'&*W-4UNQT<67VR0K]LN4M8<#.YWSC\.#S5XRQJR*TB!G^Z"PRWTH YI/ ]
ME-I&JV&JWU]JC:HJK<SW4B[L+]T(% 5-IY&!UY.:@M/ $$6KZ9JE]KFKZE>:
M8[&V>ZD3"J4*E2%09R#DGJ2!SQBNIO)_LME/<!=WE1L^W.,X&<5F^&M=37_#
MVF:FR)!+?6R7'D>9N*[AG Z9^N* %\2^';+Q5HDND:@THM97C=_*8!CL<,!D
M@\$K@^U9UCX)MX-9CU._U74=5EMX7@M4O70K C\-C:HRQ P6;)Q72M+&CJCR
M(K/]U2P!;Z4X,"2 1D=1Z4 <,OPPLA86MFVN:RT5A(DFF[I8S]B*,"NP;,,>
M,9?=QP.IJW)X MY;ADDUG56TM[G[4^F&1#"TF_?UV[]N[YMN[&?;BM_6;J^M
M-+GFTNTAO+U-NRWEG$2MD@'+8..,GIVJX)0L0:8K&VW<P+<+Z\^E '+W_@*V
MO+Z^E@U?5+&TU!_,OK*UE58YVP 3DJ64L  VTC-2ZIX+@OM:&K66JZCI5VT"
MVT[63H!-&#D!@RMR,G##D9KI5='0.K*R$9# Y!%(DL<BAD=6#="ISF@#)\,^
M&;'PIIDFGZ>TS0/<23XF?<5+G) ..@]\GW-4M4\&QWNLSZM8:OJ6D7=U&L5T
MUDR8G5>%+!U8!@#@,,'%'COQ6W@SPT=72S%V1/'%Y1DV?>.,YP>E=')+'%CS
M)$3<<#<P&3Z4 <_:^"=)LET%+7SXDT1Y)+=0X/F,ZLK%R1DD[B>,<FK\&A6U
MOXEN]=624W5U;QV[H2-@5"Q! QG/S'O3]0UNQTR_TZRN9"L^H2M% H'4JC.2
M?084\^N*O-+&CJC2*'?[JDX)^E &'XE\*0>(Y=.N3?7EA>:=*TMO<VC*'4LN
MUA\RD$$>U6=*\/VVDWNJ7<,T\DNI2K-,92#AE0)Q@#LH/?FM1Y8XP2[JH R2
MQQ@4N0!G(QUS0!R2?#ZPMM&T>QL-0U"SN-(5UM+Z)T\X*WWE;*E6!XX*]A6W
MH>BQ:%8-;)=75U))*TTUQ=2;Y)';J3@ #H!@  8K0$L9D,8D0N!G:#SCUQ09
M8UE6(R()&&0I89/X4 8-WX2@G\7P^)(-1OK2Z6%;>:*%D\NXC5BP5PRD]3V(
M.*H1_#C2(O#.J:"+F]^RZE?_ &^9RZ;UDWH^%.W&W,8Z@GKS77A@<X(..N*3
M>N<;AG.,9H S;S0;6]\1:9K<DDPN=/CFCB12-C"4*&W#&?X1C!%9]QX)TJ[3
M7DG:X==:ECFG^< QNBJ%:,@9!&T'G/(_"M_[1 8FE\Z/RU.&?<,#ZFGET";R
MR[,9W9XQZT 8>B>&3I5_+?W6L:EJEV\0@62\=<1Q@YPJHJC).,D@DXJ7Q#X;
MM?$,=J9)[BTN[.7SK6[M6"R0OC!QD$$$'!!!!%:ZR(\8D5U*'HP/!_&D66-G
M=%D0LGW@&&5^OI0!@Z3X1MM,_M&::]O+^_U%!'<WERR^85 (55"J%51D\ =3
MSFK?AGP_:^%?#MGHEE)-);6JLJ/,07.6+<D #J3VJ;2=;LM:6Z:RD+BUN9+6
M3(Q\Z'#8]1GO5V26.%=TDBHN<98X&: //KOP_<ZG\5]3NH;S4--9-)MTBO+4
M#!S))N0[U*M_"<8R, \5J_\ "O-/BT>SL[2_U"VN[2[>]344=6G:9P0[,64J
MVX,01C'2M/0?$!UF]URW:W$(TR^-H&WY\P!%;=TX^]C'/2M2:^MH+&6]>9/L
M\2,[R!@0 !DT <O#HFF^!I[[Q ;W5KC[3&B7<>S[0T\@/RR%53=NY(XPH'8
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M!(,_.K<_-R<DYSDYH XG6]/M/#OB;Q%IFCV\=I87OA2YNI[6!=L8E0E%<*.
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MWN(I0)HIB[/D';CJ[#!'2F7?P]L[MIP=9UJ*&[15OH(KE0EV0@0L_P N0S*
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M.]H"Q4#[O//%=3K>C:=X6\<^$9] T^"SFG^U6\R6Z!?M$8A+C?C[Q#*#D\T
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MLH4X]!A15N34+*&\CM);RW2YD&4A:50[?1<Y-3R2QPQ-+*ZI&HRS,< #U)H
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M >*Z5[F",1EYHU$GW,L!NXSQZ\<U5_MK2S83WR:A:R6L /FRQS*RKCL2#C-
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M=Z;<F!Y5'0/CAL>XK>N[^SL(UDO+N"WC8X5II @)] 31<W]G96XN+N[@@@.
M))9 JG/3DG% &1I/@S1=(T^^LX[=[G^T 1>S7<AFEN<C'SNW)X)&.G-5--\
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M]IEO=V%ZU_JMQ?6,@>"ZGNR\@0 CR^F-A!.1CGN:ZB:>&VA::>5(HE^\[L%
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M>3Q00F-U.XNP4,,D#:,Y)["@#9HJI)JFGPF 2W]JAN #"&F4>9GIMYY_"K=
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MCX<6;^"]%368M1AD0"6XTU[AU@>56)#/%G&>%..AQDYKJKWP/HVH:Q<:C/\
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M=NW-'G!RP!(Z$]J?>^!-&OM9N=2=KV-KS;]LMX;IT@N=HP/,0'#<<>A[YYH
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M[FTF&)(G'!_J#Z$<B@!VIZI8Z-ITNH:E<QVUI" 7ED/ R<#]2*XC2=.L-?\
MB7XO?5[.WO3:):6]JES&)!'"T6\[0W3<Q.?I6E9_#70K:ZMYIY=3U!+5P]M;
MW]])/#"PZ%48XX[9S6AK'@[3M8U+^TC/?V5Z8O)DGL+IH&EC!R%;;U R<=QZ
MT >6V=G#?:?X;TB<&73;?Q9>6D",Q(:W42X3W7&5QZ<5NZII&FV7C+Q786MA
M;0V<_AA;B6W2)1&TBO(%;;C&1@<^U=Q%X0T6WM='MK>U,,.D3>=:(CGY7(8$
MGNV=S$YZDYJS+X?T^?6;C5)8F>XN+,6,N6.UHMQ;&/JQYH \>UZSM;3X&>#6
MMK:&%IKNPDE,:!3(Y4Y9L=3[FNRBT;3M6^,6N'4;2&[2'3+0I'.@= 2T@W;3
MQG&0#V!/K6HGPWT)=!AT2234)K""Y2YACFNV?RF3[JKGHHSTK?AT:SM]=N]8
MC5A>74,<,K%N"J$E<#M]XT >/Z;;07%KX=\/W$:MH_\ PE5]$;=N8RL9D:.,
MCH5W=NG%7/$5M;^'/&GBN30D2UD7PC)<>7 -JQ2>81N4#A3A0>._/>NK\3>%
M[.R\,FWLM$NM2C.I_;Y$M[HQW$+LQ9I86XRP)X7(X)YJAX/\/&;Q;J.L-I.H
M6FG2:<MC_P 39R]Q>.7+.[Y9CC&U1GL..* *6@>'=6BU#PM>6GAS1])@M!B2
MZMK[?)<P-$058>6NXD[7R2>1FL*'0-+D^ VLZI)90R7^Z[E2Y= 9(V2X<+M;
MJH&.@]3ZFO3-)\":/H]_;W<,E]-]D5ELX;F[>6.U!&"(U8\<<=SCBK*^$=)3
MPI/X:$<O]FSB0.OF'=^\<NWS?5C0!R-KIUC<_&^">>RMI)3X:CN2[0J3YPGP
M),X^]@ 9ZX%:'Q:^3P?!<R*6M+74K2>[ &?W*RC=D>G(K<O/"&FWFN6&L^9>
M6]]91+ DEO<-'YD0;<(W ^\N><=ZVKFV@O+:6VN8DF@E4I)&ZY5E/!!'<4 -
MDO+:*Q:]DGC6U6,RM,6&P)C.[/ICFN!=M-\5?%73_M"PW^EIH'VVQ25-T;.\
MVTR!2.NT*.1QFKZ?"OPXJK;E]4DTU6W+IDFH2M:C!R!Y9/3/8\5M:SX4TW6F
MLY7^T6ES9@K;7-C,89(E(P5!7^$X'!XXH \I\16T5IH_C[1K(>1ID&L:<T$<
M/RK$\C0M($Q]WYN<#IFNDU7PKH4/Q5\-6L.E6L5K+I]SYT$<0$<WEE"F]>C8
M)SSGD ]JZM? VAKX?ET7R9FMIKA;J>1YF:6:4.K[W<\DY4?EBM.?1;.YUVSU
MB17-Y9Q211,&X"OC=D=_NB@#QO7K6WL_"GC[3K<"ULHM?M"B1?(L6YH"Q7'W
M>>>*ZK7])L/#?COP?+H.GV]I/,MW;R1V\83SHU@+ -C[V&"GGO5SQUX2CD\+
M:PNFV4MS<ZI?VMQ<Q#+[]LL88@=@%7GZ&MS2_!>EZ5JZZHLM]=7,41AMS>73
MS"W0]5C#'C. ,\G ZT >9^&=%UO4_"OAR_M/#^DPW(N(;XZR;_\ TB5B^9-P
M\O)+@LI4MWQVK;T7P[I.JR?$&XU"P@NI/[3N(E,Z!_+'DH?ES]TDGDCG@>@K
MJK?X?Z';:C%<Q_;?(AN/M4-BUTYM8I<YWK'G .22!T!/ K6LM L+!=4$".!J
M<[W%SER<NRA3CTX44 >9Z7I&HZAX:\(ZY#I>G^(/(T5;>73;Z15;#;2)(RP*
M[OEVG.,CO4]O-I&M-X=L=!\,1WLUO8SRQ6VJW)6&R3S?+<,"K[GWJ5&!P!P0
M*ZZ3P!H_V;3XK6;4;%[&V%I%/9W;Q2&$<[&(^\,\\]#TI9?A]H;1V"VWVVQ-
ME"UNCV=V\3O$S;F1V!RP+<G)SDDYH \P>SM[GP)H$5U:6;B#QC]ECC4"2..(
MW+;HT) )3C'09 '%=9=P16WQ_P!#@@B2*&/0'5(XU"JH$C8  Z"N@D^'/A]]
M*NM,2.YAM)[I;Q$BN&7[/,#D-%_<YYXJ_!X2TV#7++62UU-J%G9_8XYIIV<M
M'DD[L_>.2>30!YOIFC:5J?P.U77-0M()-6GAO;R:]=!YRSH\FTA^H*E5  ]/
M>M+1K"W\0_$6SN-:M8[N3_A%K.9HIT#)YK.^6*GC(RP'IDUT]S\.M!NKFX=_
MMRVES-Y]QI\=VZVLTF<EFC!QR0"1T/<5N1Z+91:_)K2(PO)+5;0G=\OEJQ8#
M'U8T <Q\,HDM=.\064"B.VM=>O(8(EX6- P(4#L.3Q67(?$8^+'B+_A'DTIF
M^PV7G?V@TBC'[S&W8#[YS[5W>E:-9Z,+T6:NOVR[DO)MS9S(YRQ'H..E%OHU
MG;:W>:O&K"[O(HXIF+9!6/=MP.WWC0!P>JZ,VC^']4N?$<2:OJGB'4+:)K2S
M<P0NX*K%$&.3L&WYB>HSQ5"R\/MJ?BWQ+X=O],TO2X]0T*+S+?39"\8;S) D
MARB8<<=N@'->DZYH=EXATTV-\)/+WK*CQ2%)(W4Y5U8<@@CK6/'X6TKPW<G7
M[>+5;J_@A9)2D[3378)Z."?G([>F..@H XFTU.X\::9X3\*WF3>0W3MK:$YP
MMF0"&_WW\L_C3K70-+U+3OB9=WUC!<S)?7:1O*@8Q8@5LIG[IR<Y'H/05TW@
M?0)4UW7_ !9?::=.NM8F416KXWQ0H  6P2 SD;B/I70P>&M-MK;6+>-)!'J\
MLDUT"Y^9G0(V/3@"@#S1M(L+'PC\-=5@MHUU*?4=/::\VCSI/-0F0,_4@YZ$
M]AZ5572-7\1V?BTQ>'=+NKF?5+J)=4N;[RY[9HVVQ[1Y9*A JD889_&O4I/"
MVERZ5H^FM')]FTB6"6T&\Y5H1A,GOQ^=4=1\ Z+J=_<W,IO8X[Q@]Y:0W3QP
M7+  9D0'!X !Z9QSF@#G=-T6VU7XIZH=;M+>\F@T>RW1RJ)(_,/F!FVG@GJ
M<="?6N2ET^R?P=H]K):PR0VOC8VD*/&&"0FX;,8S_">,CH<5[-;Z)96NMW6K
MQ(RW=S#'!(=WR[$SM ';[QK+NO FB7>B3:4Z7"P2WK7X>.8K)'.7W[U8<@Y)
MQ0!ROB?PY_9VJZKJ9\,Z=KVBRVD<,MLK+'<6,<:'(B!&-N#N 4J<].U>B:5/
M;76CV-Q9,S6LMO&\)<DL4*@KDGG.,=:YZZ^'NDW3L[7FKH9HEAN_+U"1?MBJ
M-H\W!^8XXSP2.*ZB""*UMXK>"-8X8D"(BC 50, #\* )**** "BBB@ HHHH
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M&"V2>>>U37OBE=.\;KH]Y):V^GC2FOGN9GV;6$JH 23@##?G7.?"3_6^-O\
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MC1YCMB5G +G&<*.YQSQ5=]9TN/4ETU]2LUOFY6V:=1*?HN<URGBZ1/\ A,/
M:;AN:_F8#/4"W?)_4?G6'X3T?P]JWPWDU/Q$MO%/-?3W%[?2,(Y8IEN& /F=
M5(PH'/3ZT >CW6L:98W<-K=ZC:6]S-_JH99U1Y.WR@G)_"EO]6TW2EC;4=0M
M;-9#M0W$RQACZ#<1FO*?[+U;7[_QPJZ/H=ZLU]):O<ZA=-'+#&L2;-H$;84
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M<6PO9F2WA"* SN #N/S@ 8."<\56^& ECB\3V\J6D1AUN53%9DF&,^7&6"9
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ML%P^J+R>YDD 'ZBK^A6EKJWQ $.J6\-RMKX=M#:13H'4*Y;S& /&20H)]L4
M=GJ^HW4)TM].NM*6*YNHTD:\F*^9$>HAQ]YSV'0U:O-<TG3Q(;W5+*V$;!'\
MZX1-K$9 .3P2.<5Y=XQLM(TZV\!V6AS)+8P^*854)+Y@C;S"60'M@DC';I6]
MHFC:=J7Q.\<2W]E!=,C6<:"= X4-;KNP#P,X&?H* .XN-2L;2R%[<WMM#:$
MB>255CP>AW$XYI;;4+*].+6\MYSL63$4JM\ISAN#T.#@^U>,^%(8K^'X::??
M(L]B/[3=891N1I(F*QY!Z[5)Q76>$[*QT_XL^,;?3T2*(6UFS11C"QNPD)
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MT*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(QS].: *</@G08?#T^A_8VDL[B0S3&25FDDE)!\PR$[M^0#G.1@5/H?AC3M
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M5M'.F?9[,65C!,Z-,P+$M(^TD#KM R>":ZV/2+&+6IM72#%]-"L$DNX\HI)
MQG'4GM0!XU'H^G1? OQ7(EG#YBW5X4?8,ILF(0*>P&. /?UK?\G6]1^(NLFT
MLM&O&CTRSC4:J[C$3JY;8%5L@MG=]!7=?\(KHO\ 8-WHGV/_ (EUVTCSP^8_
MSEVW-SG(R3V-1:QX.T37)H)KRWE$T,7DK+;W$D+F/^X61@67V- 'G]EH/V?6
M/AOI6J26=\+=-1(,#F6$JNTQ@$@9"C:.1U7VJ+Q%:V\/_"V8(H(TB%A:S!%4
M!0YA?+ =B<#FO3H?#>D6\VERPV21-I4;Q600D")7 ## .#D =<T2^'-)GEU6
M26S5VU:)8;W<S$2HJE0,9XX8],4 +X<BBA\-:8L4:(IM8B0B@#)0<UY<T"_:
M[OX=NN8I_$:S>5V^Q,OVIA]-RLOXUZIH>AV'AW35T_3DE2V4Y599WE(X P"Y
M) P!QTJ-O#FDMXE7Q$;-?[56#[.+C<WW,DXQG'<\XS0!YMX8DDUG6/"/AZ=B
M[>&ENI+P'^_"QMX3]<$M^%<TJ(_P.^(!9%8KKL[*2,X/F1#(_,U[=I_AS2=*
MU?4=5LK-8KW42K74H9CYA7.."<#J>F,U6B\&Z!#HNHZ.FGK]@U&5YKJ%I'/F
M.^-QR3D=!TQC'% '.:SIEC<?%3PG#):PM#%87DJ1;!L# QX..G?/UYJSX-AB
MM?'/CJVMXUB@6\MG6-!A0S6ZECCW/-;NG>$]'TN:RFMH)3-8QR1022W$DC*K
MD%AEF.<X'7ICC%7K32;*RU&_O[>'9<W[(]R^XG>44*O!.!A0!QB@#D=<>6_\
M>26NEZ3I<U_9Z:K7%YJ;N42*1VPBH."24)+<<8%6/A0_F?#32#N5@/.52GW=
MHF< #VP!CVK6U?P?HFN:E'?W]H[W"1^262=XQ)'G.QPI =<D\-D<U<T?0]/T
M&":#386@AFF:=H_,9E#,<MM!)"C/.!@<GB@#RV[FN;?Q[\5IK,L+F/186B*]
M0PM^"/>K6O:?IMC\(O#5SI<$"74,NG26,D:@.96=,D$<DL"V?7FO1K?P_I=K
MK=_K,-J%O[]$2YE+L?,5!A1M)P./05F6/P_\-:=?P7EM8.&MW,EO$]Q(\,#G
M^)(V8HIY[#CM0!P6HK]DU/7O X^[J^NVT\2_].\_[R; ]!Y,H_X%3M%!O]3\
M,^#6)8:#J=W-<#TCMSBW)]CYT?Y5Z9/X<TFY\1VOB":S5M4M8C##<;FRJ'.1
MC.#]YNH[FBT\.:38Z_>Z[;V:IJ5\JI<3AF.\* !P3@=!T'.* /)-#T;Q%K/P
M^M9%C\.6WF7OVHZA<3R+<K<"X)+,=F-^X;>O0XKJO#>EV5W\7?'%Y<VT4TUN
M]D(6D4-Y>8 25ST)VKS["NB/@/PXVKG4S8MYQG^TF/SY/),W7S/*W;-V><XZ
M\]:UK31["QU34-2MH-EWJ!C-S)N)\PHNU>"<# XXQ0!ROQ:BD;P!<3K&TL5K
M<V]S/&HR6B252W'L.?PKK1JE@=)_M7[7#]@\KS_M&\;-F,[L^F*LNB21M'(J
MNC AE89!![$5R ^%G@Y9MXTD^5O\S[+]HE^S[LYSY6[9^&,4 9:7EAXD^*NB
M79 N-.;0)+O3_.C(!D:50S!6'79C\#7*>*+>**S^)%A:J(]/&H:6RI%\JK*[
M1>;C'0_=)]Z]9UGPQI.O1VRWULV^U)-O+!*T,D.1@[70@@$=LXJ"/P9H$6@R
M:(M@/L$LHGE0RN6DD#!@[/G<QRJ\D]L=* .?UK3;&P^)7@A+.S@MT>*^@98H
MPH:,1*0IQU /:N0@@AC^!'B]TBC5S=7JEE4 X$QP*]@N=)LKS4['4IX=]W8^
M9]FDW$;-Z[6X!P<CUK'7P#X;5-5C6Q<0ZKN^UPBYE\MRQRQ"[L*21U7% ''V
M]E;7_B'X8QW4*31IHLT@1QE2PB@P2.^#S]0#VK&\4Q1VA^(EI$JP6+W^E>>L
M8VJ$D$?F'CIGO7K<7A[2X;G3+B.UQ+ID#6UHV]OW<;!01UYX5>3D\50USP[;
MOIFOS6&EVMY?ZI$HGANI&$=R47:JGGY?EX!&.<'WH YOQ'I^F6/Q4\"-:006
M]RQNT*1*%W1K VW('8$G'U-<MX?T;Q%K'P]TZ58_#EL'O%N_[0GGD6Y6X%QD
MECLQO+ IC/?%;WA_PM-+XNT6_@\,W6B6FF+*\TE]>"XEF=HS&L:'>YV*&8\D
M#G@5UO\ P@?AP:O_ &G]A;SO/^T^7Y\GD^=U\SRMVS=GG..O/6@# \-Z3I][
MXQ\>S7=I#.[7D<),J!L)Y"$@9Z9SSZX'I7)Z##%<Z;\)#/&DI+7$9WJ#E1$^
M <]A7L-II%C87=_=6T&R:_D$MRVXG>P4*#R>. !QBLJY\">';K1=/TE[%UM-
M.;?:".XD1X3ST<,&[GO0!)XWLKB_\!Z]9V:EIY;"9(T7JQV'Y1]>GXT>"=3L
MM4\$:/=V4B&#['&A"G[A50&4^A!!'X5NQQK%$D:9VH HR23@>YKD[SX9>$KZ
M\GNI-,:-KAMT\<%S+%'*>Y9$8*?RYH Q-?U;2_%'B/P5Y$R7>C/J=TDA93Y<
MD\43;.HPPW9P1D'%4O%,,5GXR\5164:11S^#YY;M(P &D#,$9@/XMI8?05W]
M[X8T74-%BT>?3XA80E3#%%F/R2OW2A7!4CU!!J"Q\':'IUCJ%I#:.RZBACO)
M)IY)99E*E<-(S%L8) YXSQ0!YYJ>A:7_ ,(9\-$^Q0_O=0L5E;8,R"2%C(&/
M<,>H/6K?B.W@L_%_C*.VB2%)?"#22+&H4,P,J@D#OCBO0I?#NES6>EVDEKF#
M2Y(Y;-=[?NFC4JASGG )ZYJAXF\/07FFZ[>VEJ9-7N])EL48.<NNUBJ8)Q]Y
MNOOUH X/4=.TZS^%7@N[T^"%;Q+K39+>9%&]Y79=_/4DY;-5XM)UO7=.\;1)
M;>'O)N-4O(IKR_GD2:'8<1MD(0 BA"O/O7:>&O &C6-EHMY<V$BZA:6\3^4]
MP[113[ &98]VP-G/('7FM#4O GAW5M2EO[RQ=I9BIG1)Y$CG*_=\R-6"OC Z
M@T <YHVF1W'Q6OGU)(;NZM]"LU,A&]2Y9PS#/KCKUP3ZUBZ'HDU[HX32IM.2
M[TKQ)J#V5C?#]Q,H9U*8'(P')! .#VKU.+2+&#5Y]5C@VWL\*022;CRB$E1C
M.!C<>U9=SX(\/W5FUJ]DZ*;N2]#Q3R)(DSDEG5PP9<Y/ ./:@#B6U*TNK6#2
M$\)V<.N/KQ5[*6Y/V5+E8?-,Y91\R[,';CJ>F1FLC4HYAHGQ3@O4T_SHX+=W
M2R4^4LAB.2 W1L 9/K7I3^ _#KZ.FF?8I%A2X^U+(MQ()A-C!D\W=OW8XSGI
MQ3H? OARW%TL6G;4N[4VEPGG2%9H\D_.-V&;)/SGYN3SS0!P_C"**&3X8+%&
MB*=4MSA% &=J\UM>#[&QU+6/',NJV\$]RVK/;R^>@8BW6)/+7G^'!)K=@\"^
M'K>VTVW%I*Z:9<"YM/-NI7,4@P <EB2!@<'CVI=7\#Z!K=_)>WEI*)YD$<[0
M7,L(G4=%D", X[<YXXH \R\*VT>J+\+8[]/M$*1ZF8UE&X,B$>5D'J  I'T%
M=OX5@BM?B7XWAMXTBB(L)-B#"[C$^3@=S@5TPT#2Q=:9<I9HDFF1O%9["56%
M74*P"@XQA0.1QBI;;2;*TU2^U*"';=WPC%Q)N)WB,$+P3@8!/2@#B?%B:O)\
M4/#PT2>RAN_[.N_FO(FD3;NBSPK YZ=Z74-*GT/3O$'BSQ;=1:I<'3&M3;V4
M;01K!R2BG<6RS'EL\?A7:RZ393:O;ZK)#F]MXGABEW'Y4<@L,9P<[1V[5->V
M5MJ5C/97D*S6UQ&8Y8VZ,I&"* /,+6SOK/X@>$+74+'1;))+*[B2VL"S,(A&
MOR2%@-P! QQUS649;BT\/W_PNCD87CZJMA;-G+"PES,7]\1B13^%>AV_@+P[
MIYMKB"RN'N;.0302M=RM*"H("[V?)7!(V$[>3QR:SM#T:]UCQY/XQU;2#IAA
MLQ8V-O*Z-,1N+-(^TD \[0,GC- %73='T\_&#5(VM(GCM-%M8X$=0RHNYQP#
M[#'TSZUQR:1I\/P#\23):0B5;FZ97V#<FRX(3![  #&/?UKV>+2+&'6;C5XX
M,7UQ$D,LNX_,BDE1C.."3VJG_P (IHI\/W.A?8O^);<L[30^8_S%VW-\V<C)
M.>#0!PHM];U+XB>)/LECHE[LL[.'&JNX*Q-&Q(0*C?*6+Y]P*K6&A>3KWPWT
MS5);34/LMGJ&&A<RPL%\OR\$CY@HV]1U7VKOM8\&Z)KMQ%<7MM*)XXO($L%S
M)"S1]=C%&!9?8YJU'X=TF&YTVXALDCDTR%X+/82HB1@ P !P<A1U]* /+/$M
MK;P6OQ9@BAC2%8+258U4!5=H>6 [$^M>KZ'%%#H5@L4:1K]G0X10!G:*AF\-
M:1</JS36:N=718[[<[$2JJ[5&,\8![8J;1=$L?#^FII^GK*MNARJRS/*1[9<
MDXXZ=* /-_#MAXFNO$'C630M<L["-=9D!BN+'SM[^6G.[>,#H.AJ/0KNTM_
M?BOQ)K_GZAK$P:UUBU8B(HT8*+ NW[JX;[PZALUZ=I^CV&ES7TUG!Y4E].;F
MX.XG?(0 3R>. .!Q52;PKHEQ<:K/+8JSZK$L-\"[;9E P,KG&0.,@9]Z .%L
M[2_LOB3X8M=0L]%M-^G7<8M].W$B("/"R%@-P!'''8USZP11_LXZ^Z1(KM-<
M!F50"0+HX!KTZT\!>'K*>TN(;6<W-I+YL5P]W*\H.,8+ELE<<;3\OM2+\/\
MPTMKJEJ+!Q:ZF2;J#[3+Y;$MN.U=V$R>?EQ0!S&EPQ7GQ!\+PWT:2P0>%Q-:
M)(,J)BZ*Y /\6W'X&M+P>(;+QSXYMK8)#IT=S:R*JX5%E:',F.P)(4GWKH-3
M\):-JUI96UU:N!8C%K+#,\4L(QM^5U(8<  \\XYIL?@W08_#MSH*V _LZZ):
MXC,CEI6)!+,^=Q)P.2<\4 ;M<%XY_P"1Y\ _]A";_P!%&N[1%C144851@#VJ
ME?:+I^I7UA>W=OYEQI\C2VS[V'EL1@G .#QZYH Y3XF6D%\?"5K<QB2"3Q#
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M),D[448 R>3P.]6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%4M7U:ST/2;G4[^98;6W7<[L>/0#\20/QH
MNUSFM> _#/B"_P#MVI:4DEV5VM/'(\3L/1BC M^.:Y]OB5;7^E^%]4L+FVAM
MKZ]6'4%D<-]G'DM(REN ",#)KK=&\3Z)XA2=])U.WNQ;D"7RVY3/3(/0'!Y]
MJ 'VOAW1K+0VT6WTVVCTQE*-;",;&!ZY'?/J>:JZ-X-T#0+LW>G6'EW!C\H2
MR3/*RI_=4NQVK[# J32?%F@:[>2VFEZO:7=Q$-S1Q29.W.,CU&>XR*O7>IV5
MC<6L%U<QPRW<GE0*YP9'QG:/?% %5?#6CKH$VA+9*-,F#B2WW-AM[%FYSGDD
MGKWJ.]\)Z)J.IV.I7-B&O+ !;>99'0JH.0#M(W#(S@Y%7KG4[*SN[2TN+F..
MXO&9;>)C\TI49.!WP.:S[#QAX=U357TRQUFTN+U=W[F.0$G;UQV..^,T )_P
MA^@?8-3L?[.3[-JDYN+R/>W[V0D$L><CD#IBM"ZTNRO;VRO+B 27%D[/;N21
MY;,I4GCKP2.:Y/P_XPGN/$?C6#5IX(=.T2:,1R;=NQ"K%BQ[]*ZV?5+&V6T:
M:ZBC6\D6*W+'_6NP)"CU) )_"@#RW7?!VIZC)K5G#X+LDO=0ED1-7BNP+=4?
M@RM$6W"7:3G"\GO7?:CX,T+6(;-=1LS-):PB&.9)7B?9@94LA!(..AXJ:?Q;
MX?MM:71Y]8M(]09@@@:0;MQZ*>P)[ \FMF@#,C\/:3#+IDD5C%&VF(\=GLRH
MA5E"L !QR .M.?0=+EGU*:2SC=]3B6&\+$D3(H*A2,XQAB./6J5KXU\,WVJC
M3+76[*6]+%%B64'<PZA3T)]A7&ZM\2#+\28_#FGZYI=A8P0AKBXGB,K23^9M
M, ^8 &@#OM#T'3?#FGBPTJW,%J&W!#*\F#@#@L2<8 XZ55U[P?H'B:2*35]-
MCN)H1B.8,T<BCT#H0V/;-,\9>++'P9X>FU:]PVWY8H=^TS.>B@X/;)_"L:Y\
M?V$7B?3BNJ68\/W&FSW+7)/!=)408;ZDC'<T ='HOAK1O#MG)::3I\-M#*=T
M@4%C(?5F.2WXDU1T_P !^&=*U&.^L]*2.>$EH<R.R0D]2B,Q5/\ @(%7K/Q+
MHFH:-)K%KJEK)IT6[S+D2 (F.NXGICWIVC>(M'\0Q2R:1J,%XL1 D\MN4)Z9
M'49[>M #X=$TZW_M#RK55_M%S)=_,?WK%0I)YXX '&*C;PYI+:98::;-39Z>
M\4EK%N;$;1_<(.<G'O4FL:[I>@6BW6K7T-I"S;%:5L;F] .I/L*B3Q+HDFE6
M^J)JEJUC<2+%%<"0;&<G 7/KGC% '*6'P_LM2UCQ+<>(-,+)=ZB9+9UG9#)"
M8HP0?+8$KE3\K?E74:EX5T/5M/M+&[T^,V]GC[,(F:)H<#'R,A!7CC@TFD^+
M- UV6XBTO5K6[DMQNE6)\E5_O>X]QQ5>+QUX5GO;:SBUZQ>XN@IA02CY]WW1
MZ9/8=3F@"Q#X4T.WT^RL8=.C2VLK@75N@9OEF&2')SECR>3G.>:LW.B:;>:@
MU]<V<<MP]JUFS/DAH6.60CH02/2N>M_$FH2?%V[\-,8O[.BTA;Q1L^?S#(%Z
M^F#TJ]H&MQMX>N=1U'7M/O8()I!)>0KY44:C^%LD\CN: ':9X&\-Z/)+)9Z8
MH:6$P-YLKS8C/5%#L=JGT&!4-M\/?"UI%%'#I07RI4FC8SR,Z,F=NUBV0HW'
MY0<<GBM#2?%.@Z[;7%QIFJVMS%;#,S+(!Y8QG+9Z# /)XXINC^+-!\02S0Z1
MJMK>2PKN=(GR0O3..X]QQ0!#_P (5X=%YJET-.42ZI&\=[B5PLROC=E=V 3C
MD@ ^]2W7A+0KS1+71Y]/1K&T"BWC#L&AVC"E7!W @=P<USO@[XCZ5J6@:.-:
MUBQBUF]3YH-P7YBQ"C'8D 8!ZU;C\2:@WQ?E\-$Q?V<NCB\ V?/YGFA>OI@]
M* -6W\'>'[71;O2(M.065YG[2C.[--GNSD[B?<FK]UI%A>R6+W%N)&L91-;$
MDCRW"E<\'G@D<U2M?%OA^]UE](MM8M)=04LI@60%B5^\!V)'<#D5=U?5;71-
M(N]4OG*6MK$TLA R< =!ZGL* ':II=EK.G2Z?J$ GM9L;XR2 V"".1SU JW7
M!6^L_$34=.75[31=$AM9$\V'3[F>3[2Z'D N!L5B.Q'&>:WX?%EA%X8M=<UC
M=HT<ZC=#?#RW1^1LP>2>#C Y'- $<_@3PS<W]W>SZ3%)-=[_ #PSN48LNUFV
M9VAB"1N !YZU@^(_#5WK\FG>%(]%$'ANSGBFFO9[A9#*B#(CC4DODD[2S8X!
MZYKJ+;Q5H-YH\^KV^JVLEA;Y\Z=7XBQU#=P?K3;3Q=X>O]8?2;76+2:_3=F!
M) 6^7[V/4CN!TQ0!>O\ 2K'4_LGVRW67[)<+<P9)&R5<[6X],GVH&E60UEM7
M$ ^WM;BV,V3DQ!BP7&<=237+Z5\1-'\20Z]#INHVL$^GB7RYI&WJ8U13YY7C
MY S8Q_L^]:ECXCT^UT'3;G5=<L)&N86=;M?W<4^U2S,H)X  )ZT 3R^$]"FT
MNZTV73HVM+JX:ZEC+-S*S;BX.<J<\Y!&.U0P^"O#T&C7FD)IJFSO3FY5Y7=I
MCQC<Y)8]!WJUI/B;1-=M)[K3-3MKF&W.)F1\>7QGYL]./6JMCXV\,:G(B66N
M64[O,L"JD@)9VS@ =\[6P>G!H T[O2[*^N[*ZN8!)/92&2W<DCRV*E2>.O!(
MYJG8>%]&TS6[S6+*R$-]>9-Q(LC[7)().S.T$D#D#-)/XM\/VNM+H\^L6D>H
M,P00-(-VX]%/8$]@>32:GXO\/:+)-'J.KVMM) 5$B._S*6!*\=>0"?PH NSZ
M38W.JVFIS6X>]LU=()<G*!\!AC..<#K2:AHVGZI/93WEL)9K*;S[:3<5:-\8
MR"".W4=#WK U_P"(F@:#:Z1<O>V\T.ISHD4B2C:(S]Z7/.57O]:Z>*Z@FLTO
M(Y4:W>,2K(#\I0C(.?3'- &%-X"\,7%[>7<VDQ/+>;_/#.Y1BXVLP3.U6()R
MP //6I6\&: ]_IU^U@3=Z=&L5M-Y\FY44Y"D[OG //S9KGM/\2^,?%5N^J>&
M].TBWT=F86KZF\OFW2@XW@(/D4D'&<FM[1O$SS^'[C4?$%DVAR6<CQ70N6Q&
M"IQO1S@,AR,'\* +5KX7T2RL-0L8-.B%KJ$SSW<39=97< ,2&)ZX%0Z-X-T#
M0+LW>FV'EW!3RA+),\K*G]U2[':OL,"IM(\4Z%KRSMI>J6UUY S*J-\R#U(/
M./>JT7CGPM/?6UG%KUBUQ<J&A02CY\C(YZ9(Y ZT =!5>^L;74[&:RO8$GMI
MT*212#*L#V-9VE>+- UR:YATS5K6[DMEW2K$^2J_WO<>XXJO#XZ\+3WUM91:
M]8O<7(4PH)1\^X94>F3Q@=3F@ LO WAS3[:]MX-.^2]@-O<&6>21GB((*;F8
MD+ST!%:-QHFG75O8036JO%82QS6JEC^[=!A2.>< ]ZK:KXL\/Z'>16FJ:O:6
MEQ( RQRR '!. 3Z#/<X%2:GXET71F*ZCJ=M;,(O/Q(^"4W!<CUY('% %";P#
MX7N+N\N9M(B>2\WF<,[E&+C#,%SM5B,Y8 'GK5ZT\,Z18ZI#J=O9[;V&T%DD
MS2.S"$'(7DG//<\^]-C\5Z!+H+:XFKVATQ3AKGS!L!SC!]\\8ZT6WBO0+O1I
MM8@U>T?3H"1+<>8 L9&.&ST/(X/J/6@"QI&AZ;H,$\.F6JV\=Q.UQ*JL3ND;
M&YN2>N!4G]E60UDZOY ^WFW^S&;)SY6[=MQG'7FLA_'7AP^'K[6[?5;:>SLQ
M^]9'Y5OX5(Z@DX SZUF+XUM=<\+Z1J^F:W8:<+F[ABG%P/-&]DW-;@\?/R.?
M;I0!T2^'=)73=0TY;-1::B\LEU'N;$K2??).<C/MBJVJ>#M!UB*T2]L-_P!D
MC\J!XY7C=$P!MW(P8KP."<5+K/BK0?#TD4>K:I;6DDH+(DC?,0.^!SCWZ5+-
MXAT:WLK6]EU2T2UNL^1.91LDPI8X;I]U2?PH J7O@OP[J%C864^F((+ $6JP
MN\1B!&" 4(.#W&>>](G@GPY$TABTN*-9)89F1'94WQ8\M@H. 1@=!S@9S5K1
M?$NB^(EF.D:E;WGD$"41-RF>F1UYP<'OBLKQ=KVLZ9J>AZ9HD%A)=:I-+'NO
M2X1 D9?^'GL>U &]+I=E/JMOJ<D :]MHWBBER<JKXW#'3G:/RJ'6M TSQ%:Q
MVVJ6OGQQR"6,AV1D<9 964A@>3T/>L+2O$6O6_BBWT#Q-8V$<UY!)/:7.GRN
MT;^61O1@X!! 8'/2M2P\8>'=4U1]-L=9M+B\3=F*.3).WKC^]COC- #],\+:
M+HUZ;S3K!+:=H!;LT;-AD!R,C."<_P 1&>3SS5F^T33M2O["^O+59;FP=I+6
M0L1Y;$8)&#@\#O4FGZI8ZKIZ:A8745Q:/DK-&V5."0>?8@C\*S)/&WAF*T2Z
M?6[-8'A\]',GWX]VS</7YN.* -&#2;&VU:[U2&W"WMVB)/+DY=4SM&,XXR>E
M8\O@#PM/<WMQ+I$3O>;S.&D<J2_#,%SM5CW90#[TZ7Q_X2AM;6YD\06"PW63
M"_FC# '!/L,\<XYJ]K'B71?#\4,FJZE;VBS9\KS&Y?'4@#D@>M %'4O ?AK5
MQ;?;M-\UK>$6Z/Y\BN8QT1F# N/9B:GU+P=X?U:+3X[S38RNG#%IY3M%Y(P!
MA2A'& ..G%69_$>BVMK:W4^J6D=O=(SP2M*-DBJI<D-T("@FLYO'GAHZ!?ZS
M;ZM;7%I8C]\4?E6/W5(Z@D\#UH TK70-+LK_ %*^M[-%N=2*F\<DMYVT$#()
MQT)Z>M9^F>!/#6CZA'?6.EI'/%N\DM*[K#GKY:LQ5/\ @(%6?"WB6Q\6:!;:
MK8R(PD1?-C5]WDR%0QC)]1N%8@^(VD7>M:YHEG<P_;M/A)B)?/G2!'9U"X_@
MV<\]Z .EM]%T^TBOXX+942_E>:Y 8_O'8 ,3SQD =*GL+"VTO3[>PLHA%:V\
M:Q11@DA5 P!SS7*^%O'^CZGI>B6]_K%DNMWMK#(]N&"DR.@;:!T!.>!UY%:^
MH^,/#ND:DFG:AK%I;7CXQ%)( 1GIG^[GWQ0!#+X&\-S7>I73Z8OFZFC)>8E<
M+*#C.5#8!.!R #[UJ76D6%Z]BUQ;B1K&436Q)(\MPI4'KSP2.:PK[Q]HNG^-
M;?PQ<7,27,L19G:3&QR4"1XQR6#Y'T]ZZ&_U"TTNS:[OKB.WMT*JTDAP 68*
M/S) _&@#'G\#^&[G6#JLNEQM=M*)F/F.(VD'1VC!V%N!R1FMRYMHKRUFM;A
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MTTRU$$3.9'^9F9V/5F9B2QX'))Z5H444 %%%% !1110 4444 %%%% !1110
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M7HS+G:Q'J036]0!Y-KRV2_ WP]_9PC\X'3C8;,;O/\R/.W_:^_GOUK3M0/\
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MRQ]R:O7.EV5W)9O<6R2-9R>;;D_\LWP5R/P)'XT >::1C_A#OBH.,_VGJ?\
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MYW89\R,9PI'3'S'\Z ,WP-@_#_PWC'_(+MO_ $4M<I8X_P"$U^* XS]FM/\
MTF:NWT/P]I7ANS>TTBS2TMW?S"B,2-V .Y/H*AN/"FA7>MG69M-A;43&8C/R
M"RE2N#@X/!(YH \YGM(+;X&>$C#$B%9M-F! Y#M*A+?4[C^=+XJO+R^T'Q]=
M62:/I^FPM+:7;3P/+<7<J1*,Y#J%ZJJ\-V->FOH.ER:3;Z4UE&;"V\OR8.=J
M>604Q]"!^54Y_!OAVZU:;5)](MI+R8$22,"0_P NW)7H3MXSC.* .3TYM_Q5
M\/.S99O"Q.3W/F)6C\7D63X8ZHC#*M); _3[1%6S)X(\-RIIJOI,)&F\6AW-
MF(9S@'.2,]CD5JZEIMGJ]C)8ZA;I<6TA4M&_0E6##\B ?PH XO7["T_X6OX(
M MH@(K6^V * %VK'MX]LG'I7(^)@L.G?$D* D2ZOI\A X R8"Q_J:]BFTVSN
M-1M=0EMT>[M5=8)3U0/C<!]<#\JKR>'])F344EL(774L?;%9<B;"A1N_  ?A
M0!R_BBY@'Q0\$Q-*@=4OY&&[[J>2.3Z#@_D:R]&CN?##>&=/N!I6M>'9;@0Z
M3?PC;<0,R.48CE6!7(+*0><D5V&E^"_#NC303Z?I4,,T!9HY,LSKE=I^8DDC
M'&.U)I_@GPWI6IC4K'2+>"Z4L4=<XC+==JDX7//0"@#$^%>/[#UG&,C7+T'_
M +^5'=):-\>+ W 0RKH$AM]W]_SN<>^W=^&:ZC3_  SHVE:M=ZI8Z?%;WMX2
M;B5"1O).22,XR2,GBDU7PMHFMW'VC4M.AN)_*$0D;(95#;@ 0<CGN.: /)-6
M6?\ M'6X]-:U2R/C&T!-PI:W$GE#=O (R/-\O//6N^T#3-4A\=7VH:MJ6CO=
MRZ?'%+::>CHQ =BDCAF)[NH/^%;L/A?0[?07T./2[8:8X.^V*95LG))SR3GG
M)YIVB^&]'\.QS)I-C';><096!+,Y'3+$DG';GB@#F?%^/^%E> ,X_P"/B]_]
M)S7+^+;R\OO"_CRZLTT?3]+CFFM;GSH'DN+N9$5=V[>%4YVA>#T!KT_6_#FC
M^)((H=7L([M(7\R/?D%&Z9!!!%5)/!/AJ749K^31K9[F9"DC,"0P*[#E<XSM
MXSC..] 'FGBI/$EWX[2/PTR?;I?"2F1S)MD\OSB6$9P?G;@ GIG-7=2N+&\\
M(^!_^$52UM; :O&GE7B,R13!),+, 02PDZ\\M@\UZ3I_AS2-+N8;BRL8XIH;
M;[)&X))6'=NV9)Z9YJ.3PKH4UOJ-O)I=NT.HR>;=QE?EE?\ O$= W3D8/% '
MFWB[3-2M]!\<WVIZEI,MW/I<*3VNGHR%2K-LD<,Q.2"1GN%]JZ+Q+:P6>L_#
MU+>)(EAOS%&%&-J&W?('MP*Z.V\'>'K/2;O2X-+A6SO/^/F,Y8S?[S$Y/XFM
M&YTRRO);.6XMTDDLY/-MV/\ RS;!7(_ D4 <M\6O^25^(/\ KW'_ *&M8MC;
MPS^-_ 32QJYB\/RR)N&=K;8AG\B:]$U'3;/5]/FL+^W2XM)UVR1/T89SS4<>
MC:=%=6ETEI&L]I ;>!QG,<9QE1[?*/RH \B\6HL>A?%J-%"I]HM7VCIDQ1$G
MZDUUUQL;XO>'_M6TPC1)S9[NGG[TW[??9^E=7+X?TF=-22:PA==3Q]L##(FP
MH49^@ 'X51;P1X;?1H-);28396[F2%"S9C8]2K9W _0T 8_A0*/B3XY%MC[+
MYEF6V_=\_P H[_QQLS[UW%4=)T;3M"L19:79Q6MON+E(Q]YCU)/4GW/-7J "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *;)(D,3RRNJ1H"
MS,QP% ZDGTIU87C/4HM(\%ZQ?SVB7D4-JY:WD^[*",;6]CGGVS0 NC>,/#_B
M"[>UTK5(;F=$\PH RDIG&Y<@;ESW&13$\;>&GUO^QUUBV-_YAA\O)P9/[F[&
MW=_LYS7$E=6MOB'X4MK[4],GN?L-V8;:PM#$L"F)=HW%VW*2O' ^Z:L^#;CP
M['\(="_MORC"LR(Z.I9_M?G'C"_-OW\^O?I0!UNI>-O#>CZG_9VH:Q;P7?R[
MD8G$>[IO(&$S_M$5-K/BS0O#\L46J:C'!+*I=(@K.Y4=6VJ"<>_2N0\,S:3%
MHWCL>(#"(4UB\;4%F&?W) V9'4@IC&/PYJ?PF]H/B9XE*X57T_3VL X(;[+Y
M;9VAN0-W7WQF@#KD\0Z1):Z?<QZA!)!J,@BM)$;<LSD$X!'?"G\JDN-:TZUO
M9K.>[1+B&U-Y)&<Y6$$@O],@UY!I[QI'I$\;*-.;QW.;1Q]SRRL@&WM@MNQ7
M0>(+F&?XB^)(XI%=H?"+I( <[6\QVP??!!_$4 =9;^._"]WJ5MI\&LV[W-SM
M\E1G#DC( ;&-V"/ESGVJMH_C[2=9\7ZGX>@D GLRJQM\W[YMI+@#'&W&.O-<
ME?6\,'PC\!B*-4VW>DR+@=&9D)/U)8_F:W?"1'_"S_'ZY&?-L3C_ +84 :'B
M[Q+)X>UCPX'NHK>PNKF5+QY0,!%A9QR>G(%6H/'7AFYTR[U&+5X3:V;*MR[*
MRF$L<+N4C(!)X.,5A?$ V@\4^!3>[/)_M5OO]-_E-L_\>VU7U#2[77OBKKFF
M, UM<^&U@O=O:1I6V$_[07)'X4 =UJ6JV.CV)O=0N4@M]RIO;)RS$!0,=221
M1J6JV.CVRW.H7*6\+2+$)'SC<QPH/IDUY5X>O;KQ7?>&/#%_EI_#DDD^K ]Y
M+<^5!SWW$[_?%>E>*-"B\2^&-1T:; 6ZA**Q_@?JK?@P!_"@"WJ.JV.DQP/?
M7*0+/,EO%NS\\C<*H ZDUE7OCKPQIVIOI]WK-O%<QL$D!R5C8] [@;5/L2*X
M?PQJL_CS7_#D5XIW>';5Y]21NU]EH5!]QLD?\13M >RC^"WB1=1,8G5]274
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M17LL4848VI]G<8'MP/RH [JBBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQG**@)88(.0,<UD^$O$S^(?$GB:.*[2XTVTDMA:%4 VAH0S \9SNSP>1TXH
MVM1\-:+JUW9W5_IEM<7%D0UO(Z?-&00>#]0*GM=&TVR-Z;:Q@C^W2-+=;4'[
MYCU+>N:YC6?&"Z%\0XK#4+T0Z4VD-<",1;V>?SE4;0H+$[<\#W/:M>U\:>';
MVULKFWU.-HKVY^R0$HPS-_SS((RK<=&Q0!)I/A#P[H5V]WI>CV=I<,"IDCC
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MTN[BUN+BWCDEM7,D#L,F-B"I(]."15FB@ HHHH **** "BBB@ HHHH ****
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M";?-0*-K 9.,C'>I-4\,:%K=S#<ZIH]C>SPC$<D\"N5'7&2.GM6H %    '
M H \1N-2NK[PUX5U.34-,L[&]UNUFM](L[0+Y(^T DE]V<C)W' &6QWKJ/#=
M[I5B/'\>O20*$U6>6[2?&6MFB39D=2I7( KK!X-\,@7@&@:;B]_X^1]F3][S
MN^;CGD _7FGWWA3P]J=W!=7VB6%S/  L4DMNK%0.@R1T'84 <AI\]B/C%ISV
MFV&SD\)*+9&79\GVA2JA3R#C''6L**_M+7X%>*(9[B-)5FU&!HRPW"1I7PN/
M7D5ZG?Z#I&J7EK=W^FVES<VC!K>66(,T1SGY2>G(!JM+X1\.3:A<7\NA:<]W
M<*R33-;J6D###9..<@D'U% '&KJ-W/K$\%I?:9HR:;H]J]S?3V@FFG5PQ"@E
MAA%P?7EJY&)MWA/X2<YQJZ ]L8<C&.WTKV:Z\-:'>WMK>76D64US: +;RR0*
MS1@= #CC';TI(_#.A1>7Y>CV*>5<F[CVP*-DQQF0<<-P.>O% %7QMJ2:/X*U
MB_DLXKQ(K9LV\R[HY,\88=UYY]LUQL!O;?XH^%K;4-;LK^865T1%:6HA2!2B
M8 .XY!VG&>RYKTV>"*Y@D@GB26&12CQNH964\$$'J*RK7PCX<LHK>.VT/3XD
MMYOM$(2W4;)?[XXX;@<^PH \H^S0G]F-U\I<23;GXZG[=C/Y<5VOB:,I\3?!
MJVX5'^R:BB8& ,1QX'T!KK/[#TK^R?[*_LZU_L[.?LOE+Y?WMWW<8^]S]:GE
ML;2>\M[R6VB>YMPPAF9 6C#8#;3VS@9^E 'D5O<:>G[-<UM*T8F%I);O"Q^?
M[5YA&TCKOWX/KWKH_#<WV'XD:\FHS)%<-I%@[&1P,[1(';GL#U-=4WA3P\VL
M?VNVB:>=1W;_ +2;==^[^]G'7WZU)JGAK0];N8+C5-(LKR:#_5R3P*Y4=<9(
MZ9[4 >2:8UOJ'A_PK( LL$OC6:1<C@C=.P/\C76:P,?%'5,#EO";9QW_ 'S8
MKM%T32T6)5TZU"Q7!NHP(EPDQSF0>C'<>>O)J<V-H;\WQMHOM9B\@S[!O\O.
M=N>N,\XH YGX72QR?#/P^$=6*V:!MIS@^AK&C:3_ (6AXTA@<+=2Z1;" ;L$
MMM<#'XD5V^E:%I.AI,FE:;:V2S-OD%O$$#'U.*2XT'2+O5H-5N--M9=0MQB*
MY>(&1!ST;KW/YT >67=QI\G[-EK;6[1F9[2&WBB4C>;KS%RH'7=OR?7O7IVO
MAAX2U0.<O]AEW'W\LTU/"GAZ/6#JZ:)IZZB6W_:1;KOW?WLXZ^_6M66*.>%X
M945XY%*NC#(8'@@B@#QZ\GL)O@'X;M[!XC=2/816R(1N^TB5-P _O9WY_&G1
M66HW$?CRWG\2Z;I=DVHW/VV*[L/-<1.B[7+>8O!3 '';BO28/"7AVUU&+4+?
M0]/BO(4"1S);J&0 ;1@XXP./IQ3[_P +Z#JNH17^H:-8W5W%C9-- K,,=.2.
MW:@"SHUN;30]/MC<?:3#;1QF?;M\W"@;L<XSU_&O)-$M'_X9LU3[%&1--%>/
M)L'+ 3.&^OR+C\*]HJM9:?9Z=9K9V5K#;VRY(AB0*HR23P..22?QH \^M]-O
MKO6O#MW/XOTNZ>*&:73K:UT_R6F1H2IPWFMA1E3T["F>#M1\.0?"?P_#K'DN
MJRQP&W=-[_:_-Z;!SOW\_K7<:7X8T+1+J:YTO1[&SGF&))((%1F&<XR!TSVI
M$\+Z!'K)UA-&L5U(DL;H0+YF3U.<=??K0!Y9!I]_>>'O&-K>>*=,TS3VU.]2
M^BN=/\R1-[G:V_S!U4J5X],9Q6TD31?'[3(9)/.9/"X5I",;R)6!./>NYN_"
M^@W^JQZI=Z-8SW\>"MQ) K.,=.2.W;TJX=,L6U1=3-G ;]8O)%R8QY@CSG;N
MZXSSB@#QN598;6Z^%4996FUD1Q8/*Z<^;AB#[ ,GXXK>%KJL?Q(\4Q6&MZ=I
M*"VM'6.[LO.WVXB*Y4^8N%#!P>O6O1#I6GMJJZJ;&W.H+'Y0NC&/,"==N[KC
MGI5?5O#>B:\\3ZMI-E?-#_JVN(5<K[#(Z>U 'G/AFUM=%\8^#[=]3BOK,Z%<
MQV%WL\M)7,JM\@)./W9 Z]!6WX%GM+GQUX\EL61H3>VXW)T+"'#_ /CP-=;J
M?A_1]9LH[/4M,M+NVB(,<4T2LJ8&!M';CCBIK#2=.TLR?V?86UKY@4/Y$03<
M%&U0<>@X'M0!QE]+:1?'73/M3(LCZ%*MN7/_ "T\X<#WVAOUK DT1O$L7Q$7
M2V&Z/4XKC3Y(^@NX8D9BI]2PVD^YKTS4?#^CZPS-J6EV=VS1>26GA5R4SNVY
M(Z9 /UJI>V=YH6@QV?A#1].#AMJ022>1%$""2_RJ=W.,C@G)YH Y/P;JB>/O
M%R^* N+33-/CM8%/1;F50\^/=1L3\ZV_B/I5QJ'A.2\L%SJ6DRIJ-F>^^(Y*
M_BNX8]ZT/!_AQ?"WAN#3?,6:XW--<S*NT2S.=SMCL,G ]@*E\1R:^M@(O#UK
M9RW4N4,MW,42#(X? 4[\>G% 'G\%P_C>'Q=XMTX.T:Z.^F:5CKN,1DD(]][*
MN?\ 9-&NW-A<_!+P]!ILD37,QTZ.P2,C=YPDCR /[P ?/XUZ#X5\/6_A7PS8
MZ+;-O2VCPTF,>8Y.6;'NQ)HM?"GAZRU5M4M=$T^&_8DFXCMU#Y/4YQP3W/>@
M#F/#FH6FG>)OB UY<1PB*\CF?>P!"&W3#?3@U=^%'_)+?#__ %[?^S&MV[\,
MZ%?ZK%JEWI%E/?PX\NXD@5G7'3DCMV]*O6=G:Z?:1VEG;Q6]O$,)%$H55'L!
MTH \@7_D/?&C_L'Q_P#I-+6QJ\,</@;X=)$BHJ:GI>T 8Q\O/\S7H']BZ7YE
M_)_9UKOU!0EXWE#-PH!4!_[PP2.?6GR:982V]M!)9P/#:NCVZ-&"L3)]TJ.Q
M';'2@#"^)'_)-?$?_8/E_P#037+^*;:2W\!>"$LIX+&&"^L2TTL6^.(>6P5F
M7(R-Y3N.<&O2KJUM[ZUEM;N".>WE4I)%(H974]00>HIDVGV=QI[6$]K#+9LG
MEF!XP4*^FT\8H \VOM#MYKS7W\2^,;.2273[>VN#:6?D?9\S$PR-\[@G=D<]
MO:J7BC4-5AT/Q3HNMR:;J%TN@R7$.IVD7ER-%NV[)%R<$DY&#@\\5Z78^&M#
MTS3IM/LM(LH+.?/G0) H23/'S#'S<>M8FM^"-/3P3KFD>'-+L;*XO[9HQY48
MC#L1QN('2@#!\03V%SHOPZBTQXF=M5LGMEC(R(E0^9@#L%R#7/V6F:A?^!M:
MLK[Q9INFV3:C=17D4VG[Y8Y3<,02_FC+'Y2/E[CKBO4M*\*Z+IERFH0Z18PZ
MF8PLMS'"H<G'S?-C//?UJ6?POH-SK":O/HUC)J*$%;EX%,@(Z'..H['M0!RO
MAZYM;'QQXYCU:>%)2;:5FF(4/;B #//\((?/H36?'=:0WQ!\"SZ2J6^ER:5=
MFU4H8QL^0C ;!''-=WJOAG0M=FAEU;2+*]DA_P!6]Q KE1Z9(Z>U/U+P]HVL
M);IJ6EV=VML<P":%6\L\?=R..@_(4 <[\6$D?X::ML5F1?)>8*.3$)4+_AM!
MS[55\8W%K>:]X%33I8I;EM4$\1A8'_1A"_F$8_AP5]NE=XZ+(C(ZAD8896&0
M1Z&LO2O"V@:'<R7&E:-8V4T@P\D$"HQ'ID#I[4 <AX#_ .2E?$3_ *^[7_T6
MU6OB>ZQQ^$7=@J+XFLBS$X 'S]:[&VTVQL[JZNK:T@AN+M@UQ+&@#2D# +$=
M<#UI-2TK3]9LFLM3LH+RV8@F*= ZDCH<'O0!R6C)%)\8/$DX56<:99JCCGY2
M9"<'T.!^5<)9QW@3P^;2]@L(T\3:G&L]Q!YL4<A\P1@KN7D_,!SP37LUEI&G
M:<^^RL;>W;RDAS%&%/EIPB\=ADX':HY=!TB;3IM.ETRT>RG=I)8&A4H[DY+$
M8QDGG/K0!S_A#39;7Q%XANKKQ!::I>SFW2YCM;7R1"R*<9&]LDJ5_P"^1576
MM0NYO'5U9V5[IFC_ &'3$GN-1N;42S21L[_(I+* B[23UY-==I>D:=HEF+32
M[&WL[<$MY<$81<GJ>.I]ZBU#P]HVK7EO>:CI5G=W-M_J99H5=DYSP2/7F@#Q
M[P_<6:6?PNEO9$\I;[4!ND&T!\R!,C^$[MN!V.*O^-V2;6_B!):,K11^&XH[
MHH<CSMSE0??9^E=CJ_@BTNO$NAW-IIE@NGQ3W<VHQ&-0)C+"4R5QAB3C.:GU
MWP=:#P'K.A>'=.L[)[VW=52-!&K.1C+$#]: .>\03V%SHOP[BTQXF=M5LFME
MC(R(E0[\ =@O!K+TC_D(?&#Z'_T3)7HVE>%=%TRY34(=(L8=3,866YCA4.3C
MYOFQGGOZU=31M,C:^9-/ME:__P"/LB(#S^"/G_O<$CGUH \E\-R);Z3\)KF[
M94L5%RC.YP@F:)A%GW/S >]=+XGUO18Y+V'2+;3IM6GU.RM+JXN8-\,4K<QN
MQX#,@' !R#C.*[*30=(FT<:1)IEH^FJH46C0J8P!R,+C J)/"^@QZ*^C)H]B
MNF.<O:B!?+8]<D8Y/ YZ\4 >6ZI)<#4_B!!=ZO#J5PGA8J\L4 A (\X[< G)
M&X<Y[X[5I:Q/87'P_P# ,.G/$TK:AIWV58R,@KC?QVP V?3O7?+X3\.I'%&N
MAZ>$BA>W11;K\L;YW)TZ')R.^3ZTMKX6T"RU3^T[71;"&^QC[1' JN!C'4#T
MXH \DOX[B6]^,R6H8R&"VX7J5\I]W_CN:ZS3].NKGQ'X7O+WQ=I=TL*2RV-M
M:Z?Y331M$58!O-;Y0"IZ=A7=P:786MW=7=O9P17%V5-S*D8#38&!N/? )ZU5
MTOPQH6BW4MSI>CV-G/,,2200*C,.N,@=/:@#G/BE'+'X?TS5HX7FBT?5K;4;
MB-!EC$C$,0/8-G\*V+[QMX=L/#[:V^JVLMGY>^,Q2JS2GLJC.2QZ8K?(!!!&
M0>H-8=MX+\+V>HC4+;P_ID5X&W"9+5 RGU''!]Q0!SNGW<<GQ?>YNXWMVO-
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M&F:;=7]T^RWMHFFE;T502?T%6:QO%VF3:UX.UG3+;_7W5E+%&,XRQ4@#\\4
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MF*,2S);6LL_DH>C/L4[1]:DO?&7A_3[:PN+C4D$.H(TEHZ(SB8* 3MV@\\C
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M[YC@=2)R ?R _*M*--13X@ZYY7B2VT8RZ?92I]IM4E\Z)48$@LPP%;=G_>H
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M)8#I6>^N6MKXTU&WFUV:3[-IWVF32DLBWEJ",RAU4EB>FT$GGI7G=QJ^GGX
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MD<S1^%I8YI(B"N[SE(7(ZD C\Q0!U-E\0?#&H0W-Q;:ENMK:V%U-.T,BQHA
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML8K)K*V-I%M\N Q+L3:<KA<8&"!CTQ3)-&TN;5(M4ETZT?4(EVQW30J94'/
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M\B=I)%56D5FRKLH  W#GH!S75>,()[GQ[=06JDW,OA*^CC"]2Q= H_,UW_\
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M/&L95L&53]U@>!_>KN?!%E::?X+TNWL+J:ZM!%OAFGC\MW5B6!*X&.O''3%
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M74-?U%S::9K=S"CR<^5$I&U0!R>N .IS5#01IVK:EX6=_'4VIS1G[3:6,=O
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M1I+=PXC5H&P&(Z$X/!Y^4^E 'I5<=J'CAK+XBVGAD:=>2126S2R2QVKN=Q9
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MECP,X(Y[D#O7(:R?[1N?$NOZ?>F'2$\1Z>YOH5614$4:I)* 058*[*<\CY:
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M6=KJ$T]O<RVUS(EOF*W9,\N^<!200.YQTH W8=+TZV_U%A:Q?/YG[N%5^?\
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MQ>0<YBV#:<G)XZ=:\Z\'_$:V3PEX?.JQZK,;B.*"75'@+0>>W&&D)SG/!."
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M;V#,.>V:KP:A9^(OBW8W>C74-Y:Z?I4R75S;N'C#2.NR/<."?E)Q7?LH92K
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MKGS?07/A?Q%K$2LMC%XTANWD*D8A!A)DQUP0<_C7N$]M!<J%GACE4'<!(H8
M^O-8OA[P\^CS:\T\D<R:GJ+WBJ%^ZK(B[3GK]T_G0!S)UW3=;^+^A-I=Y%>0
MPZ;=AIX&#Q[B8SM##@D#!([9'K7!67'[/6NM@[4UG>Q S@"YB)/Y5[[%;6\"
MHL,$4:H"%"( %SUQCI2B"$1-$(D$;9W)M&#GKD4 >?>-=0L[4:#\0=,N([JS
MTZ<PW4ULPD62UE.QR"/O;7"G'J#6Q\.M/FM_"_\ :5ZFV_UF=]2N0>JF0Y5?
M^ IM&/:G>)/#&H>(6ATD7=I:>&R4:ZMXH3YTVUMQCW9VJAP,X&>OK75 !0
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MX[,7>C6*P7$QPCM"K)(@;INR0<=>:P+"?&C6_B%X)4T^R\9W%W=*T9!@B?<
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M!@V<^O2@#O[3QK=W'Q(U'P\VE7BV=K!&?.\M<*Q+YD8[ON$!<<9ZY JSI_Q
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MC8L,[F8  ;><_P!X8SFM+PWXAM?$VDB_MHIX-LKP303J%DAD0[65@"1D$>M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY&)+:YB:*5/56&#63X7T"_\ #UF;&YUR?4[2-%CM5GA17A1<C!9>7XP,GTH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"F<-TZ9%9N@Z_=3^);+2++Q9?ZJFIV%P99[BR\L03*JE9(28U!7YC\OS#@4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>XWQW!C9KH0;]WE;2-F>=N_/3G&:[BB@#G]$T"?2]:\1WLLL;IJETDT2KG*
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M,I5@"I&"#WJ*UM+>QM8[6T@B@MXEVQQ1(%5!Z #@"@#F8/"]Q:_$Z]\627,
MLI=,6S$>2'5@X8L>,8P/6N8T/2+;5?C'JNH:?<B?1K BZ=8\&(:A)'L;!Z$A
M!D^A:O4)8HYX7AFC62*12KHXR&!X(([BH;'3[+2[5;73[."TMU.5B@C"*/P'
M% $MQ"+BVEA)($B%"1VR,5YUI_@/Q!#X.TW2)[W34O=#NH[C2[F)797*%N)5
M., JQ!V_6N^N=3L[6"]E>=&^Q1&6X1"&9%VEN1U&0#CUIVG7\&JZ7::C:EC;
MW<*3Q%A@E64,,CMP: .;TK0-9N/%:^(O$4MB)[>U:UM+6Q+LB!F!=V9@"6.
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MCE$PHPISWR>!S7HDFAZ_J?AC7K'6=2M7NM3MI8(4MXBL-J&C*#!/S-R<DG\
M*R=9^']WJ?PQTKPHE] D]D+<-.RG:WEXS@=>: *D^FS3_'Q"-6U"-%T,70C1
MTVX%P%,?*_<.T$CKGOVJ#PGJUW=:]:P:GXGO[7Q#YLGVW1KZ%5AD3YN(!M'
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MLA<Z>'QB*2+B6,'W!#UH>%?#T^B1ZA=7]U'=:GJ5R;FZEB0H@. JH@))VJH
M&3FN6^+*P:I;Z5I6FWR1^)6O5CLTB8&1%D4K*6'54\MB2?84 4(_$NOZGIMM
M<6^HRVZ^)==:VL9 JDVMD@;YD!&-[!"<G/W@:TKF[U7PKXBN-'_MF]O[.\T>
MYN[=[PJ\L$T6,X8*,J0P.#T(K>UGP<MUX?TFQTF=;*YT66*:PD=-ZAHUV[7
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M[>I'4"H(/!=S#\.]7\-&[B,U]]KVS;3M7SG9AD=>-U & MK<:G\:-,NCJM_
MLN@+>^5$Z;5_>H#&,J?D;&3WSW%=7X^UF]T7PT&TV18KZ\NH+*"5E#")I7"[
ML'K@$GZXJE-X4U>W\5Z-KFF7EEFVTX:;=17,;$-'N5BR%3][COQ6UXK\/KXF
MT"73OM!MIMZ36]PJ[C%*C!D;'?D<CTS0!SA&I>$O&7A^R.N7^IV&KF:"9+]D
M=HY$CWJZ%5&,X((Z<U!\,6UK6],CU_5M<NYP);BWBM1M$;*LK#<_&2W&!R
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M"R7\S^< L+JQXVGKA<D*.@->N67AV:U\=:EX@:=&AN[.&V6( [E*%B23Z'-
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MQ"H\<!^TSQ*,)&^25 QC)')QVH [.BBB@ HHHH **** "BBB@ HHHH ****
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M)!RIYS@BLN;_ (2*T\/>"];B\3ZB;_6)[2TN$D96@5)XSRL9&-R\$$]3UZT
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MT'[MKE6! V9X3 "XS[U=TOPOK"^,HO$VLZI:SW"V+V9M[6!HXT!=6!7<Q/\
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MU\AMP/M3298;?[@#L3@=N*Z:BB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7;:WXHTW0);>&[-Q)<W 8Q6UK;O/*RK]YMJ G R.>E<G\%?^1&G_ .PE<_\
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M26QD*7206<LI@PH8L^U3A<,.>G7T-<'X<^U:QJNA>!K[>Y\+W<L]\S# D2'
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M3I9;J:]M"OG6]M:2S.@*AMV%4_+@C)Z<XZUA>-O%\JZ3X1U+P[J0^R:GK5M
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO=P-$X1\X.#[@@^E %VYT/2;VZANKK2[*>X@ $4LMNC-'CIM)&1^%6?LMO\
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ML+6WFN#NFDAA5&E/JQ R3R>OK1=Z5IU_<07%Y86MQ/;MNADFA5VB/7*DC(/
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MA@.)I+:S2,YQAC 0/UK&\-06M]X=\)V5[XWDW13VPBTA+2'S(KB$@^6=J^8
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M*<_#!-P=X9-3216QNC<(W# =&Y''O3_'-O-<77Q+2"-G8:?ILC*HY**SL_\
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MXTO3[NVCMKFQMIK>/&R*2%65<<# (P,5/%;P0%S##'&7(+;% W$# SCKP *
M)**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTVNZ@#&X9(X%=MX[C>#QQX<OI=;ET6T:WN;87RK&525MC!6,BE5W!6Y_V<4
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M4$E"O4-D%<8^]Q567XAVQT?79X])U2&_TB$2RV-Q %EVL"5? 8@IP22#P :
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MQLG4-E"N!DYQZT 1:'X8U2/Q&NN:Y/I_FP6C6EK:Z="R0Q*S!G8[B26) '8
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M6UR&$]O%*'78P= V5SG!SVS6=K5MK TI+;PW)I]G-G9ON8F9(TP>45<?,#C
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M<[N0>E:?AVQ\/ZSXENGA\47_ (CE737MIFD:*2!8I6&4+1HHW';G&>F:]%
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MC\.YTD:S\/ZC)J+.PX>U7#6RD]_GDP1_TSK?T77M*\(>)O&%MX@OX+"6>_\
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MB/K4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M60?Q#+=1T*GTKI]*OK3P+XVU8>([J.SAU#3[$VUU,<1N88RDB;NFX'!QUYH
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M6../[,N?Y-6#9ZA:1^$/BCHKS*NI"ZU2Z^S-D/Y3(,/CT.1S0!VUKXML-/\
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M[XIP6<#S3#7/.$2#)D$<BNR@=R0IXKT$>/-%\0R-8:*6U O9333SQ+\MH O
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M3+G3K+54TC5QH]RZ1G4&A011.S!0&^?. QP2 0#QFL^V!_X: UDXX_X1Y?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5PWC_ ,IM6\.Q7EM-J-B\TPFT
MN ;GG.SY7V9 94.<Y.!N!ZXKN:P->T*\OM4T[5]+O8;;4+!98U%Q"98I(Y-N
MY6 92#E%((/;OF@#-^'#;M"OPGF10+J4ZP6<Q/F6<>1B)@>A'+8Y ##!Q78U
MB>&]"ET6&^DN[M;J^U"Z:[N94C\M-Q55"JN20H5%'))[UMT %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
..444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>sesenbio_minorirosales-e009.jpg
<TEXT>
begin 644 sesenbio_minorirosales-e009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZK/*'BMMR;")?D&UCNP%ZY'M5'PS&5_9KOUV$,=/U+(QR3OFKUH #. !FEH
M\UUB/_B4_#,;.%U"TR,=/]'>DUH60\>^*CJEE/=Z>?#\"W$,"%G9/,DW8 (.
M0.>.>.*]+HH \Y\$ZH&\4OIFC>([G7]"%D96DN?WC6DH=0J>;@;MREOE.2-M
M6_&$\>B^._#/B&_)32H8KJUGN"I*V[R!2C-CH#M(ST'%=T !T 'TI2,C!H \
MRM;F+7_$/C+Q!IQ,NE?V0EE%<A2$N)%$C,4/\07<!FMGX2@K\+- # @B \'_
M 'VKM  !@=** //+K4+72OCHC7\P@6^T..VMF<'$LOV@_(#Z\CBL*"-A^S?J
MB[#N,=[QCG_CYDKV# ]** /+V#+\==*?RV=1X8/ '7]XW'UJIX=U33[+7]&M
M/"&M7TUK=3LEYX?NEW_88]K%F&1NBVL -I)!SQ7K=)@ DX&3U- '#?&-2WPG
MUX*"24BX'_75*6R^*?@J*PMXWUV(,L2J1Y,G! _W:[FB@#QZ_P#[,TGQ=XG.
MN>(]8TA;R5+NT2TEV)=QF)5(4%#N<%2N.O3BK-PVF>$_%W@*29KBSTN/2Y[:
M)[T?.C$(51\# ;'&*]7(!QD XZ4I /44 >*W8%Y:_$WPW$S?VQ=7;W5O:8(>
M:,(C97CG.TC\:W/#9\-ZOXITFXL?$>OZS>6L<DZI/*'CM=R;")?D&UCN( ZY
M'M7IV!G..:0 #. !F@#AOA FSX<68*[2;BZ)XQ_RW>J?Q,%SXDO-(\"6,QA?
M4W-Q>S!-PBMH^>1_M, !],=Z]&HH \J\9^#_ !6-#35E\3_VA=:(XO[2W&G1
MQ9:/DJ&4YP5R,=^!4EGXJTRS\=KXCOY6MM,US1;<VMPZ$J)$=BT1('#?,.*]
M1K US2-;NM1@OM%U[[ Z1&*2WGM_/@D!.0VW<I##USTXH \GFE^W^!_$,XMI
M(EG\:*_E2)A@I>$_,O8X/(/2NQ^(-O%!XL\/:K?ZG?:9IB0W-M+>VC[/)=]C
M)N;!PK;2,XZ@5U?A?P\/#FF2V[7;WEU<W$EW=7+J%,LKG+':.%'  '8"ML@$
M8(R* /%]2TS3)?#\6MZ7J>O3V$>OQ7%[J4C RLBQ&(S1$+RB[EYQ_"?2I-2@
MT2[\+>,]1TC6-7UJ5-'-L]Y=2"2$@[F"(P498').,@;AZU[)2  #   ]J //
MM<3.H?#@!>%NQVZ?Z,U8GBW3+O5=:^(5K9Q223OI-BR(@^9]K.Q4>I(&/QKU
MVB@#S'PX?#>K>*=,N;#Q'KVM7EI#+.JSRAXK;<FPB7Y!M8[L!>N1[5CF-A^S
M#$@0[O(3C'/_ !\BO90 ,X &:6@#SN#4+72_C?JD-],('U'3;9+0.#^^8,^0
MI[D5VFC:S9Z]IPOK!G: R/'ET*G<C%3P?<&M# SG%% &5XGM8+WPKJUM<PK+
M%):2AD89!^4X_6N>^$=K%:_"_1/+A$;2Q-++@8+.6.6/J:[:B@#RS1_$>F>#
MK3Q1I&MRF#4#J5U<P0,A+7D<IW(8^/GSG;@=".:S]&QX&O\ P//XB?[% NAS
M6DDTH.V.8LCA&/8XR.?2O8B 2"0,CI00",$ _6@#@_A]>)J'B+QG>1)(L,VH
M1-&9$*ED\A,-@\X(P1[&JGBC6$7QQ-IVL:WJ.EV$=C%)8P6#%'O969PX#*"S
M,,( H/?->D4F 2#CITH \"\P2>!?AY;#=]HL_%$<-S$QR\,@E<E6]\$'\:Z/
MQ7JFFZ3K&L7NAZS?Z3XF209TMTWQ:E(%4*1$0=VX87>I!&.>E>MTF 2#@9'>
M@#S?3]=L/!_C7Q2?$<ZZ>-1>"\M990=LRB((R*0.65E(QUY%;'PSM+FV\(>=
M<P26YO;RXO(X9%VLD<DK,H([<8./>NP(!Z@'%+0!XEXMU)M5LO&5G?ZOJO\
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MCTG4&C3'WG C*C\37>44 >%)K-E<Q^$-6G\0ZGJ-U'J$$^JM-(1;V3LC JR
M!4.]MH'7 -:'BR"]TWQ+K/A*Q618?&$D$L+H.(23MNB?JBAO^!5[( !T I:
M/*_$UA8:+X]M;B_UB_T+2'T>.TM[FTE$:!XI&/E,Q4@?*P(Z9P:Z[P):Z?;^
M&_-TR349;:[N);D2Z@,2REF.7Z#AB-PR!D'/>NE(!&" 1[TM 'ED*M_PN/QJ
MVTX.B1 ''7Y15:[0CX >'E"G(&G<8_Z;1UZY10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M'IQ110!@:+XML-9\.7&M;);6*T:9+J*?&^!HB0X;!(Z#/T(K+C^(*7=KI(T[
M0[^[U'4[4WL=BK1HT<&<"21F8*H.1CDYS7(>++"]LO&-]X5LD<67C-XI=Z=(
M2AQ='_@48!^IKH-2N+7PC\2XM6U!3;:-<Z,MC%<",F.&2.0L$; .T%6XSZ&@
M#43X@V!T<WTEE=PS1:C'IMS:2!1)!,[!1GG!7Y@<@G(K9NM>@M?$NGZ&\4AG
MOH9IDD&-JB/;D'OD[A7E>I17%[H_B3Q3#:7/]GSZ]97<*^2P=[> QJTH3&<'
M!/3H,UT2:[9^(OBIX=N]+\V>QBL+Q?M7E,L;.?+)4$@9(&,]N<=0< &WX3\<
MIXP9);#1[^.Q*/ONYM@19%;'E]<DXYR..W6K7B/Q=!X=U/2].-A=WMWJ8E%M
M%;!26:,*2#N( SNZG@ $FLGX0PO!\,M+22-HW\RX)5A@_P"ODJKXXU*'2?B-
MX)O;E'-O&FH>8Z(7,:F.,;L#G SSZ#)[4 :MKX_L/[/UJ?5K2YTJXT4*U[;3
M[695890J5)#!N@P>O%+8>-7EU6PL-5T'4-(.H[OL4ERT;+(P&[8VQB4;'.#Z
M'O7!Z[:S^,AXVU?0X);JT-O8Q6S!"!=M!)YL@0$9; ^7W/2M_5=>L?'&N^%;
M706EN&L]174+M_)=1;1I&XVN2!AB6 QUXH W=.\<?VE>6YBT+4AI5U.UO;ZE
MA&C=@2,E0Q=5)4@,1Z9QFBP\<?VA>P&+0M2_LJYN&MH-2 1HV<$KDH&+JA*D
M!B,=,XKC]/O[&T\1Z<OA.]U:VN;G4 FH>'KF-FBAC9CYK[2"(B.6RK;3T'6B
MSU"QM/$=B/"EYJUI>7&I!+_P]<1LT4:,Y\Y]I!$>.6W*VT_C0!U4OQ"MXYY9
MQI%\^B0W7V275@4\I9-VPG;NWE WRE@,9S4U]XX^S:C?0VV@ZE?66GRK#>WE
MN$*Q.55B A;>^ RD[1W[UYQ8:7HUOI4_AK7=0\3'4_MDL#:3:S2;)U>8E71<
M;=A5@Q)..N:V/%=]IVG:QJMUHM]J^D^*D<!+%8V>+4W"@(?+P58,,+N!!&#G
MI0!U]]XX^RZA?0VNA:E?V>G2+%>WEL$*Q.55B A;>^ RD[1W[TV#5-,/Q3O=
M/ OAJ$>E+.[O,?LWE;U'"9P&SCG'3-<CXJO["QU35+W2KW5M&\6J5VV,<;/#
MJ<@4;#Y>"K@_=W @C'/2K7V*ZOOC5K2-&T37'ACRM^#M5V=1C/M0!LK\2H#:
M1ZLVAZBGAV241+JS&/9@MM#E-V\(3_%C\*NWWC9HM?U'0].T._U+4+%8Y)$A
M:-$V.N[.YV 'ICJ3T& 2."GU>&]^$$/@>*WG_P"$F-M'IS:<8'#(ZL%+DXP$
MP"V[.,5VGAF!X?B3XQ+*VTPZ>JN1][$3YYH Z'PYKUKXFT&UU>S25(9PW[N5
M<.C*Q5E8>H((JY?WL6G:?<WT^_R;>)I7V*6;"C)P!U/'2N$\":M;Z!X'TQ;]
M)D:]UBXM(@(R<.]Q+MSZ#CK]*Z;QI=ZE8>"]7NM(5C?Q6S-#L3<P/<@=R!D@
M>U %31O&+ZCJUOIU_HE]I4UW UQ9FY:-A,BXW#Y&.U@&4[3ZUCQ_%2WET6'7
M4T#5/[$+A+B^/EA827V?=W;F .,D# _ US^F76E+\0/"][I^I:QJ5DR7%N]_
M?2RR1F=U7:B[N%8X.< #D#MPP6\P_9FE@\F3S?(?]WM.[_CY)Z4 =YJ7C!K;
M7Y=&TW1;[5;FUA2:\-LT:B!6SM&78;F(!(4=JI?"Z_?4_![W;S2S"34+LHTI
M);;YS;1SR,#'':LN'6;/PC\1_$TFM&6"+5H[2>RD$+N)MD7EL@V@_,"/N]>:
MT?A2)O\ A#':>WDMI&U"[9H9!ADS,QP: -)?&MA_9'B'4989HET.::&YC;&Y
MC&H8%>>C C&?6HCX[L?^$2L-?6UN2M]<1VL5K@"7S6D\O8><9!!SSV-<?XLL
M+E/B$^B0P2/9>*)+*:=E4[5^SL3,">@RB(/QHL;&YE^)Z^&W@D_L_3=3N-<#
ME2$(DC7RU!Z9$LLIQ[4 :ZZM83P_$2/3O[1CO+*)Q</-.63?Y3D&(9^0<=L=
MJY.ZU/4!\+/AM<"^N1-<:Q:)-()6W2*3)D,<Y(..AK2TB"87OQ<)BD'F;MF5
M/S?N9.GK61=VTY^%'PSC$$F^/6;0NNPY49DY([4 >UZA>)IVFW5](K,EM"\S
M*O4A020/RKD;;XD17"Z3=OH6I0Z1JDD4$&H2>7M\R3[H*;MP7/&[&/3C!KH_
M$JEO"NL*H))LI@ ._P AK@]2@E/PF\#QB)]Z3:1N4*<K@QYR.U '27_C9XM3
MO[/2M!U#5QIN!>RVS1JL;$;MB[V!=@.2!ZCO6/K/Q"NSJ7A(Z!IMQ?V&L;Y=
MT;1*9E$;$QC>PVLIVL2<#C ).14.D:_8^!]7\566NF:"6ZU234+0B%V^U1R(
MN A .6!4KBN>MK:;PEI7PSNM:BDM8;.>[>Z8QLWD&979%8 $@_,!^% 'L&HZ
MC;Z5I5SJ5Z_E6UM"TTI/.U5&3]37G.N^+[[4YO"(;2-3TA+S6K9X7E=,3Q$-
ME6V,2IY4[6Z^^#CJ_'UA<:Y\.]:M+!6EGGLV,2*.7.-P 'J<8_&N,UGQ7I_B
M8^"H-*CGF>'6;66Z_<.HM2%8;')  ;)/'^R: -^R\3Z)IVO>-[EAJ*OI2PRW
MS2RF2,C8Q7R4S\O .1QDXK4L?%[.UT-9T2_T98+5KSS+K8\;1+]X[D9@&'=3
MS]:XS2XXHO&'Q4DU#3+F]L9%M1);Q1[FF3RG#!1D9X/8Y].:I".35[+6_#WA
M36M0UG2+G1I_DO S?99_E$<:R,H/S L-I)QC- ';Z5X[%_?Z?!=Z%J6G6VJ
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MHMS=?9(-58IY3R%M@.W=O"%N Q&.GK6SXKU:YT+PKJ>J6EJ]S-:V[RA%*C&
M3N.X@8'4CK@< FO)_#NF:*NCZ7X<U:_\32:Q#/'!-I$4\GEJR29$FTC:(A@/
MNSC'3GBO5_&$$MSX)UZW@C:2:73KA$11DLQC8  >M &!IWCNXC\(:'>:CI%X
M^K:FL<=M:1&(O=L8PYD7#;43J?F(P.HK:T'Q0NL7]YIEUI]SINJ6:H\MK<%6
MRC9VNK*2&7@CCH17GUEJUI_9_P /?$49EET[18'L-1=87)MI'MT7+#&<!A@D
M<#-='X?N8_$?Q,U#Q%IP=]*ATJ+3TN2A59Y?-:0[,@9"@@9]30!T6O>()-'F
ML[2TTJ[U.^O"_E06Y50%4 LS.Y"J.1U/)/%94WQ$TZW\/VNK365ZOFZA_9LM
MJ$!EAGRP*D \\KV)SD50\<:B+?Q1I5IJNJ:AIFA26TSM+9,Z--<!E"QLZ#</
ME+$ 8R?6N-TT$Z;9V(@O$G@\;PSO#=AFF2)R61G+<DD=3D\YH []?'S13:E:
MW_A[4;.^L[%M12V=HG:>!3@E2K$;@?X2>]:&H>,M.L/!<?B@++/9RQ120QQ
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M;?:[>W@*(5AP#O=G("CY@.O7BK?AGQ;:^)YM2AM[2ZMI-.F6"9+E0K!RH)&
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MMTN'CD69%(#;61B-PR,@\\U'X[UZ^T31[2'21'_:FIWD5A:-(,K&[YRY'<*
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M$\4?BO?&R%_$EZPW#&X97!^E=Q0 4444 %%%% !1110 4444 %%%% !1110
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M!)C;;S@T :6O:+J>HW%I=Z5KL^EW%ON!7RO.AE5L</&2,D8X.01S1X9\.?\
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M;RK [HTWV@G82H(!P0><"LFVL[H? /7+8VTPN'&H;8O+.XYGD(P.O(Q7J]%
M'D-]86.E^++N]UZZUVQM+^PM&MIM.FN$5GC0J\;B+^+[I&?4XKT+P?96MAX4
ML(+.SO+. HTBP7K;IDWL7.\Y/.6)Y.>:W** /--.U3_A7>O:[8ZU:W:Z1J%_
M)J-GJ$%N\T8,F"\3[ 2I##CCD5-J]_JOQ \,>);+3-+F@TM[$QV=Q=(T4EU-
MR<*C8(3  R<<G\O1:* /+=4UN+QE8>&]%TRTO1?I?VMQ>QRVLD?V-(CN?>S
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MOLMPZD1S^6'V'UVG@_2LOPUX;C\/073/=S7U_>S&>\O)@ \SXP.!PJ@  *.
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M'8X4$CWKC?$MN^IW_BRRU.SUN]U=]T>CVT)G6V$)A&UP4(C^]N+;B2<8P>E
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MT2*6-T"04W]-N 6W>@-$WCV33])UV;5-&>UU'1X%N9;,7"NLL;9VLD@'(RK
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MC&1GJ,Y%<+I^A)9:7X.U+7K35X]/31FLK@V1G26VEWAU+K%A]I&X=",XSVH
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MF%E+A>".K% ,'&-W)XK1F\7:LDMEIL7AII-=G@>YGLC>H$MH@^T,TN""6/0
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MD8?@=L9Q6Q7"^"'N;OQ=XPU&6PNK2"[GM7M_M$10N@A"AL'Z9QU&<'!XKNJ
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MNC7]QJ6EQW-WI\VGW)++);3$$HRL0<$<,IQD$=010!?HKC-;\::IH[ZC=_\
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MXX\>8"0JX9=RDC!&#P: .LHKC--\;W]Q<:3)J6@-8:9K#A+&Y-T)'W%2Z"1
MHV;E!Q@M@\&NSH **YK6/$M_;ZZ-%T32%U*^2W%U<>9<B".)"2JC=M;+,5;
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M8D# '@_>SC/;WH W:*\R\,>/=7'A?5M8UO3O,2/4)8+58;A6>21IMB0!=HP
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M.1Z;XPHSW)KU^N>TCPI'IVN7&M7FHW>IZC+'Y*37.T""+.=B*H  )QD]3@4
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MT;KQ=JUSXHO-!T+2;:ZEAM8;I;FXN3'%L?=UPI.>!@#KD],<\G&FMVWPSD\
MCP_J+ZMY+Z>EP(?]$:-F($OF] -ASCKGC%=7X?T>ZTWQ_J\C0R_8_P"R[*WB
MG9<+(R>8" ?49'YT :WA'Q"WB;05OI;3[)<I-);W$&_>(Y(W*L W&1D9_&F:
M'XE;4]<U[2+JU6UNM*G4 !]PEA==R2=!C/((YQCK5/X?V%WI^CZE'>6\D#R:
MM>2HLBX+(TI*L/8CFN9^*%MJ.FZUIVJ:(!]LUF%]!E&<']YEHY/^ $.<^AH
MTK;XBW>I6.GG3='CEO-7O+B+38Y+@HCV\/WIY&VDJ./N@'J,&I+CQ]?:7I_B
M*/5M)ABU;1;5;OR8;@O#<Q-G#*Q4$<@@@CBF:SH<OAO4?".IZ7I]Q>6&B0RV
M4\%LF^41.BJ'5?XL%!D#GFLG5=%U;QA_PE^K0Z9=6B76CKIUA#=IY4LY4L[,
M5/*@L0HS^E ':ZOXD;3)?#R"U$G]K7:VQ)?'E9C9\].?NXQQUJ3QAX@/A7PI
M?ZV+<7'V15;RBVW=E@O7!]:XVZO=3\1WW@TP>'=5M8=/OTDO'N[<Q^6?*=>
M>2H).6Z<KZ\=#\3;"[U3X=:Q96-O)<7,J($BB7<S8D4\#Z T 9]SXT\1V.NV
M&F77AJW\S5TD.G!+TDJR $K/\F$PIW$KNZ8&:M:=XQU26S\007>A;]:T9T1K
M2RF,BW&]0R%6*@@'/.1QC/M4VOV%W<?$'P=>0VTCVUK]M\^55RL>Z(!=Q[9/
M KF->TG7/MOCR>SL[TQW<^G%?L^5DN($51,L1XR=NX<?2@#>'BWQ!:3ZEIVH
M:):?VK!IS:C:QVMVSQSHIVLA)0%6!QV(.:L:AXZ@@\ 6?B:RMOM4E\L*VMIO
MP9)9&"B/..H).>/X37.>&=-AT_XC6VHZ7X5O=+TBZTV2T61[<JQE#H^Z4$DH
M" 0"W)(/J*I>'M$N5^)$GAAE#:'X?NY-6@P<@-.H\J/';8S3,/PH [[QKN_X
M5[XAW@!_[*N=P!R,^4U<QHOBS6=+TOPI]NT6"/1]1%O8PS+=$SJ[1_(SIMP
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MO<;4G6,$O,QVG:@VMT!)Q[UN^'->N]3NM2TW5+**TU33G03)#*9(W1URCHQ
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M:9X@&J)9R#8\R(^2%SW*DD?2@#M$\5:_9:LNCZOHUFE_=VDUQIQM;MGBG>,
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M;WAR&\U?QWJ?BB;3[JPLS8Q6%JEW'Y<LNUV=G*'E1E@!GK0!VU%%% !1110
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MD8D>,NI4.F-RY'49[UC^'_"]GX>:[FCN+N\O;QP]S>7D@>67 PH)    Z
M5MT4 %%%% $*VL"WCW8B47#HL;28Y*J20/H"Q_.IJ** "BBB@ HHHH ****
M"BBB@#C;CX;Z7<R3QOJ.K#3+B<W$VEBY'V9W+;B,;=VTMSM#8KL@,# Z444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@'L#R*OMI\5OH/P]T>QT'[?9:A:-?WEA%*L2W4JP18+EB 1EMQ!Z[1Z4 >U
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M8[4 >ZE@" 2 3T&>M+7BUY87OB;5O%DS>%;C5;R.^DL[._6]BB-D(T78(PS
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M@61B1"?)0ED'9CQSU^44 >L5S_B/Q;:>'I[2S%K=:AJ=X3]FL;- TC@=6.2
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4W O;9 HB5P(G90X5V7&2RB1L'-=#+-% F^:5(USC<[ #/XTXLHQE@,].>M
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M;>01W9"RVLA_AF1@Z?AD 'V)K?,B+&9"ZA ,[B>,>N:$D25 \;JZ,,AE.0:
M./CTP>-++2=<>?5-"U>VC>&3R J2(6P)(V#J05RH(./0BEM_AOI-J2L5YJ(@
M_M&'4Q TJLHGCQ\V2NX[\ MDG)Z8KKGFCB#&21$"C<2S 8'K7/>./%)\(^#+
MS7X;9+S[/Y>V/S-H<,ZK]X _WLT 7KGP]97?B&+69C(T\=G)9^42/+:-V!;(
MQG/RCO7-#X6::UA#ITVLZS-IUM*DMG:/.A2W*L&&WY,D<%1N)P"<<\UV@NHE
MM8IYI$B60 _.P R1TYJ8LJD L 3TR>M $5Y:I>V5Q:2%A'/&T;%>H##!Q^=<
M99_#4:?90V=IXQ\4PVT"".*-+N(!%'0#]W7;1313IOAD21.FY&!%$4T4REHI
M$D4'&48$9H P[?PI;Q:AH]_-?W]W=Z7%-%%+<2*S2"7&XOA1DC:,8Q^-3VGA
MRSLKS6KF.2<OJ[A[@,PPI"!/EXXX'?/-;%4=4U*/3=/NY\H\T%O).L)?!8*I
M/Y<=: . U+P8EOXG\$Z392ZC%::=8W<<=]$1YD+ 1[26V[<GD8(P1D8KHX?
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MG1[(R0[;AA2.H/I0!S ^'^E'0KK3);F]F:\NH[RZO))%,\TB,K*2=N,?(!@
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MR#(>3&=I X P,=: .:U/3++P9JOA+Q'IEI#:6/&F7Z0H$7RI\%'..,"7!/\
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MFN!&45OX0%]._-=3X5TAKSX@1ZS!;:V+6UT^2"6]UI&2:>1V7"*K ':JJ>@
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M4J01[6D)&&QO9L'KCVKT1?!.F_\ ".:EHLUQ>W":F6-Y=33;IY20!G=C P
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MA^":8ZE<!+>%)0.<%'S(Q0\@=!UKF[Z1Y/A-X%WD?)XE2-0K[PJK-,JJ#W
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M<K-#(S,S%7'^^PQTP:%\"Z/_ &//ITK7<XN;F.[N+B:<O--(C*5+,>PV*,#
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M'.+72+P7MJHDP1(&9AGCD98\5;E\)V$GBM?$<<][!>^6L4JPSE8YU7.T.O\
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MI*@=4<HWS 'C<,<'J,GUKHKCP!H5UJ4MW(EV(YYQ<SV273K;32@@[VB!VDY
M)[$CG-:]KHEC9ZW?ZQ#&PO+](TG8L2&$8(7 Z#J: /.DTM/#.HP/K.A66HZ;
M+K'GV^NVDN+B*668E/-'#'#,$)#$8P".U8MKH^N>(?#NMR0:'H[7=QJ5R_\
M:UQ>E+B"5)B$./+)79M4 ;N@[9KTB+P!H<.HI=+]M\F.X^U1V)NY#;)+NW;Q
M%G:#NYQT![47G@#0K[49[J5+L1W,HGN;..Z=;:>08^9X@=I/ SZXYS0!A:%I
M=EKOQ \9MKEE;7D\ M+9$GC#B.(P[B%ST!8L:XG0TN9M \#:?96=MJEN]_J<
MHM[V<I%,T;OL+-M;) 9F&0>17K&K>"=(U?5FU.4WMO<R1B&<VEW) +B,=%D"
MD;AR??%(? F@C08-&BMY8+:VG:YMF@F9)()&9F+(X.5^\?;!Q0!2\#Z1J>E7
MVNO>V5AI]M=3QS0V5E<&5(7V8D/W5V[L*V,=S6?K\<>K^-[NWLO#VFZE>65A
M&MU<:K<%888Y&8JB($;YCM)+8'  S76Z'X?L?#]O-'9B9WGD\V>>XE:669\
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M (LIK>Y>.6($8(#@YY'!H X_5]+3P_?:IJ6KZ%8ZQH=SJ(NWU*WEVW=D=R@
M]R$8 #:P(';K77_$>[NK+X<:_<6;,DZ6;[63@J#P2/3 )-)-\/\ 0Y[^2X<W
MWDS3"XFLEO)!;2RY!WM'G!)(!/8GK72W$$5U;2V]Q&LL,J%)(W&0RD8((],4
M >:^)=$TC0=*\&7>B6=O;W,6JV4,$T"!7D1_E=2PY8,I).>O6I? &BZ?<>*/
M&.J7%I%-=PZ[,D,DB!C#\JDE,_=)SR1UP/2NATSP#HFEWUK=1F^G^Q9^QPW5
MY)-%:Y&/W:L2!QP.N.U:^EZ)8Z/+J$MG&R-?W+7<^YB=TC  D9Z< <4 <O\
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MB]*7$,R3$(<>6=NS:H W=!VS72Z?HUEJWQE\02ZI:07+6UA9,D<J!T60AOF
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M->-S1"^T'X27%_!'+<37<,<CR("TB!?E#$]1C'6O:KG3K2[TN;39($^QS0M
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M4\(6DZG.FQ-J6JQG^&YC)A13Z'S!(V/0"LY-'TZ?X;_$B\FLX9;G^T=3(E=
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MZ5:I>"TE6TTZ9G6*0.H9B"J[2P"'ISC-;_C?P]I5I8>#M,@LH8[237[9941
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MU[:Z?'*TML9D4%HY%*J</M#8 /K0!Z1::MIM_8M>V>H6ES:+G=/#,KQC'7+
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MQ);+@D^?DX!XSVX!JYI6O:1KB2/I.IV=\L1PYMIEDVGWP>* (QX>TP>))/$
MMS_:<EK]D:;S&P8MV[;MSCJ.N,U ?"6BGPJOAK[(?[)5540>:^<!@X^;.[J
M>M5O$OBB30=:\.V"6JS+JUX;9G+X,8 SD#'-=)0 C*&4JP!!&"#WKF=-^'_A
MS2=2AOK2TE#V[,UM%)<R/%;ENICC9BJ9R>@^E:B^(]$?6#I"ZO8G4AUM!.OF
M^N-N<YQVK(@^(?AN;7=5TM]5LH7TX+ODDN4"N2"6"\_P8PWH: &'X:^&&BGA
M:SG,,K%DB-W+L@8N')B7=B,[@#E<?EQ6[IVB6&E7-Y<VD3K->LCW#O(SEV5
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MPK<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=1-((GE'1VB#;"W Y(K3LM%T_3[V_O;:V"W-^X>YE9F9I"!@<DG  X ' ]*
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MVOV2X59I )8\Y^8;N6R3\WWN3SS5J7PIHDT.CQ26(*:.R-8#S'_<E0 O?G
MZYH P/"DL</B[QZ\KJBQWT+N6.-J_9TY/MP:X+0;*VU+3?A%;742RP.;QFC8
M9#;4+ $=QD#BO5;_ ,$^'M3UEM6N[#?=N%64K,ZK,%^Z)$#!7Q_M U/;>$]#
MLQI(M[$)_9/F?8?WCGR=X(;J><@GKF@#BKBTU>7XHZU%I=EHL@@TRUCBCU'>
MH6%C)N\L*I&"P^;Z"NJ\!Z;/I'@VRL+BZM+EH3($DM)"\03S&*JI/)"@A?PJ
MUK?A/1O$,\5QJ-J[3Q(8UFAGDA?8>JED8$K['BM*QL;73+&"QLH$@M8$"1Q(
M,!0.U 'G_A*ST^^TKQO+JT,,DLNKWL=XTR@D1K@("3_"$QBN3=7N/"WPCEO8
MP\SW\"%G7)9 /E!]1MQ7J.J>!/#FL:A->WM@S33@"?R[B2-9P.GF*K!7_P"!
M UH7WA[2=1?36NK-&_LV59K,*Q00NHP" I X'8\4 )KYFMO"VJ-8C9/'93&$
M(,88(=N/QQ7FWA_0]:N=%\$SC_A&[.RM9+>>WGAED$\JE/G097!9U+9&>3]*
M]=KG=/\  OAS2]334+/3O+GB9FA4S2-'"6SN,<98JA.3]T#K0!YO:HKV7QG#
M*& \\C(SR(9,&M.73[2Z_P"%46\UO&\+H9&0J,,PM-P)'?D"O0;?PQHULVK-
M%8H/[7):^#,S"8D$'()P."1QBJNF>"= T=;%;*R=182O-:[[B63RF9-AQN8\
M;>,=!V&: /.?&JM8ZC\0UL%6'S='LFE"#:"#(ZN3C_8R"?2NET_1-;3QAH-]
M>#PY90VL$T*Q:?(XDGA*#"@,H!56"'V_&NQ?0M,DO[V]DM$>>]@6VN2Y+"2,
M9PI4G&/F;MWJCHO@S0?#]X;O3K)DG\ORD>6>24QIUV)O8[5X' QTH YCX+:;
M9P?#G3KV.WC%U</.9)MHWMB5E SUQA0,>U3>,;:SNOBAX"BO41X\7[*D@RK.
M(XRO'?!&1[@5V.D:/8:#I<.FZ9;BWLX=WEQABVW<Q8\DD]237->+/#+>(/&7
MAF2>R-QIEM%>"Y</M\MF6/RR""&!RIP5Y&.U ')ZW+8Z9XH\<6XTV.\M+J'3
M8Y+(.8HWN9'*+N*_=!RI/J!5NW34(/B/?P:D-*CN#X9E9H].5E4*)5"[MW4C
M+8Z<5V</@?P[!HM[I(TX/:7K;[GS97=Y6&,,TC$MD8&#GC'%):^!?#MG/!<0
MV+BXA611,US*SN' #!V+9?( ^]G&!C&* //+'2K&V_9KGN([6$3S:2\DDI0%
MV8YZMUXX ] !Z5L^(K==$T;PCXOM8U0:3Y27FP8W6LRJDA..N"5;\":[F'P_
MI4'AX:!'9I_9?DFW^SLQ8>61@KDG/?UKE]>T*YTWPK+X2\+:%)-!J$3PM<7%
MUOAM0PVEF\QBYPO(501Q0!)X)0:SX@\0^+6^:.ZN/L-BW4?9X"5+*?1I-Y_
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M  FOAC[3<V_]OZ=YUKQ,GVA<IR%YY]2!]34]]XHT+3+A[>^U:TMYT>-&CDE
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M: /5KBXAM+>2XN)4A@B4O))(P554=22>@KGY/'OAD:%?ZO;ZS97-M9+F4QS
MX)^ZOU8\#UJQXQTZVU;PI?:?=W\=C%<*J"XDQM1]XV9!P#EMHQWSCO7$:M=W
MZ6/BG3/$&F::NK_\([<2Q:A8$[9X%##:RMRI#$'&2.3CI0!V&D^.- U30;+5
M?[4LX8[E<%7G7]W((P[QD_WE')^E-?Q##?:GH$FF:[IGV"^\X^4XW2784?\
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M"16M@+-(E\<W2HETI\@,%<QA@O.-W0>N* /8])UK3-=M#=Z5?07D 8H7A<,
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M&"2I0H./0]*RO#^D:S=^'O \KWOANUT^VEMI[5HA(L\GR?-&"3@NRE\CN<T
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ME33H-/>.XGAGM[<@QB5965RI &06!.?>F'X?>$VTZ&P.AVWV:!VDB4;@49@
M<-G(R ,C/85NV%A::78PV5C;QVUK"NV.*)=JJ/84 <+X,^QBU\=?VGY>_P#M
MF[^V>;C_ %.T;-V?X?+Z=NM<GX:M6NKOX2)J$?F%+&]D59!G@(IC./8;2/H*
M]1U3P7X;UJ_^W:EH]K<7) #2.OWP.@;'# >^:T9-*L);ZSO7M(C<V2NEM)C!
MB5@ P7TR !^% ":OYXT2_P#LF?M'V:3R=O7?M.W'XXKB?"S^&1\,O!K:CY'E
MYMA;<$G[;[;>=V_=G\<UZ'6%;>"_#=GK1UBWT:TCORQ?SE3HQZL!T!/J!F@#
MCO"_V(?#_P 8_P!I>7YGV[4?[1\S&<Y;[W_ =N/PJEX,MWE\5^"WOX]UQ#X3
MWJ9!RIWQJ#]=K$?C7>ZAX*\-:KJ1U&^T:TGNF*EW=/\ 68Z;AT;'N#6H=-LS
MJ2:C]GC^V)"8%FQ\PC)!*_3(!_"@#QO6!'&WB".0*NG_ /":6378/W/+*Q%B
MWL6QFNPUHVG_  NKPN(]GVO^S[OS<?>V?+LS[9WX_&NLE\/Z1-;ZA!+I]O)#
MJ+;[M'3(F; &6'K@#\JJZ7X.\/:+-#-IVDV]O-#O\N102PW !N3R<A0.?2@#
MQBWX^ 'BP_\ 4;;_ -*(:[KQUS\5/AS_ -=KS_T6E=FGA?0X](NM)33+<:?=
M.SSV^WY9&;&2??@?E3+;PGH-F--%OID"?V87-F>282_WMI)[T <EX/\ L0T/
MQQ_:?E[_ .UK[[=YF/\ 5_PYS_#LQCMBL+P5;O-K'P[:_CW31>'[B2/>.5^:
M,*?^^#7HNI^"_#>LZA]OU'1K6XNB &D=?O@=-P'#8]\UIG3+)M0@OS;1_:H(
MFABEQRB-C*CVX'Y4 >9MIMOJ&O>,[(ZC%ILW]MV,UG*ZAD^TB)'4%3@-N(Z=
MZZ3PYK$\&L:Y;>(K;2K34K2*WEN=0M&VQ3Q-O"%BW*D;6X)/7BMZZ\-:+?17
M\=UIMO,FH,KW0=<^:R@!2?< #!]J@M?!_AZSTFZTN#2;=+*[_P"/B+!/F_[Q
M/)_$T ;8(90000>01WKR#0?^/OXO?]=)/_14E>OHJHBHHPJC  ["LZ'0-*@;
M46BL84.I$F\('^OR"/F_ G\Z /.KZV@MOA5X $,2ILO=)D7 Z,Q4L?J2QS]3
M7=>-?^1#\1?]@RY_]%-5Z31=-EL+2P>SB:ULVC:WB(XC,>-A'TP,5<EBCGA>
M&9%DBD4JZ,,A@>""/2@#RPP0W5C\(XYD62/$;8(R,K:%@?P(!_"J?CU9DUCQ
MY]D!5W\/6S2;1U42.&)QU^3(^E>C:;X/\/:0MNMAI4$ MYFGAVY^21EVEAD_
MW>*T?[+L3?SWQM8C<SPB"60KDO&"2%/J.3^= '$V6F:M+XJ\-7NHZQX>$=M%
M-]D@L+=XGN(FCP0NZ1LJ/D;@=A4OQ&%\VI^$19R6D?\ Q-3A[R-GA$ODR>7N
M"D$G.<<CG%=#H_A#P_H%U)=:5I-M:SNNPNB\A<YVC/W1GL,"M#4]+L=9L)+'
M4K6*ZM9,;HI5R#CD'ZCUH \[NO!]_KD7C&VU#5-*GU*^M;?]QI\;1^1/&&:*
M1@SL03\O.1D+47A[6#\0_%7AVZ89@T73OMEVN.!>R9C"D>J[)"/K7H>CZ#I?
MA^U>VTJQBM8G;>X0<NWJQ/)/UI=,T/2]&>Z?3;&&U:[E,TYB7'F.>YH \BT+
M3-=U/X:VD%QK'A^QLC>[GEFMY!<1W*W.>7\S'F%QC[O0UV?A*TMW\=>/97A1
MGDNX(F)&<I]G3Y?IR:WCX-\.'6_[9.CVO]H>9YOG;/\ EI_?QTW?[6,UI6VG
M6=G=75S;VZ1S7;AYW4<R, %!/X "@#QOPVW_ !)/A&6/_+Q<#)/^Q(!7I?C_
M .T_\*]\0_9-WG_V?-MV]?N'./?&:GNO!WAV]T:VTBXTFV?3[5M\$!! C//*
MGJ.I_.MF.*.*%840"-%"JO8 #&* /-/%'V+_ (5]X/&F>7O^W:=_9WEXSG*_
M=_X#NS^-6=&_Y+UXF_[!5M_,5T^G^"?#6DZD-0L-&M(+I=Q1T3_5YZ[1T7/L
M!6C%I-A#JT^JQVL:W\\:Q2S@?,ZCH#]* ,+QW>&VL-*MXK.SN;J]U.&"V-X"
M8H9?F<2, 03C8< $9.*\^U=[P-\3HK^^L[NZ71(!*]I 84#!9>"I9N0".<^E
M>NZMH^G:[8-8ZI:1W5LS!MD@Z$<@@]01ZBL]?!7AI4"+HUJJ_9FM" N,Q,22
MI]<DD\\Y)]: .8\0VT%I:?#I+>)8UBU2WC3:,;5,$F1^.!7/:M<7/AF;Q-X'
MLR4EURXCDTC_ &5NFV3 >@0AV_&O6KC2K&Z%F)[6.06<BRV^1_JW4$ CW )'
MXURUGHNJZWXYM_$6N:=!80Z7#)#80+,)9'=^&E9@, ;1@+[DT =7INGV^DZ7
M::=:KMM[6%88QZ*HP/Y5:HHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#F+#7[:WNO$D][XBANK73I 98A:^7]@7!)5F&=_3.?:K%GXV\
M.7^LII-KJL,EZ^[8@5@'*_>"L1M8CG(!)&#7EK?\>/QF_P!X_P#HMZZSQ%!%
M;67PZ2&-46/5;9$"C&U?(DX% '2WOCCPUIVK'2[O5X(KL,J.I#%49N@9P-JD
M^A(J36?&&@>'[I+74]12&X9/,$2QO(P3IN(0$A?<X%<=X7NM$MO _B=?$C0>
M3%JMY_::3#=DF4D94<G*[<8Z\8K0\)201?$'QH)B$F;[')%YGRG[,(0%(SS@
M'=GT/6@#I;CQ5H-I8V=[/JMLEK>!FMYMV4D 4L<$<= 3^%1Z;XQ\/ZM:7MU9
MZG$T-B-UT9 T9A&"<L' (& >>G%>6:%!%<1>#/W:M8/XFOY;,$?+Y0\UD(]L
MC(K?\0VFG7GCKQ5::I="RL;GP_;+-< XV$S2!6/T..M '86'B_0]=M;T:5JL
M9EMX3([-$P:-<'#[6 ++QU'!JKIWBO3-/\(:?J>J^(H;^.X)1+Z.V,?VEMS<
M+$N3D $8&>F:PQ>ZM:ZEJ.C:]_9E_=MHD\]MJEI#Y<IB4@,DB\[<EE(VG!QT
MXK"\%:>;[X<^!VL=8ATW7(!<R6'GQ^8DPW.)$*Y&>".0<B@#L-<^)F@Z3IFE
MW\%REW#J%VENC)N^5=P61C\I(*@_=.">E:>H>-_#FE):M>ZHD7VF$7$8\MV/
ME'H[  E5]VP*\^UG5)+_ $G1?MEG8VE[9^-;:"\>S_U,T@Y,@)YY##.><@@U
MIB'6I/B5XN%AJNEV0:&T<K?6AF+P>41D$2+A0V_/7DT =MJ'BK0M*6!KW4X(
MEN(3/"<EA*@*C*XSGEUP!R<C%&G>*M#U72;C5+/4H7LK8L)Y7S'Y149(<, 5
MP/45Y_H6EV]EXH^'UJM[#J45MI=ZT%TB85@2FTJ"3@!6QUK-\5C9<?$+(_T1
M-3TF2Z4#CRML1<D>G<T >BVWQ!\*W=G>74.KQF*SC$L^Z-U94)P'VE02N3U
M(K7U'6=.TG2GU2^NXX;% I,QR1AB N,=<DC\ZR=33PQJ^M1Z9=+!/J5WITRI
ML4LWV5L!_F' 4DC&>IZ5Y[H<USKLWA[P'?$R3:!>R2:F2/OQ6Q M\^H??&??
M:: /2?&6IW.C^"=9U.R<)<VUG)+$S+G#!<C@U6T;QSH&J7-KIB:K#)J4L?\
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M\?>*@HQO\)@MCN=\PS^5 &[HOQ$T+4O#%AK5W=Q62W16-TDW;8YBF\IN(&<
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M_"OPVB2>-GFU/37C56R64+R?H,@?4BO2H;VUN+B>WAN89)[<@31HX+1$C(#
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M^M %NR\'^&].U4ZG9Z)807I)/G1PJ&!/4CT)]JT8M-LH9+N2*UB1[QMURRJ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>*+CX=>%VT'4].M(AIZ"1;NU:4L>V"&&!BO08;&TMS<&&U@C-RYDGV1@>:Q
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M@54ZM^^?@>^,C\:FT:WCU'4?"4\_C>VO?+_TBQLX+%$9@(65@2I)4!20<\9
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MA'_L&W/_ *"U 'I-%5;/4;/4&N5M+F.8VTS6\P0Y\N08)4^XR/SJU0 4444
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MM)Y&?:EFL;2XN8+F:U@DN+?)AE>,,T>>#M)Y&>^*GHH SQH.CC5/[4&E6/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZZ3Q]H%UXH\#ZIHUD\:7-Q&OEF0X7<KJV">V=N/QK(NM+\2/JMAXF31].DU
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MY4TOF!(W*G'ED #(Y&>E:5]X?U_5],T<WL>G075OKD%_)#;D[(H$)^3=CYW
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M)N7:ZOU[\$ \<\5B0W/C+_A-+OPHWB&!U-BFH)J)L4$D2EV0QA,[3D@')S@
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M:2QYP",8K:-SXEUWQQXDT:SUS^S+'3EMFBDCM8Y)-TD>=OS C;D$G.3T (H
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M8R&5455,?&-O#9SSTKH** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** ./G\:7T]_?P:%X8O-6@L)FM[BX6>*%?-7[RH'.6(S@].>*
MO:=XCN=;31;W2[%6TR]60W,EQ+Y4UN5X"^7@[CN!!YXQWK$/AW6K2^O]5\$>
M([(V]Y<O//87D0FMS/G#E9$.Y,D<CGG-<M+X@D\2?$+X<7UQ:BUNDFU*WN(5
M;<JR1KL;:>XR,CZT >Q&XA#HAEC#/]Q=PRWT]:5YHHY$C>1%=_NJ6 +?0=Z\
M(B\.Z8GP!DU_[*C:Q"'FAO2,RPE+@A0C=5  Z#CDGO74Z+X;T?QFOBV_\00K
M)>#5;BT2[8@26<404)Y;'[F/O9'<\YH ].::))$C:1%=_NJ6 +?04--$AP\B
M+\P7E@.3T'UKQ&+2K_Q&GB=H_#8UN\^VRVEIK,M_&DL B4+$4R,KCA\KC<6-
M6+'2C<>(_'.K:O;)/JVDV5G<PQL=R1W0M Q< <%@R#![<XZT >S+-$\C1K(C
M2)]Y0P)7ZBN;\"^+3XQT%]1DM4M76YE@\I9-^0AQG.!7!>&-!U4Q>%-1TWPG
M'93I)#-=ZL+^-I+N&1?WID ^9MV[=@YP0,5@>%$.D>"])\91 YTC6[B.[QWM
M96"2?7:2K#Z&@#Z"W*&"Y&3T&:6N'\/(->^(VO>(3A[;3D72+(]BP^>9A_P(
MA<_[)KN* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%1M/"LZ0-+&)G4LL98;F ZD#J0,BI* "BHX
MIX9FD6*6.0QML<*P.QNN#Z'D<4IEC!P9%!^M #Z*AENK>"%YI;B*.)!EG=P%
M4>I/:INM !1110 4444 %%%% !133+&IP74'T)IP((R#D4 %%%-=TC4L[*JC
MJ6.!0 ZBD5E=0R,&4]"#D&EH **** "BBF2RQP1/+-(D<: LSN<!0.I)/04
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M%K.XT_PMIEG=1^7/#;JDB9!VD#ID<5KT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2, RE
M2,@C!I:* ,C_ (1?1/\ H'Q?F?\ &C_A%]$_Z!\7YG_&N5\4Z&-,.D-;:MK"
M_:]4AMI<ZA(?D?.0.>.E6?$^F1:#X?62*YU"X#7]JS">X:9N)!PN3QG/X\4
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MD+E62!.HR.1N/'X5B3:M?:=\2[ZX>ZF;2TFM[26%I"4C\V/*N!T'S*,G_:H
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MWH]I-!XSUV1HI!"T%HL<C*0K[5<'![XXS6 =/O/^%/R6?V2?[47;]SY9W_\
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M1+B\DO+6XE^6.5'P2 W3*G@@U+%=Q>)O&VG7>G-YUAI,4Q>Z4?(\L@"A%/?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@! JKG: ,G
M)P.IH*JQ!*@D'(R.E+10 R6&*9-DL:2+G.'4$420Q2Q^7)&CI_=901^5/HH
M;Y4955*+M7H,<"D>&*5E:2-'9#E2R@E3[4^B@!ABC,9C**4;JI'!_"@0Q+&(
MUC01CHH48'X4^B@!"JE@Q4$CH<=*:L4:2-(L:*[?>8+@GZFGT4 ,>*-W1WC1
MF3E25!*_2@11JVX1J#DG('<]Z?10 FU0Q8*-QZG')IB6\,8PD,:_-N^50.?7
MZU)10 5&;>$S><88_-'\>T;OSJ2B@!"JE@Q4%AT..E(8T.[**=WWN.OUIU%
M#'ABDB\IXT:/&-A4$?E2^6GE^7L79C&W''Y4ZB@ Z5&UO [%FAC)/4E14E%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS9(L,$EI*S^8H_B8,HVGIP,UU%% ' W?A7Q$-0\2VUA+IR:?KS[Y+R1F^T0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6^T^VNT!59XEE /8, ?ZT 3T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5%+<P0-$LTT<;2OLC
M#L 7;&<#/4X!X]J\]\.Z0VC_ !?OHI;ZYOKB;0HII[BX;)=S.X.!T50  %'
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ME6;>P8GG(/3'WO88KV^@0:YH7CG4-0NKV2>RU/4!9%;J1!;%!N!4*0,Y]<\
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MI#+:7MJVV6!B,'!/!!'!!X-9MGX'GDU6TU'Q#X@O=<DLG\RUAEBCAAC?LY1
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MYKM** .2LO!=Q;^([3Q!<Z_=W>I11/;SN\4:I-"Q4A H&$ *YR.22<GTSO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<+X]:Q_MSP\FOR!/#C&X^TF1BL)GVKY
M0E/3&/,QGC.*[JLG7++5[H6TNCZE#:30N2\=Q!YL,ZD8PP!5ACJ"#^= &!\-
MKZ*YT[6;6UDEDT^QU22"R,A8D0E$=0"W)4;SC/\ #BNUK(\.Z(=#T^6.:Y-U
M=W,[W5U<;-@DE<\D+DX    R> *UZ "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459908976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Aug. 01, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Sesen Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-2025616<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">245 First Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">444-8550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SESN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001485003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458749888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 72,090<span></span>
</td>
<td class="nump">$ 162,636<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short term marketable securities</a></td>
<td class="nump">69,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">14,046<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">757<span></span>
</td>
<td class="nump">18,476<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">156,420<span></span>
</td>
<td class="nump">205,605<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrentAbstract', window );"><strong>Non-current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">19,641<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">30<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,064<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsNoncurrent', window );">Total non-current assets</a></td>
<td class="nump">19,743<span></span>
</td>
<td class="nump">35,142<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">176,163<span></span>
</td>
<td class="nump">240,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">2,853<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">29,851<span></span>
</td>
<td class="nump">8,255<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">487<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">32,005<span></span>
</td>
<td class="nump">11,568<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,969<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total non-current liabilities</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">57,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total Liabilities</a></td>
<td class="nump">33,805<span></span>
</td>
<td class="nump">69,037<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; no shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value per share; 400,000,000 shares authorized at June&#160;30, 2022 and December&#160;31, 2021; 199,463,645 shares issued and outstanding at June&#160;30, 2022 and December&#160;31, 2021</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">491,464<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(349,024)<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Stockholders&#8217; Equity</a></td>
<td class="nump">142,358<span></span>
</td>
<td class="nump">171,710<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 176,163<span></span>
</td>
<td class="nump">$ 240,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493460021920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 03, 2021</div></th>
<th class="th"><div>May 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458842672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,234<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 6,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">29,944<span></span>
</td>
<td class="nump">7,228<span></span>
</td>
<td class="nump">34,705<span></span>
</td>
<td class="nump">13,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">15,589<span></span>
</td>
<td class="nump">6,805<span></span>
</td>
<td class="nump">24,564<span></span>
</td>
<td class="nump">12,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(37,300)<span></span>
</td>
<td class="nump">13,600<span></span>
</td>
<td class="num">(50,200)<span></span>
</td>
<td class="nump">61,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">35,997<span></span>
</td>
<td class="nump">27,633<span></span>
</td>
<td class="nump">36,833<span></span>
</td>
<td class="nump">87,164<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from Operations</a></td>
<td class="num">(35,997)<span></span>
</td>
<td class="num">(25,399)<span></span>
</td>
<td class="num">(36,833)<span></span>
</td>
<td class="num">(80,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">162<span></span>
</td>
<td class="num">(43)<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="num">(46)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Loss Before Taxes</a></td>
<td class="num">(35,835)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(36,642)<span></span>
</td>
<td class="num">(80,666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">3,875<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,875<span></span>
</td>
<td class="num">(288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Loss After Taxes</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(32,767)<span></span>
</td>
<td class="num">(80,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders - basic</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
<td class="num">(32,767)<span></span>
</td>
<td class="num">(80,954)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common stockholders - diluted</a></td>
<td class="num">$ (31,960)<span></span>
</td>
<td class="num">$ (25,442)<span></span>
</td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.16)<span></span>
</td>
<td class="num">$ (0.49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">175,393<span></span>
</td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">166,264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">175,393<span></span>
</td>
<td class="nump">199,464<span></span>
</td>
<td class="nump">166,264<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList', window );">Revenue from Contract with Customer, Product and Service [Extensible Enumeration]</a></td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
<td class="text">License [Member]<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920602&amp;loc=SL49130690-203046-203046<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458467344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 31,960<span></span>
</td>
<td class="nump">$ 25,442<span></span>
</td>
<td class="nump">$ 32,767<span></span>
</td>
<td class="nump">$ 80,954<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (32,241)<span></span>
</td>
<td class="num">$ (25,442)<span></span>
</td>
<td class="num">$ (33,048)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454736000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>ATM Facility</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th">
<div>Common Stock </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th">
<div>Additional Paid-in Capital </div>
<div>ATM Facility</div>
</th>
<th class="th"><div>Accumulated Other Comprehensive Loss Investments</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">$ (9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (315,921)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(55,512)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(55,512)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">958<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercises of stock options</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">852,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue', window );">Exercises of common stock warrants</a></td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">468<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,645,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants</a></td>
<td class="nump">72,543<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 72,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,449,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="num">(9,227)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(315,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,954)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">49,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(396,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171,978,799<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">9,270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">380,531<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(371,433)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(25,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25,442)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock and common stock warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,482,152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock and common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">188,460,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">49,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">446,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(396,875)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(807)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(807)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">172,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(317,064)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">171,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">487,768<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(316,257)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Exercise of common stock warrants (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="num">$ (281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">142,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="num">(349,024)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">172,797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">489,662<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(317,064)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(31,960)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,960)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation</a></td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized loss of investments</a></td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(281)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 142,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,464<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (281)<span></span>
</td>
<td class="num">$ (349,024)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Exercise Of Warrants, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459785664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS&#8217; EQUITY (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance costs</a></td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459956320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (32,767)<span></span>
</td>
<td class="num">$ (80,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">3,696<span></span>
</td>
<td class="nump">2,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(50,200)<span></span>
</td>
<td class="nump">61,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Intangibles impairment charge</a></td>
<td class="nump">27,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable (net)</a></td>
<td class="nump">20,939<span></span>
</td>
<td class="num">(2,303)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="num">(10,565)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">17,719<span></span>
</td>
<td class="num">(20,287)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent', window );">Long term prepaid expenses</a></td>
<td class="nump">7,192<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized loss on marketable securities</a></td>
<td class="num">(281)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,186)<span></span>
</td>
<td class="num">(1,875)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="nump">17,654<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="num">(1,500)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(1,441)<span></span>
</td>
<td class="num">(41,616)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchase of marketable securities</a></td>
<td class="num">(89,095)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(89,095)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash Flows from Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock under ATM Offering, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">136,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercises of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercises of common stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">469<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">137,312<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="num">(90,536)<span></span>
</td>
<td class="nump">95,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - beginning of period</a></td>
<td class="nump">162,656<span></span>
</td>
<td class="nump">55,409<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash - end of period</a></td>
<td class="nump">72,120<span></span>
</td>
<td class="nump">151,056<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">87<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of equipment included in accrued expenses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) of Prepaid Expenses, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Related To Adoption of Accounting Standard</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459170208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">DESCRIPTION OF BUSINESS</a></td>
<td class="text">DESCRIPTION OF BUSINESS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sesen Bio, Inc. ("Sesen" or the &#8220;Company&#8221;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#8217;s most advanced product candidate, Vicineum</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#8220;NMIBC&#8221;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#233;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#8220;CRL&#8221;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#8220;CMC&#8221;) issues pertaining to a recent pre-approval inspection and product quality.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Viventia Acquisition</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#8220;Selling Shareholders&#8221;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#8220;Clairmark&#8221;) (the &#8220;Share Purchase Agreement&#8221;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#8220;Viventia Acquisition&#8221;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#8220;Purchased Product&#8221;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that </span></div>became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493462503104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">BASIS OF PRESENTATION</a></td>
<td class="text">BASIS OF PRESENTATION<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim Financial Statements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#8220;SEC&#8221;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#8217; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#8217;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493465789072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461584128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECENT ACCOUNTING PRONOUNCEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract', window );"><strong>Accounting Standards Update and Change in Accounting Principle [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">RECENT ACCOUNTING PRONOUNCEMENTS</a></td>
<td class="text">RECENT ACCOUNTING PRONOUNCEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI https://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126986314&amp;loc=SL124402458-218513<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL122150809-237846<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL126838806-209984<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL126732908-238011<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983955&amp;loc=SL121967933-165497<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461576816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of the Company&#8217;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 10.2% as of June&#160;30, 2022 to 8.0% and 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).</span></div><div style="margin-bottom:10pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company&#8217;s weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $50.2&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461662544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Receivables [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">RECEIVABLES</a></td>
<td class="text">RECEIVABLES <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounts receivable balance as of June&#160;30, 2022 is $0.1&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#8220;Roche&#8221;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other receivable balance as of June&#160;30, 2022 is $14.0&#160;million compared to $3.5&#160;million as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The increase is driven by expected insurance recovery of $13.0&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $2.4&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -URI https://asc.fasb.org/subtopic&amp;trid=2196772<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461406720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses</a></td>
<td class="text">PREPAID EXPENSES The prepaid expenses balance as of June&#160;30, 2022 is $0.8&#160;million compared to $25.7&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $25.2&#160;million of prepaids during the three months ended June 30, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461576816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS AND GOODWIL</a></td>
<td class="text">INTANGIBLE ASSETS AND GOODWILL<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangibles</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#8217;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#8220;MAA&#8221;) to the European Medicines Agency (the &#8220;EMA&#8221;) for Vysyneum&#8482; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox </span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#8217;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#8217;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#8217;s intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#8217;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#8217;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461421200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES</a></td>
<td class="text">ACCRUED EXPENSES<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461519728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#8217;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#8217; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#8220;Securities Litigation&#8221;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#8220;Lead Plaintiffs&#8221;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#8220;Amended Complaint&#8221;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#8217;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#8217;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#8217;s board of directors and certain of its officers (the &#8220;State Derivative Litigation&#8221;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">treatment of BCG-unresponsive NMIBC. The D&#8217;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#8217; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#8220;Federal Derivative Litigation&#8221;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $21.6&#160;million to litigation related liability. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Executive Employment Agreements</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461506320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,000 at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,100 at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $83,000 and $165,000 for the three and six months ended June&#160;30, 2022, respectively, and $84,000 and $166,000 for the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The asset component of the Company&#8217;s operating leases is recorded as operating lease right-of-use assets and reported within <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_4843e629-dcdb-4616-b8a6-a27047f3d904"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_97400fbf-3c91-4d39-b5d3-04d3e2f63a2e">other assets</span></span> on the Company's condensed consolidated balance sheets. The right of use asset total was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. The short-term lease liability is recorded in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_8d631678-1039-4b69-9e83-f467e7b5b77b"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_bedfdad2-e676-46e0-be70-8fe59f2f9fc1">other current liabilities</span></span> and the long-term lease liability is recorded in other liabilities on the Company&#8217;s condensed consolidated balance sheets. The short-term lease liability was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $2,200 and $21,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461568688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">STOCKHOLDERS' EQUITY <div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Financings</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ATM Offering</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into an Open Market Sale Agreement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#8220;ATM Offering&#8221;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#8217;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and six months ended June&#160;30, 2022. The Company raised $136.8&#160;million of net proceeds from the sale of 47.1&#160;million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021. The Company raised $64.3&#160;million of net proceeds from the sale of 16.5&#160;million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0&#160;million and $4.2&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">during the three and six months ended June&#160;30, 2021, respectively.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval by the Company&#8217;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approximately 199&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021</span><span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:9pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#8217;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Warrants</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#8217;s Own Equity. The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):</span></div><div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461662544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">EARNINGS (LOSS) PER SHARE</a></td>
<td class="text">EARNINGS (LOSS) PER SHARE<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#8217;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461391600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">SHARE-BASED COMPENSATION</a></td>
<td class="text">SHARE-BASED COMPENSATION<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:238.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#8220;evergreen&#8221; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#8217;s stockholders in May 2021, the Company&#8217;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.1&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.6 million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#8220;Retention Program&#8221;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#8217;s common stock. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#8217;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#8220;PSU&#8221;) award equal to the value of approximately fifty percent of then-current base salary. The fair value of PSUs at the grant date was $0.4&#160;million. Each PSU represents a contingent right to receive one share of the Company&#8217;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $87,000, 20% of the PSU awards. Therefore, $11,000 and $33,000 have been expensed during the three and six months ended June 30, 2022, respectively and $54,000 remains measured but unrecognized.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2009 Stock Incentive Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-of-Plan Inducement Grants</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized share-based compensation expense, related to stock options, of $1.2 million and $2.5 million for the three and six months ended June&#160;30, 2022, respectively and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.3 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.2 million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $8.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.36 years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $0.46 and $2.17, respectively. No stock options were exercised during the six months ended June 30, 2022. </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units and Performance Stock Units </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not grant any RSUs or PSUs during the six months ended June 30, 2021. </span></div>The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively. There was no shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $3.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461448096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFIT PLANS</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2014 Employee Stock Purchase Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plans</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States - 401(k) Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Canada - Defined Contribution Plan</span></div>The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461473856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $4.0 million as an income tax benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#8220;Qilu&#8221;) (the &#8220;Qilu License Agreement&#8221;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461448096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementTextBlock', window );">LICENSE AGREEMENTS</a></td>
<td class="text">LICENSE AGREEMENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Zurich</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#8220;Zurich License Agreement&#8221;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to meeting a development milestone, (the submission of the Company&#8217;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#8217;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with Micromet</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#8220;Micromet License Agreement&#8221;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#8364;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.5&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#8364;50,000 (approximately $52,148 at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#8364;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ecember 2020. The Company recorded an expense of &#8364;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#8482; in the first quarter of 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">License Agreement with XOMA</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#8220;XOMA License Agreement&#8221;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#8217;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Out-License Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Roche License Agreement </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the Company entered into the license agreement with Roche (the &#8220;Roche License Agreement&#8221;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#8217;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#8220;Roche Licensed Product&#8221;) and pursue ongoing patent prosecution, at its cost.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financial Terms</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provisions of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounting Standards Codification 606, Revenue from Contracts with Customers ("</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 606&#8221;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Buy-Out Options</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche License Agreement provides for two &#8220;option periods&#8221; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#8220;Initiation&#8221;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#8217;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#8217;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Termination</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. See further discussion in Note 19. "Subsequent Events".</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS Business Development Partnership Agreements</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Qilu License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to develop, manufacture and commercialize</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vicineum (the &#8220;Qilu Licensed Product&#8221;) for the treatment of NMIBC and other types of cancer (the &#8220;Field&#8221;) in China, Hong Kong, Macau and Taiwan ("Greater China&#8221;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#8221;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#8220;Royalty Terms&#8221;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#8217;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MENA License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $1.5&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 2022, the Company terminated the MENA License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">EIP License Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 5, 2021, the Company entered into an exclusive license agreement with E&#304;P Eczac&#305;ba&#351;&#305; &#304;la&#231; Pazarlama A.&#350;., (&#8220;EIP&#8221;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#8220;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No initial transaction price was estimated by management;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> therefore, no revenue was recorded </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. </span></div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30</span>, 2022, the Company terminated the EIP License Agreement as a result of the Company&#8217;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461473856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">RESTRUCTURING AND RELATED ACTIVITIES</a></td>
<td class="text">RESTRUCTURING AND RELATED ACTIVITIES<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#8220;2021 Restructuring Plan&#8221;). </span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2021 Restructuring Plan included a reduction in the Company&#8217;s workforce by 18 positions (or approximately 35% of the Company&#8217;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of September 2022.</span></div>Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461450096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text">SUBSEQUENT EVENTS<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vicineum</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#8217;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#8217;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business Development Partnerships</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 Restructuring Plan</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#8220;2022 Restructuring Plan&#8221;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#8217;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8&#160;million</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sale of Legacy Technology to Roche</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, the Company executed an asset purchase agreement (the &#8220;Roche Asset Purchase Agreement&#8221;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payment to the Company upon Roche&#8217;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities and Derivative Litigation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">will cause the Company to adopt certain enhancements to the Company&#8217;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#8217;s stockholders, court approval. </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Transfer to Nasdaq Capital Market </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) to transfer the listing of the Company&#8217;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#8220;Approval&#8221;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#8220;SESN&#8221;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#8217;s corporate governance requirements.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#8217;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493460034080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#8217;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Translation</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The functional currency of the Company and each of its subsidiaries is the US dollar.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adopted in 2022</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020, the FASB issued ASU No. 2020-06, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt&#8212;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#8217;s Own Equity </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2020-06")</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2020-06 simplifies the complexity associated with applying US </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#8217;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the FASB issued ASU No. 2021-04,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">("ASU 2021-04")</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASU 2021-04 clarifies and reduces diversity in an issuer&#8217;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#8217;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of the Company&#8217;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Level 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. </span></div>Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#8217;s own assumptions, based on the best information available, including the Company&#8217;s own data.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461458224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of Carrying Amounts and Fair Values of Financial Instruments Measured</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:13pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,765&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,095&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.473%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value Measurement Based on</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Quoted Prices in Active<br/>Markets<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Other Observable<br/>Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Significant Unobservable<br/>Inputs<br/>(Level&#160;3)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds<br/>(cash equivalents)</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock', window );">Summary of Contingent Consideration Liability</a></td>
<td class="text">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,200)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,800</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461575504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock', window );">Schedule of Composition of Intangible Assets</a></td>
<td class="text">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D intangible assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vicineum European Union rights</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Intangibles</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,700</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).</span></div><div style="text-align:center;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"><tr><td style="width:1.0%"/><td style="width:81.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December&#160;31, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,064&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Impairment loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,064)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461576816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Expenses</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"><tr><td style="width:1.0%"/><td style="width:65.015%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.428%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.626%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,847&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,841&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payroll-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,099&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,967&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring charge related</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Legal expenses, including preliminary litigation settlement </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,344&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Accrued Expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,851</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,255</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493465712544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Summary of Common Stock</a></td>
<td class="text">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"><tr><td style="width:1.0%"/><td style="width:67.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.097%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.100%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock issued</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,464</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares of common stock reserved for issuance for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for grant under 2014 Stock Incentive Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,076&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,933&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares available for sale under 2014 Employee Stock Purchase Plan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shares of common stock issued and reserved for issuance</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">230,263</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">229,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants Outstanding and Warrant Activity</a></td>
<td class="text">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):<div style="margin-bottom:10pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.971%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.588%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.518%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Exercised)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Cancelled)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mar-2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.55*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May-2015</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2014</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$11.04</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nov-2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">199</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#8220;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#8217; Equity (Deficit)&#8221; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461480016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Potentially Dilutive Securities</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:45.958%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs and PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,423</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,743</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493452587280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Share-Based Compensation Expense</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):</span></div><div style="margin-bottom:7pt;margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"><tr><td style="width:1.0pt"/><td style="width:238.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.75pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:1.00pt"/><td style="width:1.0pt"/><td style="width:1.0pt"/><td style="width:63.25pt"/><td style="width:1.0pt"/></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>&#160;June 30,</span></td></tr><tr style="height:17pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">473&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">975&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:17pt"><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Share Based Compensation </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,802</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,259</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,696</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,217</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company&#8217;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:</span></div><div style="margin-bottom:6pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"><tr><td style="width:1.0%"/><td style="width:41.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.593%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares under Option<br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining<br/>Contractual&#160;<br/>Life<br/>(in years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.93</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled or forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.20</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at June 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.83</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable at June 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,555&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.11</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option</a></td>
<td class="text"><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:</span></div><div style="margin-bottom:7pt;margin-top:15pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"><tr><td style="width:1.0%"/><td style="width:64.733%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.633%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.568%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair market value</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$3.34</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.04</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of the Status of Restricted Stock Units</a></td>
<td class="text"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:</span></div><div style="margin-bottom:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"><tr><td style="width:1.0%"/><td style="width:60.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.521%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.524%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted Stock Units     <br/>(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,041&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.80</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted RSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.68</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled RSU</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(143)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.75</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted PSU</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.67</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested at June&#160;30, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,063</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$0.72</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458454592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Components of Pre-tax Income (Loss)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of the Company's loss before income taxes by country (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"><tr><td style="width:1.0%"/><td style="width:63.870%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.265%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.548%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.817%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Country:</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55,939)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,210)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canada</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,456)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Loss before Income Taxes</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(36,642)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(80,666)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Components of Income Tax Benefit (Provision)</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's tax benefit (provision) is comprised of the following components (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:63.579%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.187%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.545%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current tax benefit (provision)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Foreign</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(288)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,875</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(288)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Deferred Tax Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's deferred tax liability is comprised of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:63.632%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.161%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.163%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,969</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454657904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:81.252%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.548%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance as of December 31, 2021</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,497&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash payments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,103)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2022</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458808928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>DESCRIPTION OF BUSINESS (Details) - Viventia Bio Inc.<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare', window );">Shares of common stock issued to the selling shareholders (in shares) | shares</a></td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Percentage of voting interests acquired</a></td>
<td class="nump">19.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales', window );">Period during which quarterly earn-outs are payable after date of net sales</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations', window );">Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods', window );">Percentage of net sales of quarterly earn-out payments during earn-out periods</a></td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | United States</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member', window );">Vicinium | Collaborative Arrangement, Revenue based on Specified Milestone | Japan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct', window );">One-time milestone payment upon first sale of product</a></td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_ViventiaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454601488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Quoted Prices in Active Markets (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="nump">52,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">40,765<span></span>
</td>
<td class="nump">16,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">89,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459027264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in the fair value of contingent consideration</a></td>
<td class="num">$ (37,300)<span></span>
</td>
<td class="nump">$ 13,600<span></span>
</td>
<td class="num">$ (50,200)<span></span>
</td>
<td class="nump">$ 61,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WeightedAverageCostOfCapital', window );">Weighted-average cost of capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="nump">0.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember', window );">Discount Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems', window );"><strong>Fair Value, Option, Quantitative Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Contingent consideration liability, measurement input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.093<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WeightedAverageCostOfCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Cost of Capital</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WeightedAverageCostOfCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionQuantitativeDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionQuantitativeDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458746544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details) - Significant Unobservable Inputs (Level&#160;3)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Beginning balance</a></td>
<td class="nump">$ 52,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent', window );">Change in fair value of contingent consideration</a></td>
<td class="num">(50,200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Ending balance</a></td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454524528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RECEIVABLES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,565)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember', window );">Litigation Settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember', window );">German VAT recovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Decrease in other receivables</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Accounts, Notes, Loans and Financing Receivable [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_LitigationSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=sesn_GermanVATRecoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493466181872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PREPAID EXPENSES (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="nump">$ 25.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ExpensesPreviouslyClassifiedAsPrepaid', window );">Expenses previously classified as prepaid</a></td>
<td class="nump">$ 25.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ExpensesPreviouslyClassifiedAsPrepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses Previously Classified as Prepaid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ExpensesPreviouslyClassifiedAsPrepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454362192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details) - IPR&amp;D intangible assets: - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">European Union | Vicinium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Total Intangibles</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459684704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="nump">$ 27,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 27,764<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 31,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangibles impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage', window );">Impairment of intangible assets risk adjusted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Impairment of Intangible Assets, Cost of Capital, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459784320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Beginning Balance</a></td>
<td class="nump">$ 13,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment loss</a></td>
<td class="num">(13,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, Ending Balance</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454480880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES - Components of Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development</a></td>
<td class="nump">$ 1,847<span></span>
</td>
<td class="nump">$ 1,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll-related expenses</a></td>
<td class="nump">3,099<span></span>
</td>
<td class="nump">2,967<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedRestructuringChargesRelatedCurrent', window );">Restructuring charge related</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccruedLegalFees', window );">Legal expenses, including preliminary litigation settlement</a></td>
<td class="nump">22,477<span></span>
</td>
<td class="nump">1,344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total Accrued Expenses</a></td>
<td class="nump">$ 29,851<span></span>
</td>
<td class="nump">$ 8,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedLegalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedLegalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccruedRestructuringChargesRelatedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Restructuring Charges Related, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccruedRestructuringChargesRelatedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454360656">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>lawsuit</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationReserve', window );">Estimated litigation liability | $</a></td>
<td class="nump">$ 21.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493457891744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASES (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>CAD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost, including related operating cost</a></td>
<td class="nump">$ 84,000<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use asset</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Short term lease liability</a></td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeasesAreaOfOfficeSpace', window );">Office space (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="nump">31,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,100<span></span>
</td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses', window );">Related operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,200<span></span>
</td>
<td class="nump">14,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OperatingLeaseMonthlyRent', window );">Monthly rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Monthly Rent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeaseOtherMonthlyOperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Other Monthly Operating Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeaseOtherMonthlyOperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OperatingLeasesAreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Area Of Office Space</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OperatingLeasesAreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458439296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Equity Financing (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Nov. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember', window );">ATM Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction', window );">Aggregate sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance', window );">Shares reserved for future issuance amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 97.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockCommissionFixedRate', window );">Commission fixed rate</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.3<span></span>
</td>
<td class="nump">$ 136.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of units issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SaleOfStockWeightedAveragePricePerShare', window );">Weighted-average stock price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts', window );">Issuance of common stock, issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockCommissionFixedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Commission Fixed Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockCommissionFixedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Sales Price In Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Remaining Shares Amount Available For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SaleOfStockWeightedAveragePricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Weighted-Average Price Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SaleOfStockWeightedAveragePricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, New Issues, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=sesn_ATMFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454510800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454671904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>vote </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 03, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 02, 2021 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_NumberofVotesEntitledForEachShare', window );">Number of votes | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_NumberofVotesEntitledForEachShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Votes Entitled For Each Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_NumberofVotesEntitledForEachShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459714640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares of common stock issued (in shares)</a></td>
<td class="nump">199,463,645<span></span>
</td>
<td class="nump">199,463,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CommonStockSharesIssuedAndReservedForFuture', window );">Total shares of common stock issued and reserved for issuance (in shares)</a></td>
<td class="nump">230,263,000<span></span>
</td>
<td class="nump">229,640,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">17,161,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">8,063,000<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Shares available for grant under 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">3,076,000<span></span>
</td>
<td class="nump">8,933,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Shares available for sale under 2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract', window );"><strong>Shares of common stock reserved for issuance for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="nump">2,300,000<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockSharesIssuedAndReservedForFuture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Shares Issued And Reserved For Future</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockSharesIssuedAndReservedForFuture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_SharesOfCommonStockReservedForIssuanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares Of Common Stock Reserved For Issuance [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_SharesOfCommonStockReservedForIssuanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458338048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY - Warrants (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member', window );">Warrants, Expiring March 2023</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member', window );">Warrants, Expiring November 2022</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member', window );">Warrants, Expiring November 2024, Issued May 2015</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.83<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member', window );">Warrants, Expiring November 2024, Issued November 2014</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price per warrant (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 11.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_WarrantOrRightOutstandingRollForward', window );"><strong>Warrant Or Right Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, beginning balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod', window );">Warrants Issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Warrants Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod', window );">Warrants Cancelled (in shares)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding, ending balance (in shares)</a></td>
<td class="nump">27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightIssuedDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightIssuedDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right Number Of Expirations During The Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period Shares Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_WarrantOrRightOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrant Or Right Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_WarrantOrRightOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringMarch2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedMay2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=sesn_WarrantsExpiringNovember2024IssuedNovember2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454477696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNINGS (LOSS) PER SHARE (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">25,423<span></span>
</td>
<td class="nump">18,743<span></span>
</td>
<td class="nump">25,423<span></span>
</td>
<td class="nump">18,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">199<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">17,161<span></span>
</td>
<td class="nump">17,349<span></span>
</td>
<td class="nump">17,161<span></span>
</td>
<td class="nump">17,349<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)</a></td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,063<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454578784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,802<span></span>
</td>
<td class="nump">$ 1,259<span></span>
</td>
<td class="nump">$ 3,696<span></span>
</td>
<td class="nump">$ 2,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="nump">975<span></span>
</td>
<td class="nump">386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total Share Based Compensation</a></td>
<td class="nump">$ 1,329<span></span>
</td>
<td class="nump">$ 1,052<span></span>
</td>
<td class="nump">$ 2,721<span></span>
</td>
<td class="nump">$ 1,831<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493453928064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,802,000<span></span>
</td>
<td class="nump">$ 1,259,000<span></span>
</td>
<td class="nump">$ 3,696,000<span></span>
</td>
<td class="nump">$ 2,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost, non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period unvested stock to be recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 4 months 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of stock options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="nump">$ 2.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember', window );">Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,161,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance', window );">Number of shares reserved for issuance (in shares)</a></td>
<td class="nump">12,000,000<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting on the First Anniversary of Date of Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | 2014 Stock Incentive Plan | Vesting at End of Each Successive Three-Month Period Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of original number of shares subject to the option vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options | Stock Incentive Plan 2009</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested stock options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,161,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Unvested grant restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Retention Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward', window );">Shares received per award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary', window );">Percent of base salary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent', window );">Achievement deemed probable, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock, Additional Capital Shares Reserved for Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlanTwoThousandFourteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_StockIncentivePlan2009Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_RetentionProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_RetentionProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454634784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Stock Options (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares under Option (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">15,703,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Canceled or forfeited (in shares)</a></td>
<td class="num">(53,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">17,161,000<span></span>
</td>
<td class="nump">15,703,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares)</a></td>
<td class="nump">9,555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 1.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Cancelled or forfeited (in dollars per share)</a></td>
<td class="nump">1.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">1.83<span></span>
</td>
<td class="nump">$ 1.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share)</a></td>
<td class="nump">$ 1.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual Life (in years), Outstanding</a></td>
<td class="text">7 years 8 months 19 days<span></span>
</td>
<td class="text">8 years 10 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-average Remaining Contractual Life (in years), Exercisable</a></td>
<td class="text">7 years 1 month 9 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493458438224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue', window );">Fair market value (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Grant exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="nump">$ 3.34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years 14 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">71.80%<span></span>
</td>
<td class="nump">74.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454515968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, beginning balance (in shares)</a></td>
<td class="nump">3,041,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, ending balance (in shares)</a></td>
<td class="nump">8,063,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested beginning balance (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested ending balance (in dollars per share)</a></td>
<td class="nump">$ 0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSU</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">4,161,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Cancelled RSU (in shares)</a></td>
<td class="num">(143,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Cancelled RSU (in dollars per share)</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,004,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 0.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454637024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EMPLOYEE BENEFIT PLANS (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Feb. 28, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined contribution retirement plan, maximum employee contribution deferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee', window );">Discretionary match per participating employee, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA', window );">Canada</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Employer matching contribution, percent of employees' eligible compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember', window );">2014 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares of common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized (in shares)</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate', window );">Common stock purchase price, discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock available for sale (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discount rate from fair value on purchase date that participants pay for shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sesn_A2014EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493454704512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Pre-tax Income (Loss) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Pre-tax income (loss) U.S.</a></td>
<td class="num">$ (55,939)<span></span>
</td>
<td class="num">$ (21,210)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Pre-tax income (loss) Canada</a></td>
<td class="nump">19,297<span></span>
</td>
<td class="num">(59,456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Total Loss before Income Taxes</a></td>
<td class="num">$ (36,642)<span></span>
</td>
<td class="num">$ (80,666)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461377696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Components of Income Tax Provisions (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current tax benefit (provision)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current benefit (provision)</a></td>
<td class="num">$ (3,875)<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461398784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES - Components of Deferred Tax Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities, Gross [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts', window );">IPR&amp;D</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,969<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493453809040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit (provision) from income taxes</a></td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,875<span></span>
</td>
<td class="num">$ (288)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncreaseDecreaseInDeferredTaxLiability', window );">Increase (decrease) in deferred tax liability</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income Taxes Paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=sesn_ViciniumMember', window );">Vicinium | Europe | IPR&amp;D intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsCurrent', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Impairment of intangible assets</a></td>
<td class="nump">$ 14,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_IncreaseDecreaseInDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_IncreaseDecreaseInDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_ViciniumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_ViciniumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493445789728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LICENSE AGREEMENTS (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="9">3 Months Ended</th>
<th class="th" colspan="3">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2016 </div>
<div>USD ($) </div>
<div>period</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 08, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 15, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,234,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,544,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payments for restructuring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd. | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="nump">2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount', window );">Total milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationRoyaltyPaymentPercent', window );">Royalty payment, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_BusinessCombinationMilestonePayments', window );">Business combination, milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember', window );">University of Zurich | Collaborative Arrangement, Revenue Based on Clinical Development Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember', window );">Micromet AG</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchievementExpense', window );">Expenses related to achievement of development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">&#8364; 500<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">&#8364; 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="nump">&#8364; 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent', window );">License agreement, royalty payment, reduction, conditions not met</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseMaintenanceFees', window );">License maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52,148<span></span>
</td>
<td class="nump">&#8364; 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember', window );">XOMA Ireland Limited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales', window );">Royalty payment obligation, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed', window );">Third party maximum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum', window );">Third party minimum ownership, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="nump">1.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementUpfrontFee', window );">License agreement, up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAdditionalUpFrontFee', window );">License agreement, additional up-front fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementOptionPeriods', window );">License agreement, option periods | period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod', window );">License agreement, buyout amount under first option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised', window );">License agreement, period to pay buyout option once exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod', window );">License agreement, buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct', window );">Buyout amount under second option period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementMilestoneAchieved', window );">Milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_AccountsReceivablePaymentTerms', window );">Payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved', window );">Proceeds from milestone achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | EBI-031 | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementRoyaltyRate', window );">License agreement, royalty rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | First Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on development milestone | EBI-031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative Arrangement, Revenue Based on Development Milestone, Phase II</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on regulatory milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Collaborative arrangement, revenue based on commercialization milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_RocheMember', window );">Roche | Second Indication</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone', window );">License agreement, amount payable upon achievement of specified milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember', window );">Qilu Pharmaceutical Co., Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_CollaborativeArrangementRoyaltyPeriod', window );">Royalty period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember', window );">MENA License Agreement | Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">License and related revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Transaction price</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember', window );">Eczacibasi Pharmaceuticals Marketing Agreement | TURKEY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OrganizationAndBasisOfPresentationLineItems', window );"><strong>Organization And Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_RoyaltyRevenuePercentage', window );">Royalty revenue, percentage</a></td>
<td class="nump">0.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_AccountsReceivablePaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, Payment Terms</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_AccountsReceivablePaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Long-term Purchase Commitment, Milestone Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_BusinessCombinationRoyaltyPaymentPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Royalty Payment Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_BusinessCombinationRoyaltyPaymentPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_CollaborativeArrangementRoyaltyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Royalty Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_CollaborativeArrangementRoyaltyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAdditionalUpFrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Additional Up-Front Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAdditionalUpFrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Amount Payable Upon Achievement of Specified Milestone</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under First Option Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementMilestoneAchievementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Milestone Achievement Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementMilestoneAchievementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementOptionPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Option Periods</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementOptionPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty On Net Product Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage of Royalty on Net Product Sales, Minimum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Period to Pay Buyout Option Once Exercised</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementProceedsFromMilestoneAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Proceeds From Milestone Achieved</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementProceedsFromMilestoneAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Royalty Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseAgreementUpfrontFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Agreement, Up-front Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseAgreementUpfrontFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_LicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>License Maintenance Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_LicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OrganizationAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization And Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OrganizationAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherReceivableAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Receivable, Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherReceivableAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue Recognition, Milestone Method, Potential Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_RoyaltyRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Revenue, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_RoyaltyRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_UniversityOfZurichMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MicrometAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MicrometAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_XOMAIrelandLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_RocheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_RocheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=sesn_EBI031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=sesn_EBI031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_FirstIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=sesn_SecondIndicationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_QiluPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_MENALicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=sesn_EczacibasiPharmaceuticalsMarketingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_TR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_TR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493459170208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Aug. 30, 2021 </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Number of positions eliminated</a></td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Number of positions eliminated, period percent</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493461398784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RESTRUCTURING AND RELATED ACTIVITIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning Balance</a></td>
<td class="nump">$ 1,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Cash payments</a></td>
<td class="num">(1,103)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending Balance</a></td>
<td class="nump">$ 394<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140493466214752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SUBSEQUENT EVENTS (Details) - Subsequent Event - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 15, 2022</div></th>
<th class="th"><div>Aug. 08, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement', window );">Payments to company upon execution of the Roche Asset Purchase Agreement</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_sesn_OtherReceivableAssetPurchaseAgreement', window );">Other receivable, asset purchase agreement</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_OtherReceivableAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Receivable, Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_OtherReceivableAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sesn_ProceedsFromExecutionOfAssetPurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Execution Of Asset Purchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sesn_ProceedsFromExecutionOfAssetPurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sesn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>sesn-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:sesn="http://www.sesenbio.com/20220630"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="sesn-20220630.xsd" xlink:type="simple"/>
    <context id="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id869177d11624fb384af0cf8700149ba_I20220801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-08-01</instant>
        </period>
    </context>
    <context id="i816282644abc45028662a05fb3344b4b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i08198d39a53746e381e9ad22e2530e7c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0888396debb34c04a3b1ce7017d15b49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e2dde9a518a491ebd8912a185f23cd6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9dfef576366a44c8899c23968e5a7571_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5e31cbf599b140739ed935ff1dd609b8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia9495f0a57df45ff8db57ca5375f6705_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i64fafc918b1a455ea5d13849a58f83dc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib0975aa547f74b7a9de06d3efa3be13c_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ibad650e0476f4f16801d09e1becece4e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib01a1af0204e41fd93a01011d3d198fa_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i14a46440132b42f0b7fa05821b7ebc4f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i5de9e1ce23744a739794e84c9513c251_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c2011e9ea8d46969474d1ff815da0fb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if5212a49218248398de938ab0ff078dc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="idad59db36cee439984f3d4ad8b4fb9b5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic947583800d54749af298a1e2b9bc920_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2ee39dd3da244ec9bcff222871e71116_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i117a5180e4eb4c3391864589aa813213_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7012d9b8cefc416d86192851d3aa476f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i171789775ea34e329cab101dfc95862e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3b5d4ce18c0f4291b85fddcf3869fa34_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idea9cc2fd581441895f394010022516a_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iec33aebf75ea4629a482858c3bee531c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i52eaa414326e448c937bf26df0576971_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib764d38ef5924a26af92778deac4a289_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib39f955c83294b19b2d55b161745582b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i30af2746204648089c84cb29d5101717_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ib30024337b1546b7bd2a070c42de470b_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i9dd0f583a45649359ab4f630a2d1d044_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2eb92ef2739448ac91cb470697a88bf3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i8d04fd3863f8493db4c151a0f56ee9f6_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i9147fb1c8cf34577b359bd45f28c4a7c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ic3b387a8bf0243d9b0d1e9d51425a534_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i732a7b94c2394e6caed25b643f1504ce_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iae31b43c606e4c19b17a44b2508f083c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i62880df550724456b3e687c3c6d85445_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i73c2ea2a03e7419a8e4196a69096b610_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6d7821756c804d898a7d8834c7925d7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7984a6629ab74eb390c3df7ff75f05d2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0cd0bb43b0ee429f964e6eb8b8925e53_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iad1dbbda2c1f497da6b3ad0608eb76ac_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib07c0124fe234223a9d340e9c94f5559_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i407298c7856d4211867c26d5eaa28887_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="ief96b00f443a4686a885891ec4c615be_I20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="i19de5e3ec9b24f1ea8494afb290825f1_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i826b000227f54693aaaf1920a6d1aa63_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i0f56438c3aeb45edb4022475af4e3db5_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i4a90ce4acc1b4bf68182efbf79fd5720_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:ViventiaBioInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i00b74714225f4d449b61808db2c2c804_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia4884e6cf1834287a8e4032056a092dd_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ba330c2936d403bb2d4a10535dd51e4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iced2721a212d43848f8133e3f4186dda_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i149ccd24ae824eb0955599b4c37f7358_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4e27122d96e44ef1888f4f1425b3c91c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb703a0172774df7b5fad376a5cac8da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8d011b45a374b0784b3c71627d06003_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie42072eca3cd43a19d6e850e7b53ebd2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc528568b4234010b987e7ed2c26110d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie23847c7ec884b868685a03832f736b6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icba9e1576f6248d4b9e8e786bce57457_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie44b4e5d665d480d86d36cea88a338ab_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia00d97ca9441426bb9adfaa45c3d754c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:LitigationSettlementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0c25a0b2ddf74ac2b722c896a5913d4c_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">sesn:GermanVATRecoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ifedd00e94bff4f138a71518235d8f0c2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifefc2cc3cebe45d78a99c0e68849b7ca_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie19452cececa4a96a54f4c9ced19321f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5913171b77dd4a8db206d874b45307ba_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90478a97ea0d40c7a94bea0d8f484eac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4e724420d5a41518add1245efed2632_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6f1af4670f5349589e2c8544533b3f92_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i000d73058a0b4403961f473fd89fbb67_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5ac9bf36e8db4b3398a967b1e06528c6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c8d5912a42e4ad2833bfc6f61c043f2_I20191129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-29</instant>
        </period>
    </context>
    <context id="i78ad6147eb974d38affb24031a858c3d_D20210601-20210731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="i5a0705a329ea41ed96157e39c6c49855_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7eda749d94fb48398a0924800d09ac3d_D20211129-20211129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-29</startDate>
            <endDate>2021-11-29</endDate>
        </period>
    </context>
    <context id="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">sesn:ATMFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i75b910d027ce46cda21c3171ea8cf644_I20210502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-02</instant>
        </period>
    </context>
    <context id="ice21145cb84b458994eb2b4953cd1b79_I20210503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2021-05-03</instant>
        </period>
    </context>
    <context id="i4e03d5c4d214485ca8ef8d4f2b1c22b5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie93e937a2ca743998879eaab73aba23e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78713773a6f644369d0e8eec39199597_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if34834f39ec94e458f57f689cde2c633_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i81b6cc446ab44fa08e173a103f7b7289_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7ba233a853c42b89272f4f6b9633315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i90db0d74d54b4275b25f685df0f5b309_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6074b6e43f5c46f5a2bb46e072ef5f2d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4996e48caa5c4590b4980c71c163ae64_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6b96cadcfc494bd094e17b7ef53a0601_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie6b33ca5238c45cc9793e8772152abcb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8b97f878936d417582c679e49408c3cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringMarch2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id796b6b8583646e18ef4317244b84a3a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i34c5a07fd1b449558c518b3bbcbe3efa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifaca184cb85744059ede4889bd0bec15_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i07151ff5feff4986a1a7cf1407f3f033_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedMay2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i89b961b26f78447680b3d6eea476fce2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7d480b8de55f4a309d196db12c0a8524_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">sesn:WarrantsExpiringNovember2024IssuedNovember2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2a77deceed914ab4aa6c3a9a9c4f3afa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ife468ed832424422bc39059d7df8b085_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0adbc934f3b24c239d0f1300083008f6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a25de0176e248178dc11989f74804f0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47327dd48deb4402885aa3afa6af22a2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifc6aa26487504d41b6a549bc657400e8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i19b7d9796cd54f35ba0a1cef95f329d2_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2c9a4489987e4bd2a05ab6cfd1a362f6_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i9a33702caa4644da8978da5e0013ddb8_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i67fcaaf0286a4c1783c880c53e54d424_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5e730560bfe346738f8e589866aba60d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6ad0ec9b6a7b42cdbf789fb6d8f39ca9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i568a2b3022284d34a0aff47db073a523_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i41e29d2263d34ad692781e2266eefd53_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec8d3d4dfe0d4122b647ec6d4619e69e_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia71281c8b42c4511ab6edd8ce3378ba3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cc85ab1a955410a8b2ba5d9aef9c0d5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id53e901c0ef94dd18db696d73878aa08_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55970a0d5f344348a35d5e2c4bd4282e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i84b0564ab20a40a485edffa15b757c33_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iee95e6730e374d6e9aab606275edaf82_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i342e97e8062b4c4cab492cc8c00c70d8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6db64e1a961546e3bd8121ee3879f09d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieac62593b40f4880b423bfc9580273ab_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i77bc1a747a0f4fdd9e81b59820c9d0e3_D20190601-20190630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="iacb6642dacce42dda98c5135fee1f003_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i05439e7daefd4ac8b3d2d78445d47366_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i08ec180c3533409b8010a63003f3a00d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib466f1439d304e268b42a9bfb03f0f4a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlanTwoThousandFourteenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8a67da80633540d9868f347e7148156e_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i177a51cfef854bb4a48b39dac3ead017_I20211001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-01</instant>
        </period>
    </context>
    <context id="i75b2d9dc879b4976951e57e3d6a98fe8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i570bf630b283493eb8aac676692c8fb5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6cc8c46f0ceb44d5806951413bb59ee1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic7729b36949f4e6f8b449bc2e11e0ac1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:RetentionProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:StockIncentivePlan2009Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i044e86b9b1004169acd873b958541512_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i66d0ce796f154e90aded5d0cbce94189_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i23ea04149ec74feea107a21a6ba9a68e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id3da850769cc4728a10aba8d8db52095_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia0710da839aa43a793cc2cb6c1c4a9b3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ica4c1635be564e9db6a99db680002144_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie8c92e1f22ad4644a192da4d2c4a4794_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib8f284269de6489baf1956eaba755358_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id083216cd3834a9a8398563d69c8b21d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i129a8282c6be44f2baa56e32efc338ec_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i11cba79393924023a9e75dd2910cde3a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8f9cc9d2301a4433a98cf0413fade87d_I20140228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-02-28</instant>
        </period>
    </context>
    <context id="ic63732dc872f413f8025dd7bf4720b9f_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i76c65c4ee1e64946ab281633bdefbe71_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iac5769fcff7b47898a71e23efd9d7b5a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sesn:A2014EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id065aa16b3944940b083af3709622dd4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic2092edc5bbb470eaa1bb592509fc775_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if2acfaa03f15458fb09624b5d55af0b1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:ViciniumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9efed9b3cf4e4e64b6b1d76a87c5d8a5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie802f22fd3164257a0a27630574179f1_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i854149fe8e0748178452739c0ae5c742_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:UniversityOfZurichMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MicrometAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:XOMAIrelandLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ifecdde588859469e8e663b340243baa1_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:FirstIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i4b29722132a2491b9d2cee4b49fb0c77_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i3d68c476afcf40a88a2b8fed6118ee9c_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="ia2a1e9da126143cfb0de4e11868d0606_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i8e7b4ebb5c66413dafd7bfce298dfeae_D20160801-20160831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-08-01</startDate>
            <endDate>2016-08-31</endDate>
        </period>
    </context>
    <context id="i3267071fa5d04b21a986ab51df8e6d15_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:SecondIndicationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i1ee271f6d7d2411fb58ddc98730fe4e1_D20160901-20160930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sesn:CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="i2df0e9d706854cfeb872dc1154160218_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i766fbeb7225c4f8d80f3cee6c943dbef_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i02e5980cf4114748bd928cad4eae85c4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i09f960acf0aa42bf81e936538879aed3_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia91fb5103aca4101b34beb81fb97be24_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i679f24e2f48e415897b49d6af88b722c_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ifd9b09daca514c3cad0def62ecf0ce84_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">sesn:EBI031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:RocheMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-01</startDate>
            <endDate>2016-06-30</endDate>
        </period>
    </context>
    <context id="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-15</instant>
        </period>
    </context>
    <context id="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="id66556ce8bf24b0293558cdda62bbe4b_D20200730-20200730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-30</startDate>
            <endDate>2020-07-30</endDate>
        </period>
    </context>
    <context id="i954601fe3b9448cbaecd65eed3c97e5d_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i1291fa4c92d24233b8c7dd158c7d657d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i93a8a67c88394769861872b5ee4d03a3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ia72f93a71c7a43cb954ae37e2265780b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sesn:QiluPharmaceuticalCoLtdMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i026b9908503a4d88b10ca249424b3644_D20201130-20201130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-30</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="i12906e74084048d2b9fe524e7469bfd5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib2e92c8a7aef406ca55775a1f5db7e70_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic828b0a647374e389c1cd7b05992e6a6_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:MENALicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ied4b92f7d8494337810a4188d290be4d_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="i6b11a504e94346c7b3df6f09cff921f5_D20210805-20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-05</startDate>
            <endDate>2021-08-05</endDate>
        </period>
    </context>
    <context id="i5f2b242b85564774a29503984368afdf_I20210805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">sesn:EczacibasiPharmaceuticalsMarketingAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:TR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-05</instant>
        </period>
    </context>
    <context id="if5efc2997de54bc79f8412086513351d_D20210830-20210830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
        </entity>
        <period>
            <startDate>2021-08-30</startDate>
            <endDate>2021-08-30</endDate>
        </period>
    </context>
    <context id="ic23bc63aeb3e40ed84c761fb713ce86a_D20220715-20220715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-15</startDate>
            <endDate>2022-07-15</endDate>
        </period>
    </context>
    <context id="ic081fe4045014466be04516c1871acf9_I20220808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001485003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-08</instant>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lawsuit">
        <measure>sesn:lawsuit</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="cad">
        <measure>iso4217:CAD</measure>
    </unit>
    <unit id="vote">
        <measure>sesn:vote</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="period">
        <measure>sesn:period</measure>
    </unit>
    <unit id="position">
        <measure>sesn:position</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF81LTEtMS0xLTgxNzIz_6aad6bff-20a1-46ec-b06d-83f3626c0bca">0001485003</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF82LTEtMS0xLTgxNzIz_143f0f15-e19f-4e61-8d86-956ce9345190">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF83LTEtMS0xLTgxNzIz_ebf73534-f052-4156-ae74-9bc13dd330fe">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF84LTEtMS0xLTgxNzIz_811799cb-eae9-4387-bac9-2c418fd2c195">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80L2ZyYWc6ODMwZDcwNmUyYTdkNGJlMWFmNGRhMjE5ODI1MTQyMzUvdGFibGU6NTdkYTVhNmQ4NDkxNDExMWFjMzRhMjBjZTA5ZjA3MGQvdGFibGVyYW5nZTo1N2RhNWE2ZDg0OTE0MTExYWMzNGEyMGNlMDlmMDcwZF85LTEtMS0xLTgxNzIz_4d996a33-5ab5-480a-ad3f-19420be17771">false</dei:AmendmentFlag>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_4947fedc-4360-4141-b0e3-0237b2c47548">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_c6767d49-0588-49f3-8fff-685b494e5363">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_d6497809-9e60-4366-b51d-775001f6d3f2">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0wLTEtMS04MTcyMw_dffcdb59-fa88-4ed6-aabc-b93cd31c5568">http://fasb.org/us-gaap/2022#LicenseMember</us-gaap:RevenueFromContractWithCustomerProductAndServiceExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_4843e629-dcdb-4616-b8a6-a27047f3d904">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_97400fbf-3c91-4d39-b5d3-04d3e2f63a2e">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_8d631678-1039-4b69-9e83-f467e7b5b77b">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_bedfdad2-e676-46e0-be70-8fe59f2f9fc1">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV81NDk3NTU4MTU4ODM_911537a9-dd1e-4f88-9c04-b78a3721c533">10-Q/A</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6NDM2NDk3YjY4MzJhNDhhYWExY2NiMjYxZmY5ZTVkMGMvdGFibGVyYW5nZTo0MzY0OTdiNjgzMmE0OGFhYTFjY2IyNjFmZjllNWQwY18wLTAtMS0xLTgxNzIz_d142ce40-5479-46e9-9de5-0fc3dec1ac0f">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xMzY_2794d8f5-dfac-42c8-a5fc-13eecf4c60fa">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MGYyNjdlYzFhY2MyNDViYmExNjlkNGI2NGVkODMyZmIvdGFibGVyYW5nZTowZjI2N2VjMWFjYzI0NWJiYTE2OWQ0YjY0ZWQ4MzJmYl8wLTAtMS0xLTgxNzIz_f18887f4-ab28-45c1-98cb-2ce4dc6b2a4d">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg0_70744e98-7708-42b3-a6fa-f8d0a6f8ead7">001-36296</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg1_f378958b-9ce0-4ec4-ada3-21305b2d5210">Sesen Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6YzNkNjE2NDQ4NmQ4NDgwYTljYTQzMzZjNzk0Njg0NmQvdGFibGVyYW5nZTpjM2Q2MTY0NDg2ZDg0ODBhOWNhNDMzNmM3OTQ2ODQ2ZF8wLTAtMS0xLTgxNzIz_3dfc2601-d90d-4138-80cb-f1fe19f21f91">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6YzNkNjE2NDQ4NmQ4NDgwYTljYTQzMzZjNzk0Njg0NmQvdGFibGVyYW5nZTpjM2Q2MTY0NDg2ZDg0ODBhOWNhNDMzNmM3OTQ2ODQ2ZF8wLTEtMS0xLTgxNzIz_84779fdd-2c6b-4f3e-9cbb-d9a63a3a6ec4">26-2025616</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfNA_b4e3145f-e2b9-49d7-9161-fa3f63860c46">245 First Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfOA_7cc0cddb-3350-4d68-a7b5-fcff2fcea7a6">Suite 1800</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfMTE_8a45c5a5-19d7-4d5b-9b40-666abd9dfc93">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTAtMS0xLTgxNzIzL3RleHRyZWdpb246YjFjMzg1ZmQ1ZGNjNDdjZjgyZWEzZjEwMjQ2ZGU2OGJfMTU_197634ef-c03a-4ef2-8b23-6c624ea531f4">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGE0YTk2N2VhOWRjNDMwZjkyMTAzYmZiZDU3M2JkMDUvdGFibGVyYW5nZTo4YTRhOTY3ZWE5ZGM0MzBmOTIxMDNiZmJkNTczYmQwNV8wLTEtMS0xLTgxNzIz_8f747c97-a03d-4680-9822-23be7f4bbeb2">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8zNTY_e1613a07-b392-4978-ba54-4a24ba0853e3">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg5_667b21e5-4647-48ae-83ac-190d0be498f1">444-8550</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTAtMS0xLTgxNzIz_848426a3-3a8b-4d88-a969-380ad7b02cb7">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTEtMS0xLTgxNzIz_b76384cf-116c-4aa6-8c19-fa460f06b01b">SESN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6MTVmYzk1ZTcwZjM1NDQwNmE1NWNkMmU3MjhiZDQzOGMvdGFibGVyYW5nZToxNWZjOTVlNzBmMzU0NDA2YTU1Y2QyZTcyOGJkNDM4Y18xLTItMS0xLTgxNzIz_9372ebba-3fa3-493a-9ac4-1e516228c66a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg2_d07fc27e-14ec-4b87-8b39-91c57f8660af">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTg3_eeded8d2-4ea0-4828-9636-6ddbc640bea4">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18wLTAtMS0xLTgxNzIz_84106c15-2c0c-4650-bc5b-9be139c4da8f">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18wLTMtMS0xLTgxNzIz_68ed8c3b-66b8-4f95-92d9-de337fb26b3b">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGFibGU6OGJkMTFlY2ZkMTQ5NDg0ZjgzMjlkNTFiNjUwNTg3MGMvdGFibGVyYW5nZTo4YmQxMWVjZmQxNDk0ODRmODMyOWQ1MWI2NTA1ODcwY18xLTMtMS0xLTgxNzIz_d6d3012a-f4d6-4c41-8923-e53711ffa86c">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTgz_ccf7e112-72ec-4c3d-823b-9e781cd98563">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id869177d11624fb384af0cf8700149ba_I20220801"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xL2ZyYWc6ZDE3N2VhMDk5NTM4NDk3YWFjNTY5Y2ZiZTNhMTM4M2UvdGV4dHJlZ2lvbjpkMTc3ZWEwOTk1Mzg0OTdhYWM1NjljZmJlM2ExMzgzZV8xOTE4_37e12830-4fb7-43c9-9c30-ef88128a10e0"
      unitRef="shares">199463645</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMy0xLTEtMS04MTcyMw_6009ecce-dbfc-4731-9af2-fea3351f3ac6"
      unitRef="usd">72090000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMy0zLTEtMS04MTcyMw_08334ad4-5fed-4ab1-92a2-100563ca7ff9"
      unitRef="usd">162636000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNC0xLTEtMS04MTcyMw_8fdc0941-6a30-4ad8-9eae-f6c838bbd1b8"
      unitRef="usd">69454000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNC0zLTEtMS04MTcyMw_383ec08c-8625-49b2-a9d8-9b6d63047832"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNS0xLTEtMS04MTcyMw_1c8b9d3c-ffbe-44b2-ad7e-30ecc2f3aeb1"
      unitRef="usd">73000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNS0zLTEtMS04MTcyMw_04e6933a-ccba-4123-a840-c6c1ccb0cb4b"
      unitRef="usd">21011000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNi0xLTEtMS04MTcyMw_bcddac76-36f1-4331-b3a8-3a005444ad6d"
      unitRef="usd">14046000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNi0zLTEtMS04MTcyMw_818c3578-2204-4b78-96b7-82a4b234515a"
      unitRef="usd">3482000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNy0xLTEtMS04MTcyMw_aabbe5d6-7fea-4ab3-a257-57a1b216b537"
      unitRef="usd">757000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNy0zLTEtMS04MTcyMw_e5dfaad6-61f7-48df-98af-28195f05ea36"
      unitRef="usd">18476000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfOS0xLTEtMS04MTcyMw_0e898afb-b059-4a84-b5f4-d6ea1c002c0e"
      unitRef="usd">156420000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfOS0zLTEtMS04MTcyMw_fe749af5-c022-48b8-b526-9cd793e5b3f5"
      unitRef="usd">205605000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTItMS0xLTEtODE3MjM_d5d7760d-c401-4e5b-b8d4-60df0882b778"
      unitRef="usd">30000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTItMy0xLTEtODE3MjM_289ea35c-65b0-41a3-912a-3755d01880cd"
      unitRef="usd">20000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTMtMS0xLTEtODE3MjM_86094727-330f-4865-95bc-ee2a0d670a18"
      unitRef="usd">19641000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTMtMy0xLTEtODE3MjM_0b7e77eb-4129-4fd1-8daf-a33c82a879fc"
      unitRef="usd">0</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTQtMS0xLTEtODE3MjM_d562dc35-ae50-4cb7-bbf3-97685b846f9c"
      unitRef="usd">30000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTQtMy0xLTEtODE3MjM_bbe6c306-503e-410b-8f32-02c0f57f3004"
      unitRef="usd">43000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTUtMS0xLTEtODE3MjM_6b1347ff-fa8b-439a-b25b-0205bd85488f"
      unitRef="usd">0</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTUtMy0xLTEtODE3MjM_b78b0caa-2745-4af8-a2ec-a68a054efc4d"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTYtMS0xLTEtODE3MjM_9adeab32-5faf-4559-88cd-407a21e6be92"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTYtMy0xLTEtODE3MjM_5723c927-3aaa-4141-a5b0-2dddc7f78e93"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTctMS0xLTEtODE3MjM_bebd0b51-952c-4244-92af-a52b1cea832a"
      unitRef="usd">0</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:PrepaidExpenseNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTctMy0xLTEtODE3MjM_4d1393ef-7de1-4b36-ad8d-158aa2e7fce0"
      unitRef="usd">7192000</us-gaap:PrepaidExpenseNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTgtMS0xLTEtODE3MjM_1a665764-3af4-4aad-af21-bc6b43ef5f01"
      unitRef="usd">42000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTgtMy0xLTEtODE3MjM_72bb22b6-ce60-4710-b3a9-e08201f2b59d"
      unitRef="usd">123000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTktMS0xLTEtODE3MjM_a784b7d6-a33e-46bf-b7c7-d608c8849569"
      unitRef="usd">19743000</us-gaap:AssetsNoncurrent>
    <us-gaap:AssetsNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMTktMy0xLTEtODE3MjM_389b0875-d1eb-4226-9873-d9d3f82cac92"
      unitRef="usd">35142000</us-gaap:AssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjAtMS0xLTEtODE3MjM_0372b835-16a9-48c2-b705-f797efafd7d4"
      unitRef="usd">176163000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjAtMy0xLTEtODE3MjM_76709a15-dffa-419d-acd3-468cf35416e1"
      unitRef="usd">240747000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjQtMS0xLTEtODE3MjM_542b950d-a2db-43d1-9151-f7b069c1d019"
      unitRef="usd">1667000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjQtMy0xLTEtODE3MjM_eeaa9191-58a0-4282-9c43-e10a0abf18eb"
      unitRef="usd">2853000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjUtMS0xLTEtODE3MjM_8c11befa-9d03-4d83-83ae-a760b523b596"
      unitRef="usd">29851000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjUtMy0xLTEtODE3MjM_1814f821-312b-4650-9df8-317bfc7be04f"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjgtMS0xLTEtODE3MjM_1fd64ba5-e298-42ad-b6ac-bc82e413cf0e"
      unitRef="usd">487000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjgtMy0xLTEtODE3MjM_59dca2b4-5de6-4624-9de8-fcfe011e2801"
      unitRef="usd">460000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjktMS0xLTEtODE3MjM_abda99a8-c8c5-4155-9e6c-103fb6ea568f"
      unitRef="usd">32005000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMjktMy0xLTEtODE3MjM_18adf6d7-4cc2-40be-b0f4-6c3c667fe2aa"
      unitRef="usd">11568000</us-gaap:LiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzItMS0xLTEtODE3MjM_4d389571-f847-4dee-abde-e21ac5de2ef9"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzItMy0xLTEtODE3MjM_a35fe3e7-fe92-41a3-a0d8-38aa99727a8f"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzMtMS0xLTEtODE3MjM_e06e8b04-531d-4f64-afc9-5a4c17e20aa5"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzMtMy0xLTEtODE3MjM_77826d26-d95e-40a6-a775-deeffb6299ca"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzQtMS0xLTEtODE3MjM_514696d9-7f9d-46a7-a6dd-e24575a5e1cb"
      unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzQtMy0xLTEtODE3MjM_f75aef45-2ea2-4fe8-ac4e-73b4b7c7f688"
      unitRef="usd">1500000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzYtMS0xLTEtODE3MjM_6260bc46-7fdd-4c49-bdcc-1ef203b7dbb1"
      unitRef="usd">1800000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzYtMy0xLTEtODE3MjM_f15e4ef4-3aec-4d5b-b42a-8fe717067e22"
      unitRef="usd">57469000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzctMS0xLTEtODE3MjM_29082eff-26b5-436c-90d9-dbe0ca6a149b"
      unitRef="usd">33805000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfMzctMy0xLTEtODE3MjM_fa68336e-d905-4bfa-88a7-e013504f36a5"
      unitRef="usd">69037000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF8yMQ_4059875c-e9ee-40ac-af05-3a92bac1ff02"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF8yMQ_e063d2cc-b846-4dd0-930e-b5194a2169e2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF80NQ_6080b51e-ca1e-4ba4-9ede-4b40c95b23c2"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF80NQ_a347d7f2-c80d-4646-80ff-4b32359b6a78"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_2662d5c2-e437-4645-91a5-5f7a1918f7db"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_349e5195-bd0e-4c8d-9d3c-8a7eadc1f4cd"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_ba49e03a-cc6c-4709-99dc-a3f597bbae0b"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0YjBmMmQ5Yjc1Yzc0MDcxODI5YjI4NTU2YmEzYjU4OF84MA_c2bdefdc-8303-44e2-becd-0804d7e4e581"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMS0xLTEtODE3MjM_fa72f0b8-4ca7-412a-8e57-f33554cff25d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDAtMy0xLTEtODE3MjM_14676be3-95c7-41fd-827e-c91195ee9a14"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV8xOA_3303f3af-21c9-4d1d-b7b9-3960be5f4d8d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV8xOA_cea24c3e-c310-4f34-b212-58639d5edcba"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV80Mg_6d3a05cc-ad1d-4715-ba55-852c2378b4b9"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV80Mg_9a5ac7ac-5e99-48ea-8a82-beeec1990818"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_198d36f4-c41b-47e7-8f2d-ead81d882589"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_59ee66e1-578d-41a5-ac01-328c48f2bca6"
      unitRef="shares">199463645</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_ac13c67b-d492-4127-8da5-90dd401a8228"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjo0OWNiNTljOWU5MTA0NjE5YjRhZTE3M2Q2MDQxMGEzNV83Nw_f214229a-3fab-4d62-be72-778a8cb946fd"
      unitRef="shares">199463645</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMS0xLTEtODE3MjM_5f59aa7f-d5d0-4fc5-9dc4-990be1b2cd9f"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDEtMy0xLTEtODE3MjM_197e4f30-745b-47f0-b867-490e58e01225"
      unitRef="usd">199000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDItMS0xLTEtODE3MjM_58fe40ab-0e9e-4af0-a24f-a02d7842ca7b"
      unitRef="usd">491464000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDItMy0xLTEtODE3MjM_e24d419e-e0cd-4f46-bfec-f79b5cb62044"
      unitRef="usd">487768000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDMtMS0xLTEtODE3MjM_cf61a00c-5c10-4fc9-bd89-9692682beb42"
      unitRef="usd">-281000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDMtMy0xLTEtODE3MjM_2645ce12-d778-46f2-b9f7-553bc2009f6b"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDQtMS0xLTEtODE3MjM_9bdab8f1-75db-4aea-b642-023c4386eff1"
      unitRef="usd">-349024000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDQtMy0xLTEtODE3MjM_67014757-7858-4650-8955-2309e8d22293"
      unitRef="usd">-316257000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDUtMS0xLTEtODE3MjM_41439625-f97b-441b-9d0d-fbb0bf627787"
      unitRef="usd">142358000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDUtMy0xLTEtODE3MjM_bd08f432-efe5-4cd7-81fb-82b587bef1ad"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDYtMS0xLTEtODE3MjM_8aad2806-a9d4-44d4-9edb-32666ed9181a"
      unitRef="usd">176163000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xNi9mcmFnOjlkZDkzN2EyMWI3MjQ4NTNhZTdmNWQxYTY4ODY2OWFhL3RhYmxlOjc0YmZjMzkyNzU0YzQxOTdiMWU5NmRmY2U0MTI2YzM0L3RhYmxlcmFuZ2U6NzRiZmMzOTI3NTRjNDE5N2IxZTk2ZGZjZTQxMjZjMzRfNDYtMy0xLTEtODE3MjM_cf68f67a-e0c1-463d-8058-94ae12db1ae4"
      unitRef="usd">240747000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0xLTEtMS04MTcyMw_fc56402c-e593-4bd1-b595-a8bbdcc18381"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC0zLTEtMS04MTcyMw_d35e22d8-27f5-4c7e-b103-2f29f040183c"
      unitRef="usd">2234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC01LTEtMS04MTcyMw_699d96ab-6684-4426-8827-48393666f99d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNC03LTEtMS04MTcyMw_8bc89500-3124-4619-b8fa-a7423b64d00b"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS0xLTEtMS04MTcyMw_6cccf768-6155-404b-b85c-db2581bb570c"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS0zLTEtMS04MTcyMw_512e5dbf-d56e-4ed2-97f9-938ba26b70ea"
      unitRef="usd">2234000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS01LTEtMS04MTcyMw_bde54e0d-299f-46fb-9689-5f4fd2bee12d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfNS03LTEtMS04MTcyMw_cdc1e193-f820-4285-9490-9a99b68df3d0"
      unitRef="usd">6544000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC0xLTEtMS04MTcyMw_b4c2b69c-3347-4e0b-93a2-b4eb1e068f1d"
      unitRef="usd">29944000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC0zLTEtMS04MTcyMw_2067611f-32c4-419b-863e-fd41b295fa4c"
      unitRef="usd">7228000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC01LTEtMS04MTcyMw_1fb3eb2c-d373-492d-985e-8e957d75af48"
      unitRef="usd">34705000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOC03LTEtMS04MTcyMw_c0e63241-5b30-435a-a8be-59f0f59917e6"
      unitRef="usd">13306000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS0xLTEtMS04MTcyMw_316e55e8-7e02-4cef-8c03-e8970d34e913"
      unitRef="usd">15589000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS0zLTEtMS04MTcyMw_79006e83-5f80-4247-88ad-6738145509d2"
      unitRef="usd">6805000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS01LTEtMS04MTcyMw_57d16276-f41a-4c99-a095-135926619700"
      unitRef="usd">24564000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfOS03LTEtMS04MTcyMw_7825db19-393c-42fc-af8e-a465bbe8c81f"
      unitRef="usd">12098000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtMS0xLTEtODE3MjM_a522af7b-e0f8-4fef-9e47-a5625b9a1970"
      unitRef="usd">27764000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtMy0xLTEtODE3MjM_5d97468a-716c-475d-8f69-e6234d06ec2f"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtNS0xLTEtODE3MjM_79ba8ecc-859e-40ec-bbe4-46e9e4613be3"
      unitRef="usd">27764000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTEtNy0xLTEtODE3MjM_94892cfd-3a93-4477-bd9f-ab008a7d9e2a"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItMS0xLTEtODE3MjM_d6e9fe3f-62ff-409d-900a-99c3550eb20a"
      unitRef="usd">-37300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItMy0xLTEtODE3MjM_09997eb4-ef4b-4742-82e8-4d79bf577b09"
      unitRef="usd">13600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItNS0xLTEtODE3MjM_5b50f1d8-eb29-4e47-8274-d8e3894f1222"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTItNy0xLTEtODE3MjM_3df30173-5e52-465e-8ec9-8ffe8207308b"
      unitRef="usd">61760000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OperatingExpenses
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtMS0xLTEtODE3MjM_1f3e120e-1044-4b46-af8b-4179d302db38"
      unitRef="usd">35997000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtMy0xLTEtODE3MjM_a779ccd7-2a7b-4a41-a3b1-fa39adf827f7"
      unitRef="usd">27633000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtNS0xLTEtODE3MjM_a14a447b-c6c8-48ac-9f98-eb49aabc12c1"
      unitRef="usd">36833000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTMtNy0xLTEtODE3MjM_715da502-a6bd-44b9-a402-6b6f97099aaf"
      unitRef="usd">87164000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtMS0xLTEtODE3MjM_33f5e542-4691-4cb3-8cf9-0e661be77a8f"
      unitRef="usd">-35997000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtMy0xLTEtODE3MjM_6ab40c9f-9b8c-4d91-829e-e62006eff5b8"
      unitRef="usd">-25399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtNS0xLTEtODE3MjM_777e2954-6103-4355-8f95-b75a7234a328"
      unitRef="usd">-36833000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTUtNy0xLTEtODE3MjM_f4b3c8c3-0dea-4f9a-9357-7a9497ef5237"
      unitRef="usd">-80620000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtMS0xLTEtODE3MjM_53959149-1852-40f8-b414-1fded076c749"
      unitRef="usd">162000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtMy0xLTEtODE3MjM_09cfeb90-6c0d-4361-aa3c-0c288c01d5fd"
      unitRef="usd">-43000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtNS0xLTEtODE3MjM_d2fdfdee-720e-4cbb-9ce4-6e85036911b7"
      unitRef="usd">191000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTYtNy0xLTEtODE3MjM_b6f2d5ed-288a-4958-bc4c-e5bee97cd09d"
      unitRef="usd">-46000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctMS0xLTEtODE3MjM_3e2bf00e-1581-47d0-aa9e-54661c72421b"
      unitRef="usd">-35835000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctMy0xLTEtODE3MjM_8afe3cbb-c2de-4fd3-9420-b7231e80c5e7"
      unitRef="usd">-25442000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctNS0xLTEtODE3MjM_4809017e-8d06-4ae5-9ab1-1a5091ed5260"
      unitRef="usd">-36642000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTctNy0xLTEtODE3MjM_00e2190c-51f5-48a4-8f5d-002c94569754"
      unitRef="usd">-80666000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtMS0xLTEtODE3MjM_58f4ef59-13c4-4e21-b72f-c71e008858e8"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtMy0xLTEtODE3MjM_b2be0dfe-f187-409a-ac4f-02647d46f0e4"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtNS0xLTEtODE3MjM_c6978148-fd68-4edc-bab1-f8570589b22b"
      unitRef="usd">-3875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTgtNy0xLTEtODE3MjM_7f3fd4d4-d45e-4ed6-915c-1ea0b20f3f99"
      unitRef="usd">288000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktMS0xLTEtODE3MjM_fe7f404a-1e3c-4e26-bb68-c3b2c0c9975f"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktMy0xLTEtODE3MjM_33ec3c13-ffd7-4c7a-aed2-b7b066e95e32"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktNS0xLTEtODE3MjM_1ac6e617-3b30-47b6-8cfb-bd764e6654e6"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMTktNy0xLTEtODE3MjM_90ef1be6-9521-4ce5-b9c4-b8dbd8d4a71b"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMS0xLTEtODE3MjM_a7ecb888-7f72-4599-b48c-4113f868e0e7"
      unitRef="usd">-31960000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMS0xLTEtODE3MjM_dd51984a-ee5d-4e18-a43e-7429232aa180"
      unitRef="usd">-31960000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMy0xLTEtODE3MjM_65cb7dec-92a5-4b30-9d42-fd488561bc93"
      unitRef="usd">-25442000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtMy0xLTEtODE3MjM_69861aa4-3f17-4b98-b434-e57325879ccc"
      unitRef="usd">-25442000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNS0xLTEtODE3MjM_2ebbc695-fc52-4dd0-8dba-18301af192a9"
      unitRef="usd">-32767000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNS0xLTEtODE3MjM_f7d35c01-47a5-4b5f-bddc-edd9f6b77b56"
      unitRef="usd">-32767000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNy0xLTEtODE3MjM_226ba156-dedb-4cd3-88f9-695b5a923fc4"
      unitRef="usd">-80954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjMtNy0xLTEtODE3MjM_a2e30ad0-a34c-48d3-b4fe-3f4c584703d9"
      unitRef="usd">-80954000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMS0xLTEtODE3MjM_37ff3b59-ceab-4dec-81f4-4561ca9494c4"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMS0xLTEtODE3MjM_87becfb5-0922-4a44-9ee7-3817b8922042"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMy0xLTEtODE3MjM_8676b4de-5249-43b2-8f8a-932967756bb0"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtMy0xLTEtODE3MjM_cbc8451f-bb34-4866-b62f-a89624f83669"
      unitRef="usdPerShare">-0.15</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNS0xLTEtODE3MjM_1f765df5-99cd-46b7-86e3-5b727ea68121"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNS0xLTEtODE3MjM_86863cab-94c6-4c37-a059-d505c1883b47"
      unitRef="usdPerShare">-0.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNy0xLTEtODE3MjM_bf0fd9c1-f493-44f4-b4d1-e990ab6787c4"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjQtNy0xLTEtODE3MjM_e23df7ea-02ee-450f-ad10-f3204d68f173"
      unitRef="usdPerShare">-0.49</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMS0xLTEtODE3MjM_10dede7e-ba33-434c-89cf-db1359ec4995"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMS0xLTEtODE3MjM_80fd4f08-5fb7-4f8d-96c6-63de974315f0"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMy0xLTEtODE3MjM_1bf2c2bd-dd29-41d2-8100-ca2cd53fe288"
      unitRef="shares">175393000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtMy0xLTEtODE3MjM_49bb69b7-38e7-4d26-8fe9-70a7c70bf56f"
      unitRef="shares">175393000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNS0xLTEtODE3MjM_2bc5e500-ed1c-4091-bd87-6a1396d5362f"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNS0xLTEtODE3MjM_d8c8cdf7-3db1-45ae-8f36-5f4b58703860"
      unitRef="shares">199464000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNy0xLTEtODE3MjM_aa77e433-5bed-4b3f-adb1-0990b90fcd81"
      unitRef="shares">166264000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8xOS9mcmFnOmU1ZmY0ZDZjY2NiMjRhMTFhNTEzNjQ1MjM0NzNjNmUwL3RhYmxlOjZhMmQ5ZDc3MjgwNjQ2OGY4NTFiN2FjNjQ2ZjZlNDQ4L3RhYmxlcmFuZ2U6NmEyZDlkNzcyODA2NDY4Zjg1MWI3YWM2NDZmNmU0NDhfMjUtNy0xLTEtODE3MjM_cea0d19e-c030-44c0-b6f3-6c2573f4e788"
      unitRef="shares">166264000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy0xLTEtMS04MTcyMw_b85c5bd4-6fbc-4ed3-a88f-3b32264af7f0"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy0zLTEtMS04MTcyMw_a21285b3-b464-4790-bce4-ee8507960450"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy01LTEtMS04MTcyMw_fa45bf98-862b-47cf-a9b4-93c237c63a49"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfMy03LTEtMS04MTcyMw_83d3bfd3-eea8-424d-99be-7d8b8495d8ee"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC0xLTEtMS04MTcyMw_1302d74c-50b3-47b2-8dbe-a949f0c35a53"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC0zLTEtMS04MTcyMw_1ebd35fe-cf5f-4546-b001-52d412bc6c83"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC01LTEtMS04MTcyMw_2fd4d84c-698c-44b4-8908-03089b6f55fe"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNC03LTEtMS04MTcyMw_a46b3559-27d0-4ac8-a4ef-973c4bcbd0b8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS0xLTEtMS04MTcyMw_111bf465-6537-432a-ad86-06a3e12e2397"
      unitRef="usd">-32241000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS0zLTEtMS04MTcyMw_469c39d8-c46c-41ad-88a3-cdb41f00b4a3"
      unitRef="usd">-25442000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS01LTEtMS04MTcyMw_e369e6f6-7196-4527-8cbb-defbee927301"
      unitRef="usd">-33048000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yMi9mcmFnOmY2ZGYyZmNmMjRlNDRmZjE4ZmZkMmE3ZjY0Nzg3MzljL3RhYmxlOjZlNzk2NzdhODgxYTRlOGViZWVjNjk5M2ZlYWZlMDU3L3RhYmxlcmFuZ2U6NmU3OTY3N2E4ODFhNGU4ZWJlZWM2OTkzZmVhZmUwNTdfNS03LTEtMS04MTcyMw_02eff8ad-b1b6-4d82-9cb2-60608727b74c"
      unitRef="usd">-80954000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="i0888396debb34c04a3b1ce7017d15b49_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0xLTEtMS04MTcyMw_5c1c56f3-3e61-4b81-a198-ae8618bb1cad"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0888396debb34c04a3b1ce7017d15b49_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0zLTEtMS04MTcyMw_f1c16c80-b20a-4543-b318-d38a706f63d5"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e2dde9a518a491ebd8912a185f23cd6_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi01LTEtMS04MTcyMw_c08b9f27-5b5b-46eb-ae3e-ab8cbb46bed0"
      unitRef="usd">487768000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9dfef576366a44c8899c23968e5a7571_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi03LTEtMS04MTcyMw_036a5bb5-67ed-47be-89d2-d934addfb213"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5e31cbf599b140739ed935ff1dd609b8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi05LTEtMS04MTcyMw_ff2f580e-76f3-45f7-a680-3a292384cd84"
      unitRef="usd">-316257000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMi0xMS0xLTEtODE3MjM_b28cabd7-1c84-4e2a-aafa-ff8ae7565f79"
      unitRef="usd">171710000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ia9495f0a57df45ff8db57ca5375f6705_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMy05LTEtMS04MTcyMw_c84e290c-76e5-42a5-9802-3963d747b8b1"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMy0xMS0xLTEtODE3MjM_72f93ea8-7a11-4796-bd71-686684259eff"
      unitRef="usd">-807000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i64fafc918b1a455ea5d13849a58f83dc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfNC01LTEtMS04MTcyMw_d466adbc-5545-49d7-8dd2-e539d329c6ed"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9042e4d133fa4cd5843ec8b84e4fc260_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfNC0xMS0xLTEtODE3MjM_ed4d92bd-ea8d-4eed-88b0-e7cffb124412"
      unitRef="usd">1894000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding
      contextRef="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMS0xLTEtODE3MjM_1f36d076-b725-4b9e-a6a7-15d003a4fde0"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0ccefaf64a5c4b9db26cb870bb1345ca_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMy0xLTEtODE3MjM_bcb4eec0-5d2d-4669-b6e8-bf32a9448849"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib0975aa547f74b7a9de06d3efa3be13c_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtNS0xLTEtODE3MjM_1f526ecc-a286-4630-be6b-f67badfe4e62"
      unitRef="usd">489662000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibad650e0476f4f16801d09e1becece4e_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtNy0xLTEtODE3MjM_1a83ba40-5aeb-43bc-8df1-6970023c2094"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib01a1af0204e41fd93a01011d3d198fa_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtOS0xLTEtODE3MjM_59799335-43a1-45f5-aa93-07f3558ae6cc"
      unitRef="usd">-317064000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i14a46440132b42f0b7fa05821b7ebc4f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTAtMTEtMS0xLTgxNzIz_c3552eb7-ff71-4f27-a20f-05feec4182e9"
      unitRef="usd">172797000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i5de9e1ce23744a739794e84c9513c251_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTEtOS0xLTEtODE3MjM_ac33ea04-6029-47cd-b303-8cd63352e3f6"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTEtMTEtMS0xLTgxNzIz_52cae8d1-14b4-4a38-9e67-906e2adddbb1"
      unitRef="usd">-31960000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0c2011e9ea8d46969474d1ff815da0fb_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTItNS0xLTEtODE3MjM_486f22a4-a597-4a55-aa4c-34eb475cfd20"
      unitRef="usd">1802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTItMTEtMS0xLTgxNzIz_886660f2-4dc6-4241-985c-3fdb90a387e6"
      unitRef="usd">1802000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="if5212a49218248398de938ab0ff078dc_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTQtNy0xLTEtODE3MjM_6d05a181-b037-47a8-9b3f-702eec4dc305"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTQtMTEtMS0xLTgxNzIz_e51eda34-5c1f-481a-ba94-bdcb05e5b0c1"
      unitRef="usd">-281000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="idad59db36cee439984f3d4ad8b4fb9b5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMS0xLTEtODE3MjM_3ceeda3a-0ad2-447c-b0f9-5b2bd05dc381"
      unitRef="shares">199463645</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idad59db36cee439984f3d4ad8b4fb9b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMy0xLTEtODE3MjM_5d1dad8b-061f-46e2-ba2c-8161b3eba43c"
      unitRef="usd">199000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic947583800d54749af298a1e2b9bc920_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtNS0xLTEtODE3MjM_b2c692db-4756-491d-81eb-242e3f081575"
      unitRef="usd">491464000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2ee39dd3da244ec9bcff222871e71116_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtNy0xLTEtODE3MjM_7024a01f-19a0-44fe-8f53-3ca032b33f0f"
      unitRef="usd">-281000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i117a5180e4eb4c3391864589aa813213_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtOS0xLTEtODE3MjM_c01b2ce0-6cae-4e0f-b601-afa01267a821"
      unitRef="usd">-349024000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTUtMTEtMS0xLTgxNzIz_c051006f-8e64-4e08-934b-d1fe8e99ae24"
      unitRef="usd">142358000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i7012d9b8cefc416d86192851d3aa476f_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMS0xLTEtODE3MjM_3cb06925-fc91-4f12-af15-b094a805aa9e"
      unitRef="shares">140449647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7012d9b8cefc416d86192851d3aa476f_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMy0xLTEtODE3MjM_9ab699f9-851b-4b2c-961e-d84ce179c03b"
      unitRef="usd">140000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i171789775ea34e329cab101dfc95862e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktNS0xLTEtODE3MjM_81864bc5-f243-40c1-88bd-293158fcf64c"
      unitRef="usd">306554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3b5d4ce18c0f4291b85fddcf3869fa34_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktNy0xLTEtODE3MjM_198a192c-5345-4c8e-841a-afd3a3fa58d8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idea9cc2fd581441895f394010022516a_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktOS0xLTEtODE3MjM_00df8e85-1d26-4200-9a90-53cd111b350a"
      unitRef="usd">-315921000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMTktMTEtMS0xLTgxNzIz_fff444a9-386a-4da6-9d97-129ab2bb1715"
      unitRef="usd">-9227000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i52eaa414326e448c937bf26df0576971_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjAtOS0xLTEtODE3MjM_b721e70a-7961-4fcc-8124-90d4c161c2a9"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjAtMTEtMS0xLTgxNzIz_b468d738-b533-4069-bee3-c6d6ac8c44e3"
      unitRef="usd">-55512000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjEtNS0xLTEtODE3MjM_1d8ae17b-0f08-42c8-a92b-08313e70574c"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjEtMTEtMS0xLTgxNzIz_9f0b85ba-fe4a-41de-a9e7-cbe26f2f7492"
      unitRef="usd">958000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItMS0xLTEtODE3MjM_43781a60-cca0-4578-a74c-e27b01f22eda"
      unitRef="shares">30610</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItNS0xLTEtODE3MjM_8a4b1c4b-ab90-44ba-98a4-6b00fb368dd2"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjItMTEtMS0xLTgxNzIz_002fde59-dfda-4016-8b2c-c1f81dbe5ca9"
      unitRef="usd">39000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMS0xLTEtODE3MjM_b02ca74b-dee2-4ada-a721-1e8c51a3f56a"
      unitRef="shares">852840</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ib39f955c83294b19b2d55b161745582b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMy0xLTEtODE3MjM_5356104b-6e0a-4809-87da-0762e7da7c79"
      unitRef="usd">1000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="i3ff4a04455bc4375b33396b1952a257a_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtNS0xLTEtODE3MjM_0b6d61f8-436a-4725-b47f-ef8ae1c9e9d9"
      unitRef="usd">468000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjQtMTEtMS0xLTgxNzIz_366e294b-1b7c-4295-bd25-ef1c8dfe4bd8"
      unitRef="usd">469000</sesn:StockIssuedDuringPeriodExerciseOfWarrantsValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjowZmQxMWY0Y2JlZTg0ZGI3ODI5ZTRmNTgzOTlmZTgxNV83NA_f39c04a2-6313-492f-aad1-c51af333f4e0"
      unitRef="usd">2200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i30af2746204648089c84cb29d5101717_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMS0xLTEtODE3MjM_f379640b-1efe-42c7-8e72-98cdfe760865"
      unitRef="shares">30645702</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i30af2746204648089c84cb29d5101717_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMy0xLTEtODE3MjM_b46920e7-62de-4e68-8825-133390f6976e"
      unitRef="usd">31000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib30024337b1546b7bd2a070c42de470b_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtNS0xLTEtODE3MjM_15f032c3-42a3-4931-ad29-b3a751d3047f"
      unitRef="usd">72512000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="ib764d38ef5924a26af92778deac4a289_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjUtMTEtMS0xLTgxNzIz_c32030b7-56d2-41b7-8e72-e8d20a75491d"
      unitRef="usd">72543000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i9dd0f583a45649359ab4f630a2d1d044_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMS0xLTEtODE3MjM_fd83e970-d6b2-4b8b-a3ff-2058e90a2cc7"
      unitRef="shares">171978799</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9dd0f583a45649359ab4f630a2d1d044_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMy0xLTEtODE3MjM_989424ec-67f5-4a51-8f43-2277e2a2ed7a"
      unitRef="usd">172000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2eb92ef2739448ac91cb470697a88bf3_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtNS0xLTEtODE3MjM_3980454b-7a31-44f2-99d6-ddc57b280ff0"
      unitRef="usd">380531000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d04fd3863f8493db4c151a0f56ee9f6_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtNy0xLTEtODE3MjM_16d0c79d-57df-4e71-a4cb-8f97a78996fb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9147fb1c8cf34577b359bd45f28c4a7c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtOS0xLTEtODE3MjM_3cb0c232-7ba1-4b2e-be58-f423a09d7ffc"
      unitRef="usd">-371433000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3b387a8bf0243d9b0d1e9d51425a534_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjYtMTEtMS0xLTgxNzIz_07eb9872-dc7e-4ba3-a80f-8d981e6fdcaf"
      unitRef="usd">9270000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i732a7b94c2394e6caed25b643f1504ce_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjctOS0xLTEtODE3MjM_fa861e63-a954-451e-9fb9-631a48ad152b"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjctMTEtMS0xLTgxNzIz_636f346e-68c8-4181-a68c-66133d2dbabe"
      unitRef="usd">-25442000</us-gaap:NetIncomeLoss>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iae31b43c606e4c19b17a44b2508f083c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjgtNS0xLTEtODE3MjM_bf9e283d-cde1-433b-b7a5-3ef28a9e2ea7"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjgtMTEtMS0xLTgxNzIz_2df8ce6d-236d-4771-a2f6-be4e71157bbd"
      unitRef="usd">1260000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMC0xLTEtODE3MjMvdGV4dHJlZ2lvbjpiY2VhNGFiZDE4MjE0OTkyOGEyZjFhNTczYzFiOTY4OV83NA_09807cce-54e8-40d3-8245-c32b54770d1a"
      unitRef="usd">2000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i62880df550724456b3e687c3c6d85445_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMS0xLTEtODE3MjM_7db6c369-3e8a-4bca-a4ab-115485fe2a2f"
      unitRef="shares">16482152</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i62880df550724456b3e687c3c6d85445_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMy0xLTEtODE3MjM_f74e4c10-c873-491a-8309-6aa1ff3ba744"
      unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i73c2ea2a03e7419a8e4196a69096b610_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktNS0xLTEtODE3MjM_31f0552f-b96a-41fb-8cc4-caf44ecfc43a"
      unitRef="usd">64245000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i6d7821756c804d898a7d8834c7925d7c_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMjktMTEtMS0xLTgxNzIz_23c292e7-62f9-46da-b74a-796e678b4eb8"
      unitRef="usd">64261000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="i7984a6629ab74eb390c3df7ff75f05d2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMS0xLTEtODE3MjM_09fdf3ce-7cb0-47ad-87cf-50febb92c6bf"
      unitRef="shares">188460951</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i7984a6629ab74eb390c3df7ff75f05d2_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMy0xLTEtODE3MjM_61cf431d-3067-4f9a-8ad3-8edba15da0ab"
      unitRef="usd">188000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0cd0bb43b0ee429f964e6eb8b8925e53_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtNS0xLTEtODE3MjM_99d5504c-4062-4ea5-81ac-c9329f7f9180"
      unitRef="usd">446036000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iad1dbbda2c1f497da6b3ad0608eb76ac_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtNy0xLTEtODE3MjM_d87e1f30-39f2-4128-92a1-56358a699fb8"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib07c0124fe234223a9d340e9c94f5559_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtOS0xLTEtODE3MjM_e2fa46b9-62fa-42f2-92c6-997aabb942fc"
      unitRef="usd">-396875000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i407298c7856d4211867c26d5eaa28887_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8yNS9mcmFnOjYzOGQ2ZjY5NjI5NzQzYWQ4NGZkNTc4NDRkYWFhOWMyL3RhYmxlOmM4MjViYTEzOTE5YzRiM2NiMjRlMTRhZDI1NmJkYTdkL3RhYmxlcmFuZ2U6YzgyNWJhMTM5MTljNGIzY2IyNGUxNGFkMjU2YmRhN2RfMzAtMTEtMS0xLTgxNzIz_4b075887-68d5-4a20-b348-23ff50e92229"
      unitRef="usd">49349000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMy0xLTEtMS04MTcyMw_91482af7-407b-4b62-b042-f0b84303c905"
      unitRef="usd">-32767000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMy0zLTEtMS04MTcyMw_c99c693a-8a14-4ef6-b6dc-f9d8ac466d8a"
      unitRef="usd">-80954000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNS0xLTEtMS04MTcyMw_35bf9865-ad4e-4a73-a3c6-8708ef25520a"
      unitRef="usd">13000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNS0zLTEtMS04MTcyMw_9767d5f3-3144-47e4-82a7-9de428ecdf19"
      unitRef="usd">64000</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNi0xLTEtMS04MTcyMw_2062b0d5-4b9f-4728-af55-ad5802bc819a"
      unitRef="usd">3696000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNi0zLTEtMS04MTcyMw_c0b6d58e-03da-4fc5-a126-2aa71d9c7f57"
      unitRef="usd">2217000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNy0xLTEtMS04MTcyMw_5b50f1d8-eb29-4e47-8274-d8e3894f1222"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNy0zLTEtMS04MTcyMw_3df30173-5e52-465e-8ec9-8ffe8207308b"
      unitRef="usd">61760000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AssetImpairmentCharges
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfOS0xLTEtMS04MTcyMw_a7112dc6-5ae6-4c5e-9ad9-abefcb1025c3"
      unitRef="usd">27764000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfOS0zLTEtMS04MTcyMw_150e7df0-0745-4a07-b44c-ce68efe54f2b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTEtMS0xLTEtODE3MjM_27e954b8-d557-476c-aadb-7042d1c8f693"
      unitRef="usd">-20939000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTEtMy0xLTEtODE3MjM_0e3b23b6-3151-4f01-989d-dc8136db8d06"
      unitRef="usd">2303000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTItMS0xLTEtODE3MjM_42b1f87c-d071-42f3-863e-7bd0fe3cf5b2"
      unitRef="usd">10565000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTItMy0xLTEtODE3MjM_b1f1e929-6601-4382-91ec-e7a885ae9470"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTMtMS0xLTEtODE3MjM_eea1198a-6d7b-4207-9da9-565970849495"
      unitRef="usd">-17719000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTMtMy0xLTEtODE3MjM_c8c5923f-5dd4-4cd2-adc3-573566e425b2"
      unitRef="usd">20287000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTQtMS0xLTEtODE3MjM_18104084-24d2-45d7-8791-69e74f16bb14"
      unitRef="usd">-7192000</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTQtMy0xLTEtODE3MjM_a2144cd7-3914-4ad5-8d46-9b05e6dfb3e2"
      unitRef="usd">0</sesn:IncreaseDecreaseOfPrepaidExpensesNoncurrent>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTUtMS0xLTEtODE3MjM_0ab71139-8ed9-4e6b-b003-20faf406c46d"
      unitRef="usd">281000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTUtMy0xLTEtODE3MjM_f6e40e52-7f16-45b5-9178-ced608f8697c"
      unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTYtMS0xLTEtODE3MjM_6f983dec-b906-4334-9896-7228ce87c5ff"
      unitRef="usd">-81000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTYtMy0xLTEtODE3MjM_27ff555b-c9f5-4395-8957-037a1d4e8a4c"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTgtMS0xLTEtODE3MjM_b7c09cae-7e9c-44c4-8014-8ae9e7c1b407"
      unitRef="usd">-1186000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTgtMy0xLTEtODE3MjM_94d4c040-df65-4da9-922d-37758f331a8b"
      unitRef="usd">-1875000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTktMS0xLTEtODE3MjM_06b5e5f1-2960-4ffc-9270-f2b3a76f9963"
      unitRef="usd">17654000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMTktMy0xLTEtODE3MjM_0278beeb-fc7b-4040-a5fa-7b67dbb5f6ee"
      unitRef="usd">1262000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjAtMS0xLTEtODE3MjM_4db5b460-f902-4027-870a-2b5a918b14d2"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjAtMy0xLTEtODE3MjM_25bf5958-5988-493a-850d-b1e8c57b0d6d"
      unitRef="usd">-1500000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjEtMS0xLTEtODE3MjM_571aecfc-a7fd-428d-b9af-09c7a84be936"
      unitRef="usd">-1441000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjEtMy0xLTEtODE3MjM_199d137a-db86-42d7-9188-da48fd0774ca"
      unitRef="usd">-41616000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjMtMS0xLTEtODE3MjM_773eb765-a069-418b-9c28-1ac588ff0cd8"
      unitRef="usd">89095000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjMtMy0xLTEtODE3MjM_43a8d699-4263-469c-b18a-9ee47e7e7660"
      unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjQtMS0xLTEtODE3MjM_572da9c3-d4b1-41be-9ce5-4490dd74b4ff"
      unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjQtMy0xLTEtODE3MjM_5f397494-b047-40ff-b0d2-19ed70ccd63a"
      unitRef="usd">49000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjUtMS0xLTEtODE3MjM_0438b914-745c-4e93-9d21-1ac62b3d5682"
      unitRef="usd">-89095000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjUtMy0xLTEtODE3MjM_19fcf548-6d28-46f9-b52f-b704eccd5dbb"
      unitRef="usd">-49000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjgtMS0xLTEtODE3MjM_2c44593e-cfb2-49a8-828c-48aa1d50aeb8"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjgtMy0xLTEtODE3MjM_1402dc93-f03a-4925-b667-5e3d4e036257"
      unitRef="usd">136804000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjktMS0xLTEtODE3MjM_35b7c83e-afcb-4114-9543-801a74f1b7e7"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMjktMy0xLTEtODE3MjM_61a53bb6-8893-4223-a0ae-20f3d158a3f2"
      unitRef="usd">39000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzAtMS0xLTEtODE3MjM_89a6f47b-297c-4631-b75e-0f86c21ab8e9"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzAtMy0xLTEtODE3MjM_18e401c0-be51-4327-a0e5-99996961a009"
      unitRef="usd">469000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzItMS0xLTEtODE3MjM_2e5c2623-2add-4533-a0f1-98a063716758"
      unitRef="usd">0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzItMy0xLTEtODE3MjM_b37eae9b-addd-467a-906e-9cbb25722117"
      unitRef="usd">137312000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzMtMS0xLTEtODE3MjM_a62c0763-e2d5-490c-a872-ec7f0051a1d1"
      unitRef="usd">-90536000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzMtMy0xLTEtODE3MjM_f44595d5-9463-4fcc-a2b4-177407be17a1"
      unitRef="usd">95647000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzQtMS0xLTEtODE3MjM_76f2f48f-546c-46bd-8708-5ee2e0b9b348"
      unitRef="usd">162656000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzQtMy0xLTEtODE3MjM_3d55db99-1beb-4242-a3f2-f7e4a2b44ab1"
      unitRef="usd">55409000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzUtMS0xLTEtODE3MjM_7b54b84f-d6c7-425f-8a54-018feedb12d4"
      unitRef="usd">72120000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i407298c7856d4211867c26d5eaa28887_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzUtMy0xLTEtODE3MjM_9e02a8c5-f1c9-493e-9669-4d44b79c4b85"
      unitRef="usd">151056000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzgtMS0xLTEtODE3MjM_8613229b-f40a-4d22-9e70-7db152dadfe8"
      unitRef="usd">86000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfMzgtMy0xLTEtODE3MjM_94b42cc8-2609-46dc-81de-228ac76b7c86"
      unitRef="usd">87000</sesn:RightOfUseAssetRelatedToAdoptionOfAccountingStandard>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNDMtMS0xLTEtODE3MjM_349de866-be4a-4dc5-be11-bb8ed194e3c5"
      unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zMS9mcmFnOjdlOWY0N2RmOTFjNDQ4MGViZDdhNWQyN2QxMDZmZWYyL3RhYmxlOmRkMDA1MDBhOTJjMTRkYzk4ZGNmZTljMDhmNGZlNmY4L3RhYmxlcmFuZ2U6ZGQwMDUwMGE5MmMxNGRjOThkY2ZlOWMwOGY0ZmU2ZjhfNDMtMy0xLTEtODE3MjM_19c1b197-a897-4fa9-a3d8-906c91c55d1e"
      unitRef="usd">27000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:NatureOfOperations
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNjE1OQ_3a4da1a7-cb35-4f09-929d-f55388a79bae">DESCRIPTION OF BUSINESS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sesen Bio, Inc. ("Sesen" or the &#x201c;Company&#x201d;), a Delaware corporation formed in February 2008, is a late-stage clinical company focused on advancing targeted fusion protein therapeutics for the treatment of patients with cancer. The Company&#x2019;s most advanced product candidate, Vicineum&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;TM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also known as VB4-845, is a locally-administered targeted fusion protein composed of an anti-epithelial cell adhesion molecule ("EpCAM") antibody fragment tethered to a truncated form of Pseudomonas exotoxin A for the treatment of non-muscle invasive bladder cancer (&#x201c;NMIBC&#x201d;). On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the United States. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA, which are further described below. The Company has turned its primary focus to the careful assessment of potential strategic alternatives with the goal of maximizing shareholder value, which it believes will be complete by the end of 2022. Additionally, the Company intends to seek a partner for the further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has completed the follow-up stage of its single-arm, multi-center, open-label Phase 3 clinical trial of Vicineum as a monotherapy in patients with bacillus Calmette-Gu&#xe9;rin ("BCG")-unresponsive NMIBC (the "VISTA Trial"). The VISTA Trial completed enrollment in April 2018 with a total of 133 patients. On December 18, 2020, the Company submitted its completed Biologics License Application (the "BLA") for Vicineum for the treatment of BCG-unresponsive NMIBC to the United States Food and Drug Administration ("FDA"). On February 12, 2021, the FDA notified the Company that it had accepted the BLA file. The FDA also granted Priority Review for the BLA and set a target Prescription Drug User Fee Act ("PDUFA") date for a decision on the BLA of August 18, 2021. On August 13, 2021, the Company received a complete response letter (&#x201c;CRL&#x201d;) from the FDA indicating that the FDA had determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to chemistry, manufacturing and controls (&#x201c;CMC&#x201d;) issues pertaining to a recent pre-approval inspection and product quality.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021 and December 2021, the Company participated in a CMC Type A meeting and a Clinical Type A meeting, respectively, with the FDA to discuss issues raised in the CRL and design elements of an additional Phase 3 clinical trial for Vicineum, which the FDA confirmed would be required for a potential resubmission of a BLA. In March 2022, the Company participated in a Type C meeting with the FDA. During the Type C meeting, the FDA agreed to a majority of the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Viventia Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, the Company entered into a Share Purchase Agreement with Viventia Bio, Inc., a corporation incorporated under the laws of the Province of Ontario, Canada ("Viventia"), the shareholders of Viventia named therein (the &#x201c;Selling Shareholders&#x201d;) and, solely in its capacity as seller representative, Clairmark Investments Ltd., a corporation incorporated under the laws of the Province of Ontario, Canada (&#x201c;Clairmark&#x201d;) (the &#x201c;Share Purchase Agreement&#x201d;), pursuant to which the Company agreed to and simultaneously completed the acquisition of all of the outstanding capital stock of Viventia from the Selling Shareholders (the &#x201c;Viventia Acquisition&#x201d;). In connection with the closing of the Viventia Acquisition, the Company issued 4.0 million shares of its common stock to the Selling Shareholders, which at that time represented approximately 19.9% of the voting power of the Company as of immediately prior to the issuance of such shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, under the Share Purchase Agreement, the Company is obligated to pay to the Selling Shareholders certain post-closing contingent cash payments upon the achievement of specified milestones and based upon net sales, in each case subject to the terms and conditions set forth in the Share Purchase Agreement, including: (i) a one-time milestone payment of $12.5 million payable upon the first sale of Vicineum (the &#x201c;Purchased Product&#x201d;), in the United States; (ii) a one-time milestone payment of $7.0 million payable upon the first sale of the Purchased Product in any one of certain specified European countries; (iii) a one-time milestone payment of $3.0 million payable upon the first sale of the Purchased Product in Japan; and (iv) quarterly earn-out payments equal to 2% of net sales of the Purchased Product during specified earn-out periods. Such earn-out payments are payable with respect to net sales in a country beginning on the date of the first sale in such country and ending on the earlier of (i) December 31, 2033, and (ii) fifteen years after the date of such sale, subject to early termination in certain circumstances if a biosimilar product is on the market in the applicable country. Under the Share Purchase Agreement, the Company, its affiliates, licensees and subcontractors are required to use commercially reasonable efforts, for the first seven years following the closing of the Viventia Acquisition, to achieve marketing authorizations throughout the world and, during the applicable earn-out period, to commercialize the Purchased Product in the United States, France, Germany, Italy, Spain, United Kingdom, Japan, China and Canada. Certain of these payments are payable to individuals or affiliates of individuals that &lt;/span&gt;&lt;/div&gt;became employees or members of the Company's board of directors. However, as of June&#160;30, 2022, none of these individuals are active employees of the Company or members of the Company's board of directors.</us-gaap:NatureOfOperations>
    <sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare
      contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDA1OQ_34c58e8f-9dac-4c5b-91c8-47dbbd956bb1"
      unitRef="shares">4000000</sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare>
    <us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired
      contextRef="ief96b00f443a4686a885891ec4c615be_I20160930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDE2Mw_6790b9cc-40e1-40fc-a174-281707775d00"
      unitRef="number">0.199</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i19de5e3ec9b24f1ea8494afb290825f1_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDYyMg_453e191c-8409-435a-a1e2-73dcbf10851f"
      unitRef="usd">12500000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i826b000227f54693aaaf1920a6d1aa63_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDc1MQ_8938e287-be9a-4fbc-8d67-0d6e43211b64"
      unitRef="usd">7000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct
      contextRef="i0f56438c3aeb45edb4022475af4e3db5_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNDg5Nw_cfcc1774-b265-4a98-8a24-a9b2a79d973a"
      unitRef="usd">3000000</sesn:SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct>
    <sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods
      contextRef="i4a90ce4acc1b4bf68182efbf79fd5720_D20160901-20160930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTAwOQ_407e3e56-b2cd-45e5-8538-7e15f6b077a8"
      unitRef="number">0.02</sesn:SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods>
    <sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales
      contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTI3Ng_4740635d-a8fc-416f-8beb-982410f598b8">P15Y</sesn:SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales>
    <sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations
      contextRef="i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV8zNy9mcmFnOjE5YjgyNjhmYmQ1NzQxZjE5YWRmNDcwZTE5ZTI5N2RkL3RleHRyZWdpb246MTliODI2OGZiZDU3NDFmMTlhZGY0NzBlMTllMjk3ZGRfNTU5MQ_1350e039-e384-4f97-9cf5-93cd3528cc31">P7Y</sesn:SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations>
    <us-gaap:BasisOfAccounting
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1OA_8939b86e-ff98-4372-9e54-609d031cae72">BASIS OF PRESENTATION&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles ("GAAP"). Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates ("ASUs"), promulgated by the Financial Accounting Standards Board ("FASB").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interim Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited interim condensed consolidated financial statements have been prepared from the books and records of the Company in accordance with GAAP for interim financial information and Rule 10-01 of Regulation S-X promulgated by the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;), which permit reduced disclosures for interim periods. All adjustments, consisting only of normal recurring adjustments, which are, in the opinion of management, necessary for a fair presentation of the accompanying condensed consolidated balance sheets and statements of operations and comprehensive (loss) income, stockholders&#x2019; equity (deficit) and cash flows have been made. Although these interim financial statements do not include all of the information and footnotes required for complete annual financial statements, management believes the disclosures are adequate to make the information presented not misleading. These unaudited interim results of operations and cash flows for the six months ended June 30, 2022 are not necessarily indicative of the results that may be expected for the full year. These unaudited interim condensed consolidated financial statements and footnotes should be read in conjunction with the Company&#x2019;s audited annual consolidated financial statements and footnotes included in its Annual Report on Form 10-K, as filed with the SEC on February 28, 2022, wherein a more complete discussion of significant accounting policies and certain other information can be found.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
    <us-gaap:UseOfEstimates
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1NQ_243ab476-c381-4d36-bab5-cbc692c465e7">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in accordance with GAAP and the rules and regulations of the SEC requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company&#x2019;s business and evolving market conditions, and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. The most significant estimates and judgments impact the fair value of intangible assets; goodwill and contingent consideration; income taxes (including the valuation allowance for deferred tax assets); and research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1Ng_3226f22f-8142-48a6-8e5d-a627a0e47796">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary Viventia and its indirect subsidiary, Viventia Bio USA&#160;Inc. All intercompany transactions and balances have been eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80MC9mcmFnOjJiZWFlMzI1YjE1YzQwMGY5ZGJiOWI5NjdhM2UzNWJjL3RleHRyZWdpb246MmJlYWUzMjViMTVjNDAwZjlkYmI5Yjk2N2EzZTM1YmNfMzg1Nw_43a52c32-8f1c-429f-aaeb-e6064e25efd8">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The functional currency of the Company and each of its subsidiaries is the US dollar.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80My9mcmFnOmZmZmJiMjg1YTJiMzRlMzE5NmFhMGI5ZDNhMTRjNzVkL3RleHRyZWdpb246ZmZmYmIyODVhMmIzNGUzMTk2YWEwYjlkM2ExNGM3NWRfMzYw_eb5f5067-45e0-4b13-ae55-8180861b049b">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIESThe Company's complete summary of significant accounting policies can be found in "Item 15. Exhibits and Financial Statement Schedules - Note 3. Summary of Significant Accounting Policies" in the audited annual consolidated financial statements included in its Annual Report on Form 10-K for the year ended December&#160;31, 2021.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80Ni9mcmFnOjJjYjVlZjcxNWY2ODRlMmE4MjAxZjdmNjQzZWZjOGI4L3RleHRyZWdpb246MmNiNWVmNzE1ZjY4NGUyYTgyMDFmN2Y2NDNlZmM4YjhfMjQ3Nw_da8e4a19-ba63-4c14-82e7-71502695f21f">RECENT ACCOUNTING PRONOUNCEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80Ni9mcmFnOjJjYjVlZjcxNWY2ODRlMmE4MjAxZjdmNjQzZWZjOGI4L3RleHRyZWdpb246MmNiNWVmNzE1ZjY4NGUyYTgyMDFmN2Y2NDNlZmM4YjhfMjQ3Ng_258defce-7aa2-4262-bf57-2cecb8bf5687">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Adopted in 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020, the FASB issued ASU No. 2020-06, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt&#x2014;Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity&#x2019;s Own Equity &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2020-06")&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2020-06 simplifies the complexity associated with applying US &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;GAAP for certain financial instruments with characteristics of both liability and equity. More specifically, the amendments focus on the guidance for convertible instruments and derivative scope exception for contracts in an entity&#x2019;s own equity. The ASU also amends the diluted earnings per share (EPS) guidance, including the requirement to use the if-converted method for all convertible instruments. ASU 2020-06 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a full or modified retrospective basis. The Company adopted this guidance on a modified retrospective basis effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the FASB issued ASU No. 2021-04,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;("ASU 2021-04")&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASU 2021-04 clarifies and reduces diversity in an issuer&#x2019;s accounting for modifications or exchanges of freestanding equity-classified written call options (for example, warrants) that remain equity classified after modification or exchange. ASU 2021-04 is effective for public companies for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2021, and should be applied on a prospective basis. The Company adopted this guidance effective January 1, 2022 and it did not have an impact on the Company's financial position, results of operations including per-share amounts, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other recent accounting pronouncements issued, but not yet effective, are not expected to be applicable to the Company or have a material effect on the consolidated financial statements upon future adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExNw_cccf1ea1-acff-4f5f-9b0e-8b5d723862ef">FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 3&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company evaluates transfers between fair value levels at the end of each reporting period. There were no transfers of assets or liabilities between fair value levels during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2016, the Company acquired Viventia through the issuance of shares of common stock plus contingent consideration, pursuant to the terms of a Share Purchase Agreement. The Company recorded the acquired assets and liabilities based on their estimated fair values as of the acquisition date and finalized its purchase accounting for the Viventia Acquisition during the third quarter of 2017. The contingent consideration relates to amounts potentially payable to the former shareholders of Viventia under the Share Purchase Agreement. Contingent consideration is measured at its estimated fair value at each reporting period, with fluctuations in value resulting in a non-cash charge to earnings (or loss) during the period. The estimated fair value measurement is based on significant inputs, including internally developed financial forecasts, probabilities of success, and the timing of certain milestone events and achievements, which are not observable in the market, representing a Level 3 measurement within the fair value hierarchy. The valuation of contingent consideration requires the use of significant assumptions and judgments, which management believes are consistent with those that would be made by a market participant. Management reviews its assumptions and judgments on an ongoing basis as additional market and other data is obtained, and any future changes in the assumptions and judgments utilized by management may cause the estimated fair value of contingent consideration to fluctuate materially, resulting in earnings volatility. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of the Company&#x2019;s contingent consideration was determined using probabilities of successful achievement of regulatory milestones and commercial sales, the period in which these milestones and sales are expected to be achieved through 2033, the level of commercial sales of Vicineum forecasted for the US, Europe, Japan, China and other potential markets and discount rates ranging from 10.2% as of June&#160;30, 2022 to 8.0% and 9.3% as of December&#160;31, 2021. There have been no changes to the valuation methods utilized during the six months ended June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development in the US of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Additionally, the Company intends to seek a partner for the further development of Vicineum. The Company expects that any partner who acquires Vicineum from the Company will be obligated to make any payments that become payable to the former shareholders of Viventia under the Share Purchase Agreement. Accordingly, as of June&#160;30, 2022, the Company no longer expects to pay related milestone and earnout payments to the former shareholders of Viventia, with the exception of the potential 2% earnout payment related to the Greater China region since those territory rights have already been out-licensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Therefore, the balance as of June&#160;30, 2022 relates to contingent consideration for projected net sales in the Greater China region as compared to the balance as of December&#160;31, 2021 which was based upon projected world-wide net sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s contingent consideration was determined based on the present value of projected future cash flows associated with sales-based milestones and earnouts on net sales and is heavily dependent on discount rates to estimate the fair value at each reporting period. Earnouts were determined using an earnout rate of 2% on all commercial net sales of Vicineum through December 2033. The discount rate applied to the 2% earnout was derived from the Company&#x2019;s weighted-average cost of capital, which has fluctuated from 9.3% as of December&#160;31, 2021 to 10.2% as of June&#160;30, 2022. As of December&#160;31, 2021, the balance also reflected potential milestone payments which constitute debt-like obligations, and therefore a high-yield debt index rate was applied to the milestones in order to determine the estimated fair value. This index rate was 8.0% as of December&#160;31, 2021. The decrease in the fair value of contingent consideration of $50.2&#160;million for the six months ended June 30, 2022 was driven by the Company's decision to voluntarily pause further development of Vicineum.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExOA_dca8b190-6623-490c-9b08-a8b44aa8e88a">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of cash and cash equivalents, restricted cash, prepaid expenses and other current assets, and accounts payable on the Company&#x2019;s condensed consolidated balance sheets approximated their fair values as of June&#160;30, 2022 and December&#160;31, 2021 due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of the Company&#x2019;s financial instruments are measured at fair value using a three-level hierarchy that prioritizes the inputs used to measure fair value. This fair value hierarchy prioritizes the use of observable inputs and minimizes the use of unobservable inputs. The three levels of inputs used to measure fair value are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 1&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for identical instruments in active markets, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;padding-left:72pt;text-align:justify;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Level 2&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&#160;&#160;&#160;&#160;Inputs are quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; or model-derived valuations whose inputs are observable or whose significant value drivers are observable. &lt;/span&gt;&lt;/div&gt;Level 3:&#160;&#160;&#160;&#160;Inputs are unobservable and reflect the Company&#x2019;s own assumptions, based on the best information available, including the Company&#x2019;s own data.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjExOQ_e0f8c4b4-d54a-4648-b18c-ee52a851e0c7">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables set forth the carrying amounts and fair values of the Company's financial instruments measured at fair value on a recurring basis as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:13pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,765&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:36.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value Measurement Based on&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Quoted Prices in Active&lt;br/&gt;Markets&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Significant Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;br/&gt;(cash equivalents)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i00b74714225f4d449b61808db2c2c804_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS0xLTEtMS04MTcyMw_1e7e920c-5e79-4f0f-9770-62dad22e7998"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS0zLTEtMS04MTcyMw_18e24ef0-9d22-4996-aefa-6bf9887273c7"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS01LTEtMS04MTcyMw_2d3bcdcb-7c0a-4a3a-a57b-49516da3981c"
      unitRef="usd">40765000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS03LTEtMS04MTcyMw_7e1a192f-645a-469e-8b7b-711d0fd8e891"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNS05LTEtMS04MTcyMw_10c4bd09-1a60-42a1-90fa-055e101b90ac"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00b74714225f4d449b61808db2c2c804_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi0xLTEtMS04MTcyMw_4755a319-9135-4527-a21a-686e4ad16a8e"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi0zLTEtMS04MTcyMw_36b5ab70-a8f0-4d7b-9562-1bd0aa905804"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi01LTEtMS04MTcyMw_d6d7d627-6caf-4298-aaeb-c2a31e21457f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi03LTEtMS04MTcyMw_bb56c8b8-6290-4cd8-9002-aa147c592d78"
      unitRef="usd">89095000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfNi05LTEtMS04MTcyMw_23b72696-0a35-48c0-accc-76ff5b27897c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i00b74714225f4d449b61808db2c2c804_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS0xLTEtMS04MTcyMw_43c03f0a-85b5-4f57-b031-a08368780fb3"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia255f7c7fbf94cfc9de8c1f065d8c7d1_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS0zLTEtMS04MTcyMw_7c30c5b1-6230-4932-8592-5e1c8f7cb8a4"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="ia4884e6cf1834287a8e4032056a092dd_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS01LTEtMS04MTcyMw_90c43df7-38b3-4ac8-93d3-2b5c983814f0"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6ba330c2936d403bb2d4a10535dd51e4_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS03LTEtMS04MTcyMw_722d86b4-1cd3-4140-9932-8952ac68e2dd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="icdfabbf29e4842ea8a9a1c8f8e4e3eb6_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmNhNDZjMGUyNjczNDRiMThhNjVkOGE2ZDlkYzgzNzc0L3RhYmxlcmFuZ2U6Y2E0NmMwZTI2NzM0NGIxOGE2NWQ4YTZkOWRjODM3NzRfOS05LTEtMS04MTcyMw_966eae52-c0de-4d2c-9879-3a7787270ee4"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iced2721a212d43848f8133e3f4186dda_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC0xLTEtMS04MTcyMw_47372c96-6467-49af-867e-e6eebcc9d03e"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC0zLTEtMS04MTcyMw_fc9e2df5-70f4-4a03-9b7c-14fff02a64a3"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i149ccd24ae824eb0955599b4c37f7358_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC01LTEtMS04MTcyMw_bad5592e-314f-4fe9-a3a2-609adf0b5a86"
      unitRef="usd">16382000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC03LTEtMS04MTcyMw_20330422-e377-4f28-ab27-e516048cb53e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4e27122d96e44ef1888f4f1425b3c91c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNC05LTEtMS04MTcyMw_ae364cf4-c015-43c0-96b0-ddbeefca380a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="iced2721a212d43848f8133e3f4186dda_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy0xLTEtMS04MTcyMw_888d20e8-db57-4b38-a19e-a08d6c8ae30a"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2a3b35a74f76415e927e1f0b93aab7c2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy0zLTEtMS04MTcyMw_1d36476b-6f88-432a-a2cb-ba8a33fb521d"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i149ccd24ae824eb0955599b4c37f7358_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy01LTEtMS04MTcyMw_4ae0fa2c-7778-4b10-95f3-05094ff6d623"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="if61cc1aaeea642b4a0e8ae2a0c2ed861_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy03LTEtMS04MTcyMw_d9eb5bc1-f626-47cc-acd1-9194131cf94b"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i4e27122d96e44ef1888f4f1425b3c91c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmY3MjQzMDhiNDEzMjQ5MjRiNDg2MDEzY2YxN2FlNjBmL3RhYmxlcmFuZ2U6ZjcyNDMwOGI0MTMyNDkyNGI0ODYwMTNjZjE3YWU2MGZfNy05LTEtMS04MTcyMw_0e6e3e45-5bc2-4ad3-a869-99aa739d6bfe"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU0Ng_f5aaaef4-10cc-425f-a001-f3fb3e96da4f"
      unitRef="number">0.102</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="idb703a0172774df7b5fad376a5cac8da_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU2MQ_c0f91ab8-cf48-40a5-8235-1c952444c4e1"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="id8d011b45a374b0784b3c71627d06003_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfMzU2OA_dd44d937-805c-4c2a-98dc-00fa27f3d18d"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNDU5OA_d9080129-974b-47b1-ab54-72da551e2126"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjEyMA_a8190d7f-f82c-45eb-af3a-77bcc299f04e">The following table sets forth a summary of the change in the fair value of the Company's contingent consideration liability, measured on a recurring basis at each reporting period (in thousands).&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(50,200)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,800&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMC0xLTEtMS04MTcyMw_20bf8f5a-9a28-4933-ad30-cc6427e48058"
      unitRef="usd">52000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent
      contextRef="ie42072eca3cd43a19d6e850e7b53ebd2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMi0xLTEtMS04MTcyMw_73261a74-142f-4f58-8fda-77b225a7843b"
      unitRef="usd">-50200000</sesn:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ifc528568b4234010b987e7ed2c26110d_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RhYmxlOmZiNGI5OWY1Yzc4ZDQ2NjJhNWZmN2FmNmY5YWRiOGM4L3RhYmxlcmFuZ2U6ZmI0Yjk5ZjVjNzhkNDY2MmE1ZmY3YWY2ZjlhZGI4YzhfMy0xLTEtMS04MTcyMw_43325ea7-0264-445c-b5c1-39b8226b205a"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTQ2Mw_a84d3b3f-25ad-4bb3-9b09-e964d9d8d5dd"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTU2Mg_6671c16c-b622-4b15-9d8a-9298198f17fa"
      unitRef="number">0.02</sesn:LicenseAgreementRoyaltyRate>
    <sesn:WeightedAverageCostOfCapital
      contextRef="ie23847c7ec884b868685a03832f736b6_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTY2NA_7c8fbadf-81d3-4151-b741-cbb3050abf8d"
      unitRef="number">0.093</sesn:WeightedAverageCostOfCapital>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i366d8bdb060a44de9b57a2a8e8f5f226_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTY3OQ_f5aaaef4-10cc-425f-a001-f3fb3e96da4f"
      unitRef="number">0.102</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNTkzOQ_f42385ae-b3cd-41ad-9799-5b8ceb2d5cf5"
      unitRef="number">0.080</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV80OS9mcmFnOjFiNWI0YTYyMWE2NDRlOWE5NTc2MjE1OTIwNjRiYTAxL3RleHRyZWdpb246MWI1YjRhNjIxYTY0NGU5YTk1NzYyMTU5MjA2NGJhMDFfNjAxNA_5b50f1d8-eb29-4e47-8274-d8e3894f1222"
      unitRef="usd">-50200000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNjk5_25a7aba0-8bf9-4bf9-bf3f-10bbd5303e00">RECEIVABLES &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounts receivable balance as of June&#160;30, 2022 is $0.1&#160;million compared to $21.0&#160;million as of December&#160;31, 2021. The decrease is driven by the receipt of the $20.0&#160;million milestone from F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. (collectively, &#x201c;Roche&#x201d;) for the initiation of a Phase II clinical trial in the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other receivable balance as of June&#160;30, 2022 is $14.0&#160;million compared to $3.5&#160;million as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The increase is driven by expected insurance recovery of $13.0&#160;million related to the preliminary settlements of the securities and derivative litigation. This was partially offset by the receipt of $2.4&#160;million for German value-added tax ("VAT") recovery in the first half of 2022, related to drug substance sent to Baxter in 2020 and 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="icba9e1576f6248d4b9e8e786bce57457_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNjU_f04f06da-c180-4f4a-bdd7-26a3e1fd7e27"
      unitRef="usd">100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfODA_c4037a19-f5b0-47f8-9e21-33d140f07698"
      unitRef="usd">21000000</us-gaap:AccountsReceivableNetCurrent>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="ie44b4e5d665d480d86d36cea88a338ab_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMTM4_6f808512-d2b2-4b78-80e0-55b4bae60259"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMzUy_935a3bdb-d76d-4e2e-bdc6-b937c5b58680"
      unitRef="usd">14000000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfMzY3_98ae4fdd-e7dd-4d3f-a507-a7b356ee1c6d"
      unitRef="usd">3500000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="ia00d97ca9441426bb9adfaa45c3d754c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNDM3_a10ab14c-87bc-4a04-9fe9-be057e8a6d42"
      unitRef="usd">-13000000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="i0c25a0b2ddf74ac2b722c896a5913d4c_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81Mi9mcmFnOjVmODQ1MmQ0MTViMjQyOGJhMzliZmYzMTA3YmY0YTQwL3RleHRyZWdpb246NWY4NDUyZDQxNWIyNDI4YmEzOWJmZjMxMDdiZjRhNDBfNTY4_6ceb0ea1-9721-47b4-8b46-bdfc5aba22df"
      unitRef="usd">-2400000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:OtherCurrentAssetsTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNDc0_f19d1e29-490b-4020-83a4-cd73d8a7f095">PREPAID EXPENSES The prepaid expenses balance as of June&#160;30, 2022 is $0.8&#160;million compared to $25.7&#160;million as of December&#160;31, 2021. In light of the Company's decision to voluntarily pause further development of Vicineum, the Company evaluated prepaid balances and determined that the prepayments for the manufacturing of Vicineum, including consumables, had no future economic benefit or value. Pursuant to ASC Topic 730, Certain Nonrefundable Advance Payment, the Company expensed $25.2&#160;million of prepaids during the three months ended June 30, 2022.</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNjc_e904632d-9028-4466-9554-f23e7f940a38"
      unitRef="usd">800000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfODI_57fb7258-a817-4d25-8f9e-377e921424cd"
      unitRef="usd">25700000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <sesn:ExpensesPreviouslyClassifiedAsPrepaid
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81NS9mcmFnOmQxN2UyMjhhNDUzZTRlNDE4YjY1YmIxZGJkMmY4Yjg3L3RleHRyZWdpb246ZDE3ZTIyOGE0NTNlNGU0MThiNjViYjFkYmQyZjhiODdfNDQ1_53e0ae8e-90b3-418e-841f-cd03c80c9fc1"
      unitRef="usd">25200000</sesn:ExpensesPreviouslyClassifiedAsPrepaid>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwOQ_1ae65a2d-6ffd-4294-93c3-497531ab6664">INTANGIBLE ASSETS AND GOODWILL&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangibles&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets on the Company's condensed consolidated balance sheets are the result of the Viventia Acquisition in September 2016. The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the acquired intangible assets for the European Union ("EU") rights of Vicineum is determined using a risk-adjusted discounted cash flow approach, which includes probability adjustments for projected revenues and operating expenses based on the success rates assigned to each stage of development for each geographical region; as well as discount rates applied to the projected cash flows. In August 2021, the Company received a CRL from the FDA regarding its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC, the Company&#x2019;s former lead product candidate. In the CRL, the FDA determined that it could not approve the BLA for Vicineum in its present form and provided recommendations specific to additional clinical/statistical data and analyses in addition to CMC issues pertaining to a recent pre-approval inspection and product quality. Also in August 2021, the Company withdrew its marketing authorization application (&#x201c;MAA&#x201d;) to the European Medicines Agency (the &#x201c;EMA&#x201d;) for Vysyneum&#x2122; for the treatment of BCG-unresponsive NMIBC in order to pause its plans to pursue regulatory approval of Vysyneum in the EU until there was more clarity from the FDA on next steps for Vicineum in the United States. Vysyneum is the proprietary brand name that was conditionally approved by the EMA for oportuzumab monatox &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the EU. Given the inherent uncertainty in the development plans for Vicineum as a result of the CRL and the Company&#x2019;s withdrawal of its MAA, an impairment analysis was conducted in the third quarter of 2021, which concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum US rights was fully impaired as of September 30, 2021. The $31.7&#160;million of impairment charges as of September 30, 2021 were due to delays in the expected start of commercialization and lower probabilities of success, combined with higher operating expenses expected to be incurred prior to commercialization, resulting in lower expected future cash flows estimated in the US market. At that time, management assessed that the carrying value of the Vicineum EU rights was not at significant risk of impairment in the future within the current range of commercialization timelines and probability of success assumptions. This was primarily due to the fact that the EU asset was burdened with significantly less expense than the US asset, as the Company&#x2019;s strategic operating plan was to sublicense Vicineum to business development partners in all regions outside the US, including the EU, with it earning a potential combination of upfront, milestone, and royalty payments, and the business development partner bearing the majority of regulatory and commercialization costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022, the Company observed an evolution of the current market treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage. The Company has also experienced a sustained decline in its share price and a resulting decrease in our market capitalization. On July 15, 2022 the Company made the strategic decision to voluntarily pause further development in the US of Vicineum and intends to seek a partner for the further development of Vicineum. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial for the treatment of NMIBC, following recent discussions with the FDA and the updated market data obtained through market research during the ongoing BCG shortage. Management updated the discounted cash flow model using the market participant approach and considered preliminary terms of a potential partnering deal to conclude the fair value of EU asset. The Company concluded that the carrying value of the Company&#x2019;s intangible asset of Vicineum EU rights of $14.7&#160;million was fully impaired and written off as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#x2019;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill on the Company's condensed consolidated balance sheets is the result of the Viventia Acquisition in September 2016. During the second quarter of 2022 the Company observed continued trends in the Company&#x2019;s market capitalization as compared to the carrying value of its single reporting unit as well as changes in certain assumptions in the fair value of the business including market share, length and cost of a clinical study, and time to potential market launch. The Company identified these changes as potential impairment indicators and performed a quantitative impairment analysis, in advance of the Company's typical annual assessment date of October 1. The Company reassessed the underlying assumptions used to develop its revenue projections, which were then used as significant inputs to determine the fair value of equity. Management updated its revenue forecast models based on further launch delays in both the US and outside the US ("OUS") regions. The Company also recently observed an evolution of the current treatment paradigm in NMIBC, with substantial uptake of intravesical chemotherapy (monotherapy and combination therapy) during the ongoing BCG shortage resulting in lower projected peak market share for Vicineum. Management also considered other factors including the preliminary valuations of strategic alternatives during the fair value assessment. As a result of the interim impairment test, the Company concluded that the carrying value of its goodwill of $13.1&#160;million was fully impaired as of June&#160;30, 2022. The weighted average cost of capital used in the Company&#x2019;s most recent impairment test, which was 24.5%, was risk-adjusted to reflect the specific risk profile of the reporting unit. Management used considerable judgment to determine key assumptions, including projected revenue and appropriate discount rates, which are classified as level 3 in fair value measurement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwNw_88933c75-6a8a-4a31-8eba-6d195261b5c1">The following table sets forth the composition of intangible assets as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vicineum European Union rights&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Intangibles&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,700&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ifedd00e94bff4f138a71518235d8f0c2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfMy0xLTEtMS04MTcyMw_71b63e5a-2140-4b80-b284-61f87f6b4d47"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ifefc2cc3cebe45d78a99c0e68849b7ca_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfMy0zLTEtMS04MTcyMw_96711c0a-dcf1-41cb-b971-994a6a0affde"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ie19452cececa4a96a54f4c9ced19321f_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfNC0xLTEtMS04MTcyMw_ed1c49d0-856e-4f2b-93cf-6d6d7f2fc7a0"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="i5913171b77dd4a8db206d874b45307ba_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOjJjODcyN2FiNjcyZTRkMzM5MGVkOWY3N2UyZTNhZjM2L3RhYmxlcmFuZ2U6MmM4NzI3YWI2NzJlNGQzMzkwZWQ5Zjc3ZTJlM2FmMzZfNC0zLTEtMS04MTcyMw_125ddebe-5c67-4a47-b72c-77ef1c74cb05"
      unitRef="usd">14700000</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i90478a97ea0d40c7a94bea0d8f484eac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfMTk4Mg_95e5b9d9-ad7d-4fb3-8735-354eb0735b19"
      unitRef="usd">31700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNDE4Nw_05688097-655b-4987-8ba3-a06f0e94b956"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage
      contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNDMzMw_911d7f3c-06ac-44d6-b54a-396f7526532d"
      unitRef="number">0.245</sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage>
    <us-gaap:Goodwill
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjEwNg_a5c521da-c994-4190-8656-577974656a5b"
      unitRef="usd">13100000</us-gaap:Goodwill>
    <sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage
      contextRef="ic4e724420d5a41518add1245efed2632_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjIzNg_767cee26-7668-4619-a4eb-3534f810a1f4"
      unitRef="number">0.245</sesn:ImpairmentOfIntangibleAssetsCostOfCapitalPercentage>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RleHRyZWdpb246ZDBkYWI3MWU5YWMyNDc4NzllOThiZTMyODQ3MDg0NzFfNjYwOA_d3aed490-585c-457d-bb75-f2fd1c53959a">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the change in goodwill as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;text-indent:36pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.894%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,064&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Impairment loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,064)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMC0xLTEtMS04MTcyMw_8620a830-b6be-41a4-a406-ca28fcbbc803"
      unitRef="usd">13064000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMS0xLTEtMS04MTcyMw_7c1a4186-1a78-40a5-88cf-38764074a589"
      unitRef="usd">13064000</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:Goodwill
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV81OC9mcmFnOmQwZGFiNzFlOWFjMjQ3ODc5ZTk4YmUzMjg0NzA4NDcxL3RhYmxlOmFlMjcyMjI4MmE0MTRjMzFiODlkZmExNjI3OGM4Mjc2L3RhYmxlcmFuZ2U6YWUyNzIyMjgyYTQxNGMzMWI4OWRmYTE2Mjc4YzgyNzZfMi0xLTEtMS04MTcyMw_5407922f-5016-468a-82a6-14bfdc23a7c9"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RleHRyZWdpb246ZGY1NDEwMWJhNWFjNGMxNDhmM2MwYmM2NWZkNGE5OWFfMTMz_2899a2a7-7ff7-41c1-8c54-ebd0b9ef2cad">ACCRUED EXPENSES&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including preliminary litigation settlement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RleHRyZWdpb246ZGY1NDEwMWJhNWFjNGMxNDhmM2MwYmM2NWZkNGE5OWFfMTI4_be532793-95e7-434a-ad3e-b90836f8ef9d">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the composition of accrued expenses as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.450%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.015%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.428%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.626%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.431%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,841&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payroll-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,967&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restructuring charge related&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Legal expenses, including preliminary litigation settlement &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Accrued Expenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,851&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,255&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMS0xLTEtMS04MTcyMw_7e866451-22fe-407e-a14f-16ee7659e808"
      unitRef="usd">1847000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <sesn:AccruedResearchAndDevelopmentExpenseCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMS0zLTEtMS04MTcyMw_fcb6f822-c200-4088-ab50-021b73304a91"
      unitRef="usd">1841000</sesn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMi0xLTEtMS04MTcyMw_fdff577d-9d1d-4004-9df9-bf7c6b8dbf61"
      unitRef="usd">3099000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMi0zLTEtMS04MTcyMw_28129dca-5edd-4512-8d5b-97275379907a"
      unitRef="usd">2967000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMy0xLTEtMS04MTcyMw_0ae0b1dd-5f86-4249-9008-83c968d2f54a"
      unitRef="usd">394000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <sesn:AccruedRestructuringChargesRelatedCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfMy0zLTEtMS04MTcyMw_6a387163-36db-43d1-8a88-928a34f9f832"
      unitRef="usd">1497000</sesn:AccruedRestructuringChargesRelatedCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNC0xLTEtMS04MTcyMw_7a9c4536-41b1-4195-bac5-4041e7d83afc"
      unitRef="usd">507000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNC0zLTEtMS04MTcyMw_76e9f29c-22f7-4183-98fe-45d22e90ae9a"
      unitRef="usd">597000</us-gaap:AccruedProfessionalFeesCurrent>
    <sesn:AccruedLegalFees
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNS0xLTEtMS04MTcyMw_5869c4c3-6393-4cc8-bb2d-edf2d4c25555"
      unitRef="usd">22477000</sesn:AccruedLegalFees>
    <sesn:AccruedLegalFees
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNS0zLTEtMS04MTcyMw_86039753-3523-4ab5-a1fe-227e22341434"
      unitRef="usd">1344000</sesn:AccruedLegalFees>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNi0xLTEtMS04MTcyMw_18df4c99-7861-4b08-866d-52e5e4c5f2e8"
      unitRef="usd">1527000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNi0zLTEtMS04MTcyMw_d8ee6037-9d98-48bd-99c8-f9384c987262"
      unitRef="usd">9000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNy0xLTEtMS04MTcyMw_d5134933-6e5a-43e7-81b7-ca780434be72"
      unitRef="usd">29851000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82MS9mcmFnOmRmNTQxMDFiYTVhYzRjMTQ4ZjNjMGJjNjVmZDRhOTlhL3RhYmxlOjcyMTQ4ZWY5ZTM0MDQwNmE5MzlmYWI4NjE1ZTAzMDRhL3RhYmxlcmFuZ2U6NzIxNDhlZjllMzQwNDA2YTkzOWZhYjg2MTVlMDMwNGFfNy0zLTEtMS04MTcyMw_b5c0e6c5-356b-41b9-9c6e-bfc9e45da61d"
      unitRef="usd">8255000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNjM3Mg_91e96aa0-26c1-4e40-b777-2467159bb82b">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business. When the Company becomes aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. In accordance with authoritative guidance, the Company records loss contingencies in its financial statements only for matters in which losses are probable and can be reasonably estimated. Where a range of loss can be reasonably estimated with no best estimate in the range, the Company records the minimum estimated liability. If the loss is not probable or the amount of the loss cannot be reasonably estimated, the Company discloses the nature of the specific claim if the likelihood of a potential loss is reasonably possible, and the amount involved is material. The Company continuously assesses the potential liability related to the Company&#x2019;s pending litigation and revises its estimates when additional information becomes available. The Company is not currently a party to any material legal proceedings, other than as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 19, 2021, August 31, 2021, and October 7, 2021, three substantially identical securities class action lawsuits captioned Bibb v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07025, Cizek v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-07309, and Markman v. Sesen Bio, Inc. et al., Case No. 1:21-cv-08308 were filed against the Company and certain of its officers in the US District Court for the Southern District of New York. The three complaints alleged violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder based on statements made by the Company concerning its BLA for Vicineum for the treatment of BCG-unresponsive NMIBC. The three complaints sought compensatory damages and costs and expenses, including attorneys&#x2019; fees. On October 29, 2021, the court consolidated the three cases under the caption In re Sesen Bio, Inc. Securities Litigation, Master File No. 1:21-cv-07025-AKH (the &#x201c;Securities Litigation&#x201d;), and appointed Ryan Bibb, Rodney Samaan, Lionel Dreshaj and Benjamin Dreshaj (&#x201c;Lead Plaintiffs&#x201d;) collectively as the lead plaintiffs under the Private Securities Litigation Reform Act. On November 1, 2021, two stockholders filed motions to reconsider asking the court to appoint a different lead plaintiff. The court has not ruled on those motions at this time. On November 24, 2021, defendants filed a motion to transfer venue to the US District Court for the District of Massachusetts. That motion was fully briefed as of December 13, 2021, but the court has not yet ruled on that motion. On December 6, 2021, the Lead Plaintiffs filed an amended class action complaint (the &#x201c;Amended Complaint&#x201d;). The Amended Complaint alleges the same violations of Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder on the same theory as the prior complaints. The defendants moved to dismiss the Amended Complaint on March 7, 2022. The plaintiffs filed their opposition to that motion on April 6, 2022 and Defendants filed their reply in further support of the motion to dismiss on May 6, 2022. After the motion was fully briefed and before the court ruled on the motion, on June 3, 2022, the parties requested that the court hold any decision on the motion to dismiss in abeyance to provide the parties with an opportunity to engage in mediation. The parties engaged in mediation on June 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 20, 2021 and September 24, 2021, two substantially similar derivative lawsuits captioned Myers v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11538 and D&#x2019;Arcy v. Sesen Bio, Inc., et. al., Case No. 1:21-cv-11577 were filed against the Company&#x2019;s board of directors and certain of its officers in the US District Court for the District of Massachusetts, with the Company named as a nominal defendant. On January 12, 2022, a third derivative complaint captioned Tang v. Sesen Bio, Inc., et al., was filed in Superior Court in Massachusetts against the Company&#x2019;s board of directors and certain of its officers (the &#x201c;State Derivative Litigation&#x201d;). The three derivative complaints allege breach of fiduciary duties, waste of corporate assets, and violations of federal securities laws based on statements made by the Company concerning its BLA for Vicineum for the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;treatment of BCG-unresponsive NMIBC. The D&#x2019;Arcy complaint further alleges unjust enrichment, abuse of control, gross mismanagement and aiding and abetting thereof. The three derivative complaints seek unspecified damages, restitution and disgorgement of profits, benefits and compensation obtained by the defendants and costs and expenses, including attorneys&#x2019; fees. On October 18, 2021, the court consolidated the two federal court cases under the caption In re Sesen Bio, Inc. Derivative Litigation, Lead Case No. 1:21-cv-11538 (the &#x201c;Federal Derivative Litigation&#x201d;). On December 22, 2021, the court entered a joint stipulation among the parties to stay the Federal Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. On May 1, 2022, the plaintiffs filed a verified consolidated shareholder derivative complaint in the Federal Derivative Litigation. On May 18, 2022, the court entered a joint stipulation among the parties to stay the State Derivative Litigation until after a ruling on any motion to dismiss filed by defendants in the Securities Litigation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company deemed the settlements of the Securities Litigation, the State Derivative Litigation, the Federal Derivative Litigation, and other potential related derivative claims, probable and amounts reasonably estimable as of June 30, 2022 and accrued $21.6&#160;million to litigation related liability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, its board of directors and the individual defendants continue to deny all allegations of any wrongdoing, but are seeking to settle the Securities Litigation, the State Derivative Litigation and the Federal Derivative Litigation to avoid the uncertainty, risk, expense and distraction of protracted litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Executive Employment Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into employment agreements or offer letters with certain of its key executives, providing for separation payments and benefits in certain circumstances, as defined in the agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <sesn:NumberOfLawsuits
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTIxNQ_875fa51e-69a0-4f90-9187-ef20a0dbcd2b"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTU5MQ_520261b9-1d7d-40ee-89ed-7edd7d6296c5"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTgzMQ_a1241674-6c14-4bf3-8965-4e0fdf0fa99e"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfMTk3Mg_206cdeaa-2f19-4944-a617-bbb7671d97cf"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <sesn:NumberOfLawsuits
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNDE4NA_52651805-ff33-460c-bf4c-648ac65918fc"
      unitRef="lawsuit">3</sesn:NumberOfLawsuits>
    <us-gaap:LitigationReserve
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82NC9mcmFnOjQzMjRjNTI3ZmMwOTRkZTY4YWMyZjMzYjgzZTljNTlhL3RleHRyZWdpb246NDMyNGM1MjdmYzA5NGRlNjhhYzJmMzNiODNlOWM1OWFfNTc3NA_fc5c11eb-8581-4b1a-9861-ab12f9632ff1"
      unitRef="usd">21600000</us-gaap:LitigationReserve>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3Mw_fc4cc357-c1a0-421c-a5b7-0a53d5127125">LEASES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's lease portfolio includes an operating lease for its 31,100 square foot facility in Winnipeg, Manitoba which consists of manufacturing, laboratory, warehouse and office space. In September 2020, the Company entered into an extension of this lease for an additional two years, through September 2022. The minimum monthly rent under this lease is CAD $18,100 (approximately $14,000 at exchange rates in effect on June&#160;30, 2022). In addition to rent expense, the Company expects to incur CAD $18,200 per month related to operating expenses (approximately $14,100 at exchange rates in effect on June&#160;30, 2022). Operating lease cost under this lease, including the related operating costs, were $83,000 and $165,000 for the three and six months ended June&#160;30, 2022, respectively, and $84,000 and $166,000 for the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The asset component of the Company&#x2019;s operating leases is recorded as operating lease right-of-use assets and reported within &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_4843e629-dcdb-4616-b8a6-a27047f3d904"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MA_97400fbf-3c91-4d39-b5d3-04d3e2f63a2e"&gt;other assets&lt;/span&gt;&lt;/span&gt; on the Company's condensed consolidated balance sheets. The right of use asset total was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. The short-term lease liability is recorded in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_8d631678-1039-4b69-9e83-f467e7b5b77b"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTg3MQ_bedfdad2-e676-46e0-be70-8fe59f2f9fc1"&gt;other current liabilities&lt;/span&gt;&lt;/span&gt; and the long-term lease liability is recorded in other liabilities on the Company&#x2019;s condensed consolidated balance sheets. The short-term lease liability was $41,700 as of June&#160;30, 2022 and $123,300 as of December&#160;31, 2021. There was no long-term operating lease liability as of June&#160;30, 2022 or December&#160;31, 2021. Operating lease cost is recognized on a straight-line basis over the term of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has short-term property leases for modular office space for 1) its corporate headquarters in Cambridge, MA and 2) office space in Philadelphia, PA. The short-term leases are renewed on a month-to-month basis. The minimum monthly rent for these office spaces is $2,200 and $21,000, respectively, which is subject to change if and as the Company adds space to or deducts space from the leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <sesn:OperatingLeasesAreaOfOfficeSpace
      contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfODI_3c9a1b5d-dd64-41d0-a1a2-6848788a3477"
      unitRef="sqft">31100</sesn:OperatingLeasesAreaOfOfficeSpace>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i6f1af4670f5349589e2c8544533b3f92_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMjkw_a6c73a10-8117-4e4b-a660-c7feb91586bb">P2Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMzY3_38c96517-3ec3-49fc-bdd4-36df83ea2e9d"
      unitRef="cad">18100</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMzg1_bba43691-83f6-480b-84ba-cd612f0f0e43"
      unitRef="usd">14000</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNDg2_de981cf0-4aa8-4f3b-9ab0-edf0a5dddf65"
      unitRef="cad">18200</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <sesn:OperatingLeaseOtherMonthlyOperatingExpenses
      contextRef="i4a0ae9c23785494c84090f1c9e99efed_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNTQ0_fd5c2c33-be91-4122-a156-d43844e4d0ec"
      unitRef="usd">14100</sesn:OperatingLeaseOtherMonthlyOperatingExpenses>
    <us-gaap:OperatingLeaseCost
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNjY2_29b95280-5e70-41de-ab2e-7f72ada6c594"
      unitRef="usd">83000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNjcz_f28ffa81-5333-4d68-8ca0-2fea1974d00c"
      unitRef="usd">165000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNzMz_544e0607-7d50-417b-a15c-ab33f76340d7"
      unitRef="usd">84000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfNzQw_809ca5a0-75a9-43c6-b369-f68ac26dd9ee"
      unitRef="usd">166000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTAyMw_e6381c03-f929-4ee1-a916-88657a2e7e68"
      unitRef="usd">41700</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTAzOQ_4d14af85-3976-464c-be5f-4390fe240d26"
      unitRef="usd">123300</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTI4Mg_add54a51-7c08-4d46-87bf-d4cd3b8d2811"
      unitRef="usd">41700</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTI5OA_7926b718-f9aa-4426-9361-4fb46ce782d7"
      unitRef="usd">123300</us-gaap:OperatingLeaseLiabilityCurrent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i000d73058a0b4403961f473fd89fbb67_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTc1MA_bc7d5622-3205-4216-b4cf-a80a71782feb"
      unitRef="usd">2200</sesn:OperatingLeaseMonthlyRent>
    <sesn:OperatingLeaseMonthlyRent
      contextRef="i5ac9bf36e8db4b3398a967b1e06528c6_D20220101-20220630"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV82Ny9mcmFnOjEwN2RlZmNhMGVjMjQ2YjM5MmFlZjdlNWUyZDkyZTUyL3RleHRyZWdpb246MTA3ZGVmY2EwZWMyNDZiMzkyYWVmN2U1ZTJkOTJlNTJfMTc1Nw_004aaf50-b17a-494e-a1ae-953a1b55f58b"
      unitRef="usd">21000</sesn:OperatingLeaseMonthlyRent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczNA_15459bbc-b71c-4872-8762-0da41f4c9b5c">STOCKHOLDERS' EQUITY &lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Equity Financings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ATM Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has entered into an Open Market Sale Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with Jefferies LLC ("Jefferies"), dated November 29, 2019, as amended by Amendment No. 1 dated October 30, 2020, Amendment No. 2 dated February 17, 2021 and Amendment No. 3, dated June 1, 2021 (as amended, the "Sale Agreement"), under which the Company may issue and sell shares of its common stock, par value $0.001 per share, from time to time through Jefferies (the &#x201c;ATM Offering&#x201d;). In June and July 2021, the Company filed prospectus supplements with the SEC in connection with the offer and sale of up to an aggregate of $200&#160;million of common stock pursuant to the Sale Agreement of which $97.8&#160;million of common stock remain available for future issuance as of June&#160;30, 2022. Sales of common stock under the Sale Agreement are made by any method that is deemed to be an ATM offering as defined in Rule 415(a)(4) of the Securities Act of 1933, as amended, including but not limited to sales made directly on or through the Nasdaq Stock Market or any other existing trading market for the Company's common stock. The Company may sell shares of its common stock efficiently from time to time but has no obligation to sell any of its common stock and may at any time suspend offers under the Sale Agreement or terminate the Sale Agreement. Subject to the terms and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conditions of the Sale Agreement, Jefferies will use its commercially reasonable efforts to sell common stock from time to time, as the sales agent, based upon the Company&#x2019;s instructions, which include a prohibition on sales below a minimum price set by the Company from time to time. The Company has provided Jefferies with customary indemnification rights, and Jefferies is entitled to a commission at a fixed rate equal to 3.0% of the gross proceeds for each sale of common stock under the Sale Agreement. The Company did not sell any shares of common stock pursuant to the Sale Agreement during the&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and six months ended June&#160;30, 2022. The Company raised $136.8&#160;million of net proceeds from the sale of 47.1&#160;million shares of common stock at a weighted-average price of $2.99 per share during the six months ended June 30, 2021. The Company raised $64.3&#160;million of net proceeds from the sale of 16.5&#160;million shares of common stock at a weighted-average price of $4.02 per share during the three months ended June 30, 2021. Share issuance costs, including sales agent commissions, related to the ATM Offering totaled&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.0&#160;million and $4.2&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;during the three and six months ended June&#160;30, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to its Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), the Company is authorized to issue 5.0 million shares of "blank check" preferred stock, $0.001 par value per share, which enables its board of directors, from time to time, to create one or more series of preferred stock. Each series of preferred stock issued shall have the rights, preferences, privileges and restrictions as designated by the board of directors. The issuance of any series of preferred stock could affect, among other things, the dividend, voting and liquidation rights of the Company's common stock. The Company had no preferred stock issued and outstanding as of June&#160;30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following approval by the Company&#x2019;s stockholders on May 3, 2021, an amendment became effective to the Certificate of Incorporation that increased the number of authorized shares of common stock from 200&#160;million to 400&#160;million, of which&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;approximately 199&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares were issued and outstanding as of June&#160;30, 2022 and December&#160;31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;230,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The voting, dividend and liquidation rights of holders of shares of common stock are subject to and qualified by the rights, powers and preferences of holders of shares of preferred stock. Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company's stockholders; provided, however, that, except as otherwise required by law, holders of common stock shall not be entitled to vote on any amendment to the Company&#x2019;s Certificate of Incorporation that relates solely to the terms of one or more outstanding series of preferred stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more such series, to vote thereon. There shall be no cumulative voting.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dividends may be declared and paid on the common stock from funds lawfully available thereof as and when determined by the board of directors and subject to any preferential dividend or other rights of any then-outstanding preferred stock. The Company has never declared or paid, and for the foreseeable future does not expect to declare or pay, dividends on its common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the dissolution or liquidation of the Company, whether voluntary or involuntary, holders of common stock will be entitled to receive all assets of the Company available for distribution to its stockholders, subject to any preferential or other rights of any then-outstanding preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s outstanding warrants are non-tradeable and equity-classified because they meet the derivative scope exception under ASC Topic 815-40, Derivatives and Hedging - Contracts in Entity&#x2019;s Own Equity. The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8c8d5912a42e4ad2833bfc6f61c043f2_I20191129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNDM0_02f23d1d-b19c-41d6-b43f-2d12d810fdc2"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction
      contextRef="i78ad6147eb974d38affb24031a858c3d_D20210601-20210731"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNjQ2_8accd469-b56b-4e19-a19c-a6efa313da9d"
      unitRef="usd">200000000</sesn:SaleOfStockMaximumAggregateSalesPriceInTransaction>
    <sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance
      contextRef="i5a0705a329ea41ed96157e39c6c49855_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNzA1_64d0041c-b568-4f9b-9a3d-1f42ca746b76"
      unitRef="usd">97800000</sesn:SaleOfStockRemainingSharesAmountAvailableForFutureIssuance>
    <sesn:SaleOfStockCommissionFixedRate
      contextRef="i7eda749d94fb48398a0924800d09ac3d_D20211129-20211129"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMTc4Mg_dfc62715-9407-4ff3-be01-ec1201623598"
      unitRef="number">0.030</sesn:SaleOfStockCommissionFixedRate>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMTk5Ng_cd890d4b-9964-435b-b832-5afc57e02bff"
      unitRef="usd">136800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjAzMg_e2f9ea85-12f9-4866-9bdc-acd1df7b31f5"
      unitRef="shares">47100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjA4OQ_62adfb87-574f-48c0-b68d-fee4638e8e03"
      unitRef="usdPerShare">2.99</sesn:SaleOfStockWeightedAveragePricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjEzNw_631386ba-5f9c-48c3-b57e-def155147e78"
      unitRef="usd">64300000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjE3Mw_a673e7d5-15b1-46b4-a2e4-d4fd760f9bf6"
      unitRef="shares">16500000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <sesn:SaleOfStockWeightedAveragePricePerShare
      contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjIzMA_bca58306-b70c-4c61-a174-6d029d319533"
      unitRef="usdPerShare">4.02</sesn:SaleOfStockWeightedAveragePricePerShare>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="ia6d4fc9148aa43c8b9c14abb2cc4eb0a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjM1Mg_74e57a39-77cb-46af-a931-52ffcbfc6834"
      unitRef="usd">2000000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts
      contextRef="ie7750b03d0da4d598cf326a44f9e812d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjM1OQ_0275853b-fe89-4431-885d-f9e07c757fe2"
      unitRef="usd">4200000</sesn:StockIssuedDuringPeriodNewIssuesIssuanceCosts>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjU2Mg_f4ae62fb-a29e-4976-a3ba-03be01048390"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMjYwNg_693a429a-ded6-4786-b8df-92bacbf498ee"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_33fe28be-824d-4dcd-b34c-c035fa366bd9"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_5071d813-7fa9-43a8-a894-b2b0ed891079"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_b3a6a981-d08a-4efb-9ff4-1c5ace21f457"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzA1MA_f6bfc898-35b3-46c3-b068-60c105a5b3e8"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i75b910d027ce46cda21c3171ea8cf644_I20210502"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzMyMQ_397c577e-529f-4dfa-b48a-628becc7e045"
      unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ice21145cb84b458994eb2b4953cd1b79_I20210503"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzMyNw_4a1a0e8b-7820-4471-820b-36e2f64f8e30"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_0624cacb-fe35-44f5-8a4b-e02f405bf12f"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_23e1e4dc-d6f6-45f6-8388-7b87db6667ae"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_e61e0c8d-6e0d-4768-979f-736058e7496e"
      unitRef="shares">199000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzM1NA_f4c66783-2e6e-4c86-ad25-de1537c1585b"
      unitRef="shares">199000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczOA_98b4cbaf-f0d1-4589-8f1b-c88c8c961243">In addition, the Company had reserved for issuance the following amounts of shares of its common stock for the purposes described below as of June&#160;30, 2022 and December&#160;31, 2021 (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.198%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.097%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.100%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,464&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares of common stock reserved for issuance for:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for grant under 2014 Stock Incentive Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,076&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares available for sale under 2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total shares of common stock issued and reserved for issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;230,263&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;229,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMS0xLTEtMS04MTcyMw_9ba4cdff-db1f-4325-8316-444c92f2a623"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMS0zLTEtMS04MTcyMw_3982916e-c465-4955-852d-a07c131a4003"
      unitRef="shares">199464000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4e03d5c4d214485ca8ef8d4f2b1c22b5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMy0xLTEtMS04MTcyMw_3143c7ff-57f9-420a-ad5d-c97aa01043fb"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ie93e937a2ca743998879eaab73aba23e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfMy0zLTEtMS04MTcyMw_21a0e5bb-e535-4e3b-b22a-afe337216ccc"
      unitRef="shares">199000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i78713773a6f644369d0e8eec39199597_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNC0xLTEtMS04MTcyMw_dba21261-5b03-4099-bbf8-385540ea030c"
      unitRef="shares">17161000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="if34834f39ec94e458f57f689cde2c633_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNC0zLTEtMS04MTcyMw_e1b8f1eb-49b2-4702-850e-9f347d0458c8"
      unitRef="shares">15703000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i81b6cc446ab44fa08e173a103f7b7289_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNS0xLTEtMS04MTcyMw_388c0b57-026e-4172-8f8d-2fd7eb618207"
      unitRef="shares">8063000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ia7ba233a853c42b89272f4f6b9633315_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNS0zLTEtMS04MTcyMw_b1038497-e591-4e23-a4d4-e5997891f419"
      unitRef="shares">3041000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i90db0d74d54b4275b25f685df0f5b309_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNi0xLTEtMS04MTcyMw_a5249ca5-c6c6-42b1-9659-083ea8890551"
      unitRef="shares">3076000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6074b6e43f5c46f5a2bb46e072ef5f2d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNi0zLTEtMS04MTcyMw_1179b183-0c85-4c4a-87d8-17766a5ab1db"
      unitRef="shares">8933000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4996e48caa5c4590b4980c71c163ae64_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNy0xLTEtMS04MTcyMw_84b7affe-5ab6-4556-8fa2-d8b4d8bb950d"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6b96cadcfc494bd094e17b7ef53a0601_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfNy0zLTEtMS04MTcyMw_40fc2b43-e0d7-4a8c-85af-4c40573492e5"
      unitRef="shares">2300000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfOC0xLTEtMS04MTcyMw_1cdf400f-3efe-4848-857d-6553af57306e"
      unitRef="shares">230263000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:CommonStockSharesIssuedAndReservedForFuture
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjdkM2EzOTY0ZGVmNTQ4Y2ZiMzljMTM2YjczNWQxY2RhL3RhYmxlcmFuZ2U6N2QzYTM5NjRkZWY1NDhjZmIzOWMxMzZiNzM1ZDFjZGFfOC0zLTEtMS04MTcyMw_21e83732-c6cd-481f-8bf8-66421a25ee67"
      unitRef="shares">229640000</sesn:CommonStockSharesIssuedAndReservedForFuture>
    <sesn:NumberofVotesEntitledForEachShare
      contextRef="ie6b33ca5238c45cc9793e8772152abcb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfMzgxOA_d8f8c77f-c478-4235-b767-e88c40ecb6b1"
      unitRef="vote">1</sesn:NumberofVotesEntitledForEachShare>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RleHRyZWdpb246N2QzOTg5NzAwMDUzNGM5MmJlZTIwM2ZmZWZhMmZkZmNfNTczOQ_203ebf01-fd76-4cdd-ba1d-9a2dcd14d5e5">The following table sets forth the Company's warrant activity for the three months ended June 30, 2022 (in thousands):&lt;div style="margin-bottom:10pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.613%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.971%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Exercised)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(Cancelled)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2018&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Mar-2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.55*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;May-2015&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2014&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$11.04&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Nov-2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;199&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;padding-left:45pt;padding-right:45pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Exercise price shown (i) reflects modification and (ii) is subject to further adjustment based on down round provision added by amendment described in &#x201c;Item 15. Exhibits and Financial Statement Schedules - Note 12. Stockholders&#x2019; Equity (Deficit)&#x201d; in the audited annual consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0yLTEtMS04MTcyMw_8a70e5da-8202-4084-83dc-d529b95a362c"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8b97f878936d417582c679e49408c3cf_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS02LTEtMS04MTcyMw_b8517259-bebe-4588-931e-65cf099c5a9d"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS04LTEtMS04MTcyMw_73bb14e2-a096-417f-b69d-b0af006259b9"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xMC0xLTEtODE3MjM_d7a896d2-801d-4f5e-8332-00ba7a60ba37"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i2816e6d6e5a5490aa12b1dd7fbaceef5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xMi0xLTEtODE3MjM_9d303348-75fe-4dc6-814e-81fbbe9e00af"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ibcfd1f7c9fea49949fedfb2aae58489c_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMS0xNC0xLTEtODE3MjM_30dc9ead-fe8b-457c-abe7-c7a592baac3b"
      unitRef="shares">132000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="id796b6b8583646e18ef4317244b84a3a_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0yLTEtMS04MTcyMw_1191f7cc-385e-4b0e-b70a-0751bdd7980a"
      unitRef="usdPerShare">0.55</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i34c5a07fd1b449558c518b3bbcbe3efa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi02LTEtMS04MTcyMw_82a4bf62-240e-4cc8-bb2d-4350ece34e7a"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi04LTEtMS04MTcyMw_8ab65b3c-5877-437a-b324-613a6699d599"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xMC0xLTEtODE3MjM_b78b2bab-fdc8-4f88-9983-f50619e1fbbc"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i3c736c8f407d4f7da2671e7528ca8bfe_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xMi0xLTEtODE3MjM_79a2b8eb-ac20-47e9-92fd-b94db410e296"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="id796b6b8583646e18ef4317244b84a3a_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMi0xNC0xLTEtODE3MjM_1d4a914a-bb32-4b1e-ba4d-3ab76aa142b5"
      unitRef="shares">12000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifaca184cb85744059ede4889bd0bec15_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0yLTEtMS04MTcyMw_63334804-00e7-41c9-9a2f-00cc3da1809c"
      unitRef="usdPerShare">11.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i07151ff5feff4986a1a7cf1407f3f033_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy02LTEtMS04MTcyMw_455a09c8-f808-4c84-84e5-e6705805a5f3"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy04LTEtMS04MTcyMw_06a39415-5bb3-4f5a-aa12-d1c10a7056f0"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xMC0xLTEtODE3MjM_84455461-c477-4bc0-ac81-efaeb4fc4484"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i54c46b874d0842ba8bf45d8c65ab8cc5_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xMi0xLTEtODE3MjM_d317318a-9af5-4308-bfdc-295e861eb809"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ifaca184cb85744059ede4889bd0bec15_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfMy0xNC0xLTEtODE3MjM_68dc0ff0-9570-4288-af99-28b8b51119e2"
      unitRef="shares">28000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i89b961b26f78447680b3d6eea476fce2_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0yLTEtMS04MTcyMw_40779bc6-6c90-4759-afec-b8260b9ecf78"
      unitRef="usdPerShare">11.04</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7d480b8de55f4a309d196db12c0a8524_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC02LTEtMS04MTcyMw_a27ff05d-b702-4895-89e8-552652026dd8"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC04LTEtMS04MTcyMw_f4776b85-1d36-4ce4-8993-97b9db5e04a0"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xMC0xLTEtODE3MjM_fbc6ea7f-fdc0-4ff8-9b15-d9cf7fe9a208"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="iff31c864c6de460e97f4ab12d1639a88_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xMi0xLTEtODE3MjM_b26e3170-7e5a-4c3e-9ba3-360a2ee1cc10"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i89b961b26f78447680b3d6eea476fce2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNC0xNC0xLTEtODE3MjM_00d85465-44e1-4e84-8370-0e8e21de2c6e"
      unitRef="shares">27000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS02LTEtMS04MTcyMw_2de88ce8-848c-485c-a6df-3fb662c399e2"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <sesn:ClassOfWarrantOrRightIssuedDuringThePeriod
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS04LTEtMS04MTcyMw_76f50bae-2deb-4e38-85e8-6dfb38a1bf1e"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightIssuedDuringThePeriod>
    <sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xMC0xLTEtODE3MjM_598d2280-8cac-444c-8b05-49a56e9ad7bb"
      unitRef="shares">0</sesn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xMi0xLTEtODE3MjM_095a4fe6-0c67-4f7c-9130-0bb06ab4bcc1"
      unitRef="shares">0</sesn:ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83MC9mcmFnOjdkMzk4OTcwMDA1MzRjOTJiZWUyMDNmZmVmYTJmZGZjL3RhYmxlOjI5YzMyOGI2MWJiZTQ3ZWE4MjkxNTUwOTkxNmEzZDQwL3RhYmxlcmFuZ2U6MjljMzI4YjYxYmJlNDdlYTgyOTE1NTA5OTE2YTNkNDBfNS0xNC0xLTEtODE3MjM_770008bf-6f70-47bf-8887-81333eaf4725"
      unitRef="shares">199000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RleHRyZWdpb246MGE3NjAzYWE2OWIzNDQ2NzljZDUwOTViMzE0M2ZkNWZfMTM4OQ_2d170216-bb76-45f4-af83-7f956a9068a5">EARNINGS (LOSS) PER SHARE&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A net loss cannot be diluted. Therefore, when the Company is in a net loss position, basic and diluted loss per common share are the same. If the Company achieves profitability, the denominator of a diluted earnings per common share calculation includes both the weighted-average number of shares outstanding and the number of common stock equivalents, if the inclusion of such common stock equivalents would be dilutive. Dilutive common stock equivalents potentially include warrants, stock options and unvested restricted stock awards and units using the treasury stock method, along with the effect, if any, from outstanding convertible securities. The majority of the Company&#x2019;s outstanding warrants to purchase common stock have participation rights to any dividends that may be declared in the future and are therefore considered to be participating securities. Participating securities have the effect of diluting both basic and diluted earnings per share during periods of income. During periods of loss, no loss is allocated to the participating securities since the holders have no contractual obligation to share in the losses of the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RleHRyZWdpb246MGE3NjAzYWE2OWIzNDQ2NzljZDUwOTViMzE0M2ZkNWZfMTM5MA_22ab939d-8279-4a23-bc05-b8f635bd0a3d">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding as of June&#160;30, 2022 and 2021 have been excluded from the denominator of the diluted loss per share of common stock outstanding calculation (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.958%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs and PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,423&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,743&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2a77deceed914ab4aa6c3a9a9c4f3afa_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi0xLTEtMS04MTcyMw_77c9eca1-7938-42ee-9b91-6e941e5189a1"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ife468ed832424422bc39059d7df8b085_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi0zLTEtMS04MTcyMw_01b950b3-f33e-472c-b4ea-ab86d66a91de"
      unitRef="shares">1394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0adbc934f3b24c239d0f1300083008f6_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi01LTEtMS04MTcyMw_c68c787f-f5e9-4e6f-be3b-cfdb71e0c0ff"
      unitRef="shares">199000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6a25de0176e248178dc11989f74804f0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMi03LTEtMS04MTcyMw_fa22b399-95a7-43b8-a5bd-cd83e40235f8"
      unitRef="shares">1394000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i47327dd48deb4402885aa3afa6af22a2_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy0xLTEtMS04MTcyMw_7aab9f19-adf4-4bdd-be07-6f00c66b112f"
      unitRef="shares">17161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifc6aa26487504d41b6a549bc657400e8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy0zLTEtMS04MTcyMw_5a6a8d6f-1d1c-49d5-960c-a8b02ddbdaa9"
      unitRef="shares">17349000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i19b7d9796cd54f35ba0a1cef95f329d2_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy01LTEtMS04MTcyMw_857b0233-bade-4f3c-be4e-301814843640"
      unitRef="shares">17161000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i2c9a4489987e4bd2a05ab6cfd1a362f6_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfMy03LTEtMS04MTcyMw_3021583c-c880-4628-ae9f-33ef3eabebe8"
      unitRef="shares">17349000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a33702caa4644da8978da5e0013ddb8_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0xLTEtMS04MTcyMw_849717ff-c13d-42f0-b28f-5d1eddcae47b"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i67fcaaf0286a4c1783c880c53e54d424_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0xLTEtMS04MTcyMw_91a8a818-d76d-4463-90ba-608554620d28"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5e730560bfe346738f8e589866aba60d_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0zLTEtMS04MTcyMw_65114c19-a399-476c-ad9c-4810ff920759"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i6ad0ec9b6a7b42cdbf789fb6d8f39ca9_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC0zLTEtMS04MTcyMw_af2ab350-7802-4185-9eb3-b12fc788c84f"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i568a2b3022284d34a0aff47db073a523_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC01LTEtMS04MTcyMw_208be008-40b6-4e1a-b657-80cd151aa837"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i41e29d2263d34ad692781e2266eefd53_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC01LTEtMS04MTcyMw_52f4d907-6812-407e-bfe8-2d2704b63d1b"
      unitRef="shares">8063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iec8d3d4dfe0d4122b647ec6d4619e69e_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC03LTEtMS04MTcyMw_d4a856f9-7882-4b04-90e5-7b0b775c9e7c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia71281c8b42c4511ab6edd8ce3378ba3_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNC03LTEtMS04MTcyMw_d5d30a38-98af-47bd-ada0-3cc07d1b86e2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS0xLTEtMS04MTcyMw_8ba4aa15-1fdf-4c11-934e-8a65f7bd6271"
      unitRef="shares">25423000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS0zLTEtMS04MTcyMw_60598642-7a02-42a6-b8f1-31af4532ebbb"
      unitRef="shares">18743000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS01LTEtMS04MTcyMw_8329edd8-7592-4923-9cca-ac68b4135e1c"
      unitRef="shares">25423000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83My9mcmFnOjBhNzYwM2FhNjliMzQ0Njc5Y2Q1MDk1YjMxNDNmZDVmL3RhYmxlOjQwYWY4Y2E5YjI2NDQyZjk4MDE5NzVkM2U4NTA3MTUzL3RhYmxlcmFuZ2U6NDBhZjhjYTliMjY0NDJmOTgwMTk3NWQzZTg1MDcxNTNfNS03LTEtMS04MTcyMw_f405d59b-9260-46aa-bcb2-4ac90c8b4cc8"
      unitRef="shares">18743000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyMQ_d0c2c42f-fc30-4276-b2bd-059ab34eeb23">SHARE-BASED COMPENSATION&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Stock Incentive Plan, as amended (the "2014 Plan"), was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 Plan became effective immediately prior to the closing of the Company's IPO in February 2014 and provides for the grant of incentive and non-qualified stock options, restricted stock awards, restricted stock units ("RSU"), stock appreciation rights and other stock-based awards, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to the Company's employees, officers, directors, consultants and advisors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the Annual Meeting of the Company's stockholders in June 2019, the Company's stockholders approved an amendment to the 2014 Plan that (i) increased by 7.9&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan and (ii) eliminated the &#x201c;evergreen&#x201d; or automatic replenishment provision of the 2014 Plan, pursuant to which the number of shares of common stock authorized for issuance under the 2014 Plan was automatically increased on an annual basis. At the Annual Meeting of the Company&#x2019;s stockholders in May 2021, the Company&#x2019;s stockholders approved an amendment to the 2014 Plan that increased by 12&#160;million the number of shares of common stock reserved for issuance under the 2014 Plan. There were approximately 3.1&#160;million shares of common stock available for issuance under the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding under the 2014 Plan generally vest over a four-year period at the rate of 25% of the grant vesting on the first anniversary of the date of grant and 6.25% of the grant vesting at the end of each successive three-month period thereafter. Stock options granted under the 2014 Plan are exercisable for a period of ten years from the date of grant. There were approximately 13.6 million stock options outstanding under the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Board of Directors and the Compensation Committee of the Company approved a retention program for all current employees, except for the Chief Executive Officer, pursuant to which the Company will provide certain incentives designed to retain such employees (the &#x201c;Retention Program&#x201d;). Pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s non-executive employees received a combination of a cash bonus award and a one-time RSU award which will vest in full on September 30, 2022, subject to continued employment through September 30, 2022. Each RSU represents a contingent right to receive one share of the Company&#x2019;s common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also pursuant to the Retention Program and effective as of October 1, 2021, the Company&#x2019;s executive officers, except for the Chief Executive Officer, were granted a one-time performance-based restricted stock unit (&#x201c;PSU&#x201d;) award equal to the value of approximately fifty percent of then-current base salary. The fair value of PSUs at the grant date was $0.4&#160;million. Each PSU represents a contingent right to receive one share of the Company&#x2019;s common stock upon the satisfaction of pre-determined performance criteria. Subject to continued employment, such awards vest on September 30, 2023 upon the determination by the Compensation Committee of the level of achievement of certain key milestones consisting of a clinical trial milestone, an employee retention milestone and cash management milestones. As of June&#160;30, 2022 achievement was deemed probable for only the cash management milestone, representing $87,000, 20% of the PSU awards. Therefore, $11,000 and $33,000 have been expensed during the three and six months ended June 30, 2022, respectively and $54,000 remains measured but unrecognized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2009 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 2009 Stock Incentive Plan, as amended and restated (the "2009 Plan"), which provided for the grant of incentive and non-qualified stock options and restricted stock awards and restricted stock units, with amounts and terms of grants determined by the Company's board of directors at the time of grant, to its employees, officers, directors, consultants and advisors. Upon the closing of its IPO in February 2014, the Company ceased granting awards under the 2009 Plan and all &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;shares (i) available for issuance under the 2009 Plan at such time and (ii) subject to outstanding awards under the 2009 Plan that expire, terminate or are otherwise surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued were carried over to the 2014 Plan. Stock options granted under the 2009 Plan are exercisable for a period of ten years from the date of grant. There were approximately 0.1 million fully vested stock options outstanding under the 2009 Plan as of June&#160;30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-of-Plan Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has granted equity awards to its newly hired employees, including executives, in accordance with the Nasdaq Stock Market LLC ("Nasdaq") employment inducement grant exemption (Nasdaq Listing Rule 5635(c)(4)). Such grants are made outside of the 2014 Plan and act as an inducement material to the employee's acceptance of employment with the Company. T&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;here were approximately 3.5 million stock options outstanding which were granted as employment inducement awards outside of the 2014 Plan as of June&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized share-based compensation expense, related to stock options, of $1.2 million and $2.5 million for the three and six months ended June&#160;30, 2022, respectively and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.3 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2.2 million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for the three and six months ended June&#160;30, 2021, respectively. As of June&#160;30, 2022, there was $8.6 million of total unrecognized compensation cost related to unvested stock options which the Company expects to recognize over a weighted-average period of 2.36 years. The weighted-average grant-date fair value of stock options granted during the six months ended June 30, 2022 and 2021 were $0.46 and $2.17, respectively. No stock options were exercised during the six months ended June 30, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units and Performance Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company did not grant any RSUs or PSUs during the six months ended June 30, 2021. &lt;/span&gt;&lt;/div&gt;The share-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2022 was $0.6 million and $1.2 million, respectively. There was no shared-based compensation expense related to RSUs and PSUs for the three and six months ended June 30, 2021. As of June&#160;30, 2022, there was $3.0&#160;million of total unrecognized compensation cost related to unvested RSUs and PSUs.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyMg_939b282a-90a5-4bea-8d88-cd8171ec8721">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the amount of share-based compensation expense recognized by the Company by line item on its Condensed Consolidated Statements of Operations for the three and six months ended June&#160;30, 2022 and 2021 (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:510.75pt"&gt;&lt;tr&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:238.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.75pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.00pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;td style="width:63.25pt"/&gt;&lt;td style="width:1.0pt"/&gt;&lt;/tr&gt;&lt;tr style="height:26pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Three Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;&#160;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:17pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Share Based Compensation &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,802&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,259&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,696&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,217&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1cc85ab1a955410a8b2ba5d9aef9c0d5_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi0xLTEtMS04MTcyMw_eeb9e1d1-8aaa-466c-bc62-8ff069f4bac4"
      unitRef="usd">473000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id53e901c0ef94dd18db696d73878aa08_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi0zLTEtMS04MTcyMw_bfd05e52-4d5e-4262-8f2d-745fe1e8e636"
      unitRef="usd">207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55970a0d5f344348a35d5e2c4bd4282e_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi01LTEtMS04MTcyMw_f3ab2f41-6716-419c-9ce8-327306412b27"
      unitRef="usd">975000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i84b0564ab20a40a485edffa15b757c33_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMi03LTEtMS04MTcyMw_d5b76350-152c-44f5-8ae1-3cf9b1b8368a"
      unitRef="usd">386000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iee95e6730e374d6e9aab606275edaf82_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy0xLTEtMS04MTcyMw_02530c3c-cfec-4fa3-afb8-b0c0063a3ac8"
      unitRef="usd">1329000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i342e97e8062b4c4cab492cc8c00c70d8_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy0zLTEtMS04MTcyMw_a8a3cbe8-9efe-4e25-9c30-6ace894fab0c"
      unitRef="usd">1052000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6db64e1a961546e3bd8121ee3879f09d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy01LTEtMS04MTcyMw_0fcbd128-5cdb-4409-9611-35838595c821"
      unitRef="usd">2721000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieac62593b40f4880b423bfc9580273ab_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfMy03LTEtMS04MTcyMw_a59b3527-916f-44dc-b163-6f2d3fd362c9"
      unitRef="usd">1831000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC0xLTEtMS04MTcyMw_07fa53e9-6f02-4ded-b76c-1f785b18ea28"
      unitRef="usd">1802000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC0zLTEtMS04MTcyMw_3dfe9992-eafd-4437-96ba-b2c61d55a90a"
      unitRef="usd">1259000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC01LTEtMS04MTcyMw_e9090a26-eaec-4dfc-ad0d-2b57bd096943"
      unitRef="usd">3696000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOmE5MGFhMWY0YzEwYTQ5MGFiY2UxMmQxMTY1YzkyY2ZkL3RhYmxlcmFuZ2U6YTkwYWExZjRjMTBhNDkwYWJjZTEyZDExNjVjOTJjZmRfNC03LTEtMS04MTcyMw_98d7d499-e151-4b31-9902-63618181821f"
      unitRef="usd">2217000</us-gaap:AllocatedShareBasedCompensationExpense>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="i77bc1a747a0f4fdd9e81b59820c9d0e3_D20190601-20190630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTA5Mg_e724b5b9-a7b3-4859-9e24-5a819ec85af0"
      unitRef="shares">7900000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance
      contextRef="iacb6642dacce42dda98c5135fee1f003_D20210501-20210531"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTU2MQ_4d4a70c1-1bad-42c5-9e56-2597f4840efe"
      unitRef="shares">12000000</sesn:CommonStockAdditionalCapitalSharesReservedforFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i05439e7daefd4ac8b3d2d78445d47366_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTY2OQ_cfa0c016-caf5-4b08-bc15-386a6ac50474"
      unitRef="shares">3100000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNw_7e51667d-9087-4bcb-bb68-f6a4761fbb3f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i08ec180c3533409b8010a63003f3a00d_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTg0Ng_800cbf6d-e732-49b8-a4fe-7de53a46d581"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ib466f1439d304e268b42a9bfb03f0f4a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMTkyMA_77178516-1f43-4fb6-91af-c4a58cedc2f1"
      unitRef="number">0.0625</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i114a360dd13d410baf35d40814e8fc5b_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjA3OQ_a3cd8fb9-b4d3-42c4-b131-6bc14e79775b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i05439e7daefd4ac8b3d2d78445d47366_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjEzMQ_d2c37fef-e671-43ca-8404-05b6abcaf5af"
      unitRef="shares">13600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i8a67da80633540d9868f347e7148156e_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMjgzNg_3118cbec-1985-4aa5-af0a-d925e5ab4262"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary
      contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzE0MQ_c60c6577-15a3-4d70-9c69-18d1b42cc504"
      unitRef="number">0.50</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzIyNg_407619b8-8da6-42db-8f7e-4ceb1357b225"
      unitRef="usd">400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward
      contextRef="i177a51cfef854bb4a48b39dac3ead017_I20211001"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzI4MA_f8755f45-d41b-43fa-8ac2-79ffe20a320c"
      unitRef="shares">1</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i75b2d9dc879b4976951e57e3d6a98fe8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc2MA_38d596d0-47e1-45cd-9e52-18fa4c6f44d3"
      unitRef="usd">87000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent
      contextRef="i570bf630b283493eb8aac676692c8fb5_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc2NA_1e06df41-8d73-4188-befb-674ff36a5f0e"
      unitRef="number">0.20</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cc8c46f0ceb44d5806951413bb59ee1_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzc5Nw_85232209-1cff-4cfe-a815-5139466435d4"
      unitRef="usd">11000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic7729b36949f4e6f8b449bc2e11e0ac1_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzgwNA_556600d1-6152-414e-9dd9-54cd16af5ec7"
      unitRef="usd">33000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i570bf630b283493eb8aac676692c8fb5_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfMzg5Ng_b4660de6-9c03-48e3-b4a9-a4e4b8bebece"
      unitRef="usd">54000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNDg2Ng_ed2d9fc1-2aec-430b-aeee-f1fe6788230c">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="if9b8d33ffa27439aa3ee253b9a03da74_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNDkxOA_64c55c83-ab5f-4f48-b06f-547a2826c6a6"
      unitRef="shares">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i044e86b9b1004169acd873b958541512_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTQyNg_f9c11519-71f3-4993-9b73-0f9eeba390f9"
      unitRef="shares">3500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNA_5c51f6b4-5191-493e-9ea4-c7186f2fcd59">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company&#x2019;s total stock option activity, including awards granted under the 2014 Plan and the 2009 Plan and inducement grants made outside of stockholder approved plans, for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.105%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares under Option&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;br/&gt;Contractual&#160;&lt;br/&gt;Life&lt;br/&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.93&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled or forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.20&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.83&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.11&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS0xLTEtMS04MTcyMw_75493444-e40f-4791-82dd-9239092e615d"
      unitRef="shares">15703000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS0zLTEtMS04MTcyMw_4f87a760-28b9-4ce0-a81c-b9e155b088fb"
      unitRef="usdPerShare">1.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i66d0ce796f154e90aded5d0cbce94189_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS01LTEtMS04MTcyMw_d9764be5-98c6-4300-82a0-ba8692c5eb57">P8Y10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMS03LTEtMS04MTcyMw_268ea5d6-dbed-43bc-a7a7-64b0868bf80c"
      unitRef="usd">82000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMi0xLTEtMS04MTcyMw_bb3d01b2-0ddd-425a-86f7-7dd565ce0cd2"
      unitRef="shares">1511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMi0zLTEtMS04MTcyMw_12b86c2d-dcfa-424e-a8b9-ee51c467151e"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMy0xLTEtMS04MTcyMw_bfe7b78c-6d80-4ad3-b61d-10d15d173c12"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfMy0zLTEtMS04MTcyMw_ab2aa6f5-81ee-49d8-916a-b291884ae615"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNC0xLTEtMS04MTcyMw_9ee9d332-678a-41a3-985c-3a770e6c20b8"
      unitRef="shares">53000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNC0zLTEtMS04MTcyMw_458b1d50-7c20-426a-9bd3-796ab2777054"
      unitRef="usdPerShare">1.20</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS0xLTEtMS04MTcyMw_40bb1a11-dea5-4abf-8f5c-7363f7abaa64"
      unitRef="shares">17161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS0zLTEtMS04MTcyMw_70dc6896-7d50-44d0-b29a-3d50a939e498"
      unitRef="usdPerShare">1.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS01LTEtMS04MTcyMw_c24d6793-8bb3-4815-836f-ce92bce590bd">P7Y8M19D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNS03LTEtMS04MTcyMw_12a7e154-997e-4bdb-8322-d4a7f84607c7"
      unitRef="usd">218000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi0xLTEtMS04MTcyMw_85b59f08-7d49-4b1c-a334-6df214fb526f"
      unitRef="shares">9555000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi0zLTEtMS04MTcyMw_335e2079-4202-44fa-beec-cf1ef3ec9734"
      unitRef="usdPerShare">1.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi01LTEtMS04MTcyMw_6076eb26-17c5-44ed-9df2-67342cd957c3">P7Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjZkYzZlODY5ZTgwZjRmZDBiODE1ZGZiZDU2NGI4ODU3L3RhYmxlcmFuZ2U6NmRjNmU4NjllODBmNGZkMGI4MTVkZmJkNTY0Yjg4NTdfNi03LTEtMS04MTcyMw_91955cae-317e-4b84-9308-571d65e187c6"
      unitRef="usd">64000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i23ea04149ec74feea107a21a6ba9a68e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTg3MQ_45b9c8ab-8977-422f-84ed-b3f6d3a128fa"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTg3OA_f9239527-6c3c-4bc1-9dca-06960bd15ca0"
      unitRef="usd">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia0710da839aa43a793cc2cb6c1c4a9b3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTkyNg_caa7463e-8fcb-429f-9a87-01511f32d4fa"
      unitRef="usd">1300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTkzMw_fdf8bb00-6b2b-44a0-a520-a3eb7f5f17da"
      unitRef="usd">2200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNTk5OA_a0448256-9bce-4f07-bd01-372c6cd161c2"
      unitRef="usd">8600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjE0OQ_d14aa02d-4f73-490a-9bbc-c5e735bedc48">P2Y4M9D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI1NA_34daa9ee-3d86-4c51-8679-520a970ae1c2"
      unitRef="usdPerShare">0.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI2MQ_523b55ec-29a8-4844-8672-5e2584fab98b"
      unitRef="usdPerShare">2.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjI3OQ_966fb8dd-adea-4721-a348-dc6bfa7adcbe"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAyNQ_eb073d00-49b9-4a08-8009-137bb341c9ab">&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022 and 2021, the grant-date fair value of stock options was determined using the following weighted-average inputs and assumptions in the Black-Scholes option pricing model:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt;margin-top:15pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.719%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.733%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.568%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair market value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Grant exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$3.34&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.04&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.8%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.7%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMS0xLTEtMS04MTcyMw_0228ba3d-ebda-4db3-bcb2-2e8fa440e45b"
      unitRef="usdPerShare">0.72</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMS0zLTEtMS04MTcyMw_908a4b4b-f30d-4da8-860e-1fa3663470aa"
      unitRef="usdPerShare">3.34</sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="i78713773a6f644369d0e8eec39199597_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMi0xLTEtMS04MTcyMw_cdd98723-daac-4534-9b23-7559afe87e95"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="ie8c92e1f22ad4644a192da4d2c4a4794_I20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMi0zLTEtMS04MTcyMw_2d6d2fde-5ff8-4c74-99ed-a6b023f4513b"
      unitRef="usdPerShare">3.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMy0xLTEtMS04MTcyMw_0d459035-8b66-4615-886a-49b0e59a4058">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfMy0zLTEtMS04MTcyMw_2afc0359-fc3a-4bb2-a7fa-2c048930a0cd">P6Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNC0xLTEtMS04MTcyMw_cd9d30ba-5dd2-40ab-8483-d9e9d7890b0e"
      unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNC0zLTEtMS04MTcyMw_4c6203a2-d6a2-45d9-9251-987457fac289"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNS0xLTEtMS04MTcyMw_ba8c994a-6549-4280-b7ab-572d9c703eee"
      unitRef="number">0.718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNS0zLTEtMS04MTcyMw_dbcb2dce-f9fa-439d-858b-c15a2feef1c3"
      unitRef="number">0.747</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id3da850769cc4728a10aba8d8db52095_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNi0xLTEtMS04MTcyMw_a02e4027-53e0-4434-8ed4-14609cdc5410"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ica4c1635be564e9db6a99db680002144_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjliN2MxYmFhNTcwNDRjYmNiMWQyMWRjYWViNDJmYjcxL3RhYmxlcmFuZ2U6OWI3YzFiYWE1NzA0NGNiY2IxZDIxZGNhZWI0MmZiNzFfNi0zLTEtMS04MTcyMw_ab8e7e78-3376-45a9-b3ae-71d0bb725812"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNzAzMg_043cff08-f8e9-4f46-bd34-cb5c07aaa33b">&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the Company's RSU and PSU activity for the six months ended June 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:78.508%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:60.911%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.521%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.524%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted Stock Units     &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.80&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.68&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled RSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(143)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.75&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:justify;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted PSU&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.67&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,063&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$0.72&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMS0xLTEtMS04MTcyMw_67d92006-b22b-4489-9bf6-72ad99448c2b"
      unitRef="shares">3041000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMS0zLTEtMS04MTcyMw_5d58e901-e871-4032-9271-91238cff9a71"
      unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMi0xLTEtMS04MTcyMw_4f828429-76c0-48e7-8bb5-97504afa79ed"
      unitRef="shares">4161000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMi0zLTEtMS04MTcyMw_758f18d5-da44-4258-8dc8-6db88147ef98"
      unitRef="usdPerShare">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMy0xLTEtMS04MTcyMw_6d506eb4-adb1-4692-92a3-c68fc5b09c6c"
      unitRef="shares">143000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfMy0zLTEtMS04MTcyMw_7039e7b6-e85d-4c2c-b299-9fa5b5f25366"
      unitRef="usdPerShare">0.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNC0xLTEtMS04MTcyMw_bf917997-bba2-4bec-a07a-9a33ae0cb142"
      unitRef="shares">1004000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNC0zLTEtMS04MTcyMw_17e17e1d-8569-4af9-8713-263e88ea8464"
      unitRef="usdPerShare">0.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNS0xLTEtMS04MTcyMw_49c55f7d-b245-4c15-8d80-42b212074e50"
      unitRef="shares">8063000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RhYmxlOjFiM2JmNjJmY2VmYjQ5M2E5YjE3YmM1NDEzNzA1NGNmL3RhYmxlcmFuZ2U6MWIzYmY2MmZjZWZiNDkzYTliMTdiYzU0MTM3MDU0Y2ZfNS0zLTEtMS04MTcyMw_76b5dfb6-c499-46fa-9975-17e300711974"
      unitRef="usdPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjY3NA_a5fc28c8-f739-4e67-96ca-01903d5706ec"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjY3NA_df07b31a-28c9-42a7-a68e-b9c630f00da9"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id083216cd3834a9a8398563d69c8b21d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgwNA_0d371e93-5a33-4674-8441-0727aca454f7"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i129a8282c6be44f2baa56e32efc338ec_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgwNA_4d0e9a01-c016-4690-bc96-4271dc2f4dea"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib8f284269de6489baf1956eaba755358_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgxMQ_0e3f59aa-f7bb-49a6-bdee-77a11fa6efe0"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib747a4a28ae447afa2a134e1e742067d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgxMQ_6f8974aa-20b1-49f5-be66-958b7f5c0091"
      unitRef="usd">1200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7752870e32f641c0b525e700f59d4d99_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgzOQ_720a6a5c-f58e-4ade-a569-a6b3d5f79bff"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic07632e7179a47ffad5e3a3a2ba4be33_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjgzOQ_890f4680-59ef-4a51-969a-20499eecb2ac"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i11cba79393924023a9e75dd2910cde3a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjk0Mw_429b2787-bd90-464c-ba64-733abd291efb"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i81b6cc446ab44fa08e173a103f7b7289_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83Ni9mcmFnOmM0ZGM1ODc0ZWFhODRkOTFhMmY5ZGUyY2FhZWE1Mzg4L3RleHRyZWdpb246YzRkYzU4NzRlYWE4NGQ5MWEyZjlkZTJjYWFlYTUzODhfNjk0Mw_563b662b-7b3a-4a82-9eab-e97b0a1e05ff"
      unitRef="usd">3000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjY0MQ_4afaa745-7e64-43e1-83c5-5e052ea54321">EMPLOYEE BENEFIT PLANS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2014 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's 2014 Employee Stock Purchase Plan ("2014 ESPP") was adopted by its board of directors in December 2013 and subsequently approved by its stockholders in January 2014. The 2014 ESPP became effective immediately prior to the closing of the Company's IPO in February 2014 and established an initial reserve of 0.2&#160;million shares of the Company's common stock for issuance to participating employees. At the Annual Meeting of the Company's stockholders in May 2021, the Company's stockholders approved an amendment to the 2014 ESPP that increased by 2.3&#160;million the number of shares of common stock reserved for issuance under the 2014 ESPP. The purpose of the 2014 ESPP is to enhance employee interest in the success and progress of the Company by encouraging employee ownership of common stock of the Company. The 2014 ESPP provides employees with the opportunity to purchase shares of common stock at a 15% discount to the market price through payroll deductions or lump sum cash investments. The Company estimates the number of shares to be issued at the end of an offering period and recognizes expense over the requisite service period. Shares of the common stock issued and sold pursuant to the 2014 ESPP are shown on the condensed consolidated statements of changes in stockholders' equity (deficit). As of June&#160;30, 2022, there were 2.3&#160;million shares of common stock available for sale under the 2014 ESPP. The Company did not sell any shares under the ESPP during the six months ended June 30, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;United States - 401(k) Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a 401(k) defined contribution retirement plan which covers all of its US employees. Employees are eligible to participate on the first of the month following their date of hire. Under the 401(k) plan, participating employees may defer up to 100% of their pre-tax salary, subject to certain statutory limitations. Employee contributions vest immediately. The plan allows for a discretionary match per participating employee up to a maximum of $4,000 per year. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Canada - Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;The Company maintains a defined contribution plan for its Canadian employees. Participants may contribute a percentage of their annual compensation to this plan, subject to statutory limitations. The Company contributes up to the first 4% of eligible compensation for its Canadian-based employees to the retirement plan. The expenses incurred for the periods presented were de minimis amount for each of the six months ended June 30, 2022 and 2021, respectively.</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i8f9cc9d2301a4433a98cf0413fade87d_I20140228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMzg2_6e707362-7455-4f59-9216-075357bc5cca"
      unitRef="shares">200000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="ic63732dc872f413f8025dd7bf4720b9f_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfNjE2_4e48b947-c7c3-44b5-ac5f-88bda1153fd2"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate
      contextRef="i76c65c4ee1e64946ab281633bdefbe71_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfOTYz_8b097815-238a-42a2-836b-0257da4da083"
      unitRef="number">0.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="iac5769fcff7b47898a71e23efd9d7b5a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMTM4Ng_87fa31f9-1c63-4308-9d4d-c14598177787"
      unitRef="shares">2300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="id065aa16b3944940b083af3709622dd4_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMTg0Mw_e017b787-4228-4a52-94e7-dfa18c6f4ab9"
      unitRef="number">1</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee
      contextRef="id065aa16b3944940b083af3709622dd4_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjA0Mg_8550787f-4e22-40c5-8d8c-5b3e746a5093"
      unitRef="usd">4000</sesn:DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="ic2092edc5bbb470eaa1bb592509fc775_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV83OS9mcmFnOjYwZjM4YzY5MjkxZjQwNDlhZjM0ZmM5OTUxZjY2NzE2L3RleHRyZWdpb246NjBmMzhjNjkyOTFmNDA0OWFmMzRmYzk5NTFmNjY3MTZfMjQzOQ_67aeaa9e-a04c-4491-8427-37f015ed9739"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTEzOQ_758c0a8f-b78f-40e8-bc0a-7cfb171945c8">INCOME TAXES&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the six months ended June 30, 2022, the Company recorded a benefit from income taxes of $3.9 million. In the second quarter of 2022, the Company determined that the fair value of the Vicineum EU rights was zero, which resulted in an impairment charge of $14.7&#160;million. In connection with this impairment charge, the Company reversed the associated deferred tax liability by $4.0 million as an income tax benefit, partially offset by $0.1 million income tax paid to foreign jurisdictions pursuant to the exclusive license agreement with Qilu Pharmaceutical Co., Ltd. (&#x201c;Qilu&#x201d;) (the &#x201c;Qilu License Agreement&#x201d;). Please refer to Note 8, "Intangible Assets and Goodwill," for further information regarding the impairment charge. For the six months ended June 30, 2021, the Company recorded a provision for income taxes of $0.3 million. This provision consisted of income taxes paid to foreign jurisdictions pursuant to the Qilu License Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0MA_8f37f0a1-6158-49e7-9c9d-969986d9673a">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of the Company's loss before income taxes by country (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.660%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.265%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.817%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Country:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55,939)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,210)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canada&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,456)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total Loss before Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(36,642)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(80,666)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfMy0xLTEtMS04MTcyMw_0bfbb4f0-a9bf-4e56-9921-bc477b4ff8e7"
      unitRef="usd">-55939000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfMy0zLTEtMS04MTcyMw_92a5dcbf-9e6a-4523-a55d-7bcb62c01105"
      unitRef="usd">-21210000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNC0xLTEtMS04MTcyMw_3d826212-5d1f-4ac6-bfa8-5a8e62aeba04"
      unitRef="usd">19297000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNC0zLTEtMS04MTcyMw_d5ae8eb7-3ab7-46b7-a66e-07ad6d60f700"
      unitRef="usd">-59456000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNS0xLTEtMS04MTcyMw_0ddab297-096b-45d2-a4e5-dcae92f682ab"
      unitRef="usd">-36642000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjhmYjQyMGMwYjVmYTQ0YTdhMDBkMDc1MzA1NDFhZjgyL3RhYmxlcmFuZ2U6OGZiNDIwYzBiNWZhNDRhN2EwMGQwNzUzMDU0MWFmODJfNS0zLTEtMS04MTcyMw_ad5378d5-747c-42e2-8f98-f702300262e1"
      unitRef="usd">-80666000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0MQ_1e13c53e-afc3-4d1d-bf51-10d1aa8d3f47">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's tax benefit (provision) is comprised of the following components (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.579%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.187%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Six Months Ended&lt;br/&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current tax benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current benefit (provision)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,875&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(288)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNS0xLTEtMS04MTcyMw_f1b2e555-5d2f-47c7-9aaf-e998a760eff4"
      unitRef="usd">3875000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNS0zLTEtMS04MTcyMw_a8decd77-aea4-480c-aef3-54aae744dfe4"
      unitRef="usd">-288000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNi0xLTEtMS04MTcyMw_89bce2d0-5a87-4b68-8573-4b0692687029"
      unitRef="usd">3875000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOjMyODVlYjMzMmJmYTQwYmVhOTc4YjIzNDJhMWU1OTgzL3RhYmxlcmFuZ2U6MzI4NWViMzMyYmZhNDBiZWE5NzhiMjM0MmExZTU5ODNfNi0zLTEtMS04MTcyMw_75122650-bb73-4496-ad65-0b471558e29f"
      unitRef="usd">-288000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTE0Mg_0fe1cf52-880d-42d8-af63-35541b7b3314">&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's deferred tax liability is comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:63.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,969&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfMi0xLTEtMS04MTcyMw_ad1c0821-0e43-4db5-9d79-9e7a19d53888"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfMi0zLTEtMS04MTcyMw_27407cb2-4576-43a3-bebf-910d9b1bc934"
      unitRef="usd">3969000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfNC0xLTEtMS04MTcyMw_f7b14c34-15ed-4f4f-819f-a030a4f3b294"
      unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RhYmxlOmQwNzVkZDdiMjUxMjQ5MzY4NjJjOTI2MWU4NDZmZjViL3RhYmxlcmFuZ2U6ZDA3NWRkN2IyNTEyNDkzNjg2MmM5MjYxZTg0NmZmNWJfNC0zLTEtMS04MTcyMw_92b658c3-a9c7-4013-b438-e9463ad7e114"
      unitRef="usd">3969000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMzcw_0bad64ba-e318-4a86-befe-34e386fb083a"
      unitRef="usd">-3900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IntangibleAssetsCurrent
      contextRef="ifedd00e94bff4f138a71518235d8f0c2_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNDc4_44b93f47-6c86-4c2d-b0b3-ffaf5552e92b"
      unitRef="usd">0</us-gaap:IntangibleAssetsCurrent>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived
      contextRef="if2acfaa03f15458fb09624b5d55af0b1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNTI0_0f04f25f-a7ff-4067-abf9-1cd44335d92e"
      unitRef="usd">14700000</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <sesn:IncreaseDecreaseInDeferredTaxLiability
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNjMz_c24841ee-d0c4-439b-9e1c-c146ff6281e5"
      unitRef="usd">-4000000</sesn:IncreaseDecreaseInDeferredTaxLiability>
    <us-gaap:IncomeTaxesPaid
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfNjgy_39029350-37a3-4bce-816f-9edb05d5b81f"
      unitRef="usd">100000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if960ee7ba05f4679a07bd2524406feb0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84Mi9mcmFnOmQyY2Q0OGRkMjQyYTRlZTJhMTA5ZWRkNjE4YTRjZTcxL3RleHRyZWdpb246ZDJjZDQ4ZGQyNDJhNGVlMmExMDllZGQ2MThhNGNlNzFfMTAyNg_679a3195-aed6-4373-b457-2eb43b1d0b7f"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <sesn:LicenseAgreementTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjE2OTQ_473c7e7d-5c2e-489d-a73d-c715cac7daf1">LICENSE AGREEMENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;In-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Zurich&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with the University of Zurich ("Zurich") which grants the Company exclusive license rights, with the right to sublicense, to make, have made, use and sell under certain patents primarily directed to the Company's targeting agent, including an EpCAM chimera and related immunoconjugates and methods of use and manufacture of the same (the &#x201c;Zurich License Agreement&#x201d;). These patents cover some key aspects of Vicineum. The Company's receipt of the CRL regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC triggered a $0.5&#160;million milestone payment to Zurich. Under the Zurich License Agreement, the Company is also obligated to pay up to a 4% royalty on the net product sales for products covered by or manufactured using a method covered by a valid claim in the Zurich patent rights, which includes Vicineum. Royalties owed to Zurich will be reduced if the total royalty rate owed by the Company to Zurich and any other third party is 10% or greater, provided that the royalty rate to Zurich may not be less than 2% of net sales. The obligation to pay royalties in a particular country expires upon the expiration or termination of the last of the Zurich patent rights that covers the manufacture, use or sale of a product. There is no obligation to pay royalties in a country if there is no valid claim that covers the product or a method of manufacturing the product. The Company recorded an expense of $0.3&#160;million and $0.5&#160;million &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to meeting a development milestone, (the submission of the Company&#x2019;s BLA with the FDA in December 2020), in the fourth quarter of 2020, and a regulatory milestone, (the Company&#x2019;s receipt of the CRL from the FDA in August 2021), in the third quarter of 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with Micromet&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a License Agreement with Micromet AG ("Micromet"), now part of Amgen, Inc., which grants it nonexclusive rights, with certain sublicense rights, for know-how and patents allowing exploitation of certain single chain antibody products (the &#x201c;Micromet License Agreement&#x201d;). These patents cover some key aspects of Vicineum. Under the terms of the Micromet License Agreement, as of June&#160;30, 2022, the Company may be obligated to pay up to &#x20ac;2.4&#160;million in milestone payments for the first product candidate that achieves applicable regulatory and sales-based development milestones (approximately $2.5&#160;million at exchange rates in effect on June&#160;30, 2022). The Company is also required to pay up to a 3.5% royalty on the net sales for products covered by the agreement, which includes Vicineum. The royalty rate owed to Micromet in a particular country will be reduced to 1.5% if there are no valid claims covering the product in that country. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country. Finally, the Company is required to pay to Micromet an annual license maintenance fee of &#x20ac;50,000 (approximately $52,148 at exchange rates in effect as of June&#160;30, 2022), that can be credited towards any royalty payment the Company owes to Micromet. The Company recorded an expense of &#x20ac;0.7&#160;million ($0.9&#160;million) related to achievement of a development milestone in the three months ended December 31, 2020, due to the submission of the Company's BLA for Vicineum with the FDA in D&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ecember 2020. The Company recorded an expense of &#x20ac;0.5&#160;million ($0.6&#160;million) related to the submission of the MAA to the EMA for Vysyneum&#x2122; in the first quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;License Agreement with XOMA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a license agreement with XOMA Ireland Limited ("XOMA") which grants it non-exclusive rights to certain XOMA patent rights and know-how related to certain expression technology, including plasmids, expression strains, plasmid maps and production systems (the &#x201c;XOMA License Agreement&#x201d;). These patents and related know-how cover some key aspects of Vicineum. Under the terms of the XOMA License Agreement, the Company is required to pay up to $0.25&#160;million in milestone payments for a product candidate that incorporates know-how under the license and achieves applicable clinical development milestones. The Company is also required to pay a 2.5% royalty on the net sales for products incorporating XOMA&#x2019;s technology, which includes Vicineum. The Company has the right to reduce the amount of royalties owed to XOMA on a country-by-country basis by the amount of royalties paid to other third parties, provided that the royalty rate to XOMA may not be less than 1.75% of net sales. In addition, the foregoing royalty rates are reduced by 50% with respect to products that are not covered by a valid patent claim in the country of sale. The obligation to pay royalties in a particular country expires upon the later of the expiration date of the last valid claim covering the product and the tenth anniversary of the first commercial sale of the product in such country.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Out-License Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Roche License Agreement &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the Company entered into the license agreement with Roche (the &#x201c;Roche License Agreement&#x201d;), pursuant to which the Company granted Roche an exclusive, worldwide license, including the right to sublicense, to its patent rights and know-how related to the Company&#x2019;s monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company (collectively, the "Roche Licensed Intellectual Property"). Under the Roche License Agreement, Roche is required to continue developing, at its cost, EBI-031 and any other product made from the Roche Licensed Intellectual Property that contains an IL-6 antagonist anti-IL monoclonal antibody (&#x201c;Roche Licensed Product&#x201d;) and pursue ongoing patent prosecution, at its cost.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Financial Terms&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company received from Roche an upfront license fee of $7.5&#160;million in August 2016 upon the effectiveness of the Roche License Agreement following approval by the Company's stockholders, and Roche agreed to pay up to an additional $262.5&#160;million upon the achievement of specified regulatory, development and commercialization milestones with respect to up to two unrelated indications. Specifically, an aggregate amount of up to $197.5&#160;million is payable to the Company for the achievement of specified milestones with respect to the first indication, consisting of (i) $72.5&#160;million in development milestones, the next of which is $30&#160;million for initiation of the first Phase III clinical trial, (ii) $50&#160;million in regulatory milestones and (iii) $75&#160;million in commercialization milestones. Additional amounts of up to $65&#160;million are payable upon the achievement of specified development and regulatory milestones in a second indication. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2016, Roche paid the Company the first development milestone of $22.5&#160;million as a result of the Investigational New Drug application for EBI-031 becoming effective on or before September 15, 2016. In December 2021, a $20&#160;million milestone was achieved due to Roche initiating a Phase II clinical trial. Management evaluated the milestone under the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;provisions of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounting Standards Codification 606, Revenue from Contracts with Customers ("&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 606&#x201d;), and determined it is probable that a significant revenue reversal will not occur in future periods, which was not the case in previous periods. Accordingly, the Company invoiced Roche $20&#160;million with payment terms of 30 days following the achievement of the corresponding milestone event, pursuant to the Roche License Agreement and $20&#160;million was recorded as license revenue and accounts receivables in the fourth quarter of 2021. In January 2022, the payment of $20&#160;million was received. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company is entitled to receive royalty payments in accordance with a tiered royalty rate scale, with rates ranging from 7.5% to 15% of net sales of potential future products containing EBI-031 and up to 50% of these rates for net sales of potential future products containing other IL-6 compounds, with each of the royalties subject to reduction under certain circumstances and to the buy-out options of Roche.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Buy-Out Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche License Agreement provides for two &#x201c;option periods&#x201d; during which Roche may elect to make a one-time payment to the Company and, in turn, terminate its diligence, milestone and royalty payment obligations under the Roche License Agreement. Specifically, (i) Roche may exercise a buy-out option following the first dosing (&#x201c;Initiation&#x201d;) in the first Phase 2 study for a Roche Licensed Product until the day before Initiation of the first Phase 3 study for a Roche Licensed Product, in which case Roche is required to pay the Company $135&#160;million within 30 days after Roche's exercise of such buy-out option and receipt of an invoice from the Company, or (ii) Roche may exercise a buy-out option following the day after Initiation of the first Phase 3 study for a Roche Licensed Product until the day before the acceptance for review by the FDA or other regulatory authority of a BLA or similar application for marketing approval for a Roche Licensed Product in either the United States or in the EU, in which case Roche is required to pay the Company, within 30 days after Roche&#x2019;s exercise of such buy-out option and receipt of an invoice from the Company, $265&#160;million, which amount would be reduced to $220&#160;million if none of the Company&#x2019;s patent rights containing a composition of matter claim covering any compound or Roche Licensed Product has issued in the EU.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Either the Company or Roche may each terminate the Roche License Agreement if the other party breaches any of its material obligations under the Roche License Agreement and does not cure such breach within a specified cure period. Roche may terminate the Roche License Agreement following effectiveness by providing advance written notice to the Company or by providing written notice if the Company is debarred, disqualified, suspended, excluded, or otherwise declared ineligible from certain federal or state agencies or programs. The Company may terminate the Roche License Agreement if, prior to the first filing of a BLA for a Roche Licensed Product, there is a period of twelve months where Roche is not conducting sufficient development activities with respect to the products made from the Roche Licensed Intellectual Property.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to June 30, 2022, the Company executed an asset purchase agreement with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. See further discussion in Note 19. "Subsequent Events".&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS Business Development Partnership Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Qilu License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2020, the Company and its wholly-owned subsidiary, Viventia Bio, Inc., entered into the Qilu License Agreement pursuant to which the Company granted Qilu an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to develop, manufacture and commercialize&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Vicineum (the &#x201c;Qilu Licensed Product&#x201d;) for the treatment of NMIBC and other types of cancer (the &#x201c;Field&#x201d;) in China, Hong Kong, Macau and Taiwan ("Greater China&#x201d;). The Company also granted Qilu a non-exclusive, sublicensable, royalty-bearing sublicense, under certain other intellectual property licensed by the Company to develop, manufacture and commercialize the Qilu Licensed Product in Greater China. The Company retains (i) development, and commercialization rights in the rest of the world excluding Greater China, the Middle East and North Africa region ("MENA&#x201d;) and Turkey and (ii) manufacturing rights with respect to Vicineum in the rest of the world excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the rights granted by the Company, Qilu agreed to pay to the Company a one-time upfront cash payment of $12&#160;million, and milestone payments totaling up to $23&#160;million upon the achievement of certain technology transfer, development and regulatory milestones. All payments were to be inclusive of VAT, which can be withheld by Qilu upon payment, and for which future recovery of such taxes may be available. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu also agreed to pay the Company a 12% royalty based upon annual net sales of Qilu Licensed Products in Greater China. The royalties are payable on a Qilu Licensed Product-by-Licensed Product and region-by-region basis commencing on the first commercial sale of a Qilu Licensed Product in a region and continuing until the latest of (i) twelve years after the first commercial sale of such Qilu Licensed Product in such region, (ii) the expiration of the last valid patent claim covering or claiming the composition of matter, method of treatment, or method of manufacture of such Qilu Licensed Product in such &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;region, and (iii) the expiration of regulatory or data exclusivity for such Qilu Licensed Product in such region (collectively, the &#x201c;Royalty Terms&#x201d;). The royalty rate is subject to reduction under certain circumstances, including when there is no valid claim of a licensed patent that covers a Qilu Licensed Product in a particular region or no data or regulatory exclusivity of a Qilu Licensed Product in a particular region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Qilu is responsible for all costs related to developing, obtaining regulatory approval of and commercializing the Qilu Licensed Products in the Field in Greater China. Qilu is required to use commercially reasonable efforts to develop, seek regulatory approval for, and commercialize at least one Qilu Licensed Product in the Field in Greater China. A joint development committee was established between the Company and Qilu to coordinate and review the development, manufacturing and commercialization plans with respect to the Qilu Licensed Products in Greater China. The Company and Qilu also executed the terms and conditions of a supply agreement and related quality agreement pursuant to which the Company will manufacture or have manufactured and supply Qilu with all quantities of the Qilu Licensed Product necessary for Qilu to develop and commercialize the Qilu Licensed Product in the Field in Greater China until the Company has completed manufacturing technology transfer to Qilu and approval of a Qilu manufactured product by the National Medical Products Administration in China ("NMPA") for the Qilu Licensed Product has been obtained.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement will expire on a Qilu Licensed Product-by-Licensed Product and region-by-region basis on the date of the expiration of all applicable Royalty Terms. Either party may terminate the Qilu License Agreement for the other party&#x2019;s material breach following a cure period or upon certain insolvency events. Qilu has the right to receive a refund of all amounts paid to the Company in the event the Qilu License Agreement is terminated under certain circumstances. The Qilu License Agreement includes customary representations and warranties, covenants and indemnification obligations for a transaction of this nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Qilu License Agreement is subject to the provisions of ASC 606. In 2020, the initial transaction price was estimated to be $11.2&#160;million and was based on the up-front fixed consideration of $12&#160;million less amounts withheld for VAT. The Company concluded that its agreements under the Qilu License Agreement represented one bundled performance obligation that had been achieved as of September 30, 2020. As such, $11.2&#160;million of the total $11.2&#160;million transaction price was considered earned and the Company recorded $11.2&#160;million of revenue during the three-month period ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Investigational New Drug application for Vicineum submitted by Qilu to the Center for Drug Evaluation of the NMPA was accepted for review in January 2021 and approved in March 2021, resulting in a $3&#160;million milestone payment from Qilu, the first milestone payment out of the $23&#160;million in potential milestone payments. The Company recorded $2.8&#160;million (net of VAT) as license revenue during the three-month period ended March 31, 2021. The Company received the payment in 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Qilu License Agreement was recognized by Shandong Province, Bureau of Science and Technology as a "Technology Transfer". An agreement that is designated as a Technology Transfer shall be entitled to a tax incentive of VAT recovery. As such, the Company recorded $0.9&#160;million of revenue during the three months ended June 30, 2021 for additional purchase price resulting from Qilu's obligation to pay Sesen an amount equal to its recovery of VAT. The Company will not be subject to VAT on future potential milestone payments from Qilu.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MENA License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2020, the Company entered into a license agreement with a third party pursuant to which the Company granted an exclusive, sublicensable, royalty-bearing license, under certain intellectual property owned or exclusively licensed by the Company, to commercialize Vicineum in the MENA region, ("MENA License Agreement"). The Company retains development and commercialization rights in the rest of the world excluding Greater China, Turkey and MENA. In consideration for the rights granted by the Company, the counterparty to the MENA License Agreement agreed to pay to the Company an upfront payment of $3&#160;million, which would be subject to certain tax withholdings. In addition, the counterparty agreed to pay to the Company milestone payments upon the achievement of certain sales-based milestones as well as a royalty based upon annual net sales in the MENA region for the term of the MENA License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The MENA License Agreement is subject to the provisions of ASC 606. The initial transaction price was estimated by management as $1.5&#160;million as of December 31, 2020 and was based on 50% of the upfront payment, or the amount not subject to a refund if certain regulatory approvals in MENA are not obtained. The remaining upfront payment ($1.5&#160;million) is subject to a refund if certain regulatory approvals in MENA are not obtained within the stated timeline and was initially recorded as deferred revenue. During the second quarter of 2022, the Company changed assumptions in the clinical study design which resulted in longer clinical trial and further delay in regulatory approval in the MENA region. Therefore, the Company reclassed $1.5&#160;million of deferred revenue to short-term accrued liability as of June 30, 2022. The Company also concluded that its agreements under the MENA License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license, associated know-how and certain documentation. The second performance obligation relates to the delivery of manufactured product. The first performance obligation (delivery of the license, associated know-how and certain documentation) was achieved during the quarter ended March 31, 2021; as such, revenue of $1.5&#160;million was recognized in the first quarter of 2021. Additional variable consideration, determined to be &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future sales levels will be recognized as revenue when the underlying sales of the licensed product occurs. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022, none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 2022, the Company terminated the MENA License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events."&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;EIP License Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 5, 2021, the Company entered into an exclusive license agreement with E&#x130;P Eczac&#x131;ba&#x15f;&#x131; &#x130;la&#xe7; Pazarlama A.&#x15e;., (&#x201c;EIP&#x201d;) pursuant to which it granted EIP an exclusive license to register and commercialize Vicineum for the treatment of BCG-unresponsive NMIBC in Turkey and Northern Cyprus (the &#x201c;EIP License Agreement"). Under the terms of the EIP License Agreement, the Company is entitled to receive an upfront payment of $1.5&#160;million. The Company and EIP have amended the license agreement to defer EIP's payment of the upfront payment to coincide with the potential FDA approval of Vicineum. The Company is eligible to receive additional regulatory and commercial milestone payments of $2.0&#160;million and is also entitled to receive a 30% royalty on net sales in Turkey and Northern Cyprus. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The EIP License Agreement is subject to the provisions of ASC 606 and as of June&#160;30, 2022, none of these amounts have been received by the Company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No initial transaction price was estimated by management;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; therefore, no revenue was recorded &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company also concluded that its promises under the EIP License Agreement represented two distinct performance obligations, the first of which is a bundled performance obligation related to the delivery of the license and associated know-how. The second performance obligation relates to the delivery of manufactured product. Additional variable consideration, determined to be allocated entirely to the bundled license performance obligation, to be paid to the Company based upon future regulatory milestones will be recognized as achievement of those milestones. In addition, variable consideration related to any future delivery of product will be recognized in future periods as the product is delivered. As of June&#160;30, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; none of these additional amounts were reasonably certain to be achieved due to the nature and timing of the underlying activities. &lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30&lt;/span&gt;, 2022, the Company terminated the EIP License Agreement as a result of the Company&#x2019;s strategic decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</sesn:LicenseAgreementTextBlock>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i9efed9b3cf4e4e64b6b1d76a87c5d8a5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjUz_75e1d140-a312-4812-a2d6-b0883ae90a7f"
      unitRef="usd">500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzY2_8a03ccde-d6eb-4919-a043-fb785271b4c2"
      unitRef="number">0.04</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTA2Mg_6fa2f0c6-d252-4295-a8dc-e3146f3fd42f"
      unitRef="number">0.10</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="ib83f84e5d9ac49848aafdf134464432e_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTEzOQ_be421c80-f473-4b07-abc8-3238f7a772c2"
      unitRef="number">0.02</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="ie802f22fd3164257a0a27630574179f1_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzMQ_b4e6c2b7-3abe-4121-80b3-b91147922624"
      unitRef="usd">300000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i854149fe8e0748178452739c0ae5c742_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzOA_369aa0c0-0fca-4104-917e-936fc3dd82be"
      unitRef="usd">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjI5Mw_937ae177-4720-4dc2-a3af-2d2659de2eaa"
      unitRef="eur">2400000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjQ0MA_5a319b4b-e3f5-4c6b-8da2-20133cd11de9"
      unitRef="usd">2500000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjUyMw_6d51955c-14bf-4dca-956e-55f21b91c404"
      unitRef="number">0.035</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjY5Mg_30551dd6-0ed9-4b1a-a6cf-8e40bc471564"
      unitRef="number">0.015</sesn:LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent>
    <sesn:LicenseMaintenanceFees
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzA4NQ_48cde6ac-ee1d-4090-8f87-3cbd8aa43c65"
      unitRef="eur">50000</sesn:LicenseMaintenanceFees>
    <sesn:LicenseMaintenanceFees
      contextRef="ib74816b1f9494ef488c765837e6c60eb_D20220101-20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzEwMw_fb64c5a5-80aa-4c4a-b5f2-e251717f0f49"
      unitRef="usd">52148</sesn:LicenseMaintenanceFees>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzI1OQ_79112045-aebc-4d0a-837a-cc61094adef8"
      unitRef="eur">700000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i033f950f56f34e84a96a28cb36fb68a0_D20201001-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzI2Mw_678d85eb-f04f-48b0-9759-ec6e1d4bf712"
      unitRef="usd">900000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzQ4NA_d97d75d7-30dc-4fa1-ba2c-4b1c897f5a56"
      unitRef="eur">500000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementMilestoneAchievementExpense
      contextRef="i980f097377234f229ea80f8ed5bc7ed4_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMzQ4OA_048c4f36-2ec0-4dcb-87c8-faccb003b69c"
      unitRef="usd">600000</sesn:LicenseAgreementMilestoneAchievementExpense>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630"
      decimals="-4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDA2OA_5428a9eb-29a2-465f-9e6b-280f6c9a4f23"
      unitRef="usd">250000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales
      contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDI1Nw_433513b4-37a7-42c3-b019-3944fbb8aa39"
      unitRef="number">0.025</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSales>
    <sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum
      contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDU3NQ_180281d5-5113-4a12-9677-1b93dff773b4"
      unitRef="number">0.0175</sesn:LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum>
    <sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed
      contextRef="id0c1946a99904ebb962b5469f86c71b5_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNDY0OA_661d9885-ab0d-4d23-a96b-090345717008"
      unitRef="number">0.50</sesn:LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed>
    <sesn:LicenseAgreementUpfrontFee
      contextRef="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNTg1OA_f89d6e57-7873-44b6-bbdb-6fb2043fa5e0"
      unitRef="usd">7500000</sesn:LicenseAgreementUpfrontFee>
    <sesn:LicenseAgreementAdditionalUpFrontFee
      contextRef="i9a8e729d26fa4a699d50fafbba426b27_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjAyNA_ee3bbf3f-069e-4e39-8593-5ca190fd1f7c"
      unitRef="usd">262500000</sesn:LicenseAgreementAdditionalUpFrontFee>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ifecdde588859469e8e663b340243baa1_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjIxMA_f57a476b-0dff-4839-9373-21d63f09c029"
      unitRef="usd">197500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i4b29722132a2491b9d2cee4b49fb0c77_D20160801-20160831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjMzOQ_a8d3ea21-8efd-4a3c-aede-640d81e4d0eb"
      unitRef="usd">72500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i3d68c476afcf40a88a2b8fed6118ee9c_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjM5MA_56066336-17d8-41d0-b8a9-5d1a0278d490"
      unitRef="usd">30000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="ia2a1e9da126143cfb0de4e11868d0606_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjQ1Mg_01613410-ade8-45b0-a9a5-99f503ade19a"
      unitRef="usd">50000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i8e7b4ebb5c66413dafd7bfce298dfeae_D20160801-20160831"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjQ5MA_7972f4e9-ad91-4f60-829b-cedef0a4898e"
      unitRef="usd">75000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i3267071fa5d04b21a986ab51df8e6d15_D20220101-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjU1NA_4144fadd-8ad1-41e2-b3fc-1e76fa3f3bca"
      unitRef="usd">65000000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone
      contextRef="i1ee271f6d7d2411fb58ddc98730fe4e1_D20160901-20160930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjc0Mw_ebb95cb1-a319-4bd0-8bc0-4bf8f9738383"
      unitRef="usd">22500000</sesn:LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i2df0e9d706854cfeb872dc1154160218_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNjg4Ng_a20cf78e-4212-4cd5-9e02-e42826bdb246"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:LicenseAgreementMilestoneAchieved
      contextRef="i766fbeb7225c4f8d80f3cee6c943dbef_I20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzI5Ng_139b5105-5fa6-483d-9157-489db9c12a4d"
      unitRef="usd">20000000</sesn:LicenseAgreementMilestoneAchieved>
    <sesn:AccountsReceivablePaymentTerms
      contextRef="i02e5980cf4114748bd928cad4eae85c4_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzMyMQ_b19f3048-e0dc-4e35-8352-9fc78fff7ffd">P30D</sesn:AccountsReceivablePaymentTerms>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i09f960acf0aa42bf81e936538879aed3_D20211001-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzQzNw_a8fe8e89-9afb-4e70-a0e2-18da67d1d559"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:LicenseAgreementProceedsFromMilestoneAchieved
      contextRef="ia91fb5103aca4101b34beb81fb97be24_D20220101-20220131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzU2MA_28b0456d-a829-405c-a3b2-1f1ff44185af"
      unitRef="usd">20000000</sesn:LicenseAgreementProceedsFromMilestoneAchieved>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="i679f24e2f48e415897b49d6af88b722c_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzcxNQ_70837cd7-c80e-4fc3-b8cb-5503d8c175dc"
      unitRef="number">0.075</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementRoyaltyRate
      contextRef="ifd9b09daca514c3cad0def62ecf0ce84_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfNzcyMQ_27374077-a679-4259-9365-083759c3c520"
      unitRef="number">0.15</sesn:LicenseAgreementRoyaltyRate>
    <sesn:LicenseAgreementOptionPeriods
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODA2MA_362c3205-44d8-4c4b-a75f-ee325980f532"
      unitRef="period">2</sesn:LicenseAgreementOptionPeriods>
    <sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODU1OQ_30d4b1c8-409d-4abe-98a4-7faa5804cec8"
      unitRef="usd">135000000</sesn:LicenseAgreementBuyoutAmountUnderFirstOptionPeriod>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfODU2OQ_ce9e1195-d782-4874-8adf-c9c851865f1b">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTA3NQ_2899ffc0-18ba-46b9-885b-0c561c0faa46">P30D</sesn:LicenseAgreementPeriodToPayBuyoutOptionOnceExercised>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTE3Mw_417f00ed-319b-4627-bb50-2444f3bb9cca"
      unitRef="usd">265000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriod>
    <sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct
      contextRef="id0a797c403f24393a9d05321e3e945c9_D20160601-20160630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfOTIxMA_ca0813b4-f531-4f3a-a630-1296b59504ce"
      unitRef="usd">220000000</sesn:LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTA1MDA_7fdb9290-e6e2-4941-aeec-d5c126ac0da8"
      unitRef="usd">70000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTE3Nzk_a43653d3-ec11-41e6-91d3-866ca9e9c4c6"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount
      contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTE4MjE_c0ac7e28-c0a6-4f8f-bf30-b28cb217f019"
      unitRef="usd">23000000</sesn:BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount>
    <sesn:BusinessCombinationRoyaltyPaymentPercent
      contextRef="i87703817c9f44a1cbeaa383e420f5264_D20200730-20200730"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTIxMDM_6e5ca68e-8024-49c6-991a-79cd372e52f2"
      unitRef="number">0.12</sesn:BusinessCombinationRoyaltyPaymentPercent>
    <sesn:CollaborativeArrangementRoyaltyPeriod
      contextRef="id66556ce8bf24b0293558cdda62bbe4b_D20200730-20200730"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjE2OTU_ef53f4e7-3f86-4f90-9913-b6c37290abf1">P12Y</sesn:CollaborativeArrangementRoyaltyPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="iec33aebf75ea4629a482858c3bee531c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUwMjI_0c54161a-ec8d-4384-88c7-a61607951196"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i954601fe3b9448cbaecd65eed3c97e5d_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUwNzg_b46c4ae1-dd45-4622-9629-e5af04805591"
      unitRef="usd">12000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1291fa4c92d24233b8c7dd158c7d657d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUyOTI_66f5bb52-d546-4d13-9123-46fb956586ad"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1291fa4c92d24233b8c7dd158c7d657d_I20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzMDg_7b7f72c7-9d58-4736-9480-f3ddae239166"
      unitRef="usd">11200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="i93a8a67c88394769861872b5ee4d03a3_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTUzNzY_b5d15a83-b030-498d-a265-94756fe33cf9"
      unitRef="usd">11200000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <sesn:BusinessCombinationMilestonePayments
      contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU2NDg_ffa78f66-5540-42d9-8fde-317a6803dd0e"
      unitRef="usd">3000000</sesn:BusinessCombinationMilestonePayments>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU3MTk_abf31f1b-9f86-481a-8b5f-2838e5cef094"
      unitRef="usd">23000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="idf187f653b3a4559ae16ca3c2c3f77b6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTU3NzY_3f4615a6-3410-4b9b-89c8-995568a43693"
      unitRef="usd">2800000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ia72f93a71c7a43cb954ae37e2265780b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTYxODU_41219984-76fb-4c71-837c-c178c803857d"
      unitRef="usd">900000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i026b9908503a4d88b10ca249424b3644_D20201130-20201130"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTcwODg_c3c031c1-b877-49f4-aece-f1086de143ab"
      unitRef="usd">3000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc1MTk_9937cab8-587d-4879-be50-c4c66bf75cd6"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc1NjM_ac3e60fe-7596-415a-b6c7-256a83b10ea9"
      unitRef="number">0.50</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i12906e74084048d2b9fe524e7469bfd5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTc3MTc_18b8009a-9ee9-4439-ac22-b22e60390449"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:DeferredRevenue
      contextRef="ib2e92c8a7aef406ca55775a1f5db7e70_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTgxMDY_2841c319-b014-4300-a1fe-0c3181559db2"
      unitRef="usd">1500000</us-gaap:DeferredRevenue>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="ic828b0a647374e389c1cd7b05992e6a6_D20210101-20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMTg3MTc_37c897d6-5336-4e68-a8e5-11b0f2185a6e"
      unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ied4b92f7d8494337810a4188d290be4d_I20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAwMDg_bb67d81f-3e94-44c4-8435-68afdf50f48c"
      unitRef="usd">1500000</us-gaap:RevenueRemainingPerformanceObligation>
    <sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments
      contextRef="i6b11a504e94346c7b3df6f09cff921f5_D20210805-20210805"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAyNjQ_d215bd97-2281-4e52-bd61-21948d9e691d"
      unitRef="usd">2000000</sesn:RevenueRecognitionMilestoneMethodPotentialMilestonePayments>
    <sesn:RoyaltyRevenuePercentage
      contextRef="i5f2b242b85564774a29503984368afdf_I20210805"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84NS9mcmFnOjgzYzdmOWQ4ZDYwNjRmNDY5MjEwMDE0MmM2ODgzZmNkL3RleHRyZWdpb246ODNjN2Y5ZDhkNjA2NGY0NjkyMTAwMTQyYzY4ODNmY2RfMjAzMDE_1e42bbc6-b496-4784-af0c-61c043e1ed9d"
      unitRef="number">0.30</sesn:RoyaltyRevenuePercentage>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfMTIyMw_e5ef7ba1-65f5-4321-b184-6e9c09e4ee0b">RESTRUCTURING AND RELATED ACTIVITIES&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 30, 2021, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following receipt of the CRL from the FDA regarding the BLA for Vicineum for the treatment of BCG-unresponsive NMIBC (the &#x201c;2021 Restructuring Plan&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The 2021 Restructuring Plan included a reduction in the Company&#x2019;s workforce by 18 positions (or approximately 35% of the Company&#x2019;s workforce as of the date of the 2021 Restructuring Plan), as well as additional cost-saving initiatives intended to preserve capital while the Company continues development of Vicineum. The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that substantially all of the accrued restructuring costs as of June&#160;30, 2022 will be paid in cash by the end&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of September 2022.&lt;/span&gt;&lt;/div&gt;Subsequent to June 30, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to voluntarily pause further development of Vicineum in the US. See further discussion in Note 19. "Subsequent Events.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="if5efc2997de54bc79f8412086513351d_D20210830-20210830"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfNDI5_f2127c09-8b0c-40bc-ad2e-80e810972094"
      unitRef="position">18</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
      contextRef="if5efc2997de54bc79f8412086513351d_D20210830-20210830"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfNDYw_37912e45-1e25-4851-ab55-e0c65e23f300"
      unitRef="number">0.35</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RleHRyZWdpb246MmM5NDMxNjJhZDQ0NGU0Y2FmMjJjMDFhNDYwYjA1MzZfMTIyNA_56da16ff-f4a3-4259-8c9d-9255dbee3e6b">The following is a summary of accrued restructuring costs related to the 2021 Restructuring Plan, (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:81.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.548%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i08198d39a53746e381e9ad22e2530e7c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMC0xLTEtMS04MTcyMw_e2f1eb9a-30b3-4233-883f-db8525b4befe"
      unitRef="usd">1497000</us-gaap:RestructuringReserve>
    <us-gaap:PaymentsForRestructuring
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMS0xLTEtMS04MTcyMw_6c9ea117-72b2-4e9f-96ee-6188643b8280"
      unitRef="usd">1103000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="i816282644abc45028662a05fb3344b4b_I20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV84OC9mcmFnOjJjOTQzMTYyYWQ0NDRlNGNhZjIyYzAxYTQ2MGIwNTM2L3RhYmxlOjJlNDUzZDNiMWZlODQyNTdhNjUzM2Q2OTExODE0OTQ0L3RhYmxlcmFuZ2U6MmU0NTNkM2IxZmU4NDI1N2E2NTMzZDY5MTE4MTQ5NDRfMi0xLTEtMS04MTcyMw_c354c4b9-deff-4995-ba68-87cb2ae921d3"
      unitRef="usd">394000</us-gaap:RestructuringReserve>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfODQ4NA_ee36ed15-2b52-4757-827c-7b60d47a7dcb">SUBSEQUENT EVENTS&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Vicineum&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 11, 2022, the Company participated in a Type B meeting with the FDA to discuss outstanding items related to the Company&#x2019;s proposed protocol and statistical analysis plan design elements for an additional Phase 3 clinical trial for Vicineum for the treatment of NMIBC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company made the strategic decision to voluntarily pause further development of Vicineum in the US. The decision was based on a thorough reassessment of Vicineum, which included the incremental development timeline and associated costs for an additional Phase 3 clinical trial, following its discussions with the FDA. The Company has turned its primary focus to assessing potential strategic alternatives with the goal of maximizing shareholder value. Additionally, the Company intends to seek a partner for the further development of Vicineum.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our decision to voluntarily pause further development of Vicineum, we have commenced the process to wind down our manufacturing operations by terminating the Master Bioprocessing Services Agreement with Fujifilm Diosynth Biotechnologies U.S.A. and the Commercial Manufacturing and Supply Agreement with Baxter on July 17, 2022 and July 20, 2022, respectively. We requested that Fujifilm and Baxter cease all work under the respective agreements and refrain from incurring any additional costs or expenses. As a result of the termination, and in accordance with the terms of the Fujifilm MSA, we have the responsibility to pay Fujifilm for certain non-manufacturing stage services and current Good Manufacturing Practice batches of drug substance of Vicineum. The Company is in the process of assessing the estimated impact of the termination of the Fujifilm MSA and the Baxter CMSA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 21, 2022, the Company terminated its Cooperative Research and Development Agreement with the National Cancer Institute for the development of Vicineum in combination with AstraZeneca&#x2019;s immune checkpoint inhibitor durvalumab for the treatment of BCG-unresponsive NMIBC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;OUS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Business Development Partnerships&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s decision to voluntarily pause further development of Vicineum in the US, the Company has commenced the process to wind down its OUS business development partnerships in MENA and Turkey by providing notice of termination for the MENA License Agreement and EIP License Agreement on July 20, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;2022 Restructuring Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company approved a restructuring plan to reduce operating expenses and better align its workforce with the needs of its business following the decision to pause further development of Vicineum in the US (the &#x201c;2022 Restructuring Plan&#x201d;). Execution of the 2022 Restructuring Plan is expected to be substantially complete by the end of the fourth quarter of 2022. The 2022 Restructuring Plan includes an incremental reduction in the Company&#x2019;s workforce as well as additional cost-saving initiatives intended to preserve capital while the Company continues to assess potential strategic alternatives with the goal of maximizing shareholder value and seek a potential partner for the further development of Vicineum. As of the filing of this Quarterly Report on Form 10-Q, the Company estimates that it will incur in the third and fourth quarters of 2022 severance and other employee-related costs of approximately $8&#160;million&lt;/span&gt;&lt;span style="color:#8c56ee;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also expects to incur one-time cash costs associated with the termination of certain contracts and all other activities under the 2022 Restructuring Plan, and is in the process of assessing the estimated impact.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Sale of Legacy Technology to Roche&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, the Company executed an asset purchase agreement (the &#x201c;Roche Asset Purchase Agreement&#x201d;) with Roche pursuant to which Roche purchased all patent rights and know-how related to the monoclonal antibody EBI-031 and all other IL-6 antagonist monoclonal antibody technology owned by the Company for up to $70&#160;million. As a result of the Roche Asset Purchase Agreement, the Roche License Agreement was terminated resulting in no further diligence, milestone or royalty payment obligations under the Roche License Agreement. Pursuant to the Roche Asset Purchase Agreement, Roche made a $40&#160;million payment to the Company upon execution of the Roche Asset Purchase Agreement. The Roche Asset Purchase Agreement also provides that Roche will make an additional $30&#160;million payment to the Company upon Roche&#x2019;s initiation of a Phase 3 clinical trial with EBI-031 for a defined indication if initiated prior to December 31, 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Securities and Derivative Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 30, 2022 and July 6, 2022, the Company and the plaintiffs in the Securities Litigation engaged in in-person mediation sessions in an attempt to resolve the litigation and continued to discuss a potential settlement over the following weeks. On July 19, 2022, the parties reached an agreement in principle to settle the Securities Litigation. Pursuant to that agreement, the Company and the individual defendants will pay or cause to be paid to members of the class who submit timely and valid proofs of claims. In exchange, the Lead Plaintiffs will dismiss the action and all class members who do not timely and validly opt-out of the settlement will provide broad customary releases to the Company and the individual defendants. On August 3, 2022, the parties entered into a Stipulation and Agreement of Settlement to settle the Securities Litigation, which is subject to court approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 6, 2022, the Company and the plaintiffs to the Federal Derivative Litigation and the State Derivative Litigation engaged in an in-person mediation session in an attempt to resolve the litigation, with settlement discussions continuing over the following days. On July 19, 2022, the parties reached an agreement in principle to settle the Federal Derivative Litigation, the State Derivative Litigation and other potential related derivative claims. Pursuant to that agreement, the individual defendants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;will cause the Company to adopt certain enhancements to the Company&#x2019;s corporate governance policies and procedures. In exchange, the plaintiffs will dismiss the complaints and, on behalf of the Company, provide broad customary releases to the individual defendants. The agreement is subject to the execution of a definitive stipulation of settlement and, after notice to the Company&#x2019;s stockholders, court approval. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Transfer to Nasdaq Capital Market &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 26, 2022, the Company received approval from the Listing Qualifications Department of The Nasdaq Stock Market LLC (&#x201c;Nasdaq&#x201d;) to transfer the listing of the Company&#x2019;s common stock from the Nasdaq Global Market to the Nasdaq Capital Market (the &#x201c;Approval&#x201d;). As a result of the Approval, the Company has been granted a second 180-day grace period, or until January 23, 2023, to regain compliance with the minimum bid price requirement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As previously disclosed, on January 24, 2022, the Company received written notice from Nasdaq indicating that the Company was not in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Global Market, as set forth in Nasdaq Listing Rule 5450(a)(1). The Company was given until July 25, 2022, to regain compliance with the minimum bid price requirement. In response, the Company submitted an application to transfer the listing of its common stock from the Nasdaq Global Market to the Nasdaq Capital Market.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s common stock was transferred to the Nasdaq Capital Market effective at the opening of business on July 28, 2022 and will continue to trade under the symbol &#x201c;SESN&#x201d;. The Nasdaq Capital Market operates in substantially the same manner as the Nasdaq Global Market and requires that listed companies meet certain financial and liquidity requirements and comply with Nasdaq&#x2019;s corporate governance requirements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To regain compliance with the minimum bid price requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company&#x2019;s common stock must be at least $1.00 for at least ten consecutive business days during the second 180-day grace period. If the Company does not regain compliance during this second grace period, its common stock would be subject to delisting by Nasdaq. As part of its transfer application, the Company notified Nasdaq that if its stock price does not recover sufficiently during the second grace period, it would implement a reverse stock split, if necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfMzM4MA_bff56a23-0762-4696-a81b-02a3dff4af0f"
      unitRef="usd">8000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="i468fa4c2a4da459b9116e1932ec1a1d7_I20220715"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfMzk2MQ_19e73d48-dee9-495e-8e60-263bc2250400"
      unitRef="usd">70000000</sesn:OtherReceivableAssetPurchaseAgreement>
    <sesn:ProceedsFromExecutionOfAssetPurchaseAgreement
      contextRef="ic23bc63aeb3e40ed84c761fb713ce86a_D20220715-20220715"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfNDIzMQ_37eeebba-ce75-419e-ade6-3364708724f7"
      unitRef="usd">40000000</sesn:ProceedsFromExecutionOfAssetPurchaseAgreement>
    <sesn:OtherReceivableAssetPurchaseAgreement
      contextRef="ic081fe4045014466be04516c1871acf9_I20220808"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRhZGYxMzM3NmYzOTQ4NmRhMjgzYmRhN2E1MjFhNzk1L3NlYzo0YWRmMTMzNzZmMzk0ODZkYTI4M2JkYTdhNTIxYTc5NV85MS9mcmFnOmM3MmIzNTIxMmJmNDQxMGM5OTMwOWViYTViZTgxYmVhL3RleHRyZWdpb246YzcyYjM1MjEyYmY0NDEwYzk5MzA5ZWJhNWJlODFiZWFfNDM5NQ_eaed9ee8-6702-4b44-9ec6-c019231acd21"
      unitRef="usd">30000000</sesn:OtherReceivableAssetPurchaseAgreement>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>90
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M9)[.>==U/2O$,?*.5^4=#X\KV^GR-DQ-IOTB()MA:[<'[-IMRMH>M>XH'",
M>54 \O#<4B[<[I+>PD7K"'O ;-_*-"YKREA%( \/+.\9-VOQ^REQNT<[XS'B
MC[>S$8:'E2$ !@5DQ*V#S &#O<,JKON_8,[.9JB9\?(]XI3X9N6UV!<MKY;[
MT,-\]]6I'B\VL3]Q,V&F)!(SD+JG9S#BJ6)?N#C1<IEOK4ZEUC+.#Q>"!T*9
M!^#^3$J]/3$_4.[.#_X#4$L#!!0    ( !1 &5669YN2D@8  -8=   8
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M,-#4H(W]FAM2-UO-X<;JL4JUX"<V4FDQ"@<@@#I((3>DMGO$MW2:),+(V^@
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MSU!ZN]8"[[+SWJ!A?;N],XC(?%EAV_):[*Q;WO'&2S?]QO,;X8]9*4!.']1
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M%%0^_[CD#'9D#8#OYT*HMP-]@>KUVO _4$L#!!0    ( !1 &55BWZ+B'P,
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M@R0PH\M<W?'U%=1ZNIHOYKDLGV1=VUH&B9=2\:(&8P1%QJHW?:SSL % GG:
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MI$G _840>AN8 ^J^[O\#4$L#!!0    ( !1 &54Q"L?N#0<  (T>   8
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MS^_S+%4;= UIHM!*BA3=;9FD.<_6Z%)O79YSILYL;JO4CNUJ=5J?J2V-V,4
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M+8\/'T6>B[2\W# *+9<6@-]70N0_;_0+FA/H^7]02P,$%     @ %$ 9524
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MXEK0L\2PET/#( $KY\%NZ)JU8T:B402>QC7KPQKHG7I2\%%"$PTZC"+PI3L
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M)CC0>:6U.V["!<,';_XO4$L#!!0    ( !1 &57%\U.F=0L  $4@   9
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M%K#0=E<9N[G!/(,WY7;4^_<CZ,SU(L[?:2#JQ[;M"'=NJ=INH@M^4I6I;8@
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MVGSPIN8?BE%/O:GX<:DPZ%E:@._G!@R8/M ![?\<./T/4$L#!!0    ( !1
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M-3@=]#Q033MK)D96KH6LI*&&Y(8Y_0%0V0VTGDEI=A-[0/M/F?T&4$L#!!0
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MS]4A<!6Q)Y,ZC0HS*5:-67"5YF+H%)J,P*]$3F:A^&?:OHLDDZYWLM*3O]9
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M_K%1@7[ '>\MC[(Q1XRVMI0(%#@6HCQ@2";8UV"H$@U?,-S1BA]_..[W>V\
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M\#0_ZUT,7UV>\/JTX#=-J[!S+3B2F7.W?/-&G?4R!D2&\L@>)'Z6=$7&L"/
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ME0H<ELHW2:9*\"8RPY4"@KX%\D0YEY4JYG!0>*B?J )HS.A"D5ROKB:W2;H
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M/;MX?CD>//=&HCHBEO&1<*9*TX23%/B+4%2R=0O "&!-P.K5"L0BIKD,]9J
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M7X'8*/>_TAD9+K'A8HBR -(PU) /O0*_B5U>:V)7U(+'BOM1+YG<7^$3#7!
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MU S+Q@I#=Y@$SR"&<M(K?+]K=W"HW,"-L+(C"UK+_-$WW=9TB_<87/LM"+#
M/J:>06!52%"4*:(,%>&<KGS= ZBG%ZL@FM=3 V[+8HL]XPO@G-*ZXHZ=, 9'
MV>HRI4C063G=+H;ZZ_045Q</KUW^[]8J4= VV7_A'2-P2P*#,2. ;4#!TYK;
M9J"=[P'6)J/O!TDOX.@U)B^F-T@^_'P/8!+0#MKAVT"T=^!J"DCA%FH5EK7_
M5>5UAY9^P*IVOG$2&L820BZ@DUHOP % X*!S 3 V8+L"2UF_H"> B)Z\4=I-
M^FR5PW=L?5AMFQZ.2]N^8(UY5=^!SY.I%!0,?#$[!NLJU-:5*ZWRD4 T?GU@
M1NXT?-J*N$"IM:)^-/?:KN+)IH4=EOM#1FQ78#L'4GG^%->W?:G-BI.>%'UM
M&2W_HY)Y%@+=*P@"HI_\0P-7_D5CG?I6I**FY1Z$6@-;CWH_\90DWQRU5QLU
MP/9@+)"XP?Q%F80]AE@L?*QNX>R0PQ/$T%:_")I%)V\/$W"M'7.1P&_V=]1K
MK;.QH *<J2]"4!O&!BAD1+0G&]NMRC*(3-?"<%A_K[$^,)F5@#P1JM+(0N_V
M^OTD*M8_U"4UM;D8>=P:KK04M9V[5\L#2+5LN2FX6(NAT@-AWT R7B_:ML)Z
M$E72VZEFDXRZM@"@WT54]!B-&\A)T^;;G72:'4:"K7<=GWVQ+N^4+_#9%1S#
MS'!:^*"*ZB"94*RQ-*PQ!L/F4\E=-IJZP#F#R4/? WN:^$&)+&1._"(6$8UV
M(3XC,IB?L?4,+#<!TMUX%%^)S]*X\3_Q*"!9F6+SEGF.UMIB?,3UT;CIZO.T
M'M%@!Z*BTDJG[9@=QM/43L(2-C7D.]?!]OR675J.@_3P:ZO^W+PGNP-\AO I
MS.([&K\[=N0ZN%V439F:>:0]/J]$D,!F@>9OT=8&/)G+L?9N30+:N3M]RP38
MED.K/;[=&8_:]C[ET38)<CEV9Y[4#X:O?5@AE-PUE/U4\IL^R/89 J.!W3)1
M"1]A,=E&%3]XIZXVKV]JLAI3_S$.7E'A4CV]GA?VRP%C%PT6;PV_D[KY4&6E
M%4[$[U7&8)3"GA;+FYI9IJ-:1<C +^GXUK+6.5!-@=]NH70(LP]P9-C/-2$^
M#IO;>NK2\;!PX@H@5#:(@Z+3R=W>@THR"%<Z7$E#9U/[P%<9FAUR#-#" /[&
M,T!*"A'31*C 2/FIDUJX=3N(2VQKYY)>MBCV (9]5$^27[5J95FX!V:WW&H"
MGP+T*K/ 8"G!K;!.16";MJ8A ^J64$Y*#I%J653T"M%('/.[L<DJA\#6F>4]
MR;EO44EAQJ=P/)^#+1KK5KD?85A13;U:@=!$5+YPVD8Y?15^NS\SH,94Y+5*
M]]I<\'X3#:3SMD0N=S7@R=]P94Y]K:_MEG<AP0G0E!$:B1.,9?]3H>9NS0GB
M3CC_ANX\E\B>UDLSVX@%R;)94A:;)5^.V.*F4"Q:>^]:L;<RH]:FUX))!J%%
MX?1F9?-1)O>H]_[V#B=.'0SL/C.>88H:SLX#VU0/NU-!$BE/D/V%>,&"A'#@
M+ Y2J [!U&043 :N%LBEN^VZSXZC.+8$=;]F.,K5^FR9+IA1">MS"54*@,0F
M=34:,$B1;KAY::R3[!B4Y X?8IP9U4+M(>V\@9MQC!NPS)E'-VJ^XV#*- S(
M]@7.O9+VHY_\!CF:5RE7P5O.[$#6HL2T@F8O,8H6P@WY*MAX631]\K!LRK4T
ML@N1-F@*0[9 ]=]/6001.EKVW&*GA*BIE/"D0!YMNBJQDFE=/KTOD-G<X-EH
M-!@W$Q)T4&,QN-76>G7"J=!,?999*_6*,R*>,76R]8D%S:=/'F*W#>MPC921
M"19U1%,<:NK-.YCC942$8H.SR+"K# I+/[^ ==]P:A3W6(B,78"?L>#W(9JA
M#5=T@NAI"/#U6QS2X=NA\5?=#'?L@LT KQ<V#H3J[EOW6SNY!G[6O)Y(;S><
M4*'5V2:_X]!U!F3WP1,N/A&GUPTJFT"[*$,$4QV-;J85KGG$)& +.F([Q(*=
M+YF%?2\5C1.,@N# W8];48('\F\)UCF5BPD[/COK&)9Q23D5@Y'.?I &;=]&
M/28F,TS(<3;$=^NW<_D=;W0\&P^^:][>P 254^OCKOF+0\3'A[?OIXRV=N7!
MQ7#^0A7!E 9/ 2/C]EB,&Q.9%P .2+CW"Y !EN+NT*]0%_T-."51DU%@C3YE
MM/?0Q'@:HNH%%QYLT.^!S10!9&*KQFX)#O60RZ%G.QY-S$+P:V?A<(C H@*Z
M9[SHBQ>^]!"8:+<U!:\3[3.F^%6AL#DP8O?=#,GY9@";=Z.D7@6_-1VCZO?H
MIZBEP+U)B?C2#3:'E90M'^DGGJ8R# 7(!MU,/^U1WX:R08+UNNYZ^WN@('(=
M>Z;)=[X-))+PG??#2NE_HRKZCF*YQ2+$.U\DZ76SLG?<7;+]\G3M'Z[6!B57
MI.F/UT:Y8%.CI%F UN?O4)K]5=1FJ#HLG)ZU6_6^1Q^HMJ^#@ND3?M YGKOK
M!96(W+T$==C%E^JPX9O#X: M%E81OM(HZ0$5RVW]:;HJ@%W]"WV=;&9UVB&"
M@]'APQ- X13S"C]#"E\]&\4#M+#PUMN4V["QF9%K:P*5^HCO[ O1N07'\&F"
M:D31430AOA)?W,M%<5)7RJ6M#[45\2@\T'&+B7]Z=S?F@ >D_CUHI%I*_ $A
MSR0KBCQ\/Q1]!,1!FF[D,#5(WC9QRHY)QP.:K=8UO_"+:YEZ:4?YW!M5;DJ8
M9YDX(%L;Y!C& "P'*$"3+.%0,=?_73M8YF*3='.E0]7MSWK@/-16D,ZQOY[%
M^@4':_.!7@=:Z+(Z(7,!7%GBL$RNQ%1QC6;[C>:.5N&AR<8.6PN3#1Q[S.A%
M 5":[FS#A$@T?"= ?"E-:<T# +^5 P=4@W<A$)BG(8!$[Y92:+%:FVG(?ET"
MR_RP2K1W8].U<5>UAI>T/\_0O>+17T/\<7LHWEN%,X<N 'V)>L'@T"D29:J!
MLK7@\/[WI8,W)1X!C? KK6&<[8>S[9Q:XR^ I'1*A&<E A _C,M*X)!4-P?[
M=IVN$DD0<BP*Y'"3(]0PP:\X^//1:9D3KG? >I]OJ!WN^FN!I)K:' W<MV-P
M-R.B%_=QR(3)"Y7!K=I!Y=9,?R+BW^^AA(*60E\_Z?H]DF"L#U'J]CLNU!KU
MY?I-@SE8;*WW+W!W+M9PYLX-+A?=&@XV TP[!HZ2KHFCH("U#VYMO[G2'EBD
MNBAXW12'S)2QZ<>CSN'(_(-L*X$]B\:5-Z T>/W<V<'/]W]P$&C02ZYO[KKS
M#/L.W7D_2%:[DXP@+]B5;UQ_\]79\/GE77*=_BY2_'!^.17P[_GHDC\E?$<.
M%\=GX!+NQ.^BS,52)),!WC>\'/3]8#80[8<9MI,757GDC*?KI(^JG7.(#,"N
M/>,W3_F5-V!U@/!I#$.617*U695U_-L$G3R/7RJ-?DV@\_Z#WM78@>X#U[K=
MGL'=J"$BENRM R\3E@PTQW^\_UL3+M^!)#EI@RB,;Q3[G^5HDF&<KPY[#]UO
M]N,AW21F>,C&:[1^4BCHKW>D%?16S& 8%53=KQET,A/\0O2#!E'FL%OV?(AN
M0SLP,>#ZVP$.U'I-DA]53WT]*DXB!T#D'TLT+KF3S3BQT$V@:KW8U"8U.0SI
MP?&7RL@0YW5S[F\&\ZR$ML#2_PB>^_LCG.[W2+NASM;+=]K(:%;J_P"22?Z^
M4*;KAWA/@Q]6!@\YIY^/-EREX=]8]E<3]PO5$_YAYN9V_GEKP/)S+)SE<@:/
M#@<OSGM<OW(?*KVBGVF>ZJK22_IS(070CS? ]S,-8<!^P W\[W:__F]02P,$
M%     @ %$ 956$4:\#S P  T0@  !D   !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&ULI5;;;N)($/V5DF=VE$A,C(%<)@$D()E95DDF(B3[L-J'QBYP:^QN
M;W<;DK_?JC9VB!1XV'W!?:DZ=>K25?0WVORR*:*#ESQ3=A"DSA6786CC%'-A
M3W2!BFZ6VN3"T=:L0EL8%(E7RK.PTVZ?A;F0*ACV_=F#&?9UZ3*I\,& +?-<
MF-<Q9GHS"**@/IC)5>KX(!SV"['"1W1/Q8.A7=B@)#)'9:568' Y"$;1Y;C'
M\E[@6>+&[JR!/5EH_8LWTV00M)D09A@[1A#T6>,$LXR!B,8_6\R@,<F*N^L:
M_;OWG7Q9"(L3G?TI$Y<.@HL $ER*,G,SO?D=M_Z<,EZL,^M_85/)]D@X+JW3
M^5:9&.1255_QLHW#CL)%>X]"9ZO0\;PK0Y[EM7!BV#=Z X:E"8T7WE6O3>2D
MXJ0\.D.WDO3<<';S.)\]3>9/L^G]#QC=7\/LYG8TO[F&T60^?9[.IS>/_="1
M)98/XRWJN$+M[$$]@SNM7&KA1B68O-</B6%#LU/3''<. OY1JA/HMEO0:7<Z
M!_"ZC=M=C]?=YS9:9\K8E4:J%0B5P PSX3"!$9>)=!(M_#5:D!35S=\?1: R
MT/O8 +^E2UN(& <!/1:+9HW!\,NGZ*Q]=8!^KZ'?.X3^G[/V_U'AIX)1N:+"
MK-,1M<"E"!.=%T*]@B@*H]<42$%O=C?(1284.$VG21DC4%LQPO$%OE"'L11O
M3L,"G4,#(I,K!=)9_ZBI]Y#&1KK4FU*(B06]]/>+TI(;UL)29]1A&-!@C+)P
M+.&9S6YA:73N-]^O1W2_$B9A23X9WXY(U\"SC FHS/V&+QPU.4?]QP.-)S^^
MEHH\*C0UI#7"_=UT/($C%OSRZ:+3:5]Q+.!]83V0S_XVNCH^@3G)[A$"J>*L
M3+9AHP#YEB75;F@9*#J_V@W)XA6B"RBTE2QOX8BH^P2\2&I8F+U"]_2W)@Y[
M882M91+2JM=[J!ZW6'Y#?92_(DF\;9%!K*W[:L6:!:6B4\$-U]+:(;<!3G[]
M%B 6A72DM$EEAN\***;.(55)B@FN:6@4=0KJ!%6!?$NW)!;U4&$Y$<>F)'/O
MRX_963JK7CE1.>!B"XY\Z'5IJ2;M\26,!1TWD;JF LL75*;=J'H"\!FB5N_;
M.4R$3:$0K\R9TA&UHG;W^$W; 34R;!H9J76_];P[M??\&&)2=2D)VY(:D*!P
MB(Q223]U:@ZY6%%\;V<C27>!Q$PF7%4QTZ3B82S*#2L\8N$JIUCCY*,F%>Z,
MF1S-R@]32V9+Y:J)TYPV\WI4C:DW\6K8WPFSDE2P&2Y)M7UR?AJ J09HM7&Z
M\$-KH1V-0+],Z3\'&A:@^Z76KMZP@>9?S/!?4$L#!!0    ( !1 &56B9C;A
M*PT  $4F   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*U:;5,;.1+^
M*RHVM96M F,,>=E-0A40LL<6Y-B8[%;=U7V09V1;R\QH(FD WZ^_IUO2S-C8
M#KE-%078([5:_?+TTVV_O3?VULV5\N*A+"KW;F?N??W+_K[+YJJ4;F!J5>')
MU-A2>KRTLWU76R5SWE06^Z/A\.5^*76U<_R6W[NVQV]-XPM=J6LK7%.6TBY.
M56'NW^T<[*0W/NG9W-,;^\=O:SE38^4_U]<6K_9;*;DN5>6TJ815TW<[)P>_
MG![1>E[PAU;WKO>_H)M,C+FE%Q?YNYTA*:0*E7F2(/'G3IVIHB!!4.-+E+G3
M'DD;^_\GZ1_X[KC+1#IU9HH_=>[G[W9>[XA<3653^$_F_A\JWN<%R<M,X?BW
MN ]K1S_OB*QQWI1Q,S0H=17^RH=HA]Z&U\,-&T9QPXCU#@>QEN^EE\=OK;D7
MEE9#&OW#5^7=4$Y7Y)2QMWBJL<\?CS^?CL]__WS^\4:<_X'?X[?['F+IX7X6
M19P&$:,-(EZ**U/YN1/G5:[RY?W[4*?5:91T.AUM%?A;4PW$X7!7C(:CT19Y
MA^T=#UG>X:8[-A.GOC2J\N+\#K^=^/?)Q'F+B/C/NNL&:4?KI5&6_.)JF:EW
M.T@#I^R=VCG^\8>#E\,W6W0]:G4]VB;]:?[X1A'B#YUA35.*?U;BMZ98B(.#
M8-Q=X>=*G)FREM5"U-)ZK*RE5[G0R!AQLZB5.!4EHDM7,X2FG_..#^]/A#<B
MUPXAZ@22W7E9Y;1&>U4ZI&O!4K"H=\*//[P>';QZXT1M36T<GN,?;RCJL5M
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MP.L,")9\3=K0W<@3OQJ3KWCLFLHC%@*./)@@*Y?;!F)033UKOY0)_60';$>
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ME,A8A'>X5!]E*J5RSD5ZWAJR*^>^3T487+[)K^(Y_:5H&0W?;# "/SUX\]-
MG#^HK.GG^2:S 4WHIEGDDQ.5((A( LR)X*D+A3RD<D?0 FM$D5-#NHLO#>*#
MBLPT>NAFVW&!2I%5EY@4FY_UC1=>S8[.X(CH>_29]'>E8NPY><?$J<*[D<\$
M&A(NESH*D<E:TZF@=X5:BA,D*KR/NM?1IN_,F0(9CXRHE?S-W.BD+6A ;V8F
M] K>_#VX Z[[I&IC.86HQ18'P[W?EY,BE0D7*KPF/(9AN2HG/T"FS5GG97>[
MY&_<Y0XY0R6+5AE66R%HS$*IO=2JQ((^#8GXP,="Q6>OT787!?E]N<C)PID8
MF.R*H).IU![Q;#C0S:/,'M5>*OB].I>J-CF7"F_(::(M05L>7B!D8(B.PFR(
MX$@TOKT&#\18%@R,EVHFLX6X252/J<8G@\KT%1!3G-0$8A4?!FAN4%^9@[6(
MV8>)(/2$EUZGI2VX)K0(=@MK(= UDMH9$YN?]GW>'<Q&32S66!K*!&/>5N9^
M;T[=^')O6IK*9 5G*$'*Q.0+<7YZL3<\/%AQPL7EWDM:(V>F0I^Z=J?O3(:J
MA5,B*"4#4?8T-9W][-4P1=9:ZKC=,KN]-8]K$K61/=H3! ?<0?GK4A=Y.:.Z
MNTN:(!P0O41IK5D /:BN+T):3[ N]A1=^&TX?$#:MAYZRDW"<^ZQI7AVU)JE
M/7]YB@#[X9E:+1_;3PFYNWU-2.E %!+BA!T,.J6\52L=\K/#IRG+4CJ>%\$_
MZ"XWS2XXYE,D<G=.XT;-+7258V$H1M,DC\<IFM#9@.EEJIS 48>!$K]$;L->
M-D!(8+M6WP46?(EW@WM#=B,(TO2M:\->KN4LD8V#HJ"*Z>FT!9W>:3WQJIJA
M!^$N2%=[(#(.;Y8JC]9@<*(@HRX)/V T9>T#]W&FB$U0T<GC'B;6P[P_D>H7
M+CC;%Y&KW<78[3C//>J<Z\U_?N[?DR=BBL99$@X,J-9&"Y2$O:M,UU2A33QG
M\^U7$P/1)9?3>=6LY&;$8L-SG"E(@J0>E8.1^C[J]IBA!5942\TV*-GS;?'-
M"@ QD-(0;2IU' .%0U#N-0_AS)378ZTN'8\UU .RHYJIH-FEDCD5E^1EU@'&
M+C7Q="R06>L0 LQP:-*$#L\-$>]'A^-_4_L]T[2XUW-7N&G(1S&Q1N9Q)$ZC
M(\ X]?9N->&V&H\=?=+,($4<KO,TCE66(Y38E1A[73=%%VP]VC^%EUM-G^#^
M=E3GR!%_@3;0KHPH2^3^LNCB\*GI%B__00&5<=/U69WVC3U08L.:7FK*K=GY
MU.3<#0#6<V=_4ABSEFGAXZ3,Y>*[Y^16$^U^U3X=<^R0)3&)O-N1,NAKJ;XE
MM6-.]R<8",4<:=+21%7-B<Z&F=6&&7MF+,@U76A&%JZ8_]:F #^/)8")8=Y8
MM2[CZRW)SAT7/68YN\3?)VHNBVG*X:C+[I.3=T.R4LWN.7<I<YC!]DE +(^:
M_>!ZB8MGO2ADC>64^L$X"=A@0.B:W8:^R.T^2M0;-!1NJKC:?I0NEU_$6>S9
MKJ2]!<%HIU)K<]FB0FMN]Z/(,&]DL*4/09 %Z),*/8V%GJ8W%/H)?&YX),7G
MCDG1=.KEY9EX'LEU>-Z2:+IGJS7G:CAGV6F] "I+2GN6WBH7S_RU,)/NJM&"
MZ^W0I_LG\;+=&& -\TV+'L^))DI58H8[<(L!KP)&<G'P>K@'Q* '%.)(1D-!
M":*- "[$;[)J*.9& ?#QFS%K%OHM1+)>GL6"->NR*<6$2R,%",V9M8T\\H0^
MO5!WVC0.SB5,*^BC+,Z"]JBCK2Z_1W$ AJ3X8]M&VR5FQRT:8*._GU@]U= -
M>C\[& R'V[4/$^*6,+4!4&UT[2X-,8@N8Z>GSYG2JA2DGQK@ZXNC%\/G\J?G
M!S\M]\BD\0Q7KI(K.!^ZSO'O^.&B2N-PM6SF0'-2$UI#;J3*6^*?!F+?*=Z7
M++ ^F;@]BYK8KA-=GSYJ.DV?4X1PH"]D1+7;&5X[A'S=X^VAFD1OQ]L#B[L.
MSBW*B2E2;H[/QQ]C7@[Z\+*B3Y@_\MQJ91#'(F5)K5Q%DR+I-ELP?-#"[HR=
M%GF#QS!D."I1]*ES6_$ [(@.+<,GQ87&SIP^ NF%1/Q(@R)I$:*HP[_-%;$O
M -?^_R.23__"D+UX4IXMVW5WPPFP=IC0/0FF2R*V$PX5*K ^@@)WC^DM0IZ,
MTH9*)\*JFZB#==$'#6D^M 5>D7Y+VH#>JP!.C\W72J3Z'40N(_6CY+LW39''
M06\J][E*5IPLH@4#%DOK4P:WV=W+^F5L(,2=:K@D^B!,%</N<':P>N\Z&?-3
MUTRGQ)PJ3Z#_R$:K%XI7T#29#L$!29#C5#S&04'X'$=7BJ9SJ!J#=5\?V>]]
MM:=4=L9?8")S 5##MWS:=]OO2)V$KP9UR\,7K!!G,PT>4:@IM@X'KU[LA/E8
M>N%-S5\4FA@/FL;_SM'W*4L+\'QJP'SC"SJ@_>;8\?\ 4$L#!!0    ( !1
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M3,NQSK37\=A4NR0SKK(L$@ZA:,"!.VG"*2GD7NFWU6*U9;:(8]5<%5440+T
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MTP:L3PRL&Q_H@/H#X<V?4$L#!!0    ( !1 &557$6W[Z0,  *$*   9
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MKVV$LM?]IPG%\HFN"(5MYHD-:\1+1K# =3'N\,);5HD_*FRV2:&SY9AV5C&
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M9M N%8CG2:DYBWLX@8Z_B'1&,=G"OL&2K"^AVW3IUX:)T"]7<RKP L6,&65
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MK 'MKZ4TQXD-4/V>C/\'4$L#!!0    ( !1 &57@H$5?K0(  +\%   9
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M2P=4TRZ:B9%E7:)+::C@ZV%&'1:5#:#]E91F/[$";<\._P%02P,$%     @
M%$ 957Q8C#A:!   5A   !D   !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
MO5A14^,V$/XK&O>F S,06X8$0I/,$."FZ92#P84^=/H@[$VLP9:,)">73G]\
M5[9CY^X<7\N0OA#+UJZ^;_7MKL1H)=6+C@$,^9PF0H^=V)CLPG5U&$/*=$]F
M(/#+7*J4&1RJA:LS!2PJC-+$]3UOX*:,"V<R*M[=J\E(YB;A NX5T7F:,K6>
M0B)78X<ZFQ</?!$;^\*=C#*V@ #,8W:O<.367B*>@M!<"J)@/G8NZ<64#JU!
M,>.)PTIO/1-+Y5G*%SN816/'LX@@@=!8%PQ_EG %26(](8[7RJE3KVD-MY\W
MWC\6Y)',,]-P)9/?>63BL7/ND CF+$_,@US]#!6AOO47RD07?\FJFNLY),RU
MD6EEC A2+LI?]KD*Q):!/]QAX%<&?H&[7*A ><T,FXR47!%E9Z,W^U!0+:P1
M'!=V5P*C\"M'.S.YO@FN'F;WO\WN/I&[CV3Z&,P^W00!.;@&PWBB#\DQ><*X
M"<,9F7))9B+L$1TS!9IP06YYDF!T]1'YL#T<N0;!V27<L (R+8'X.X!0<BN%
MB36Y$1%$7]J[2*IFYF^83?U.AP%D/7+B'1'?HP/R&%R3@P^'%?(.]R=UX$X*
M]R<[W#\QQ=ES A@0 ^C2('##S9K\\2O.)#,#J?ZS+0REV]-VMS8)+W3&0A@[
MF&4:U!*<R8\_T('W4P?HTQKT:9?W25#NFYR34*8I)@7J*WPA7.L<(F(D,3$0
M3!FT6Y2ABF42@=+D #>WC-TA^;LUBB6[<OU^L;ZM",O)Z<A=MD#NUY#[G9#O
M086H/JP0%O92&@N-5S'7F-6O.5=?"Z;$4CJFWA88KT>'PW9 @QK0X'N N(Q(
ME"N+9!7S,":O.5.(*%D38$H<8_5#9 I(QM:%1M@<OY*(F8*$P&*K6=(>P.[%
M:9^L<8DN 9_5/,[^#0_<UY)#%4E -5@EY!H*D6#X.4N0&=9\+45!!^;8#DPQ
MC84QAR5@25(O4.P-RTTL%?^+F5V%H!O7V7<9GM<,SSL]/?&0"YZG*%@LV@E[
MEHK9'D NE6)B =A<S!%Y0/@BAZ*V1P1S(L@@Y'.. ZQF*#(IH(U%Y]IOS.-A
MS6RXG^(SW -HZC6]QOL/N5RG@1U\FT$V>>P.Z4VJ-1\*Y;;WF!( I5_DO.>W
MISS=ZI+T?Y(2>G@4W."KP& ]:&?1">:MV^0W9/W]J*OR^\ZXFXY,.WOGY$[
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M,_JAH'8&=+]2RNXW+D#SBXI^ U!+ P04    "  40!E5>!X#'R0$  #[&0
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M&\SH-=GOE;S>*[Q)'/-UKN1'] =7H#=WG.82Z52CSRRG><SR)9I!#&Q#GU-
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MY;M)B(X.WJ,#M8RF"2L$IG/AVU+YT-78<57S>5FS^T;-GPMZ@MK.!^0ZKMM
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MP++NU_5$B]*UO*G0IH&Z86ZN.) VP.S/A-#W$]M%VTLS^0502P,$%     @
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M**35^#LPYCPAS)B))0C!71HS:>73OM-LL4):C?]0QIQG>;;>&I8;L= @0&C
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M=>LN=B^>98W7OGLYU*_.;G45#NMGUK,D\8 D@;FU5R5&@T-Y%A@>$!A@M_;
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MH&EQNL8HPDPUD,^7E(K=A>J@WGV:_@M02P,$%     @ %$ 95:B>AKR; P
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MTI'5MU "*[S-Q1W=7T/E4%?Q+6G.]2?:5[*.A99;+FA1@:4%14;*;_Q0!>(
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M]WS\WOK.,%US"CT/!J5Q%$T5;>UJ.697*RA'_6-Y7U<ALH56K5 /"TKSH;0
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M@?+U^S0M7I[(!$]I]F/U-D?_ U!+ P04    "  40!E5AFBW^MH$  "<%0
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MDX.=LE0[QL3_(]4D$)P/7X KC876VPF-.?6AMM0ZQTSVQ_+V'G]%JN!CY/N
MA2'A0C=E<UX[Y?E8G>HZO.@V-B;<'-&AB-T2L;MWZM\35N80-ZNI\Z+M;N(R
MCGLHKE+!8*,NV*@#>R)K[*P)YE$/157*$6S6(UE9J*T+>T)L;D\>OMB:N\\0
M([A4(]@L1W86B3VQ>G58.UL;T#-OT_<@2AV"]Q(B'Q>+/4&T:J+;WFR?H55P
M*59PVU@VTE/"N3[K!FC$HJ4Z@Y/TJ##D*KW,01W*53)]0]5^8_*6-@]7A =G
MZT/@&1H& =6/)$375/@A$XD^@?P[G K)U9'\OUJ6CJ1I<C8_0R'A4B)ALT8J
MBC#)B_ CZ-L2O1M&ZMBI24@4.__0&:0+Z0W4,CI5%);;II8C\ZCMS _JH"@[
MV^(N"LA;W?%ZM,-5)W>%G1H/[TDII1<V:Z]#2:ELPUI2S*.N2<$9*<A R6<(
M-[<4;JY1& V&\SF'.9& ;A49-!;41]])F,#.99$[;E42C(L[&_FEIE/'K<^0
M;BFV7+/8,L2\8]9RQ]5P6LW-D(^JJ^S*_5<$?)Y>"PKDLR26V558T5I</0[3
M"S>[[)[=6]X1KE2E0"',E*E23JK^\.PJ,'N1;)G>IDV9E"Q*'Q=  N"Z@_H^
M8TRN7_0 Q87LX']02P,$%     @ %$ 9599L3D]= P  F0D  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3@N>&ULK59M;]LV$/XK!VT86J".7NS83F8+D!UW
M3=&T1KRN'X9]8*2S39@2-9*VXW_?(^5H=JH(&5!_L/ARS\/G[D@>1WNI-GJ-
M:. Q%X4>>VMCRFO?U^D:<Z8O9(D%S2RERIFAKEKYNE3(,@?*A1\%0=_/&2^\
M>.3&YBH>R:T1O,"Y KW-<Z8.$Q1R/_9"[VG@GJ_6Q@[X\:AD*UR@^5K.%?7\
MFB7C.1::RP(4+L=>$EY/KZR],_B+XUZ?M,%Z\B#EQG9NL[$76$$H,#66@=%G
MAU,4PA*1C'^/G%Z]I 6>MI_8WSO?R9<'IG$JQ3>>F?78&WJ0X9)MA;F7^P]X
M].?2\J52:/</^Z-MX$&ZU4;F1S IR'E1?=GC,0XG .)I!D1'0/0<T'\!T#T"
MNL[12IESZX89%H^4W(.RUL1F&RXV#DW>\,)F<6$4S7+"F7CQ(;F?=2;)8G8#
MTR]W\]GG1?+G[9?/T(%O+@28=9(=*LHHW!;EUFA@10:)IK27-A$:WMR@85SH
MMX19&)EN0!YG.O K^*#73*$>^8;DVD7]]"AM4DF+7I#6ASM9F+6&69%A=H[W
MR<W:U^C)UTG42OAQ6UQ -W@'41!%#7JFKX>'+7*Z=>B[CJ_[4NAM7#IV#V8P
ME3F=2\W<UDZ48L4*Z:P8>#C J=V<'=QPLF<J@[\_$27<&LSU/TWQK=;O-:]O
M[X=K7;(4QQY= !K5#KWXMU_"?O![4W!^$ME9J'IUJ'IM[/%[QA7M>K6A:VW'
MQ!;A#2\@DT(PI:%$56VRMTU!J)B'CMG>:;LXN!A0^G>GSOUHU+WH]FJC,]&7
MM>C+5M%_4!8-X".JE&N$4O'T_^B^?(WN'XU>UMVO=?=;=<\>2[IC:;,95+D3
M?$"2VRBRG:E?(9MVTZN $/8@8P?=LH,&M5.#5L9[KC>=I4($7I!?J TH9K#)
MIXHH#,XB[X[\6>B;S8+AU?FO.1?#6O;P=;G824&7@^#FT"1YV*1E$ Z?26XV
MZPV:-5[5&J]:-=[P'<^0BL*!H\B:Y%7X,#Q=]YFT5I-*EG]2Y7)4*U?\-:1R
M6YBJ"-2C]?LB<67UV?B$WAW5,^$_FNK1<L?4BE/A$K@D2HH-G2]5/02JCI&E
MJZ4/TE!E=LTUO9U060.:7TIIGCIV@?HU%G\'4$L#!!0    ( !1 &54+Y[B=
M!P0   X4   9    >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;+58;8_:.!#^
M*U:N.K52=Q.'U]T#)&"WUYZT6T1*^]DD T2;V)QMH/?OSTY"0B"X+,U^(;'C
M>3R/7V8>IK=C_$6L "3Z&4=4]*V5E.M[VQ;^"F(B;MD:J/JR8#PF4C7YTA9K
M#B1(C.+(=AVG;<<DI-:@E_1-^*#'-C(**4PX$ILX)OR_$41LU[>PM>^8ALN5
MU!WVH+<F2_! SM83KEIVCA*$,5 1,HHX+/K6$-^/74<;)".^A[ 3!^](4YDS
M]J(;7X*^Y6B/( )?:@BB'EL80Q1I).7'OQFHE<^I#0_?]^B?$O**S)P(&+/H
M1QC(5=_J6BB !=E$<LIVGR$CU-)X/HM$\HMVV5C'0OY&2!9GQLJ#.*3ID_S,
M%N+ 0.%4&[B9@7MLT#QCT,@,&@G1U+.$U@.19-#C;(>X'JW0]$NR-HFU8A-2
MO8V>Y.IKJ.SDP/L\G#[>C(;>XP,:?WV:/#Y[PV]?OCZC&^2E.XO8 GF2R(U
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M^)0V)%LG]9LYDY+%R>L*2 !<#U#?%XS)?4-/D)< !_\#4$L#!!0    ( !1
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M4HH3#F*5YX3_&F+&-@.K8^TF[M-E(O6$'?8+LL0IRH=BPE5DURQQFB,5*:/
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M2FAL,G:8XV\ I G _4P(O9N8 [H?2_074$L#!!0    ( !1 &55>B]%_7@(
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MG5+C1L2EV4LGS'./U+*/M-+I,- $JVC5+;7J-FLU??R(X_2S)S>1P,F2S")
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M[6X9/5XN_[-/[$1K75!-1C4%U514TU!-1S4#U4Q4LU#-1C4'U5Q4\U#-1[4
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MK=$_M7:O>G^)^@>]4Z#<N FA(!45UTT;M;OM$!HVO?<[O9E@-T2:#Z" X=I
M@XM+4[!LID(3:%&Z3GP0VO2U6^9FD**T">9\+83>!U:@'<W)+U!+ P04
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M:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  40!E5G"N/0&4%  #@+
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MVVBSFT!O0[V-0&]#O8U ;T.]C4!O0[V-0&]#O8U ;T>]G4!O1[V=0&]'O9U
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MK 9%5H,BJT&1U:#(:OY3UGOGUG\</S[+SC;]6SX;_YJW> %02P$"% ,4
M"  40!E5!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( !1 &56WOQ5([@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !1 &5697)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ %$ 958#0FW#<!0  J1\  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !1 &5669YN2
MD@8  -8=   8              " @1\.  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    "  40!E5W/K=V78#  !G$   &
M@('G%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ %$ 9
M5?@EP\4_!@  :AL  !@              ("!DQ@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( !1 &55BWZ+B'P,  ,\)   8
M      " @0@?  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M"  40!E5P4ZGFSD,   #CP  &               @(%=(@  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ %$ 950B99C>? @  XP4  !@
M             ("!S"X  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( !1 &54Q"L?N#0<  (T>   8              " @:$Q  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    "  40!E5)0!F8G$+  #I
M'   &               @('D.   >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ %$ 95?6>S]_[!P  ZA,  !D              ("!BT0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    "  40!E5&])O
MZ<P"   T!@  &0              @(&]3   >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( !1 &56P$P\ON@4  , .   9
M  " @<!/  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
M%$ 957O%(=%?"P  ,"$  !D              ("!L54  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    "  40!E58!2 NWH#  "X!P  &0
M            @(%'80  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( !1 &54O(]3 2@,  /P&   9              " @?AD  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ %$ 95<7S4Z9U"P
M12   !D              ("!>6@  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    "  40!E5A>)+KOD"  !?!@  &0              @($E
M=   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !1 &57$
MNK&8PPH  !,>   9              " @55W  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ %$ 959ESAF9L!   *0H  !D
M     ("!3X(  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !1 &56(JY)'KP0   \+   9              "
M@5FJ  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ %$ 9
M50)4<TC+&0  PUL  !D              ("!/Z\  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    "  40!E5811KP/,#  #1"   &0
M        @(%!R0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( !1 &56B9C;A*PT  $4F   9              " @6O-  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ %$ 956YAV9Y#"@  +!P
M !D              ("!S=H  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    "  40!E55Q%M^^D#  "A"@  &0              @(%'Y0
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !1 &54#0?2Y
M!0,  '@'   9              " @6?I  !X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ %$ 95=/3,F<$ P  908  !D
M ("!H^P  'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  4
M0!E5XV ML<L$   R"P  &0              @('>[P  >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( !1 &56.C-P']P(  &T&   9
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M970S-RYX;6Q02P$"% ,4    "  40!E5RSN!E@D%  "&'@  &0
M    @($)"0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M !1 &55%].SQG 0  '(=   9              " @4D. 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ %$ 959:L,K8# P  K@8  !D
M             ("!'!,! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    "  40!E5>!X#'R0$  #[&0  &0              @(%6%@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( !1 &55R4O[[O@(
M .4'   9              " @;$: 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ %$ 95>U+#LRC @  [0<  !D              ("!
MIAT! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    "  40!E5
M<TK\8-4#  !,%   &0              @(& ( $ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( !1 &57P/_*&C (  -P%   9
M      " @8PD 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ %$ 95>+M5F\G P  " D  !D              ("!3R<! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    "  40!E5EJQX6E4"  #0!
M&0              @(&M*@$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( !1 &55'M<\SEP4  /<J   9              " @3DM 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ %$ 95>4/410=
M!0  Y2(  !D              ("!!S,! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    "  40!E5MH(19)$"  ! !P  &0
M@(%;. $ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !1
M&57LJX0@/ ,  +D.   9              " @2,[ 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ %$ 95;T_I=$3!   H14  !D
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M=#4V+GAM;%!+ 0(4 Q0    ( !1 &56&:+?ZV@0  )P5   9
M  " @=-< 0!X;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @
M%$ 9599L3D]= P  F0D  !D              ("!Y&$! 'AL+W=O<FMS:&5E
M=',O<VAE970U."YX;6Q02P$"% ,4    "  40!E5"^>XG0<$   .%   &0
M            @(%X90$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4
M Q0    ( !1 &54L3H':;00  !,5   9              " @;9I 0!X;"]W
M;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ %$ 95=B!-)2_ @
M(@<  !D              ("!6FX! 'AL+W=O<FMS:&5E=',O<VAE970V,2YX
M;6Q02P$"% ,4    "  40!E5[R+#284"  !D!@  &0              @(%0
M<0$ >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !1 &55>
MB]%_7@(  ,<%   9              " @0QT 0!X;"]W;W)K<VAE971S+W-H
M965T-C,N>&UL4$L! A0#%     @ %$ 958%S=-<@!   /1@  !D
M     ("!H78! 'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !1 &56,G<=6: ,  *H6   -              "
M <ZD 0!X;"]S='EL97,N>&UL4$L! A0#%     @ %$ 959>*NQS     $P(
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9>&UL4$L%!@    !, $P RQ0  %^S 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>220</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>11</UnitCount>
  <MyReports>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS</Role>
      <ShortName>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - DESCRIPTION OF BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</Role>
      <ShortName>DESCRIPTION OF BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - BASIS OF PRESENTATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATION</Role>
      <ShortName>BASIS OF PRESENTATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES</Role>
      <ShortName>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS</Role>
      <ShortName>RECENT ACCOUNTING PRONOUNCEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2112106 - Disclosure - RECEIVABLES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLES</Role>
      <ShortName>RECEIVABLES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2114107 - Disclosure - PREPAID EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PREPAIDEXPENSES</Role>
      <ShortName>PREPAID EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2121109 - Disclosure - ACCRUED EXPENSES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSES</Role>
      <ShortName>ACCRUED EXPENSES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2126111 - Disclosure - LEASES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASES</Role>
      <ShortName>LEASES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2128112 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2135113 - Disclosure - EARNINGS (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2138114 - Disclosure - SHARE-BASED COMPENSATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</Role>
      <ShortName>SHARE-BASED COMPENSATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2145115 - Disclosure - EMPLOYEE BENEFIT PLANS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2147116 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXES</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2153117 - Disclosure - LICENSE AGREEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTS</Role>
      <ShortName>LICENSE AGREEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2159119 - Disclosure - SUBSEQUENT EVENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</Role>
      <ShortName>SUBSEQUENT EVENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - BASIS OF PRESENTATION (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies</Role>
      <ShortName>BASIS OF PRESENTATION (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - ACCRUED EXPENSES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESTables</Role>
      <ShortName>ACCRUED EXPENSES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/ACCRUEDEXPENSES</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables</Role>
      <ShortName>STOCKHOLDERS' EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/STOCKHOLDERSEQUITY</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables</Role>
      <ShortName>SHARE-BASED COMPENSATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2348307 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/INCOMETAXES</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails</Role>
      <ShortName>DESCRIPTION OF BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails</Role>
      <ShortName>FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - RECEIVABLES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RECEIVABLESDetails</Role>
      <ShortName>RECEIVABLES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RECEIVABLES</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - PREPAID EXPENSES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/PREPAIDEXPENSESDetails</Role>
      <ShortName>PREPAID EXPENSES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/PREPAIDEXPENSES</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails</Role>
      <ShortName>INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails</Role>
      <ShortName>ACCRUED EXPENSES - Components of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2427412 - Disclosure - LEASES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LEASESDetails</Role>
      <ShortName>LEASES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LEASES</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Equity Financing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails</Role>
      <ShortName>EARNINGS (LOSS) PER SHARE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails</Role>
      <ShortName>SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails</Role>
      <ShortName>EMPLOYEE BENEFIT PLANS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails</Role>
      <ShortName>INCOME TAXES - Components of Pre-tax Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails</Role>
      <ShortName>INCOME TAXES - Components of Income Tax Provisions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails</Role>
      <ShortName>INCOME TAXES - Components of Deferred Tax Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2452428 - Disclosure - INCOME TAXES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails</Role>
      <ShortName>INCOME TAXES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454429 - Disclosure - LICENSE AGREEMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails</Role>
      <ShortName>LICENSE AGREEMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/LICENSEAGREEMENTS</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails</Role>
      <ShortName>RESTRUCTURING AND RELATED ACTIVITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="sesn-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2460432 - Disclosure - SUBSEQUENT EVENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails</Role>
      <ShortName>SUBSEQUENT EVENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sesenbio.com/role/SUBSEQUENTEVENTS</ParentRole>
      <Position>68</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q/A" original="sesn-20220630.htm">sesn-20220630.htm</File>
    <File>sesenbio_minorirosales-e.htm</File>
    <File>sesn-06302022x10qa_ex311.htm</File>
    <File>sesn-06302022x10qa_ex312.htm</File>
    <File>sesn-06302022x10qa_ex321.htm</File>
    <File>sesn-06302022xx10qa_ex322.htm</File>
    <File>sesn-20220630.xsd</File>
    <File>sesn-20220630_cal.xml</File>
    <File>sesn-20220630_def.xml</File>
    <File>sesn-20220630_lab.xml</File>
    <File>sesn-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="588">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>95
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "sesn-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "contextCount": 220,
   "dts": {
    "calculationLink": {
     "local": [
      "sesn-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "sesn-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "sesn-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "sesn-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "sesn-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "sesn-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 495,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 13
   },
   "keyCustom": 63,
   "keyStandard": 236,
   "memberCustom": 29,
   "memberStandard": 34,
   "nsprefix": "sesn",
   "nsuri": "http://www.sesenbio.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover",
     "role": "http://www.sesenbio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - BASIS OF PRESENTATION",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATION",
     "shortName": "BASIS OF PRESENTATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccounting",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105103 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "role": "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES",
     "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106104 - Disclosure - RECENT ACCOUNTING PRONOUNCEMENTS",
     "role": "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS",
     "shortName": "RECENT ACCOUNTING PRONOUNCEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107105 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112106 - Disclosure - RECEIVABLES",
     "role": "http://www.sesenbio.com/role/RECEIVABLES",
     "shortName": "RECEIVABLES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114107 - Disclosure - PREPAID EXPENSES",
     "role": "http://www.sesenbio.com/role/PREPAIDEXPENSES",
     "shortName": "PREPAID EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116108 - Disclosure - INTANGIBLE ASSETS AND GOODWIL",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121109 - Disclosure - ACCRUED EXPENSES",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSES",
     "shortName": "ACCRUED EXPENSES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124110 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2126111 - Disclosure - LEASES",
     "role": "http://www.sesenbio.com/role/LEASES",
     "shortName": "LEASES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128112 - Disclosure - STOCKHOLDERS' EQUITY",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135113 - Disclosure - EARNINGS (LOSS) PER SHARE",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE",
     "shortName": "EARNINGS (LOSS) PER SHARE",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2138114 - Disclosure - SHARE-BASED COMPENSATION",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION",
     "shortName": "SHARE-BASED COMPENSATION",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2145115 - Disclosure - EMPLOYEE BENEFIT PLANS",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS",
     "shortName": "EMPLOYEE BENEFIT PLANS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147116 - Disclosure - INCOME TAXES",
     "role": "http://www.sesenbio.com/role/INCOMETAXES",
     "shortName": "INCOME TAXES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153117 - Disclosure - LICENSE AGREEMENTS",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTS",
     "shortName": "LICENSE AGREEMENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "sesn:LicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2155118 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2159119 - Disclosure - SUBSEQUENT EVENTS",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTS",
     "shortName": "SUBSEQUENT EVENTS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - BASIS OF PRESENTATION (Policies)",
     "role": "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies",
     "shortName": "BASIS OF PRESENTATION (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UseOfEstimates",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
     "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - INTANGIBLE ASSETS AND GOODWIL (Tables)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - ACCRUED EXPENSES (Tables)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables",
     "shortName": "ACCRUED EXPENSES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - STOCKHOLDERS' EQUITY (Tables)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables",
     "shortName": "STOCKHOLDERS' EQUITY (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336305 - Disclosure - EARNINGS (LOSS) PER SHARE (Tables)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables",
     "shortName": "EARNINGS (LOSS) PER SHARE (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2339306 - Disclosure - SHARE-BASED COMPENSATION (Tables)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables",
     "shortName": "SHARE-BASED COMPENSATION (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2348307 - Disclosure - INCOME TAXES (Tables)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESTables",
     "shortName": "INCOME TAXES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2356308 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - DESCRIPTION OF BUSINESS (Details)",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
     "shortName": "DESCRIPTION OF BUSINESS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i354156cc43db49a6863c0550a1e1bebd_D20160901-20160930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "sesn:BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ia4884e6cf1834287a8e4032056a092dd_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "role": "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails",
     "shortName": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS - Summary of Changes in Fair Value of Company's Total Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "iea7a9f45aacd43cfbe0a38116fe07ad1_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - RECEIVABLES (Details)",
     "role": "http://www.sesenbio.com/role/RECEIVABLESDetails",
     "shortName": "RECEIVABLES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ia00d97ca9441426bb9adfaa45c3d754c_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncreaseDecreaseInOtherReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - PREPAID EXPENSES (Details)",
     "role": "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails",
     "shortName": "PREPAID EXPENSES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ie19452cececa4a96a54f4c9ced19321f_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Composition of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i90478a97ea0d40c7a94bea0d8f484eac_D20210101-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)",
     "role": "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails",
     "shortName": "INTANGIBLE ASSETS AND GOODWIL - Schedule of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423410 - Disclosure - ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "role": "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
     "shortName": "ACCRUED EXPENSES - Components of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "sesn:AccruedResearchAndDevelopmentExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425411 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "role": "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "sesn:NumberOfLawsuits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "lawsuit",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427412 - Disclosure - LEASES (Details)",
     "role": "http://www.sesenbio.com/role/LEASESDetails",
     "shortName": "LEASES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430413 - Disclosure - STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Equity Financing (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i8c8d5912a42e4ad2833bfc6f61c043f2_I20191129",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431414 - Disclosure - STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432415 - Disclosure - STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "ie6b33ca5238c45cc9793e8772152abcb_D20220101-20220630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "sesn:NumberofVotesEntitledForEachShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433416 - Disclosure - STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Summary of Common Stock Issued and Reserved for Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "sesn:CommonStockSharesIssuedAndReservedForFuture",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434417 - Disclosure - STOCKHOLDERS' EQUITY - Warrants (Details)",
     "role": "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails",
     "shortName": "STOCKHOLDERS' EQUITY - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437418 - Disclosure - EARNINGS (LOSS) PER SHARE (Details)",
     "role": "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
     "shortName": "EARNINGS (LOSS) PER SHARE (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440419 - Disclosure - SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
     "shortName": "SHARE-BASED COMPENSATION - Share-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i1cc85ab1a955410a8b2ba5d9aef9c0d5_D20220401-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441420 - Disclosure - SHARE-BASED COMPENSATION - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
     "shortName": "SHARE-BASED COMPENSATION - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442421 - Disclosure - SHARE-BASED COMPENSATION - Stock Options (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id3da850769cc4728a10aba8d8db52095_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443422 - Disclosure - SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
     "shortName": "SHARE-BASED COMPENSATION - Weighted-Average Inputs and Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id3da850769cc4728a10aba8d8db52095_D20220101-20220630",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "sesn:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444423 - Disclosure - SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "role": "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
     "shortName": "SHARE-BASED COMPENSATION - Summary of Status and Changes of Unvested Restricted Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i7012d9b8cefc416d86192851d3aa476f_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i52eaa414326e448c937bf26df0576971_D20210101-20210331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id065aa16b3944940b083af3709622dd4_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446424 - Disclosure - EMPLOYEE BENEFIT PLANS (Details)",
     "role": "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
     "shortName": "EMPLOYEE BENEFIT PLANS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "id065aa16b3944940b083af3709622dd4_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2449425 - Disclosure - INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
     "shortName": "INCOME TAXES - Components of Pre-tax Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450426 - Disclosure - INCOME TAXES - Components of Income Tax Provisions (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails",
     "shortName": "INCOME TAXES - Components of Income Tax Provisions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentForeignTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451427 - Disclosure - INCOME TAXES - Components of Deferred Tax Liabilities (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails",
     "shortName": "INCOME TAXES - Components of Deferred Tax Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i816282644abc45028662a05fb3344b4b_I20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452428 - Disclosure - INCOME TAXES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
     "shortName": "INCOME TAXES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxesPaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i50d0c092ca734a0e8f9fdcc2d1d4c753_D20220401-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454429 - Disclosure - LICENSE AGREEMENTS (Details)",
     "role": "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
     "shortName": "LICENSE AGREEMENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i1291fa4c92d24233b8c7dd158c7d657d_I20200930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "if5efc2997de54bc79f8412086513351d_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457430 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "if5efc2997de54bc79f8412086513351d_D20210830-20210830",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "position",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458431 - Disclosure - RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "role": "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails",
     "shortName": "RESTRUCTURING AND RELATED ACTIVITIES (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i08198d39a53746e381e9ad22e2530e7c_I20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i468fa4c2a4da459b9116e1932ec1a1d7_I20220715",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460432 - Disclosure - SUBSEQUENT EVENTS (Details)",
     "role": "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails",
     "shortName": "SUBSEQUENT EVENTS (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i468fa4c2a4da459b9116e1932ec1a1d7_I20220715",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostExpectedCost1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i1fa8be48baf24bd8840e28a8fa91aa16_D20210401-20210630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "role": "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
     "shortName": "CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - DESCRIPTION OF BUSINESS",
     "role": "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS",
     "shortName": "DESCRIPTION OF BUSINESS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "sesn-20220630.htm",
      "contextRef": "i49ebf71c92fe41aea0823e2a8525f857_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_CA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CANADA",
        "terseLabel": "Canada"
       }
      }
     },
     "localname": "CA",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_TR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TURKEY",
        "terseLabel": "TURKEY"
       }
      }
     },
     "localname": "TR",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sesenbio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "sesn_A2014EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A2014 Employee Stock Purchase Plan [Member]",
        "label": "A2014 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2014EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ATMFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ATM Facility [Member]",
        "label": "ATM Facility [Member]",
        "terseLabel": "ATM Facility"
       }
      }
     },
     "localname": "ATMFacilityMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_AccountsReceivablePaymentTerms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounts Receivable, Payment Terms",
        "label": "Accounts Receivable, Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "AccountsReceivablePaymentTerms",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_AccruedLegalFees": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Legal Fees",
        "label": "Accrued Legal Fees",
        "terseLabel": "Legal expenses, including preliminary litigation settlement"
       }
      }
     },
     "localname": "AccruedLegalFees",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expense current.",
        "label": "Accrued Research And Development Expense, Current",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_AccruedRestructuringChargesRelatedCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Restructuring Charges Related, Current",
        "label": "Accrued Restructuring Charges Related, Current",
        "terseLabel": "Restructuring charge related"
       }
      }
     },
     "localname": "AccruedRestructuringChargesRelatedCurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable, Entity Shares Issued Per Acquiree Share",
        "terseLabel": "Shares of common stock issued to the selling shareholders (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedandIssuableEntitySharesIssuedPerAcquireeShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "label": "Business Combination, Long-term Purchase Commitment, Milestone Amount",
        "terseLabel": "Total milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationLongTermPurchaseCommitmentMilestoneAmount",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Milestone Payments",
        "label": "Business Combination, Milestone Payments",
        "terseLabel": "Business combination, milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_BusinessCombinationRoyaltyPaymentPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Royalty Payment Percent",
        "label": "Business Combination, Royalty Payment Percent",
        "terseLabel": "Royalty payment, percentage"
       }
      }
     },
     "localname": "BusinessCombinationRoyaltyPaymentPercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ClassOfWarrantOrRightIssuedDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued During The Period",
        "label": "Class Of Warrant Or Right, Issued During The Period",
        "terseLabel": "Warrants Issued (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssuedDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "label": "Class Of Warrant Or Right Number Of Expirations During The Period",
        "negatedTerseLabel": "Warrants Cancelled (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfExpirationsDuringThePeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone",
        "label": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Clinical Development Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnClinicalDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue Based on Development Milestone, Phase II"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedOnDevelopmentMilestonePhaseIIMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Commercialization Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on commercialization milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonCommercializationMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Development Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on development milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonDevelopmentMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue Based on Regulatory Milestone [Member]",
        "terseLabel": "Collaborative arrangement, revenue based on regulatory milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueBasedonRegulatoryMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "label": "Collaborative Arrangement, Revenue based on Specified Milestone [Member]",
        "terseLabel": "Collaborative Arrangement, Revenue based on Specified Milestone"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenuebasedonSpecifiedMilestoneMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_CollaborativeArrangementRoyaltyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Royalty Period",
        "label": "Collaborative Arrangement, Royalty Period",
        "terseLabel": "Royalty period"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltyPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_CommonStockAdditionalCapitalSharesReservedforFutureIssuance": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockAdditionalCapitalSharesReservedforFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_CommonStockSharesIssuedAndReservedForFuture": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Shares Issued And Reserved For Future",
        "label": "Common Stock Shares Issued And Reserved For Future",
        "totalLabel": "Total shares of common stock issued and reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssuedAndReservedForFuture",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "label": "Defined Contribution Plan, Employer Discretionary Matching Contribution, Maximum Annual Amount Per Employee",
        "terseLabel": "Discretionary match per participating employee, maximum"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryMatchingContributionMaximumAnnualAmountPerEmployee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_EBI031Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EBI-031 [Member]",
        "label": "EBI-031 [Member]",
        "terseLabel": "EBI-031"
       }
      }
     },
     "localname": "EBI031Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_EczacibasiPharmaceuticalsMarketingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eczacibasi Pharmaceuticals Marketing Agreement",
        "label": "Eczacibasi Pharmaceuticals Marketing Agreement [Member]",
        "terseLabel": "Eczacibasi Pharmaceuticals Marketing Agreement"
       }
      }
     },
     "localname": "EczacibasiPharmaceuticalsMarketingAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ExpensesPreviouslyClassifiedAsPrepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses Previously Classified as Prepaid",
        "label": "Expenses Previously Classified as Prepaid",
        "terseLabel": "Expenses previously classified as prepaid"
       }
      }
     },
     "localname": "ExpensesPreviouslyClassifiedAsPrepaid",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_FirstIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First Indication [Member]",
        "label": "First Indication [Member]",
        "terseLabel": "First Indication"
       }
      }
     },
     "localname": "FirstIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_GermanVATRecoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "German VAT recovery",
        "label": "German VAT recovery [Member]",
        "terseLabel": "German VAT recovery"
       }
      }
     },
     "localname": "GermanVATRecoveryMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ImpairmentOfIntangibleAssetsCostOfCapitalPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of Intangible Assets, Cost of Capital, Percentage",
        "label": "Impairment of Intangible Assets, Cost of Capital, Percentage",
        "terseLabel": "Impairment of intangible assets risk adjusted"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsCostOfCapitalPercentage",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_IncreaseDecreaseInDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Tax Liability",
        "label": "Increase (Decrease) in Deferred Tax Liability",
        "terseLabel": "Increase (decrease) in deferred tax liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiability",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_IncreaseDecreaseOfPrepaidExpensesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "label": "Increase (Decrease) of Prepaid Expenses, Noncurrent",
        "negatedTerseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseOfPrepaidExpensesNoncurrent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAdditionalUpFrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Additional Up-Front Fee",
        "label": "License Agreement, Additional Up-Front Fee",
        "terseLabel": "License agreement, additional up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalUpFrontFee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "label": "License Agreement, Amount Payable Upon Achievement of Specified Milestone",
        "terseLabel": "License agreement, amount payable upon achievement of specified milestone"
       }
      }
     },
     "localname": "LicenseAgreementAmountPayableUponAchievementofSpecifiedMilestone",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderFirstOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under First Option Period",
        "label": "License Agreement, Buyout Amount Under First Option Period",
        "terseLabel": "License agreement, buyout amount under first option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderFirstOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period",
        "label": "License Agreement, Buyout Amount Under Second Option Period",
        "terseLabel": "License agreement, buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriod",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "label": "License Agreement, Buyout Amount Under Second Option Period, Upon Non-issuance of Patent Rights or Licensed Product",
        "terseLabel": "Buyout amount under second option period"
       }
      }
     },
     "localname": "LicenseAgreementBuyoutAmountUnderSecondOptionPeriodUponNonIssuanceOfPatentRightsOrLicensedProduct",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achieved",
        "label": "License Agreement, Milestone Achieved",
        "terseLabel": "Milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementMilestoneAchievementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Milestone Achievement Expense",
        "label": "License Agreement, Milestone Achievement Expense",
        "terseLabel": "Expenses related to achievement of development milestone"
       }
      }
     },
     "localname": "LicenseAgreementMilestoneAchievementExpense",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementOptionPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Option Periods",
        "label": "License Agreement, Option Periods",
        "terseLabel": "License agreement, option periods"
       }
      }
     },
     "localname": "LicenseAgreementOptionPeriods",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty On Net Product Sales",
        "label": "License Agreement, Percentage of Royalty On Net Product Sales",
        "terseLabel": "Royalty payment obligation, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSales",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "label": "License Agreement, Percentage of Royalty on Net Product Sales, Minimum",
        "terseLabel": "Third party minimum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageOfRoyaltyOnNetProductSalesMinimum",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "label": "License Agreement, Percentage Rate Requiring Reduction in the Amount of Royalties Owed",
        "terseLabel": "Third party maximum ownership, percent"
       }
      }
     },
     "localname": "LicenseAgreementPercentageRateRequiringReductionInTheAmountOfRoyaltiesOwed",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementPeriodToPayBuyoutOptionOnceExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "label": "License Agreement, Period to Pay Buyout Option Once Exercised",
        "terseLabel": "License agreement, period to pay buyout option once exercised"
       }
      }
     },
     "localname": "LicenseAgreementPeriodToPayBuyoutOptionOnceExercised",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_LicenseAgreementProceedsFromMilestoneAchieved": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Proceeds From Milestone Achieved",
        "label": "License Agreement, Proceeds From Milestone Achieved",
        "terseLabel": "Proceeds from milestone achieved"
       }
      }
     },
     "localname": "LicenseAgreementProceedsFromMilestoneAchieved",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "label": "License Agreement, Royalty Payment, Reduction, Conditions Not Met, Percent",
        "terseLabel": "License agreement, royalty payment, reduction, conditions not met"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyPaymentReductionConditionsNotMetPercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementRoyaltyRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Royalty Rate",
        "label": "License Agreement, Royalty Rate",
        "terseLabel": "License agreement, royalty rate"
       }
      }
     },
     "localname": "LicenseAgreementRoyaltyRate",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_LicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Text Block]",
        "label": "License Agreement [Text Block]",
        "terseLabel": "LICENSE AGREEMENTS"
       }
      }
     },
     "localname": "LicenseAgreementTextBlock",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "sesn_LicenseAgreementUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement, Up-front Fee",
        "label": "License Agreement, Up-front Fee",
        "terseLabel": "License agreement, up-front fee"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontFee",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Maintenance Fees",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_LitigationSettlementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation Settlement Member",
        "label": "Litigation Settlement [Member]",
        "terseLabel": "Litigation Settlement"
       }
      }
     },
     "localname": "LitigationSettlementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MENALicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MENA License Agreement",
        "label": "MENA License Agreement [Member]",
        "terseLabel": "MENA License Agreement"
       }
      }
     },
     "localname": "MENALicenseAgreementMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_MicrometAGMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Micromet [Member]",
        "label": "Micromet AG [Member]",
        "terseLabel": "Micromet AG"
       }
      }
     },
     "localname": "MicrometAGMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_NumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Lawsuits",
        "label": "Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "NumberOfLawsuits",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_NumberofVotesEntitledForEachShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Votes Entitled For Each Share",
        "label": "Number of Votes Entitled For Each Share",
        "terseLabel": "Number of votes"
       }
      }
     },
     "localname": "NumberofVotesEntitledForEachShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "sesn_OperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Monthly Rent",
        "label": "Operating Lease, Monthly Rent",
        "verboseLabel": "Monthly rent"
       }
      }
     },
     "localname": "OperatingLeaseMonthlyRent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeaseOtherMonthlyOperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Other Monthly Operating Expenses",
        "label": "Operating Lease, Other Monthly Operating Expenses",
        "terseLabel": "Related operating expenses"
       }
      }
     },
     "localname": "OperatingLeaseOtherMonthlyOperatingExpenses",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_OperatingLeasesAreaOfOfficeSpace": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Area Of Office Space",
        "label": "Operating Leases Area Of Office Space",
        "terseLabel": "Office space (in square feet)"
       }
      }
     },
     "localname": "OperatingLeasesAreaOfOfficeSpace",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Line Items]",
        "label": "Organization And Basis Of Presentation [Line Items]",
        "terseLabel": "Organization And Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationLineItems",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OrganizationAndBasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Basis Of Presentation [Table]",
        "label": "Organization And Basis Of Presentation [Table]",
        "terseLabel": "Organization And Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "OrganizationAndBasisOfPresentationTable",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_OtherReceivableAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivable, Asset Purchase Agreement",
        "label": "Other Receivable, Asset Purchase Agreement",
        "terseLabel": "Other receivable, asset purchase agreement"
       }
      }
     },
     "localname": "OtherReceivableAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_ProceedsFromExecutionOfAssetPurchaseAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From Execution Of Asset Purchase Agreement",
        "label": "Proceeds From Execution Of Asset Purchase Agreement",
        "terseLabel": "Payments to company upon execution of the Roche Asset Purchase Agreement"
       }
      }
     },
     "localname": "ProceedsFromExecutionOfAssetPurchaseAgreement",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_QiluPharmaceuticalCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qilu Pharmaceutical Co., Ltd.",
        "label": "Qilu Pharmaceutical Co., Ltd. [Member]",
        "terseLabel": "Qilu Pharmaceutical Co., Ltd."
       }
      }
     },
     "localname": "QiluPharmaceuticalCoLtdMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RetentionProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Retention Program [Member]",
        "label": "Retention Program [Member]",
        "terseLabel": "Retention Program"
       }
      }
     },
     "localname": "RetentionProgramMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RevenueRecognitionMilestoneMethodPotentialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "label": "Revenue Recognition, Milestone Method, Potential Milestone Payments",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodPotentialMilestonePayments",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RightOfUseAssetRelatedToAdoptionOfAccountingStandard": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "label": "Right-of-Use Asset Related To Adoption of Accounting Standard",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetRelatedToAdoptionOfAccountingStandard",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_RocheMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche [Member]",
        "label": "Roche [Member]",
        "terseLabel": "Roche"
       }
      }
     },
     "localname": "RocheMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_RoyaltyRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty Revenue, Percentage",
        "label": "Royalty Revenue, Percentage",
        "terseLabel": "Royalty revenue, percentage"
       }
      }
     },
     "localname": "RoyaltyRevenuePercentage",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "sesn_SaleOfStockCommissionFixedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Commission Fixed Rate",
        "label": "Sale Of Stock, Commission Fixed Rate",
        "terseLabel": "Commission fixed rate"
       }
      }
     },
     "localname": "SaleOfStockCommissionFixedRate",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SaleOfStockMaximumAggregateSalesPriceInTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "label": "Sale Of Stock, Maximum Aggregate Sales Price In Transaction",
        "terseLabel": "Aggregate sales price"
       }
      }
     },
     "localname": "SaleOfStockMaximumAggregateSalesPriceInTransaction",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockRemainingSharesAmountAvailableForFutureIssuance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "label": "Sale Of Stock, Remaining Shares Amount Available For Future Issuance",
        "terseLabel": "Shares reserved for future issuance amount"
       }
      }
     },
     "localname": "SaleOfStockRemainingSharesAmountAvailableForFutureIssuance",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SaleOfStockWeightedAveragePricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Weighted-Average Price Per Share",
        "label": "Sale of Stock, Weighted-Average Price Per Share",
        "terseLabel": "Weighted-average stock price per share (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockWeightedAveragePricePerShare",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_SecondIndicationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second Indication [Member]",
        "label": "Second Indication [Member]",
        "terseLabel": "Second Indication"
       }
      }
     },
     "localname": "SecondIndicationMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Achievement Deemed Probable, Percent",
        "terseLabel": "Achievement deemed probable, percent"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAchievementDeemedProbablePercent",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Fair Market Value",
        "terseLabel": "Fair market value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairMarketValue",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percent Of Base Salary",
        "terseLabel": "Percent of base salary"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentOfBaseSalary",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Received Per Award",
        "terseLabel": "Shares received per award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesReceivedPerAward",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "label": "Share Purchase Agreement, One-Time Milestone Payment Upon First Sale of Product",
        "terseLabel": "One-time milestone payment upon first sale of product"
       }
      }
     },
     "localname": "SharePurchaseAgreementOneTimeMilestonePaymentUponFirstSaleofProduct",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "label": "Share Purchase Agreement, Percentage of Net Sales of Quarterly Earn-Out Payments During Earn-Out Periods",
        "terseLabel": "Percentage of net sales of quarterly earn-out payments during earn-out periods"
       }
      }
     },
     "localname": "SharePurchaseAgreementPercentageofNetSalesofQuarterlyEarnOutPaymentsDuringEarnOutPeriods",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "label": "Share Purchase Agreement, Period During Which Quarterly Earn-Outs are Payable After Date of Net Sales",
        "terseLabel": "Period during which quarterly earn-outs are payable after date of net sales"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodDuringWhichQuarterlyEarnOutsarePayableAfterDateofNetSales",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "label": "Share Purchase Agreement, Period in Which Acquiree is to Use Commercially Reasonable Efforts to Achieve Marketing Authorizations",
        "terseLabel": "Period in which acquiree is to use commercially reasonable efforts to achieve marketing authorizations"
       }
      }
     },
     "localname": "SharePurchaseAgreementPeriodinWhichAcquireeistoUseCommerciallyReasonableEffortstoAchieveMarketingAuthorizations",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "sesn_SharesOfCommonStockReservedForIssuanceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "label": "Shares Of Common Stock Reserved For Issuance [Abstract]",
        "terseLabel": "Shares of common stock reserved for issuance for:"
       }
      }
     },
     "localname": "SharesOfCommonStockReservedForIssuanceAbstract",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_StockIncentivePlan2009Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2009",
        "label": "Stock Incentive Plan 2009 [Member]",
        "terseLabel": "Stock Incentive Plan 2009"
       }
      }
     },
     "localname": "StockIncentivePlan2009Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIncentivePlanTwoThousandFourteenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "label": "Stock Incentive Plan Two Thousand Fourteen [Member]",
        "verboseLabel": "2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockIncentivePlanTwoThousandFourteenMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_StockIssuedDuringPeriodExerciseOfWarrantsValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Exercise Of Warrants, Value",
        "label": "Stock Issued During Period, Exercise Of Warrants, Value",
        "terseLabel": "Exercises of common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodExerciseOfWarrantsValue",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodNewIssuesIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, New Issues, Issuance Costs",
        "label": "Stock Issued During Period, New Issues, Issuance Costs",
        "terseLabel": "Issuance of common stock, issuance cost"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodNewIssuesIssuanceCosts",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "sesn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period Shares Exercise Of Warrants",
        "label": "Stock Issued During Period Shares Exercise Of Warrants",
        "negatedTerseLabel": "Warrants Exercised (in shares)",
        "verboseLabel": "Exercise of common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "sesn_UniversityOfZurichMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "University of Zurich",
        "label": "University of Zurich [Member]",
        "terseLabel": "University of Zurich"
       }
      }
     },
     "localname": "UniversityOfZurichMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViciniumMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vicinium [Member]",
        "label": "Vicinium [Member]",
        "terseLabel": "Vicinium"
       }
      }
     },
     "localname": "ViciniumMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_ViventiaBioInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Viventia Bio, Inc.",
        "label": "Viventia Bio, Inc. [Member]",
        "terseLabel": "Viventia Bio Inc."
       }
      }
     },
     "localname": "ViventiaBioInc.Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantOrRightOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrant Or Right Outstanding [Roll Forward]",
        "label": "Warrant Or Right Outstanding [Roll Forward]",
        "terseLabel": "Warrant Or Right Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "WarrantOrRightOutstandingRollForward",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "sesn_WarrantsExpiringMarch2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring March 2023 [Member]",
        "label": "Warrants, Expiring March 2023 [Member]",
        "terseLabel": "Warrants, Expiring March 2023"
       }
      }
     },
     "localname": "WarrantsExpiringMarch2023Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2022 [Member]",
        "label": "Warrants, Expiring November 2022 [Member]",
        "terseLabel": "Warrants, Expiring November 2022"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2022Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedMay2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "label": "Warrants, Expiring November 2024, Issued May 2015 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued May 2015"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedMay2015Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WarrantsExpiringNovember2024IssuedNovember2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "label": "Warrants, Expiring November 2024, Issued November 2014 [Member]",
        "terseLabel": "Warrants, Expiring November 2024, Issued November 2014"
       }
      }
     },
     "localname": "WarrantsExpiringNovember2024IssuedNovember2014Member",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "sesn_WeightedAverageCostOfCapital": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Cost of Capital",
        "label": "Weighted Average Cost of Capital",
        "terseLabel": "Weighted-average cost of capital"
       }
      }
     },
     "localname": "WeightedAverageCostOfCapital",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "sesn_XOMAIrelandLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "XOMA Ireland Limited [Member]",
        "label": "XOMA Ireland Limited [Member]",
        "terseLabel": "XOMA Ireland Limited"
       }
      }
     },
     "localname": "XOMAIrelandLimitedMember",
     "nsuri": "http://www.sesenbio.com/20220630",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r42",
      "r92",
      "r93",
      "r239",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe",
        "verboseLabel": "European Union"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r351",
      "r354",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r351",
      "r354",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r160",
      "r223",
      "r224",
      "r277",
      "r279",
      "r529",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r160",
      "r223",
      "r224",
      "r277",
      "r279",
      "r529",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r304",
      "r351",
      "r354",
      "r388",
      "r389",
      "r390",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r222",
      "r223",
      "r224",
      "r225",
      "r238",
      "r249",
      "r304",
      "r351",
      "r354",
      "r388",
      "r389",
      "r390",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r523",
      "r527",
      "r561",
      "r564",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r41",
      "r42",
      "r92",
      "r93",
      "r239",
      "r250"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r161",
      "r162",
      "r277",
      "r280",
      "r563",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r161",
      "r162",
      "r277",
      "r280",
      "r563",
      "r573",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LEASESDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_MA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MASSACHUSETTS",
        "terseLabel": "Massachusetts"
       }
      }
     },
     "localname": "MA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_PA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "PENNSYLVANIA",
        "terseLabel": "Pennsylvania"
       }
      }
     },
     "localname": "PA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r32"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "ACCRUED EXPENSES"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r31",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r164",
      "r165"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivables"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total Accrued Expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r45",
      "r46",
      "r47",
      "r550",
      "r569",
      "r572"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r449",
      "r507",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss Investments"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r400",
      "r401",
      "r402",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r357",
      "r403",
      "r404"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r263",
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Issuance costs"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITYParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r393"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense",
        "verboseLabel": "Total Share Based Compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "netLabel": "Common stock equivalents excluded from calculation of diluted net (loss) income per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r75",
      "r201"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r13",
      "r87",
      "r149",
      "r152",
      "r158",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509",
      "r511",
      "r537",
      "r549"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r30",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsNoncurrent": {
     "auth_ref": [
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r446",
      "r450",
      "r480",
      "r509"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.",
        "label": "Assets, Noncurrent",
        "totalLabel": "Total non-current assets"
       }
      }
     },
     "localname": "AssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Noncurrent [Abstract]",
        "terseLabel": "Non-current assets:"
       }
      }
     },
     "localname": "AssetsNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r170",
      "r172",
      "r177",
      "r540"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccounting": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting [Text Block]",
        "terseLabel": "BASIS OF PRESENTATION"
       }
      }
     },
     "localname": "BasisOfAccounting",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r349",
      "r352",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r349",
      "r352",
      "r435",
      "r436",
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.",
        "label": "Business Acquisition, Percentage of Voting Interests Acquired",
        "terseLabel": "Percentage of voting interests acquired"
       }
      }
     },
     "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r74",
      "r444"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Decrease in the fair value of contingent consideration",
        "verboseLabel": "Change in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r439",
      "r440",
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Contingent consideration liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r439",
      "r441"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of equipment included in accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r478",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r10",
      "r77"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r71",
      "r77",
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash - end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash - beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r71",
      "r487"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "verboseLabel": "Exercise price per warrant (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Warrants outstanding, ending balance (in shares)",
        "periodStartLabel": "Warrants outstanding, beginning balance (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r218",
      "r219",
      "r220",
      "r226",
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 1.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "netLabel": "Shares of common stock reserved for issuance (in shares)",
        "terseLabel": "Shares reserved for future issuance (in shares)",
        "verboseLabel": "Shares of common stock reserved for issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r95",
      "r96",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "verboseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails": {
       "order": 2.0,
       "parentTag": "sesn_CommonStockSharesIssuedAndReservedForFuture",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)",
        "verboseLabel": "Shares of common stock issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r22",
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r22",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value per share; 400,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; 199,463,645 shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r281",
      "r282",
      "r355",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "terseLabel": "EMPLOYEE BENEFIT PLANS"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r58",
      "r544",
      "r556"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r84",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r273",
      "r274",
      "r278"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current tax benefit (provision)"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r417"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r88",
      "r417",
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "negatedTotalLabel": "Total current benefit (provision)"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofIncomeTaxProvisionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r16",
      "r17",
      "r412",
      "r538",
      "r548"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "totalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r407",
      "r408"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r18"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred Tax Liabilities, Gross [Abstract]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts": {
     "auth_ref": [
      "r415",
      "r416"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from research and development costs.",
        "label": "Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofDeferredTaxLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "terseLabel": "Employer matching contribution, percent of employees' eligible compensation"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Defined contribution retirement plan, maximum employee contribution deferred"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r75",
      "r202"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r360",
      "r361",
      "r394",
      "r395",
      "r397",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "SHARE-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATION"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r59",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r115",
      "r118",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r460",
      "r461",
      "r545",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r59",
      "r104",
      "r105",
      "r106",
      "r107",
      "r108",
      "r118",
      "r125",
      "r126",
      "r127",
      "r131",
      "r132",
      "r460",
      "r461",
      "r545",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "EARNINGS (LOSS) PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARE"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost, non-vested stock options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period unvested stock to be recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r396"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Shares available for sale under 2014 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r134",
      "r174",
      "r263",
      "r270",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r465",
      "r466",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r466",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r465",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r465",
      "r466",
      "r468",
      "r469",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENT AND FINANCIAL INSTRUMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r240",
      "r305",
      "r306",
      "r311",
      "r347",
      "r466",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r311",
      "r347",
      "r466",
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r466",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r347",
      "r515",
      "r516",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r471",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofChangesinFairValueofCompanysTotalContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock": {
     "auth_ref": [
      "r470",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset) using recurring unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Contingent Consideration Liability"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Option, Quantitative Disclosures [Line Items]",
        "terseLabel": "Fair Value, Option, Quantitative Disclosures [Line Items]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueOptionQuantitativeDisclosuresTable": {
     "auth_ref": [
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value under fair value option.",
        "label": "Fair Value Option, Disclosures [Table]",
        "terseLabel": "Fair Value Option, Disclosures [Table]"
       }
      }
     },
     "localname": "FairValueOptionQuantitativeDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r193",
      "r194",
      "r197",
      "r198",
      "r530",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r193",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "verboseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r11",
      "r178",
      "r180",
      "r187",
      "r191",
      "r511",
      "r536"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "INTANGIBLE ASSETS AND GOODWIL"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWIL"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r75",
      "r179",
      "r184",
      "r190",
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "negatedTerseLabel": "Impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILScheduleofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GranteeStatusAxis": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of recipient to whom award is granted.",
        "label": "Grantee Status [Axis]",
        "terseLabel": "Grantee Status [Axis]"
       }
      }
     },
     "localname": "GranteeStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GranteeStatusDomain": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of recipient to whom award is granted.",
        "label": "Grantee Status [Domain]",
        "terseLabel": "Grantee Status [Domain]"
       }
      }
     },
     "localname": "GranteeStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r75",
      "r199"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangibles impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "auth_ref": [
      "r75",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "IPR&amp;D intangible assets:"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "auth_ref": [
      "r55",
      "r62"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "totalLabel": "Loss Before Taxes"
       }
      }
     },
     "localname": "IncomeLossAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r89",
      "r428"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "Pre-tax income (loss) U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r56",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r535",
      "r542",
      "r546",
      "r558"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Total Loss before Income Taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r89",
      "r428"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "Pre-tax income (loss) Canada"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESComponentsofPretaxIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r204",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r90",
      "r410",
      "r411",
      "r414",
      "r424",
      "r429",
      "r431",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r110",
      "r111",
      "r148",
      "r409",
      "r425",
      "r430",
      "r559"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Benefit (provision) from income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r72",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income Taxes Paid"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable (net)"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Decrease in other receivables",
        "negatedTerseLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsCurrent": {
     "auth_ref": [
      "r2"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current portion of nonphysical assets, excluding financial assets, if these assets are classified into the current and noncurrent portions.",
        "label": "Intangible Assets, Current",
        "terseLabel": "Total Intangibles",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESNarrativeDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r192",
      "r195"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33",
      "r87",
      "r153",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total Liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r28",
      "r87",
      "r173",
      "r480",
      "r511",
      "r539",
      "r552"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "terseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r14",
      "r15",
      "r87",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r447",
      "r450",
      "r451",
      "r480",
      "r509",
      "r510"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.",
        "label": "Liabilities, Noncurrent",
        "totalLabel": "Total non-current liabilities"
       }
      }
     },
     "localname": "LiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Noncurrent [Abstract]",
        "terseLabel": "Non-current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserve": {
     "auth_ref": [
      "r36",
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying amount of the estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs.",
        "label": "Estimated Litigation Liability",
        "terseLabel": "Estimated litigation liability"
       }
      }
     },
     "localname": "LitigationReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/COMMITMENTSANDCONTINGENCIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.",
        "label": "Loans, Notes, Trade and Other Receivables Disclosure [Text Block]",
        "terseLabel": "RECEIVABLES"
       }
      }
     },
     "localname": "LoansNotesTradeAndOtherReceivablesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Short term marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "negatedTerseLabel": "Unrealized loss on marketable securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount Rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r137",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]",
        "terseLabel": "DESCRIPTION OF BUSINESS"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Financing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Investing Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r71",
      "r73",
      "r76"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Cash Flows from Operating Activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r3",
      "r48",
      "r50",
      "r55",
      "r57",
      "r76",
      "r87",
      "r100",
      "r104",
      "r105",
      "r106",
      "r107",
      "r110",
      "r111",
      "r123",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159",
      "r173",
      "r227",
      "r228",
      "r229",
      "r231",
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r461",
      "r480",
      "r543",
      "r555"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedLabel": "Net loss",
        "totalLabel": "Net Loss After Taxes",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r104",
      "r105",
      "r106",
      "r107",
      "r115",
      "r116",
      "r124",
      "r127",
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable to common stockholders - basic"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r117",
      "r119",
      "r120",
      "r121",
      "r122",
      "r124",
      "r127"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net loss attributable to common stockholders - diluted"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update and Change in Accounting Principle [Abstract]",
        "terseLabel": "New Accounting Pronouncements and Changes in Accounting Principles [Abstract]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r98",
      "r99",
      "r102",
      "r103",
      "r112",
      "r113",
      "r114",
      "r168",
      "r169",
      "r175",
      "r176",
      "r421",
      "r422",
      "r423",
      "r458",
      "r462",
      "r463",
      "r464",
      "r484",
      "r485",
      "r486",
      "r496",
      "r497",
      "r506",
      "r508",
      "r531",
      "r532",
      "r533",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "terseLabel": "RECENT ACCOUNTING PRONOUNCEMENTS"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECENTACCOUNTINGPRONOUNCEMENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r149",
      "r151",
      "r154",
      "r157",
      "r159"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from Operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r503",
      "r504"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "verboseLabel": "Operating lease cost, including related operating cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Short term lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LEASESDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESComponentsofAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized loss on marketable securities",
        "verboseLabel": "Unrealized loss of investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCOMPREHENSIVELOSS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for other current assets.",
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses"
       }
      }
     },
     "localname": "OtherCurrentAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r34",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]",
        "terseLabel": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r70",
      "r208"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Cash payments",
        "terseLabel": "Payments for restructuring"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r65",
      "r66",
      "r171"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchase of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r67",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "verboseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSSummaryofAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r21",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETSParenthetical",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r21",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value per share; 5,000,000 shares authorized at June\u00a030, 2022 and December\u00a031, 2021; no shares issued and outstanding at June\u00a030, 2022 and December\u00a031, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrentAndNoncurrent": {
     "auth_ref": [
      "r29",
      "r541",
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.",
        "label": "Prepaid Expense",
        "terseLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/PREPAIDEXPENSESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseNoncurrent": {
     "auth_ref": [
      "r12"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer.",
        "label": "Prepaid Expense, Noncurrent",
        "terseLabel": "Long term prepaid expenses"
       }
      }
     },
     "localname": "PrepaidExpenseNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "verboseLabel": "Proceeds from issuance of common stock under ATM Offering, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r69",
      "r399"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercises of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercises of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r203",
      "r511",
      "r547",
      "r553"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Receivables [Abstract]"
       }
      }
     },
     "localname": "ReceivablesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r406",
      "r528",
      "r587"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r77",
      "r82",
      "r574"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSU",
        "verboseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r206",
      "r208",
      "r211",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "RESTRUCTURING AND RELATED ACTIVITIES"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r207",
      "r210",
      "r213",
      "r215"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated",
        "terseLabel": "Number of positions eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "terseLabel": "Number of positions eliminated, period percent"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r208",
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r270",
      "r511",
      "r551",
      "r568",
      "r572"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r174",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r565",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r334",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r348",
      "r350",
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r146",
      "r147",
      "r150",
      "r155",
      "r156",
      "r160",
      "r161",
      "r163",
      "r276",
      "r277",
      "r529"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue from Contract with Customer, Including Assessed Tax",
        "terseLabel": "License and related revenue",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": {
     "auth_ref": [
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.",
        "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]",
        "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r275"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Transaction price"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Proceeds from sale of stock"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of units issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RECEIVABLESDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Expenses"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/ACCRUEDEXPENSESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Components of Income Tax Benefit (Provision)"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r331",
      "r332",
      "r335",
      "r336",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHARETables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Share-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r465",
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Summary of Carrying Amounts and Fair Values of Financial Instruments Measured"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/FAIRVALUEMEASUREMENTANDFINANCIALINSTRUMENTSTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r193",
      "r196",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILCompositionofIntangibleAssetsDetails",
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Components of Pre-tax Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INCOMETAXESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class.",
        "label": "Schedule of Intangible Assets and Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Composition of Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/INTANGIBLEASSETSANDGOODWILTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of the Status of Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r208",
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/RESTRUCTURINGANDRELATEDACTIVITIESTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r356",
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r364",
      "r380",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Weighted-Average Inputs and Assumptions in Black-Scholes Option"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r19",
      "r21",
      "r22",
      "r85",
      "r135",
      "r136",
      "r243",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r256",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYEquityFinancingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r20",
      "r21",
      "r22",
      "r244",
      "r245",
      "r246",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Summary of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r271",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrants Outstanding and Warrant Activity"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r446",
      "r447",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r524",
      "r525",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discount rate from fair value on purchase date that participants pay for shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Discount from Market Price, Purchase Date",
        "terseLabel": "Common stock purchase price, discount rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardDiscountFromMarketPricePurchaseDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Cancelled RSU (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Cancelled RSU (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Unvested grant restricted stock units (in shares)",
        "verboseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested, ending balance (in shares)",
        "periodStartLabel": "Unvested, beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r374",
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested ending balance (in dollars per share)",
        "periodStartLabel": "Unvested beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "terseLabel": "Grant exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONShareBasedCompensationExpenseDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "verboseLabel": "Common stock available for sale (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EMPLOYEEBENEFITPLANSDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Canceled or forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of stock options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares under Option (in thousands)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONSummaryofStatusandChangesofUnvestedRestrictedStockDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Cancelled or forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Vesting on the First Anniversary of Date of Grant"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Vesting at End of Each Successive Three-Month Period Thereafter"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "auth_ref": [
      "r358",
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires.",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "terseLabel": "Share-based Payment Arrangement, Employee"
       }
      }
     },
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Percentage of original number of shares subject to the option vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONWeightedAverageInputsandAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-average Remaining Contractual Life (in years), Exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r384"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Weighted-average Remaining Contractual Life (in years), Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "Vested stock options outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r83",
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r38",
      "r53",
      "r54",
      "r55",
      "r95",
      "r96",
      "r97",
      "r101",
      "r109",
      "r111",
      "r134",
      "r174",
      "r263",
      "r270",
      "r400",
      "r401",
      "r402",
      "r419",
      "r420",
      "r459",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r507",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r134",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Shares available for grant under 2014 Stock Incentive Plan"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "terseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails",
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r21",
      "r22",
      "r263",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock and common stock warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r38",
      "r263",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercises of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r22",
      "r26",
      "r27",
      "r87",
      "r166",
      "r173",
      "r480",
      "r511"
     ],
     "calculation": {
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS",
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r86",
      "r248",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r270",
      "r272",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITY"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r494",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails",
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTSDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]",
        "terseLabel": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r512",
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SUBSEQUENTEVENTS"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails",
      "http://www.sesenbio.com/role/LICENSEAGREEMENTSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/BASISOFPRESENTATIONPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/DESCRIPTIONOFBUSINESSDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r382",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/SHAREBASEDCOMPENSATIONNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/EARNINGSLOSSPERSHAREDetails",
      "http://www.sesenbio.com/role/STOCKHOLDERSEQUITYSummaryofCommonStockIssuedandReservedforIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r117",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r115",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sesenbio.com/role/CONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONS"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 11
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "https://asc.fasb.org/topic&trid=2122394"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1930-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(23))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/subtopic&trid=2196772"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=126986314&loc=SL124402458-218513"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL126732908-238011"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14210-108612"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14217-108612"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=126983955&loc=SL121967933-165497"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL126838806-209984"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL122150809-237846"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r588": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r589": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r590": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r591": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r592": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r593": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.20)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(25))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 201.5-02(26))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>96
<FILENAME>0001485003-22-000121-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001485003-22-000121-xbrl.zip
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MT!_^-[O*7,G57^.FPS28%:Q4\G$#(X*#&@OWXRS;6^0. R<?6)EABA-W3WK
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M+S'S-^P /%)0EU>#:37DN6HM\7D9\+:U?C>.^<LW\L8M3!#LI37(#P<<@"V
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M=6=PRP]W"+?--HW#-1@<*9Q"EQ#_&E]ERM4AS\WV52AI!H!8*7KR:5CE&AM
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MG7$$*S=YYVSI)'Q]7H4'2)FYW5QETX72C=>"BT]_2=E=ES[_$U!+ P04
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M?_7E:08ASS(:ZC(!*Z:6H)84WA5$8("3-5S0G L%2#SA(@7'-MX]WVL=]H?
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M"9B2 &@?A S>Y%4&8RVR+O/"2AXB]=J>SP"?Q1G@$Y@! :B%91"148&C"\Y
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MM8JYE9#'(\8$\UJ5YSPXR;A!R0C!:O07C=:,2N9\\'.P##M+'22GFRCSM3N
MFQ.F\I'QU;?.K/ A19ITL D<:E"!?\?DF7,@C4 _:?:U9I5&MY5&H8*MWG:Y
M?W"QV/[H0'_CY*BL:O#DO#I\J7G926R\U<EH4Y7:I5H:=%RU!=2KQ 0>TNRK
MTMFDT 2+1QJJ0$4%TDEAB7.4>1JC3MX%0),W1_IUAD@U_3R8J'/+=6^DX0KA
M/360!*<YX=H;X;A;/-W8Z'ZM[I7?:T[4(Q<AYU>@%?-"6"E-D-1X[A'7 (<T
M!_L^9I9($RPH%S17P21!=!1)1\>4IJ!S$J S/L$":\B'I=;TE61RP5$C JI)
M+021%B)ZX<:BT^<AT#E8 KP'1<5FOW\,L>Y.D7GEG&A,DO=[IR03I"2L48XZ
M'1)%V4P\D7E8$YD/BDU.?4H1!.(0+2(Q@OFL,D5N^J.D\R:$10:8CTBZZ>M2
MU)I64<]4TD8(K0SQ'-T*],RU2@%F>-O*Y,C[_1<JYD2AZERUR)L(4B;T"XB-
MU*KH*0O$&<G$4U"HCT:V"=993YP&HT10B%@4 :N1>DBU2!6WSI@GI54?EG[3
M5ZW,:1TA $2;$TV%<RIP9YT-(G&7W(C88@Z(O89WB&7K.#</W<F5Q<M!"4C:
MT#J.$%_WNNT<%C\>5 MX6VG#]3I(\OX[Z.T<N![\>7KS#1XI\^HJ*]PV<76"
M'@M*NX%H.!-Y[SSS@5OT6Z*.R7ABY!SE'B\0*TPEAYFXZ(/-"6*>B<"XC211
MCK0R^(=)\[!!<0%982H&0CDF(Q"J%3!AJ#8Q4&J-31K!G4ADCC:5+! K3&5S
MBM"<Y2I"B.CS;G-FC'0N@P3E$F..+;'"%')19P W!.4<4\)H2404U.<"8=8'
M);4@!,P2-TR;+::"(:CU.EIM58@2@83TCC@:(%F9.+-S57M_0=EB.@YGL$X(
M8W.5?N$C<T0ZKW*VC>.*C:#E$D],5UL\/K:PCG--6'!.*"&B,Q:1II. A.,Q
M>K/$%I?9 L].W5R5.4!U57\1D872"1DB(=)43@3T/7@PA@3)02+08&+)%%/:
MTC%]UI"0ZUXIXA-PH33/'=*EL48IYYTB<0DZIZLOI@(YE8L$@D4'1'O!0O1)
MYT)H*IK$;7!VR12SH"^FPAI2&<<\1Q7$C(@\%\-,2>CHB>9Y!\#2&YD%UIB*
M1R(H9'^4*9[Y(BK+M,&?F%( *<HE:TP?>CX^4T PD4<1$Y H*&->"0U!1:&H
M!65AZ:9.'5],H3J3ILS0D%L-!B$I=5Y!C"8 ^J[&.[YDBEDP(E-A#1J"D<Y3
M9Z44E#CCF7<R6@?)!A+E'+FJFYW0;</YCL*WW5 QP372WE"(?>,D[Y!^@-9N
MTW<X$0B )300)*B(D9KHE541/4]MG"/SM,HQ\P2>CH<@K28.135Q(;@PCLLH
M 16]CX(9-D][,6:>P-/)(A:>2"6<9\0)_,](B"DY*KV6.O!YLMXS3^"IV&
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MP4,GPI',.-\5Q-\GI%XZ]3X)C4I)J1 T>#0#GC#+I30A1J>8]R#\'/#83\S
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MO6Z[]CG_4QMTAQ]N8QS4#P)"TWBY7#*U[.=UN=KK$HT5\K*'WLMI8H A.GE
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M-%L\%U$[FUC>U5HCB4Q;G:RAUE(YQBQZB5ET"9C5UDRY%0&NS]/4AHO(6-#
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MC'Z._9AZ9YU_O!L.WO=&61#_G%3J720=G5T7T5SS@Y06Q?&.[,>+DY,+054
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MTMD[9#PK<R<2\5Q8P;,7J&D[YOLT?1RQGBJ_W$C.LA3]*JM)O8\QP.<X'%0
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M+![&X?N>CY..WG]$/WC='U_E3WMR'FODNRFF<$U__X!2VN \"(&9T9N@0(?
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MGO-H"8(DS  J'\!QPD'[(#G/K@9/LD1*ND;.-F.\3[O9"@+K 0(D$$\,\QD
MT)*HDTG!>Q9H0*\$KR#00A"8B2J(++^H P6*#@$MUV"B5&"(C"QOX.!*LZG5
M08''U(ZUT28WJ]M:JW8JK&*J8GJ0#%U&*,VN@-4!I9$&%0::DJ8B6)+<+1A
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M-$Y@I!2<6 .9D!A%-!HT(C,4U56T1D563.E;%A6IRKYT99\B,%Y[81A/($)
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MTOS_7X\W_!4!^%^^]HC@#(]H@+M<,N[2* @HJL*)[S.6L,0 _!VN9-< OR(
M/Y^/(TPX2R*6$A7($ ">IR02G!'7BU*M5>)1Q39>AW33H_,U59[/_<<SRP>R
M1N(U$D]??[@AC2,91CQ0#-3G* @E#100;T&C* JM5KU&XN>$Q+-5OK5+120Y
M23T98W$K3>( LU<K.&O#6 ),<]"JN;?I+M"JUU"\1 >H.U)WF1N@?=H<(CX,
M214CS-6_PIE.[MK+O^#:_W#4[^<:<VJ*W*I2:5Y<.BHK95Z4HX'^N10X=W6_
M?\HV'O)2P(M7>YE-LJ.^ """@\X171@6:-*9N6"SN1Z'Y]KI:H%+CM* NG1N
M'$#R20WJ7S%XK!A?6SQ-=^=KBT:X(I1L=2*\2EWV7AU@)_;3XU*WRE+#*W(!
M!.RH:"D;U[^?MJ1$>81Y/!R*GA*#=3#J_2C7?#Z;*/!\2N.$I,P50+0H);$.
M71*"WLNI$BK56";D#[S#6&/2'XE)#^:OLL:DWX9)LVH@2QB5,B(T<$'Y"Y0D
MD:<TH302,@PP\44 F/3+'B6_[[;EV<6NK3O\^Z,#G[E..-$$426 F2!&2UR4
M&GZM*OX)JF*S].*XPM&4JBBD'(S@1_VCKWOE6BW\2RC8@\>S;HM^!A"SBV*D
MLB% 3+G7DZ/!0*LWHV&G&)[HX4>1K;.-/00CZ^S,!Q7X+%8Z"@*2:(9:HN3P
MD^>1)(FT\F*F?<G_X&QC:YSZ(W'J$4(;[HI3:SRZ'Q[-%5"07N+%(1$1_,-2
M$1/AJP@#5V7L2<Z5!Z2(KC7$OT[A^I>I_PW_5=GWU_\'_JF?Z(K!6=:SEZUT
M&ITE\%8]>&BX\MP:KTR+KQ 9,GDS@E%$L*-SC<RYZ$)OKE!QZA5#>)\ Q4I@
MJ:VA/AN OM47 W/Y,CS7)2;@[RGDV#A;/7.3C(:J.D,+?+T<PA],U;RML?C/
MSE'5#4:W0DQ'TR_*#'?-JP&:O;+O^I_+3 W/:Z!M/&A%_94[>40DT(G1</DC
MOW'^;YQM/CT;S7^QMP:>F5"IY_MAD/HQBP(E:.0G2H2"4T^$,0=^M%$_=#Z^
M;N^+,TV2@1;?B$AA@*]$?BFNRHU_3<LE".7,O,].F9V8UZ;BPJ+>/NFLSOGU
MF%D]W#W<[3AO]O8WG;W.]G*)6Y7^=O:/=@^=HWUG>[^SL]LYW-W!GP[W/^SM
MM([@E[=[G59G>Z_UP3D\@C^T=SM'ATL'54%-M2F"WPLV-P[SQ7%/C("9:/5R
MOO=W%/5PX[Y#OAB5PRR]>J(Q>UM.Q0D[HRXT(1] 69W)9"*0ZNVG^WT]$"99
M[A/3NLY53>MV^<G%V57GXKQ[TOWD=:X__3C%OT%;G1UY>7JTRT^/]CC0OF]
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M U^F\K4VW+66/3-<<+FT!%&7=6> -L]1U8$Z*VC3^&@?,JAG2-5TM"Y.3FF
M>>D,XM2=HUE[8 (K\!V#3!N[HXU*'PY,5*SIP/=QA[^C+_FHK& UK0S]U?&W
MX. OJI.I-O-/7.RF+C,VITY3F "[:":@S7!GM**8 Q6H HYZLNHBJ<VT4@P&
MAKV92.$;5M5TMS[@\=C$PQWT3_@31M$A8;?C*XO10.JRP;,6#?+F>;:7(.,)
M@!/.DC<SY"OS<<-Q;XJ*?1=9;AZJ1,IX@8R?L@RP/>F0QG&;/I@[RIM67F!4
MY%F!DV6GUABWLW1"ES<-*2N;K!M#I'3M.CC(RDJ;&?6JL];,;=;[7N3?&^%C
M,\0CJ7Q^*\&"[V(GJINJB1>BO4$]0PN^96OVBLS8/?.Q*^3-X[2SC%&)5?@8
MRA:2-)6E:$LP"UT_KNIOV)UD,E\T><;T:R;BE\'P*EPQJL58]F ^0(/*S/(9
M,?S'.2L*98+5ZP#)VN^SZ9O_3Z4@.$/Q RT08Q]+Z[=KEMA(!]Y\&+#%;:&T
M=>?'IZKWO?RG+NRJ38"<#>*;1+#7L+(U;]!OVLL>EQ-MCXDG.G\C@;LZ@O;?
MY* ;_8T,Z>RK3VF04IJ2R&.4L$@$)-)X^1S04+B:A6$\E^QG=;C$/1G2QXFE
M$+;,E# \5[(T"WCW4>UJW;RV1]1T8.X*_O*\0.,KG-/:W+H#?&2H28VO/'&S
M9Z9%>]'3^-+F5)"=<WS8LM=/)L<16F:,4EKG'AIBJ)#UZJF]S'/K?S"Q1<!!
M:-P5=*U_3E;Q2<$%E%!8G=XV)I;M ; TAM+J*?-K1437R-.Y_ JJ&:?2IR1*
M/4D8C5,BA$Z(#MR :<IUJJ(_!GDJV7!JX7 :XO L(UF.C*7)VGW0HE./:S:X
M!VD7QH/4*5UJ7##DS5+'XT-' ;Z(P2V[=_'=_QVOBOUG=E7L/_I5\>&$;DXN
ME#Y61JV5P:;:5:A["O][GT&[WLD1_/?Z '!JEW>Z;\_;[_;XZ4[GO'UT<-&Y
M_CSG*H1/ @Y=[>]\/F]W]ZX[[P"GCK[1DR^[ER> 46VZ^Z/S#OK_Y0"PZ>3R
MJTYXRMT@1 ]4E[#$\XG0G -%BMPH\!*7Q<GL[;'TT\2GG/F>2ICG>4G$HEBE
M4J61 FC3LTAV>-QNMPY.\/[X<.]=9^_MWG:K<^2TMK?WCV$".N^<C_L?]K;W
M=F_)H?A,X&+QU?>MD]:D./\SR6L$,-(U"<'N8)UMVE^1+VSL ?UQ/+[E[/XX
MSY*L4M@7W# ZA_)<*V-((DZG@-?ZZ!\\?G-C S6O9.LMM#'VA+RO\?ONYNZQ
MT1_M_=7%0NT>7'GY>%7BH07P^;-N-\$SPU+V^*EF]64#0P=%KT SA5E-H'[;
MYG*SW.LUOU-K(JN"M)ULS (O3BX^YZ<7\D?GRPG=WP&D[>ZR]D7KQ^F%ZG8N
M/EV??CF]V'^WQ^998"?K?/G<[5SO>J<7)PR0]NKDZ.RJO?.VVZ$GM+/3R:$G
M[ 0KS%U\\H$%*A%I)KR8)"+P"9,>(Q'5(0D][M(@YBGUTKF4KU1+@ I74>ZS
MP%,QIX$.A10\$I)Q.8NU![O;NS/8>K#?@9^WZXS1]W;:N;T+TUWFB10J\5GH
ML9!Q 2(G61(S[J9I%*61W'ALY>0&";7:R&KI)$\BC6=?*8^43J4FH1 4=)*
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M+Y($U%]<"D^[<LXG+O:I0.4XCF+-(AXD01J$C&OI"P[[>4[G?R:TVP2]3'*
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MX]/]\,F?P:=0>\*+:4H"QM'K,\8@3\"GT/.4FZI(1[&W\;K*;K$&J#5 /1.
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M@7?&L12/L2J)[WQ&<@.+XM(B!8(*X!WF_'4R^&(V,*^Q&%X%H.-^'569$*K
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M>!-CJV]8"_XRUY$GN%[<[?;SXDKK SOS#4O>&JX>&J[F+Q]3E:8\#!6)E:<
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M[S][SO=WCP25@F@L4$J,(2ZQ1RYQCR37UDMAB,ZU%-;HW*M(>>RW:.4&7B!
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M[+^>[]ZN#?:5+]H\XKX2I?Y[D..V@YS*VQ\FL)9ZM=5<\CI:O3%UUE=EM,F
MLE8%'?R;%EW"W.8BD9XRI04WW&N.#4[ .A$6$*SIE:PRHXS2.=?P K_L@@I]
MD Z*B_O-F?775$R_NZ_X&[/7P;,71\P;2YP(* 3)$2<!(TLL15)SK72N\:T
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M+F,Q*5OWYOEOY11OK]NMJG%.OZI.#Q<BSL2?X[!G59>+ECT&3LC%-_.G-['
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MST F_.#5D:0V)*<5$HHG(!./D9,ZH!0CETQ''3';>DIWC+G$]SPCJU=+JG%
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M;F/M$I(I'X=0\)O66B%-&&/1)JZH:%QF=P54)6[RGZ&%E\*_H?WIZ?_ C_'
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M5N8JD@0Q8A,7C$:76TX1O:UX@WL-[OV8N'=G;:<:W-M4W%M*Z6;49%\*4L(
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M"&NPS?@.9EZ#[PV^-_C^ ^/[W1</;/#]6^/[HJ<V&@P(3B7@>XZOAI1;W>&
MJ!/*!6RDX6SK*=N69CEEI,'W!M\W!,4:?+\#?+_[(HD-OG]K?%]TUQL=5.#&
MH$@$0=PQ@HS!%$DFB<[_I23E2!PER\<Z&GR_EQJ(&UNZKCSQ27L(K_/7*&8'
MFAYOO1GV_,?6BVX^K-[^%%LO.[9[S4)&EQ8*_!YEI^K24/\]:*V=VG;+#EJ
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MB RT6ZW);A<(L]/:BW&XDK*6"#D7R 'R,MN773AA!YA7X;Y<:V&\X%/*'Y[
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M>GE_&M#MR+#1@+X+9?&]W:.DE1")"Q0X<6"W)K!;K:=(&9#J%%M&<\6HK].
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M9^.N>V:ZWA;/;= =F>2->5W!O#;>S  P'8+VC%&4205A+#$,:24<8D9*'"#
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M2<:\Q*9]B+#[Z?'#9W]_\P<:M+NA=QF!!3R*1OW@]S?PGN;I:>@F4+H*[-2
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M9;NTN&!+P&L[L#3-(OR^,EW?2UT.%1 8]A*-62C !;UQF[14<6UUDX09R[7
MN<ARQH/B1F>&*F=9!K=,&;PIL3VRN!Z0P_<G4A-",8^3%-8!=,4&@:TPR+F,
M8,V-#[F*195;9BEKKU:Q41M16#=1H#&*D<HK$2R*\[6(*XN1ED*CX++8H!]G
M-&@4A46$A:4H_%(;*SV8T2,H6@KF)E]&27MXA)/C7=,<Z&#S_"!4O<D+:Q;_
M[LVVZ<Z4+N8QFRRD5WRLU/=X/>4'66*M<(ZU9%)2QG-*=3#PB@I>6">#Y],C
M;&RC?C]6_>#\=T^\EEX*#Q 1>[#$N2'(&NIBP.:4ECE@BFR9\O9*EG@C"FLG
M"H>[)QBB!YZS#-'@4D[=(B6= H/CG,68V4R[* K9"I9XOKFL[^Y6O]ROE_;R
MNG<=[278%:[H;\.*;@J)IPJJ.VM:7'R8"NK_.ZSOKND%/LR 4KS VD$4DK:O
M_=6\2&'#JZWX\O1H4E$H1=.5TB@\564S'6VRW3 >=U@F'1/&ZB/@QKJA$,A^
M<&=MN$&GU^-S19<MT[MH^M[V^%M[_2Y\&%XK?UN[,)?%=Y6IF?2FZUX_7$P6
M5-,9+EU,'1]A&E[$/2JL\[_]UFQ14198Q:A[[(CFF=%:8QZLU1FU@F<Z5YF3
MQ-XZ*\0WLT(_?HIC;Y>"I1><*J,!<U-M*.*9B 02&?P5O'#FM &?S**EI[=Y
M_<7E4[.H;!J'W+N7G2+-,!3PP5!XAT8C]NS,*;$ZL#R)66)^076YHM>JY:Y[
MRO:FW'4_H3T@C:N32+)$F.61^D0B3AU#%A.-F.8\MU89PQ844I<M=XU$,SJ!
M:#B'#6'C?N+&VM>X!YR8EBW*6D4=+=FR:*"[,_-&R5QWQAK:D;U&57'"FAY(
M=%6-FW.4BC1B>KP(?K?,/$GZ\@>8)ED#=7GQTR2-O4^L\?Z$*$P5\0()0ACB
MAE"D,RD1L9KY/)<2-"J6X>9LU)X>*#D J?1%K7.[;+?LAM-.U)5Q0>JEJEU5
MQ05A75/9V8RU+2]*QQA00Y81KY42R-BX2=732.P+J %KS+B01&*L8G%ICB E
MW%]VP28?7)G<HI,J57G[\X8Y2V _,=-964.0SBB9+ZC6NZ9AX8JL(X>#_K.E
M'?G0<?#\9B/[-;VZ&Z_EH.@JJX&QS2;CQ30HDMA.RRS.@DB_N!OCL?""^U,%
MP]L3Q%8%T!K_XI06@"\N#I,RTF5F &!9I]OR5P!PJK,9C^AO(BYI1B*2I1((
M\T8%+CKMCFMUVJ#"P[[J_=\/$&:DB&%:K1*.'?R%LO@><]II-T'YYWURA#,!
M$;9G)\E?Q<7*U2A!\5"V)NZI!S?=#^D]L;T#(-%EZ/:OMWX93Q L> K;Y2^F
MT@'5J$H5<<']W(XEXV;J$.O!QR:N=SC=7EFQR 8S&I]8YFRK7IYV3-<D&LOI
M>Q=O&#KX:^X]?#5/UGRM1(=#ZL&4N8G2!F:W7<"84@K@Q'O!#0J@,W:AZVI_
M;]#BXCQ\K.$D5_9K"K3CN[9>Q\:A=O(]1S%A]/0N;C+GF&9VOL*#3J(VM!"#
M2_@[/-3*1)7-32N5*XP*DFI/L]QPDVGM!<X-Q)R&T\S21!5',JP2)(T_K%2N
M^%2<X-NPR5G-1Y]'IP309ZZTSX*02*HX%L]MAJSU%F6YI9BSW(B MU[+6PM5
MXZ-;)!N;<D_M+B! [1CTED!LD3O/.]7 36J9 C@X9:C_W0-5Z+@O9YT6Z%NO
M&$$K93(>9;K]>A1:P:'61S9WAR?UZ?+M1DIO9&':O6[LGH3 K,U9CG"F ^*!
M::2$9D@X0S3./<FEVWI-L]O[_8>".=7,T*M2W6/#)ML3R= H:J/ HOF]B&'&
M9DZFH[%"!OM7\%-[R)[6]DV7/@F1?YE>=T6?:136T]/(3M8?ST*M7C$ A?,^
M" 4Q)43\.JB09<PRCBEGUAAR3]G=5 P>1*X/OM7!^@IIN(S!OH_L]PKD6D?^
M6TI\QG*L':9ZZS712]C?"+;3,YE"U,.IJX4"?X,(CT+JD>!N5^RZT4[#@5XU
M?UF-YMQ2+0$K,FHHU\2"D74A<,MU;K&3]S6M&_%\$/&L1\X<HSP+)A)UA-PC
M;IB+',T!91Q[10+W.%@ ![=;74 '\^M*VV7AX%N2R;($T%M)GIC/E ,E,KG+
M.39*&6I5'GQ&B I!N]OD*=O(TV/(DXA#>QD&5\0R1*17B!./D55&(^&)P50J
MSS6 33:;ZIR4IH+U'1#4!%U28:?>G44R^X.#@U%%L]\%?[T-=FI%0V6H(4%[
M0VA&.'-@G7S@ :0J4Q[#E6P$:QT$ZSVIGY[ [2>,$XR,#R!8PL)/V@BD=2XP
M@Q>)-G-SZ#-F:AZ;19&Y OE948 @A+"QUB)<EG'"O,F]M+D+5"N?!Q,V K06
M A0MDP1(DO.@08 T03S/,%)46^3 W>78<*55 $^WA)^[*438J8TBOQ+B]^Z&
M\1G-))8$PG./ 5 1HU5FK" ^![3OR:U=01O1>A0&80*Q*R><Y\9[I(P'T2*!
M(LMRATB066Y8SJP#VY3=.JC>#4.$?WL0.QVXSC=KJ8)7+NH; ?RUI=*YK:SR
M,5SVJW[[6%LI$D-%\\8X;>P0+,R?7U@QC4E"H*")F9>><D)R*Y3W3BO)<![Q
M0FGE=67E5^.7VZCBPZBBP_6KD]CW()PED<X[#D\#_E0V-F7;7.5:,@7_;+VF
M2[!&]!+Q5=Q.6,'/@_97> )EL1S,>Q3KO>[@M&JRZU?(M:KJ6-"[BT0N5*5(
M:P45J VQ V1,FHG83A*=>D7&.;K(]HK$\]3G&""MQ)D2W.7!*DF](T1PN#I*
MU(+=SS=[B^G!@">R:.SQ9?"4-TY/#,4NERH@3B.EO/. 4@.F*/"X*-#Z>%B0
MP=N@ZLA<Q5VHI1_PU3A567 L8Z3$%E<%1E-QT4ZM;MKFM' A(>Y=+:JRD4YV
M^!6C-M(-W>+-=(OZ.=$MWDJ?.$6W&%>H\5PXX1SE/',:+!F51LD\IT[HM5KI
M<^-C'"X22^A\+2<+=UWJ7HJZ_;$/""\-A[_I^%1/2(\PPQ$"%?131?'V#1PU
M6I,RS_L&[G'G(K(VO]KZ27OABTOY^":>[*A9)0+6L=70S7ZM6.YFB_1VZFU+
M^U'3Q<;^DO(JBUVN8-H2Z4WL?>LX-XC)HEH^2)MH+N$4.WZXJR#:SOBVU/\6
M[6-<H@-':78&O>J]$+2Y.*L9J?ZFZ4#:7SM--VR<6<43RRS+;;"24N%XKKS"
M.7,A@-)PYD%O%BR&W7CB!UFZ<2# $Q.F(6+& HG<9+'XXI$F0J8E:U8[0@WW
M2WCBI$M#*H9J1NBF'7F8!J$5P  >F:^YLEY3Y8SGP00%XG#;CKQ2]WL?4FM&
M5(J2/2DUG$P\<]!)]ZL?=+VY?G$/N7X=6<>)SAGF"H4TB!N80(H)BG3NI *#
M#;[)CZ><JXUW-;ACO;&&A#G1=M$TVRVV0J5VN!%BB@:IOSVS3W)1X\.JG.98
MQ\VEQN78&$XA>B%!LTPPI:0VP;-BTK?B7+@!T%=[2TL_\1;<1.4E_@&YKES$
M0=7Q%Q?!PO_CONF-;9DO=N^_-ZY.C(J$\THC;7(+8B<Q,CA01)0WF?3$"Z&7
ML2VF-\84T!MMCRL=7C'-55B#LE,KFH/>C<S-),61?QK >MWK,>K7RH:MF/\P
M.N8\"&;&&0XVRS(.CDW!BUK:0&>L&5DIN'S7[8!;]+THF1OWMJ0(?J+UW1.J
M+.8B\\@HJA''PB'#+(A@3O*<<Z*$R9<7P=0#^&0S@Y,#-F-CC)%ZM=\J^L;*
MJYRF5RK2I D")AJWY.]-K=],O=H3LUY)X$J^Z6)FIQLW:(-G2/A[M8F=3.J<
M\D!S#D$7$0JTB6N?F5RI"!O=?(2X)-UBG-)YP9,WW]VWQOL3&??3.B^14S@@
MGL?11^4L$@(SKQR1PKOYO8__6IU&,_?:8NW!2 K"'0.XAWW(,QK B;N@^.9Q
MWN=Q1JA')9,<2XG PX+!HR(V4V4"Q:<L--QR0?'6:W+;1%[\RV5%RCR,&T?<
MK:E[/NKT>'M^4<$3^%\E,.Q5C&\QX[OZH<<F&QP8JYAGJ'CL Z#0"GV.9K%Z
M WM>]FQUJYF[J>6PKMEU@XM>/QJQHJ)=@E([N$:= ?C]RWZ5\D@X]9GUY?\.
MEWD(EWE87.;3N[BB+W]1"%&.(1<2M] T%3F-F=E0([5T'#-P.$PSHST6C)+
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M"4PB^"W=GJ'CD06M[ZKGP&8!\$PHBU;T2Z:1N,,^9S_\N?\WM6*:L9AC/WF
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MXBM<[J,:WGN*^(JMLQ".G((AJ&7R!I7JYI-KQ8HGJ$+^EX.P8]K"]N=SC.L
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M<,@C]-)!L*,K%8+!U[1.L*(@)N=5B1\- [26<7&T"ETPD$1MA/9'\#GM.IJ
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MON>!ZGR'N2T48Q\CV(QU,@&["?VT*66-E.Y\]S&7^?CPURQ&T38F77OIDSP
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MYHXC"JSOEBX?7<$5:V,V>%M(,0CC:0BK$X%>S( Z(LK<1I<^7=MY ^(9;&H
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M)MK#H]@Z)YLS:F6'YP=H9A.F&L@"9_'X4MQCL^!-N+!>A:#B(7/22C-VR4$
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M_4U0OX$X-?T8]$!]%["4S?5IQ!+XGC$I.?@'@YU%<91-9Q:>%61PLOQSI6L
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M523M)8EN+SV4;:CM698"98--A5XW^>"TKT3)%C*#4U_8_$"WB<L6W+9F<!I
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M19$_8$*\TP=$9?T)NBSQ?%?$]+8+O3>MSP%9/S'N%I_]".>QAK;U(A^%89V
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M9<N66+Y%(DN,C8LBQ@L&MG[#<AL(]39<6%0J6 U9JM T#DK== 0>&K0H61H
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MM]2H\(M,M6/^"+[?59)OG'Z,YSU8S^"V ]WO'D!58?8UL[-'+;O7V<%UN',
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MC!)E PN4>&>?O_P'FR]>O\5^Q0'0HL?5("MU@Q>(6\_%IN'1@KF4F"KTPIC
MHY?4.1H%?+OE])O&*Y3L4R]''5#:-H-XS)#+*ZR4T?UQ->(^X(KOV1B(.0KU
MY/GBA.RU%"]G)%25YC=B_^Q&,4/0_ N#,L VLCLU*$D5<3&BB7H.' O#C'IR
M&3IC$N'L;7,H.7T*B@X$Y34 UM:]3*))RD.\T V(PZ$,LEVR^::8+(B$)B*<
MY9^GTEO<2GXJ&P#O&VO!#N2J[ "Q0='8!Q4RBG+N+8T%Q!E&N)J5)3*DHZP&
M-?E/C?4QK0-L)YTWCLY". M.\29G7K0)G>$5>1Q^H[5>$T/R&=WSEFVD]#[H
MOK1/4Y:T?9U;,]J97H&3&.R@HF]+ ^G%W&F\34[FP6J3 O,MWI+VHB!:$=[8
M<!['G.&/0S'?AL7Q-4*-?D8CJ-1U=ALU-%/4 F  "\P7;1M (>/E8?%M(&E2
M]>F1IJ26"DLSZ93&QG.)V467I.'JBZ7FQ=)A?;'T'L&+33J  Z:R 9X?N]D<
M&Y1@/PRR5B-7SGP5$@+D3N I4<ASUBMRCZ+\52F'+CXV9T ^QW;#\!6U;2AR
MNQ:UR*9R]H,O.GZ(1B'^O"" \^80&'D3+,F]#4F/H=OK<WZ/<#W,D.=;(PS)
MT0DQ-:2>2AV-<2X[3<H D:5Z8"A/3TYFE6/74N#)5(V@9)X_G5,_@/.S-Z>V
M\)3-CCC9@CJ9D,),_W][5][<-I+=OPK*M5LKIRB*ATY/DBI9MB=.?*UE9Y*_
M4B#1%#$F 2Y 6N9^^KRKNU^# $7Y$B6S:H\9D03Z>/?Q>P60'R,:#\=F2B9_
M/%M&>],\<__"<1]O:\G?'VM=;V'EGU[\'I5CL(U 5OB)3/&DS,FM+%)#PT.Q
M];A$%4?CD'&J R5*>%@.3]'A5 J;CH2-HA,JZ'?QW@54)?VG3)U_F_$LP^Z1
M&O%- ^\84M2"DB#82"F82WB\P$04S)K%&!L8H>5BBL#FD\S0QTN%[9 PR[6<
MP=L293XWK$%+8S[AB"L&<O,C6VN>3[8P/Z4=?2 L"%DB\K.+1\3H2S(>$)Z'
M1FSQBPC2<.SI4X8+OTFP-/ZU"*=$YR\A$&O[,B89#?O--.;,.PRX1WT_BF->
MR,QBA@ERM @+$A+T/>@X&!<C\6!;+7APD0<!??'LW(4E%C..7<@EP[_$P!%"
M,!8.23YT1OHFY&@?3+&3&@L/S-'$3,2TPR_)2PAL#V?SHB2<@<,3BU>@G XP
MZ1!@)V-(/4%+\L-VA0:8EGE8&/S80PB&YM3SCTQ:M&K[O>2VND!3!3[28RS]
MI7M8R>@3F3&0#XM]DZR9AKFEDO>6WO[O$D[9TMVLU2-V[6ZV>'WX;Q!/*&):
MC@W:!FDI\3SKDA/P4[-+?FEF<YFZ"\ZYQ('$$1/4&W)#4*Z#SS._1@!\PMB4
MW)P2YZM43H))3 ]&N7+DFP7^&V84JM$ GSK0ZY<YJ^B1N%A<.W*'E;)I%$\Q
MG/E/1(\&C< X;7%&%E.1^# GHE?Q-P6=\TH]Y_YYR&[UW\4/5D'A!7C=]]0?
M?CEJH$L'^;>Z4_-E*'"!IO(1M8R<_%;U='59BKT$ N?+ HI2R@2)E$_-"N.J
MZZY^Z;=UD_=^JVT&[OOJ7O^VR2Z]$9AG-(6K^I2[# )\G6-633 (FJ',C8_8
M0FZ,D] $T,I!LW!<E-[GBY7AH*[7#A:U-[\23_DQ3M[6JOOOZ6AQ0F6!TJI
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M\I," 1;[0G9IT4!_#(X$P<6C/1!>F)T+I**MQ/G09&U.%9AMJE2(5E:+C)4
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MO#.B.=0B;_<IAEZGW^<GN_+$ZHN#$+N5<A('Y'Q1*WJ^P(Z$5O2?,5Q>*[H
MH1KKB1X5OPM,]>>L#&69*T<89TY=%N+V]/Y*C#:9Z!5Z[:I7:7?W#/P 4O"[
M8@A=#'&V*X;X@<>++"7Y33$?F83CV6R2^F *D+.E<!8B!95TD4Y&D>/%$;_-
M)/LQUCI<&1?LD(B-U8A8P.N$MCSIK-W_JSA!EADDT=65I@=83K?3[OUU32KL
M]6K]+$I!G+LUYY$L^UB=' XMD'Q(85!D@*8=PR;VEZF9)#S$!8O9OO#)X/XK
MIZ,D&D:I"DJ$5.,-=1(;3Y[B*L'33]N=]<>PK4[A^C+7GU,*L$O:_]"D_;G;
M!=I7U^8[%%?\X29!T4Q'^?GU.+>YQ5)I=!03"S\729B869&&=?$S]$RNF_U5
MG[IL]E3/AY*+Q'W7!&KH,+(<_$*PO HUVPH6XT:L>.>)>B$K+G;+7R2FM&8Z
M_.>-$B6*Y8=Z@@M^]W>D'U@#&S8<;\3 ]] V/L"'14IFG%0@2%D0_"Y9\M!T
MU>S-/BV+1K:^PL98&]C@59122='D2+F5^NB@-XN$DVLW4!/B=Q:3TP]V+1(8
M=DR_F,$3_!NI6'Z?JN7=R[=5J-XRTO8RHRF;'^(O][,W3=8_Q_63BRQU V+#
MJRH#JJC1C5A+J3; V60C0XE">$QCRU81 !]X<44>+?X021<<?YZ4%L]!2 \6
M<SO]R]=9E$&A14U_EP\-!VU=,E5M31<:/"^E9BB4)9B4P54-7(<UDJX',Z!R
M\?6-01B+D=7 =J_C(BDW/RL7CF.?QV0QNVHQ6RYEX+VA@21CVKY(+(NN51@<
MBRE*[1>R5)K.\@)C^OILXU6_4 II#36>X73YB;%Q-Y?S33;8%6?@*'1!"W,[
M24M-&1XR0B4 Q;75\^PX.D3GXC)@H#=4B"E&'4[R2=Y0)*9:&\")?BHRL4UT
MF.^G @1\&4V-I;"FM,QP;H$"P#5[)D6)/^:"#PJ^4+:CUGHF)<;SZ#C_%3Q2
MG]U@&?WET$.-5#N+?*U0N0IWTXH2=!\R?,A<&VFD+6T4J,E>N(]"[6,6T).5
M<' IF1FEU EC0_;J4^NLES3LD/(+ZM/"@*#*9*0B*7"^9I-5B+=!*I65"A9*
M8O-Z7 /)RE*X; 3KGIK)=.]*U#?]Y:CSU\<^218\RQIQOOB8U#1^QWR)IVX&
M,ZOP,I\8*EGA!^&09+*=P;)+YZZU6+^@S?/ZKM,22"[+W>X"]F;!4;D,=WR!
MX'/^ T6@D)++N7NH7 .R077_?$+I..="N(%A,YZ9D?>,44J*7[,X8Y,S+# :
M#HL%=U'1T%#)WH,A3ORH#"L75Z\0$4_%M#<J;<6VK*(A::5ZE"N]N$TBA-95
M[[:2=$E2KJ9BDS-;-BUW:T.SM[3'WFMM_$S)M MT#K=TCVN%V?LF^T+!6EBM
MG95>!KEH,!=QM:/&![F6=]4$2V44-JO%[M,7^1>9U^W];G*C4#%B=F.H#"*W
MP);WO9MV@/:7$S+285J9XLK5*;'KN!W"CU)6^R_M2M>T:?/> N0..*,RSS(C
MFPKPLV(<2XM+=X**PN<-L%HMK)VPVIKG7K;<8MRL<;2CQN#U81K0[%,I_6=:
MM OT4W0_C%/(TH"0%EB?P2$#W:/.,T)1?)CB,SB19<N-S1P9H_O9PSN\E[K]
MI2\4"TH66W9BL*89#E%(#94.4X YE&"ARRCGFI&2;5L^/DD(BKK$ ) TU&J/
MA;PC%NB--.?IF^H\:5AR9='D6E47:'TELE>QL@S!0])$&]:.VZGFE<O Z65+
MTHIDE_ABL[SPW^/MDCZPU@OM;\NIH4G<2S'7R[)$=:U@9"[AB!/TN>XEI)';
M6,H;4] :I=T8T8D$)ID^9?CM#QAK*S^+#E&/4$14(_84>9:C85$=M#O'</O?
M73WS>RH009/N!18S=SO[?_\&K*.CC;".[H@PZ0KZ[8A-LM7_O4NXS+M=4_UY
M_5T7PZ* ^[NJ<W_FX('*Z'R H=C7'$A_GY:?;@-9=H<5!'H$N(VJ82X*Z22U
M'<M><PU, &963L&^,H4JL>+)[VEM('53#CK=>@XZ;.:@IO^E(?+YA-7D.\1A
M2Y!P[J5Z>Q[42WDVB!HV^3WWV(A0_K.XY@_,5V)D"Q2; @@;ZJW/W-8I2T00
M**P*GW^14.,Y> IW*6W?$S1;MQ_O=X_V#*/D=H\2_K<6VYJDR V6N$E]749;
MU3*C(ASD0%@Z4.^,R 8LFHE&*8(-%EB;/L7>-!?%#TY%145;?))H1[1D,#8'
M9+CNE5'25$$D-4VPAUE&&"_GG@CY]/+YQ=]*A4F'N[ A=HRI+BC3Z_>6[A!)
M I(Y[.R*<'[@\8(MO9@NV".WU72+C%K/B+VX[\E62^J@ 'XR _\;JT$GX(.9
MX8(,E'PT L>Q$)%D/_=18/F\1;D:S$IP#</2Q>*1$Z]B;KYUG.Z%WM9&YVY$
M6M/GZ-+MKJ)6PV%>C%,S @%ES_2M.E/^S/LE;^UY&E:04C#"^2C,=1C&9Z><
MRHVJ S4'YY(2E__GX)E-?%'FY$97)GKJD]_T=>/4=^MKMUAM?=EP1US?:8_#
MXF7Z%F2J&2XHZL"UG8T%7MM->/5FTZMT2JX#=2F!*5 EBY]@/?TL'CNW)!"5
MRQ(L9LJ\@%K%A,@8Y SU62(-<0R+0H&45D!%/XPSZV5PIDGWJ!-0@&C,EJ(7
MEUS*!W_RL;IL4+@4*2?@HN)V]((+DUJ2;41C1U+"X:^F"TKSV-H26/,56( E
M54T!]0^YBG]>H&E8+25LZ;1::8O8Z:KM8P/\6C8A)"6<"MYG._J=TJ5<@L;]
M$]%$D53*E<:\WN M=/IFI<F!%J /VYZK.E:N7>:3H)A/*0T<MB4;VXJ*> '7
MEF*Z<-FR]E@LON!2!?6P%A)#PI1N*QOWX?%7*#]&P6NZ7]]"@,:W31A/XT_D
M>L).!MCWL9@(-"W]ADR1)+_.>*_4/0[?XT8#NNDR1?3)R!0%V*:([9"6F&JM
MEKD%1X971B%3+!ZSHMA07RT<)77!#OFJ.55/$7V,VB]QX-AD4=JJKNO<P4G,
M3#YC SGLBT!I7Q S^'NSA8V.7N&<A5+U[6)7![94<F8 #@UU'*N"NK[FF*(8
ME-@,DI427.9>'T7<]BB O"J<B.N1U5'$FMH)> G,>]2. 2=$N<4DNLIAG>(1
M(,WY2C?7M";(P.5O="!DJJA+P>81N%4N+XD3,%8PD:KN6;=TNV=%4N^3&*SQ
MDU:"V23U>-9<=J>@OY4ZH[XD+.]-\X++/'1YX-7-[$J<O>\5XNH-MFI+B8!"
M54Y6>O(<_1(_TN*8V''5^&]2 .*9\.V&=DC%#;3B8A.Q3) O]KY9FGD!;7&4
M*&WFP%U,V,Q+_?JKE$WNZ!C?@46Z2(N904\Q+I8MU_^"4JOA\NZE!7'A:=BE
M%L5JB-XB4WA#[;T-R=W+/(."B9B/D3.;9T.T1!21;0F"2/&YH&_9W"*?$PD/
MSU0N=+DV4A-$2T9!M&3TV+?WV9XSP9Q'8V8=*OK*#UJW6W(S#?^2X8GN0PM/
M$$]^R_-O$77O=6^.NM-%_/SKKI>%[\[??XA>OHSVH[<?_N/Y^^CEFQ=OW[\^
M__#R[9NO/X3#>S:H!+,1[!EWVTV9AU?F"KM->/0+MKYNN>IK;!PZ7URAM]0]
MLX5D\@=?64;H*@(U<V+_R I$X:%,+& .0>[PT"Z::#6)L7B:8&6B27Q=+A@>
MFXQC4 I/T\$@^MR.+K%&$_XM;^&D[78K0D3(>-*F,=LF>I.WH^Z37G=_^'F_
M<]+I'<'?8:.?;OW3?N>,=H1913B_FM]'6/M>_^O3?N>4=2)&W;V[NI!6W<I4
M/P[KN,+FCY>8UJ'IX&!@@(OL*N,OP4, ?9OYS[$]">[X?_/BDY11TH&3(4W>
M,!KTY@K6\#G-U0R82P'PB;J=O0&KU%YG+WYLW?9  =.\<E#"\.7!_A':<=/%
MY,J&V I#GH.:$*/,8]LYOR@YXD#]W_2&IZ_. PB:^MZKIQ>_[R\RK+]''QVL
M=&K&:MAJB0U5<U^#A<5323R-KUR+=!F6R@3573'P79&992F0=50H1?BYEJI[
M9YZL\<5X-4&MIC>9AM0BX),L0LA8\@-44:6D2\\'K^#_KB0^^!H;I]&NG-00
M]O[Y?_U'M(?/E@J/VH=(X84=3CJ;Y2FYS.^7<48\U0+YD,"NHTLX*.S%?H7\
M-HF>P9F/XS_I9T]-]B<6 [L_[LDK7R'@[SLZ_70TLE4>C\G+9C<#K:M2^L7A
MNS/W774V[XKT,_J+M1L 6YI0[H .Z2[>@#U&#4=.[J 73Z.S;%\9\]PT=W!W
MF-'B" \LYI,E0+X_[I3 4\%QL]+U,*^LENF-?S"V6.*+B2U%QM8)^SH*A"&R
M#,C?<,&]0[MB+.G/DAA)5N2#_)RB3N"[E8BVP;!7TIK0+!.T* ""*<'C6V )
M,T4IXKE]LL<Z&A0IO#^IM+>"?6V7-Y P1+C?I0GV[)Y,FW1/.=8<4B$/NUGP
MO:?L2P1"WS%R0-7G\M4+^ZDE,KZ3E8]%WC'-E?"B'R[X;#DZO0S^@4HV^?TS
M#$XH"64#1^[ZI[F @29IB7$%^M7JGN -KZF:\,2V6.-S9M63%1=_YLK[B7@\
M#<!_SF%)$[DE6RA>(4;;\H3M0ZF'5RL7,TYO\#EY@K5+IT4N[;/;T?EH+@S>
M3((9PJM0P[<G.$5D]J>$@LF.I_([.6=DN"28L68]%!C3+D@$B89)N#)XK%X]
M1H0&9LE!-!]FT:_AFN:,#KB8(VKADB,A5S&W+TW!Q-.HZ]79I=1\?:QW8#$$
M;<>PNE*;-Z\5BOQ.F0^ZSP%.__H(VZE=G"M#S6:FLSF+PI)&C7&8T3U/@+LM
MW&-N2P@#V$W?&"%!0.KKM4W1U\9\*A7<_%G]38%X$AE@&WLI,LH)4N[KX_<T
M[[Z-W<$*W0HCGO9A]<>J(L.*^2@VBKW!R*/<],1%5EA7BQ$"$FD^DT'""INB
MI81"\K7XDL]@I5. *Q]Q\!_N<<H5OD8$2KU(I#5HYA=A2-H:P__T4KL2?'F2
M<R=:Y>58O#Z;[V,(6=:KKHMW*B0]*')8 ]PNN!G8ZE<8KDVWJF:CPZ.+MBY
MW4V3=\K-,J!AH\MY.I,9A/1@U];-,MFM=(/K=[@ )5[$G]+CS0QOR^?OJY>E
M(>;4D%'UY\/ [ G\JC*%1<4%0X-P%JO&D7J]1$JZG3O4[1[U3UE;B'%\7@R7
MMW_(R4F=5T1 Q7E<\##C%*PUAXWZU9Y2HU4D)0?@CV3QE*V@+,=&-T7=+,7B
M;('LT>U9\D;,BK1(]/EZF\4?\(<8$2AKCX9/AO0@G0"""BXH]E[(^M,L7.ZW
M'%+@',P;+>S0H&+WI6Z+UI6DI![P'Z:F0"P,4^H77G!/SS6Z+)PK*&8YX]CX
M#H70% ,+P!1A% #I]><[D@%1^RNUEH^U*!<9R@>0;$!88U8V\< FN#A:W(JN
M"FP"!W&N<H@DS-/$]NB G3&?R^H+DX]N/GC"]5ADOJA.O%IJ)R)8'2M7095<
MY<65$ZT@#C'M7>E8TEU*'I'$]0([#?D]G.;NZ29.,P@S2P[RE5LYT,_\L6E%
M0=JV09II[G@AKZY]C.</[>CT>JO;LCHOCOXDA[+42F^:6Y1*T9"HZN8QG_G:
M!<BL1HJ88XOW8D)U9QE9MJN6+(N6P5)?Y#ICDO:%EGLWT.,K;ALXI 537]B?
MZB%=ZB6CO'OM%OT:3O4BOO586>K=V:'>RMX7ZVL])=C?K=N8\@WBM>[!IMZ!
M!;7V5II&/A*W@4YOU2M(XN6*4]#Y1J=@[1&U;CR?.IA!VXRI"5A,^)M\C36^
MA<?3M/>.MG "=KK3V9)&#["2Y,M^<H93I5=XPADW!C9DUD.78[;&T]"*/4O(
MQ1Z8<3P960="UM':V'-H\!10NZF+#<QVJK'DXL=<:K]D9BF59"A.QVH>3X&T
M8F9>\(;2H6DZ/!T9;%6]A$U+:+<K/_]!WPVJ] :[L)DZK:O//=0HCW#R IHY
MWCI#<KTN0+HF.27H,2J(R72T161B]\V>VB:\>+/40Z[YG*=V8($;@0[F3UI^
M:CD@!3& J/592 8NVG9">X&V2]T'J?M><^K^-NG;DT?W.^&/SYLA1&!VM3\Q
MH_F3DWJNYS\A8&0V?[)_\C-:"&_,/Y\W)J"Q'3)ZP3,<[F541 ^M2;^LK45B
MK4Z8+SB!Q% X "R7@0%KI%JJY*85V9HE42"/](D]\NB34M)TSF-65FO]_\OY
MG0BM)0ML  ^-_C=?(*(CPHL/0:AR5-PEJ>:5WM#$E,,B'=BL0YI)&7!T<P-"
M*QC4M%+S1%ORQ4VN-M/B=E<P9]@A=-CP6TY/]5R#=9>@,"9YX>V*^I$EMFQ3
M,+7(6IOSO$J*:MK4CF$0.<[<L>II>0N?>^@8NQO!X;E=O_:%.)2*M?-0BI3Y
MVF2>5GAK9-CP+,$MOX?&5DZJ32=;C_NNW&&1*T)SS!I.RE4'8^DRGNTT_I).
MTW_2X2J'5"!^W_D<1OWS./#/9"%Y*=]&I!!9955VG4@ANF(>42P]!+Q8:#'B
M8UUA@40P6Z00<>6F5JF9/_@COU+!8RW'Z8PWCNBEKFZ=G:B6+:9FE!>RV'@U
M6&7\F:-$A7$U\;)(V A0D)GSA-;A.(/+OTJE.)A[-22+?YT79/;9)%B:X4-Y
MG$*<?7+22&'YRBGY&5%V\(+#41'V,3;T)-U6G#^\ [3BM/1/,U1<C?,M!$Z5
M)D.Q](,-38P,(7*&-.]<Y\MJ:>U' /C>1_[_T-C#0(ZREZ61#.@D(>Q&D%3]
MO+##IO'H$9K875#P$COK(S$S0[8=PU1G"PKW8;A:!F%Q1ITZ'N _2QRCITK>
M57"T)=$I:Y9@^5_+3<]S;1#XBP2N EF0YNS9N(*@S#%F"CAX-EY"S0L-N^#<
M1DN"NJQKG /L'%^GG>+/<3JQT*T4T"=3@-V[A71HW.[=$36FNZ9"FOLL]0JW
M4(5ROM13CKRWF-KH.<O<SRY.E1B:IF<O7HV$L<UAI?N=M-$*3Q,,6O"+U5AW
M.WHY%RV<D7=,PA#Q-$4-V\-# 3 G5Q-M)V[NR;@*B8J;/IEE9$#:Y4MCI(L'
MWH&50[P8?Z8J+<_M,IE1!TQ"UIUD0<SB9ZRH^Z#9EX)_M<@L9JYK=YG8+B=M
MI;2:[$&+:EMC$@XMXU2M%&QR"2:98OK"1G-\:S.79SBY%N H*I7;;*;)#$7I
M9O3A@0HF(\M1JP25AI8=2*]2:%F%<VT4J4R6JGN1^K_J%A?("AK)Y=O+2?$E
M#G:2[H/MS02TI(VD8G*7NJ(Q^NQZ& L;-ZPS=JJ"]0K\ WB,46V:BA.MW&QF
M12U^'50EG]QZ>[A93-@A16IS=LQ5@15TH!FW7*<U>.3$<5*AX8?X3);>TM&&
M7> P-"1XN<UM2+5(N= 052J6I1U/R:#*(-F2H'E>+LG#S-%,2Q>W9B!L'@L"
M)HUH@@FCV%$4#;&VQ:YR;&%K+#F:3*HR&IOX<ZIP8=W ,GJK7ID:\EJS! ^Q
MEQF%-"T3.4=,7M-T/C4^-^E [A4R\I:3SF;FT!JN1=7%,V>73>149=JXGAJ3
M%861Y<%CTM)_=R,2)3!N"O(+CP_0A-&VS HI<9:-$T]:N&BRYD^XDH (FEYT
M!]3LW -*0'CAW5HA]I:;]W";U5F'0J;E#M&2,LPWH+W$U*P$9*RG*ONJMWP#
M39R.FNZ2!_GF8BD:T?LT0"N3H7.KIQ?^IE413U5_&';BC&V':\*)_F>@KJ]Y
M*)]-><$?[ @/VOIB3EB'="?!^" E6@3D4UFAE,&B>V,QXL0&;FB1?<KRZRQ\
M'I?N\J.<F:)NB@A<R[8:NJJ9:9LZ %LI(/% \B-%XVP+U$A!)%$?C-!G3/2G
MME"Y<O*=EXSU[;)ORM1T\0C.>VK+Z9;:9G3##XA<Q!AJDBDM,7WQX&)O_%+]
M2@(W25^Y%K-<\+$L%\QYQ!WA75C3_Q/I3!D&);J(VNWC  "%V903X7C>E:9R
M-;A&MCRE(B4T%]F(1/@MG@=0$+:!=RW4-7.!M0J@B*@D<28Y4']^K?"T"S@)
M)H'%K'KVVZWWUIE,H9."SD&:U:(!3&1DAV(B5Z#[)BZ3^!_1!4\Y$SS(UNI5
M"1^@F5VZP6>-#P@"Z R9[G,'XO.HJ1=$SS:DQS8*1]Z!!-,YQ^RPS20=4C@#
M[G.9+SCT V2S)!&"-OW]M&+>5L\:Y)V<LNC3ADO"DQ(ZF+LA<$I2I2IKG=12
M@:Y*"ZB#:$<FN+AQ<7RU;F;G; &"<SA9PFXF4M+D0S7N6[(3]W&:I=/%-!I0
MZ3=ZBS,[XHHW9+^@=<+?9,Y]$!R2@$"P;$XY<R2&!:3%)4OG:!9B I(C54-C
M??T1V!5$2_#+<K0, L7").&1>:VP(3?<3ZKTU;Q2/VW'K$C00$I(J"3PT1OZ
MET>/5T[BDBA:I,*K5Q?1WB/^Y)&,U[AVV<5Y1 C[C-9<+\G^TFUW.C4TI"Y(
M&2N:ZD-.^GV2#S0CZ<0GO%J^]4I^2]U,1X='V/*TUY6:7]XQU8H(X!WLIF7A
M\=UDY-I'G78[>\/'>_W'>^>/Z5!WM16ZMJ+_T& 1MHJQQW$2=4\[X%5-L+2I
MH')#2H5Q=2?ECWHN?[3>M%C/B@."TG*]HV#HT>QN]]TZFW!J<#Q80:,$@:N8
MXYV.X*F4U&H*GC&P&2>9! ?0V1!A!67ON$Y^N;B^$UF620DR>R0!\A(<+ SD
MN\&6S-"ZZ53;6'5;JLK$0/I8[5JO.;0SU'*R\HJB')C\+;%+E^YS'_:,'PPM
MZ**^4BO(N>NH_TVW>B^U61!D7-TY$.KJ&5T;&Q$BBB&%9ZF"[]32@@64K%IQ
MRA9C4P$A<*)SF;K$>&!B3<QQK 20I,'([]CX[U<\,'(MY;UC$Q<T&1X.U$S:
MT25ZL\$J:?TR9"M*IUS-7+6\ZU5DU=C,R(N"QZ5N"%+M$[F))$Z:F,$ZX^1Z
MRPY6X^\NL8D.Y#4X>47+FPN2"+_!\^%]N%SG>IH66_ [/,J63#4"S=7LP,%S
MUS'C>@O>I;OK_3#ZL(XZ]8"]39VZ8'!+8ZC$NZ0LRKD=""=/#^F#K_!&O9-B
M3XK^6:Z!@%<9N5#Y#+:WACT'LNB59U(?CW"3';&1IL8)'OI\MYP8G"!>E ^O
MA=G-Q$P98W-N?A%!^\S)K1N(":F%T 79PR+X &KTXH2P0IEM*C\29J**&Z$X
M6PW8JB__4C=3Q"E&G?QP:Y7%ER'3E#X@'Q>I9R: &[9<2>C*]^&UPE2G?2^%
MLGVQ $>P<@[AHYR4"+1Z#+Q,I<W58]BG]J%!>6253+&SRUX"86FJ, QSHWV\
MS4YK#J-=^[QZ+AE/R<+C"8]2\I\YAV"_D&:NIPY^YG>9%SZ1 >SE+31=E>.P
M >YK(LH'Y$)9*J2O C4,.\G4.DG+&LE,T5\[9LSVI#2+HG\L<A4I>OOA(GJZ
MF% Z.7K*(>+""FYIW)NEV2>PI@VFA>R,H:J9R8\?H36I [(V=!>,&*ZOW2F?
M;'B1_6H)>;_^:L,2\N[IG4VAH3,[OL/)0^%Q=0_;1W@6,8M3= LJ!4JB^)!2
MQ*5!HR$4.[_M;NLGWU;%KF_R(6+'MB:CDAGXN^5:J1%E)X6KM 9%_HD2Q&*"
M^^(3_U1JJ!M+ I+BG)BBX]R>'S8R \F>#B:V4HHSXG;(,H/=H]4F[W%3\T36
ML&-*);+R#:'"'>G=/>DY0>%2[)FYMH/&J3T-;1"@$M#ERQ)K^4#L8]D;#VO<
M7=C/O3"7_(<KF8""!<O@'Q2B6M*%F"_&PJ&3T4$ $!H@ KQ::O"3(L(@ER$X
MP-4R3W)6EE*X[GVWE4<C]L1O2#BWL-IV)/%]U ?7N23:JZ&!!]JK45>UYVW\
MF6K/+L=@>^\37.![32=J9*7MC;K<[S^FFH<!E^K6.4]AC&"[;?GF7B=T5XJ%
MG1$\F\29[PY6 YMQ!#$-[V2]R#RXV@&E2S9+BH=S5_4D45^:YW,_$UH54T=N
ML%DPGQT_'OK!2_BL)"V+Q6P>9-.W_ 9N0LZ5-D4>P2ZE4@E[*I7[X4 @&B>V
MT@L^<&?(F'DTS(4V2&>$W3E ]SH>@W4Q+C3D?%6/S$"AX)E#"[MX_\J'.5X\
M.U<5VOB ;P'9":!6"-/J?;#G=[#G &1EM>UG"\Z+IBRI5J/F]B+5F:-:C2J'
MT%M[",\U) +^L.'8"$LJ1 'SM9TK357=^@?7+07-=<>77(.V\6L$GK+QR=PP
M5W(7V9#U-V%PB-RQAU9M\?&7IHK]E.2F>1XLE&Q7(477N+W*CL\PMH^+0WC<
MRJ4Q.H(2S V;NF[7D$@T:5N]W)-OV_2%@0ZYQ%$ZD1S%)AW!>K/8&(C53*4K
MW>7$"+7&V,&.U '$0QMQ36BQ%7,IA*-;+C&K(;U;;JZ\A-G<H'O6!UC>ALS\
MQ78]_.4T KD[60O+L,4"7H%Q<(22N48U&.7P$^YCPMI?T8I>\3K*T2XT5@K;
MB?;85T;SC"PFI*0AW"!YA9+5P'-<7N2+LE7_!Q.XC99:<DBDQ>DV@Y2WYT[^
M,,IR@07]T[08R98+,V424ZNQP:9E31L^MBGI'C?ZBF,0)>)0\2D;5ISYBK%E
M1B.:OBHS@A;8T@_B!V=QV0I BI(GP"'+DG/<3NC*W+$7Y!7%*&Q=9HKI:I'I
MM0]!R""*05A[A,2#C,C]U=5B9%-G'-;WC<DY,I'8);HZ=!&^[MB<(1$\OZ6+
MU\D"X7XRDBPU/6?7:SK+=E5&NLKH\*%5&:V7)]\X;:7?N8>#1J)>(\1+T_]^
MS#A:0N!YE_&$,\7/.=FG )N0_SXRC*4,*MG8U]HZN9^DE,BVT0-0R@M]"BN9
M3@WNL!Y>9LNMDS64TV]'MR6=9X8F.9;11YQ6>&DR;(;Q)',_R>--/E<!P/M[
MGX>WO\_7\"00 2,#Q/_,#1W<W>.=WN/1[>_Q+9G^+STVU'V]P6S-O?V2)MS1
MSH2[C0G7KS/AX/"'^_!&=)>?E(LI@I3^5K.J>XKR=]QH 3[_,DX'X+C>2UDH
MBP>IEI@O-VT *?6H81#B7/)Z(@N*Q!3[.(DJGI7FB?V'WY*T!#]W^23-:"GT
MHPJ1X O XZ09=?(2>A]_+,QT=M8^/>HC/\T+^&]B7RRLUB96.Y@GJY^=MD\Z
M9XV?=MK=QL_6/O6LW3EK_JE^[ &MF%<-YX(G_F^/^H^\E"'V>-*;?8FZX5DC
MQU2/AD^%Y<I/IZ".HJ 5VKF+U?!I)68H^()/*#B'WT*U5V%0>U/?\1*V:\?/
M"+F2,OINY]^? D$H_'RU3937;W>#?7W'[:RCW]'HA^UIW6W^:URK:0VSWV]W
MOL!H7)@1V(_S^>S)P<'U]74;EMF^RC\?G!?#,>9I#DQR%1<'23R/#[J'IT>=
M3O\ EMOMGO6[O:/N8>?H^*QS>) <GYR='!V#/NIWV^,Y\!7&U"F(>H%W14TI
M%#!YF5FH"@G;/\=R,AI-@:9Z/#,+N-I2QE3X;W/>#):+XP899\KJ0: I"R9Q
MP8'<:AKG%,%F4YF2]L(,"AY40Z,3NH?1GAL8"3O;[Q_WSHX?@^")J_;;PV+$
MWHX1'P C\C]V3W'M)]T#V5&_NV\&:?YEZ)F/V;+"C30YT29*UW'JCV%%&F!"
M(QJ[I[\H%_8?$A=V>UO.A>L7J+BP_"HV['7QG^%/H ?[^XKY\A%-<)W^)";L
M6R9<6]A0X4,[/^_7Y,/#'1\^'#Y<48>]?4-FYL!9F<R)=G(PS2VV%NO3Y?ZK
M^+K<F-MZ.Y5W"U8[?%@>X*_+:LX%[)X>'Z(+V.T?GG;!!3P4%_ 2IR\"@PD.
MD-9LYC/UD;I$,@%$\5A(W<NZ$0,>>INSOHA=U;!W#\X]*X:H#X$?V ?UC?OK
M=W\!?MPY@EOI"'XM/QX>GIZ>'ATD)YW#_M$)\&.WT^LS1Q(7 )?]$1>((L-%
M'U3F>YE.TB'PQ'_C4+-E]!0G5*!2?)6.3'0Y3(GI7N4Q(GTBDA>/LGR#97XT
MW/.(66A#ENUVVKW^YDSK6=9-$^7!B"L\"W_JGOP*.G3G-CX('2KFZ@G^<[]W
M@+H3XS:SPNPC>+%)KIE3NR'_7K"6%#:^O9[<Q%!UO,W:\80YK?W+6:L[Q_ A
M<1HYAKT3ZQ@>=FL5XX_AJ-<QK-%:FZ>_*C\=[?CI ?'3&2[^M'=0FC)#Z^M$
M%%9L8YIQR&"D2:SYZ0.?YW;:\<:<=ZN@R]OA/"<SE:W&LU\T\'*\8[T'S'JG
M-[/>Z7=AO<.?RWH'5'%VQV6OM9626U,+>_S@:F&I>G17GW@G]8EWIZ*ZL*E_
M":GENVFJ:9HD$[.+2GY#5!(T#:70_@^$1%ZD18YXF.6^Y-*>4_]ZJ%-:$BBT
MH78'43%86IR):VSOO<0G8PV8U'WA9Z_I); O>LM#M\[Z723]'=5O)=5G^YWC
M?@<I]TNW\X_X_[#,L5NMY5 8(1?CU(PL=,AG$[W%YG4P@MXI[*5+&5(*S[4_
MNXR+09P!1[W]@D'X\^&<[;9.[Q>@_MZ.^N\1]?=NI/X7#J!@1_TW47\/9/^.
M_.\/^?>^5?B#)_ZQ?=F^:#M&Z/:/.C2,Z#S)9V@RU7'+6>=XQRW +;T=M]P#
M;O'L\JW:8L<NW^)3_U"_XBZV]!)C;3PG(GH6S^.(0HI[JK!9$.%\^?,[&HM4
M!U,BH<HTB_[GZ?M7,N#-HRNE'CJ P*%B6$UB8<'P%PZN+<F'"\&\*J-'BRQ>
M) BT_(B<V4>(JO(Y-=<F:3^B5^#0!$* L[^#?Q X*AH%Y-#D4K5;7"LXS4."
M4L01C[B":!XC\E9A(DS8)XE@I,G/7U)8C+]H7]4.".+A4/KA0Z/T"P3?CMXA
M_'8#T3-U"EJ9OFL[[MT1K"^^HJ+&*@'8,/M]";KV[ ^_:]#U[+!]=GCR/8*N
M<G08'0<JB\I\DB:1I9@U-&CA%+:&K?XEVH"I'LQN7Y VP $)*$._EZ#<NFW^
M" /:Y8+M[[<!/J?#F*.@DH>!]0E_&!@:5;4HLK0<(SQW/D'(1 2Q'<J$\ W@
M80- ]7I#U8*)\L@U>BE1&9HI\.M97G+QN_O-J3-;/>[:<YD'9&W7[EG_D"S@
MF'M86FXB_35.MU+C!WE$I9H)0\BU);^,A_N5XYBG^]%\,S,EC=&4# :#)">D
M.(VB:]RD 3@)CZ^J-N#7W5]9]ZWW>CTVA.PTQ2%: YY^C=-!1W-Y,>8=B(WS
M44N@N2<6P166?F4RT*83M4L\^ F\=('*%M0ES2CD'=:!4*Q/3==E,YM2H;N,
M=DU&^Z0YHWT;U*-CAWIT/_/@E>?]I#NIAQVZ?/G[F_,/']\_O[R7$&HZ0%"=
MZ[ZQN*W(N7&,>)@(&XP.6<+:HF =(1CPL'$NA$%O;6! SHXL #Q)2?Z"# Y=
MH&2E!\:+^3@O8'MKD'M7A(P^[ *W_M-K*(ZZW?91AXLWZNUY^JS6MNZ?$)NM
ML=J_]D-AX.__Y!^VY-[I4;NWZ9/%+*THD2[_?+UEUXFZP4M^^E>W'ZT)!-_S
MR^=OHJ<OW[:BEV\N:EV"W=G_(,M][[V3MH\?S,$'7_V&C=R'"WP&=OB3[^]K
MWNF>9$!13ZJ9'MCNGBX?VGT=E ?1AS$\IXS>MZ.+.,O,9-**GK7_N_UZ(Y#X
M[98\]^$*WH#GO@E9?6T<<>LVW$AO.UKZYJ--YY,'IU/>%0:GU^.<[2QIJB'9
MT<ZW'G.-/+__F]I[5Z09SC6:U)0=(3D]PY#"N0LIV,]J+.K-(YIUP88-0IP_
M]3D_/9=YTCGYFESF<?OX9+-.CUME2$_:W;/OWY?R8Q9[=-3N'&VVV*T3?-_H
M^CT$$;1S\^[;[AZFF_<ZSV YF)T=F/(V[MS.9-JY;K+A@(9VM/++NV8-%<H[
MRM@Y7M[Q6B&/KW>N,.G_+34%C0\^"Q_</=RT+F7WF!_^F%]RAMMI<Y7/P2!/
MEO!_X_ET\N__#U!+ P04    "  40!E5!7P!G]L5  #[X@  $0   '-E<VXM
M,C R,C V,S N>'-D[5W_<Z.XDO]]_PHN5W5OMNH\,3;Y-K<SKXB#,]39QFL[
M,[OWRRL9A*T:#'X"DOC]]=<28&-C9'"<"?M(U=9L#.INJ3^M5DMJB=_^_KQP
MI$=,?>*YG\_DC\TS";NF9Q%W]OGL8=)M7)_]_<LOO_SV'XW&'[>CGG3GF>$"
MNX'4H1@%V)*>2#"7OEO8_R'9U%M(WSWZ@SRB1N,+)^IXRQ4ELWD@M9JMUNY;
M^FEJ75FRC-H-N3DU&TK+MAK7^.*F@17;FEZ9TRO+NOCOV:>+J\LIOFE-&[8I
M7S04NW7=0)=VLW%Y<7F#E6O3M"V%,WWV/_GF'"^0! US_4_/_N>S>1 L/YV?
M/ST]?7QJ?_3H[+S5;,KG?_1[8U[T+"[K$/?'5NGG*762\NUS]GJ*?)P4]['O
M;A6'!]B=$N^CZ2W.67.;E^UF4IKQ(@+NQ/4#Y)IK[E9 &\%JB?W]-/#ZG+UF
M<IJ-IMQHR6E)5K F2XNY.(]>GDDH""B9A@'N>G1QAVT4.D 2NO\,D4-L@BVP
M P<SI+<*I%X'B,YP,$ +["^1B0MHXLLODL0 (HNE1P/)S9#:R)_RJOHTX&1G
M4@1FSS-1P"V4E?235F7*GV,G\-FO!OOU\=FWSLZ+2PW]Q@RA92G):9I(>ORD
M3 U2EBG?W-R</S-3VU^#O;;#RS?8GPVYU6C+)<3F&6%QV?"KD="=H@Z;;E:N
M#@G="^NPMV/EV<(A2O[;+UB-_1VUH!(2 M;ZBS("?6Q^G'F/YZ87N@%=%3'^
M?23)CS)FO\7,PJ2,[*0X^^-HF7ZPI&6$KLOSO_:(1:[K!9P#>Q(_6RZ):WO1
M WC$[/138JPC;"=>.S/Z[/$(_'^?$#6IYQQP'^=+ZBTQ#0CVTR,79S"GV/Y\
MQL:O1N*<_^&@Z4>H25(D(V"[Q['7YT""G=ZF)0DM,WI@#Q@X.-)-E1N^I+AL
MPX$$QK<(Z+]\^TWDE&T_D)BA\^_1? O;99L/),0E1[2>44_@O42LSV<=#\+N
M,XD]>QCI^>$3%QD53K@E_#85^=*$B!;^DQJ;"+TA<:K?SG?+[G )?6P9[A?^
M]ZYEQ\1Q$0'ACDD4IMO6Y5ZR^&&B/)%*C<&=-AAK=_#'V.CI=^I$N[M5>^J@
MHXV_:MID7%C?ASD)P) Y&"U 8 RJQ D:"4\IS52*N4H1VW>T4CH>(@K-F^.
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MT>%&$=</D%O4-#8C+? PH?8O#TRF+'" H6")36(3;)TF'#G(M0I!2(^8[(C
MVH9OPY47!E$\\.!"G#H&/^%:4?YR9."Y=G 4K^IZ%.B3ALW# QXQ^6R7ODN>
ML36";IOO&@Z0O2+H)?J#@WS?L..CP 8=L0X<S2HB]S69XP-@EV'QUL'2?G=M
MN'A"%GAWE'M8,KRHSYTR2_OQK-#,CS1.PKNRG6"W2T>(3CQH3]2[H\YL0%4@
MS*(F 9=7V#\48_;V@^((\X (?!;U9A0MQ*-"7ND*>?L^E(9*,@/J8D&8DU>\
MJN'RMC-B 1?$%1;XHA&,U%V//B%JY<%6C/:U/%G /&:!%AK!'-/-Y*WDK*@@
M=8F([6>B&]V%XK(A#N*M(8B</'F3N<?/;'2]$$)M[(K[9BD65>BP>T?90<@J
M:-C:\Y)$%?!?-&H7X??F0W@&N5:S>5,6[31-%> UEGPAV)WU,'1!7Z48&;9A
MV^!WQTLD6+LZ3/B*S0/(T''KF\57*8H15S9NTLQ_(9/ #) ,P<(7@ @(,*&!
M?41_8 ;<VM^*;?@(1E4P[-2]59$KB?Q($M:M/9#/OV:7'UR79%-9>RBR<\'V
MAA8+UC+DD']MF_S+]T6*<*^"Y6Q[MK[G!G-G-1)&-?D450U4D^O<AQ0_$H@^
MG!4?F/DRD<J>+A')'\0+4E>U\6JK*2O:8NEX*XQY#T]B4#9$BRV]&&T5[#B^
MN;^'9\@13K*R!8^/O]]HC9U%6&B66LKV[-VE[V3,CMQX\I WZ8AE]A<+K,0J
MW/Z;8E+^^W:U*1*W1V7ST/67:U,7";!G44QP8$A]5:&OJU=>L7)+MSM[$T,*
M$?(PYE1D#5=,7Y'F[H^2!OB)/_2376NV,2/H;.6X5'5T26'71\]D$2[4&7B.
M&0HP]Q0<03W*O $E\/H=-H/"K*JJ%G72[\)$PB'!ZL (FRU8A>'4H#/DQG&K
MZEK@G8AOL#.YZV1"GCB?UZK"Y"=HJQ5\FJ_8*!!.>>\]<JDOC@OX;1^A&? N
MV0&/,&-Y*0[8H-4)*14%QB4X5#7DT!<0RU*^HY+Y..36/O,F*,A5QU&\*A$H
M[&Z<;-*5'I9="A,>B!L+[[KL)Z[LS#E3?;Z='&=1L/TTU9P3F.>R=YZ=W6PO
MKI?2C"NLLX#,N. Q#@*GP#*3B*(*[G_DK9 3K.(%C0*=/9_@U/DH,7U8*%3;
M-;JDFJ*, B'-7R"[)EY^&N$92]_WZ.JDJUH"ME4PW-Q&1" >VJXI1EV!+7+/
MG!^ <ZM(%:#I:P-UMV\=.+(AH*A"BQY<,!/J0^ANV/\'X9XY%[<GOWP56K.K
MZ73>V,&<A3RJ5^HJ+$%BAFG111^8>Z2RSY,T\^[FLQYJW+C<K<V27-XZ;R':
M8O;L;UZ ?8T=97%X335DSL5K,04HWQS3G!$Z7CT;89;D1?C1GRCT]@<>^(UD
M(;/LP%^8;27F+JE%E!%F/1\,)K+>*.!6'Q'AM>P6/KCQ$I85S6W9L]V]C?8A
M6RG.H!)6<<<.9;(E:!<\R)3S9QLX\<X.92=/*>:S5(CK4  S,7>6+IRLQ[EN
MB)QXYH9ILC&4JZ77%EO5U;_M+5*>!A;ODZ[?))N*!;=9#_"HJB+VI*#&$T/#
MCON+X0[ AT:9N7R9MP\.!D OD]9:G&<E>F.21<$3P #'@??(X\!6LZ5$.P)]
MM&HUY0MQ.%F:316BS%0$E3Y<JVZ^MK8>18J<)#S,XW76'PHGTAUQ2(,MA@U@
M&A@/HH8]1"S%F><.^@:-.5J',N5_@N0*K\AMM_UA:9==MTV3_&7:.<'/P:T#
M_:)P,U,4K^@>@D3**7H,/]%QFA-2>UC]9;#>C'ML:7*$V=4$+'\^F:?H[F0>
MGS1/!D8"<]BG<B=&CA91B9&VV)KFZ]R,(.9;C;&XR/T.^UHQ9!E"NGZ*ZR,*
ML*^"KG+2-:+X(YL@6S;M(Y_/FY\$.#:!*78>ALW>0!0.7N[T65)[A51AD^8;
M,6'.$1XXO+9;J@J6_CMQPNWD]X[7"RQQ0PX05:%=T4$S^\&/<A#BE(R)IUI>
M= [2CF_K8,M;[##:SNFU[?W.HYA5=9J^R5S!B)ISF$BEO'*\RE \^Z4 CZKF
MO^R_0(J!",6VKI)*^28_^FJ0[B:14 Y)<A_Y"J98Y@%M_OR*5-4V17=_$)??
M^Y%<RT4@>'B(+ER*#EZP<PG(]UQ^H9=M>S2 $G&>R>9 3QC,/1HGJQUW!\FK
MU./M=YGY[$AW+7#G?#56. +D%*Z"Y__#Z*LZ!1?M6CVR &8'!K/\\E5HS3V&
M4=;]ID[8E4*/F!Y(,,TM7H6VZ"[X<\2^TQK]G^>(LN,TR=)V 5=9BD=E9_>'
M%W,W3V3EI0O#^WA5T1YT=\_G0_*G$47)JQI^K#^)@WUA>G6V7'7RJ#,).^M+
M#S?YG7'/++P.)>11U<!%N]6;;?G <>.M,A7I@8EI]2 "911^ 3-,E7WKW)==
M[]=GTQ%P?>UR3C-#5@5TCEXG22[89'>11%?9[E[.<IKUF#PY%=N%2]]7N>M<
M2BR/B[E4U3$=#6[*^]XQ#;"-P"F_U/1 MLPK2JS"6I\@WFH=':FUJN1WDBMK
M>NC)#XE@>3M;\'5Z_O')@D7214Z:>U*1K;!HM[_H;#ZO=!6,\5!T6-R!'^6T
MWR1A\?"!RH/16BD6/RV(XY]Y\,TY7J OO_P_4$L#!!0    ( !1 &55OP!GA
MN18  !_0   5    <V5S;BTR,#(R,#8S,%]C86PN>&ULW5U9<QNWEG[/K]!X
M7@<1]B65Y)8LR3>N<2R/Y=QDGEA8#NRN4*2&W;+E^^OG@!*U4A)%HJ6V*RDM
M%$U\P/GZ;#@X^/D?IT?CK<\P:YOIY)<7[$?Z8@LF<9J:R<=?7OSQX16Q+_[Q
MZP\__/P?A/SU\OV;K;UI/#F"2;>U.P/?0=KZTG2?MOY,T/Z]E6?3HZT_I[._
MF\^>D%_G_VAW>OQUUGS\U&UQROG-O\Y^"LDDQKP@C(9(),^)6%".@,PIF!A,
M2NJ_/OZDC [@>" Y,D5DYI9XG2G12CN0-L:<Y/Q#Q\WD[Y_*E^!;V,+)3=KY
MK[^\^-1UQS]M;W_Y\N7'TS ;_SB=?=SFE(KMQ;M?G+_]]-;[OXCYNYES;GO^
MUXNWMLVR-^+'LNV_?G]S&#_!D2?-I.W\))8!VN:G=O[BFVGTW7S-'\2U=><[
MRF]D\3927B*,$\%^/&W3BU]_V-HZ6X[9= SO(6^5[W^\?WUMR!9:F(1F^F.<
M'FV7-VSO'KS=VW][N+^'/QP>O'F]M_-A?^_ESIN=M[O[A[_M[W\XQ'G,/[?[
M>@R_O&B;H^,Q+%[[-(.,KT$[(47@5 M:T/SG"I^Z?8DX^G$\&<\7Z W^?O[9
M!5YE\'#:P23!V6HM1A]/X[4WC8NLIK/%OQS[ ./YJZ.3EGST_GATV$WCWY^F
MXX0/TO[_G33=UY%G@K$L*'&1,B*-B,0')+;@48? 5,[!75^T,K$69S:7<?9M
MF OZ?(CMLIK;,.[:Q2OS]9VO[=THSM9T_7GM3H^.II/YY_[+CT]@1(,-EE$@
MX)0A,ME G#"<.)^9R#K+%&/E6=W$<'U.5YBR,XM;TQE.'O78BZTO4+3.N4H[
M ^1G\1:%KC]0Y^_8;D^.CN:?29H.CA;_ONBWJG+OIA67^TRF.(--A?X.Y0:S
M&:0K0)@+@><@$(,&(CW.RC$=4&O[F%)(2BFH+/<E,%81/?\V1;_IHE>3_GOH
M?#.!M.]G$W0"VIV(!K\L,Z0]R$ULNI%6()4SC"BM I$6#;=//!$:;61>1@J1
M52;#PZA6X8;X-KE16235J+*34E-6PX_?^2:]GNSZXZ;SXU'*UC-I#8F6(1@P
MR%MJ+#&&J2"XBX+ERORX \HJI)#?)BEJ+'X])EPR\J#[!#,T9,<S^ 23MOD,
MKS&>.((WT[9]"]U!_N!/1][F9!EP8G)R.'$I29#HP4?%&&?96LMD;88\#N(J
MS%'?*'-Z%%8]1K4M=.WN"9K$23>R&$E0Z101BB$$@6 \U8S0' .8(+T,NC9?
MK@+8V(_V[:>=22K?B@ _^S%^:+O3[?K9["NJ]#-[SX5D6?I(J*48"].HT-$+
MFDBM$PW!,,-J.UDK 1N2Q[T^+VXYV]5E4E.=3D\0S'N(@,#"&/!A7,Q9&D--
MC)Y0(U#!<T=)H. (X-.I0$3%30^Z\TX\0_+)ZY&CF@2J<6*NJB_AM%?PL&+5
ML[3$2T".,M!H##@J:$@Q"28DE:8R(^Y&,R0_O!X?*JU^S1C]&-V^_=-C--N
M:FP.\/I\E?,B^:@)!% X7S3>CG.&PK36>:I8B+4S4"O &I)+7H\?M>51C2B_
M^]G?&#XB9P\AGLPP9( +0-*#1IUEB%'4$^G0I[-H[0@3ULL45&)<5";(/7"&
MY''7(T:M]:]&B#>-#\UXCN/M=!(72LQH1[TQQ,T3C2SB%-',D6RXR"IFPRRO
M3(6E0#9/6$^ZF8_=GTWW:?>D[3"6F2T&^GIEOEH*8R"$8K-QZ=&;(U:H1(S/
M)=]J<K2UJ;\BM"$YVYMSY7:&N[Y\JCT:+T_:9@)MBP%Q:";S!2IX,19 2/A3
MV^#JGV]*W89,C=4FY41REAB2*XN1 BX%L88*FRVJ"E"5*;41X"$Y[O6)]G2R
MK$:_O?,=@+,4S =_>G55H,-0U&:FHB4,[1&1.2D2M.*$2ZM4$E$:&RH3[ %(
M0_+UZU.HICSZ,-^CP+Q.,3HB-$6'TEI&K J1Q,PB5<8%+6KGBZX,WX\CD@(^
M>U%8HLM#)[G,."=<U"RRE2K%$$5Z>D=D,&;X43*_2>C-5[P/&E_$T2E;+:DF
MS"I!)#ZX)##\*:(G##Y9IGQM^WD;Q4"-8BVQK[/6?<K<.AS),B2;3"4D+EL+
M*6($Q(*,'&*4H78YR4,R7S];^\Y_+7'>8F[@/87H)!&LY(6\5,0&?,Q06DD$
MBD\=JZW)EB,9J"I;AP-WI6DW6/J:2?O9":0E,P1T&K7Q%-V#A-ZDM(($$0U)
M(D=AO)2@:R?B[@0S4 57B0P5!% W8;\$C.8\@A>&"%YVE+0NV:3@B)),1IUT
M3K27;/UZ7'@&][T&%VHL?N6][%&(/&>O*(:2"N>#[R-.!48R TVCRYJIZ@9A
M/G(=_%=<1@5!,Z'1_1#>8WBL-+&0T'V0C#GEA&?!]S*38?KG:\CWEN[:9(E[
M*KI(CHH0?20A&)R/#)(XX0PQ&80P05DK:N<;'KU3]+0[RQ5$O,[B]N&![TS2
MDK(B09T2X#(Q3&-<P'"FEK),1.8"0DPFJ]JVZ2%,F\YYR2RITT$HR$3YDK@)
M7A"K@R%>:!5\I%&;VO6)#\UK,%[YYKRXR?L-!=!+YBSSE&,IXTD,GUZI32(N
M24.T=#%QSW+D/?)\2(JM5]&ON^25#=H5L^K+UI&TDBC!<3:4)N*#Y42A5TAS
M *ZKY]#O]UP>/Z=_3J?I2S,>CT(6FE+J28H@B<1YD<!3(%2"X=1P'J!V\F0Q
M]I"4UT8ROLG8M1:WIZJ>*U.R4COT._"1\>4A%![1:)Y(=EE1!N"5JBWJN[ ,
M27E5%7V5Q:^;/;@=%?#DD\2@%5RP&!6@_G0TH1-J8L#9R<A$[;*%I4"&E#FH
M2H+-E[VB,I@>PZS[^F[L)QW:YF*/C\O1Z[+WZ*FD%I@@(=I2DH21@]6 G!0:
MO$9LBM/J"N%N/,,KZJNF%"H)H1HM7D\Z/_G8A#&<3Q2Z_=,X/BDG]B^LE[$T
M*.G1NV(\ET- B@2J)*%@N:9,EOKERO18!=?P2OPJT:2Z4"H>YVR[61,[2,O/
M.UQ= )YL"DR1&(4GT@)&91SM' =I@F06([;:AVQ61[<*=?2W2)V>!-1K ?'5
MZ@$(0H+UQ#J,Z"0P2QQ03712 $H*RVCMI/;]B%8ABOD6B5)1$#?(\?/VS;5Z
M@[]7[1]R^ &__K[_]L/AP:N#=_OO=SZ\QK]>Q[-!(Y$[/KZWCB*K3*=2:Q$T
M)9=G,G<^^V9<*/!A>J57Q'G"YJ5OFSBB)8-<#$RRV1#IK2%!<4UBD!BUIA"%
MK/U /A+BIAKIVG CZ1V+C'%B;4"K2I4FCE-!7%!6NFQ]JKZY?@W D%(A?7+E
MICI:7PKU8N3C>0GOY.-YS-Z.DDP!LHQ$NU*W*QD&[<7%BCA/#-LT:L'J>^LW
M03Q=%?K.;(9>)Y1PI-W]5'Y\/=DY*@4Q!_FA8F<VDC*AU (EV0N%!B-P$HQF
M) 7\SW!5CK557JLGFMJ0'LG-.+I^5?O3<:/:X_Q/F""2,;K .^FHF33H%R.N
MSW"^<B.;<-FR!5RXA!Y.@$@L T_0@<HBB&1I];8S#T :4BZT+M%JRJ)F+ OX
M,25(VH//,)[.,S$+2"%'YR,:,R=$+) 2"=J6<T.),NV<9J9^5Z)[  TI1UJ7
M'/7D4"\K=G3LFUF!<9!O)F-N9V) Q62,CR0J4\(P@^RU.I%$M1$YZ:BJ5[8\
M"N"0TJEUJ=.?G.I[E5?<6X0AHLZ1J!21TP;TF3U4'+6@$\"EJK[O<AO&YOKS
M,TQ.X!7*>-DY3!SH;/V+./#_5)K_:%JZGY14I708(@B*S[7RDC#FF$_<>5=]
MQVD-F(/T^-;DSVUMVZ_4>@S'O/ \4(4P6 9\?K,D.+XD&62*-FEFJW>@>" <
M>]!'(]\4-S9;\FJ2OYX+2#)HH%ICM.!8V2]WQ&NK2,YH^;UDP?G:U<'W9&36
MV6&[2*%TW:P))]U9%N6=GR=:!8].X0R)X!)7.."S97GT) JNO,L1;9:MOK=V
M'Z(A*;_UF7![2ZV:%"KNO9Z?!#Y_W%YBE)2;;A1\Y@#,D$ACJ9&SDGBK.>'<
M1!891LRZ_G;K4BB#TG:UR;#9PE=FP9W,U#%:ZK4A-%O4Y['H<XVA<?316>=B
M0GW_C/IAS5*DM]/)]+KQ6L1[(F2K>/ $@BH6ASH27%+$9YHI.AU*^MJGT.]'
M-"1]6)$K2TN5ZHBEU]C)):-YADR8%ZEL#91N>08]$BN$!! QY-YR\H_;IGFJ
M5%V?I-A0 /VXA/=N1>TUXY,.TDA($XV-0'BBDB P24+),%KT6=$^4,>K=S%\
M-,BZCC**,H?2T)TR7J(TX=%7=YYPC[8P,HS:8NUS*-_!UN4Z?+E_\_(Q<GC>
MTHG=@]_?O=__#=_S^E_[;PX.^ZF@N#W*DQ12/#"Y2O442[I=7W2Z5I;Q+*@E
M(:)^E$&@IN2"H8O*C7)&RAQJYX7O@5,Y*K>4&VT"8;8T&TPN$,M<)M0X85)F
M3%=OKS)895.+ _>KE<>L>-US TOF]\=D!G[<_!O2;ZA&2Y+=-Y,"\V!R64ZV
M,VM:_-,>_CKY^ YFS31=KDM2B4<=2=&()=0RQ"J?<5VH4P 60JAMK/J:RY!\
MP;ZH. @>/+.QW#G\[=6;@S][,I(7G_XTQG'Y9.H5&9:RXW>SZ><&/^WEUS_:
MTO?N53/QDUCV%F+7?#X[QUG*2WE@G$"R&$UPJ@@2TQ'&N%,8:B:?:MO(U=%5
M.',3 5);-EOF/N?!<9%ENW\*L]C@J"-*N0N)48*KP$J9+2\]>RGA0%W./F-P
M5KO[_H.@AF1:>V+2DG,Y%055\\S6!:P_?2G!ZA:(T!\PE"D;);$F9R(-P[@^
M:4]RH-1JKK(SM9^<^_ ,R0H^ VLV$D\OA'G=MB?EFM!2H'<1](Z<,^""ID0G
MC% E,PYY3".!0"%[F2#;VG[[@Z"&5-KT#-397%#5^%.F?N/ T*T#1==?N/+.
M,\\._4)T"5O8@[/O%P4%^Z=Q7CCZWG>PGS/$;A2 <AE+-6B*EDCI$WJD,#_)
M8FRYC#)6/W;ZM#.L$'.ORL884O !%8S3TI?3HV6GWFD2191!VN1#[&&;?"U'
MZIFC]>%R?$D"H _QU\S*+\/W>O(9U^\ZOE0ZH$MIB()@4%DF5&?&!F*MLTIK
MR-GU<*YF171#\EV^?7IN*OZ^Z7FQJ74%GZ"2"^HI.FHNEQ92E#A/,\%'1]JH
M,O>N=K7WZNB&Y!]]^_3<5/S/H3U#$A:BYH2JK,M1;70U?:*HW?&%1!7-[(FR
M) ]JSS6"%O]U?J[HPW0G(E=F<+%?]VHZ._17#RCO0>A&T3%O.6/$*.>(="R2
MDB8DPD>%P;C*2(W:(<SC(#[2W>F];*H/FMV*:'J48KWX^";(.QNRC!3S2=&D
M<"W*+5T.72NKI2)"9LXT%4&[VAL4JZ,;6EW>LQ"LCNR>P]M@06B04I),?;E>
MW69BG4+[IL'3Q!GWU7MVK^MMK%7/>,.\G[="6UR L_16PY'(RB7G<25$J31/
MBJ$^B)*85.[L2LDFVD,=]!I(OP7EOBGIEA3,]BW39[AV;;-#S4YP(:F@Y0:H
M<C!16&(E:C4E&;>6Z212[>35@ Z\/W,JOS;!ATB:FA7F-Y[>VW=;C$S4@#Z9
M(9ZG7"ZUL*5_<B0A2JIIC-9"[;KK57 -*?9]-F6[H;AZ)-)"_Y^?*AS)%*R*
M)I!@2Y];B=@<SPGG+2-U(?H,U8]"/P1J2,>?GXU"FPBJIX-]T7K!C>?$A,3+
MM#1Q0I4(4.IHA4F!UFX0^.@2PJ=J'_E$O%A? /T:HZNW;HUX<HY++PBCY09!
MK1+QU@CBT$!Z+QPP7_ORZ =!#:E?Y'.:H;4%]03\>0\1FL]S9$JK''.RA":-
MUA'Q(3)O" AOJ-#.*58[>;,*KD<VD_Q.0\<-Y57Q@N3C&<3F3 "3A$[\K&O^
M/?]U1)V,G!F#02LZ51*=*02$J*(%@[YZ%C'5MDWWP%F%-_;[TCZUA%.-+8>?
M_ Q>(H%3*8.&27N&A3MCF*9 G!>"R(A?K"P]#ZG6-EJ>J:Q==K$<R2H<<=\7
M1RJ(I$>S-$^$7>JX=F1-5H*S3)33Y69DD=#=XHI8%HSUC+O@:R>,'D:U4C:3
M?O<V:2-A]4VBR[;,YWE5)X,V5%N<>W'<5?8DJ.)]!6J#U2+SZDIG16@KT>G[
MSXYO+K:Z=U9=]DG;19WY$>?+LV1@4SFVS5@Y%2Y)$*Z<YX;L A>:L=H.SG(D
M*S'F.\LV5Y!)KPWY+T]U+8YSC9"M0@<>"8NL>.@9/703.8F.E>:ND*2J7;^W
M&K*5^".^,XW3@] V)E0Y]'9+%1[DZ_=@7;UB@ I/N4^91"E*DV\3B'=)D.QX
M8MI3&_4-*W;[7-UC!UV)+?([84NO$NGU,.;.[N[[/_;W]O]Z5TXQ'A;W?CHI
M.V[3?+X7LD"_AX]!,VZOHUKM3.;C!ZEQ-'/#J54ZH7GWY?;9,0$H=5(ZPY0[
MB4OTA(I#>*M"CH"LJ]UOZDXP=6Z]NW.J:&65H3$2KX"6.T05<:PX94X;#@Q,
MYK5]H/L1#>F81!V&++\0KXI$ZABL!1;XZ,>OH'2\E%D'S3UA/)2;M*TF7GLU
MKPP.5I9\9%K)*MW\Y"%55=05[N8+62_:.4.!%C5#V^)"G(%9S(X:'GG"6)ZQ
MTDS<.O2P)>4D68SMM?9<B]J=%>]'-*3RAGZ>^(H2J?K$W]MU?H%.<V.E"YXD
M%25.'%TO)W*YDI$J!8QG(]QCE,$J@PZI7*$_/5%]^6N3HYN=Q&[>L>0\/'\/
M* 9("VP"-%7E4$H(I<:X9'1"RD"4SE&!+*YT>"0U'AAR2/4*O1*CYM)7LRS[
M&%),OP*<8UDR\Z!P)07GI:&.1X-'';$(%2,V)94U*3!;.T7R(*@AU2WT8U_J
MRJ77J/;PP\'N?_]V\&9O__WA_O_\\?K#_QZ6I9M]G5X]^5_: 4#R\V-T,/L,
M*4]GBQ8!&T2[]0:O$07WM!0;1L=S/71E_/D&8WN&8N<2Q:OI[-4)*B@8Y2BC
MD0'0J37X!1+ZN 8<$M=1&9&\$58+%AXQZ,8]'BZ'VO7'3>?'9R/>&FBQTB/M
MP>E@!*&"T[.I.H.33I&#*7OQOGJ<_&B00PB=>Z7/3;W7KQCK=119OARC&+V@
MH-'O%^C?R>!*6[K,2.9<1P\8[%<_7G<'E"'$Y<_%G+5%TJN=?/UV]^#W_0\[
M?UU/C[Z;H<H_O:Q?W< 8/G*$&A9ODTE52OI>CK*X_:>9G*"7?;[?,)VT+P$M
M+%Q<CP#M_FDW\_@0-!.TS:^1N_/M@G)OT'0\GO<%[P 9U)43])"]RT08,2=D
M(H%Q77H6)1E#$JQZN^T>IU/O3H>5H>WA#VW7Q%&PSM"@)/&TU$*J($M'3$'P
M&;3)4.,2ZZ'\>5VX0["[0^/WW7?/],N&'JXD61DPFB84\61DRX4 5L_OC2\U
M+O,KZ3%*#Y&"S-3)^GU^UD<[!-/_'9)W'2X\AT-Q 7F^ 5]RTSWX%/<,TJ-;
ML>K4:G7!/TNUW'6ODM&4*9H=NI(6^:=1DUF+;$C&YRA4QC_7=@[N1[1Q5'/V
MZ>=$OSUA;SR-J=P>40XU2"H"\=HP(K(P#J*VD==N)_4 I"'9Z8ILN17;5!3,
M<ZBDQ3%-1'XEDUE?*]T_3H^*Z1$3K*2;%B->T.WJ,>I22"7%_'Y+CUQ3(A$T
M6)GHD(!++Y/2M;N.W(=G\R--RU?W6I..\W11J11<O@NW.VV[=F19-#;9LOF6
M2\59=&B]C2=@9=)!&."IMM*N"'](^JX: V\?DGH><:^H&<]?+U^";^'7'_X?
M4$L#!!0    ( !1 &57J7-OW0ET  %'L P 5    <V5S;BTR,#(R,#8S,%]D
M968N>&UL[+UK5YM)DB[Z?7Y%G3I?3W3E_=)K>O:B;%SMO6WC,:[JF4]:D3>C
MW2 QDG"5^]>?2$E<# ATR5<24-.S*!#X?9^,>#(S(C(B\M__UQ]GIS]\S:-Q
M?SCXVX_\+^S''_(@#E-_\.5O/_[Z^0VX'__7?_S;O_W[_P/P7S]_>O?#ZV&\
M.,N#R0^O1ADG.?WP>W]R\L,_4A[_\X<R&I[]\(_AZ)_]KPCP']-_]&IX_FW4
M_W(R^4$P(6[_=O37D&SB'"5P%B(H41*XK#UD55*P,=B4]/_WY:_:FI"]"% B
MUZ"*<("F,##:^*Q<C"6IZ4-/^X-__K5^"3C./]#@!N/ICW_[\60R.?_K3S_]
M_OOO?_DCC$[_,AQ]^4DP)G^Z_.L?YW_^QYV__UU._YI[[W^:_O;J3\?]^_Z0
M'LM_^J_W[X[C23Y#Z _&$QS$ZQ?0Z]/DZA_>1*-_FOV2_G3<_^MX^N_?#2-.
MINIY= @_+/R+^A-<_AG4CX +D/PO?XS3C__Q;S_\,),<CN)H>)H_Y?+#_-M?
M/[V]B[0_F/R4^F<_S?_F)SP])<33)TR^G>>__3CNGYV?YLO/3D:Y+$1_.>0*
M2E<X_V]]VD\;8SHA(*-X$3+0IWE0"=X0XWU/WQSSU;,@Y8(7IY.&B.\^NRG>
MX1GV6PKXSJ,;H)T^",[R6<BCEE"_>^X-G)<@;R.LCQSG<1Z$_O O<7CVTQ3>
MJZ,/KP\_'!^^IF^.C]Z]?7WP^?#U\6?Z^O[PP^?CHS>O_G[PX9?#X[<?CC\?
MO?H_?S]Z]_KPT_'A?_[Z]O-_/SX:>M\ ZAK,C&13V!N][\8HB4[]0;^N4._H
MQ_E+ZXBV-M[\QR0/4DX__M!/?_NQ'W/)GC&6'>T*SFJO5+#2:*T0!7>VM]&;
MZ\ OAWXZC-\!.:U+]?"*6Z<8\NGTT][%&+X@GO>.)[1KU@V49)7?TK?C'B^>
M^QPMV&(8*,,C>%2TU?E"R(4)//F[S!Q?,KW@.$RY.7_%3U7)/^73R?CRDZG:
MIRI?C&*FT/7']780R2 8Y]=Y]M^W@^/),/[S9'B:R+@X_)^+_N3;I^'IZ9OA
MZ'<<I5XI I/BA<:;:=\/+H%G)0/3QJ1L64(=&P]Z18C?2^2:Y >C2]G,UY4U
M%YYJ+37EQF2X/97,:$'C^_&'X8@>][<?V:8,.C[!41X?74RJL53MSU[R/(>8
M&63C"%7*'+SA'BRJ'*3TF@?3>F+<!K%]%G2JMF%+F=\E =^8!'>&VI.:"(]9
M0T+N:'S)@@^<0U Z1JN406V;+X^W43QS&FPF];L\$)ORX$.>D "&9_G=<#SN
M2>-8MK3V,4;^H5)U%<R*073,*)^3U2(TIL!W )ZW]M>7]5W%RTT5?Y#^[\5X
M4C?!\>?A04I3.>/I1^RGMX-7>-Z?X.ETU:I^;'HU/#LG+V'J'G_*))5Q?Y*/
M\^@KV8 ?\Z@_3)]R''Z9:>LW/+W(/>[1"6X51..(V(E%0)(.B"0"NL2S4ZVY
MU/68GC<]]XH1=QFOFFQY;\?CBYQ>7XQH#Y[!G&W-TU\>G5>PX\,_\BCV:8P]
MB2X[23-3)2Y)IHG694;2#3)G$JM'J]I[#*NB?-ZL[%AK=WFF.^+9= [<#U@;
MX94-&J)GGK8"EP$MDR0?SA/S0OLDMT.SQ2!?),L:Z>PNR<RZ)*O1I8?GQ"7$
MH_(/'(V05O.>54QR5P3HP#,HE@*9&L*#0,>"YMZYV_RZ&\1:Y\7/DS.=J^ N
M76P7=+F+<KY-!ZUD]@:4B_2%O! @;[2 %L5P*XK(QF_"E@7O?7ED::& NUQQ
MG=I)'_+OTU^->]XH$Z0E_P4YH91DUSE6#!&<]EDAC,G);=,VND+V/(G4H7;N
M<LAW:0-=@V0V%NFT!<>#):(;#>0(,."(DF%4S/-[CHHZLWM>-H,VT,T]\<F-
MH]1'DY,\JD[F*)_4\\FO>18[^75  CKM_RNGOY-P"/TO)-\:4#D:'.=(XYGT
M\_A@1.[HX,O-X7W(DZ/R&?_H(;,D.$W+:=("%+<,G+((D1D5#(K(56O2=366
MY\W3O6# /=3>//9^YS @(^.AH :M50*E40$RAT">A%&.2V]MZUC9(P<P34X4
MDDT662Y0L!ZJ%:?!D^#!9.NRT-;;N.T3A0T.DC]C.,V]S&1(7 60-M"8> Z
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M!R$%F9LFMK87[H#8OI_00#G#EI+M((UJP0GI'%PF;%*F"+G4='N''K 8&J_
MHF.RD7O=_/3[ 4#/@0+M)-[!S#^(\>+LXK26:BQR7.= 16:)H>+ L7!:^<@'
M==%;D%Q;D]$2UM:G?4N#>Q8TZ403'>1>?<H3&FM.AS@:D ,^GJ.2/G$;).V"
MI:YK1GD((A9@;II8G17+K9,.[D?R',C00,8=)%\=7X1Q/_5Q].T83_-1F6YK
M4XO(!UYRKD>$6A"P8#@XEBSHXF510J'GS4]5%H%Y#AYD$T%W,/=OP/F 9_3M
MYQ$.QABK?.>T7P9A1Z[DX^AVY%>V4>=MDG2CBRZRMA]'2D!%<45!G1=U93.T
MQM&\LU@BHR_D<+4V/'?%EL=<SUV19145-"3)--7@X//[-QC[I[2-SK<ZQH+@
MC$R;Z&J">:QN4@H)@F.TGW)9V.VXY()TCCN/WD'A3F/A#YM);J&#^>\_W9+.
M._IQW<K%UX?'KSZ]_?CY[=&'HS<__WK\]L/A\?'K:N*<CK]'LEQEXH//:U!Y
MN#S>6Y6%PG!;G"T*752&15</G;D6D69GR2;U'GSR9HOL;SCJ5\/C[6"21WD\
M.1Q,B!,W3D%XB6AL %.\!V4+,<QF 1YU+%$&B[;U"OL(I(U6C)\OQO2<\9BL
M[M ?3/.Y7PUIA2423W^83K&21R,RHJ?F^26(\2R'  >I?E/AS6#-3A9GO_R8
M1P>1_M4HY^G'/5%3441M*,"DJ'DIY*4K%D$&\KGH8<)@6FHUVBKL[:]T+4GX
MW3*WO^KN($9W.=@IJ/%4900QDFN!7VCW^&TX(9_P:H!SZ*E'*SLOI0B0+*C9
M'N*]58!6A>R==%ZUCM"LA_1Y\'*+VFIM;DU9_O%B%$]PG ^^$.^KWWHTR)_)
M3'W?/R6@PT'^B-_JQ[^>#P=O^J/QI)HQP_)Q-$P7<=(S,>I@H@,1)9D9-A=P
M-5%&J5)[L7"5N%@NWW9S,,^#4#M13<,@P0/XKR?$L'S(4[CC8?G/"QR1^$Z_
MU3#7T<5D/JKQ+/WI\L-I%M2XIS$)FA,!)-9DHU0DN&PY^)RS\L%YSI;;@KM"
M^.Q)N&4E-@Q@/CPH0C8#^X^3?CRY/9YQ_5?XK<KYH- O7N/DQOA[L59!))IK
M9"307%."@8LT+"U+D:$4E&)#6FX"[R5P<FOJ:UC<^>B(^H/I:"[-TCZM^K^.
M<SU-KL47>'KZ[5/&\7 P-6A+&8XF]!<'\:2?O^;W./IGKD;'P<7D9#CJ_VMJ
M(8][!9%+)021+W%03G":?"% X)PQ3%:RVWF-:U"U ^ OA,2[5GD7-:7Q)*>+
M&ORZ5Z+]/)Z=E7A3F/:R0(BU*I$913N"1] Y2V.R35&T[O:S)+1MI:UVZ:!T
MH85]26Z]Q_F:QLI5TL4Y50.HG,8BR 1&(\B#%SK82*Z7RJQ[7WBGQY%=:/UQ
MUW=EZ7=PWG0?K/FJ.@^W+P.PHT/*1\'MYHRRB2J7H,?F>M@)88I!+72QD"V:
M6@B=(/C,P2A$&9Q6IGDV[(Z(\LCQY&YXLHKX6P?+?NM_I8VJCS_WAV\'\2_S
M4S:=M0U1)##99*B=CR"4[($;9%'7E+[;F9(+C.E['[]]D[>Q#H9-!=@PQCX>
M37KS.-G1:-[X9W:ZCJ@,XQ9"J#E;S$IP6O.:N"62Q&*E7,IBH!?<F-WTT_7,
M7O3NYV@B-)%SR^#D-9[QP2#-$8TO$V66 +6*/; <">X"V>[>WT9'=Q7>2, M
M%_('P=&"(X2)$;@2M6B<:4#!)13GHU?<RJ26JH';+ZTOV,BWJ/15Y-I^UXXD
MQ8NS^6[CF"Q2&@Z">X*2:F,)+P4(VM,4[4*$32VY7=]\[O;VZ8:2'K814P<'
MWY_I[X[*0>TJ\V4:)Y@24P8TP2D)&8L#E7T$U%& 2=Q:)WSMC];8]KX7R'/<
MIMM)OHMFG]=P*N<_# =X_<F-'+JK]/@EX';DU:\(=3<^?@,EWRY:V8*&NJAZ
M6A&V+YZ\G%C;7"."THI#D+: 9UQ&AFA**L^14(_$ G;/IU44T]K">#4\I8^&
M-?_L:[X!_%,F=_=BUFYV.#@^S[%?^CE=Y6[,H9>L4:$($#DGZ*ZNUIPIVK=#
MDM8C4WRY@^/-<&P_TM"ICH>[45#C ,55*=$O>?AEA.<G_8BGT\F5$VKKD@!M
M3"T7C0C!\4SV&IEG1AHFF[@J"P$\1QNHG<1;9@A44+,SLIN0YO;^,J :QBL6
M ME^O**1HH9=2;EQT&(Q.(F9&5X\,.$K..TA:%J>;"P9K25W3:>GI_H'@A;;
MU/PJPFVH\3B\&$Q&WWJ_'O?09A,3!L@LT.ZCF #O0@'NLRN!*?+N'^KW-\[Q
M+U^&7W^:/W&FX?D/UPJ^?M]V QF-!#_<2&J-]^S#B]'P_-)V8($'[ZP GIT&
M)9D!9XJ";#@RFYDHJ<4V??.=3UF#&\FO@_GWOS_VM(E!6,N!OAA0PCAPVA60
M6D7T,7*-#_4V7&W^_>^/3UE[:TIMX>%.T]K#-P=O/_UV\.[7P_>'!\>_?IK>
MX'?PX?6;MQ\./KQZ>_"NWN'WZ=?IO7['%V=G./HV+ ?C<9Z,<9#>D:592RO)
MO'R?<7PQHIUF\@;[HVG7V7J#2+P8U=33GW'<'V]0T;@#E WJ)'<MV]OW.HK
MF),VH6$JU*:HF2N6DQ92L%)<;P=X-XM373U^AN+@7A1'UZ^>N=.C[Y"\N\HA
M1"EE0I6!:T6^D0\20LH&K)&>?%I!WK189E-:(8K5=  ;1_VF&*X@O>Z/:Z8B
M(3@(X\D(XX0DY(A.T@(&D6GY0@7.TMX3$[>*16N8:-W&Y%%0VP_0[(YU=\*!
M3376P8'5*QR?T/#K?VK9Z5<\K5&M>P#W:+&/ED57[XZJE2\RT,::.)!]HU3
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M>A.\+\'6V+I>._"UOT<TGVS+8.KHT/H^/+LYF]Z>5H<=J:2#F-V]V%3646-
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MO6*JYTLE@0Y%B:A#\GZIR.)^J7ZMC-[VFE]%N)UF])K@?=02ZN8+2J*!((L
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M/&EPWD?P(GM)GJG6I77BYX. _F120X5U$$"X[-]Q):@Z\,O2"H/1<,Z!<\U
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M)VX4<".GM]0[P*0S>*VMY>BMX\^V?>W>,:B%DKIH?3P?X>R&8<5CD K!,5]
M<:P.4<Y0DDFRIJV+Y@' F^]_V1[EVIKHD!67-X<O@:8C5W ?G+CU-;- Q1N(
MM8OMXWM4*:G(4&;2!7>@I+5D&CD.M*OIP%!(%5I?B+$''D]7.EY%FJUO7YZ=
M=0UJ-F__:Z[ /O\^_'PRO!CC(+T97HPF.5\:Q+1NN:Q9 ,FCI)7+V7I!- -N
MT12C6/2W+^A;E->]_$NW;Q5LHISA%B3;^L[U3WE2(0X''T?#+R,\FT-RB)R)
M6N!35+W\G=%WCI@NT')AN0YDLRZE[/N?_W3UVD!>W4]BP9B_=#QR89Q9 99&
M#,JQ D$4A.BQ2*5*U)C6G+77;WFZZFPFNPY,K'EGB>E^PZ>&(9G_(L4$*FL#
M/B Y M9C\EZ3&]#:4;OQ^I=M=J^KAPZZ>LRAS%F_#)B.C.[O@.S&YEY;+?>K
M=P.9=F!Q?P]*.!ZR+A&2H)5-Q9(!2ZK5@@3+DO^/L77>P184_(B]W8U^5Q'E
M]LZQI@L5K66TWAT-+INT%B.=*<C!:TE0<W#@8S"0,PN:ET(V1^M+W5> M_T]
M?P-%+G?DM+$6NKCQY%&HY%?,H=:B-&LY69V698+J:STF:HC!!62>G%+>2>WB
M<O">-V'6TT('*\PT^2Y/>TM?S&YJ52K+2 X(,!USO511 0:GZF6;3%KR6C)K
MWG;[-HB7;4%NII,.NFM]!V@^/Y:!U)$U>0^<W=B4&RKJ(;5O(.6N5XDY-%VX
M]V@1O-2UXUL2X!RC+R(9EFK>I6X=UMV:XA^Q-;O7^RK"[=3NO%S9KA>^RQR(
MRVADPNR5$:!EHO'FPJ#N7%"4]T*:[ EV9U;$8^BV;T1LK,R%ID1332PT/;=P
M2\.MXJRW@_.+20US'XS'%V>SDH#F]S>L\,[.;G98=]RW[GQP6>88E6>96:5=
MO1I/"!N$JU422N"".Q]6>/O.;X.@H9FD:0T-R010J9K=SM3.B]PPFY%FT]YT
M^W[7Y#:(M5]_5=%X0X_UL_<X^F>>S&H=<_(F!XX@<KV P"8$%QD#HR2Z8JT(
MT2X7U.\0Y1YF]+0E:ILN2ZWUO;T8Q'ICNZR:_#CJQ]QCJ>C,F(+L!((B)PM\
M#O2%LV"84$%L/P5[[=&\&,;O&3&ZLI?7:2=U_\C.<TT,_9Q'9[R'9"0:IBRD
M.CRE]30[4$(-- 8M@_=L;SJ,/3J:ETGYW1.CJULQ6DWF3_WQ/]^,,EFEDSS*
MX\DGG-0YK56P+@*7M)<IS!8\*@=%!IVSMU8W;Z/:^:!>Y@38&YIT=7-&NTUM
M-L-_&Y[28T[[DV_3(9I4O.$^@1>*##I4!EQ@]=;IX 1C4:FX-_[0\L/Z<R[L
MF"K[= _'0T-\W?_:3WF0I@/T400?<X*LC 0E<X 0I0%NLE4NI^1M>0ISX>:@
M_IP).Z5)PWL[VA\D.IZS289#*#+5"T@2.!UH( FMTQ*#<<WY_@*;B&S$YITH
M>S^;B&AA.;>"UWN@2(Y9T/Z#Q4.,A1M4$7UL?6W2,VLBLA(''FPBLHHNGDH3
MAF7&]&<3D96:B*Q$DVUT8UA'QT^%O\6Q)%FQ-4> U]DMP1O)@47F'/FNG-G6
MS=>?#F]7:B*R=[1=1;5;;2+BLHH\>P.6+)EZ$;2N!6,&DF+H40OR";$QYYY[
M$Y&5=+UT$Y%5%+7+#([CB[,S''T;EEF:"P[2JY,JS?&P_#KO:7VKOT7SA([U
M(726W]%(*K?2/4R]6%7ZHD)*BK,<N))2DA%(5"-+4"Q(]U@?S,ZS/X1467/N
M:5K%.L&"!6]-!HU*,\F2=V5+A0Q;R/[8&,&C[56OVLQ_&IZ>OAF.9I=&!JEC
MP0C6UB:K/#&2L57 7"DZT7*6Q=Y$T=8:X1[N,VV9O[W^O!L3:)]R3)8?[?P"
MX%R<,X[V9,]5S>>U$4(P"-99QX7WEOSRIS=3GMS]T%M@Z?8GU!H4VX6?VZJS
M=W"ZF"@"<,-J%Q2G &,1((NVW@9F,;:N2M_6V/Z<23N921L0;)]28AX=)VFA
MY#ZIY,90$5%J&B"K7=XPD0-:I",OE%Q%PXO,LG6<?8O#^W,Z[60Z;4:S?4JN
M67D/=HXYD7D&1KLMJ"3(] Y>0^:\Y$P^-R][DUF\F9FWEUIX],*FFY/'F!1T
M, 94GEXLSSEXC!X<XXI;YNEW>Y,8V(T(GM#Z^&2\V\XH^*1,]N7%T6,F&^ZR
M@)B\KWWH- 3A:2/STD97K([L"<:0GM/5?/M _CV<R"LQ]TG-WE5O00RQ.!N%
M@5R;DZH02(DD&& F9FE0!LSRR4SAYWO%YHN:QUUR^"DZ_1>C/'Y<"DG+;'5F
M8&+150JE=CLS$",F'I+FK'V:Z%Z,_,]IO)_3N#/V/LTPP^,RT%(GM$F!L)Z#
MBM+6&@X+) P>(V,2;>M+6O9AW/N3:6^R,\$6 R+Z2%9A+233R,%9ADX[%[AF
MK17P C/M-PH#[$39^YEI+[PPEAL'67 )JB0&F)&!DRPS;5@0N76:S#/+M%^)
M P]?U[F"+IY*IO(R8_HSTWZUZSI7H<E6KNM<0\=/A;\A6/I_S%"4%:!J18U+
M7D!43B:3>=!ZZZ<$>\/;U:[KW#?:KJ+:#NCZ\-U]F>P889F!% B7PH!DQVL!
MF6572C+:N]9],5_"98LKZ7RERQ9745@'J8R+[O&3LO:J%QRLX+HVH.: )FA
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MW??N_8B=KZ3%84-I-HZ9SO&,#P9ICFA\V1!Z"5 -P^8+@6P_;+ZYCNXJO)&
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MWAIS+^?G:^(<V]6.^VHXF-WQ./XPG-" +J\>01,REXR#$>09*&0%T$0)S+!
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M\WSKZ'G6_BL:'%U0P+6*8=RH#!@T7% Q48(_=('5/LM=">3H4G+UQ%[1B5N
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MA+<*7% !<G!9&D:EM:VR)]^7ZA\XVMJGYC<1;D6-3UML#[_VWE_T" W:2L6
M4*YP3HYCR*X]!)X8XRPIO<S[>T>]HQ1^N6P^/YL_<:;A^3]N%'PSWG[/2RH)
MOME):ATD.MY-_"C]=X)3._U<2E#QUV:)/)Y%"I8 MU'BKA3BHC]Q]MFZG&GU
MR[IKH!S=YEU3]/<M8F?"YQ6P%FGZ%L Z2DNL!768!$05U3UN#CO(O8/ ;SW
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M&%$H@C2,E%&&"$^-[;)]HXR-7AHY05$+>J:]5XVH%O;&7DP-+#,72/7M'6]
MNFU!NG$*DH5)Y@*L@0RR+J#9V6/'P#AHC>V]>3A;[)C\&Y;8T8LMJ;"83VZU
MJV.Y*?5CC),8AD0[_&.*(5'$!W$HF4=2$B>1F<-_\[ECH[L[_=:7\XR1Z0GF
MU&OPCK!<=TCZ=HYW1</\.]VM^R'#1]VR9O2H?ZT,GM=/&^93W:W"\N/<\^MN
MVZ(J2>ZJ+!>"OZ]B@YK2W)7/L?KE]5-U1G7Y0S% 5@H^P91SK$L9)9ZO#_K#
M"*:<29@($:O_DS3&5ILD>Q'&]I&W@H&9K!-LP:R6N'M2;8=YX=(+O#!)81"B
M6#$J"2%AD8 !I[[ 5,V*QR?K):'?:F:.UK_N8VXZ!$>=,!=F6]I^W_R^N;P*
M;GEG& 3S;E<03*/=&6CU*[5#N0;!W0:Y.\J.MLL=!!AT\]P=H-=;Z1.>U&WY
M6FW9K^7Z2W@KIII;+F;EO*Q&IVM1-2N?)PJ#)$6Q@)AX 412F:,X3(F:0K6V
M12A2"QJQ6<I.$V=LR]K.\+6UC[MK>O>)DV;&K<--Q8 \VW$6K"G3#7B.Z/-$
M80:E4C? O:951T_MY%5FNM[A^7TAJK?MZY/2.9]_$&+"0I$$"0N4D9GJ#3Q/
M((DI@D*P2/HB#$@J+;S*^\89&RDVD@+2BGH&%D^PDA9(87,\=P!;(_^R"\1Z
M]R_78)VOP/K:@O7!%5A6#F87H WF8.X&GJV/^1@D1WS,>V\?TL=\3(=7/N:C
MEW<\3.D:XKUT09TKV_EQTT2^*92X$^;+-&04PS 0RE+U> R)%Q'H49\22B(N
ML9&OJ']1QT;8?U,JS8%HCVB>M(S560"?3:>D**OTJ>I<P/98H+_9-CP^&,4<
MCO^88<T5OZ;PZM0!5#H[/'#H?5Y<'4ST)^BP!QB] [YUT-'_B ZL]973[EHV
M[KSK_+.8-U45[LA4E)^R/'M</$[4ZL(B/TI@(A,$D6YI1S%A,"0H8E)*'J3F
MP0@G"#*VY>/+0U9P\$2*^0MXK$4$L^^Y&ODA>UI&+YQ@R=I,4H=]04_0#[]Q
M6"FBW2RMLU\M!#J"OZTE4ZES!AJ%!IJ5$S8@/<W.V^U07,[2:1N9#M!:[71L
MGO]V6Z$.*!S<*W5YWHF55D6IL]TF B?4]U(*PTBM3<BG$E*6(IW4@ +* \*Q
M56;JJ^>/;=U9U085995KV;&$:H.>V8[B!$QZ7A#,X>A>&W53:=?U4)NGOTT-
MU$W5]M8]?759YWS2^H$?9V4YT66S<)*$ZF-57RR2%$$:\1AZ<9IZTHLC#R>3
M^;+GLTD"XNKI5A_MGO;5KI,)M5S@7"J.J-]6ZV3.-?!\@GT_]911'E5&>:C
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MCC9!:FN#^TU+"RIQG>=('</%:9K4WL'>(%/JF.*[DZ6.WN4RU7+-*L$!]U!
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MC-)M$7DOI+*.>14\E-&%'DB'D7^J74+G>;[0U956O]2#M^&^S5GEA$8D3+U
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M,& GA>X3,52SA X2CJL?0G>(K5L>G#!45_NV]>K9%M;:<>>(/O$UZ7JIH75
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MJD[?I'1@3P0Q#94-&X4A1.J?$/M80 \Q&:0H3&)NU/G0>,2Q6;-:Y*4;NZE
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MNG7+U1SH#3&,9QCMO/>]\=_E\UM9!%5:4S/YC2M0:ZE^.@<O8@Y6BIXU!9*
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MV"B@V\5)A.CBM -E.S8(BUW/Y+#=W>F7'?VP]I^EGMSJ:3\Z/;5]VC'@A[:
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M[,P,L1D$K3K=LWXS74:E3@V]=A=8'>Y7:H&[9KK<XSM"3)?+>="PTS;4P=!
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M298S(JE3+?,1/@[#^#+X7)J@.OTX+!_D7_J1L-OCC'"B>S8D6HU!1^4SL-8
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M;_458*#J1 F.H')F7_/_T?4V@^OUUZC2V==T!JOMV9N GF8"?Y#BY5'>J&[
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MQX7>!-2N0]<&,\,_#8[GXF.:XP'/S,V&?:UW?80.?EFI_NNA%L1GH(L J"
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MDNO%_C]GC_HVIAORK5[[)PSCA"0L@=IHR2#*D]@T=HIAFI)"_SFG##G5/Q]
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MS&2EH.EKMEB:8SGP)I=@K=,9.'\R!GVX/5?O\ ?:IO4GYZ [N][A?K\9['_
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M:YT^F]-%]JUFA-?*'XLE4:<Q,5A0#HWTX*>"I?E@:_\,[#S0S-J,PL,2*"]
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MA31@"4IM%FX=[9@:7=S<WC[]=O<>W/U_K2)V]\52;;WC8)C%&2- /##1-!Z
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M?LJ7ZV>]/9+E7/U*K 21RCXGM9_.CI$A/0V#_- \U5Z]= 9JVX$R?H#[$1U
M&[8XTMF>IU#FJ T2PX)%K4V,7"JO_$?]QE>OLC\/ A\+2G2-C22"**URL0,H
M<"0]GGJ>;QEO.31N:F19F@B^UY3Y6AHY4O6[<T/7BR(''Y 1.;1C3;MJ.)L9
M\+%].,<K7->"^UO7J#MGVA1XNA>HSBK/M?71O412<??C-5NI)C_GW\O90PTG
MNB^*C>"?R,_ \Z,Z8O)0$$OJ!3"5.F]*>#ZD08IA@J.04\_G/C478[7L?&I,
MW9@_ XT#H/$ :!=FH'("*"^ =L.^XH_QN+33]-!H#TS#UD!W48:U1=R^W-(0
MR(];><GE"'0JQ&0+H4E-)N,V1R_/9.OMN4I-UFWTE=DIMU_>_;Q=D*+8NXWI
MI5$4Q@3B& <0(2^&-/(8%%PD*4N)H)'=;DA[?U.;*KYL7E[(ZF=9,W+O7+6K
M-,YYC U#=7?(#1U][TG;5+NM*M0NK1U)NJ85(.?2-.=[>R/IF5;7+TO+M#_6
M\0(X_^]-L2XE*+_F-YQG>JHCBT>2\?ME726TC)7I<3C])/Z^R8IL+;Z(U?>,
MB2I>?A(L_[8L6RFE*>8T]D@D @Z#"''%3;[BIC!%$+&8D3A"?D*L)+Z&-GAR
MY%:N?DMG=,[.UAO+J^5##[,9/4YI\ ;FUYO'^]O9^;V+_7WB^R5;"?5G(/-5
M5?EXSR>'%]9' M[5S?:AS1WW"OQ(X)_<E1^KWPY;(_6M_2=1"/7@\\V2O]?R
M1?FK-E=%U?J"6G/Y.\4D(!@+R#P=W@8DA6DL/#6%)!*%OA\'6!IOBUAT/+6I
MH+&YU+W@.ZLMUN$VL!OL>@P$YM#47$N&;/&\T6I%.\-!;?GU._G] +;8Y!@(
MZ)$V.!K 5Q>^P$!4'@!6N>"JFDX'U%KW-&S:&V\_HX.7!WL979[O77RZ>0<4
MR#[E2)%YZ$6Z<(^$V LBR-- 2D(P2S'M6&ZZ"XN/5F"Z_J:#1=<"KF>P-(O!
M^R$T,#7O&3> (LIEU]U7AWX3_9/+#K94@';S;I\/)$_/W.CQF=O#J_Y@H4_=
M!/^\T=NE#[+\:#'W2,0]R9 ^$/,ABG@ TS A,/ ][(=Q@&+/2"YE2".G%B56
M-E87>T!>V0WRS;I8JUE7GRWHZX3E%4)K]? AAM@B!>(-!V[ZJ1"UHS-0N3H#
ME;/E]F[IKN.\B($&PV5^A&L3Q\^3& CDL_D20_7587/@2<6?RXW8VV_XE"U4
M'_E2?!+KYYP_YFNA2T@NMK^OK2KF+,)1XJ41Q!A3J"8(!'$H$8SB)(D)H2$*
MS',H>A@RM6EA:REX:4QM2AS9B$WU&1J##861 !^8SFLO]K=R9V!K,*@\F8'=
MD.S^]CCND%AL08PT-"-M20PY1':;% YP;=VTZ-/^>)L8#E XV-1PT5ZWA="V
M9WTEILHCE/GJ1<NL/6Q+R<V3*,4T4$N9& 4$(A82B'W,H4<Q%1QA'*#(9F5C
MU.O4YJ2]&T3@=94Q0TE].Z3-%AC.\1MGBIF!K<5@SV3PL%>T\.9%*R:["_^M
MH'(4SYOU.6J ;@7#<<1M]W!7E8!&DN"#,OXV5VRWW*B^'E[%JFR_.*I2)(JF
M3M$\%2Q!A L8)0A!%"(*28I2Z <IH=@+8TFM-EYZV#(UTFK*L&6UNL>B5/?X
M[4]?+I]:.!\>,TX;"?2!F>Y0146_AV#G"MCY<EJ93>\A-PZY5"GHC:HS\8+N
MEHRL:= ;LE.I@_Y-CKS17>8*EQ^NTBGF***"1%Q+@/,8(AYP2&4H(>/8%SSA
M(C*[[N'<LJE1KCZ$9'I36Y<:&&G/^F2T!MZH[C,&T]^=WGDWS"T]EXB_]1;T
MB5W_&OO.E^!TMME\L0.W-_.:ZHT)QPA'W%=TG/H021)"@BF''(51(+$?IG'@
MXC)>AUJ/$[A_%[BY_&56*G, " >FS&OH.;Y#%SB]-M<!SFG<E'-9BM02I*YW
MX4:M-6KID^F-M_XU1^]4^+[^><.Y^K(4];\^9DL1S ,DA&):'WJ(8XB\4$7+
M'DYAX/N41I13QHUBY-9>IL:]E:&@-G'6_ "TL5I1QKSRZ&5@VQG7&5P#\VQG
MI*SJCUY%HE,!TLNMCE:!]*IC^R5(KW_8W8OOSU,O2KS0CV"88GUO#*60"@]#
MG\>ZIEX@/&E<;?AB+_]2+_[#TJ+D\&5@N[_X4Q*/Z8R4DQ>_3<ZE^XL_DA*+
MD6,F+WXO;92Z"-7-MY6H5GV;G_EF79U5_;94C7S(5L6Z2C"J=V X12$C/H&I
M'T;Z FD"<1JD,"*2I'XL8K4FLRV>9]'_U,BB*89&&A=F@)9. %)Z 3;:#2"U
M'W4BJ)7B5==A,EC+#0O^P-33X'ZSP[VROSYI!:4'H'2A3LN\MNGEYO6P+O@W
M$/XC%P-T. Z=R@5V0-&DE*!-LZ.7&>S@\[D2A%V:Z3#7W+^\DFRE^WF0QQK9
M^L[U@ZQOPZJNF/[B?A/S(/73"(L0!F& 5/Q)/8AI(&$21SQB* UC9I2@T]6
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M1F4.\1V'QG8&'X2<>U#OA97N&,P.)T?L9=CIJ,QE!\0Q:UD^W8VQ[OZ^T?M
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MX;O/2F+M&1S%ZAU,DUO0[7ABWAD/+##TDG1,X'T2X),30E.5_8X'R?W5U@-
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M=\/1-9K& 5'E?B\;\,XJ9-!1,$HI8-1YZ7"/<=NI#5N'R+5@:/^8,-Q&3PT
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MC\AL)"EQ5KW)?5>\--.8I7,P-X&&!CS19T1PU]Q44")*;V:C]&(<'0%CHX1
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M[B?G^-7,A<4-Z6J/V&S1/PL677KG0$A!P7.=P1+* W%.Y5@[5W=#$OMU>RN
MXO$@APXUU/>9=3@9X8\FY1+^:[K'Z*I1DR_3B2;CLZL4AGF8XL?A"'?P9)Q6
MK.8DG7#,0Z 4635E]U(BT/K[R+5U1-"XUAFW&QT]CS3K$A^3?I35L\=]>^GZ
M:YI<3-W5ES+W?;&14W12E_)UJ51 )H(K+4$2>@SH("BN"*_B<;](0,^5!!U'
M:G7DWC=XTL5C%E9^*G>)*)HM$&8+$]*"E[@#=,C):8T^IERKY\I;X'F)@/Y\
M]TJ*G=26<H]06:0C3K\/?CL;.)U4B,Y#(AXMHR ,K/&Y/.B8[(G 6.:UQ+Q9
M"G^^F'S]>?6)2VBLOKE#QMUZ/<*@CM(F.TFP9_-P=%U:^:S.1.*IMT8SH,E(
M$)RHDO J("GJB$Z$Y5CC.+F_9C]W??6UOY,L&]CW__O30*K@F=84\ \%@BD#
M1IH,7(K@; A4NM>JS#?;]__[4S\1>7?[?D,)-A!L/^LU??\P'*=C/![+7/8<
MG-(>5"XC+W16X'5BI20YY,"]=KIV<M@;)/5<UK>'6YR:.ND[G'Y^=NG=^-%%
M-+@:ZO//:V3SANE9:2Z#KM@X+KK,H#B68EC,"%[]Y:<TO7G 6_QXP 37@F4"
MZ*0Q-+C:@A,D /=4:ORPTE)LK>A[KV3W&ZQ71=ODAU!] W;WF;=H9"D4Q5\4
MXS(IJ?2W EFQ&@<\$YIS9L!)&86MA )KM0"GA4_6<&-%[8FBVU':[_MM%YC>
MH^;Z-MJ+'?7I>AJ^N%DZN, ]MB@Y&J?SX66ZO41;=03][6HR?C^<SN:E9^TD
MK][$!BH$Z54PP (W*.*4P7@3,1+*"AFF(E*VEBFN0$R_#S^=&=A]JZE-6-YM
MODD^20OV9I/\UVLWQ65'WX_<='QZ/;]I7_ON>EI:>:Q^N*CWG@VDBPSWGP?N
M1"P#C4H;#UU:XZ0DK#=EJ-$.6-V=PG[O6/<,X#TKM%E4(R=+YOZ.X>F7Q_S/
MRK]:3D<ZR/@7[]S\GKP&05)K(NYK=(1P7PM&P 04@^0Y<Y^SXVQ'2.]"7K\Q
MW/[QO#=5M@SFX7C!_8W;/L33Z;=9*IU#2]L\-QI]_YS<;#)>./PY3Z9S_(T#
MU&7ZFI;C$4M%Z?7\RV2Z*E@H\Q =Y8(Q!&ZDI4\TQ8WN/7A*"7%1<Q+TSC#O
M@/!^>[STL@'Z5G^K)7*_')P=GYV^__3YZ.SHY/R@%)X])'F]RKCG/J9*0=R;
M]%6J@[MKA_%I,AJ&8;HK+T(;QU3($K(BY3@OC0T\!OA1H'^J4E)!U2[>>IF:
MG2-_-QO.[G?_& BFE6!10FD8!R(ON\@I"#9JA?M->5M[\NX3(GI.&*FC^R>A
M^DZB_H$,QHW4*AF.VX_KRH \3V_WAL1Q'H*0&A(K]1TR1'!&!8C).\(P%":F
M]HB9[@S);V58^=%L/KQ$?W$V2"(ZRD2&0&(HP\E3:;ON@!)%D4=T(D/M&K"'
M%#1K0C;1^F,3LH.0&[AE?E#1NY#+]W/<9;^,2I]^GQ-ARAF(.B<0*63PN31A
MH4E)*;BTCTN]=N]L\PH]_=X8=P2?:@IH $SO)],TO!@?+F:!(Q_W\C@/QG'Q
M[6CIES]F-!,:J$%&2=DPHB13>4E1H($F/-\C2Z]F%6R#M*V)[?>NN",8[D=U
M#6#T)/U^3X33R1B_#,M$Y"5GC_D+W!J3!(<0*$:021"PV7B(*CBI$GX=:W>@
MVY3&?B]_.T)DIXIJ (COW7#Z-S>Z3A^3*UW/%O<@SS)F Y7&N0B>E9!$84CB
MO61 E);)<%+R!VL;QW6)Z_>>MBMCV(EJ6HT6SW[[^/'@\W^?OC\[_O7D^/WQ
MX0'&8(>'I[^=G!^?_/KI],/QX?'15MWDUOSD*C'D-EQT'TX2$RC:H BTS-P6
M!$](SWT &1ACT:B8!:N\=;L+)\_001CF82C3/)\L<K<G<)LQ3M AR,PZ$%J;
M<A\305-GT!F@EI/:H[#6HZS9\',3E#QICE1?*:T:JL]'AT</-O7GTQ/\\O#H
M(_YX*P/UQB=6,4R;4%W)(+WB.J$S?[B843(['M__G>$X#%%@]UH%*\FLCQP<
MGG$@LM+@LN5 HK>,&4=BJ!V152"[P^C@+1+N.P56)EW>G'S"[>R$!&\P:L^.
MTA"T"TG4GDI9@^Z^!U?N%[,;A!O=:+Y5*_O^X/CSWPX^_(;VZ>#LM\\+,W5P
M\N[]\<G!R>'QP8?CD[/SS[]M;7(W^?@J]G=K?BH9X]M@XJ[!]1UB0T[&1.$A
MI3+*+7B+B.46LD[9N=+KWU2_]WJ%GFHQ[;W/OML=L=0S&>LA*VDQ6$IEC'9*
MX+Q >* /Q$3MFY17">K7X%7#Q8O1Z\Y*^ .8J$6MS5:OGILOLF]S]1QO^S!:
M1F7*2@1!M3$@\& %'S&JT*D R%MBJF<C=&FT[@JV;E=9#&0IY_Z'H?/#T:)J
M:W47%$_'GU.9(X NP")[8*&%N_U%?>#)&P9)&5+Z.E$P01E(%G>6\CS)]>KE
M-XE^:S+0L%'<!'<O]Q#>MY);NFH^2?-W:3K\NNR&4OB_X?W[2YS_-I[X69I^
M768#7EW/\:\GZ/B.ALL2K8>"*2,M4141%&H#A"8)#!,!K'3&:T8,KQ[Z[(VY
M?I^?.]L9;8+C#^!ZG%U?7KKI]TE>&AKWK*%Q\UOY3QX)=X<A"#U0N6_GIQ/I
M[L-[$H%[KCT#K7,ND]]=::NF0)&H1134Y.JIJGL)^=8\3I?=OJ9/3]<!$UD(
M+AS0E$6)>118AS$/4\1*FE%:U3VG:L0W[#5M@K<7SX:]*K<EC^F7[_?>@!?\
M+#I &<\S%;YT !=XE-E P!I:6K@FHTR*+(O.L/H\28T@<+] >0FN%;36$@CO
MMG6IOCFX+#?0-WV$ _7)BI!*!Q%2.B-F< :=*A64IR):EN(>@O$G=#4"QQI
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M*XO\"('6;LBJ*N:^X?+W-+SX4CI0?,5=<)$.)[/Y:3YT5RBTT4 &2F1.!K)
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MDEPQR@VK72>W'\X:.0/V#]W]#<?:%D<-[*XMWB$'A!E/ J5 C"RAM8E@@XY
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MD(],D+BZM+X^V&_.](F(*7'D&83*&L@S#N"R(P)+CD;I1!]L!JDM7SQ.:.(
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M!(=Z94P;.S*(FNG O)-)FD-[6#O0,7+ES.ZPVM9O&EK&'>#\\6ISP>BX0<:
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M&9Q# ]H9(H'+[$MK;^CV^WLI$FXNYON%0KORO".\K.NEM$B8,!#QNC;,9NC
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M8_#!AL>%!:U%9"!*G3(1,$'(9#0F[EWF.9#[P ^'P^/N8;X55/;L8;Z-W#J
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M4$L! A0#%     @ %$ 95<],:80_*   0(D  !P              ( !
M '-E<V5N8FEO7VUI;F]R:7)O<V%L97,M92YH=&U02P$"% ,4    "  40!E5
MTH#.%VX(  #M+0  '               @ %Y*   <V5S;BTP-C,P,C R,G@Q
M,'%A7V5X,S$Q+FAT;5!+ 0(4 Q0    ( !1 &55I+$AP10@  (DM   <
M          "  2$Q  !S97-N+3 V,S R,#(R>#$P<6%?97@S,3(N:'1M4$L!
M A0#%     @ %$ 95>HZ8[<+!0  9!@  !P              ( !H#D  '-E
M<VXM,#8S,#(P,C)X,3!Q85]E>#,R,2YH=&U02P$"% ,4    "  40!E5YA5.
MG>H$  !+&   '0              @ 'E/@  <V5S;BTP-C,P,C R,GAX,3!Q
M85]E>#,R,BYH=&U02P$"% ,4    "  40!E5E&Y?++4O @!!-14 $0
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64$L%!@     +  L _0(  %Y_!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
